<SEC-DOCUMENT>0001564590-21-012240.txt : 20210311
<SEC-HEADER>0001564590-21-012240.hdr.sgml : 20210311
<ACCEPTANCE-DATETIME>20210311071953
ACCESSION NUMBER:		0001564590-21-012240
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		115
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210311
DATE AS OF CHANGE:		20210311

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Kymera Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001815442
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				812992166
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39460
		FILM NUMBER:		21731843

	BUSINESS ADDRESS:	
		STREET 1:		300 TECHNOLOGY SQUARE
		STREET 2:		2ND FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		857-285-5314

	MAIL ADDRESS:	
		STREET 1:		300 TECHNOLOGY SQUARE
		STREET 2:		2ND FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>kymr-10k_20201231.htm
<DESCRIPTION>10-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
kymr-10k_20201231.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="border-top:Double 2.25pt;padding-top:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549 </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 10-K<font style="font-weight:normal;"> </font></p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> (Mark&#160;One) </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Segoe UI Symbol;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:97%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934 </p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">For the fiscal year ended December 31, 2020</p>
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:40%;text-indent:6.67%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">OR </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:2.04%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Segoe UI Symbol;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:97%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934 FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;TO &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Commission File Number&#160;001-39460</p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:22pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">KYMERA THERAPEUTICS, INC.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of Registrant as specified in its Charter) </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Delaware</font></p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">81-2992166</font></p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">incorporation or organization)</p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer<br />Identification No.)</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">200 Arsenal Yards Blvd., Suite 230</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Watertown, Massachusetts </p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">02472</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s telephone number, including area code: <font style="Background-color:#FFFFFF;color:#000000;">(857)&#160;285-5300</font></p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(b) of the Act: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:39%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:20%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading Symbol(s)</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:39%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top"  style="width:39%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Common Stock, par value $0.0001 per share</font></p></td>
<td valign="bottom"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:20%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">KYMR</font></p></td>
<td valign="bottom"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:39%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The Nasdaq Global Market&#160;</font></p></td>
</tr>
</table></div>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(g) of the Act: <font style="font-weight:bold;">None </font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;YES&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font> NO<font style="font-family:Segoe UI Symbol;">&#9746;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Act. &#160;YES&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font>  NO&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. &#160;YES&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font> NO&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the Registrant was required to submit such files). &#160;YES&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font> NO&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:10.8pt;">
<td valign="top"  style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large&#160;accelerated&#160;filer</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:20.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated&#160;filer</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
</tr>
<tr style="height:1.9pt;">
<td valign="top"  style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:56.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:21.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:2.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-accelerated filer</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:20.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller&#160;reporting&#160;company</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
</tr>
<tr style="height:1.9pt;">
<td valign="top"  style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:20.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:20.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). &#160;YES&#160;<font style="font-size:8.5pt;font-family:Segoe UI Symbol;">&#9744;</font> NO&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The registrant&#8217;s common stock was not publicly traded as of the last business day of the registrant&#8217;s most recently completed second fiscal quarter. </p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of shares of Registrant&#8217;s Common Stock outstanding as of February 26, 2021 was 44,811,485. </p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE</p>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Portions of the registrant&#8217;s Proxy Statement for its 2021 Annual Meeting of Stockholders, which the registrant intends to file with the Securities and Exchange Commission not later<font style="color:#000000;font-family:Arial;"> </font>than 120 days after the registrant&#8217;s fiscal year ended December&#160;31, 2020, are incorporated by reference into Part III of this Annual Report on Form 10-K</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Table of Contents</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:82.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART I</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_BUSINESS"><font style="text-decoration:underline;">Business</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1A.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_RISK_FACTORS"><font style="text-decoration:underline;">Risk Factors</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1B.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1B_UNRESOLVED_STAFF_COMMENTS"><font style="text-decoration:underline;">Unresolved Staff Comments</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;2.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_PROPERTIES"><font style="text-decoration:underline;">Properties</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;3.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_LEGAL_PROCEEDINGS"><font style="text-decoration:underline;">Legal Proceedings</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;4.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_MINE_SAFETY_DISCLOSURES"><font style="text-decoration:underline;">Mine Safety Disclosures</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;II</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;5.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"><font style="text-decoration:underline;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;6.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_SELECTED_FINANCIAL_DATA"><font style="text-decoration:underline;">Selected Financial Data</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"><font style="text-decoration:underline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7A.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"><font style="text-decoration:underline;">Quantitative and Qualitative Disclosures About Market Risk</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;8.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"><font style="text-decoration:underline;">Financial Statements and Supplementary Data</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"><font style="text-decoration:underline;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9A.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9A_CONTROLS_PROCEDURES"><font style="text-decoration:underline;">Controls and Procedures</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9B.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9B_OR_INFORMATION"><font style="text-decoration:underline;">Other Information</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;III</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;10.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"><font style="text-decoration:underline;">Directors, Executive Officers and Corporate Governance</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;11.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_11_EXECUTIVE_COMPENSATION"><font style="text-decoration:underline;">Executive Compensation</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;12.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"><font style="text-decoration:underline;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;13.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"><font style="text-decoration:underline;">Certain Relationships and Related Transactions, and Director Independence</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;14.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"><font style="text-decoration:underline;">Principal Accounting Fees and Services</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;IV</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;15.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"><font style="text-decoration:underline;">Exhibits, Financial Statement Schedules</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;16</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_16_FORM_10K_SUMMARY"><font style="text-decoration:underline;">Form 10-K Summary</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SUMMARY OF THE MATERIAL AND OTHER RISKS ASSOCIATED WITH OUR BUSINESS</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">We are a biopharmaceutical company with a limited operating history and have not generated any revenue to date from drug sales, and may never become profitable.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">We have incurred significant operating losses in recent periods and anticipate that we will incur continued losses for the foreseeable future.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">We will need to raise substantial additional funding. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, scale back or discontinue some of our product candidate development programs or future commercialization efforts.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">We are very early in our development efforts and our IRAK4, IRAKIMiD, and STAT3 programs are still in preclinical or early clinical development. If we are unable to advance them into and through the clinic for safety or efficacy reasons or commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Our approach to the discovery and development of product candidates based on our Pegasus platform is novel and unproven, which makes it difficult to predict the time, cost of development, and likelihood of successfully developing any products.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Business interruptions resulting from the coronavirus disease (COVID-19) outbreak or similar public health crises could cause a disruption of the development of our product candidates and adversely impact our business.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">We may not be successful in our efforts to identify or discover additional product candidates or we may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">If we experience delays or difficulties in the initiation or enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Our current or future product candidates may cause adverse or other undesirable side effects that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Even if we receive regulatory approval for any of our current or future product candidates, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">We rely, and expect to continue to rely, on third parties to conduct our ongoing and planned clinical trials for our current and future product candidates. If these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, we may not be able to obtain marketing approval for or commercialize our current and potential future product candidates and our business could be substantially harmed.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">If we are unable to obtain and maintain patent and other intellectual property protection for our technology and product candidates or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and drugs similar or identical to ours, and our ability to successfully commercialize our technology and drugs may be impaired.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.67%;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ii</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K, or Annual Report, contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this Annual Report are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;may&#8221;, &#8220;will&#8221;, &#8220;should&#8221;, &#8220;expects&#8221;, &#8220;intends&#8221;, &#8220;plans&#8221;, &#8220;anticipates&#8221;, &#8220;believes&#8221;, &#8220;estimates&#8221;, &#8220;predicts&#8221;, &#8220;potential&#8221;, &#8220;continue&#8221; or the negative of these terms or other comparable terminology. These statements are not guarantees of future results or performance and involve substantial risks and uncertainties. Forward-looking statements in this Annual Report include, but are not limited to, express or implied statements about:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the initiation, timing, progress, results, and cost of our research and development programs, and our current and future preclinical and future clinical studies, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available, and our research and development programs;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our ability to continue to construct Pegasus, our drug discovery platform, and to enable a rational and effective drug discovery and development engine;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the timing and the success of preclinical and clinical studies under our IRAK4, IRAKIMiD, and STAT3 programs;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our plans to submit investigational new drug applications to the FDA for current and future product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the subsequent initiation of planned clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our ability to identify research priorities and apply a risk-mitigated strategy to efficiently discover and develop product candidates, including by applying learnings from one program to other programs and from one modality to our other modalities;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our potential ability to manufacture our drug substances, delivery vehicles, and product candidates for preclinical use, for clinical trials and on a larger scale for commercial use, if approved;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the ability and willingness of our third-party strategic collaborators to continue research and development activities relating to our development candidates and product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our ability to obtain funding for our operations necessary to complete further development and commercialization of our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our ability to obtain and maintain regulatory approval of our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our ability to commercialize our products, if approved;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the pricing and reimbursement of our product candidates, if approved;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the implementation of our business model, and strategic plans for our business, product candidates, and technology;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">estimates of our future expenses, revenues, capital requirements, and our needs for additional financing;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the potential benefits of strategic collaboration agreements, our ability to enter into strategic collaborations or arrangements, and our ability to attract collaborators with development, regulatory and commercialization expertise;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">future agreements with third parties in connection with the commercialization of product candidates and any other approved product;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the size and growth potential of the markets for our product candidates, and our ability to serve those markets;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our financial performance;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the rate and degree of market acceptance of our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">regulatory developments in the United States and foreign countries;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our ability to produce our products or product candidates with advantages in turnaround times or manufacturing cost;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the success of competing therapies that are or may become available;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our ability to attract and retain key scientific or management personnel;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the impact of laws and regulations;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">developments relating to our competitors and our industry;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the effect of the COVID-19 pandemic, including mitigation efforts and economic effects, on any of the foregoing or other aspects of our business operations, including but not limited to our preclinical studies and future clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our expectations regarding the time during which we will continue to be an emerging growth company or smaller reporting company as defined in federal securities regulations; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">other risks and uncertainties, including those listed under the caption &#8220;Risk Factors.&#8221;</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any forward-looking statements in this Annual Report reflect our current views with respect to future events and with respect to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those described under Part II, Item 1A, &#8220;Risk Factors&#8221; and elsewhere in this Annual Report. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of our forward-looking statements are as of the date of this Annual Report only. In each case, actual results may differ materially from such forward-looking information. We can give no assurance that such expectations or forward-looking statements will prove to be correct. An occurrence of or any material adverse change in one or more of the risk factors or risks and uncertainties referred to in this Annual Report or included in our other public disclosures or our other periodic reports or other documents or filings filed with or furnished to the Securities and Exchange Commission, or the SEC, could materially and adversely affect our business, prospects, financial condition and results of operations. Except as required by law, we do not undertake or plan to update or revise any such forward-looking statements to reflect actual results, changes in plans, assumptions, estimates or projections or other circumstances affecting such forward-looking statements occurring after the date of this Annual Report, even if such results, changes or circumstances make it clear that any forward-looking information will not be realized. Any public statements or disclosures by us following this Annual Report that modify or impact any of the forward-looking statements contained in this Annual Report will be deemed to modify or supersede such statements in this Annual Report.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may from time to time provide estimates, projections and other information concerning our industry, the general business environment, and the markets for certain diseases, including estimates regarding the potential size of those markets and the estimated incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties, and actual events, circumstances or numbers, including actual disease prevalence rates and market size, may differ materially from the information reflected in this Annual Report. Unless otherwise expressly stated, we obtained this industry, business information, market data, prevalence information and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data, and similar sources, in some cases applying our own assumptions and analysis that may, in the future, prove not to have been accurate.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU3"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART I</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1_BUSINESS"></a><a name="ITEM_1_BUSINESS"></a>Item 1. Business. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body&#8217;s own natural protein degradation system. Our proprietary targeted protein degradation platform, which we refer to as Pegasus&#8482;, allows us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have unique advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. We focus on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or inadequately drugged. To date, we have utilized our Pegasus&#8482; platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform&#8217;s capabilities to additional therapeutic areas. Our initial programs are IRAK4, IRAKIMiD, and STAT3, which each address high impact targets within the interleukin-1 receptor/toll-like receptor, or IL-1R/TLR, and janus kinase/signal transducers and activators of transcription, or JAK/STAT, providing the opportunity to treat a broad range of immune-inflammatory diseases, hematologic malignancies, and solid tumors.&nbsp;&nbsp;<font style="Background-color:#FFFFFF;">Our programs exemplify our focus on addressing high impact targets that have been elusive to conventional modalities and that drive the pathogenesis of multiple serious diseases with significant unmet medical needs. </font>With respect to our IRAK4 program, we are collaborating with Genzyme Corporation, a subsidiary of Sanofi S.A, or Sanofi, on the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. We submitted an Investigational New Drug Application, or IND, to the U.S. Food and Drug Administration, or FDA, for KT-474 in 2020, and initiated the single ascending dose, or SAD, portion of our Phase 1 trial in adult healthy volunteers in February 2021. We also expect to submit INDs for degraders from our IRAKIMiD and STAT3 programs in the second half of 2021, and if cleared, to initiate Phase 1 trials in patients thereafter.  </p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our Strategy</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our mission is to discover, develop and commercialize novel and transformative therapies that improve the lives of patients with serious diseases, and we are committed to the selection of targets that enable a broad impact across multiple clinical indications with high unmet medical need. We believe the unique discovery capabilities of our Pegasus<font style="font-weight:bold;"><sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup></font> platform will position us to be a leader in the area of targeted protein degradation. Our goal is to become a fully integrated biopharmaceutical company with a pipeline of novel degrader medicines targeting disease-causing proteins that were previously intractable. We intend to achieve this goal by pursuing the strategic objectives set forth below.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_Hlk64287054"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Advance the development of our IRAK4, IRAKIMiD</font><font style="color:#000000;">, </font><font style="font-weight:bold;color:#000000;">and STAT3 programs to deliver transformative therapies to patients</font><font style="color:#000000;">. We maintain a core set of drug development principles which guide our protein target selection and our discovery and development efforts. We are specifically focused on delivering therapeutic solutions that reach previously inaccessible targets, in particular those in which the biological pathways are clinically and genetically well-validated, in order to address significant unmet medical needs within broad patient populations. We believe our IRAK4, IRAKIMiD, and STAT3 programs have the potential to treat multiple immune-inflammatory and oncology disease indications that fit these criteria. </font><font style="color:#000000;">In February 2021, we initiated the SAD portion of our Phase 1 clinical trial for KT-474, our lead drug candidate in our IRAK4 program, in adult healthy volunteers. This is the first time that a heterobifunctional small molecule degrader has been administered to healthy volunteers.<a name="_Hlk64287054"></a> In the second half of 2021, we expect to initiate enrollment in the Multiple Ascending Dose (MAD) portion of the Phase 1 trial of KT-474, including healthy volunteers and a subsequent cohort of </font><font style="Background-color:#FFFFFF;color:#000000;">hidradenitis suppurativa, or</font><font style="color:#000000;"> HS, and </font><font style="Background-color:#FFFFFF;color:#000000;">atopic dermatitis, or AD,</font><font style="color:#000000;"> patients, pending FDA&#8217;s removal of the partial clinical hold for this portion of the trial. W</font><font style="color:#000000;">e also expect to initiate Phase 1 clinical trials for degrader drug candidates from our IRAKIMiD and STAT3 programs, including KT-413, our IRAKIMiD development candidate following a planned IND filing in the second half of 2021, and in KT-333, our STAT3 development candidate following a planned IND filing in the fourth quarter of 2021. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Further expand the capabilities of our Pegasus<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> platform to identify the optimal pairing of therapeutic targets with E3 ligases for a range of disease states</font><font style="color:#000000;">. Our targeted protein degradation, or TPD, platform, Pegasus</font><font style="font-weight:bold;color:#000000;"><sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup></font><font style="color:#000000;">, enables us to identify an expanded library of E3 ubiquitin ligases, or E3 ligases, to discover highly selective degraders with activity against disease causing proteins throughout the body. Pegasus has the potential to help us better understand not only the optimal pairing of disease-causing protein targets with E3 ligases, but also the degradation profiles across different cell types and tissues, further enabling us to convert our differentiated E3 binders into novel degraders. We believe our ability to identify and utilize previously unliganded E3 ligases, particularly those with selective or restricted expression, may unlock new opportunities across broad therapeutic applications.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Continue to build a broad and diverse pipeline of novel protein degraders</font><font style="color:#000000;">. Guided by our drug development principles and the learnings from our IRAK4, </font><font style="color:#000000;">IRAKIMiD</font><font style="color:#000000;">, and STAT3 programs, we intend to continue to identify therapeutic targets that have disruptive therapeutic potential and are predicted to be well-suited for a TPD approach. Given the unique genetic profiles in some of the patient populations that we aim to serve, we plan to continue to leverage a precision medicine approach to help identify patients with the highest probability of responding to our degrader drug candidates. The capabilities of our discovery platform, such as our expanded toolbox that includes E3 ligases beyond the two predominantly used in the field today, </font><font style="color:#000000;">cereblon</font><font style="color:#000000;"> and von Hippel-Lindau, or VHL, enable us to pursue targets linked to a wider range of indications.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Expand and protect our proprietary know-how and intellectual property</font><font style="color:#000000;">. We have developed a broad patent estate protecting our intellectual property, which we intend to expand to further protect our Pegasus</font><font style="font-weight:bold;color:#000000;"><sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup></font><font style="color:#000000;"> platform and the drug candidates we develop. Our intellectual property, which includes proprietary know-how as well as a series of patents, applies to not only our invented compounds but also to our E3 Ligase Whole-Body Atlas and our E3 Ligase Binders Toolbox.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Pursue synergistic collaboration opportunities</font><font style="color:#000000;">. To further our goal of delivering transformative therapies to the broadest possible patient population, we intend to become a fully integrated biopharmaceutical company. As part of this plan, in addition to our ongoing collaborations with Vertex and Sanofi, we expect to leverage additional strategic partnerships that can contribute complementary capabilities in discovery, development and commercialization in disease areas both within and outside of our core areas of therapeutic focus.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Background of Targeted Protein Degradation</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proteins are responsible for the structure, function and regulation of tissues and organs. Cells in the body continuously synthesize and degrade proteins, maintaining an equilibrium called protein homeostasis. Most diseases are the result of aberrant protein behavior driven by activation, mutation, or downregulation of the protein itself, or by the gene responsible for the transcription and translation of that particular protein. With a deepened molecular understanding of various diseases and the characterization of the full human genome, research efforts have increasingly focused on the development of medicines to address malfunctioning proteins responsible for oncologic, auto-immune, cardio-metabolic, neurodegenerative, and rare genetic diseases.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The &#8216;druggable&#8217; genome challenge</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Several therapeutic modalities have been developed over the years to address aberrant protein activity. These have included small molecule inhibitors of protein function, therapeutic antibodies, oligo-based therapeutics such as RNA interference therapeutics, antisense oligonucleotides, or ASO, and other genetic therapies.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some of these modalities have had a tremendous impact on the treatment of diseases and quality of life of patients, and several others, while earlier stage, offer potential. However, these traditional modalities face specific challenges that limit their therapeutic impact and reach. Some of the limitations of existing modalities include the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Traditional small molecule therapeutics</font><font style="color:#000000;"> are unable to block the function of proteins without a catalytic or substrate binding site and cannot block proteins with dual function, as such are not effective against transcription factors, scaffolding and adaptor proteins, many of which play a key role in certain diseases.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Therapeutic antibodies</font><font style="color:#000000;"> are generally too large to penetrate cells and are therefore typically limited to protein targets that are extracellular, or outside of the cell, whereas most proteins are inside the cell. They also have to be dosed parenterally and can be costly and complex to develop and manufacture.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Oligo-based therapeutics</font><font style="color:#000000;"> are capable of drugging proteins elusive to small molecules in some cases but have significant drug delivery challenges with dosing and in achieving systemic distribution, greatly limiting the breadth of diseases they are able to address effectively. These therapeutics can also be costly and complex to develop and manufacture.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of these limitations, we believe that only 20% of the full human genome has been effectively drugged to date. New therapeutic modalities which can overcome some of these challenges are necessary to expand the drugged proteome/genome and provide new efficacious medicines to patients in need. We believe that targeted protein degradation is such a modality.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Figure 1. Expanding the Druggable Human Proteome.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g23ode3tb50n000001.jpg" title="" alt="" style="width:606px;height:172px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Targeted Protein Degradation</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">One of the methods that cells use to control the balance between the synthesis of new proteins and the degradation and disposal of damaged and/or misfolded proteins, is ubiquitin-proteasome system, or UPS. The discovery of ubiquitin-mediated protein degradation provided important insights into specific processes like cellular division and DNA repair and led to the discovery of UPS&#8217; critical roles in various cellular pathways, including the cell cycle, signaling pathways, the regulation of gene expression, and responses to oxidative stress. The discovery of the UPS also revealed a new modality to harness this cellular process for the treatment of diseases.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The UPS comprises a series of finely orchestrated enzymatic sequences that ultimately lead to protein polyubiquitination and degradation by the proteasome in cells. Protein ubiquitination is a cellular process involving an enzymatic cascade consisting of ubiquitin-activating enzymes (E1), ubiquitin-conjugating enzymes (E2), and ubiquitin-protein ligases (E3). In humans, there are two classes of ubiquitin activating E1 enzymes, more than 30 E2 enzymes, and approximately 600 E3 ligases.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As illustrated in the figure below, the E3/E2/ubiquitin ligase complex (shown in blue) binds to a substrate protein (shown in purple) to mediate the transfer of ubiquitin, which leads to degradation of the target protein through the proteasome.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Figure 2. Natural Protein Degradation Through Ubiquitin-Proteasome System.</font><font style="font-weight:normal;">&#160;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g23ode3tb50n000002.jpg" title="" alt="" style="width:606px;height:454px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.53%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Targeted protein degradation is a new modality that co-opts this innate cellular process. The core of the TPD modality consists of a small molecule (shown in magenta in the figure below) that we refer to as a heterobifunctional degrader. The role of this heterobifunctional degrader molecule is to mediate a &#8220;new&#8221; interaction through the formation of a ternary complex between a disease-causing protein and an E3 ligase. The E3 ligase tags the protein target for degradation by attaching a series of ubiquitin, and the proteasome recognizes the tagged protein and degrades it into small peptides.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forming an efficient ternary complex, as shown in step 2 in the figure below, is a critical step in TPD, and its formation, function, and effect on cellular and <font style="font-style:italic;">in vivo</font> systems is vital to the success of the degradation and its impact on disease. In addition, the degrader molecule needs to be able to effect degradation in a variety of different cell types and contexts and have the right pharmaceutical properties to be therapeutically dosed to patients.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As shown in the figure below, after the degrader facilitates the ubiquitination of the target protein, and as the protein is degraded by the proteasome, the molecule separates from the protein, and is able to form another ternary complex to conduct the degradation process again. This iterative mechanism is catalytic, which results in increased potency even at lower concentrations, another key differentiator from other modalities such as small molecule inhibitors and therapeutic antibodies.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Figure 3. Overview of Targeted Protein Degradation.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g23ode3tb50n000003.jpg" title="" alt="" style="width:672px;height:298px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.53%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to the unique advantages of targeted protein degradation, this transformative modality is capable of targeting proteins traditionally undrugged by small molecules. Specifically, TPD can target proteins without a catalytic function such as scaffolding proteins and transcription factors, with small molecule-like drug properties that can potentially be dosed orally and distributed systemically unlike oligo-based therapeutics such as RNAi&#8217;s. TPD molecules also are amenable to existing small molecule manufacturing principles which are less costly than other therapeutic modalities. Because of the catalytic nature of the degradation process, we believe the modality has the potential to be therapeutically effective with smaller amounts of drug substance and less frequent dosing than traditional therapeutics.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The use of small molecules to affect protein homeostasis has been clinically and commercially validated by multiple drugs over the past two decades. Drugs such as bortezomib and fulvestrant have been understood to inhibit the proteasome and target the estrogen receptor for proteasome-dependent degradation, respectively. More recently, immunomodulatory imide drugs such as lenalidomide and pomalidomide have been understood on a post-hoc basis to direct the degradation of a series of transcription factors via the UPS.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These immunomodulatory drugs have validated the concept of using the UPS to degrade proteins and elicit a pharmacological and therapeutic effect in disease settings. However, unlike earlier approaches in this field, TPD takes this proven concept further to prospectively target the degradation of a wider range of proteins through the rational design of heterobifunctional degraders which coordinate the discreet binding of target proteins and E3 ligases to drive the desired protein degradation.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currently, the field of TPD has largely been focused on the generation of heterobifunctional small molecule degraders against various targets by using the generally well-characterized E3 ligases, cereblon and VHL. Heterobifunctional degraders targeting either the androgen receptor or estrogen receptor for the treatment of castration-resistant prostate cancer or advanced breast cancer are currently in Phase 2 and Phase 1 clinical testing, respectively. Both degrader compounds are oral drugs administered daily with early signs of acceptable pharmacokinetics and safety and, in the case of the androgen receptor degrader, preliminary evidence of tumor growth inhibition.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An important factor for the efficiency of a degrader is the specificity and affinity to the targeted E3 ligase. The various E3 ligases have different distribution and cellular localization profiles that are important factors when considering which E3 ligase to use for a particular disease protein target. There are approximately 600 E3 ligases that occur in nature, but to date only a handful of these E3 ligases have been evaluated for therapeutic purposes, leaving a substantial portion of the genome available for targeting.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Pegasus</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup></font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> Platform</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our proprietary Pegasus<font style="font-weight:bold;"><sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup></font> platform enables us to design highly active and selective molecules that utilize the UPS, the body&#8217;s natural E3 ligase-directed protein disposal system, to target and degrade disease-causing proteins. E3 ligases bind to a target to mediate the transfer of ubiquitin, which leads to degradation of the protein through the proteasome. We believe our platform enables us to discover and develop novel protein degraders that optimize the use of the three essential elements of our small molecule protein degraders: an E3 ligase, a binding moiety, a target protein binding moiety, and a linker connecting the two. The key components of our Pegasus<font style="font-weight:bold;"><sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup></font> platform described below combine our broad understanding of the localization and expression levels of the hundreds of E3 ligases in the human body with our proprietary E3 Ligase Binders Toolbox, as well as our chemistry, biology, and computational capabilities to develop protein degraders that address significant, unmet medical needs.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">E3 Ligase Whole-Body Atlas</font><font style="color:#000000;">: We have identified the expression profiles of approximately 600 naturally-occurring unique E3 ligases across different tissues. This knowledge enables us to match a target protein with the appropriate E3 ligase based on expression, distribution, intracellular localization, and biology.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">E3 Ligase Binders Toolbox</font><font style="color:#000000;">: Our E3 Ligase Whole-Body Atlas has allowed us to generate a toolbox of proprietary ligands designed to bind to an expanded library of E3 ligases that we believe will enable us to develop novel small molecule protein degraders with specific degradation profiles.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Ternary Complex Modeling</font><font style="color:#000000;">: Our structural biology information, combined with biochemical, biophysical, and computational characterization of ternary complexes is used to prospectively design highly efficient and selective degraders.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Quantitative Systems Pharmacology Model</font><font style="color:#000000;">: Our understanding of the </font><font style="font-style:italic;color:#000000;">in vitro</font><font style="color:#000000;"> and </font><font style="font-style:italic;color:#000000;">in vivo</font><font style="color:#000000;"> pharmacokinetic/pharmacodynamic, or PK/PD, relationships of our degraders across different tissues and cell types has allowed us to build an understanding of the diverse parameters that impact protein levels, and to model these parameters in different species, including humans.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Proprietary Chemistry</font><font style="color:#000000;">: Our expertise in proprietary chemistry provides us the opportunity to design degraders with optimized pharmaceutical properties tailored to not only specific diseases but also potentially targeted patient populations.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our Therapeutic Pipeline</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk64189804"></a>Our initial programs are IRAK4, IRAKIMiD, and STAT3, which each focus on a single critical signaling node within the genetically and clinically validated IL-1R/TLR and JAK/STAT pathways. Our programs exemplify our focus on addressing high impact targets that have been elusive to conventional modalities and that drive the pathogenesis of multiple serious diseases with significant unmet medical needs. We believe degrading these targets has the potential to treat multiple immune-inflammatory diseases, hematologic malignancies, and solid tumors. In February 2021, we initiated the healthy volunteer Single Ascending Dose (SAD) portion of our Phase 1 clinical trial for KT-474, the lead drug candidate in our IRAK4 program. In the second half of 2021, we expect to initiate enrollment in the Multiple Ascending Dose (MAD) portion of the Phase 1 trial of KT-474, including healthy volunteers and a subsequent cohort of HS and AD patients, pending FDA&#8217;s removal of the partial clinical hold for this portion of the trial. We also expect to submit INDs for degraders from our IRAKIMiD and STAT3 programs in the second half of 2021, and if cleared, to initiate Phase 1 trials in adult cancer patients thereafter. We also have multiple programs in earlier stages of development and are exploring targets in therapeutic areas outside of our core areas of focus. The following table summarizes our development pipeline:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><img src="g23ode3tb50n000004.jpg" title="" alt="" style="width:660px;height:296px;"></p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our IRAK4, IRAKIMiD, and STAT3 Programs</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing KT-474, a highly active and selective, orally bioavailable IRAK4 degrader, for the treatment of IL-1R/TLR-driven immunology-inflammation conditions and diseases with high unmet medical need, including HS, an inflammatory skin disease, as well as AD and rheumatoid arthritis. We have chosen to pursue IRAK4 degradation due to the well-validated role of the IL-1R/TLR pathway in immunology and inflammation and the potential advantage that drugging a single node of multiple different mediators of inflammation has over other approaches focused on targeting one of many cytokines that stimulate the IRAK4 node. IRAK4 is a critical node in the IL-1R/TLR signaling pathway, which is dependent on both IRAK4&#8217;s kinase activity and scaffolding function. We have demonstrated through our <font style="font-style:italic;">in vitro</font> and <font style="font-style:italic;">in vivo</font> studies that KT-474 induces IRAK4 degradation, impacting both the kinase and the scaffolding functions, and therefore can efficiently and selectively block IL-1R/TLR-mediated inflammation in a way we believe to be superior to IRAK4 kinase inhibitors. We therefore believe KT-474 has the potential to improve outcomes over current treatment options as well as other drugs currently in development. We submitted an IND for KT 474 to FDA in 2020 and initiated the SAD portion of our Phase 1 trial in adult healthy volunteers in February 2021. We are collaborating with Sanofi on the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. See &#8220;Business&#8212;Collaborations&#8212;Collaboration Agreement with Genzyme Corporation.&#8221;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing another group of IRAK4 degraders, which we call </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IRAKIMiDs</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, with a unique profile that combines the activity of IRAK4 degradation and immunomodulatory imide drugs, or </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IMiDs</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, for the treatment of MYD88-mutated diffuse large B-cell lymphoma, or DLBCL. In oncology, IRAK4 is an obligate protein in MYD88 signaling and this activated mutation is well characterized to drive oncogenesis. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IMiDs</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> are a class of drugs that degrade zinc-finger transcription factors, such as </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ikaros</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Aiolos</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, resulting in the restoration of Type 1 interferon, or Type 1 IFN, signaling pathway which is relevant in treating lymphoma. Our </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IRAKIMiDs</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> combine the activity of the </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IMiDs</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> with IRAK4 degradation in a single agent and address both the IL-1R/TLR and the Type 1 IFN pathways synergistically and in doing so demonstrate broad activity against MYD88-mutant lymphomas. We believe this will be the first precision medicine in lymphoma to target a genetically defined population, which accounts for 25% to 30% of DLBCL patients. We have observed that the functional synergy between the degradation of IRAK4 and </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IMiD</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> activity results in broad activity against MYD88-mutant lymphomas </font><font style="font-style:italic;">in vitro</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and in mouse xenograft models, leading to rapid, complete and sustained tumor regressions, even when dosed intermittently. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the third quarter of 2020, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> declared KT-413 as a development candidate and initiated IND</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">enabling activities. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> expect to file an IND </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the second half of 2021 </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and, if </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cleared</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, to begin a Phase 1 clinical trial </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">thereafter</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing our selective STAT3 degraders for the treatment of hematological malignancies and solid tumors, as well as autoimmune diseases and fibrosis. STAT3 is a transcription factor activated through a variety of different cytokine and growth factor receptors via janus kinases, or JAKs, as well as through oncogenic fusion proteins and mutations in STAT3 itself. We believe the diverse functions of STAT3 in tumor biology, evasion of immune surveillance by tumor cells, and inflammation and fibrosis provide opportunities to address a wide variety of high unmet need disease indications through the targeting of a single genetically and clinically validated pathway. While the JAK-STAT pathway has been partially addressed with several clinically successful JAK-targeting agents, we believe there are currently no drugs that specifically affect STAT3 broadly across all the relevant cell types. Small molecule STAT3 dimerization inhibitors targeting the SH2 domain have been in development, but significant challenges remain: first, homology of SH2 domains among all STAT family members impacts the ability to achieve specificity for STAT3, and second, inability to block dimerization independent transcriptional activities of STAT3. For these reasons, we believe that STAT3 degraders may provide a transformative solution to the development of targeted and selective drugs to address multiple STAT3 dependent pathologies. We recently nominated KT-333 as a STAT3 development candidate for liquid and solid tumor indications, and we expect to submit an IND to the FDA in the fourth quarter of 2021 and if cleared, initiate a Phase&#160;1 trial thereafter.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our Pegasus<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> Platform</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We built Pegasus<font style="font-weight:bold;"><sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup></font>, our proprietary TPD platform, to serve as an effective drug discovery and development engine leveraging our proprietary expertise and knowledge, as well as numerous chemistry, biology and computational capabilities. Our platform allows us to discover highly efficient and selective degraders by matching the right target with the ideal E3 ligase and optimizing molecular properties in order to increase the likelihood of therapeutic success for a particular disease state. Pegasus<font style="font-weight:bold;"><sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup></font> also allows us to design degraders with the appropriate pharmaceutical properties through our ability to study and model ternary complexes. We believe our understanding of degradation profiles across multiple tissues and cell types in different species increases the probability of clinical translation success. We believe our TPD platform is an engine for innovation, allowing us to expand the druggable proteome and thereby access critical disease pathway nodes that have to date been considered either undruggable or inadequately addressed with conventional modalities. Our capabilities have been developed through the key features of our Pegasus<font style="font-weight:bold;"><sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup></font> platform, which include the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">E3 Ligase Whole-Body Atlas</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">E3 Ligase Binders Toolbox</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Ternary Complex Modeling</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Quantitative System Pharmacology Model</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Proprietary Chemistry</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">E3 Ligase Whole-Body Atlas.<font style="font-weight:normal;font-style:normal;"> We have developed a proprietary human whole body E3 Atlas for mapping expression patterns of all known human E3 ligases in both disease and healthy contexts by combining the power of quantitative, high-resolution proteomics with proprietary algorithms. We are refining the characterization of the expression profiles in healthy and diseased tissues of generally well-established liganded E3 ligases like cereblon and VHL and, more importantly, of the approximately 600 naturally-occurring E3 ligases, most of which are still unliganded. We are establishing subcellular localization indices for each E3 ligase and determining their absolute abundances. We believe our approach overcomes the limitations of relying on publicly available RNA or antibody-based protein expression datasets, which often lead to inaccuracies in determining relative E3 ligase expression levels in different biological contexts.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our proprietary E3 Ligase Whole-Body Atlas enables data-driven disease-selective protein degradation strategies based on all of the mapped E3 ligases, which we view as a paradigm shift from relying on the limited number of E3 ligases typically exploited for TPD and provide us with a distinct competitive advantage. Using comparative analyses of expression patterns, we can identify selective pairings of E3 ligases with therapeutic targets of interest, including tissue-selective or tissue-restrictive pairings. We believe this approach is central to building out a toolbox of differentiated E3 ligase binders. Furthermore, we are able to use our custom-built Quantitative Systems Pharmacology Models in combination with proprietary data on the absolute abundance of E3 ligases and targets to predict cellular efficacy. The graph below shows an example of diverse expression profiles, using circle size as a relative abundance measure, for E3 ligases and selected targets across a panel of healthy tissues (on the x-axis), taken from our proprietary E3 Ligase Whole-Body Atlas.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Figure 4. Example of Diverse Expression Profiles for Selected Targets and E3 Ligases Across a Panel of Healthy Tissues, Taken from Our Proprietary E3 Ligase Whole-Body Atlas.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><img src="g23ode3tb50n000005.jpg" title="" alt="" style="width:596px;height:480px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.53%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">E3 Ligase Binders Toolbox<font style="font-weight:normal;">.</font><font style="font-weight:normal;font-style:normal;"> Leveraging the knowledge generated by our E3 Ligase Whole-Body Atlas, we are building a proprietary toolbox of differentiated E3 ligase binders for the development of next-generation targets and disease-specific degraders. We are focused on building an expanded library of E3 ligases and novel ligands with differentiated expression profiles in order to selectively pair them with targets in specific tissues, cell types and subcellular compartments. We believe that this approach to degrader design will lead to more selective target degradation in disease contexts, while avoiding target degradation in tissues associated with known toxicities, which we believe will lead to a substantially improved overall safety profile for our degrader molecules. Through our knowledge of E3 ligases and proprietary data on expression profiling, we believe we are uniquely positioned to identify both differentiated and ligandable E3 ligases that can be deployed against multiple targets, spanning broad therapeutic areas.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Ternary Complex Modeling</font><font style="font-weight:normal;">.</font><font style="font-weight:normal;font-style:normal;"> We believe that the understanding of the activity of the ternary complex is critical to the optimization and development of our degrader therapeutics. Ternary complexes are formed when a degrader binds to both an E3 ligase and the protein of interest. We characterize this interaction with both structural biology and biophysical techniques and utilize a sophisticated, structure-based approach to modeling. Our proprietary approach is tailored to the unique features of heterobifunctional degraders, which, unlike small-molecule inhibitors, facilitates proximity-based engagement of an E3 ligase with a target protein. Design of degraders requires consideration of both the length and composition of the linker, which can have a significant impact on the formation of the ternary complex and ultimately the efficiency of the degradation. We have developed and fully integrated into our discovery platform an efficient and powerful Ternary Complex Modeling, or TCM, method. The TCM method combines computational evaluation of tens of millions of potential protein-protein complexes, leveraging cloud computing resources, with statistical analyses to establish optimal linker lengths and geometry and to predict key aspects of target/degrader/E3 ligase ternary complexes. Our approach allows for rapid design of degraders, which in combination with design-build-test cycles, allows us to optimize our degraders by identifying key interactions and geometric constraints.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Quantitative Systems Pharmacology Model<font style="font-weight:normal;">.</font><font style="font-weight:normal;font-style:normal;"> Our proprietary Quantitative Systems Pharmacology, or QSP, model helps solve the complex equations required in TPD to accurately translate PK/PD into optimal human dosing. Our QSP model enables us to refine the understanding of each parameter that impacts the protein degradation profiles of degraders in tissues and then predict these varying parameters in different contexts. These parameters can include the affinity of binding to proteins and E3 ligases, ternary complex kinetics, protein half-life, target protein and E3 ligase concentrations. Using data from our proprietary E3 Ligase Whole-Body Atlas, combined with relevant biochemical and cellular degradation assays, we deploy the model to enhance optimal target and E3 ligase selection. QSP modeling is able to predict how the relative concentrations of the E3 ligase and the target protein impact the maximal degree of degradation and can be used to exclude E3 ligases whose concentration in target tissues may be insufficient to achieve the desired level of degradation. Our model is able to predict the impact of differential targeting versus E3 ligase expression profiles on degradation efficiencies. These insights are taken into consideration in the selection of the optimal E3 ligase for the target of interest to achieve the desired degradation profile whether it is systemic or restricted degradation across different cell types.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Proprietary Chemistry<font style="font-weight:normal;font-style:normal;">. We are leveraging our experienced team of dedicated scientists and experts with decades of experience in chemistry, structural biology and computational chemistry to optimize both E3 binders and target protein binders to convert them into highly efficient and selective degraders. We deploy diverse compound and virtual libraries for identification of starting ligands that bind to both the E3 ligase of interest and target. Our curated libraries include compounds with preferred physicochemical properties conducive to achieving oral bioavailability, and incorporate both covalent and non-covalent chemical scaffolds, as well as DNA-encoded libraries. We deploy direct-affinity assays and bead-based separation for fragment-based and DNA-encoded library screening. Computational chemistry is used to find suitable binding pockets to enable virtual screening. These </font><font style="font-weight:normal;">in silico</font><font style="font-weight:normal;font-style:normal;"> exercises rely upon structural biology, and together enable structure-based drug discovery. To support rapid synthesis of degrader molecules, we have built our own readily accessible and diverse library of linkers to connect binders to the E3 ligase and the target. We then integrate our TCM capabilities with proprietary linker chemistry to enable rational degrader design and optimization, reducing the time to development of highly efficient and selective degraders with the pharmaceutical properties tailored to specific patient populations and diseases. In this way, we were able to develop second-generation molecules with significantly improved permeability and bioavailability while sustaining the strong degrader properties exhibited in our first-generation molecules. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our Programs</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">IRAK4 Degrader for IL-1R/TLR-driven Immunology-inflammation Diseases</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Summary</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing KT-474, a highly active and selective, orally bioavailable IRAK4 degrader, for the treatment of IL-1R/TLR-driven immune-inflammatory conditions and diseases with high unmet medical need, including HS, AD and <font style="Background-color:#FFFFFF;color:#000000;">rheumatoid arthritis, or</font> RA. We have chosen to pursue IRAK4 degradation due to the well-validated role of the IL-1R/TLR pathway in immunology and inflammation and the potential advantage that drugging a single node of multiple different mediators of inflammation has over other approaches focused on targeting one of many cytokines that stimulate the IRAK4 node. IRAK4 is a critical node in the IL-1R/TLR signaling pathway, which is dependent on both IRAK4&#8217;s kinase activity and scaffolding function. We have demonstrated through our <font style="font-style:italic;">in vitro</font> and <font style="font-style:italic;">in vivo</font> studies that KT-474 induces IRAK4 degradation, impacting both the kinase and the scaffolding functions, and therefore can selectively block IL-1R/TLR-mediated inflammation in a way we believe to be superior to IRAK4 kinase inhibitors. We therefore believe KT-474 has the potential to improve outcomes over current treatment options as well as other drugs currently in development. In December 2020, we submitted an IND for KT-474 to the FDA, and in February 2021 we initiated dosing in a Phase 1 trial evaluating KT-474. In July 2020, we announced a strategic collaboration with Sanofi to develop and commercialize therapies targeting IRAK4 in patients with immune-inflammatory diseases. See the section entitled &#8220;Business&#8212;Collaborations&#8212;Collaboration Agreement with Genzyme Corporation&#8221; appearing elsewhere in this Annual Report for more information.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Biology and Mechanism of Action of IRAK4 Degrader</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IRAK4 is a key component of the myddosome, a multiprotein complex involved in innate immunity that mediates signaling through TLRs and IL-1Rs. The IRAK4 protein is ubiquitously expressed across multiple different tissue types, including skin, lymphoid tissue, bone marrow, gastrointestinal tract, and lung.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The function of IRAK4 is dependent both on its kinase activity and on its scaffolding function, which are required for the assembly of the myddosome complex following TLR or IL-1R engagement and MYD88 activation. While the kinase function is primarily responsible for the phosphorylation events in the IRAK4-JNK axis, the scaffolding function is primarily responsible for the NF-KB activation and downstream gene traction of several key pro-inflammatory cytokines and chemokines.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe IRAK4 degradation is superior to IRAK4 kinase inhibition as our preclinical data suggests that it is critical to block both the kinase activity and scaffolding functions of the IRAK4 protein, which requires removal, as opposed to just inhibition, of the protein. IL-1 family cytokines, including IL-1<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">a</font></font>, IL-1&#223;, IL-18, IL-36, and IL-33, have been implicated in a variety of different immunology-inflammation conditions and diseases. As both TLRs and IL-1Rs are involved in the production and response to all of these IL-1 family cytokines, IRAK4 targeting with a single small molecule degrader could impact multiple different cytokines and chemokines and thereby provide a transformative approach to the treatment of IL-1R/TLR-driven diseases.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Figure 5. IRAK4 Function is Comprised of Both Kinase-Dependent and -Independent Activity.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g23ode3tb50n000006.jpg" title="" alt="" style="width:606px;height:316px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.53%;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Non-Interventional Trial evaluating IRAK4 expression in HS and AD patients</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2020, we announced interim data from a non-interventional trial evaluating IRAK4 expression in the skin and blood of patients with HS and AD, as well as the effect of KT-474 on IRAK4 levels in peripheral blood mononuclear cells (PBMC) following <font style="font-style:italic;">ex vivo</font> treatment. The goal of conducting a non-interventional study in HS and AD is to understand IRAK4 expression in diseased tissues and demonstrate <font style="font-style:italic;">ex vivo</font> proof of mechanism with KT-474 in patients prior to conducting our clinical trials. The non-interventional trial was designed to enroll up to 30 patients with mild, moderate and severe HS and up to 10 patients with moderate or severe AD. The interim data from HS patients were presented at the 5th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA).</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IRAK4 levels were measured in skin biopsies obtained from lesional, peri-lesional and non-lesional skin and in blood from HS patients. The effect of KT-474 or an IRAK4 kinase inhibitor on IRAK4 levels were measured following <font style="font-style:italic;">ex vivo</font> incubation of whole blood. Interim results showed:</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#2E2E2E;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#2E2E2E;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#2E2E2E;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#2E2E2E;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;">IRAK4 expression can be quantified in the skin using immunofluorescence and mass spectrometry, and in PBMC by flow cytometry.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#2E2E2E;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#2E2E2E;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#2E2E2E;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#2E2E2E;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;">IRAK4 expression in the skin was higher in lesional and peri-lesional skin compared to unaffected skin (see Figure 6).</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>IRAK4 was detected in the blood across all PBMC subsets, with the highest expression in monocytes. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;">Ex vivo</font> treatment of whole blood with KT-474 substantially lowered IRAK4 levels across all PBMC subsets in the blood, whereas <font style="font-style:italic;">ex vivo</font> treatment with an IRAK4 kinase inhibitor increased IRAK4 levels in T and NK cells (see Figure 7).</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Figure 6: IRAK4 Expression in Skin of HS Patients, as Quantified by Immunofluorescence and Mass Spectrometry</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#2E2E2E;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g23ode3tb50n000007.jpg" title="" alt="" style="width:392px;height:160px;"></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Figure 7: IRAK4 Levels in PBMC Subsets Following Treatment with IRAK4 Degrader or Kinase Inhibitor</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g23ode3tb50n000008.jpg" title="" alt="" style="width:458px;height:152px;"></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These data support the relevance of the IRAK4 signaling pathway in HS and provide ex vivo proof of mechanism for KT-474 in PBMC of HS patients. We expect to present final results from the non-interventional trial, including additional data in HS patients as well as in AD, in the second quarter of 2021.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2020, we announced a strategic collaboration with Sanofi to develop and commercialize therapies targeting IRAK4 in patients with immune-inflammatory diseases. See the section entitled &#8220;Business&#8212;Collaborations&#8212;Collaboration Agreement with Genzyme Corporation&#8221; appearing elsewhere in this Annual Report for more information.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Development Opportunities and Differentiation from IL-1 Family Cytokine Antibodies</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are numerous cutaneous, rheumatic and gastrointestinal immunology-inflammation disease indications for which pathogenesis involves IL-1 family cytokines as well as TLR stimulation. These present opportunities where we believe a highly efficient and selective IRAK4 degrader would provide significant advantages over both currently approved treatment options and those in clinical development. We are initially prioritizing indications such as HS, AD, and RA where there is clinical proof of concept for targeting cytokines impacted by the IL-1R/TLR pathway but for which there continues to be a high level of unmet need.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Hidradenitis Suppurativa</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HS is a chronic, destructive, painful and debilitating inflammatory skin disease affecting up to 1% of both the U.S. and global population. Patients with HS have numerous painful, draining nodules and abscesses, usually within skin folds, that are characterized by inflammation and bacterial colonization. Currently HS is treated symptomatically with corticosteroids, antibiotics and surgery. The only FDA-approved treatment for HS is the anti-TNF antibody adalimumab, which provides some benefit to approximately 50% of patients with moderate-to-severe disease but is not curative. Thus, there remains a high unmet need for better therapies for the treatment of HS.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bacterial activation of TLRs, as well as the production of IL-1<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">a</font></font>, IL-1&#223;, and IL-36 by keratinocytes and inflammatory cells leading to inflammation characterized by high levels of TNF-<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">a</font></font>, IL-6, and IL-17, are central to the pathogenesis of HS. Monoclonal antibodies targeting individual cytokines such as IL-1<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">a</font></font> (bermekimab), IL-1<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">a</font></font>/&#223; receptor (anakinra), and IL-17 (secukinumab and bimekizumab) have shown preliminary clinical activity in HS and provide clinical validation for targeting the IL-1R/TLR pathway in HS. As such, an IRAK4 degrader which acts on multiple cytokines as well as TLRs has the potential to offer a significant advantage over the single-cytokine-targeting agents currently being developed.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Atopic Dermatitis</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AD is a chronic, pruritic inflammatory skin disease that occurs most frequently in children but also affects adults. In the U.S., the prevalence of AD is approximately seven to ten percent. AD follows a chronic relapsing course over month to years, with dry skin and severe pruritus as the primary symptoms, sometimes accompanied by skin thickening from chronic scratching and fissuring. AD is treated symptomatically with topical therapies, including emollients, corticosteroids, and phosphodiesterase inhibitors. The lone FDA-approved systemic treatment is the IL-4R<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">a</font></font> targeting antibody dupilumab, though only approximately 40% of moderate-to-severe disease patients met the primary endpoint in its Phase 3 trials, leaving a significant percentage of patients who are currently underserved.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, there is evidence that IL-33 and IL-1 are both involved in the generation of inflammation in both AD and other allergic diseases, including eosinophilic asthma and chronic rhinosinusitis. Single-cytokine-targeting monoclonal antibodies against IL-33 (etokimab) and IL-1<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">a</font></font> (bermekimab) have shown preliminary clinical activity in AD. Thus, the ability of an IRAK4 degrader to impact the production of both IL-33 and IL-1, through complete TLR signaling blockade, and the cellular response to both cytokines, through complete IL-1R signaling blockade, provides a compelling mechanistic rationale for development in AD.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Rheumatoid Arthritis</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RA is the most common inflammatory arthritis, affecting approximately 0.5% of the U.S. population. The synovial inflammation characteristic of RA is driven by Th1 and Th17 immune responses with production of TNF-<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">a</font></font> and IL-1 family cytokines, including IL-1, IL-18 and IL-33, IL-6 and IL-17. Multiple therapies targeting the IL-1R/TLR pathway are approved for RA, and recently an IRAK4 kinase inhibitor (PF-06650833) has shown clinical activity comparable to the JAK inhibitor tofacitinib and a favorable safety profile in a randomized, placebo-controlled Phase 2b study in RA patients with inadequate response to methotrexate. Based on these early signs of activation, we believe a degrader-based approach which impacts both the kinase activity and the scaffolding function of IRAK4 may have the potential for a more transformative effect on the disease.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:4.53%;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Preclinical Studies and Data</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In support of our IND-enabling studies, we have demonstrated&#160;KT-474&#8217;s&#160;high activity, selectivity and therapeutic potential in both <font style="font-style:italic;">in vitro</font> and <font style="font-style:italic;">in vivo</font>&#160;<font style="color:#000000;">studies.</font></p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:4.53%;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Stimulation and Comparison to IRAK4 Kinase Inhibitors</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We assessed the functional activity of KT-474 by measuring pro-inflammatory cytokine levels upon activation. Cells were pretreated with KT-474, a negative control, and small molecule IRAK4 kinase inhibitors.&nbsp;&nbsp;The figure below shows KT-474 is better able to inhibit IL-6 under both LPS and LPS + IL-1B than clinically active IRAK4 small molecule kinase inhibitors. </p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Figure 8. IRAK4 Degradation Superior to Kinase Inhibition in Cytokine Production</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><img src="g23ode3tb50n000009.jpg" title="" alt="" style="width:606px;height:350px;"></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">In Vivo Data</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Topical application of the TLR7/8 agonist, imiquimod, or IMQ, induces skin thickening associated with inflammatory cell infiltration, activates the&#160;NF-KB pathway and&#160;IL-23/IL-17&#160;axis, and produces&#160;IL-1&#160;family cytokines from keratinocytes, recapitulating several key pathological features of skin inflammation, including HS and psoriasis. In this&#160;<font style="font-style:italic;">in vivo&#160;</font>model, orally administered KT-474 inhibited topical IMQ-induced skin thickening, which was a reflection of local and systemic inflammation, to an extent comparable to a topical corticosteroid (clobetasol) at doses achieving at least&#160;60-70%&#160;IRAK4 knockdown in skin and spleen (Figure&#160;9).</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Figure 9. KT-474 Downregulates IRAK4 Expression and Inhibits Skin Thickening in Mouse Imiquimod Model of Psoriasis.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g23ode3tb50n000010.jpg" title="" alt="" style="width:394px;height:276px;"></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In a&#160;14-day&#160;non-GLP toxicology study of daily, orally-administered KT-474 in rats and&#160;non-rodents,&#160;the compound was well-tolerated at doses of up to 600 mg/kg in rats and 100&#160;mg/kg in&#160;non-rodents.&#160;Notably, pharmacodynamic assessment demonstrated complete knockdown of IRAK4 24 hours after the last dose on day 15 in multiple tissues including skin, spleen, lymph nodes and animal peripheral blood monocytes, PBMCs, as shown in Figure 10. Together this demonstrates that nearly complete systemic degradation of IRAK4 was well-tolerated and supported the advancement of KT-474 into further development.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Figure 10. IRAK4 Knockdown in Tissues After 14 Days of KT-474 Dosing</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">in&#160;Non-Rodent&#160;Non-GLP Toxicology Study.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:13.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g23ode3tb50n000011.jpg" title="" alt="" style="width:428px;height:260px;"></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the reversibility of IRAK4 knockdown&#160;<font style="font-style:italic;">in vivo</font>&#160;was demonstrated in mice and&#160;non-rodents,&#160;where recovery of IRAK4 levels in blood (PBMC) and skin was observed within 48 to 72 hours following cessation of daily oral dosing. We believe these data point to a potential safety advantage for TPD relative to genetic medicines approaches of protein knockdown, as cessation of the TPD agent is sufficient to restore protein levels back to steady state within a reasonable timeframe.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In summary, these preclinical data show that orally administered KT-474 safely and selectively suppresses IRAK4 expression in rodents and&#160;non-rodents,&#160;inhibits inflammation, including neutrophil infiltration, in murine models mechanistically relevant to the pathogenesis of HS, AD, and RA and potentially other diseases, and demonstrates a therapeutic advantage of IRAK4 degradation over IRAK4 kinase inhibition.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Clinical Development Plan</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020 we submitted an Investigational New Drug Application, or IND, to the U.S. Food and Drug Administration, or FDA, for KT-474, and in February 2021 we initiated the SAD portion of our Phase 1 trial in adult healthy volunteers. This is the first time that a heterobifunctional small molecule degrader has been administered to healthy volunteers in a placebo-controlled, randomized clinical trial. In the second half of 2021, we expect to initiate enrollment in the MAD portion of the Phase 1 trial of KT-474, including healthy volunteers and a subsequent cohort of HS and AD patients, pending FDA&#8217;s removal of the partial clinical hold for this portion of the trial.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The primary endpoints of the Phase 1 trial are to determine the safety and tolerability of KT-474 when administered as daily oral doses at escalating dose levels. Secondary endpoints will include characterization of the pharmacokinetic and pharmacodynamic profiles of multiple doses of KT-474 over an established timeframe.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmacodynamic endpoints to demonstrate proof of mechanism and proof of biology will include IRAK4 levels in blood and skin, levels of pro-inflammatory cytokines in <font style="font-style:italic;">ex vivo</font> stimulated PBMC, and plasma levels of high sensitivity C-reactive protein. We plan to also characterize the pharmacokinetic and pharmacodynamic profile of the recommended Phase 2 dose of KT-474 in an additional cohort of up to 20 AD and HS patients before initiation of Phase 2 studies. We expect that the combination of safety, pharmacokinetic and pharmacodynamic endpoints, including PK/PD relationships, will inform selection of one or more predicted-effective doses to take into subsequent proof of concept trials in our prioritized indications. Phase 2 randomized placebo-controlled trials are expected to be conducted in one or more indications including but not limited to AD, HS, and&#160;RA.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">IRAKIMiD</font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> Program in Oncology</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Summary</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing another group of IRAK4 degraders, which we call IRAKIMiDs, with a unique profile that combines the activity of IRAK4 degradation and IMiDs for the treatment of MYD88-mutated DLBCL. In oncology, IRAK4 is an obligate protein in MYD88 signaling and this activated mutation is well characterized to drive oncogenesis. IMiDs are a class of drugs that degrade zinc-finger transcription factors, such as Ikaros and Aiolos, resulting in the restoration of Type 1 IFN signaling pathway which is relevant in treating lymphoma. Our IRAKIMiDs combine the activity of the IMiDs with IRAK4 degradation in a single agent and address both the IL-1R/TLR and the Type 1 IFN pathways synergistically with a goal of demonstrating broad activity against MYD88-mutant lymphomas. We believe this will be the first precision medicine in lymphoma to target a genetically defined population, which accounts for at least 25% of DLBCL patients. We have observed the degradation of IRAK4 and IMiD activity results in additivity and synergy <font style="font-style:italic;">in vitro</font>. IRAKIMiDs combine both of these mechanisms in a single compound. Our IRAKIMiD degrader, KT-413, has demonstrated broad activity against MYD88-mutant lymphomas <font style="font-style:italic;">in vitro</font> and in mouse xenograft models, leading to rapid, complete and sustained tumor regressions, even when dosed intermittently. During the third quarter of 2020, we declared KT-413 as our development candidate for our IRAKIMiD program, and we expect to submit an IND to the FDA in the second half of 2021 and, if cleared by the FDA, initiate a Phase 1 trial thereafter.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Target Rationale and Mechanism of Action</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In DLBCL, the activating mutation of MYD88 drives activation of the NF-KB transcription factor and pro-survival mechanisms such as IRF4. MYD88 is a protein that forms a multiprotein signaling complex, known as the myddosome, which transduces receptor agonism from both the TLR and IL-1<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'"> </font><font style="font-size:10pt;font-family:'Times New Roman'">b</font></font> receptors. IRAK4 is an integral component of the myddosome, and both its catalytic kinase activity as well as its scaffolding function are required to drive downstream signals from the myddosome.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The constitutive activation of NF-KB is a hallmark of several B-cell lymphoma subtypes. In DLBCL, NF-KB activation is driven by a range of oncogenic alterations in several upstream pathways and regulators. Multiple co-mutations in these complexes often occur within the same tumor, emphasizing the dependence of these cancers on NF-KB activation. IMiDs such as lenalidomide drive a partial downregulation of NF-KB and IRF4, resulting in the restoration of Type 1 IFN signaling and promoting cell death.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Figure 11. NF-KB is Activated by Complimentary Mechanisms in Diffuse Large B Cell Lymphoma.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g23ode3tb50n000012.jpg" title="" alt="" style="width:436px;height:326px;"></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leveraging knowledge and chemistry expertise derived from the design of our selective IRAK4 degrader program, we have designed a novel class of heterobifunctional IRAK4 degraders, which we call IRAKIMiDs, that utilize an active IMiD as the cereblon binder to simultaneously engage and degrade both IRAK4 and IMiD substrates, such as Ikaros and Aiolos, thus combining the activity of two molecules in a single agent. IRAKIMiDs therefore combine two highly relevant therapeutic mechanisms in a single compound, enabling the functional synergy of NF-kB inhibition and upregulation of the Type 1 IFN response that results in increased and broader single-agent activity in MYD88-mutated DLBCL as compared to either mechanism alone.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Figure 12. IRAKIMiDs (right) Combine Both IRAK4 Degradation and IMiD Activity in a Single Agent.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g23ode3tb50n000013.jpg" title="" alt="" style="width:322px;height:174px;"></p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Pre-IND Status and Next Steps</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">KT-413, our development candidate in our IRAKIMiD program, is currently in preclinical development, and we expect to file an IND with the FDA in the second half of 2021 and, if cleared, initiate a Phase&#160;1 trial thereafter. Our planned Phase 1a trial is expected to include dose escalation and will assess safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary clinical activity in patients with B-cell lymphomas, including MYD88-mutant and -wild type DLBCL, leading to selection of the dose and schedule to take into Phase 1b. The Phase 1b expansion cohorts are expected to assess safety and clinical efficacy in MYD88-mutant versus MYD88-wild-type DLBCL, as well as Waldenstrom&#8217;s macroglobulinemia, and other MYD88MT NHL subsets. We are also planning expansion into other tumors sensitive to IL-1R/TLR targeting.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Development Opportunities&#160;and Differentiation of Novel Therapies in MYD88-Mutated DLBCL</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Oncogenic mutations of MYD88, most commonly MYD88L265P, are common in several subsets of DLBCL. In particular, MYD88 is estimated to be mutated in approximately 30-40% of activated B cell DLBCL, or ABC-DLBCL, cases, 30-80% of primary CNS lymphoma cases, and 45-75% of primary extranodal lymphomas cases. In addition, MYD88 is mutated in approximately 90% of Waldenstr&#246;m macroglobulinemia cases. The presence of MYD88 mutations in DLBCL is often associated with poorer response to chemotherapy and reduced overall survival compared to other genetic subtypes, supporting the need for more effective therapies targeting MYD88-mutated DLBCL.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Front-line treatment of DLBCL typically involves the R-CHOP treatment regimen of chemotherapy combined with rituximab. While effective in many other patients, front-line chemotherapy has significantly poorer survival rates in DLBCL subsets where MYD88 mutations are prevalent. In additional lines of therapy, several novel targeted therapies have been approved recently, including the combination of polatuzumab, bendamustine and rituximab, as well as CD19-targeting chimeric antigen receptor T-cells. While these agents have some notable activity, many patients fail to respond to or subsequently relapse from these therapies, with no adequate treatment options. Several targeted therapies that impact the NF-kB pathway, such as the Bruton&#8217;s tyrosine kinase inhibitor ibrutinib, or the IMiD lenalidomide, have shown modest single agent activity, with poor durability of response in MYD88-mutated DLBCL.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on our preclinical data, we believe KT-413, which synergistically combines the activity of both IRAK4 and IMiD substrate degradation to exploit complimentary pathway signaling, will have the potential to improve upon the efficacy of IRAK4 kinase inhibitors and other therapies, including BTK inhibitors and IMiDs, and provide single-agent activity in MYD88-mutated DLBCL.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Preclinical Studies and Data</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In support of our preclinical development, we have demonstrated our IRAKIMiD degraders&#8217; high selectivity and therapeutic potential in both <font style="font-style:italic;">in vitro</font> and <font style="font-style:italic;">in vivo</font> studies.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To assess the activity of our IRAKIMiD degraders in both MYD88-mutated and -wild-type cells lines, we conducted various <font style="font-style:italic;">in vitro</font> studies in a panel of cell lines. MYD-88-mutated cell lines included ABC-DLBCL lines such as OCI-Ly10, SUDHL2, and TMD8 while MYD-88-wild-type cell lines included OCI-Ly19, U2932, and SUDHL6. We have shown that IRAK4 degradation, as opposed to IRAK4 inhibition, shows additivity and synergy when combined with IMiDs <font style="font-style:italic;">in vitro</font>. Specifically, combining an IRAK4 degrader with the IMiD pomalidomide shows additive and synergistic activity in several MYD88-mutated cell lines <font style="font-style:italic;">in vitro</font>, supporting the combined effect of targeting both the MYD88 and IRAK4 pathways together. Notably, we did not see an additive effect when IRAK4 kinase inhibitors were combined with IMiDs, suggesting that the greater activity of IRAK4 degradation is needed for synergistic activity. We believe these data support the development of our unique class of degraders, which we call IRAKIMiDs.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To characterize the relationship between cell killing activity and the pharmacodynamic effect of an IRAKIMiD degrader, we measured protein levels of IRAK4, Ikaros and Aiolos in OCI-Ly10 cells after 24 hours of drug exposure. As shown in Figure 13, treatment with an IRAKIMiD degrader resulted in significant degradation of each of IRAK4, Ikaros, and Aiolos. Moreover, the degree of target protein degradation was strongly associated with the degree of cell killing, providing proof of concept that dual targeting of IRAK4 and IMiD substrates is capable of strongly affecting tumor biology in MYD88-mutated DLBCL.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Figure 13. Pharmacodynamic Analysis of IRAK4, Ikaros, and Aiolos in the MYD88MT Cell Line OCI-Ly10 Treated with an IRAKIMiD Degrader. Degree of Cell Killing Activity is Strongly Associated with the Degree of Degradation of Both IRAK4 and IMiD Substrates.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g23ode3tb50n000014.jpg" title="" alt="" style="width:348px;height:248px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">KT-413 is a selective and efficient degrader of both IRAK4 (DC50 = 8nM) and the IMiD substrates Ikaros and Aiolos (DC50 = 2nM) and shows activity in a range of MYD88-mutated cell lines, including OCI-Ly10, TMD8 and SUDHL2, irrespective of other co-mutations, as shown in Figure&#160;14. Notably, KT-413 is significantly less active in MYD88-wild-type cell lines, including U2932 and OCI-Ly19, supporting the potential for targeting tumors harboring MYD88 mutations.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Figure 1</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">. KT-413 Degrader is Significantly More Active in MYD88MT versus MYD88WT Cell Lines.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><img src="g23ode3tb50n000015.jpg" title="" alt="" style="width:492px;height:160px;"></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To assess the <font style="font-style:italic;">in vivo</font> activity of KT-413, we used a MYD88MT OCI-LY10 xenograft mouse model. Mice were administered KT-413 orally or parenterally on an intermittent schedule every 3rd or 4th day and monitored for tumor volume over time. As shown in Figure&#160;15, KT-413 induced tumor responses and complete regressions when given under either an oral, or PO, or intravenous, or IV, administration and under an intermittent schedule. Tumor responses were durable, maintaining regression for upwards of 4 weeks past the last dose, suggesting that infrequent dosing may be adopted with this mechanism with little impact on potential for activity.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Figure 15. KT-413 Induced Strong and Durable Regressions on Intermittent PO or IV Dosing in OCI-Ly10 Xenograft Tumors.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g23ode3tb50n000016.jpg" title="" alt="" style="width:530px;height:308px;"></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In patient-derived xenograft models <font style="font-style:italic;">in vivo</font>, KT-413 showed single-agent antitumor activity, including inducing tumor regressions in multiple models of MYD88-mutated DLBCL at well-tolerated doses (Figure 16).</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Figure </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">. </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">KT-413</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Shows Regressions in MYD88-mutant Patient-Derived Xenograft Models</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g23ode3tb50n000017.jpg" title="" alt="" style="width:624px;height:272px;"></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In summary, these preclinical data show that KT-413 is able to affect similar levels of IRAK4 and IMiD substrates degradation and antitumor activities in a dose-dependent manner <font style="font-style:italic;">in vivo</font> using either PO or IV formulations. Together, given the potential for intermittent and discontinuous dosing as sufficient to drive deep and sustained regressions, we believe these data support the potential for KT-413 as a transformative therapy that synergistically combines the activity of both IRAK4 and IRAKIMiD substrate degradation to exploit complimentary pathway signaling.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Developing IRAK4-selective Degraders for Other Hematologic Malignancies and Solid Tumors</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to our IRAKIMiD program, we are also exploring the therapeutic potential of IRAK4-selective degradation without IMiD biology, in both liquid and solid tumors, as there are certain cancers where this approach may be effective either as a monotherapy or in a combination therapy. Potential indications could include MYD88-mutant Waldenstrom&#8217;s macroglobulinemia, subsets of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), and non-small cell lung cancer. This program is in an earlier stage of development.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">STAT3 Degrader for Cancer and Autoimmune/Fibrotic Diseases</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Summary</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing our selective STAT3 degraders for the treatment of hematological malignancies and solid tumors, as well as autoimmune diseases and fibrosis. STAT3 is a transcription factor activated through a variety of different cytokine and growth factor receptors via JAKs, as well as through oncogenic fusion proteins and mutations in STAT3 itself. We believe the diverse functions of STAT3 in tumor biology, evasion of immune surveillance by tumor cells, and inflammation and fibrosis provide opportunities to address a wide variety of high unmet need disease indications through the targeting of a single genetically and clinically validated pathway. While the JAK-STAT pathway has been partially addressed with several clinically successful JAK-targeting agents, we believe there are currently no drugs that specifically affect STAT3 broadly across all the relevant cell types. Small molecule STAT3 dimerization inhibitors targeting the SH2 domain have been in development, but significant challenges remain: first, homology of SH2 domains among all STAT family members impacts the ability to achieve specificity for STAT3, and second, inability to block dimerization independent transcriptional activities of STAT3. For these reasons, we believe that STAT3 degraders may provide a transformative solution to develop targeted and specific drugs to address multiple STAT3 dependent pathologies.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2021, we nominated KT-333 as our STAT3 development candidate for liquid and solid tumor indications, and we have initiated IND-enabling activities.&nbsp;&nbsp;We expect to submit an IND to the FDA in the fourth quarter of 2021 and, if cleared, initiate a Phase&#160;1 trial thereafter. KT-333 has demonstrated high potency and selectivity in both in vitro and in vivo preclinical models, including significant and sustained anti-tumor activity in several preclinical models of liquid and solid tumors.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Biology and Mechanism of Action of STAT3 Degrader</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">STAT3 (signal transducer and activator of transcription 3) is a transcription factor and a member of the STAT protein family. In response to cytokines and growth factors, STAT3 is phosphorylated by receptor-associated serine/threonine kinases, and phosphorylated STAT3, or p-STAT3, then forms dimers that translocate into the nucleus, bind to DNA, and regulate transcription of a wide variety of genes involved in oncogenesis, inflammation and fibrosis. STAT3 is frequently mutated and activated in numerous cancers, including clinically aggressive hematologic malignancies with high unmet medical need. Mechanistically, aberrant activation of STAT3 has been directly linked to the promotion of cancer cell survival, proliferation, and metastasis. In addition, STAT3 regulates the crosstalk between tumor, stroma, and immune cells to promote an immunosuppressive tumor microenvironment. STAT3 activation by IL-6 and TGF-&#223; is also involved in the pathogenesis of autoimmunity and fibrosis. These various roles of STAT3 in disease pathogenesis make it an attractive target for drug development in cancer and autoimmune and fibrotic diseases.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Differentiation&#160;from JAK and IL-6 Inhibitors</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Small molecule inhibitors against JAK family kinases, such as JAK1, JAK2, JAK3, and TYK2, have been approved for the treatment of autoimmune diseases such as RA, psoriatic arthritis, and ulcerative colitis and target the JAK2/STAT5 pathway. In oncology, JAK inhibitors have been approved for hematological malignancies with mutations leading to activation of the JAK2/STAT5 pathway, including primary myelofibrosis and polycythemia vera, and for acute graft versus host disease. JAK inhibitors block signaling of a number of cytokines and growth factors and reduce activation not only of STAT3 but also STAT1 and STAT5 in response to these stimuli. For modulating anti-tumor effects, this broad activity may have conflicting consequences. In particular, the inhibition of STAT1 activity dampens anti-tumor immune responses by cytolytic T cells and antigen presenting cells, thereby counteracting a productive immune response that could be achieved by inhibition of STAT3 alone. As a result, JAK inhibitors have not shown clinical activity in cancer beyond the myeloproliferative neoplasms. The broad activity of JAK inhibitors is also associated with class-specific adverse effects. By targeting STAT3 selectively, these immunosuppressive and safety liabilities associated with broader STAT1 and STAT5 inhibition through JAK inhibition may be avoided while also effectively addressing JAK-dependent and independent activation of STAT3.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Monoclonal antibodies directed against pro-inflammatory cytokines such as IL-6 or their receptors IL-6R have also been approved for select autoimmune diseases. However, autoimmune and fibrotic diseases and certain cancers are often regulated by multiple cytokines. As such, targeting STAT3 has the potential to be more effective since it is involved in signaling by not just IL-6, but also by TGF-&#223; and cytokines such as IL-12, IL-2 and IL-15. Consequently, targeting STAT3 directly has the potential to block multiple signaling pathways that converge on STAT3 and reverse pathological processes that contribute to a tumor-permissive microenvironment.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Pre-IND Status and Next Steps</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">KT-333 is in IND-enabling activities and we expect to file an IND with the FDA in the fourth quarter of 2021 and, if cleared, initiate a Phase 1 trial thereafter. Our Phase 1 clinical trial in hematological malignancies and solid tumors is expected to include dose escalation and assess safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity. We expect that our Phase 1b clinical trial using the optimal dose and schedule from Phase 1 will include multiple expansion cohorts intended to assess clinical activity across different STAT3-dependent hematologic malignancies and solid tumors. We believe early development data from our STAT3 degraders in oncology will help inform subsequent development in autoimmunity and fibrosis indications.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Development Opportunities</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The multiple effects of a STAT3 degrader on oncogenesis, tumor cell resistance to tyrosine kinase inhibitors and chemotherapy, and evasion of immune surveillance provide multiple development opportunities in hematologic malignancies and solid tumors. Additionally, the role of STAT3 in chronic inflammation and fibrosis, as also observed in patients with germline STAT3 gain-of-function mutations, informs opportunities in autoimmune and fibrotic diseases.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hematologic Malignancies</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Oncogenic STAT3 mutations and/or STAT3 pathway activations are highly common in peripheral T-cell lymphoma, or PTCL, and cutaneous T-cell lymphoma, or CTCL, indications with an estimated US incidence of approximately 5,000 and 2,000 annual cases, respectively. STAT3 mutations and pathway activations along with responsiveness of PTCL subsets and CTCL to immune checkpoint inhibitors point to a dependency on STAT3 in these indications and therefore the opportunity to develop a STAT3 degrader as a monotherapy. The standard of care for first-line treatment of PTCL is the combination of brentuximab vedotin, a CD30-directed antibody-drug conjugate, and chemotherapy. The majority of PTCL patients, including ALK-ALCL, PTCL-Not Otherwise Specified, AITL and NK/T lymphoma subtypes, eventually progress and die of their disease. For patients with refractory/relapsed disease, current treatment options are limited and approved therapies pralatrexate and romidepsin have shown limited efficacy. High prevalence of STAT3 mutations (approximately 13-38%) and STAT3 pathway activation (up to 90%) is found in these refractory/relapsed PTCL subsets with high unmet need. Given the documented effect of STAT3 downregulation on levels of programmed death-ligand 1, or PD-L1, we expect our STAT3 degrader to have a dual effect in these patients. In CTCL patients with advanced stage disease and the highest levels of STAT3 activation, there are no curative therapies and no standard of care. Antibody-drug conjugates, HDAC inhibitors, and immune checkpoint inhibitors have some activity and are used upfront or in refractory/relapsed patients, but there remains a high unmet need for an effective therapeutic with both tumor-intrinsic as well as immunomodulatory antitumor effects.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">STAT3 pathway activation is also present in virtually all patients with T- and NK-cell large granular lymphocytic leukemia, and up to 70% of patients have oncogenic STAT3 mutations. These findings are highly indicative of STAT3 dependency, which is further supported by the preliminary clinical activity of JAK inhibitors in these patients. STAT3 activation is also commonly observed in AML and in DLBCL even though STAT3 mutations are infrequent. PD-L1 overexpression in DLBCL has been linked to worse disease outcomes and responses to anti-PD-1/PD-L1 drugs have been reported in these patients. Given STAT3 has downstream impact on PD-1/PD-L1, we believe that a STAT3 degrader has the potential to achieve profound clinical effects both as a monotherapy and in combination with other active drugs.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Solid Tumors</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancers that are responsive to anti-PD-1/PD-L1 immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs), including non-small cell lung cancer, or NSCLC, head and neck squamous cell carcinoma, or HNSCC, breast cancer and colorectal cancer, are compelling development opportunities due to the established role of STAT3 in solid tumor resistance to ICIs and TKIs. Specifically, STAT3 degraders have the potential to improve responses upfront in combination with these modalities or overcome acquired resistance as add-on therapy in second-line. </p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Autoimmune and Fibrotic Diseases</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patients with rare germline STAT3 gain-of-function mutations develop multiple autoimmune and fibrotic diseases, including systemic sclerosis, or SSc, AD, interstitial lung disease, enteropathies, and RA. We believe these manifestations, and their response to JAK inhibitors, provide support for STAT3 degrader development in immunology and inflammation. There are numerous publications that highlight the role of STAT3-mediated IL-6 and TGF-&#223; signaling in the pathogenesis of SSc, idiopathic pulmonary fibrosis, or IPF, Crohn&#8217;s disease, and multiple sclerosis. There remains a high unmet need for drugs that can target both the inflammation and fibrosis in SSc and IPF and halt or reverse disease progression. A STAT3 degrader has the potential for this dual effect and could therefore provide a transformative approach to treating both IPF as well as the various clinical manifestations of SSc.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Hematologic Malignancies&#8212;In Vitro Data</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We performed deep mass spectrometry-based proteomics to assess the specificity of a STAT3 degrader tool compound. In the example below, hPBMC and tumor cells (SU-DHL-1) were treated with the STAT3 degrader tool compound to assess its ability to affect protein levels on a proteome scale. As shown below, measurement of over 10,000 proteins showed that STAT3 is the only protein degraded by the tool compound with statistical significance, demonstrating its highly selective degradation profile (Figure 17).</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Figure </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">. Proteomic Analysis of STAT3 Degradation Selectivity</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">in </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">hPBMC</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> and SU-DHL-1 with </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">a</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> STAT3 Degrader</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> Tool Compound</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g23ode3tb50n000018.jpg" title="" alt="" style="width:392px;height:282px;"></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To assess the <font style="font-style:italic;">in vitro</font> degradation potency of the STAT3 degrader tool compound, we measured STAT3 protein levels in two STAT3-dependent ALK+ ALCL cell lines SU-DHL-1 and SUP-M2 after 24 hours of drug exposure. As shown in Figure&#160;18, the tool compound decreased the levels of STAT3 by greater than 95% with a DC50 of 15 nM and 86 nM, respectively.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Figure 18. Cellular Degradation of STAT3 in SU-DHL-1 and SUP-M2 Cell Lines Upon Treatment with a STAT3 Degrader Tool Compound.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g23ode3tb50n000019.jpg" title="" alt="" style="width:324px;height:282px;"></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As STAT3 plays a role in regulating gene expression, we measured the expression of downstream target genes in SU-DHL-1 cells treated with a STAT3 degrader tool compound. As shown in Figure&#160;19, treatment with the tool compound for 24 hours also led to significant downregulation of STAT3 target genes, such as SOCS3 and MYC, with IC50 of 36 and 37 nM, respectively.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Figure </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">. Effect of </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">a</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> STAT3 Degrader </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Tool Compound </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">on STAT3-Dependent Gene Expression in SU-DHL-1 Cells.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g23ode3tb50n000020.jpg" title="" alt="" style="width:322px;height:286px;"></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to assess the impact of STAT3 degradation on viability of lymphoma cells, we treated SU-DHL-1 and SUP-M2 cells with a STAT3 degrader tool compound for 96 hours and evaluated cell growth inhibition. As shown in Figure&#160;20, the tool compound inhibited the growth of both SU-DHL-1 and SUP-M2 cells with IC50 values of 64 and 105 nM, respectively. Additionally, a separate <font style="font-style:italic;">in vitro</font> experiment revealed that 48 hours compound treatment with greater than 90% degradation led to the complete inhibition of cell growth.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Figure 20. Growth Inhibition of SU-DHL-1 and SUP- M2 Cell Lines Upon Treatment with a STAT3 Degrader Tool Compound.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g23ode3tb50n000021.jpg" title="" alt="" style="width:310px;height:272px;"></p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Hematologic Malignancies&#8212;In Vivo Data</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To evaluate the <font style="font-style:italic;">in vivo</font> activity of a STAT3 degrader tool compound, we used the ALK+ ALCL SU-DHL-1 xenograft mouse model. Mice were administered the tool compound intravenously once a week and monitored for tumor volume over time. As shown in Figure&#160;21, the tool compound showed tumor responses with complete regressions and durable responses when dosed at 50mg/kg dose.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Figure </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">. Regression in SU-DHL-1 Xenograft Tumors Upon Weekly Dosing of </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">a</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> STAT3 Degrader</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> Tool Compound</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g23ode3tb50n000022.jpg" title="" alt="" style="width:364px;height:150px;"></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We characterized the degradation profile of STAT3 in a SU-DHL-1 mouse xenograft model following single intravenous administration. A STAT3 degrader tool compound exhibited a dose-dependent increase in plasma across the dose range of 5 to 25 mg/kg (Figure 22).</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Figure 22. Dose-Dependent Plasma Exposure in SU-DHL-1 Xenograft Mice Upon Single IV Dose of a STAT3 Degrader Tool Compound.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g23ode3tb50n000023.jpg" title="" alt="" style="width:236px;height:244px;"></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We assessed STAT3 degradation in tumors with a STAT3 degrader tool compound as a measure of pharmacodynamic effect and showed a dose-dependent reduction with maximal degradation of greater than 90% after 24 hours of a single intravenous administration. At 25 mg/kg, STAT3 levels in tumor were still below 50% of baseline ten days post-dose (Figure 23). The data demonstrated that tumor response was dependent on both the level and duration of STAT3 knockdown.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Figure </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">. Dose-Dependent Reduction of STAT3 in SU-DHL-1 Xenograft Mice</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Upon Single IV Dose of </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">a</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> STAT3 Degrader</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> Tool Compound</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g23ode3tb50n000024.jpg" title="" alt="" style="width:268px;height:290px;"></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To confirm the anti-tumor activity of a STAT3 degrader tool compound in additional STAT3-driven ALK+ ALCL models, we evaluated the effects of the degrader in the SUP-M2 xenograft model. Mice were dosed with 30mg/kg of our STAT3 degrader intravenously once a week for 3 weeks and monitored for tumor volume over time. As shown in Figure&#160;24, the tool compound induced complete regression of SUP-M2 tumors that was durable for multiple weeks after the last dose.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Figure 24. Regression in SUP-M2 Xenograft Tumors Upon Weekly Dosing of a STAT3 Degrader Tool Compound.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g23ode3tb50n000025.jpg" title="" alt="" style="width:340px;height:144px;"></p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Immuno-Oncology Mechanism&#8212;In Vitro Data</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">STAT3 degradation with a STAT3 degrader tool compound has demonstrated tumor-intrinsic and tumor-extrinsic effects that may contribute towards restoring an immune-permissive tumor microenvironment. A mechanism by which tumor cells evade immune surveillance is through increased expression of PD-L1 that interacts with PD-1, an immune checkpoint protein expressed on activated T cells that leads to the inhibition of T cell function. As shown in Figure&#160;25, treatment of SU-DHL-1 or SUP-M2 ALC cells with the tool compound for 24 hours reduced transcription of PD-L1 mRNA indicating that STAT3 degradation may reverse a key tumor-intrinsic mechanism for immune suppression.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Figure </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">. Reduced Transcription of PD-LI mRNA Upon 24 Hour Dose of </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">a</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> STAT3 Degrader</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> Tool Compound</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g23ode3tb50n000026.jpg" title="" alt="" style="width:250px;height:228px;"></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To assess the effect of STAT3 on the gene expression of immune-suppressive cytokines and immune-regulatory factors, we stimulated hPBMC with IL-6 in the presence or absence of a STAT3 degrader tool compound. The results below show that the tool compound blocked IL-6-induced increases in the expression of genes involved with immune suppression, including immune markers (e.g., CD163), and signaling cytokines (e.g., IL-10) (Figure 26). Collectively, these data show that degradation of STAT3 in tumor and immune cells reverses expression of genes that contribute to immune suppression and highlights the potential of STAT3 degraders as immunotherapies.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Figure 26. Reduced Gene Expression of Immune-suppressive Cytokines and Immune-regulatory Factors with a STAT3 Degrader Tool Compound.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g23ode3tb50n000027.jpg" title="" alt="" style="width:350px;height:126px;"></p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Immuno-Oncology Mechanism&#8212;In Vivo Data</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To assess the <font style="font-style:italic;">in vivo</font> effect of a STAT3 degrader tool compound on modulating tumor immunity, we conducted a study using CT-26 syngeneic colorectal cancer tumors known to be refractory to approved immunotherapies like PD-1 and PD-L1. We observed that the tool compound significantly reduced tumor growth when administrated every two days at 25 mg/kg (Figure 27).</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Figure </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">. Modulating Tumor Immunity with </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">a</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> STAT3 Degrader</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> Tool Compound</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g23ode3tb50n000028.jpg" title="" alt="" style="width:204px;height:234px;"></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We performed flow cytometry analysis of tumors from the same study to assess whether the anti-tumor effect was related to changes in the abundance of infiltrating immune cells in the tumor. The results showed a decreased number of immuno-suppressive M2 macrophages and CD4+ T cells relative to the vehicle and an increased number of anti-tumor M1 macrophages and cytolytic effector CD8+ T cells relative to the vehicle (Figure 28). The data demonstrate a synergistic modulation of immune cells within the tumor microenvironment to favor an anti-tumor response.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Figure 28. Synergistic Modulation of Immune Cells within Tumor Microenvironment.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:463.5pt;;">
<tr>
<td style="width:229.5pt;"></td>
<td style="width:7.05pt;"></td>
<td style="width:226.95pt;"></td>
</tr>
<tr>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g23ode3tb50n000029.jpg" title="" alt="" style="width:286px;height:208px;"></p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g23ode3tb50n000030.jpg" title="" alt="" style="width:286px;height:192px;"></p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.58%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe these results demonstrate the favorable immunomodulatory effects of STAT3 downregulation in both tumor cells and the tumor microenvironment associated with antitumor activity, underscoring the therapeutic potential of STAT3 degraders in oncology based on both tumor cell intrinsic and extrinsic biology.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:4.58%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Cell Intrinsic Mechanism in Solid Tumors</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.58%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Through its regulation of cell survival genes, STAT3 is activated across a wide range of cancer cells in response to TKIs and chemotherapies. Prolonged activation of STAT3 is associated with selection for tumor cells that are tolerant to the therapy, eventually leading to resistance and disease progression. A STAT3 degrader could therefore be used in combination with TKIs and/or chemotherapy, either upfront as a way to deepen and maintain response to first-line treatment, or as an add-on in second-line therapy to overcome acquired resistance to frontline therapy.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.58%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In EGFR mutant non-small cell lung cancer, or NSCLC, treatment with an EGFR kinase inhibitor such as erlotinib leads to upregulation of p-STAT3 indicating STAT3 activation. This is not observed in EGFR wild type NSCLC, pointing to STAT3 as a potential resistance mechanism. In fact, when we treated the EGFR mutant NSCLC cell line H1650 with erlotinib, we observed an upregulation of p-STAT3 which was reversed in the presence of a STAT3 degrader tool compound. We are expanding these efforts to <font style="font-style:italic;">in vivo</font> studies to complete our preclinical research to validate STAT3 degradation as a new mechanism for first line EGFR mutant therapy in NSCLC.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Figure </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">. </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">A </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">STAT3 degrader </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">tool compound </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">reverses pSTAT3 upregulation when administered</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">in combination with an EGFR inhibitor.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g23ode3tb50n000031.jpg" title="" alt="" style="width:396px;height:184px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.53%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Autoimmunity</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also exploring the effects of STAT3 in several immunology-inflammation <font style="font-style:italic;">in vitro</font> and <font style="font-style:italic;">in vivo</font> models. In a preclinical model of experimental autoimmune encephalomyelitis, a STAT3 degrader tool compound was able to completely prevent the onset of the disease in mice and was equivalent to steroid treatment with dexamethasone (Figure 30). These data, together with <font style="font-style:italic;">in vitro</font> mechanisms of action studies that we are conducting, highlight the potential of STAT3 degradation for the treatment of immunology-inflammation disease.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Figure 30. A STAT3 Degrader Tool Compound is Highly Active in Experimental Autoimmune Encephalomyelitis Model.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g23ode3tb50n000032.jpg" title="" alt="" style="width:420px;height:190px;"></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2021, we nominated KT-333 as our STAT3 development candidate for liquid and solid tumor indications, and we have initiated IND-enabling activities.&nbsp;&nbsp;We expect to submit an IND to the FDA in the fourth quarter of 2021 and, if cleared, initiate a Phase&#160;1 trial thereafter. KT-333 has demonstrated high potency and selectivity in both <font style="font-style:italic;">in vitro</font> and<font style="font-style:italic;"> in vivo </font>preclinical models, including significant and sustained anti-tumor activity including significant and sustained anti-tumor activity in several preclinical models of liquid and solid tumors.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Figure 31. KT-333 STAT3 Degrader Development Candidate is Highly Active <font style="font-style:italic;">In Vitro</font>.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><img src="g23ode3tb50n000033.jpg" title="" alt="" style="width:392px;height:239px;"></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Figure 32. KT-333 STAT3 Degrader Development Candidate Demonstrates <font style="font-style:italic;">in vivo</font> Tumor Growth Regression.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g23ode3tb50n000034.jpg" title="" alt="" style="width:306px;height:322px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Other Programs</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our focus on key undrugged or inadequately drugged nodes within therapeutically validated pathways combined with the target and disease agnostic features of our Pegasus<font style="font-weight:bold;"><sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup></font> platform gives us opportunity to develop new therapies across various therapeutic areas. We are taking advantage of our proprietary E3 Ligase Whole-Body Atlas on the differential expression profile of E3 ligases to pursue targets that can benefit from potentially tissue-restricted degradation. Our early pipeline includes programs in genetically defined oncology and immunology indications. Through our Vertex collaboration, we are engaged in the discovery of additional targets that are able to fully leverage our aforementioned capabilities and expand our impact across several diseases outside of oncology and immunology.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Collaborations</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Collaboration Agreement with GlaxoSmithKline Intellectual Property Development Limited</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 3, 2017, we entered into a collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited, or GSK, to jointly identify, research and conduct preclinical development of collaboration compounds against specified collaboration targets to identify drug candidates. We refer to this agreement as the GSK Agreement.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the GSK Agreement, GSK is using its DNA-encoded libraries, which can be used to scan trillions of compounds tagged with DNA bar codes that can be sequenced to reveal the structure of any hits, to screen a limited number of drug discovery targets of interest. The GSK Agreement also provides that the parties will collaborate to discover novel ligase binders. The GSK Agreement supports ongoing collaboration between the parties, with each party having a right to use certain insights gained in the collaboration for its own programs. The GSK Agreement also provides a mechanism for GSK to negotiate to license certain collaboration programs.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GSK has granted us a royalty-bearing, exclusive, non-transferrable, worldwide, sublicenseable right and license to research, develop and commercialize certain compounds.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As partial consideration for this agreement, we issued GSK 886,305 Series A preferred units of Kymera Therapeutics, LLC. In addition, low single-digit royalties would become payable by us to GSK on worldwide net sales in a given calendar year if a product comprising certain licensed compounds were to be commercialized. Royalties would be payable on a product-by-product and country-by-country basis for a period commencing upon the first commercial sale of any such product and continuing for ten (10) years thereafter.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless earlier terminated, the GSK Agreement will continue on a product-by-product and country-by-country basis until there are no more royalty payments owed to GSK on any product under the agreement. Either party may terminate the GSK Agreement upon an uncured material breach, or upon the bankruptcy, insolvency, dissolution or winding up of the other party. The GSK Agreement may also be terminated by either party for convenience upon sixty (60) days&#8217; prior written notice to the other party.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Master Collaboration Agreement with Vertex Pharmaceuticals Incorporated</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May&#160;9, 2019, we entered into a collaboration agreement with Vertex, focused on the research and development of our small molecule targeted protein degraders against multiple targets in disease areas outside our core strategic focus. The collaboration leverages our expertise in targeted protein degradation and our Pegasus<font style="font-weight:bold;"><sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup></font> platform as well as Vertex&#8217;s scientific, clinical, and regulatory capabilities to accelerate the development of medicines for people with serious diseases. We refer to this agreement as the Vertex Agreement.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Vertex Agreement, we conduct research activities in multiple targets pursuant to an agreed-upon research plan. Upon designation of a clinical development candidate, Vertex has the option to exclusively license molecules against the designated target. We are eligible to receive an aggregate of up to $170&#160;million in potential payments per licensing product based upon the successful achievement of specified research, development, regulatory and commercial milestones, as well as option exercise payments, for up to six (6)&#160;programs optioned by Vertex for licensing as part of the collaboration. No milestones have been achieved to date under the Vertex Agreement.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, Vertex will pay low single-digit royalties on future net sales on any products that may result from the commercialization of the licensed molecules. Vertex&#8217;s royalty obligations are on a product-by-product and country-by-country basis and are subject to certain reductions, including (i)&#160;in the event that the exploitation of a product is not covered by a valid claim with the licensed patent rights and (ii)&#160;in the event of third parties achieving specifically negotiated levels of competitive market share. Such royalty obligations will expire on a country-by-country and product-by-product basis upon the later of (a)&#160;the expiration of the last patent which covers a product in such country, (b)&#160;the expiration of any exclusivity granted by a regulatory authority and (c)&#160;10 years following the first commercial sale of a product in such country. No additional payments have been made by Vertex under the Vertex Agreement to date.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As initial consideration for the collaboration, Vertex paid us $70&#160;million upfront including an equity investment in us through the purchase of 3,059,695 shares of our Series B-1 preferred stock. In connection with its equity investment, Vertex holds certain rights to invest, in its sole discretion, in future private placements or public securities offerings by Kymera, on a pro rata basis and subject to certain conditions.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Vertex Agreement, the parties established a joint advisory committee, or JAC. The JAC will, among other responsibilities, review and oversee, certain strategic activities performed under the Vertex Agreement, including reviewing the research plan and budget for the research activities and reviewing the research activities performed by each party.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The initial research term of the collaboration is four years, extendable for an additional one-year period upon mutual agreement by the parties and payment by Vertex of certain per-target fees.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Vertex Agreement may be terminated by Vertex either in its entirety or on a target-by-target basis, upon prior written notice to Kymera. Either party may terminate the collaboration agreement upon the other party&#8217;s material breach, subject to specified notice and cure provisions, or upon the bankruptcy, insolvency, dissolution or winding up of the other party. Kymera also has the right to terminate the agreement with respect to a certain target upon 30&#160;days&#8217; prior written notice in the event that Vertex ceases all research, development and commercialization activities related to such target for a certain period of time, provided that the cessation is not the result of events outside of Vertex&#8217;s control.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Collaboration Agreement with Genzyme Corporation</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 7, 2020, we entered into a collaboration agreement, or the Sanofi Agreement, with Genzyme Corporation, a subsidiary of Sanofi, to co-develop drug candidates directed to two biological targets. The Sanofi Agreement became effective during the third quarter of 2020.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Sanofi Agreement, Kymera grants to Sanofi a worldwide exclusive license to develop, manufacture and commercialize certain lead compounds generated during the collaboration directed against IRAK4 and one additional undisclosed target in an undisclosed field of use. Such license is exercisable on a collaboration target-by-collaboration target basis only after a specified milestone. For compounds directed against IRAK4, the field of use includes diagnosis, treatment, cure, mitigation or prevention of any diseases, disorders or conditions, excluding oncology and immuno-oncology.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the Sanofi Agreement, with respect to both targets we are responsible for discovery and preclinical research and conducting a phase 1 clinical trial for at least one degrader directed against IRAK4 plus up to three back up degraders, the costs of which will be borne by us, except in certain circumstances. With respect to both targets, Sanofi is responsible for development, manufacturing, and commercialization of product candidates after a specified development milestone occurs with respect to each collaboration candidate.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, pursuant to the Sanofi Agreement, Sanofi will grant to us an exclusive option, or Opt-In Right, exercisable, at our sole discretion, on a collaboration target-by-collaboration target basis that will include the right to (i)&#160;fund 50% of the United States development costs for collaboration products directed against such target in the applicable field of use and (ii) share equally in the net profits and net losses of commercializing collaboration products directed against such target in the applicable field of use in the United States. In&#160;addition, if we exercise our Opt-In Right, Sanofi will grant to us an exclusive option, applicable to each collaboration target, which upon exercise will allow us to conduct certain co-promotion activities in the field in the United States.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In consideration for the exclusive licenses granted to Sanofi under the Sanofi Agreement, Sanofi paid to us an upfront payment of $150 million. In addition to the upfront payment, we will also be eligible to receive certain development milestone payments of up to $1.48 billion in the aggregate, of which more than $1.0 billion relates to the IRAK4 program, upon the achievement of certain developmental or regulatory events. We will also be eligible to receive certain commercial milestone payments up to $700 million in the aggregate, of which $400 million relates to the IRAK4 program, which are payable upon the achievement of certain net sales thresholds. We will further be eligible to receive tiered royalties for each program on net sales ranging from the high single digits to high teens, subject to low-single digits upward adjustments in certain circumstances.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Sanofi Agreement, unless earlier terminated, will expire on a product-by-product basis on the date of expiration of all payment obligations under the Sanofi Agreement with respect to such product. We or Sanofi may terminate the agreement upon the other party&#8217;s material breach or insolvency or for certain patent challenges. In addition, Sanofi may terminate the agreement for convenience or for a material safety event upon advance prior written notice, and we may terminate the agreement with respect to any collaboration candidate if, following Sanofi&#8217;s assumption of responsibility for the development, commercialization or manufacturing of collaboration candidates with respect to a particular target, Sanofi ceases to exploit any collaboration candidates directed to such target for a specified period.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Manufacturing / Supply Chain</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not own or operate manufacturing facilities for the production of our drug candidates and currently have no plans to build our own clinical or commercial scale manufacturing capabilities. We currently engage with third-party contract manufacturing organizations, or CMOs,&#160;for the manufacture of our drug candidates for preclinical studies, and we intend to continue to do so in the future. We rely on and expect to continue to rely on third-party manufacturers for the production of both drug substance and finished drug product. We have engaged third-party manufacturers to supply the drug substances for our drug candidates and a third-party manufacturer to develop and manufacture finished drug product for KT-474 that we are using in our Phase 1 clinical trial. We currently obtain our supplies from these manufacturers on a purchase order basis and do not have long-term supply arrangements in place. Should any of these manufacturers become unavailable to us for any reason, we believe that there are a number of potential replacements, although we may incur some delay in identifying and qualifying such replacements.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of our drug candidates are organic compounds of low molecular weight, generally called small molecules, but which are larger than traditional small molecule therapeutics. We have selected these compounds not only on the basis of their potential efficacy and safety, but also because we anticipate an ease of synthesis and cost of goods. We have produced drug substances and drug product for use in our KT-474 Phase 1 clinical trial, and continue to refine our production processes. The drug substance and drug product processes are amenable to scale-up and do not require unusual equipment in the manufacturing process. To adequately meet our needs for late-stage clinical and commercial manufacturing, our suppliers will need to scale their production,&#160;or we will need to secure alternate suppliers.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Competition</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The biotechnology industry is extremely competitive in the race to develop new products. While we believe we have significant competitive advantages with our years of expertise in targeted protein degradation, clinical development expertise, and intellectual property position, we currently face and will continue to face competition for our development programs from companies that use targeted protein degradation or targeted protein degradation development platforms, and from companies focused on more traditional therapeutic modalities such as small molecules and antibodies. The competition is likely to come from multiple sources, including larger pharmaceutical companies, biotechnology companies, and academia.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competitors in our efforts to develop small molecule protein degraders therapies for patients, include, but are not limited to, Arvinas, Inc., which we believe is in clinical development, and C4 Therapeutics, Inc., Nurix Therapeutics, Inc., Foghorn Therapeutics, Inc., and Vividion Therapeutics, Inc., each of which we believe is in preclinical development. Further, several large pharmaceutical companies have disclosed preclinical investments in this field. Our competitors will also include companies that are or will be developing other targeted protein degradation methods as well as small molecule, antibody, or gene therapies for the same indications that we are targeting. In addition to the competitors we face in developing small molecule protein degraders, we will also face competition in the indications we expect to pursue with our IRAK4, IRAKIMiD and STAT3 programs. Many of these indications already have approved standards of care which may include more traditional therapeutic modalities. In order to compete effectively with these existing therapies, we will need to demonstrate that our protein degrader therapies are favorable to existing therapeutics. </p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Intellectual Property</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our success depends in part on our ability to secure intellectual property protection for our product candidates and future products, as well as our platform protein degradation technologies and any other relevant inventions and improvements that are considered commercially important to our business. Our success also depends on our ability to defend and enforce our intellectual property rights, preserve the confidentiality of our proprietary information, and operate without infringing, misappropriating or otherwise violating the valid and enforceable patents and proprietary rights of third parties.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As with other biotechnology and pharmaceutical companies, our ability to secure and maintain intellectual property protection for our product candidates, future products, and other proprietary technologies will depend on our success in obtaining effective patent coverage and enforcing those patents if granted. However, we cannot guarantee that our pending patent applications, and any patent applications that we may in the future file, will result in the issuance of patents, or that any issued patents we may obtain will provide sufficient proprietary protection from competitors. Any issued patents that we obtain may be challenged, invalidated, or circumvented by third parties.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to patents, we also rely on trade secrets, know-how and continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary technology, in part, through confidentiality agreements and invention assignment agreements with our employees, consultants, scientific advisors, contractors and potential collaborators.</font></p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Patent Portfolio</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our intellectual property includes a portfolio of wholly owned patent families covering our platform E3 ligase ligand technology and our novel bifunctional degrader product candidates, including claims to compositions of matter, pharmaceutical compositions, methods of use, methods of treatment, and other related methods. Our intellectual property portfolio is in its very early stages, and, as of February 28, 2021, included one granted U.S. patent, 52 U.S. patent applications, and 53 foreign patent applications. Our patent portfolio is generally organized into two categories: (1)&#160;platform E3 ligase ligand patent families and (2)&#160;protein degrader patent families, including various target-specific degrader patent families.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Platform E3 Ligase Ligand Patent Families</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our platform E3 ligase ligand patent families are wholly owned and include four patent families directed to novel ligands for the cereblon E3 ubiquitin ligase, as well as methods of treatment and other related methods. As of February 28, 2021, our platform E3 ligase ligand patent families included three U.S. patent applications and four foreign patent applications, including one international patent application and three patent applications in Europe. Any U.S. or foreign patents resulting from these applications, if granted and all appropriate maintenance fees paid, are expected to expire between 2038 and 2040, absent any patent term adjustments or extensions.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Protein Degrader Patent Families</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our protein degrader patent families are wholly owned and are directed to novel bifunctional degrader compounds that are useful in affecting ubiquitination of a target protein, as well as methods of treatment and other related methods. As of February 28, 2021, our protein degrader patent families included four U.S. patent applications and 12 foreign patent applications, including one international patent application and 11 patent applications filed in Europe, Australia, Canada, Hong Kong, Israel, Japan, Mexico, New Zealand, and the Russian Federation. Any U.S. or foreign patents resulting from these applications, if granted and all appropriate maintenance fees paid, are expected to expire between 2038 and 2041, absent any patent term adjustments or extensions.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Target-Specific Degrader Patent Families</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our target-specific degrader patent families are wholly owned and focus protection around degrader compounds that are designed to target specific proteins for degradation, as well as methods of treatment and other related methods. Such targets include, for example, IRAK (interleukin-1 receptor-associated kinases) and STAT (signal transducers and activators of transcription). As of February 28, 2021, our target-specific degrader patent families included one granted U.S. patent, 45 U.S. patent applications and 37 foreign patent applications, including 17 international patent applications and 20 patent applications filed in Europe, Australia, Brazil, Canada, Eurasia, Israel, Japan, Mexico, New Zealand, Singapore, South Africa, Taiwan. Any U.S. or foreign patents resulting from our target-specific degrader patent families, if granted and all appropriate maintenance fees paid, are expected to expire between 2038 and 2041, absent any patent term adjustments or extensions.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">IRAK-Specific Patent Families</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our IRAK-specific patent families are wholly owned and include patent families covering degrader compounds that are designed to specifically target IRAK for degradation and patent families covering novel IRAK ligands. As of February 28, 2021, our IRAK-specific patent families included one granted U.S. patent, 28 U.S. patent applications, nine international patent applications, and 16 patent applications filed in Europe, Australia, Argentina, Brazil, Canada, Eurasia, Gulf Cooperation Council, Israel, Japan, Mexico, New Zealand, Singapore, South Africa, and Taiwan. Any U.S. or foreign patents resulting from our IRAK-specific patent families, if granted and all appropriate maintenance fees paid, are expected to expire between 2038 and 2042, absent any patent term adjustments or extensions.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to the KT-474 product candidate, we own six pending U.S. provisional patent applications, one allowed U.S. non-provisional patent application and one pending international patent application, each with claims directed to compositions of matter covering KT-474 and/or methods of making or using KT-474. Any U.S. or foreign patents resulting from these patent families, if granted and all appropriate maintenance fees paid, are expected to expire between 2039 and 2041, absent any patent term adjustments or extensions.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">STAT-Specific Patent Families</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our STAT-specific patent families are wholly owned and focus on degrader compounds that are designed to specifically target signal transducers and activators of transcription (STAT) for degradation. As of February 28, 2021, our STAT-specific patent families included six U.S. patent applications, one international patent application, and one patent application in Taiwan. Any U.S. or foreign patents resulting from our STAT-specific patent families, if granted and all appropriate maintenance fees paid, are expected to expire between 2040 and 2041, absent any patent term adjustments or extensions.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Other Target-Specific Patent Families</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of February 28, 2021, we own 11 U.S. patent applications and 10 foreign patent applications, including 7 international patent applications and 3 patent applications filed in Argentina, Gulf Cooperation Council, and Taiwan, which focus on degrader compounds designed to specifically target other proteins. Any U.S. or foreign patents resulting from these patent families, if granted and all appropriate maintenance fees paid, are expected to expire between 2040 and 2042, absent any patent term adjustments or extensions.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The term of individual patents may vary based on the countries in which they are obtained. Generally, patents issued from applications filed in the United States are effective for 20 years from the earliest effective non-provisional filing date. In certain cases, a patent term can be extended to recapture a portion of the term effectively lost as a result of the FDA regulatory review period. The Hatch-Waxman Act permits a patent term extension of up to five years beyond the expiration of the patent, though the total patent term, including any extension, must not exceed 14 years following FDA approval. A patent can only be extended once, such that, if a single patent is applicable to multiple products, it can only be extended based on one product.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The duration of patents outside of the United States varies in accordance with provisions of applicable local law, but typically is also 20 years from the earliest effective national filing date.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Similar patent term extension provisions are available in Europe and other foreign jurisdictions to extend the term of a patent covering an approved drug. When possible, we expect to apply for patent term extensions for patents covering our product candidates and their methods of use.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Trademarks</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to file applications for trademark registrations in connection with our product candidates and other technologies in various jurisdictions, including the United States. We have applied to register both the KYMERA mark and the KYMERA THERAPEUTICS mark in the United States, Europe, and Canada. We also filed applications in the same jurisdictions for the mark IRAKIMiD, for pharmaceutical and medical preparations and therapeutics, as well as diagnostic reagents, for the treatment of oncology, autoimmune, immune-oncology and other related diseases. In addition, we filed applications in the United States for E3 HUMAN ATLAS and E3 LIGASE WHOLE BODY ATLAS in connection with pharmaceutical research and development and drug development and discovery services.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Government Regulation</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA and other regulatory authorities at federal, state and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring and post-approval reporting of drugs. We, along with our vendors, contract research organizations and contract manufacturers, will be required to navigate the various preclinical, clinical, manufacturing and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval of our product candidates. The process of obtaining regulatory approvals of drugs and ensuring subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the U.S., the FDA regulates drug products under the Federal Food, Drug, and Cosmetic Act, or FD&amp;C Act, as amended, its implementing regulations and other laws. If we fail to comply with applicable FDA or other requirements at any time with respect to product development, clinical testing, approval or any other legal requirements relating to product manufacture, processing, handling, storage, quality control, safety, marketing, advertising, promotion, packaging, labeling, export, import, distribution, or sale, we may become subject to administrative or judicial sanctions or other legal consequences. These sanctions or consequences could include, among other things, the FDA&#8217;s refusal to approve pending applications, issuance of clinical holds for ongoing studies, suspension or revocation of approved applications, warning or untitled letters, product withdrawals or recalls, product seizures, relabeling or repackaging, total or partial suspensions of manufacturing or distribution, injunctions, fines, civil penalties or criminal prosecution.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process required by the FDA before our product candidates are approved as drugs for therapeutic indications and may be marketed in the U.S. generally involves the following:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">completion of extensive preclinical studies in accordance with applicable regulations, including studies conducted in accordance with good laboratory practice, or GLP, requirements;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">completion of the manufacture, under current Good Manufacturing Practices, or cGMP, conditions, of the drug substance and drug product that the sponsor intends to use in human clinical trials along with required analytical and stability testing; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">submission to the FDA of an IND application, which must become effective before clinical trials may begin;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">approval by an institutional review board, or IRB, or independent ethics committee at each clinical trial site before each trial may be initiated;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">performance of adequate and well-controlled clinical trials in accordance with applicable IND regulations, good clinical practice, or GCP, requirements and other clinical trial-related regulations to establish the safety and efficacy of the investigational product for each proposed indication;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">submission to the FDA of a NDA;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">a determination by the FDA within 60 days of its receipt of an NDA, to accept the filing for review;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">satisfactory completion of one or more FDA pre-approval inspections of the manufacturing facility or facilities where the drug will be produced to assess compliance with cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">potential FDA audit of the clinical trial sites that generated the data in support of the NDA;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">payment of user fees for FDA review of the NDA; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">FDA review and approval of the NDA, including consideration of the views of any FDA advisory committee, prior to any commercial marketing or sale of the drug in the U.S.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Preclinical Studies and Clinical Trials for Drugs</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before testing any drug in humans, the product candidate must undergo rigorous preclinical testing. Preclinical studies include laboratory evaluations of drug chemistry, formulation and stability, as well as <font style="font-style:italic;">in vitro</font> and animal studies to assess safety and in some cases to establish the rationale for therapeutic use. The conduct of preclinical studies is subject to federal and state regulations and requirements, including GLP requirements for safety/toxicology studies. The results of the preclinical studies, together with manufacturing information and analytical data must be submitted to the FDA as part of an IND. An IND is a request for authorization from the FDA to administer an investigational product to humans and must become effective before clinical trials may begin. Some long-term preclinical testing may continue after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises concerns or questions about the conduct of the clinical trial, including concerns that human research patients will be exposed to unreasonable health risks, and imposes a full or partial clinical hold. FDA must notify the sponsor of the grounds for the hold and any identified deficiencies must be resolved before the clinical trial can begin. Submission of an IND may result in the FDA not allowing clinical trials to commence or not allowing clinical trials to commence on the terms originally specified in the IND.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The clinical stage of development involves the administration of the product candidate to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#8217;s control, in accordance with GCP requirements, which include the requirements that all research patients provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria and the parameters and criteria to be used in monitoring safety and evaluating effectiveness. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Furthermore, each clinical trial must be reviewed and approved by an IRB for each institution at which the clinical trial will be conducted to ensure that the risks to individuals participating in the clinical trials are minimized and are reasonable related to the anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative, and must monitor the clinical trial until completed. The FDA, the IRB or the sponsor may suspend or discontinue a clinical trial at any time on various grounds, including a finding that the patients are being exposed to an unacceptable health risk. There also are requirements governing the reporting of ongoing clinical trials and completed clinical trials to public registries. Information about applicable clinical trials, including clinical trial results, must be submitted within specific timeframes for publication on the www.clinicaltrials.gov website.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A sponsor who wishes to conduct a clinical trial outside of the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, FDA will nevertheless accept the results of the study in support of an NDA if the study was conducted in accordance with GCP requirements, and the FDA is able to validate the data through an onsite inspection if deemed necessary</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials to evaluate therapeutic indications to support NDAs for marketing approval are typically conducted in three sequential phases, which may overlap.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;color:#000000;">Phase</font><font style="color:#000000;"> </font><font style="font-style:italic;color:#000000;">1</font><font style="color:#000000;">&#8212;Phase 1 clinical trials involve initial introduction of the investigational product into healthy human volunteers or patients with the target disease or condition. These studies are typically designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, excretion the side effects associated with increasing doses, and, if possible, to gain early evidence of effectiveness.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;color:#000000;">Phase</font><font style="color:#000000;"> </font><font style="font-style:italic;color:#000000;">2</font><font style="color:#000000;">&#8212;Phase 2 clinical trials typically involve administration of the investigational product to a limited patient population with a specified disease or condition to evaluate the drug&#8217;s potential efficacy, to determine the optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;color:#000000;">Phase</font><font style="color:#000000;"> </font><font style="font-style:italic;color:#000000;">3</font><font style="color:#000000;">&#8212;Phase 3 clinical trials typically involve administration of the investigational product to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval and physician labeling.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FDA released a draft guidance entitled &#8220;Expansion Cohorts: Use in First-In-Human Clinical Trials to Expedite Development of Oncology Drugs and Biologics,&#8221; which outlines how drug developers can utilize an adaptive trial design commonly referred to as a seamless trial design in early stages of oncology drug development (i.e., the first-in-human clinical trial) to compress the traditional three phases of trials into one continuous trial called an expansion cohort trial. Information to support the design of individual expansion cohorts are included in IND applications and assessed by FDA. Expansion cohort trials can potentially bring efficiency to drug development and reduce development costs and time. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Post-approval trials, sometimes referred to as Phase 4 clinical trials or post-marketing studies, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication and are commonly intended to generate additional safety data regarding use of the product in a clinical setting. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Progress reports detailing the results of the clinical trials, among other information, must be submitted at least annually to the FDA. Written IND safety reports must be submitted to the FDA and the investigators fifteen days after the trial sponsor determines the information qualifies for reporting for serious and unexpected suspected adverse events, findings from other studies or animal or <font style="font-style:italic;">in vitro</font> testing that suggest a significant risk for human volunteers and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must also notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction as soon as possible but in no case later than seven calendar days after the sponsor&#8217;s initial receipt of the information.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the product candidate and finalize a process for manufacturing the drug product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and manufacturers must develop, among other things, methods for testing the identity, strength, quality and purity of the final drug product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">U.S. Marketing Approval for Drugs</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assuming successful completion of the required clinical testing, the results of the preclinical studies and clinical trials, together with detailed information relating to the product&#8217;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the product for one or more indications. An NDA is a request for approval to market a new drug for one or more specified indications and must contain proof of the drug&#8217;s safety and efficacy for the requested indications. The marketing application is required to include both negative and ambiguous results of preclinical studies and clinical trials, as well as positive findings. Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a product&#8217;s use or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational product to the satisfaction of the FDA. FDA approval of an NDA must be obtained before a drug may be marketed in the U.S.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA reviews all submitted NDAs before it accepts them for filing and may request additional information rather than accepting the NDA for filing. The FDA must make a decision on accepting an NDA for filing within 60 days of receipt, and such decision could include a refusal to file by the FDA. Once the submission is accepted for filing, the FDA begins an in-depth substantive review of the NDA. The FDA reviews an NDA to determine, among other things, whether the drug is safe and effective for the indications sought and whether the facility in which it is manufactured, processed, packaged or held meets standards designed to assure the product&#8217;s continued safety, quality and purity. Under the goals and polices agreed to by the FDA under the Prescription Drug User Fee Act, or PDUFA, the FDA targets ten months, from the filing date, in which to complete its initial review of a new molecular entity NDA and respond to the applicant, and six months from the filing date of a new molecular entity NDA for priority review. The FDA does not always meet its PDUFA goal dates for standard or priority NDAs, and the review process is often extended by FDA requests for additional information or clarification.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, under PDUFA, as amended, each NDA must be accompanied by a user fee. The FDA adjusts the PDUFA user fees on an annual basis. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on NDAs for products designated as orphan drugs, unless the product also includes a non-orphan indication.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA also may require submission of a Risk Evaluation and Mitigation Strategy, or REMS, program if it believes that a risk evaluation and mitigation strategy is necessary to ensure that the benefits of the drug outweigh its risks. The REMS program could include use of risk evaluation and mitigation strategies like  medication guides, physician communication plans, assessment plans and/or elements to assure safe use, such as restricted distribution methods, patient registries or other risk-minimization tools.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, which reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP and other requirements and the integrity of the clinical data submitted to the FDA.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After evaluating the NDA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a complete response letter. A complete response letter generally contains a statement of specific conditions that must be met in order to secure final approval of the NDA and may require additional clinical or preclinical testing in order for the FDA to reconsider the application. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#8217;s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if the FDA approves a product, depending on the specific risk(s) to be addressed it may limit the approved indications for use of the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a drug&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.</font></p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Orphan Drug Designation and Exclusivity</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Orphan Drug Act of 1983, the FDA may grant orphan designation to a drug intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the U.S., or if it affects more than 200,000 individuals in the U.S., there is no reasonable expectation that the cost of developing and making the product available in the U.S. for the disease or condition will be recovered from sales of the product. Orphan designation must be requested before submitting an NDA. Orphan designation does not convey any advantage in or shorten the duration of the regulatory review and approval process, though companies developing orphan products are eligible for certain incentives, including tax credits for qualified clinical testing and waiver of application fees.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to a seven-year period of marketing exclusivity during which the FDA may not approve any other applications to market the same therapeutic agent for the same indication, except in limited circumstances, such as a subsequent product&#8217;s showing of clinical superiority over the product with orphan exclusivity or where the original applicant cannot produce sufficient quantities of product. Competitors, however, may receive approval of different therapeutic agents for the indication for which the orphan product has exclusivity or obtain approval for the same therapeutic agent for a different indication than that for which the orphan product has exclusivity. Orphan product exclusivity could block the approval of one of our products for seven years if a competitor obtains approval for the same therapeutic agent for the same indication before we do, unless we are able to demonstrate that our product is clinically superior. If an orphan designated product receives marketing approval for an indication broader than what is designated, it may not be entitled to orphan exclusivity. Further, orphan drug exclusive marketing rights in the U.S. may be lost if the FDA later determines that the request for designation was materially defective or the manufacturer of the approved product is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Expedited Development and Review Programs for Drugs</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA maintains several programs intended to facilitate and expedite development and review of new drugs to address unmet medical needs in the treatment of serious or life-threatening diseases or conditions. These programs include Fast Track designation, Breakthrough Therapy designation, Priority Review and Accelerated Approval, and the purpose of these programs is to either expedite the development or review of important new drugs to get them to patients earlier than under standard FDA development and review procedures.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A new drug is eligible for Fast Track designation if it is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address unmet medical needs for such disease or condition. Fast Track designation provides increased opportunities for sponsor interactions with the FDA during preclinical and clinical development, in addition to the potential for rolling review once a marketing application is filed, meaning that the agency may review portions of the marketing application before the sponsor submits the complete application, as well as Priority Review, discussed below.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, a new drug may be eligible for Breakthrough Therapy designation if it is intended to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Breakthrough Therapy designation provides all the features of Fast Track designation in addition to intensive guidance on an efficient drug development program beginning as early as Phase 1, and FDA organizational commitment to expedited development, including involvement of senior managers and experienced review staff in a cross-disciplinary review, where appropriate.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any product submitted to the FDA for approval, including a product with Fast Track or Breakthrough Therapy designation, may also be eligible for additional FDA programs intended to expedite the review and approval process, including Priority Review designation and Accelerated Approval. A product is eligible for Priority Review if it has the potential to provide a significant improvement in safety or effectiveness in the treatment, diagnosis or prevention of a serious disease or condition. Under priority review, the FDA must review an application in six months compared to ten months for a standard review.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, products are eligible for Accelerated Approval if they can be shown to have an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or an effect on a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality which is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated Approval is usually contingent on a sponsor&#8217;s agreement to conduct additional post-approval studies to verify and describe the product&#8217;s clinical benefit. The FDA may withdraw approval of a drug or indication approved under Accelerated Approval if, for example, the confirmatory trial fails to verify the predicted clinical benefit of the product. In addition, unless otherwise informed by the FDA, the FDA currently requires, as a condition for Accelerated Approval, that all advertising and promotional materials that are intended for dissemination or publication within 120 days following marketing approval be submitted to the agency for review during the pre-approval review period, and that after 120 days following marketing approval, all advertising and promotional materials must be submitted at least 30 days prior to the intended time of initial dissemination or publication.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or the time period for FDA review or approval may not be shortened. Furthermore, Fast Track designation, Breakthrough Therapy designation, Priority Review and Accelerated Approval do not change the scientific or medical standards for approval or the quality of evidence necessary to support approval but may expedite the development or review process.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Pediatric Information and Pediatric Exclusivity</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Pediatric Research Equity Act, or PREA, as amended, certain NDAs and certain supplements to an NDA must contain data to assess the safety and efficacy of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals for submission of pediatric data or full or partial waivers. The FD&amp;C Act requires that a sponsor who is planning to submit a marketing application for a drug that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration submit an initial Pediatric Study Plan, or PSP, within 60 days of an end-of-Phase 2 meeting or, if there is no such meeting, as early as practicable before the initiation of the Phase 3 or Phase 2/3 trial. The initial PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct, including study objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. The FDA and the sponsor must reach an agreement on the PSP. A sponsor can submit amendments to an agreed-upon initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from preclinical studies, early phase clinical trials and/or other clinical development programs.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A drug can also obtain pediatric market exclusivity in the U.S. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric trial or of multiple pediatric trials in accordance with an FDA-issued &#8220;Written Request&#8221; for such trials.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">U.S. Post-Approval Requirements for Drugs</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, reporting of adverse experiences with the product, complying with promotion and advertising requirements, which include restrictions on promoting products for unapproved uses or patient populations (known as &#8220;off-label use&#8221;) and limitations on industry-sponsored scientific and educational activities. Although physicians may prescribe legally available products for off-label uses, manufacturers and individuals working on behalf of manufacturers may not market or promote such uses. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability, including investigation by federal and state authorities. Prescription drug promotional materials must be submitted to the FDA in conjunction with their first use or first publication. Further, if there are any modifications to the drug, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new NDA or NDA supplement, which may require the development of additional data or preclinical studies and clinical trials.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-market testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, drug manufacturers and their subcontractors involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including cGMP, which impose certain procedural and documentation requirements upon us and our contract manufacturers. Failure to comply with statutory and regulatory requirements can subject a manufacturer to possible legal or regulatory action, such as warning letters, suspension of manufacturing, product seizures, injunctions, civil penalties or criminal prosecution. There is also a continuing, annual prescription drug product program user fee.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, requirements for post-market studies or clinical trials to assess new safety risks, or imposition of distribution or other restrictions under a REMS. Other potential consequences include, among other things:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">fines, warning letters or holds on post-approval clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">refusal of the FDA to approve applications or supplements to approved applications, or withdrawal of product approvals;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">product seizure or detention, or refusal to permit the import or export of products;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">injunctions or the imposition of civil or criminal penalties; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs; or mandated modification of promotional materials and labeling and issuance of corrective information.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Regulation of Companion Diagnostics</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Companion diagnostics identify patients who are most likely to benefit from a particular therapeutic product; identify patients likely to be at increased risk for serious side effects as a result of treatment with a particular therapeutic product; or monitor response to treatment with a particular therapeutic product for the purpose of adjusting treatment to achieve improved safety or effectiveness. Companion diagnostics are regulated as medical devices by the FDA. In the U.S., the FD&amp;C Act, and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market surveillance. Unless an exemption or FDA exercise of enforcement discretion applies, diagnostic tests generally require marketing clearance or approval from the FDA prior to commercialization. The two primary types of FDA marketing authorization applicable to a medical device are clearance of a premarket notification, or 510(k), and approval of a premarket approval application, or PMA.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To obtain 510(k) clearance for a medical device, or for certain modifications to devices that have received 510(k) clearance, a manufacturer must submit a premarket notification demonstrating that the proposed device is substantially equivalent to a previously cleared 510(k) device or to a preamendment device that was in commercial distribution before May&#160;28, 1976, or a predicate device, for which the FDA has not yet called for the submission of a PMA. In making a determination that the device is substantially equivalent to a predicate device, the FDA compares the proposed device to the predicate device and assesses whether the subject device is comparable to the predicate device with respect to intended use, technology, design and other features which could affect safety and effectiveness. If the FDA determines that the subject device is substantially equivalent to the predicate device, the subject device may be cleared for marketing. The 510(k) premarket notification pathway generally takes from three to twelve months from the date the application is completed, but can take significantly longer.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A PMA must be supported by valid scientific evidence, which typically requires extensive data, including technical, preclinical, clinical and manufacturing data, to demonstrate to the FDA&#8217;s satisfaction the safety and effectiveness of the device. For diagnostic tests, a PMA typically includes data regarding analytical and clinical validation studies. As part of its review of the PMA, the FDA will conduct a pre-approval inspection of the manufacturing facility or facilities to ensure compliance with the Quality System Regulation, or QSR, which requires manufacturers to follow design, testing, control, documentation and other quality assurance procedures. The FDA&#8217;s review of an initial PMA is required by statute to take between six months, although the process typically takes longer, and may require several years to complete. If the FDA evaluations of both the PMA and the manufacturing facilities are favorable, the FDA will either issue an approval letter or an approvable letter, which usually contains a number of conditions that must be met in order to secure the final approval of the PMA. If the FDA&#8217;s evaluation of the PMA or manufacturing facilities is not favorable, the FDA will deny the approval of the PMA or issue a not approvable letter. A not approvable letter will outline the deficiencies in the application and, where practical, will identify what is necessary to make the PMA approvable. Once granted, PMA approval may be withdrawn by the FDA if compliance with post-approval requirements, conditions of approval or other regulatory standards is not maintained or problems are identified following initial marketing.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July&#160;31, 2014, the FDA issued a final guidance document addressing the development and approval process for &#8220;In Vitro Companion Diagnostic Devices.&#8221; According to the guidance document, for novel therapeutic products that depend on the use of a diagnostic test and where the diagnostic device could be essential for the safe and effective use of the corresponding therapeutic product, the premarket application for the companion diagnostic device should be developed and approved or cleared contemporaneously with the therapeutic, although the FDA recognizes that there may be cases when contemporaneous development may not be possible. However, in cases where a drug cannot be used safely or effectively without the companion diagnostic, the FDA&#8217;s guidance indicates it will generally not approve the drug without the approval or clearance of the diagnostic device. The FDA also issued a draft guidance in July 2016 setting forth the principles for co-development of an in vitro companion diagnostic device with a therapeutic product. The draft guidance describes principles to guide the development and contemporaneous marketing authorization for the therapeutic product and its corresponding in vitro companion diagnostic.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once cleared or approved, the companion diagnostic device must adhere to post-marketing requirements including the requirements of the FDA&#8217;s QSR, adverse event reporting, recalls and corrections along with product marketing requirements and limitations. Like drug makers, companion diagnostic makers are subject to unannounced FDA inspections at any time during which the FDA will conduct an audit of the product(s) and our facilities for compliance with its authorities.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Other Regulatory Matters</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing, sales, promotion and other activities of product candidates following product approval, where applicable, or commercialization are also subject to regulation by numerous regulatory authorities in the U.S. in addition to the FDA, which may include the Centers for Medicare&#160;&amp; Medicaid Services, or CMS, other divisions of the Department of Health and Human Services, the Department of Justice, the Drug Enforcement Administration, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety&#160;&amp; Health Administration, the Environmental Protection Agency and state and local governments and governmental agencies.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other healthcare laws </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Healthcare providers, physicians, and third-party payors will play a primary role in the recommendation and prescription of any products for which we obtain marketing approval. Our business operations and any current or future arrangements with third-party payors, healthcare providers and physicians may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we develop, market, sell and distribute any drugs for which we obtain marketing approval. In the United States, these laws include, without limitation, state and federal anti-kickback, false claims, physician transparency, and patient data privacy and security laws and regulations, including but not limited to those described below. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, paying, receiving or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid; a person or entity need not have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it in order to have committed a violation. Violations are subject to civil and criminal fines and penalties for each violation, plus up to three times the remuneration involved, imprisonment, and exclusion from government healthcare programs. In addition, the government may assert that a claim that includes items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:none;Background-color:#auto;font-size:10pt;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The federal civil and criminal false claims laws, including the civil False Claims Act, or FCA, prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment or approval that are false, fictitious or fraudulent; knowingly making, using, or causing to be made or used, a false statement or record material to a false or fraudulent claim or obligation to pay or transmit money or property to the federal government; or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay money to the federal government. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. The FCA also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery. When an entity is determined to have violated the federal civil False Claims Act, the government may impose civil fines and penalties for each false claim, plus treble damages, and exclude the entity from participation in Medicare, Medicaid and other federal healthcare programs. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The federal civil monetary penalties laws impose civil fines for, among other things, the offering or transfer or remuneration to a Medicare or state healthcare program beneficiary, if the person knows or should know it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state health care program, unless an exception applies. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for knowingly and willfully executing a scheme, or attempting to execute a scheme, to defraud any healthcare benefit program, including private payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, or falsifying, concealing or covering up a material fact or making any materially false statements in connection with the delivery of or payment for healthcare benefits, items or services. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations, impose, among other things, specified requirements on covered entities and their business associates relating to the privacy and security of individually identifiable health information including mandatory contractual terms and required implementation of technical safeguards of such information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates in some cases, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The Physician Payments Sunshine Act, enacted as part of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, the ACA, imposed new annual reporting requirements for certain manufacturers of drugs, devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, for certain payments and &#8220;transfers of value&#8221; provided to physicians (currently defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members.&#160;In addition, many states also require reporting of payments or other transfers of value, many of which differ from each other in significant ways, are often not pre-empted, and may have a more prohibitive effect than the Sunshine Act, thus further complicating compliance efforts. Effective January&#160;1, 2022, these reporting obligations will extend to include transfers of value made in the previous year to certain non-physician providers such as physician assistants and nurse practitioners. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Federal consumer protection and unfair competition laws broadly regulate marketplace activities and activities that potentially harm consumers. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Analogous state and foreign laws and regulations may be broader in scope than the provisions described above and may apply regardless of payor. Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and relevant federal government compliance guidance; require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers; restrict marketing practices or require disclosure of marketing expenditures and pricing information. State and foreign laws may govern the privacy and security of health information in some circumstances. These data privacy and security laws may differ from each other in significant ways and often are not pre-empted by HIPAA, which may complicate compliance efforts. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other related governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, disgorgement, exclusion from government funded healthcare programs, such as Medicare and Medicaid, reputational harm, additional oversight and reporting obligations if we become subject to a corporate integrity agreement or similar settlement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, they may be subject to similar actions, penalties and sanctions. Ensuring business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource-consuming and can divert a company&#8217;s attention from its business. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:6.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Insurance Coverage and Reimbursement </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Thus, even if a product candidate is approved, sales of the product will depend, in part, on the extent to which third-party payors, including government health programs in the United States such as Medicare and Medicaid, commercial health insurers and managed care organizations, provide coverage, and establish adequate reimbursement levels for, the product. In the United States, the principal decisions about reimbursement for new medicines are typically made by the Centers for Medicare&#160;&amp; Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services. CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare and private payors tend to follow CMS to a substantial degree. No uniform policy of coverage and reimbursement for drug products exists among third-party payors. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. The process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors are increasingly challenging the prices charged, examining the medical necessity, reviewing the cost-effectiveness of medical products and services and imposing controls to manage costs. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the approved products for a particular indication. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, which will require additional expenditure above and beyond the costs required to obtain FDA or other comparable regulatory approvals. Additionally, companies may also need to provide discounts to purchasers, private health plans or government healthcare programs. Nonetheless, product candidates may not be considered medically necessary or cost effective. A decision by a third-party payor not to cover a product could reduce physician utilization once the product is approved and have a material adverse effect on sales, our operations and financial condition. Additionally, a third-party payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly from payor to payor. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The containment of healthcare costs has become a priority of federal, state and foreign governments, and the prices of products have been a focus in this effort. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company&#8217;s revenue generated from the sale of any approved products. Coverage policies and third-party payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which a company or its collaborators receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:6.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Current and future healthcare reform legislation </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States and some foreign jurisdictions, there have been, and likely will continue to be, a number of legislative and regulatory changes and proposed changes regarding the healthcare system directed at broadening the availability of healthcare, improving the quality of healthcare, and containing or lowering the cost of healthcare. For example, in March 2010, the United States Congress enacted the Affordable Care Act, which, among other things, includes changes to the coverage and payment for products under government health care programs. The Affordable Care Act includes provisions of importance to our potential product candidates that: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">created an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic products, apportioned among these entities according to their market share in certain government healthcare programs; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#8217;s Medicaid rebate liability; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">expanded manufacturers&#8217; rebate liability under the Medicaid Drug Rebate Program by increasing the minimum rebate for both branded and generic drugs and revising the definition of &#8220;average manufacturer price,&#8221; or AMP, for calculating and reporting Medicaid drug rebates on outpatient prescription drug prices; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">expanded the types of entities eligible for the 340B drug discount program; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">established the Medicare Part D coverage gap discount program by requiring manufacturers to provide point-of-sale-discounts off the negotiated price of applicable brand drugs to eligible beneficiaries during their coverage gap period as a condition for the manufacturers&#8217; outpatient drugs to be covered under Medicare Part D; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research. </p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since its enactment, there have been numerous judicial, administrative, executive, and legislative challenges to certain aspects of the Affordable Care Act, and we expect there will be additional challenges and amendments to the Affordable Care Act in the future. For example, various portions of the Affordable Care Act are currently facing legal and constitutional challenges in the Fifth Circuit Court of Appeals and the United States Supreme Court. Additionally, the current administration has issued various Executive Orders which eliminated cost sharing subsidies and various provisions that would impose a fiscal burden on states or a cost, fee, tax, penalty or regulatory burden on individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices, and Congress has introduced several pieces of legislation aimed at significantly revising or repealing the Affordable Care Act. It is unclear whether the Affordable Care Act will be overturned, repealed, replaced, or further amended. We cannot predict what effect further changes to the Affordable Care Act would have on our business. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other legislative changes have been proposed and adopted in the United States since the Affordable Care Act was enacted. In August 2011, the Budget Control Act of 2011, among other things, included aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went into effect in April 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030 unless additional Congressional action is taken. The Coronavirus Aid, Relief and Economic Security Act, or CARES Act, which was signed into law in March 2020 and is designed to provide financial support and resources to individuals and businesses affected by the COVID-19 pandemic, suspended these reductions from May&#160;1, 2020 through December&#160;31, 2020. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, including bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their commercial products, which has resulted in several Congressional inquiries and proposed and enacted state and federal legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products. For example, at the federal level, the current administration&#8217;s budgets for fiscal years 2019 and 2020 contained further drug price control measures that could be enacted in future legislation, including, for example, measures to permit Medicare Part D plans to negotiate the price of certain drugs under Medicare Part B, to allow some states to negotiate drug prices under Medicaid, and to eliminate cost sharing for generic drugs for low-income patients. Additionally, the current administration released a &#8220;Blueprint&#8221; to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out of pocket costs of drug products paid by consumers. The U.S. Department of Health and Human Services has already started the process of soliciting feedback on some of these measures and, at the same time, is immediately implementing others under its existing authority. For example, in May 2019, CMS issued a final rule to allow Medicare Advantage Plans the option of using step therapy, a type of prior authorization, for Part B drugs beginning January&#160;1, 2020. This final rule codified CMS&#8217;s policy change that was effective January&#160;1, 2019. Although a number of these and other measures may require additional authorization to become effective, Congress and the current administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. Additionally,</font><font style="font-size:11pt;font-family:Calibri;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n the United States, the Medicare Modernization Act, or MMA, contains provisions that call for the promulgation of regulations that expand pharmacists&#8217; and wholesalers&#8217; ability to import cheaper versions of an approved drug and competing products from Canada, where there are government price controls. Further, the MMA provides that these changes to U.S. importation laws will not take effect,&#160;unless and until the Secretary of the HHS certifies that the changes will pose no additional risk to the public&#8217;s health and safety and will result in a significant reduction in the cost of products to consumers. On September 23, 2020, the Secretary of the HHS made such certification to Congress, and on October 1, 2020, FDA published a final rule that allows for the importation of certain prescription drugs from Canada. Under the final rule, States and Indian Tribes, and in certain future circumstances pharmacists and wholesalers, may submit importation program proposals to the FDA for review and authorization. Since the issuance of the final rule, several industry groups have filed federal lawsuits challenging multiple aspects of the final rule, and authorities in Canada have passed rules designed to safeguard the Canadian drug supply from shortages.&#160;On September 25, 2020, CMS stated drugs imported by States under this rule will not be eligible for federal rebates under Section 1927 of the Social Security Act and manufacturers would not report these drugs for &#8220;best price&#8221; or Average Manufacturer Price purposes. Since these drugs are not considered covered outpatient drugs, CMS further stated it will not publish a National Average Drug Acquisition Cost for these drugs. Separately, the FDA also issued a final guidance document outlining a pathway for manufacturers to obtain an additional National Drug Code, or NDC, for an FDA-approved drug that was originally intended to be marketed in a foreign country and that was authorized for sale in that foreign country. The market implications of the final rule and guidance are unknown at this time. Proponents of drug reimportation may attempt to pass legislation that would directly allow reimportation under certain circumstances. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May&#160;30, 2018, the Right to Try Act was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a drug manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outside the United States, ensuring coverage and adequate payment for a product also involves challenges. Pricing of prescription pharmaceuticals is subject to government control in many countries. Pricing negotiations with government authorities can extend well beyond the receipt of regulatory approval for a product and may require a clinical trial that compares the cost-effectiveness of a product to other available therapies. The conduct of such a clinical trial could be expensive and result in delays in commercialization. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed upon. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies or so-called health technology assessments, in order to obtain reimbursement or pricing approval. For example, the European Union provides options for its member states to restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. European Union member states may approve a specific price for a product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other member states allow companies to fix their own prices for products, but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many countries in the European Union have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to manage healthcare expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the European Union. The downward pressure on healthcare costs in general, particularly prescription products, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European Union member states, and parallel trade, i.e., arbitrage between low-priced and high-priced member states, can further reduce prices. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any products, if approved in those countries. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:6.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Compliance with other federal and state laws or requirements; changing legal requirements </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any products that we may develop are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. Products must meet applicable child-resistant packaging requirements under the U.S. Poison Prevention Packaging Act. Manufacturing, labeling, packaging, distribution, sales, promotion and other activities also are potentially subject to federal and state consumer protection and unfair competition laws, among other requirements to which we may be subject. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive recordkeeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The failure to comply with any of these laws or regulatory requirements may subject firms to legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in criminal prosecution, fines or other penalties, injunctions, exclusion from federal healthcare programs, requests for recall, seizure of products, total or partial suspension of production, denial or withdrawal of product approvals, relabeling or repackaging, or refusal to allow a firm to enter into supply contracts, including government contracts. Any claim or action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. Prohibitions or restrictions on marketing, sales or withdrawal of future products marketed by us could materially affect our business in an adverse way. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: (i)&#160;changes to our manufacturing arrangements; (ii)&#160;additions or modifications to product labeling or packaging; (iii)&#160;the recall or discontinuation of our products; or (iv)&#160;additional recordkeeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:6.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other U.S. environmental, health and safety laws and regulations </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may be subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, our operations may involve the use of hazardous and flammable materials, including chemicals and biological materials, and may also produce hazardous waste products. Even if we contract with third parties for the disposal of these materials and waste products, we cannot completely eliminate the risk of contamination or injury resulting from these materials. In the event of contamination or injury resulting from the use or disposal of our hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees, but this insurance may not provide adequate coverage against potential liabilities. However, we do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. Current or future environmental laws and regulations may impair our research, development or production efforts. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions. </font></p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Government Regulation of Drugs Outside of the United States</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To market any product outside of the U.S., we would need to comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy and governing, among other things, clinical trials, marketing authorization or identification of an alternate regulatory pathway, manufacturing, commercial sales and distribution of our products. For instance, in the United Kingdom and the European Economic Area, or the EEA (comprised of the 27 EU Member States plus Iceland, Liechtenstein and Norway), medicinal products must be authorized for marketing by using either the centralized authorization procedure or national authorization procedures.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;color:#000000;">Centralized procedure</font><font style="color:#000000;">&#8212;If pursuing marketing authorization of a product candidate for a therapeutic indication under the centralized procedure, following the opining of the European Medicines Agency&#8217;s Committee for Medicinal Products for Human Use, or, CHMP, the European Commission issues a single marketing authorization valid across the EEA. The centralized procedure is compulsory for human medicines derived from biotechnology processes or advanced therapy medicinal products (such as gene therapy, somatic cell therapy and tissue engineered products), products that contain a new active substance indicated for the treatment of certain diseases, such as HIV/AIDS, cancer, neurodegenerative disorders, diabetes, autoimmune diseases and other immune dysfunctions, viral diseases, and officially designated orphan medicines. For medicines that do not fall within these categories, an applicant has the option of submitting an application for a centralized marketing authorization to the European Medicines Agency, or EMA, as long as the medicine concerned contains a new active substance not yet authorized in the EEA, is a significant therapeutic, scientific or technical innovation, or if its authorization would be in the interest of public health in the EEA. Under the centralized procedure the maximum timeframe for the evaluation of an MAA by the EMA is 210 days, excluding clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP. Accelerated assessment might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of a major public health interest, particularly from the point of view of therapeutic innovation. The timeframe for the evaluation of an MAA under the accelerated assessment procedure is 150 days, excluding clock stops.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;color:#000000;">National authorization procedures</font><font style="color:#000000;">&#8212;There are also two other possible routes to authorize products for therapeutic indications in several countries, which are available for products that fall outside the scope of the centralized procedure:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.07%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;color:#000000;">Decentralized procedure</font><font style="color:#000000;">&#8212;Using the decentralized procedure, an applicant may apply for simultaneous authorization in more than one EU country of medicinal products that have not yet been authorized in any EU country and that do not fall within the mandatory scope of the centralized procedure.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.07%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;color:#000000;">Mutual recognition procedure</font><font style="color:#000000;">&#8212;In the mutual recognition procedure, a medicine is first authorized in one EU Member State, in accordance with the national procedures of that country. Following this, additional marketing authorizations can be sought from other EU countries in a procedure whereby the countries concerned recognize the validity of the original, national marketing authorization.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the EEA, new products for therapeutic indications that are authorized for marketing (i.e., reference products) qualify for eight years of data exclusivity and an additional two years of market exclusivity upon marketing authorization. The data exclusivity period prevents generic or biosimilar applicants from relying on the preclinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar marketing authorization in the EU during a period of eight years from the date on which the reference product was first authorized in the EU. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until ten years have elapsed from the initial authorization of the reference product in the EU. The ten-year market exclusivity period can be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The criteria for designating an &#8220;orphan medicinal product&#8221; in the EEA are similar in principle to those in the U.S. In the EEA a medicinal product may be designated as orphan if (1)&#160;it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition; (2)&#160;either (a)&#160;such condition affects no more than five in 10,000 persons in the EU when the application is made, or (b)&#160;the product, without the benefits derived from orphan status, would not generate sufficient return in the EU to justify investment; and (3)&#160;there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the EU, or if such a method exists, the product will be of significant benefit to those affected by the condition. Orphan medicinal products are eligible for financial incentives such as reduction of fees or fee waivers and are, upon grant of a marketing authorization, entitled to ten years of market exclusivity for the approved therapeutic indication. During this ten-year orphan market exclusivity period, no marketing authorization application shall be accepted, and no marketing authorization shall be granted for a similar medicinal product for the same indication. An orphan product can also obtain an additional two years of market exclusivity in the EU for pediatric studies. The ten-year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity. Additionally, marketing authorization may be granted to a similar product for the same indication at any time if (</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)&#160;the second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically superior; (ii)&#160;the applicant consents to a second orphan medicinal product application; or (iii)&#160;the applicant cannot supply enough orphan medicinal product.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Similar to as in the U.S., the various phases of non-clinical and clinical research in the European Union are subject to significant regulatory controls.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Clinical Trials Directive 2001/20/EC, the Directive 2005/28/EC on GCP and the related national implementing provisions of the individual EU Member States govern the system for the approval of clinical trials in the European Union. Under this system, an applicant must obtain prior approval from the competent national authority of the EU Member States in which the clinical trial is to be conducted. Furthermore, the applicant may only start a clinical trial at a specific trial site after the competent ethics committee has issued a favorable opinion. The clinical trial application must be accompanied by, among other documents, an investigational medicinal product dossier (the Common Technical Document) with supporting information prescribed by Directive 2001/20/EC, Directive 2005/28/EC, where relevant the implementing national provisions of the individual EU Member States and further detailed in applicable guidance documents.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2014, the new Clinical Trials Regulation, (EU) No 536/2014 (Clinical Trials Regulation) was adopted. It is expected that the new Clinical Trials Regulation (EU) No 536/2014 will apply following confirmation of full functionality of the Clinical Trials Information System, or CTIS, the centralized European Union portal and database for clinical trials foreseen by the regulation, through an independent audit. The regulation becomes applicable six months after the European Commission publishes notice of this confirmation. The Clinical Trials Regulation will be directly applicable in all the EU Member States, repealing the current Clinical Trials Directive 2001/20/EC. Conduct of all clinical trials performed in the European Union will continue to be bound by currently applicable provisions until the new Clinical Trials Regulation becomes applicable. The extent to which ongoing clinical trials will be governed by the Clinical Trials Regulation will depend on when the Clinical Trials Regulation becomes applicable and on the duration of the individual clinical trial. If a clinical trial continues for more than three years from the day on which the Clinical Trials Regulation becomes applicable the Clinical Trials Regulation will at that time begin to apply to the clinical trial. The new Clinical Trials Regulation aims to simplify and streamline the approval of clinical trials in the European Union.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The main characteristics of the regulation include: a streamlined application procedure via a single-entry point, the &#8220;EU portal&#8221;; a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures for clinical trial sponsors; and a harmonized procedure for the assessment of applications for clinical trials, which is divided in two parts. Part I is assessed by the competent authorities of all EU Member States in which an application for authorization of a clinical trial has been submitted (Member States concerned). Part II is assessed separately by each Member State concerned. Strict deadlines have been established for the assessment of clinical trial applications. The role of the relevant ethics committees in the assessment procedure will continue to be governed by the national law of the concerned EU Member State. However, overall related timelines will be defined by the Clinical Trials Regulation.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Government regulation of data collection outside of the United States </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event we conduct clinical trials in the European Union, we will be subject to additional privacy restrictions. The collection and use of personal health data in the European Economic Area, or EEA (being the European Union plus Norway, Iceland, and Liechtenstein), is governed by the General Data Protection Regulation, or the GDPR, which became effective on May&#160;25, 2018. The GDPR applies to the processing of personal data by any company established in the EEA and to companies established outside the EEA to the extent they process personal data in connection with the offering of goods or services to data subjects in the EEA or the monitoring of the behavior of data subjects in the EEA. The GDPR enhances data protection obligations for data controllers of personal data, including stringent requirements relating to the consent of data subjects, expanded disclosures about how personal data is used, requirements to conduct privacy impact assessments for &#8220;high risk&#8221; processing, limitations on retention of personal data, mandatory data breach notification and &#8220;privacy by design&#8221; requirements, and creates direct obligations on service providers acting as processors. The GDPR also imposes strict rules on the transfer of personal data outside of the EEA to countries that do not ensure an adequate level of protection, like the United States (which, while deemed a third country, has the benefit of the Privacy Shield regime for transatlantic data transfers). Failure to comply with the requirements of the GDPR and the related national data protection laws of the European Union Member States and Norway, Iceland and Liechtenstein, which may deviate slightly from the GDPR, may result in fines of up to 4% of a company&#8217;s global revenues for the preceding financial year, or &#8364;20,000,000, whichever is greater. Moreover, the GDPR grants data subjects the right to claim material and non-material damages resulting from infringement of the GDPR. Given the breadth and depth of changes in data protection obligations, maintaining compliance with the GDPR will require significant time, resources and expense, and we may be required to put in place additional controls and processes ensuring compliance with the new data protection rules. There has been limited enforcement of the GDPR to date, particularly in biopharmaceutical development, so we face uncertainty as to the exact interpretation of the new requirements on any future trials and we may be unsuccessful in implementing all measures required by data protection authorities or courts in interpretation of the new law. Further, the United Kingdom&#8217;s decision to leave the European Union, often referred to as Brexit, has created uncertainty with regard to data protection regulation in the United Kingdom. In particular, it is unclear how data transfers to and from the United Kingdom will be regulated now that the United Kingdom has left the European Union. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is significant uncertainty related to the manner in which data protection authorities will seek to enforce compliance with GDPR. For example, it is not clear if the authorities will conduct random audits of companies doing business in the EU, or if the authorities will wait for complaints to be filed by individuals who claim their rights have been violated. Enforcement uncertainty and the costs associated with ensuring GDPR compliance are onerous and may adversely affect our business, financial condition, results of operations and prospects. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Should we utilize third party distributors, compliance with such foreign governmental regulations would generally be the responsibility of such distributors, who may be independent contractors over whom we have limited control. </p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Brexit and the Regulatory Framework in the United Kingdom</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the electorate in the United Kingdom voted in favor of leaving the European Union (commonly referred to as &#8220;Brexit&#8221;). Thereafter, in March 2017, the country formally notified the European Union of its intention to withdraw pursuant to Article 50 of the Lisbon Treaty. The United Kingdom formally left the European Union on January&#160;31, 2020. A transition period began on February&#160;1, 2020, during which European Union pharmaceutical law remains applicable to the United Kingdom. This transition period is due to end on December&#160;31, 2020. Since the regulatory framework for pharmaceutical products in the United Kingdom covering quality, safety and efficacy of pharmaceutical products, clinical trials, marketing authorization, commercial sales and distribution of pharmaceutical products is derived from European Union directives and regulations, Brexit could materially impact the future regulatory regime which applies to products and the approval of product candidates in the United Kingdom. It remains to be seen how, if at all, Brexit will impact regulatory requirements for product candidates and products in the United Kingdom.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Employees and Human Capital</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, we had 75 full-time employees, of which 46 have M.D. or Ph.D. degrees. Within our workforce, 54 employees are engaged in research and development and 21 are engaged in business development, finance, legal, and general management and administration.<font style="color:#000000;"> We consider the intellectual capital of our employees to be an essential driver of our business and key to our future prospects. Our workforce expanded during FY20; new employees were hired to support and extend our clinical and preclinical pipeline, with hires in commercial, clinical development and operations, research, manufacturing, and general and administrative functions. We expect to continue to add additional employees in 2021 with a focus on expanding increasing expertise and bandwidth in clinical and preclinical research and development.&#160;&#160;The Company continually evaluates the business need and opportunity and balances in house expertise and capacity with outsourced expertise and capacity.&#160;&#160;Currently, the Company outsources substantial all clinical trial work to clinical research organizations and certain drug manufacturing to contract manufacturers. Drug development is a complex endeavor which requires deep expertise and experience across a broad array of disciplines.&#160;&#160;Pharmaceutical companies both large and small compete for a limited number qualified applicants to fill specialized positions.&#160;&#160;We monitor our compensation programs closely and provide what we consider to be a very competitive mix of compensation and insurance benefits for all our employees, as well as participation in our equity programs. To attract qualified applicants, the Company offers a total rewards package consisting of base salary and cash target bonus, a comprehensive benefit package and equity compensation for every employee.&#160;&#160;Bonus opportunity and equity compensation increase as a percentage of total compensation based on level of responsibility.&#160;&#160;Actual bonus payout is based on performance.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:3.03%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:3.03%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None of our employees is subject to a collective bargaining agreement or represented by a trade or labor union. We consider our relations with our employees to be good.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:3.03%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We support our employees&#8217; further development with individualized development plans, mentoring, coaching, group training, conference attendance and financial support including tuition reimbursement.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:3.03%;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:3.03%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Response to COVID-19</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:3.03%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning in March 2020, we have supported our employees and government efforts to curb the COVID-19 pandemic through a multifaceted communication, infrastructure, and behavior modification and enforcement effort:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:3.03%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Establishing clear and regular COVID-19 policies, safety protocols, and updates to all employees;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Decrease <font style="color:#000000;">density and increasing physical distancing in workspaces for employees working onsite by scheduling adjustments and adding work from home flexibility&#894;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Adjusting attendance policies to encourage those who are sick to stay home&#894;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Increasing cleaning protocols at our Watertown, MA headquarters&#894;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Providing additional personal protective equipment and cleaning supplies&#894;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Implemented weekly COVID-19 testing;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Implementing protocols to address actual and suspected COVID-19 cases and potential exposure&#894;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Prohibiting all domestic and international non-essential travel for all employees&#894;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Requiring masks to be worn in all locations; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Established a subsidy to support employees during COVID-19</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Facilities</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our corporate headquarters are located in Watertown, Massachusetts, where we lease and occupy approximately 34,522 square feet of office and laboratory space. The current term of our Watertown lease expires March&#160;31, 2030, with an option to extend the term five additional years with 12 months&#8217; notice with rent set at an agreed upon market rate.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our existing facilities are sufficient to meet our current needs. To meet the future needs of our business, we may lease additional or alternate space, and we believe suitable additional or alternative space will be available in the future on commercially reasonable terms.</p><a name="_AEIOULastRenderedPageBreakAEIOU4"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1A_RISK_FACTORS"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1A_RISK_FACTORS"></a>Item 1A. Ris</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">k Factors. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Our business involves a high degree of risk. You should carefully consider the material and other risks and uncertainties described and summarized below, as well as the other information in this Annual Report on Form 10-K, including our consolidated financial statements and related notes and the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and &#8220;Special Note Regarding Forward-Looking Statements,&#8221; before you make an investment decision. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of factors that are described below and elsewhere in this Annual Report on Form 10-K. The risks described below are not the only risks that we face. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations and prospects. As a result, the market price of our common stock could decline, and you may lose all or part of your investment in our common stock. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Financial Position and Need for Additional Capital </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are a biopharmaceutical company with a limited operating history and have not generated any revenue to date from drug sales, and may never become profitable. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biopharmaceutical drug development is a highly speculative undertaking and involves a substantial degree of risk. Since our formation in 2015 and our initial funding in 2016, our operations to date have been limited primarily to organizing and staffing our company, business planning, raising capital, researching and developing our drug discovery technology, developing our pipeline, building our intellectual property portfolio, undertaking preclinical studies of our product candidates and initiating a Phase 1 first-in-human clinical trial of KT-474, a highly active and selective, orally bioavailable IRAK4 degrader. We have never generated any revenue from drug sales. We have not obtained regulatory approvals for any of our current or future product candidates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Typically, it takes many years to develop one new pharmaceutical drug from the time it is discovered to when it is available for treating patients. Consequently, any predictions we make about our future success or viability may not be as accurate as they could be if we had a longer operating history. In addition, as a business with a limited operating history, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors, such as the COVID-19 pandemic. We will need to transition from a company with a research and development focus to a company capable of supporting late-stage development and commercial activities. We may not be successful in such a transition. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have incurred significant operating losses since our inception and anticipate that we will incur continued losses for the foreseeable future. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since inception, we have focused substantially all of our efforts and financial resources on developing our proprietary targeted protein degradation drug discovery platform, or the Pegasus platform, and initial product candidates as well as supporting our collaborations and partnerships. To date, we have financed our operations primarily through the issuance and sale of our convertible preferred stock to outside investors and collaborators in private equity financings, upfront payments under our existing collaborations and our initial public offering. From our inception through December 31, 2020, we raised an aggregate of $617.8&#160;million of gross proceeds from such transactions and through our collaborations with Genzyme Corporation, or Sanofi and Vertex Pharmaceuticals Incorporated, or Vertex. As of December 31, 2020, our cash and cash equivalents and investments were $458.7&#160;million. We have incurred net losses in each year since our inception, and we had an accumulated deficit of $128.8&#160;million as of December 31, 2020. For the years ended December&#160;31, 2020 and 2019, we reported net losses of $45.6 million and $41.2 million, respectively. Substantially all of our operating losses have resulted from costs incurred in connection with our research and development programs and from general and administrative costs associated with our operations. We expect to continue to incur significant expenses and increasing operating losses over the next several years and for the foreseeable future. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders&#8217; deficit and working capital. We expect our expenses to significantly increase in connection with our ongoing activities, as we: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">initiate and complete clinical trials for current or future product candidates, including the ongoing Phase 1 trial of KT-474; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">prepare and submit Investigational New Drug applications, or INDs, with the U.S. Food and Drug Administration, or FDA, for KT-413,</font><font style="color:#000000;"> </font><font style="font-size:10pt;color:#000000;">a highly active and selective, IRAKIMiD degrader and other current and future product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">prepare and submit Investigational New Drug applications, or INDs, with the U.S. Food and Drug Administration, or FDA, for KT-333,</font><font style="color:#000000;"> </font><font style="font-size:10pt;color:#000000;">a highly active and selective STAT3 degrader and other current and future product candidates;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">develop and scale up our capabilities to support our ongoing preclinical activities and clinical trials for our product candidates</font><font style="font-size:10pt;color:#000000;"> and commercialization of any of our product candidates for which we may obtain marketing approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">secure facilities to support continued growth in our research, development and commercialization efforts;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">advance research and development related activities to expand our product pipeline; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">expand and improve the capabilities of our Pegasus platform; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">seek regulatory approval for our product candidates that successfully complete clinical development; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">contract to manufacture our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">maintain, expand and protect our intellectual property portfolio; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">hire additional staff, including clinical, scientific and management personnel; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">incur additional costs associated with continuing to operate as a public company. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, if we obtain marketing approval for our current or future product candidates, we will incur significant expenses relating to sales, marketing, product manufacturing and distribution. Because of the numerous risks and uncertainties associated with developing pharmaceutical drugs, including in light of the ongoing evolution of the COVID-19 pandemic, we are unable to predict the extent of any future losses or when we will become profitable, if at all. Even if we do become profitable, we may not be able to sustain or increase our profitability on a quarterly or annual basis. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Risks Related to Future Financial Condition</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We will need to raise substantial additional funding. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, scale back or discontinue some of our product candidate development programs or future commercialization efforts. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The development of pharmaceutical drugs is capital-intensive. We are currently advancing multiple development candidates through preclinical development across a number of potential indications and, in the first quarter of 2021, commenced clinical development of KT-474. We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we continue the research and development of, advance the preclinical and clinical activities of, and seek marketing approval for, our current or future product candidates. In addition, if we obtain marketing approval for any of our current or future product candidates, we expect to incur significant commercialization expenses related to sales, marketing, product manufacturing and distribution to the extent that such sales, marketing, product manufacturing and distribution are not the responsibility of our collaborators. We may also need to raise additional funds sooner if we choose to pursue additional indications and/or geographies for our current or future product candidates or otherwise expand more rapidly than we presently anticipate. Furthermore, we expect to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, scale back or discontinue the development and commercialization of one or more of our product candidates, and may be unable to expand our operations or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition and results of operations. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, we had approximately $458.7 million of cash and cash equivalents and investments. On August 25, 2020, we completed an initial public offering of our common stock by issuing 9,987,520 shares of our common stock, including the exercise in full by the underwriters of their option to purchase up to 1,302,720 additional shares of common stock, at a public offering price of $20.00 per share. The aggregate gross proceeds to the Company from the offering, before deducting underwriting discounts and commissions, and other estimated offering expenses payable by the Company, were approximately $199.8 million. Concurrent with the initial public offering, the Company announced the sale of 676,354 common shares at the public offering price per share in a private placement to Vertex. The aggregate gross proceeds to the Company from the concurrent private placement were approximately $13.5 million. The concurrent private placement also closed on August 25, 2020. We expect that the approximately $458.7 million of cash and cash equivalents and investments at December 31, 2020 will be sufficient to fund our operations into 2025. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. This estimate also assumes that we do not obtain any additional funding through collaborations or other strategic alliances. Our future capital requirements will depend on, and could increase significantly as a result of, many factors, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the scope, progress, results and costs of drug discovery, preclinical development, laboratory testing and clinical trials for our current or future product candidates, including additional expenses attributable to adjusting our development plans (including any supply related matters) in response to the COVID-19 pandemic; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the scope, prioritization and number of our research and development programs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the costs, timing and outcome of regulatory review of our current or future product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our ability to establish and maintain additional collaborations on favorable terms, if at all; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the achievement of milestones or occurrence of other developments that trigger payments under any existing or additional collaboration agreements we obtain; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the extent to which we are obligated to reimburse, or entitled to reimbursement of, clinical trial costs under future collaboration agreements, if any; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the extent to which we acquire or in-license other current or future product candidates and technologies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the costs of securing manufacturing arrangements for commercial production; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the costs of establishing or contracting for sales and marketing capabilities if we obtain regulatory clearances to market our current or future product candidates. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Identifying potential current or future product candidates and conducting preclinical studies and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve drug sales. In addition, our current or future product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of drugs that we do not expect to be commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional funding to achieve our business objectives. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our current or future product candidates. Disruptions in the financial markets in general may make equity and debt financing more difficult to obtain and may have a material adverse effect on our ability to meet our fundraising needs. We cannot guarantee that future financing will be available in sufficient amounts or on terms favorable to us, if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of our stockholders and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our shares to decline. The sale of additional equity or convertible securities would dilute all of our stockholders. The incurrence of indebtedness would result in increased fixed payment obligations and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. We could also be required to seek funds through arrangements with collaborators or otherwise at an earlier stage than otherwise would be desirable and we may be required to relinquish rights to some of our technologies or current or future product candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We will continue to incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a public company, we will continue to incur significant legal, accounting and other expenses that we did not incur as a private company. We are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which require, among other things, that we file with the Securities and Exchange Commission, or the SEC, annual quarterly and current reports with respect to our business and financial condition. In addition, the Sarbanes-Oxley Act of 2002, as amended, or Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and The Nasdaq Global Market to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, in July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, was enacted. There are significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas, such as &#8220;say on pay&#8221; and proxy access. Emerging growth companies may implement many of these requirements over a longer period and up to five years from the pricing of our initial public offering. We intend to take advantage of these extended transition periods, but cannot guarantee that we will not be required to implement these requirements sooner than budgeted or planned and thereby incur unexpected expenses. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The rules and regulations applicable to public companies substantially increase our legal and financial compliance costs and make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition and results of operations. The increased costs will decrease our net income or increase our net loss and may require us to reduce costs in other areas of our business or increase the prices of our products or services. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain the same or similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Drug Development and Regulatory Approval </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Risks Related to Preclinical and Clinical Development</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are very early in our development efforts. All of our product candidates are in preclinical or early clinical development. If we are unable to commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to become profitable depends upon our ability to generate revenue. To date, while we have generated collaboration revenue, we have not generated any revenue from our product candidates, and we do not expect to generate any revenue from the sale of drugs in the near future. We do not expect to generate revenue from product sales unless and until we complete the development of, obtain marketing approval for, and begin to sell, one or more of our product candidates. We are also unable to predict when, if ever, we will be able to generate revenue from such product candidates due to the numerous risks and uncertainties associated with drug development, including the uncertainty of: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the results of the single ascending dose, or SAD, portion of the Phase 1 trial of KT-474 in healthy volunteers; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our plans to initiate enrollment of the multiple ascending dose, or MAD, portion of the Phase 1 trial of KT-474, which is currently on partial clinical hold pending FDA review and clearance of interim data from the SAD portion of the trial, in healthy volunteers in the second half of 2021;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">submitting INDs to the FDA for KT-413, KT-333 and other current or future product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our successful initiation, enrollment of and completion of clinical trials for other current and future product candidates, including our ability to generate positive data from any such clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our ability to receive regulatory approvals from applicable regulatory authorities; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the initiation and successful completion of all safety studies required to obtain U.S. and foreign marketing approval for our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the costs associated with the development of any additional development programs we identify in-house or acquire through collaborations or other arrangements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our ability to establish manufacturing capabilities or make arrangements with third-party manufacturers for clinical supply and commercial manufacturing; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">obtaining and maintaining patent and trade secret protection or regulatory exclusivity for our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">launching commercial sales of our product candidates, if and when approved, whether alone or in collaboration with others; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">obtaining and maintaining acceptance of our product candidates, if and when approved, by patients, the medical community and third-party payors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">effectively competing with other therapies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">obtaining and maintaining healthcare coverage and adequate reimbursement; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the success of our existing collaborations as well as the terms and timing of any additional collaboration, license or other arrangement, including the terms and timing of any payments thereunder; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our ability to enforce and defend intellectual property rights and claims; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our ability maintain a continued acceptable safety profile of our product candidates following approval. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to incur significant sales and marketing costs as we prepare to commercialize our current or future product candidates. Even if we initiate and successfully complete pivotal or registration-enabling clinical trials of our current or future product candidates, and our current or future product candidates are approved for commercial sale, and despite expending these costs, our current or future product candidates may not be commercially successful. We may not achieve profitability soon after generating drug sales, if ever. If we are unable to generate revenue, we will not become profitable and may be unable to continue operations without continued funding.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our approach to the discovery and development of product candidates based on our Pegasus platform is novel and unproven, which makes it difficult to predict the time, cost of development and likelihood of successfully developing any products. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Pegasus platform utilizes a method known as targeted protein degradation, or TPD, to discover and develop product candidates. Our future success depends on the successful development of this novel therapeutic approach. No product candidates using TPD have been approved in the United States or Europe, and the data underlying the feasibility of developing such therapeutic products is both preliminary and limited. In addition, we have not yet succeeded and may not succeed in demonstrating the efficacy and safety of any of our product candidates in clinical trials or in obtaining marketing approval thereafter. In particular, our ability to successfully achieve TPD with a therapeutic result requires the successful development of heterobifunctional molecules that were intentionally designed with a rational drug development process and developing those molecules with the right combination of protein targets and E3 ligases. This is a complex process requiring a number of component parts or biological mechanisms to work in unison to achieve the desired effect. We cannot be certain that we will be able to discover degraders by matching the right target with the ideal E3 ligase and the right linker in a timely manner, or at all. We have recently initiated a first-in-human Phase 1 clinical trial of KT-474, but we have not yet assessed safety of any other product candidates in humans. As such, there may be adverse effects from treatment with any of our current or future product candidates that we cannot predict at this time. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of these factors, it is more difficult for us to predict the time and cost of product candidate development, and we cannot predict whether the application of our Pegasus platform, or any similar or competitive platforms, will result in the development and marketing approval of any products. Any development problems we experience in the future related to our Pegasus platform or any of our research programs may cause significant delays or unanticipated costs or may prevent the development of a commercially viable product. Any of these factors may prevent us from completing our preclinical studies and clinical trials or commercializing any product candidates we may develop on a timely or profitable basis, if at all. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may not be successful in our efforts to identify or discover additional product candidates or we may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A key element of our strategy is to apply our Pegasus platform and product pipeline to address a broad array of targets and new therapeutic areas. The therapeutic discovery activities that we are conducting may not be successful in identifying product candidates that are useful in treating oncology, inflammation, immunology or genetic diseases. Our research programs may be unsuccessful in identifying potential product candidates, or our potential product candidates may be shown to have harmful side effects or may have other characteristics that may make the products unmarketable or unlikely to receive marketing approval. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because we have limited financial and management resources, we focus on a limited number of research programs and product candidates. We are currently focused on our three most advanced development programs IRAK4, IRAKIMiD, and STAT3, which target key signaling pathways implicated in multiple inflammatory and autoimmune diseases as well as numerous cancers. As a result, we may forego or delay pursuit of opportunities with other current or future product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial drugs or profitable market opportunities. Our spending on current and future research and development programs and current or future product candidates for specific indications may not yield any commercially viable drugs. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through future collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We depend heavily on the successful development of our lead programs. We cannot be certain that we will be able to obtain regulatory approval for, or successfully commercialize, any of our current or future product candidates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently have no product candidates approved for sale and may never be able to develop marketable product candidates. Our business depends heavily on the successful development, regulatory approval and commercialization of our current or future product candidates, including our IRAK4, IRAKIMiD, and STAT3 programs. The preclinical studies and clinical trials of our current or future product candidates are, and the manufacturing and marketing of our current or future product candidates will be, subject to extensive and rigorous review and regulation by numerous government authorities in the U.S. and in other countries where we intend to test or, if approved, market any of our current or future product candidates. Before obtaining regulatory approvals for the commercial sale of any of our current or future product candidates, we must demonstrate through preclinical studies and clinical trials that each product candidate is safe and effective for use in each target indication. Drug development is a long, expensive and uncertain process, and delay or failure can occur at any stage of any of our preclinical studies and clinical trials. This process can take many years and may include post-marketing studies and surveillance, which will require the expenditure of substantial resources. Of the large number of drugs in development in the U.S., only a small percentage will successfully complete the FDA regulatory approval process and will be commercialized, with similarly low rates of success for drugs in development in the European Union obtaining regulatory approval from the European Medicines Agency, or EMA. Accordingly, even if we are able to obtain the requisite financing to continue to fund our development and preclinical studies and clinical trials, we cannot assure you that any of our current or future product candidates will be successfully developed or commercialized. For example, in December 2020, we submitted an IND application for KT-474 to initiate a first-in-human Phase 1 randomized, double-blind, placebo-controlled clinical trial in healthy volunteers and patients with hidradenitis suppurativa (HS) or atopic dermatitis (AD). We were notified by the FDA that we may initiate dosing of healthy volunteers in the SAD portion of the Phase 1 clinical trial and that the program is on partial clinical hold regarding the MAD portion of the Phase 1 trial, pending FDA review of interim data in healthy volunteers from the SAD portion of the trial. We cannot be certain that the FDA will lift the partial clinical hold on KT-474 for the MAD portion of the Phase 1 trial to proceed which could negatively impact the future clinical development of KT-474. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are not permitted to market our current or future product candidates in the U.S. until we receive approval of a New Drug Application, or an NDA, from the FDA, in the European Economic Area, or EEA, until we receive approval of a marketing authorization application, or an MAA, from the EMA, or in any other foreign countries until we receive the requisite approval from such countries. Obtaining approval of an NDA or MAA is a complex, lengthy, expensive and uncertain process, and the FDA or EMA may delay, limit or deny approval of any of our current or future product candidates for many reasons, including, among others: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">we may not be able to demonstrate that our current or future product candidates are safe and effective in treating their target indications to the satisfaction of the FDA or applicable foreign regulatory agency; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the results of our preclinical studies and clinical trials may not meet the level of statistical or clinical significance required by the FDA or applicable foreign regulatory agency for marketing approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the FDA or applicable foreign regulatory agency may disagree with the number, design, size, conduct or implementation of our preclinical studies and clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the FDA or applicable foreign regulatory agency may require that we conduct additional preclinical studies and clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the FDA or applicable foreign regulatory agency may not approve the formulation, labeling or specifications of any of our current or future product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the contract research organizations, or CROs, that we retain to conduct our preclinical studies and clinical trials may take actions outside of our control that materially adversely impact our preclinical studies and clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the FDA or applicable foreign regulatory agency may find the data from preclinical studies and clinical trials insufficient to demonstrate that our current or future product candidates&#8217; clinical and other benefits outweigh their safety risks; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the FDA or applicable foreign regulatory agency may disagree with our interpretation of data from our preclinical studies and clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the FDA or applicable foreign regulatory agency may not accept data generated at our preclinical studies and clinical trial sites; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">if our NDA, if and when submitted, is reviewed by an advisory committee, the FDA may have difficulties scheduling an advisory committee meeting in a timely manner or the advisory committee may recommend against approval of our application or may recommend that the FDA require, as a condition of approval, additional preclinical studies or clinical trials, limitations on approved labeling or distribution and use restrictions; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the FDA may require development of a Risk Evaluation and Mitigation Strategy, or REMS, as a condition of approval or post-approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the FDA or the applicable foreign regulatory agency may determine that the manufacturing processes or facilities of third-party manufacturers with which we contract do not conform to applicable requirements, including current Good Manufacturing Practices, or cGMPs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the FDA or applicable foreign regulatory agency may be delayed in its review processes due to staffing or other constraints arising from the COVID-19 pandemic; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the FDA or applicable foreign regulatory agency may change its approval policies or adopt new regulations. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these factors, many of which are beyond our control, could jeopardize our ability to obtain regulatory approval for and successfully market our current or future product candidates. Any such setback in our pursuit of regulatory approval would have a material adverse effect on our business and prospects. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we experience delays or difficulties in the initiation or enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There may be delays in trial initiation, and we may not be able to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside the U.S. In particular, our ability to open clinical sites and enroll patients may be significantly delayed by the evolving COVID-19 pandemic and we do not know the extent and scope of such delays at this point. Moreover, some of our competitors have ongoing clinical trials for current or future product candidates that treat the same patient populations as our current or future product candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; current or future product candidates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patient enrollment may be affected by other factors including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the size and nature of the patient population; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">competition with other companies for clinical sites or patients; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the willingness of participants to enroll in our clinical trials in our countries of interest; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the severity of the disease under investigation; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the eligibility criteria for the clinical trial in question; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the availability of an appropriate screening test for the indications we are pursuing; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the perceived risks and benefits of the product candidate under study; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the efforts to facilitate timely enrollment in and completion of clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the patient referral practices of physicians; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the ability to monitor patients adequately during and after treatment; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the proximity and availability of clinical trial sites for prospective patients; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">factors we may not be able to control, such as potential pandemics that may limit subjects, principal investigators or staff or clinical site availability (e.g., the outbreak of COVID-19). </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Interim, &#8220;topline,&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may publicly disclose preliminary or topline data from our preclinical studies and clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available. From time to time, we may also disclose interim data from our clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available or as patients from our clinical trials continue other treatments for their disease</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our common stock. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the interim, topline, or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, results of operations, prospects or financial condition. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The incidence and prevalence for target patient populations of our product candidates have not been established with precision. If the market opportunities for our product candidates are smaller than we estimate or if any approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability will be adversely affected, possibly materially. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The precise incidence and prevalence for the indications being pursued by our current and future product candidates are currently unknown. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, are based on estimates. We are developing KT-474 for the treatment of a broad set of immunology-inflammation diseases, such as HS, an inflammatory skin disease, AD, and rheumatoid arthritis. The total addressable market opportunity for our product candidates will ultimately depend upon, among other things, their proven safety and efficacy, the diagnosis criteria included in the final label for each, whether our product candidates are approved for sale for these indications, acceptance by the medical community and patient access, product pricing and reimbursement. The number of patients for our product candidates in the United States and elsewhere may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our products, or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">A pandemic, epidemic, or outbreak of an infectious disease, such as&#160;COVID-19, may materially and adversely affect our business and our financial results and could cause a disruption to the development of our product candidate.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Public health crises such as pandemics or similar outbreaks could adversely impact our business. In December 2019, a novel strain of a virus named SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), or coronavirus, which causes COVID-19, surfaced in Wuhan, China and has since spread worldwide, including to Eastern Massachusetts where our primary office and laboratory space is located. The coronavirus pandemic is evolving, and to date has led to the implementation of various responses, including government-imposed quarantines, travel restrictions and other public health safety measures. The extent to which the coronavirus impacts our operations or those of our third-party partners, including our preclinical studies or clinical trial operations, will also depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the outbreak, new information that will emerge concerning the severity of the coronavirus and the actions to contain the coronavirus or treat its impact, among others. The continued spread of&#160;COVID-19&#160;globally could adversely impact our preclinical or clinical trial operations in the U.S. and abroad, including our ability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to&#160;COVID-19.&#160;For example, similar to other biopharmaceutical companies, we may experience delays in enrolling the MAD portion of our Phase 1 clinical trial for KT-474, which is currently planned for the second half of 2021. COVID-19 may also affect employees of third-party CROs located in affected geographies that we rely upon to carry out our clinical trials. In addition, the patient populations that our lead and other core product candidates target may be particularly susceptible to COVID-19, which may make it more difficult for us to identify patients able to enroll in our clinical trials and may impact the ability of enrolled patients to complete any such trials. Any negative impact&#160;COVID-19&#160;has to patient enrollment or treatment or the execution of our product candidates could cause costly delays to clinical trial activities, which could adversely affect our ability to obtain regulatory approval for and to commercialize our product candidates, increase our operating expenses, and have a material adverse effect on our financial results. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, timely enrollment in clinical trials is dependent upon clinical trial sites which will be adversely affected by global health matters, such as pandemics. We are conducting and plan to conduct clinical trials for our product candidates in geographies which are currently being affected by the coronavirus. Some factors from the coronavirus outbreak that will delay or otherwise adversely affect enrollment in the clinical trials of our product candidates, as well as our business generally, include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the potential diversion of healthcare resources away from the conduct of clinical trials to focus on pandemic concerns, including the attention of physicians serving as our clinical trial investigators, hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our prospective clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">limitations on travel that could interrupt key trial and business activities, such as clinical trial site initiations and monitoring, domestic and international travel by employees, contractors or patients to clinical trial sites, including any government-imposed travel restrictions or quarantines that will impact the ability or willingness of patients, employees or contractors to travel to our clinical trial sites or secure visas or entry permissions, a loss of face-to-face meetings and other interactions with potential partners, any of which could delay or adversely impact the conduct or progress of our clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the potential negative affect on the operations of our third-party manufacturers and the supply chain for our product candidates. For example, in February 2020, one of our vendors for active pharmaceutical ingredient, or API, starting materials based in Wuhan, China ceased its operations for several weeks due to the COVID-19 pandemic, which caused a minor delay in the delivery of API starting materials to a separate vendor who manufactures API; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">interruptions in global shipping affecting the transport of clinical trial materials, such as patient samples, investigational drug product and conditioning drugs and other supplies used in our current and prospective clinical trials; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">business disruptions caused by potential workplace, laboratory and office closures and an increased reliance on employees working from home, disruptions to or delays in ongoing laboratory experiments and operations, staffing shortages, travel limitations or mass transit disruptions, any of which could adversely impact our business operations or delay necessary interactions with local regulators, ethics committees and other important agencies and contractors. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have taken temporary precautionary measures intended to help minimize the risk of the virus to our employees, including temporarily requiring part or all of our employees to work remotely, suspending all non-essential travel worldwide for our employees and discouraging employee attendance at industry events and in-person work-related meetings, which could negatively affect our business. We cannot presently predict the scope and severity of the planned and potential shutdowns or disruptions of businesses and government agencies, such as the SEC or FDA. For example, since March 2020, foreign and domestic inspections by the FDA have largely been on hold with the FDA announcing plans in July 2020 to resume prioritized domestic inspections. Regulatory authorities outside the U.S. may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic and may experience delays in their regulatory activities.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These and other factors arising from the coronavirus could worsen. Any of these factors, and other factors related to any such disruptions that are unforeseen, could have a material adverse effect on our business and our results of operations and financial condition. Further, uncertainty around these and related issues could lead to adverse effects on the economy of the United States and other economies, which could impact our ability to raise the necessary capital needed to develop and commercialize our product candidates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our current or future product candidates may cause adverse or other undesirable side effects that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have initiated a first-in-human Phase 1 clinical trial of KT-474, but have not evaluated any other product candidates in human clinical trials. Undesirable side effects caused by our current or future product candidates could cause us to interrupt, delay or halt preclinical studies or could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other regulatory authorities. As is the case with many treatments for inflammatory and autoimmune diseases, cancer or other diseases, it is likely that there may be adverse side effects associated with the use of our product candidates. Additionally, a potential risk in any protein degradation product is that healthy proteins or proteins not targeted for degradation will be degraded or that the degradation of the targeted protein in itself could cause adverse events, undesirable side effects, or unexpected characteristics. It is possible that healthy proteins or proteins not targeted for degradation could be degraded using our degrader molecules in any of our current or future clinical studies. There is also the potential risk of delayed adverse events following treatment using any of our current or future product candidates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These side effects could arise due to off-target activity, allergic reactions in trial subjects, or unwanted on-target effects in the body. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of these or other side effects. In such an event, our trials could be suspended or terminated and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our current or future product candidates for any or all targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, our current or future product candidates could cause undesirable side effects in clinical trials related to on-target toxicity. If on-target toxicity is observed, or if our current or future product candidates have characteristics that are unexpected, we may need to abandon their development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Many compounds that initially showed promise in early-stage testing for treating cancer or other diseases have later been found to cause side effects that prevented further development of the compound. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of patients and limited duration of exposure, rare and severe side effects of our current or future product candidates may only be uncovered with a significantly larger number of patients exposed to the product candidate. If our current or future product candidates receive marketing approval and we or others identify undesirable side effects caused by such current or future product candidates after such approval, a number of potentially significant negative consequences could result, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">regulatory authorities may withdraw or limit their approval of such current or future product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">regulatory authorities may require the addition of labeling statements, such as a &#8220;boxed&#8221; warning or a contraindication; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">we may be required to create a medication guide outlining the risks of such side effects for distribution to patients; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">we may be required to change the way such current or future product candidates are distributed or administered, conduct additional clinical trials or change the labeling of the current or future product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">regulatory authorities may require a REMS plan to mitigate risks, which could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">we may be subject to regulatory investigations and government enforcement actions; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">we may decide to remove such current or future product candidates from the marketplace; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">we could be sued and held liable for injury caused to individuals exposed to or taking our current or future product candidates; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our reputation may suffer. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that any of these events could prevent us from achieving or maintaining market acceptance of the affected product candidates and could substantially increase the costs of commercializing our current or future product candidates, if approved, and significantly impact our ability to successfully commercialize our current or future product candidates and generate revenues. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Positive results from early preclinical studies and clinical trials of our current or future product candidates are not necessarily predictive of the results of later preclinical studies and clinical trials of our current or future product candidates. If we cannot replicate the positive results from our preclinical studies of our current or future product candidates in our future clinical trials, we may be unable to successfully develop, obtain regulatory approval for and commercialize our current or future product candidates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Positive results from our preclinical studies of our current or future product candidates, and any positive results we may obtain from our early clinical trials of our current or future product candidates, may not necessarily be predictive of the results from required later preclinical studies and clinical trials. Similarly, even if we are able to complete our planned preclinical studies or clinical trials of our current or future product candidates according to our current development timeline, the positive results from such preclinical studies and clinical trials of our current or future product candidates may not be replicated in subsequent preclinical studies or clinical trials. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in early-stage development, and we cannot be certain that we will not face similar setbacks. These setbacks have been caused by, among other things, preclinical findings </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">made while clinical trials were underway or safety or efficacy observations made in preclinical studies and clinical trials, including previously unreported adverse events. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain approval from the FDA or comparable foreign regulatory authority. If we fail to produce positive results in our planned preclinical studies or clinical trials of any of our current or future product candidates, the development timeline and regulatory approval and commercialization prospects for our current or future product candidates, and, correspondingly, our business and financial prospects, would be materially adversely affected. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, our planned or future clinical trials may utilize an &#8220;open-label&#8221; trial design. An &#8220;open-label&#8221; clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing approved drug or placebo. Most typically, open-label clinical trials test only the investigational product candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a &#8220;patient bias&#8221; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. The results from an open-label trial may not be predictive of future clinical trial results with any of our product candidates for which we include an open-label clinical trial when studied in a controlled environment with a placebo or active control.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_Hlk62738662"></a>Manufacturing our current or future product candidates is complex and we may encounter difficulties in production. If we encounter such difficulties, our ability to provide supply of our current or future product candidates for preclinical studies and clinical trials or for commercial purposes could be delayed or stopped. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process of manufacturing our current or future product candidates is complex and highly regulated.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have our own manufacturing facilities or personnel and currently rely, and expect to continue to rely, on third parties for the manufacture of our current or future product candidates. These third-party manufacturing providers may not be able to provide adequate resources or capacity to meet our needs and may incorporate their own proprietary processes into our product candidate manufacturing processes. We have limited control and oversight of a third party&#8217;s proprietary process, and a third party may elect to modify its process without our consent or knowledge. These modifications, such as any impacting the product formulation, could negatively impact our manufacturing, including by resulting in product loss or failure that requires additional manufacturing runs or a change in manufacturer, either of which could significantly increase the cost of and significantly delay the manufacture of our current or future product candidates. Changes in manufacturers often involve changes in manufacturing procedures and processes, which could require that we conduct bridging studies between our prior clinical supply used in our clinical trials and that of any new manufacturer. We may be unsuccessful in demonstrating the comparability of clinical supplies which could require the conduct of additional clinical trials.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As our current or future product candidates progress through preclinical studies and clinical trials towards potential approval and commercialization, it is expected that various aspects of the manufacturing process will be altered in an effort to optimize processes and results. Such changes may require amendments to be made to regulatory applications which may further delay the timeframes under which modified manufacturing processes can be used for any of our current or future product candidates and additional bridging studies or trials may be required. Any such delay could have a material adverse impact on our business, results of operations and prospects. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Risks Related to Regulatory Approval</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_Hlk62738729"></a>If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our current or future product candidates, we will not be able to commercialize, or will be delayed in commercializing, our current or future product candidates, and our ability to generate revenue will be materially impaired. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current or future product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, import, and export, are subject to comprehensive regulation by the FDA and other regulatory agencies in the U.S. and by comparable authorities in other countries. Before we can commercialize any of our current or future product candidates, we must obtain marketing approval from the regulatory authorities in the relevant jurisdictions. We have not received approval to market any of our current or future product candidates from regulatory authorities in any jurisdiction, and it is possible that none of our current product candidates, nor any product candidates we may seek to develop in the future, will ever obtain regulatory approval. As a company, we have only limited experience in filing and supporting the applications necessary to gain </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulatory approvals and expect to rely on third-party CROs and/or regulatory consultants to assist us in this process. Securing regulatory approval requires the submission of extensive preclinical and clinical data and supporting information to the various regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. Securing regulatory approval also requires the submission of information about the drug manufacturing process to, and inspection of manufacturing facilities</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and often clinical sites</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> by, the relevant regulatory authority. Our current or future product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process of obtaining regulatory approvals, both in the U.S. and abroad, is expensive, may take many years if additional clinical trials are required, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted NDA or equivalent application type outside the U.S., may cause delays in the approval or rejection of an application. The FDA and comparable authorities in other countries have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. Our current or future product candidates could be delayed in receiving, or fail to receive, regulatory approval for many reasons, including the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the data collected from clinical trials of our current or future product candidates may not be sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the U.S. or elsewhere; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the FDA or comparable foreign regulatory authorities may find deficiencies with or fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk62738705"></a>As of June 23, 2020, the FDA noted it is continuing to ensure timely reviews of applications for medical products during the COVID-19 pandemic in line with its user fee performance goals; however, the FDA may not be able to continue its current pace and review timelines could be extended. In addition, even if we were to obtain approval, regulatory authorities may approve any of our current or future product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our drugs, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our current or future product candidates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we experience delays in obtaining approval or if we fail to obtain approval of our current or future product candidates, the commercial prospects for our current or future product candidates may be harmed and our ability to generate revenues will be materially impaired. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Breakthrough Therapy Designation and Fast Track Designation by the FDA, even if granted for any of our current or future product candidates, may not lead to a faster development, regulatory review or approval process, and such designations do not increase the likelihood that any of our product candidates will receive marketing approval in the United States. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may seek a Breakthrough Therapy Designation for one or more of our current or future product candidates. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA may also be eligible for priority review and accelerated approval. Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our current or future product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a Breakthrough Therapy Designation for a current or future product candidate may not result in a faster development process, review or approval compared to therapies considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our current or future product candidates qualify as breakthrough therapies, the FDA may later decide that such product candidates no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may seek Fast Track Designation for one or more of our current or future product candidates. If a drug is intended for the treatment of a serious or life-threatening condition and the drug demonstrates the potential to address unmet medical needs for this condition, the drug sponsor may apply for Fast Track Designation. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular current or future product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Even if we do receive Fast Track Designation for certain current or future product candidates, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw Fast Track Designation if it believes that the designation is no longer supported by data from our clinical development program. Fast Track Designation alone does not guarantee qualification for the FDA&#8217;s priority review procedures. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may seek Orphan Drug Designation for certain of our current or future product candidates, and we may be unsuccessful or may be unable to maintain the benefits associated with Orphan Drug Designation, including the potential for market exclusivity. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of our business strategy, we may seek Orphan Drug Designation for certain indications of our current or future product candidates, and we may be unsuccessful. Regulatory authorities in some jurisdictions, including the U.S. and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the U.S., or a patient population greater than 200,000 in the U.S. where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the U.S. In the U.S., Orphan Drug Designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Similarly, in Europe, the European Commission, upon the recommendation of the EMA&#8217;s Committee for Orphan Medicinal Products, grants Orphan Drug Designation to promote the development of drugs that are intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions affecting not more than 5 in 10,000 persons in Europe and for which no satisfactory method of diagnosis, prevention, or treatment has been authorized (or the product would be a significant benefit to those affected). Additionally, designation is granted for drugs intended for the diagnosis, prevention, or treatment of a life-threatening, seriously debilitating or serious and chronic condition and when, without incentives, it is unlikely that sales of the drug in Europe would be sufficient to justify the necessary investment in developing the drug. In Europe, Orphan Drug Designation entitles a party to financial incentives such as reduction of fees or fee waivers. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Generally, if a product with an Orphan Drug Designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA or the EMA from approving another marketing application for the same drug for that time period. The applicable period is seven years in the U.S. and ten years in the European Union. The exclusivity period in the European Union can be reduced to six years if a drug no longer meets the criteria for Orphan Drug Designation or if the drug is sufficiently profitable so that market exclusivity is no longer justified. Orphan Drug exclusivity may be lost if the FDA or EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we obtain Orphan Drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because competing drugs containing a different active ingredient can be approved for the same condition. In addition, even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August&#160;3, 2017, the U.S. Congress passed the FDA Reauthorization Act of 2017, or FDARA. FDARA, among other things, codified the FDA&#8217;s pre-existing regulatory interpretation to require that a drug sponsor demonstrate the clinical superiority of an orphan drug that is otherwise the same as a previously approved drug for the same rare disease in order to receive orphan drug exclusivity. The new legislation reverses prior precedent holding that the Orphan Drug Act unambiguously requires that the FDA recognize the orphan exclusivity period regardless of a showing of clinical superiority. Moreover, in the Consolidated Appropriations Act of 2021, Congress did not further change this interpretation when it clarified that the interpretation codified in FDARA would apply in cases where the FDA issued an orphan designation before the enactment of FDARA but where product approval came after the enactment of FDARA. The FDA may further reevaluate the Orphan Drug Act and its regulations and policies. We do not know if, when or how the FDA may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business. Depending on what changes the FDA may make to its Orphan Drug regulations and policies, our business could be adversely impacted. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Even if we receive regulatory approval for any of our current or future product candidates, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense. Additionally, our current or future product candidates, if approved, could be subject to labeling and other restrictions and market withdrawal and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates when and if any of them are approved. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the FDA or a comparable foreign regulatory authority approves any of our current or future product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for the drug will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration requirements, and continued compliance with cGMPs and Good Clinical Practices, or GCPs, for any clinical trials that we conduct post-approval. Any regulatory approvals that we receive for our current or future product candidates may also be subject to limitations on the approved indicated uses for which the drug may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials, and surveillance to monitor the safety and efficacy of the drug. Later discovery of previously unknown problems with a drug, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">restrictions on the marketing or manufacturing of the drug, withdrawal of the drug from the market, or voluntary drug recalls; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">fines, warning letters or holds on clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">refusal by the FDA to approve pending applications or supplements to approved applications filed by us, or suspension or revocation of drug license approvals; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">drug seizure or detention, or refusal to permit the import or export of drugs; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">injunctions or the imposition of civil or criminal penalties. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA&#8217;s policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our current or future product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Risks Related to Foreign Regulatory Approval and Foreign Markets </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Even if we receive marketing approval for our current or future product candidates in the U.S., we may never receive regulatory approval to market our current or future product candidates outside of the U.S. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We plan to seek regulatory approval of our current or future product candidates outside of the U.S. In order to market any product outside of the U.S., however, we must establish and comply with the numerous and varying safety, efficacy and other regulatory requirements of other countries. Approval procedures vary among countries and can involve additional product candidate testing and additional administrative review periods. The time required to obtain approvals in other countries might differ substantially from that required to obtain FDA approval. The marketing approval processes in other countries generally implicate all of the risks detailed above regarding FDA approval in the U.S. as well as other risks. In particular, in many countries outside of the U.S., products must receive pricing and reimbursement approval before the product can be commercialized. Obtaining this approval can result in substantial delays in bringing products to market in such countries. Marketing approval in one country does not ensure marketing approval in another, but a failure or delay in obtaining marketing approval in one country may have a negative effect on the regulatory process in others. Failure to obtain marketing approval in other countries or any delay or other setback in obtaining such approval would impair our ability to market our current or future product candidates in such foreign markets. Any such impairment would reduce the size of our potential market, which could have a material adverse impact on our business, results of operations and prospects. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our future growth may depend, in part, on our ability to penetrate foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties that could materially adversely affect our business. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are not permitted to market or promote any of our current or future product candidates before we receive regulatory approval from the applicable regulatory authority in that foreign market, and we may never receive such regulatory approval for any of our current or future product candidates. To obtain separate regulatory approval in many other countries we must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and distribution of our current or future product candidates, and we cannot predict success in these jurisdictions. If we obtain approval of our current or future product candidates and ultimately commercialize our current or future product candidates in foreign markets, we would be subject to additional risks and uncertainties, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">differing regulatory requirements in foreign countries, such that obtaining regulatory approvals outside of the U.S. may take longer and be more costly than obtaining approval in the U.S.; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our customers&#8217; ability to obtain reimbursement for our current or future product candidates in foreign markets; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">different medical practices and customs in foreign countries affecting acceptance in the marketplace; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">import or export licensing requirements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">longer accounts receivable collection times; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">longer lead times for shipping; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">language barriers for technical training; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">reduced protection of intellectual property rights in some foreign countries; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the existence of additional potentially relevant third-party intellectual property rights; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">economic weakness, including inflation, or political instability in particular foreign economies and markets; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">foreign taxes, including withholding of payroll taxes; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">difficulties staffing and managing foreign operations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">workforce uncertainty in countries where labor unrest is more common than in the U.S.; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">potential liability under the Foreign Corrupt Practices Act of 1977 or comparable foreign regulations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the interpretation of contractual provisions governed by foreign laws in the event of a contract dispute; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">business interruptions resulting from geo-political actions, including war and terrorism. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign sales of our current or future product candidates could also be adversely affected by the imposition of governmental controls, political and economic instability, trade restrictions and changes in tariffs. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may in the future conduct clinical trials for current or future product candidates outside the U.S., and the FDA and comparable foreign regulatory authorities may not accept data from such trials. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may in the future choose to conduct one or more clinical trials outside the U.S., including in Europe. The acceptance of study data from clinical trials conducted outside the U.S. or another jurisdiction by the FDA or comparable foreign regulatory authority may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the basis for marketing approval in the U.S., the FDA will generally not approve the application on the basis of foreign data alone unless (i)&#160;the data are applicable to the U.S. population and U.S. medical practice and (ii)&#160;the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations. Additionally, the FDA&#8217;s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory authorities have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the U.S. or the applicable jurisdiction. If the FDA or any comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which could be costly and time-consuming, and which may result in current or future product candidates that we may develop not receiving approval for commercialization in the applicable jurisdiction. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations. We can face serious consequences for violations. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Among other matters, U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations, which we collectively refer to as Trade Laws, prohibit companies and their employees, agents, clinical research organizations, legal counsel, accountants, consultants, contractors, and other partners from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of Trade Laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Governments outside the United States tend to impose strict price controls, which may adversely affect our revenues, if any. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In some countries, particularly in the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a drug. To obtain coverage and reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. In addition, many countries outside the U.S. have limited government support programs that provide for reimbursement of drugs such as our product candidates, with an emphasis on private payors for access to commercial products. If reimbursement of our product candidates is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be materially harmed. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Risks Related to Compliance with Healthcare and Other Regulations </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Even if we are able to commercialize any current or future product candidates, such drugs may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies, which would harm our business. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant uncertainty exists as to the coverage and reimbursement status of any products for which we may obtain regulatory approval. In the U.S. and in other countries, sales of any products for which we may receive regulatory marketing approval for commercial sale will depend, in part, on the availability of coverage and reimbursement from third-party payors. Third-party payors include government healthcare programs (e.g., Medicare and Medicaid), managed care providers, private health insurers, health maintenance organizations and other organizations. These third-party payors decide which medications they will pay for and establish reimbursement levels. The availability of coverage and extent of reimbursement by governmental and other third-party payors is essential for most patients to be able to afford treatments such as targeted protein degradation therapies. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, the principal decisions about reimbursement for new medicines are typically made by the Centers for Medicare&#160;&amp; Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services, or HHS. CMS decides whether and to what extent our products will be covered and reimbursed under Medicare. Private payors tend to follow CMS to a substantial degree. Factors payors consider in determining reimbursement are based on whether the product is: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a covered benefit under its health plan; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">safe, effective and medically necessary; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">appropriate for the specific patient; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">cost-effective; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">neither experimental nor investigational. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to commercialize any current or future product candidates successfully also will depend in part on the extent to which coverage and reimbursement for these current or future product candidates and related treatments will be available from government authorities, private health insurers and other organizations. Moreover, a payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. We cannot be sure that coverage will be available for any product candidate that we commercialize. If coverage is available, but reimbursement is available only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the U.S., no uniform policy exists for coverage and reimbursement for products among third-party payors. Therefore, decisions regarding the extent of coverage and amount of reimbursement to be provided can differ significantly from payor to payor. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the reimbursement rate a payor will pay for the product. One third-party payor&#8217;s decision to cover a particular product or service does not ensure that other payors will also provide coverage for the medical product or service. Third-party payors may limit coverage to specific products on an approved list or formulary, which may not include all FDA-approved products for a particular indication. Also, third-party payors may refuse to include a particular branded product on their formularies or otherwise restrict patient access to a branded drug when a less costly generic equivalent or other alternative is available. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. In order to secure coverage and reimbursement for any product that might be approved for sale, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain FDA or comparable regulatory approvals. Additionally, we may also need to provide discounts to purchasers, private health plans or government healthcare programs. Despite our best efforts, our product candidates may not be considered medically necessary or cost-effective. If third-party payors do not consider a product to be cost-effective compared to other available therapies, they may not cover an approved product as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our products at a profit. A decision by a third-party payor not to cover a product could reduce physician utilization once the product is approved and have a material adverse effect on sales, our operations and financial condition. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finally, in some foreign countries, the proposed pricing for a product candidate must be approved before it may be lawfully marketed. The requirements governing product pricing vary widely from country to country. For example, in the EU pricing and reimbursement of pharmaceutical products are regulated at a national level under the individual EU Member States&#8217; social security systems. Some foreign countries provide options to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and can control the prices of medicinal products for human use. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">effectiveness of a particular product candidate to currently available therapies. A country may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for products will allow favorable reimbursement and pricing arrangements for any of our product candidates. Even if approved for reimbursement, historically, product candidates launched in some foreign countries, such as some countries in the EU, do not follow price structures of the U.S. and prices generally tend to be significantly lower. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Current and future healthcare legislative reform measures may have a material adverse effect on our business and results of operations. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in regulations, statutes or the interpretation of existing regulations could impact our business by requiring, for example: (i)&#160;changes to our manufacturing arrangements, (ii)&#160;additions or modifications to product labeling, (iii)&#160;the recall or discontinuation of our products or (iv)&#160;additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States and in some foreign jurisdictions, there have been, and likely will continue to be, a number of legislative and regulatory changes and proposed changes intended to broaden access to healthcare, improve the quality of healthcare, and contain or lower the cost of healthcare. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or the ACA, was passed, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacted the U.S. pharmaceutical industry. The ACA, among other things, subjects biological products to potential competition by lower-cost biosimilars, expands the types of entities eligible for the 340B drug discount program, addresses a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increases rebates owed by manufacturers under the Medicaid Drug Rebate Program and extends the rebate program to individuals enrolled in Medicaid managed care organizations, establishes annual fees and taxes on manufacturers of certain branded prescription drugs, and creates a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% (increased to 70% pursuant to the Bipartisan Budget Act of 2018, or BBA, effective as of January 2019) point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part&#160;D. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since its enactment, there have been judicial, administrative, executive and Congressional legislative challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. For example, various portions of the ACA are currently undergoing constitutional challenges in the U.S. Supreme Court, the Trump Administration has issued various Executive Orders eliminating cost sharing subsidies and various provisions that would impose a fiscal burden on states or a cost, fee, tax, penalty or regulatory burden on individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices, and Congress has introduced several pieces of legislation aimed at significantly revising or repealing the ACA. It is unclear whether the ACA will be overturned, repealed, replaced, or further amended. We cannot predict what affect further changes to the ACA would have on our business. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example, in August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. Specifically, the Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013, and, due to subsequent legislative amendments, will remain in effect through 2030 unless additional Congressional action is taken. However, pursuant to the Coronavirus Aid, Relief and Economic Security Act, or CARES Act, and subsequent legislation, the 2% Medicare sequester reductions have been suspended from May&#160;1, 2020 through March&#160;31, 2021 due to the COVID-19 pandemic. Proposed legislation, if passed, would extend this suspension until the end of the pandemic. On January&#160;2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. The BBA also amended the ACA, effective January&#160;1, 2019, by increasing the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D and closing the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole.&#8221; </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment models. Recently, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products. Such scrutiny has resulted in several recent U.S. Congressional inquiries and has further resulted in proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. For example, at the federal level, the Trump administration&#8217;s budget for fiscal year 2021 includes a $135&#160;billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower out-of-pocket drug costs for patients, and increase patient access to lower-cost generic and biosimilar drugs. On March&#160;10, 2020, the Trump administration sent &#8220;principles&#8221; for drug pricing to Congress, calling for legislation that would, among other things, cap Medicare Part D beneficiary out-of-pocket pharmacy expenses, provide an option to cap Medicare Part D beneficiary monthly out-of-pocket expenses, and place limits on pharmaceutical price increases. Additionally, the Trump Administration previously released a &#8220;Blueprint&#8221; to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the out of pocket costs of product candidates paid by consumers. However, it is unclear whether the Biden administration will challenge, reverse, revoke or otherwise modify these executive and administrative actions after January 20, 2021. HHS has solicited feedback on some of these measures and, at the same time, is immediately implementing others under its existing authority. For example, in May 2019, CMS issued a final rule to allow Medicare Advantage Plans the option of using step therapy, a type of prior authorization, for Part B drugs beginning January&#160;1, 2020. This final rule codified CMS&#8217;s policy change that was effective January&#160;1, 2019. It is unclear how these developments could affect covered hospitals who might purchase our future products and affect the rates we may charge such facilities for our approved products in the future, if any. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, former President Trump signed a series of Executive Orders on July 24, 2020 and September 13, 2020 aimed at lowering drug pricing and seeking to implement several of the administration&#8217;s proposals. The FDA also released a final rule on September 24, 2020, which went into effect on November 30, 2020, providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, CMS issued an Interim Final Rule implementing the Most Favored Nation, or MFN, Model&nbsp;&nbsp;under which&nbsp;&nbsp;Medicare Part B reimbursement rates will be calculated for certain drugs and biologicals based on the lowest price drug manufacturers receive in Organization for Economic Cooperation and Development countries with a similar gross domestic product per capita.&nbsp;&nbsp;The MFN Model regulations mandate participation by identified Part B providers and will apply in all U.S. states and territories for a seven-year period beginning January 1, 2021, and ending December 31, 2027.&nbsp;&nbsp;The Interim Final Rule has not been finalized and is subject to revision and challenge. Additionally, on November 20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. Although a number of these, and other proposed measures will require authorization through additional legislation to become effective, and the Biden administration may reverse or otherwise change these measures, Congress has indicated that it will continue to seek new legislative and/or administrative measures to control drug costs.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our current or future product candidates or additional pricing pressures. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action in the United States. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our relationships with customers, health care providers, physicians, and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, exclusion from government healthcare programs, contractual damages, reputational harm and diminished future profits and earnings. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any current or future product candidates for which we obtain marketing approval. Our business operations and any current or future arrangements with third-party payors and customers may expose us to broadly applicable federal and state laws relating to fraud and abuse, as well as other healthcare laws and regulations. These laws may impact, among other things, the business or financial arrangements and relationships through which we market, sell and distribute any current or future product candidates for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations, include, among others: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the federal Anti-Kickback Statute, which prohibits, among other things, any person or entity from knowingly and willfully soliciting, offering, receiving, providing or paying remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, or arranging for, any item, good, facility, or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid. The federal Anti-Kickback Statute has been interpreted to apply to arrangements between manufacturers on one hand and prescribers, purchasers, and formulary managers on the other. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Violations can result in significant civil monetary and criminal penalties for each violation, plus up to three times the amount of remuneration, imprisonment, and exclusion from government healthcare programs. Further, a violation of the federal Anti-Kickback Statute can also form the basis for False Claims Act liability; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the federal civil and criminal false claims laws and civil monetary penalty laws, including the federal False Claims Act, which prohibits individuals or entities from knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. Actions under the False Claims Act may be brought by the Attorney General or as a qui tam action by a private individual in the name of the government. Violations of the False Claims Act can result in very significant monetary penalties for each false claim and three times the amount of the government&#8217;s damages. Manufacturers can be held liable under the False Claims Act even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. In addition, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes additional criminal and civil liability for knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private), and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the federal physician payment transparency laws, including the federal Physician Payment Sunshine Act created under the ACA, which requires manufacturers of certain drugs, devices, biologics and medical supplies, among others, to track and disclose payments under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program (with certain exceptions) and other transfers of value they make to U.S. physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Effective January&#160;1, 2022, these reporting obligations will extend to include transfers of value made to certain non-physician providers such as physician assistants and nurse practitioners. This information is subsequently made publicly available in a searchable format on a CMS website. Failure to disclose required information may result in civil monetary penalties for all payments, transfers of value or ownership or investment interests that are not timely, accurately and completely reported in an annual submission; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and its implementing regulations, including the final omnibus rule published on January&#160;25, 2013, which imposes, among other things, certain requirements relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#8217;s privacy and security standards directly applicable to &#8220;business associates,&#8221; defined as independent contractors or agents of covered entities that create, receive, maintain, transmit, or obtain, protected health information in connection with providing a service for or on behalf of a covered entity. HITECH also increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">analogous state law equivalents of each of the above U.S. federal laws, such as state anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers or patients; state and local marketing and/or transparency laws applicable to manufacturers that may be broader in scope than the federal requirements; state laws that require the reporting of information related to drug pricing; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures and pricing information; state and local laws that require the licensure and/or registration of pharmaceutical sales representatives; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the above, on November 20, 2020, the Office of Inspector General, or OIG, finalized further modifications to the federal Anti-Kickback Statute. Under the final rules, OIG added safe harbor protections under the Anti-Kickback Statute for certain coordinated care and value-based arrangements among clinicians, providers, and others. The final rule (with some exceptions) became&nbsp;&nbsp;effective January 19, 2021. We continue to evaluate what effect, if any, these rules will have on our business.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are to be found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or similar settlement to resolve allegations of non-compliance with these laws, any of which could adversely affect our ability to operate our business and our financial results. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to similar actions, penalties, and sanctions. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the EU. The provision of benefits or advantages to physicians is governed by the national anti-bribery laws of EU Member States, such as the U.K. Bribery Act 2010. Infringement of these laws could result in substantial fines and imprisonment. Payments made to physicians in certain EU Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization and/or the regulatory authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. Current or future environmental laws and regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition or results of operations. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our employees, principal investigators, CROs and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading laws. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to the risk that our employees, principal investigators, CROs and consultants may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violate the regulations of the FDA and other regulatory authorities, including those laws requiring the reporting of true, complete and accurate information to such authorities; healthcare fraud and abuse laws and regulations in the U.S. and abroad; or laws that require the reporting of financial information or data accurately. In particular, sales, marketing, patient support and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Other activities subject to these laws include the improper use of information obtained in the course of clinical trials or creating fraudulent data in our preclinical studies or clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of conduct applicable to all of our employees, but it is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. Additionally, we are subject to the risk that a person could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant criminal, civil and administrative sanctions including monetary penalties, damages, fines, disgorgement, individual imprisonment, reputational harm, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Commercialization </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Even if we receive marketing approval for our current or future product candidates, our current or future product candidates may not achieve broad market acceptance, which would limit the revenue that we generate from their sales. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The commercial success of our current or future product candidates, if approved by the FDA or other applicable regulatory authorities, will depend upon the awareness and acceptance of our current or future product candidates among the medical community, including physicians, patients and healthcare payors. Market acceptance of our current or future product candidates, if approved, will depend on a number of factors, including, among others: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the efficacy of our current or future product candidates as demonstrated in clinical trials, and, if required by any applicable regulatory authority in connection with the approval for the applicable indications, to provide patients with incremental health benefits, as compared with other available medicines; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">limitations or warnings contained in the labeling approved for our current or future product candidates by the FDA or other applicable regulatory authorities; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the clinical indications for which our current or future product candidates are approved; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">availability of alternative treatments already approved or expected to be commercially launched in the near future; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the potential and perceived advantages of our current or future product candidates over current treatment options or alternative treatments, including future alternative treatments; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the willingness of the target patient population to try new therapies or treatment methods and of physicians to prescribe these therapies or methods; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the need to dose such product candidates in combination with other therapeutic agents, and related costs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the strength of marketing and distribution support and timing of market introduction of competitive products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">publicity concerning our products or competing products and treatments; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">pricing and cost effectiveness; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the effectiveness of our sales and marketing strategies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our ability to increase awareness of our current or future product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our ability to obtain sufficient third-party coverage or reimbursement; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the willingness of patients to pay out-of-pocket in the absence of third-party coverage. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our current or future product candidates are approved but do not achieve an adequate level of acceptance by patients, physicians and payors, we may not generate sufficient revenue from our current or future product candidates to become or remain profitable. Before granting reimbursement approval, healthcare payors may require us to demonstrate that our current or future product candidates, in addition to treating these target indications, also provide incremental health benefits to patients. Our efforts to educate the medical community, patient organizations and third-party payors about the benefits of our current or future product candidates may require significant resources and may never be successful. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We face substantial competition, which may result in others discovering, developing or commercializing drugs before or more successfully than we do. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The development and commercialization of new drugs is highly competitive. We face and will continue to face competition from third parties that use protein degradation, antibody therapy, inhibitory nucleic acid, gene editing or gene therapy development platforms and from companies focused on more traditional therapeutic modalities, such as small molecule inhibitors. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization of new drugs. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competitors in our efforts to develop small molecule protein degraders therapies for patients, include, but are not limited to, Arvinas, Inc. and C4 Therapeutics, Inc., which are both in clinical development, Nurix Therapeutics, Inc.,&nbsp;&nbsp;Foghorn Therapeutics, Inc., and Vividion Therapeutics, Inc., each of which is in preclinical development. Further, several large pharmaceutical companies have disclosed preclinical investments in this field. Our competitors will also include companies that are or will be developing other targeted protein degradation methods as well as small molecule, antibody, or gene therapies for the same indications that we are targeting. In addition to the competitors we face in developing small molecule protein degraders, we will also face competition in the indications we expect to pursue with our IRAK4, IRAKIMiD and STAT3 programs. Many of these indications already have approved standards of care which may include more traditional therapeutic modalities. In order to compete effectively with these existing therapies, we will need to demonstrate that our protein degrader therapies are favorable to existing therapeutics. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of our current or future competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and reimbursement and marketing approved drugs than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific, sales, marketing and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize drugs that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any drugs that we or our collaborators may develop. Our competitors also may obtain FDA or other regulatory approval for their drugs more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we or our collaborators are able to enter the market. The key competitive factors affecting the success of all of our current or future product candidates, if approved, are likely to be their efficacy, safety, convenience, price, the level of generic competition and the availability of reimbursement from government and other third-party payors. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any current or future product candidates that we may develop. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We face an inherent risk of product liability exposure related to the testing of our current or future product candidates in human clinical trials and will face an even greater risk if we commercially sell any current or future product candidates that we may develop. If we cannot successfully defend ourselves against claims that our current or future product candidates caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">decreased demand for any current or future product candidates that we may develop; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">injury to our reputation and significant negative media attention; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">withdrawal of clinical trial participants; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">significant costs to defend the related litigation; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">substantial monetary awards to trial participants or patients; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">loss of revenue; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the inability to commercialize any current or future product candidates that we may develop. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not yet maintain product liability insurance, and we anticipate that we will need to increase our insurance coverage when we begin clinical trials and if we successfully commercialize any product candidate. Insurance coverage is increasingly expensive. We may not be able to maintain product liability insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If, in the future, we are unable to establish sales and marketing and patient support capabilities or enter into agreements with third parties to sell and market our current or future product candidates, we may not be successful in commercializing our current or future product candidates if and when they are approved, and we may not be able to generate any revenue. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not currently have a sales or marketing infrastructure and have no experience in the sales, marketing, patient support or distribution of drugs. To achieve commercial success for any approved product candidate for which we retain sales and marketing responsibilities, we must build our sales, marketing, patient support, managerial and other non-technical capabilities or make arrangements with third parties to perform these services. In the future, we may choose to build a focused sales and marketing infrastructure to sell, or participate in sales activities with our collaborators for, some of our current or future product candidates if and when they are approved. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are risks involved with both establishing our own sales and marketing and patient support capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time consuming and could delay any drug launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Factors that may inhibit our efforts to commercialize our current or future product candidates on our own include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our inability to recruit and retain adequate numbers of effective sales and marketing personnel; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future drugs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the lack of complementary drugs to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">unforeseen costs and expenses associated with creating an independent sales and marketing organization. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we enter into arrangements with third parties to perform sales, marketing, patient support and distribution services, our drug revenues or the profitability of these drug revenues to us are likely to be lower than if we were to market and sell any current or future product candidates that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell and market our current or future product candidates or may be unable to do so on terms that are favorable to us. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our current or future product candidates effectively. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our current or future product candidates. Further, our business, results of operations, financial condition and prospects will be materially adversely affected. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Dependence on Third Parties </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We rely on third parties to conduct preclinical studies, and we expect to rely on third parties to conduct our clinical trials for our current and future product candidates. If these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, we may not be able to obtain marketing approval for or commercialize our current and potential future product candidates and our business could be substantially harmed. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We utilize and depend upon independent investigators and collaborators, such as medical institutions, CROs, contract manufacturing organizations and strategic partners to help conduct our preclinical studies. We do not have the ability to independently conduct clinical trials. We rely on medical institutions, clinical investigators, contract laboratories, and other third parties, including collaboration partners, to conduct or otherwise support clinical trials for our current or future product candidates. We rely heavily on these parties for execution of clinical trials for our product candidates and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on CROs will not relieve us of our regulatory responsibilities. For any violations of laws and regulations during the conduct of our preclinical studies or clinical trials, we could be subject to untitled and warning letters or enforcement action that may include civil penalties up to and including criminal prosecution. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and any third parties that we contract with are required to comply with regulations and requirements, including GCP, for conducting, monitoring, recording and reporting the results of clinical trials to ensure that the data and results are scientifically credible and accurate, and that the trial patients are adequately informed of the potential risks of participating in clinical trials and their rights are protected. These regulations are enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area and comparable foreign regulatory authorities for any drugs in clinical development. The FDA enforces GCP requirements through periodic inspections of clinical trial sponsors, principal investigators and trial sites. If we or the third parties we contract with fail to comply with applicable GCP, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that, upon inspection, the FDA will determine that any of our clinical trials will comply with GCP. In addition, our clinical trials must be conducted with current or future product candidates produced under cGMP regulations. Our failure or the failure of third parties that we may contract with to comply with these regulations may require us to repeat some aspects of a specific, or an entire, clinical trial, which would delay the marketing approval process and could also subject us to enforcement action. We also are required to register certain ongoing clinical trials and provide certain information, including information relating to the trial&#8217;s protocol, on a government-sponsored database, ClinicalTrials.gov, within specific timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we designed the Phase 1 trial of KT-474 and intend to design other clinical trials for our current or future product candidates, or be involved in the design when other parties sponsor the trials, we anticipate that third parties will conduct all of our clinical trials. As a result, many important aspects of our clinical development, including their conduct, timing and response to the ongoing COVID-19 pandemic, will be outside of our direct control. Our reliance on third parties to conduct clinical trials will also result in less direct control over the management of data developed through clinical trials than would be the case if we were relying entirely upon our own staff. Communicating with outside parties can also be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. Outside parties may: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">have staffing difficulties; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">fail to comply with contractual obligations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">experience regulatory compliance issues; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">form relationships with other entities, some of which may be our competitors. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These factors may materially adversely affect the willingness or ability of third parties to conduct our clinical trials and may subject us to unexpected cost increases that are beyond our control. If our CROs do not perform clinical trials in a satisfactory manner, breach their obligations to us or fail to comply with regulatory requirements, the development, marketing approval and commercialization of our current or future product candidates may be delayed, we may not be able to obtain marketing approval and commercialize our current or future product candidates, or our development programs may be materially and irreversibly harmed. If we are unable to rely on clinical data collected by our CROs, we could be required to repeat, extend the duration of, or increase the size of clinical trials we conduct and this could significantly delay commercialization and require significantly greater expenditures. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs on commercially reasonable terms, or at all. If our CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain are compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, any clinical trials such CROs are associated with may be extended, delayed or terminated, and we may not be able to obtain marketing approval for or successfully commercialize our current or future product candidates. As a result, we believe that our financial results and the commercial prospects for our current or future product candidates in the subject indication would be harmed, our costs could increase and our ability to generate revenue could be delayed. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The third parties upon whom we rely for the supply of the API, drug product, and starting materials used in our product candidates are limited in number, and the loss of any of these suppliers could significantly harm our business. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The drug substance and drug product in our product candidates are supplied to us from a small number of suppliers, and in some cases sole source suppliers. Our ability to successfully develop our current or future product candidates, and to ultimately supply our commercial drugs in quantities sufficient to meet the market demand, depends in part on our ability to obtain the drug product and drug substance for these drugs in accordance with regulatory requirements and in sufficient quantities for commercialization and clinical testing. We do not currently have arrangements in place for a redundant or second-source supply of all drug product or drug substance in the event any of our current suppliers of such drug product and drug substance cease their operations for any reason. Any delays in the delivery of our drug substance, drug product or starting materials could have an adverse effect and potentially harm our business. For example, in February 2020, one of our vendors for API starting materials based in Wuhan, China ceased its operations for several weeks due to the COVID-19 pandemic, which caused a minor delay in the delivery of API starting materials to a separate vendor who manufactures API. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For all of our current or future product candidates, we intend to identify and qualify additional manufacturers to provide such API, drug product and drug substance prior to submission of an NDA to the FDA and/or an MAA to the EMA. We are not certain, however, that our single-source and dual source suppliers will be able to meet our demand for their products, either because of the nature of our agreements with those suppliers, our limited experience with those suppliers or our relative importance as a customer to those suppliers. It may be difficult for us to assess their ability to timely meet our demand in the future based on past performance. While our suppliers have generally met our demand for their products on a timely basis in the past, they may subordinate our needs in the future to their other customers. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Establishing additional or replacement suppliers for the drug product and drug substance used in our current or future product candidates, if required, may not be accomplished quickly. If we are able to find a replacement supplier, such replacement supplier would need to be qualified and may require additional regulatory approval, which could result in further delay. While we seek to maintain adequate inventory of the drug product and drug substance used in our current or future product candidates, any interruption or delay in the supply of components or materials, or our inability to obtain such API, drug product and drug substance from alternate sources at acceptable prices in a timely manner, could impede, delay, limit or prevent our development efforts, which could harm our business, results of operations, financial condition and prospects. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our success is dependent on our executive management team&#8217;s ability to successfully pursue business development, strategic partnerships and investment opportunities as our company matures. We may also form or seek strategic alliances or acquisitions or enter into additional collaboration and licensing arrangements in the future, and we may not realize the benefits of such collaborations, alliances, acquisitions or licensing arrangements. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have entered into collaboration and licensing arrangements with Vertex and Sanofi<sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup>and may in the future form or seek strategic alliances or acquisitions, create joint ventures, or enter into additional collaboration and licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our current product candidates and any future product candidates that we may develop. Any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or acquisition or other alternative arrangements for our current or future product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view our current or future product candidates as having the requisite potential to demonstrate safety, potency, purity and efficacy and obtain marketing approval. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, collaborations involving our technologies or current or future product candidates are subject to numerous risks, which may include the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">collaborators have significant discretion in determining the efforts and resources that they will apply to a collaboration; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">collaborators may not pursue development and commercialization of our current or future product candidates or may elect not to continue or renew development or commercialization of our current or future product candidates based on clinical trial results, changes in their strategic focus due to the acquisition of competitive products, availability of funding or other external factors, such as a business combination that diverts resources or creates competing priorities; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial, stop a clinical trial, abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our current or future product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a collaborator with marketing and distribution rights to one or more products may not commit sufficient resources to their marketing and distribution; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">disputes may arise between us and a collaborator that cause the delay or termination of the research, development or commercialization of our current or future product candidates, or that result in costly litigation or arbitration that diverts management attention and resources; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable current or future product candidates. For example, the collaboration agreement with Vertex may be terminated by Vertex either in its entirety or on a target-by-target basis, upon one hundred eighty days&#8217; prior written notice to us, upon our material breach, subject to specified notice and cure provisions, or upon our bankruptcy, insolvency, dissolution or winding up; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">collaborators may own or co-own intellectual property covering our products that results from our collaborating with them, and in such cases, we would not have the exclusive right to commercialize such intellectual property; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">collaborators may not pay milestones and royalties due to the company in a timely manner. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result, we may not be able to realize the benefit of our existing collaboration and licensing arrangements or any future strategic partnerships or acquisitions, collaborations or license arrangements we may enter into if we are unable to successfully integrate them with our existing operations and company culture, which could delay our timelines or otherwise adversely affect our business. We also cannot be certain that, following a strategic transaction, license, collaboration or other business development partnership, we will achieve the revenue or specific net income that justifies such transaction. Any delays in entering into new collaborations or strategic partnership agreements related to our current or future product candidates could delay the development and commercialization of our current or future product candidates in certain geographies or for certain indications, which would harm our business prospects, financial condition and results of operations. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our manufacturing process needs to comply with FDA regulations relating to the quality and reliability of such processes. Any failure to comply with relevant regulations could result in delays in or termination of our preclinical and clinical programs and suspension or withdrawal of any regulatory approvals. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to commercially produce our products either at our own facility or at a third party&#8217;s facility, we will need to comply with the FDA&#8217;s cGMP regulations and guidelines. We may encounter difficulties in achieving quality control and quality assurance and may experience shortages in qualified personnel. We are subject to inspections by the FDA and comparable foreign regulatory authorities to confirm compliance with applicable regulatory requirements. Any failure to follow cGMP or other regulatory requirements or delay, interruption or other issues that arise in the manufacture, fill-finish, packaging, or storage of our product candidates as a result of a failure of our facilities or the facilities or operations of third parties to comply with regulatory requirements or pass any regulatory authority inspection could significantly impair our ability to develop and commercialize our current or future product candidates, including leading to significant delays in the availability of our product candidates for our clinical trials or the termination of or suspension of a clinical trial, or the delay or prevention of a filing or approval of marketing applications for our current or future product candidates. Significant non-compliance could also result in the imposition of sanctions, including warning or untitled letters, fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approvals for our current or future product candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could damage our reputation and our business. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If our third-party manufacturers use hazardous and biological materials in a manner that causes injury or violates applicable law, we may be liable for damages. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our research and development activities involve the controlled use of potentially hazardous substances, including chemical materials, by our third-party manufacturers. Our manufacturers are subject to federal, state and local laws and regulations in the U.S. governing the use, manufacture, storage, handling and disposal of medical and hazardous materials. Although we believe that our manufacturers&#8217; procedures for using, handling, storing and disposing of these materials comply with legally prescribed standards, we cannot completely eliminate the risk of contamination or injury resulting from medical or hazardous materials. As a result of any such contamination or injury, we may incur liability or local, city, state or federal authorities may curtail the use of these materials and interrupt our business operations. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources. We do not have any insurance for liabilities arising from medical or hazardous materials. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition or results of operations. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Intellectual Property</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we are unable to obtain and maintain patent and other intellectual property protection for our technology and product candidates or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and drugs similar or identical to ours, and our ability to successfully commercialize our technology and drugs may be impaired, and we may not be able to compete effectively in our market. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends in part on our ability to obtain and maintain patent or other intellectual property protection in the U.S. and other countries for our current or future product candidates and our core technologies, including our proprietary Pegasus platform, our initial IRAK4, IRAKIMiD, and STAT3 programs, which are our three most advanced development programs, as well as our proprietary compound library and other know-how. We seek to protect our proprietary and intellectual property position by, among other methods, filing patent applications in the U.S. and abroad related to our proprietary technology, inventions and improvements that are important to the development and implementation of our business. We also rely on trade secrets, know-how and continuing technological innovation to develop and maintain our proprietary and intellectual property position. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own patent applications related to our platform E3 ligase ligand technology and our novel bifunctional degrader compounds, including claims to compositions of matter, pharmaceutical compositions, methods of use, methods of treatment, and other related methods. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, our patent portfolio covering novel compounds discovered by our Pegasus platform included 43 patent families. Patent term adjustments, supplementary protection certificate filings, or patent term extensions could result in later expiration dates in various countries, while terminal disclaimers could result in earlier expiration dates in the U.S. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The degree of patent protection we require to successfully commercialize our current or future product candidates may be unavailable or severely limited in some cases and may not adequately protect our rights or permit us to gain or keep any competitive advantage. We cannot provide any assurances that any of our pending patent applications that mature into issued patents will include claims with a scope sufficient to protect our Pegasus platform and our current or future product candidates. In addition, if the breadth or strength of protection provided by our patent applications or any patents we may own or in-license is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the U.S. For example, in jurisdictions outside the U.S., a license may not be enforceable unless all the owners of the intellectual property agree or consent to the license. Accordingly, any actual or purported co-owner of our patent rights could seek monetary or equitable relief requiring us to pay it compensation for, or refrain from, exploiting these patents due to such co-ownership. Furthermore, patents have a limited lifespan. In the U.S., and most other jurisdictions in which we have undertaken patent filings, the natural expiration of a patent is generally twenty years after it is filed, assuming all maintenance fees are paid. Various extensions may be available, on a jurisdiction-by-jurisdiction basis; however, the life of a patent, and thus the protection it affords, is limited. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, patents we may own or in-license may not provide us with adequate and continuing patent protection sufficient to exclude others from commercializing drugs similar or identical to our current or future product candidates, including generic versions of such drugs. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other parties have developed technologies that may be related or competitive to our own, and such parties may have filed or may file patent applications, or may have received or may receive patents, claiming inventions that may overlap or conflict with those claimed in our own patent applications or issued patents, with respect to either the same compounds, methods, formulations or other subject matter, in either case that we may rely upon to dominate our patent position in the market. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the U.S. and other jurisdictions are typically not published until at least 18&#160;months after the earliest priority date of the patent filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in patents we may own or in-license patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights cannot be predicted with any certainty. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. Further, with respect to certain pending patent applications covering our current or future product candidates or technologies, prosecution has yet to commence. Patent prosecution is a lengthy process, during which the scope of the claims initially submitted for examination by the relevant patent office(s) may be significantly narrowed by the time they issue, if they ever do. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from or to third parties. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we acquire patent protection that we expect should enable us to establish and/or maintain a competitive advantage, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the U.S. and abroad. We may become involved in opposition, derivation, reexamination, <font style="font-style:italic;">inter partes</font> review, or post-grant review proceedings challenging our patent rights or the patent rights of others from whom we may in the future obtain licenses to such rights, in the U.S. Patent and Trademark Office, or USPTO, the European Patent Office, or EPO, or in other countries. In addition, we may be subject to third-party submissions to the USPTO, the EPO, or elsewhere, that may reduce the scope or preclude the granting of claims from our pending patent applications. Competitors may challenge our issued patents or may file patent applications before we do. Competitors may also claim that we are infringing their patents and that we therefore cannot practice our technology as claimed under our patents or patent applications. Competitors may also contest our patents by showing an administrative patent authority or judge that the invention was not patent-eligible, was not novel, was obvious, and/or lacked inventive step, and/or that the patent application failed to meet relevant requirements relating to description, basis, enablement, and/or support; in litigation, a competitor could assert that our patents are not valid or are unenforceable for a number of reasons. If a court or administrative patent authority agrees, we would lose our protection of those challenged patents. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An adverse determination in any such submission or proceeding may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and drugs, without payment to us, or could limit the duration of the patent protection covering our technology and current or future product candidates. Such challenges may also result in our inability to manufacture or commercialize our current or future product candidates without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we may in the future be subject to claims by our former employees or consultants asserting an ownership right in our patents or patent applications, as a result of the work they performed on our behalf. Although we generally require all of our employees, consultants and advisors and any other third parties who have access to our proprietary know-how, information or technology to assign or grant similar rights to their inventions to us, we cannot be certain that we have executed such agreements with all parties who may have contributed to our intellectual property, nor can we be certain that our agreements with such parties will be upheld in the face of a potential challenge, or that they will not be breached, for which we may not have an adequate remedy. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if they are unchallenged, our issued patents and our pending patent applications, if issued, may not provide us with any meaningful protection or prevent competitors from designing around our patent claims to circumvent patents we may own or in-license by developing similar or alternative technologies or drugs in a non-infringing manner. For example, a third party may develop a competitive drug that provides benefits similar to one or more of our current or future product candidates but that has a different composition that falls outside the scope of our patent protection. If the patent protection provided by the patents and patent applications we hold or pursue with respect to our current or future product candidates is not sufficiently broad to impede such competition, our ability to successfully commercialize our current or future product candidates could be negatively affected, which would harm our business. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, even if we are able to issue patents with claims of valuable scope in one or more jurisdictions, we may not be able to secure such claims in all relevant jurisdictions, or in a sufficient number to meaningfully reduce competition. Our competitors may be able to develop and commercialize their products, including products identical to ours, in any jurisdiction in which we are unable to obtain, maintain, or enforce such patent claims. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We will not obtain patent or other intellectual property protection for </font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">all</font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"> current or future product candidates in all jurisdictions throughout the world, and we may not be able to adequately enforce our intellectual property rights even in the jurisdictions where we seek protection. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be able to pursue patent coverage of our current or future product candidates, the Pegasus platform, or other technologies in all countries. Filing, prosecuting and defending patents on current or future product candidates, the Pegasus platform, and other technologies in all countries throughout the world would be prohibitively expensive, and intellectual property rights in some countries outside the U.S. can be less extensive than those in the U.S. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the U.S. Consequently, we may not be able to prevent third parties from infringing on our inventions in all countries outside the U.S., or from selling or importing products made using our inventions in and into the U.S. or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but where enforcement is not as strong as that in the U.S. These products may compete with our current or future product candidates and in jurisdictions where we do not have any issued patents our patent applications or other intellectual property rights may not be effective or sufficient to prevent them from competing. Much of our patent portfolio is at the very early stage. We will need to decide whether and in which jurisdictions to pursue protection for the various inventions in our portfolio prior to applicable deadlines. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to pharmaceutical products, which could make it difficult for us to stop the infringement of any patents we may own or in-license or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce any rights we may have in our patent applications or any patents we may own or in-license in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put any patents we may own or in-license at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we are forced to grant a license to third parties with respect to any patents we may own or license that are relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations, and prospects may be adversely affected. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may not obtain or grant licenses or sublicenses to intellectual property rights in all markets on equally or sufficiently favorable terms with third parties. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our products, in which case we would be required to obtain a license from these third parties. The licensing of third-party intellectual property rights is a competitive area, and more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. More established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to license such technology, or if we are forced to license such technology on unfavorable terms, our business could be materially harmed. If we are unable to obtain a necessary license, we may be unable to develop or commercialize the affected current or future product candidates, which could materially harm our business, and the third parties owning such intellectual property rights could seek either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties or other forms of compensation. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. Any of the foregoing could harm our competitive position, business, financial condition, results of operations and prospects. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we fail to comply with our obligations in our current or any future agreements under which we may license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are dependent on patents, know-how and proprietary technology, both our own and in-licensed from Vertex, Sanofi and other collaborators. Our commercial success depends upon our ability to develop, manufacture, market and sell our current or future product candidates and use our and our licensors&#8217; proprietary technologies without infringing the proprietary rights of third parties. Vertex, Sanofi and other collaborators may have the right to terminate their respective license agreements in full in the event that we materially breach or default in the performance of any of the obligations under such license agreements. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any termination of these licenses, or if the underlying patents fail to provide the intended exclusivity, could result in the loss of significant rights and could harm our ability to commercialize our current or future product candidates, the Pegasus platform, or other technologies, competitors or other third parties would have the freedom to seek regulatory approval of, and to market, products identical to ours, and we may be required to cease our development and commercialization of certain of our current or future product candidates. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disputes may also arise between us and our current or future licensors regarding intellectual property subject to a license agreement, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the scope of rights granted under the license agreement and other interpretation-related issues; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">whether and the extent to which our technology and processes infringe, misappropriate or otherwise violate intellectual property rights of the licensor that is not subject to the licensing agreement; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our right to sublicense patent and other rights to third parties under collaborative development relationships; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our current or future product candidates, and what activities satisfy those diligence obligations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the priority of invention of any patented technology; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our current or future licensors and us and our partners. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the agreements under which we may license intellectual property or technology from third parties are likely to be complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we may license prevent or impair our ability to maintain current or future licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected current or future product candidates or technologies, which could have a material adverse effect on our business, financial conditions, results of operations and prospects. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Intellectual property rights do not guarantee commercial success of current or future product candidates or other business activities. Numerous factors may limit any potential competitive advantage provided by our intellectual property rights. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The degree of future protection afforded by our intellectual property rights, whether owned or in-licensed, is uncertain because intellectual property rights have limitations, and may not adequately protect our business, provide a barrier to entry against our competitors or potential competitors, or permit us to maintain our competitive advantage. Moreover, if a third party has intellectual property rights that cover the practice of our technology, we may not be able to fully exercise or extract value from our intellectual property rights. The following examples are illustrative: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">patent applications that we own or may in-license may not lead to issued patents; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">patents, should they issue, that we may own or in-license, may not provide us with any competitive advantages, may be narrowed in scope, or may be challenged and held invalid or unenforceable; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.58%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.58%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">others may be able to develop and/or practice technology, including compounds that are similar to the chemical compositions of our current or future product candidates, that is similar to our technology or aspects of our technology but that is not covered by the claims of any patents we may own or in-license, should any patents issue; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.58%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.58%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">third parties may compete with us in jurisdictions where we do not pursue and obtain patent protection; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.58%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.58%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">we, or our future licensors or collaborators, might not have been the first to make the inventions covered by a patent application that we own or may in-license; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.58%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.58%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">we, or our future licensors or collaborators, might not have been the first to file patent applications covering a particular invention; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.58%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.58%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">others may independently develop similar or alternative technologies without infringing, misappropriating or otherwise violating our intellectual property rights; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.58%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.58%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our competitors might conduct research and development activities in the U.S. and other countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights, and may then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.58%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.58%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">we may not be able to obtain and/or maintain necessary licenses on reasonable terms or at all; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">third parties may assert an ownership interest in our intellectual property and, if successful, such disputes may preclude us from exercising exclusive rights, or any rights at all, over that intellectual property; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such trade secrets or know-how; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">we may not be able to maintain the confidentiality of our trade secrets or other proprietary information; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">we may not develop or in-license additional proprietary technologies that are patentable; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the patents of others may have an adverse effect on our business. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Should any of these events occur, they could significantly harm our business, financial condition, results of operations and prospects. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Patent Protection </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Obtaining and maintaining our patent protection, including patent term, depends on compliance with various procedural, document submission, deadlines, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated if we miss a filing deadline for patent protection on these inventions or otherwise fail to comply with these requirements. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The USPTO and foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process and after issuance of any patent. In addition, periodic maintenance fees, renewal fees, annuity fees and/or various other government fees are required to be paid periodically. While an inadvertent lapse can in some cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, our competitors might be able to enter the market with similar or identical products or platforms, which could have a material adverse effect on our business prospects and financial condition. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depending upon the timing, duration and specifics of FDA marketing approval of our current or future product candidates, one or more of the U.S. patents we own or license may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. Different laws govern the extension of patents on approved pharmaceutical products in Europe and other jurisdictions. However, we may not be granted a patent extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. For example, we may not be granted an extension in the U.S. if all of our patents covering an approved product expire more than fourteen years from the date of NDA approval for a product covered by those patents. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or restoration or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our ability to generate revenues could be materially adversely affected. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our current or future product candidates. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity and is therefore costly, time consuming and inherently uncertain. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. Additionally, there have been recent proposals for additional changes to the patent laws of the U.S. and other countries that, if adopted, could impact our ability to obtain patent protection for our proprietary technology or our ability to enforce our proprietary technology. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Risks Related to our Trademarks, Trade Names and Trade Secrets</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If our trademarks and trade names for our products or company name are not adequately protected in one or more countries where we intend to market our products, we may delay the launch of product brand names, use different trademarks or tradenames in different countries, or face other potentially adverse consequences to building our product brand recognition. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our trademarks or trade name may be challenged, infringed, diluted, circumvented, declared generic, or determined to be infringing on other marks. In such a circumstance, we may not be able to protect our rights to these marks or may be forced to stop using product names, which we need for name recognition by potential partners and customers in our markets of interest. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, during the trademark registration process, we may receive Office Actions from the USPTO or from comparable agencies in foreign jurisdictions refusing registration of our trademarks. In the USPTO and in comparable agencies in many foreign jurisdictions, third parties are also given an opportunity to oppose pending trademark applications and/or to seek the cancellation of registered trademarks. For example, in November 2019, Novartis AG filed actions in the U.S. and European Union trademark offices opposing our applications to register KYMERA and KYMERA THERAPEUTICS for pharmaceuticals and drug development services on the basis of its claimed rights in the KYMRIAH mark.&nbsp;&nbsp;This dispute was amicably settled in October 2020 and Kymera&#8217;s pending applications for KYMERA and KYMERA THERAPEUTICS should proceed to registration in both jurisdictions. Opposition or cancellation proceedings may be filed against future trademark applications or registrations, and our trademark applications or registrations may not survive such proceedings.&nbsp;&nbsp;In the United States and other jurisdictions that recognize common law trademark rights, we intend to rely on both registration and common law protection for our trademarks.&nbsp;&nbsp;However, if we are unable to obtain registrations of future trademarks due to trademark office obstacles or third party objections, we may not be able to compete as effectively and our business may be adversely affected. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we are unable to adequately protect and enforce our trade secrets, our business and competitive position would be harmed. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the protection afforded by patents we may own or in-license, we seek to rely on trade secret protection, confidentiality agreements, and license agreements to protect proprietary know-how that may not be patentable, processes for which patents are difficult to enforce and any other elements of our product discovery and development processes that involve proprietary know-how, information, or technology that may not be covered by patents. Although we require all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information, or technology to enter into confidentiality agreements, trade secrets can be difficult to protect and we have limited control over the protection of trade secrets used by our collaborators and suppliers. We cannot be certain that we have or will obtain these agreements in all circumstances and we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary information. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, any of these parties might breach the agreements and intentionally or inadvertently disclose our trade secret information and we may not be able to obtain adequate remedies for such breaches. In addition, competitors may otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. If we choose to go to court to stop a third party from using any of our trade secrets, we may incur substantial costs. These lawsuits may consume our time and other resources even if we are successful. Furthermore, the laws of some foreign countries do not protect proprietary rights and trade secrets to the same extent or in the same manner as the laws of the U.S. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the U.S. and abroad. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, we will not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, financial condition, results of operations and future prospects. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the case of employees, we enter into agreements providing that all inventions conceived by the individual, and which are related to our current or planned business or research and development or made during normal working hours, on our premises or using our equipment or proprietary information, are our exclusive property. Although we require all of our employees to assign their inventions to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations, and prospects. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Risks Related to Intellectual Property Litigation and Infringement Claims</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may initiate, become a defendant in, or otherwise become party to lawsuits to protect or enforce our intellectual property rights, which could be expensive, time-consuming and unsuccessful. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competitors may infringe any intellectual property we may own or in-license, including our patents and trademarks. In addition, any intellectual property we may own or in-license also may become the subject of a dispute, including those based on inventorship, priority, validity or unenforceability. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. In addition, in an infringement proceeding, a court may decide that any intellectual property we may own or in-license is not valid or is unenforceable or that the other party&#8217;s use of our technology that may be patented falls under the safe harbor to patent infringement under 35 U.S.C. &#167;271(e)(1). There is also the risk that, even if the validity of these patents is upheld, the court may refuse to stop the other party from using the technology at issue on the grounds that any patents we may own or in-license do not cover the technology in question or that such third party&#8217;s activities do not infringe our patent applications or any patents we may own or in-license. An adverse result in any litigation or defense proceedings could put one or more of any patents or other intellectual property we may own or in-license at risk of being invalidated, held unenforceable, or interpreted narrowly and could put our own applications at risk of not issuing. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, patient support or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.58%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Post-grant proceedings provoked by third parties or brought by the USPTO may be necessary to determine the validity or priority of inventions with respect to our patent applications or any patents we may own or in-license. These proceedings are expensive and an unfavorable outcome could result in a loss of our current patent rights and could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. In addition to potential USPTO post-grant proceedings, we may become a party to patent opposition proceedings in the EPO, or similar proceedings in other foreign patent offices or courts where our patents may be challenged. The costs of these proceedings could be substantial, and may result in a loss of scope of some claims or a loss of the entire patent. An unfavorable result in a post-grant challenge proceeding may result in the loss of our right to exclude others from practicing one or more of our inventions in the relevant country or jurisdiction, which could have a material adverse effect on our business. Litigation or post-grant proceedings within patent offices may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent misappropriation of our trade secrets or confidential information, particularly in countries where the laws may not protect those rights as fully as in the U.S. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.58%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.58%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be able to detect infringement against any intellectual property we may own or in-license. Even if we detect infringement by a third party of any intellectual property we may own or in-license, we may choose not to pursue litigation against or settlement with the third party. If we later sue such third party for infringement, the third party may have certain legal defenses available to it, which otherwise would not be available except for the delay between when the infringement was first detected and when the suit was brought. Such legal defenses may make it impossible for us to enforce any patents or other intellectual property we may own or in-license against such third party. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intellectual property litigation and administrative office challenges in one or more countries could cause us to spend substantial resources and distract our personnel from their normal responsibilities. Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, patient support or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. As noted above, some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace, including compromising our ability to raise the funds necessary to continue our preclinical studies and future clinical trials, continue our research programs, license necessary technology from third parties, or enter into development collaborations that would help us commercialize our current or future product candidates, if approved. Any of the foregoing events would harm our business, financial condition, results of operations and prospects. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may be subject to damages or settlement costs resulting from claims that we or our employees have violated the intellectual property rights of third parties, or are in breach of our agreements. We may be accused of, allege or otherwise become party to lawsuits or disputes alleging wrongful disclosure of third-party confidential information by us or by another party, including current or former employees, contractors or consultants. In addition to diverting attention and resources, such disputes could adversely impact our business reputation and/or protection of our proprietary technology. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The intellectual property landscape relevant to our products and programs is crowded, and third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business. Our commercial success depends upon our ability to develop, manufacture, market and sell our current and future product candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property rights of third parties. There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including derivation, interference, reexamination, <font style="font-style:italic;">inter partes</font> review and post grant review proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. We or any of our current or future licensors or strategic partners may be party to, exposed to, or threatened with, future adversarial proceedings or litigation by third parties having patent or other intellectual property rights alleging that our current or future product candidates and/or proprietary technologies infringe, misappropriate or otherwise violate their intellectual property rights. We cannot assure you that our current or future product candidates, the Pegasus platform, and other technologies that we have developed, are developing or may develop in the future do not or will not infringe, misappropriate or otherwise violate existing or future patents or other intellectual property rights owned by third parties. For example, many of our employees were previously employed at other biotechnology or pharmaceutical companies. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these individuals have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s former employer. We may also be subject to claims that patents and applications we have filed to protect inventions of our employees, consultants and advisors, even those related to one or more of our current or future product candidates, the Pegasus platform, or other technologies, are rightfully owned by their former or concurrent employer. Litigation may be necessary to defend against these claims. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While certain activities related to development and preclinical and clinical testing of our current or future product candidates may be subject to safe harbor of patent infringement under 35 U.S.C. &#167;271(e)(1), upon receiving FDA approval for such candidates we or any of our future licensors or strategic partners may immediately become party to, exposed to, or threatened with, future adversarial proceedings or litigation by third parties having patent or other intellectual property rights alleging that such product candidates infringe, misappropriate or otherwise violate their intellectual property rights. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing our current or future product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our current or future product candidates may give rise to claims of infringement of the patent rights of others. Moreover, it is not always clear to industry participants, including us, which patents cover various types of drugs, products or their methods of use or manufacture. Thus, because of the large number of patents issued and patent applications filed in our fields, there may be a risk that third parties may allege they have patent rights encompassing our current or future product candidates, technologies or methods. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a third party claims that we infringe, misappropriate or otherwise violate its intellectual property rights, we may face a number of issues, including, but not limited to: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">infringement, misappropriation and other intellectual property claims which, regardless of merit, may be expensive and time-consuming to litigate and may divert our management&#8217;s attention from our core business and may impact our reputation; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">substantial damages for infringement, misappropriation or other violations, which we may have to pay if a court decides that the product candidate or technology at issue infringes, misappropriates or violates the third party&#8217;s rights, and, if the court finds that the infringement was willful, we could be ordered to pay treble damages and the patent owner&#8217;s attorneys&#8217; fees; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a court prohibiting us from developing, manufacturing, marketing or selling our current or future product candidates, or from using our proprietary technologies, including our Pegasus platform, unless the third-party licenses its product rights to us, which it is not required to do on commercially reasonable terms or at all; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">if a license is available from a third party, we may have to pay substantial royalties, upfront fees and other amounts, and/or grant cross-licenses to intellectual property rights for our products, or the license to us may be non-exclusive, which would permit third parties to use the same intellectual property to compete with us; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">redesigning our current or future product candidates or processes so they do not infringe, misappropriate or violate third-party intellectual property rights, which may not be possible or may require substantial monetary expenditures and time; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and, if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some of our competitors may be able to sustain the costs of litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations or could otherwise have a material adverse effect on our business, results of operations, financial condition and prospects. The occurrence of any of the foregoing could have a material adverse effect on our business, financial condition, results of operations or prospects. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.58%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third parties may assert that we are employing their proprietary technology without authorization. Patents issued in the U.S. by law enjoy a presumption of validity that can be rebutted in U.S. courts only with evidence that is &#8220;clear and convincing,&#8221; a heightened standard of proof. There may be issued third-party patents of which we are currently unaware with claims to compositions, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our current or future product candidates. Patent applications can take many years to issue. In addition, because some patent applications in the U.S. may be maintained in secrecy until the patents are issued, patent applications in the U.S. and many foreign jurisdictions are typically not published until 18 months after their earliest priority filing date, and publications in the scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed patent applications covering our current or future product candidates or technology. If any such patent applications issue as patents, and if such patents have priority over our patent applications or patents we may own or in-license, we may be required to obtain rights to such patents owned by third parties which may not be available on commercially reasonable terms or at all, or may only be available on a non-exclusive basis. There may be currently pending third-party patent applications which may later result in issued patents that our current or future product candidates may infringe. It is also possible that patents owned by third parties of which we are aware, but which we do not believe are relevant to our current or future product candidates or other technologies, could be found to be infringed by our current or future product candidates or other technologies. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Moreover, we may fail to identify relevant patents or incorrectly conclude that a patent is invalid, not enforceable, exhausted, or not infringed by our activities. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of our current or future product candidates, molecules used in or formed during the manufacturing process, or any final product itself, the holders of any such patents may be able to block our ability to commercialize the product candidate unless we obtained a license under the applicable patents, or until such patents expire or they are finally determined to be held invalid or unenforceable. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy or patient selection methods, the holders of any such patent may be able to block our ability to develop and commercialize the product candidate unless we obtained a license or until such patent expires or is finally determined to be held invalid or unenforceable. In either case, such a license may not be available on commercially reasonable terms or at all. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, or at all, our ability to commercialize our current or future product candidates or Pegasus platform may be impaired or delayed, which could in turn significantly harm our business. Even if we obtain a license, it may be nonexclusive, thereby giving our competitors access to the same technologies licensed to us. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Parties making claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our current or future product candidates. Defense of these claims, regardless of their merit, could involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement, misappropriation or other violation against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need or may choose to obtain licenses from third parties to advance our research or allow commercialization of our current or future product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize our current or future product candidates or technologies, which could harm our business significantly. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might subject us to infringement claims or adversely affect our ability to develop and market our current or future product candidates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot guarantee that any of our or our licensors&#8217; patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending patent application in the U.S. and abroad that is relevant to or necessary for the commercialization of our current or future product candidates in any jurisdiction. For example, U.S. patent applications filed before November&#160;29, 2000 and certain U.S. patent applications filed after that date that will not be filed outside the U.S. remain confidential until patents issue. As mentioned above, patent applications in the U.S. and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our current or future product candidates could have been filed by third parties without our knowledge. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our current or future product candidates or the use of our current or future product candidates. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our current or future product candidates. We may incorrectly determine that our current or future product candidates are not covered by a third-party patent or may incorrectly predict whether a third party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the U.S. or abroad that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our current or future product candidates. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our current or future product candidates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we fail to identify and correctly interpret relevant patents, we may be subject to infringement claims. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we fail in any such dispute, in addition to being forced to pay damages, which may be significant, we may be temporarily or permanently prohibited from commercializing any of our current or future product candidates or technologies that are held to be infringing. We might, if possible, also be forced to redesign current or future product candidates so that we no longer infringe the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business and could adversely affect our business, financial condition, results of operations and prospects. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Employee Matters, Managing Growth and Other Risks Related to Our Business </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Risks Related to Employee Matters and Managing Growth</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are highly dependent on the research and development, clinical and business development expertise of Nello Mainolfi, Ph.D., our President and Chief Executive Officer, Jared Gollob, M.D., our Chief Medical Officer, Bruce Jacobs, our Chief Financial Officer, and Richard Chesworth, DPhil, our Chief Scientific Officer, as well as the other principal members of our management, scientific and clinical teams. Although we have entered into employment letter agreements with our executive officers, each of them may terminate their employment with us at any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recruiting and retaining qualified scientific, clinical, manufacturing and sales and marketing personnel will also be critical to our success. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize drugs. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. Failure to succeed in clinical trials may make it more challenging to recruit and retain qualified scientific personnel. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We will need to develop and expand our company, and we may encounter difficulties in managing this development and expansion, which could disrupt our operations. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, we had 75 full-time employees, and we will continue to increase our number of employees and the scope of our operations. To manage our anticipated development and expansion, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Our management may need to divert a disproportionate amount of its attention away from its day-to-day activities and devote a substantial amount of time to managing these development activities. Due to our limited resources, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. This may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. The expansion of our operations may lead to significant costs and may divert financial resources from other projects, such as the development of our current or future product candidates. If our management is unable to effectively manage our expected development and expansion, our expenses may increase more than expected, our ability to generate or increase our revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize our current or future product candidates, if approved, and compete effectively will depend, in part, on our ability to effectively manage the future development and expansion of our company. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We or the third parties upon whom we depend may be adversely affected by natural disasters, and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any unplanned event, such as flood, fire, explosion, earthquake, extreme weather condition, medical epidemics, including any potential effects from the current global spread of&#160;COVID-19, power shortage, telecommunication failure or other natural or man-made accidents or incidents that result in us being unable to fully utilize our facilities, or the manufacturing facilities of our third-party contract manufacturers, may have a material and adverse effect on our ability to operate our business and have significant negative consequences on our financial and operating conditions. Loss of access to these facilities may result in increased costs, delays in the development of our product candidates or interruption of our business operations. Natural disasters or pandemics such as the&#160;COVID-19&#160;outbreak could further disrupt our operations, and have a material and adverse effect on our business, financial condition, results of operations and prospects. For example, we have instituted a temporary work from home policy for non-essential office personnel and it is possible that this could have a negative impact on the execution of our business plans and operations. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as our research facilities or the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business. As part of our risk management policy, we maintain insurance coverage at levels that we believe are appropriate for our business. However, in the event of an accident or incident at these facilities, we cannot assure our investors that the amounts of insurance will be sufficient to satisfy any damages and losses. If our facilities or the manufacturing facilities of our third-party contract manufacturers are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs may be harmed. Any business interruption may have a material and adverse effect on our business, financial condition, results of operations and prospects. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Risks Related to Data and Privacy</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our internal computer systems, or those of our third-party CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our current or future product candidates&#8217; development programs. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Despite the implementation of security measures, our internal computer systems and those of our third-party CROs and other contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While we have not experienced any such system failure, accident, or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our programs. For example, the loss of data from preclinical studies or clinical trials for our current or future product candidates could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach results in a loss of or damage to our data or applications, other data or applications relating to our technology or current or future product candidates, or inappropriate disclosure of confidential or proprietary information, we could incur liabilities and the further development of our current or future product candidates could be delayed. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may be unable to adequately protect our information systems from cyberattacks, which could result in the disclosure of confidential or proprietary information, including personal data, damage our reputation, and subject us to significant financial and legal exposure. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely on information technology systems that we or our third-party providers operate to process, transmit and store electronic information in our day-to-day operations. In connection with our product discovery efforts, we may collect and use a variety of personal data, such as names, mailing addresses, email addresses, phone numbers and clinical trial information. A successful cyberattack could result in the theft or destruction of intellectual property, data or other misappropriation of assets, or otherwise compromise our confidential or proprietary information and disrupt our operations. Cyberattacks are increasing in their frequency, sophistication and intensity, and have become increasingly difficult to detect. Cyberattacks could include wrongful conduct by hostile foreign governments, industrial espionage, wire fraud and other forms of cyber fraud, the deployment of harmful malware,&#160;denial-of-service,&#160;social engineering fraud or other means to threaten data security, confidentiality, integrity and availability. A successful cyberattack could cause serious negative consequences for us, including, without limitation, the disruption of operations, the misappropriation of confidential business information, including financial information, trade secrets, financial loss and the disclosure of corporate strategic plans. Although we devote resources to protect our information systems, we realize that cyberattacks are a threat, and there can be no assurance that our efforts will prevent information security breaches that would result in business, legal, financial or reputational harm to us, or would have a material adverse effect on our results of operations and financial condition. Any failure to prevent or mitigate security breaches or improper access to, use of, or disclosure of our clinical data or patients&#8217; personal data could result in significant liability under state (<font style="font-style:italic;">e.g.</font>, state breach notification laws), federal (<font style="font-style:italic;">e.g.</font>, HIPAA, as amended by HITECH), and international law (<font style="font-style:italic;">e.g.</font>, the EU General Data Protection Regulation, or GDPR) and may cause a material adverse impact to our reputation, affect our ability to use collected data, conduct new studies and potentially disrupt our business. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely on our third-party providers to implement effective security measures and identify and correct for any such failures, deficiencies or breaches. We also rely on our employees and consultants to safeguard their security credentials and follow our policies and procedures regarding use and access of computers and other devices that may contain our sensitive information. If we or our third-party providers fail to maintain or protect our information technology systems and data integrity effectively or fail to anticipate, plan for or manage significant disruptions to our information technology systems, we or our third-party providers could have difficulty preventing, detecting and controlling such cyber-attacks and any such attacks could result in losses described above, as well as disputes with physicians, patients and our partners, regulatory sanctions or penalties, increases in operating expenses, expenses or lost revenues or other adverse consequences, any of which could have a material adverse effect on our business, results of operations, financial condition, prospects and cash flows. Any failure by such third parties to prevent or mitigate security breaches or improper access to or disclosure of such information could have similarly adverse consequences for us. If we are unable to prevent or mitigate the impact of such security or data privacy breaches, we could be exposed to litigation and governmental investigations, which could lead to a potential disruption to our business. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Common Stock </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The price of our common stock may be volatile and fluctuate substantially, <font style="color:#000000;">and you may lose all or part of your investment</font>. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our stock price is likely to be volatile. The stock market in general and the market for biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, you may lose all or part of your investment.&nbsp;&nbsp;The market price for our common stock may be influenced by many factors, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the success of competitive drugs or technologies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">results of preclinical studies and clinical trials of our current or future product candidates or those of our competitors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">regulatory or legal developments in the U.S. and other countries; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">developments or disputes concerning patent applications, issued patents or other proprietary rights; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the recruitment or departure of key personnel; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the level of expenses related to any of our current or future product candidates or clinical development programs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the results of our efforts to discover, develop, acquire or in-license additional current or future product candidates or drugs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">variations in our financial results or those of companies that are perceived to be similar to us; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">changes in the structure of healthcare payment systems; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">market conditions in the pharmaceutical and biotechnology sectors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">general economic, industry and market conditions; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the other factors described in this &#8220;Risk Factors&#8221; section. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COVID-19 has been spreading rapidly around the world since December 2019 and has negatively affected the stock market and investor sentiment. The price of our common stock may be disproportionately affected as investors may favor traditional profit-making industries and companies during the times of market uncertainty and instability. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As widely reported, global credit and financial markets have experienced extreme volatility and disruptions in the past several years, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability, including most recently in connection with the COVID-19 pandemic. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, or do not improve, it may make any necessary debt or equity financing more difficult, more costly, and more dilutive. Furthermore, our stock price may decline due in part to the volatility of the stock market and the general economic downturn. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay, scale back or discontinue the development and commercialization of one or more of our product candidates or delay our pursuit of potential in-licenses or acquisitions. In addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive these difficult economic times, which could directly affect our ability to attain our operating goals on schedule and on budget. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or current or future product candidates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of private and public equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. We do not currently have any committed external source of funds. To the extent that we raise additional capital through the sale of common stock or securities convertible or exchangeable into common stock, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that materially adversely affect your rights as a common stockholder. Debt financing, if available, would increase our fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we raise funds through additional collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our intellectual property, future revenue streams, research programs or current or future product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, scale back or discontinue the development and commercialization of one or more of our product candidates, delay our pursuit of potential in-licenses or acquisitions or grant rights to develop and market current or future product candidates that we would otherwise prefer to develop and market ourselves. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trading market for our common stock will rely in part on the research and reports that industry or financial analysts publish about us or our business. We may never obtain research coverage by industry or financial analysts. If no or few analysts commence coverage of us, the trading price of our stock would likely decrease. Even if we do obtain analyst coverage, if one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our executive officers, directors, principal stockholders and their affiliates exercise significant influence over our company, which will limit your ability to influence corporate matters and could delay or prevent a change in corporate control. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The existing holdings of our executive officers, directors, principal stockholders and their affiliates will represent beneficial ownership, in the aggregate, of approximately&#160;36% of our outstanding common stock. As a result, these stockholders, if they act together, will be able to influence our management and affairs and the outcome of matters submitted to our stockholders for approval, including the election of directors and any merger, consolidation or sale of all or substantially all of our assets. The concentration of voting power among these stockholders may have an adverse effect on the price of our common stock. In addition, this concentration of ownership might adversely affect the market price of our common stock by: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">delaying, deferring or preventing a change of control of us; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">impeding a merger, consolidation, takeover or other business combination involving us; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of us. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:9.07%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, upon the expiration of the lock-up agreements, the early release of these agreements, or the perception in the market that the holders of a large number of shares of common stock intend to sell shares, could reduce the market price of our common stock.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All shares of common stock sold in our initial public offering or otherwise outstanding as of our initial public offering are able to be sold in the public market. Shares issued upon the exercise of stock options outstanding under our equity incentive plans or pursuant to future awards granted under those plans will become available for sale in the public market to the extent permitted by the provisions of applicable vesting schedules, any applicable market standoff and lock-up agreements, and Rule 144 and Rule 701 under the Securities Act.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain holders of our common stock have rights, subject to conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. We also filed a registration statement on Form S-8 registering the issuance of 9.5 million shares of common stock issued or reserved for future issuance under our equity compensation plans. Shares registered under this registration statement on Form S-8 can be freely sold in the public market upon issuance and once vested, subject to volume limitations applicable to affiliates and the lock-up agreements described above. If any of these additional shares are sold, or if it is perceived that they will be sold, in the public market, the market price of our common stock could decline.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may be at an increased risk of securities class action litigation. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Historically, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biotechnology and pharmaceutical companies have experienced significant stock price volatility in recent years. If we were to be sued, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Tax</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Changes in tax law may adversely affect us or our investors. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The rules dealing with U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service, or IRS, and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, many changes have been made and changes are likely to continue to occur in the future. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, the Tax Cuts and Jobs Act, or the TCJA, was enacted in 2017 and made significant changes to corporate taxation, including the reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, the limitation of the tax deduction for net interest expense to 30% of adjusted taxable income (except for certain small businesses), the limitation of the deduction for net operating losses from taxable years beginning after December&#160;31, 2017 to 80% of current year taxable income and the elimination of net operating loss carrybacks generated in taxable years ending after December&#160;31, 2017 (though any such net operating losses may be carried forward indefinitely), and the modification or repeal of many business deductions and credits. In addition, on March&#160;27, 2020, former President Trump signed into law the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, which, among other things, suspends the 80% limitation on the deduction for net operating losses in taxable years beginning before January 1, 2021, permits a 5-year carryback of net operating losses arising in taxable years beginning after December 31, 2017 and before January 1, 2021, and generally caps the limitation on the deduction for net interest expense at 50% of adjusted taxable income for taxable years beginning in 2019 and 2020. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It cannot be predicted whether, when, in what form, or with what effective dates, new tax laws may be enacted, or regulations and rulings may be enacted, promulgated or issued under existing or new tax laws, which could result in an increase in our or our stockholders&#8217; tax liability or require changes in the manner in which we operate in order to minimize or mitigate any adverse effects of changes in tax law or in the interpretation thereof. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our ability to utilize our net operating loss carryforwards and certain other tax attributes to offset future taxable income may be subject to certain limitations, and, as a result, unavailable to reduce our future tax liability. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk64628539"></a>As of December&#160;31, 2020, we had federal and state net operating loss carryforwards of&#160;$74.4&#160;million and $61.2&#160;million, respectively, which begin to expire in various amounts in&#160;2036&#160;(other than federal net operating loss carryforwards arising in taxable years beginning after December&#160;31, 2017, which are not subject to expiration). As of December&#160;31, 2020, we also had federal and state research and development tax credit carryforwards of&#160;$2.7&#160;million and $1.3&#160;million, respectively, which begin to expire in&#160;2036. These net operating loss and tax credit carryforwards could expire unused and be unavailable to offset future income tax liabilities. In addition, in general, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, a corporation that undergoes an &#8220;ownership change&#8221; is subject to limitations on its ability to utilize its pre-change </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk64628539"></a>net operating losses or tax credits, or NOLs or credits, to offset future taxable income or taxes. For these purposes, an ownership change generally occurs where the aggregate stock ownership of one or more stockholders or groups of stockholders who own at least 5% of a corporation&#8217;s stock increases by more than 50 percentage points over the lowest ownership percentage of such stockholders or groups of stockholders within a specified testing period. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">O</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ur existing NOLs or credits may be subject to limitations arising from previous ownership changes</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Moreover, if we undergo any additional ownership changes, our ability to utilize NOLs or credits could be further limited by Sections 382 and 383 of the Code. In addition, future changes in our stock ownership, many of which are outside of our control, could result in an ownership change under Sections 382 and 383 of the Code. Our NOLs or credits may also be impaired under state law. Accordingly, we may not be able to utilize a material portion of our NOLs or credits. Furthermore, our ability to utilize our NOLs or credits is conditioned upon our attaining profitability and generating U.S. federal and state taxable income. As described above under &#8220;Risk Factors&#8212;Risks Related to our Financial Position and Need for Additional Capital,&#8221; we have incurred significant net losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future; and therefore, we do not know whether or when we will generate the U.S. federal or state taxable income necessary to utilize our NOL</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or credit carryforwards that are subject to limitation by Sections 382 and 383 of the Code. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Controls and Reporting Requirements </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we fail to establish and maintain proper and effective internal control over financial reporting, our operating results and our ability to operate our business could be harmed. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ensuring that we have adequate internal financial and accounting controls and procedures in place so that we can produce accurate financial statements on a timely basis is a costly and time-consuming effort that needs to be re-evaluated frequently. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with generally accepted accounting principles. We have begun the process of documenting, reviewing and improving our internal controls and procedures for compliance with Section&#160;404 of the Sarbanes-Oxley Act, which will require annual management assessment of the effectiveness of our internal control over financial reporting. We have begun recruiting additional finance and accounting personnel with certain skill sets that we will need as a public company. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Implementing any appropriate changes to our internal controls may distract our officers and employees, entail substantial costs to modify our existing processes, and take significant time to complete. These changes may not, however, be effective in maintaining the adequacy of our internal controls, and any failure to maintain that adequacy, or consequent inability to produce accurate financial statements on a timely basis, could increase our operating costs and harm our business. In addition, investors&#8217; perceptions that our internal controls are inadequate or that we are unable to produce accurate financial statements on a timely basis may harm our stock price and make it more difficult for us to effectively market and sell any of our present or future product candidates that may receive regulatory approval. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to certain reporting requirements of the Exchange Act. Our disclosure controls and procedures are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management, recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements or insufficient disclosures due to error or fraud may occur and not be detected. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are an emerging growth company and a smaller reporting company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies will make our common stock less attractive to investors. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act, or JOBS Act, enacted in April 2012. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in this Annual Report and our periodic reports and proxy statements, and exemptions from the requirements of holding nonbinding advisory votes on executive compensation and stockholder </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approval of any golden parachute payments not previously approved. We could be an emerging growth company for up to five years following the year in which we complete</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> our initial public offering, although circumstances could cause us to lose that status earlier. We will remain an emerging growth company until the earlier of (</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)&#160;the last day of the fiscal year (a)&#160;following the fifth anniversary of the closing of our initial public offering, (b)&#160;in which we have total annual gross revenue of at least $1.07&#160;billion, or (c)&#160;in which we are deemed to be a large accelerated filer, which requires the market value of our common stock that is held by non-affiliates to exceed $700&#160;million as of the prior June 30th, and (ii)&#160;the date on which we have issued more than $1&#160;billion in non-convertible debt during the prior three-year period. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have elected to not &#8220;opt out&#8221; of this exemption from complying with new or revised accounting standards and, therefore, we will adopt new or revised accounting standards at the time private companies adopt the new or revised accounting standard and will do so until such time that we either (i)&#160;irrevocably elect to &#8220;opt out&#8221; of such extended transition period or (ii)&#160;no longer qualify as an emerging growth company. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even after we no longer qualify as an emerging growth company, we may still qualify as a &#8220;smaller reporting company,&#8221; which would allow us to continue to take advantage of many of the same exemptions from disclosure requirements, including not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Charter and Bylaws </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control, which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our fourth amended and restated certificate of incorporation and our second amended and restated bylaws contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board will be elected at one time; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at a meeting of our stockholders; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a requirement that special meetings of stockholders be called only by the board of directors acting pursuant to a resolution approved by the affirmative vote of a majority of the directors then in office; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">advance notice requirements for stockholder proposals and nominations for election to our board of directors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a requirement that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than two-thirds of all outstanding shares of our voting stock then entitled to vote in the election of directors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a requirement of approval of not less than two-thirds of all outstanding shares of our voting stock to amend any bylaws by stockholder action or to amend specific provisions of our certificate of incorporation; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the authority of the board of directors to issue preferred stock on terms determined by the board of directors without stockholder approval and which preferred stock may include rights superior to the rights of the holders of common stock. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporate Law, or DGCL, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These antitakeover provisions and other provisions in our fourth amended and restated certificate of incorporation and amended and restated bylaws could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our amended and restated bylaws designate specific courts as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to our amended and restated bylaws, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware is the sole and exclusive forum for any state law claims for (1)&#160;any derivative action or proceeding brought on our behalf; (2)&#160;any action asserting a claim of or based on a breach of a fiduciary duty owed by any director, officer or other employee of ours to us or our stockholders; (3)&#160;any action asserting a claim pursuant to any provision of the DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws; or (4)&#160;any action asserting a claim governed by the internal affairs doctrine, or the Delaware Forum Provision. The Delaware Forum Provision will not apply to any causes of action arising under the Securities Act or the Exchange Act. Our amended and restated bylaws further provide that unless we consent in writing to the selection of an alternative forum, the United States District Court for the District of Massachusetts shall be the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, or the Federal Forum Provision. In addition, our amended and restated bylaws provide that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock is deemed to have notice of and consented to the Delaware Forum Provision and the Federal Forum Provision; provided, however, that stockholders cannot and will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize that the Delaware Forum Provision and the Federal Forum Provision in our amended and restated bylaws may impose additional litigation costs on stockholders in pursuing any such claims, particularly if the stockholders do not reside in or near the State of Delaware or the Commonwealth of Massachusetts, as applicable. Additionally, the forum selection clauses in our amended and restated bylaws may limit our stockholders&#8217; ability to bring a claim in a judicial forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage the filing of lawsuits against us and our directors, officers and employees, even though an action, if successful, might benefit our stockholders. In addition, while the Delaware Supreme Court ruled in March 2020 that federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court are &#8220;facially valid&#8221; under Delaware law, there is uncertainty as to whether other courts will enforce our Federal Forum Provision. If the Federal Forum Provision is found to be unenforceable, we may incur additional costs associated with resolving such matters. The Federal Forum Provision may also impose additional litigation costs on stockholders who assert that the provision is not enforceable or invalid. The Court of Chancery of the State of Delaware and the United States District Court for the District of Massachusetts may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1B_UNRESOLVED_STAFF_COMMENTS"></a><a name="ITEM_1B_UNRESOLVED_STAFF_COMMENTS"></a>Item 1B. Unresolved Staff Comments. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_2_PROPERTIES"></a><a name="ITEM_2_PROPERTIES"></a>Item 2. Properties. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently occupy approximately 34,522 rentable square feet of office and laboratory space in Watertown, Massachusetts under a lease that expires in March 2030. We have an option to extend the lease term for five additional years. We believe that our office and laboratory space is sufficient to meet our current needs and that suitable additional space will be available as and when needed.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_3_LEGAL_PROCEEDINGS"></a><a name="ITEM_3_LEGAL_PROCEEDINGS"></a>Item 3. Legal Proceedings. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may be subject to legal proceedings and claims in the ordinary course of business. We are not currently aware of any such proceedings or claims that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_4_MINE_SAFETY_DISCLOSURES"></a><a name="ITEM_4_MINE_SAFETY_DISCLOSURES"></a>Item 4. Mine Safety Disclosures.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p><a name="_AEIOULastRenderedPageBreakAEIOU5"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART II</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"></a><a name="ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"></a>Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Certain Information Regarding the Trading of Our Common Stock</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock trades under the symbol &#8220;KYMR&#8221; on the Nasdaq Global Select Market and has been publicly traded since August 21, 2020. Prior to this time, there was no public market for our common stock.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Holders of Our Common Stock</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of February 28, 2021, there were approximately 69 holders of record of shares of our common stock. This number does not include stockholders for whom shares are held in &#8220;nominee&#8221; or &#8220;street&#8221; name.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities Authorized for Issuance Under Equity Compensation Plans</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by Item 5 of Form 10-K regarding equity compensation plans is incorporated herein by reference to Item 12 of Part III of this Annual Report.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recent Sales of Unregistered Securities</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_6_SELECTED_FINANCIAL_DATA"></a><a name="ITEM_6_SELECTED_FINANCIAL_DATA"></a>Item 6. Selected Financial Data. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reserved.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"></a><a name="ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"></a>Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our audited financial statements and related notes appearing elsewhere in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis and set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. You should review the section titled &#8220;Risk Factors&#8221; in Part I, Item&#160;1A of this Annual Report for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Overview </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body&#8217;s own natural protein degradation system. Our proprietary targeted protein degradation platform, which we refer to as Pegasus&#8482;, allows us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have unique advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. We focus on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or inadequately drugged. To date, we have utilized our Pegasus&#8482; platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform&#8217;s capabilities to additional therapeutic areas. Our initial programs are IRAK4, IRAKIMiD, and STAT3, which each address high impact targets within the interleukin-1 receptor/toll-like receptor, or IL-1R/TLR, and janus kinase/signal transducers and activators of transcription, or JAK/STAT, providing the opportunity to treat a broad range of immune-inflammatory diseases, hematologic malignancies, and solid tumors.&nbsp;&nbsp;<font style="Background-color:#FFFFFF;">Our programs exemplify our focus on addressing high impact targets that have been elusive to conventional modalities and that drive the pathogenesis of multiple serious diseases with significant unmet medical needs. </font>With respect to our IRAK4 program, we are collaborating with Genzyme Corporation, a subsidiary of Sanofi S.A, or Sanofi, on the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. We submitted an Investigational New Drug Application, or IND, to the U.S. Food and Drug Administration, or FDA, for KT-474 in 2020, and initiated the SAD portion of our Phase 1 trial in adult healthy volunteers in February 2021. We also expect to submit INDs for degraders from our IRAKIMiD and STAT3 programs in the second half of 2021, and if cleared, to initiate Phase 1 trials in patients thereafter.  </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception in 2015, we have devoted substantially all of our efforts to organizing and staffing our company, research and development activities, business planning, raising capital, building our intellectual property portfolio and providing general and administrative support for these operations To date, we had received gross proceeds of $617.8&#160;million from the sale of common stock including our August 2020 initial public offering and concurrent private placement, sales of our convertible preferred stock and through our collaborations with Vertex Pharmaceuticals Incorporated, or Vertex, and Genzyme Corporation, or Sanofi.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred significant operating losses since inception. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our current product candidates or any future product candidates. Our net losses were $45.6 million and $41.2 million for the years ended December&#160;31, 2020 and 2019, respectively. In addition, as of December&#160;31, 2020 and 2019 we had an accumulated deficit of $128.8 million and $76.5 million, respectively. We expect that our expense and capital requirements will increase substantially in connection with our ongoing activities, particularly if and as we: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">continue preclinical activities of our initial programs, IRAK4, IRAKIMiD and STAT3, including the advancement of our IRAK4 program into a Phase 1 Clinical Trial; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">initiate and continue research and preclinical and clinical development of our other product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">advance the development of our product candidate pipeline; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">continue to develop and expand our Pegasus platform to identify additional product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">maintain, expand and protect our intellectual property portfolio; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">seek marketing approvals for our product candidates that successfully complete clinical trials, if any; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">acquire or in-license additional product candidates and technologies; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">expand our infrastructure and facilities to accommodate our growing employee base and ongoing development activity; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">require the manufacture of larger quantities of our product candidates for clinical development and potential commercialization; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">add operational, financial and management information systems and personnel, including personnel to support our research and development programs, any future commercialization efforts and operating as a public company. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, if we obtain marketing approval for any of our lead product candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through the sale of equity, debt financings, or other capital sources, which may include collaborations with other companies or other strategic transactions. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, reduce or eliminate the development and commercialization of one or more of our product candidates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will not generate revenue from product sales unless and until we successfully complete clinical development and obtain marketing approval for our drug candidates. The lengthy process of securing marketing approvals for new drugs requires the expenditure of substantial resources. Any delay or failure to obtain regulatory approvals would materially adversely affect our product candidate development efforts and our business overall. Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, we had cash, cash equivalents and marketable securities of $458.7 million. We believe the existing cash, cash equivalents and marketable securities on hand, will enable us to fund our operating expenses and capital expenditure requirements into 2025. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. See &#8220;&#8212;Liquidity and capital resources.&#8221; </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since it was reported to have surfaced in December 2019, a novel strain of coronavirus, Sars-Cov-2 which leads to COVID-19, has spread across the world and has been declared a pandemic by the World Health Organization. Efforts to contain the spread of COVID-19 have intensified and governments around the world, including in the United States, Europe and Asia, have implemented severe travel restrictions, social distancing requirements, stay-at-home orders and have delayed the commencement of non-COVID-19-related clinical trials, among other restrictions. As a result, the current COVID-19 pandemic has presented a substantial public health and economic challenge around the world and is affecting our employees, patients, communities and business operations, as well as contributing to significant volatility and negative pressure on the U.S. economy and in financial markets We expect that COVID-19 precautions will directly or indirectly impact the timeline for some of our planned clinical trials and are continuing to assess the potential impact of the COVID-19 pandemic on our current and future business and operations, including our expenses and clinical trials, as well as on our industry and the healthcare system. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of the outbreak, many companies have experienced disruptions in their operations and in markets served. To date, we have instated some and may take additional temporary precautionary measures intended to help ensure our employees&#8217; well-being and minimize business disruption. These measures include devising contingency plans and securing additional resources from third-party service providers. For the safety of our employees and their families, we have temporarily reduced the presence of our scientists in our labs and continue to rely on third parties to conduct many of the experiments and studies for our research programs. Certain of our third-party service providers have also experienced shutdowns or other business disruptions. We are continuing to assess the impact of the COVID-19 pandemic on our current and future business and operations, including our expenses and planned clinical trial and other development timelines, as well as on our industry and the healthcare system. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Components of Our Results of Operations </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products in the foreseeable future. Our only revenues have been derived from research collaboration arrangements with Vertex and Sanofi. We expect that our revenue for the next several years will be derived primarily from our current collaboration agreements and any additional collaborations that we may enter into in the future. To date, we have not received any royalties under any of the collaboration agreements. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Vertex Collaboration Agreement </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May&#160;9, 2019, we entered into a collaboration agreement, or the Vertex Agreement, with Vertex, to advance small molecule protein degradation against up to six targets. Under the Vertex Agreement, Vertex has the exclusive option to license the rights to the product candidates developed through the collaboration at which point Vertex will control development and commercialization. Pursuant to the Vertex Agreement, we are responsible for discovery and preclinical research on the targets, and Vertex is responsible for development, manufacturing, and commercialization of the product candidates after it exercises its option to license. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vertex provided us with a non-refundable upfront payment of $50.0&#160;million and purchased 3,059,695 shares of our Series B-1 convertible preferred stock at $6.54 a share, pursuant to a separate, but simultaneously executed Share Purchase Agreement. We are eligible to receive up to $170&#160;million in payments per target, including development, regulatory, and commercial milestones, as well as option exercise payments. In addition, Vertex is obligated to pay us tiered royalties on future net sales on any products that may result from the Vertex Agreement. None of the payments under the Vertex Agreement are refundable. We may also perform follow-on research activities for an optioned target upon Vertex&#8217;s request and at Vertex&#8217;s expense. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Sanofi Agreement </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 7, 2020, we entered into a collaboration agreement, or the Sanofi Agreement, with Sanofi to co-develop drug candidates directed to two biological targets. Under the Sanofi Agreement, we granted to Sanofi a worldwide exclusive license to develop, manufacture and commercialize certain lead compounds generated during the collaboration directed against IRAK4 and one additional undisclosed target in an undisclosed field of use. Such license is exercisable on a collaboration target-by-collaboration target basis only after a specified milestone. For compounds directed against IRAK4, the field of use includes diagnosis, treatment, cure, mitigation or prevention of any diseases, disorders or conditions, excluding oncology and immune-oncology. We are responsible for discovery and preclinical research and conducting a phase 1 clinical trial for at least one degrader directed against IRAK4 plus up to three backup degraders. With respect to both targets, Sanofi is responsible for development, manufacturing, and commercialization of product candidates after a specified development milestone occurs with respect to each collaboration candidate. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have an exclusive option, or Opt-In Right, exercisable on a collaboration target-by-collaboration target basis that will include the right to (i) to fund 50% of the United States development costs for collaboration products directed against such target in the applicable field of use and (ii)&#160;share equally in the net profits and net losses of commercializing collaboration products directed against such target in the applicable field of use in the United States. In addition, if we exercise the Opt-In Right, Sanofi will grant to us an exclusive option, applicable to each collaboration target, which upon exercise will allow us to conduct certain co-promotion activities in the field in the United States. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Sanofi Agreement, unless earlier terminated, will expire on a product-by-product basis on the date of expiration of all payment obligations under the Sanofi Agreement with respect to such product. We or Sanofi may terminate the agreement upon the other party&#8217;s material breach or insolvency or for certain patent challenges. In addition, Sanofi may terminate the agreement for convenience or for a material safety event upon advance prior written notice, and we may terminate the agreement with respect to any collaboration candidate if, following Sanofi&#8217;s assumption of responsibility for the development, commercialization or manufacturing of collaboration candidates with respect to a particular target, Sanofi ceases to exploit any collaboration candidates directed to such target for a specified period. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In consideration for the exclusive licenses granted to Sanofi under the Sanofi Agreement, Sanofi </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">made an</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> upfront payment of $150 million. In addition to the upfront payment, we are eligible to receive certain development milestone payments of up to $1.48 billion in the aggregate, of which more than $1.0 billion relates to the IRAK4 program, upon the achievement of certain developmental or regulatory events. We will be eligible to receive certain commercial milestone payments up to $700 million in the aggregate, of which $400 million relates to the IRAK4 program, which are payable upon the achievement of certain net sales thresholds. We will be eligible to receive tiered royalties for each program on net sales ranging from the high single digits to high teens, subject to low-single digits upward adjustments in certain circumstances. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Operating expenses </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operating expenses since inception have consisted solely of research and development expenses and general and administrative expenses. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Research and development expenses </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses consist primarily of costs incurred in connection with the discovery and development of targeted protein degradation therapeutics, including those in our initial programs, IRAK4, IRAKIMiD and STAT3. These research efforts and costs, which also support the development of, and enhancements to, our Pegasus platform, include external research costs, personnel costs, supplies, license fees and facility-related expenses. We expense research and development costs as incurred. These expenses include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">employee-related expenses, including salaries, related benefits and stock-based compensation expense, for employees engaged in research and development functions; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">expenses incurred under agreements with organizations that support our platform program development; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">contract manufacturing organizations, or CMOs, that are primarily engaged to provide drug substance and product for our preclinical research and development programs, nonclinical studies and other scientific development services; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the cost of acquiring and manufacturing nonclinical trial materials, including manufacturing registration and validation batches; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">facilities, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities and insurance; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">costs related to compliance with quality and regulatory requirements; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">payments made under third-party licensing agreements. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Advance payments that we make for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such amounts are recognized as an expense as the goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered or the services rendered. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect that our research and development expenses will increase substantially in connection with our planned clinical development activities in the near term and in the future. At this time, we cannot accurately estimate or know the nature, timing and costs of the efforts that will be necessary to complete the clinical development of any future product candidates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future clinical development costs may vary significantly based on factors such as: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">per patient trial costs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the number of trials required for approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the number of sites included in the trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the countries in which the trials are conducted; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the length of time required to enroll eligible patients; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the number of patients that participate in the trials; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the number of doses that patients receive; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the drop-out or discontinuation rates of patients; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">potential additional safety monitoring requested by regulatory agencies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the duration of patient participation in the trials and follow-up; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the cost and timing of manufacturing our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the phase of development of our product candidates; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the efficacy and safety profile of our product candidates. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The successful development and commercialization of product candidates is highly uncertain. This is due to the numerous risks and uncertainties associated with product development and commercialization, including the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the timing and progress of nonclinical and clinical development activities; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the number and scope of nonclinical and clinical programs we decide to pursue; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the ability to raise necessary additional funds; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the progress of the development efforts of parties with whom we may enter into collaboration arrangements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our ability to maintain our current development program and to establish new ones; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our ability to establish new licensing or collaboration arrangements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the successful initiation and completion of clinical trials with safety, tolerability and efficacy profiles that are satisfactory to the FDA or any comparable foreign regulatory authority; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the receipt and related terms of regulatory approvals from applicable regulatory authorities; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the availability of drug substance and drug product for use in production of our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our ability to establish and maintain agreements with third-party manufacturers for clinical supply for our clinical trials and commercial manufacturing, if any of our product candidates are approved; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our ability to obtain and maintain patents, trade secret protection and regulatory exclusivity, both in the United States and internationally; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our ability to protect our rights in our intellectual property portfolio; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our ability to obtain and maintain third-party insurance coverage and adequate reimbursement; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the acceptance of our product candidates, if approved, by patients, the medical community and third-party payors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the impact of competition with other products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the impact of any business interruptions to our operations, including the timing and enrollment of patients in our planned clinical trials, or to those of our manufacturers, suppliers, or other vendors resulting from the COVID-19 pandemic or similar public health crisis; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our ability to maintain a continued acceptable safety profile for our therapies following approval. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A change in the outcome of any of these variables with respect to the development of our product candidates could significantly change the costs and timing associated with the development of that product candidate. We may never succeed in obtaining regulatory approval for any of our product candidates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">General and administrative expenses </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, corporate and business development, and administrative functions. General and administrative expenses also include legal fees relating to patent and corporate matters, professional fees for accounting, auditing, tax and administrative consulting services, insurance costs, administrative travel expenses, marketing expenses and other operating costs. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support development of our product candidates and our continued research activities. We also anticipate that we will incur increased accounting, audit, legal, regulatory, compliance and director and officer insurance costs as well as legal, investor and public relations expenses associated with being a public company. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other Income (Expense) </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.53%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Interest income and expense, net </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income consists of interest earned on our invested cash balances. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Results of Operations </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.53%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Comparison of years ended December&#160;31, 2020 and 2019</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our results of operations for the years ended December&#160;31, 2020 and 2019:</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue&#8212;from related parties</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,034</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,934</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,100</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,105</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,158</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,947</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,233</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,981</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,252</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,338</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,139</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,199</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,304</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(42,205</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,099</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income, net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">711</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">959</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(248</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,593</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41,246</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,347</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Collaboration revenue</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.53%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">W<font style="color:#000000;">e recognize revenue under each of the Vertex Agreement and Sanofi Agreement based on our pattern of performance related to the respective identified performance obligation, which is the period over which we will perform research services under each of the Vertex Agreement and Sanofi Agreement.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.53%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaboration revenues were $34.0&#160;million for the year ended December 31, 2020, of which $15.2 million and $18.8 million were attributable to our collaboration agreements with Vertex and Sanofi, respectively. Collaboration revenue was $2.9&#160;million for the year ended December 31, 2019, all of which was attributable to our collaboration with Vertex.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Research and development expenses</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our research and development expenses for each period presented:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">External research and development costs:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IRAK4 and IRAKIMiD</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,186</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,478</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,708</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">STAT3</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,674</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,474</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,200</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,579</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,822</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,757</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Internal research and development costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,666</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,384</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,282</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total research and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,105</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,158</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,947</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.53%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses were $62.1&#160;million for the year ended December&#160;31, 2020, compared to $37.2 million for the year ended December&#160;31, 2019. The increase of $25.0&#160;million was primarily due to higher direct expenses related lead optimization activities for our IRAK programs of $6.7&#160;million and STAT3 programs of $4.2&#160;million, as well as increased investment in our platform, exploratory programs, and Vertex collaboration of $3.8&#160;million.&#160;We also had a $10.2&#160;million increase in personnel, occupancy and related costs due to increases in employee headcount in the research and development functions.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">General and administrative expenses</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses were $18.2&#160;million for the year ended December&#160;31, 2020, compared to $8.0&#160;million for the year ended December&#160;31, 2019. The increase was primarily due to an increase in legal and professional service fees and an increase in personnel, facility, occupancy and other expenses stemming from an increase in headcount to support our growth as a public company.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:6.26%;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Other Income, Net</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income, net was $0.7 million for the year ended December 31, 2020, compared to $1.0 million for the year ended December 31, 2019. The decrease in was primarily due to the prevailing interest rates in the respective periods.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Liquidity and capital resources </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not yet generated any revenue from any product sales, and we have incurred significant operating losses since our inception. We have not yet commercialized any products and we do not expect to generate revenue from sales of products for several years, if at all. To date, we have funded our operations primarily with proceeds from our initial public offering, sale of our convertible preferred stock and collaboration agreements. To date, we had received gross proceeds of $617.8&#160;million from the sale of common stock in our August 2020 initial public offering and concurrent private placement, sales of our convertible preferred stock and through our collaborations with Vertex and Sanofi. As of December&#160;31, 2020, we had cash and cash equivalents and marketable securities of $458.7 million.<font style="font-weight:bold;"> </font></p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Cash flows</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our sources and uses of cash for each of the periods presented:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash provided by operating activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,130</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,905</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash used in investing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(422,588</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,486</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash provided by financing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">289,262</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,911</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net (decrease) increase in cash, cash equivalents and restricted</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; cash</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,196</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,330</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Cash Flow from Operating Activities</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2020, operating activities provided $88.1 million of cash, primarily resulting from $150.0 million of proceeds received under our collaboration agreement with Sanofi executed in July 2020.&#160;<font style="Background-color:#FFFFFF;">Cash provided by operating activities also includes an increase of accounts payable and accruals of $6.7 million, an increase in net operating assets and liabilities of $0.7 million, offset by our net loss of $45.6 million adjusted for net non-cash items of $8.9 million (primarily stock-based compensation, depreciation expense and amortization of premiums and discounts on securities).</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2019, operating activities provided $17.9&#160;million of cash, resulting from the $55.9&#160;million in aggregate payments received in connection with the Vertex Agreement, including the premium paid on the Series B-1 convertible preferred stock purchase. Cash provided by operating activities also includes an increase of accounts payable and accruals of $3.2&#160;million, an increase of net operating lease right-of-use assets and liabilities of $1.0&#160;million offset by a net decrease of operating assets and liabilities of $1.0&#160;million and our net loss of $41.2&#160;million.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Cash Flow used in Investing Activities</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2020, <font style="color:#000000;">cash used in investing activities was $422.6 million comprised of purchases of marketable securities of $529.4 million and purchases of property and equipment of $9.1 million offset by maturities of marketable securities of $115.9 million.</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2019, investing activities used $16.5&#160;million of cash, primarily due to $16.0&#160;million in purchases of marketable securities and $0.5&#160;million in purchases of property and equipment.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Cash Flow from Financing Activities</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2020, net cash provided by financing activities was $289.3 million, primarily consisting of $183.1 million of net proceeds received in our August 2020 initial public offering, $13.5 million from our August 2020 concurrent private placement, $88.2 million of proceeds from our issuances of Series C convertible preferred stock in March 2020, net of issuance costs, and $4.8 million of proceeds from the second closing of our Series B convertible preferred stock financing in January 2020, net of issuance costs.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2019, net cash provided by financing activities was $34.9&#160;million, which consisted of $14.0&#160;million of proceeds from our issuances of Series B-1 convertible preferred stock in May 2019, net of issuance costs, and $21.2&#160;million of proceeds from the second closing of our Series B convertible preferred stock financing in December 2019, net of issuance costs.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Future funding requirements </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance the later-stage clinical development of our product candidates. In addition, we expect to incur additional costs associated with operating as a public company. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the numerous risks and uncertainties associated with the development of our product candidates and programs and because the extent to which we may enter into collaborations with third parties for development of our product candidates is unknown, we are unable to estimate the timing and amounts of increased capital outlays and operating expenses associated with completing the research and development of our product candidates. The timing and amount of our operating expenditures will depend largely on: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the initiation, progress, timing, costs and results of nonclinical studies and clinical trials for our product candidates or any future product candidates we may develop; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our ability to maintain our relationships with Vertex and other key collaborators; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the outcome, timing and cost of seeking and obtaining regulatory approvals from the FDA and comparable foreign regulatory authorities, including the potential for such authorities to require that we perform more nonclinical studies or clinical trials than those that we currently expect or change their requirements on studies that had previously been agreed to; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the cost to establish, maintain, expand, enforce and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with licensing, preparing, filing, prosecuting, defending and enforcing any patents or other intellectual property rights; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the effect of competing technological and market developments; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the costs of continuing to grow our business, including hiring key personnel and maintaining or acquiring operating space; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the degree of market acceptance of any approved product candidates, including product pricing, as well as product coverage and the adequacy of reimbursement by third-party payors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the cost of acquiring, licensing or investing in additional businesses, products, product candidates and technologies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the cost and timing of selecting, auditing and potentially validating a manufacturing site for commercial-scale manufacturing; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the cost of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval and that we determine to commercialize; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our need to implement additional internal systems and infrastructure, including financial and reporting systems. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe the existing cash, cash equivalents and marketable securities on enable us to fund our operating expenses and capital expenditure requirements into 2025. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. We expect that we will require additional funding to continue the clinical development of our IRAK4, IRAKIMiD and STAT3 programs, commercialize our product candidates if we receive regulatory approval, and pursue in-licenses or acquisitions of other product candidates. If we receive regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution, depending on where we choose to commercialize our product candidates. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Identifying potential product candidates and conducting preclinical studies and clinical trials is a time consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if ever. Accordingly, we will need to obtain substantial additional funds to achieve our </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">business objectives. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances, and marketing, distribution or licensing arrangements with third parties. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Market volatility resulting from the COVID-19 pandemic or other factors could also adversely impact our ability to access capital as and when needed. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our existing stockholders may be materially diluted, and the terms of such securities could include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include restrictive covenants that limit our ability to take specified actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, reduce or eliminate our product development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Contractual Obligations and Other Commitments </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ending December 31, 2020, there have been no material changes to our contractual obligations and commitments outside the ordinary course of business.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Critical Accounting Policies and Estimates </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles, or GAAP, in the United States. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, costs and expenses, and the disclosure of contingent assets and liabilities in our consolidated </font>financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While our significant accounting policies are described in more detail in Note 2 to our consolidated financial statements appearing at the end of this Annual Report, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, we perform the following five steps: (i)&#160;identification of the contract(s) with the customer, (ii)&#160;identification of the promised goods or services in the contract and determination of whether the promised goods or services are performance obligations, (iii)&#160;measurement of the transaction price, (iv)&#160;allocation of the transaction price to the performance obligations, and (v)&#160;recognition of revenue when (or as) we satisfy each performance obligation. We only apply the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When optional goods or services are offered, we assess the options to determine whether the options grant the customer a material right. This determination includes whether the option is priced at an amount that the customer would not have received without entering into the contract. If we conclude the option conveys a material right, it is accounted for as a separate performance obligation. In identifying performance obligations in a contract, we identify those promises that are distinct. Promised goods or services are considered distinct when the customer can benefit from the goods or services on their own, or together with readily available resources, and the goods or services are separately identifiable from other promises in the contract. If a promise is not distinct, it is combined with other promises in the contract until the combined group of promises is capable of being distinct.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We estimate the transaction price based on the amount of consideration we expect to receive for transferring the promised goods or services in the contract. The consideration may include both fixed consideration and variable consideration. At the inception of each arrangement that includes variable consideration, we evaluate the amount of the potential payments and the likelihood that the payments will be received. If it is probable that a significant revenue reversal would not occur, the variable consideration is included in the transaction price. For contracts that include sales-based royalties for licensed compounds, we recognize revenue at the date when the related sales occur. Finally, we determine whether the contract contains a significant financing component by analyzing the promised consideration relative to the standalone selling price of the promised goods and services and the timing of payment relative to the transfer of the promised goods and services. At each reporting date, we reassess the transaction price and probability of achievement of the performance obligations and the associated constraints on transaction price. If necessary, we adjust the transaction price, recording a&#160;cumulative&#160;catch-up&#160;based&#160;on progress for the amount that was previously constrained.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue is recognized when (or as) control of a performance obligation is transferred to the customer. When combined performance obligations contain a promised license and related services or other promises, management judgment is required to determine the appropriate timing of revenue recognition. In doing so, we must identify the predominant promise or promises in the contract to determine whether revenue is recognized at a point in time or over time. If over time, we must determine the appropriate measure of progress. If a license is deemed to be the predominant promise in a performance obligation, we must determine the nature of the license, whether functional or symbolic intellectual property, to conclude&#160;whether&#160;point-in-time&#160;or&#160;over-time revenue recognition is most appropriate. The determination of functional or symbolic intellectual property requires an assessment of whether the customer is able to exploit and benefit from the license in its current condition, or if the utility of the license is dependent on or influenced by our ongoing activities or being associated with us.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At each reporting date, we calculate the measure of progress for the performance obligations transferred over time. The calculation generally uses an input measure based on costs&#160;incurred&#160;to-date&#160;relative&#160;to estimated total costs to complete the transfer of the performance obligation. The measurement of progress is then used to calculate the total revenue earned, including any&#160;cumulative&#160;catch-up&#160;adjustment.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:4.53%;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development Contract Costs and Accruals</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with our applicable personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. The majority of our service providers invoice us in arrears for services performed, on a&#160;pre-determined&#160;schedule or when contractual milestones are met; however, some require advance payments. We make estimates of our accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of these estimates with the service providers and make adjustments, if necessary. Examples of estimated accrued research and development expenses include fees paid to:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">vendors, including research laboratories, in connection with preclinical development activities;</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CROs and investigative sites in connection with preclinical studies; and</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CMOs in connection with drug substance and drug product formulation of preclinical studies.</p></td>
</tr>
</table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.58%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We base the expense recorded related to external research and development on our estimates of the services received and efforts expended pursuant to quotes and contracts with multiple CMOs and CROs that supply, conduct and manage nonclinical studies on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual or the amount of prepaid expenses accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to our prior estimates of accrued research and development expenses.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;margin-left:4.53%;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Equity-Based Compensation Expense</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.53%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">We measure equity-based awards granted to employees, directors, and nonemployees based on their fair value on the date of the grant and recognize compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. The equity-based payments include stock options and grants of common stock, including common stock subject to vesting. The measurement date for equity awards is the date of grant, and equity-based compensation costs are recognized as expense over the requisite service period, which is the vesting period, on a straight-line basis. We have issued stock options and restricted stock with performance-based vesting conditions and record the expense for these awards if we conclude that it is probable that the performance condition will be achieved. The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model, which requires inputs based on certain subjective assumptions, including the expected stock price volatility, the expected term of the option, the risk-free interest rate for a period that approximates the expected term of the option, and our expected dividend yield. Expected volatility is calculated based on reported volatility data for a representative group of publicly traded companies for which historical information is available. We select companies with comparable characteristics to us with historical share price information that approximates the expected term of the equity-based awards. We compute the historical volatility data using the daily closing prices for the selected companies&#8217; shares during the equivalent period that approximates the calculated expected term of our stock options. We will continue to apply this method until a sufficient amount of historical information regarding the volatility of our stock price becomes available. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption. We use the simplified method, under which the expected term is presumed to be the midpoint between the vesting date and the end of the contractual term. We utilize this method due to lack of historical exercise data. The expected dividend yield is assumed to be zero as we have no current plans to pay any dividends on common stock. The fair value of each restricted common stock award is estimated on the date of grant based on the fair value of our common stock on that same date.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">JOBS Act Accounting Election </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Section&#160;107(b) of the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, an &#8220;emerging growth company&#8221; can delay the adoption of new or revised accounting standards until such time as those standards would apply to private companies. We have elected to avail ourselves of this exemption to delay adopting new or revised accounting standards until such time as those standards apply to private companies. However, where allowable we have early adopted certain standards as described in Note&#160;2 of our consolidated financial statements. There are other exemptions and reduced reporting requirements provided by the JOBS Act that we are currently evaluating. For example, as an &#8220;emerging growth company,&#8221; we are exempt from Sections&#160;14A(a) and (b)&#160;of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which would otherwise require us to (1)&#160;submit certain executive compensation matters to shareholder advisory votes, such as &#8220;say-on-pay,&#8221; &#8220;say-on-frequency,&#8221; and &#8220;golden parachutes;&#8221; and (2)&#160;disclose certain executive compensation related items such as the correlation between executive compensation and performance and comparisons of our chief executive officer&#8217;s compensation to our median employee compensation. We also intend to rely on an exemption from the rule requiring us to provide an auditor&#8217;s attestation report on our internal controls over financial reporting pursuant to Section&#160;404(b) of the Sarbanes-Oxley Act. We will continue to remain an &#8220;emerging growth company&#8221; until the earliest of the following: (1)&#160;the last day of the fiscal year following the fifth anniversary of the date of the completion of our initial public offering; (2)&#160;the last day of the fiscal year in which our total annual gross revenue is equal to or more than $1.07&#160;billion; (3)&#160;the date on which we have issued more than $1&#160;billion in nonconvertible debt during the previous three years; or (4)&#160;the date on which we are deemed to be a large accelerated filer under the rules of the SEC. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also a &#8220;smaller reporting company&#8221; as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies until the fiscal year following the determination that our voting and non-voting common stock held by non-affiliates is more than $250 million measured on the last business day of our second fiscal quarter, or our annual revenues are less than $100 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is more than $700 million measured on the last business day of our second fiscal quarter.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Off-Balance Sheet Arrangements </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"></a>Item 7A. Quantitative and Qualitat</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ive Disclosures About Market Risk. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to market risk related to changes in interest rates. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because our investments, including cash equivalents, are in the form of money market funds and marketable securities and are invested in U.S. treasury or government obligations and corporate securities.&#160;However, because of the short-term nature of the duration of our portfolio and the low-risk profile of our investments, we believe an immediate 10% change in market interest rates would not be expected to have a material impact on the fair market value of our investments portfolio or on our financial condition or results of operations.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also exposed to market risk related to changes in foreign currency exchange rates. We contract with vendors that are located in Asia and Europe and certain invoices are denominated in foreign currencies. We are subject to fluctuations in foreign currency rates in connection with these arrangements. We do not currently hedge our foreign currency exchange rate risk. As of December&#160;31,&#160;2020, we had no significant liabilities denominated in foreign currencies.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inflation generally affects us by increasing our cost of labor and clinical trial costs. We do not believe that inflation had a material effect on our business, financial condition or results of operations during the year ended December&#160;31,&#160;2020.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"></a><a name="ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"></a>Item 8. Financial Statements and Supplementary Data. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"><font style="text-decoration:underline;">Report of Independent Registered Public Accounting Firm</font></a></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_BALANCE_SHEETS"><font style="text-decoration:underline;">Consolidated Balance Sheets as of December 31, 2020 and 2019</font></a></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_OPERATIONS"><font style="text-decoration:underline;">Consolidated Statements of Operations and Comprehensive Loss for the Years ended December 31, 2020 and 2019</font></a></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_STOCKHOLDERS_EQU"><font style="text-decoration:underline;">Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit) for the Years ended December 31, 2020 and 2019</font></a></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_CASH_FLOWS"><font style="text-decoration:underline;">Consolidated Statements of Cash Flows for the Years ended December 31, 2020 and 2019</font></a></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"><font style="text-decoration:underline;">Notes to Consolidated Financial Statements</font></a></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-9</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-1</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU7"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"></a><a name="REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"></a>Report of Independent Registered Public Accounting Firm</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#333333;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the Stockholders and the Board of Directors of Kymera Therapeutics, Inc.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#333333;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Opinion on the Financial Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#333333;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have audited the accompanying consolidated balance sheets of Kymera Therapeutics, Inc. (the Company) as of December 31, 2020 and 2019, the related consolidated statements of operations and comprehensive loss, convertible preferred stock and stockholders&#8217; equity (deficit) <font style="color:#000000;">and cash flows for the years then ended, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material aspects, the financial position of the Company at December 31, 2020 and 2019, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#333333;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> <font style="font-style:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#333333;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Basis for Opinion</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our audits included performing procedures to assess the risk of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Ernst &amp; Young LLP</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have served as the Company&#8217;s auditor since 2018. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Boston, Massachusetts</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2021</p><a name="_AEIOULastRenderedPageBreakAEIOU8"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">KYMERA </font><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">THERAPEUTICS</font><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">, INC.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_BALANCE_SHEETS"></a><a name="CONSOLIDATED_BALANCE_SHEETS"></a>Consolidated Balance Sheets </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except share and per share amounts) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="8" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,004</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,015</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities (Note 4)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">265,198</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,942</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable&#8212;due from related parties</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">577</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract assets&#8212;due from related parties</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">856</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,704</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">888</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">302,339</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92,845</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities, non-current (Note 4)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">162,531</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net (Note 6)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,841</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,794</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets, operating leases</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,845</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,289</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,589</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,774</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.76%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">487,175</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116,702</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liabilities and Stockholders&#8217; Equity</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,368</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,276</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses (Note 8)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,330</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,568</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue, current</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92,552</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,349</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, current portion</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,572</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,696</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities, current portion</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">689</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">681</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,617</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,570</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue, net of current portion</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77,838</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,642</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, net of current portion</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,128</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,651</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities, net of current portion</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">604</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,165</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other non-current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">203,287</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,028</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and contingencies (Note 9)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series Seed Convertible Preferred Stock, $0.0001 par value; 0 and 3,000,000</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; shares authorized, issued and outstanding at December 31, 2020 and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; December 31, 2019, respectively (liquidation preference of $3,000 at December 31, 2019)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,900</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A Convertible Preferred Stock, $0.0001 par value; 0 and 14,886,305</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; shares authorized and issued at December 31, 2020 and December 31, 2019,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; respectively and 0 and 14,720,126 shares outstanding at December 31, 2020</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; and December 31, 2019, respectively (liquidation preference of $29,440 at December 31, 2019)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,237</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series B Convertible Preferred Stock, $0.0001 par value; 0 and 16,009,848 shares</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; authorized at December 31, 2020 and December 31, 2019, respectively and 0</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; and 14,827,580 shares issued and outstanding at December 31, 2020 and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; December 31, 2019, respectively (liquidation preference of $60,200 at December 31, 2019)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,918</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series B-1 Convertible Preferred Stock, $0.0001 par value; 0 and 3,059,695</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; shares authorized, issued and outstanding at December 31, 2020 and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; December 31, 2019, respectively (liquidation preference of $20,000 at December 31, 2019)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,025</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217; equity (deficit):</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock, $0.0001 par value; 10,000,000 and 0 shares authorized as of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;December 31, 2020 and December 31, 2019, respectively; 0 shares issued</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; or outstanding as of December 31, 2020 and December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, $0.0001 par value; 150,000,000 and 45,000,000 shares</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; authorized at December 31, 2020 and December 31, 2019, respectively, 44,592,288</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; and 2,208,982 shares issued at December 31, 2020 and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; December 31, 2019, respectively; 44,482,186 and 1,929,516 shares</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; outstanding at December 31, 2020 and December 31, 2019, respectively</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">412,777</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,044</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(128,765</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(76,456</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated other comprehensive (loss) income</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(128</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders&#8217; equity (deficit)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">283,888</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(74,406</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.76%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities, convertible preferred stock and stockholders&#8217; equity (deficit)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">487,175</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116,702</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The accompanying notes are an integral part of these consolidated financial statements.</font></p><a name="_AEIOULastRenderedPageBreakAEIOU9"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">KYMERA </font><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">THERAPEUTICS, INC.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_OPERATIONS"></a><a name="CONSOLIDATED_STATEMENTS_OPERATIONS"></a>Consolidated Statements of Operations and Comprehensive Loss</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except share and per share amounts) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Statement of Operations Data:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaboration Revenue&#8212;from related party</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,034</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,934</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,105</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,158</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,233</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,981</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,338</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,139</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,304</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(42,205</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense):</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest Income</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">826</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,005</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest Expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(115</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other income</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">711</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">959</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,593</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41,246</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive loss:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized (loss) gain on marketable securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(134</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total comprehensive loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,727</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41,240</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reconciliation of net loss to net loss attributable to common stockholders:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net Loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,593</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41,246</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deemed dividend from exchange of convertible preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,050</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(54,643</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41,246</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common stockholders, basic</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; and diluted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.15</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24.28</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average common stocks outstanding, basic and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; diluted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,349,582</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,698,522</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The accompanying notes are an integral part of these consolidated financial statements.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU10"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">KYMERA THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_STOCKHOLDERS_EQU"></a><a name="CONSOLIDATED_STATEMENTS_STOCKHOLDERS_EQU"></a>Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except share and per share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="5" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series Seed</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Convertible</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="5" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series A</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Convertible</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="5" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series B</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Convertible</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2018</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,000,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,900</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,498,547</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,794</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,605,905</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,735</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vesting of Series A Preferred Stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; in connection with collaboration</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; arrangement (Note 5)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">221,579</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">443</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of Series B Convertible Preferred</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; Stock, net of issuance costs of $17</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,221,675</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,183</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of Series B-1 Preferred Stock,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; net of issuance costs of $49</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of Stock Options</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vesting Restricted Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gain on marketable securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net Loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,000,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,900</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,720,126</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,237</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,827,580</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,918</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vesting of Series A Preferred Stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; in connection with collaboration</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; arrangement (Note 5)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,788</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">222</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of Series B Preferred Stock,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; net of issuance costs of $0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,182,265</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,800</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of Series C Preferred Stock,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; net of issuance costs of $320</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exchange of Series A Convertible</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; Preferred Stock for Series C</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; Preferred Convertible Preferred</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,988,802</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,950</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of Stock Options</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vesting Restricted Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized loss on marketable securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of shares in connection</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; with initial public offering net</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; of underwriting discounts and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; offering costs of $17,003</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of convertible preferred</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; stock into common stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,000,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,900</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,842,112</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25,509</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,009,845</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(64,718</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of shares in concurrent</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; private placement</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net Loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The accompanying notes are an integral part of these consolidated financial statements.</font></p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</a></p>
<hr style="page-break-after:always;width:100%;">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="5" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series B-1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Convertible</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="5" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series C</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Convertible</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="5" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid in</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consolidated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Members&#8217;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Income (Loss)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Deficit)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2018</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-left:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,479,188</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">774</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(35,210</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34,436</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vesting of Series A Preferred Stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; in connection with collaboration</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; arrangement (Note 5)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of Series B Convertible Preferred</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; Stock, net of issuance costs of $17</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of Series B-1 Preferred Stock,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; net of issuance costs of $49</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,059,695</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,025</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of Stock Options</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95,904</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vesting Restricted Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">354,424</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,196</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,196</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gain on marketable securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net Loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41,246</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41,246</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,059,695</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,025</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-left:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,929,516</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,044</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(76,456</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(74,406</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vesting of Series A Preferred Stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; in connection with collaboration</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; arrangement (Note 5)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of Series B Preferred Stock,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; net of issuance costs of $0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of Series C Preferred Stock,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; net of issuance costs of $320</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,539,141</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,180</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exchange of Series A Convertible</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; Preferred Stock for Series C</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; Preferred Convertible Preferred</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,988,802</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,334</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,716</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,050</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of Stock Options</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,852</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">162</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">162</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vesting Restricted Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">184,410</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,190</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,190</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized loss on marketable securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(134</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(134</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of shares in connection</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; with initial public offering net</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; of underwriting discounts and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; offering costs of $17,003</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,987,520</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">182,747</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">182,748</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of convertible preferred</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; stock into common stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,059,695</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,025</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,527,943</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(101,180</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,625,534</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">211,329</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">211,332</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of shares in concurrent</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; private placement</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">676,354</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,527</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,527</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net Loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,593</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,593</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-left:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,482,186</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">412,777</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(128,765</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(128</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">283,888</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">(Continued from previous page)</font></p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The accompanying notes are an integral part of these consolidated financial statements.</font></p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">KYMERA THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_CASH_FLOWS"></a><a name="CONSOLIDATED_STATEMENTS_CASH_FLOWS"></a>Consolidated Statements of Cash Flows </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,593</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41,246</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,190</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,196</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,763</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">825</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-cash research and development expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">332</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">443</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net amortization of premiums and discounts on investments</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,571</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in operating assets and liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,816</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(564</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable&#8212;due from related party</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(577</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract asset&#8212;due from related parties</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(856</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other receivables&#8212;due from related parties</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">148</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">990</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">904</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,754</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,248</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117,400</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,991</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other non-current assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(30</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,444</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,350</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,647</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(383</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other non-current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">205</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by operating activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,130</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,905</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Investing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase of property and equipment, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,096</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(532</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase of marketable securities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(529,382</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,954</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturities of marketable securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115,890</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(422,588</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,486</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Financing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from the issuance of Series B Convertible Preferred Stock, net of issuance costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,183</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from the issuance of Series B-1 Convertible Preferred Stock, net of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; issuance costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,800</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,025</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from the issuance of Series C Convertible Preferred Stock, net of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; issuance costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,181</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from stock option exercises</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">162</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payments on financing leases</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(554</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(371</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from initial public offering, net of underwriting discounts and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; offering costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">183,146</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from concurrent private placement</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,527</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">289,262</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,911</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net (decrease) increase in cash, cash equivalents and restricted cash</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,196</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,330</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and restricted cash at beginning of period</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77,789</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,459</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and restricted cash at end of period</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,593</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77,789</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosure of cash flow activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for interest</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosure of noncash investing and financing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property and equipment through finance and lease liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,642</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment purchases included in accounts payable and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; accrued expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">315</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Offering costs included in accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">397</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosure of noncash operating activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets obtained in exchange for operating lease liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,522</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant improvement receivable included in other assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">287</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reduction of right-of-use asset and liability due to lease modification</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,161</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The accompanying notes are an integral part of these consolidated financial statements.</font></p><a name="_AEIOULastRenderedPageBreakAEIOU11"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The following table provides a reconciliation of the cash, cash equivalents, and restricted cash balances as of each of the periods shown above:</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,004</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,015</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,589</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,774</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents, and restricted cash</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,593</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77,789</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-8</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">KYMERA THERAPEUTICS, INC</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"></a><a name="NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"></a>Notes to Consolidated Financial Statements</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Note 1. Description of Business and Summary of Significant Accounting Policies</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kymera Therapeutics, Inc., together with its subsidiary Kymera Securities Corporation, is referred to on a consolidated basis as the &#8220;Company&#8221;. The Company is a biopharmaceutical company focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body&#8217;s own natural cellular process, a method known as targeted protein degradation. The Company has devoted its efforts principally to research and development since formation. The Company has not yet completed product development, filed for or obtained regulatory approvals for any products, nor verified the market acceptance and demand for such products. As a result, the Company is subject to a number of risks common to emerging companies in the biotech industry. Principal among these risks are the uncertainties of the product discovery and development process, dependence on key individuals, development of the same or similar technological innovations by the Company&#8217;s competitors, protection of proprietary technology, compliance with government regulations and approval requirements, the Company&#8217;s ability to access capital and uncertainty of market acceptance of products.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has historical net losses and anticipates that it will continue to incur losses for the foreseeable future and had an accumulated deficit of $128.8&#160;million as of December 31, 2020. The Company has funded these losses principally through issuance common stock, including its initial public offering (&#8220;IPO), which was completed in August 2020, preferred stock, convertible notes and from cash proceeds received in connection with the Company&#8217;s collaboration agreements with Vertex Pharmaceuticals Incorporated (&#8220;Vertex&#8221;) and Genzyme Corporation (&#8220;Sanofi&#8221;) (see Note 5). The Company expects to continue to incur operating losses and negative cash flows until such time as it generates a level of revenue that is sufficient to support its cost structure.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the Company had cash, cash equivalents and marketable securities of $458.7 million. The Company believes these cash, cash equivalents and marketable securities will be sufficient to fund its operations and capital expenditure requirements through at least twelve months from the issuance of these consolidated financial statements.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expects to finance the future research and development costs of its product portfolio with its existing cash, cash equivalents and marketable securities, or through strategic financing opportunities that could include, but are not limited to future offerings of its equity, collaboration agreements, or the incurrence of debt. However, there is no guarantee that any of these strategic or financing opportunities will be executed or realized on favorable terms, if at all, and some could be dilutive to existing stockholders. If the Company fails to obtain additional future capital, it may be unable to complete its planned preclinical studies and clinical trials.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Reverse Stock Split</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August&#160;20, 2020, the Board approved a 1-for-1.5949 reverse stock&#160;split of the Company&#8217;s issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for each of the Company&#8217;s outstanding series of preferred stock.&#160;&#160;All share and per share amounts in the accompanying consolidated financial statements and notes thereto have been retroactively adjusted for all periods presented to give effect to this reverse stock split, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital.&#160;&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Initial Public Offering</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 20, 2020, the Company&#8217;s registration statement on Form S-1 relating to its initial public offering of its common stock was declared effective by the Securities and Exchange Commission (&#8220;SEC&#8221;). In the IPO, which closed on August 25, 2020, the Company issued and sold&#160;9,987,520&#160;shares of common stock, including full exercise of the underwriters&#8217; over-allotment option to purchase an additional 1,302,720 shares, at a public offering price of $20.00 per share and the aggregate gross proceeds before deducting before deducting underwriting discounts and commissions, and other estimated offering expenses payable by the Company, were approximately $199.8 million. Concurrent with the IPO, the Company issued and sold 676,354 shares of common stock at $20.00 per share in a private placement to Vertex.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Note 2. Summary of Significant Accounting Policies</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements reflect the application of certain significant accounting policies as described in this note, and elsewhere in the accompanying consolidated financial statements and&#160;notes.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-9</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Principles of Consolidation</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary Kymera Securities Corporation. All intercompany transactions and balances have been eliminated in consolidation.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Presentation</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosure of contingencies at the date of the financial statements and the reported amounts of expenses during the reporting period. Management&#8217;s estimates and judgments are derived and continually evaluated based on available information, historical experience and various other assumptions that are believed to be reasonable under the circumstances. Because the use of estimates is inherent in the financial reporting process, actual results could differ from those estimates. In recording transactions and balances resulting from business operations, management makes estimates based on the best information available at the time the estimate is made. Significant estimates relied upon in preparing these financial statements include revenue recognized under our collaboration agreement with Sanofi and Vertex, accrual for research and development expenses, equity-based compensation expense, and the valuation of equity. As better information becomes available or actual amounts are determinable, the recorded estimates are revised. Consequently, operating results can be affected by revisions to prior estimates.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Segment and Geographic Information</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company&#8217;s chief operating decision maker is the Chief Executive Officer. The Company views its operations and manages its business in one operating segment.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash and <font style="color:#000000;">Cash</font> Equivalents</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents are highly liquid investments that are readily convertible into cash with original maturities of three months or less when purchased. These assets include investments in money market funds that invest in U.S. Treasury obligations and corporate bonds. The Company maintains its bank accounts at major financial institutions.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Restricted Cash</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash represents the cash held to secure a letter of credit associated with the Company&#8217;s facility lease.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Marketable Securities</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies marketable securities with a remaining maturity of greater than three months when purchased as available-for-sale. The Company classifies investments available to fund current operations as current assets on its balance sheets. Marketable securities with a remaining maturity date greater than one year are classified as non-current. Available-for-sale securities are maintained by investment managers and consist of U.S. Treasury securities and corporate bonds. Available-for-sale securities are carried at fair value with the unrealized gains and losses included in other comprehensive income (loss) as a component of stockholders&#8217; equity until realized. Any premium or discount arising at purchase is amortized and/or accreted to interest income and/or expense over the life of the instrument. Realized gains and losses are determined using the specific identification method and are included in other (expense) income, net.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any adjustment to fair value reflects a decline in value of the investment, the Company considers all available evidence to evaluate the extent to which the decline is &#8220;other-than-temporary&#8221; and, if so, marks the investment to market through a charge to the Company&#8217;s statement of operations and comprehensive loss.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-10</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Fair Value Measurements</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Level&#160;1&#8212;<font style="font-style:normal;">Quoted prices in active markets for identical assets</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Level&#160;2&#8212;<font style="font-style:normal;">Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar asset, or other inputs that are observable or can be corroborated by observable market data.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Level&#160;3&#8212;<font style="font-style:normal;">Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets, including pricing models, discounted cash flow methodologies and similar techniques.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying values of the Company&#8217;s cash equivalents, prepaid expenses, accounts payable, and certain accruals approximate their fair value due to their short-term nature.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Leases</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company adopted ASC Topic 842, <font style="font-style:italic;">Leases</font> (&#8220;ASC 842&#8221;) on January&#160;1, 2019. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Leases that are economically similar to the purchase of assets are generally classified as finance leases; otherwise the leases are classified as operating leases. The Company has elected not to recognize leases with an original term of one year or less on the balance sheet. Options to renew a lease are not included in the Company&#8217;s assessment unless there is reasonable certainty that the Company will renew. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. However, certain adjustments to the right-of-use asset may be required for items such as incentives received. The Company has elected as an accounting policy to combine lease and non- lease components, such as common area maintenance, for all classes of underlying assets. The interest rate implicit in lease contracts has not historically been readily determinable. As a result, the Company utilizes its incremental borrowing rates, which are the rates incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. To estimate its incremental borrowing rate, a credit rating applicable to the Company is estimated using synthetic credit rating analysis since the Company does not currently have a rating agency-based credit rating.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property and Equipment</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are recorded at cost, net of accumulated depreciation. Major additions and betterments are capitalized; maintenance and repairs, which do not improve or extend the life of the respective assets, are charged to operations as incurred. Depreciation expense is recorded using the straight-line method over the estimated useful life of the related asset as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated Useful Life</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.86%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furnitures and fixtures</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office equipment</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shorter of life of lease or remaining lease term</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon retirement or sale, the cost and related accumulated depreciation of assets disposed of are removed from the accounts and any resulting gain or loss is included in loss from operations.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-11</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction-in-progress is stated at cost, which includes direct costs attributable to the setup or construction of the related asset. Depreciation expense is not recorded on construction-in-progress until the relevant assets are completed and put into use.</font></p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its fair value, determined based on discounted cash flows. The Company did not record any impairment losses on long-lived assets during the years ended December&#160;31, 2020 and 2019.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Convertible Preferred Stock</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classified convertible preferred stock as temporary equity in the accompanying consolidated balance sheet due to terms that allow for redemption of the shares in cash upon certain change in control events that are outside of the Company&#8217;s control, including the sale or transfer of the Company as holders of the convertible preferred stock which could trigger redemption of the shares. The Company did not accrete the value of the convertible preferred stock to the redemption values since a liquidation event was not considered probable as of December&#160;31, 2019. Subsequent adjustments of the carrying values to the ultimate redemption values will be made only when it becomes probable that such liquidation events will occur. In connection with the Company&#8217;s initial public offering on August 21, 2020, all outstanding shares of convertible preferred stock converted to common stock.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Costs</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs consist primarily of costs incurred in connection with the discovery and development of targeted protein degradation therapeutics, including those in the Company&#8217;s most advanced development programs, IRAK4, IRAKIMiD and STAT3. These research efforts and costs, which also support the development of, and enhancements to, the Company&#8217;s Pegasus targeted protein degradation platform, include external research costs, personnel costs, supplies, license fees and facility related expenses. The Company expenses research and development costs as incurred.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Patent Costs</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recoverability of the expenditure. Amounts incurred are classified as general and administrative expenses.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Financing Costs</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs incurred in connection with the issuance of equity units and shares are recorded as a reduction of proceeds to the equity carrying value. The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process financings as deferred offering costs until such financings are consummated. After consummation of the financing, these costs are recorded as a reduction of the proceeds received from the financing. If a planned financing is abandoned, the deferred offering costs are expensed immediately as a charge to operating expenses in the consolidated statement of operations and comprehensive loss. There was $0.4 million of deferred financing costs included in accounts payable on the Company&#8217;s consolidated balance sheet as of December 31, 2020. There was no deferred offering costs on the Company&#8217;s consolidated balance sheet at December 31, 2019.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-12</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue Recognition</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company adopted ASC Topic 606, <font style="font-style:italic;">Revenue from Contracts with Customers</font> (&#8220;ASC 606&#8221;) on January&#160;1, 2017. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identification of the contract(s) with the customer; (ii)&#160;identification of the promised goods or services in the contract and determination of whether the promised goods or services are performance obligations; (iii)&#160;measurement of the transaction price; (iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the accounting for these arrangements, the Company must use significant judgment to determine: a) the number of performance obligations based on the determination under step (ii)&#160;above and whether those performance obligations are distinct from other performance obligations in the contract; b) the transaction price under step (iii)&#160;above; and c) the standalone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv)&#160;above. The Company uses judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. In determining the stand-alone selling price of a license to the Company&#8217;s proprietary technology or a material right provided by a customer option, the Company considers market conditions as well as entity-specific factors, including those factors contemplated in negotiating the agreements as well as internally developed estimates that include assumptions related to the market opportunity, estimated development costs, probability of success and the time needed to commercialize a product candidate pursuant to the license. In validating its estimated stand-alone selling prices, the Company evaluates whether changes in the key assumptions used to determine its estimated stand-alone selling prices will have a significant effect on the allocation of arrangement consideration between performance obligations.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimates the transaction price based on the amount of consideration the Company expects to be received for transferring the promised goods or services in the contract. The consideration may include both fixed consideration and variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of the potential payments and the likelihood that the payments will be received. The Company utilizes either the most likely amount method or expected value method to estimate the transaction price based on which method better predicts the amount of consideration expected to be received. If it is probable that a significant revenue reversal would not occur, the variable consideration is included in the transaction price.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer. Promised goods or services are considered distinct when: (i)&#160;the customer can benefit from the good or service on its own or together with other readily available resources and (ii)&#160;the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on their own and whether the required expertise is readily available.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation in order to determine whether the combined performance obligation is satisfied over time or at a point in time. The Company receives payments from customers based on billing schedules established in each contract. Up-front payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion. Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional. Amounts recognized as revenue, but not yet received or invoiced are generally recognized as contract assets.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-13</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Exclusive Licenses</font><font style="font-style:normal;">&#8212;If the license granted in the arrangement is determined to be distinct from the other promises or performance obligations identified in the arrangement, which generally include research and development services, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whether a license is distinct from the other promises, the Company considers relevant facts and circumstances of each arrangement, including the research and development capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the collaboration partner can benefit from the license for its intended purpose without the receipt of the remaining promise, whether the value of the license is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of</font><font style="font-style:normal;"> </font><font style="font-style:normal;">progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the arrangement.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development Services<font style="font-style:normal;">&#8212;The promises under the Company&#8217;s collaboration and license agreements generally include research and development services to be performed by the Company on behalf of the collaboration partner. For performance obligations that include research and development services, the Company generally recognizes revenue allocated to such performance obligations based on an appropriate measure of progress. The Company utilizes judgment to determine the appropriate method of measuring progress for purposes of recognizing revenue, which is generally an input measure, such as costs incurred. The Company evaluates the measure of progress each reporting period as described under Exclusive Licenses above. Reimbursements from the partner that are the result of a collaborative relationship with the partner, instead of a customer relationship, such as co-development activities, are generally recorded as a reduction to research and development expense.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Customer Options<font style="font-style:normal;">&#8212;The Company&#8217;s arrangements may provide a collaborator with the right to certain optional purchases, such as the right to license a target either at the inception of the arrangement or within a pre-defined option period. Under these agreements, fees may be due to the Company at the inception of the arrangement as an upfront fee or payment or upon the exercise of an option to acquire a license. If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. The Company evaluates the customer options for material rights, or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the inception of the arrangement. The Company allocates the transaction price to material rights based on the relative stand-alone selling price, which is determined based on the identified discount, and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised or expires.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Milestone Payments<font style="font-style:normal;">&#8212;At the inception of each arrangement that includes milestone payments based on certain events, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. If a milestone or other variable consideration relates specifically to the Company&#8217;s efforts to satisfy a single performance obligation or to a specific outcome from satisfying the performance obligation, the Company generally allocates the milestone amount entirely to that performance obligation once it is probable that a significant revenue reversal would not occur.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Royalties<font style="font-style:normal;">&#8212;For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i)&#160;when the related sales occur or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-14</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Collaboration revenue&#8212;</font><font style="font-style:normal;">The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808,</font><font style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&#160;Collaborative Arrangements</font><font style="font-style:normal;">&#160;(&#8220;ASC 808&#8221;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities.&#160;This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement.&#160;For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship and therefore within the scope of Topic 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently, generally by analogy to Topic 606. For those elements of the arrangement that are accounted for pursuant to Topic 606, the Company applies the five-step model described above.</font></p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Costs associated with License and Collaborative Arrangements</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs associated with licenses of technology acquired as part of collaborative arrangements are expensed as incurred and are generally included in research and development expense in the consolidated statements of operations.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for all stock-based awards granted to employees, directors, and nonemployees based on their fair value on the date of the grant and recognize compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. Stock-based payments include stock options and grants of common stock, including common stock subject to vesting. The measurement date for stock awards is the date of grant, and stock-based compensation costs are recognized as expense over the requisite service period, which is the vesting period, on a straight-line basis. The Company has issued stock options and restricted stock with performance-based vesting conditions and records the expense for these awards if the Company concludes that it is probable that the performance condition will be achieved. Stock-based compensation is classified in the accompanying consolidated statements of operations and comprehensive loss based on the function to which the related services are provided. The Company recognizes stock-based compensation expense for the portion of awards that have vested. Forfeitures are accounted for as they occur.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes options-pricing model, which requires inputs based on certain subjective assumptions, including the expected stock price volatility, the expected term of the option, the risk-free interest rate for a period that approximates the expected term of the option, and the Company&#8217;s expected dividend yield. Prior to the IPO, as there was no active market for the Company&#8217;s common stock, the Company estimated the fair value of common stock on the date of grant based on the then current facts and circumstances. Upon becoming a public company, the fair value of the underlying common shares equals the closing price of the Company&#8217;s stock on the date of grant. The Company historically has been a private company and lacks company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of guideline companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options. The expected term of stock options granted to non-employees is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future. The fair value of each restricted common stock award is estimated on the date of grant based on the fair value of the Company&#8217;s common stock on that same date.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compensation expense for discounted purchases under the employee stock purchase plan is measured using the Black-Scholes model to compute the fair value of the lookback provision plus the purchase discount and is recognized as compensation expense over the offering period.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Common and Preferred Stock Valuation</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company utilized significant estimates and assumptions in determining the fair value of its equity and equity-based awards. The Company utilized various valuation methodologies in accordance with the framework of the 2013 American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its equity awards.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company used a hybrid of the probability-weighted expected returns method (&#8220;PWERM&#8221;), and the option pricing method (&#8220;OPM&#8221;) when allocating enterprise value to classes of securities.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-15</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the probability-weighted expected return method, or PWERM, the value of an enterprise, and its underlying common securities, are estimated based on an analysis of future values for the enterprise, assuming various outcomes. The value of the common securities is based on the probability-weighted present value of expected future investment returns considering each of the possible outcomes and the rights of each class of equity. The future values of the common securities under the various outcomes are discounted back to the valuation date at an appropriate risk-adjusted discount rate and then probability weighted to determine the value for the common securities.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The option pricing method, or OPM, treats common securities and preferred securities as call options on the enterprise&#8217;s equity value, with exercise prices based on the liquidation preferences of the preferred securities. Under this method, the common securities have value only if the funds available for distribution to shareholders exceed the value of the liquidation preferences at the time of a liquidity event. The Black-Scholes model is used to price the call option, and the model includes assumptions for the time to liquidity and the volatility of equity value.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The hybrid method is a hybrid between the PWERM and OPM, estimating the probability-weighted value across multiple scenarios but using the OPM to estimate the allocation of value within one or more of those scenarios.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuations performed in the year ended December&#160;31, 2020 and 2019, used a hybrid of the PWERM and OPM when allocating the Company&#8217;s enterprise value to classes of securities.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When using the hybrid method, the Company assumed two scenarios: an IPO scenario and a trade-sale scenario. The IPO scenario estimated an equity value based on the guideline public company method under a market approach. The guideline public companies considered for this scenario consist of biopharmaceutical companies with recently completed initial public offerings. The Company converted its estimated future value in an IPO to present value using a risk-adjusted discount rate. The equity value for the trade-sale scenario was estimated using the price of a recently issued preferred security, as well as a milestone-based tranche closing. The Company utilized an option pricing model to quantify or attribute value to these economic rights of convertible preferred stock vs. the common stock (e.g. liquidation preferences, dividend provisions, participation rights after liquidation preferences.)</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the OPM, volatility is estimated based on the trading histories of selected guideline public companies. The relative probability of each scenario was determined based on an assessment of then-current market conditions and the Company&#8217;s expectations as to timing and prospects of an IPO.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each valuation methodology includes estimates and assumptions that require significant judgment. These estimates and assumptions include a number of objective and subjective factors, including the prices at which shares were traded between holders of the Company, external market conditions, the prices at which the Company sold convertible preferred shares, the superior rights and preferences of securities senior to common shares at the time, and the likelihood of achieving a voluntary or involuntary liquidity event.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant changes to the key assumptions used in the valuations could result in different fair values of common shares at each valuation date, as applicable.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income taxes for Kymera Therapeutics, Inc. are recorded in accordance with FASB Accounting Standards Codification Topic 740, <font style="font-style:italic;">Income Taxes</font> (&#8220;ASC 740&#8221;), which provides for deferred taxes using an asset and liability approach. Under this method, deferred income tax assets and liabilities are recognized based on future income tax consequences attributable to differences between the financial statement carrying amount of existing assets and liabilities, and their respective income tax basis. Deferred income tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of changes in income tax rates on deferred income tax assets and liabilities is recognized as income or expense in the period that a valuation allowance for any income tax benefits of which future realization is not more likely than not.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions. The tax benefits recorded are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filings or positions is &#8220;more likely than not&#8221; to be realized following resolution of any uncertainty related to the tax benefit, assuming that the matter in question will be raised by the tax authorities.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-16</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Off Balance Sheet Risk and Concentration of Credit Risk</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has no significant off-balance sheet risk such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, and restricted cash. The Company&#8217;s cash, cash equivalents, and restricted cash are deposited in accounts at large financial institutions. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash, cash equivalents and restricted cash are held. The Company maintains its cash equivalents in money market funds that invest in U.S. Treasury securities and U.S. Treasury obligations and corporate bonds. The Company&#8217;s marketable securities primarily consist of corporate bonds and U.S. Treasury securities paper, and potentially subject the Company to concentrations of credit risk. The Company has adopted an investment policy that limits the amounts the Company may invest in any one type of investment. The Company has not experienced any credit losses and does not believe it is exposed to any significant credit risk on these funds.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Comprehensive Loss</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss includes net loss as well as unrealized gains on marketable securities and other changes in stockholders&#8217; equity (deficit) that result from transactions and economic events other than those with stockholders.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss Per Share</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company applies the two-class method to compute basic and diluted net income (loss) per share attributable to common stockholders when it has issued shares that meet the definition of participating securities. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income (loss) available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to share in the earnings as if all income (loss) for the period had been distributed. The Company&#8217;s convertible preferred stock participates in any dividends declared by the Company and are therefore considered to be participating securities. The participating securities are not required to participate in the losses of the Company, and therefore during periods of loss there is no allocation required under the two-class method.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net income (loss) per share attributable to common stockholders is computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) attributable to common stockholders is computed by adjusting net income (loss) per share attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period, including potential dilutive common shares. For purpose of this calculation, outstanding options to purchase common stock, unvested restricted stock awards, and shares of convertible preferred stock are considered potential dilutive common shares. The Company has generated a net loss in all periods presented, and therefore the basic and diluted net loss per share attributable to common stockholders are the same as the inclusion of the potentially dilutive securities would be anti-dilutive.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Emerging Growth Company Status</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is an emerging growth company (&#8220;EGC&#8221;), as defined in the Jumpstart Our Business Startups Act (the &#8220;JOBS Act&#8221;), and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not EGCs. The Company may take advantage of these exemptions until it is no longer an EGC under Section&#160;107 of the JOBS Act, which provides that an EGC can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to use this exemption to delay adopting new or revised.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Recently Adopted Accounting Standards</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2019, the FASB issued ASU 2019-04,&#160;<font style="font-style:italic;">Codification Improvements to Topic 326, Financial Instruments&#8212;Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments</font>. This update provides clarifications for three topics related to financial instruments accounting, some of which apply to the Company. The Company adopted as of January&#160;1, 2020 and it did not have a significant impact on its financial position or results of operation</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-17</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU 2018-15, </font><font style="font-style:italic;">Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The new standard will align the requirements for capitalizing implementation costs for hosting arrangements (services) with costs for internal-use software (assets). As a result, certain implementation costs incurred in hosting arrangements will be deferred and amortized. The Company adopted as of </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January&#160;1, 2020</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and it did not have a significant impact on its financial position or results of operation.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement. The new standard will be effective beginning January&#160;1, 2020. The Company adopted as of January&#160;1, 2020 and it did not have a significant impact on its financial position or results of operation.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Recently Issued Accounting Standards Not Yet Adopted</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU 2019-12, <font style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</font>, which is intended to simplify the accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. The new standard will be effective beginning January&#160;1, 2021. The Company is currently evaluating the potential impact ASU 2019-12 may have on its financial position and results of operations upon adoption.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU 2016-13,&#160;<font style="font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Statements</font>. The new standard requires that expected credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. It also limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value increases. As an emerging growth company, the Company expects to delay adoption until January 1, 2023 and is evaluating the impact that the adoption of ASU 2016-13 will have on its consolidated financial statements.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Note 3. Fair Value Measurements</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values as of December 31,&#160;2020 and December 31, 2019 (in thousands): </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market fund</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,943</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,943</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,499</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,499</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities, current</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US treasuries</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">192,275</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">192,275</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,923</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,923</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities, non-current</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US treasuries</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132,589</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132,589</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,942</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,942</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,589</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,589</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">346,396</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113,364</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">459,760</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,942</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,942</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,774</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,774</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,716</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,716</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-18</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December 31, 2020 and 2019, there were no transfers between Level&#160;1, Level&#160;2 and Level&#160;3. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 4. Marketable Securities</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the available-for-sale debt securities held at December 31, 2020 and 2019 and (in thousands): </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">324,917</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(53</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">324,864</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate securities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,946</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(81</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,865</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">427,863</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(134</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">427,729</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,936</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,942</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,936</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,942</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the Company held&#160;65 securities that had been in an unrealized loss position for less than&#160;12 months with an aggregate fair value of $392.2 million. As of December 31, 2019, the Company did not hold any securities that were in an unrealized loss position.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the Company had 48 securities with a fair value of $295.6 million with a contractual maturity of less than 12 months and 25 securities with a fair value of $162.5 million with a contractual maturity of greater than 12 months. As of December&#160;31, 2019, all of the Company&#8217;s marketable securities had remaining contractual maturity dates of less than one year from the consolidated balance sheet date. During the year ending December 31, 2020, the Company sold one security prior maturity which resulted in an immaterial realized gain on the sale. There were no sales of marketable securities during the year ended December&#160;31, 2019. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk54600670"></a>The Company evaluates securities for other-than-temporary impairments based on quantitative and qualitative factors, and considered the decline in market value for the&#160;65&#160;securities in an unrealized loss position as of&#160;December&#160;31<a name="_Hlk54600670"></a>, 2020, to be primarily attributable to the then current economic and market conditions. <font style="color:#000000;">The Company</font><font style="Background-color:#FFFFFF;color:#000000;"> neither intends to sell these investments nor concludes that it is more-likely-than-not that the Company will have to sell them before recovery of their carrying values. The Company also believe that it will be able to collect both principal and interest amounts due to it at maturity.</font></p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 5. Collaborations</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Sanofi Collaboration Arrangement</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Agreement Terms</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July&#160;7, 2020, the Company entered into a collaboration agreement, or the Sanofi Agreement, with Sanofi, to co-develop drug candidates directed to two biological targets. Under the Sanofi Agreement, the Company granted to Sanofi a worldwide exclusive license to develop, manufacture and commercialize certain lead compounds generated during the collaboration directed against IRAK4, or Collaboration Target 1, and one additional undisclosed target in an undisclosed field of use, or Collaboration Target 2. Such license is exercisable on a collaboration target-by-collaboration target basis only after specified milestones. For compounds directed against IRAK4, the field of use includes diagnosis, treatment, cure, mitigation or prevention of any diseases, disorders or conditions, excluding oncology and immune-oncology.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk54954968"></a>Pursuant to the Sanofi Agreement, the Company is responsible for discovery and preclinical research and conducting a Phase&#160;1 clinical trial for at least one degrader directed against IRAK4 plus up to three backup degraders. With respect to both targets, Sanofi is responsible for development, manufacturing, and commercialization of product candidates after a specified development milestone occurs with respect to each collaboration candidate.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-19</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, pursuant to the Sanofi Agreement, Sanofi will grant to the Company an exclusive option, or Opt-In Right, exercisable on a collaboration target-by-collaboration target basis that will include the right to (</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)&#160;to fund 50% of the United States development costs for collaboration products directed against such target in the applicable field of use and (ii)&#160;share equally in the net profits and net losses of commercializing collaboration products directed against such target in the applicable field of use in the United States. In addition, if the Company exercises the Opt-In Right, Sanofi will grant to the Company an exclusive option, applicable to each collaboration target, which upon exercise will allow the Company to conduct certain co-promotion activities in the field in the United States.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Sanofi Agreement, unless earlier terminated, will expire on a product-by-product basis on the date of expiration of all payment obligations under the Sanofi Agreement with respect to such product. The Company or Sanofi may terminate the agreement upon the other party&#8217;s material breach or insolvency or for certain patent challenges. In addition, Sanofi may terminate the agreement for convenience or for a material safety event upon advance prior written notice, and the Company may terminate the agreement with respect to any collaboration candidate if, following Sanofi&#8217;s assumption of responsibility for the development, commercialization or manufacturing of collaboration candidates with respect to a particular target, Sanofi ceases to exploit any collaboration candidates directed to such target for a specified period.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In consideration for the exclusive licenses granted to Sanofi under the Sanofi Agreement, Sanofi paid to the Company an upfront payment of $150.0&#160;million. The Company will also be reimbursed for certain research activities for a certain backup degrader under the IRAK4 program, unless certain criteria are not met for an initial IRAK4 degrader. In addition to the upfront payment and the reimbursements, the Company is eligible to receive certain development milestone payments of up to $1.48&#160;billion in the aggregate, of which more than $1.0 billion relates to the IRAK4 program, upon the achievement of certain developmental or regulatory events. The Company will be eligible to receive certain commercial milestone payments up to $700.0&#160;million in the aggregate, of which $400&#160;million relates to the IRAK4 program, which are payable upon the achievement of certain net sales thresholds. The Company will be eligible to receive tiered royalties for each program on net sales ranging from the high single digits to high teens, subject to low-single digits upward adjustments in certain circumstances.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-align:justify;margin-left:4.54%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Accounting Treatment </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company analyzed the discovery and pre-clinical research activities as well as the exclusive license grants under the Sanofi Agreement and concluded that the arrangement was indicative of a vendor-customer relationship and would be accounted for under ASC 606. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company identified the following material promises under the arrangement: (1) research services for Collaboration Target 1, (2) research license for Collaboration Target 1, (3) exclusive license for Collaboration Target 1, (4) research services for Collaboration Target 2, (5) research license for Collaboration Target 2, (6) exclusive license for Collaboration Target 2, (7) option to extend the research term, and (8) optional research services during the development period. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined that Collaboration Targets 1 and 2 are distinct from each other. The research associated with degraders directed to each target is at different stages and the licensed field, should development activities be successful, are different from each other. As such, all promises associated with each target are considered distinct from promises associated with the other target.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The research and development services for each collaboration target were determined not to be distinct from the research license and the exclusive license and have been combined into a single performance obligation for each collaboration target. That is, two performance obligations were identified, the combined research services, research license and exclusive license for Collaboration Target 1 and the combined research services, research license and exclusive license for Collaboration Target 2. The exclusive license for each target is not distinct from the pre-clinical and clinical research and development services under the Sanofi Agreement, primarily due to the highly specialized nature of the research and novel technology involved with developing protein degraders &#8211; the pre-clinical activities and studies and first phase 1 clinical trial could not be conducted by another party in the manner required.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The option to extend the research term and optional research services during the development period were evaluated as material rights. The fees associated with each option are at or above the standalone selling price. As such, the underlying options are not performance obligations and fees associated with each option are excluded from the transaction price until the underlying option is exercised.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-20</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The Company determined the total transaction price to be $</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">150.0</font><font style="Background-color:#FFFFFF;">&#160;million, which consists solely of the upfront payment. All milestones payments and option payments are constrained as the achievement of such milestones are contingent upon the success of the underlying research and development activities and are generally outside the control of the Company. The reimbursement of costs for the IRAK4 backup degrader is also treated as constrained variable consideration as the criteria for reimbursement may not always be met, under which circumstances the Company would be responsible for the costs related to the backup degrader. Upon becoming unconstrained, the reimbursement consideration will be added to the transaction price and allocated to Collaboration Target 1.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The Company allocated the upfront payment to each performance obligation based on the relative standalone selling price, as follows:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">Collaboration Target 1: $120.0 million</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><a name="_Hlk41427270"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">Collaboration Target 2: $30.0<a name="_Hlk41427270"></a> million</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined the allocation of the $150.0 million transaction price between Collaboration Target 1 and Collaboration Target 2 based on the value of the research and development for the programs from projected research and development costs for each collaboration target plus a developer&#8217;s profit and the total potential milestones for each collaboration target.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The Company recognizes revenue associated with each performance obligation as the research and development services are provided using an input method, according to costs incurred as related to the research and development activities for each individual program and the costs expected to be incurred in the future to satisfy that individual performance obligation. The transfer of control occurs over this time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying each performance obligation. The amounts received that have not yet been recognized as revenue are deferred as a contract liability on the Company&#8217;s consolidated balance sheet and will be recognized over the remaining research and development period until the performance obligation is satisfied. Reimbursement consideration added to the transaction price will be recognized as revenue on the same pattern as Collaboration Target 1, with a cumulative catch-up upon becoming unconstrained. </font>The performance obligation has not been fully satisfied as of December 31, 2020. During the year ended December 31, 2020, the Company recognized $18.8 million<font style="color:#000000;"> </font>in revenue under the Sanofi Agreement, of which $16.7 million was associated with Collaboration Target 1 and $2.1 million was associated with Collaboration Target 2. The aggregate amount of the transaction price allocated to the Company&#8217;s unsatisfied performance obligations and recorded in deferred revenue at December 31, 2020 is <font style="color:#000000;">$132.6 </font>million. As of December&#160;31, 2020, the Company had not received cost reimbursement payments, and no milestone or royalty payments under the Sanofi Agreement. As of December&#160;31, 2020, the Company recorded unbilled accounts receivable of $0.9 million related to reimbursable research and development costs<font style="font-size:12pt;color:#000000;"> </font>under the Sanofi Agreement for activities performed during the three months ended December&#160;31, 2020 and $0.6 million in accounts receivable for amounts billed under the Sanofi Agreement as of December 31, 2020. The Company will recognize the deferred revenue related to the performance obligations based on a cost input method, as described, over the remaining research term, which is a maximum of three years as of December 31, 2020.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any consideration related to performance-based milestones will be recognized when the risk of probable reversal is resolved, at which point the Company shall adjust the transaction price determined for the agreement accordingly and recognize revenue on a cumulative-catch up basis, reallocating the revised arrangement consideration to the performance obligations. Any consideration related to sales milestone payments and royalties will be recognized when the related milestone events or sales occur and therefore are recognized at the later of when the related sales occur or the relevant performance obligation is satisfied. <font style="Background-color:#FFFFFF;">As part of its evaluation of constraining the milestones, the Company considered numerous factors, including the fact that the achievement of the research and development milestones are contingent upon the results of the underlying research and development activities and are thus outside of the control of the Company.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sanofi participated in the Company&#8217;s Series B Convertible Preferred Stock offering and as a result of this, is considered a related party.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Vertex Agreement </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May&#160;9, 2019 (the &#8220;Effective Date&#8221;), the Company entered into a collaboration agreement (the &#8220;Vertex Agreement&#8221;) with Vertex to advance small molecule protein degraders against up to six targets. Under the Vertex Agreement, Vertex has the exclusive option to license the rights to the product candidates developed for the designated targets at which point Vertex will control development and commercialization. Pursuant to the Vertex Agreement, the Company is only responsible for discovery and preclinical research on the targets, and Vertex is responsible for development, manufacturing, and commercialization of the product candidates after it exercises its option to license. The initial research term of the collaboration is four (4)&#160;years, extendable for an additional one (1)&#160;year period upon mutual agreement by the parties and payment by Vertex of certain per-target fees. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-21</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vertex provided the Company with a non-refundable upfront payment of $</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50.0&#160;</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million and purchased </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,059,695</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares of the Company&#8217;s Series B-1 Convertible Preferred Stock (&#8220;Series B-1&#8221;) at $</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.54</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> a share, pursuant to a separate, but simultaneously executed Share Purchase Agreement. The shares were purchased at a premium of $</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.9&#160;</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million, which was included in the transaction price and will be recognized as revenue over the period of performance. As a result of this purchase, Vertex is considered a related party. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is eligible to receive up to $170.0&#160;million in payments per target, including development, regulatory and commercial milestones as well as option exercise payments. In addition, Vertex is obligated to pay the Company tiered royalties on future net sales on any products that may result from the Vertex Agreement. None of the payments under the Vertex Agreement are refundable. The Company may also perform follow-on research for an optioned target upon Vertex&#8217;s request and at Vertex&#8217;s expense. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The term of the Vertex Agreement began on the Effective Date and expires upon the expiration of all payment obligations from Vertex to Company under the Vertex Agreement or, if Vertex does not exercise any of its options, the lapse of all Vertex&#8217;s option rights under the Vertex Agreement. Vertex also has the ability to terminate for convenience with prior written notice to the Company, and either party may terminate for an uncured material breach. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Accounting Treatment </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company analyzed the joint research activities required under the Vertex Agreement and concluded that the arrangement was indicative of a vendor-customer relationship and would be accounted for under ASC&#160;606. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company identified the following material promises under the arrangement: (1)&#160;the non-exclusive, royalty-free research license; and (2)&#160;the research and development services to be performed on up to six targets; and (3)&#160;the option to license each of the targets for development, manufacturing, and commercialization efforts. The research and development services were determined not to be distinct from the research and development license and have been combined into a single performance obligation. The Company determined that the option to license the targets in the future was not priced at a discount, and that the option exercise fee for each target is at or above the standalone selling price for research at this stage of development; as such, the options and the underlying licenses are excluded from the performance obligation and the option exercise fees are excluded from the transaction price until the underlying option is exercised. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of its evaluation of constraining the research and development milestones, the Company considered numerous factors, including the fact that the achievement of the research and development milestones are contingent upon the results of the underlying research and development activities and are thus outside of the control of the Company. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the commencement of the arrangement, two units of accounting were identified, the issuance of&#160;3,059,695 shares of the Company&#8217;s Series B-1 Convertible Preferred Stock and the research activities the Company will perform over the&#160;Research Term. The Company determined the total transaction price to be $55.9&#160;million, which consists of $5.9&#160;million attributed to the premium from the Series B-1 shares sold to Vertex and the $50.0&#160;million upfront payment. To determine the fair value of the Series B-1 issued to Vertex, the Company performed a valuation of the shares of the Company&#8217;s common and preferred stock, which took into consideration recent financings, and the Company&#8217;s recent development and future exit strategies, as well as a discount for lack of marketability. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes revenue associated with the performance obligation as the research and development services are provided using an input method, according to the costs incurred as related to the research and development activities on each program and the costs expected to be incurred in the future to satisfy the performance obligation. The transfer of control occurs over this time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligation. The amounts received that have not yet been recognized as revenue are deferred as a contract liability on the Company&#8217;s consolidated balance sheet and will be recognized over the remaining research and development period until the performance obligation is satisfied. The performance obligation has not been fully satisfied as of December 31, 2020. During the years ended December 31, 2020 and 2019, the Company recognized $15.2 million and $2.9 million in revenue under the Vertex Agreement. All $15.2&#160;million revenue recognized during the year ended December 31, 2020 was recognized from amounts that were recorded in deferred revenue as of December&#160;31, 2019. The aggregate amount of the transaction price allocated to the Company&#8217;s unsatisfied performance obligation and recorded in deferred revenue at December&#160;31, 2020 and 2019 is $37.7 million and $53.0&#160;million, respectively. The Company will recognize the deferred revenue related to the research and development services based on a cost input method, over the remaining research term, which is a maximum of 2.0 years as of December&#160;31, 2020. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-22</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any consideration related to sales milestone payments (including royalties) will be recognized when the related milestone events or sales occur and therefore are recognized at the later of when the related sales occur or the relevant performance obligation is satisfied. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Compound Collaboration </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2017, the Company entered into a collaboration agreement (the &#8220;Collaboration&#8221;) with a pharmaceutical company to jointly identify, research and conduct preclinical development of collaboration compounds against specified collaboration targets to identify drug candidates. Under the terms of the Collaboration, both parties provided one another with a non-exclusive, royalty-free, sub-licensable research and development license to each party&#8217;s intellectual property to develop five agreed-upon collaboration targets, as well as an exclusive, royalty-bearing development and commercialization license to sell any licensed products that stem from such research. The parties also have the ability to nominate additional collaboration targets if agreed-upon, as long as there are no more than five targets at any given time. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In exchange for the non-exclusive license rights, the Company provided the pharmaceutical company with an equity grant and is required to make tiered royalty payments based on net sales of all products licensed under the agreement in the low single-digit percentages. In conjunction with the Collaboration, the Company initially issued 886,305 Series A Preferred Units (&#8220;Series A Preferred Units&#8221;) to the pharmaceutical company. On November&#160;1, 2018, these Series A Preferred Units were exchanged on a one-for-one basis for shares of Series A Convertible Preferred Stock (the &#8220;Series A Preferred Stock&#8221;). These shares vest in equal installments over three years. The Company is recording expense over the remaining vesting period based on the fair value of the shares under the Collaboration. The Company recorded $0.3&#160;million and $0.4 million to research and development expense related to the vesting of 166,183 and 221,579 shares of Series A Preferred Stock during the years ended December 31, 2020 and 2019, respectively. As of December 31, 2020, all shares under the Collaboration were fully vested and all expense had been recognized.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The royalty payments are contingent and as such are not being recorded until incurred. The Company determined that the license is representative of an in-process research and development asset, with no future alternative use. As such, the Company records the expense related to the vesting of shares as research and development expense in the Company&#8217;s consolidated statements of operations and comprehensive loss. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Collaboration can be terminated by either party for convenience with 60-days written notice and may also be terminated in the event of a material breach. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The <font style="color:#000000;">following table presents the changes in accounts receivable, contract assets and liabilities for the year ended December 31,&#160;2020 (in thousands)</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additions</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deductions</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable and contract assets:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Billed receivables &#8211; Sanofi</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">150,577</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(150,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">577</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unbilled receivables &#8211; Sanofi</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,433</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(577</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">856</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accounts receivable and contract assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">152,010</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(150,577</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,433</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract Liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred Revenue &#8211; Vertex</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,991</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,243</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,748</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred Revenue &#8211; Sanofi</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">151,433</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,791</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132,642</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total contract liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,991</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">151,433</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34,034</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">170,390</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-23</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 6. Property and equipment</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consist of the following as of December&#160;31, 2020 and 2019 (in thousands): </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab and office equipment under and financing</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; right-of-use asset</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,771</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,751</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,636</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">919</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture &amp; fixtures</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">861</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,599</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">545</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets not yet in service</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">453</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,988</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,843</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,147</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,049</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,841</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,794</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense for the years ended December&#160;31, 2020 and 2019 was $1.8 million and $0.9&#160;million, respectively.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Included in property and equipment is lab and office equipment right-of-use assets under financing leases with a cost basis of $2.8&#160;million and accumulated amortization expense of $1.2 million and $0.5&#160;million as of December 31, 2020 and 2019.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization expense related to right-of-use assets was $0.7 million and $0.4&#160;million the years ended December&#160;31, 2020 and 2019 and is included in depreciation expense.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 7. Leases</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2018, the Company entered into a noncancelable facility lease agreement (the &#8220;Lease&#8221;) for 9,836 square feet of research and development and office space in Cambridge, Massachusetts. In March 2020, the Company signed a termination agreement for this lease which was determined to be a lease modification that resulted in a reduction of the right-of-use asset and liability of $2.2 million. The lease termination was effective July&#160;31, 2020 and the Company no longer has any obligations under the Lease.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with the lease agreement, the Company was required to maintain a security deposit and provided a letter of credit to the landlord for $0.2&#160;million, which was recorded in other assets as of December&#160;31, 2019. In October 2020, the Company was released from the security deposit and letter of credit and collected the $0.2 million previously classified in other current assets. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2019, the Company entered into a facility sublease agreement (the &#8220;Sublease&#8221;) for 1,471 square feet of office space in Cambridge, Massachusetts. The term of the lease began on June&#160;24, 2019 and terminated on June 30, 2020, and following termination, the Company had no further obligations under the Sublease. The Sublease required the Company to share in prorated operating expenses and property taxes based upon actual amounts incurred; those amounts were considered variable lease costs and, therefore, are not included in the measurement of the lease and are instead recognized to expense as incurred.<font style="font-weight:bold;"> </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2019, the Company entered into a noncancelable facility lease agreement (the &#8220;New Lease&#8221;) for 34,522 square feet of research and development and office space in Watertown, Massachusetts. The term of the New Lease is 120 months and expires on March&#160;31, 2030. The New Lease has an option to be extended for an additional five years. The lease is not reasonably certain to be extended and as such the additional term is not included in the measurement of the lease. The New Lease includes a rent escalation clause, and rent expense is being recorded on a straight-line basis. The Company received a tenant incentive allowance of $5.5&#160;million in 2020 as the tenant improvements were completed all of which has been collected from its landlord as of December 31, 2020. In accordance with the lease agreement, the Company is required to maintain a security deposit and provided a letter of credit to the landlord for $1.6&#160;million, which is recorded in other assets as of December 31, 2020. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s financing lease obligations consist of certain property and equipment financed through capital leases. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-24</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of the lease costs for the years ended December 31, 2020</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 2019 (in thousands): </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,719</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,597</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing lease costs:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of right-to-use assets, financing</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; leases</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">716</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">385</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense for financing lease liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Variable lease costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">621</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">340</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,177</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,368</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental cash flow information relating to the Company&#8217;s leases for the years ended December 31, 2020 and 2019 was as follows (in thousands): </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for amounts included in the measurement</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; of lease liabilities:</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flows used in (provided by)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; operating leases</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,024</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">635</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flows used in finance leases</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">587</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing cash flows used in finance leases</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">385</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average remaining lease terms and discount rates as of December 31, 2020 and 2019 were as follows: </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Remaining lease term:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing lease</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.8 Years</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.7 Years</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discount Rate:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing lease</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.8</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The undiscounted future lease payments for operating and finance leases as of December&#160;31, 2020, were as follows (in thousands): </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Fiscal Year</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Leases</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Financing</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Leases</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,691</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">712</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,581</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">459</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,659</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">245</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,732</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,814</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,925</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total minimum lease payments</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,402</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,416</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less amounts representing interest or imputed interest</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,702</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(123</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of lease liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,700</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,293</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-25</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 8. Accrued Expenses</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consist of the following as of December 31, 2020 and 2019 (in thousands): </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,821</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,617</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll and payroll-related</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,918</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,256</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional fees</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,585</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">606</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,330</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,568</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 9. Other Commitments and Contingencies</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the ordinary course of business, the Company may be subject to legal proceedings, claims and litigation as the Company operates in an industry susceptible to patent legal claims. The Company accounts for estimated losses with respect to legal proceedings and claims when such losses are probable and estimable. Legal costs associated with these matters are expensed when incurred.&#160;The Company is not currently a party to any legal proceedings.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Indemnification Arrangements</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As permitted under Delaware law, the Company has agreements whereby it indemnifies its investors, employees, officers, and directors (collectively, the &#8220;Indemnified Parties&#8221;) for certain events or occurrences while the Indemnified Parties are, or were serving, at its request in such capacity. The term of the indemnification period is for the Indemnified Parties&#8217; lifetime. The Company believes the estimated fair value of these indemnification agreements is minimal. The Company enters into standard indemnification agreements in the ordinary course of business. Pursuant to these agreements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified party for losses suffered or incurred by the indemnified party, generally the Company&#8217;s business partners or customers, in connection with any U.S. patent or any copyright or other intellectual property infringement claim by any third party with respect to the Company&#8217;s products. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited. The Company is not aware of any claims under indemnification arrangements, and it has not accrued any liabilities related to such obligations as of December&#160;31, 2020 or 2019.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 10. Convertible Preferred Stock</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Immediately prior to the IPO, the Company&#8217;s Articles of Association (the &#8220;Articles&#8221;), as further amended and restated (the &#8220;2018 Amended Articles&#8221;), authorized a total of 52,483,788 convertible preferred stocks with a par value of $0.0001 per share, of which 3,000,000 shares have been designated as Series Seed Preferred Stock, 14,886,305 shares have been designated as Series A Preferred Stock, 16,009,845 shares have been designated as Series B Preferred Stock, 3,059,695 shares have been designated as Series B-1 Preferred Stock and 15,527,943 shares have been designated as Series C Preferred Stock. The Series A, Series B, Series B-1 and Series C convertible preferred stocks will be collectively referred to as the Convertible Preferred Stock. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2020, the Company issued 1,182,265 shares of Series B Preferred Stock at $4.06 per share to complete the second closing of the Series B Preferred Stock issuance for total proceeds of $4.8&#160;million. The issuance costs related to the second tranche were insignificant.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, the Company executed a Series&#160;C Preferred Stock Purchase Agreement (the &#8220;Series&#160;C SPA&#8221;) to issue 13,539,141 shares of Series&#160;C Preferred Stock at a purchase price of $6.5366 per share for a total consideration of $88.2&#160;million, net of issuance costs of $0.3&#160;million. In conjunction with the Series&#160;C SPA, the Company exchanged 1,988,802 shares of Series A Preferred Stock for an equal number of shares of Series&#160;C Preferred Stock related to a transaction amongst investors. This resulted in a total issuance of 15,527,943 shares of Series&#160;C Preferred Stock. The fair value of the shares of Series&#160;C Preferred Stock issued exceeded the carrying value of the shares of Series&#160;A Preferred Stock exchanged by $9.1&#160;million, which was recognized as a deemed dividend through a reduction of $2.3&#160;million to additional&#160;paid-in&#160;capital and an increase of $6.7&#160;million to the accumulated deficit. The $9.1&#160;million deemed dividend increased the net loss for the year ending December 31, 2020 to arrive at net loss attributable to common stockholders in the calculation of earnings per share.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Company&#8217;s August 21, 2020, IPO all issued and outstanding Convertible Preferred Stock of 50,439,595 were converted to 31,625,534 shares of the Company&#8217;s common stock and are no longer issued or outstanding as of December 31, 2020.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-26</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 11. </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Equity-Based Compensation </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2018 Stock Option and Grant Plan </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2018, the Company adopted, and its stockholders approved, the 2018 Stock Option and Grant Plan (the &#8220;2018 Plan&#8221;), which provides for the granting of stock options and other equity-based awards at the discretion of the Board of Directors or any subcommittee of the Board of Directors to its employees, officers, directors, and independent contractors. No further grants will be made under the 2018 Plan. However, the 2018 Plan will continue to govern outstanding equity awards granted thereunder. To the extent outstanding options granted under the 2018 Plan are cancelled, forfeited or otherwise terminated without being exercised and would otherwise have been returned to the share reserve under the 2018 Plan, the number of shares underlying such awards will be available for future grant under the 2020 Stock Option and Incentive Plan. Following the completion of the Company&#8217;s initial public offering no additional shares will be granted under the 2018 Plan. However, the 2018 Plan will continue to govern outstanding equity awards granted thereunder.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2020 Stock Option and Incentive Plan </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, the Company and its stockholders approved the 2020 Stock Option and Incentive Plan (the &#8220;2020 Plan&#8221;), which became effective on August 20, 2020. The 2020 Plan replaced the 2018 Plan as the Company&#8217;s board of directors has determined not to make additional awards under the 2018 Plan following the closing of the Company&#8217;s IPO. The 2020 Plan allows the Company to make equity-based and cash-based incentive awards to its officers, employees, directors and consultants. The Company has initially reserved 4,457,370 shares of its common stock for the issuance of awards under the 2020 Plan, which includes the shares of common stock remaining available for issuance under its 2018 Plan as of the business day immediately prior to the effective date of the registration statement. The 2020 Plan provides that the number of shares reserved and available for issuance will automatically increase on January 1, 2021 and each January 1 thereafter, by 4% of the Company&#8217;s outstanding number of shares of common stock on the immediately preceding December 31, or such lesser number of shares as determined by the Company&#8217;s compensation committee. These limits are subject to adjustment in the event of a stock split, stock dividend or other change in the Company&#8217;s capitalization. As of December&#160;31, 2020, there were an aggregate of 3,148,671 shares remaining available for future grants. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2020 Employee Stock Purchase Plan </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, the Company and its stockholders approved the 2020 Employee Stock Purchase Plan (the &#8220;2020 ESPP&#8221;), which became effective August 20, 2020. The 2020 ESPP initially reserves and authorizes the issuance of up to a total of 445,653 shares of common stock to participating employees. The 2020 ESPP provides that the number of shares reserved and available for issuance will automatically increase on January 1, 2021 and each January 1 thereafter through January 1, 2030, by the least of (i) 438,898 shares of common stock, (ii) 1% of the Company&#8217;s outstanding number of shares of common stock on the immediately preceding December 31 or (iii) such lesser number of shares of common stock as determined by the administrator of the 2020 ESPP. The number of shares reserved under the 2020 ESPP is subject to adjustment in the event of a stock split, stock dividend or other change in the Company&#8217;s capitalization. As of December&#160;31, 2020, there were an aggregate of 445,653 shares remaining available for future grants. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock Options </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of stock option activity under the 2020 Stock Option and Grant Plan during the year ended December 31, 2020 is as follows (in thousands except share and per share data): </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Strike</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price per</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,945,297</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.03</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.93</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,798</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,213,204</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.22</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(78,852</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.06</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(246,937</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.55</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,832,712</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.17</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.08</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">314,001</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,580,924</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.38</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.76</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92,674</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-27</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The i<font style="Background-color:#FFFFFF;color:#000000;">ntrinsic value of stock options exercised during the years ended December 31, 2020 and 2019 was $1.6 million, $0.1 million, respectively.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average fair value of options granted during the years ended December&#160;31, 2020 and 2019 was $8.35 and $1.69 per share, respectively.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the total unrecognized stock-based compensation expense for unvested stock options was $25.6&#160;million, which is expected to be recognized over 3.3 years. The total fair value of stock options vested during the years ended December&#160;31, 2020 and 2019 was $4.0 million, $0.2&#160;million, respectively.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table outlines our equity-based compensation expense for stock options for the years ended December 31, 2020 and 2019:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="8" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ending December 31,</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,084</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">380</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,864</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">212</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total equity-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,948</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">592</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average assumptions that the Company used in Black-Scholes option pricing model to determine the grant date fair value of stock options granted to employees and non-employees for the years ended December 31, 2020 and 2019: </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="8" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ending December 31,</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.3%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.09</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.49</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.5</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.83</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Restricted Common Stock </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has granted shares of restricted common stock with service-based and performance-based vesting conditions. A summary of restricted stock activity under the 2018 Plan during the year ended December 31, 2020 is as follows: </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Units</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">per Share</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">232,434</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.60</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(102,651</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.60</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,679</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.60</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,104</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.60</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no grants of restricted stock during the years ended December 31, 2020 and 2019.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the total unrecognized stock-based compensation expense for unvested restricted stock was $0.3&#160;million, which is expected to be recognized over 1.6 years. The total fair value of restricted stock vested during the years ended December&#160;31, 2020 and 2019 was $0.1 million and $0.5&#160;million, respectively.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December 31, 2020 and 2019, the Company recorded stock-based compensation expense for restricted stock of $0.2 million and $0.4&#160;million, of which $0.2 million and $0.2 million was included in research and development expense and an immaterial amount and $0.2 million was included in general and administrative expense, respectively. Included within the 2019 general and administrative stock-based compensation expense was $0.1&#160;million from a modification of an employee&#8217;s awards.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-28</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Equity-Based Compensation Expense </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total equity-based compensation expense recorded as research and development and general and administrative expenses for employees, directors, and non-employees during the years ended December 31, 2020 and 2019 is as follows (in thousands): </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="8" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years ending December 31,</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,305</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">688</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,885</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">508</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total equity-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,190</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,196</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 12. Related-Party Transactions</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the collaboration discussed in Note 5, the Company had the following related party transactions for the periods presented in the accompanying consolidated financial statements, which has not otherwise been discussed in these notes to the consolidated financial statement. The Company made payments of $0.8 million and $1.0&#160;million to an investor for rent expenses for the years ended December 31, 2020 and 2019, respectively. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 13. Income Taxes </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.53%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company records income tax expense related to profits realized by its U.S. operating subsidiaries.&#160;For the years ended December&#160;31, 2020 and 2019, no income tax expense was recorded due the group&#8217;s net operating loss (&#8220;NOL&#8221;) and full valuation allowance.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.53%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The rate reconciliation of the U.S. statutory income tax rate to the Company&#8217;s effective tax rate for the years ended December&#160;31, 2020 and 2019 are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax effect at statutory rate</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State taxes</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.8</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.9</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.6</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent differences</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal research and development credits</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.6</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.0</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.7</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28.8</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29.4</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.53%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company&#8217;s net deferred income taxes are as&#160;follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160; </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Deferred Tax Assets:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal net operating loss carryforwards</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,621</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,011</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State net operating loss carryforwards</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,866</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,319</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credit carryforwards</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,757</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,637</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,563</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,286</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,313</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accruals and reserves, stock and other</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,589</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">525</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,709</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,778</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34,075</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,949</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,634</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,829</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed and intangible assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,506</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(754</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,128</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,075</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax asset</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-29</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.53%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As required by ASC 740, management of the Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, which are composed principally of NOL carryforwards and research and development credit carryforwards. Management has determined that it is more likely than not that the Company will not recognize the benefits of its federal and state deferred tax assets, and, as a result, a valuation allowance of $34.1&#160;million and $20.9&#160;million has been established at December&#160;31, 2020 and 2019, respectively. During 2020, the valuation allowance increased by $13.1&#160;million primarily due to the increase in the Company&#8217;s NOL during the period.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.53%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has incurred NOLs from inception. At December&#160;31, 2020 and 2019, the Company has federal NOL carryforwards of approximately $74.4&#160;million and $71.5&#160;million, respectively, and state NOL carryforwards of approximately $61.2&#160;million and $68.3&#160;million, respectively. Of the federal net operating loss carryovers, $64.6 million is not subject to expiration and the remaining federal and state NOLs begin to expire in 2036. These loss carryforwards are subject to review and possible adjustment by the appropriate taxing authorities.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.53%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Utilization of net operating loss and research and development credit carryforwards may generally be subject to limitation under Sections 382 and 383 of the Internal Revenue Code due to ownership changes that have occurred previously, or that could occur in the future. These ownership changes may limit the amount of net operating loss and research and development credit carryforwards that can be utilized annually to offset any post-ownership change taxable income and tax, respectively. The latest Section 382 study was performed through December 31, 2020, noting that a historic ownership change has likely occurred. Nonetheless, the Company has determined that as of December 31, 2020 the prospective utilization of all net operating loss and tax credit carryforwards generated from inception through December 31, 2020, and therefore the corresponding Federal and Massachusetts deferred tax assets, should not be restricted by Sections 382 and 383, although ownership changes after December 31, 2020 could impact the Company&#8217;s ability to utilize these tax attributes in the future.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.53%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2020 and 2019, the Company had federal research and development credit carryforwards of $2.7&#160;million and $1.1&#160;million, respectively, and state research and development credit carryforwards of $1.3&#160;million and $0.7&#160;million, respectively. These carryforwards begin to expire in&#160;2036.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.53%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company follows the provisions of ASC 740-10, &#8220;Accounting for Uncertainty in Income Taxes,&#8221; which specifies how tax benefits for uncertain tax positions are to be recognized, measured, and recorded in financial statements; requires certain disclosures of uncertain tax matters; specifies how reserves for uncertain tax positions should be classified on the balance sheet; and provides transition and interim period guidance, among other provisions.&#160;As of December 31, 2020, and 2019, the Company has not recorded any amounts for uncertain tax positions.&#160;The Company&#8217;s policy is to recognize interest and penalties accrued on any uncertain tax positions as a component of income tax expense, if any, in its statements of income. As of December&#160;31, 2020 and 2019, the Company had no reserves for uncertain tax positions.&#160;For the years ended December&#160;31, 2020 and 2019, no estimated interest or penalties were recognized on uncertain tax positions.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.53%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company's tax returns for the years ended December 31, 2017 to December 31, 2020 remain open and subject to examination by the Internal Revenue Service and state taxing authorities.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 14. Net Loss per Share</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss per Share</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding (in thousands, except for share and per share data):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="8" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,593</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41,246</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deemed dividend from exchange of convertible</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,050</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(54,643</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41,246</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average common shares outstanding, basic</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; and diluted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,349,582</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,698,522</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share, basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.15</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24.28</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-30</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s potentially dilutive securities, which include convertible preferred stock, restricted stock, and stock options, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following from the computation of diluted net loss per share attributable to common stockholders at December&#160;31, 2020 and 2019 because including them would have had an anti-dilutive effect:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="8" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible Preferred Stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,325,780</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested Restricted Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,104</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">232,434</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase Common Stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,580,924</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,945,298</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,691,028</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,503,512</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-31</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"></a><a name="ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"></a>Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None. </p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_9A_CONTROLS_PROCEDURES"></a><a name="ITEM_9A_CONTROLS_PROCEDURES"></a>Item 9A. Controls and Procedures. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Management&#8217;s Evaluation of Disclosure Controls and Procedures</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We <font style="color:#000000;">maintain</font> &#8220;disclosure controls and procedures,&#8221; as defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Securities Exchange Act of 1934, as amended, or the Exchange Act, that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is (1)&#160;recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules&#160;and forms and (2)&#160;accumulated and communicated to our management, including our principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their control objectives.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management, with the participation of our Chief Executive Officer, who serves as our principal executive officer, and our Chief Financial Officer, who serves as our principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures as of December 31,&#160;2020, the end of the period covered by this Annual Report on Form 10-K. Based upon such evaluation, our chief executive officer and chief financial officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of such date.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Internal Control Over Financial Reporting</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Management&#8217;s Report on Internal Control Over Financial Reporting</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K does not include a report of management&#8217;s assessment regarding internal control over financial reporting or an attestation report of our independent registered public accounting firm due to a transition period established by rules of the SEC for newly public companies.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Changes in Internal Control Over Financial Reporting</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_9B_OR_INFORMATION"></a><a name="ITEM_9B_OR_INFORMATION"></a>Item 9B. Other Information. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The registrant must disclose under this item any information required to be disclosed in a report on Form 8-K during the fourth quarter of the year covered by this Form 10-K, but not reported, whether or not otherwise required by this Form 10-K. If disclosure of such information is made under this item, it need not be repeated in a report on Form 8-K which would otherwise be required to be filed with respect to such information or in a subsequent report on Form 10-K. </p><a name="_AEIOULastRenderedPageBreakAEIOU13"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART III </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"></a><a name="ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"></a>Item 10. Directors, Executive Officers and Corporate Governance. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item&#160;10 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2021 Annual Meeting of Stockholders and is incorporated herein by reference.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_11_EXECUTIVE_COMPENSATION"></a><a name="ITEM_11_EXECUTIVE_COMPENSATION"></a>Item 11. Executive Compensation. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item&#160;11 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2021 Annual Meeting of Stockholders and is incorporated herein by reference</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"></a><a name="ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"></a>Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item&#160;12 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2021 Annual Meeting of Stockholders and is incorporated herein by reference.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"></a><a name="ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"></a>Item 13. Certain Relationships and Related Transactions, and Director Independence. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item&#160;13 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2021 Annual Meeting of Stockholders and is incorporated herein by reference.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"></a><a name="ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"></a>Item 14. Principal Accounting Fees and Services. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item&#160;14 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2021 Annual Meeting of Stockholders and is incorporated herein by reference</p><a name="_AEIOULastRenderedPageBreakAEIOU14"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART IV</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"></a><a name="ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"></a>Item 15. Exhibits, Financial Statement Schedules. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;color:#000000;">Financial Statements </font><font style="color:#000000;"> </font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For<font style="color:#000000;"> a list of the consolidated financial statements included herein, see Index to the Consolidated Financial Statements on page F-1 of this Annual Report on Form 10-K, which is incorporated into this Item by reference.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;color:#000000;">Exhibits</font><font style="color:#000000;"> </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;3.1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1815442/000119312520229873/d45025dex31.htm"><font style="text-decoration:underline;">Fourth Amended and Restated Certificate of Incorporation of Kymera Therapeutics, Inc. (Incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on August&#160;25, 2020).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;3.2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1815442/000119312520229873/d45025dex32.htm"><font style="text-decoration:underline;">Second Amended and Restated Bylaws of Kymera Therapeutics, Inc. (Incorporated by reference to Exhibit 3.2 to the Registrant&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on August&#160;25, 2020).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;4.1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1773427/000114420419040443/tv525698_ex4-1.htm"><font style="text-decoration:underline;">Specimen Common Stock Certificate (Incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-240264) filed with the Securities and Exchange Commission on August 17, 2020).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;4.2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1815442/000119312520206645/d940105dex42.htm"><font style="text-decoration:underline;">Second Amended and Restated Investors&#8217; Rights Agreement among the Registrant and certain of its stockholders, effective as of March&#160;11, 2020 (Incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-240264) filed with the Securities and Exchange Commission on July 31, 2020).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;4.3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="kymr-ex43_735.htm"><font style="text-decoration:underline;">Description of Securities</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1#</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001815442/000119312520206645/d940105dex101.htm"><font style="text-decoration:underline;">2018 Stock Option and Grant Plan, and form of award agreements thereunder (Incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-240264) filed with the Securities and Exchange Commission on July 31, 2020).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2#</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001815442/000119312520221618/d940105dex102.htm"><font style="text-decoration:underline;">2020 Stock Option and Incentive Plan, and form of award agreements thereunder (Incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-240264) filed with the Securities and Exchange Commission on August 17, 2020).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3#</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001815442/000119312520218412/d940105dex103.htm"><font style="text-decoration:underline;">Non-Employee Director Compensation Policy (Incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-240264) filed with the Securities and Exchange Commission on August 13, 2020).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.4#</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001815442/000119312520218412/d940105dex104.htm"><font style="text-decoration:underline;">Senior Executive Cash Incentive Bonus Plan (Incorporated by reference to Exhibit 10.4 to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-240264) filed with the Securities and Exchange Commission on August 13, 2020).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.5#</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001815442/000156459020050872/kymr-ex101_540.htm"><font style="text-decoration:underline;">Amended and Restated 2020 Employee Stock Purchase Plan (Incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 5, 2020).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.6</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001815442/000119312520221618/d940105dex106.htm"><font style="text-decoration:underline;">Form of Indemnification Agreement between the Registrant and each of its directors and executive officers (Incorporated by reference to Exhibit 10.6 to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-240264) filed with the Securities and Exchange Commission on August 17, 2020).</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.7</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001815442/000119312520206645/d940105dex107.htm"><font style="text-decoration:underline;">Lease Agreement between the Registrant and ARE-TECH SQUARE, LLC, dated as of February&nbsp;&nbsp;28, 2018 (Incorporated by reference to Exhibit 10.7 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-240264) filed with the Securities and Exchange Commission on July 31, 2020).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.8</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001815442/000119312520206645/d940105dex108.htm"><font style="text-decoration:underline;">Lease between the Registrant and Arsenal Yards Holding LLC, dated as of August 15, 2019 (Incorporated by reference to Exhibit 10.8 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-240264) filed with the Securities and Exchange Commission on July 31, 2020).</font></a></p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.9#</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001815442/000119312520218412/d940105dex109.htm"><font style="text-decoration:underline;">Form of Amended and Restated Employment Agreement (Incorporated by reference to Exhibit 10.9 to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-240264) filed with the Securities and Exchange Commission on August 13, 2020).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.10</font>&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001815442/000119312520206645/d940105dex1010.htm"><font style="text-decoration:underline;">Master Collaboration Agreement between the Registrant and Vertex Pharmaceuticals Incorporated, dated as of May 9, 2019 (Incorporated by reference to Exhibit 10.11 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-240264) filed with the Securities and Exchange Commission on July 31, 2020).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.11</font>&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001815442/000119312520210375/d940105dex1012.htm"><font style="text-decoration:underline;">Collaboration Agreement between the Registrant and GlaxoSmithKline Intellectual Property Development Limited, dated as of October 3, 2017 (Incorporated by reference to Exhibit 10.12 to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-240264) filed with the Securities and Exchange Commission on August 5, 2020).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.12</font>&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001815442/000119312520206645/d940105dex1014.htm"><font style="text-decoration:underline;">Collaboration and License Agreement between the Registrant and Genzyme Corporation, dated as of July 7, 2020 (Incorporated by reference to Exhibit 10.14 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-240264) filed with the Securities and Exchange Commission on July 31, 2020).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.13</font>&#8224;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001815442/000156459020050872/kymr-ex102_541.htm"><font style="text-decoration:underline;">First Amendment to Collaboration Agreement between the Registrant and GlaxoSmithKline Intellectual Property Development Limited, dated as of August&#160;27, 2020 (Incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 5, 2020).</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.14</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001815442/000156459020050872/kymr-ex103_542.htm"><font style="text-decoration:underline;">First Amendment to Master Collaboration Agreement between the Registrant and Vertex Pharmaceuticals Incorporated, dated as of August&#160;27, 2020 (Incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 5, 2020).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">21.1</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="kymr-ex211_1388.htm"><font style="text-decoration:underline;">List of Subsidiaries of Registrant.</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">23.1</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="kymr-ex231_895.htm"><font style="text-decoration:underline;">Consent of Ernst &amp; Young LLP, independent registered public accounting firm.</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">24.1</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#SIGNATURES"><font style="text-decoration:underline;">Power of Attorney (included on signature page to this Annual Report on Form 10-K).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">31.1</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="kymr-ex311_11.htm"><font style="text-decoration:underline;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">31.2</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="kymr-ex312_10.htm"><font style="text-decoration:underline;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">32.1<sup style="font-size:85%;line-height:120%;vertical-align:top"><strike>+</strike></sup></font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="kymr-ex321_9.htm"><font style="text-decoration:underline;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">32.2<sup style="font-size:85%;line-height:120%;vertical-align:top"><strike>+</strike></sup></font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="kymr-ex322_8.htm"><font style="text-decoration:underline;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">&nbsp;</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.INS</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Instance Document</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.SCH</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Schema Document</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.CAL</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Calculation Linkbase Document</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.DEF</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Definition Linkbase Document</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.LAB</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Label Linkbase Document</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.PRE</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Presentation Linkbase Document</p></td>
</tr>
</table></div>
<p style="text-align:justify;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:73.33%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">+</sup></font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">This certification will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, except to the extent specifically incorporated by reference into such filing.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">#</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Indicates a management contract or any compensatory plan, contract or arrangement.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8224;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Application has been made to the Securities and Exchange Commission for confidential treatment of certain provisions. Omitted material for which confidential treatment has been requested has been filed separately with the Securities and Exchange Commission.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Financial Statement Schedules</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No financial statements <font style="color:#000000;">have been submitted because they are not required or are not applicable or because the information required is included in the consolidated financial statements or the notes thereto.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_16_FORM_10K_SUMMARY"></a><a name="ITEM_16_FORM_10K_SUMMARY"></a>Item 16. Form 10-K Summary</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p><a name="_AEIOULastRenderedPageBreakAEIOU18"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="SIGNATURES"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES</font></p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized<font style="font-weight:bold;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="top"  BGCOLOR="#FFFFFF" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kymera Therapeutics, Inc.</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 11, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Nello Mainolfi, Ph.D.</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Nello Mainolfi, Ph.D<font style="font-weight:normal;">.</font></p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each person whose individual signature appears below hereby constitutes and appoints Nello Mainolfi, Ph.D. and Bruce Jacobs, CFA, MBA and each of them, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue thereof.</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Nello Mainolfi, Ph.D.</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nello Mainolfi, Ph.D.</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (Principal Executive Officer)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Bruce Jacobs, CFA, MBA</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2021 </p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bruce Jacobs, CFA, MBA</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (Principal Financial and Accounting Officer)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Bruce Booth, DPhil</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chair of the Board of Directors</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bruce Booth, DPhil</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Jeff Albers, MBA</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jeff Albers, MBA</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Pamela Esposito, PhD</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pamela Esposito, PhD</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Steve Hall, PhD</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2021 </p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Steve Hall, PhD</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Andrew Hedin, MBA</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Andrew Hedin, MBA</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Joanna Horobin, MB, ChB</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Joanna Horobin, MB, ChB</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Gorjan Hrustanovic, PhD</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gorjan Hrustanovic, PhD</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Donald W. Nicholson, PhD</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Donald W. Nicholson, PhD</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</a></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>2
<FILENAME>kymr-ex43_735.htm
<DESCRIPTION>EX-4.3
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
kymr-ex43_735.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 4.3</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Description of the Registrant&#8217;s Securities Registered Pursuant to<br />Section 12 of the Securities Exchange Act of 1934, as amended</font></p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The common stock, par value $0.0001 per share (&#8220;Common Stock&#8221;), of Kymera Therapeutics, Inc. (&#8220;Kymera,&#8221; &#8220;we,&#8221; or &#8220;our&#8221;) is registered under Section 12 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). The following description sets forth certain general terms and provisions of our Common Stock. These descriptions are in all respects subject to and qualified in their entirety by, and should be read in conjunction with, the applicable provisions of our Amended and Restated Certificate of Incorporation (our &#8220;Charter&#8221;) and our Amended and Restated By-laws (our &#8220;By-laws&#8221;), each of which is incorporated herein by reference and copies of which are incorporated by reference as exhibits to our most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, and the applicable provisions of General Corporation Law of the State of Delaware (the &#8220;DGCL&#8221;).</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Authorized Capital Stock</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are authorized to issue 150,000,000 shares of Common Stock and 10,000,000 shares of preferred stock, par value $0.0001 per share (&#8220;Preferred Stock&#8221;). </p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock </p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The holders of Common Stock are entitled to one vote for each share held on all matters submitted to a vote of the stockholders. The holders of Common Stock do not have any cumulative voting rights. Holders of Common Stock are entitled to receive ratably any dividends declared by our board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. The Common Stock has no preemptive rights, conversion rights or other subscription rights or redemption or sinking fund provisions. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of our liquidation, dissolution or winding up, holders of Common Stock will be entitled to share ratably in all assets remaining after payment of all debts and other liabilities and any liquidation preference of any outstanding Preferred Stock. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred Stock </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our board of directors has the authority, without further action by our stockholders, to issue up to 10,000,000 shares of Preferred Stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of Common Stock. The issuance of our Preferred Stock could adversely affect the voting power of holders of Common Stock and the likelihood that such holders will receive dividend payments and payments upon our liquidation. In addition, the issuance of Preferred Stock could have the effect of delaying, deferring or preventing a change in control of our company or other corporate action. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registration Rights </p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Pursuant to the terms of our Second Amended and Restated Investors&#8217; Rights Agreement, dated as of March 11, 2020, with certain</font><font style="color:#000000;"> of our stockholders (the &#8220;Investors</font>&#8217;<font style="color:#000000;"> Rights Agreement&#8221;), certain of our stockholders are entitled to rights with respect to the registration of their shares (which we refer to herein as &#8220;registrable securities&#8221;) under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), including demand registration rights, short-form registration rights and piggyback registration rights. </font></p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/107610274.1&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:11pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Demand Registration Rights </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The holders of our registrable securities are entitled to demand registration rights. Under the terms of the Investors<font style="color:#000000;">&#8217;</font> Rights Agreement, upon the written request of holders of at least 55% of these securities, which must include (i) at least one Major Series A Investor, (ii) at least one Major Series B Investor and (iii) at least one Major Series C Investor, as such terms are defined in the Investors&#8217; Rights Agreement), to file a registration statement and use commercially reasonable efforts to effect the registration of all or a portion of these shares for public resale. We are required to effect only two registrations pursuant to this provision of the investors&#8217; rights agreement. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:11pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Short-Form Registration Rights </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The holders of our registrable securities are entitled to short-form registration rights. Pursuant to the Investors<font style="color:#000000;">&#8217;</font> Rights Agreement, if we are eligible to file a registration statement on Form S-3, upon the written request of holders of at least 5% of the Registrable Securities then outstanding, as such term is defined in the Investors&#8217; Rights Agreement at an aggregate offer price of at least $2.0 million, we will be required to use commercially reasonable efforts to effect a registration of such shares. We are required to effect only two registrations in any twelve month period. The right to have such shares registered on Form S-3 is further subject to other specified conditions and limitations.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:11pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Piggyback Registration Rights </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the Investors<font style="color:#000000;">&#8217;</font> Rights Agreement, if we register any of our securities either for our own account or for the account of other security holders, the holders of our outstanding registrable securities are entitled to include their shares in the registration. Subject to certain exceptions contained in the Investors<font style="color:#000000;">&#8217;</font> Rights Agreement, we and the underwriters may limit the number of shares included in the underwritten offering to the number of shares which we and the underwriters determine in our sole discretion will not jeopardize the success of the offering. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:11pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Indemnification </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Investors<font style="color:#000000;">&#8217;</font> Rights Agreement contains customary cross-indemnification provisions, under which we are obligated to indemnify holders of registrable securities in the event of material misstatements or omissions in the registration statement attributable to us, and they are obligated to indemnify us for material misstatements or omissions attributable to them. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:11pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expiration of Registration Rights </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The registration rights granted under the Investors<font style="color:#000000;">&#8217;</font> Rights Agreement will terminate the earliest to occur of: (i) on the fifth anniversary of the our initial public offering, (ii) at such time after our initial public offering when all registrable securities could be sold under Rule 144 of the Securities Act or another similar exemption without restriction within a three-month period or (iii) a merger, sale or liquidation of our company. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Anti-Takeover Effects of Delaware Law and Certain Provisions of our Charter and By-Laws </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Charter and By-Laws include a number of provisions that may have the effect of delaying, deferring or preventing another party from acquiring control of us and encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our board of directors rather than pursue non-negotiated takeover attempts. These provisions include the items described below. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/107610274.1&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:11pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-size:11pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Board Composition and Filling Vacancies </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Charter provides for the division of our board of directors into three classes serving staggered three-year terms, with one class being elected each year. Our Charter also provides that directors may be removed only for cause and then only by the affirmative vote of the holders of two-thirds or more of the shares then entitled to vote at an election of directors. Furthermore, any vacancy on our board of directors, however occurring, including a vacancy resulting from an increase in the size of our board, may only be filled by the affirmative vote of a majority of our directors then in office even if less than a quorum. The classification of directors, together with the limitations on removal of directors and treatment of vacancies, has the effect of making it more difficult for stockholders to change the composition of our board of directors. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:11pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">No Written Consent of Stockholders </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Charter provides that all stockholder actions are required to be taken by a vote of the stockholders at an annual or special meeting, and that stockholders may not take any action by written consent in lieu of a meeting. This limit may lengthen the amount of time required to take stockholder actions and would prevent the amendment of our By-Laws or removal of directors by our stockholders without holding a meeting of stockholders. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:11pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Meetings of Stockholders </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Charter and By-Laws provide that only a majority of the members of our board of directors then in office may call special meetings of stockholders and only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders. Our By-Laws limit the business that may be conducted at an annual meeting of stockholders to those matters properly brought before the meeting. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:11pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Advance Notice Requirements </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our By-Laws establish advance notice procedures with regard to stockholder proposals relating to the nomination of candidates for election as directors or new business to be brought before meetings of our stockholders. These procedures provide that notice of stockholder proposals must be timely given in writing to our corporate secretary prior to the meeting at which the action is to be taken. Generally, to be timely, notice must be received at our principal executive offices not less than 90 days nor more than 120 days prior to the first anniversary date of the annual meeting for the preceding year. Our By-Laws specify the requirements as to form and content of all stockholders&#8217; notices. These requirements may preclude stockholders from bringing matters before the stockholders at an annual or special meeting. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:11pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Amendment to Charter and By-Laws </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any amendment of our Charter must first be approved by a majority of our board of directors, and if required by law or our Charter, must thereafter be approved by a majority of the outstanding shares entitled to vote on the amendment and a majority of the outstanding shares of each class entitled to vote thereon as a class, except that the amendment of the provisions relating to stockholder action, board composition, limitation of liability and the amendment of our By-Laws and Charter must be approved by not less than two-thirds of the outstanding shares entitled to vote on the amendment, and not less than a majority of the outstanding shares of each class entitled to vote thereon as a class. Our By-Laws may be amended by the affirmative vote of a majority of the directors then in office, subject to any limitations set forth in the By-Laws; and may also be amended by the affirmative vote of at least two-thirds of the outstanding shares entitled to vote on the amendment, or, if our board of directors recommends that the stockholders approve the amendment, by the affirmative vote of the majority of the outstanding shares entitled to vote on the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/107610274.1&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">amendment, in each case voting together as a single class. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:11pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Undesignated Preferred Stock </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Charter provides for 10,000,000 authorized shares of Preferred Stock. The existence of authorized but unissued shares of Preferred Stock may enable our board of directors to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary obligations, our board of directors were to determine that a takeover proposal is not in the best interests of our stockholders, our board of directors could cause shares of Preferred Stock to be issued without stockholder approval in one or more private offerings or other transactions that might dilute the voting or other rights of the proposed acquirer or insurgent stockholder or stockholder group. In this regard, our Charter grants our board of directors broad power to establish the rights and preferences of authorized and unissued shares of Preferred Stock. The issuance of shares of Preferred Stock could decrease the amount of earnings and assets available for distribution to holders of shares of Common Stock. The issuance may also adversely affect the rights and powers, including voting rights, of these holders and may have the effect of delaying, deterring or preventing a change in control of us. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:11pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Delaware Anti-Takeover Statute </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to the provisions of Section 203 of the DGCL. In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a three-year period following the time that this stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. Under Section 203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:11pt;font-family:Times New Roman;color:#000000;">before the stockholder became interested, our board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:11pt;font-family:Times New Roman;color:#000000;">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans, in some instances, but not the outstanding voting stock owned by the interested stockholder; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:11pt;font-family:Times New Roman;color:#000000;">at or after the time the stockholder became interested, the business combination was approved by our board of directors and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least two-thirds of the outstanding voting stock which is not owned by the interested stockholder. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 203 defines a business combination to include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:11pt;font-family:Times New Roman;color:#000000;">any merger or consolidation involving the corporation and the interested stockholder; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:11pt;font-family:Times New Roman;color:#000000;">any sale, transfer, lease, pledge, exchange, mortgage or other disposition involving the interested stockholder of 10% or more of the assets of the corporation; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:11pt;font-family:Times New Roman;color:#000000;">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder; or </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/107610274.1&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="text-decoration:none;Background-color:#auto;font-size:11pt;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="font-size:11pt;font-family:Times New Roman;color:#000000;">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In general, Section 203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:11pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Choice of Forum </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our By-Laws provide that, unless we consent in writing to the selection of an alternative form, the Court of Chancery of the State of Delaware (or, if the Chancery Court does not have jurisdiction, the federal district court for the District of Delaware or other state courts of the State of Delaware) will be the sole and exclusive forum for state law claims for (i) any derivative action or proceeding brought on our behalf; (ii) any action asserting a claim of breach of a fiduciary duty or other wrongdoing by any of our directors, officers, employees or agents to us or our stockholders; (iii) any action asserting a claim against us, or any current or former director, officer, or other employee or stockholder, arising out of or pursuant to any provision of the General Corporation Law of the State of Delaware or our certificate of incorporation or By-Laws; and (iv) any action asserting a claim against us or any current or former director or officer or other employee governed by the internal affairs doctrine; provided, however, that this choice of forum provision does not apply to any causes of action arising under the Securities Act or the Exchange Act. Our By-Laws further provide that, unless we consent in writing to an alternative forum, the United States District Court for the District of Massachusetts will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. Our By-Laws also provides that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice of and to have consented to this choice of forum provision. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize that the forum selection clause in our By-Laws may impose additional litigation costs on stockholders in pursuing any such claims, particularly if the stockholders do not reside in or near the State of Delaware or the Commonwealth of Massachusetts, as applicable. Additionally, the forum selection clause in our By-Laws may limit our stockholders&#8217; ability to bring a claim in a forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees even though an action, if successful, might benefit our stockholders. The Court of Chancery of the State of Delaware or the United States of Massachusetts may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders.</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock Exchange Listing</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Common Stock is listed on The Nasdaq Global Market under the trading symbol &#8220;KYMR.&#8221;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Transfer Agent and Registrar</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Transfer Agent and Registrar for our Common Stock is<font style="font-size:10pt;font-family:Arial;"> </font>Computershare Trust Company, N.A. The transfer agent and registrar&#8217;s address is 250 Royall Street, Canton, Massachusetts 02021, and its telephone number is (800) 962-428.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/107610274.1&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>kymr-ex211_1388.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
kymr-ex211_1388.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 21.1 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SUBSIDIARIES </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:37%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:35%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Subsidiary</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Jurisdiction of Incorporation</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kymera Securities Corporation</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Massachusetts</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="margin-top:12pt;margin-bottom:8pt;text-indent:0%;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/107610297.1&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>kymr-ex231_895.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
kymr-ex231_895.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Exhibit_23_1"></a><a name="Exhibit_23_1"></a>Exhibit 23.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consent of Independent Registered Public Accounting Firm</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We consent to the incorporation by reference in the following Registration Statement (Form S-8 No. 333- 248249) pertaining to the Kymera Therapeutics, Inc. 2018 Stock Option and Grant Plan, Kymera Therapeutics, Inc. 2020 Stock Option and Incentive Plan, and Kymera Therapeutics, Inc. 2020 Employee Stock Purchase Plan of our report dated March 11, 2021, with respect to the consolidated financial statements of Kymera Therapeutics, Inc. included in this Annual Report (Form 10-K) of Kymera Therapeutics, Inc. for the year ended December 31, 2020.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Ernst&#160;&amp; Young LLP</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Boston, Massachusetts</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2021 </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>kymr-ex311_11.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
kymr-ex311_11.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Nello Mainolfi, Ph.D., certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">I have reviewed this Annual Report on Form 10-K of Kymera Therapeutics, Inc.;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:-4.86%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 11, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Nello Mainolfi, Ph.D.</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Nello Mainolfi, Ph.D<font style="font-weight:normal;">.</font></p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>kymr-ex312_10.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
kymr-ex312_10.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.2</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Bruce Jacobs, CFA, MBA, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">I have reviewed this Annual Report on Form 10-K of Kymera Therapeutics, Inc.:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:-4.86%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 11, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Bruce Jacobs, CFA, MBA</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bruce Jacobs, CFA, MBA</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>kymr-ex321_9.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
kymr-ex321_9.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Annual Report of Kymera Therapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ending December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:-4.86%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 11, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Nello Mainolfi, Ph.D.</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Nello Mainolfi, Ph.D<font style="font-weight:normal;">.</font></p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>kymr-ex322_8.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
kymr-ex322_8.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.2</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Annual Report of Kymera Therapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ending December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 11, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;<font style="color:#000000;">Bruce Jacobs, CFA, MBA</font></p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bruce Jacobs, CFA, MBA</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:-4.86%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g23ode3tb50n000012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g23ode3tb50n000012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /[!5,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@!"0H)/05YSXG\57M]J@T71"WG'(>1#]W%=7XKU-=,T&XEW8<H0OUKFO
MAQH_^CS:K<+NEN&#J6[ BFNXBG'\-[V>'SKC4Y#<-SN*\BJQF\3^#I0T\DMY
M9 XRQP *]6J*XMXKF)HY45E88((S1<+&7H'B*SUZT$L#C=CYE]*V:\JU[1KS
MPAJ@U;3-QMMVZ2,9/'TKOO#^NV^N6"31,-^/F7/0T6&:]%%%( HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUDZ_HL&M:;)!*H+8RI]#VIH"[8WL5_:)<0L&1QD59KR_P?JMQX>UB30=0?Y
MVV)C7IX(8 @Y!&:& M%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#RKQM_P CSI7_  +^=3^/_P#C
MZT7_ *[)_*H/&W_(\Z5_P+^=/^(T\=M)H\LK!46522>W% 'I-A_QX0_[M2RS
MQ0C,LJ1CU=@*Y6S\>^&X[.)6U.$$+R,U+>PZ9XVL0+6[5T4DY6@#H4O[.1MJ
M7<#,>RR FL36?"UGJ5Q]KN'9MO(0\BLK2_AU;:;?)<K/N*]N:[&X&VT8>@H
M\W^'$20ZU?1HH"K(X %.^+4C10V;H,L,X%+\/O\ D/ZA_P!=7J3XHCFP^IH
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M74Z_,>0#67X9T,WLXN9E^0'C-=^3';P]E5179@\.DN>15.-E=C;FX2U@+L0
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M.3C/%1XYP!R:3A1@5N:!I!O)O,D!V UY$8RK3L<Z3DR]X<T4LPN)5X[9KLE
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M&14ZT$9% (S3JV.$R;ZR$AW <BJ(!0X/:NB*;JC:WB<_,OY"IE&YI"=C+M)
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M%=&#P_+[S+A'J.)8'(-.,TG'S&FXXQFD&.AKTC84LX;.:=YS^M, R.30,=*
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MIJ6G<::*[=*@?I5MX)0N2C8J%H)#_ :?*Q70_3?^/H?2NC63BL*RM)DFW%&
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MM #LD4%R*:,DTN,4 /5V#YZ5JP2>8@]16.,YJ:"4QO\ >XH UZ6F(X=0PI]
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M=#0 -@J.:4@%/E-  *D4B[=I4<'UH 5U!4$'ZTN%:+Y2<T@P4(-$>W!4\>]
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M(I1Q0 G7I2E1ZT< \C.:%QGK0 $ C@\T%1CK1PISCBCOG/% #?84[ (YZTG
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M3S1D\&I[5U:8 >M<_ [74N%/*]:ZC3K-8DWDY8T :%':BCM0 M%%% !1110
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MW+9H CME"M/&WW0.*F@4)( >I'&:;;R+,\OR %1^=%LTKW+&5,;?N_2@!L*
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MQ6R&/G Z>E #=I$;@_W.U1Q1E]/ QE@/EI[S>5&9".'&,>]/#F.SB:->@YH
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MC:[50.H)4T ,6#!9V]>](5=KZ-01C833WD:1VR-JC[V/2G0S1&Y4#J%.#ZT
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MN5/:@#* $>EIY/+8X[XJSE&A>$@']WDU<MM.9+-D";F'3(H&FD-(0#\R8/%
M&2BB+3LQ<MQBK";61H&4$*NYL#UJ_;Z<8K.1 A8@C&12+IS"65@&^=-IXZ4
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M($V8X4?/380L5F649>1BE:?]GLOF+M.'.=V*2'36^SJ,'(<G.* ,^*)0A3'
M'S_6FQ!8;4N@S)*2M:?]GNOF @X<YSBDCTYA$@"D[6)SB@#.CB7RR@[C+_6D
MB"0VK.@S(_ K26P=!(-IPYSNQ2PZ<1$ORD[3D'% &='$ODF/&<_,WUI(@D,$
MDB#,C#Y1Z5I"P>/<,'#=\4D6G,L9^4G;T.* ,Y8%\G8.<G<U+"(H5FFC&=I^
M05H+8/'N&"0PZXI;?2V2&1,$YZ<4 9T<8Z8^<\M]*(UACD><#YHSM4?6M3[
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MFFC#'RP 5502:U1IY%M& NTX["H/L;F-EVD'UQUH S8E\N%UB7_7'.?2G31
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M\R7"Y!'4UTF@2&WD(ER%Z"@#M+<N\NX?<J[5>S8/;JRC (JQ0 4444 %%%%
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M)SBM]M#7.58TXZ''N!#'WH P84@4OO0'/2HK>*".9BR YZ5T;:&F<J3[T_\
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M*** "BBB@ HHHH 2BEHH *2EHH 2BEI,T &*6DS2T %)BEHH **** "DI:*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !15>YO;:T4M/,D8']XXKD]3^)6BZ?<"$2>8<XRA!% ':457LKN
M.^M([B(Y5U!%6* .7\:?\@W\:\FE^\:]:\9_\@W\:\DE/S&F<>(^(@:K5ET:
MJC5;LONM09(CDZU"34LG4U":8NITGAS_ %4WT%6KG/(H\'69O/.1>N!BM^;P
MS<O)@8KR,91G*I>*-XQ;6AL>#AC3_P !5+Q>#YJ_A6]HFFMIUH$8Y;'-4/$F
MG2W>'C&<5O5I2^K\O4W:?)8X?/SK]:]+T4?\2R.N$71[LSJOEMU]*]!T^$P6
M:1MU K' 4Y1DVT3231:HHHKU#8**** "BBD/2@!:*XW5O'=OI=XT#QN2OH*W
M-&UN'5K-)TXW#.#41J1D[(WGAJL(*<EHS6HKC=7\=P:5?O;/&Y*C.0*9I7Q
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M?I4)ZTQG4>%QR3758KF/# X-=17HT?A.&K\0F*,4M%:F8F*,4M% "8HQ2T4
M)BC%+10 F*,4M% "8HQ2T4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-9%<889IU% $)M83
M_ *7RD2-@JXX-2T=J=Q61\P?$-6MO&<AZ< _SKW;P(ZW'A:S8@$B,5Y!\9+,
MQ>)3<8P&517H?PCOS=>'#$6SY1"_I213L>B  =!2T44""BBB@ HHHH ****
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M:F?[U1'K0([[X=#]_(?I7I=>;_#H?O)#]*](I'=2^$*,9HHH-!NQ0>E.HHH
M**** "BBB@ I#]T_2EI#]T_2@#Q'QH!_;4GTKJ? K'R8AGC;TKEO&@_XG4GT
MKIO 0(CC_P!VO/H_Q6?28_\ W&G\CE_&7/B.4?[(K&A9[6ZC<<'/%;?C$?\
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M,&F^'+=-N"ZAC^5=-4-K"+>UBB'1% J:@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BJ]Y>P6%NT]
MQ(L<:]6-9M[XETVWTN2\2YC=54D8/6@"'Q3XGM/#NGO+-(/,Q\JU\[:WKVJ^
M,-6,:,[*S85 >*7Q-KM]XLU]TC9FC+XC4>E>N_#SX?1:1:I>WJ!KAAD9'2@9
MG>!/A?%:I'>ZH@9SR$(R*]8@@BMXQ'$@51T IX  P!@4M @HHHH **** .?\
M6QE]+; Z5X]-PY%>\WEJMW;/$_1ABO)]>\-7=G=.8XF://! IHYJ\&]3EG%:
M5E&QLW.#UI;;1;VZF"+ _)]*]&TSPC'%HS12C]ZPS]*#*%-R/+)/O$5">M;^
MK>'KVSN6'DL5SP0*@T_P]>WEPJB%MN>3B@GD?-8[+X>P,L;R$<$"N_K+T+24
MTJQ2(#YL<FM2D=T59!11104%%%% !1110 4444 %(?NGZ4M(>A^E 'B/C3_D
M-2?2NH\"']U'_NUS/C5#_;,GTKI/ :%$CYZK7!0_BNY])C_]QIG,^,<_\)))
MCT%.FLS-X=:<#YD(%-\9(Q\22'V%=+H.GBZ\/S(W((S^E9P5Y21M7J.G1HR7
M0X2*]:&TD@!X<8-6]%MS('SGH:S;F(Q3R)CHQKM/#NF,;5I-O!B)_2IHQO+4
MZ,QG&%'W/M,Y#&-14>C5[!X<!&A/_NG^5>1.I&JX(_BKV#P^<Z&XQ_"?Y5OA
M>IYN<M-P/(]>)_MB<X'WJ]-\+<Z4QZ?NZ\SU^-O[8G&/XJ]-\*KC2&_ZYTL-
M\3*S9_NJ7R/+]7XUZ[R?^6E>I^!2/[.&WI7ENM*W]N79Q_RTK3TKQ9?:7 (H
MC\H]JSI5%3DVSKQV$J8FC!4^B/9;^=(+.5V8#"GO[5X+J,_VK59)!T+5J:EX
MLU74T,1<[#U %4]+TN>ZN5RA.XU52?MI)11EA:"R^G*=5ZL[SP]I<5_H302$
M8([^N*Y#5/"UW83N8L,H/&#FNYNM(O+;P[BS)68 $C%<+;:[J&G7I^V(S+GY
ME(JJRBK)HPR^59J52DT_(H1WVIV1VB250.U=5X4\3Q/>)!>1J68X#'K5'4_%
M-E>6ICBLF1R,9.*PM*L9I+Q'4$$'CWK.#:FE%G77C&IAI2KP46>X7[J^CW#)
MT,1Q^5<'\-?^/[4_^NH_E781I)'X:F$F=WE'^5<?\-/^/[4_^NH_E7J+8^3>
MYZ71112 **** "@C(P:** ,Z\TF&ZR<;2?05D2^&GS\AR*ZBBLY4HRW1:J21
MS5OX97(,I(K=M;.*UC"QJ![U8K(\0>(+;P]9"ZN1E"<=<4XTXQV$Y.6Y/J&G
M+=+D#YJYFYT:YC8X7BK?AOQU8>);@PVJ$,/5LUU14'J!43HQF7&K*.AY]_9U
MR[;1&<U?LO#DTCYF&%KL=B]E'Y4N .@J8X:*=QNM)HAM;5+6$1H.E3T45T)6
M,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#<XU35%[>:/Y5Z'J7_(,N?\ KF:\[^''_(7U3_KJ/Y5HMC(].HHHJ0"BBB@
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M/\J]]KP+X*?\AA_J?Y5[[0 4444 %%%% !1110 4444 %%%% !1110 4444
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MA1@,CE?Y5U]% '#:'\/XK"Z6ZO)Y9Y4.5WR%@/SK1T_PDEMKSZE(=S'(49Z
MUU%% %:^M$OK.2VD&5<8-<79_#_[--@RDPB7S N[OFN]HH S-8TE=3TF2R!P
M&&*X%/AC?0[EBU&9$))PLS#^M>HT4 </H7P^AT^]2\O)Y9YD^[OD+#]:[<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M ]*\VNDJC2/6H-NFFS-T&T2TTJ$"'RG9074CO6G1161L%%%% !1110 4444
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M%\%/^0P_U/\ *O?: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJIJ-XEC923.P
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MGM,\2Q7)"3?*Q[DUT"L'7*G(-=-*M"JKP9SSIR@[2%HHHK4@**** "BC(HH
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ME.F?)\4[@#O*?Y"O5FZ&O*;#Y/BK*#_%(W\A51$>K]J*!THJ1A1110 4444
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MT@MO(EC7().:YS3;R32]6#(Q&U]I_.FINDT[W1G6PM/%QDE'EFCW>Z$+1$3
M$>]<?J>DPRN6MSCVJT^JM>0)(O1A46)!\Q->?B\?[27+!'S<'*DSG9[&> _,
MN?I54JPZJ?RKLE^91NQ4$MM Y.4S6"J:79T1Q5MT<D?<4G6NH.FVC+]RF"PM
M0?N4W.*+^MKL<V%)X /Y5/%9S2D (?QKHD@M8SQ%4_F(HPB@4G55B'BV4=.T
M9/,5K@\5VEE!;PQ 0@5RIF(/6K=IJ+0,.I%;X3&QIRM)'-4G*>YTTJ))&5D
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M 0]#7E5MQ\5CGN[8_2O53TKRM?\ DJZ?[S52$>J#I2T@Z"EJ1A1110 4444
M%%%% !7G?Q?D>/PS$48@[ST^E>B5YS\8O^18B_WS_*@#B_@O-))J[AW)&3U^
ME>]5X%\%/^0P_P!3_*O?: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MD(!&#43@IJS-:%5T:BG'H>)VO@C4[JW\W;MP>A'-12^'+VT.# Y]]M>X@ #
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0YDM;QR]J3C).=OTKW_2=8M-8M%GMI P(Z9YH T:*** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH W[R]M[&!IKF58T R2:\N\4_%ZVL]]OIH\Q^F]6KS?Q#XTUCQ3>F*%I C'
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M/#' _"O1N@H$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%><?%ZU,WAQI,9V#^M>CUSOC32Y-7\.3VD2YD?&.* /E2ULYKRY6"!"SL<#
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MT8G%FG13$D2094@T^NM-/8D****8!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 >%_&C1O+NH;V-."I+$?6O'NAKZB^)>FK?
M^%9SMRZXP:^7Y%VRLOH2* /HCX0ZT+S0VM6;+QD #VQ7I=?.?P@U0VOB1;8M
MA'5B17T6#D T +1110 4444 %%%% !1110 4444 %</XW\2K9VYM('_>MUQZ
M5O\ B'6H]'TZ24L/,Q\H]:\1U&^EO[MYY&)+'BN3$UN5<J/:RG ^VG[2?PHK
ML[2/N8DL:[KP)X;-S*+ZX3]V#\N1W%<_X9T.36+]5VGRP?F->V65I'96J0QJ
M % Z5AAJ/,^9['HYQCO9Q]C3W9850J@ 8 I:**](^4"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKFO$VO#3X3#$?WK<?2HG-0
MC=E0@YNR+^H>(+.PX=\MZ5@7'C.1B?)B4CZFN2,DES(9)&))YJ= H'(KSYXJ
M;?NG?'#1CN=)!XQF!_>PKCZFM[3_ !%:7I";MKGM7 Y6HRQ1MZ$@CT-..*FG
MJ$L/%['K0((R#D4M<CX;U\RD6UPWS#H:Z[J*[Z=135T<,X.#LPHHHJR HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC%_R+$7^^?Y4 9'PP\8:EKVI-%=ME0?[V>U>NUX%\%/^0P_U/\J]]H ****
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MURVF7QBE"YX-=.C!T##O7T>$Q*KPOU(8ZBBBNH04444 %%%% !1110 4444
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M\DUNZ9X,<R*]SP/3%3'#5)O5%3Q$(K1F5X;T1[V[61U/EKSDUZ=#$L,2QJ,
M# J*TLX;*$1PH%4>E6*]6A15*-CS*U5U)7"BBBMS$**** "BBB@ KSGXQ?\
M(L1?[Y_E7HU><_&+_D6(O]\_RH XCX*?\AA_J?Y5[[7@7P4_Y##_ %/\J]]H
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+4]<\#6Q@T*)B,%UKJ*K6%JMG9QP*.%&*LURO<\B3N[A1112)"BBB@ HHHH
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MB/@I_P AA_J?Y5[[7@7P4_Y##_4_RKWV@ HHHH **** "BBB@ HHHH ****
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ME\">&A:P?;;A/WC#@$=*[RF11K%&J*, #%/KU*<%"-D?&XBO*O4<Y!1115F
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4456OK^WT^V>>XD5$49.30!+-/';Q-)*P55&237CGQ ^)X026&EOSR"X
M.16+X^^)DVHRO9:<Y6$<%@<$UY:[M(Q=R2QZDT 23W,MU.9IG+,QR237T?\
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M@UN^,?$;ZG=M!&W[I#CCVKF(('N)ECC4EF/:O,Q%5SE9;'U^58%4*?M:F[_
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MY90F\%@K'I7U/I-E_9^FPVVXL47&2<T 7:*** "BBB@ HHHH **** "BBB@
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M[H]!HI <J#ZBEKL/#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7'>(?F\06*GD>9TI2=E<:5V/&O:Q(-R6,>#_ +1H_MO6_P#GPC_[[-:X50H
M _*C ST%<[K-&JIHR/[;UO\ Y\(_^^S1_;>M_P#/A'_WV:U\#T%&/84>V8_9
MHR/[;UO_ )\(_P#OLT?VWK?_ #X1_P#?9K7Q["C'L*/;,/9HR/[;UO\ Y\(_
M^^S1_;>M_P#/A'_WV:U\>PHQ["CVS#V:,G^V];_Y\(_^^S1_;>M_\^$?_?9K
M7P/048'H/RH]LQ>S1C_VWK?_ #XQ_P#?9I!KVLL,BRB/TDK0OSLLI2HYQ7%^
M"KJ:?2]0:1RQ663&?J::J-@X)'0GQ%JH.#;0#ZRT?\)%JO\ S[6__?VN"T?1
M+CQ%JNI%KIE$4N -Q]*WHO $D<BO]M8[3G[YINI87(="=?U@#)LX0#TS)3AK
MFM'I8Q_]]FN2\?-=:=IMK%;.=Z@<COS6WX/UQK^R6VN\+=(,D$<X[4>T=KAR
MHT3KVLK]ZRB'UDI?[;UO_GPC_P"^S6!XUN9;>]M%B8J"RYQ]1796^/(0XYVB
ME[5V'R(S?[;UO_GPC_[[-']MZW_SX1_]]FM? ]!1@>@J568_9HQ_[;UO_GPC
M_P"^S1_;>M_\^$?_ 'V:U\#T%&/84_;,/9HR/[;UO_GPC_[[-']MZW_SX1_]
M]FM?'L*,>PH]LP]FC(_MO6_^?"/_ +[-']MZW_SX1_\ ?9K7Q["EP/04>V8>
MS1D?VWK?_/A'_P!]FFGQ!K$0W26,84=3N-;.!Z"F3JIA<$#[I[4>V8O9HGTC
M54U.WW@8<#YAZ5I5RGA/B\O .@(XKJZZ%L8L****8!1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% 'D/Q#_Y#,GT%</7<?$/_D,R?05P]=-+
M8]/"?PPHHHJSI"BBB@ HHHH ,48HHH 2NC\)V(N-1$\@^2$@FN=QD@>M=]HK
M6NB^'S/=Q[_/7[H.":F;T,JTK1L64O5UVWNK)N3'N*_A7#6L+6^K)&XP5;!K
ML-*U_0X+[]Q9-&\GRDE_6J7B#3A;^(DN(Q^[E;(Q6:=M#"FVFUW)O%]M>230
M&%7*^4G0>U0>%;748[[?*66$ [MQQ6CXH\07VG201V[J%\I>JY[5S$_BG5+B
M(QO,-IZX7%-)LJ"G*%K$U]<VD7B%Y)%#1C'&,UUNEZPFH:;<I#$J1*"!CZ5Y
MF[EV+-R379^$O^07==O_ -55):%5::43CIA^_D_WC4=23?Z^3_>-,JEL="M9
M)!1113 **** "BBB@ HHHH&*OWU^M>V^!O\ D"1_2O$E^^OUKVWP-_R!(_I6
M54\_%G44445@<04444 %<)KG_(SP?[C5W=<)KG_(SP?[C5SXK^$P"BBBOE2@
MHHHH **** "BBB@!KG$;?[IKSF+3FN=:OKB'B:%0RX[G->C.,QM_NFN3\-@?
M\)!?Y_N#^==>'FX1E)"9JZ/J8O;"1'.)HU*L/?%9OA7_ )"NHY]!_.F:O ^B
MW;:A I,3@AU'J:9X+N$NKR^E0Y#*/YUM&"5.4H;,5]=3/T_5+&PUZY^UJQRS
M?=7-=+;>(='N9EBB23<W3,9%8FB65O=:]=>='NPS5U::591N&2'!'0T8B5)/
M6][ K]"#4M<M=,\H.&^<@#Y?6K$VHQ1V8N#DJ1G &36'XT7&G6Y4?,)1BH-&
MU+9*D&H+M)_U;-T(K.-!2I*8-M,UCJ*ZAHEU($90%8?,,5SOA[7=+LX)8[A9
M"P;M'FNLU(+_ &5<;  IC.,"N?\ "^G64]G*TJ MN%.DX.G*ZT I:MJEAJM[
M:162%9!)RS+MKM[<-':Q(QR0N*Y?Q+8:?9P1S0 )<*<KSU-=#I<CR:9;O)]\
MH,TL1R^S7+L"W+=%%%<104444 %%%% !4<W^H?Z5)4<W^H?Z4X[H#7\%?\>5
MS_UTKJ*Y?P5_QY7/_72NHKZ^'PHD***1F"KN8X J@%HJ**YAGSY4@;!P<5+0
M 4444 %8WB'7(=&L'D=OGQP*UW8(A8]!7B?C?67U#57B#'9&2N*WP]+VD[/8
MBI/E1DZMK-SJUTTDKDKG@9JBBFHT !JPI%>RDHJR.&4G)DL<=3[<4D*22C$2
M%L>E+''/,Y2.-F8=0*FZZBU>PTMCO2>:1WJ8Z;?_ //K)5*YAGMCB:-D/O0G
M'N#YB7[1@]:/M/J:ACLKRX7=# [KZBG-I6ICG[))3]T=F.,^:A=@:KN9(F*2
M*58=0:?%'-<9\J-GQUQVIVL(V=$\07&DW*LCGR\\C->SZ+K,&KV:RQ,-V.17
MSRQ96VD8(/-==X*UU]/U..-V_=N0#S7+B:"G'F6YO2J-.S/;**9%()8E=>C#
M-/KR3K"BBB@ HHHH *KWG_'J_P!#5BJ][_QZO]#2>PUN<6>C<UN^'N]86#@U
MN>'OXJR@]3IJKW3<FE2"-I'. *\W\1^(Y;R=H8&(C''%;WC/53;V_D1G#,.:
M\]0[FRW4FO5PM%6YV>1B:K7NHGAC+G)Y)K4M[;@'%5;?:,5I1S*%'-=DCA<B
MPD>T4_=MJ-I6$>_'R^M1@3RINCC9A[5GYLE)[$IN-O>HS?8[U5E@O/\ G@_2
MLR2602;,'=Z52BF4T[&W_:('>D;4 >]8QL]0;D6[X-,>VOHTW/"Z@=<T[1'R
M-FI+<JX-5%N6@D#1L0?:J\=K?2+N6!R/44/87H!9H' I^Z-0DCO?#OB$7*B&
M=OF[&NJ!R,BO%K6YDM9PRD@@UZGH.HK?6*$GY@,&N#$T5'WD=^'JN7NLUJ**
M*XSJ$8$K@5\X_%&RU>TU=FN)9'MVY7)R!7T?6!XH\,6WB33S!,HW=F/:@#Y.
M@MYKF0)$C.Q]!FO3O!WPKN]0=+G4%\N'K@'K^%>D^%OAMIN@A9)566<?Q5VZ
M(L:A44 #T% %#2=&L]'M$@M8E4*,$@8S6C110 4444 %<?K_ /R,-A_UT_I7
M85Q^O_\ (Q6'_72IGL..YM#H*6@=!]**XI;G0@HHHH&%%%% PHHHH ****!%
M34?^/&7Z5PW@,_\ $IU+_KM+_,UW6H O92A1DD5Q7@JSN;?2]066)D9I9" >
M_)JXLF1S6B6.MW.L:H=,DVJ)1N^?':NNTK2_$\-ZCW<H,6>1YF:;X(M)[?4=
M6:6-D#R@J3WXKM^]-R0)'!_$ ?/: ^H_G3=;L)M+EM=7LP0H ,H'< 59\<VD
M]S+:F&-GP1G'UKJA;)<Z<D$JY4H 1^%"=D#1P'B?4(]2_L^=",DID>G(KT:#
M_CWC_P!T5Y'K&A:E9>(HHXHW>U:0,,#@<BO7(/\ 4(#_ '11)Z B2EI*6LRP
MQ1110 4444 %%%% @IDW^I?_ '33Z9+_ *E_]TT 9GA3_C^O?J*ZNN4\*?\
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M+\J4LMC+=@</'/9PD^6%7)R<4GG6(E\U44.>K8&:[G^P=+_Y\HORH_L'2_\
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M<W+ +&<'OBNRT?PG%;;9)QEJZ6*WBA&(T"CVJ6N6IB92T1O"@EN,CC6)0J
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!0UB&:?2YDMVVR8R#7S%XIUK6FNI;"_F)5'. 17U61D8]:\0^,'A7
MRY%U2WC^\<-@>@H \LTC5[[2YPUE(4=C7T?\.AJ<NBK=:C(6>0< BO"O ?AV
M37==B78?+4Y8XKZBL[9+2UCAC4*JJ!@4 3T444 %%%% !1110 4444 %%%%
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHIDG^J;Z4
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M4ZL3VS7E_AGP+I6JZ4ES<WMV)&QG%PPJMXJ\,VGA>S^W:;J$_FIR$>=FS^%
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MBUZQDX\T9KE!IT=-?3@.0Q'T-)T*8+$SZH[J.ZAEY1P:FKSKRKBW.Z.5^/\
M:-7[3Q)<VK!)QN7V%9RPS^R:QQ47I([:BL^QU:WO4!5@&]":T*YFFG9G2FFK
MH****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM% #J*;10 ZBFT4 .HIM% #J*;10 ZBFT4 .HIM% #J*;10 ZBFT4 .HIM%
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MFC- #J,TF:2@!U%-HS0 ZBFYHS0 ZBFYHS0 ZBFYI: %HIN:,T .S129I,T
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M>2ZN%ZD'-39KRWX;ZM?%;A9[7;#G+2$].*U;SQU=R73QZ58BZC0X9MV*.5W
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M5QEA6#;?#O38+H2NWF*#D(R\"DFNH%CP%:R6^@HT@P9 & K(\;C_ (J'1O\
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M  GIFO4H$,<*J3R!6?K&@V6M0[+J)6;LQ'(H3LQ''^-I-$DT<BS,!N.-GD@
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M=Y"X4'( /:E4U0(Z>BBBL2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4VG44 -I*?10
M RBGXHH CI#4N*,"@"*@5)@4N!0!'25+BDP* (Z<O6G8%+0 4444 %%%% !1
1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g23ode3tb50n000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g23ode3tb50n000003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .D"#0# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M10 4444 %%%% !1110 4444 %<'\5?\ D7H/^NO^%=Y7"_%)'?P_"$5F/F]
M,^E:4OC1U8+_ 'B/J=-X=_Y%O3_^O=?Y5PGB#1I6U"XDU;Q:+)LDPQJ^WCL#
MBNWT=9!X2M%C!$OV4!1WSMXKR&R^SKJMY%K6CW>H7S2MY:G[O4]>15TUJV=6
M$BW4G)/;TO\ B:5KXDO+SP%JL$EV[2VK[8YE;!*^N:U?"6@:MJFFV>M7NKW(
M$:%H85.0XY^]SZURNGV<\'AKQ!$UL\9W<1[3P,=*]5\%9B\!Z;O^0K;DG<.G
M)JZCY5IW.C%R5*#]GU?Z'FCW1UF_U*76?$4VFS0D^7"K;=Q].HJQX2NKK3-&
MU'Q!+?W$WD@Q1)(Y96)R >351+>^U/6]2OK?0(=<A:8A9F8J!CTP170Z?J!\
M3Z+?^'/[+2PN8DW+''TR >.2:J6UC:JTH<MM-+[:+KY_><[!+_:>G2:K=^+E
MM]0)+):B7 _&KFKW5QXE\"#49KR19++]TZ)]V7G.3^=5-/DT/2[8V.M>%99K
M]"0'3.&^O-=3?::+CX<W0T_1FL2_SF$'.[WZFAM)H52:A.+MU5GI:WD4_#^F
M-X<\(1^)O[3N9=UN"MLQ^1">!CGWK"MIO[5L)=4O?%HMK[EDMA+@'ZBN@T"_
M;Q%X-/AD6<T4D-L%\QQA68'.*Y[3VT728&L=<\*RS7R$@.F?F^O-"O=WW"%^
M:?-\5^EMOF:\OCW4'\#*J.#?-)Y/FCNO(S4&N>$]2TSPFVH3:Q/.TJ!I87.5
MP>>,U+K.A->>#HKW3-&:Q:*3<T&22RYZ]32ZOXKNO$/A*2QMM(N T,0$\C+\
MJ@<<<TE_=[DPT:=%)+FUV/0?!W_(H:9_UQ_J:YCQUX:U:?6K?7M&!DN(D"%
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MS3Q_#.]B:%PZWZ#;M/8M56M:_<W4$N52U::[?A;H:WB[_D%>'/\ =%>NP?\
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MS?@G2KRYTB2&+QTVB-#(V^T=B@!]?O#FCE6[#G>B1[9X/\96WB;1'O9@MK+
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M>*1?S^([C4M793''+<1-'P<C'S?6O<*FI9/1&E.[5VPHHHK,T"BBB@ HHHH
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MD_ZP?XUA.G;5'32K<VDCU>BBBL3H"BBB@ HHHH **** "BBB@ HHHH ****
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MSW&G6L\F-\D*.V/4@$U8K(X6FG80*J]% ^@I"B$Y*J?PKC-<\4:CI_CNPT>
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.FG4C4CS0=T%%%%(L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV8GRW\Q<GH, 5[-7'-6E8[X2YHIA1114EA1110 4444 %%%% !1110 4444
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M>R6T<#=Y1 ;'X+6LHWC'6QC"34I*USGO@[<26OB+5A 2ULD.X@'CC<173_\
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M/GC=A5X=!5&KPZ"BF.8M%%%:F84444 %%%% !1110!S?C^V:\\":O @)9X.
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M":G?P;HDN@1Z)):![*,816Y*_0UO4478<J.*TGX5>%-&O5N[:R=Y5.5\Z3>
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MPQ#]KAG)9K<>_4&O8Z*%4:=["=)-6;//-"N/'^KZ];W6I6T>EV,?^MMNN_\
MGS^-9GC_ ,%:L_B2V\2:!%Y]RAW/$.I;U_*O5J*%4:=T@=).-FSQGQ)8>/\
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MN;D+$,FJB821Z#\.]/AN+S[3,N[:?E'O7K?08%>?_#[1K^R+37*;8V' ]:]
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MB@ HHHH **** "HI_P#5?C4M13_ZK\:4MAK<JT445SFP4444 %%%% !1110
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M,[7,3A@I]ZRLS6Z+M%9-YXGT+3YC#=ZK:02 X*R2@&KUG?6M_")K2XCGC/\
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M/UK6<O?47MH8TX>XY+?4Y'P'\.]+UWPW'K&MJ]Y/> NI=S\G..Q]JRM.GF\
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M HHHH **** "KPZ"J-7AT%:4R)BT445J9A1110 4444 %%%% !1110 4444
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M4_/_ .O1_:_B/_H"I^?_ ->CZ[3[2_\  6'U6?=?>CIJ*YG^U_$?_0%3\_\
MZ]']K^(_^@*GY_\ UZ/KM/M+_P !8?59]U]Z.FHKF?[7\1_] 5/S_P#KT?VO
MXC_Z J?G_P#7H^NT^TO_  %A]5GW7WHZ:BN9_M?Q'_T!4_/_ .O1_:_B/_H"
MI^?_ ->CZ[3[2_\  6'U6?=?>CIJ*YG^U_$?_0%3\_\ Z]']K^(_^@*GY_\
MUZ/KM/M+_P !8?59]U]Z.FHKF?[7\1_] 5/S_P#KT?VOXC_Z J?G_P#7H^NT
M^TO_  %A]5GW7WHZ:BN9_M?Q'_T!4_/_ .O1_:_B/_H"I^?_ ->CZ[3[2_\
M 6'U6?=?>CIJ*YG^U_$?_0%3\_\ Z]']K^(_^@*GY_\ UZ/KM/M+_P !8?59
M]U]Z.FHKF?[7\1_] 5/S_P#KT?VOXC_Z J?G_P#7H^NT^TO_  %A]5GW7WHZ
M:BN9_M?Q'_T!4_/_ .O1_:_B/_H"I^?_ ->CZ[3[2_\  6'U6?=?>CIJ*YG^
MU_$?_0%3\_\ Z]']K^(_^@*GY_\ UZ/KM/M+_P !8?59]U]Z.FHKF?[7\1_]
M 5/S_P#KT?VOXC_Z J?G_P#7H^NT^TO_  %A]5GW7WHZ:BN9_M?Q'_T!4_/_
M .O1_:_B/_H"I^?_ ->CZ[3[2_\  6'U6?=?>CIJ*YG^U_$?_0%3\_\ Z]']
MK^(_^@*GY_\ UZ/KM/M+_P !8?59]U]Z.FHKF?[7\1_] 5/S_P#KT?VOXC_Z
M J?G_P#7H^NT^TO_  %A]5GW7WHZ:BN9_M?Q'_T!4_/_ .O1_:_B/_H"I^?_
M ->CZ[3[2_\  6'U6?=?>CIJ*YG^U_$?_0%3\_\ Z]']K^(_^@*GY_\ UZ/K
MM/M+_P !8?59]U]Z.FHKF?[7\1_] 5/S_P#KT?VOXC_Z J?G_P#7H^NT^TO_
M  %A]5GW7WHZ:BN9_M?Q'_T!4_/_ .O1_:_B/_H"I^?_ ->CZ[3[2_\  6'U
M6?=?>CIJ*YG^U_$?_0%3\_\ Z]']K^(_^@*GY_\ UZ/KM/M+_P !8?59]U]Z
M.FHKF?[7\1_] 5/S_P#KT?VOXC_Z J?G_P#7H^NT^TO_  %A]5GW7WHZ:BN9
M_M?Q'_T!4_/_ .O1_:_B/_H"I^?_ ->CZ[3[2_\  6'U6?=?>CIJ*YG^U_$?
M_0%3\_\ Z]']K^(_^@*GY_\ UZ/KM/M+_P !8?59]U]Z.FHKF?[7\1_] 5/S
M_P#KT?VOXC_Z J?G_P#7H^NT^TO_  %A]5GW7WHZ:BN9_M?Q'_T!4_/_ .O1
M_:_B/_H"I^?_ ->CZ[3[2_\  6'U6?=?>CIJ*YG^U_$?_0%3\_\ Z]']K^(_
M^@*GY_\ UZ/KM/M+_P !8?59]U]Z.FHKF?[7\1_] 5/S_P#KT?VOXC_Z J?G
M_P#7H^NT^TO_  %A]5GW7WHZ:BN9_M?Q'_T!4_/_ .O1_:_B/_H"I^?_ ->C
MZ[3[2_\  6'U6?=?>CIJ*YG^U_$?_0%3\_\ Z]7--U#6+B\6.\TU8(2#EP?_
M *]5'%PE)12?W,4L/**NVOO1M4445U'.%%%% !1110 4444 %%%% !5X=!5&
MKPZ"M*9$Q:***U,PHHHH **** "BBB@ KSGXIZ;/+9PWL SL.'^E>C$@#)Z"
MO.O'WC"TCLYM,A42R,,%^RUVX#G]NG!>IRXOD]DU)GC,T\"SXF&6[XJU%=Q2
MQ;(PH/K56+3QJ%QGS B#J_J:)-,6)ML+N[*>?<5]-<\2RV-6%GMMLB7?EL.>
M#276H7LD[2W]PTJC[I)ZUEL7$H C;:O6IM3BED5753M Z4=;BMT+5MJLEQ=)
M$,"'^[6G/J$%B?)@B4AN?6N1LI)([I6*D8KH6V3C<@ F(R :>CU)E%;$\T%E
M=*NX$.W) [52^PR03X4X0=":GB@VN))24/IZT^[421K(F1[5BX/<3=M$9\Z'
M[S'.#Q6DLZ&T2,)P1R154#,6#DFI-/67SE"#<"<$5GLRMXE:^2"VM&(R6;D
MU@(F]R0#74ZWI\I_>'A>XK#FMRFS8,*!G-9R1K3:L9=S=;9/+* XXS2JKRJH
M  7/-0.CR71QSS4A,S2E ,(!VJ'H:V+<VW8JB4#':M#3+B%(V02%<\9S7--%
M*TI!S6A:V4IPHSBA,4HJQZ#I^I;46!WQ)C@^M=GHOC9[)DLYP''J*\XM8?,1
M=XQ)&O!]:TK*\3S5"H"ZGG-:2IPJQY9JYR<TJ4N:#LSWJTN4N[99H_NL*GKF
M/"FJQRV*P,P!!^45T]?.UZ;IS<3Z+#555IJ74*CFF2")I)&"J.])<7$5K"TL
MK!549)-<5J.L2:E/A<K"I^5?6HC%R-F[&I-J3WMTH7B(-P*Z2/\ U:_2N*M>
MHK>MII" "YJI1$F;-%1Q$E>34E9E!1110 45EZUKUGH=OYMT^"?NJ.IKSS_A
M9US+JX$: 6^[&WVK2%*4MCKH8*M77-%:'J]-D_U;?0U4M;^*]LDFC=<LN<9Z
M5FWMQ*N0'(J5%WL<LDXNS,Z#5GTZ]<-EH2QW#TKJ[>XCN85EB8,C#@BO/KPD
MDDTFDZ[+I-QALO;L?F7T]Q6LJ=U=&2E8[[4%F?3YUMSB8H=A]Z^<=4M+Z?4W
MAU%Y&F1L,&)-?2-M<Q7=NLT+AD89!%<!\0++2H;.XO(BOV\GD+U]ZSAO9G'C
MZ;E#G3V/+&^SQKY3.%C7@**R[B\M8PR1IDCN:D)1OF8\]ZH3QHV645O9(\B+
M6[)$NUFB95)SZ53=F+X9?RIP&T\#%23R-%;!E7)8X)J66K-Z%&3=GOBK5M,T
M6UD)!%5E9MO(SFK=NH<CC\*E();'0Z?>N(\L,\]!776,'G6Q$BE8G&[-<;8=
MTQR.E=/#>20QVT8.>[?2M(G#50OC<2BRL8HR#;[<@^]<6GRCIS7IFH6]KJ^E
M)!'Q*O*Y[>U<2^DR+O4D91MI]JN1%*2M899Y:12!DYKTCP7HTMW?/<7, \H#
MFO-[:46DF4&YE/>NP\*>+Y=,N#YWSQ.?F%2XNVAT4?9QJISV/84B@M8@%545
M1UQTJ1)$E7<C!E/<5Y'XM\:/?3B.S=E@ Z9ZFMOP/X@C@T]Q>S8!/!8]*P]F
M[7/:CF-/VWLTK1[E#XMW5_:K:M#+(D# YV,1SQ7C4]U-/)^\=W8]V.:]B^*'
MB.PGLDTZ%%FD.'$@/"UXV(W,V_IS50T1Q8MIUFT[HERZ*">I[4^.02/C&&I)
M&;>O<]ZT;&R#2!V..^*K=G&Y6);2,ICN:Z_0]*N;JXB;=M&>]6/"?A2/5K[S
M6E*QIU&*[RU\,R6FJ)(C@PITI\R3U$L-5JQ4H*ZO8Z2V0Q6T:$YPH%2T#@45
MS'UD59)!1110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "JVH6PO+">W/\ RT0K^8JS7->+/%<7A^U8)M:X(X!/ K6C3G4FHPW,
MZDXPBW/8\*\06LFCWL\$A+,KG /I69!JP0CY OX5<U746UO4I)97!>0Y9NRB
MG/IUG'$GEPF0G@DFOK$W97W/GFHA%+;2%G>1C]*=*5DAW1S2*BGD%N#5=M/G
MACV(H^8\?2K$-I,UF\4@ QR:J]T*R3*<NIR$>5&2J#N.];L>H?9],5E&9>S8
MSFN6EL;E9/D&Y3Z5L6=P8[8K*N1'S]*=[B<58OQZ@7C8W2!B?N@BH;BUAEB$
MB;8\]<4U8HR#*95:(\@'M5B-TF0QQK\F.*B4')MDNRV*31(0%1BV!S3K&9X1
M(B@!FZ4J1,KGY2::(&DN=BCYCTQ6#0T[JS+,H"(998@&'2N7F9I[ACM&,_E7
M=3:3+-IP+DG ZBN7DLBL<B@8.>OK421=.2,:[D:%%$9'-10>9,I).,TZ_BS(
MJ*<XXIA@<*L:-SU-9O0W5F3^;!##L9NO7%26-Y##/E>0.I-4+BV;<,$58M;
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M U[CX:FDGT2!I/O!:PG&WO(]K XB567L*BT2_(T);2">'RI(E9!T!'2N=NO
M^GSWJ3H2B@Y* 5U-%9J36QZ=3#TJOQQN<]KGA>UU*VRJXECCVICOQQ7AVHP7
MMGJ3V\F8_+?&,XKZ2KP3Q_;R#Q;-ELJQ!&/I5P;>AY>9X>$4JB6K.E\)>)I;
M%TMI6S$Y'OS7JJL&4,.AKRKP3X<^VF*XF5A$G.?6O50 J@#H**EKFN5*HH-R
MVZ"T445F>J%%%% !1110!@>++2ZO-),=J&+9R0O6O,7\/Z@L<TLL;1A.[\$_
M2O7;C6M/M;@037"*Y[$UYQXZUB.751'#-N5%Z*>*VIM['B9C2HR;JWN]K'(R
M!57:WWO6I+*VCF:0,>B''UK+FNB6X;+9J_IV1EG;:>N/6MSQXIQU8R/2&=6\
MR0HQ/R\=:IQ6[V_F+(VYB>!6K$TTEV9)#B-35;4VCMYMR@MNY!HW*4I/0I^;
MY9QT;O564AR64]ZN6L'VZ3:A 9NN:T8],M$#0OEY"#\PI6$W&)S4Z$INVYK*
MG<+SWK;DD5)7C/&TD5@S0RM=$$?)GK4'13UW);:X#@QFMJVNWMX/+ R&&36%
M&(H-Q#9-:4%Q'*H7/S8Q4WU+FDQ+]U\I)(5V'/.*WO!VH7KW\213,HW<G/ K
M'06X1H)6)#'/TK7TE$T]MT1WQM_$.U6K,RFTEL?15N<V\9W;OE&34M<3I'B"
M'3O#CW,\NX_P*3SFJ7A;7;S5=<.9]R')*^E8NF]3VX9A%J"MK+\#T.HFN(5.
M&E4'T)I9U9X)%0X8J0#[UXUXG76M+O2LLCX+9!!ZU,8\QKC,3*@DU&Y[0"",
M@Y%+7DMMXHOK6&%EFR=O*D\U?TOQ==S7@9I#M)P0:OV3.-9S3^U%GI=%5K&Z
M%W;+(",]\59K-JSL>K3G&I%3CLPHHHI%A1110 4444 %13_ZK\:EJ*?_ %7X
MTI;#6Y5HHHKG-@HHHH **** "BBB@ HHHH *Y3QIXXL?"-B2Y$MVX_=Q \_4
MULZ_K$&@Z+<ZC<'"0ID#/)-?*?B'7;OQ%J\U_=R%F=OE'91Z"MZ-+G=WL<]>
MMR*RW)_$7BS5?$MXT]]<-MS\L2GY5^E8=%%=Z22LCSFVW=A1113$*&*G*D@^
MHKT3P/\ %'4- FBL]1D:YT\D+\QYC^E>=45,HJ2LRHS<7='V5I^H6VIV4=W:
M2K)#(,@J:LU\]?"3QI)I&K)H]W+_ *#<G"9_@?M^'6OH0$$ CD'I7G5*;A*Q
MZE*HJD;BT445F:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM-)MV14(2G+ECN4[/1C>7;33C$(8\'^*NF1%C0(@ 4#  IEM*)K6*55VAT#
M>F14M.4FR;6"BBBI **** "BBB@#@OBGJJ6GA\68C5Y9S@9_AQBO"HX95.3G
M::^C/&/A:/Q%8?+Q<Q@E#ZUXM>Z>^FLUC/$?.5N<#I6M/8\/,5-5+RV,NW$J
ML, BM:!G1E*U4@$BOM93UXK=MX?(DC:> E6/!Q6MCR)-'I/A'28Y]*6:ZC#.
MXX-=5:V<5FI6(=:I>'@PT:'( XXQZ5JUA.3O8^DP.'IQI0G;6VXC,$4LQ  Z
MDUY)\0?$L%]+]EMFW+&,%AZUZ;K2/)HUVD8)9HR !UKPV]T.[:XP4*[VP"PQ
M54U?4Y\TJR25)=3EU^\S9ILTI.W: ?6NAU708M'(0W$<[$9;9V/I6#Y9$F=O
M':M'KL>2URNS);2/SYMK+@8ZUV7A'25OK\(R!U4\CUKG+&V>0#Y2S$\ 5Z+X
M-T;4+._CF$;*C'))':FM%=D).I-17X'7KX0TO[1%<"+8Z=EZ&M\  8'04O:B
MN9ML^KIT84_@5@HHHI&H4444 --,:GFF-4L:(FJ!ZG:H'K&9K$K254DJW)52
M2N2H=,"G+5&:KTM49JX*IUTS/GK.G[UHSUG3]Z\NL=](SG^]3:<_WJ;7GO<[
M0HHHH **** +-K?W5D^ZWG>,^QJ%Y7DE,CL6<G))IE%4Y2:M?07*KWL>P>'Y
MO/T*T?.2(P"??%:=<UX(N/-T$(?O(Y'X<5TM?=X2?/0A+R1\CB8\E:4?,***
M*Z3 @O;C[+933E2WEH6P.^!7S'XJ\7WVIZA.$#1(6/%?2VK7'V72[B787PA^
M7UKYFUJ'S[R>4Q+&S.2 ![U[&5QTE(\W'./-%,Y!U+OD]3UIPMWQD5I36:@Y
M8@ =:KSQ%%\R-L@>G:O3.52N36,;=^/:M$7,5B5DDZD\*.]9=K*Q89;%%Y/]
MHG (X7CFG>VQ-KO4T78W<S2$;=U:VC1M%<*OF%<G-8UM<Q^5Y;#@=ZZWP[;V
MMX1^\QC@DUO%VU9SU-CV/P;J\%[8BVBBV&)>3ZUU%9.A:39Z;9H;4 EUY8'.
M:UJ^4Q4H2JMPV/?PT9QI)3W"BBBN<W"BBB@#&\4;ET"Z>.W6:0(< CVZU\RZ
MFD[W#,4QDU]67D3SV4T49P[H5'XBOG+Q1ILUGJ$D,@&Y6RP'>O4R]IQ:/-QV
MDDSE!R0K=5HM\RN5(P>U6_)C<GG#$8P:8'AM1L)RY[CM7><8;2AVYR:L6\;2
M3JNWY>]-@MQ*V5;.:TV3[/$-N,XYJD1S-/0K2K]G8=U;I5ZVN$=0TF,+VJK<
MQF:U1E&2#4,$3OP"0PJ;2@_=V/1=;#XR/^T>[/\ F6S]5^J/5_AU<>;?\>E>
MI5X+X6U/5]&G\RUMXYUZ$'@UVX^(>IVXQ<>&[QR>\?3^5>9CHRG4ND=V!P$U
M3:IR4M>C/0Z1F5%+,P4#J2:\]/C7Q'=C%EH$L;'IYM,.@>,]?XU34DLK=OO0
MQ=QZ<&N/V=OB=CM^J./\227SO^1-XR\2:7.O]G6=NM_?N=JA!G8?>J6C?#F6
M+3IKJ^8&_E7Y4[1__7KL-!\(Z5X?0&U@!G[S/RQ_&MVG[3E5HF55T5&4*2^)
M6;ZL^?=4T.\T[4=CQ-P>I%5+Y%CM3_>(S7O&N:+'J]H8\A9!RK5Y/KG@W5K>
M0RLH,"'DYJN?F1\M7PDZ,M-5W.1MHW;2;D.Y3(X-94%NI;:IR!U-=)J/E);B
M) ,A<'%<\T3[=L8Z]<5I;0PC*Z'SF$X1&!V\&JA1V<H.!4B694^F.M6(;221
MQZ5(FTM42Z;;@3 .WT%37!9+OYU(K<TCPKJ&H /;0D[3]ZNFU/P->I$DTRB0
MD?PCD&A-;"<)M<ZCH<!$TDUUP2 M=!#(X4?-G%8-W!<Z;J,\6TKS@AA4=G//
M%>'=*2&[$UXF882K4E*JWHMCZS)\=AJ<(8>*]Y[^IUL,%G<DA@D4QY63WKT3
MP3:7D%F[W$P=&X7%>1R3_.&'->C>!_%%L(5T^<%')^4^M<^ QDX/V=1^Z^YW
MX[+:,YK$0C[R['H5%("&&0<@TM>T< =!S7B/Q#OXCXA8!!\A'([UZKXF>]32
M)&LCAQU(ZXKP_6;2YF?S;B-MQ/)(K2"TN>+FE;54K>9Z7X"\46,^EM;,/*:$
M9)/>NC'BO26D2-;E26.*\2TB]CT\;%'W^#3+J]*W3!!@*>"*T]FGJSEAF-:$
M5"*6A[7J/BVQL+V*VW!R_4@]*W(YHY(5E5AL89!S7S@]U)(_F,Q+>];[>.+Y
M--BL]^%48..]2Z:.BGFDTY.:]#U/5O%EEISO$"'D4=CQ4>@>*XM68QRJ(Y.H
MYX->*7^H/>S"0$AN_-7-,U"YMG#^< <<9-/DC8YWF5=5.?IV/9=0\46MLKQQ
MD&8#@$UQ=WXQU-%?]YU/%<)?:K/-?&0L2:=]MF>/+<K5**70Y:V*Q%5WE+[M
M"74=9NKF<O(26)JJ7DNOGF;  ZFH79GDWTLX=U48^6G>QE&Y59=DZ[#NYJW)
M$\DP<.57'-,M+8RS\ _+U%:,Z)':YVD$G!S3EL:RL+&S*BLKF1>]5KZ"ZEF5
MHXR\)[ ]*KS2$6I6,D#/:I+#4'CA999"%['-)2L2E;4U+&Q,$._;MD<>O2D9
M_L4ZM(<YZ&J,NH;HB(9& !Y)-07%T)84W2;]M.]R7!O<;X@AMY,7=MP2<./>
MN==99UX; %=-9I'J$#VSX0-T;T-8]_IUS82E)4.P=' X-2S2E*VC,T0B) #\
MS'K4+N8YLIQ4[2@<$8IL<8DERQ^6H:.A=V7(3]HVE@<GO6]93QVH"O\ ,IZB
MLBW#*0!RIZ8JZRJK 8R:N)C*S-NZDCN+=?(E/7E2:W_!.H0Z)J>9OF\T!1CM
M7,P6R-!G.UO2NA\)VM@^IQR7SC8G.#5-::DTG*-2/*[.YZ/KGBZTT0QB1&<N
M-W'I7FWB?Q4NN7!DMT*A!@*:Z'QKJ6CZE;I'!AIUXW =!7#16T;2+#'R['
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MMI;3Q)NN(AD?2O [V)HY&&"".#D5]#^*O$<.BV>P,AGDX"DUX=K%RMQ/+(%
M8G) %?09<JCH^]MT/&QK@JON[]3D)#(Y8C(9:9=*KI'(!\^.:NNQ9R0,9H^Q
MI)\F_#GG%=MGU,>9%2.,O"1@D57".&V[2.:V;6%P-BXRO44^>W?!/E@XZD4+
MN)NV@VSL99FCV-Z9YZ5W_A76IK/58H8Y" I"D'O7$Z"?+O27;Y2#73Z<;2SU
M:&ZESLW9-:N*E%IZF$VTU8]_B;?$C>H!I]5K"YBN[&&:$YC91BK-?'25FTSZ
M:+NDPHHHI#"BBB@#D/'?B*'2M-:V*;Y9A@ CI7A%TS-)\Z9ST.*^DM5T#3]9
M:-KR'>4/'-<1X\\$1O8)-I-KAD/SA?2O4P=>E&*I]6>9BZ%24G4Z(\5D$T)^
M4DJ?TK/C+BYW$G;FNSCTMHHV2Z7;VR:SY-&B1BP;<,]J]%Q.%5$16UP(TX-/
M>3S2"IR:8M@WS%&!QVJ:)88/GF<#';O31+L3I%]H8"1<*!RWI2+=6EM.8=K$
MCO4]O(URPCAC(1SR:N/H\+SJT@VD# ]ZM1?0S<DMSO\ P/)///$;5F^S@?."
M:I_%'_D/:/\ ]=$_]"KH/A_IOV*TED&</TKG?BHZQZWI+N0%5U))[#->1B97
MQ-NQ]-P["S3[W/4;FU@O(&AN(EDC8$$,,UY1X4O%\.^--6L=Q%FB23%<\ +7
M;7WC_P .6EL\L>IP3N <)$V237":%H5]KZ:WKC1/']HBD6 =VSGC^5<E--1?
M-L>KA:<HTYJKI%]^YIP^*O&6N^?>:+;6ZV43'AU!+ >E7O\ A8C_ /")O?>0
M!?))Y+(>@;KGZ5POA_3M*DLY([_Q/<Z7<1L5:$'"]>W-;1T[2;'P/JLNG7;Z
MFC/\S.H!0\<\&M)0C>UCJJ4*"ER\O5=&OO?4DU+Q7XZTVPMKZ>2Q$%R?W6U%
M)_&M#6O%_B30]*T2>?R'N+MV,J*@^9>, >AY-<;I4WAD-:MJ6I:I-LP3"R?N
MU/L=W2NJ\?W5K>/X7FLF#6[2G9CT^6FXKF2L.5*FJD8."Z]+=#=L]3\9_8KB
M_N;.!XF3=! F-PSTSQ61>^)?&VBI%J&IP6PL7;'EJ!N'UKHO&VL7>A^#5NK(
M[9F*1AL= 0>?TKRS68[>;24NF\1R7MVYW-;JV57Z\U%.*EJT8X6G&K[THJS=
MMG_2]3TGQ-XX?3],L3IL8DO+T Q@C( />N/\5W/BI[*Q3Q!#!L:961XL#'(X
M(J+6&-DOA;4)@?LRPJ"V.^36O\0/$VE:Q:6$&GW2W#"96;8<A>1UIQCRM61I
M1I*G*"A&][W?8U=:\6W]C)I^BZ-"LE_) A)89"Y Q2:9XI\0:=K\&E^)8H0;
MG_521 !<UR/B73(X?%EG->WL]G:W%M'MN8^H(49[]*T+#1/#KZ[9;/%EQ?3A
M\QJ<,,^F<\4<L>47L:*I*ZW5]G>_J6[;QEXKU/6;W2]-B@EE1_D=D 5![UZ1
MI7V_^R[?^TRAO=@\[R_N[N^*\]^'( \7:X/1<9_$5Z=656R=DCAQW+&?LXQ2
MV_(****R.$**** "LRYT#3+NY^T3VJ-)W) YK3HH)E",E:2N<O=>!M+N+D2J
MFP9Y4"M.7P]ITUO%"\ VQ_=(ZUJT57,S".#H1;:BM1D,200K%&,(HP!3Z**D
MZ$DE9!7"_$2 QV4,\>%"G!Q^-=U5'5=,M=4LF@NUS'U^E5%V=S#%476I."W/
MG.YF,V[ 9CGFF/!,ZJR_*%_A-=;XC32_M(L]) "1<%AU)K<\-^#(-9TY9IY&
M09P<#FM^9;GSL*4G4]G#5F#X33_B:6J2)N4L.,5[A&H6-0HP,=*Y;0?!L6CW
M9E+^8 ?D)ZUU=95))['KY;AIT5)S5FPHHHK,],**** "BBB@!#4;5+43<5+&
MB)J@>K!!)P*!;9^\:R<6]C1-(SG&>E1&UFD^ZA_&MM843HHJ2I^KWW97MK;&
M!_8UP_4J/QI#X;+_ 'I\?\!KH**7U.D]T'UFIT9S+^$E<?\ 'T1_P&J4_@AV
M'[N[!^JXKLZ*SEEV&EO'\S2.-KQV9YI=>"-40YB$;K_O8-8UUHNH6A/FVL@
M_B"G'YU[)2,BN,.H8>A&:XJN1T)? VCJIYM57Q),\-HKUK4O#FEWL;/+"L9
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M-<JWP^N_X;N+\<_X5Z#17%7R^A7ESU%=^IU4<95HQY8,\Z;X?Z@.ES;G\_\
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MM[F&[B$L$@=#W%2UXK33LSUDTU=!1112&%%%% %+4].BU2R:VEX!Z'TKD?\
MA6MHZ,))R23Q@=*[NBMZ>)JTURQ>AA4PU*I+FDM3Q/Q=X2D\/^6]NQ>-N,XJ
M/2M"GNK9'^R,^X9+D5[1=V5M?1>5<Q+(F<X84^"WBMHEBAC5$48  KMCF34-
M5=G%/+5*6CLCR2TT*XAU.*)K/&3UQ74S^!E=U>*3;GDUVNQ2V[:,CO3JSGF-
M1M..@X9735^=W*6F6"Z?9K"""1U-7:**X92<G=GHP@H148[(****DH**** "
MBBB@ HHHH B:V@:3S&B0OZD5(  , 8%+10))(*Y#Q[&7TV,C=G/:NN)"C+$
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M,7NY_+NB"&Z$#I7:HZR*&1@RGN*QE%QW/H<-BJ>(5X#J***DZ0HHHH ****
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MY:*?<****@[@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HI_\
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M6I:**Q/92LK!1110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*Z$$$9'0UC*+3/H:%>%:-XO7KY"T444C8**** "BBB@ HHHH **** "BBB@
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MY@Q_NY.:W+748U:,,"".]56MDE)=5.14L=GYK(<8'>B4DQJ+/7/A]<V,E]N
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M>1P*Z.U*1Z;,WE9V#-5+>R*9(&:W](BBSY<ZY5Q@BN&<[,[$KHY=;T22E8X
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M'QWHFJ:!XXM_&6E6C7484+/$O4 8_GBKANT9U-DSOO''_(D:O_U[FO%I<_\
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MF386 SBL[PGX:3PKHJ:;'<M<*ISO9=I_*MVBG=VL*RO<****0PHHHH ****
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M*I\]._8>&J>SK+ST.\I&;:A;T%+574)5BLY"Q(R,5XLG:+9[L5=V,/4-7W9
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MM8ZM)IUD+PF9XOOELMC'(XQFNM^&6JZNFLZWX6O+YYY;1"\4TGS$=!W^M/\
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M6#X*O'\#ZAH,^K/<7-XN#<398*<CMZ<5HY1?*[[&:C)<RMN.^%__ "(.F_\
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MYUV>@^%;?0-%EL+>:21YLF220Y)8]_UHG/3XKCA#6_+8XOX)@?8M?..?M_\
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MB\RG4J?N_A.R.$@XKGW/)X?A?=2M)YTB*/X?>L2\^'-YIK,QC,@)X*U[G2$
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M:<,00J,C!R*3FD;4\'5K)/9'EOA_PC<:HS)*-B*>N,8IOBS1YM)N/L]M\S;
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M,\NP=6<XU[VC^98HHHKG/I@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,AE6:)9$.589%/KF/K$U)704444#"BBB@ HHHH **** "BBB@ HHHH ****
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M*.$N69\,<]JZ+-?$XZHJF(E).ZN>O1BXTTF+129HKD-1:*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *BG_ -5^-2U%/_JOQI2V&MRK1117.;!1110
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M(I]4B6%%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ JO?7D-A:27$S81!GZU.2 ,DX KS7Q=KYU"Z-K W[B,X)'\1KBQV,CA
M:7-U>QU83#.O4Y>G4QM6U.;5;YYY3P3\J^@JA117Q$YRG)RENSZN,5%*,=@H
MHHJ1G2^%_$CZ7.+:=LVKGG/\->F1R++&KHP96&017AU==X3\3&S=;*\8F%CA
M'/\ #7O95F7LVJ-5Z='V/(S# \_[VFM>IZ+12 @C(.0>]+7U!X 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !2,,J12T4 4"V"11OIER=D["HO,KD<K.QT*-U<L[Z7?58/3M]'.
M'*7(7^?%6*SHI,2+]:T:WIRNC*:LPHHHK0@**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB6Y\IC,,Z%2RV>PM%%%=YR!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 8'B*3:\(]16()?>KOBB
M?_3HES]U:PQ-7S^+J_OI(]G#T_W2-$2TX2UG";WIPF]ZQ54U=,T1+[UV,/\
MJ4_W17!1/OD5?4XKOH_]4G^Z*]/+Y<W,SS\;&UAU%%%>F<(4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %13_ .J_&I:BG_U7XTI;#6Y5HHHKG-@HHHH **** "BB
MB@ HHHH **** "D(##! (]Z6B@"(V\!ZPQG_ ("*401+]V)!]%%244 %%%%
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M[XCT;/2NE1U=0RD$'TKZ>E551=GV/ JTI4I68ZBBBM3(**** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !44_^J_&I:BG_P!5^-*6PUN5:***YS8**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:;I*;AB63YFKTLJPOMZZ;V6IPYA7]E1:6[-RBBBOM#Y<**** "BBB@ HHHH
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M844450@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ JM+:(YRORFK-%)Q3W&FUL9QA9#@BGJM72 >HIAB':L_9V
MV+Y[[D06I *7;BE JDA-@!3A0!2U2)"BBBF(**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *\F\57'VCQ!<XZ(VT5ZM*P2%V)QA2:\6
MO9C<7LTIZLQ->!GU2U.,.[/8RB%YREV(****^8/>"BBK6GV,NHWD=O"I+,>?
M84XQ<FHK=BE)15V;G@_1C?W_ -IE7,$7//<UZ:!@8%4],TZ'2[&.VA'"CD^I
MJY7V^ PBPU%1ZO<^5QF)=>IS=.@4445W'(%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 444UW$:[B,T .HJ#[4O]TT?:E_NF@">BH/M2_W31]J7^Z: )Z*@
M^U+_ '31]J7^Z: )Z*@^U+_=-'VI?[IH GHJ#[4O]TT?:E_NF@">BH/M2_W3
M1]J7^Z: )Z*@^U+_ '31]J7^Z: )Z*@^U+_=-'VI?[IH GHJ#[4O]TT?:E_N
MF@">BH/M2_W31]J7^Z: )Z*@^U+_ '31]J7^Z: )Z*@^U+_=-'VI?[IH GHJ
M#[4O]TT?:E_NF@">BH/M2_W31]J7^Z: )Z*@^U+_ '31]J7^Z: )Z*@^U+_=
M-'VI?[IH GHJ#[4O]TT?:E_NF@">BH/M2_W31]J7^Z: )Z*@^U+_ '31]J7^
MZ: )Z*@^U+_=-'VI?[IH GHJ#[4O]TT?:E_NF@">BH/M2_W31]J7^Z: )Z*@
M^U+_ '31]J7^Z: )Z*@^U+_=-'VI?[IH GHJ#[4O]TT?:E_NF@">BH/M2_W3
M1]J7^Z: )Z*@^U+_ '31]J7^Z: )Z*@^U+_=-'VI?[IH GHJ#[4O]TT?:E_N
MF@">BH/M2_W31]J7^Z: )Z*@^U+_ '31]J7^Z: )Z*@^U+_=-'VI?[IH GHJ
M#[4O]TT?:E_NF@">BH/M2_W31]J7^Z: )Z*@^U+_ '31]J7^Z: )Z*@^U+_=
M-'VI?[IH GHJ#[4O]TT?:E_NF@">BH/M2_W31]J7^Z: )Z*@^U+_ '31]J7^
MZ: )Z*@^U+_=-'VI?[IH GHJ#[4O]TT?:E_NF@">BH/M2_W31]J7^Z: )Z*@
M^U+_ '31]J7^Z: )Z*@^U+_=-'VI?[IH GHJ#[4O]TT?:E_NF@">BH/M2_W3
M4_:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@#.UV<6VBW4I.,)Q7CQ.237KO
MB"PGU+3&MH&56<\EO2N/'@"^/6ZA'X&OG<WPU>O57LXW21[66UZ-*F^>5FV<
MC179+\/;K^*]A_ &I!\/9>]Y'^ ->6LKQ;^Q^1Z#S##?S'$UT_@S5+>QU Q3
MJH\WA9#V-:8^'P[W8_*I8_ $*L&-V^0<C'_ZJZ,-E^,HU54C'8PKXW"U8.#E
MN=I14-I"UO:QPO(9"@QN/4U-7UJ;:NSYUZ/0****8@HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "HKC_5?C4M17'^J_&@"G1113$%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5H#H*SZT!T%(8M%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !14<\\=M \TSA(
MT&68G@"O!O'_ ,8I[J6;3= ?RX%)5K@=6^GI51BY/0B<U%:GK^M^,]!\/INO
M]0C4_P!Q#N;\AS7#7OQXT&"0K;65Q<J/X@VW^8KYYN+F>[F::XE>61NK.V2:
MBK=48]3F=>3V/H&/]H'2V<!]&N4&>OG _P!*Z31_B]X6U:18C<M;RG^&12!^
M?2OEJBFZ41*O,^W;>Y@NXA+;S1RQGHT;!A^E2U\A^%O'6M>%;M)+2Y=X1P8)
M&)0CV':OI+P5XYT[QCIXD@81W2C]Y 3R/I[5C.FXG1"JI:'54445F:A1110
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M/G5KG1^*+ZXT[PY>W=J^R:*)F1L9P<5Q_P )/%.K^)[/4Y-6N1.T$B+&0@7
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M13M;^*>N>*+=K#1M-D@68;6V9=OS XI^S=Q>VC8S-#8:I\9K>>W&4CO=QQZ
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M5DYQSV-%[MI"LTHMGJ?Q,T6QO?!UW+) @E@7<CXY&!TKD_@_=2S^"]:A=LI
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MVCC;(ID%@RR&:X4E<< &MHP03D](Q1J"47KARC CD<\5-=EO(^8DX%5XVB8
M)(R!1D@U2O+QBQ"L2E;QC8;:@FY,EMYC@HQ&/0U%<-*S[(E)'M4<%O),I?<
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %17'^J_&I:BN/]5^- %.BBBF(**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MN^+?%?C'5;#2]=CT:*Q<A(Y#CS!DX_'BJGAK3?AO)XDLSHHUBXF4[A(=VU2
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MR]\S+]T&NA125F?+5<54J5'-2:717/;=8\12+X9^WV(S(V,@=5KS:]\<WUU
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M3<(Z,O4445!W!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %17'^J_&I:BN/]5^- %.BBBF(**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ K0'05GUH#H*0Q:*** "BBB@ HHHH ****
M*]__ ,@ZZ_ZXO_(UY#\!/^//4O\ ?_K7KU__ ,@ZZ_ZXO_(UX%\)/&FA>%[>
M^CU:\,#2/E1L9L\^PK2*;B[&4VE-7.S^-^FP?\(BNJ*JK=6TZ!' P>2*R]0^
M(6JKHN@Z+I.U=2O(E5IW./+P  ?UJIXS\2/\2[BU\/\ AZWEDM&D#2W!4A2
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M=KV9=LI  8^IK0;P],%)749PW8[C5+0=3M+/[6D\H1C*< _4UKOXBTU4)^T
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MC&4 Z8/:K]%*X613OM)T_4C&;ZS@N#&<IYJ!MOTJV %4*!@ 8 I:*!A1110
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MKQRUE9-1A,65"X->P:-=F\T])&SD<<U%5:7/0RF<56<7NT:-%%%8'T04444
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M=Y?M AN1<&,2$<A=H.*UO&,VHS_"::758ECO&AS(JU3^!?\ R*=[_P!?9_\
M0147]QFB2YUZ')_%JUAMO'UE+#&(V<1%BHZG=UKT7QR2WPQD).284)/_  &N
M ^,/_(\Z?_NQ_P Z](\4V,^H_#AX+9"\GV96"CJ<+0]H@MY'.? W_D7+[_KL
MO\C7J=?-_@CQU?\ A&*?2H],:>664$C.&7';&*^BK2?[3:0SE&0NH8JPP12J
M)IW*I23C8FHHHK,U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K0'05GUH#H*0Q:***
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M%% !1110 4444 %%%% !45Q_JOQJ6HKC_5?C0!3HHHIB"BBB@ HHHH ****
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M 863DL#SQ77UQ/Q%C66PA&0&!./6HQ-_9.QJN6ZYMCFK#4M6U&&?R3([NNW
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M;>&)G#H,-Z&M#R8BX^;!')%7/^$9U5)I(?LCC:"W S@#WK,M+">6\*A78KV
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT7UOK]QSUZ%.E>/-[R\C1HHHKN.0**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *T!T%9]: Z"D,6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5H#H*SZT!T%(8M%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 51U;34U2R-N[%><@BKU%3**DN5[
M9ND:4NEVWEE][9.6K0$B%MH<$^F:).8V&">.U<=IZ:C#KQ+1.J.2%W<@#-<L
MY_5U&$(Z".SHII8(N6('UIP.1D5UW6PPHHHI@%%(SJBEG8*HZDFHUN(7;:LB
MD^QJ7)+=@2UQ=WXTDLKNXC>(,$?:..U=7/J%K;2B.:948C.&.*HOI6C:DYF,
M,,K,.2,&LJO-*RA*S,JU.I))P=CSF^\1ZGJ<<D#L3'(WW5':NP\+^'H(K=;J
M16;S%^Y+U!K;M]!TVV8M':Q@D@\CTK1  &!TK*EAFI<TW<PI89J7--W  *
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M2U6/=W'-/F=KA P[U28E3[FQ<.RPF2:X#9Z#-58(%O L@P-I^\:RFMF>$DS
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M 4444 %%%% !1110 4444 %17'^J_&I:BN/]5^- %.BBBF(**** "BBB@!"
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M-J=9Q5GJBGH=_'?Z<CHS,5&&)'>M&0LL;%1E@.!7,^([^W\.:0T5K^ZEER5
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M]7L9'BGX43V5M')I!:XC'WEQ\P^GK6U\/O SQNFHZK;LC1<1QNN#]2*]3 P
M/2EKL6'@I\Q\]+-\1*@Z+^_J'04445T'EA1110 4444 %%%% !1110 4444
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M;M4<4\F[)'':IOJ:O4VFDC@C8M\S;>*PD0R.Q<'!.:22[<$YSD]Z=;EG&"<
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M986;[[:QMH'/&Z*)5/Z"DI6302A>2?8\.^*?_)2[+_ME_2O4/&G_ "3'5/\
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M("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_0DHI"P"[B0%ZYS3//AP#YJ8/0[AS5MI$V9)136DC099U4>YQ3/M,'_/:/\
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M=M\U,^FX4<R"S)****8@K0'05GUH#H*0Q:*** "BBB@ HHHH **** "BBB@
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M%% !1110 4444 %%%% !45Q_JOQJ6HKC_5?C0!3HHHIB"BBB@ HHHH ****
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M1%&%'Z4N=6'[-W/%O GCG3_ ^EWFC:[%<6US%*?+'E,=_P"E4=(M;O5QXO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&:411!]XC0,.^T9I]%'*NP78M1^3#OW^4F_^]M&:?10TGN%VA:8\<<H D17
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M7T(S2T46078BJJ+M10JCL!BG4E%,0M: Z"LZM =!2&.HI** %HI** %HI**
M%HI** %HI** %HI** %HI** %HI** %HI** %HI** %HI** %HI** %HI**
M,^_T>TU!U>9/G7H15V&)(8E11PHQFGT5"A%2<DM6.[%HI**L0M%)2,P52QZ
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MZ?RH 2BEV-_=/Y4;&_NG\J $HI=C?W3^5&QO[I_*@!**78W]T_E1L;^Z?RH
M2BEV-_=/Y4;&_NG\J $HI=C?W3^5&QO[I_*@!**78W]T_E1L;^Z?RH 2BEV-
M_=/Y4;&_NG\J $HI=C?W3^5&QO[I_*@!**78W]T_E1L;^Z?RH 2BEV-_=/Y4
M;&_NG\J $HI=C?W3^5&QO[I_*@!**78W]T_E1L;^Z?RH 2BEV-_=/Y4;&_NG
M\J $HI=C?W3^5&QO[I_*@!**78W]T_E1L;^Z?RH 2BEV-_=/Y4;&_NG\J $H
MI=C?W3^5&QO[I_*@!**78W]T_E1L;^Z?RH 2BEV-_=/Y4;&_NG\J $HI=C?W
M3^5&QO[I_*@!**78W]T_E1L;^Z?RH 2BEV-_=/Y4;&_NG\J $HI=C?W3^5&Q
MO[I_*@!**78W]T_E1L;^Z?RH 2BEV-_=/Y4;&_NG\J $HI=C?W3^5&QO[I_*
M@!**78W]T_E1L;^Z?RH 2BEV-_=/Y4;&_NG\J $HI=C?W3^5&QO[I_*@!**7
M8W]T_E1L;^Z?RH 2BEV-_=/Y4;&_NG\J $HI=C?W3^5&QO[I_*@!**78W]T_
ME1L;^Z?RH 2BEV-_=/Y4;&_NG\J $K0'050V-_=/Y5?'04ABT4E% "T4E% "
MT4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "
MT4E% "T4E% "US7BC4YK3RXH)"I;K@'FNDJK>6%O?(%F3.#D$=:QQ$)3IN,'
MJ#'6$CR6<;2*0Q4=:G=5="C#*D8-"J$0*.@&!2UI"/+%18')_P#")O::L+JR
MD40L^YHR.E=8. !1144Z,*;;CU)C!1V*]_9QW]E);2='&,^E5M*T>#2H]L1)
M.,$FM&N6U77YX]76PM,DD8/R]#6==TZ=JDE=C.JHJ&W5UMT61MS@<FI:Z$[J
MXS,U70[34U+R1CSAT8=:YY/!K7;1+?D&.-N@[BNTHK">%ISFIM:HN,Y1V*UA
M8PZ=9I;0#"(,#-6J2BMTDE9$-WU%HI**8"T4E% "T4E% "T4E% "T4E% "T4
ME% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4
ME% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4
ME% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4
ME% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4
ME% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4
ME% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% #J*2B@!N:,TVB@!
MV:,TVB@!V:,TVB@!V:,TVB@!V:,TVB@!V:,TVB@!V:,TVB@!V:,TVB@!V:,T
MVB@!V:,TVB@!V:,TVB@!V:,TVB@!V:,TVB@!V:,TVB@!V:,TVB@!V:,TVB@!
MV:,TVB@!V:,TVB@!V:,TVB@!V:,TVB@!V:,TVB@!V:,TVB@!V:,TVB@!V:,T
MVB@!V:,TVB@!V:,TVB@!V:,TVB@!V:,TVB@!V:,TVB@!V:,TVB@!V:,TVB@!
MV:,TVB@!V:,TVB@!V:,TVB@!V:,TVB@!V:,TVB@!V:,TVB@!V:,TVB@!V:,T
MVB@!V:,TVB@!V:,TVB@!V:,TVB@!V:,TVB@!V:,TVB@!V:,TVB@!V:,TVB@!
MV:,TVB@!V:,TVB@!V:,TVB@!V:,TVB@!V:,TVB@!V:,TVB@!V:,TVB@!V:,T
MVB@!V:,TVB@!V:,TVB@!V:,TVB@!V:,TVB@!V:,TVB@!V:,TVB@!V:,TVB@!
MV:,TVB@!V:,TVB@!V:,TVB@!V:@-I;F<3^4OF#^+'-2T4FD]P'9HS3:*8#LT
M9IM% #LT9IM% #LT9IM% #LT9IM% #LT9IM% #LT9IM% #LT9IM% #LT9IM%
M #LT9IM% #LT9IM% #LT9IM% #LT9IM% #LT9IM% #LT9IM% #LT9IM% #LT
M9IM% #LT9IM% #LT9IM% #LT9IM% #LT9IM% #LT9IM% #LT9IM% #LT9IM%
M #LT9IM% #LT9IM% #LT9IM% #LT9IM% #LT9IM% #LT9IM% #LT9IM% #LT
M9IM% #LT9IM% #LT9IM% #LT9IM% #LT9IM% #LT9IM% #LT9IM% #LT9IM%
M #LT9IM% #LT9IM% #LT9IM% #LT9IM% #LT9IM% #LT9IM% #LT9IM% #LT
M9IM% #LT9IM% #LT9IM% #LT9IM% #LT9IM% #LT9IM% #LT9IM% #LT9IM%
M #LT9IM% #LT9IM% #LT9IM% #LT9IM% #LT9IM% #LT9IM% #LT9IM% #LT
M9IM% #LT9IM% #LT9IM% #LT9IM% #LT9IM% #P:*:.E% $FU?2C:OI110 ;
M5]*-J^E%% !M7THVKZ444 &U?2C:OI110 ;5]*-J^E%% !M7THVKZ444 &U?
M2C:OI110 ;5]*-J^E%% !M7THVKZ444 &U?2C:OI110 ;5]*-J^E%% !M7TH
MVKZ444 &U?2C:OI110 ;5]*-J^E%% !M7THVKZ444 &U?2C:OI110 ;5]*-J
M^E%% !M7THVKZ444 &U?2C:OI110 ;5]*-J^E%% !M7THVKZ444 &U?2C:OI
M110 ;5]*-J^E%% !M7THVKZ444 &U?2C:OI110 ;5]*-J^E%% !M7THVKZ44
M4 &U?2C:OI110 ;5]*-J^E%% !M7THVKZ444 &U?2C:OI110 ;5]*-J^E%%
M!M7THVKZ444 &U?2C:OI110 ;5]*-J^E%% !M7THVKZ444 &U?2C:OI110 ;
M5]*-J^E%% !M7THVKZ444 &U?2C:OI110 ;5]*-J^E%% !M7THVKZ444 &U?
M2C:OI110 ;5]*-J^E%% !M7THVKZ444 &U?2C:OI110 ;5]*-J^E%% !M7TH
MVKZ444 &U?2C:OI110 ;5]*-J^E%% !M7THVKZ444 &U?2C:OI110 ;5]*-J
M^E%% !M7THVKZ444 &U?2C:OI110 ;5]*-J^E%% !M7THVKZ444 &U?2C:OI
M110 ;5]*-J^E%% !M7THVKZ444 &U?2C:OI110 ;5]*-J^E%% !M7THVKZ44
M4 &U?2C:OI110 ;5]*-J^E%% !M7THVKZ444 &U?2C:OI110 ;5]*-J^E%%
M!M7THVKZ444 &U?2C:OI110 ;5]*-J^E%% !M7THVKZ444 &U?2C:OI110 ;
M5]*-J^E%% !M7THVKZ444 &U?2C:OI110 ;5]*-J^E%% !M7THVKZ444 &U?
M2C:OI110 ;5]*-J^E%% !M7THVKZ444 &U?2C:OI110 ;5]*-J^E%% !M7TH
MVKZ444 &U?2C:OI110 ;5]*-J^E%% !M7THVKZ444 &U?2C:OI110 ;5]*-J
M^E%% !M7THVKZ444 &U?2C:OI110 ;5]*-J^E%% !M7THVKZ444 &U?2C:OI
M110 ;5]*-J^E%% !M7THVKZ444 &U?2C:OI110 ;5]*-J^E%% !M7THVKZ44
M4 &U?2C:OI110 ;5]*-J^E%% !M7THVKZ444 &U?2C:OI110 ;5]*-J^E%%
M!M7THVKZ444 &U?2C:OI110 ;5]*-J^E%% !M7THVKZ444 &U?2C:OI110 ;
M5]*-J^E%% !M7THVKZ444 &U?2C:OI110 ;5]*-J^E%% !M7THVKZ444 &U?
M2C:OI110 ;5]*-J^E%% !M7THVKZ444 &U?2C:OI110 ;5]*-J^E%% !M7TH
MVKZ444 &U?2C:OI110 ;5]*-J^E%% !M7THVKZ444 &U?2C:OI110 ;5]*-J
M^E%% !M7THVKZ444 &U?2C:OI110 ;5]*-J^E%% !M7THVKZ444 &U?2C:OI
4110 ;5]*-J^E%% !M'I1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g23ode3tb50n000021.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g23ode3tb50n000021.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -2 \D# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBDH 6BDHH **0T9H 6BDS29H =13<T
M9H =13<T9H =13<T9H =13<T9H =13<T9H =13<T9H =13<T9H =13<T9H =
M13<T9H =13<T9H =13<T9H =13<T9H =13<T9H =13<T9H =13<T9H =13<T
M9H =13<T9H =13<T9H =13<T9H =13<T9H =13<T9H =13<T9H =13<T9H =
M13<T9H =13<T9H =13<T9H =13<T9H =13<T9H =13<T9H =13<T9H =13<T
M9H =13<T9H =13<T9H =13<T9H =13<T9H =13<T9H =13<T9H =13<T9H =
M13<T9H =13<T9H =13<T9H =13<T9H =13<T9H =13<T9H =13<T9H =13<T
M9H =13<T9H =13<T9H =13<T9H =13<T9H =13<T9H =13<T9H =1249H =1
M244 +1110 4444 %%%% !244E "TE%-S0 M(:0FDP<4 +FDW4FUJ;M:@!^ZD
MW4W:U)L:@!^ZC=3-C4;&H ?NHW4S8U&QJ '[J-U,V-1L:@!^ZC=3-C4;&H ?
MNHW4S8U&QJ '[J-U,V-1L:@!^ZC=3-C4;&H ?NHW4S8U&QJ '[J-U,V-1L:@
M!^ZC=3-C4;&H ?NHW4S8U&QJ '[J-U,V-1L:@!^ZC=3-C4;&H ?NHW4S8U&Q
MJ '[J-U,V-1L:@!^ZC=3-C4;&H ?NHW4S8U&QJ '[J-U,V-1L:@!^ZC=3-C4
M;&H ?NHW4S8U&QJ '[J-U,V-1L:@!^ZC=3-C4;&H ?NHW4S8U&QJ '[J-U,V
M-1L:@!^ZC=3-C4;&H ?NHW4S8U&QJ '[J-U,V-1L:@!^ZC=3-C4;&H ?NHW4
MS8U&QJ '[J-U,V-1L:@!^ZC=3-C4;&H ?NHW4S8U&QJ '[J-U,V-1L:@!^ZC
M=3-C4;&H ?NHW4S8U&QJ '[J-U,V-1L:@!^ZC=3-C4;&H ?NHW4S8U&QJ '[
MJ-U,V-1L:@!^ZC=3-C4;&H ?NHW4S8U&QJ '[J-U,V-1L:@!^ZC=3-C4;&H
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M*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&***
M#%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*
M** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #
M%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&!110 F!1@
M4M% "8%+@444 &*9)TI],DZ4 1@T\5$*D% #Q3J:M.H **** "DI:2@!*;3J
M;0 AIAIYJ,T -[U93[M5N]64^[0 ZBBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS6I3':,!W%14ERP;+IQYI)'&ZG>O?79P>.F,ULZ7X<CEB$D^1D9%86F1B74
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M )%I],6GT %%%% !24M)0 E-IU-H 0U&:D-1F@!O>K*?=JMWJRGW: '4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !3)$$D;(PR#3Z* ,9_#UJ\FXQBKMKIM
MM:#]TF*N45E&C3B[I&DJLY*S84445J9A1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !4<OW:DJ.7[M $(IZTP4]: )%I],6GT %%%%
M!24M)0 E-IU-H 0U&:D-1F@!O>K*?=JMWJRGW: '4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !4<OW:DJ.7[M $(IZTP4]: )%I],6GT %%%% !
M24M)0 E-IU-H 0U&:D-1F@!O>K*?=JMWJRGW: '4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !12$@#)K-37;-]1>R5\RKUYH TZ*IWVHP6%N9IC
M\H&:S;#Q;IVH3&*)F#>].S%=&]165J>OV>E#-P3TSQ4.E^*+#5Y&2WWY7KD4
M6871MT444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1R_=J2HY?N
MT 0BGK3!3UH D6GTQ:?0 4444 %)2TE "4VG4V@!#49J0U&: &]ZLI]VJW>K
M*?=H =1110 4444 %%%% !1110 4444 %%%% !1110 4444 5-1MGN[&6%)#
M&S# 8=J\VT;2YM-\6S)+<M,P Y;\:]/N)EMX6E8$A1GBO+Y/$$ \832^1-M;
M !VGU/M5QN1*USN=0T,ZE<PSM.5C5>8^QKE/$MO$+BU@TO F24>9Y?7&:T_$
MGC!=.TW9!'+Y[H"I"GBL/PUKMAYZW5S;3&[FX9MI_P *$GN)M7L3^)#?Q>(K
M*1+)[F$0C<O;.!6[X?U2TFDD0V<=M*O4 <U:U/Q39:9=1Q2PRLS+N!53_A7-
MZ0RZOKDTUM&Z -D[QUHW0;,[EKN8'B$D4)>OO"O'MSTJXHPH'H*HWW_'Q#]:
M@T+]%':B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB_R/L]I]FQY7GKC!]Q56U(YM+GIJ2AX%D[, :RM/UV*^U6>R4@M%U J[;?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MDI:2@!*;3J;0 AJ,U(:C- #>]64^[5;O5E/NT .HHHH **** "BBB@ HHHH
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M%%%% !1110 4444 %%%% !5"^_X^(?K5^J%]_P ?$/UH O\ :BCM10 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%95_P"(++3IC%.Q##T%4O\ A,]*_P">C4[,5T5/
M'FN#1]&#(WSR-LP/?BLKX<Z#]F@GN[A=SS/O4GMFN;UO4(_%_BIM-A):*-@X
M'X__ %J]<TZW%M801 8VH!5/16(7O2N6J***@T"BBB@ HJI?W?V2!I,]!FN5
M/C(9^_6%7$4Z3M)FU/#SJ*\4=K17(6OBY);A$9^":VI/$%E$<,QHAB:4E=,<
ML/4B[-&K3=Z^HKG;WQ99+;N(F/F8XKE)?%=]YAV$8K*KCJ5-[W-:6"JSZ6/3
M=Z^HIU>90>*[[S1N(Q710^)LPKD_-BE3QU*85,%4@=717+?\)%)61-XQNTE9
M01@&JEC:4=R8X.K+8] HKSQ?&=X6 W#DUVVFW375LLC=2,U='%4ZSM$FMAIT
ME>1=HHHKH.<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "HY?NU)4<OW: (13UI@IZT 2+3Z8M/H **** "DI
M:2@!*;3J;0 AJ,U(:C- #>]64^[5;O5E/NT .HHHH **** "BBB@ HHHH Q_
M$D,DVDRB/.0K'CZ5Y[\+-3M;5M0M[ADBE:=L!NIYKUB1!)$R-T8$&O)O$OP]
MOX+_ .W:$%C;)8D^M7%JUF1).]T>I37MM'"SO*H4#O7CM[<Q:E\6]/ELB&C5
M2"R=,Y6JO]E>/[P?9I+A"G0\'I^==IX)\!?V,PN[Y ;L-D,*:2B2VY'?1 B,
M ]:?1169J%%%% !1110 4444 %%%% !5"^_X^(?K5^J%]_Q\0_6@"_VHH[44
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM11VHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ3[>TAMD"QH![XJ>B@ JA??\?$/UJ_5"^_X^(?K0!?[44=J* "BBB@ HHHH
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MH **** "BBB@ HHHH **** "HY?NU)4<OW: (13UI@IZT 2+3Z8M/H ****
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MOZ=JKLMI-O*]:+,+HTZH7W_'Q#]:OU0OO^/B'ZTAE_M11VHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *\>O?\ B:^,%4_-Y$_'M7KTL@CC+$X KR+P-&=1\:ZTS\B.7(_(
M5<>K(GND>O)Q&H]A5;4Y?*T^9\]%JT.@%8?B*XVPB#/^L&*PJRY8-F]*/--(
MJ>&X_/D%[CEAUKJ*R?#MO]GTF-,<BM:HP\>6FBL1+FJ,****W,0HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MLS0T.U%':B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MDI:2@!*;3J;0 AJ,U(:C- #>]64^[5;O5E/NT .HHHH **** "BBB@ HHHH
M*YWQG97FH>';FVLHA)*ZX45IZM)+%9,T();!QBO'KK7O$JW,JK#=;0QQ\M5%
M7(E)+0@T_3OB#IUJL$.G+L7I\Q_PKHO#0\;_ -MP_P!I6*I:_P 3;C_A7/\
M]O\ B;_GA=?]\UL>%]8UZXUZ".ZBN!$>I8<5H[V,TU<]<7.T9ZTM-3)49IU8
MFX4444 %%%% !15:[OH;.,M(Z@CL35&U\06MQ+L9U3T)/6BPKFO16=?:O!9$
M!F4L1D#/6FV.L)?.55<8IV"YIU0OO^/B'ZU?JA??\?$/UI#+_:BCM10 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%-D)$3$=<&@# \2>+M.\.QD74P27&0#7CWBWQ]#XDO=/@@D5E689Q
M]:R_B]=73Z\B.6"[>AKSJU9DNHV3[P88K>$%:YSSJ.]C['T%8DTN+R3D%03^
M585^WV_5XEZ^4]4_AS?3GPD9KHL6! &ZM#P_"9]4O)7Y&[(KS\5[THT^YZ.&
MT@ZG8ZM!A /:G445TG,%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^Z,5PP?M*SEV.Z:Y**CW)Z***ZSE"BBB@ HHHH **** "BBB@ HHHH ****
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MJ*!THH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5'+]VI
M*CE^[0!"*>M,%/6@"1:?3%I] !1110 4E+24 )3:=3: $-1FI#49H ;WJRGW
M:K=ZLI]V@!U%%% !1110 4444 %%%% !69KNGV^HZ9+!<%0C#!+'BM.L3Q1
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<$F P.=IQUJW3A4A:6J,E4G3G>.C/K'PS.)](AD]4!K:K$\,6QM='@C88(C
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M WO5E/NU6[U93[M #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5'+]VI*CE^[0!"*>M,%/6@"1:?3%I] !1110 4E+24 )3:=3: $-1FI#49
MH ;WJRGW:K=ZLI]V@!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %(QPI/H*6FO_JV^AH \UM_
M&4TGB9[([L"7;7I8Z5X39?\ (]R?]?']*]ONKE;6U:5CC"D_I5R1$'?<E>:.
M+[[A?K0DJ2#*,&^E>/)XAU_Q3JD\6G[6AAD*&GVOBC6O#VLR6VIE5@487ZT<
M@<Z/7GECC^^X7ZTBSQ/]UU/T->2ZEXFU;5];M[2S*^5(.<FJ5OKWB6UU_P"P
M#:41P#SVHY YT>K>(9WM]'EDB8JPZ$5Y]X6?5[S4KRXFU%S#$=VP^E=MKQD/
MAIC)]XJ"?RKE/!<)N/[3A7JZX'Z4+8);HJ:WX]N9=7.G6,$C,!]].:73/%NL
M*)(IK"X)/ 8CI7-WEOJWA+Q*;SRU\D=R,UW/AKQ]I6KRK;R;?/SC&T=:IK31
M$)W>K.;U;Q7K-@S.T$X3UQ5#3?&^L:F',$,[;#@X%>C^/(XQH!(1>I[5S/P@
MC1H-1W(I_>'J/>A-6O8&GS6N=98:Q);^&%NKP%)"AX?KG%<%X>^),M[XG6QF
MC=4:0C<>F,UK?%/61;V-M:6Y =I@K >A(%<EJ_AO^P[./64 #*@?.?49HBE;
M4)-WTZ'H?BS5K^WB1[*.1P3_  "O/;GQ_JMMJ*V3Q3B5AD ]:]6\(7\>J>&[
M65MK.5R<C->9^+D4?%FT 5<>7TQ]*(VO9CE>UT=#X?\ $.JS;I;B&81CGYA4
M6K^-KVYU,VEE;2XQG>HKT*SM8IM)2)D4*Z8.!6)?Z;9>&[%[R!<L,\D9J;JX
M[.VYS?AOQY-_:(L;V%P[OM4O7H>J7)M;)Y1V4G]*\4T>ZCUSQ9'-/PT4V4P,
M5[)K_P#R"I?]QOY426H0;:/([?QUJFH7US';QS,(Y"ORBM.#X@:AI,ZB]L)R
MC$+N8<54^%**VHZEN4'_ $@]1[UZ)XNTBVU#1Y1)&HV(S# ]JIM)V$DVKW-/
M1]7@UBT$\+*1@9 /2KC7$*-AI%!]":\+\%^*)=!\.ZE)O_U<[ 9/N:M0>(]:
MU5)+T$>7C<G-2X:C530]N#!AD'(J,W,"MM,J@^F:\ITKQ]?QZ!*]T1]I5L#Z
M<U2CU'Q!?V]W?J5VQ+O7FCD8^='LOF)C.X4AGB'5U_.O'-!\5:_>:8;JXV^6
M"1FJ^D:WXK\0WMQ'8A6BB;#<FCD%SH]L\V/9OWC;ZTU+B%SA9%)]C7!W4'BR
M/1HX8%3S@><GM7+RZUX@\/Z[:Q7941R<O@TE&XW.Q[.S*@RQ 'O7&^._$)TK
M1)Y[>7YD'\)KFO$WCB]GBA@TM@9F<*V?0FN9\:V?B"'0))+M1Y+H&;\151CW
M%*>FA[#X1U%]2\.VMU(26=,DFMG[3#NV^8N[TS7D\/BE_#O@/2_*8!YDVC/K
M62^OZ^FGM?Y'F@\<]J7+<.>R/<2Z@9+ 9ICSQ;2/,49'K7E\_C2[ET-)%8>>
MD>6^M9_AZ]\6^(8UNHU4VI;KDT<@^=%WQ4=8TKQ#9E-2<PS/G:/2O2-)G:32
MUED.3C))KS[QRLB:AHRR_P"L ^;Z\UW.F''A]CZ1M_*A[(([LXW5O$-U<^,[
M&UM)&6'.'"]*]$CD15V-("PZUY3X*C^WZ[<SOR8IV _.JVM>)=='C&ZL-/VE
M0<8--QOH2I65V>P+<0NVU9%)] :X#XA>+Y/#;6K*&(=\'%<U<ZQXBT#6[?[7
MM$3+N//TJC\3I#J]EI+'DSR ?K1&.H2GIH>J^$/$47B#2A<J0&SC&:N>(-7B
MTC2YIW8!E3*@GK7E'A*ZE\)^(;?2YB5MV0.<_A_C4OC[6W\07%O:V#;HU.V7
MZ<T<OO#Y_=-3P9XZE\1:L\&UE&TXS5GPWXANK;7KJTOI6?S)2(]W85S'P[TY
M=.\:?9U'&RM'Q@G]G>/=&$? EDR?R--I7L2F[79[#12*=RYI:R-@HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *CE^[4E1R_=H A%/6F"GK0!(M/IBT^@ HHHH *2EI* $IM.IM "&HS4AJ,T
M -[U93[M5N]64^[0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU[#O).:J6_P]T&VQY=N1BA220G!MGD4\<NFW<%[+&?*>0<GIUKI/B'K]M?\
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MMU>7X#!)2T?L*KF6Y/*TK'HZC:,4M%%9FH4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1R_=J2HY?NT 0BGK
M3!3UH D6GTQ:?0 4444 %)2TE "4VG4V@!#49J0U&: &]ZLI]VJW>K*?=H =
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% %>6QM9SF6!'/N*6*SMH#F*%$^
M@J>B@!"H88(R*C%M K;A$H/KBI:* "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH 1E5UPP!'O54Z98LVXVL1/KMJW10 R.*.)=L:!1Z"GT44 %%%
M% !1110 4444 %%%% $)M8"VXQ)N]<5*  , 8I:* &E%)R5!([TZBB@ HHHH
M **** "FJBIG:H&>N*=10 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !4<OW:DJ.7[M $(IZTP4]: )
M%I],6GT %%%% !24M)0 E-IU-H 0U&:D-1F@!O>K*?=JMWJRGW: '4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !4<OW:DJ.7[M $(IZTP4]: )%
MI],6GT %%%% !24M)0 E-IU-- "&HS4AIA% #.]64^[5;N*LI]V@!U%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4NVC;0!%BC%2[:-M $6*,5+MHVT 18HQ4NVC;0!%BC%2[:-M $6*,5+MHVT
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
=44 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g23ode3tb50n000009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g23ode3tb50n000009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 1'!V8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#%/_'X_THH/_'X_THH VJ*** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "N$U;XJ:+H^OKI$\<QN&<(
M"!QDUW9Z5\P>/?\ DJD/_7=/YBKA%2>IG4DXK0^G8W$D22#HR@C\:CNKA;2U
MDN'SMC7<<46G_'G!_P!<U_E5;6_^0)>?]<C4%]#SV7XY^&XI7C:*XRI(/R__
M %JDM?CAX9N9EC/G1Y_B8<5Y)X T.PU_QS-9ZA%YD)9CM_&O6/$/P=\//I,S
M6$)@G525;-;.,$[,QC*<E='H.E:S8:U:BXL+A)HSW4YQ5+Q#XKTKPS;^9J%P
MJ$]$SR:\*^$.JWFE>-I-(,I:!LJ5SQD5G^(9I/%?Q.:RO[AD@$PC )P *7L_
M>'[7W;]3U.'XX>&9;CRL3+SC<1Q7>Z1K=AKEJ+BPN$E3OM.<5P\WP:\,SZ8(
MX8BDQ3B4'O6WX$\%1^#;"6W6=IF=L[CZ5,N6VA4>>^IUU%%%0:!7"^)/BAI?
MA?439W]K<J>SA#@_I7=5SOB[PC8>*M+DMKF)?-Q\DF.5-.-KZDRO;0NZ!XAL
M/$>G)>V$H=&ZC/(K5KYBL[S7?A/XG\F<.UD6Y&/E9?:OH;P]XALO$>F1WEG*
MK!A\R@\J:J<+:K8F$[Z/<UZJ:GJ$6EZ=->S F.)=S8JW6#XS_P"12U#_ *Y&
MI6Y;T1F>$_B+I/C"_GM+!)5DA7+;Q[XJ7Q=X_P!+\'2PQWZ2,91\NP5Y/\!O
M^1HU3_KF?_0A5SX^?\?NG_2M.1<]C+G?)S'L^AZQ;Z]I4.H6P812C*[NM:-<
MC\-?^1&L/]P5UU9M69K%W5PHHHI#"N,\3?$K1?#%\EG<%YIW.-D0R14_CWQA
M;^$]#DF+ W,BE8DSSFO)? .F:5JVL-KWB74X#<.^Z*%Y!GVXK2,=+LSE.SLC
MWC2=2&JZ?'=K#)$L@R%D&#5ZHX&B:!# 5,>/E*],5)69H%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M10?^/Q_I10!M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(C&16N!@8%9R:>QK%-;G'_%#_DG^I_\ 7,_RKSGX!_ZZ]^E>C?%#_DG^I_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3N &!@4445!84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &*?^/Q_I10?^/Q_I10
M!M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 8I_X_'^E%!_X_'^E% &U1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!BG_C\?Z44'_C\?Z44 ;5%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1129'K0 M%%)O7^\/SH 6BBDW G (H 6BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** ,4_\?C_2B@_\?C_2B@#:HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* ,4_P#'X_THH/\ Q^/]** -JBBB@ HHHH **** "BBB@ HHHH **** *6J7
M4]G9--;P&:0=$'>O.+.;7X?&-QK#:/)Y<Z!-OIT]O:O5*3 ]*I.Q+C<Y?7=5
MU^R2WN+"P$\;#,L>?F'Z5SIM->\::Q:2:A9&QL+5MY1NK&O2Z*%*P.-^IPOB
M?1-3M-:@U_15#S1IY<L7]]?\BLY[37/&NK6?]HV)L]/MG$C(_5R*]+HHYA.
MQ8D6$1 ?*!C%4CHE@S$F!<FM"BI+,N;1-/$+D0+P#3?#Z!+)U7H'.*TI_P#4
M2?[IK.T+_CUD_P!\T :M%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 8I_X_'^E%!_X_'^E% &U1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!'/_ *B3_=-9VA?\>LG^^:T9
M_P#42?[IK.T+_CUD_P!\T :M%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 ':LBP_Y"UU6OVK(L/\ D+75 &O1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 F!Z"N%UH#_A8^D\?PG^1KNZX76O^
M2CZ3_NG^1J63+8[G ]!2T45104444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 8I_P"/Q_I10?\ C\?Z44 ;
M5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $<_^HD_
MW36=H7_'K)_OFM&?_42?[IK.T+_CUD_WS0!JT444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %-WK_>'YT.N]"N2,]Q63-HP"._VJ;."
M>M9U)3C\*N7",7\3L:V]/[P_.G @]*YS3---U;L[W4V0Q'6MRUM_LT7E[V?W
M:HHU)U%=QLBJD(P=D[LGHHHK<R"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#.U[_ ) -]_UQ;^54?!W_ "+=
MO^-7M>_Y -]_UQ;^54?!W_(MV_XU7V2?M&_1114E!1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 ':LBP_P"0M=5K]JR+#_D+75 &O1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K \8_\
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MVA?\>LG^^: -6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG_?5%H!>9Y_\;==TS6I]/.G7D5P$SN\M@<=:\EKV+Q[\)'LY+;_A'K9W5O\
M69.:X&7P+KT%_%9/:D3R_=7UKHA**CN<M2,G+4U/A5J5GI?C*&YO9T@A .7<
MX%?0_P#PGOA?_H,6O_?P5X?X0^%.HW.N1QZU:,EH?O$<5Z7_ ,*5\,_W)/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^BBBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH .U9%A_R%KJM?M618?\
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M HHHH Q3_P ?C_2BHVGC%_(A)W <C%% &]1110 4444 %%%% !1110 4444
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M[Z[FD4VCK;2TN8')ENC*/3%7:R-%U:;5%9V@\M!T/K6O7JX6=.=)2I[/O?\
M4AWOJ%%%%= @H)P,T4R5TCB9Y#A0,DT <%XHU+[7?>0AS''_ #KA?#Q*RW;+
MD$2DBO1YO$'@\2N'O;?S,\Y;O7,>%=:\+0RW_P!INH5W3$KENHJTG8S;5T>B
M>'[\7NFH2?G48-:U86@ZKH=]))'I-Q'(RC+!#TK=J&:(**** "L[7?\ D!WG
M_7(UHU1UF-YM'NXT&6:,@"FMQ/8^,K__ )"-Q_UT-5F^Z:ZG4?!7B!+FYG;3
MIA&&+%MO:JD/@OQ!=6_FPZ=,R-T(6NRZL<'*[GTQ\-?^1(T__<KKJYCP!9SV
M/A"RM[F,QRJF&4]JZ>N.6YW1V04444B@HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@".>>.V@>:9@L:#+$]J\Z'
MQ*>]\8VFF6-L6L921YY'#'CI7HEQ!'<P/#*NZ-Q@CUKS?Q+8VVG>-O#=O:Q+
M%&I; 4?[M7&W4B;:V.V\0Z]!X?TE[R8;F'"(.K&N-?Q7XKTZ%=4U#38AIK8+
M!?O*OK3OB4Y_M'086YB>X&X=NU==KD4,GA6Z27'E_9S_ "H5DD)MMOR*6K^,
M;73_  ]!J<*F5KG A0?Q,>U<\_BSQ3I*QW^K:;$-/D89V?>0'UYKDM*N))W\
M-VTP/V=+@[<]#S7JGC-$;PA?A@-HB.*;26@DW)7-FTNHKVTBN86W1R*&!^M3
MURGP[E>7P=9ER3@$#/IFM^74[6&0H\@##M4-6=C1.ZN7.U9%A_R%KJK']L67
M_/453TJ>.?4[IXSE:0S;HHHH **** "BBB@ HHHH **** "BBB@ J&XN8K6/
MS)6VKZU-7(?$F_GTWPA<W%N0)%Z$BIFIN+4-P;2U9O?VY8?\]U_.C^V[#.//
M7\Z^4QX\UW_GX'Y59T_QSK<FI6J-."K2 'BN/V>9]H_>R/;4SZRC=9$#KT/2
MG57L26L86/4H#5BNU7MJ6%%%%, KR7XD^"XM9U>.\GD95*X&*]:K,URP%]I[
MKCYU&17+C56=%NB[20))Z2/ O^%;V'_/=J[?X;>#H]$U>2ZMY25(PV:/+;S?
M+P=V<8KT70=/%CIZ CYV&6KY_*L7C<56M4F^5;ERI0CJD:E%%%?5$!1110 A
M&01ZUYQJ7P?T.^O;F]E+^9*S.WU/->D4V3_5/_NFFFUL)Q3W/$/"?PKT;68K
M]IRV8+EXEQZ D?TKU;POX9M/"VF&QLR3&6W<UB_#O_4:O_U_2?\ H35VM5.3
M;L1"*2N%%%%0:!1110 5@>,?^1?F^H_G3M4\46NE7/D307#MC.4C)'\JYOQ'
MXOM+_2)((;2[+L1@>4W^%5%.Y$I*QV.A_P#(%M/^N8_E6A7$Z7XULK;3+>%[
M2[#(@!_=-Z?2M_2/$%OK+,(89DV]?,0C^=#BQJ2->BBBI*"D90RE6&0>HI:*
M ,YM!TIF+-80$GJ=M9MSHFEKJMNHL(-IZC;71UEW7_(8MZY\4WRKU7Y@DAW]
M@:3_ - ^#_OFK\44<$:QQ($1> HZ"GT5T!8**** "BBB@"IJ5JMY8R1,,DCB
MN/\ #NEF75&,@^6$\UW1^Z?I65HZ*LMR0.2YKRL9@X5<52G+I?\  N+:3-;H
M,4445ZI 4444 %8OBW_D5-3_ .O=_P"1K:K&\6_\BIJ7_7N_\C36XGL?&K#Y
MW_WC_.@<$'T-*WWW_P!X_P Z3KQ7<>>]SZ\^'TZ3^"M-9"#B)0?RKIZ\<^!>
MNM-IEQI,K9:)MRY/:O8ZXIJTCN@[Q3"BBBI+"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@#&L2/[5O>?2BH6MU.H2R98,1S@T4 ;]%%% !1110 4444 %%%% !1110 44
M44 4M4U*+2K)[J9)'1>H1237E]AXK@C\?7>IM87PMIHPB-Y+=>/:O7&56&&4
M$>A%,^SP_P#/&/\ [Y%4FD3)-GG_ (I@NK76+#Q786SS(J@31 ?-MQZ5FZUK
M=WX\N+32=/L;B&WWAYY94*@8[<UZJ54KM*C;Z8IJ11QG*1HI]EQ34A.!YSX@
MLKSPMXBM=?L;9I[<1^3.B#)QQSC\*JZE?W'Q!U6QLK2SGBL87$DTDJ%<^W->
MI,JL,,H(]"*:D4<?W(U7_=&*.8.0;'"L=NL(^ZJ[:IG1;5F)(;)]ZT:*@LRI
MM%M1"Y ;[I[TWP^@CLF4= YK3G_U$G^Z:SM"_P"/63_?- &K1110 4444 %%
M%% !1110 4444 %%%% !7S9\;U*^+5;)Y0=Z^DZ^</C@DC>*8]J,WR]A6E)>
M\95OA/*\GU->L? @9\1W9)/"5Y059?O*1]17IGP6U2RTO7;J2]G2%63 +&NB
MHO=.:D_>/I:BL'_A,] _Z"4'_?5'_"9Z!_T$H/\ OJN2S.VZ-ZBL'_A,] _Z
M"4'_ 'U1_P )GH'_ $$H/^^J+,+HWJR?$&H+8Z9(<_,XV@57_P"$ST#_ *"4
M'_?5<7XG\7:9?W6R*]C,:=#GK2<78:DKG0^#-1\R.2TD(SDD9[UM:GX>L=20
M[H@C]F7@UY=IGB2PLKJ.9;R,8;GYNU>C0^-M DA5CJ,()'3=7/"C&I149JYM
M.JX57*+L8S6NM^&G+0,UQ:YZ'DXK>TCQ/::B CGRINZ-Q36\8^'F&&U& @^I
MKG=7N?#%[F:UU.""X'(*MC-<SPU?#ZT'=?RO]#=8BC7TK:/NOU/0001D45YI
MI/C^VTZ<6E_>Q21C@2!JZM?&OA]E##4H,'_:KKH5E6C=)I]F<]:E[)VO='+_
M !M!_P"$!D.?^6@KYD[5]%_%C7-,UGP7):V-[#+,7!"AJ^?VTZ9$R2G_ 'U7
M;3G&*LV<-6$I.Z*9Z5]6_"I2O@BTR<Y%?+PTV9DR"G/^U7T?\//$6D:7X2M;
M:ZOX4E4<J6I5)QGI%W'2C*+NSTFBL'_A,] _Z"4'_?5'_"9Z!_T$H/\ OJLK
M,WNC>HK _P"$S\/_ /02@_[ZI?\ A,_#_P#T$H/^^J+,+HNZU8B_T]TQ\P&1
M7G:6[O=" #YBVVNLN/B%X:@D,;ZC$3[<US4'C#PM'K\ES]O3R\9''>O!S;*Y
M8FK"<%UL_0N%6*6YZ'IMHME8QQ 8('-6ZY>W^(/ANY8JFHQ#'J<59_X3/P__
M -!*#_OJO<A3Y(J"6B(YD^IOT5@?\)GX?_Z"4'_?5'_"9^'_ /H)0?\ ?559
MA=&_5#6O^0-=_P#7,UG_ /"9^'_^@E!_WU5/5O&&A2Z3<HFHPEC&0!NH28FU
M8^4M2+?VI=?,W^L/>JN3_>/YU/J#*^I7+*<J9"0:KUW(X'N>Q_L_DG6-3R2?
MW8ZFOH"OG+X'ZM8Z5JNH/>W"0JR#:6.,U[=_PF?A_P#Z"4'_ 'U7+53YCLI-
M<IOT5@?\)GX?_P"@E!_WU1_PF?A__H)0?]]5G9FET;]%8'_"9^'_ /H)0?\
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M2PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?MW@RPDSG$87]*MZQ3,UI-HZFBBBH- HHHH **** "BBLZ>35!*1#'$8^Q-
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% &*?\ C\?Z44'_ (_'^E%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %,FC$T+QGHRD4QKNW1MK3Q@CL6%)]MM?^?B+_OL4 8/A
MCPA;>&);MX)6?[0Y=L]JL)XLTV3Q"VBJY^UJ,D5K?;;7_GXB_P"^Q7D-@Z2?
M&ZX9&##R^H.>U6ES7;(;Y;)'LM%%%06%%%% !1110 4444 %%%% !VK(L/\
MD+75:_:LBP_Y"UU0!KT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M% !1110 4'I10>E 'A7BWP%XXU+Q)=W6GSNMJ[90"4#C\ZQ/^%:?$7_GY?\
M[_C_ !KJ?%'Q=U+0_$%SI\5B72)L!L=:Q_\ A>FJ_P#0-/\ WS6ZY[',^2YG
M?\*T^(O_ #\O_P!_Q_C72_#SX?>)M$\5?VCJX#(4P7+@G^=9?_"]-5_Z!I_[
MYKIO OQ0O_%&O?8)[/RDVYW8HESVU''DOH>LT445@= 4444 %%%% !1110 4
M444 ':LBP_Y"UU6OVK(L/^0M=4 :]%%% !1110 4444 %%%% !1110 4444
M%%%0W5REI;/-(<*@S2;25V-)MV0Z>=+:%I9#A5&35&RUW3[Y<Q3J/9CBN!U;
MQ==WTCQQ + > /6L[31#=WJQ2L86?A64X KPJF<IU5&DKKS/6AE;5-RJ:,]@
M5U895@1[&EKACI&OZ41):71N$Z[2:G@\87-LWEZE9NGJX'%=T<PC%VK1<?R^
M\Y'@VU>DU+\SLJ*S;'7=/OUS%.N?0\5H@@C(.:[85(S5XNYRRA*#M)6%HHJ&
MYNH;2!IIG"HO<U3:2NQ)-NR,P_\ (Q?\ K9KBCXJL/[;\[)\O&-U==:7<-[
M)H'#J>XKCPE>G4<E&5]3IQ%&<%%R5M">BBBNTY0HHHH **** "BBB@ HHHH
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M@VK_ !*OM6TRV>WTXKCD8!XJG'0B,M3V^BBBL3<**** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M5K__ (\9O]VDT[_CPB_W:6__ ./&;_=I-._X\(O]VN;_ )B/E^H^A:HHHKI$
M-=0R,I[C%>*>%,:1\:M2LL[(I%R%]3S7MM>+^.HQH7Q0TC5!\L<S@2-^-7#J
MC.IT9[15#5[);ZPDC(RP&15N&19H$D4Y5E!!J2L:M.-2#A+9FB9Y-(ABD9&X
M*G!KJ_"6G?>O)%]EJOK^E$:O&8U^69AFNOL[=;6UCB48"BOELKRUPQDG/:!M
M.7ND]%%%?6&(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 8I_X_'^E%!_X_'^E% &U1110 4444 %%%% $4]M
M!=)LGB21?1AFJ\&DZ?;2>9#9PQN.ZK5VB@ HHHH **** "BBB@ HHHH ****
M "BBB@".?_42?[IK.T+_ (]9/]\UHS_ZB3_=-9VA?\>LG^^: -6BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MEA@[1251MI<K)5V:]%%%:%!1110 4444 %%%% !1110 4444 %%%% !1110
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M:SM"_P"/63_?-7IYH_(?YU^Z>]4="(-H^/[YH U:*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH @DL[>9]\D2LWJ16);V5N?$-PAB7:$&!BM/5=6M]*MC-.W
MT7UKB(?&*IJ\ETT)\M^,=Z\S&8C#TIQ4VKW._#4:U2$G':QW\5G!"28XU4GK
M@5QVM6L^@ZNNJ6H_<N?WBBNMT_4(-1M5G@;*G]*?>VD=[:R02@%6&*WKT(UZ
M2=/=:IF-&K*E4]_;9B6%Y'?6D<\; AAFK-<+H]T_AS6)-.NB1;NW[MC7<JP9
M0P.0>E5A,1[:'O:26C0L11]E+39["TR5F6-F498#@4^D/0UU,YT<OJ'BF736
MQ<6^TGH,U13Q\K-M,!&:YKQ+<2SZU-YA/RG !K(KY&OFF(C5<82T1])1R^C*
MFG):L]@TS4+B]^:2#;&1E6SUK3KF/!$\LVCXD)(5L FNGKZ7"5'4HQFWN>%B
M8*%5Q70****Z3 **** *6J6T5S8RK*H.%)%<M975[HA4NI>T<_E77WG_ !YS
M?[AJK8P1W&F+'*@93V->7B\,ZM=2IOEDEO\ YEIV18L[Z"^B#PN#ZCTJS7)W
M>DW>DSFZTXDQDY*5H:=XBAN2(K@>5*.,'O54<?:7LL2N67X/T$X]4;E%(K*X
MRI!'M2UZ1(5Q/Q'\6MX5T7S5B\PR_+BNVKR;XZ@?\(S$?]NJ@KR(F[1;/%].
M\52Z?J4MTD>0\HDV^E>K>'?C1<:KK%K8/:!5D(7->#UTG@, ^,K#/_/0?SKI
ME!-7.2$Y)V/KY#N16]1FEIL?^J3_ '13JY#N"BBB@ I"1ZBEKQ#XB?$K4M!\
M53:?;* B#KFHGSI?NXW8G)1U9V>@D?\ "R=:Y_Y9)_-J[L$'H:^5+7XE:G:Z
MO<ZB@'FSJ%;GTS_C7L'PJ\9WGBE;I;L#,>,&DO;<UI0LN]R(3B]$STRBBBM#
M0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M/&OBE:_V/XNT;78A@"0"0_C7KMC<"[L(+A>DB!J\]^--@]SX1%Q&"6@D#'Z<
M5T_@;44U+PC82H<[8PI^HJWK%,SCI-HZ.BBBH- HHHH **** "BBB@ HHHH
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MO_K5VHU[1R,^0!_P&G+K>CL?]6H^JU:S+!O[:^\/9U.YQ'_"U=6_Z ,_Y?\
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MX_THH VJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT+_CUD_WS0!JT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0O\ CUD_WS6C/_J)/]TUG:%_QZR?[YH U:*** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** #M618?\
MA:ZK7[5D6'_(6NJ ->BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *5SI5E=
MR>9/"';U-8VLV&CVEHWR(DG;GFMO4KK[%833]U7(KR"]OI[ZY>:9R2QZ9Z5X
MV:8FEAUR\J<F>I@*%2L[\UDCTO3M,T>ZM8V2-';:,\U)>^%].NK9HTA6-NS
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MR\\5RY1C:KJ^RD[IF^986FJ?M(JS1VE%%%?4'@!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !VK(L/^0M=5K]JR+#_ )"UU0!KT444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV2W_ .>*?E3XX(HCF.-5SZ"I**2C%= YF%%%%4(**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH .U9%A_P A:ZK7[5D6'_(6NJ ->BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $V@]A6%X
MFU-=*TXM&H\U^%XK>KF/&FGRW>FB2(%C'R0*Y,:YQP\G3WL=&%476BI['G<M
M]<S2F5IFW$YX-=;X/U^=[L65S(7#?<)[5Q1!!P1@BNE\&Z?+<:LMQM(CCZFO
ME,OJUEB8\KW>I]'C*=/V$N9'IU%%%?;'R@4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 8I_X_'^E%!_X_'^E%
M &U1110 4444 %%%% !1110 4444 %%%% !1110 4444 1S3Q6T32S.J1J,E
MF. *R;7Q9HEY=?9H-0A:4G &X<URGQ'O);B_TK0XI61;N;$FT]5J;QAX2T^V
M\(RS6,"P75JF])4X;(%6HKJ0Y/6W0[_K16%X/U"34O#%G<2G,A7#'Z5N;AZB
MH:L4G=7&3_ZB3_=-9VA?\>LG^^:T)V7R).1]T]ZS=#D06KY=?OGO0,UZ*9YL
M?]]?SH\V/^^OYT /HIGFQ_WU_.CS8_[Z_G0 ^BF>;'_?7\Z/-C_OK^= #Z*9
MYL?]]?SH\V/^^OYT /HIGFQ_WU_.CS8_[Z_G0 ^BF>;'_?7\Z/-C_OK^= #Z
M*9YL?]]?SH\V/^^OYT /HIGFQ_WU_.CS8_[Z_G0 ^BF>;'_?7\Z/-C_OK^=
M#Z*9YL?]]?SH\V/^^OYT /HIGFQ_WU_.CS8_[Z_G0 ^BF>;'_?7\Z/-C_OK^
M= #Z*9YL?]]?SH\V/^^OYT /HIGFQ_WU_.CS8_[Z_G0 ^BF>;'_?7\Z/-C_O
MK^= #Z*9YL?]]?SH\V/^^OYT /HIGFQ_WU_.CS8_[Z_G0 ^BF>;'_?7\Z/-C
M_OK^= #Z*9YL?]]?SH\V/^^OYT /HIGFQ_WU_.CS8_[Z_G0 ^BF>;'_?7\Z/
M-C_OK^= #Z*9YL?]]?SH\V/^^OYT /HIGFQ_WU_.CS8_[Z_G0 ^BF>;'_?7\
MZ/-C_OK^= #Z*9YL?]]?SH\V/^^OYT /HIGFQ_WU_.CS8_[Z_G0 ^BF>;'_?
M7\Z/-C_OK^= #Z*9YL?]]?SH\V/^^OYT /HIGFQ_WU_.CS8_[Z_G0 ^BF>;'
M_?7\Z/-C_OK^= #Z*9YL?]]?SH\V/^^OYT /HIGFQ_WU_.CS8_[Z_G0 ^BF>
M;'_?7\Z/-C_OK^= #Z*9YL?]]?SH\V/^^OYT /HIGFQ_WU_.CS8_[Z_G0 ^B
MF>;'_?7\Z/-C_OK^= #Z*9YL?]]?SH\V/^^OYT /HIGFQ_WU_.CS8_[Z_G0
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ML.#_ )ZR_P#?1K4HH R_[#@_YZR_]]&C^PX/^>LO_?1K4HH R_[#@_YZR_\
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M** ,O^PX/^>LO_?1H_L.#_GK+_WT:U** ,O^PX/^>LO_ 'T:/[#@_P">LO\
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MV'!_SUE_[Z-']AP?\]9?^^C6I10!E_V'!_SUE_[Z-']AP?\ /67_ +Z-:E%
M&7_8<'_/67_OHT?V'!_SUE_[Z-:E% &7_8<'_/67_OHT?V'!_P ]9?\ OHUJ
M44 9?]AP?\]9?^^C5*TL5CUQD$LA5!D M70UD0?\A^7_ ': ->BBB@ HHHH
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M?ZLMT:GRNUR>97L=C1112*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M** "BBB@ HHHH **** "BBB@ JCJ>K6ND6_G73;4SC-7JCF@BG7;+&KKZ,*
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M/OC5L$9&<&G5F:A1110 4444 %%%% !1110!BG_C\?Z44'_C\?Z44 ;5%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !UJ,01!MPC0'
MUQ4E% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MNR!U(J6K.Q:=U<6BC.>E)D>M(8M%)D>HI<@=Z "BC(/0TF1ZT +129'J*6@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ KE/B+_P B7??[E=77*?$7_D2[[_<IQW1,MF>>_ '_ %.H
M?6O:Y'$<;.QP%&37BGP"_P!1J'UKV+4@S:9<JGWC&<5=3XB:7P'CVM>-]?\
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M=TX5R,19X:J_B%?'^DV">(YM2Q$,,UNI. *I?$I73QKH2N<N-@/UKTCXA_\
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M#_I1')/K5J>MV9RAI9&II-FMAI5M:J,>7&!C\*NT45!H%%%% !1110 4444
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MH^%9\2ZG)=S:O.B/_P L@?EJE*[38G"R:CU-KX9_\B+I_P#US%=1>6XNK.:
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#%/\ Q^/]**#_ ,?C
M_2B@#:HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH Q3_Q^/]**#_Q^/]** -JBBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@#%/\ Q^/]**#_ ,?C_2B@#:HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2<UUMO&88$C)SM&*Z\'2JJO4J3C:]CFQ-2FZ4(0=[$M%%%>F< 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!2U?_D%W'^X:Y7P1_Q[WGU-=A>P&YM)(0<%
MUQFL?0- DTB*=7E#^83C':O/KT9RQ4)I:),[:56$</.#>K:,'PO_ ,C5>_0_
MSKO&Y4@'DBN,?P??K?2W-M?"(N>U7M.T/5K6\66?4C+&.JY/-8X-UJ,?9RIO
M=ZFN*5*K+G4UML12^&=5>=Y%UAU4MD+D\52\9)(D%C;R.63H[>M=Q6=J^DPZ
MO:&&7@]F]*UQ&!3HRC3W?F94<6_:QE4V7D9,FAZ4- ^Y'PF0_?-5/ KR>5/'
MDF)6^4FF?\(?J#*(6U%C;C^#)Z5T^E:9#I5HL$(Z=3ZUC0H3E7C4Y.117WFM
M6M"-*4.?F;?W#M5_Y!EQ_N&N,\)PF?3]0B'5LUW%Y ;FTDA!P77&:Q_#V@R:
M,)O,E#^8<\5MB*$ZF)A)+2SN94:L84)1OK=&#X-O$LKVYLIR$8L2,UW,D\42
M;WD55]2:Y_5_"<-]<?:;>0PS^HXJA_PB.HS82YU)GB] 365#ZSAH>R4.9+9W
M-:OL*\O:.5NZ-W6=2:UTSS[9U)8@*>U,L5U+8EQ<W431[<LH'/\ *F7.@6SZ
M3'8-,RHI!!+<UCW8N-'O4M(;EYXYD(VL<D5=6I4IS]I46FFSZD4X0G'DAOKN
MNA;_ +5U._>XFLMJP0GC</O5KZ+J?]IV0E(VNIPP]ZR/#<J1Z'<1.P$B,Q8&
MG>#T;R+B3^!I#BIP]6?/!MWYD[CK4X<DTE;E:L48R$\<'=QGI3/&"AM:L589
M!(R/QJ7Q1&]AK%IJ4:\!@K8^M:&I:,^M7%G>QRA50 D$=:YYTI2A4H15WS)_
M(WC4C&5.JWI:WS*WBZ&-/#L6U%&",8'M524EO J$FN@UO2'U33%M4D"$8Y-5
MVT"0^'AIOFC</XJVK8:HZTY16CC;YF5*O!4XIO52N8<>E_VAX/B=/];%\RFL
M^UGN?$5W:V,H(CA^]7=:/IIT[3%M)&#XZFI+72[2SF>6&)5=SDD"E_9TI*#O
M;1<R[V']=C%R5KZNS]3C]8B6'Q59Q(,*H  K6\9.!HRKW8C%3:CX?DO-;BOE
ME"JG\-9OBAGO]4M--C!.&!:LZM.5*G637Q/0NG.-2=.S^%:G1Z("-&M0?[E:
M%16T0AMHXQT5<5+7LTX\L%'LCRYOFDV%%%%62%%%% !1110 4444 %%%% !1
M110 4444 %%%% &!XO\ ^0')3?!A'_"/1<]S_.M#6M.;5+!K=7"ENYKFX/">
MK6T0BAU,H@Z $UY=:-6&+]K&%U:QZ%)TYX;V<I6=[EWQP7_L?Y"=N><5A:>=
M=.EK';6\!MV7KQ73V>AS_P!GRVNHW)N _0GM64/".H09CM=29(3_  Y-<^(H
M5IU?;*+U5K)JZ-J-:E&G[)M:/JM"'3-+G@T*]COB$C<9^4YQ658S:B]@]G;M
M!]G)(RQ -=)?64VC>'9D1GN'8<[CFN9M;706LM\]S-'<8Y0$CFN6O3=.4(+1
MI:W=OE<Z*,U-2F];OM?\#J;#3O[.\.3I'(KR,I)*_2N7T%]53SCI\,3DL=Q?
M&:V?!D5RTMQN+FT/"[^]6;KPC.ET\VG7C0;SDC)K;V,ZM.G5I1:2NK)Z^IDJ
MD:<YTZC3OK=[%/2+#5!KS7ES'''E3N"$>E,\/1))XHO"Z!B&.,CWK=T?0)[&
M5IKB[>:1ACDG%-TOP_+8:M/>-*&60DX%:PPE1.F^5[MN^IG/$P:FK]$E8P=;
M 3QE;E0%R1TI2L<GCW%QT&<!NE;>H^');W6XK]9@JI_#2:YX7_M*[6[MYO)G
M'>IGA*UYR4;^\G;NBH8BE:,6_LV]#-\=B(16NS;OW]NM=3I'_(*M_P#<KF9_
M!ES<Q*9[XR3 ]6)Q75V4!M;..$G)08S75A:=7ZQ.K.-DTCGQ$Z?L(TXRNTV6
M****],X HHHH *\\U;.E>,8[F0?NV.<UZ'69J^B6VKP;)AAAT8=17%CL/*M3
M7)\2=T=6$K1I3?-L]&7H;B*:%9$=2I&<YJCJ=U'+IMRL$@9U4Y"GD5SR^$M3
MA'EP:FRQ?W<FM?1O#J:8)&>5I9)!ALG(J8U<15]R5.W=W*=.C3]Y3OY6,GP,
MMN8+AB%,V\YSUJCJ(1/&L'V; RPW;:T[GPA,ET\VG7C6^\Y(R:M:-X66PNC=
M7,IFG/<UPK#5W"%!PMRO<ZW7I*<JRE>ZV,>1%?Q[AE!&!U^E1^)8T_X2FS&T
M8+#(Q6^?#\A\1_VGYHV_W:;JOAV6_P!8@O5F"K&0=OK3J82JZ<ERZN5_D*&)
MIJ<7?:-OF9_C:*-%LRJ 8; P*A\4_P#(#L,^U;WB#1)-86$)($\ML\UB^,83
M#I5G"3DJ0N12QE&4?;3:T:08:I&7LHWU39IR):KX3PX0)Y?]*YFQ\P>#;TH3
MMWG'TJ]!X5O;RRB']H-]F89V$FNGM-%MK;2_L.W,9&&]ZJ-"K7DI./*E&WWB
M=:G15E+F;E<R_"*6O]@J1M+$'?FL31_E\7W M_\ 5X.<=.E:#>#KN!W6ROVB
MB8\KDUJZ'X<BTC?(SF29_O,:(4*\W2A*%N3J$JU**J34K\W0Y[PL0/$EZ"<?
M.>M.U9E;QI;[6!QCI5Z]\(S/J+W5E=F N<G%$'A"6'4(;HW6]E.6+=367U?$
M*FJ/)M*]_F:>VHN;J\VZM8I>(45_%EJK $$#@U8\;QHEA;E4 PW&!6EJ/A^2
M]UJ&^64*L?\ #4WB#1)-8MHXDD"%3G)K:>%J.%=<NLGH90Q$%*D[[+4Y/7&+
M6.EB0GRR!G]*Z;6TMD\+2!0FWR_E_*G7OAM+W1H;-WQ)$/E<5EKX.O)+<PW.
MH,Z ?(N3@5/L*]-SM"_,E\M"O:TIJ-Y6Y6_GJ6? W_()/UKJJR- TA]'M#"\
M@?)SD5KUZ6"IRIT(QENCAQ4XSK2E'8****ZCG"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ IK_<;Z4ZD894CUH8' :3_ ,CI/]:=JW_([VO^^/YUM67AN6VUV34#,I5C
M]VH=9\+W.H:F+R"Y$3#IZBO!>%K*A;EUYK_(]A8BDZM[Z<MCJ01@<BN?U30=
M0OKQIH-3:%".$%48_#FM)(K-JS%0>1DUUD2LD2JQRP&"?6O22>)CRU8./S_R
M.%M4'S4Y)_+_ #.6U6TN],\*S127+3R9Y?VS4?AG1]-FTCS9521V'S%NU=7<
MV\=U;O#(H*L,&N1;P?>0NZV>H-%"QY7)KEKX:4*T:D8<R2M;_AS>E74Z;A*7
M*[WN4=$06GBV6"U8F'/(!XKOW^XWTK&T/P]%I 9RWF3-U<UM,,J1ZUT8"A.C
M2:EI=WMV,<76C4J)QZ=>YY_I7_(ZSCU)ID<G]D>-6:;Y4<XW&N@L_#<MMKTF
MH&92K'[M7-:\/VVL(-_RR#HPKAC@JWL[I6DI71V2Q5+VEF_=<;,U%FC:,2!U
M*XZYJ&2]B-K-+#(K[%)X-<J/">J*OE+J;"'^[DUL:=H$6G:?- 9F8R@AF)KN
MA6Q$W9T[?,XY4J,5=3O\B#3)=6U*+[0+F)$W<+CM^5/O]4NO[1CTZS*^<1EW
M/05F7]B_AZUCGL[QV&\90MD')I-,D?\ X2?S9^&EC!&:X_;3C:C*ZDVKN]SI
M]G&5ZBLUK;0U]*U:=K^6PO<><G(8=#63XP^74K)CTW=:>JF7QJ6CY55^8BKO
MB^P:YTP31C+PMNIU.>KA9QWY7^0H<M/$0>UU^9!XPY\/)]13[2"(>#FQ&O,9
M)X]J8+=_$OAJ&-7\MQC.16M#I;QZ&; N"VS;NK2-.52K*JEHXZ$RFH4U3;U4
MCFO")/\ 9-^.P!Q4?AFS2_M=2MW&0Q./K6YHOA^33+.YA>4,9>A':I- T.32
M'G+RA_,.1CM6-'"5/W2FM$G?YFE7$P_>.+U=K'$M=WL$;Z& W,F ?:M?Q!8+
MIWA^S@48.X%OK77MI5FUZ+LPKYH[XJGX@T9]8MXXTD";&SS0\NG"E/7F>R]
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M7Q!_T#Q^=']J^(/^@>/SH^O4^S^YA]4GW7WHZFBN6_M7Q!_T#Q^=']J^(/\
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M]U]Z.IHKEO[5\0?] \?G1_:OB#_H'C\Z/KU/L_N8?5)]U]Z.IHKEO[5\0?\
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M5FZU-?:1?LYOHR_14-O=072[H)5D7U4YJ:K335T2TT[,****8@HHHH ****
M"BBB@ HHK/N];TVQNDM;F\ABG?[J,X!- &A15'4-8T_2HEDOKN*!'^Z9& !J
MA'XQ\/2N$35[1F/0"44[,5T;M%,BECFC$D3AU/0@Y%)//%;0M-,ZI&HRS,<
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MPL>C2HX)S5IW.9DE>:1I)&)9CDG-,Y]3^=%%?+ML]^QM^'-:DTN_7<Q,+'#
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M0 4444 %%%% !1110 4CC*,!Z4M% 'D_PZ\):SHGBO4[R^M_+@F<E&R.:O\
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M3]*A&FI_K@H !_"O5;.T@LK6.WMXEBB085%& *GHJG)LE12=T%%%%24%%%%
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MJ/MQ_P">35;P/2C ]* *GVX_\\FH^W'_ )Y-5O ]*,#TH J?;C_SR:C[<?\
MGDU6\#THP/2@"I]N/_/)J/MQ_P">35;P/2C ]* *GVX_\\FH^W'_ )Y-5O ]
M*,#TH J?;C_SR:C[<?\ GDU6\#THP/2@"I]N/_/)J/MQ_P">35;P/2C ]* *
MGVX_\\FH^W'_ )Y-5O ]*,#TH J?;C_SR:C[<?\ GDU6\#THP/2@"I]N/_/)
MJ/MQ_P">35;P/2C ]* *GVX_\\FH^W'_ )Y-5O ]*,#TH J?;C_SR:C[<?\
MGDU6\#THP/2@"I]N/_/)J/MQ_P">35;P/2C ]* *GVX_\\FH^W'_ )Y-5O ]
M*,#TH J?;C_SR:C[<?\ GDU6\#THP/2@"I]N/_/)J/MQ_P">35;P/2C ]* *
MGVX_\\FH^W'_ )Y-5O ]*,#TH J?;C_SR:C[<?\ GDU6\#THP/2@"I]N/_/)
MJ/MQ_P">35;P/2C ]* *GVX_\\FH^W'_ )Y-5O ]*,#TH J?;C_SR:C[<?\
MGDU6\#THP/2@"I]N/_/)J/MQ_P">35;P/2C ]* *GVX_\\FH^W'_ )Y-5O ]
M*,#TH J?;C_SR:C[<?\ GDU6\#THP/2@"I]N/_/)J/MQ_P">35;P/2C ]* *
MGVX_\\FH^W'_ )Y-5O ]*,#TH J?;C_SR:C[<?\ GDU6\#THP/2@"I]N/_/)
MJ/MQ_P">35;P/2C ]* *GVX_\\FH^W'_ )Y-5O ]*,#TH J?;C_SR:C[<?\
MGDU6\#THP/2@"I]N/_/)J/MQ_P">35;P/2C ]* *GVX_\\FH^W'_ )Y-5O ]
M*,#TH J?;C_SR:C[<?\ GDU6\#THP/2@"I]N/_/)J/MQ_P">35;P/2C ]* *
MGVX_\\FH^W'_ )Y-5O ]*,#TH J?;C_SR:C[<?\ GDU6\#THP/2@"I]N/_/)
MJ/MQ_P">35;P/2C ]* *GVX_\\FH^W'_ )Y-5O ]*,#TH J?;C_SR:C[<?\
MGDU6\#THP/2@"I]N/_/)J/MQ_P">35;P/2C ]* *GVX_\\FH^W'_ )Y-5O ]
M*,#TH J?;C_SR:C[<?\ GDU6\#THP/2@"I]N/_/)J/MQ_P">35;P/2C ]* *
MGVX_\\FH^W'_ )Y-5O ]*,#TH J?;C_SR:C[<?\ GDU6\#THP/2@"I]N/_/)
MJ/MQ_P">35;P/2C ]* *GVX_\\FH^W'_ )Y-5O ]*,#TH J?;C_SR:C[<?\
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M3XTZB8O!RM9W>R3S1S&W/:OGK^VM5Q_R$;G_ +[K6%/F5S*=51=C[0^TP_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MT-ZH%'1G(:/\)]-O_"J7EY+*^HRQF02[^AK.^&VLWK6NOZ)=3-,EL'6,L>@
MIMEXX\5Z+HW]A2:!<2W**8UG"G%:_@'P=J&DZ/JVIZ@A%W>JS",=1D4.]G<%
M:ZL+\%?O:S_UV/\ .O6Z\L^#UC=V9U?[5;R0[IB5WKC/->IU$_B-*?PA1114
M%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:?\ /M#_ -\"C[#:9S]FB_[X%-^WQ>_Y4?;XO?\ *@"R %& , 4M5?M\7O\
ME1]OB]_RH M455^WQ>_Y4?;XO?\ *@"U157[?%[_ )4?;XO?\J +5%5?M\7O
M^5'V^+W_ "H M455^WQ>_P"5'V^+W_*@"U157[?%[_E1]OB]_P J + 15.54
M#/H*=57[?%[_ )4?;XO?\J +(55^ZH'T%(R*WWE!^HJO]OB]_P J/M\7O^5
M$S0QM$T>T!6&" *\NU/X270U.:\T+6I+#SF+.H)KTO[?%[_E1]OB]_RIJ36Q
M+BGN<)X:^&(TW54U36+]]1O(_N.Y)Q7H9C1NJ*?J*K_;XO?\J/M\7O\ E0VW
MN-)+8L[%R#M&1TXH*JPPR@_456^WQ>_Y4?;XO?\ *D,L!$ P$4#TQ2A0HPH
M'L*K?;XO?\J/M\7O^5 %@HA;<54GUQ3JJ_;XO?\ *C[?%[_E0!8:-&.613]1
M2@!1@  >U5OM\7O^5'V^+W_*@"U36C1CED4_457^WQ>_Y4?;XO?\J +(  P
M /:D,:,<LBD^XJO]OB]_RH^WQ>_Y4 60 !@  >U($4'(4 GN!5?[?%[_ )4?
M;XO?\J +!1"<E5)]2*4J&&" 1Z$56^WQ>_Y4?;XO?\J + 1 ,!% /8"E5548
M50/H*K?;XO?\J/M\7O\ E0!9(!&" 1[T@C13E44'V%5_M\7O^5'V^+W_ "H
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MJ +5%5?M\7O^5'V^+W_*@"U157[?%[_E1]OB]_RH M455^WQ>_Y4?;XO?\J
M+5-**3DJ"?4BJ_V^+W_*C[?%[_E0!:I-B[MVT9]<56^WQ>_Y4?;XO?\ *@"R
M0",$9I!'&IR$4'V%5_M\7O\ E1]OB]_RH Y+QI\/8?%-Q%>0W+6MY%]R12>*
MYN'X2:K=3(NM>(I;RU4Y\K<>:]1^WQ>_Y4?;XO?\JI3:(<(MW$L--MM-L(K.
MWC588U"A<59$: 8"+CTQ5?[?%[_E1]OB]_RJ2RS@ 8 &/2D$: Y"*#Z@57^W
MQ>_Y4?;XO?\ *@"P$4-N"@'UQ2LJL,,H(]Q5;[?%[_E1]OB]_P J +(  P
M/:@JK## $>XJM]OB]_RH^WQ>_P"5 %A41?NHH^@IU5?M\7O^5'V^+W_*@"R5
M### $>XI%1%^ZJCZ"J_V^+W_ "H^WQ>_Y4 62JL,,H(]Q2*B+]U5'T%5_M\7
MO^5'V^+W_*@"R45B"R@XZ9%!56&" 1Z$56^WQ>_Y4?;XO?\ *@"R% &  !Z
M4@C0'(1<^N*K_;XO?\J/M\7O^5 %C8N[=M&?7%.JK]OB]_RH^WQ>_P"5 $YB
MC)R8U)]<4[ QC'%5OM\7O^5'V^+W_*@"RJ*OW5 ^@I:J_;XO?\J/M\7O^5 %
MJBJOV^+W_*C[?%[_ )4 6J*J_;XO?\J/M\7O^5 %JBJOV^+W_*C[?%[_ )4
M6J*J_;XO?\J/M\7O^5 %JBJOV^+W_*C[?%[_ )4 6J*J_;XO?\J/M\7O^5 %
MJBJOV^+W_*C[?%[_ )4 6J*J_;XO?\J/M\7O^5 %JBJOV^+W_*C[?%[_ )4
M6J*J_;XO?\J/M\7O^5 %JBJOV^+W_*C[?%[_ )4 6J*J_;XO?\J/M\7O^5 %
MJBJOV^+W_*C[?%[_ )4 6J*J_;XO?\J/M\7O^5 %JBJOV^+W_*C[?%[_ )4
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M /\ (C_NC\J/(C_NC\J(IXIAF*17'L:26YAA.)940^YH 7R(_P"Z/RH\B/\
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M+WBG5;KQ+J@\.Z1-LB4_Z5.#]T>E=KI&FP:)I,=K"S,D:_>8Y)K@=*^&L/\
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M*0$$ CH:6L#H"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4W^@_$6XN&GE>U%PRR*3P!FOIJUNXKNSCNHF#1NH8$>E> ^%] A\0WGBVT=
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M170?%G5&:TL]"MV/G7TJJ<=0,\U,E>=BHRM"X?"RWN[XZAK]W)(?M4I\M6/
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M=NY;W0;.>>)XY6C&Y7&"#6I2  # &*6H+04444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %&!Z444 )@>@HP/04
MM% %34;-+VRDB('(XKEO#VCO_:,CSH0L1P,BNTI BJ20H&>N*X,1@*=:M"M+
M>/XE*32L&!Z"C ]!2T5WDB8'H*6BB@ HHHH **** "BBB@ KQ?XC:3J%W\1M
M+N+>SFEA0C<ZH2!TKVBD*J3DJ"?I51ERNY,H\RL>3_&33+[4-'TI+.UEG9)0
M6"*3CI6[J/A!/$GP_M[&:+R[I(LH2,%6Q7=E5;JH/U%+TZ4<SL'(KW/&_!&L
M:_H&F:AHVI:?=2&W1O(D"$@\<5E>!OAW_P )-?:CJ7B6UF3?(3&K J:]WV)G
M.U?RI0H7H /H*?/V)]GM<\NUWX.: -&N6T^"072H3'\V>:SO G]KIX"UC1KZ
MSG22&-A'N0C=SVKV.D"*,X4#/7BCG=K,?(KW1Y1\%=*O++1+N&_M)(=[?=D4
MC(Y]:R?&/A34_"GBN+Q%X<AD>)WS+#&,_7@5[:%5>@ ^@H*AA@@'ZBCG=[AR
M*UCAI?"6B^/+:WU75+&6.Y* %6RI%<EXZ^%FD:;H#3Z193R76[ "DM7LP  P
M !]*" 1@@'ZTE-I@X)HX[X>>%[30-"BDAA>*>9090YYS6QXI_M7^PY_['"_:
M\?+FMK&.E%*^MRK:6/%X?'WC6QM&L+OP_-<7)&T3*AQ6G\.O!VH:<-2UK5$V
M75YN81@=,\UZGL0G)1?RIU4YZ:(E0UU9Y+\+=,OK/Q5X@ENK66*.60[&=2 W
M/:KOB#X36VL^+XM72;RX<[I8Q_$:],"J#D #Z"EI<[O=!R*UF>=_%72YYO!0
MM+"V>4H<!(US3X;*Z'PC^RFWD^T?9R/+V_-G'I7H! (P0#]:,#&,#'I1S:6#
MDUN>9?!G3[S3]#N4O+:2!C*2 ZD9KKO&MK]K\)7\8&6$1(_"M\*%Z #Z"F3P
MI<020N,JZE2/K0Y7=QJ-HV.(T&X>X^%[^2A:5+=D"KR21D4SX4:9/9>%2;RW
M:*:25F*R+@]372^'M CT"RDMHY"Z/(7 /;)Z5L  #  'TH<MTA*.S8U_EB;
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M4?8X/[@H 7[3%_?%'VF+^^*3['!_<%'V.#^X* )$E23[K T^HXX8XON+BI*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%)10 M%)10!C'_C\?Z44'_C[?Z44 ;.:,TE% "YHS244 +FC-)10 N:,TE%
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MQS4]% ')Z-X7FA\37FM:@XDE<XA']U?\XKK<TE%-NXDK"YHS244ABYHS244
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..H S=C?:F..U%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g23ode3tb50n000034.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g23ode3tb50n000034.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /O [T# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_#D@6)4.7"\_6NFT+4VU2P2=@,LH/%/E=KDJ2;L:E%%%(H**Q?$>L/HU@TZ
M$A2>:R_!/BN;Q-8M/*J@ARORT[.UQ<RO8ZZBBBD,**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP-Q[5[G42CRLTA+F04445)04444 %%%% !1110 4444 %%%% !1110 4444
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MG+<TCL%%%%(H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHI-Z_P!X?G0 M%&0>AHH ***3<H_B'YT +11D'H:3('4B@!:***
M"BDR,XR*6@ HHSCK2 @]#F@!:*** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$!F)R#Z5+GJ4H:*Y?C!5 #0Z+(NUAD&G45F:G#:]\/+&_E-Q"K"4G)QQ7/\
M_" ZHK;5#;?]XUZS15*;(<$SYY\0>#+_ $+4+:_=6,:-O?))XKUGP7X@L]6T
MA%@/S$=,5T.HZ=!J5J\,R*VX8R>U<WH_@O\ L;4//@N<1XXC'2J<N9:DJ#B]
M# \7> ;KQ!?++M8JI[&LZW^'>IVD(BA0A1TYKU]1A0*6ESO8ITT]3RBV\$:O
M%<JY#8'N:]+TR"2VL(XI?O*.:N44G)L<8I;'*>-/"L?B32Y8"F788IG@KPE'
MX9A953!88-==12YG:P^57N':O/O&7@"+Q%>V\_EY\LY.*]!HH3:V!I/<Q_#>
MCKHND16:KC96Q112&M HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "@G%!.!FO,OB-XYDT%S;6Y=9&7((IQ3;LB9245=G9ZOXFTW28F:XN%5@.
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M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MUT*U$%L"%'K2YO=L/E]ZYKT445!H%%%% !1110 4444 %%%% !1110 4444
M%%%% !6?'_R%'^E:%9\?_(4?Z4 :%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1132Z#JRC\
M: ([BYAM8R\T@10,Y-4+?Q#IEP^Q+R(MZ UG^+K"YU/37BLI4#E,<FO.=!\
M:[; 3221F3/8_P#UZM136I$I-.R1[4K*ZAE.0>AI:R-"AOH+;R[U@2HPN*UZ
MAEH**** "BBB@ HHHH **** "BBB@ HHHH **** "L^/_D*/]*T*SX_^0H_T
MH T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)1N]*M AAD=#0 M%0S74-N,R.%I(;R"?_5N&H GHI"<#)JL^HVL;[&E ;TH
MM44Q)%D7*'(-/H *SX_^0H_TK0K/C_Y"C_2@#0HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1F"C)Z5@:KKT$*M&,[NG%
M7-<N6@L)"O7%>=33M,Y9B>:: Z;2M?BA;:^>3FNMM[E+B,.AX->4*2#D5U_A
MB]9BR$YQ0(ZZBBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9KT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I&8(I)
M.,4M8.O:H+>,Q1GY\XH SM:U!KNX%O"3@\'%:^B:8+6W5V&7(Y-9NA:67<W$
MPY)R*ZD# P* %J"[_P!0_P!*GJ"Z_P!0WTH SM&^XW^]6Q61HWW&_P!ZM>@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %-==ZE?6G44 9<NCI(Q?S6'XUD2Z
M=C48XO-?!]ZZH]#6'-_R%X: +":*B,#YK<>]::)L7&:=10 C$*I)Z"N4U[46
MG<VT!SGTK2UO4Q;0[%/S-QQ67H6G/<2BYF&>>],#1T/2Q;Q>8X^9AGFMVD50
MJA1T%+2 **** "H+K_4-]*GJ"Z_U#?2@#/T;[C?[U:]9&C?<;_>K7H ****
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MK(KC##(J/[)!_P \Q0!SMC>7%NI!4<G-:UG?23N0P%7/LD'_ #S%.2"-#E4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MTI60'&1BMH.5M#"HHWU,D^$/%6/]:E>A?#C1=7TZY5KY@5 [5R7_  L36_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBHIYE@C9V.,#- #;FY2VB+N:X^ZN9]7O!'&3L!P<BGZA
M?RZG=&"#E?8UOZ3I:6D08C+$9.:8$FF:<EE;@!?GQR:I3@'5X:W3T-8<W_(7
MAI ;M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%(3@9]*KB^@:3RPWS4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML%%%%(84444 %%%% !1110 4444 %%%% !1110 5GQ_\A1_I6A6?'_R%'^E
M&A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'H:ZZ*)8D"J  *;! D$81!@8J6D 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC41J"!T%*?0J'4K?:)*K6LC/J;9]*U-B_P!T50B &J/@=J@T-&BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D8A1DTM5=08I9N1UH
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MW"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K/C_Y"C_2M"L^/_D*/]*
M-"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK:'[)OV#<#UK=JGIMM]EM@GK5RI&%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 A&1BO,/B'X-N]6NA=VDSJRK@!:]0HIQDT[DRBI*S/F:*Y\4^&K@[DNI8U
M/?&*ZW1_BA!,%BU*Q4'N9/\ ]=>NWVE6=]&5N$!!ZUYWXG^'7A_R7FC5 _\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM&JMG([Q@LI'UJU2&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% 'E7Q?DD^SV2$G87P:U_AQIU@NA
MB1 I;=WQ6IXW\/#7=,*K]^,$KCUKQ:VN/$OA69H([6XDB#$]>*UC[T;(PD^6
M=V>W^*]/L9M"NVE5 5C.,8KS?X5_)K0CC)\H"N<N=:\3^("ML+2XC1OE8@UZ
MC\//";:+8QRSD^;WSUIM<L;,$^>5T=]1116)N%%%% !1110 4444 %%%% !1
M110 4444 %%%% !6?'_R%'^E:%9\?_(4?Z4 :%%%% !1110 4444 %%%% !1
M16=?:M#9\;@3Z4 :-%<XOBA"^"H K6@U.WEBW^8HH NTQY5C&6(K%OO$$<.5
MBPY]JQ'GO]3?"JZ*>XI@;E]XAMX,JC'=6(]Y?ZF^(_NFM&Q\.\AYG+'K@UOP
MV<,"@+&H^@H YVR\-Y8/< Y/-=!;64-LN$6K-%( I, ]12T4 )@>@HP/04M%
M !@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH R-?UVWT.S::<]N,&O(-2^)UK>RL!',RYQP
MI/\ 2NC^+L<\EK:*A8(6^8@]JA\">$])NM(WN4=]W.5S6L4E&[,9.3ERHYBW
M^(\=H<PPS@_[I_PKT'P5XTE\03K&XDY'\0(K2_X0G2/^><?_ 'S6II.@V6F.
M&MU4$>@I2E%H<8S3U9LT445F:A1110 4444 %%%% !1110 4444 %%%% !11
M10 5GQ_\A1_I6A6?'_R%'^E &A1110 4444 %%!.*@DNX(OON!0!/165<:[:
MQ=) :S9_$I/$*AJ -^[F$,#-GL:\XU&[:XN&+'."<5LSWVH7J%1"0/:N?N;>
M6%_WBD$TT(@W&KUC)-+(+>,_>JC@UN^';)I+Z.7'RBF!MV/AR/B2= 2>:WX+
M6*W7;&N!4JC:H%+4C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+=9\?_(4?Z5+]M3WJA'=K_:3GGI4EFU153[:GO1]M3WH MT54^VI[T?;4]Z
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M:[*E)]AP36K&>4G]T5GQ1I_:C_*.E:=9\8/]IN<<8J2R[Y2?W11Y2?W13Z*
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M55RS5T73J2IN\6<?<^$X8T)#T^W\)0M$K^9717H)C.*DM.+=:Y_[/P_\IO\
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MF_\ 'N?K5VJ>G BW.1WJY0 4444 %%%% !1110 C?</TKQ/XA:-?7GBJ"6&
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MJS-$[JX4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% '+^+O#YU: 2Q+F:(?)]:Y2QU'Q%IED+%E7<!BO4R,C!J
M!K*V9MS0J6]:I2TL0XZW1PGA7PU=M>-?ZDF)0^Y*]"I%54&%&!2TF[E)6044
M44AA1110 4444 %%%% !1110 4444 %(>AQ2T4 <5XAU'7K&[1K95\GO7/:A
M=^(/$*I;JJE0P)^E>I2013?ZQ WUID=G;Q',<*J?:J4K$.+?4RO#.CC1[#R]
MN&?EOK6Y114MW*2L%%%% PHHHH **** "BBB@ HHHH **** (KAV2!V3[P'%
M>7^,I-8U5%MXU!5'W5ZH0",$9%0FRMF.3"I-5%V)E&ZL<+X/N=2@*6UPH"G@
MU!XE\.7]MJ1U+3$_>.V6SZ5Z$EI;QMN2)01W%2,BN,,H(HYM;BY-+'ENH7OB
M'6;(Z<%4AA@UV/A30?[(LE9UQ,R_/6XEG;HVY85#>HJ?I0Y75@4;.["BBBI+
M"BBB@ HHHH **** "BBB@ HHHH SM6NI[6U9X/O <5Y'J,&MWFK&[" @L#^M
M>UO&D@PZ@CWJ'[#:_P#/!/RJHRL1*-S"TB^U"YTOY@/-4 "N=N_$'B*RO9$D
M5=F<+7H<<$40PB!1[5')8VTK9DA1C[BA-#<7;<\VM-)U;Q!K<=Y?(/)Q@XKT
MRUA%O;1PCH@Q2QPQQ#$:!1[5)2;N$8V"BBBD4%%%% !1110 4444 %%%% !4
M%T[I;N4^]M.*GI" 1@C- 'B&N6_B'4-<69U!B0D=^E=!I^L:_:)% B($!QTK
MTDV5L3DPK^5)]AM0?]0GY5?.NQFH-.]SE=;T:;Q#H,FY<W)''Y5S]K?^(=+M
MC8E5 4;4KU!45!A0 *B:SMW;<T*D^M)2&X]3@?#7AV]N=775=13]YTXKT15"
MJ%'04B(J+A0 /:G4F[E1C8****0PHHHH **** "BBB@ HHHH *PO%-Q>0::W
MV(#>P(K=IDD22C#J&'O30GL>&:9:^(+?43>31@R!CC//&:[G1];UV:X$<ZJ$
MSC@5VOV&U_YX)^5*MG;H<K$H-4YW(4&NIRGB#4-=LI]]JJ^3BN<OKWQ!KR+:
MJJE&&V2O49((I1B1 P]Z9'96T1RD*J?84E)(;BWU,GPEI#:)H4=FXP5[5NT4
M5+=RDK*P4444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DR/6HKJ7R;
M:23^ZI->1:O\5)[+43;1PACDCK51BY;$RDH[GL61ZTM>*I\5[Y?F:T&VN@T/
MXJ6E],L5TT<1--PD2JD6>E45!:7<-Y"LL+AE89!%3U!H%%%% !1110 4444
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MN[:-Y K3[3M8U487O<B=2UK'O"?$739=5-DBL6'<'BM75O%=EI,"23'.Y<@
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M@'&&/6M;P9X(N]!61'B(#.3S]:MR5K$*+YD['F][_P E"?\ Z[#^=>_:G_R
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!Q7C3P3<^*91LO3#%MP4]:U_#'AQ/#VGQVP8,RC!8=ZWJ
M*?,[6)Y5>X4444B@HHHH K7UG'>VS0R*""".:Y/1O @TB:=XYAB5RV!7:T4T
MVA.*9YE<?"V2;Q&^J?;0 S!MOT/TKTJ&/RH(X^NQ0N?H*?10Y-[B44M@HHHI
M%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 A
MY!%<;K?@9=9UF"^>48B_A/>NSHIIM;":3W*]C:K96J0( %7TJQ112&%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g23ode3tb50n000026.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g23ode3tb50n000026.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +) PX# 2(  A$! Q$!_\0
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MGBB83^([>0'[T8/\J -S4O%9LY[%-Q_TAL5V"N-BL2!D9YKR3Q'_ ,?VB?\
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MM*TN6=94=UZ*K9-<1I_@W4=/ME@B$FU1C.XU?M/A]]JNEN+V><$?P%R0?UH
MSO!^CWMQ>ZCJD+>6]TN4)'0U:B\/^.5N"SZNACST]OSKT2RLHK&U2")0%08S
MBK!'% 'D/C:::76/#\$LH,D;XE.>O6O4[1[:"W5%FC Q_>%<)XC\&W&I:BER
M@<E&W#!--7P]JX(XE_[[- 'HZNCC*L&^AKBOB7>FTT:V(/+S!?U%;^@V<]I
M5FW9/J<UG^+/#QU^&&)MVV.0/Q[$?X4 6O"ME]ETM&Q_K%#5NGI45I"+>SAA
M'\"!:FH \JUE WQDTPD?\L__ (FMCXB@?Z .V^K][X9^T>-K76<-^Z7'MV_P
MJ[XFT/\ MC[/U_=MGB@"K8J%\,D <?\ UJY'PW_QY>)/]T_TKT*#3/+TO[-S
M6+I?A;['!JB8;_2AC^7^% '&^"?">D:S");VU$CG/)IGBGP1;:#?0ZA90!;>
M+YI%4=:[[PMX>_L6%4YX]:V]4L(]2L);:0##C&<4 8GAW5;;4_"C20#:#$WR
M$\CY:Y;X;Q)-_:4;C*FX;(_$UM:#X6ET:\N(T+FW:,JN2<<@BKGA3PW_ &*U
MR<-^]D+\^YH XKQ5:3^$K^XU" 'R[GY<(,\5+\.[Y+B7S\X&\YS]:](UO1X-
M8L7@F4'Y3CBN-T+P,VC64T46_+2%ADGU- '+:A:ZGXP\47$%C-Y9M),@MTJ[
MX@\&^+;W2C%=:BDL0_A_R:[KPUX;32+NXN2#OFZYKI70.A4@$$4 <%\-]6>>
M&?3IG^:T&SG\/\:[R;_42?[I_E7&:1X3;2=9N;N'?B>3<W/%=HZ[HF7U4B@#
MRKP]_P A>^_ZZFI?"Z+_ ,+0U!L<^7_\571:;X7^R7D\V&_>.6J32?#7V'Q7
M<:GAOWBX_G_C0!E^.@/M\1_V:ZOPY_R [?Z51\0:%_:EPLG/ QQ6OIEK]CL(
MX/[HH N53U.\%C8RW!4D(NX@5<J*Y@2ZMY(7^ZXP: .0TF]T7Q?9--=1J&W%
M=LAP?UK(\3>$-&T_3YK[35BBGC7</F&2:6^\!RV-Z;C37E/^R&(%1KX1U'4Y
MD6^,J1J>S'F@"+1[B[U7X=PR7!9Y=QR2/:M3X=WL!BNXVD565L8)Q75Z=H=M
MIVE"PC&8P,<BN(N_ DVG7DEQIKRL9&+$;B!0!T'C6_MXM*4>:A+'& U<_P"%
M]/U)_#EZEA+Y,\CY1C^-1CP3>:S,G]HM-&B,&&&/6O1+"QCL+5(8QPJ@=* .
M!T_0/&\5TC7.K(\889'M^=9OB(^7\5-.\Q@"(>2?7Y:];KS_ ,6^#Y=6U^/4
MH0^]%P,$^U ':07ELMLI,\8P/[PKS3Q-<KJWB\6,'S@C.Y>15G_A$]3E3RG:
M95/!(<UO^&_!%MHTRW1D>28?\]#G^= '$_$.T4ZMX8M95RN[:P_!J[^#P5H1
MB4FS'2JOBOPM_;6LZ9=@-_HK[N/Q_P :ZV)-B 4 >0^+]#L-+\7Z4+2$1Y/-
M6/BC@>'-+_Z^D_\ 0EKK?$?AK^UM:L[S#?N?2J_C+PH=>T:WM0&S%('&/J/\
M* .@T>Z@&DVN9H_]4O\ $/2DU5;F[MBFG7*+)CJ#FN%B\+ZK%&L:^;A1@?.:
MZ;PQI=Y8SNUSOP1QN)- &!9Z!XVCOM\^K(T.3\O^37H-JDL=HBS-ND ^8^M3
MT4 >5/\ \EJ7_KG_ %KU4=*Y!O#&?'0UK#<+CVKKZ .?\7)(^D$1YSGG%8OP
M^F@6&[ 958/SDUVMQ MQ"T;C(((KSZ3PC=Z1=2OIOF.)F+-ECQ0!OZEJ6GE[
MR%%#3B)LE3GL:\J\(:?KMQ-=FQOTM@9VPKG!ZGWKT;0?")AOY=0NFD\Z9=K(
M22!_G-5M4\&/;7ZWFG%]R\[02 30!SVL>'M>FGM3J6JPS*L@(&X>OUJSK43P
MZW;HYR1&/Y"M.W\(W>J7<<NHM+%Y;!@%8ULZKX9%YJ44XW81 O\ *@#C?$?_
M !^Z)_UT']:VO$>CQ:CJB_99(X;XH,2,0*T-3\*?;)[!\-_H[9H\0>%&NKP:
MC;22^>%P%#$"@#CYO^$C\/7<)O\ 4DGA)X53V_.O4- U!=2TJ.Y52H;L:XD>
M%]0U2YA^WHRI$>#D\UWVG6$>FV:V\7W5H MUROC7Q,N@Z;+C_6E<KCK755Y%
M\75;[7 YSY07YJ .(&H^+-?F:XMY[A(6Y7Y:N:3XJU_PYJD:ZG)/)%U.X<5Z
M;X!U32F\-6T:;"RKSE17)_%?4=,FMWAB*BX*_*% ]*!GK&C:BFJ:7#=ITD&<
M5?KDOAXDB^$[+?TV5UM @HHHH **** *>I_\@^7Z5Q7A$$>)KHX/W?\ &N^E
MB6:,QMT-4++1+:PNWN8L[W&#0!A:MK]M9>*;:TGM22RY\\]%Z52\::A97-O;
M)"R3,6P-ISBNEUCP]9ZTI%QD'&,KUK)L_ &EV<RRJ\K%3D;CF@#CKG3KC3M*
M:]D5F(/ Q777&LVK^#C$)D,SP8V9YS727FFP7MF;611Y9&.!7.+\.]*6Z6<2
M2Y!SC/% $/PWM9(O#JM*I5MQX-=K4-M;1VL(BC&%'M4U &;JW^J3_>J_#_J4
M^E4-6_U2_P"]5^'_ %*?2@!]%%% !1110 4444 %%%% !129%&1ZT +1110
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M:E&))3L)/^?>@#'^%UY>ZM!=W-U(^1*<*W;FO2ZX[P!8BSL)R!CS'W5V!Z4
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MH'.:D^'EO>QL2[.8O,/4\8S74R^"-"FG,SVN7)SG(_PK9LK"WT^'RK=-J>E
M%FBBB@ HHHH BN+>.YB,<BAE([BO-_$WPWTVX=KEG\M>IP*]-KS#XJ:Q>V>R
MUM79?-7M0!5L-#\)VEFD,MVFY>N5J_;V?@^"42"YB;'8J*X#2_AYXAUFR2\6
M^4"3UJY_PJ;Q'_T$$H&>YZ<;=K*,VN##CY<"K59/ANPFTS0K:TN'WR1KAF]:
MUJ!!1110 4444 %%%% !1110 4444 %%%% &;JW^J3_>J_#_ *E/I5#5O]4G
M^]5^'_4I]* 'T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5YI\4GLX(//E;$Z)\@QU
MKTNL#Q'X?M=83=<[-H&"6H \K\-?%6"QTN*VG>-=@]!6W_PN#3_^>R?D*JWG
MA?PS9OL::U+9Z9JS8>"_#NH8$,MLS'HH- STK1M135=*AO(R"L@R"*OU2TNQ
M33M/BM8P-B# Q5V@04444 %%%% !1129% "T44F0>] "T444 %%%% &;JW^J
M3_>J_#_J4^E4-6_U2?[U7X?]2GTH ?1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ)#XDNDC4*H7@#\: -'Q1XCO;35H]+T[!N95RH/^?>L:XUCQ7I4L#WJHL;L
MWTKO[BTL1.M[/'&)$Z2-U%<'XJU5M9OK>SLH_-"2 ,4["@#<\0>)I+/PI)J-
MHP\Q<=?7%<Y9ZCX\O8([B%(C%(,KSVJYXFT2Z/AIK&%'DW@'CZ5GQZ;JVC:3
M#<^?,RQ)N,= ST#0CJ1TY3J@ N,\XK4S7+>&M>?7M#6XV&.0G&WO6IMG_P!J
M@0_5O]4G^]5^'_4I]*P[L2X7?G&[O6Y#_J4^E #Z*** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 51O-(LK__ (^80_UJ]10!A+X/T-6W
M"R3-:MK96]FFR",(OH*?/<1VZ;Y#A:SXO$6G33>4DN6SC% &K1348.H9>AIU
M !1110 4444 %%%% !1110 4444 %%%% &;JW^J3_>J_#_J4^E4-6_U2?[U7
MX?\ 4I]* 'T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MFW?46BBBK((;J=;:VDF8@!%)KPGQE\5IC>/;VBD*,C<I]*]>\6>;_8L_E?\
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MNAKSWX?),_A]5@;;\YYKK?LNH?\ /<4 /U;_ %2?[U7X?]2GTK#NX+J,*9I
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB2L(BWS*.]?56FW7VRQCGQ]ZJA@X4'[HI8N==>\3&V@/_+&/_OD5$^GV[_\
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M&Q497+-%%%24%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$@L_+.<G ZUM3E9:F%2-W='D.@:-<:OJ4<,*'.0>1[U]:^'K+[#HUK$?O",
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1N5-<!?^%9Y[V64.<,V:]
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MY% 'HGP]BDC\*67F9'R=#76U2TJ.WATZ*.V_U('RU=H **** "BBB@ HHHH
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MD9%+5$A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !16-KOB.UT&#S;D$KG
M'!KG?^%IZ/\ W6_.@#NZ\E^+]U/;PMY4K)\G\)]JW_\ A:>C_P!UOSKSCXE>
M+['7(F%N",KCD^U 'KO@*1Y?!U@[L68IR372US'P_P#^1+T__<KIZ "BBB@
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MRELD';7<^6M34CA7-2J.)U*C:H'I2T44#"BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &+XIL$OM O$*Y8QD+7
MB_@#49- \3?V?,Q55'0\5] 2()(V1NAKY\^(-@^C>,Y-0C!6(D $<=Z))N#2
MW$FE--['T#!()84<'(89J2N6\&:PNHZ7'N;)50*ZFHIS4XW1I4@XRLPHHHJR
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH \Z^+.LSZ=X?46TA21GVY'X5Y78>"-6U?3Y
M=4^UE2OS8(ZUWWQE/_$KB_Z[#^8K8\+W=LGA8J2,E!0,\UTOQU>^'4DTZ9I)
M'52H^M4]/T;7O&U_NN9)5C9C@N.,5/9:59ZS\0+I)S^[0AAC\:]WTP:;IUJD
M4.T84<X% $WAW2SH^AVUBS;C$N,UJTV-UD0,IX-.H$%%%% !1110 4444 %%
M%% !1110 4444 9NK?ZI/]ZK\/\ J4^E4-6_U2?[U7X?]2GTH ?1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MLML2T"$]U%2U#:_\>T?^Z/Y5-7T$=CP9;A1113$%%%% !1110 4444 %%%%
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MK.T;5!J]@MT(7BS_  L,&M&@#-U;_5)_O5?A_P!2GTJAJW^J3_>J_#_J4^E
M#Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\?^*^K
M?V="QCP6+8(KV"O"?C/97&UI\$H7XP/>DZ4:CM(/:RIIN)XY-=O)<>;DALYX
MKJO"WB62WOX4E;*[AR37&U8LMRW<3 $@,":VK4(5(<K1A1KSISYDS[&T2^2^
MT^.12#\H_E6G7EO@/Q$C+#!O 7 SS7J",'0,.AKCP]3GC9[H[J]/DE=;,=11
M16Y@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 45PWQ$N-2LM*\^P>3<&Y">E>9:?\ %F]LY?+GBEE9
M3@B@#Z&HKR6Q^-%O(0DUBT9[EJZG3OB%I=[C=+''GU:@#L:*BM[B.Y@6:)@R
M-T(J6@ HHHH **** "BBB@#G-0\,PW_B&#4I&<F(8V_PGI6#X[ELHC9PQA4D
MW@#:H'-:WBWQ5#HT30 @S$9 !YK!\/Z?!J%S_:.I7L<H<[DC<_=- %;Q3)+!
MX)EMIR0S8(Y[8I=(UY;+2[07$$(B"\L4&<5UFM7FEQQ[+J!)80/O'I5;5H]%
M?PU,T:P@F([ #0!LZ;JUE>::MS9LIA/&0 *F_M&/^]7(?#6)VT!1(#LW'@UW
M'V6'_GF* ,J^NUG55!S\U;$/^I3Z5F:G#''&I50#NK3A_P!2GTH ?1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6+XB\.6GB&P-M<C
M &2"!S6U10@:N>#7_P &6^UDV\<C1DGGFMW3_@[80:?(\AD\\H<#WKURCK5^
MTD1[.)\QLM]X+UO[-< I%DMDGMFO=?"&OPZOI\81]Q5>:B\8>#K7Q%8R (JW
M!&!)W%>/Z;>:GX&UPP3B5H"^T-CC%8RI>_[2&_4UC5:C[.>W0^C**QM$\166
ML6J/%,F\C[H/-;-62%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!7O+5+NV>)U!!4CD5\]Z_X471O&,
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/J%JO:D>Q.?\">&?^$;T46[* S$-Q75T@&*6LF[FR5E8****0PHHHH ****
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M#8V[33.%4#N:\RU?XQV=I<-!%;.Y!QE>:M?&#4)8- 2.)B"TNW@X[BL+P/\
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MD(^QO\P/^S0!Z%16?H^JPZO8K<P'*GBM"@#-U;_5)_O5?A_U*?2J&K?ZI?\
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M04G[*>*UJ9+_ *IOI0!CQZS<.VT6IJ;^TKK_ )]6J2S!$_3M6C0!E?VE=?\
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M#E0<A#TKK** (K>WCMHA'$H51V J6BB@!&4-PP!I:Y+Q-KT]NWV2T5Q-NQN
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M444 %%%% !1110 4A&1@]Z6B@"FNFP)=BY ^<>U7*** "BBB@ HHHH ****
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MBKE%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44A8#J:6@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BD+ '!-+0 4444
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MUR]UO37EO)=[ <&O'_&>JZZVEK8:E:&-%<'<3S7H7PWO5T_PQ=73D!8U!.:
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ME@M_X9,;#.%)_2O-/AEJC6.MWMB6X:<@9^M CW*BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@"MJ'_ "#YO]VOGF8@?$9B3CC^M?0]ZI>RF51R5XKY[\2^'-?C\4O>6=J&
M'8DG_"@#W_3IH_[.@_>+]P=Z?=RH;&XVN"?*;H?:O"XM8\=Q1+&MBF%&!\Q_
MPKJ/!>H>*+[4Y8=5M5C@:,C(/U]J ///#06?XB#[5VN&QN^M>_:];V3Z%<+)
MLV+$Q7)[XKR?Q;X%U33M935-'@+E26;)(YJC<ZSXWU:U73WLD"C@D,<\_A0,
MH_#9YD\7;(L^5YS]/]ZJMUM;XES_ &CH+@8S7I_PY\#R:/ ;F^C*7!?< ??F
MN:\>^"KJ35O[0TF-I)_,W,.E 'I/B+[(WAG:[(4V#O[5Y!\.P@\57P3&WSN,
M?05+,/&-]IIM;VT"6N,%@QS_ "JK\,87B\0W<;?>63!S^% 'T2OW1]*X7XF?
M\@"X_P"N==T/NCZ5PWQ,_P"0!<?]<Z!'/?!XXTR(^B?TKH_$7BW28;Q=.U"V
M+"3CGI7.?!T9TV(>J_TJS\2O ]SK,BWEBKM-&O !(H FN/A]H6M6GVFRAB3>
M..17E/B/2;CP/K\?V>X4D#<-A^E;=AJWC;0[862V:D*,?,Q_PIEKX3\1>+-<
MBNM4M=L/1B"3_2@9[?X2NY+WPU9SRDEW3))KSSXQ_P#(/EKT_1K!=,TJ"T7I
M&N.:X#XIZ+?:I8R+:1;R:!%OX5_\@G_@ KKO$.III>ER3N<#!'Z5SGPYTVZT
M[3-ERFUMF*J_$^'4K_1C:6,>YMW8T >&_P!ISOXKDOQ#),L<Q8;%)Q6]XL\5
M3^(-,6V%A<#:V[)0UZ#\-O!!L[2=]1@ =SD;AG^==Q<^&-/>VE40QY*$#Y!Z
M4#/*/@[X@\@-82M\TC\ _6O;[C_CVD_W37@5IX1U;0_&<=S;P'R?,+'DXZU[
MK;O+/IFZ08D93D4"/G_Q+_R42W^A_F*]\T+_ ) UM_NUXWX@\,:I<>.(+J.#
M,(!R?RKV;1XFATJ"-QAE7D4#([_6[33Y/+GD16]VQ7,>)O"^C:GH]Q?^3&9=
MF]7ST-9GQ)\(7NKJ]Y8&1IP.%#$"N(_M7QLFGG2/L2%2OEY+'/\ *@19^&6L
M7=MXI_LPRE[=5X4=*]Z4[E!]:\E^&G@:[TN[74[^)DG(P0>E>MC@8H \^^+G
M_(L)_OG^E<_\$9$72[S<P'[T]3[FNK^)FFW6I^'UAM4WN&Z?E7D.AVOB_P .
MK+%9V2E7;/)/^% 'O/B/4K>UT:ZW2IEHF ^;VKP;X:6DLOC=;M02@E;G'^U5
MV\LO&WB(I#/:;8\\[6/3\J]-\ ^"T\/6.Z9")BV[D4#/$M=:=O']U@D%9_EK
MMM736=1TC[//.PB('WAQTJ7QUX&U"/5EU72X/,D\S>P/2LRZU?QEJME_9QTZ
M%>V5Z_RH TO!ND76E>'M<+3!]\?&W\*P/A=Y;>.6-U@';U;CUKU'PAH%S:Z)
M<1Z@A0SQX;]*\YUSPEJ^D^(I+W1("Z=B210!Z'\219MX=G+,A<1_+S7(?"'_
M (]I?^N#?^@FL/7H/%&H:-+-JMOY21)QM8\C\JWOA C-;. .L+ ?D:!'+O"M
MQ\1[>)QE3(<C\:]_BBM[#1V8H-B(217CL7AC5!\0;>[,'[E7)+?C7LM[:M<:
M/- ,[FC( _"@#Q^Z\7PW^O>1I,#Q3 D!@,\YKFO'D.M!K.74KHRHS?(I[59M
MM%\0^%/$1N(;)'&]F&_GOGTJQXDT[Q9XG$,MU8(B(=R[/_U4#-N)G'PE<IG=
MN[?2HO@I' ]WJ;3X\P-QD_2NK\)^'Y;CP.=/ODVN3T%>=C2/$_@_6KB73[0&
M.23*[B>1^5 '6?&9+;^QPPV^=Y@SSSVK*T1I%^'>I;,_ZNLKQ%IOBWQ-:+=7
M5F!N89"DX_E7=^#_  Y<GPK=V%W'M,JXQ0!Y3X"DOH[YGM)"LI7G K<\3:3J
MFL7*27%R!(!@;N*!H7B+P7KLUQIUDLD)&U2_X^U6XD\5^)]9@ENK%(XEX;9_
M^J@#;U^WDM/A[902-N95.34'P;L(9;*2X9 7$QY_$UTGBS1;N7PK!:0Q[I$!
MR*K?"C1KW2M*ECNXMC&4D?F:!'<ZVBIH5[@8_=&O#?AO_P E#7\?YU[GKO\
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ME^^@-2T4 ,2-(QA%P*?110! UI [;FC!/K4H4*NT#BG44 0M:P,^\Q@MZU*
M%&!TI:* $*AA@CBJO]F69DW^0N[.<U;HH 15"+A1@4M%% #)(DE7:ZY%0?V=
M:_\ /%:M44 0QVL,1RD8%3444 ,>-)%VNN15=-,LXWWK H;UJW10!7NX6ELI
M8HSM9EP#Z5X;XDM?$NDZT[QR7%Q".BJ.*]Z/2LJ^^^: /"[[4M>UV!;'[#<Q
M*PVL2O!KU#X=^%WT32(6E_UF,'(YZ5M1??%;4'^J% "?9(-^_P L;O6IL444
M 5IK"VN&W2Q*Q]Z=]D@V!/+&T=!4]% #(X8X5VQJ%%1365O<$&6,-CIFK%%
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,0 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g23ode3tb50n000018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g23ode3tb50n000018.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -R!,D# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MKHG/PI/_ %TI<MEJ/GN]#N/!7B5_$!NM[%O*..:Z^O+/A!][4O\ >_PKU(D
M$GH.:F2LRX.Z%JO=W<5G TLKJH4$\G%4)/$VDQ2F-[M0P.,5C^+=(_X2C28_
MLMU(D8.[<AQFDEW&WIH8,/Q(2_\ &%OIML["-B01^5>EH=R U\\V&C+HOQ.T
MZ!9"^1DD_A7T+%_JEJII*UB(-O<?1114&@4444 %%%% !1110 4444 %%%%
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M3REX1W XKTFLS2=$M])A"1?,1_$PYK3J6[L<59!1112*"BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M//2LBV8_VW*.V/\ &@#8HHHH **** "BBB@ HHHH 0D 9--CE24$H<XIL_\
MJF^AJCI!S'+_ +QH TZ*** "BBB@ HHHH **** &/(J?>.*<K!ER.AK/U,D1
MG'I5JSYM4SZ4 3T444 %%%% !5#625TN8@X.*OUGZW_R"IOI45?@9=/XT>5W
M%S.)F_>O^=0_:I_^>K_G1<_Z]JBKY5R=SZ=)6)?M4_\ SU?\Z/M4_P#SU?\
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M?4Z\-K)M;:$5.C_UJ?[PIM.C_P!:G^\*X5N=C/6-"_X\5_W16K65H7_'BO\
MNBM6OJJ/\-'R];XV%%%%:F92U3_CR:GV/^H7Z4S5/^/)J?8_ZA?I0!:HHHH
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M@ HHHH **** (KC_ %3?0U1T?_5R_P"\:O3_ .J;Z&J.C_ZN7_>- &G1110
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M]NNXY^M-KI?^$1G_ +S?E1_PB,_]YORH^JUNP?6:7<YJBNE_X1&?^\WY4?\
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M,#TI:* $P/2C ]*6B@ HHHH **** *6J?\>34^Q_U"_2F:I_QY-3['_4+]*
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M@I:* "BBB@ HHHH 0]*QK7_D.R_3_&MD]*QK7_D.R_3_ !H VJ*** "BBB@
MHHHH **** (I_P#5-]#5'1_]7+_O&KT_^J;Z&J.C_P"KE_WC0!IT444 %%%%
M !1110 4444 9NJ?ZL_2K5E_QZ)]*JZI_JS]*M67_'HGTH L4444 %%%% !1
M110 F!Z"C ]!2T4 )@>@HP/04M% "8'H*,#T%+10 F!Z"C ]!2T4 )@>@HP/
M04M% "8'H*,#T%+10 F!Z4M%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5AVG_(:GK<K#M/\ D-3T ;G:BCM10 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% %+5/^/)J?8_ZA?I3-4_X\FI]C_J%^E %JBBB@ HHHH *
M*** "BBB@#*UC[JU/I/_ !XK4&L?=6I])_X\5H O4444 %%%% !1110 4444
M 9-[_P ?'XUJ1_ZM?I67>_\ 'Q^-:D?^K7Z4 .HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ K*;_D.#Z5JUE-_R'!]* -6BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** $/2L:U_Y#LOT_QK9/2L:U_P"0[+]/\: -JBBB
M@ HHHH **** "BBB@"*?_5-]#5'1_P#5R_[QJ]/_ *IOH:HZ/_JY?]XT :=%
M%% !1110 4444 %%%% &;JG^K/TJU9?\>B?2JNJ?ZL_2K5E_QZ)]* +%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5AVG_(:GK<K#M/^0U/0!N=J*.U% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 4M4_P"/)J?8_P"H7Z4S5/\
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M?4BG6]A;6W^JA13Z@59HH *RF_Y#@^E:M91_Y#B_2@#5HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@!#TK&M?\ D.R_3_&MD]*QK7_D.R_3
M_&@#:HHHH **** "BBB@ HHI">,T 1S_ .J;Z&J.C_ZN7_>-3W+L48*>U5]%
M.8I/]Z@#4HHHH **** "BBB@ HHHH S=4_U9^E6K+_CT3Z55U3_5GZ5:LO\
MCT3Z4 6**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 13_ZIOH:HZ/\ ZN7_ 'C5Z?\ U3?0U1T?_5R_[QH TZ*** "BBB@
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MX\5H O4444 %%%% !1110 4444 9-[_Q\?C6I'_JU^E9=[_Q\?C6I'_JU^E
M#J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%8]H0=:GP0:LV$,DVD1QLQ4E!S^%9>D636NM7&96?CO4&AU':BCM10 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% %+5/^/)J?8_ZA?I3-4_X\FI
M]C_J%^E %JBBB@ HHHH **** "BBB@#*UC[JU/I/_'BM0:Q]U:GTG_CQ6@"]
M1110 4444 %%%% !1110!DWO_'Q^-:D?^K7Z5EWO_'Q^-:D?^K7Z4 .HHHH
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MYB#70>%+NXN;23SSPAPOTKC6UZU\3:ALEO!! "&# \'VKT"RN].M[55BF3:
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MB@ HHHH **** "BBB@ HHHH **** *6J?\>34^Q_U"_2F:I_QY-3['_4+]*
M+5%%% !1149E4'K0!)12 AAD4M !1110!E:Q]U:GTG_CQ6H-8^ZM3Z3_ ,>*
MT 7J*** "BBB@ HHHH **** ,F]_X^/QK4C_ -6OTK+O?^/C\:U(_P#5K]*
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M "BBB@#-U3_5GZ5:LO\ CT3Z55U3_5GZ5:LO^/1/I0!8HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J,SQ*<&11]32
MR$B)R.H4UXKXFUOQ(=:%KIT <LQ &X_X548W)E*Q[1]H@_YZI^=.62-_NNI^
MAKY^U+4_'.E(CW=FJ!VVCYCU_*M+1O%OBK3]0A&I6R);,,EL]ORJO9D^T1[E
M1573KL7UC%< Y#C-6JS- HHHH **** "L.T_Y#4];E8=I_R&IZ -SM11VHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"EJG_'DU/L?]0OTIFJ
M?\>34^Q_U"_2@"U1110 AZ&J?W=P922>E7:0J#VH CA!V^U2T44 %)D>M0SR
M%-H'>HF=HCB@"KK!&U>:L:3_ ,>*U1U) Z!LG-7=)R;!: +;2A3CK3U8,,BJ
MB_+NW]2>*GA!Q[4 2T444 %%%% !1110!DWO_'Q^-:D?^K7Z5EWO_'Q^-:D?
M^K7Z4 .HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *8TL:?>=1]33Z\O^(^M:MIS0)8H&:1]HR::5W84G97/2
M_M,'_/5/SI1/$QPLBGZ&O!9[OQ];6GVF2Q41>NX_X4S3_$_C&)C.UJGDQ\R$
ML>!^57R$>T1] T5@>$-<;Q!H<=ZV,DX.*WZS:L:)W"BBB@ HHHH *RF_Y#@^
ME:M93?\ (<'TH U:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH 0]*QK7_D.R_3_ !K9/2L:U_Y#LOT_QH VJ*** "BBB@ HHHH ***0G R:
M (KG_4-]#6%I3*()]XYWG%:]Q/\ (P[8K%L@I=]QPN[F@#7@1I,$M\O85> P
M,5FV4B^>RH<KVK3H **** "BBB@ HHHH S=4_P!6?I5JR_X]$^E5=4_U9^E6
MK+_CT3Z4 6**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH 9,"8) .I4X_*O$[_4[GPYXD$MS:23J7+!L=!7MYX&37F_C
M_7-$MB(+H_OF'RX JX;D3VN<QXI\=?\ "016]M!ILFX2#D#IS5;4!>B[M]/>
M"1VFC#!\?=X'^-1^'?$.@6NH*9BWS$!<KWKV6WLK#4)8;]%!94&TX[8JF^4A
M+FZC_#T#6^AVT3@AE7G-:E(  , 4M9&P4444 %%%% !6':?\AJ>MRL.T_P"0
MU/0!N=J*.U% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4M4_X
M\FI]C_J%^E,U3_CR:GV/^H7Z4 6J*** "BBB@ HHHH 9)&''TJHY,;<C?5[M
M59U99,CI0!D:IEE4AL>U6M(FQ:*#5;5D*Q[SZ9%5=.EGDM5V8ZT =/M5N2*4
M  8%5[69F7#]15F@ HHHH **** "BBB@#)O?^/C\:U(_]6OTK+O?^/C\:U(_
M]6OTH =1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5Y)\2!=V5[:70A>>-90VT#I7K=<MXSU;2]-L/^)@0 X(
M7@547J3-71PVH?$N*ZT?[,-,<M@#&/:L6PFO8=/OO-MI2MXG[M2/N]/\*I0Z
M[H,=]YS%O*S_ ':]AT5])U^PMVMP&$2Y' K1^[T,U[W4I_#"SEL?",44RE6W
M9P17:5'#$D,81  !Z5)63=W<U2LK!1112&%%%% !64W_ "'!]*U:RF_Y#@^E
M &K1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "'I6-:_P#(
M=E^G^-;)Z5C6O_(=E^G^- &U1110 4444 %%%% !39!E"*=37;:A- %"<XB*
M%#P.M9MI'O@E4?>+<&M*XG81%FQM(K/TYF>.1H_[U %FVC,94#[W>M<=!56V
MC&=S?>/6K= !1110 4444 %%%% &;JG^K/TJU9?\>B?2JNJ?ZL_2K5E_QZ)]
M* +%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 1SY^SR8Z[#C\J\45;6?Q<O]KLNT2' E[BO;B,@@]ZX#Q=\/X]8N%N
MK5 )U'!/K5Q=B)IO8R_&]MX:73X39?94E#\%,YKHOAR\[Z+)YY8X?"Y].:X-
MO %U:R1RZOM:%6!&#7J_A\6:Z>JV8PB@ TY;6%&][FO11169H%%%% !12%E7
M[S ?4TT2QL<!U/T- #ZP[3_D-3UN5AVG_(:GH W.U% Z44 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!2U3_CR:GV/^H7Z4S5/^/)J?8_ZA?I0
M!:HHHH **** "BBB@ I, ]12TA.!S0!DZVN8@OJ*I:=:2+;*5)Q5K5YU;:!5
MO2<?85H FMH2@R35FBB@ HHHH **** "BBB@#)O?^/C\:U(_]6OTK+O?^/C\
M:U(_]6OTH =1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5XY\169]7LENFVP></O=,9KV.N8\6^$K;Q';*LB;
MI$Y7ZU479DS5T8][9^$3H8"_8PVT9;GKBL?X3/(=6UA-Q-NKXC],<=*R)?AK
MJL8*S%?LV>F:[WP/::9912P62XF08E^M4[)$*[D=C11169J%%%% !133(B_>
M=1]30KHWW64_0T .K*;_ )#@^E:M93?\AP?2@#5HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@!#TK&M?^0[+]/\:V3TK&M?^0[+]/\ &@#:
MHHHH **** "BBB@ IDN#&033ZKW!((_N]Z *DZ[X&3/0$UFZ/(T<4H"[AN/-
M7IYDVLL8.<54TD/''(O]YLT ;=ORN[U[5/4<*X05)0 UG5>II0P;H:IO_K#Y
MG3M4L/WOE^[0!8HHHH **** ,W5/]6?I5JR_X]$^E5=4_P!6?I5JR_X]$^E
M%BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,D3<A%/I&X4XH S976!6!4$XJGI]SOBDP@!W<58GP[R[^RFL/3;AE\T@]'-
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M*KI?3D _=W'%=?13NQ<J&QIY<:IG.T8S6+:?\AJ>MRL.T_Y#4](9N=J*.U%
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ME &<G=4]E.ZPLI4 9J>YA&PD#IS6;;WHEB<!-N#C-,1TUN<Q*:EK*MKD^4H
M/'>KOV@>09,=* +&:*RQ<.7SSC-:,3[TS0 ^BBB@ HHHH S=4_U9^E6K+_CT
M3Z55U3_5GZ5:LO\ CT3Z4 6**** "BBB@ HHHH **** "BBB@ HHHH ****
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MEI;D;F!Z@\?X5<MC.%[G<T445D;!1110 4444 %93?\ (<'TK5K*;_D.#Z4
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M;C\::G$W!R* +=%%% !1110!FZI_JS]*M67_ !Z)]*JZI_JS]*M67_'HGTH
ML4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 U\^6VW[V#BO*?$=WXV2^(T^=1%D]0?\:]6<[48^@S7G.N>.I-.NS$+!
M'YZD542)V.+N_$'C[3FB:>X7:S <*?\ &O6_"-Y?7NE>9?2!Y..17E^M>-[G
M5(HX(]+3);&0*]#\ 6]U!HS_ &I65F;< :J6Q,-SKJ***S-0HHHH **** "L
M.T_Y#4];E8=K_P AF>@#<[44=J* "BBB@ HHHH **** "BBB@ HHHH ****
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M_>Q31.B-M;DU3ANFG' P>XJRF/NXRQH MQH&&3T-/2)$.0*<@P@IU !1110
M4444 9NJ?ZL_2K5E_P >B?2JNJ?ZL_2K5E_QZ)]* +%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <IXC\<67AYVCN+
M>:3'!V*3_2N%NO'GA*\D\R;2;IF]=I_^)KTK5O#EIJI9Y\>IXKA-:@\*:-*(
MI[E$<]BHK2-C.7,9T'C+P<DR&/1[D-D8.T__ !->I:#JEOJMB)K:-HT&  PK
MRE-4\(;UVW<9;/'RBO3O"TMM-IQ:U(*9["B00;N;M%%%9FAR?B+Q?%I4L<(B
MD+.<94' K8T&]>_TU9W.2:RO$EA"D1D*AF(SR.E6_"7_ "!$^M5I8E7N6]=O
MC8Z9-(K;7"Y!KC])OM;U&*.=;^/8Q'RD\_SKH_$MFE]$+=W*[QCBN.O]$/A7
M3[>[M9I)&>0*58G&,C_&FK6%*]STZ'=Y*;SEMHR:QK3_ )#4]7+.XDGTR-P,
MN4'%9&E-,=;N/,7%06=/VHH[44 %%%% !1110 4444 %%%0SW,5NA:1L 4FT
ME=C2;=D345FQ:U9S2;%E!.:T001D4HSC+X6.4)1^)"T4451(4444 %%%% %+
M5/\ CR:GV/\ J%^E,U3_ (\FI]C_ *A?I0!:HHHH **** (VE XJ#< V2,U)
MC:[$]Z=$G'(H 9''DLS=#5#44BCC) J_<,5V@=ZSM1A_=D DT <S=7"K(/E.
M,\\5LZ;+;M;*RKM/O69<!5^\!Q4D)62V&TX/M0!U4&  20?2K0.:P=.NLQLL
MAP1P*VH#F,4 2T444 %%%% !1110!DWO_'Q^-:D?^K7Z5EWO_'Q^-:D?^K7Z
M4 .HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH QM>\0P:!9O<3Q.ZJ,D**\[U#XD>&-3Q]JTNZ?'^P?\*].U/2
MH=4@:*;[K>U<-KFB^&]!B5[V98]W3*U<;$2N<X/&/@P'(T:Y_P"^3_\ $UZ!
MX-\1Z;K<<B:?;2PK$.0X(_I7GW]J>#O^?N/_ +Y%=MX#N],N3<?V=(K@=<#'
MI3DM"8MW.VILCB.,N>@IU-D02(4/0UF:G$ZKXU6/4?L4,<JN&&6(.#S79VSF
M2VC<]64&N'\6V<5NL)55W>:/FQSU%=K8_P#'C!_N#^54[6)5[G.>+]:FT^&%
M;:4([/M)S3-#;5Y+N)[B\CDA(R5!_P#KU!K^@Q:W>>6\KKM;/!K-MTE\.^*K
M73HG:2%UW%F.<=/\::M8EWO<]'K*;_D.#Z5H&1C 749;'%<[;75Y+XA59H@J
MXZU!H=/1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "'I6-:
M_P#(=E^G^-;)Z5C6O_(=E^G^- &U1110 4444 %%%%  3CK5.ZFB13NYJ:Y)
MV<5CZE@*"K$G% $?VJ2:1DC?:H'>J3EXMSLP(!YQ51Y9#P@Y[XJ+>_E,#DF@
M#8L+E)'Q&-I/7-;L$*C#G!:N/LIMK@#K746;/)#F@#2HJ*)R<@]JEH ****
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MZI_JS]*M67_'HGTH L4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU&,U!\W8W_[=E_Y\W_*C^W9?^?-_RK76)=O*C\J7RD_NC\J]0\PQ_P"W9?\
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MMO\ GLGYT?;;;_GLGYUG_P#"/6?^U^='_"/6?^U^= &A]MMO^>R?G1]MMO\
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M1110 4444 %93?\ (<'TK5K*;_D.#Z4 :M%%% !1110 4444 %%%% !1110
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M]Q5WC:Q'+*]SK])U.#5K);JW<,A[BK]9^CZ3;Z-8K:6R;(UZ"M"LF:H****
M"BBB@ K*;_D.#Z5JUE-_R'!]* -6BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "D;[II:* *+ 'DM@^E<]K:F,<'J*Z
MB6)!\Q%<SKGH>>.* .9R2:F7I46!NI^[TH T],N6AD("YSQ726\!GA^O>N1M
M'8R *<5U^G7(BB"-DT 31P,F01FKL*E8\&F+,KY.,4AN0#T.* +%%-5@PS3J
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&SDFI:*1C@4 +153S&_UF?E':E\UI1\IQB@"U14,4F?E/6IJ "BBB@ HHHH
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M 9]UYH&$'W:Y_4[A9%*2'#5LW\YVY!Q7*WTH<D]_6@"DQPV.U,.":#]:!P:
M+=KS,@7O7;Z86"!#V%<AI<0DG4D@8-=O:HJ)P03B@"9ID7@FER)%XJ _(<%=
MU20@]>@]* &>4_W,?*:#"R#Y!G/6K-% $44>WD]:EHHH **** "BBFNVQ2:
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M7['I6KIAD<AL':* .M#%-I'\57!TK(AWQ[2Q+ ]/:M5&W+F@!U%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5AVG_(:GK<K#M/\ D-3T ;G:
MBCM10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%1RMA: )*J7V5A9NU.#%0&SG-3.JO'ANAH Y74IF,2!._6N?N/E.VNFO[<;
MFVG/H*YFZ5EE(8$4 0"DHHH O6,H60?6NNLY6"*0>M<EIZ*QR3C%=%:S!<#J
M!0!T0 8 T[I52.[4Q\X!]*GCE#T 24444 %%%% !1110 4R1=Z$4^B@"H(Y=
MP!QM'2K8Z444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !64W_(<'TK5K*;_D.#Z4 :
MM%%% !1110 4444 %%%% !1110 4444 %%%% &'XENIK:RS%W'-<%H6JW?\
M:RC)ZUZE=6J7411P#D8YK)LO#-O9W/G#:3GTH V+=B]NC-U(YJ6D4!5 '04M
M !1110 4444 %%%% !4<K;5QW-251N&+9(.-M $%RY$6&Z5RNJ*I?(KHI+O>
MA5TPOK7+W[%I3@\9H H8-3*'QQ3!@5,I^6@!JKOD ;UKJ+&(161"5SL9 .>]
M;%E=?)M)XH V8]^T;OPJ[;MM&QNM48Y-R CG%2PES+YK @>E &E12*<C-+0
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M4-7C0:C@**W8DA6T0,J@%?2@#)B\0J7#/NV$X KH(W$D:N.A&:Y'64$<HD5
ML6X8(K7&J^3%"H (*BF!8U;4TTV%78GDXXI=*U)-1@,B'H<<USMU*=9NG@'\
M/-2:4QTR^2T8XW\\T@-"ZUP"X>&(D,AYI]CK(FF$#ABY[XK+NK)3?2RVS>8Y
M.2M/TR]==42WGMU1SWQ0!;N=<:"1P=V%/I4UKK:26GGMG;4.N21K)!$L:GS3
M@G%0ZK:"RT)40<[J )H_$"_:51MV&/%:ESJ45O;^:>0>F*YR=$%O P W;:T(
M['[1I>]W/0G% %W2-2&HQR.,X5L<UIUS?A(;8;E?1S_.NDH ***.@H *I7,+
ME6\OC/6K8<$XS3J .9NT>.#8_:N?O=NX!!]:ZS69E6(K@9KDK@@M0!2(P:D0
MFG",$TJIVH 7(JS;2B.0!@<5 5VBK=DJR#RVZGO0!TVGKB(N3P1Q5J(L[[2?
MEK/B4QQJ,G K0MVW)P.: +RC P*6D7[HI: "BBB@ HHHH **** "BBB@ IDJ
MED(%/HH J=@G<59086EVCTI: "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ K#M/^0U/6Y6':?\AJ>@#<[44=
MJ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBN?UGQ)
M%IKJJL,GUH WR<#-5FO55L;35/3=5CU2T5U8;SR0*DF#,XPHXH N13B7IQ3I
MHA*A4]ZK0*V>1BK9.%R* .8OPD;.LOS =*YFY*F4[!@5O:\"KY7N:YPYSS0
M"G9QS3** )8<F0 =ZZ2S 2-0PY%<_9N$E#=P:Z"WE,C9P* -V&3=#E2!BK43
MEAS61"I$32L2,5?AG;RU('![T 7:*C$R8ZT\'(R* %HHI&;:,T +14"SG=S]
MVIQR* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M [G8''2I+@GH>E9,T@W9!.!0!+J,@:(G&!7)SR;I" .];EQ=?:(C$O05@O\
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M4 --1Q*&G )XISYQ3(=IE&Z@#I+$&+:%DR#6NB@RX)W"L/3U4')^[706ZQL
MRT 3JBKT&*CN5+1X4U-10!27E@ F#ZU<487FD"@'-.H **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K*;_D.#Z5JUE-_R'!]* -6
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** $9@HR:HW%ZRY 3(]:LW/^I-9$LC ')XH RM3N"Y('%9(!+5IWZ9B\Q>E9
MJ,N>&&?K0!(%Q4@Z4WMFE'2@"*;I4EM:A[8R;^0:;*N5I]B__+-NA- &O9HP
MVYZ>M;,<I64*@R*I6T#E5Y&WTK22#9\T?% $T<I?((Q4M0Q(P.6I+F;RDR*
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MDR#BNCLK4%0[<5G:98O(V\@[17401JJ+\O% %NQ_U6*M4U%"K\HIU !1110
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M^Y0!I45F_P!JC^Y1_:H_N4 :5%9O]JC^Y1_:H_N4 :5%9O\ :H_N4?VJ/[E
M&E16;_:H_N4?VJ/[E &E16;_ &J/[E']JC^Y0!I45F_VJ/[E*-4!.-E &C13
M(W\Q WK3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#,U+7;'2E!NI-
MH)Q3M-UNRU6/?:R;AG%<AIZC5?&=_:7(\R*,956Z"ED_XEOCZSL;?Y(73)5>
MG:JLB.9G?UE-_P AP?2M7IS6.TL?]N#YATJ2S8HIGG1_WQ1YT?\ ?% #Z*9Y
MT?\ ?%'G1_WQ0 ^BF>='_?%'G1_WQ0 ^BF>='_?%'G1_WQ0 ^BF>='_?%'G1
M_P!\4 /HIGG1_P!\4>='_?% #Z*9YT?]\4>='_?% #)8R>5ZT11G[S?>I_G1
M_P!\4>='_?% #Z*9YT?]\4>='_?% #Z*9YT?]\4>='_?% #Z*9YT?]\4>='_
M 'Q0 ^D/(Q3?.C_OBCSH_P"^* *\UL"VX57:V8$.!]WFK_G1_P!\5%-<1+&<
M,"2* ,?4)I60XZURMX9$?)ZUU-RRR1_> -8-\JEQF@#S#Q#<327TBO\ =!K6
M\(+"5+-]\-Q4GB+17F8S0@L6/05-X<TJ:VB+R94@]#7J3J1>'LF<ZB^<Z&0@
MR<U;MH\L'[4EK;[WR1G-=-INGPQ1_.RGV->6=!DP12AF=.@ZUNZ>1)&'!.^G
MO9PELI(JCN*M0+!"N RT 65^Z*6H_.C_ +XI?.C_ +XH ?13/.C_ +XH\Z/^
M^* 'T4SSH_[XH\Z/^^* 'T4SSH_[XH\Z/^^* 'T4SSH_[XH\Z/\ OB@!]%,\
MZ/\ OBCSH_[XH ?13/.C_OBCSH_[XH ?13/.C_OBCSH_[XH ?13/.C_OBCSH
M_P"^* 'T4SSH_P"^*/.C_OB@!]%,\Z/^^*/.C_OB@!]%,\Z/^^*/.C_OB@!]
M%(&5NAS2T %%%% !1110 4444 %%%% !1110 4444 </XQM9!K=A?XS% <OB
MJ>KZI%XM,5G9AB8Y _(]_P#ZU>@2V\4XQ+&KCT-0PZ=9V[[X;:-&]0*I,EQ'
M6\.VQBA;^% #6%:V,)UF<$5TM8=I_P AJ>I*-#^SH/0TO]G0>AJWVHH J?V=
M!Z&C^SH/0U;HH J?V=!Z&C^SH/0U;HH J?V=!Z&C^SH/0U;HH J?V=!Z&C^S
MH/0U;HH J?V=!Z&C^SH/0U;HH J?V=!Z&C^SH/0U;HH J?V=!Z&C^SH/0U;H
MH J?V=!Z&C^SH/0U;HH J?V=!Z&C^SH/0U;HH J?V=!Z&C^SH/0U;HH J?V=
M!Z&C^SH/0U;HH J?V=!Z&C^S8/2K=% %)M,MRI&WK7+^(?!46HPMY"?O#7:T
M54).+NA-75CR:R\"RZ;(7N$'7*UWFCZ7!]C5BO-6-8^ZM3Z3_P >*U52I*H[
MR!126@_^SH/0T?V=!Z&K=%9C*G]G0>AH_LZ#T-6Z* *G]G0>AH_LZ#T-6Z*
M*G]G0>AH_LZ#T-6Z* *G]G0>AH_LZ#T-6Z* *G]G0>AH_LZ#T-6Z* *G]G0>
MAH_LZ#T-6Z* *G]G0>AH_LZ#T-6Z* *G]G0>AH_LZ#T-6Z* *G]G0>AH_LZ#
MT-6Z* *G]G0>AH_LZ#T-6Z* *G]G0>AH_LZ#T-6Z* *G]G0>AH_LZ#T-6Z*
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MS-'_  C7_3W)^9H V_/C_OK^='GQ?WU_.L3_ (1K_I[D_.C_ (1K_I[D_,T
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MH\^+^^OYUB?\(U_T]R?F:/\ A&O^GN3\S0!M^?%_?7\Z//B_OK^=8G_"-?\
M3W)^9H_X1K_I[D_,T ;?GQ?WU_.CSX_[Z_G6)_PC7_3W)^9I5\.;3G[5)^=
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M$GYF@#H/-C_OK^='FQ_WU_.N6N]'N8FC$<TC GGFK(T&3 _TB3\Z .@\V/\
MOK^='FQ_WU_.N?\ [!D_Y^)/S-']@R?\_$GYF@#H/-C_ +Z_G1YL?]]?SKG_
M .P9/^?B3\S1_8,G_/Q)^9H Z#S8_P"^OYT>;'_?7\ZY_P#L&3_GXD_,T?V#
M)_S\2?F: .@\V/\ OK^='FQ_WU_.N?\ [!D_Y^)/S-+_ &#)_P _$GYT ="&
M4]"#]#2U1T^R:UC"EV;ZFKU !1110 4444 %%%% !1110 4444 %%%% !111
M0 54O[^&PB\R4CV&>M23W<-N<2-C-9>KZ7;:[!&S3.JQ'>-IZTT)AI_B6WOY
MQ"$:-B<#=Q6WUZ5YC=W"#QG:QQG;&J;3CCIBO2;8@VZ8.>*;5A1=R6BBBI*"
MBBB@ HHIKNJ+N8X H 4D $GI7/:GXJM],N?)\AY3CJ@S5]]9L)6:V\[YCQ5"
M6RTW14-[<2;E'.7&?YTTNXF^Q>TG7(-6#>4"I7J#U%:E<)X*MI_[9U&Z((MY
M6S&<\$<5W=#5F$7=!1112&%%%% !1137=8T+L<*!DT .(S6=?ZQ:Z>R+(ZY;
MH-U$.MV%S-Y,4V7]*XOQ3H"O?PW+32CYMP 8XII:ZDMZ:'?6ERMW")4Z&IZR
M?#W_ ""TK6I%(**** "BBB@ HHI&^XWTH R=4UVWTXJ&4R$_W><58TW5(=0A
M#Q_*3_"3S7&^&XAK.LZFMPQ(AD^7OZ4_3F:W^(DUHC'RE3@9X[U5B.9G?444
M5)84444 %%%% !112,,J10!EZMKEII,:M*ZDLVW:&YK1AE$T"2KT<9%>:_$#
M057RM0\Z4,TRC;N..HKT/2AC2K4?],Q3:5B4W>Q;HHHI%!1110 4444 %,ED
M6*-G8@ #-/JO>6BWD/ELQ4>U './XUM(YV3[-*0IP6 .*Z*QO([ZU2>/HW:N
M2UZ&PTK2KBRB8-=3<H".:U?"5O-#HT'G AL<C-4TK$IN]CH:***DH**** "B
MBB@ K,U768=+0EU+MC.U>IK3K'U/2(KB[2^9B7C& G8TT)D&D^*+?5)6C$3Q
M$?W^*WQTKS,7+-X@9+E1#&'&PIQFO28_]4F.FT4VK"B[CZ***DH**** "BBB
M@ HHHH **** "BBB@ HHHH **** "H+F>*VB,LA 4>IITUQ';@&1L9K/U*SM
MM>T]K<RLJ$YRIP:!%2#Q5;2W7D>6R\X#'H:WU8,,@@CVKS7Q"8K*\T^UA;A#
MM+=SUKO-((-@F&)]S5-"3+]%%%24%%%% !112$@#)[4 +6%J_B*VTEU4Q-*S
M?W.<5<GUJPAE\F2;#^E49-,L+8-J$LA9/O\ S<BFO,3\B72?$=OJLOEHC1OC
M.UNM;5>?:&K7WC>?4;8?Z$Z?*1P._:O0*&K!%W0M%%%(84444 %%%(3@9/:@
M!:IWM_;V">9*ZCV)J$:[8&X\@3?O,XQ7.^+=#744\UII$7=D;6(II:ZB;TT.
MGT_48M1C9XAP#BKM<OX+7R[&5,D[3C)KJ*'N"=T%%%%(84444 %%%% &?J>K
M0:;%OD^;)Q@'FH-+URWU#(53&V>%;@FN8.=5\9W5C*Q\N,;@,_7_  IFIQ_8
MO'.G0Q$A"O('&>E59$<S/0:*3M2U)84444 %%%% !1110!0U75+;2[1YYW7Y
M?X<\U+87D=_9QW$7W'&17&?$/0Q>:9+>&612@QA6(%;_ (/3R_#5FN2<)U-5
M96N3=WL;U%%%24%%%% !1110 4A( R3BEIDL8EC*$D9]* .<OO%]K:W+0FWD
MD*'!*@FM;2M6AU6V\Z,;><8/6L6_LM.T6&YED?=+<*0H<9YJ#P7;S?9S-("!
MN.!VJK*Q-W<[&BBBI*"BBB@ HHHH *J7]_'80F23GC('K5NLW5=*CU'RWD=A
MY1R #UH0F9EAXQMKVZ\@P21?[3@@5TBL'0,.0:\WUZ=H]0$$D:Q6X_C48-=_
MINW^S8-I)79P35-"BRU1114E!1110 4444 %%%% !1110 4444 %%%% &+K.
MD3ZA(K13; !63J<MWH%G -KS[FPVT5V%,DB25=KJ"/<4[B:/-[^==1U&)+:Q
M>.9E_P!;CI7H&FQO%I\*2'+@<FEAL((&RJ#.>N*M4-W!*P4444AA1110 4R5
M/,C*^M/HH Y^70DBDDN0 2/FP*X36M9O[C7%62RGDLP,-'MX->MU&8(3R8D_
M[Y%4I6)<;['.>%M76\1H4L'MA&,?,,9KIZ:L:)]U%7Z"G4F-!1112&%%%% !
M3)8_-B9#_$,4^B@##M/#Z6MWYXQG-5_$\$D@MQ&A;'H*Z2D*@]0#]13N*QFZ
M#&T>FJK @^AK3I  .@Q2TAA1110 4444 %(W*D>U+10!YU932^%]5O96MWE%
MR^1@=.G^%6=$BFO_ !C)JQB:.-UQ@CZUVL]I#<8WH#CVIT,$<"!44#'M5<Q/
M*2T445)04444 %%%% !1110!R7C^WEN-(@6)&<B8' 'N*Z/3E*Z;;*1@B,9%
M6656&&4'ZBEZ=*=]+"MK<****0PHHHH **** "L[6+U[*Q>2.-G8@@!:T:0J
M&&" ?J* /'=/UF\-])-J&FSSE7.PE3P*]1T:^%[9HXMVA!'W2.E7O(A_YY1_
M]\BGA54850/H*INY*C86BBBI*"BBB@ HHHH *Y?Q#?W=CJ44L<;R0@?,BCK7
M44UD5Q\R@_44T)H\UNGD\1WT'V>SDM6CD#,Q'6O285*P1J>H4#]*%AC3E44?
M04^ANX)6"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** ,O6-.FU"-
M5BEV$5D7D-YH6CM(&:9P>BCFNKI&57&& (]Q3N)H\YU+48KZ&%/[/?SW& ^/
MNFNN\,V\UMH\<=PQ:0=2:O)IUNDA<(,DYZ5:  X Q0V)+J+1112*"BBB@ I&
M&5(]:6B@##N]!2>X,YQFN&\3:QJ/VV"VAM9C;QG:ZA>&%>JTPPQ$Y,2$^ZBJ
M3L2XW./\*ZQ')(+2/3)+<*,[B.*[,=*8L4:G*HH/L*?2;&E8****0PHHHH *
M1AE2/6EHH P5\/(+W[1QG=FK&N1,VGA4!)SVK6I" >HS3N*QSWA2&2&WF$B%
M26[BNBI H'0 ?04M)@E8****!A1110 4444 <%J*2Z'XCFU186E67Y<*/\^M
M0%YM:\6V-\L#QI&N#D?2N_FMXYUVNH/X4V"TBMQ\BC\JKF)Y2>BBBI*"BBB@
M HHHH **** ,'QC$\_AJYCC4LQ' %2^%XWBT"U1U*L%Y!K8(##! (]#0  ,
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MDXH N45Y?/\ %FQ\[=$9/*SUQ746/BZUU;1)[RS8DQ#G/K5.+1*FF=117/\
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MXL)5BC3<3G@BNW\!^*&\1:-#-(FUV'(JI<Q@?"UL#DV@_G6#\'01I,''\/\
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M4-ZI EHV7? VI&]T6&,G)B0 UU5<!\,D9;*9CT(XKOZSEN:1V"BBBD4%%%%
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MCJ-U7P<@'UKP70KJ^O/%DEY<,Z^81\N[@5[O!_Q[Q_[H_E2E&PXRN/)"C).
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,4 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g23ode3tb50n000007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g23ode3tb50n000007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'T!,P# 2(  A$! Q$!_\0
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M<=JD^'_B#4;VYUK0]:F\[4M+NV4RXQYD9/RG'I_0BAQ8U),[BBBBI*"BBB@
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MC 8^8>@&,X[UZ)+#'-;O Z@QNI1E]B,4E)+S&X.7D>9>+-=C\2? R758SS-
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MZD8 [UKZAJEEI4"SW]RD$;,$5G[L>@^M%F%T6Z*Q5\6Z"^,:E%RXC.01M8D
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M]J+,+HU:*R)?%&BP&,2ZA&AD4, P(P"< MQ\HSZXK6!! (.0>A%*P[BT444
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MHY8O!;QQ,6?<<JH')P,].N!5RBDW<:C9A1112*"BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ IC_</TI],?[A^E %44&@4&@"U#_JE
MI],A_P!4M/H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MSZ4UAE!0[B#<<\\TJOA^>](,#.?2F$^E))@3AQSN->C;#IWA!C:MY<BV^]7
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MY 4<]J3><\#]::6R"33-Y'0_2@"3=D\4H'?/;O4>>/\ "E'7J>>I- #P.,@
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M?PPSC/T]ZNSW4%M;-<3S)'"HR9&;  ^M<9?>%)+?5'>WL[FZL9+*.U6*WO#
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M%D+F9U4WB31H&VRZE;(VU7P7_A;[I^AJ*/Q/ILGB"71A.OGQPI+G/!W%N/J
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MG%2?V/<I9Y F,S3"+RE7*MQD<@XS[5JQ:YHMDUNMH&V)>I/P')*C(R2Q^]]
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M0Z7%J%M9->P>;<H7C/F+@@?CW[5R*:-J-MJ,EW<6,MS:IK$T[0* QD5HD59
M.^"#6G-:-_PD6CZFFC2K;"&6)HQ$NZ(LP(+#L.II60<S.I2\M9+A[>.YA>9/
MO1JX++]1U%4WURR75+73XY4FFG9U_=NK>65&3NYR*XS0_#M_!';07+ZJNH6R
MR_OBD(@+LK#=O"!V!)S@G.<9Z59T/39X[OPVO]BRVTEA#)'=SLB@%R@!.>K
MMDY]Z?*@YF=1+KUE;ZS)IMPXA9(%F,LC!4(8D 9)Z\5H+<0N7"S1L4 +88':
M#R,^E<EJUI*GB^XOI-(FOK=]/$*&.,-\^YN.?YUB3:-J>E0Z-8PL%NM6M_L%
MX V2@4[]X_W4WK^*TN5!S-'>ZEK-CI6EMJ-S.@ME PP8?-GICUJM!XFTR?4[
MJR%S$OV=(G\YI5V2>9NP%.>3\AJKXJTAKKP?/I]C;AS&J>5$!U"D' ]\"LM-
M'-_J?B*\DTDQQW.G01VJRQ@'<!+N4#L<E?TH25@;=SKYKRUMWC2:YAB:3A \
M@!;Z9ZU6U?5H-'MHIYU9DDG2$;<<%C@$Y[5PHT'4F<MJ*ZHR7%A!"!:1PN4*
MJ0RMYB,5.3G((Z^U=+XETJ6]T+3[.*![@1W=NSJ^&.Q6&2WK[T65PYFT;J7U
MG);M<)=0- OWI%D!4?4]*%OK-H%G6Z@,+'"R"0;2?3/2N*U'0[X:]?S0V!?3
M5NK6<VZ  3A48/@=R#M./:HKO0[S4+F6XCTV2*QGU.UE%JZ@$*@(=RO;/'Y4
M<J#F?8Z]==LC<S1O+''!&B.+EI4$;[L]#GVJP-4T\VQN1?6Q@!VF43+M!],Y
MQ7*ZK!J&GZSJUY8Z2UR)K6WAMP(PR!LOEBO<+G.*A@T=;%](N8=,N[BRMA,)
MXI8AYK3/@^<4Z'//TS19!S,[.2_LHHUDDNX$C9=RLT@ (]0?3FJ-[K>D6MW8
MQ7-Q;[KS<L3LZXP%))SZ'&/K7+:5X=N_[?TZXN[#%FKW<JQ. 1 '*[ ?0\$X
M[9IMMH][9SZ/<S:9)+%:7UX#$B!F6-P=A _NY_G1RH.9G:>;IS2O;J]LTRI\
MT092VT>W7%4O[8L3X:?7?LK>0(S.4VC>=N?PSQ7,26FLWFNV$RZ3':1V^H,\
MGEV^&,91UW&3=\P.1D;?3GBM3^S+S_A64NG?9G^V&T=!#W+$GBCE0^9LW[2Z
MTZ\B$D#V[%1O95928\COCH:$GTN2 RQS6C0K^[+JZE1G^'/]*XYK*]-Q#=V.
M@-&MGIKP303*%%T[%,+@?>"[6.?>LZ70]9O9=0:73P(+DV3"..W\E?DD;?E2
MQY QD]QCBCD0N=GH:WVF(T92ZM TPVH1(N7QQ@>N.E1ZCK-MI=W8P7&1]K=D
M60D!4VKN)8GMQ7.ZWIEQ#X@CN])LI6G*11LC0(]NR!R>IY0C).1UXX-7/%-I
M-/J6A7(L)+R&UN'DF2-0Q4%" <'KS0DAMLWS?6@M1=&Z@%N>DID&S\^E0_VK
M;G4K:R3,AN(6F21""N%QW_&N%;0-4+I?"&\M[)M0FN!:6ZQM)$C* IV.K+U!
M.,<9JPWAR^:V:+3Q>Q-+97:K+=;%9)),8&$ "@\]!Q3Y4+F?8[=-1L9%D9+V
MW98O]85E4A/KSQ4IGA$C1F5 ZKN9=PR!ZD>E<0-#;5YK>!-*ETZU33Y;6YWH
M%WEE  &.N""<UF?V'XCFLUOY+=QJ5\/[.N@#_JX<!1)^!#'_ (%1RKN',^QZ
M8CK(BNC!D89#*<@BG5'!#';V\<$2A8XU"*H[ # J2H+%7[PJ:H5^\*FH *8_
MW#]*?3'^X?I0!5%!H%!H M0_ZI:?3(?]4M/H .U05/VJ"@ HHHH *AFM8+B2
M%YH4D:%]\989*-C&1[U-7/KJ6J7_ (AU"RL7M(8-/:))#-$SM*74/QAAM !'
MKS30FS9DLK::ZANI((WN(01'(5RR9ZX/;-1+I6GK:S6JV4 @G=I)8P@VNS')
M)'J37,KXGU-K%=9VVG]G-?&U%OL;S=HE,6[=NQG(SMV].],3Q-K&V2]E^P_8
MH]8?3O*6)_,*^<8PV[=@'IQ@Y]J?*R>9'666G6>G1&.RMHH$)R1&N,FLO3?"
MFGV-U<7<L45S<RW;W*2O$ T>[' Z],=:J:?KFI7FF7.N/]E73HO/*VPC8RE8
MRPR7W8R2O3;WZU4;Q+K%G9V%W=BRD34;62:)(HV!A98C( 26.\8&"0!19A='
M2-HNFM>_;?L,'VK.?.V#=GUJCH7A73]$BC(BBFND9V^TF(!OF)/OZXK,M]=U
MR>VT*,O8+=ZO'YRMY+E($$89N-^6)R,<C'O573M4O+#2;GS+^QAN6U&X#-+$
M\F[!'"(#G]>/>G9A='5IHFEI(TB6%N':59R0@YD'(;ZC)YI%T+2DNC=+I]N)
MR_F>8(QG=Z_6N7T[Q3K&N3V<-E]BM_-T][J1Y8G?#+)LP &'!]^E3:3XFU3Q
M!/!;60M+:5;-;BX>:-I 6+LH50&&!\AY)/4<4K,.:)T0T/2UNWNA86XG?.YP
M@R<]:DL=*L--W_8K2&#S/O\ EKC-<S<>)M:?5+Z"PL/.2QE6%U6W9_-;:I;Y
M]P"?>XR#6EXCG\N?0MT*L9-0C7YF8%,@\C!'/UR/:BS'=&NVGV;7,MRUM$9Y
MHO)DD*C+I_=)[CDU$^C:;)816#V,!M(0!'#L&U,=,#M7,:1XFUFXMM$OKW[#
M]GU.8P>5%$X9#\V&W%B/X>F/QK5\3:S/I48-O>64+B)I-D\3RN^.@"J1@?[7
M;THL[V"ZM<U;?2[&U>)X+2&-XD,<;*@!52<D#VS3/[&TW[?]N^PP?:LY\W8-
MV?7ZUQMEJ>IZCK5UJ>G26T'G:-:W6RX1G7Y@S;>",?7]*MV?B[4+NYTZ>>**
MQT^\C@>(R0._FLXY4.& 4Y.!D'-'*Q<R.JOM,L=314OK6*X5#E1(N<'VH32[
M"-9E2SA431B.0!!\Z@8 /MBN9M/$VJ26NF:K*MH;#4+Q;98%1A+&&8JK%MV"
M<CD8'UJ+PQJ]RE_;Z9A&AE2]G9F!+;DGV@ YZ88T68<RN=-+H.DSM"TNGVSM
M"H2,F,?*HZ#Z"G/H^FO?+>O90-=+@B4H-PQTKC8-:UK5M5\.RI=6MN)UO"Z?
M9V8'RR!_?&>#^!]:O:1XGUC5+RWF33F-A-.T9 @8>6@)&_S-V#R.1M'7K19@
MI(Z)="TI;B2X73[<32 AW"#+9Z_G4ZZ?9HUL5MH@;52L!"C]V",$+Z<<5EZC
MJ6H-XAAT?36MHG^RM=2RW$;.-NX*% !').><\>E9VA>)[_4;NTAN([<"73)+
MMS&I'[Q9 F!D],&BS'=7-.\\,66H^(#JEZD=POV46X@DCR!ARV[.??&,5IQ6
M5K#<&>*WC24QK$750#L7.%^@R?SKBI_&E]'X9M=4-QIT<[6AN'MC#([2')X&
M#\@XZG/-37/BC66&MW-H+%;73(89PDL;,\@:(.5R& '?G!^E.S%S1.IAT;3+
M>\:\AL8$N&))D5 #D]:E73K));F1;6(/=?Z]@HS)QCYO7CBN'O;[4;B^\3RF
MY@>QATE9EMVA<;@8W8#<'&#ZD#GVZTPPW5YJAGEDM7M[?1DFC@>%VV90Y"MY
MG!_VL9Q^=%@YEV.SDT#2)A")-.MF$,8BCS&/E0# 4>V.U/\ [&TW<K?88-RF
M,@[!P8_N?]\]O2N9\.ZOJ>I6MG9Z<+.UCMM/MI9/.1Y-Q= =J_-D >I+&IKK
MQ1<VWB"TLUNK&>*YN_LICBB<M$2K$,7SM)RO*X'7K2LPNMS3UWPW;ZS P0Q0
MS-+'+(SP^8LVS.U9%R"RC.>HY I^@:%_8L5P#.LC3OO*11F.).,8526Q^9KD
M+&\U$Z5IL^H36]V'UX1(!&\90AY 3D2'/3@$8'?-:L?B?4S8V^L.MI_9\]ZM
ML+<(WFJK/L#;MV"<\XV].]-I["35[G10Z'I=N\SPV%NC3J5D(0?,#U!]J?::
M1IU@Z/:64,+)&8U*( 0I.2/ID UR]AXFUF2#3KZZ^P_9;N_-F8HXG#KEF56W
M%L=AQC\:[6I=T4K/8HKHVF)?&]2Q@%T3DRA!NSZ_6G?V58?9%M1:1+"DAE1
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MQ=CXTOKWRYHM(N9H)U<QK':S*4PI*EG90A!QC@]2.M(OC>5=+$SQP2W<D\<
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M_P"6FGG_ +;-_P#$T]O@]XA8?ZVP'TF;_P")KW.BE[&)7MYGA3_!WQ"P.)K
M<8_US?\ Q-(GP=\2*A!GT\GM^];_ .)KW:BCV41>VD>??#GP5JGA2YO9-1>V
M831JJ^2Y;D'/.0*]!HHJXQ459&<I.3NPHHHJA!1110 4444 12?>_"FTZ3[W
MX4V@ HHHH K76H6MG-:Q7$NQ[J3RH1M)W-@G''3@'K2W5];6<ENEQ)L:YE$4
M0VD[FP3C@<< \FN9\;B+[1X?:X=X[==0S*ZDC:OE/DDCH/>L9+B[\RU^P3W#
MZ>==1;5R[$/'Y,F1D\E=WKQ5*.A#E9V/1Z*\VM+B3RM+,%U=/KS7)&HPM(QV
MQX;?N4\*HXP?7&,U#HET)[+0&L-0NI=4>5OMV9'?9#M?<6!X !VX]3TS3Y0Y
MST^BO-+%+F>TU"ULKMKJZMH5NDOH9Y,.ZL3L=6X5B,Y [=A74>$[F?5X;K79
MO-1+YP+>%R<1Q(,#CU)W'\1Z4G&PU*YN6=[;W\!GM9/,C#O'NP1\RL58<^A!
M%3UYQ;,(HM.34I9;?1VNM0,SAVC7S//;8&8<@8W40W,VS3_[7N;F/0C<W029
MW9"R!OW.]AR 1G!.,\4^47.>CUEZC<:2I>[O60MI?[]FP6,.5(S@<GC/K7"^
M*M7ABLYUTD7;7-M:++;2R74B9')!1,$R'CG/%+K,4-E=^,I \T6H26@EM=LK
M@L/+.XJ <=?RH41.9Z8C!T5U.589!I:\[U&X ?5_[2NKN*\6W0Z6D<C@N?+X
MV <,V_L<U#+!?3Z;XHOKR:[74+.W22$),P6.00ACM .#\U+E'SGI5%<#973I
MXOMW>X^W274@S$LDBR6H,>3E/NE,CKQR>]=]2:L4G<****0PHHHH @-G;M>K
M>-$#<(AC5R>0I.2!^53T44 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%D%.C^]3:=']ZD,EHHHH 9-_JS4-33?ZLU#0 -4T?^K6H6J:/_5K0 ^BBB@
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MJ36I(=D4=LL<9W#$CG.6Q[#C)]:Z.BB['RHSM1T:VU.Z@FN"Q6**6(QCHZR
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MKX-GM;.[O;MM.U5[:XNK9@MQ-;K_ '6/\7O]*.0/:>1[-17D5WJ%X_@.?5-
MUW6;BYT:\$L\-\Y$H1<;HY, ;AWY]ZWO#NN7'B[QS-J%E=S#1+&T15C1R$DF
MD 8[@."5!QS1R=1J:O8ZK4?$.GZ5JNG:;=.ZW.H.4MPJ$@D=<GM6K7G/CO\
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MMMECB9E..A K,U/Q#<6-U#:VUF]S*8!,^U2<@\8&.AK(U-[>^"/+/YTF]_\
MGF?SKG+GQ%.HO$FMQ 8UW1Q,661QD<@],<]J?+XEN(B\IM8S;L9DAP_S%HP3
M\P]#@T ;X\ST;\Q1F3T;\Q7._P!M7MQLM9HTMYWFM\M$V1LDR?S^4BIK?Q!=
M/=XEMHEMWFFAC(<[LQYY/L<4 ;F9/1OS%&9/1OS%85OXE-T94$<,96)G#;V.
M,#/]T5F6FM:JZ"WFFDBEG,&QY47<H?.67'&/3- SL 9 >C?F*,R?W6_,5QNI
M^*+JQTJ2$W(6ZAFD0W!B)#JC =AC)SC\#6W<7=RFMP"VNVGBD!DD@V#$<>TX
M.>N2<=:!&OF3T;\Q1F3T;\Q7)6.LZA>:5=37$DL,TMHUU;@;=JA3[<^G6NMM
MI?/M89B,&2-7QZ9&: #,GHWYBC,GHWYBI:* (@21G)ZX(-:T7^J7Z5DCHW^_
M6M%_JE^E)C'TQ_N'Z4^F/]P_2I JB@T"@T 6H?\ 5+3Z9#_JEI] !1110 44
M44 %%%% !1110 4444 9GB*YFLO#.J75NYCFAM)9(W ^ZP4D&N+^&_CRYU_3
M&T[628]9BA\Y&8!?M$?9QV^N*[+Q-#+<>%=7AAC>262SE5$1268E#@ #J:X,
M^"KS4/AYH5U9QR6/B33;<&!G4HW?,; ]C[U<;6U,Y7YM#1\*^-5MO ']M^([
MYG;[9+"K; 6<AR%154<G _2MO2/'.DZQ<7%LD=Y:7<$1F:VO+<Q2,G]Y0>HK
MS:R\-:^?AUH5PVEW#7VF:O)>3V+(5>1-QSM!Z^WJ#Q70^7J7BOQQ#KJ:+?Z=
M9:?ITT/^FP^7),[JP"A>I S5.*U)4I:&Y9_$K1+^RFO+:WU*2U@A:66<6I\M
M-O52W3=[9J)/BIX<8Q[AJ$:31[[=WM&"W'^S'_>.>.*Q/#^DZC!\#+O3I=/N
MH[YH[D"V:%A(29&(^7&>156;1]4.F?#5!IUV6LRGVD"!LP?(!\_'R_C1RQN/
MFE8[;3?'>BZEINH7H:YMQIYQ=0W$#)+%Z97D\U%IWCG2];GN-/@COK2\%NTT
M<=W;M"TB8^\N>H]ZY">+Q-I/BCQUJ>D:7<232B'[,S0MMDPH#%.S$<\"J>D6
M'B*^\<Z=JU]!K4T'V.>,RWUHL7EL1]T*O(!/3=UI<J#GEL'A?6&F\*^%)=4U
MS5TN)]5>-#%(7\\AN$D).=OYUV&H_$W3-*N/)O-'U^+,WDI(^GD)(V<#:2><
M]JX'2= UF/PYX(BDTF^62VUIY9T:W<&),CYF&.![FMK^V+O4/'[ZGK/AGQ$]
MK8OY6FQ1:<[(#G!E8G'/IZ"J:39,6TCL=7\?:/I&I2V#17UW/ H:X^QVS2K
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9D;:X'.1@@CD#/:@#=HK)TF^OKG4=3M[V.!!;R*(A$2?D(R,D]3^'?'O6M0
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MMZR+ Z$+((E&$<\[E)'I79V5I:^5'<W8,EM#&QVJQQR/XAWHG);@DTCA]/\
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M=E9:CIC3.+F6"-U'E+Y9DC3^]D]?UJDVMRG9K0Z[X2VSV^D7I9%56=  1A^
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M'=_)(-T,,2LXSW\L8%>5G4'T[5$OUM5^8$-D@-SV)[5Z=.3<$EV0H;&.UO\
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M'J*IZEK\DD#PVL >V@SO*H!&I/"\?GUZUS?VN>7 ,A=68R-QW[YIMD72/2/
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M;O(K1R+_ ! @FNSKE/ M@NG:=<0JA0%P<'@]/3M75UYU7XW8RG\05RWCB_\
M$=AIT#^'K03,SD7#A/,>)/54R-QKJ:Y7QEK>JZ=+I&G:*+=;_4KAHTDN5)1%
M52S$@=ZB.YG+8X3PB=+UOXA7']KZQ=:E-:PQ26JZBQA*3$G<%BX&1QQBO9:\
MKTZ76/'FI6<EQI&G6R:9=8N=090SR.C<K%W X[UZI53W)I['-ZN^J#4R+,W/
MV;:/,V#H>VVJC2>(,'=]H!R-^T#ANVW_ &<=:Z^BH-"O+N^RKYGWL#=CUJI\
MOO5VY_U)^M4:I; +\OO1\OO244Q"_+[T?+[TE% #AMR.M!VY[T@^\/K0>IH
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M?]?]U_Z-:A;,'\2-[Q'_ ,B[??\ 7.HXO#>C-"A.GQ$E03UJ3Q'_ ,B[??\
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MC((ISS!OE<59]?FDG;UM^(<IE^&F'_"+Z0N1G[##Q_P 5CZ[_K==Q_SZP_\
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MLUKG_4GZU1JV\JW%FDL>2K@,/H:J[6]*I; )12[6]*-K>E4(2BEVMZ4;6]*
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MTM8I7O=F=XI;;H;MM+8EC^4=3\XIO]LO_P! &_\ ^_2_XU+XE_Y Y_Z[1?\
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M+4:S1H[8KIK?NE/4+Z U<8IHSG)IGT-7S_\ %#5-0M/'M_';W-PD?EQC"2,
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M#=N>*A1[FES[)^$\SS_"_0Y9;A[AVB<M(Y))/F-U)Y]J[.N&^#O_ "2?0?\
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MJ6('*8YSGD5%@YZ'K07<E?\ U1_W_P"E1KT;Z4]_]4?]_P#I4:]&^E #YO\
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MNGL4J?L^;F:V?4V:***[3E"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@!DW^K-0U--_JS4-  U31_ZM:A:IH_
M]6M #;AF2VE9(O-8(2(_[QQTKP67P]K'_"51:DGP_O'TW<TDFFRW"F(2'^-0
M#@?0@BO>;IY8[29X$WS*A*)_>..!7S_KWB?6]2MO*\1:W>Z5=-/&G]F1P-;H
MT98!COZL ">^*UIWZ&56W4]Q\.WLM_HL,\^G?V?)DJ;;<K>7@XQQQ7B?Q45Q
MX\O'$?\ !$ PZ_<%>V^'=/TO3-$M[71F5[%03&RR^8&R<D[LG->,_$Y\^-[]
M>/ECC/\ XX*[LLIJI6DMM'^APYHVJ"]5^IRUD@6V+-A@QRQ(YS4,T'ENX#;5
M8<8Z5'#<%%,1&,T^20^2Q49(_E7NODG26FQ\WRR4[]R-KB+S%20#&W!8=-WK
M3[B82QI*N%FC 67!X([&J<[12+F-DQP"O\72HXE4J(XQ]]#NV]R.17 Y-MQ7
M4W5-63-!+[]T-WS#OZKSWI2RQ2,77C^M9$19B@/RE!@$GK[5<67S(2C$%L8#
M#H:Z:=5U5:6ZV"5%1>@CM\Y))&3Q2;W#%C^8IK8'!(XZ"E$FV,MDYQCK7'.Z
MD7;0:Y<$DD8Z9%4G?(_ES5HD-G'WAT(JL\0R?+<')&<'I6,FV;4[=3V+X"N7
M7Q!DDX-O_P"U*]DKQWX#Q^7'KPR#DP<C_MI7L5>;7O[1W/?PEO8JW]:GSE\2
M=Q^*6I*@W,S0@#'?R4JH"R,V["XZH>>*M?$@,?BIJI7)V^2>.O\ J4JDI"-M
M96P1S7J8&/-%'R^9_P 9_/\ ,F8@OU !P/>FSNZR1QPKYD[\E0>@]ZAEN98B
M@@"$R?+O;G:>U9?VF>&6<0,0X8[G/(![X]#796K*G[L3BIT7+4FU.XF*XSM_
MA8!N!52RFE5E@W.IY92%X'')J(7;W2JESYKA V!TQ[YK2N+J"!8;41)+,J8)
M88"@C@#UQ7(O>?.V=G*X15.UQAMK8"!YI]T?WI2IRP/8?C4TUN()%>&5BLHP
MC9QM%4C:F!&E"ML8;2=O'T)]:KNZPJ3O??& P .1FE*T5H)0<GI*XV]ED,Z&
MW3RV!PV,_-4\WEV:1I>(6:9=^R-L9'N:LM<_V@GG.Q-R5&YMFW:/\]ZA"BYL
M)HO+1_+<-YV1D<=/6LW'7<OFT2DK6W_X<IV4D1D,4L<@AD)P%.2!_GO7LGP+
M#+8:TNX&-98P@!Z##5X-!?W%O=-(&?@\.&Q7O7P.G2XM];E0(NYX253H#AZY
MZLDZ3L>KA:<HXA/H_P#(]:KX"D_UK?4U]^U\!2?ZQOJ:XD>T7+6^FCC%L3E-
MWRYZJ?\ "M02I+&IF7<R]01TQ7/9K2MIA+;E6R&'5@>:[\'B'!M-[]SDKTE\
M218DBDO+:250J6\7.2.I]*?IEN?LQE!96)VY_#I0\\1L7M/*<.<>6 .OKFI(
MG%M"OF./EZMWS771LZWM)=%KZG/)RY''S*ZP(-4VSM&B$'.>@.*HWT"P7;QI
M(&3J"*LWDP,LI7YU;'7^=5IV260^2IVA0/I7)7Y7=)+<Z*7-=2?8K[2C*9%.
M#2'&[C.WL#4L<7F.%9L =23VJ-T"LVTY4' -<CO8Z$U>Q(Z1>2KQN=W\2'M[
MT+'O@D8!?EY'KBH><U/'*]KO V,)$P><UI%IN[0FFEH?7_PA1H_A5H*N,$1/
MQ_VT>NWKA_@\<_"C03_TRD_]&O7<5SO<M;:A1112&%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%<[XI\2R>'9='2
M.V6;^T+U;5BS8V @G(]>E<M=?$?6H)=>N(M#M9-,T:[>VFE-WMD8*<9"D8_6
MJ46R7-(]+HKD/%/C1]$T6PN["P-[=7J^9';EMIV!-[$_04_5?&B6=KX<NK2!
M)X-9GCC#,^-BN <_49Z4N5AS(ZRBN:T?Q2VNZS?)96\9T>SRC7S/Q)(.H4="
M!ZYJIH'C@>(/%=UIEO9[;&.#S8+LM_K@&VD@?W<]#1RL.9'845R\_C".T\87
MVCW<:0V=GI_VZ2Z+$D 'G(QT J2#Q]X7NH[MK;6;:7[+$9I0I/"COTYZCI1R
ML?,CI**Y#1?B-X?U3PZ^L37T-K%$P297)_=L<X'3DD#/%7Y/''AF+38-0?6;
M86D[,L<N3ABHR1TX/L:.5BYEW.@HK ;QOX:314UAM8MA8._EK-D\MZ8QG/X5
M2O\ QGI]K=07:ZQ8G3'LGN?+V,9),'AE8< 9XP>:.5CYD=917*^&O'^A^)+:
MR\F[1+RY!_T?#95@,E<XQD"M^RU.SU%[E+2=96M9C!-M!^1QU7ZBAIK<$T]B
MW1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4Q_N'Z4^F/]
MP_2@"J*#0*#0!:A_U2T^F0_ZI:?0 A 8$, 0>H-58-,L+9-D-G!&I8MA8QU)
MR35NB@ ' P**** "BBN1TC5[NXUM(VO6FFD:X%Q9_+BW",0AP!E<\=3SG- '
M13?\A2U_W7_I5RLR1KY[R&86(P@8$><.<U/]HO?^?#_R,* +E<;K?_)3?#7_
M %PN/Y"NF^T7O_/A_P"1A6+?:5?7GBC3-8^SA191R)Y?FCYMX]::)DKHZ:BJ
M?VB]_P"?#_R,*CGO[JWB,CV'R@@'$P[G%(HT*:_W&^E5?M%[_P ^'_D852O)
MM=9P+2RMA&5P?-EYS^%1.7+&]KE0CS.UQWAG_D!0_P"^_P#Z$:UZYC2X?$6G
MP1VYM;1H58DGS>>3DUM_:+W_ )\/_(PK+"M^RC%III+<UQ"7M&T[W9<HJG]H
MO?\ GP_\C"C[1>_\^'_D85T&!<HJG]HO?^?#_P C"C[1>_\ /A_Y&% %RBJ?
MVB]_Y\/_ ",*/M%[_P ^'_D84 7**I_:+W_GP_\ (PIDM[=PQ-(]A\JC)Q,*
M +]%4ENKQE#"PX(R/WPI?M%[_P ^'_D84 7**I_:+W_GP_\ (PH^T7O_ #X?
M^1A0!<HJG]HO?^?#_P C"C[1>_\ /A_Y&% %RBJ?VB]_Y\/_ ",*/M%[_P ^
M'_D84 7**I_:+W_GP_\ (PH^T7O_ #X?^1A0!<HJG]HO?^?#_P C"D>[O$1F
M-APHR?WPH NT50CO+N6)9%L/E89&9A3_ +1>_P#/A_Y&% %RBJ?VB]_Y\/\
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M-N8XG<#GV  _"NKI-6=AIW5PHHKC_B3?SZ=X;MY8;N>U#W\$<LL!.\1EL-C
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MUD+H6NF27EKI<,37T[3 ,-ZAL*,?,0#D]*9=?$":&>]DBTKS=/LKF*&6X\X
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MF0<J#CBK7P]N[B^\!Z3<W<TDT\D;%Y)&RS?.W4TG%I7!23=CIJ***104444
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MF['3.!S5JBD.R"L;_A$?#/\ T+ND_P#@%'_\36S10,QO^$0\,_\ 0NZ1_P"
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MBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@!<4N*** % IV*** "C%%% "4A%%%
M#<4F*** #%&*** # HP*** # HP*** # HP*** # HP*** # HP*** # HP*
M** # HP*** # HP*** # HP*** # HP*** # HP*** # HP*** # HP*** #
M HP*** # HP*** # HP*** # HP*** # HQ110 8HQ110 N*<!110 ZEHHH
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g23ode3tb50n000004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g23ode3tb50n000004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .="!$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *CG_U$G^Z:DJ.?_42?[IH IT444 :%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$RSMI5VL_D-MD ZC_P"M0!LT444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 44C,%4LQP ,DUSLGCSPQ#*T<FLVBNAPP,
MJ\'\Z .CHK-TWQ!I&L$C3]1MKEAR5CE#$?@#6E0 4444 %%%% !16#XB\8:/
MX6:W759WC-P2(]L9;/Y4NL>+]$T)[--0O%B:\8+$,<G/3/H*+!<W:*165T5U
M(96&01W%+0 45C:_XITCPRD#:I="'SWV1C&23_A6M%+'/$DL3J\;C*LIR"*
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M2 '1=V<_2K>EZE;:QIEOJ%FY>WN$#QL1@D'VH MT444 %%%% !1110 4444
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MU&VU?3+?4+-B]O<()(V(P2#[4 6Z*** "BBHY)XHF422(A8X4,V,T 24444
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M>*+(5V>H:]XAL_#V@3:Q=$M;Q(&PO5LXQC\Z9X6\0Q^*-"AU6*TGMHY2=J3
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M_*N2L?&=UX<O],TCQIX;BBV,([>\C7*@] 1Q_6DDFAMM$OC^'_A'?BOX<UZ
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M6([X5.<@@C)X'7^E;>@_\G#:K_UR'\EIVL*]SW"BBBH+"BBB@ HHHH ****
M"BBB@ HHHH **** /G/1- TWQ%\==:L=4MA/;[IWV$D<AN.E6/BQX1TOP/\
MV7J_A[?97#3;3&DAYQSGK63%9Z[??&C6H?#UTMM?>9,?,8X&W=R*[BW^%&O:
M]J=O>>,=<:ZC@8,MNIR#CWSQ6KT9FM4<UXUU8?\ ":^"-5U!Q&#;)+,Y'3*J
M2:[JV^-GAZ358[&2VO((W8(ES(F(V/\ .N5^)UA:R?%/PI8/"C6NT1^41QM&
M.*T_COI]I;^#+%X;>.-HI0$*KC:..E+1V'JKGH?B7QIH_A?3XKN^F)$PS"B
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M*\7V+7.G2G<AQ)$_#(?>N@KR?X>>"O$^A^-;[5]6M[*VM;J)MT5K*"/,)'.
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ML?D^SJ,.YXSQGVKUD_$[1H?"<6OWD<]K',Q2."5<2,>. /QKS[5E7_AI&U7
MP5BX_P" BNT^*7@6]\66%A+I31"[L9?-2*3A7Z<'\J3MH"OJ'AWXO:+K^JQ:
M?]CO;.68[8C<1X#GVQ7+_$_POJ^HZNMY9PK9PFYBC$RR.6E9FP&*\@ =<^]6
M]'\;2Z?XBTS1O%_AV.TO!\MK=JORY'&1QP/>O7R PY&:6S'NCE/ .EW>D:-)
M:WMDMO,K\NLC.)N/O98YKK***DH**** "BBB@ HHHH **** "HY_]1)_NFI*
MCG_U$G^Z: *=%%% &A1110 4444 %%%% %'6;)]1T:[LXV"O-$44GH":Y#X6
M^";[P3HT]G?3Q2O(^X&,''ZUWM%.^E@L,EC$L3QM]UU*G\:\EL/AOXL\-ZSJ
M,GA[6K:&SOI3(XD0EEY..W;->NT4)V$U<\R\(?#?4O#GCJYURZU,7JW$9WNX
MPY8@^@ JCXC^&&OOXUF\0^&=9CL9)P ^Y<D<#/;VKUNBCF861YAXH^'NN>((
M/#'G:C#-<Z8^ZXF<']Z?EY'Y5T/CSPO=^*/!DFCVLL<<S*H#/G'&/\*ZZBB[
M"QRFD^$VA^'J>&KYT<FV\AV7ITQ7.?##X:7?@O4;Z\O[B&=IE\N((#\BYSWK
MTZBB["QY'J7PBFN_B7'KJ3PC2S,LLMN0<L0.?;K71_$CP)-XRL+#[%=+;7EA
M+YD+.,J>G7\J[FBCF861Y!K/PW\8>)]#^RZQX@A)@4>1#$F$+#C+<9Z9Z5Z!
MH]C'X=\$6MEJ;QM'9V@2=OX2 .?PK?JIJ>FVVKZ=-8W:LUO,I5U5L9![47"Q
MXI\%?#EO>>)-7\1+%_HL4S1VH8="3G(_ FO=JSM%T2P\/Z<EAIT BMTZ#O\
MC6C0W=@E9!1112&%%%% !1110 4444 (PRI'J*\V\*?#[4=#^(FJ>()[B%[:
M[9V1%!W#/K7I5%.XK!7G.O\ @+4-5^)VF>)8;B%;6U9"\; [CM]*]&HH3L#5
MS.UO1K37]&N-,O4W0S)M/L>Q_ UY-!\,/'6BPR:;HGBQ8=+<G$;+D@'\*]JH
MH3:!JYYGIWA*Q^&W@35IYFDO+N:%OM$R?>;(/ ]AS^=>9^$?#.H7NBG4M.\:
M6>EQS.S_ &>5AO7D]<BOI.XMXKJWD@GC62*12K*PR"#7G]U\$?!=U=&=K.="
M3DJDQ _*FI=Q./8Y7P'J_B/Q&/$GAF]U$:C$D+0Q7A7Y02"!C '%=O\ #+P=
M>^#-%NK.]FBE>6?S 8P< 8 [_2NCT'PYI7AJQ%II=JD$?<@?,WU/>M6AL:1Y
M7K'PXUVW\<R^)?#6I0023KM=)E)Z]:AC^&&NMXTT[Q%?ZTEY/'_KPRXQ[+@#
MCZUZU12YF'*CSN/P'J"?%F;Q4;B'[(\:J(\'=P /Z5%XH^'VHZW\2=-\107$
M"6UJ(MZ,#N.ULFO2:*+L+(\\^)/@34/&%YI,UE<0Q+9RAW$@/(![8KT%!M0
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M_!%KX?BD,4EJ 8I^^['.?8GFN^HHYF'*CQJU^&_CZ2.'3[WQAC38F&%C7YL
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M7)'UX_E7M-%"=@:N<%\/_APOA&:YU"]O#>ZI=?ZR8]!]*[VBBDW<:5@HHHH
M**** "BBB@!KC=&RCN"*\^^'/@2_\(ZCJUQ>7$,JWA!01@\<YYKT.BG<+'+^
M.?!EGXTT*2RF"I<+S!,1RC5E^ ? <GA[P1<^']7>*Y6XED+[ <%6 &*[RBB[
MM85E>YXQ'\+?&/AVYGB\+>*!:V$S%O+=<E?TKI-*\'>)]%\,:E"FO&[U>]Z2
MRCY(CSRO&<\UZ'11S,+(\[\+_"^TTOPC?:9J12ZO;\,9Y\=&/3'L#@TOP_\
M!>L^%M.OM&U"\BN=.E+>05SN0'/\\UZ'11=A9'C6@_"WQ;X:UH_V5XBBATQI
MQ))'LY=0<X/%>R+G:-W)QS2T4-W!*QY]I_@:_M?BQ<^*GGA-I+$R", [LFND
MU[P?HGB2YM;C4[-)I;5@T;$GCO\ SK=HHNPL<UXX\.S^(_"%UH]D\<4DJX0L
M/E''M7.ZAX!U"[^#MOX12XA%Y&D:F0@[/E?<:]'HHN%CR[4_AOJ=[\+K+PRE
MS +J"7>TA!VD<_XUJW7PZAU?X<:=X;U&4"YLX55)X_X7'I['BN\HHNPLCQF'
MX=_$6.W&F+XQ5=.7Y0 G.WTSC-=1K/@;6Y_"^GZ=I?B2XAN[+D328(D/&,\=
ML?K7?44<S"R/'K3X6>)M8URSOO%WB%;V*S<-&B+@\'([5M?$?X=7OBJ_T[5-
M(ODL[ZR!"%QD<XY_2O1Z*.9A9'!VG@?4M5\&76B^+M3749IGWI,JX,?3';L1
M7(1_#+Q]96C:19>+532CE0A7G;Z9QFO:Z*.9A9' Z;\-X=#^']_H%C*KW=W$
MZO<./O,1C\JN?#SPG>>$O"ITN\FCDE))W1@XYKLJ*+L+(\W\%?#Z]\/^)=;U
M"^F@FM[]V944'."3US]:Q)OA5XFT'5;FX\'^(OL-O<-N:)USC],5['11S,+(
MXCP/X1US0KFXOM<U^74+FX&&0 !![].M=O112;&%%%% '/\ C;0[CQ)X2OM*
MMI$CFG4!6?H,,#_2J/P^\*W'A;P<FC7[Q3N'=F*#Y2"?>NNHIWTL*VMSRO1?
MAOJ_A7Q[-JVBW< TJX;]Y:OGH?\ #K4NA^"+_P ,^--:\3W4T4EK/#)MCC!W
M<D'^E>GTC*'4JP!4C!![T<S"R/F;PUHMQXCO-3UG2O%%OHHGN&_<7+C?CMG/
MUKJ/ GB#Q)#X\N/#5SK"ZS9^65:95^5..H( ^E=EJGP:\':K>/=2V,D3N<D0
MR%%_(5T7AOP;HGA.%H])M%B+<-(W+'\>M4Y(E)G.> / U_X5UW7+Z[GADCOY
M0\80'*C)Z_G4$W@#49/BU#XK%Q#]C3=F/!W<J1_6O2**F[*LCRSQQ\--7U?Q
M?#XE\/ZHEG>*J@EUS@@8!'%6M3\$^,+_ ,/:=$OBDIJMHQ8S!?E?ZC%>DT4<
MS"R/(])^%_B&^\36>L^+M=74#9G,4:KC/L>.E>N444-W!*P4444AA1110 44
M44 %%%% !1110 5'/_J)/]TU)4<_^HD_W30!3HHHH T**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ J.?_42?[IJ2HY_]1)_NF@"G1110!H4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (64'!(%)O7^\/SKS
M/QG/,GB*14FD4>6O"L0*Y_[5<?\ /Q-_W\->'7SI4JDJ?)MYGK4LJ=2"GS;^
M1[9O7^\/SHWK_>'YUXG]JN/^?B;_ +^&C[5<?\_$W_?PUE_;\?Y/Q-/['?\
M/^![9O7^\/SHWK_>'YUXG]JN/^?B;_OX:/M5Q_S\3?\ ?PT?V_'^3\0_L=_S
M_@>V;U_O#\Z-Z_WA^=>)_:KC_GXF_P"_AH^U7'_/Q-_W\-']OQ_D_$/['?\
M/^![9O7^\/SHWK_>'YUXG]JN/^?B;_OX:/M5Q_S\3?\ ?PT?V_'^3\0_L=_S
M_@>V;U_O#\Z-Z_WA^=>)_:KC_GXF_P"_AH^U7'_/Q-_W\-']OQ_D_$/['?\
M/^![9O7^\/SHWK_>'YUXG]JN/^?B;_OX:/M5Q_S\3?\ ?PT?V_'^3\0_L=_S
M_@>V;U_O#\Z-Z_WA^=>)_:KC_GXF_P"_AH^U7'_/Q-_W\-']OQ_D_$/['?\
M/^![9O7^\/SHWK_>'YUXG]JN/^?B;_OX:/M5Q_S\3?\ ?PT?V_'^3\0_L=_S
M_@>V;U_O#\Z-Z_WA^=>)_:KC_GXF_P"_AH^U7'_/Q-_W\-']OQ_D_$/['?\
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MX**** "BD9E499@/J:C^U6XZSQ_]]BDVEN-)LEHJ'[5;_P#/>+_OL4?:K?\
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M "HY_P#42?[IJ2HY_P#42?[IH IT444 :%%%% !1110 4444 %%%% !1110
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M4^#_ (]X_P#=%,O?^/5_I3X/^/>/_=% $E%%% !1110 4444 %%%% !1110
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MG((KV,/B%5CYGG5J+IOR'4445T& 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %1S_P"HD_W34E1S_P"HD_W3
M0!3HHHH T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** /+O&O_ ",DG_7-:YVNB\:_\C))_P!<UKG:^#QW^\S]
M6?783^!#T04445RG0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ J.?_4/]*DJ.?_4/]* &6?\
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MC&2DE)!1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[_\ K4?\(7K/_/*/_OO_ .M1]1Q/\C^X/K5#^=?><]170_\ "%ZS_P \H_\
MOO\ ^M1_PA>L_P#/*/\ [[_^M1]1Q/\ (_N#ZU0_G7WG/45T/_"%ZS_SRC_[
M[_\ K4?\(7K/_/*/_OO_ .M1]1Q/\C^X/K5#^=?><]170_\ "%ZS_P \H_\
MOO\ ^M1_PA>L_P#/*/\ [[_^M1]1Q/\ (_N#ZU0_G7WG/45T/_"%ZS_SRC_[
M[_\ K4?\(7K/_/*/_OO_ .M1]1Q/\C^X/K5#^=?><]170_\ "%ZS_P \H_\
MOO\ ^M1_PA>L_P#/*/\ [[_^M1]1Q/\ (_N#ZU0_G7WG/45T/_"%ZS_SRC_[
M[_\ K4?\(7K/_/*/_OO_ .M1]1Q/\C^X/K5#^=?><]170_\ "%ZS_P \H_\
MOO\ ^M1_PA>L_P#/*/\ [[_^M1]1Q/\ (_N#ZU0_G7WG/45T/_"%ZS_SRC_[
M[_\ K4?\(7K/_/*/_OO_ .M1]1Q/\C^X/K5#^=?><]170_\ "%ZS_P \H_\
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MY1_]]_\ UJ/J.)_D?W!]:H?SK[SGJ*Z'_A"]9_YY1_\ ??\ ]:C_ (0O6?\
MGE'_ -]__6H^HXG^1_<'UJA_.OO.>HKH?^$+UG_GE'_WW_\ 6H_X0O6?^>4?
M_??_ -:CZCB?Y']P?6J'\Z^\YZBNA_X0O6?^>4?_ 'W_ /6H_P"$+UG_ )Y1
M_P#??_UJ/J.)_D?W!]:H?SK[SGJ*Z'_A"]9_YY1_]]__ %J/^$+UG_GE'_WW
M_P#6H^HXG^1_<'UJA_.OO.>HKH?^$+UG_GE'_P!]_P#UJ/\ A"]9_P">4?\
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MQ8:9::9 (K6((.Y[GZFK=?29?EL<+[\M9?D>'C<=*O[L=(A1117J'GA1110
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M?VBG+F<=4W;7N0L%:/*I=OP.FUZ5&T'2T653@?,%;IUK5L8;6T@T^6T2T9"
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 07O\ QZO]*?!_Q[Q_[HIE[_QZO]*?!_Q[Q_[HH DHHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*CG_ -0_TJ2HY_\ 4/\ 2@!EG_QZ1?[HJ>H+/_CTB_W14] !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 1W&?LTN,YV'&/I7'^!],EE\-WL>JK)(+J>0,DN>8ST%=I2$JBDG@ <T[V0
MFKNXV*)((DBC4*B#"J.PJNFEV4>HMJ"0*MTZ[6D'4BN:O?%\PG9+:)=BG 9N
MIHM?&,@<"Y@!7NRGFN;ZU3O:YM[&5KV.O95=&1AE6&"/44V*)(8UCC4*JC
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M_P"HD_W30!3HHHH T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MY'^%'_"9ZS_S\#_OD?X5']N8;LR_[)K]T>IT5Y9_PF>L_P#/P/\ OD?X4?\
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M%;&04444 %%%% %6]_U:?[XJR.@JM>_ZM/\ ?%61T% "T444 %%%% !1110
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M0.97L;E%96A:[!KUK+<6\<D:QR&,A\9R/I6K4M-.S&G<****0!1110 4444
M%1S_ .HD_P!TU)4<_P#J)/\ =- %.BBB@#0HHHH **** "BHGNK>.3RWGB60
M]%9P#^5++/# H::5(U/0NP'\Z )**:CI(@=&5E/0J<@TZ@ HHHH **B-S )O
M),T8D_N;QG\JD)"@DD #J30 M%5O[2L?^?VW_P"_J_XU-'-%,,Q2(X]58&@!
M]%%,EFB@B:2:1(XUZL[8 _&@!]%5AJ-BT:R"\M]C?=;S!@_2C^TK'_G]M_\
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M8\&N=EC<.[!&V!B-V./SKEK4H*$:E.]G??R-Z=23DX3Z6_$CHHHKF-PHHHH
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M0"@!U?/'Q>4GXO:00#_J[?M_TT-?0]9M[X?TC4;U+R\T^WGN4P%E=,L,'(H
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M%% 'EWC7_D9)/^N:USM=%XU_Y&23_KFM<[7P>._WF?JSZ["?P(>B"BBBN4Z
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M7_\ Q[?\"%6:K7__ ![?\"% $Z?ZM?H*=34_U:_04Z@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH @O?^/5_
MI3X/^/>/_=%,O?\ CU?Z4^#_ (]X_P#=% $E%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4<_^H?Z5)4<_P#J
M'^E #+/_ (](O]T5/4%G_P >D7^Z*GH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J.?\ U$G^
MZ:DJ.?\ U$G^Z: *=%%% &A1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!Y=XU_P"1DD_ZYK7.UT/C8C_A))/^
MN:USN1ZU\)CO]YGZL^NPG\"'HA:*3(]:,CUKD.@6BDR/6C(]: %HI,CUHR/6
M@!:*3(]:,CUH 6BDR/6C(]: %HI,CUHR/6@!:*3(]:,CUH 6BDR/6C(]: %H
MI,CUHR/6@!:*3(]:,CUH 6NA\&?\C!']#7.Y'K71>#"/^$@C^AKJP/\ O,/5
M&&*_@2]#7^(7W[+_ (%_2N'KM_B&1OLO^!?TKA\CUK?-O][G\OR,<N_W:/\
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M:Z1;B.!,M_$YZFM&BO5PF74<-K%7?=GG8C&U:^DM%V"BBBN\Y HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$/\ A1_PT#'_ - ?_P B'_"CV#[![==SVC[);?\ /"/_ +Y%'V2V_P">$?\
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M[/\ 9+;_ )X1_P#?(H^R6W_/"/\ [Y%>,?\ #0,?_0'_ /(AH_X:!C_Z _\
MY$-'L'V#VZ[GL_V2V_YX1_\ ?(H^R6W_ #PC_P"^17C'_#0,?_0'_P#(AH_X
M:!C_ .@/_P"1#1[!]@]NNY[/]DMO^>$?_?(H^R6W_/"/_OD5XQ_PT#'_ - ?
M_P B&C_AH&/_ * __D0T>P?8/;KN>S_9+;_GA'_WR*/LEM_SPC_[Y%>,?\-
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** (+W_CU?Z4^#_CWC_P!T4R]_X]7^E/@_X]X_]T4 24444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1S_ZA
M_I4E1S_ZA_I0 RS_ ./2+_=%3U!9_P#'I%_NBIZ "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MCG_U$G^Z:DJ.?_42?[IH IT444 :%%%% !1110 4444 %%%% !1110 4444
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MC_W13+W_ (]7^E/@_P"/>/\ W10!)1110 4444 %%%% !1110 4444 %%%%
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M: HV_D[0.#Q32T);L[':44R.1984E0Y1U# ^QJE::Q9W]]<6EM)YCVY D('
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MG)K6I1Z2VEI>2K8NVYH ?E)K)P=VS95$DD>H?$+5YM>^&&C:E,?FGO'(QT
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MF8^LZA'IGQ$U&\DM8[H1W+D12?=)[9KHO'NJW&M?#[PW?W1'FRR/PHP  7
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MC0M'K*R2C$LT1D?ZFM+Q(2-)) R1(F!Z_,*F%E(-;^U<>5Y>VEUFTEO-/,4
M!DW*PS[$&B-&4,-4II=Q.HI5HR?D11W]X2H.G. >^:U/X?PK*$VL@ ?9H?S_
M /KUJC.SGKCFNFA)N][_ #5C&JDMK?(YK1M1CM8;A'AF;$SG*)D=35G3'^W:
MS/?Q1LMN8U0%AC<1G_&K>DV,EG!*DH!+2,P^A)I;.SFL]0G*8^RR_,!_=;O_
M $KEI4JJC3YME^!O4J0;GR[L=K-V+/2YI"0"1M&??BN>>[T^SM].FBNXFE@(
M$@5N2#][^5;NI6$M_=V@./L\;;Y >_!J:[TNVN;66'RD7>I&0.E57I5JLY.-
ME;:_WBI5*<(I/KO^1<1@R!AT(R*6JFFQ30V$45QS(@P3ZU;KN@VXILY9*S:0
M44450@HHHH **** "HY_]1)_NFI*CG_U$G^Z: *=%%% &A1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\O?&K
M_DH]Q_UPC_K6+X$EC77WMY&"_:+>6-2?[VQL#\36U\:O^2CW'_7"/^M>?QR/
M#(LD;%74Y5AU!KLBKP.&;M-L[RWU&RLO"&DZ;<74:7EIJ+-/$3R@#'DU?N_%
M5GK&M:]HVH:F?[)NW+VUSO.U& !'_ 20!7FLLLD\SRRN7D=BS,>I)ZFF4<B#
MVC.\OM>L- \/:?HVGFTU'YFFN9%Y'F9.WMZ&MC3/$FD7.L:3KMQ>PVMV+66V
MN$W$;<*-I_$D_E7E=%'(@]HSN4UNS\1Z=/8ZQ>1I=6;M)87<QR&&[.QCU(Y.
M.O:KGA[QVDWB&";5(+2%(X?+$I   &, <<5YU13Y$+G9M:I9_:+-];5X%CGN
MFB$*'E< '.,=*T-*U&SA\":A927"+<R:A!(D9/)4*V3^&17,&61HA$7)C4Y"
M]@:93MI87-9W/4O%GB32O%/V_3)+V"&.VD,]I<1_*DW RK8ZGY>">YJQIUYX
M7T3FSO-/$,MKLW^<S3;RN3N!' SD<'TKR6BIY%:Q7M'>YV>IZY9QVWA26&99
MVL(D,T2GE2,9!_*MB.XT:R\37?BD:W:2Q21,8[16)F+,FS!&,<9]:\THI\HN
M=GI!U&QN?#4RZOJ>EW<8M?\ 1XD&+F.3 PN<9P.1UKB=7TDZ6]J//BE6YA$R
ME#D $D8/Y5FT^6:29MTKEVQC)H4; Y7.XU/Q+8Z3IVEZ3IJ6]]#;Q"5Y"<CS
M&^8CIV)(K7N->T>\@OM6-];1WFH:<$FMP?F$P#9_/(KRVBER(?M&>D2S:1JN
MNZ?XB.MVMM'#$GFVLC$2AD7;A1C'./7O5J'QII:OI^H.ZC.J33RPC[\:,P(.
M*\MHHY$'M&>@VLFF>'(-8N$UNTO)+\!($@<LR?.#E\@8Q^/2I]8NK#4/#;1Z
MA?Z;J.I'8EF]F,2CC_EIP,]NYKS>G1R/%(LD;%74Y!':CD#G.F\<LD>KVNGH
MV[[!:I;,?]H$G^M;/P:_Y'^W_P!PUP,LLD\K2RN7D8Y9CU-=]\&O^1_M_P#<
M-$E: 1=YW.L_:#_UVC?]M/Y+7B5>V_M!_P"NT;_MI_):\2I4OA'6^,****T,
M@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "OI_X)_\ ).+?_KXE_G7S!7T_\$_^2<6__7Q+_.LJWPF]
M#XCT2HKB!+FWD@D *.I4@U+17*=9\?>-O#4_A;Q/=6$B-Y.[="Y_B0]#7.U]
M:^/O ]KXST<PMB.\BY@EQT/H?:OE[7O#VI>&]1>RU&W:)U/RMCY7'J#WKKIS
M4D<56FXN_0RZ***T,@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU(WU1S=%*05)!!!'4&DKH, HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M***4 L0 "2>@% " $G &2:[31K+['8J&'SO\S5G:-HK(RW-RO(Y5#_6NBKGJ
MSOHC:G&VK"BBBL34**** (KB$7%M+"3@2*5)^M4]#TB'0M&MM-@):.! @8C!
M;'>M&BBX6ZA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %1S_P"HD_W34E1S_P"HD_W30!3HHHH T**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /E[XU?\E'N
M/^N$?]:\]KZ^UCP'X<U[4&OM1T^.:X90I=@.@Z51_P"%5>#O^@1%^0_PKHC5
M25CFE1;=SY/HKZP_X55X._Z!$7Y#_"C_ (55X._Z!$7Y#_"G[9"]@SY/HKZP
M_P"%5>#O^@1%^0_PH_X55X._Z!$7Y#_"CVR#V#/D^BOK#_A57@[_ *!$7Y#_
M  H_X55X._Z!$7Y#_"CVR#V#/D^BOK#_ (55X._Z!$7Y#_"C_A57@[_H$1?D
M/\*/;(/8,^3Z*^L/^%5>#O\ H$1?D/\ "C_A57@[_H$1?D/\*/;(/8,^3Z*^
ML/\ A57@[_H$1?D/\*/^%5>#O^@1%^0_PH]L@]@SY/HKZP_X55X._P"@1%^0
M_P */^%5>#O^@1%^0_PH]L@]@SY/HKZP_P"%5>#O^@1%^0_PH_X55X._Z!$7
MY#_"CVR#V#/D^BOK#_A57@[_ *!$7Y#_  H_X55X._Z!$7Y#_"CVR#V#/D^B
MOK#_ (55X._Z!$7Y#_"C_A57@[_H$1?D/\*/;(/8,^3Z]!^#7_(_V_\ N&O;
M_P#A57@[_H$1?D/\*O:1X"\.:'?+>Z?IT<-PHP' %*55-6'&BT[GEW[0?^NT
M;_MI_):\2K[(U[PGHWB4PG5;-+@PYV;ATSUK'_X55X._Z!$7Y#_"E"JHJPYT
MG*5SY/HKZP_X55X._P"@1%^0_P */^%5>#O^@1%^0_PJO;(GV#/D^BOK#_A5
M7@[_ *!$7Y#_  H_X55X._Z!$7Y#_"CVR#V#/D^BOK#_ (55X._Z!$7Y#_"C
M_A57@[_H$1?D/\*/;(/8,^3Z*^L/^%5>#O\ H$1?D/\ "C_A57@[_H$1?D/\
M*/;(/8,^3Z*^L/\ A57@[_H$1?D/\*/^%5>#O^@1%^0_PH]L@]@SY/HKZP_X
M55X._P"@1%^0_P */^%5>#O^@1%^0_PH]L@]@SY/HKZP_P"%5>#O^@1%^0_P
MH_X55X._Z!$7Y#_"CVR#V#/D^BOK#_A57@[_ *!$7Y#_  H_X55X._Z!$7Y#
M_"CVR#V#/D^BOK#_ (55X._Z!$7Y#_"C_A57@[_H$1?D/\*/;(/8,^3Z*^L/
M^%5>#O\ H$1?D/\ "C_A57@[_H$1?D/\*/;(/8,^3Z*^L/\ A57@[_H$1?D/
M\*/^%5>#O^@1%^0_PH]L@]@SY/HKZP_X55X._P"@1%^0_P */^%5>#O^@1%^
M0_PH]L@]@SY/HKZP_P"%5>#O^@1%^0_PH_X55X._Z!$7Y#_"CVR#V#/D^BOK
M#_A57@[_ *!$7Y#_  H_X55X._Z!$7Y#_"CVR#V#/D^BOK#_ (55X._Z!$7Y
M#_"C_A57@[_H$1?D/\*/;(/8,^3Z^G_@G_R3BW_Z^)?YUH_\*J\'?] B+\A_
MA72:/HMAH.GK8Z; L-NK%@B^IZU%2HI*R+ITG!W9?HHHK$W"LS6?#^EZ_:FW
MU*TCG0C&2/F'T/6M.B@#QK6/@'83R/)I6HR09^[%(,J/QY-<V_P \0[CLU/3
MMO;)?/\ Z#7T316BJR1FZ4'T/G7_ (4!XC_Z">F_F_\ \31_PH#Q'_T$]-_-
M_P#XFOHJBCVLA>Q@?.O_  H#Q'_T$]-_-_\ XFC_ (4!XC_Z">F_F_\ \37T
M511[60>Q@?.O_"@/$?\ T$]-_-__ (FC_A0'B/\ Z">F_F__ ,37T511[60>
MQ@?.O_"@/$?_ $$]-_-__B:/^% >(_\ H)Z;^;__ !-?15%'M9![&!\Z_P#"
M@/$?_03TW\W_ /B:/^% >(_^@GIOYO\ _$U]%44>UD'L8'SK_P * \1_]!/3
M?S?_ .)H_P"% >(_^@GIOYO_ /$U]%44>UD'L8'SK_PH#Q'_ -!/3?S?_P")
MH_X4!XC_ .@GIOYO_P#$U]%44>UD'L8'SK_PH#Q'_P!!/3?S?_XFC_A0'B/_
M *">F_F__P 37T511[60>Q@?.O\ PH#Q'_T$]-_-_P#XFC_A0'B/_H)Z;^;_
M /Q-?15%'M9![&!\Z_\ "@/$?_03TW\W_P#B:/\ A0'B/_H)Z;^;_P#Q-?15
M%'M9![&!\Z_\* \1_P#03TW\W_\ B:/^% >(_P#H)Z;^;_\ Q-?15%'M9![&
M!\Z_\* \1_\ 03TW\W_^)H_X4!XC_P"@GIOYO_\ $U]%44>UD'L8'SE+\!?$
M,2@MJ6F\G'5__B:?_P * \1_]!/3?S?_ .)KZ O?]6G^^*LCH*/:R#V,#YV_
MX4!XC_Z">F_F_P#\31_PH#Q'_P!!/3?S?_XFOHJBCVL@]C ^=?\ A0'B/_H)
MZ;^;_P#Q-'_"@/$?_03TW\W_ /B:^BJ*/:R#V,#YU_X4!XC_ .@GIOYO_P#$
MT?\ "@/$?_03TW\W_P#B:^BJ*/:R#V,#YU_X4!XC_P"@GIOYO_\ $T?\* \1
M_P#03TW\W_\ B:^BJ*/:R#V,#YU_X4!XC_Z">F_F_P#\31_PH#Q'_P!!/3?S
M?_XFOHJBCVL@]C ^=?\ A0'B/_H)Z;^;_P#Q-'_"@/$?_03TW\W_ /B:^BJ*
M/:R#V,#YU_X4!XC_ .@GIOYO_P#$T?\ "@/$?_03TW\W_P#B:^BJ*/:R#V,#
MYU_X4!XC_P"@GIOYO_\ $T?\* \1_P#03TW\W_\ B:^BJ*/:R#V,#YW3X >(
M-PWZGIVWO@OG_P!!KH]'^ 5C#(LFJZC)-CK%&,*?QX->RT4.K)C5*"Z&7HOA
M[2_#]H+?3;2.% ,$@?,?J>M:E%%9F@4444 %%%% !1110 56O_\ CV_X$*LU
M6O\ _CV_X$* )T_U:_04ZFI_JU^@IU !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!!>_\>K_ $I\'_'O'_NB
MF7O_ !ZO]*?!_P >\?\ NB@"2BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ J.?_4/]*DJ.?\ U#_2@!EG_P >
MD7^Z*GJ"S_X](O\ =%3T %%%% !1110!1O-)M;SET"O_ 'EK(E\,/G]S.#_O
MUTM%6IR6Q+BF<K_PC%W_ ,]H?U_PH_X1B[_Y[0_K_A7544_:R%[.)RO_  C%
MW_SVA_7_  H_X1B[_P">T/Z_X5U5%'M9![.)RO\ PC%W_P ]H?U_PH_X1B[_
M .>T/Z_X5U5%'M9![.)RO_",7?\ SVA_7_"C_A&+O_GM#^O^%=511[60>SB<
MK_PC%W_SVA_7_"C_ (1B[_Y[0_K_ (5U5%'M9![.)RO_  C%W_SVA_7_  H_
MX1B[_P">T/Z_X5U5%'M9![.)RO\ PC%W_P ]H?U_PH_X1B[_ .>T/Z_X5U5%
M'M9![.)S47AA\_O9P/\ =K6L](M;/E4W/_>:K]%)SD]QJ*04445!04444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !4<_^HD_W34E1S_ZB3_=- %.BBB@#0HHHH **BECD<C9+L_#-1^1/
M_P _!_[YH LT56\B?_GX/_?-'D3_ //P?^^: +-%5O(G_P"?@_\ ?-'D3_\
M/P?^^: +-%5O(G_Y^#_WS1Y$_P#S\'_OF@"S15;R)_\ GX/_ 'S1Y$__ #\'
M_OF@"S15;R)_^?@_]\T>1/\ \_!_[YH LT56\B?_ )^#_P!\T>1/_P _!_[Y
MH LT56\B?_GX/_?-'D3_ //P?^^: +-%5O(G_P"?@_\ ?-'D3_\ /P?^^: +
M-%5O(G_Y^#_WS1Y$_P#S\'_OF@"S15;R)_\ GX/_ 'S0()\\W!_[YH LT444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!5O?]
M6G^^*LCH*K7O^K3_ 'Q5D=!0 M%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !5:_\ ^/;_ ($*LU6O_P#CV_X$
M* )T_P!6OT%.IJ?ZM?H*=0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 07O_ !ZO]*?!_P >\?\ NBF7O_'J
M_P!*?!_Q[Q_[HH DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *CG_P!0_P!*DJ.?_4/]* &6?_'I%_NBIZ@L
M_P#CTB_W14] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?;+;_GXA_P"^Q1]LMO\ GXA_[[%?%O\ :NI?]!&\_P"_[?XT?VKJ7_01O/\
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MM5O_ ,]XO^^Q1]JM_P#GO%_WV* ):*B^U6__ #WB_P"^Q1]JM_\ GO%_WV*
M):*B^U6__/>+_OL4?:K?_GO%_P!]B@"6BHOM5O\ \]XO^^Q1]JM_^>\7_?8H
M EHJ+[5;_P#/>+_OL4?:K?\ Y[Q?]]B@"6BHOM5O_P ]XO\ OL4?:K?_ )[Q
M?]]B@"6BHOM5O_SWB_[[%'VJW_Y[Q?\ ?8H EHJ+[5;_ //>+_OL4?:K?_GO
M%_WV* ):*B^U6_\ SWB_[[%'VJW_ .>\7_?8H EHJ+[5;_\ />+_ +[%'VJW
M_P">\7_?8H EHJ+[5;_\]XO^^Q1]JM_^>\7_ 'V* ):*B^U6_P#SWB_[[%'V
MJW_Y[Q?]]B@"*]_U:?[XJR.@JC>7,!C3$\1^<?QBK(NK? _?Q?\ ?8H FHJ+
M[5;_ //>+_OL4?:K?_GO%_WV* ):*B^U6_\ SWB_[[%'VJW_ .>\7_?8H EH
MJ+[5;_\ />+_ +[%'VJW_P">\7_?8H EHJ+[5;_\]XO^^Q1]JM_^>\7_ 'V*
M ):*B^U6_P#SWB_[[%*MQ"QPLT9^C"@"2BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *K7__ ![?\"%6:K7_ /Q[?\"% $Z?ZM?H*=34_P!6OT%.
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** (+W_CU?Z4^#_CWC_W13+W_CU?Z4^#_CWC_P!T4 24444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P!]5!118+LG^V7/_/>3_OJC[9<_\]Y/^^J@HHL%V3_;+G_GO)_WU1]LN?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=(U76M?F%SH\T#;;8!7);/& O*X'K0Y/<2@F['D-%*>I^M)5F84444 %%%%
M!1110 4444 %%%% !1110 4444 =O\*O$,FA>-[,;\6]TWDR@GCGO^%?58((
M!'0U\1VDS07<4JG#(X(K[5L',FGV[GJ8U/Z5SUEK<ZJ#T:+%%%%8'0%%%% !
M1110 4444 %%%% !1110 56O_P#CV_X$*LU6O_\ CV_X$* )T_U:_04ZFI_J
MU^@IU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MFMS;WEL<-&YR.1D'CMTH"YJEU#A2PW'H*=7"V=G?6OCRSEO[LS3SP2%E7[B
M 8 %=9<:EY&JVUC]GE?SU+>:H^5>O!_*@"]36=5(#, 3TSWJ.ZN8;.VDN)W"
M11C+,:X>9KV_UO2M6N"\4,TS)!!G&$ ZGWZT =\3@9/04Q)HY2?+=6QUP:Y3
M4Q+K_BQM&:5X[*UB$DRH<>83@@?K2ZQX7M+#3Y+[2=]I=6R&0%7)#8YP<DT
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M:*0'(S2UTF(4444 %%%% !1110 5'/\ ZB3_ '34E1S_ .HD_P!TT 4Z***
M-"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#Y>^-7_)1[C_KA'_6O/:]"^-7_ "4>X_ZX1_UKSVNV'PHX*GQL
M****H@**** "E&,C)P.^*2B@#U32=$\%P3V>IV/C1['9M>6!_E<D<D=>_2N:
M^(/B*T\2>-)+^S!^S*$C5V&"VT $G\JY"BI4=;EN=U9(]!^*NKZ=K.K:>^G7
MD5PB6J(S(V0IYX-;.I^,M,\,>#])T+1OL6IAD\RZWJ'4,<G!R#SS7DM%+D5D
MA^T=VSU8>,--\5_#W4M)U0V>G7%MB6T1 %#D9^4 #V%9?PQUC3M(B\0KJ%Y%
M;F>Q,<6\XWMGH*\]HHY%:P>T=TS?\(?V VN+'XB5_L,B%=Z,1L;C!/MUKN="
MF\/>!;;6[F/Q!!J!NX&AM[> [B<@@%A^/Z5Y/13<;BC.PYVWNS8QN).!3:**
MH@**** "BBB@ KT'X-?\C_;_ .X:\^KT'X-?\C_;_P"X:F?PLNG\2.L_:#_U
MVC?]M/Y+7B5>V_M!_P"NT;_MI_):\2J:7PE5OC"IK1@EY S'"K(I)/89J&BM
M#(]N\96_A/QD-)F;Q=96K6MJ(F3.><#_  K%CU+1=#^'>J:1;ZO;W<\>H+)"
M%.#*H*G('IQ7E=%9J&EKFKJ=;'L6M2>'?%NL:%JZ:]!;F*...:W;_6!ACH._
M(K8UO6M.T[XH:]8:G<K:PZA8+%Y[=$.&']:\)MYWMKB.>/[\;!ESZBK^O:[>
M^(]5?4K]E-PZA25&!@4>S'[70]"BFT+0OAUK^E1Z]:W=Y=2K(B1-D$;EZ>O
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M)V=SJDKJQ\345J>(M&N- UZ[TVY4AX7(!(^\/4>U9==RU//:L%%%% @HHHH
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MD)@ @$_3]:9_PB=G/<V^H>'/$%M:V3(K2>;<%9(FQR./\:\])).22?K0&8#
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MIU-3_5K]!3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR2['$5M>&O#&H^*-4CLK"%FR?GDQP@]37I_A[X"W3RI+KMXL<8/S00\D_P#
MO_K5[+H7AS2_#=D+32[5(8_XB!RQ]2:SE52V-846_B*WA+PO9^$]"BTZU4$@
M9ED[NW<UO445S-W.I*V@4444#"BBB@ HHHH **** "BBB@ HHHH *K7_ /Q[
M?\"%6:K7_P#Q[?\  A0!.G^K7Z"G4U/]6OT%.H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (+W_ (]7^E/@
M_P"/>/\ W13+W_CU?Z4^#_CWC_W10!)1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5'/_ *A_I4E1S_ZA_I0
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M  I_QC_T#3_WVO\ C1_PI_QC_P! T_\ ?:_XU]3T4>VD'L(GRQ_PI_QC_P!
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MT@]A$^6/^%/^,?\ H&G_ +[7_&C_ (4_XQ_Z!I_[[7_&OJ>BCVT@]A$^6/\
MA3_C'_H&G_OM?\:/^%/^,?\ H&G_ +[7_&OJ>BCVT@]A$^6/^%/^,?\ H&G_
M +[7_&C_ (4_XQ_Z!I_[[7_&OJ>BCVT@]A$^6/\ A3_C'_H&G_OM?\:/^%/^
M,?\ H&G_ +[7_&OJ>BCVT@]A$^6/^%/^,?\ H&G_ +[7_&C_ (4_XQ_Z!I_[
M[7_&OJ>BCVT@]A$^6/\ A3_C'_H&G_OM?\:/^%/^,?\ H&G_ +[7_&OJ>BCV
MT@]A$^6/^%/^,?\ H&G_ +[7_&C_ (4_XQ_Z!I_[[7_&OJ>BCVT@]A$^6/\
MA3_C'_H&G_OM?\:/^%/^,?\ H&G_ +[7_&OJ>BCVT@]A$^6/^%/^,?\ H&G_
M +[7_&C_ (4_XQ_Z!I_[[7_&OJ>BCVT@]A$^6/\ A3_C'_H&G_OM?\:/^%/^
M,?\ H&G_ +[7_&OJ>BCVT@]A$^6/^%/^,?\ H&G_ +[7_&C_ (4_XQ_Z!I_[
M[7_&OJ>BCVT@]A$^6/\ A3_C'_H&G_OM?\:/^%/^,?\ H&G_ +[7_&OJ>BCV
MT@]A$^6/^%/^,?\ H&G_ +[7_&C_ (4_XQ_Z!I_[[7_&OJ>BCVT@]A$^6/\
MA3_C'_H&G_OM?\:]U^&&A7_AWP7#I^HQ>5<+,[%<@\$\=*[*BIE4<E9E0IJ+
MN@HHHK,T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH JWO\ JT_WQ5D=!5:]_P!6G^^*LCH* %HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *K7__ ![?\"%6:K7_ /Q[?\"% $Z?ZM?H*=34_P!6OT%.H **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (
M+W_CU?Z4^#_CWC_W13+W_CU?Z4^#_CWC_P!T4 24444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1S_ .H?Z5)4
M<_\ J'^E #+/_CTB_P!T5/4%G_QZ1?[HJ>@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HY_\
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M+_\ Y]H/R/\ C7(45S_VGB_YS;ZCA_Y3K_\ A8%__P ^T'Y'_&C_ (6!?_\
M/M!^1_QKD**/[3Q?\X?4</\ RG7_ /"P+_\ Y]H/R/\ C1_PL"__ .?:#\C_
M (UR%%']IXO^</J.'_E.O_X6!?\ _/M!^1_QH_X6!?\ _/M!^1_QKD**/[3Q
M?\X?4</_ "G7_P#"P+__ )]H/R/^-'_"P+__ )]H/R/^-<A11_:>+_G#ZCA_
MY3K_ /A8%_\ \^T'Y'_&C_A8%_\ \^T'Y'_&N0HH_M/%_P X?4</_*=?_P +
M O\ _GV@_(_XT?\ "P+_ /Y]H/R/^-<A11_:>+_G#ZCA_P"4Z_\ X6!?_P#/
MM!^1_P :/^%@7_\ S[0?D?\ &N0HH_M/%_SA]1P_\IU__"P+_P#Y]H/R/^-'
M_"P+_P#Y]H/R/^-<A11_:>+_ )P^HX?^4Z__ (6!?_\ /M!^1_QH_P"%@7__
M #[0?D?\:Y"BC^T\7_.'U'#_ ,IU_P#PL"__ .?:#\C_ (UIZ#XNNM5U-;66
M&)5(ZJ#G^=>>UT/@S_D8(_H:Z,)F&)G7A&4]&S'$8.A&E*2CK8Z_Q/XAN-#:
MW$,4;^9G._/:N>_X6!?_ //M!^1_QJS\0OOV7_ OZ5P]:YCCL12Q,H0E9+_(
MSP6$HU*$92C=G7_\+ O_ /GV@_(_XT?\+ O_ /GV@_(_XUR%%<7]IXO^<ZOJ
M.'_E.O\ ^%@7_P#S[0?D?\:/^%@7_P#S[0?D?\:Y"BC^T\7_ #A]1P_\IU__
M  L"_P#^?:#\C_C1_P + O\ _GV@_(_XUR%%']IXO^</J.'_ )3K_P#A8%__
M ,^T'Y'_ !H_X6!?_P#/M!^1_P :Y"BC^T\7_.'U'#_RG7_\+ O_ /GV@_(_
MXT?\+ O_ /GV@_(_XUR%%']IXO\ G#ZCA_Y3K_\ A8%__P ^T'Y'_&C_ (6!
M?_\ /M!^1_QKD**/[3Q?\X?4</\ RG7_ /"P+_\ Y]H/R/\ C1_PL"__ .?:
M#\C_ (UR%%']IXO^</J.'_E.O_X6!?\ _/M!^1_QH_X6!?\ _/M!^1_QKD**
M/[3Q?\X?4</_ "G7_P#"P+__ )]H/R/^-'_"P+__ )]H/R/^-<A11_:>+_G#
MZCA_Y3K_ /A8%_\ \^T'Y'_&C_A8%_\ \^T'Y'_&N0HH_M/%_P X?4</_*=?
M_P + O\ _GV@_(_XT?\ "P+_ /Y]H/R/^-<A11_:>+_G#ZCA_P"4Z_\ X6!?
M_P#/M!^1_P :/^%@7_\ S[0?D?\ &N0HH_M/%_SA]1P_\IU__"P+_P#Y]H/R
M/^-'_"P+_P#Y]H/R/^-<A11_:>+_ )P^HX?^4Z__ (6!?_\ /M!^1_QH_P"%
M@7__ #[0?D?\:Y"BC^T\7_.'U'#_ ,IU_P#PL"__ .?:#\C_ (T?\+ O_P#G
MV@_(_P"-<A11_:>+_G#ZCA_Y3K_^%@7_ /S[0?D?\:Z_P_J<FKZ4MW*BHQ8K
MA>G%>0UZAX(_Y%N/_KHU>GE.,KUJ[C4E=6.#,<-2I4>:$;.YT=%%%?2'AA11
M5._U2STR+S+J94'8=S4RE&"YI.R'&+D[11<HKAKSX@ ,19VNY>S2'!K.;QYJ
MA/"1 >F/_K5YL\XPD7:]_1'='+,1)7M8]*HKS3_A.]5](O\ OD?X4?\ "=ZK
MZ1?]\C_"H_MK"^?W%_V5B/+[STNBO-/^$[U7TB_[Y'^%'_"=ZKZ1?]\C_"C^
MVL+Y_<']E8CR^\]+HKS3_A.]5](O^^1_A1_PG>J^D7_?(_PH_MK"^?W!_96(
M\OO/2Z*\T_X3O5?2+_OD?X4?\)WJOI%_WR/\*/[:POG]P?V5B/+[STNBO-/^
M$[U7TB_[Y'^%'_"=ZKZ1?]\C_"C^VL+Y_<']E8CR^\]+HKS3_A.]5](O^^1_
MA1_PG>J^D7_?(_PH_MK"^?W!_96(\OO/2Z*\T_X3O5?2+_OD?X4?\)WJOI%_
MWR/\*/[:POG]P?V5B/+[STNBO-!X[U0'E8C^ _PJ_:?$!]P%W:C;W9#D_E5P
MSC"2=KV^1,LLQ$5>USO**S]-UJQU5-UM,"W=#U%:%>E"<9QYHNZ.&4)0=I*S
M"BBBJ)"BBB@ HHHH JWO^K3_ 'Q5D=!5:]_U:?[XJR.@H 6BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JM?_
M /'M_P "%6:K7_\ Q[?\"% $Z?ZM?H*=34_U:_04Z@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH @O?^/5_I
M3X/^/>/_ '13+W_CU?Z4^#_CWC_W10!)1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5'/_J'^E25'/_J'^E #
M+/\ X](O]T5/4%G_ ,>D7^Z*GH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J.?_42?[IJ2HY_
M]1)_NF@"G1110!H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 >7>-?^1DD_ZYK7.UT7C7_D9)/^N:USM?!X[_
M 'F?JSZ["?P(>B"BBBN4Z HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ KH?!G_ ",$?T-<]70^#/\ D8(_H:ZL#_O,/5&&*_@2]#7^(7W[
M+_@7]*X>NX^(7W[+_@7]*X>M\V_WN?R_(QR[_=H_UU"BBBO..T**** "BBB@
M"]8:3>:DLC6L6\1C+$G%4F4HQ5A@@X(KN+*5_#NC6(6(F6[DW2C&<#I6?J&C
MQ#QC! ZDVUTX8=LYZ_SKTJF!M3BX_%I?Y['%#%WG*^VMOEN<M4L=O++%)(D;
M,D8R[ <"M^TTBTE\83:<Z$VZEL+D]ES6EI8LH/#VL@VQ98G*N-Q^89XJ*6!<
MF^9V6OX(JIBU%>ZK[?B<33XHVFE2-<;F.!FN@M].T]=+FUBYB?[.9-D4"G^M
M.GTBRFM+/4;$.D4D@22,GE?QJ%@IVO==[=;=RGB8WM\OGV,74=/GTR[-M<;?
M, !^4YJI7:/H-E)XCN[63S#%'"&!+DD'\:KQZ=HL^DS:B()D2VDV,F?O_K[U
MK/+Y<SY6DM>O;<B.,CRJ]WM^)R=%=5)HUA/+I=Q;HR6]R^QXV/>K,>B:/<:M
M=:8D4R/#SYF?3J.M2LOJ-VNO+STN-XR"6S_K0XRBNH;3-,O=)O9[2*2*2S?:
M2QSOJKJ6EVUN=+$:$?:%4R<]<UG/!SBN:ZM_P;%QQ,&[=?\ @7,&BNSC\/:<
M=:N+=XV\F.W\S 8YS5%=/TO4=%O;FRBDBDM1G+'[PY]_:K>7U%U5]?PW)6,@
M^CZ?CL<U178KX<MK.WMEGLYKJ64 NRL $S^(K US35TO4F@1MR$!E)]^<5G6
MP=6C#GD53Q-.I+EB0V.F7>HNRVT>[:,DDX _&FWNGW.GRB.YC*,1D=P?H:ZG
M0K!V\.RPSS+;?:SF!LX9C_A63=Z9JDMK<->2@)8C #]2#Z>O6MIX/EHJ23NU
M?^OEJ9QQ-ZCBVK+^OS,*BBBO/.P**** "BBB@ KU#P1_R+<?_71J\OKU#P1_
MR+<?_71J]G(_]Y?H_P!#S,V_@?,Z.BBF2R+#$TCG"J,DU]:W;4^<W,CQ%K\6
MBVG&&N'&$3/3W->77E[<7]PTUS(7<^O:I]9U%]4U.6Y<G!.%'H*H5\5F..EB
M:C2?NK8^IP6$C0A=_$PHHHKSCM"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH EM[B6UF6:%RCJ<@BO2_#'B-=7A\B<@72#G_ &O>O+ZLV%Y)I]['
M<Q$AD.?K[5W8#&SPM2_V7NCDQ>%C7A;KT/:J*KV5RMY90W"'*R+FK%?;Q:DK
MH^5::=F%%%%,04444 5;W_5I_OBK(Z"JU[_JT_WQ5D=!0 M%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5:__
M ./;_@0JS5:__P"/;_@0H G3_5K]!3J:G^K7Z"G4 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $%[_QZO]*?
M!_Q[Q_[HIE[_ ,>K_2GP?\>\?^Z* )**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "HY_]0_TJ2HY_]0_TH 99
M_P#'I%_NBIZ@L_\ CTB_W14] !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%17,WV>UEF(SY:%L>N!
M5'P_K$6OZ':ZE$NU9T#%?[I]*+=17UL:=%%% PHHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *CG_U$G^Z:DJ.?_42?[IH IT444 :
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% 'EWC7_D9)/^N:USM=%XU_Y&23_KFM<[7P>._P!YGZL^NPG\"'H@
MHHHKE.@**** "BBB@#J/[#TK3K: ZK<RK/,NX",<+]:J0VV@1W4\=S=3R(&'
ME-&O4=\UH6NIW#K;V&K:4;B/A5?:=P!]ZRO$&G0Z9K9@@)\OY6 /\.><5ZU5
M0C!5*<%966J=]NO<\^FYRDX3D[OM:WR[&MJFC^'M+(2:6Z\QTW+CD>U96@:/
M'J^HNCLRVT8+,W3BK_C7_C]M?^N*_P!:NZ99BS\*2;KB.WGO#PTF> /_ -5:
M2I0GBG'E2C'7U(524<.I<SO(P-8TN'2]8$!9C:MA@PY.TUM:?H_AW4EF,$MT
M?)3>^>.*?KEFMUX8MIEGCGFM/D=H^X_R*J>#_N:I_P!>QHC2A3Q7LW%.,M?P
M"524\/SJ336GXE;[!HM[?0P6-U)'&03(\_&/I4\>CZ5J,5VNGS2^=;(7)?HP
M%85E97-_,8K5"\@7=@''%=1H$QNM,O=/DMA;^5"29E!!)&>N:QPW)6E:4$KW
MZ/739=C2OS4XWC)Z6_/=]SCJ*4C#$9S@]:2O+.\**** "BBB@ KH?!G_ ",$
M?T-<]70^#/\ D8(_H:ZL#_O,/5&&*_@2]#7^(7W[+_@7]*X>NX^(7W[+_@7]
M*X>M\V_WN?R_(QR[_=H_UU"BBBO..T**** "K%D8!>PFZ)\@,"^!GBJX!)P
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M5)UHI]SRZBBBO@CZ\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** /3? URT^A^63_J7V#^?]:Z:N1^'Z%=(N"?XILC\A775]SES;PL
M&^Q\GC4EB)V[A1117:<H4444 5;W_5I_OBK(Z"JU[_JT_P!\59'04 +1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 56O_ /CV_P"!"K-5K_\ X]O^!"@"=/\ 5K]!3J:G^K7Z"G4 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M $%[_P >K_2GP?\ 'O'_ +HIE[_QZO\ 2GP?\>\?^Z* )**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HY_\
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M6X!/K5GQ*-VD$9QF1!GT^85,)U%AJCD_>5QRC!UH)+30D%OJY /V^'_OS_\
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M **** "BBB@ HHHH **** (+W_CU?Z4^#_CWC_W13+W_ (]7^E/@_P"/>/\
MW10!)1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5'/_J'^E25'/\ ZA_I0 RS_P"/2+_=%3U!9_\ 'I%_NBIZ
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&10 449%&10 449%&10 449%&10 449%&10 449%&10 449%&10 449%&10
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MBLN]U22UN3$L2L  <DU7_MR7_GBO_?5 &Y16'_;DO_/%?^^J/[<E_P">*_\
M?5 &Y16'_;DO_/%?^^J/[<E_YXK_ -]4 ;E%8?\ ;DO_ #Q7_OJC^W)?^>*_
M]]4 ;E%8?]N2_P#/%?\ OJC^W)?^>*_]]4 ;E%8?]N2_\\5_[ZH_MR7_ )XK
M_P!]4 ;E%8?]N2_\\5_[ZH_MR7_GBO\ WU0!N45A_P!N2_\ /%?^^J/[<E_Y
MXK_WU0!N45A_VY+_ ,\5_P"^J/[<E_YXK_WU0!N45A_VY+_SQ7_OJC^W)?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT-5+^]1=/OC!,OGP0NV <E2%R*0R_17GWASQ;=)\,IM=U&=);J,RD%@%W8;
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M0Q2)')*JO(<(I/+?2@"6BHY;B&#;YLBIN.%W'&33)+RVB=DDGC1E&XAFQ@4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !4<_^HD_W34E1S_ZB3_=- %.BBB@#0HHHH **** "BBB@ HHHH ****
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MG6_D/'< F-QSR,#.>:5TQV:.>\.75E;?$ZUMM'TNYTRQN[5_-MY8C&KD%0&
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M %%%% !1110 5'/_ *B3_=-25'/_ *B3_=- %.BBB@#0HHHH **** "BBB@
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M5H#P1IBZ4M@LDZHDIE20-AE8_P#ZZO:)X<L="\YK??)-,09)I#EFH UZ***
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M9L9_I19A=%ZBHKE2]M(HD,>5(WCJ/>N3\,7MEHOAF:ZNM<>^MUG(-Q(/N$G
M7IZT6"YV-%<^WC;PZMVEL=3B\Q\8.?EY]^E;%U?6ME:M=7,\<4"C)=F %%F%
MT6**\M\?^,;*]T:S_L;4OWHO45@ORDCGUZBNEO(4/Q#M'.MRQOY!Q8 ?*WOT
M_K3Y1<QUM%9&J^)]'T618[Z]CCD/\ ^9OR%3Q:YIDVG?V@E[#]E'60N !_\
M7I68[HT**Q=-\6:)JUV;6SOXWF'13QGZ9ZUR^O\ C^UTSQQI^G_;"EH(V-R
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M0 4444 %1S_ZA_I4E1S_ .H?Z4 ,L_\ CTB_W14]06?_ !Z1?[HJ>@ HHHH
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M&#FFL/*-"=./6]A>U3JQF_(JQP:N"I:]B*]QY0_QK4_AY]*RO[)NO^@K<_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P"/2+_=%3T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 UT62-D<95A@CU%1VEK#96L=M;QB.&)0J*
M!P *FHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ J.?\ U$G^Z:DJ.?\ U$G^Z: *=%%% &A1110 4444 %%%% !1110
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MPVO_ #P3\J/L-K_SP3\J .7HKJ/L-K_SP3\J/L-K_P \$_*@#EZ*ZC[#:_\
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MKJ>A!J&^U"TTRT>[OKB.WMT^])(< 4 6:*@L[RVO[6.ZM)DF@D&4D0Y#"IZ
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MT =;YB?WU_.CS$_OK^=<EN;U-&YO4T =;YB?WU_.CS$_OK^=<EN;U-&YO4T
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=+>Z9<R1(Q(4_6AQL@4KLN4445)04444 %%%% !1110 4444 %%%% !1110
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MC0!YCX1UNX\._!;3+Z#3IKZ5(S^XB!R1O.>QKBO&7C'P[XNT62VM_#-P-=?
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M1VUM&L<,8PJ+T I-IHI)IDU%%%24%%%% !1110 4444 %%%% !1110 4444
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M%%% !1110 4444 %%%% !1110 4444 %=39J5M(E/9:YRUA,]PD8'4\UU(&
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M/4$9%0+I]FD>Q;:(+G. HIJ20.+9P=SG_A=6G\?\N#_R%.\7?\E-\*\?W_\
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MBBB@ HHHH **** "HY_]1)_NFI*CG_U$G^Z: *=%%% &A1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5'/_J'^E25'/\
MZA_I0 RS_P"/2+_=%3U!9_\ 'I%_NBIZ "BBB@ HHHH **** "BBB@ HHHH
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M^VY_^>:?K6910!I_VW/_ ,\T_6C^VY_^>:?K6910!I_VW/\ \\T_6C^VY_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *CG_P!0_P!*DJ.?_4/]* &6?_'I%_NBIZ@L_P#C
MTB_W14] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %1S_ZB3_=-25'/_J)/]TT 4Z*** -"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#G=6_X_V_W15&KVK?\ '^W^Z*HT#"BBB@ HHHH **** "BBB@ HHHH
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M@TG3+B\N'V1Q(3G&?I7 >'!<>&?B7-X:AO)[G39K;ST6>0NT1^;C)R>PKO\
M5X8Y]'O$EC61?)?Y6&1T-#6H)Z''> _'MIKMF(KJ[+7TL[[$V'[N>.<8K?N/
M&GAZUO1:2ZE$)2=O'*@^Y' KD_A-#I]O\/TO[B&!3'+(6F9!D 8[UFWU_;ZE
MH5\="\'1RV#1R'[9-&%W8!RP(!SC^E4XKF)4GRH]/O=7L-/@AGN;E$BG<)&^
M<AB>G-5;'Q1HNI7-U;VE_%*]JNZ;!X4>N>E>3:FTFI?![P^LTC[FO(X]P/(
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M6]XDT#5K;QFWB*TTRWU>W>$1M;2\LF.ZC!_I3LA)OH=S8ZK8ZC9?:[2YCD@
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M-W9<59!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M 'C7/5T.D?\ '@O^\: +]5K^0Q64C X.,"K-4-7S]A./[U CGJ***!A1110
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MQN).-W3'/I4C_#Q_^$%B\.)?(/+G642E#C (.,?A7>49I\S%RHI2:;#<Z/\
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M:*AMQ.-_GE3S\NWTJ:@ HHHH **** "BBB@ J.?_ %$G^Z:DJ.?_ %$G^Z:
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M* M$O_ AQ7#V?G6OA_Q_%8AE*7(V*G8$)G'X$UZ#X.M],/@'3E"0&W:U0R9
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M;_:_.E&D6P/0GZT <\ 2<#DUIV6E/(P><%5].YK7BM((?N1J*FH$(JA%"J,
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M]\BC[/!_SQC_ .^14E% $?V>#_GC'_WR*/L\'_/&/_OD5)10!']G@_YXQ_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ J.?_ %$G^Z:DJ.?_ %$G^Z:
M*=%%% &A1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244
M +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244
M +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244
M +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244
M +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244
M +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244
M +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244
M +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244
M +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244
M +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244
M +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244
M +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244
M +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +4<_^
MHD_W33ZCF_U$G^Z: *E%%% %ZBDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH
M6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH
M6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH
M6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH
M6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH
M6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH
M6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH
M6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH
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M)CE^YA22?;'K[5SEG(NF:S&+M"6%GCIG!R.*6"TEW6<K0,J2WC2JA'W5)&*
M-T^(]-"(WFOACC_5ME?][T_&I[O6+.R">;(S%QE1&I<D>N!VK#BMV\WQ"3%]
M]QLXZ_(O2J<=O+;7%M<3R2PQR6L:AU0-M(7D'/2@#IIM;L8(XI'F)68$IM4M
MG'TJI?\ B2VAT:2]MBSD':%,9R#[CJ*H6EDL=_I.Q)'B#2-^\4#'RGM45Y;3
M-;Z\J1$[GC*@#KQSB@#I[.]BOK83Q"0+T_>(4/Y&J\6MV,UW]E21O,S@90A2
M?8]#4D-XMQ8M/"A;"G"D=2!7+++=WM_8.V0(YR6A2( 1\'OUH Z%O$6G)*8S
M*^0Y1B(SA2/4]!4E]K-I8X5W8R,NY0B%OQ..@K#-LW_".:TOE?.\LQ'')]*6
M!C87]PUS$S>? !$V,]@-M &SH5])?Z8+B4@L9& (] >*=_;=E]L^RAW:3.,K
M&2N?3=TJMX;1TT7:R%&,DGRD=.:IZ1<+96HL)[=S=!\'"YS_ +7^?2@#4FUV
MP@N?(>5MP."RH2H/NW0476NV%G.T,LK>8JAR$0MP>AX^E<_$3::1>:;-;.UU
M)*Y4;<[\L2#^5265E-#JEVLR;F73XTW$9R?FS0!N1:Y83W2VZ2DN_P!TE#M;
MOP>E,/B'3A,8C,P(<QDE#M##L3T%8?V9UTK1@L1#)<L3@<C[U,FM7;0=34PD
MLU[(1QR1DT =+::Q9WK2+%(08QE@ZE>/7GM[TVWUNQNIS#%(VX9P60J&^A/!
M_"L34;.:;5"L"%2U@%R.,GGBHK"".4V44DMP9H,$Q^4 $(&.3Z4 ;\.N6$[[
M8Y6("EBQ0A0!ZGH#[5!)KEO<6=P;25DDC7(>2)@.O7W_  K+@LII/",D449$
MI?<5Q@L!U'XU8GO8KO19;>"W<2+  ?EQMP1Q0!?.MVMI;0?:Y6:1T#,8XR1]
M3Z#ZTRZU*4:BL4,BB%K4RAB,\Y/-8MS<79B^QJODC[.H#"(,TN0>.?\ /-30
M0RAK?<C9&GNIR.^6XH T(?$-O;V%N]Y)+(SQAS)%;N5(_+BK+^(+!+:*<O(4
ME&5VQ,3CU(QQ7/K=E=)T[3)=\430J9WP>!@?+^/]*M7]Y(9$@M (;=X/DE6(
M,7ZC;S_GF@"]J/B."SELU3>ZSL"2L;-\N.V.]26NIA[Z[:2X06Z1JZJR%64'
M/7/TK%C26VL])FEC?;#.=_'(ZT7UO/>7>HO#$Q!6%\?W@&)(H Z&UUNQNV=8
MI'#("Q#H5R/49Z_A4<'B+3KB6...5R9,;6,9"GVSTS61<-_:5Y9M:1,HMT8R
MMMQCY2-OYFF0VS+X6TY?*PZSQDC'(H ZJ:>.WA:65PJ*,DFJ$6O6,\<K1M)F
M-=Q5HF#$>PQD_A4.OV\UQI(6)"Y5T9D'< @FJ9<:GKMG/:Q,L<$;>8Y7'7'R
MT 3^'=7DU;S99';U">4RA1]3P:1]1NKK5;JUANH;;R,!5D'+Y&<]>E3^&T:/
M1(5=2K#/!^M4=8.GW<DJ3VDRW2#$;J,,Q]B#0!K7&JPZ=%&+V0F4CYO*C+?C
M@=!2W&M6-LD;R2DB5=R;5+%OIBN>,^I1+!8S+Y3_ &=09O+#M(QSE>?\\T:=
M;R>9HGFQ$[/,W;ATY:@#HHM8LIK)KM9L1*<-N&"#Z8/.:B37K.:WFEB:0M$I
M8HT9#?D><5@SVLWVB\E6!GCCNTE9 /O*,YJTS?VCJ_VFUB988K=E=]N-QP>/
MUH AL]?N+NWCE^TB-I+@( T# 8YX!]:ZJ218H6E<X5%+,<=A7)""7^P],7RV
MW+>Y(QT'S5M7>GQ1P7=R'E+F%^#(2OW3VZ4 /B\0:=-.D*2ME^%8H0I_'I3Y
M=;L8;P6KR,)"VW.P[0?0MTKFHY1>Z-9V-M WG[\D[<;.3S_GUI=4GO+S[3%M
M,6R8XA2($L ?O$T =%+KUA#/)"7D:2-MKJD3-CC/8=*I:=XHMKF"XEG\Q!$[
MG=Y+ ; >.?7VIFBP,NJZJ[)@NRA6(Z_(M9^6'A[5;$Q/YV^5L8Z@MQ0!T5IK
M5E>SF&&1]X&?G0KD>V>M(FN6+W?V996WYV[MAVD^F[I6?>VSO?:<L2;3Y,BY
M QC*''ZUEV=H/)CL[B6X659#^Z$8ZY/.: .F&M61NFMQ(YD5BC80X4CKD]J2
M#6[&YNOL\<C;\X!9"%;Z$\'\*S;:TDDLM:1$VRRS2A3CD\#%9]I;+,+6W>:X
M\^(G$?E ;#@C.?2@#3UGQ%!:VUPEL[&XC!Y\LE0?3=TS6N]W';V*W,[;4"@L
M<>M<C,QC\/76G-;N;L.Q("YS_M5NZWQX:D!'2-,C\J +%MKEC=W'D12-OQD;
MD*AA[$]:(-=L+A]L<K$!2Q8H0HQZGIFL6-UU";2DMH6'V=0TC[<!0!T_SZ40
M6,TGA%H8HR)2^\KC!8 Y(_&@#;M=;L;R8Q12,& R-Z%=WTSU_"FIK^GR7'D+
M*^[. Q0[6/L>AK'F==1N-.6WA9?LWS3-MQM 4@BJ.F-'LLVNWG6U20>2OEKL
M!XQ\W4T =.FNV$D_DI([-SDB,X7'J>U.M=:LKR5HHI'WJ,X="N1ZC/6LG2_,
MM=-U*:.WWR&4E5(^]5.S:YN=:L[AV+J(7! C"JG3CCK0!N+XCTUF $S<@D$Q
MD X[ ]S[5+%K=C-:27*RD1Q??#J58?@>:P%M2='T=3#\RS$L-O3FI[ZVB?4=
M5$\4GD,(CF,=#MZT ;UEJ$%_&9("^ <$.A4_D:IC5!;W%^]U<)Y$#*,*ARN0
M/SJ+09KF1KA9"98%.(IF0*6_*LS48)'&M 1D[YHB..O"T =!9ZQ9WT[0PNWF
M+SAT*Y'J,]:JZQKJ:5=VD+*["9CNVQLW&#TQWS3)HB/$=@Z)A1#("0..V*37
MB8[K3+C8QCAF8N0.@*D4 -7Q%#%?W2W#.(56-HP(V+ ,"3D=JT;C5K.VMHYW
MD)23[FQ2Q;Z <UG6J";4M4G,7$D<>TL.HVFL:.UGAM]*N9'DCB2(JS*H8H<G
MG!^M '86MY#>P":!]RGU&"/J.U4M,OIKF_U"*0C;!,43'I3-"ACCBGDC>5Q*
M^2SJ%S] *J13'2-8OFN(W\FX;S$D R,^E "3ZY<VZ:NV%/V:5$CXX (7D_G6
MAIS7CN'>]M[F KSY8Y!_.LVS+11:C?7-G(\-U*&$>T$[0 ,D?A3-+MXEU\3:
M:DJ6?EGS02=I;M@?G0!U&:,TF:,T +FC-)FC- "YHS29HS0 N:,TF:,T +FC
M-)FC- "YHS29HS0 N:,TF:,T +FC-)FC- "YHS29HS0 N:,TF:,T +FC-)FC
M- "YHS29HS0 N:,TF:,T +FC-)FC- "YHS29HS0 N:,TF:,T +FC-)FC- "Y
MK&\5:,/$'AJ]TWC?-&1&3T#8X/YUL9HS0G8&KGQ7J.G7.E7\UE=Q-'-$Q4AA
MC/O56OKKQ+X&T+Q4,ZC: S <2H=K?B1UKE+;X&^&89P\TMQ.@/W"Q4?F#72J
MRMJ<CH2OH>5_"SPI<>(?%4%PT;"SM&$LDF.,CH ?7.*^I,U0TO2;'1;)+33[
M9((5[*.OU/>KV:QG/F9T4X<BL87B+PI8>)O)^VR3IY))7RGV]:SM)^'>CZ/J
M4-_;S7;2Q'*AY,C^5==FC-3=E617O[2/4-/N+.7_ %<\9C;Z$5YQX>\2R> K
M4^'O$5I=)#;,WV6Z@@:570DGG:#@\FO3\U')%%,NV6-)%]'4$47 \SU749/B
M5J5CIFFV5PNC6\ZSW5S<1-'OQT50P&>IK:TZ%H_BQJ!V,(QI<2AL<<.W>NT1
M$B7;&BHHZ!1@4@1!(9 B[R,%L<X^M%PL>;SZ?-?_ !1\10JKJ)M-5%DQQG:G
M>H?"?CBS\-^'+;0=3L;^/4[(>288[5W$A'0A@,8->G".,2&01J'(P6QR?QI#
M!"THE,,9D'1RHS^=%PL>=:G?GPOX\7Q'>6MR^G:C9B-GBB9V@;(/( SVI;#4
M/^$S^(MCJFGVMPFFZ;"ZFXFB:/S&?' # $_=KT9T212LB*ZGJ&&121HD2;(T
M5%'0*,"BX6/&M,T:^U#P%X@AMX',Z:F)UC88WA2K'K["M+7O'5IXA\'RZ%I]
MA?OJMY"(/(>U=1&QZDL1C KU-(XX@1'&J G)VC&::L$*2&188UD/5@H!/XT[
MA8\B\8P/H0\,01R745Y;Q.DES8J9)E&W@;0"<9SSCUK:^'FHZ,^IWD)NM1GU
MFY0/*^H0-&SJ,#C*CCI6UKWA.^N]>77=&U0V6H"(0MNC#JRC/KG'4T[0_"EW
M;ZS_ &UK>H_;]06,Q1E8E144D'C'7I1?05CA=9TJ^A\=7/A6V!_LS6)DNVVG
MA%#$R#\1BO8[>%+:WC@C&$C4(H]@,5@V?AV2/QA>Z]=3B1I(UAMT'2-1G/XG
M/Z5T.:38TA<UY;XITJ33]5DDVGR93N1@./I7J.:@NK2"]A,-Q&KH>Q%<&/P:
MQ5+EO9K8[,'BGAZG-T>YXQ3XHGGE6.-2SL<  5Z')X&TUY-R/(B_W0<UIZ;X
M?T_2VWP19D_OMR:\&GD==RM-I(]>>:T5&\;MDF@V!TW2(;=OO@9;ZGFC7-%M
MM?TQK"[>18F8,3&V#D5HYHS7U-."IQ4([(^?G)SDY/J<-'\*]"BE21;B^RC!
MAF7T_"NXC41QJBDX48&:7-&:T;N1:QYUH,4B_%/Q4YC<(UNNUBIP>3T-,\&1
M2)\.-81XW5C=79"E2"?WK5Z*(XU=G$:!VZL%&30L4:(46-%4]5"@ T7"QY=:
MPR_\*"6(Q/YGV(C9M.>A[5:FAE_X3'P0WE/M2S 8[3A?E/7TKT;R8O*\KRD\
MO&-FT8_*E\J/<K>6FY1A3M&1]*+A8\_2*3_A>CR^6_E_V=C?M.,X]:J6]C<7
M/B+QY%'$VZ6,B/*\,=B]*]+\N/S?-\M?,QC?CG'UH6.-79U10S?>8#D_6BX6
M/&V\5V\_PLF\-QV5^=56T^SO$;5P%( &=V,8XK3DAE^P_#T>4^4:3?\ *?E^
M4=?2O3Q! &9A#'N;[QVC)^M+Y47R_ND^3[ORCY?IZ4[BL<'XSBDD^(?A!E1R
MJSMN8*2%X;K5#2]>A\!Z_K=CK5M=+#<W375O<Q6[RJX8]/E!P>/UKTQHXW=7
M:-69?NDC)'TI)(8I@!+$D@'0.H-*X['E>G0W.IVWC#Q']EF@M[^+9;QR(59@
M OS8//4&H7M;O3O#W@CQ$+66:#38$6XB1"752%Y"CGC;7KFQ"FPHNW&-N.*
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MMHVT 0VUO':6ZPQ9V+TR>:ES2[:-M "9HS2[:-M !FDS2[:-M !FDS2[:-M
M"9J*ZMX[RW:"7.QNN#4VVC;0 R-%BB2-?NHH4?04_-&VC;0 U@&4J1P1@UFQ
M:%:1>6H>=HHR"D+/E%(Z8&*U-M&V@!.E&:7;1MH 3-&:7;1MH 3-&:7;1MH
M,TF:7;1MH 3-&:7;1MH 3-&:7;1MH 3-&:7;1MH ,T9HVT;: #-&:-M&V@ S
M1FC;1MH ,T9HVT;: #-&:-M&V@ S1FC;1MH ,T9HVT;: #-&:-M&V@ S1FC;
M1MH ,T9HVT;: #-&:-M&V@ S1FC;1MH ,T9HVT;: #-&:-M&V@ S1FC;1MH
M,T9HVT;: #-&:-M&V@ S1FC;1MH ,T9HVT;: #-&:-M&V@ S1FC;1MH ,T9H
MVT;: #-&:-M&V@ S1FC;1MH ,T9HVT;: #-&:-M&V@ S1FC;1MH ,T9HVT;:
M #-&:-M&V@ S1FC;1MH ,T9HVT;: #-&:-M&V@ S1FC;1MH ,T9HVT;: #-&
M:-M&V@ S1FC;1MH ,T9HVT;: #-&:-M&V@ S1FC;1MH ,T9HVT;: #-&:-M&
MV@ S1FC;1MH ,T9HVT;: #-&:-M&V@ S1FC;1MH ,T9HVT;: #-&:-M&V@ S
M1FC;1MH ,T9HVT;: #-&:-M&V@ S1FC;1MH ,T9HVT;: #-&:-M&V@ S1FC;
M1MH ,T9HVT;: #-&:-M&V@ S1FC;1MH ,T9HVT;: #-&:-M&V@ S1FC;1MH
B,T9HVT;: #-,D/[I_P#=-/VTUUS&P]10!!14GE^]% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g23ode3tb50n000013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g23ode3tb50n000013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (@ ^\# 2(  A$! Q$!_\0
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MT*&22#+'J:VO^$-T;_GW_E1X/_Y%Z"M^@# _X0W1O^??^5'_  ANC?\ /O\
MRK?HH P/^$-T;_GW_E1_PANC?\^_\JWZ* ,#_A#=&_Y]_P"5'_"&Z-_S[_RK
M?HH P/\ A#=&_P"??^5'_"&Z-_S[_P JWZS[_6]/TP W=PL>3CF@"A_PANC?
M\^_\J3_A#=&_Y]_Y5IQ:M936K7*3 Q+U:LT^,]!$PB-\F\G&* #_ (0W1O\
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ME(R#4M &!_PANC?\^_\ *D_X0W1O^??^5=!10!@?\(;HW_/O1_PANC?\^_\
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MNC?\^]'_  ANC?\ /O\ RK>5@RY'0]*6@# _X0W1O^??^5'_  ANC?\ /O\
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MJWZ* ,#_ (0W1O\ GW_E1_PANC?\^_\ *M^B@# _X0W1O^??^5'_  ANC?\
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MQ%=-X7^'374$&I7%Q<"5F!(WG''XT >RHP=%8=",BG5'!'Y5O''_ '5 J2@
MHHHH **** "BBB@"&[_X\YO]P_RKFO __'E=?]=F_F:Z6[_X\YO]P_RKFO _
M_'E=?]=F_F: .KHHHH I:O\ \@BZ_P!RLKP9_P @)?\ >K5U?_D$77^Y65X,
M_P"0$O\ O4 =%1110 4444 %%%% !1110 5ROQ 8KX2OB.OEUU5<I\0O^10O
M_P#KG0!YE\&9GDU"?<<_N3_(UB>/4EN_%L-NC8W9K7^"W_(0N/\ K@?Y&L3Q
M_<26OBZ&:( NN< T#.DT_P"%%]>6$<ZS1C</:N4\1:?JW@;55"W2A@,_+6]#
M\6->TK3HXS:Q; , D#_"L>0ZW\2M46>2V'ED;24__50![OX.U-]2\/VLDA)D
M,>6)[UD?$S6_[+\-R-&^),XX/-;WAW3!HVAV\+9!C3#9KQCXIZN]_P"(3IT+
M;HR0<9]Z!'#6E]>66NV]_)N"L^_.*^G_  KJHUC0X;L-G?7D_B+PW:'PC;W$
M?^LC@R<#O6A\&_$/FVT6E%\E%SC\*!F[\5)&31Y2IQ\E8GPKU!+;33-/(H"Q
M$\G':MGXK?\ (&F_W*\*L=9U&2Q%E:#[HYP<'% '>>-/&5WXEU,Z=IC.(FRI
M !()'%=W\/\ P3_9MJEW=J&D=<^^:\I^'MTFG>)H$U *-S$G<,]_>OI>WEBF
MMUDAQY9'&!0!\^_%Z9XO&:*AP-G^%=]K$C#X=6C \_9OZFO/?C%_R.J?[G^%
M>@:S_P DXM/^O7^IH$>":?>W-I=)<AB%W@9Q[U].PZHO_"$+<AOF2 $G-?/D
M.FB?PJLJ+EQ)FNSL/$^?!5]9E_F6+;B@9Y_XCOKB\UEKP,=CL,'\:]K^'(:X
M\*7"LP&<<FO)+W3"G@:QOR.7EQG\J]3\ $CP7=$'!XH -$\/FW\47%Q]IB;<
M?NAAFL?XQRO%( IZ1#^0K+\+3S-X]O%,KE<C@L:T/C)]]?\ KD/Y"@#.\.?#
M>]UK38KE)8QO7(S5/Q!X9U[P5F]CN@$0_P (KUKX;_\ (N6O_7.F_%.%)/!\
MVY1UZXH /ASXH_X2'3=KL3)"@#$^M=O7AGP2E:.YU% 21NQ_*O<J!'EWQ=D9
M+/Y3CY*X#PAX$O/$5C'.DJ#<,\UWGQ?_ .//_@%3?"'_ ) D'^[_ $H&</X@
M\#:[X5MVOX;E0L8S\M=U\+O%\FMP_9+AR98E^8FNJ\<1I)X5NPP!X]*\9^&4
MYL_$5\4/"K0![]>ZC;6$1>:5%QV+ 5CP^,M-FG\H2H#G&2XKQWQYKTVL>)([
M$3.D+)@E&(]*2_\ ">E6>CQWEMJ5RUPJ;F4N>OYT"/H**:.9-\;JR^JG-4M0
MUFSTY<S31CV+"O,_AAXJDETS[).^2,\DY-</JEW>^+?&)L6DD2%)BA*.1Q0!
M[Q9^*M.O/NS1CC/+BKEGK-K?.5AD1B#CALUY'XB^&Z^'])-W8W=T\O((:1L8
M_.J?PFEG-],LLKL1*0=S$]Z /9+G7K*UG:&65%8=<L*@_P"$IL#=I;K*C,PX
MPPKP?XC7%P/&4T4<T@WR!<!B.IKL_"OPXD6YM]0N)[C=M# %V(Y_&@#U*ZUB
MTLX!++-&H/JP%9">-],>79YB#WWBN'\9>&+V]FBC9YDME?EE<CBN1\3^&M T
MC1WFM-5N6NU_A+G_ !H ^A;:[ANXA)%(K C/RG-5=1UFTTV,M-,@([%AFO*_
MA'K<\NG:D9'++;I\I8Y]*Y77KJ[\6^,WM$ED"'LC$=_:@#UK7_$]C?\ AB_$
M4R!@G WCFO-O@Y.\GC"8,V1Y7^-7M=^&*:9X=>]@NKEF6/<REVQG\ZQO@NS1
M^)[EFZK 3^AH&>_7VHVUA$7FE1<=BP%8\'C'39YO+$J ^I<5X[XXU^77/$\5
MD9GCBR5;8Q'\J9J?A32[#2H[JUU*Y:Y'+*7/^- 'T+%-',@>-U8'NIS67)XC
ML8IY(GFC#)U!<5P7PH\22WNGO:SOEA)M&3DX!->6:\]Y<>/[RUCFEVR3;2 Y
MXH$?1EMXGL;J\%M%(C.?1LUM Y /K7F'A'X<_P!DZG%?R3W#':#AG)'\Z]/5
M=JA1VH 6BBB@ HHHH **** "BBB@"AK/_((N?]RJ/A'_ ) $-7M9_P"01<_[
ME4?"/_( AH ;X/\ ^1>@K?K \'_\B]!6_0 4444 %%%% !1110 5XK\9/]5'
M_P!=A_,5[57$>-/!Q\1(HVDX<-Q]: .?T'_DGMW_ +HKDOAQ&)?$&KH1G,)'
MZ&O5]/\ "YM?#DVG[3\XQBLOPIX%_L/5[FZ*$"5<<T >$^)DGTF^EM%8JLC%
ML?C_ /7KO[+3/LO@[[21S+"3FNG\5_#./6]76Y6,E0N#BNDN/"ROX:ATU5/R
M1[:!G$?"#_CR/^\?ZUR.O?\ )1;/_KY_H:]>\'>$?^$>@*;2.2>:Q[_X>&Z\
M20ZCL/R2[\T 0?%[_D1H_P#?_P *RO@[K-E8:9=+<7$<9)X#-BN\\8^&?^$@
MT%;':3ALX%>=+\'ID^X)5^C$4 =7XW\<6-OI3)!*DK."N$;/6N+^%.BS7.IM
MJ3H5 E)Y'J:U['X/Q-,INS,5!!Y8FO3]%T.UT.T$%LN%[\4 :E<A\2O^1,NO
M\]C77UC^)]*_MK1);+&=] CQ;X/ZE:Z?J>HFYF2/<>-QQZ5ZAK_CG3;#3W>.
M>.1L$85JX%OA!)YK,BR+D_PDBI[;X/[Y +DS;/=C0,Y3P=I<VM^,WU((VQ9]
M_2IOBO82IXPENB"(V< '''6O;O#?A2Q\.6Y2V7EASD57\6>#[3Q):&.93NSG
M(% CSJVT.!]#2=M4AP(P2FX5/X.T>U?4IV@9&<H>5/M5<_"W4$9H4$OD$_WC
MTKO/!_@JV\-1^<"_G%<-N- 'D?C"*31O&MM/*A**N<_E7JD7BO3?^$0S]HBW
MM"?DW<UB_$2;PQ<W0@U*5DNBORA1VKF+3P-I3:?)=F>;R0A9/F/^- S#\%78
MO/B1%(%P,G^==-\9AF;1Q[_XUSG@*WC/Q%@%ODH,C/XUZQXT\&'Q&]DVPGR3
MGC\: +?PY 3PE%@=/\*X3XF>)-035K6SMIVMT<X8]J]3\-Z3_8^D):$8Q7-^
M-O 4'B)DF56,J#Y<4".*CT. ^'?M5[J$,SLIX+<]*Q_A@%7Q RJ1@3''YUU6
MG_#&YDA^S7OF"(#C#'K6EX9^'C:#JJ3QHVP-G)H&>;^,(7L/B$]U*I$;3K@G
MIUKVFZ\3:<OAI95N8F98U&T-STJOXQ\"VGB*+<5/F YX]:X_3?A7.)O+NC*(
M,_WC0(XWPW,MWXVN94Z/*,5/\4[*6/Q:DY!\O8/F[=J[[1/AHNDZNUQ&C;-V
M0373>*O!MGXBLRLJGS,8XH&>?6>A0/X?CN&U6''EY*;AFK'@72[7^V6GA*%B
MAY!JM_PJW4$D,2>;Y!./O'I7>^$O!-MX>@#J7\[&#DT"/*?&B_\ %:6*G^_7
MN/AP!=%A KD-;\!G4M=@OMA/EMFNYTZV^R620_W: +=%%% !1110 4444 %%
M%% $-W_QYS?[A_E7->!_^/*Z_P"NS?S-=+=_\><W^X?Y5S7@?_CRNO\ KLW\
MS0!U=%%% %+5_P#D$77^Y65X,_Y 2_[U:NK_ /((NO\ <K*\&?\ ("7_ 'J
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M7H-K8^%GGDO89YL X#<]*ZCQ9\-(]3OC>VJL9F;<<51B^%\UY!MOO-STQN-
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M>M<@?AT?^$IEU38?GDWYH ]*@_X]X_\ ='\JDIJ+MC5?0 4Z@ HHHH ****
M"BBB@ HHHH H:S_R"+G_ '*H^$?^0!#5[6?^01<_[E4?"/\ R (: &^#_P#D
M7H*WZP/!_P#R+T%;] !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!PWC3X?Q^)Y?.280R!< @<UQ8^%>M(/LX
MUR;RNF.,8_*O;:* .%\&_#Z+PTRS22B:8'.\CFNZHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** (;O_CSF_P!P_P JYKP/_P >
M5U_UV;^9KI;O_CSF_P!P_P JYKP/_P >5U_UV;^9H ZNBBB@"EJ__((NO]RL
MKP9_R E_WJU=7_Y!%U_N5E>#/^0$O^]0!T5%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 C#*D>HKS'Q1\+/[6O/M=I=_9I =Q*CDG\J]/HH
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M %#6?^01<_[E4?"/_( AJ]K/_((N?]RJ/A'_ ) $- #?!_\ R+T%;]8'@_\
MY%Z"M^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH AN_^/.;_</\JYKP/_QY77_79OYFNEN_^/.;_</\
MJYKP/_QY77_79OYF@#JZ*** *6K_ /((NO\ <K*\&?\ ("7_ 'JU=7_Y!%U_
MN5E>#/\ D!+_ +U '14444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!0UG_D$7/\ N51\(_\ ( AJ]K/_ ""+G_<JCX1_Y $- #?!
M_P#R+T%;]8'@_P#Y%Z"M^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH AN_^/.;_ '#_ "KFO __ !Y7
M7_79OYFNEN_^/.;_ '#_ "KFO __ !Y77_79OYF@#JZ*** *6K_\@BZ_W*RO
M!G_("7_>K5U?_D$77^Y65X,_Y 2_[U '14444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!0UG_D$7/^Y5'PC_ ,@"&KVL_P#((N?]
MRJ/A'_D 0T -\'_\B]!6_6!X/_Y%Z"M^@ HHHH **** "BBB@ HHHH ****
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M :?0 4444 %%%% !1110 4444 %%%% !1110!#=_\><W^X?Y5S7@?_CRNO\
MKLW\S72W?_'G-_N'^5<UX'_X\KK_ *[-_,T =71110!2U?\ Y!%U_N5E>#/^
M0$O^]6KJ_P#R"+K_ '*RO!G_ " E_P!Z@#HJ*** "BBB@ J"YDV+CUJ8G S6
M;<2;G(]* (>]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 .1MK UJ1/O3-9-7+23!VF@"[1110 4444 %%%% !1110
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MX'W+ZU6O-;L+!PEQ,$).!]:+,#0HID<J3('0Y4C(I]( HHHH **** "BBB@
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MU=%%% %+5_\ D$77^Y65X,_Y 2_[U:NK_P#((NO]RLKP9_R E_WJ .BHHHH
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M.;_</\JYKP/_ ,>5U_UV;^9H ZNBBB@"EJ__ ""+K_<K*\&?\@)?]ZM75_\
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M $-7M9_Y!%S_ +E4?"/_ " (:^@/ &^#_P#D7H*WZP/!_P#R+T%;] !1110
M4444 %%%% $%S'N3/I6;T-;!&1BLZXCVN3VH @HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH @NK9+J Q/T->4:]I<EA>.2N$9OEKU
MZLG6=(BU&W(*C<!P:SJ0YD<&/PBKPTW1PG@K_D-C']VNHUJVUIYT-K!N7ZUQ
MDUK=Z%?%DW#'\0%3?\)5J(X\]^*P4DE9GBTJL:5/V52Z=SM;Q94\.P+J*!)
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MK_<K*\&?\@)?]Z@#HJ*** $(R,5FW$>UR>U:=07$>]?I0!FT4I&#24 %%%%
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M?^/V;_>JO5B]_P"/V;_>JO7R<OB9]3'X4%%%%(84444 %%%% !1110 4444
M%%%% !7HW@S_ )!J_6O.:]&\&?\ (-7ZUWY=_&.+,/X)M:S_ ,@BY_W*H^$?
M^0!#5[6?^01<_P"Y5'PC_P @"&OH#P!O@_\ Y%Z"M^L#P?\ \B]!6_0 4444
M %%%% !1110 4444 07,>Y":SB,'%:Y&1BLZXCVN30!!1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !@>E)@>@_*EHH
M ='&&<<#\JU(XU1< "JUI%W(JY0 4444 %%%% !1110 4444 %%%% !1110!
M#=_\><W^X?Y5S7@?_CRNO^NS?S-=+=_\><W^X?Y5S7@?_CRNO^NS?S- '5T4
M44 4M7_Y!%U_N5E>#/\ D!+_ +U:NK_\@BZ_W*RO!G_("7_>H Z*BBB@ I",
MC%+10!F7$>QZAK2N8]T9/>LTC!Q0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 F!Z"C ]!2TZ-=[8H LVD(Y)%7J9
M&NU!3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JIJ/_'HWTJW4%W&
M98"H[U,]8LJ/Q(\?O?\ C]F_WJKUU=SX5FDN9' ;DYJ+_A$IO1J^;EA:MWH?
M0QQ-*RU.9HKIO^$2F]&H_P"$2F]&I?5:O8KZU2[G,T5TW_")3>C4?\(E-Z-1
M]5J]@^M4NYS-%=-_PB4WHU'_  B4WHU'U6KV#ZU2[G,T5TW_  B4WHU'_")3
M>C4?5:O8/K5+N<S173?\(E-Z-1_PB4WHU'U6KV#ZU2[G,T5TW_")3>C4?\(E
M-Z-1]5J]@^M4NYS->C>#/^08OUKG_P#A$IO]JNN\/:<UA9B-L]>]=F!H5(5;
MR1QXVO"=*T67-9_Y!%S_ +E4?"/_ " (:O:S_P @BY_W*H^$?^0!#7MGC#?!
M_P#R+T%;]8'@_P#Y%Z"M^@ HHHH **** "BBB@ HHHH *@N8]Z?2IZ0C(Q0!
MCG@T5-<1['J&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "G1KO<"FU<M(N-QH M1KM0"GT44 %%%% !1110 4444 %%%%
M !1110 4444 0W?_ !YS?[A_E7->!_\ CRNO^NS?S-=+=_\ 'G-_N'^5<UX'
M_P"/*Z_Z[-_,T =71110!2U?_D$77^Y65X,_Y 2_[U:NK_\ ((NO]RLKP9_R
M E_WJ .BHHHH **** $(!&*S;B/:Y/K6G4%S'O7Z4 9M%!X-% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %7+2/\ BJK&
MNYP*U(T")B@!]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!0UG_D$7/^Y5'PC_R
M(:O:S_R"+G_<JCX1_P"0!#0 WP?_ ,B]!6_6!X/_ .1>@K?H **** "BBB@
MHHHH **** "BBB@""YCW(3WK.(P<5KD9&*A:T1CGF@#-HK0^QQ^IH^QQ^IH
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M_JH_]\4 7T.8U/J*=3(_]4GT%/H **** "BBB@ HHHH **** "BBB@ HHHH
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M_P"^* +T?^K3Z"GTR/\ U2_04^@ HHHH **** "BBB@ HHHH **** "BBB@
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MA"KN?T%0VEEN8S2_-NY /:@"_$S,@+=:?1C%% !1110 4444 %%%% !1110
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M\E2>0.U7;>X69,Y&?2@">BBB@ I&8*I)[4CNJ*68X K,E>2^F\M,J@.=P[T
M$DCWTFR/_5=&K0@@6&,*HZ40PK"F ![U+0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %#6?^01<_[E
M4?"/_( AJ]K/_((N?]RJ/A'_ ) $- #?!_\ R+T%;]8'@_\ Y%Z"M^@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *UU:K.
MN['SK]TU6MKEX9/)F/S#O6E5:ZM5G3CAASD4 6 01D55N[M8%P.6/ Q5,74\
M"M&4^;^'WJ:TM6=_/ESN;^$]J "UM&=_.GY?L?:M&@# Q10 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $-W_QYS?[A_E7-
M>!_^/*Z_Z[-_,UTMW_QYS?[A_E7->!_^/*Z_Z[-_,T =71110!2U?_D$77^Y
M65X,_P"0$O\ O5JZO_R"+K_<K*\&?\@)?]Z@#HJ*** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1E
M#*5/0UF30O9R>;%Q'Z5J4C*&&",B@"&WN%F3W[U*S!%R36;-!):R^9'DJ3D^
MU,,DU^_EX*I_>% #I))+Z79'Q&#A@>]:$$"P1A%& *(85B0 "I: "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** *&L_\@BY_P!RJ/A'_D 0U>UG_D$7/^Y5'PC_ ,@"&@!O@_\
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MM<AXT\2M/X/O+NQG*-&=NY#TZUA:+>)%X+BC9OF\LC&?:L+EOACJN<G,Q_\
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MYGRR-NS6%%\-)(L(-0D\L?P]J].HH Q= T"#1K58T +#^+%7]0L8]0LY+>0
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MI]U;%_,MUR57OUJK;>'-0UW46FODDC4C.&KUPJ",4@15Z"@#S9/"LT/B"SF
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MLU8LK?R$)[MR:F2%$/RC%24 0W?_ !YS?[A_E7->!_\ CRNO^NS?S-=+=_\
M'G-_N'^5<UX'_P"/*Z_Z[-_,T =71110!2U?_D$77^Y65X,_Y 2_[U:NK_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH A
MN_\ CSF_W#_*N:\#_P#'E=?]=F_F:Z6[_P"/.;_</\JYKP/_ ,>5U_UV;^9H
M ZNBBB@"EJ__ ""+K_<K*\&?\@)?]ZM75_\ D$77^Y65X,_Y 2_[U '14444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!0UG_ )!%
MS_N51\(_\@"&KVL_\@BY_P!RJ/A'_D 0T -\'_\ (O05OU@>#_\ D7H*WZ "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@"&[_ ./.;_</\JYKP/\ \>5U_P!=F_F:Z6[_ ./.;_</\JYK
MP/\ \>5U_P!=F_F: .KHHHH I:O_ ,@BZ_W*RO!G_("7_>K5U?\ Y!%U_N5E
M>#/^0$O^]0!T5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P">B?\ ?0KE?^$-E_Z"4W_?1H_X0V7_ *"4W_?1H ZKSHO^>B?]]"CSHO\
MGHG_ 'T*Y7_A#9?^@E-_WT:/^$-E_P"@E-_WT: .J\Z+_GHG_?0H\Z+_ )Z)
M_P!]"N5_X0V7_H)3?]]&C_A#9?\ H)3?]]&@#JO.B_YZ)_WT*/.B_P">B?\
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ME<[X&(-C=8.?WS?S-,;P7(R%3J4V",?>-:GAS0%\/VDD"S&7>V[)H VJ***
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M_P"@E-_WT: .J\Z+_GHG_?0H\Z+_ )Z)_P!]"N5_X0V7_H)3?]]&C_A#9?\
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M_P">B?\ ?0KE?^$-E_Z"4W_?1H_X0V7_ *"4W_?1H ZKSHO^>B?]]"CSHO\
MGHG_ 'T*Y7_A#9?^@E-_WT:/^$-E_P"@E-_WT: .J\Z+_GHG_?0H\Z+_ )Z)
M_P!]"N5_X0V7_H)3?]]&C_A#9?\ H)3?]]&@#JO.B_YZ)_WT*/.B_P">B?\
M?0KE?^$-E_Z"4W_?1H_X0V7_ *"4W_?1H V]9EC_ +(N?WB?<_O"JGA @^'X
@<'-9<W@AYH6C;4IL,,=36]H.D#1-+CLA*9 G\1H _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g23ode3tb50n000023.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g23ode3tb50n000023.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +[ N(# 2(  A$! Q$!_\0
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M&G .N"P!K?H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .<U>QOIGS!<.
M@ST%85[INIQVY:2ZD9?0UZ!56_MS<VK1J!DUQU<*I7=V==+$N-E8\=E!$K!C
MD@\TP=:[&;P?<O,S!1R:8/!MUD?**\9X.M?8]A8NE;<@TJPOYH<PW+H,=!6Y
MI^G:E'<9ENI&7T-;&C:>UC!L<#.*U,#TKUJ.$2BFV[GE5L4W)I6L-0$(H/)
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,F_U.6U;
M"H#S5+^W[C_GD*W);2&8_.N:@DL;5$+>5FN2I3K-W4K(>AS6I:_++$4*A<C'
M%5=)UJ2U41@;OK57489'NG"1/M!XXJO!;S)*"8GQG^[7ASQ%;VO-?8NR.L_X
M2"X(SY0JQ:ZS-/+L:, 5/8VEM-;(6B(..<U;2QMXVRJ8->U3A7=I<VA.A84Y
M4'UI:.@HKM)"BBB@#-U+2(M24K*<J>QK#\27VGZ;HS6 \OS9$V(N.IJSXN\1
M+H6F22@,7']VN-T6)-3N?[0U>9)4)WPJ6&5H FTBQOK3P:&\IEF+'Y*SM+N-
M=TX7$B:.L@)SDCK7>:MJMM;:,)88RZ XPG-+IWB&RN-.D<X38O*L<$T 5?"G
MB4:G+]EN(4@NU&6C Z5U%VY2V9AVKS7PO ]Q\1[S48T*V[QX7CZUZ3??\>C_
M $H \PBO]1UOQ+>6 WI'$,AE-5FU'4].UZ+0!O<3_-O)Y'^<UM^$T*^,;]BI
M&5Z_G5?5$;_A:NG-M.-G7'^[0!6U&YOO"U_9NSR.+F0*0QZ5J:]KUS=ZU%HM
MN#^]C#;E//:HOB>C/=:,%!/[\=![U2NM^G?$*TO9$8Q+",G'':@!=4AU/P\(
M7B:67S?O[F^[6O<ZS*O@Z.Y8G<S[34/C/Q!;&&V5 7,@_AYQUK)M9/[2TB/3
M!R0P;% $VJ6D=EIR7)X$J;B:KZ;XIDO+"'2]-_>2HP+!>H%;?BVT)T>WM\9Q
M$!7(6.C3>%[*WUF!3NE<(=HYQQ_C0!W>KZG-HVE>4I+W$B A2><UB)IVI/I)
MU3S)?,9"QCW<#%2^(9FOH(-212RQ1C> .<XK6@\16R^$V)&&:)AMSR.* (/A
MMK%UJVEW#W0(:.4H,GT)KNJ\W^$LXN-*O'4$#[0W7_>->D4 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %&!110 SR8CUC3_O
MD4>3%_SS3_OD4^BE9 ( !T 'TI:**8!1110 4444 8FM^&K77 1<.P!["L4?
M#BP486ZG ] Q_P :[6B@#&T[P[;:?:?9P[2K_M\_SK(N/A_8SW!F^TS)DY*J
MQ _G7844 4-+TF#2[=8HAG;_ !$<U=D02(5/0TZB@#-L]%M[.]DNHR=[C!ID
MNA6\VKQZBQ/FQC K5HH S-5T6WU9X'F)S"VY:Y;Q1<.FHK;7,2I8A>9@/F'X
MUWE5;O3K6^0K<1!P>QH \DO;2QGN;>/2YVN2QP^XYVUW/A[PG%82K>2%O.Q]
MT]*V;?P_IEH^^&U5&ZY%:= %&^TR&^ $G&*8='MS8+:, 47ID5HT4 <AJ5@^
MB:=.MN@EB;EB_.*Y%O[(EM'/VMQ=2*08@> ?SKUF:".XC,<J[E/45F#PSI D
M\P6:;LYS0!SOPSTFXTS1[A;B/87E++[C)KN:9'$D2;4&%':GT %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 444CG:C,!G SB@!'<(I9CP*$<.H9>AKS+Q9X@U*4NL5O+ B<%AW
MKJ- O7'@V.>5RTAC/)^E '0R7443[6;!-2JP==P/!KS'1-/U+Q+!<W'V^2+9
M*R@?B:M:#K5Q#/J=A-(SM:QG#'OQ0!W\EU%$VUVP:E5@ZAAT->9:)I^H^*+6
M2]%^\(5RNVM/P3JD\FHZA97,C-]F;:&;OTH [NBHOM4'_/1:!<PD@"1<F@"6
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#E?&D:KHMP0H
M^[Z53TI&?P-!M[(<_E6]XATXZEI\D()!88I-'TO[+X>6Q?DA"N3[B@#%^'DB
M'3;KD#$Q_F:Y:P5G\2Z^5Z!#_*MA= OM$,MO:O(Z2N7+#MD__7K9T7PP+:&X
MFD?,MRA#9ZB@"K\-W4Z#-R!^]/7ZFLOPBHG\3:PHZ>9S^0J8:%>Z*S6]H9'C
M8ELK6]X8\/?V3)-=,Y:2XY8'M0!K?V3;GL:IW%G';7D.S/)K;K,U#_C\@^M
M&D.E+2#I2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% &3K7B"UT2W,MQDX[ \UYGJWQ7>>4QZ;%
M<J1QG8?\*Z_Q/I>F7$YEO[XQ+G[N>*BL+GPC8QA?,MW/J4% 'G;>.O%KMN26
M4+Z;&J[8_%#4K*51J*W#KWPC5Z-_;GA3^];?]\"F_:?"VJ.+:(6S2/TP@H =
MX>\;6.O*%B5T?'._BNH!R*Y&#P+:V][]I@G9.<[5X%=<HVHJ^@Q0 M%%% !1
M110 4444 %%%% !1110 5F:A_P ?D'UK3K+U(A;N GIF@#3'2EIJ.'7*G(IU
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 =J\9^*L\.F^([&]8*S1C(0]Z]/OO
M$%I87!AFR"#C).!6;JWA[PYXJ>.XOQ%*RCY?G'% ' 6'Q8MA:H'LH@?2MS0?
MB1;:KJ\-FEM&K/W%:?\ PK#P?_SZI_WTM6+#P+X5TB\2\MXHHY4Z$NM '7HV
MY ?6G5B_\)'8I<"W0[VSCY3FMD'<H([C- "T444 %%%% !1110 44C,JC+,
M/<T!@1D$$>H- "T5&T\*G#2H#Z%A3U96&58'Z&@#,UW_ )!S5Y3<?\?,G^]7
MKFJV[W-F8TZFO.;_ $"ZMY6=B,$YKR,QI3G).*/6R^I",6I,QD^^OUKTWPK*
MKV1P>E>;&W99-N1D5U?A>^-M*L!/#&N/!553JV9IF$HN%DSOJ*0$,,BEKZ,\
M4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXJ6BBO=2LK'&%%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** .>U_Q98: I:[F" '%<]_PMG0/^?Q?R%9OQ,T
M"XU9E6)&8&09P/>J\?@/1;=+6&X\A9I$'#'F@#:_X6SH'_/XOY"C_A;.@?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !T%>4?$
MK6[TZQ:Z/9/@7 P0:]7[5Y/\3-"O&U:VU6SB>1K<9PM '(:=X?NM,U.3SV_>
ML-O!K6L;W4_#WC>QL)Y!Y,R[\ _3_&N5F\3ZQ]IS)IS[\]ZZ+PS8ZKXD\5V>
MIWEK)$D(V\_A_A0,]U@D$L2N.]24R*,11A!VI] @HHHH **** "BBB@ HHHH
M **** "LO41F[@!]:U*S-0_X_(/K0!Y'JB_8OBA>SC@,NW]379:*_D7\2_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:++=GH<5-#]W6E#OJ<SV-*BBBNXD**** "BBB@ HHHH **** "BBB@ HHHH
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MR\D>\*.:]UB.Z%#ZJ*\8\.:/J&I^,+NXG!\M7W+N7%>T(-L:KZ "@0ZBBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5S'BWQ+9:';%9_+:4C*HXSFNF/0UXM\2?F
M\:::MTI:W_BSTH @T[QN-1U&16TJU$:C(81BNQ\/^,;"\O4T]H8(I'/"*H&:
MXIAI%O?[K8Q)&2.-PZ5!<&T;XCZ6=,4!?+&XKSSQ0,]WCMX(R6CB12>I Q4M
M0VF[[,F[[V.:FH$%%%% !1110 4444 %%%% !1110 5F:A_Q^0?6M.LS4/\
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MNK[GZ5?\(^%];7Q=:7E\L[[.K./I0!]!PDF)2:?3(@1$H-/H$%%%% !1110
M4444 %%%% !1110 5F:A_P ?D'UK3K,U#_C\@^M &D.E+2#I2T %%%% 'F?Q
M3TGSH;.ZC7F%]Y(]J@TN\.J^%6O0<M&=F?I_^JN]\16*7NC7*LH)$9Q7DO@F
M5K=WT.4G+R%@#]:QKPYZ;1K0GR5$SUS0KD3Z?$N>57FM-@&&#7)>%[G9>74#
M'&PX&?PKK>U+#3YZ:96(AR5&CE]4LGLKI;F$?*#N:MK3+];VV5L_,:LW$"W$
M+(P'(KE\RZ-J)ZF+H/2N:2>&J<R^%F6YUU%103+/$KJ0<BI:[TTU=$A1113
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** /)/B]?W LTME8A#*![<D5SEQ\/6@T-=5LC&9A&'RI!.?PKTGQ_X?M=<
MTT12.4<-D$=<U'\/=$N=-T^X@O0SH3\@D.<B@#D/"7P_L=6L?MNLV^^5T));
MCG'O6-!8Q^&_B-96M@5$+9)"'/IZ5[9JUHQTV2*TC"L5( 48[5YOX0\!W:Z]
M_:NI>8)(Y&VAB3QF@9ZQ;.9+=6;J14M(H"C Z4M @HHHH **** *.KWHT_3)
MKH]$&:X6V&N:R)+^&Y46Q4L@/48_&NI\:9/A6]QUVU1\%8_X0R$'[WEG/Y4
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MU.0:G#5G-<LOB0-$M%%%=(@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#D&NC"8A5J:?435A]%%%=0@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<<J2C*,#]*]FG6A45XLEJP^BBBM1!1110 4444 %%%% !1110 4444 %%%%
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MNA6<+@ADCP0: %^P?6J-U:>7?0'GK6_69J'_ !^0?6@#2'2EI!TI: "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1110 4444 %%%% !69J'_'Y!]:TZS-0_X_(/K0!I#I2T@Z4M !1110 4444
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M(-+7+VNKW%HPBND"J.,FM^VO8;I08WS712Q$*FBW%8LT445N(**** "BBB@
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MHH *S-0_X_(/K6G69J'_ !^0?6@#2'2EI!TI: "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@!" 1@U1O-+AN4X55;UJ_14RA&:M)
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M //44 :611D5F_9K_P#YZBC[-?\ _/44 :611D5F_9K_ /YZBC[-?_\ /44
M:611D5F_9K__ )ZBC[-?_P#/44 :611D5F_9K_\ YZBJ5R-0BN8T$P^8T ;^
M11D5F_9K_P#YZBC[-?\ _/44 :611D5F_9K_ /YZBC[-?_\ /44 :611D5F_
M9K__ )ZBC[-?_P#/44 :611D5F_9K_\ YZBD-M?X_P!:* -/(HR*P4&H-,5\
MT=:N?9K_ /YZB@#2R*,BLW[-?_\ /44?9K__ )ZB@#2R*,BLW[-?_P#/44?9
MK_\ YZB@#2R*,BLW[-?_ //44?9K_P#YZB@#2R*,BLPVU^%)\T=*J60U"=Y
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M** ,_5_^/5?]ZKD'^H3Z4LD22KM<9%. "@ =!0 M%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% $-S<);0M(YP *X*3Q1X@N9K@Z?!'
M)#">2?\ ]5='XOD:/1B4)!S5+PM!']@GX'SCYJ +OAS76U*!8[K N\991705
MYWH3&/XAW4*\1A.!^=>B4 %%%% !1110 4444 %%%% !1110 4444 %9VKZF
MFG6C/D"0K\@]36C7G_Q'N9+>6PV D$\@=^M $/\ PDOBEX1<QVL9MRV-W^17
M1OXC":0TQ8?: F=OO7&C[<NF+> .(<_ZG%+?:G'>RVL44>S PX]: +H\4>)?
M(CN_LT?V5VQN_P BNXTK4H]1M5D5LL!\WL:RA;Q?\(TJ;1M4$@?A6;\/9'>"
M]#$X64@?G0!VU%%% !1110 4444 %%%% !1110 4444 4-3U:UTFV:>ZDV(O
M>N7\*^,I/$&HWD2E3%$V$(].*Z?4=,BU"-DF 9"/NFN"\#VT5KK^J1Q(% DQ
MQ^% '1:_XCN;:Y-CIH5[P<[#63'XF\06E];Q:G!'''(>H]/RKL;BUL(9C>S(
MBR8^^:X;6+M]>UZU2VB)CC;:S#I0!N:[XI>&!5TPK).6P0:SK3Q/KD&HP0ZI
M"D<<G.1Z?E6?9V_E^-[BUD.Y$ (S^-;/B^-%C20 ;U3@T =E#*LT8D0Y4]*?
M63X;=GT.W9CDD5K4 %%%% !1110 4444 %%%% !1110!@^(/$]GH<+&64+(.
MU5O"GB.373<.^/+3[I%2>(]&@NT:>9%<8Z&L;P(J0SZBH 5%/ ].E $NL^*-
M2&MR:;I4:23*,[33M&\3W_VL6NL(L4KG" =ZYK5))HO'<]S:(SY3 V?C4=E/
M*^J*]Z#')N^0/U- '4ZMXGU%M6ETW2$66XCY93Z?Y%.T?Q-?B^2QUA%BN)#\
MBCO5#PXH?QS=R,/G*<_K47B4;/B-I>WC(_PH ]'HI!TI: "BBB@ HHHH ***
M* "BBB@ J"]N!:V<LY. BYJ>F2QI-$T<@!5A@@T < GB7Q)J>Z?2;>.6V!QN
M/_ZJV_"OB.36'N(;C F@.' [&GZEJ-AX<L'CM(T+_P#/)>M8'A2V?25U35KC
M*K-^\"M^% '1>*?$<>A6/F[@'W8YIFA>(FO].EN[@@(@SD5Q&H7=OKL[7\UR
MGD-TA)Z&KUA<PKX3U,0R+\J\ &@"_<^)=?N;Z3^RX$DME&0Q]/RK9\+^(9-5
MAD%U@3*VW JEX&17\+1RL/G9""?PK,TG_1_$2QQ<*SDD#ZT >BT444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!G:S8_;[!HL9[UPNG:X=$6\
MMKO(=CB+ KTNJ<FE6,S[Y+6-F]2* .4\*:=+-J;:Q(O^M7&?\_6NWID4,<"!
M(D"*.@%/H **** "BBB@ HHHH **** "BBB@ HHHH *Y;QAI#ZA'%<(N3!\U
M=32,JNI5AD'J* /-O^$DC&C"Q(_TK.,8XI$\,W$5A+?;?G(WK7??V1I^_?\
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M2-)5*NH93U!H \:LM7M[O4C>ZL7\X$C '&*[VQO=/\2Z?-9Q[O+"[3QBMO\
ML/3"<_8HORJ>WL+6TS]G@2//7:* . U'X>6-GIVVW#]?6F^'_"H&D7T #;GZ
M9KTAT5QAE!'O21PQQ9V(%SUQ0!YWIFKKX;233;K(54*J .Y&*N>$;&>ZGDO;
MA>DA*?3-=A-I=C.^^6VC=O4BIXH(H%VQ($7T% $E%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5X5\6_^0BG_7=?_0A7NM>,_$_1[R^OT:"/</.4_K0!Z-X1
M_P"0)!_US7^5>=?&'I9?]=U_F*]*\+PO!I$*2##! *X+XJZ5=7XM/LZ;MLP)
M_.@"/6_^247?^ZO\C65\+-$LKFTN7GA#DQUT.KZ9=2?#.YM53,I"X'X&F?#+
M2[JQL9UG3:3'@4 <'J.DVI^(L=J(AY1'W?QKJOB)HMC:Z!9M%"%81]?SJK>:
M+>M\1X[D1_NPO7\173?$+3KF\T*VCA3+"/!_6@9QUI?36OP@BDC8[M^./I6)
MX-UBUM5NC/I<MTSMG*J3BN[\->%Y[[X<)I\\>) Q./PKE](EUOP=<74)LX2C
MO\I=<\?E0!0MI9W\8M>65E+;JY4;2IXYKZ)L2QL("WWB@S^5>3^&KC7]7U]K
MB6Q@%NP!#*O_ -:O78@1"@(P0.10(\^^+4C1Z-!M[M@T[X11A/#<V.\N?U-7
M?B1I[W^B#:,^7EJQ_@Y=J^@W,3'YA.1C\30!Y]XOA6?QS%&XRK7 !%>B^-O#
MNFVO@HM%;JK;0<_A7(>(]#OIO&T,Z19C%P#FO2_&]K+=>$##$N7VCC\* .-^
M"K'S-23/"\#]*ROBO^ZUKS%X;>/YUT'PCTNZT^;43<)MW'C]*Y_XA_\ $Q\9
M-8IRP8''XT >P^'F+>'[$GKY(K3JAHL?DZ+9QGJL0%7Z "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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I10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g23ode3tb50n000024.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g23ode3tb50n000024.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .+ T8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+<T6M$=[R.^HHHK,T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ IKQK(A5QE33J* ,_^Q-/\SS/LZ[O6KRHJ+A1@"FRS)#C><9.!4@.1
MF@ J'[+")_.V#S/6G2S)",N<4D-Q'.N4.10 LD,<P^=<TJ1)$FQ%POI3Z* *
MLEE'Y;^4 KGO7FVHZEJ>B:].]W#->VO145<XKU.F-#$YRT:-]5!IIV):N>07
M-S/XKN%M8+"6TA?A@R\5Z1HN@V^GZ7!;O&"T8ZUK+!"ARL2 ^RBI*;E<%&PQ
MXTD38PROI21P1P_<4"I**DHKR6<$CF1D!?'6O._$$VJZ-?K(?-N;<MGRU&>/
M2O2G<(,MTJ!YK9G57"L3TR ::9+5SR;4=:E\10I:6>ESVC;@2Q4]*]%\+Z.=
M)T\*QRS@$ULBW@7D0QCZ**D[<4W*ZL"C9W84445)04444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %!
MZ5A:]?W=DJ&W[]:P/^$AU;U_2N:IBH4Y<K1TT\-.<>9$_B;5Y[.9!&S#/I6#
M_P ))=_\]'JMJ]Y<7<BF?J*S*\2OB9NHW%Z'LT</!02DM3<'B2[S_K'KT+0Y
MVN=*BE<DDCO7D-=1IVM:C;V21P_<'3BML'BG&;<W<QQ>%4HKDT/1Z*XBWU[5
M'F"MT/M78VCO);([_>(YKUZ5>-78\FK0E2W)J***W,0HHHH *I:EJ":=:/.^
M#M&<5=JEJ&F6^I0M%."5(P<4 SQ3Q9XTU*]U:SCACEMX3.H#CHPS7ML,XCTR
M"60_\LE))^E>5?$S3;?3H=(B@7"K<J!^8KT'5W,?A1&7J(D_]!K25FD9QNF[
MG ^9J?C#Q#=VEM>26L=L_4=&HOK?5/!NH+>3W\D]LO!4]*U?AT@_M6_?^)NM
M6?BX@_X0V5N^\4[ZV%;W;G::7="]TRWN1_RT3=4\T\5NF^5PB^IK#\'2,_AJ
MR![1"J?Q D>+0,H<-NK.VMB[Z7-R77-+A_UM[$OU-.CUC3I4WQW<3+Z@UY=X
M8\*+XEMII-4W,5/R8/:L:TL;N'QI=:%:L?LL0Z$]N?\ "JY43SL]GCU[2I9?
M+COH6?\ N@U>,L8C\PN-O7->0^)?"EMX;@_M2RWB5%W$D]ZO:OXIN;;PCI;A
M_P!Y=G8?QHY>P^=]3T%O$&DJ^QK^$-Z9J>+4[*<XBN8WSZ&O/]+^'5I>67VJ
M\#FY?YA@^M8'AU+RQ\3SVLC'R4EP@SVHY5T#F?4[SQ_J$MGH):W<B7</N]:X
M;6[Z_MM<\- 73A9R-Z^O!KHM?F_M/Q,-)ZC:&Q7,_$.6/2M?\.R2<)"><?0U
M45T)D^I[)-=06L8:>58U/&6IT=S#*F^.167U%>4S:Q=>--;:QM7S9J0P!//6
MNIUV4>&_"\RVQ(G\L8SZU'*5S'0RZ[I<,ACEOHD<=B:DCU?3YG"1W<;,>@!K
MS?PYX-A\2Z:FJZEN,THSD'O6)-8W6A?$6QLE)$++G&?I3Y5L+F>Y[>"",BEJ
M*VYMU^E2U!H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 1R0QR_P"L0-]:C-E;8_U"?E5BBDXIC4FCSKQ9
M9GSX_)BP,]JYS[)/_P \S7KT^GV]R<R)G%0_V-9?\\Z\NME[G-R3/3I8]0@H
MM'E LY\_ZLUZ7X?LH?['A\R%=V.<BKG]C67_ #SJ[%$D,81!A16N%P7L9-O4
MRQ.,]M%):$8L[8'(A3\JF "C &!2T5WI);'"VWN%%%%,04444 %%%% 'E?Q;
MZZ5_U\K_ #%=]<VQN_#T4(_BB3^54O$WAF+7OLWF*&\F0.,^QKH(4\J"./\
MNJ%_(53>B)2U9Y;X&U"*P\2:G;W3B(!L*6[U9^)FHP:GH[:9;2!Y68$!>M;6
MM>"8+JY-U9QA9V.68U%I7@=8[Y;R_17E'&1575[DV=N4W_#%N;;P[8HPPPB
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M%9I7N>AVEPEU:QSQ'*.N0:PO&FHS:;HWG0_>W5)X-,A\.6?F9_U0ZU1^(?\
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M<?I6EX>\$SV^HIJ5]=&>9#P7Z@5=TC/E;.Y@4K"H/85+1161L%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 45%/<1VT32RL%51DDUBZ;XGMM3UB2RMW5U5<
M[A^-%A7-^BBF32I#$TCG"J,DT#'T5QUUXV"S$6<0GC4X+#L:V]&UVVU92(Y%
M\U1\Z#M3LQ*29K4444AA1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% "8'H*6BB@ HHHH **** $
MP/2E%%% !124M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4=J** .*\8V&N7Y2
M.QG5+8C$JD=?UKE?A]9-I_CBYMWQE8^WXUZO> ?99..U>;^%_P#DI5[_ -<_
M_BJN+T9FU[R9ZA7+^-K][+3D53CS3M/XUU%<7\0HFDL;8J/NOD_G4QW+EL1>
M"O#UG_9,IEBR7?<?QS6%HW_$C\5WOE_*DCX %=GX-E67225.<'!KC>+OQ;,L
M?)27FKZLAZ)'HO\ :L0 RC=/2C^UH?[C?E4ZVL>Q<J.@[4V>UC$+$ =/2LS0
MDM[E+A=R]ZGK+TT8;%:E !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4<_P#J'^E25'/_ *A_
MI0!0T_[]:=9FG_?K3H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *CG_U#_2I
M*CG_ -0_TH H:?\ ?K3K,T_[]:= !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!4<_^H?Z5)4<_P#J'^E %#3_ +]:=9FG_?K3H **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *CG_U#_2I*CG_U#_2@"AI_WZTZS-/^_6G0 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5'/_J'^E25'/_J'^E %#3_OUIUF:?\ ?K3H **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6MC1O#6GZ*6DMH=DC_>/K6U13NP44@J.?_4/]*DJ.?\ U#_2D,^<OB5I4_\
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MJH.5!]17F7P\^'D_AN>2:]5=[#J*].' Q6<[7T-(7MJ%%%%26%%%% !1110
M4444 %1S_P"H?Z5)4<_^H?Z4 >1>.FV)(?K7EVG6WFZ1J4I'W2:]+^(K;+9C
MZG%<9I=MM\*ZF^.HS6.#C:4WYF-7<]A^%4F?!-DOH/Z"NYKSSX329\*6J^B_
MTKT.NB6YI#X0HHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KSKXG>)1IM@EI"VY[@%< ]*[V]O([&V:>4X1>M
M> SM<^,O&A0'?!;3_I5P6MV1-V5D=E\*?#9AL4U.X7]\3_%UKU.JNG645A9I
M#$N% %6ZF3NQQ5E8****104444 -9%=2K#(/45R7B7P'8:[ XCCCAE/\8'-=
M?133:$TGN?/-UI_B#P1?AX&N+FW#9('3%>B^%/B1::LB17FRVD/4,>:[>]L(
M+^!H9URK#!KRGQ5\+MDC76BQA)!R,U=U+<SY7'8]<BFCG0/$X93T(J2O!M$\
M=ZMX;NEL]89S&IV\ ]*]@T3Q+8:Y;K-;R !N@)YJ91:+C-,V:*.O2BI*"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW7A7P^/D_$J^'_3/_&O=%^Z/I2J;FU/86BBBH- HHHH **** "BBB@ HHHH
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MSF-3[5X-I!\GXIWP]A_6O>(>8(_]T5Z4]S*GL/HHHJ#0**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *0D $GL,TM8OB;68]%TF2XD(&00,
M_2A W8\S^*'B"2\OX=)LWSYPVL!79_#SP^FC^'[=F3$^,,?PKS7P7I4WB7Q-
M)J4VYDAF)&>1BO>T18T"HH '85I)V7*905WS#J***S-0HHHH **** "BBB@
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MOU%;&D_#K0=,=94LP)%Z$$5U]%4Y,GE0R*)88Q&@PHZ"GT45)04444 %%%%
M!1110 4444 %1S_ZA_I4E1S_ .H?Z4 <QJ8S9#ZU9T$;[*9:@U 9L_QJSX:Y
M@E'O7GR_WQ>@^AY I\GXKWH^G\S7O5MS;1?[@_E7@>I?NOBQ>'U9?YFO>[3F
MSA/^P/Y5ZD^AE3ZDU%%%9F@4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 A(49)P!7B7Q1UZ34=2.AV[%MK@\<CK7J'BS6(M)T2Y=GVR&/*
MBO)?A_I<WB/Q*=7NT)C<<$\BM(*VIG-W]U'IO@;P^FB:/&54!ID#-75TR*,1
M1+&O11@4^H;NRTK*P4444AA1110 4444 %%%% !1110 4444 %%%% !1110
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M/-=''"D2!54#'M6*H5:SO5=EV-76IT=*2N^YCZ;X=MK109(U9_6MM5"*%48
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5;Q=WF_.IQ7LX&  .U5-]"(*_O,6BBBH- HHHH **** "BBB@ HHHH ****
M"BFLZJ,D@?4UBZGXBMK,% 27[8J)U(P5Y,N%.4W:*->6>.!=TCA1[USNJ>)U
MA)CME$I]JQ7N=3UN4I&Q\O/0BMO2_"T$ $EP@,GK7$ZU6L[4E9=SL5&G1UJN
M[[&'#9ZCK,VZ4R1H3T-=3IOA^WLE&\+(P[D5K1Q+$@51@#I3ZVI86,'S2U9C
M5Q,IZ+1#554&%&!3J**ZCF"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7HL;4S''%<\?&*@XPM:'BO\ Y S?6O+W^^?K7E8W%5*4^6)Z>#PT*L+R._\
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M^>\7_?539HIN+.CTW2[?2[98;=0%48SBKM86C^)[+6962WD1BO7::W:3&K=
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4*:M%$A1116@!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 A (P:JOIEC(VY[6)F]2M6Z* (XX(
MHEVQQJJ^@%5)=(LI[@32V\;L.[+FK]% #(XTB4+&@51T %/HHH *;(VV)V]
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2.-R,OJ,4M%
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M3_OUIUF:?]^M.@ HHHH **** ,_5H!-9R''W5K@M1MO[0\/O8GU)P:])G7?
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M>LPS1[G<+Q6?J.OL28;==Y/<5SSQ5*,>:X[,U[W4X+-"7;GVKFI]1O-4D\J
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M$?U(?=D6NNHH^H4O,.9G(?V)JR])5I/[+UA?^6JUV%)@>E+ZA3Z-_>',<?\
M8]87_EJ/RI#'K*_\M1^5=CM7T%)L3^Z/RI?45TD_O'<X[S-:7_EK^E+]LUE>
MLOZ&NO\ *3^X/RH\F/\ N+^5+ZE+I-A<Y#^T=6'60_D:/[7U)>K-^1KKO(B_
MYYK^5'V>'_GFOY4?4ZO2HPNCDO[=O5Z[_P C5.]UZ>:(QECR,'(KLKE+>&$N
MT2?E7GNHR>==/M0  \8KBQBJT8V<[W&K,CMFD9PBM@$UVNEZ)!$BRNH+GG(K
MA$W*X(SP:[[0+W[3;88\KQ49;R2G::UZ!(V%4*,#I2T45] 0%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1S_ .H?Z5)4<_\
MJ'^E %#3_OUIUF:?]^M.@ HHHH **** "JU]#Y]LR59I&QL.?2IDDU9@<;HU
MT+34986_B? KLMRXSD8KSO495AU(R1GD-DU?76KZZB$,* UY&&QD:2=.6MMB
MVKG4W>IP6JDE@WL#7/7>O37+;+97&>^*2UT*>Z;?=%US[FNAM-+@M% 4!OJ*
MW_VBO_=0M$<[;Z/>7S"2>0%?0UO6FC6MLH_=C=ZUH@ = !2UT4L)3IZ[L38@
M 48%+1174(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!DL23)M<
M9%4CHM@3DPCFM"BHE3A+XE<#._L.P_YX"K%O8V]J/W*;<U9HI*E"+ND 4445
MH 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *0J&ZC-+10 @  P!BEQGK110 @51T%(44G)&:=1
M0 F!C%)L7.<4ZB@!, ]: JCH,4M% "$ C!&148MX5;(C -2T4 %%%% %34K%
M-1LGMI "K=<UY%X>TO4_#GB^[,5K*T$TF 0. *]HI,#T'Y52E8EQOJ-50R*6
M7DBGXXQ114E#=BDY(%<+\1FU":P:QL[>219EP2O:N\I" >H%-.S$U=6.&^&_
MADZ-HL$TR;;@KALCGI7=4=.E%#=W<$K*P4444AA1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
)110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g23ode3tb50n000016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g23ode3tb50n000016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /#!GL# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MEBEM<)YHY,>?F%;%>3S6-U+XGL[W2K!K3YU64*A4%<\UZQ4221I%M[E74O\
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M9!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% &)<>%].N9FED5MS=<&L/Q%X
M<L;#33-"K!L]S7;U7O+.*]A\J496N&O@:4X248J[.NCBZD)IN3LCQ2BO5O\
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MS7HK[BC;?O8XKS'Q!X/\5>(-J3S6HC1R4P]$-[A4O:R/1=,_Y!5I_P!<4_\
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M:6^3W=CU8^IK6J).[N7%65@HHHI%!1110 4444 %%%% !1110 4444 %%%%
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M@HHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MGJM%<CX$\0W&M6EW!>$FYLY?)=B?O''6NNK)JSL;)W5PHHHI#"BBB@ HHHH
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MZ#7B6BS'Q7\7IK^S4FRMBZ^<.AR 17M@X&*<U9DTVVA:***@T"BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MN:[3M5*STR"RN+B>/)>=][$^M'-?<7+;8YGQ9JNJ*D]C::7<3HX(#HH(KGO
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M_P#70_RKTVN.^(OA:]\5Z''963QI(KEB9#@=*J#M)$33<6D:_A'_ )%'2O\
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MZNOJIR* 'T5 ]]:1-MDNH$;T:0 TY+F"3[DT;9Z;6!H EZ#)J(W, ',T?/\
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M7@W6[>PU^9[ZSN'"+<R-R/P%>AZEK-OIVDMJ#[FCV;EVKG-#BT-23-$LJ]6
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MVF?_ )YBC[3/_P \Q5RB@"G]IG_YYBC[3/\ \\Q5RB@"G]IG_P">8H^TS_\
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MQFCE8<Z.LHKS2YO?&^EV']LW-PDULJ[WMEBPRCZUV^@:S#KNDPWD7\2C<O\
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M];GRU((6)MG/X5SU_P#"_P -P:9=21K>!DA=E_TEL9 ---6):E>XWX421_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'4$?K4E% "(BQJ%10JCH ,"EHHH *0@,"" 01@@]Z6B@".*"&!=L,21KZ(H
M_2HI]/LKEMUQ9V\K>LD88_K5FB@"DND:8C!DTZT5AT(A4$?I5F6W@GC\N6&.
M1!_"Z@C\JDHH SX=#TNWD+QV%LK$YR(EX_2HM>TQ]4TX6L7DC]XI;S$W#;WQ
M[UJT4[BLBM8646G6,-I",1Q+M44^>UM[I=MQ!%*OI(@;^=344AE"VT73;1MT
M%C;HV<AA$H(_2KQ567:0"I[$4M% %#^Q-+,_G'3[7>>_DK_A5Y45%"HH51T
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M:CM+&UL(S':6\<*$Y*QK@4<_NV!PO+F+%%%%0:!1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#.GT'2KF]2]FL(7N4.5E9?F%:(&!@444 ,EBCGC:.5 Z,
M,%3T-5-/T;3=*W_8+.*WWG+>6N,U>HH *I3:3I]Q>1WDUI$]Q&<I(1RIJ[10
M 5DW?AC1+^X\^ZTRWFE_ONN36M11<+7(X+>*VA6&"-8XU&%51P*DHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,_6/^0>
MWUI^D?\ ()M_]RF:Q_R#V^M/TC_D$V_^Y0!=HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BC(HR* "BC(HR* "BC(HR* "BC(HR* "BC(HR* "BC(HR* "BC(HR* "B
MC(HR* "BC(HR* "BC(HR* "BC(HR* "BC(HR* "BC(HR* "BC(HR* "BC(HR
M* "BC(HR* "BC(HR* "BC(HR* "BC(HR* "BC(HR* "BC(HR* "BC(HR* "B
MC(HR* "BC(HR* "BC(HR* "BC(HR* "BC(HR* "BC(HR* "BC(HR* "BC(HR
M* "BC(HR* "BC(HR* "BC(HR* "BC(HR* "BC(HR* "BC(HH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#/UC_ )![?6GZ1_R";?\ W*9K'_(/;ZT_2/\ D$V_
M^Y0!=HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HJ)KB%#AI%!^M)]KM_^>J_G0!-14:7$3MM212?0&I*
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MH^P#^^W_ 'U5RB@"G]@']]O^^J/L _OM_P!]5<HH I_8!_?;_OJC[ /[[?\
M?57** *?V ?WV_[ZH^P#^^W_ 'U5RB@"G]@']]O^^J/L _OM_P!]5<HH I_8
M!_?;_OJC[ /[[?\ ?57** *?V ?WV_[ZH^P#^^W_ 'U5RB@"G]@']]O^^J/L
M _OM_P!]5<HH I_8!_?;_OJC[ /[[?\ ?57** *?V ?WV_[ZH^P#^^W_ 'U5
MRB@"G]@']]O^^JMJ-J@>@I:* "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S]8_
MY![?6GZ1_P @FW_W*9K'_(/;ZT_2/^03;_[E %VBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *,VEQ3R%V9
M@3Z5D2Z>B^((+82/Y;0LQ^HKHI94A0O(P51ZFN9FUJR_X2."?>?+2)D)QW-
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M78U#5G8TB[JX4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 54U+48-+L9;NX;;'&
MI8U;KAOBMYO_  B1\O=@2?/M'\/>FE=V%)V5RG;>+/%/B#?<>'[&U-FO1KG*
MEA[5<\/>.IKK6CHNL0"WOAG&T80XZX)K3\!36C^#-,%LRX$ R >1]:XCQO-;
MW'Q+T5+$@SHCB;9SSD5:2;M8S;:2=SMO''B6;PSH,EW:HDEQP(U?H>:R(;SX
MD3P1S+9Z/MD4,,RGH1FLOXL7 CCTF&2*5XW^]L0MT^E;%C\3?#P@@@9+^(JB
MJ6DM65>!ZFA+31 W[UFSJ-#;5VT\'6XX$N]QR(&RN.U:506EY!?6ZSV\BR1L
M."#FIZS9H@HHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% &?K'_(/;ZT_2/^03;_[E,UC_ )![?6GZ1_R";?\ W* +M%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MVT>#(Q+R-ZL>3^M;]*3N[H<$U&S"BBBI*"BBB@ HHHH **** "BBB@ HHHH
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MJ]W;M8,%F0G/K5C1_P#D$V_^Y4EEZBBB@ HHHH **** "BBB@ HHHH ****
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M_P"'>AW&@^%8[>Z $TDKS,,YQNYHE9QN$4U*QUE)L7?OP-V,9I:*S-0HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!!=W"6ML\SG  ZURNBP/JVK/?3#Y5/&>]3>([UKJY
M33X#G)^<"M_3+);&RCB4#(')H N#@8HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MAXQX>GM5/S6\@0COTKEO&G_)5-*_W&_]"%:WA];CPK\0KO3GBD-G?%IU*J2
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M+12'8J6FEV%C(SVMI%"SG+%%QFK=%% %--)T]+\WR6<(NSG,P7YCGWJY110
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M/;ZT_2/^03;_ .Y0!=HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "H+F\@LTW3.%%3UYKKE_)=ZA("QVH=H'TH UDUR"WAO-C'?(YV\=
MJT/"]@5C:^EYDDY!]JX6NY\)7SSVC0OSL.%^E,1TM%%%(84444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'_(/;ZT_2/\ D$V_^Y6)J.MF:T*?9Y1D]2AK:T8YTBV/^Q4%EZBBB@ HHHH
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M .Y4EEVBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI'_()M_]RF:Q_P @]OK3](_Y!-O_ +E %VBBB@ HHHH **** "BBB@ HHHH
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M[?WFB4G^5/F[DN/8XOX:Z=<P1ZG?RH8X;RX\V)#_ '<5WM-1$C4*BJJCH%&
M*=2;N[E15E8****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH XWX@>$KSQ;80VUK<B%5)W@L0&KSY/@KK4:
M[4U4*OH)#7<?$G3/$6I6EHOA^Z>WD5CYA5]N:\V_X13XF?\ 07F_[_&MH-VW
M,)I<VQL6OP=UN"ZCE;5LA6R1YAKV/3[=K33X+=VW-&@4GUKYU:#QUI?B"RL]
M0U>Y59I%&XR_*<]LU]%:=')%IT$<S^9(J ,V<Y-34OU8Z5M;(LT445F;!111
M0 4444 %%%% !1110 4444 9^L?\@]OK3](_Y!-O_N4S6/\ D'M]:?I'_()M
M_P#<H NT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 50O-/:YD#+,Z>P;%7Z* .9O+*:WNH
M(A<R8DSGYC5Y-'DR";F7_OLTNJ?\A&S_ !JQJ6I1Z=:&1B-V.!ZTP*NM:LNG
M6HB0[IB, 51T'27>0WUV,NW(![57TC3Y=5O#?W>=F?E!KKE4*H4# '2@!:**
M*0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJLDJ+*2%\M-W2N9_X79X,_Y^;O\ \!S4WB.]\'>)XHH]1N(Y%B)*Y'K7.?\
M"+_#CUA_+_Z]:*,;:F4I2OI8P_'OC_3_ !?-IUGH:RO)'.'#F,AJ]LT$2C0K
M(3Y\WRANSZUP6B:9\/\ 2;U)[40^?GY3CH:]+BD26)9(SE&&0:)M6L@@G=MC
MZ***S-0HHHH **** "BBB@ HHHH **** ,_6/^0>WUI^D?\ ()M_]RF:Q_R#
MV^M/TC_D$V_^Y0!=HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K-UC5%TRT+XRY^Z#6E7(
M^-%8F!@?E"\C\: .?N=9O;F<2F9@5^Z >E6;&636-2ABO)F9<\ UC5?T:-Y-
M4@"9SNZU0CTR&)(8EC084"GTU 0B@]0*=4C"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ J)KB-&*DG(J6HF@B9BS*"30 W[5%ZG\J/M47J?RI?LT
M/]P4?9H?[@H 3[5%ZG\J/M47J?RI?LT/]P4?9H?[@H 3[5%ZG\J/M47J?RI?
MLT/]P4?9H?[@H 3[5%ZG\J/M47J?RI?LT/\ <%'V:'^X* $^U1>I_*C[5%ZG
M\J7[-#_<%'V:'^X* $^U1>I_*C[5%ZG\J7[-#_<%'V:'^X* $^U1>I_*C[5%
MZG\J7[-#_<%'V:'^X* $^U1>I_*C[5%ZG\J7[-#_ '!1]FA_N"@!/M47J?RH
M^U1>I_*E^S0_W!1]FA_N"@!/M47J?RH^U1>I_*E^S0_W!1]FA_N"@!/M47J?
MRH^U1>I_*E^S0_W!1]FA_N"@!/M47J?RJ96#*&'0U%]FA_N"I5 50 , 4 +1
M110 444C.J#+L%'J3B@!:*@^VVN<?:8<_P#705,K*XRK!AZ@YH 6BC..M0F[
MME.&N(@?0N* )J*:KJZ[E8,/4&FI/#*Q6.5'(ZA6!Q0!)113%FB=RBR(6'50
MPR* 'T45&)XC)Y8E0N/X0PS0!)1110 5"US&K$$G(]JFJ(V\3$DH,F@!OVJ+
MU/Y4?:HO4_E2_9H?[@H^S0_W!0 GVJ+U/Y4?:HO4_E2_9H?[@H^S0_W!0 GV
MJ+U/Y4?:HO4_E2_9H?[@H^S0_P!P4 )]JB]3^5'VJ+U/Y4OV:'^X*/LT/]P4
M )]JB]3^5'VJ+U/Y4OV:'^X*/LT/]P4 )]JB]3^5'VJ+U/Y4OV:'^X*/LT/]
MP4 )]JB]3^5'VJ+U/Y4OV:'^X*/LT/\ <% "?:HO4_E1]JB]3^5+]FA_N"C[
M-#_<% "?:HO4_E1]JB]3^5+]FA_N"C[-#_<% "?:HO4_E1]JB]3^5+]FA_N"
MC[-#_<% "?:HO4_E1]JB]3^5+]FA_N"C[-#_ '!0 GVJ+U/Y4?:HO4_E2_9H
M?[@H^S0_W!0 GVJ+U/Y4?:HO4_E2_9H?[@H^S0_W!0 GVJ+U/Y4?:HO4_E2_
M9H?[@H^S0_W!0 GVJ+U/Y5,#D9'>HOLT/]P5*  ,#M0 M%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5Q/C?P OC">WD-WY'D@C'/.:[:BFFT[H3
M2:LSQS_A1B#KJI_6L^Z^$^EV3!;C7T0GL<UV_P 4O$T_A_P]LM>+BY!5&]#7
MG6G?"+Q)K=N+VZUKR6F&\*^_OSZ^]:QD[7;,)1BG:*N;FG?!VTDDCN8-9$BJ
MV>,UZ[8VWV.QAMMV[RT"Y]:^?1I_B3X9:[:R7%X]Q:2R!&;G:1Z#)KZ!L+H7
MUA!=*,"5 P%34OW+IV[6+-%%%9FH4444 %%%% !1110 4444 %%%% &?K'_(
M/;ZT_2/^03;_ .Y3-8_Y![?6GZ1_R";?_<H NT444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !116?
MJFJPZ;"2[#>1PM $FH:C#I\!DE8 ]AZURBPWGB6[+OE(!T)'2G6EE=Z_=_:+
MG*P Y />NPM[>*VB6.)0J@8I@</>^&6MKJ*)9@1)TXZ5TFCZ##IHWDAY#_%3
MM4_Y"-G^-:R_='TH 6BBBD 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4TM"9+UV7/(.*VM&S_9%MG^Y4&A>HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@"*>XBMXR\KA5'J:YD:[8_VT)=
MS;1D9VU0\67LDEV( 2$4<BN;IV [K5O$:+&(;++R/Z#I3-&T%FD^V7WSR'D
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M3;_[E,UC_D'M]:?I'_()M_\ <J2B[1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 <QXR\(6GBVUABNY9$2(D_*Y7K7E=[X"\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!YQ\7]$NM2\/QW=JA=[/+[5Y)KF='^-D=E8QVNJ6C1RQ($ "$YQQ7K>MZSI
M^B:>]UJ,FR$#GC)->*ZMXJ^'M[=-*-#AN)"QW.T;9/ZUK#56:,9Z.Z94UKQ9
M?_$G5['3[6S86J3!MX4_K7OFEVAL=+MK5NL484UX]H/Q&\-:3,D.F:-';;SM
M^16KV6RN1>64-RHP)%# 4I]K#IVU=[LGHHHK,U"BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***S;^._R9(;V.&,=F3-
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MM,1T^G:#:6(#;=\AZEN:U0 !@  >U+14C"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW_W*9K'_ "#V^M/TC_D$V_\ N4 7:*** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]:OT4G)L%%(S]8_Y![?6GZ1_R";?_<IFL?\ (/;ZT_2/^03;_P"Y2*+M%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4449 ZT
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MNY'!'UI^:]Y-/8\RP4444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHMIUN;:.900KKD U5'%4:S:IRO8FKAZM)7FK$M%%%=!B%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHK)\0>(+/P]IS75VX&!\J_P!XT;@W8UJ*\_'Q(FA>.6^T
MA[>RD/%P6R,>M=U:74-[:QW,#AXI%#*1W%-IH2DGL5=8_P"0>WUI^D?\@FW_
M -RF:Q_R#V^M/TC_ )!-O_N4AEVBBB@ HHHH **** "BBB@ HHHH **** "J
M]W8VU]$8KF)9$/4$58HH:ON--K5' ZW\,](N(WFM6%F5Y)05XUJL\WVJ2V>X
M:9(6*J3[<5]!^,5U.;0IK?2X&EFF4J=IQMKQ9OA[XI=RS::Y).2<BO*QE+WK
M4XGM8"M[K=67I<U/#?Q U>PLULXK?[2(^@+'@#M70Q_%B^#;9]$* =_FK"\,
M>$O%&C:U#<G3&\LD*^2.G>O:'LK:XB"RV\8SR1M%:8>-:4?B:MY&6*GAXS^%
M._9G!0_%6W('G6;1GO\ *:OQ?%#0"?WTKH/]PUT,WAK29SF2T4YK.E\ >')Q
MA[$'_@5;\N(6S3.;GPKWBT$/Q \.W !CNSR<#*XK0A\3Z3.<)=+Z\G%8$WPQ
MT)B?)A,8[?,>*SI_A5:8S'>&,#KR:.;$+=)AR85[2:-7QMKNGVFB?:-T<SEL
M* W-.\!:Q9:EHYD01QRJ0'&>]>(:[;+8ZG-:1W33I&Q&<G&:-$N;N.]2&VN3
M"9#@'W->=[:/UCVKCKL=_P#9\'1LGKW/IT2(>CJ?QIW6O)/[#\<6XQ;W#NI[
MXIN_XEVYP$=HU]A7H_66MX,X/JB>TT>NT5Y*/$?C>W^:>TD91UZ4\>/]?MA_
MI&FR-GIS3^M0ZIB^I5.C3^9ZO17E8^+<\!"3Z-)N[G=5R+XLVKD>99,GKDTU
MBJ3ZB>"KK[)Z144MO%,/WB!OK7%0_%#1WSYAV?6KL7Q'\-LN9+]4/H0:KVU*
M2LVC/ZM6C]EA?^&HCJ$?EN$20XVUT-KIMM:1*D<8&.]>0>)_'OF^*K:>QE+V
MULVY2#P>*]-LO%ND7-G%+]L3+*-WUQS7#A:&%IU9RIJS_K8UJX>K",6^IO45
MD_\ "2Z3_P _B5.FLZ?(NY;E"/K7I*<>YS.$ET+]%4O[6L?^?A/SJ>.Z@E7<
MDJ$'WIW1/*T+/;0W  E0,!ZUBZGX:MKD*T($3#J1WK<\Z+_GHG_?0KB?B!XN
M.A6D*6D@::1B& /08KEQ=&A4IOVJNC6E&<Y*$3IK30[*WA53"K-CDUHJBHH5
M0 !P!67X?U>'5M'@N5D4DJ W/?'-:GF(>CK^=;4:=.$4J:LB)\R?++H->WBD
M^^@-5GTFQD^];J:N;U_O#\Z-R_WA^=.5*G/XHIDZF5)X<TYONVZK]*J2>$[5
MONN5^@KH,CU%&1ZBN:>786>\$/F9RS>$3&<Q7;Y/M3#HFJP_ZF=C^(KK:*P>
M3X;[":]&Q\[/,-1L[B.Z8W*$R _>Q52O4[JTANX6CD0$'OBO.Q'8_P#"4MI)
MN%#*QX^E?/YADU6G43IOF39O&;G\BO90M'=K,MN9,=L<&M=YC)C?I:G'UKM+
M:TAMH%CC1=H'I4VQ/[B_E7J4,FJ4X<OM/P1+Q$GU//G2W+;Y-&1L?6J[_8V)
MVZ0J_G7I/EI_<7\J/+C_ +B_E5/)ZCVJ?^2H:Q51=7]YY<UO"W2Q*Y]C52XL
MHPZ;<KQR"*];\J,C[B_E6#K?AD:I/%)%,(-@((V]:Y,1DM=0;A+F?:R1O2QM
M1NSE8X55"K@#BHFMEDD#!MI]16CJUDND7*P2S [C@'UK<M/"#R&*=KH!>NS;
M7C4,NQ4ZKA&.JW"G5<)<W-8YUM/BD4![R4_\ IO]DVW_ #]R_P#?%>DKI-HJ
M*#$"0,9I?[*L_P#GB*]S^Q:SW:_'_,7]H5EL_P CSA-'L2/GOI5/^Y3O['T[
M/_(0E_[XKT-]&L7.6A%-_L/3_P#G@/SH_L:LOY?Q#^T*W\WY'"C3=)QS<N?^
M 5(NF:(1\]XX/^Y7;?V'I_\ SP'YU&WAW3'.3;_K5?V5B%LH/[Q?7JO\S.-.
MF:%@XO7S_N5A"T59W.<H#\ON*]-_X1K2_P#GW_6L76?#2P0M/;?=7DKZ"N/&
MY9BE3YE&.G\M_P!2XX^K9Q<MSDI(E=-I'TJSH]K9+(WVY=R]N,U)8V;WUV((
M^6ZGV%=M9^&K.","5=[=S7'EN"Q%:7/!*R[[$K%3IQ<$]SFVBT($;;4,/]TT
MYFT0 ;-)1O7@UUZZ/9(,+"*E73[5!\L0KWEEN([Q7_;IB\54?VG]YQ?VO3XT
M BT=#[8-.2]B/^IT=5/KS7;);PI]V-?RI_EI_<7\JM997ZU5\HHEUYOJ_O/+
M[Z,S77F&V,>!T -5Z]4FMHIHV1T7!&.E<%<VEC%XE33OM*J7!8+Z8[5X^/R:
MM"2E%\U_D6JDJF_03PQ#CQ##)M8?*W..*]$JO:V<-I"L<2 !1@'%6*^CRW!O
M"4?9R=WN8U*CFUY!1117H&84444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !117$>/?']OX4MO)B'FWLG"H#R*:3;LA-I*[.WH
MKP8:Y\5=0C^WV<,BVAY P.E='X*^)=S=ZE_9&O1F&ZZ!F[GTJG3:(51-GJU%
M5[V\BL+.6YF8+'&I8D^PKQ34/B7XE\2:E);>%('V(V XP=U*,7(J4U'<]SHK
MP8>._'7A>YC;Q';R/"3SD 5['X?UZT\0:1'?VKAD8<^Q[T2@T*,U+0UJ*\6U
MWQ]XFUS79].\(Q,?(X9EP>0<']:O>$/'>NP:\NB>*(F2X<?*S8&2:?LW:XO:
M*]CUNBHYYDMX'FD8*B*6)/H*\QL_%FM^*O&C6NC3&'2[9BLDNW(?H14J+93D
MD>I44@SM&>N*6D4%%>0?%GQIKGAK4(8],N_*1L9&W.>*[/P!XJ7Q3X?CN6<-
M.ORO[D=:IP:5R%-.7*=9113)I5A@DE8X5%+'\*DL?17@6J?%/6I_&YM-.N]E
MCYH4+M!R*]Y@8O;Q,W5D!/Y54HN.Y$9J6Q)1114EA1110 445PWQ,U_5]!T5
M9M)5MY^\X&=M-*[L)NRN=S17)?#O6=3UOPQ%=:I&PF+,-YXS76T-6=@3NKA1
M112&%%%% !1110 4444 %%%% !1110 445YQ\6?$^J^&M'CGTNX\F0NH)QFG
M%7=A2ERJYZ/17@&GZK\7=4L(;ZSWR6\R[HW"CD5.^M_%;2AYVH0R-$.2,"K]
MGYF?M5V9[Q17FG@SXJ6VM7":=J*?9KPG:-Q^\:]*!! (Z&H<6MS2,E)70M%%
M%(84444 %%%% !1110 4444 %%%% !117DW@;QAK6L?$C5M*O;KS+.#?Y:;<
M8P>*:C=-DN232/6:***10445SGC+Q6GA+23>M;^?UPF<9II7=A-V5V='15#1
M]1_M;2X;P1^7YBAMN>F17G'Q-\7^(M UNUM])1Q ^TE@,[CZ4U%MV%*22N>K
M45GZ'<SWFAV=S=(4GDB#.I[&M"I*"BBB@ HHHH **** "BBB@ HHHH ****
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MZ*4Y+9G ?V;HEX'0:+,=AP=KBN>\5Z3X?L-,:4Z5<Q38^0F6O5K/3HK22=E
M/FMNYK-\0>$--\2>7]M\T"/H(WVBL:M&+B^6*N=%#$2C-.<G8^;"06)'3/%=
M-X7LK?56:V<3&8<C;(0#^%>G-\)/#VY=OVG;WS+5[3/AOH>DWT=Y;&Y$D9R
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MO>QZF$C2<.?EM<^D?#VKIK6C6]XI&Z1<L/2M6O*OA7?7EJ\FFW4,BJQRA(X
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M#/?^(-7U%EQ'G*GL>338_AEXYU:01>(-5+VV>0)PW%>M^'/#=EX:TI;.T09
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ML-.NYC*D@&<<8 I\EQ<>/_%-I);0LNDVP.Z4C[QSD<5K;WN8QO[O+U/3X/\
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MIWE=&C1114&@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!3U33H=5TZ:SG&4D4CZ<5XS/\-O&'AVXD;POJ
M$@4G@;@M>Y4549-$R@I'A:>#_B9K+?9];U.46QZXD#?TKU'PAX1M/">G>1 =
M\K<O(1@G/-='10YMZ"C!+4****DL**** "BBB@ HHHH **** "BBB@ HHHH
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M[5@R,B!1Q7>_#G3/".N^&+82Z9927<2!)-X^9CZUUTW@_P 'VXS-I.GQCU<
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$SG&_:$ ->P(XDC5U.58 BB47'<<9*6PZBBBI*"BBB@ HHHH **** "BBB@
MHKG_ !CXA'AO0)KX8,HP$7U)K!MO$6O)\.I];O'A%X%+(!'@#GC(JE%M7)<D
MG8[ZBO/OACXNU7Q5:W$FIO$S(3M\M-O?%>@TFK.PXM25T%%%%(84444 %%%>
M2?$SQ]XA\-:]'8Z.T.'52%>(,22*J,7)V1,I**NSUNBO!H_&/Q=EC62/2-R,
M,@BU'/ZU)'\2O'FD-YFOZ6RQ9YQ"J\?G5>S9'M4>ZT5RG@_QUIOBVV!@<1W
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MT+UX)->[6=K9>(O"T$VHVL5Q^Z./,&<<5XM\*](T_4?&.IP7EG%/$DA"HZY
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M@D+W$B'#"(@XI_ASXHZ#XCG$,3-;NW02D#->:_#O2=&DUO4%\4JGVX2_*MP
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !7-^-_$+>&_#LUY&NZ0_*OL:Z2L/Q7H">(]#FL7."02I]Z
M:M?44KVT/'=#\*>(?B!;MJ.I:Q*EO(05575L UC^./ASIWA!;>:VU:2ZD9QE
M'"CO[5LZ?X/^).A2&RTNX>.S)QN##I6KK7PQUB]T,3S2-?:MO4@N<;1GFM^:
MSWT.;ENMM3T7PI_R)D'_ %R/\J\?^#_'CK50>,R'_P!#->U>'+">R\.06=RN
MV54VL,UY!JWP[\6Z'XCFO_"Q($C;BP8#'>HBUJC2:>C['NZNK?=8''H:6N,\
M!:1X@TVU=M=NWEE?)V-C@FNSK-JS-4[HX#Q+\17\-^)[73+BT3R)_P#EJ2<C
MG%=U!<PW,(EAD5T(R"IS7*^.O ]MXNL1G"74?W) .1[5YG#X9^*.BJ;+2[B3
M[(.!\XZ5:49(S<I1>JNC9^-M]926UE;!EDN2WR[>2.:]#\%QRQ>%K19@0^WO
M]*\X\/?"O4[S54U+Q+<-)(IW&-N<FO9(XUBB2-1A5  _"B327*@@FVY,=7@7
MQ5_Y*UI/^Y'_ #KWVO(O'_@K7-;^(6GZI8VHDM(50.^[&,=:*;2>HZJ;CH>J
M:?\ \@^#_<%>(^'O^3C-3_WI?_017N%G&T5G%&XPRK@UY=HW@W6[3XT7WB":
MV"Z=*TA23=UR!CBB#6H33=CT/Q'_ ,@&Z_W#_*O(O@/_ ,ACQ!^'_H5>Q:U;
M2W>DW$$*[I'4@"O-OA;X5U;PC=ZU=ZQ;B&*890ALYYS1%^XT*2?.F<MX_BAO
M?'ZQ:'*MI?*%+2$A/7N:9_PBOC36&%MK/B.W:R/_ $^1L<?2I#X=C^)_BB\N
M8F%@D1V&13DM@D=*U)?@*(HF==?E+ < KC-:725FS+E;;:1Z9X/T&P\/:)'9
MV,L<G +LA!W'UXKE_BWK30Z7;Z-;G_2+N1.G7;NP?YUQWP\U#5=$\:SZ)-=/
M/:Q(V1U''>MJVLY_%OQ5DN9XG-C8%XT+#@]"*CEM*[-.:\;(]#\(Z,FA>&[2
MR5<,B?,?6JWQ _Y$G4O^N==*!@ >E8GC#3[G5/"][9VB;YY4PJYQFH3]ZYHU
M[MD?.WACX>'Q5I%]>P7#BYBW%(\##'..M>A?"WQ<]A*_AS5LQ31L0A;OSC'-
M;OPK\+ZKX;M+F/4[<1,Y.!NSWIGQ ^'LFL3)JNC_ +O48CE=O&[%:RDF[,QC
M!Q2DMSHO'DE@OA6Y:_021%3MXSSCBO#?#^F>+9; S>'];AM;9B,1M=)&<?0U
MV_B'7=3L?!\&E:]IZF]F98E!?UXW5EZ7\#/M]A%<OK4D+2+DQHH(6B-HK4)W
ME+0T/!W@&0ZXFK>(M6M[JZ7GRQ.C@G\*]E4 * O0#C%?.WBCX=WG@/3VU:SU
MB24Q,!@X!Y->P_#S4KK5_!=C>7C%IW!W$U,U=7N53=GRV.IKPCXL_P#)0M/_
M . ?RKW>O'OBCX,\1:[XBAOM&M@XC5<-N P0*5-KFU*JIN.AZII'_('M/^N0
MJ>XN[>UC:2>9(U49.Y@*\,BT_P",<,2Q1SR*BC &]>!1_P (;\1M?_=:W=R)
M$3S\P/%'(NXO:/HBAXUU23Q[X]M=/TY3)#:OM##H1D&O?=,LTL-.AMHQA44"
MN8\%?#_3_"< < 2W9',I'-=A)N\MMOWL''UI3DGHAPBUJ]V*>AKPKX-?\E#\
M2?\  O\ T8:N:K:?%MM1F-E<2"W+'8-XZ5S.D^"/B7H=_<7NG1&"XN,^:ZR#
M+<Y_G5QBDFKD2DW).VQ](5"MW;/*8EN(C(.J!QG\JX[P-!XN739D\32LUP2=
MA)!P.U<#8Z-K>F_%QB\C%9]TBD-GY<BH4=]2W-V3L>W7=W#8VSSW$BI&@R23
MBO'-6U;4_B5K9TK2R\6DQMB24<;Q^-;?Q2TCQ;KWDV6BV^;/:?,P^-QSQ7$:
M3X7^*6AVHM]-0VZ=]KCFJA%6O?4F<FW:VA[?X>\/67AW38[2TB5<#YF QDUK
MUX3]D^,O_/Q)_P!]K7K7A)=9308QKI)OMQW$G/':IE&VMRX2OI:QN5X#\3 V
MF_$S2;B5/W;%6+'H!N%>_5Q7Q!\#IXNT\>6VRZCY1@.>.U$&D]0J1;CH==;7
M<%W;)<02*T3C(8&O$?CA>6]QKNAQ0RJ[1/API!Q\PJ'3_#'Q0TY5TZVN)(K%
M?E!#CI5GQ%\*-5E33[FVS=WP8-<2,<$G-7%*,KW,Y2E*-K&O\8+.6?PAI\Z+
ME(8P6_(5UOPZU6WU+PC:O%(NY<H5SSQ@=*VKW1H-5T(:=>1AD:)48'Z5X]/\
M/?&7AJ\D;PQ=.8F)( (&*2M*-BG>,N9'J'CG5;;3?">H&610[PLJ+GJ:X;X'
MP2_V1>WTJB-&F)YX[5CP^ /&WB:YC'B>Z<0JV2"0:];L_#5MI_AUM(M#Y2M'
ML9U'7C&:':,; KRES6*>J^$/#OB*1IW@MWN#SYR$,?YUYKK]SJ?PX\2V*6>J
M2W5G<M@V[, %YQT%)=>#?B!X?NI(_#U])+;D\'<!Q4^A?#7Q!J^L0ZEXJN&9
MXSNV'!R::LMWH2[O969L?&)S)X5MY#U90?SQ70>%/^2>)_N'^E5?B7X;U'7M
M"BM-,A$KH,8SBMCP_I5W9>#EL)X]MP%QMS]*FZY44D^=L\I^#'_)0M=_W&_]
M#->WZK_R"KK_ *Y-_*O,/AGX+USP]XQU6_U&U$5O.I$;!LY^;->I7\3SZ?<1
M(,NZ$ >]%1IR"FFHZGCOPF_Y&_5?^NC?RJK\5%M;KQ;;0:<PM]2YW2GY1G/J
M:Z3P#X5U?P]KVI7VH6XC@=F=6#9R,5R^LZ9%\2O&MQ;P;;1+9RK3@\MWZ5::
MYKF;3Y+%(^&?'.H*MI?^([=K%NH^VQGCZ5ZUX$\,V'AG2!;VUQ'<3-S)*K D
M_E7GS_ ,)&6&OS9'JM9?A.35O"GQ.M/#?VQY[9W4/SQ@YH?O+1CC>+U1] T4
M45@= 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !4<T*3PM$XRK#!J2B@#Q#4OA[XG\.:Q<7WAB9G$IW;%7N3FH!
M'\6]0_T:Z22.$\%M@KW:BM/:/JC+V2Z,X'P'X!/AV634;Z437\V=S$=,]17=
MK%&A)2-%)ZD*!FGT5#;;NS1125D%%%%(84444 <;X^\%CQ7IZB*3R[F,AE;'
MI7G,=C\5="06>FI)+ O1M@/\Z]XHJU-I6(E33=SQ"T\%>,_%ES&WB>=H8@0S
M(R\'\J]CTO3H=*T^*SMUQ'&, "KE%*4FQQ@HA1114E!1110 4444 %%%% ",
M"5(!P>QKG='\--9ZS=:G>3">X=B(CC&Q#VKHZ*=Q6N%%%%(84444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% #9$$D;(W1@0:\:\1?#K7M.UZ?5O#<S
M;I6W>6HZ5[/151DXDRBI;GA.[XOW7^CSPR)$W!;8.E=?X'^'DVDWQUC5I_/O
MVP1D<J17H]%-S;5B532=V%%%%0:!1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 44E% "T4E% "T4E% "T
M4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T
M4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T
M4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T
M4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T
M4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T
M4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T
M4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T
M4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T
M4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T
M4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T
M4E+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
1%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g23ode3tb50n000020.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g23ode3tb50n000020.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -^ ^\# 2(  A$! Q$!_\0
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M&^JWF4>90!9WT;ZK>91YE %G?1OJMYE'F4 6=]&^JWF4>90!9WT;ZK>91YE
M%G?1OJMYE'F4 6=]&^JWF4>90!9WT;ZK>91YE %K?1OJMOHWT 6MU+NJL'IP
M>@"QFES4(>G!J ):*:#2YH =124M !1110 444E !2&EIIH :349:G,:A8T
M&<FG>26&<U%GYA5V/[E %;[,WK2?96]:NT4 4?LK?WJ3[(W]ZK]% %#[(W]Z
MC[(_]ZK]% %#[(_]ZC[(_P#>J_10!0^R/_>H^R/_ 'JOT4 4/LC_ -ZC[(_]
MZK]% %#[(_\ >H^R/_>J_10!0^R/_>H^R/\ WJOT4 4/LC_WJ/LC_P!ZK]%
M%#[(_P#>H^R/_>J_10!0^R/_ 'J/LC_WJOT4 4/LC_WJ/LC_ -ZK]% %#[(_
M]ZC[(_\ >J_10!0^R/\ WJ/LC_WJOT4 4/LC_P!ZC[(_]ZK]% %#[(_]ZC[(
M_P#>J_10!0^R/_>H^R/_ 'JOT4 4/LC_ -ZC[(_]ZK]% %#[(_\ >H^R/_>J
M_10!0^R/_>H^R/\ WJOT4 4/LC_WJ/LC_P!ZK]% %#[(_P#>H^R/_>J_10!0
M^R/_ 'J/LC_WJOT4 4/LC_WJ/LC_ -ZK]% %#[(_]ZC[(_\ >J_10!0^R/\
MWJ/LC_WJOT4 4/LC_P!ZC[(_]ZK]% %#[(_]ZC[(_P#>J_10!0^R/_>H^R/_
M 'JOT4 4/LC_ -ZC[(_]ZK]% %#[(_\ >H^R/_>J_10!0^R/_>H^R/\ WJOT
M4 4/LC_WJ/LC_P!ZK]% %#[(_P#>H^R/_>J_10!0^R/_ 'J/LC_WJOT4 4/L
MC_WJ/LC_ -ZK]% %#[(_]ZC[(_\ >J_10!0^R/\ WJ/LC_WJOT4 4/LC_P!Z
MC[(_]ZK]% %#[(_]ZC[(_P#>J_10!0^R/_>H^R/_ 'JOT4 4/LC_ -ZC[(_]
MZK]% %#[(_\ >H^R/_>J_10!0^R/_>H^R/\ WJOT4 4/LC_WJ/LC_P!ZK]%
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M,Z?X;:WN(YS*" ,XKI@-HQ77AY591_>*QS5XTT_W;N+12;U]12]:Z# ****
M"BD+*.I% (/0T +03BCM7,>(=5DMI?)C)!(ZBLJU:-*'-(UI4G5ERHZ195=B
MJGD4^N?\/3O,"SL22.]=!11J>TAS"JPY)<H44A('4TF]3_$*U,QU%%% !111
M0 4444 %%%% !1110!GW?WZC2I+O[]1I0!.M3+4*U,M $@IU-%.H !2T@I:
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MRAS<UM2_:2Y>6^@C*&4J>]94NA6TLOF-&":UJ*<Z<9_$@C.4/A9'#"L*!5&
M*62-9%*L,@T^BJLK6)N[W,2X\/6TC[DC S3K?P_:Q'+1@FMFBL?JU*][&OMZ
MEK7,J?0K69]QC%7(K-(X#"!\I&,59HJU2A%W2(=2;5FS(70+57W",9K51 B*
MHZ 4ZBG"G"'PH)5)3^)E*\TZ&\&)%S3;/2X+,_NTQ5^BE[*'-S6U#VDN7EOH
M1301SIMD7(K)G\.VKME(P*VZ*)TH3^)#A5G#X68$?ANW#99 :UK:Q@M%Q$F*
MLT4H4*</A03K3GNQ&4,I4]#65=:%:SDL(QN/>M:BJG3C-6DA0G*#O%F GAJ
M-\R#%:EII]O:#]TF#5NBHA0IP=XHJ=:<U9LK7=G'=(5=<BJUIH]O:/NC0 UI
M453I0<N9K4E5))<J>@=JHWNFPWH'FKG%7J*J45)68HR<7=%&TTR&S.8UQ7.^
M+OOPUV%<QXEL+B[:+R4W8ZUQXRG:@XP1U86I>LI293\/VL5T DJY&*U9/#=N
MSY5!BH?#UC<6S RIMXKI*G#8>,J2YUJ/$5Y1J/D9G6>D6UI\RIAO6M#'&*6B
MNZ$(P5HHY)3E)W9EWNBV]TQ?8-QZFH;70(8)0^P9%;5%9O#TW+FMJ6J]1+EN
M9MSI%O<@!T!Q4]G816:[8UP*MT52I04N9+4EU)-<K>@R2))5*N,@UDW'AZUD
M;*1@&MFBB=*$_B00J2A\+,*+PW;JV70$5K6]I%;+MB7 %3T4H4:</A0YU9S^
M)D5Q"MQ"8W&5-9R:#:I*'$8R#FM:BG*E"3O)"C4E%63$ P /2J-[I<%Z09$!
MQ5^BJE",E9BC)Q=T4K/3HK/'EKC%7:**(Q459"E)R=V%9]YI,%ZX>1 2*T**
M)PC-6DAQDXNZ,7_A'+/_ )Y"C_A'+3_GF*VJ*R^K4OY33ZQ4[F+_ ,(Y:?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !2$ ]:6B@!  .E+110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9]W]^HTJ2[^_4:
M4 3K4RU"M3+0!(*=313J  4M(*6@ I*6DH 0TP]*>:8>E $3=:@>IVZU ] $
M/\8K3A_U8K,_C%:</^K% B2BBB@84444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!GW?WZC2I+O[]1I0!.M3+4*U,M $@IU-%.H !2T@I: "D
MI:2@!#3#TIYIAZ4 1-UJ!ZG;K4#T 0_QBM.'_5BLS^,5IP_ZL4")****!A11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &?=_?J-*DN_OU&E
M $ZU,M0K4RT 2"G4T4Z@ %+2"EH *2EI* $-,/2GFF'I0!$W6H'J=NM0/0!#
M_&*TX?\ 5BLS^,5IP_ZL4")****!A1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !5+4M0CT^V:1V ;'R@]S5VJ>H6-O>0GSTW;1D4 <YHGB
MNYU+4Q;2PA 3UJYX@UN]L'BCLK<3%SAO:L?3H4@\6QI&,+CI767OV2UC:XE
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M110 52U%[E+<_9D#L1T-7:* //+6TU]-=6\:T  _SZ4[Q3!XBOS;FVML[/O
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MUJXOW1]*IWO5/K5Q?NCZ4 +1110 4444 %%%% !1110 4444 %%%% !1110
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M%[;VN/.D"9Z9JK-KNFV\7F272*OJ:DHT !Z48!Z@5G6>NZ=?-MM[E'.>U:5
M"8 Z 4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 9]W]^HTJ2[^_4:4 3K4RU"M3+0!(*=313J  4M(*6@ I*6DH 0T
MP]*>:8>E $3=:@>IVZU ] $/\8K3A_U8K,_C%:</^K% B2BBB@84444 %%%%
M !1110 4444 %%%% !7(^,+,7,+^8RB+'()Q775A>(O#<?B"U>![AX@W=333
MLQ/8XJPT;PA H>6!3*?O$..OY5HM!X1=-IA7'^^/\*S+GX4Z?:1&2;5[E5 R
M3O/^-<Y+X?\ "D<WEGQ',/\ @1_QK71]3/5=#J#X5\.WLP?2X528'@[@>:[W
M0[&;3],CMYR"Z]2*Y#P?X5TRW?[18ZG+<@')W,:]!J)/H7%=0HHHJ"@HHHH
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M*** "BBB@ HHHH **** "BBB@ HHHH *:Z+(I5AD&G44 ,CC2-=J# %/HHH
MB,$9;<5YKG=<T"YU>[V-(#:]T-=/133L)JY!96PM+.*!1@(N*)K."<YD0-4]
M%(8R.)(EVH,"GT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 9]W]^HTJ2[^_4:4 3K4RU"M3+0!(*=313J  4M(
M*6@ I*6DH 0TP]*>:8>E $3=:@>IVZU ] $/\8K3A_U8K,_C%:</^K% B2BB
MB@84444 %%%% !1110 4444 %%%% !1110!Y]\26FA^PW$=QY0B.XK_>ZU%H
MGCVP>Q4S!0XXY-:?CB+1[J2SM]3D(\QMJ;3]:HQ_"[PXT6]7D (S]ZM%:VIF
M[WT.@TOQ5::G)LB*]<<&NAKSK0M+\/Z5J9AM))#('Q@GO7HM3)+H7%OJ%%%%
M2,*R->@N)[79;R&,D<D5KU7O)DA@8OZ4T#."\.V]S8^(DAGG,I/.:GE>36]:
M:$N?+@DP5/>HK/48#XM1@3C%(+A=#UIYI\A;F3*_Y_"K,R76H3H5XUU;'9$!
M@(*J^%6;Q3//)<G<L+8PU3:_?QZW=-8VN6?&:I^#IU\,37$-[E6F;Y:.@=31
MBWZ/XJFV-BWP L8Z#K78I?%D4^6>17%+<1ZSXLFAAR0H#?SKO8H52)5QT&*F
M142A/.974;2.:TU^Z/I5&[0*4QZU>7[H^E24+5:[NA:QERN<59J&>WCN$VOT
MJ9\UO=W S?[=7_GD:/[=7_GD:L?V1;>]']D6WH:Y>7$=QZ%;^W5_YY&C^W5_
MYY&K/]D6WH:/[(MO0T<N([AH5_[=7_GD:/[=7_GD:L?V1;>AH_LBV]#1RXCN
M&A!_;B?\\Z9+X@2-"WEYQ5G^QK;WJO?:1;I93.,Y"Y%'+B.X:&6_C).@A-+'
MXQ0D#R#7'/\ ?/UJ6T4/=1J>A-=*3Y=]1'=Q^(T=,^5BG_\ "01_\\Z+31;5
MX%8@YJ4Z#:'UIJ]@(?\ A(H_[E)_PD</]T?G3IO#]F(7(W9"DUPEP-DS*"<
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M/M"Q/7DU+I6IR"86MT<2$\"D!T-% Y%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** ,^[^_4:5)=_?J-* )UJ9:A6IEH
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M HHHH **** ,^[^_4:5)=_?J-* )UJ9:A6IEH D%.IHIU  *6D%+0 4E+24
M(:8>E/-,/2@")NM0/4[=:@>@"'^,5IP_ZL5F?QBM.'_5B@1)1110,**** "B
MBB@ HHHH **** "BBB@ KA/BI-)'X.NMG ]?P-=W6'XKT<:YH4UEG!?O3CN*
M2NC/\!01)X?MI$8EWC^;-=1.H>%P>FTUXAIOB/5?!EY-;2V4\\*G:AQQBM#4
M/BG?:C;F"UTF9';C*_\ ZZMP;=R%-)!X?D-KXMN4A=B'G.[)KV.O+_A[X=N?
M/N+^]#!I&W@..E>H4I[CAL%%%%06%%%% !1110 4444 %%%% %*]ZI]:N+]T
M?2J=[U3ZU<7[H^E "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !574?^/&7Z5:J*YB\^W>/.-PJ9IN+
M2 \QN_\ CX:FVW^O6NHF\(O)(7\_K69)HS6>H1Q,_!_BKYB>$K0ES26ES2Z.
MTTS_ )!\7TJY5:Q01VB*&S@=:LU]-35H)&9G:PFZT=O1:K^&GW:8/]ZK^H+N
ML)O]VLCPRVVU\OWK0#H:***0!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** .9U6$V=[#*G\;9.*3691)")![5K:M;>=;,
MV.4&17*W$Y.D;7/S[JXX?NJ[CT8^AV=ES90G_9JQ5336W6$/^[5NNP04444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!GW?WZC2I+O[]1
MI0!.M3+4*U,M $@IU-%.H !2T@I: "DI:2@!#3#TIYIAZ4 1-UJ!ZG;K4#T
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!#=*6M9% R2M><ZAIUTLS.86"^M>F52U&)9+5@12L[W \WLX))+E0JD
MD&O2-+C:.Q17&".U<18NUOJIQ]W?S7H$,JRQAUZ&L85.:HT^@R2BBBMQ!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 9]W]^HTJ2[^_4:4 3
MK4RU"M3+0!(*=313J  4M(*6@ I*6DH 0TP]*>:8>E $3=:@>IVZU ] $/\
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M.>]:B_<'TI#%HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MIYIAZ4 1-UJ!ZG;K4#T 0_QBM.'_ %8K,_C%:</^K% B2BBB@84444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 <]X@7-W;-Z&MBP??:J:S=>7*J_H*MZ*^_38VH OD C!K
ME[U&TW4C<KP)& KJ:S]5LQ=6_3E>:Y\33<X76Z&BY!()8E8'L*DK T&\.UH9
M3AMV #6_5T:BJ04@84445J(**** "BBB@ HHHH **** "BBB@ HHHH ****
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MZFECTVRF,\ <U9JCI7_'F*O5]13;<$V9L****L HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** ,^[^_4:5)=_?J-* )UJ9:A6IEH D%.IHIU  *6D%+0 4E+24 (:
M8>E/-,/2@")NM0/4[=:@>@"'^,5IP_ZL5F?QBM.'_5B@1)1110,**** "BBB
M@ HHHH **** "BBB@ JAJNEV^K63VUS&'C;J#5^LS7=9@T/3)+RX?:B=330,
MY6^\$>&["W:6:WA7:,X)QFO+M9TZPU?4#9Z38%,GB11D4_7?'3^(=3$,TNVS
M5\;D/:NS\-:_X,T*W7;=[G'=P#_6ME>.K,7:3LC8\">!5T*W$T^UG<9'M7H%
M<]I?C/1=7D\NSN-QSC'%=#64KWU-8VMH%%%%2,**** "BBB@ HHHH **** *
M5[U3ZU<7[H^E4[WJGUJXOW1]* %HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@"&[7?:R+ZBL#1FV:FT'<"ND8;E(]:Y>+_1_%$I_AQ_C0!U--D7?&R^H(I5
M.5!]:6@#DI/"<CR,WF#DDU7G\-2VH$N\';SQ7:TUT$B%3T(K@EE]%K1:CYF9
M.AW:RVVP\,#C!K8KE[V"32[W[1$/W0ZUOV5VEU"K*<G'-:8:H_X<]T#[EFBB
MBNL04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% &?=_?J-*DN_OU&E $ZU,M0K4RT
M 2"G4T4Z@ %+2"EH *2EI* $-,/2GFF'I0!$W6H'J=NM0/0!#_&*TX?]6*S/
MXQ6G#_JQ0(DHHHH&%%%% !1110 4444 %%%% !1110 5F:Y86^HZ=)!=%1$W
M7=TK3KD/B1J$FG^$;F:(X<=/R--;B>QS+:)X9BN/*\ZU#9QUK4_X0S1#;^>)
M(/+_ +W:N4T[P%%J&C'5I6;SGC\Q3N[UE6DGB&[/]A0.OEYSR:UMV9E>VZ.[
MT)=+M-2\JS6)SOP2G:O1JX?PAX*@TA3/-GSVY//>NXK.6YI'8****DH****
M"N:\0ZQ<VLL,%O;N_F'!9>U=+5&^>WM86N)L?(,TT)G,:=KUQ;ZQ]AN$8X&=
MS4[Q'X@DM[NVB@S^\ZE>U5K&.37?$#7R ?8R, ]\U9U/P[=37"20 '9TS5:7
M)UL:6A2W4LV92Q7'>NAKA] U;4$\13:7=%=D:9 'X_X5U1%V3D8Q4M:E+8+W
MJGUJZOW1]*RIA.'7S<8S6JOW1]*0Q:*** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *YC6E^RWGVG^\P%=/61X@M?M%FN!R&S0!I6S;[:-O514C':I/H,UE:'
M=^? R9Y3BM*?F"0=]IH YC5_$@AE\N,9]Q4.G>)RTP212=QQS7.:A')'=.'!
MY8U%:JS748 /WJ8'J,L4=Y;X(!!%<[B?2+O/S-&[?D*W]/1DM5#=<5)=6J7,
M15AU%<U>CS^]'1H:8EK=QW,896'X58KE7CN-'GW)_J!6I#KUJZ#<WS8YJ*>)
M7PU-&%C6HK-&M6A(&[K6@CB10R]#71&I&?PNXAU%%%6 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!GW?WZC2I+O[]1I0!.M3+4*U,M $@IU-%.H !2T@I: "DI:2@!#3#TIYI
MAZ4 1-UJ!ZG;K4#T 0_QBM.'_5BLS^,5IP_ZL4")****!A1110 4444 %%%%
M !1110 4444 %<7\2["YU#PG<P6L322-T5?H:[2BFG9W$U=6/GRVO/%=MIRV
M:Z9<[57;VJG9Q^)[2\^TKI=QO]>*]C\:^)SX?@A5"PEFX3'K7"+XE\7SC?'<
M$*>GRFME)O6QDU;J;'@_4M?N+K%]931+NZM7I]>=^%]5\17-SB_F++GT->B5
ME/<TCL%%%%24%%%% !7#^++34+Z>'R!($0_,%Z-7<44T[":N<3HQO;4B$6;(
MOK5J_N=1LV4Q022[^3CM76447"QR.@:)+_:\FL7!97E7!C/;K_C77444-W!*
MQ2O>J?6KB_='TJG>]4^M7%^Z/I2&+1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M:8T/512>5'_<7\J?10 SRH_[B_E1Y4?]Q?RI]% $$R(L3$(O3TKS'4'+7LHQ
MC#5ZHPW*1ZBN.U;PU(\QDB(&3DT <Q;.4G0C^\*].LT1[6,E!]T=JY/3?#,O
MG!Y2"HYKM(D$<:H.PQ1H UK>%A@QJ?PK-OM'@EB8JH!]A6O2$ C!J)0C)6D@
M/*;V/RKN2/T-0H"7&/6NRU;PTUQ*982 2<FH--\+2),'F*E1VJE%)6 Z;2P1
MI\.?[M7*9%&(HE0#A1BGTP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP_ZL5F?QBM.'_5B@1)1110,**** "BBB@ HHHH **** "BBB@ HHHH ****
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MZU<7[H^E4[WJGUJXOW1]* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU2(#)1ORH_M2+&=C?E4DUN&B "C./2C[./(5=HR/:@"+^U(L9V-^5*-4B/\
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MTIYIAZ4 1-UJ!ZG;K4#T 0_QBM.'_5BLS^,5IP_ZL4")****!A1110 4444
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M1PD&5S@ ^M4-,\2W3:BMIJ"K&Y&<#TIV8KHZVBD5@RAAT-+2&%%%% !1110
M4444 %030>9*C_W:GK"USQ%;Z0\:.X#/T%&X-V-VBJ6E7O\ :%@EQQ\U7: "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S[O[]1I4EW]^HTH G6
MIEJ%:F6@"04ZFBG4  I:04M !24M)0 AIAZ4\TP]* (FZU ]3MUJ!Z (?XQ6
MG#_JQ69_&*TX?]6*!$E%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@!*R-0ULV,ZQBW9\]Q6Q5::RBG<,XY%-"9
M4DAM=2M(Y[F)<#Y@&[5RNIE=3\0PV]M'F/;CS%Z#I5_Q7-J4%JD.G 8)PWTK
M.T W.G_NPH.X[B3ZU2VN2]['<V<)M[2.(G)48S4]1P,7A5FZD<U)4%A1110
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M !1110 4C*&&&&12T4 0?8[?_GDM2I&D8^10/I3J* "BBB@ HHR** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,^[^_4:5)=_?J-*
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M _G72_"R\N+KPVQF);#X!)SZUBK\.?$$LB+=ZH)(%/W/:O0]"T:+1;#[-$H
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9]W]^HTJ2[^_
M4:4 3K4RU"M3+0!(*=313J  4M(*6@ I*6DH 0TP]*>:8>E $3=:@>IVZU ]
M $/\8K3A_P!6*S/XQ6G#_JQ0(DHHHH&%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 9]W]^HTJ2[^_4:4 3K4RU"M3+0!(*=313J  4M(*6
M@ I*6DH 0TP]*>:8U $3=:@>IVJ%Z (/XQ6G#_JQ6;_&*TH?]6* )**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *%W]^HDJ6Z^_4:
M4Q$RU,M0K4RTAD@IU-%.%  *6BB@ I*6DH 2FFGFF&@"%AS435.PJ%A0!!_&
M*T8?]75''S"K\7W* 'T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 4+K[YJ-*FN!EJ8HH D6IEJ-14JB@!PIU(*6@!:*** "DI:* $
MIIIU)B@"-A4;"IR*85H KX^:K"R@+BF%:C*T 6//%)]H6JQ2FE#0!:^T+1]I
M6J?ET>70!<^TK1]I6J7ET>70(N_:5H^TK5+RZ/+H N_:5H^TK5+RZ/+H N_:
M5H^TK5+RZ/+H N_:5H^TK5+RZ/+H N_:5H^TK5+RZ/+H N_:5H^TK5+RZ/+H
M N_:5H^TK5+RZ/+H N_:5H^TK5+RZ/+H N_:5H^TK5+RZ/+H N_:5H^TK5+R
MZ/+H N_:5H^TK5+RZ/+H N_:5H^TK5+RZ/+H N_:5H^TK5+RZ/+H N_:5H^T
MK5+RZ/+H N_:5H^TK5+RZ/+H N_:5H^TK5+RZ/+H N_:5H^TK5+RZ/+H N_:
M5H^TK5+RZ/+H N_:5H^TK5+RZ/+H N_:5H^TK5+RZ/+H N_:5H^TK5+RZ/+H
M N_:5H^TK5+RZ/+H N_:5H^TK5+RZ/+H N_:5H^TK5+RZ/+H N_:5H^TK5+R
MZ/+H N_:5H^TK5+RZ/+H N_:5H^TK5+RZ/+H N_:5H^TK5+RZ/+H N_:5H^T
MK5+RZ/+H N_:5H^TK5+RZ/+H N_:5H^TK5+RZ/+H N_:5H^TK5+RZ/+H N_:
M5H^TK5+RZ/+H N_:5H^TK5+RZ/+H N_:5H^TK5+RZ/+H N_:5H^TK5+RZ/+H
M N_:5H^TK5+RZ/+H N_:5H^TK5+RZ/+H N_:5H^TK5+RZ/+H N_:5H^TK5+R
MZ/+H N_:5H^TK5+RZ/+H N_:5H^TK5+RZ/+H N_:5H^TK5+RZ/+H N_:5H^T
MK5+RZ/+H N_:5H^TK5+RZ/+H N_:5H^TK5+RZ/+H N_:5H^TK5+RZ/+H N_:
M5H^TK5+RZ/+H N_:5H^TK5+RZ/+H N_:5H^TK5+RZ7RZ +GVE:7[0M4O+I0E
M RYYZTOG"JFRG!: 'R?,U-44X+3PM  HJ0"@"E% "TM%+0 4444 %%%% !24
MM% "8IN*=10 S%-*U+BDQ0!%LINRI\4F* (-E&RI\48H @V4;*GQ1B@"#91L
MJ?%&* (-E&RI\48H @V4;*GQ1B@"#91LJ?%&* (-E&RI\48H @V4;*GQ1B@"
M#91LJ?%&* (-E&RI\48H @V4;*GQ1B@"#91LJ?%&* (-E&RI\48H @V4;*GQ
M1B@"#91LJ?%&* (-E&RI\48H @V4;*GQ1B@"#91LJ?%&* (-E&RI\48H @V4
M;*GQ1B@"#91LJ?%&* (-E&RI\48H @V4;*GQ1B@"#91LJ?%&* (-E&RI\48H
M @V4;*GQ1B@"#91LJ?%&* (-E&RI\48H @V4;*GQ1B@"#91LJ?%&* (-E&RI
M\48H @V4;*GQ1B@"#91LJ?%&* (-E&RI\48H @V4;*GQ1B@"#91LJ?%&* (-
ME&RI\48H @V4;*GQ1B@"#91LJ?%&* (-E&RI\48H @V4;*GQ1B@"#91LJ?%&
M* (-E&RI\48H @V4;*GQ1B@"#91LJ?%&* (-E&RI\48H @V4;*GQ1B@"#91L
MJ?%&* (-E&RI\48H @V4;*GQ1B@"#91LJ?%&* (-E&RI\48H AV4!*FQ1B@"
M+93@E28HQ0 S;3L4[%% "8I:*6@ HHHH **** "BBB@ HHHH **** "BBB@
MI*6B@!**6B@!**6B@!**6B@!**6B@!**6B@!**6B@!**6B@!**6B@!**6B@!
M**6B@!**6B@!**6B@!**6B@!**6B@!**6B@!**6B@!**6B@!**6B@!**6B@!
M**6B@!**6B@!**6B@!**6B@!**6B@!**6B@!**6B@!**6B@!**6B@!**6B@!
M**6B@!**6B@!**6B@!**6B@!**6B@!**6B@!**6B@!**6B@!**6B@!**6B@!
M**6B@!**6B@!**6B@!**6B@!**6B@!**6B@!**6B@!**6B@!**6B@!**6B@!
H**6B@!**6B@!**6B@!**6B@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g23ode3tb50n000031.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g23ode3tb50n000031.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (_!-8# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHJ&ZN$M;=II#A5ZT 345P-[\5-!LKIH);K#KU'%5_\
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MUDVMHMOL8@X[\UQOACQ'<Z-K4[6UD]RVS!"_C6UX$_Y%;7_^NA_G2_#(VO\
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MG#KZBN6\<Z5>:AI^^S^_&N:X3P=XVN=%NQI6L.1MZU2C=71+E9V9[.6"C).
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MBF[T_O"C>G]X4 .HIN]/[PHWI_>% #J*;O3^\*-Z?WA0 ZBF[T_O"C>G]X4
M.HIN]/[PHWI_>% #J*;O3^\*-Z?WA0 ZBF[T_O"C>G]X4 .HIN]/[PHWI_>%
M #J*;O3^\*-Z?WA0 ZBF[T_O"C>G]X4 .HIN]/[PHWI_>% #J*;O3^\*-Z?W
MA0 ZBF[T_O"C>G]X4 .HIN]/[PHWI_>% #J*;O3^\*-Z?WA0 ZBD!!&0<T4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHIKNJ*68X H =16<^N:?&Y5KA013?[?TW_GY6BPKHTZ*B@N8KA T3
MA@:EH&%%%% !1110 44A('6@$$9% "T444 %%%% !1110 4444 %%(&!; /(
MI: "BBB@ HHJJ^H6T<_DM*!)Z4 6J*3<-N[/!J*:ZA@C#R.%4]Z )J*B@N8K
MA=T3!@*EH ***@N;N"T7=,X4>] $]%9L6OZ;,^R.Y4MZ5;ENX88Q([@*1G-
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MLC.,T ;,LJQ+DFJ,-ZTLX49VYJG)<27LFQ0<>U:EI:K"GJ30!:HHHH ****
M"BBB@ HHHH **YCQ5XG;P]&9 @*@9)-6O#?B6UU^R22*13*1EE':G9VN*ZO8
MW:J7^H0:?;/-,X"J,]:AU;6+72+5I[B4(%]:\7UK7=4\;:M]BL4<6R/@O&>H
MIQC<4I6.TTOXAIJWB<6EN)/(QZ'%>AHV] P[UR7A#P9;:#:(2 \O4LPYKK@
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MG[YGVG;[XKA? WB74;7Q';VE](VV=MPW CBH_'VNV]YXL>TN9<6\4JL/S_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#/.CSY_P#GG5NB@"IY\_\ SSH\^?\ YYU;HH J>?/_ ,\Z//G_ .>=6Z*
M*GGS_P#/.CSY_P#GG5NB@"IY\_\ SSH\^?\ YYU;HH J>?/_ ,\Z//G_ .>=
M6Z* *GGS_P#/.CSY_P#GG5NB@"IY\_\ SSH\^?\ YYU;HH J>?/_ ,\Z//G_
M .>=6Z* *GGS_P#/.CSY_P#GG5NB@"IY\_\ SSH\^?\ YYU;HH J>?/_ ,\Z
M//G_ .>=6Z* *GGS_P#/.CSY_P#GG5NB@"IY\_\ SSH\^?\ YYU;HH J>?/_
M ,\Z//G_ .>=6Z* *GGS_P#/.CSY_P#GG5NB@"IY\_\ SSH\^?\ YYU;HH J
M>?/_ ,\Z//G_ .>=6Z* *GGS_P#/.CSY_P#GG5NB@"IY\_\ SSH\^?\ YYU;
MHH J>?/_ ,\Z//G_ .>=6Z* *GGS_P#/.CSY_P#GG5NB@"IY\_\ SSH\^?\
MYYU;HH J>?/_ ,\Z//G_ .>=6Z* *GGS_P#/.CSY_P#GG5NB@"IY\_\ SSH\
M^?\ YYU;HH J>?/_ ,\Z//G_ .>=6Z* *GGS_P#/.CSY_P#GG5NB@"IY\_\
MSSH\^?\ YYU;HH J>?/_ ,\Z//G_ .>=6Z* *GGS_P#/.CSY_P#GG5NB@"IY
M\_\ SSH\^?\ YYU;HH J>?/_ ,\Z//G_ .>=6Z* *GGS_P#/.CSY_P#GG5NB
M@"IY\_\ SSH\^?\ YYU;HH J>?/_ ,\Z//G_ .>=6Z* *GGS_P#/.CSY_P#G
MG5NB@"IY\_\ SSH\^?\ YYU;HH J>?/_ ,\Z//G_ .>=6Z* *GGS_P#/.CSY
M_P#GG5NB@"IY\_\ SSH\^?\ YYU;HH J>?/_ ,\Z//G_ .>=6Z* *GGS_P#/
M.CSY_P#GG5NB@"IY\_\ SSH\^?\ YYU;HH J>?/_ ,\Z//G_ .>=6Z* *GGS
M_P#/.CSY_P#GG5NB@"IY\_\ SSH\^?\ YYU;HH J>?/_ ,\Z//G_ .>=6Z*
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M0!>WKZT;U]:I;CZT;CZT 7=Z^M&]?6J6X^M-W'UH O[U]:7</6J0<XI=Q]:
M+>\>M&\>M4BY]:3>?6@"]O'K1O'K5'>WK1O/K0!>WCUHWCUJCO/K1O/K0!>W
MCUHWKZU1WGUI-Y]: +^]?6EW#UJAO/K3@Q]: +NX4M5%8YZU:7I0 M%%% !1
M110 4444 %%%% !1110 4449H **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J\_2K%5KC@4 56Z5
M$&YI[./6F9!IB%W4;J./6CCUH 7-&:3BEXH ,TFZEXI.* #=3@W-)@4"@"53
M3NU-4TXGBD,C>HBU/9AZU'P3UIB#?1O-&!1@4 +N-&XT<4N10 F\T;Z7BDP/
M6@!58DU.O2H5*@]:D5Q2 >>E0.V#4I;BJ[NN<9H 428I=]1C'K3LKZTP'[J-
M])D>M&10 N^DWT<4G% "%S3E8FFD"G( * )UZ4-TI%(H8\4AD3/@TGFBF2<G
MK4>TTQ$_G"D\ZH=M."T 2^;1YE1[?>C;[T 2^:*/,%0[31M- %E6S4E0QC J
M:D M1L<4^F/0 S?1O%-(I,4P'[Z7=3,48H =OHWTW%&V@!V^C?4>V@#F@"PO
M(I],0\4ZD,8_%,W4]JBQ3$.W4FZBC% !FES28I<4#$W4A?FG%:810(<KY-3#
MI5=!S5@4@'K]ZK:]*J+]ZK:]*!CJ*** "BBB@ HHHH 3<OJ/SI ZD\,/SK@K
MZ[NV\0SP1R/MSC /2G7<5[I$JSFXDD7&2":XGC-_=T1VK";>]JSO:9+*L49=
MN@K.L]6MSI\4T\JH7'>IC<VU]&8XIE;/I72JD6M&<SIR3U1S4^NZC=7<D5BP
M^0X.:2'7=1L[D1WQ^7VJC-:7>F7\LL,+R!FSQ5F'6TFG"7=FJ'U:O+525_>D
MT_P/3=./+[L4U^)LZG=ZEY<,ECC:PR<U@/XBUF.Z-NQ7>*[B#RI;="H!7'%<
M1?HO_"52C QQ_.M\3&<;24GJ889PE>+BM#;TNZU:65?M.-AJ/Q%K\NG@+;M\
MP/-;@*6]DLF ,**X@F/4M9NA(X"8R,TZSE3@H*6K%14:DW-K1'3>'=7?4K0O
M*<N#BJ&H7NMPW$IBV^4O2LK19Q8:NEL&^1B37:WBQO8S, #E#S3IN5:E:]FA
M5%&E5NE=,XRW\0:S=2;(RN:W;?4;V"TE>\^\%RN*QO#2J=2Y&?F/\Z[5X(G7
M#("*G"QJ3CS.16)E",N51.-.O:JR?:%(\G-=)H^I#4(2<Y9>M8GB%I((C;P6
MG[L'[PJYX66-()-K@L>H]*=&4XUN1NXJL82H\Z5CHB<#-<_?:M*NJPVT!X;K
M6[*<0R'T4UQND'[7JK2-R4<@5OB)M.,5U,:$$U*3Z%G4=7U'3[E?,($3,!6U
M)JL2Z:;D-P ,TW6M.2]M#T!49%<%$]S)(VFDM\['%<]6K.A-K=/8WITH5X)[
M-;G3Z=J^H7TMP4(V*,K4$FJZRK'&,"N@TFP2TLT7:-V.:JZ_-#9V#.J+OJY4
MYJGS2D0IP=3EC$Q=/\0:C<7RPN00&PU:6LZY);2FWMS^^%-\/Z<(XY+EUR9/
MF&>U94W[WQ8X;D8Z&L>:K&DKO5LUY:<JCLM$BW9Z_>QW4<5Z0/,/%:VN:HUC
M8K-$>6.*PO$L:QWUD4 &!VHUF.YO-(@6.-GP^>/PI^UG",X7NT'LH2E"5K)A
M'K>KRC*%<5LW%Y>IIT,HQOZO7.I+<Z;&LDEL2JCG-=1#<1ZAHQD"@90G'I3H
M2E*Z<G<5:*C9J*L6-*OA?VQDSD@X-7ZY#PI,R%X2>LA_G77UV8>HYTTV<E>'
M)4:04445L8A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !52[.$JW56[&4H YN\U!;=SDXJNNLQM_%^M4?$]I*8
M7>/.?:O/5O=0BG93')@&F(]675$/\53+J"G^*O,XM2O,9*/5^'5+CNK4 >@?
M;U]:3[>OK7$?VE-C[IIAU2?^Z: .Z^WKZTHOE]:X0:K-Z&I%U24]C0!W/VY?
M6E6]4G@UPS:G+CC-7-/O)I91D&@#N8I-PJ5C\M4K+)C&:NO]R@#)O;Y8#R<5
M4CUJ)OXOUK$\8R3PV[O$&.!VKRM/%5W!<,DBL,>IH ]R;6(Q_%5=]?B7^,?G
M7B]SXQN-ORAOSK'F\4WLC<!Q^- ['T FOQ-_&/SJ0ZU$!G?7S_:^)+]6'RNW
MXU>G\5WPB \IQQZT!8]K?Q' G5Q^=5V\66P_Y:#\Z\"N/$-]+GYG'XU3_M2]
M=N)9,GWH"Q]&VWB2&>3"OG\:Z"TG\Y00:^?_  <VHS7Z[Q(5XY->\Z/$RVZ[
MLYQ0(LW]Q]FMFD)X )KRS5OB0MI?&-9. 2*],UR%I=.D5>NT_P J^8/$UK+;
MZHXDSRQ//UH&>FI\4HMO,M._X6E%G_6UXMN/K1EO6D.Q[G#\4+5OO2FKJ?$B
MR/\ RUKP(&3L33O,G'\34"L>_#XC6/\ SUIX^(MC_P ]:^??/F_OM1]IF_YZ
M-0%CZ$'Q#L?^>E6+;QY93R!!)R3ZU\Y_:9O^>K5HZ0UY-?1"-W/S#I3"Q]3V
M5\MS&&4Y!J2\NUMX2['  S6+X6@E33D\S.<#K2>+C(FE2F/.=AZ4",J?QS91
M7/E-)5A/&E@RY\S]:^=M0N[G[8Y:1P<GO4'V^['_ "W?\Z0['T9+XYL$_P"6
MGZU4;XBZ>IQYM?/IO;D]9W/XTPW,QZR-0%CZ%3XBV#MCS*NQ^.;!A_K/UKYM
M%S,.DC4\7UT.D[_G0%CZ8C\86+G_ %GZU97Q/9$9\P?G7S -2O%Z7#_G4HUB
M^ _X^9/SH"Q]16^O6]P^U'!_&MF*0.,BOF[P9JU]+J2J9'<;AWKZ)T\'[,A;
MK@4P+IZ57DF"GK4YZ5S6O7SV2LX!.*0&[YR^M(9E'>O-CXZCB++(0I'J:HW7
MQ'B3.TJ?QIB/5O/7UIAND'>O&G^)ISPGZU WQ)E<_+'G\: /;!=)ZTX7*>M>
M+P_$&<\M$1^-65^(F/O #\: /8//7UI#.H[UY3#\1(B.2!^-/C\?)/<I&I!W
M''6@9ZM'*&/%6"?EK#T*X:YA60]ZW6^Y0(J23JAY-(+A#WKF_$M[-91LZ*3B
MO/W^(KPNR.F"#CDT >QFY3UI/M:>M>+/\27)^5,_C3D\>W,I^6$G\: /9OMB
M>HH^V)_>%>3)XIOI%R('J&;QA>P=8&_.@#V#[8G]ZD^U(>]>*-\0;E#AHB/Q
MII^),BC[GZT >UF\0'&:M6\F\9%>*Z-XUGU34(XPAP3CK7L6E[C;*6ZT :2]
M:MI]VJB]:MI]VD,=1110 4444 %%%% 'G=W=K:>*9W8$@GM5S7=32_A%O"K;
MF4=J5]/EE\2W#M%E#T)KI(-&@C99"H) [BO*ITJDU**V;/4G5IP<9/=(R(=
M%YI-NDBY*BK$&B-IT):W 5QTKH54*N%& *7&>M=JPT%KU.-XF;TZ'%6GB&6W
MNYXK\.PS@8!K/UFYM;^7;;1.')ZD5VMSI-O<G)10?7%);Z-;P/NV*Q]Q7/+#
M59+D;T-XXBE%\Z6H[28WCL(@W]T5R=^K?\)5*<''';WKN@ HP!@"JCZ=$]P9
MB!N/M6]:@YQC%=#"E64).3ZF9KMV8=',:@[B@QBN=TK0KRXA%RA +CO7;W%E
M'< !P, 8J:&%8(A&@  ]*B>&]I4YI;(N&)]G3Y8[GGNHZ5=Z;.+EN2H["NOM
M;C[1H))SN,9S6A<VL=RA5U!SZTD5HD41C'W<8HIX9TY/EV85,0JD5S;HX_PT
MK#4LD$?,>WO74ZI/-;P&2(_=&34D%A%;R;T S]*LNBR*58 @^M72HRA3Y;D5
M:RG4YK'(MXDBGT_9.CF0^U.\)0R![B3!"LV1D5M/HELTF[:H]L5?A@C@3:B@
M?05G"A4<U*;V-)UX*#C!;BS#,$G^Z?Y5QWA\>3J$JMU:0X_.NT894CU%<K<V
MDEIKL+1J3&3EC58F+YHS[$X>2Y91[G42_P"I?Z&N%MD/_"6PG:<<\X]Q7=J=
MZ?6JJZ?$MR)P!N'M5UJ3J.+70FC55-23ZEOM7(>(F:?4/LV"5(]*["JLMC%+
M/YK ;OI55Z;J1Y431J*G+F86,>RPA3T7%<AJJM8>('NBIV=.!7<* J@#M5>Z
MLHKI<.HSZXJ:U%S@DMT51K*$VWLSB;^\&KZC9B)6PO!R*VK^[GTFTC SM#8P
M!6M;:5!;-N"J3VXJS/;1W";70$>XK*&'FDVWJS25>#:26B.1U?7(;^P,$:/O
M9?2M+1X&M]")?C]V:OQ:);QR[]H/MBF:PS0V@CB7AN,"A4IQ;J5'K8;J0DE3
M@NIA^&$,EPT@Z!S_ #KLJQ?#M@;.T8./F9L\UM5KA8.--7,L3-2J.P4445T'
M.%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M 4444 %1RPI-C>,XZ5)10U<!  !@4M%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 56N>@JS5:YZ4
M4) #4)C%3L*8:8B QBC94I%&V@"+;1MJ7%)B@"$I2 '-38HVT ,VDT]%YHVU
M*@H E0<4YNE"BE:@"A,N35?H:N2BJQ3F@!N:3!-2A*<%H A"&D\LYJR%HVT
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *@:4@XJ<]*J2?>H =YQH\XU%10!+YQH\XU%10!+YQH\X
MU%10!+YQH\XU%10!+YQH\XU%10!*)32^::AI30!)YQH\XU%10(E\XT><:BHH
M E\XT><:BHH E\XT><:BHH&2^::7S345% $IE-)YQJ.DH E\XT><:BHH E\X
MT><:BHH E\XT><:BHH E\XT><:BHH$2^<:/.-144#)?.-'G&HJ* )?.-'G&H
MJ* )?.-'G&HJ* )?.-'G&HLT9H E\TT><:BHH E\XT><:BHH E\XT><:BHH
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M=#YC8'2NLUK78-&TO[;,X5/4UA^$_"NC'P_IUV;-/.\L-N]ZY#XIZBUV[:+
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#TKGM:U);&-I'(
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M/!#X(U,#_45 W@_4@<>37T%]FA/_ "S%-^PVQ/\ JEH"YX)'X*U)A_J34O\
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MR.E5H^M61TH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M $/2J<PR35PU4D^\: ,Z>'=5)X".U;! J-H@>U,1C>41VINPUJM /2HS![4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2[6]*-K>E "44NUO2C:WI0 E%.V'THV'TH ;13MA]*-A]*!C:*=L/I2;#Z4
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M/SI/D]1^=0?8Q_?;\Z/L8_OM^= %CY/4?G1\GJ/SJO\ 8Q_?;\Z/L8_OM^=
M%CY/4?G1\GJ/SJO]C']]OSH^QC^^WYT 6/D]1^='R>H_.J_V,?WV_.C[&/[[
M?G0!8^3U'YT?)ZC\ZK_8Q_?;\Z/L8_OM^= %CY/4?G1\GJ/SJO\ 8Q_?;\Z/
ML8_OM^= %CY/4?G1\GJ/SJO]C']]OSH^QC^^WYT 6/D]1^='R>H_.J_V,?WV
M_.C[&/[[?G0!8^3U'YT?)ZC\ZK_8Q_?;\Z/L8_OM^= %CY/4?G1\GJ/SJO\
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MZK?8Q_?;\Z7[&O\ ?;\Z +.0>E%,C3RUV@DT4 /HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "C-%5Y&(- $^11D54\PT>8: +>11D54\PT>8: +>11D
M54\PT>8: +>11D54\PT>8: +>1ZT9'K53S#1YAH MY'K1D>M5?,-'F&@"UD>
MM&153S#1YAH MY%&153S&H\PT 6\BC(JIYAH\PT 6\BC(JIYAH\PT 6\CUHR
M/6JGF&E\PT 6LCUHR*J>8:/,- %O(HR*J>8U'F&@"WD49%5/,-'F&@"WD49%
M5/,-'F&@"WD49'K53S#1YAH MY'K1D55\PTGF&@"WD49%5/,-'F&@"WD49%5
M/,-'F&@"WD49%5/,-'F&@"WD49%5/,-)YC4 7,CUHR/6JGF&E\PT 6LBC(JI
MO-)YAH N9%&153S#1YAH MY%&153S#1YAH MY%&153S#1YAH MY%&15/S#2^
M8: +>1ZT9'K53S#2^8: +611D54\PT>8: +>11D54\PT>8: +>11D54\PT>8
M: +>11D54\PT>8: +>11D53\QJ7S#0!<S15>-B35B@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MD],X)YI68[HVJ***0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?YT#Q5IQ'_'S'^=?+YUF\/\ RTH_MJ\_YZ4#L?3K^+M/7_EXC_.HQXQT_/\
MKX_SKYE.KW9ZO3?[5NO[] K'T_\ \)=IW_/Q'^=3VWB:QN'VK.A/L:^6O[7N
M_P"_5FS\17UI,'27'- 6/K6*=)5RK T]G"C)KRSP#XPDU,)#,Y+$XKL?$>L#
M3M/:3.#M.*8C0N=9M+8D22JOUJHWB?3U&?M$?YU\]:]XQO[R\?9+\N2*Q6UZ
M^88,E(=CZ8;QAIP_Y>(_SH'C'3C_ ,MX_P Z^8CJUT?XZ3^U;K^_0%CZEC\4
MZ?)TN(_SJ;_A(K''^O2OEF/7+Z/E9*F_X2;4L8\ZF%CZCCURSE.!,E61J%O_
M ,]5KY8A\6ZK"V5FQ6BOC[5P/^/BD%F?3T<\<GW6!J3->+^"?'D][<^3<2EC
MG%>Q02>9$K>HH$3$XJK+>0Q'#.!4>IW8M+.24G[JYKPGQ5X]O1J,D=M,0HH&
M>Z/JELHR95JLWB*P4X-PE?.$WCC5I$V^?UK-;Q'J+MDR\T!8^HO^$@L<?\?"
M?G3?^$CL1_R\)^=?,/\ PDNI8_UM-_X2/4?^>M 6/J(>(+$_\O"?G3O[<LO^
M>Z?G7RZ/$VI*>)J?_P )7JG_ #VH"S/J./5[23[LRFIEO[<G D6OEVW\9ZM"
M^?/J];^/]52=6:?Y0>: L?3R.K#*G-+7$^!_$IUBPC9V)8BNT9L)NH ;)/'&
M,NP%5O[2M<_ZY:\R\?\ C&;3G>&WD*L#BO,&\<:SO)%QW]Z8'TU_:EJ/^6RT
M?VI:_P#/9:^8CXWUK/\ Q\4O_";ZS_S\?SI!9GTX=5M1_P MEH&JVQ_Y:K7S
M$?&VL_\ /Q3E\;ZP/^7BF%CZ6DUJTCZS)21ZY:2G"S(:^8Y?%^K2_>GH@\7:
MI"V1-2"Q]0C5K;=M\U<FKL<JR+E2"*^64\;ZL)U<S\"O9O 'B=]7@2.1RSA<
MFF%CTJ+K5FJD')%6Z0!1110 4444 %%%5K]WCLY&C^\!Q0!XK\6/$ N+V+3U
M?'DS*6QZ9K#\1:AI\FB V[IYPC ^7KG%=38>"Y-=\9W=UJ4>^!AD C'K797G
MPU\/R612*R428X/%;<R6AARR=V8W@CQ%]L\'2VX;,D%N3[]*Y7P9:#Q#X@\Z
M\D+8<KM;GO6EX8\.7NC:SJ5L 1!*-B@#BJD^@:OX6UL7%HQ$/WB$7-&FM@UT
MN=<O@:PMM3\U+]HRSYV#H:X+Q5I<0^(Q@XV@#^=='H%EXCU75A<SW!$*/NVL
M,<5!XZT#4/\ A*#JEOG;@#@9I)V>XWJM$2^-[866CV8C.,Q=JHZD[GX3Z?\
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M"_\ 6O'^]?3OCKP\-7TX@*"PR:^>=3T*ZLKIT:-CR>BT@1D45<33+E^D3_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %59>M6JB>+<>M %:BIO(]Z/(]Z!$-%3>1[T>1[T 0
MT5-Y'O1Y'O0!!14_D>]'D>] $&*6IO(]Z/(]Z (:*F\CWH\CWH @HJ?R/>CR
M/>@""BI_(]Z/(]Z (**G\CWH\CWH @HJ?R/>CR/>@""EJ;R/>CR/>@"&D-3^
M1[T>1[T 045/Y'O1Y'O0!!2U-Y'O1Y'O0!!14_D>]'D>] $%**F\CWH\CWH
MAHJ;R/>CR/>@""BI_(]Z/(]Z (:2I_(]Z/(]Z (**G\CWH\CWH @HJ?R/>CR
M/>@"&BIO(]Z/(]Z (:3%3^3[T>1[T 045/Y'O1Y'O0!!2U-Y'O1Y'O0!#14W
MD>]'D>] $-)4_D>]'D>] $-%3>1[T>1[T 0TE3^1[T>1[T 04M3>1[T>1[T
M0T5-Y'O1Y'O0!#1Q4WD>]'D>] $%%3^1[T>1[T )%]ZK-1)%M/6I:!A1110
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M]E?_ )ZF@"UD49%5?LK_ //4T?97_P">IH M9%&157[*_P#SU-'V5_\ GJ:
M+611D55^RO\ \]31]E?_ )ZF@"UD49%5?LK_ //4T?97_P">IH M9%&157[*
M_P#SU-'V5_\ GJ: +611D55^RO\ \]31]E?_ )ZF@"UD49%5?LK_ //4T?97
M_P">IH M9%&157[*_P#SU-'V5_\ GJ: +611D55^RO\ \]31]E?_ )ZF@"UD
M49%5?LK_ //4T?97_P">IH M9%)FJWV5_P#GJ:/LK_\ /4T 6LBC(JK]E?\
MYZFC[*__ #U- %K(HR*J_97_ .>IH^RO_P ]30!:R*,BJOV5_P#GJ:/LK_\
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G[*__ #U- %K(HR*J_97_ .>IH^RO_P ]30!:HID:%%P3GWHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g23ode3tb50n000029.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g23ode3tb50n000029.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *- WX# 2(  A$! Q$!_\0
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M!:**8\T<8RSJ/QH ?14*74,A^61?SJ7((X- "T4TNJ\,RCZFD::-!EG4#ZT
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M!U%0+=P.VT2+GZU,"#T(- "T4=*B>XBC'S2*/QH EHJ%+J&3[LBG\:ESGI0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P"NJ?\ H5?2WAS_ ) \'^XO\JFILBZ6[/(XOAE?:SXENKG4'E2'SB5STQ7
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M#7QKX@\2:FT%Y)NB";L[3CO6%9_!_4;B=1?>?Y>>[$UZWX6\)6?AFR2&W&6
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** *U^K/IURBC+-$P _"OFNS\)ZXOBIICITPC
M\QCNQ[U].TW8OI51ERD2AS%72D:/2K9'&&5 "*N445)84444 %%%% !1110
M4444 9NNZ8-7TJ6S+;0_>OG36_"/B/1M8>6RCN)$5\@KBOIVF21K(N&&151E
MRD2@I'S4^K^-);7[/]GN\D8)R.:O>"OA_JFH:NEUJD<L8SD^8*]_&FVH;<(Q
MFK2J%&!TJO:::$JEKJR*U@%M:10#HBA14U%%9FH4444 %%%% !1110 4444
M<KX[\/KKWA^>!4_>MT8#FN&^%L>IZ)?7EE<VTGEE]JLWIQ7L=5ULH$D\P)\Q
M.<U2EI8EQUN6****DH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH Y7Q[<W,?ANZBM8F>5EXV]:X3X7^$+A;V;4-1A8.XW ..AKV":WCG&)
M%S3HXDA4*@P!5*5E8EQN[CQP,4445)04444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \X^*O_('/^^*
MZ[2X?/\ "UI'ZPBJOBGP[_;UGY.,\@UM6%O]DL(+?_GF@6J;T)2]ZYYCX*N5
MT[QQK$5P1&"<*6XS6Q\3=1A71((XW5W,RC:#SU%6_$'@Q;RY^V6(VW!;<3GO
M5"S\$7=[=K+K.'52"-I[BJNKW)LTK&!XBTN6S\%R7>TGY < >U>A>%]2MF\,
MV9,R I$-P)Z5H7^D6VH:5_9\RYA*A<?2N&?P5JMK))#8LHMI#@@GM2NF@LXO
M0SM/']J?$S4/+^:-<$,.AZUZR@PBCT%<YX9\+0:(OG%?])888UTE*3N5%605
ME:O_ *VW_P!ZM6LK5_\ 6V_^]4E&C#_JQ4E1P_ZL5)0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB/\ Y]A^?_UZ[3PAXQ'B1681;-IQUI.+0U)/8[.BBBD4%%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH T8?]6*DJ.'_5BI* "BBB@ HHHH **** "BBB@ HHHH **** "J][_QZO\
M2K%5[W_CU?Z4 ?)GC;_D/7'_ %T-<S73>-_^0]<?]=#7,UUQV..6X4444R0H
MHHH !U%>\_!C_CVF_P!ZO!AU%>\_!C_CVF_WJSJ_":4OB/:****YSJ"BBB@
MHHHH **** "BBB@ HHI,T +44TRPC)I_F)_?7\ZBE2"88<J?QH A_M&/VIIU
M2%>"P%+]@LO1?SK+OK.U$X"@8R.] &K_ &C'[4^*]25L#%1)866Q>%Z>M21V
MMK$VY-H/UH MT4WS$_OK^=*&!Z$&@!:*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N0^)*2/X0N!'G=GM
M77U5U"RCO[1X) "K#O33LQ-75CQ;X.75C!<7T-UM\]I/EW 5[3<26J6[M)Y>
MP#)Z5\]>*/ NN:)JLEUI0F*.Q8E.,5C,_C*Y7R,W1SP?FK5Q4M;F*FXJS1K>
M))8;WXDE].^YE?NC'?VKZ)T[(TVV!Z^4N?RKQOX<> +R*_74M55Q(1]UZ]K1
M0B*@Z 8%3-K8NFGNQU%%%9F@4444 %%%% !1110 4444 %96K_ZVW_WJU:RM
M7_UMO_O4 :,/^K%25'#_ *L5)0 4444 %%%% !1110 4444 %%%% !1110 5
M7O?^/5_I5BJ][_QZO]* /DSQO_R'KC_KH:YFNF\;_P#(>N/^NAKF:ZX['%+<
M****8@HHHH !U%>\_!C_ (]IO]ZO!AU%>\_!C_CVF_WJSJ_":4OB/:****YS
MJ"BBB@ HHHH **** "BBB@ JKJ$C16DC+U"FK54M4_X\9/\ =- ' '7KS>W/
M0GO2?V[>>OZUF_QM_O&BF!I?V[>>OZTQM8NG.3BJ%% &E_;MYCK^M+_;MYZ_
MK6910!I?V[>>OZUT_AN_FNP/,KAJZ_PCT% '84444@"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,3Q-XCB\-V
M"W4L9=2<8%8FG?$2UU#1I-16W(1&VXS6UXG\/P^(=/6UF&5!S6!:>"+'2-!E
MM"NV-FW')JE:Q#YKF#=_&;2R[PRV+, <'FJ*?%?0$?>NED-ZYJ6'X7:-J<TK
MQ ,=W.&%3GX,::!_JC_WU5^X1[Y?TKXNV&HW2VT=HRD^]>DPR"6%)!T90:\B
ML? VAZ-K"K@+*,<%A7K=NJK;1JOW0H J96Z%PYNI+1114%A1110 4444 %%%
M% !1110 5E:O_K;?_>K5K*U?_6V_^]0!HP_ZL5)4</\ JQ4E !1110 4444
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M['9_\]36;O;>WS'[QHWMZFF!I?8[/_GJ:/L=G_SU-9N]O4T;V]30!I?8[/\
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MXT4P"BBB@ HHHH *Z_PCT%<A77^$>@H ["BBBD 4444 %%%% !1110 4444
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M;_>-%!^^W^\:*8!1110 4444 %=?X1Z"N0KK_"/04 =A1112 **** "BBB@
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M^/=/I4M $/V2#_GDOY4Y(8X_N(!]*DHH **** "BBB@ HHHH **** "BBB@
MJ*XA$\31DXR,5+10!S!\(1$D^=U.>E'_  A\7_/;]*Z>B@#F/^$/B_Y[?I5*
MY\.1PR;?,SSBNTK'U#_CX'^\* ,]?"$14'SNH]*7_A#XO^>WZ5TJ?ZM?H*=0
M!S'_  A\7_/:M33-(33AA7W5IT4 %%%% !1110 4444 %%%% !1110 4444
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M3V]W+N$K! W8U5DU8B[3N>[UY!\0_P#DH>E_]<_\*]=C8/&K#G(!KR+XA_\
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MB@ HHHH **** "BBB@ K*U?_ %MO_O5JUE:O_K;?_>H T8?]6*DJ.'_5BI*
M"BBB@ HHHH *R-?_ ./>'_KH/YBM>LC7_P#CWA_ZZ#^8H U(O]2G^Z*?3(O]
M2G^Z*?0 4444 %%%% !1110 4444 %9>I_ZP?2M2LO4_]8/I0!?M_P#CW3Z5
M+45O_P >Z?2I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q]
M0_X^!_O"MBL?4/\ CX'^\* -9/\ 5K]!3J:G^K7Z"G4 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !3)8UEB:-ONL,&GT4 <G>?#
MS0[VX,TL3%SUJO\ \*P\/?\ /%J[2BGS,GE1QT?PTT"*0.L39'2NILK.*PM5
MMX1A%Z58HH;;&DEL%%%%(84444 4=6TNWUBP>TN5S&_6O,IO .NZ5<R/HC*J
M,<X=J];HJE)HEQ3/(QX0\6ZFZQZJ\9ASSM->A>'/#UMX?T];:W7 SDY]:VJ*
M')L%%(JZA;FZLWB7JU<GX-\*7.@:QJ5U,!MN3E<?A7;44KZ6&TKW,_6+>XN;
M"2&V(W.I4Y]Q7.^!_"3^'[:8W('G/*7!'N2:[*BB^E@LKW"N$\9>"Y-9N[6Z
MLP!+'*'8FN[HH3L#5RGID4\-DD=QCS ,<5R?BCPE<ZQXHL]1B"^7"N#G\*[B
MBA.P-75B"SA,%I'$W51BL+Q9X7@\162QLOSHV]?KVKI**$[:@U=6/*ET#QS;
MQFU@DA^S=!D\XKH/"G@E-)D>ZNES<NVXG.>:[6BFY,2@@HHHJ2@HHHH ****
M "L/Q9=16FA32S0B5!_":W*J:CI\&IVC6URFZ-NHIK<3V/F'3_&\WA[6[B6V
M1A$TI8QJ>M=9-\<Y)+9HUL&5B,;L_P#UZ[B]^&O@^)FEN+>)6)R=S@5G1^"/
M DDNP109_P"NBUKS1?0QY9KJ>2VOC@KXC;5KRV-P2,;6->@6'QQ\Z6.W&F%1
MC Y_^O771?"KPE,NZ*TC<>JL#4\/PH\,P2B1+$!A[C_"AR@P49H[#2[S^T-,
MM[O;M\U=V/2K=0VEM'9VL=O$,1QC"BIJQ-PHHHH ***C:XA1MK2H&]"U $E%
M&<C(JN]]:1MM>YB4^A<"@"Q13(YHIAF.17'JIS3Z "LK5_\ 6V_^]6K65J_^
MMM_]Z@#1A_U8J2HX?]6*DH **** "BBB@ K(U_\ X]X?^N@_F*UZR-?_ ./>
M'_KH/YB@#4B_U*?[HI],B_U*?[HI] !1110 4444 %%%% !1110 5EZG_K!]
M*U*R]3_U@^E %^W_ ./=/I4M16__ ![I]*EH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ K'U#_CX'^\*V*Q]0_P"/@?[PH UD_P!6OT%.IJ?Z
MM?H*=0 4444 %%%% !1110 55O+F2V0&.(R$]A5JB@#&_M>Z_P"?)Z@?Q!.E
MPL)LFW-TKH*QKO\ Y#]O]* #^U[K_GR>I[749YY-KVK(/4UI44 )VI:** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH CGN(K:(RS.$0=6-4#XB
MT@''V^'\ZQ/B3*\'@NZ>,X8$<_@:X'PKX/DUNT:9V0G&>:I15KLAR=[(]<BU
MS3)FVQWL3$]@:OJP894Y%>3ZCX U2PMVN=/GCC:,;C^'XUI?#_Q9<WD@TO4G
M9KM2>3QQ0XZ70*3O9GH]%1RSQ0+NED1!ZL<52&N:>9-GVJ'_ +[%26:-%,CE
M25=T;JRGN#FH;G4+6T'[Z>-#Z,P% %FBJ,6L6$JEA=0X'^V*LK<0O%YBRH4Q
MG<&XH EHJC)J]A''O-W"1G'WQ4\=Y;21>:LT>P=6W#% 7)Z*S9-=T^-]INH3
M_P #%6[>]MKI<P31O[*P- 7)Z1F"+N8X [U'-<0VZ[I940#NQQ6/J6M63Z?.
ML=U%N X^<4[";-:&]MKB1HX9E=EZ@=JGKS'X>7<EQXGU)6?<H'%>C7%[;6PS
M-/&G^\P%#5G847=7+%%4(=9L)VVK=0Y]-XJZ9$$?F%AL SNSQ2*'451EU>PB
M0,UU#@_[8JS;W,-U'OAD5U]5.: ):H:OJ,>EZ?)<RG"J*OUR'Q)$C>$+@1YW
M9[4UN)NR/$];UG7?&FLRVUH3M5RJ[6(_E4,OPW\7V</VEO,VJ-Q_>-76_!VX
MT^*XOH[S9]H,GR;AS7M5S):K:LTNWR\<YK5R<79&,8*2NSQ#X=^-+[3]572=
M2;$:CN<G->[1N)8E<=&&17S?XC>WN?B26TW'EY7[GUKZ*TX'^S;;/7RES^53
M-=2J;W19HHHK,U"BBD9@HR> * *VH7B6-G).YP$7->+W'B2^U;Q9YT3$698
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M** "BBB@ HHHH **** "BBB@ HHHH **** "L?4/^/@?[PK8K'U#_CX'^\*
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MU-1_B:8'I/\ ;]K_ 'E_.L_5=6M[F&-5=>'!ZUPWXFC'N: /1TUVU$:C>O
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M_D)#Z5SE='X2_P"0D/I0!WE%%%( HHHH **** "BBB@ HHHH **** "BBB@
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M ,(M4TS4TN)+E"H(XQ7N=M&8K6*,]50 U)@>@I:F4G+<N,5'8****DH****
M"BBB@ HHHH **** "LK5_P#6V_\ O5JUE:O_ *VW_P!Z@#1A_P!6*DJ.'_5B
MI* "H+S_ (\YO]PU/4%Y_P ><W^X: /++C_7O]3452W'^O?ZFHJ8!1110 44
M44 %='X2_P"0D/I7.5T?A+_D)#Z4 =Y1112 **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ IK2(GWF ^M.JO<VD=TN')_ T
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1110 4444 %%%% !1110 4444 %%%% !1110 5F:]_R"I?I6G69KW_(*E^E
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M7E'BSY/%,;)U,RY_.O1Y+>ZF@C,,VSY!_*E+N.'8T:RM7_UMO_O5'_9^I?\
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M* "BBB@ HHHH **** "BBB@ K*U?_6V_^]6K65J_^MM_]Z@#1A_U8J2HX?\
M5BI* "BBB@ J*XA,T14-M)[U+10!E?V5+_S\FFOHK2 !YRP'/-:]% &5_9,@
M&/M!J2+39(Y%8SDX[5HT4  Z4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5F:]_P @J7Z5IUF:]_R"I?I0!\B>(/\ D.7G_70UF5I^(/\ D.7G_70UF5V+
M8X7N%%%% !1110 J_>'UKZ2^#O\ R!YOPKYM7[P^M?27P=_Y \WX5G5V-:.Y
MZ=1117.=(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !65J_^MM_]ZM6LK5_];;_ .]0!HP_ZL5)
M4</^K%24 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !69KW_ ""I?I6G69KW_(*E^E 'R)X@_P"0Y>?]=#696GX@_P"0Y>?]
M=#6978MCA>X4444 %%%% "K]X?6OI+X._P#('F_"OFU?O#ZU])?!W_D#S?A6
M=78UH[GIU%%%<YTA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %96K_ZVW_WJU:RM7_UMO\ [U &
MC#_JQ4E1P_ZL5)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %9FO?\ (*E^E:=9FO?\@J7Z4 ?(GB#_ )#EY_UT-9E:?B#_
M )#EY_UT-9E=BV.%[A1110 4444 *OWA]:^DO@[_ ,@>;\*^;5^\/K7TE\'?
M^0/-^%9U=C6CN>G4445SG2%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%9UWKFFV+!;FZ2,GUH T:*J6>I6=
M^,VLZR#VJW0 5E:O_K;?_>K5K*U?_6V_^]0!HP_ZL5)4</\ JQ4E !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5F:]_R"I?
MI6G5:_M?MEJT.<9[T ?'?B#_ )#EW_UT-9>*^CKOX0VMU=23-<<NV>E5V^#E
MFOWKD#\*Z%41S.DSYYHKZ$_X5!8?\_8_*JTGPJL$NT@^U+\W?%'M4'LI'@E%
M?0G_  J"P_Y^Q^5*/@[8MTN@?PH]J@]E(^>U^\/K7TE\'O\ D#S?A50?!FT_
MY^!^5=OX5\-)X<MGB23>&J)S4D73@XO4Z*BBBLC8**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*/0U+4MW+2L@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
#'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g23ode3tb50n000015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g23ode3tb50n000015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'W!@0# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *2BB@ HHI* $HHI* "DS0
M:2@!<T9IM% "YHS3<TF: '44W-&: '44W-&: '44W-&: '44W-&: '44W-&:
M '44W-&: '44W-&: '44W-&: '44W-&: '44W-&: '44W-&: '44W-&: '44
MW-&: '44W-&: '44W-&: '44W-&: '44W-&: '44W-&: '44W-&: '9I<TS-
M&: 'YI<TS-+0 [-&:;2B@!U+244 .I:;2T +2TE% "T444 %%%% !14<KE ,
M5%YS^U %FBJWG/[4><_M0!9HJMYS^U'G/[4 6:*K><_M1YS^U %FBJWG/[4>
M<_M0!9HJMYS^U'G/[4 6:*K><_M1YS^U %FBJWG/[4><_M0!9HJMYS^U'G/[
M4 6:*K><_M1YS^U %FBJWG/[4><_M0!9HJMYS^U'G/[4 6:*K><_M1YS^U %
MFBH%E8L <5/0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% "4444 )244E !0O)I#2I]
MZ@!VP4;%IU% #?+6CRU]*=10 SRU]*/+7TI]% #/+7TH\M?2GT4 ,\M?2CRU
M]*?10 SRU]*/+7TI]% #/+7TH\M?2GT4 ,\M?2CRU]*?10 SRU]*/+7TI]%
M#/+7TH\M?2GT4 ,\M?2CRU]*?10 SRU]*/+7TI]% #/+7TH\M?2GT4 ,\M?2
MCRU]*?10 SRU]*/+7TI]% #/+7TH\M?2GT4 ,\M?2CRU]*?10 SRU]*/+7TI
M]% #/+7TH\M?2GT4 ,\M?2CRU]*?10 SRU]*/+7TI]% #/+7TH\M?2GT4 ,\
MM?2CRU]*?10 SRU]*7RUIU% #=BT;!3J* &[13 :D/0U%0 ^BFBG4 +2TE+0
M M%%% !1110!#/T%05//T%04 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 .3[Z_6K=5$^^OUJW0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %)2TE !24M)0 AIIIU-- "&EC^]332Q?>H FHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0]#
M4(-3'H:KB@"04HIHIPH =124M #J*** "BBB@"&?H*@J>?H*@H ***\$'Q+U
MK3OB3>65Y>N^GK<F)8R.%Y%-*XF['O=%1P3QW$"31,&C<94CO7DOQ5^(5]H=
MW#8:/<&.;.)67^&A*[!NRN>O45Y9<:KXFO?AI!J]A?R"\0,SD 9>NB^'OBT>
M)M"#7#_Z;$2LJGVXS18%([&BO(]7\9:UK'CJ+1]!N&B@B8><R\]\&JWQ&\3>
M(M)\7Z/I&GZK);I<QJLC #DDXS3Y6+F1[+17G\_AKQE:0M-%XLGN609$1C W
M4G@_QY-J&K2:%J\0@U&([>3G=2L.YZ#17FOB?Q9J5WXNB\,:-,;>?.))EZKD
M<<51U#7O$7@76[)-7U%]1LKMP@=P%VG&3P*?*+F/6**XGQKXS;1-&M7LUW7-
M[A8^<;<C(-<Y>OXST?18]=DUJ6Y0@.]L5  'UI) Y'K-%8/A'Q OB308+X+M
M=E&]?0UO4B@HHHH **** "BBB@ HHHH <GWU^M6ZJ)]]?K5N@ HHK/UC5(]*
MLFF?KT J)SC"+E+9%0BYR48[FA17GL>K>(]5<O8[E3TK4T35=7_M%;._C9LG
M!8]JX:>94ZDDE%V?6VAUSP,X1;;5UTN==136=%^\RCZFA71ONLI^AKT+HXK#
MJ*Y;3-4O)_%<]I),6@4-A:33M4O)O%UU9R3$P(S!4].*XXXZF[:/5\OS.IX2
M:OKLKG544C'"D^U<?9ZQ?2>*OLCSDP;L;:UKXB-%Q4OM.QG2HRJ*3734[&BB
MN>T[^V?[6F^TR9MLG:-P]:NI5Y)15F[DPI\R;O:QT-%,\V,=77CWI5D1C\KJ
M?H:TNB+,=12%E7[S ?4T@D1CA74_0T70K#J***8!1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%>>_$+XAKX95;*R7S;V3@ 'E37#1ZC\5K
MM/[0A:46OWMNX=*M0;5S-U$G8][HKCO 'B+5-=TYO[3M#%+&2"Y/WB#BNL:Y
M@0X:>-3Z%P*EJSL6FFKDM%-5U<91@P]0<TZD,**8\L<8S(ZI_O'%-^U6^[;Y
M\6?3>* ):*B:ZMU.&GB!]"XIYD0)O+J%]<\4 .HIJ2)(NY'5E]0<TT3PDD"5
M"1U^8<4 245P%GXV>X^(EQHOFI]GB9ANW#'2N\\V/9O\Q-OKN&*;30E)/8?1
M42W,#MM2>-CZ!P:Y;X@>*&\,Z)]HA=?.)("[N:$KNP-I*YUU%8FG:E)J?A>&
MYAE0W<ML' ##(8BL7P4?%!O+S^W9A)%YA\H!P<#'M187,=K14;W$,9P\T:GT
M9@*<DD<@RCJP]5.:10ZBHS<0J2#-&".H+#BA+B"0X2:-CZ*P- $E%,>6.,9D
MD5!_M'%(EQ#(<1S1L?\ 98&@"2BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *2EI* "DI:;0 AIIIQIIH ::=%]^F&G0_?H GHHHH **** "BBB@
M HHHH **** "BBB@ HK!\6^)[7PKHLE_<$?W47U;M7C,/BWXD>+I'N- 62&#
M.0 PQC\:I1;)<K'T)17DW@GQ/XP77X]&\0VCN[@YE+=,5ZL\T48_>2(G^\P%
M)JPT[CZ*9'-%+_JY4?\ W6!KR[_A*=8_X6J=)^V-]A\M#Y6.,DFA*X-V/5**
M\KL_%.L2?%&32GO&-D(R1%CC.:]4H:L"=QCS11L%>5%9N@9@":?7D&J7MWXD
M^+D&FP2LMO8;TD(Z9X(HUCQ;K=I\5;?1XKYUL2V#%C@\4^47,>OT5P'Q!^(<
M7A+3XXX5\V]E&%4'D'&:\\BU3XLZHO\ :%DTJVA^8)N'2A1;!R2/H*BN$^'?
MB76=;MY8=7LVCEA)5I&/4BN[I-6&G<****0PHI"0HR2 /4U$;NV R;B+'3.\
M4 344Q)8Y1F.17'JIS7@NL_$O7='^(KV<EZ[6 FV&/L!FFE<3=CWVBH+*\AO
M[.*Z@8-%(NY2/2O+?B[\0;OPY'#8Z1<&.[<'<Z]5Q0E=V!NRN>K221Q+ND=4
M4=V.!3E8,,J00>A!KRG3IM5\7_!?[3<W;O?R!OWF.3@UN_"WQ!)K7A@)<MFY
MMY'C;/HIP*&@3.ZHHHI#"BBB@ HHHH **** "BBB@ HHHH **** $/0U7%6#
M]TU6% #Q3A313A0 X4M)2B@!U%%% !1110!#/T%05//T%04 %?.*^'D\0>-O
M$D1'[R*261"/4#(KZ.KQGP$ ?BSKP(R#+)Q51=KD2UL7/!'CA;'P9=6VI/LN
M-. A"L>2<$UQ%_I,VL>$M7\67H.^>1&ASV&<5UGC7X9W^H>*4N-,8I;74GFW
M  . 01Q^5;_Q#TR'2/A1<64"@)'L _.JNKZ"L[:FK\.(UE\!6D;@%6W @UY9
MXD%[\-/$M_)9!C;7R (1TW$EC7JWPT_Y$>R_&N&^-8!O-)R ?W__ ++27Q _
MAN=!\+?##V%C)J]ZG^F7;%\L/X3R*Y#XK_\ )4_#_P#P#_T(5[-H8 T*Q &/
MW"?RKQ;XO31V_P 3="FF<)&@1F8]  PHB[R"2M$]YKPOQ2BV?Q<MYX/DDD<E
MB._2O2+KXC^%X[=VM]6M[F4#Y8HVY8UPOASP_J/BKQO/XDO[:6WM"28DDZG(
MHCIN.6NB*GBF=--^)=IJ.D-]LU%B/-M4^]TXJOXKUB\UOQ+I$7B.P?2[..4,
M!*0<DKSTJULD\*_$Z6]U2 _8I"-MRX^50![U-\2-4L_&W]GZ9X?*W<WF'=-%
MSMR/SIDFI\4H=-/AO3I5O$BGAVM #SYGR\ 5@:SXH\1W'@NVM;G1)K>V9 K7
M3$%2N.N*N>/]#U&V&A7WV=[B&U6,2H!TVKSG-;.M>.-!O/"#6-L\4]Y+#Y8M
MDQN1B*%L-[LZ+X<QZ?%X1M%L)EE 0;V'K76UP7PGT:]T;PKMO59'F*N$;JO%
M=[4/<N.P4444AA1110 4444 %%%% #D^^OUJW51/OK]:MT %</X[=OM5E%SL
M8<_G7<5SWBG2)-1M5EAYEBZ#]:X<QIRJ8:48[G5@IQA73D:6C01P:9"J*  O
MI5TJHRVT9]<5S6C^(K:"T2WOS]GE08.\]:N0^)+6[O5MH$:16./,!X%.CB:'
MLXJZ] J4*O/)V.7_ +4@U36YEU&Z\JVC. N2-V#CM4MOJ$-CK\,6FW!EMY2%
M(Y./SI+-4T+7[C[9"I@FY#NH(&3FNAAUG2Y;U(;:"*0D\.BCBO*HQ<M9S2ES
M>=_SV/0JR4=(Q;C;Y&1HW_(\77^ZU)I/_(]WO^\W\A2Z-_R/%U_NM2:3_P C
MW>_[S?R%.GM3_P"OC%/[?^!':O\ <;Z5P%A_R.__  *N_?[C?2O.X+F&T\9&
M6>18T#<LU=F9-*=)O^8YL"FXU$NQZ+7%^&G=O%-\&=B IP"?>NDAUS3+B98H
MKV)Y'.%4'DUS/AG_ )&J_P#]T_SJL34C.M1<'?7]":$)1I5.96T_4JZ=:-J7
MB.\@DE;R@[$C<:<6;1/$R0P2,(GR,,<^U6/#G_(UWW^\U5/$'_(TV_\ O?U%
M>;91H*JOBYM_F=]W*LZ;VY?T)M:U47'B V,]QY-M&2&:J]Y>V6FW<$NDW1?G
MYER3_.K.IP-IGBC^T)8=\$A)8D9%;#:[H^^-8889F;LBCC]*TY7.<_:3497T
MOOY6U(YE&,.2+:M\OF;\+%X(W/5E!/Y4^FH044@8!&0*=7T"V/&>X4444Q!1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !2,2$8CD@4M% 'S\D7]L?'F2WO
M5)CWD[&[8%>_)$D<8C5%"@8QBO)?&?AZ^T+QG%XMTZ!IQN)E5!R,\5U=M\3/
M#;V0>?4(89P.87;YLUI*[2L8PM%M,TO%NK+X<\,7M_ BK)'&60* ,FO/_!7A
MB/QII4VKZS/+)+)(P0+(5V^G2MS4=37XA^%=3L[*TEBD$9$;.00QSCC%8_P]
M\4Z?X7T.;2M;F6SN(9&P)3C=]*:34=-P;3DK[">#=<O=$\97?AV[E+V:AFC+
M=@.E=K<?$3PM:7;VLVJQI,C;64@\&N$\(:?>:_\ $"ZUXPE; !DC<CAO2O6&
MTO3W<N]A:LQ.2QA4D_I2G:^HX7MH>8?%K44O="L;FQN&,4I&UT)&?FK/\2>&
M%T[P,OB&WN)A?PH&9_,.#^%:?QDC2+3;%(T5%#KA5& /FK0\8_\ )';K_KBO
M]*I/1$R5V[G+V?AT:O\ #>Y\0WUS*^H(C%'60J!C&.*9IWB&]U/X57RW,K&:
M$R*L@.#@<"M_0O\ DB-W_P!<W_F*Y?P5ITFI_#G6((5+29EVJ.YS3[W[DVVM
MV.Q^%$LDG@2=I)&=MQY8Y/2L3P"G]H>,==M;F21XFE=2-YZ;:;\.O$^FZ)X8
MN]+U"=8+U7($+G#'BCX5S"X\::O,%*AY6.#VXI-;C33Y48FC^$]+G^+NHZ3(
MDQM(96" 2G/ '>O5]8\(O=:?:Z?87QM;2+(=6))8?6O.X[V'P_\ &G4KW4V%
MM;2RL4D?@-P!6A\0_%%[(VGFSG$6E3D[YQTQ]10[MH(\J3,[QUI"> /[/U31
MKB02>8?-#2%MV![U/\7--M;KPOIVMN'^V31+N.\XQM!Z5R7CJRT3^QK>?2;R
MYOY>LTGVAG1>/0].:[[XEVL]S\--*,,3/Y<*,V.PV"GLT+=21L>&/"NF:3X2
MCU2T69;J:R&\M*2.1V%<O\/M5DL8O$-U)*[&*1RNYL\A>*ZOP]XGTK4/"$>F
MVUW')<PV0#JIY4@=*X[X?Z>=3M_$=J/O/(X7Z[>*GH[E.UU8E\$::?B*]]JN
MM32L@<>7&CE<9'M4VFZA>^#_ (@'05E9].F)"!CDC ]34?PXU:V\#C4-(U^0
M6CK(-LDAP&P.U);PW'C#XEC5+2,G3;<G$P&0V1ZU3W?82V5MRC%:3:U\4+VQ
M>YD6VD"!T#'D>WI4NN6G_""^.M-73;B1+>9U617<MGC)ZU8T ;?C#=+Z!!_.
MF_%C_D<=*_ZZK_Z#1UL+[-_,K?$7Q',WBBQM;\R1:6\:.V&QG/?(KL? ^G>&
MWO!=Z'?M,FT[HC(S8/XU3\07OA*\AM-/\0+Y>85Q.7"XXZ=,URG@/1UMOB$Y
MT22672E1@) Y*GTI;Q'M+N>]4445B= 4444 %%%% !1110 4444 %%%% !11
M10 4444 %)2TE "4E+2&@!#3#3Z8: &FG0_?_"FFG0_?/TH GHHHH **** "
MBBB@ HHHH **** "BBB@#Q+XWR22W^G63!OL[NF[GCK7J/A&QM['PQ8101JJ
MB(#@=:Y[XG>$IO$6D+/9?\?=NPD48SG':J7A/XB:=9:1!I_B&0:;=VZ;&\\X
MW'V J]UH1M+4]$E6.)'G\M=R*3NQSTKP2[\5Z?XC\8W<'B#4S;:7"V%C!(+>
MO(KTR'XA:9J^J#2]/B>ZCF1@;F-AL7BO/--@M_ _CZ]&L6<9TVY8%;B9 57\
MZ(H).XS2_$>GZ)X^L+3PU?M<Z9<R*DB$EL#!)Y/O5R-M_P :]W]Z&,_J:[>Q
M\6^%;S6[>STJSM+EG8#SX(UPGOTS7%#'_"[3CIY2?S-,0:?_ ,EIF_ZY'^=>
MSW;;+.9O2-C^E>,:?_R6F;_KD?YU[5,GFP21_P!Y2*F143Q_X9%;OQSX@NG7
MY_M'!/;Y:R/$?_)<+?\ WS_*M;P*RZ5\4=<TQ^&DG)3/<!165XB_Y+C;?[_]
M*KJ1T,[6E.K?'G3[*\4F%FC!0]/NFOH:&"."%8HT4(H   KR3Q]X7OK'Q)8>
M,-+@:>6W(:2-!DX KJ;#XG^&Y+%6O=0AM;D*-T,C?-FD]4K%1T;N=3J$B6&F
M75Q&J1F.,MD+BO/]"7QEKTAOH_$EO#:>8"L)AR2OIFMW3/%EAXOM[VS%M+%;
M;&5IF889?48KB_$GAC3?"%C::KH5_<K.T\:[9+AG1@3V7I22Z#?<W_$&OZW>
M>)(?#^A7:P7"HQFG*;@".V*M^#_$>I2:Q>Z%K3B2[MB )0,!_P *Y[PU>/%\
M1I)=07RYKP/*FX8X &:NZ.ZWGQ6U.2W.](G&\CMQ3L*YVWBEBOAJ]*D@B/J*
M\C^&OAB/Q5H]U_:=S-)"EQ+Y:"1@5.[UKUOQ7_R+-]_USKA/@E_R ;K_ *^9
M?_0J2V!_$97PRU*?3?'.I:!)<LUG&&:(.23G/K7-SZ!%XB^*6L6<@R5@F=/]
MX#BM'PC_ ,EBU'_@7_H5:'A+GXZZ@#_SREJMM2>A9^'/C'^R-"U#2-5DV7&F
M_NXPQY.%S7'7.G3^*].UKQ=>J57<# K=P>.*Z_XA_#6_U/Q+;W^CDI'*?])"
M@\Y/M[5T'BK1(O#_ ,)YM.B Q$@&1WHNN@[/9DGPD17^&-JC#(+2?SK"^$*-
M;:]KEKNS&K,X'IES6O\ "^\CL/A1!<R_<0R$_G67\&H)9YM5U1Q\D\LB*?HY
MI/J-=#UNBBBH+"BBB@ HHHH **** "BBB@ HHHH **** $/W3545:;[IJJ*
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M,'%2VNGV=D,6MK%"/^F: 59HHN%@HHHH **** "BBB@ HHHH **** "BBB@
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MT5SWVS7O^?!?^^Z/MFO?\^"_]]T?7(_RR^YA]6EW7WHZ&BN>^V:]_P ^"_\
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M_P!_*/MOB+_H'K_W\H^N1_EE]S#ZM+NOO1TM%<U]M\1?] ]?^_E'VWQ%_P!
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M_P!_*/MOB+_H'K_W\H^N1_EE]S#ZM+NOO1TM%<U]M\1?] ]?^_E'VWQ%_P!
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?_(#;_KL_P#.L9.NL0J7/HTWLC1*DZ+J<NSMNS3&J1+9?:;A&@']V3@UG_\
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MG5[1[OQ-<+&<.K%A^%1B<;)4XSH][%T,*G-QJ]KGH8.1GUJGJFJ0Z5:F>;)
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MB@ HHHH **** "BBB@ I*6DH 2D-+2&@!IIIIQIIH 8:?#]\_2F&GP_?/TH
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MI/AO2-#S_9ME';YZ[:FZM8:34KFK1114EA1110 4444 %%%% !1110 4444
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M7]\4?:(O[XIB):*B^T1?WQ1]HB_OB@"6BHOM$7]\4?:(O[XH D95888 CWH
M &!T%1_:(O[XH^T1?WQ0!+147VB+^^*/M$7]\4 2T5%]HB_OBC[1%_?% $M%
M1?:(O[XH^T1?WQ0!+147VB+^^*/M$7]\4 2T5%]HB_OBC[1%_?% $M%1?:(O
M[XH^T1?WQ0!+147VB+^^*/M$7]\4 2T5%]HB_OBC[1%_?% $M%1?:(O[XH^T
M1?WQ0!+147VB+^^*/M$7]\4 2T5%]HB_OBC[1%_?% $M%1?:(O[XH^T1?WQ0
M!+147VB+^^*/M$7]\4 2T5%]HB_OBC[1%_?% $M%1?:(O[XH^T1?WQ0!+147
MVB+^^*/M$7]\4 2T5%]HB_OBC[1%_?% $M%1?:(O[XH^T1?WQ0!+147VB+^^
M*/M$7]\4 2T5%]HB_OBC[1%_?% $M%1?:(O[XH^T1?WQ0!+147VB+^^*/M$7
M]\4 2T5%]HB_OBC[1%_?% $M%1?:(O[XH^T1?WQ0!+147VB+^^*/M$7]\4 2
MT5%]HB_OBC[1%_?% $M%1?:(O[XH^T1?WQ0!+25']HB_OBC[1%_?% #Z0TS[
M1%_?%(9XO[XH <::::9XO[XIIFC_ +XH 4T^'[Y^E0F:/^\*=%-&'.7% %NB
MHOM$7]\4?:(O[XH EHJ+[1%_?%'VB+^^* ):*B^T1?WQ1]HB_OB@"6BHOM$7
M]\4?:(O[XH EHJ+[1%_?%'VB+^^* ):*B^T1?WQ1]HB_OB@"6BHOM$7]\4?:
M(O[XH EHJ+[1%_?%'VB+^^* ):*B^T1?WQ1]HB_OB@"6BHOM$7]\4?:(O[XH
M EHJ+[1%_?%'VB+^^* ):*B^T1?WQ1]HB_OB@"6BHOM$7]\4?:(O[XH EHJ+
M[1%_?%'VB+^^* ):*B^T1?WQ1]HB_OB@"6BHOM$7]\4?:(O[XH EHJ+[1%_?
M%'VB+^^* ):*B^T1?WQ1]HB_OB@"6BHOM$7]\4?:(O[XH EHJ+[1%_?%'VB+
M^^* ):*B^T1?WQ1]HB_OB@"6BHOM$7]\4?:(O[XH EHJ+[1%_?%'VB+^^* )
M:*B^T1?WQ1]HB_OB@"6BHOM$7]\4?:(O[XH D;[I^E514QN(MI^<571E;[IS
M0!(*>*8*>* '"G4T4Z@!:*** %HHHH KW2!PN>U5?LZ>]7)^@J"@"+[.GO1]
MG3WJ6B@"+[.GO1]G3WJ6B@"+[.GO1]G3WJ6B@"+[.GO1]G3WJ6B@"+[.GO1]
MG3WJ6B@"+[.GO1]G3WJ6B@"+[.GO1]G3WJ6B@"+[.GO1]G3WJ6B@"+[.GO1]
MG3WJ6B@"+[.GO1]G3WJ6B@"+[.GO1]G3WJ6B@"+[.GO1]G3WJ6B@!B6\9<#G
M\ZL_9(O?\ZC3[Z_6K= $'V2+W_.C[)%[_G4]% $'V2+W_.C[)%[_ )U/10!!
M]DB]_P Z/LD7O^=3T4 0?9(O?\Z/LD7O^=3T4 0?9(O?\Z/LD7O^=3T4 0?9
M(O?\Z/LD7O\ G4]% $'V2+W_ #H^R1>_YU/10!!]DB]_SH^R1>_YU/10!!]D
MB]_SH^R1>_YU/10!!]DB]_SH^R1>_P"=3T4 0?9(O?\ .C[)%[_G4]% $'V2
M+W_.C[)%[_G4]% $'V2+W_.C[)%[_G4]% $'V2+W_.C[)%[_ )U/10!!]DB]
M_P Z/LD7O^=3T4 0?9(O?\Z/LD7O^=3T4 0?9(O?\Z/LD7O^=3T4 0?9(O?\
MZ/LD7O\ G4]% $'V2+W_ #H^R1>_YU/10!!]DB]_SH^R1>_YU/10!!]DB]_S
MH^R1>_YU/10!!]DB]_SH^R1>_P"=3T4 0?9(O?\ .C[)%[_G4]% $'V2+W_.
MC[)%[_G4]% $'V2+W_.C[)%[_G4]% $'V2+W_.C[)%[_ )U/10!!]DB]_P Z
M/LD7O^=3T4 0?9(O?\Z/LD7O^=3T4 0?9(O?\Z/LD7O^=3T4 0?9(O?\Z/LD
M7O\ G4]% $'V2+W_ #H^R1>_YU/10!!]DB]_SH^R1>_YU/10!!]DB]_SH^R1
M>_YU/10!!]DB]_SH^R1>_P"=3T4 0?9(O?\ .C[)%[_G4]% $'V2+W_.C[)%
M[_G4]% $'V2+W_.C[)%[_G4]% $'V2+W_.C[)%[_ )U/10!!]DB]_P Z/LD7
MO^=3T4 0?9(O?\Z/LD7O^=3T4 0?9(O?\Z/LD7O^=3T4 0?9(O?\Z/LD7O\
MG4]% $'V2+W_ #H^R1>_YU/10!!]DB]_SH^R1>_YU/10!!]DB]_SH^R1>_YU
M/10!!]DB]_SH^R1>_P"=3T4 0?9(O?\ .C[)%[_G4]% $'V2+W_.C[)%[_G4
M]% $'V2+W_.C[)%[_G4]% %?[)%[_G1]DC]_SJQ24 5_LD?O^=(;6/W_ #JQ
M2&@"O]EC]_SIIMH_>K!IIH K_9X_>G16T9<YS3S3X?OGZ4 'V2+W_.C[)%[_
M )U/10!!]DB]_P Z/LD7O^=3T4 0?9(O?\Z/LD7O^=3T4 0?9(O?\Z/LD7O^
M=3T4 0?9(O?\Z/LD7O\ G4]% $'V2+W_ #H^R1>_YU/10!!]DB]_SH^R1>_Y
MU/10!!]DB]_SH^R1>_YU/10!!]DB]_SH^R1>_P"=3T4 0?9(O?\ .C[)%[_G
M4]% $'V2+W_.C[)%[_G4]% $'V2+W_.C[)%[_G4]% $'V2+W_.C[)%[_ )U/
M10!!]DB]_P Z/LD7O^=3T4 0?9(O?\Z/LD7O^=3T4 0?9(O?\Z/LD7O^=3T4
M 0?9(O?\Z/LD7O\ G4]% $'V2+W_ #H^R1>_YU/10!!]DB]_SH^R1>_YU/10
M!!]DB]_SH^R1>_YU/10!!]DB]_SH^R1>_P"=3T4 0?9(O?\ .C[)%[_G4]%
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MC'"MFNY^)X/_  K2V_Z^H/\ T*JLKJQ%VU*XSP_XD\70Z':QP>$_-B"?*_G
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M&]0<?G1+;P3Q>5+#')&#D*Z@C\JEHH 1$6-0J*%4= !@"H_LUOYWG>1'YO\
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MB@ HHHH **** "BBB@!&^Z?I545:;[I^E510 X4\4P4\4 .%.IHIU "T444
M+1110!4O#* NP _6JNZX_NK^=7Y^@J"@"ONN/[J_G1NN/[J_G5BB@"ONN/[J
M_G1NN/[J_G5BB@"ONN/[J_G1NN/[J_G5BB@"ONN/[J_G1NN/[J_G5BB@"ONN
M/[J_G1NN/[J_G5BB@"ONN/[J_G1NN/[J_G5BB@"ONN/[J_G1NN/[J_G5BB@"
MONN/[J_G1NN/[J_G5BB@"ONN/[J_G1NN/[J_G5BB@"ONN/[J_G1NN/[J_G5B
MB@"ONN/[J_G1NN/[J_G5BB@"ONN/[J_G1NN/[J_G5BB@"!6N=PPJ_G5C?>?W
M$_.E3[Z_6K= %/?>?W$_.C?>?W$_.KE% %/?>?W$_.C?>?W$_.KE% %/?>?W
M$_.C?>?W$_.KE% %/?>?W$_.C?>?W$_.KE% %/?>?W$_.C?>?W$_.KE% %/?
M>?W$_.C?>?W$_.KE% %/?>?W$_.C?>?W$_.KE% %/?>?W$_.C?>?W$_.KE%
M%/?>?W$_.C?>?W$_.KE% %/?>?W$_.C?>?W$_.KE% %/?>?W$_.C?>?W$_.K
ME% %/?>?W$_.C?>?W$_.KE% %/?>?W$_.C?>?W$_.KE% %/?>?W$_.C?>?W$
M_.KE% %/?>?W$_.C?>?W$_.KE% %/?>?W$_.C?>?W$_.KE% %/?>?W$_.C?>
M?W$_.KE% %/?>?W$_.C?>?W$_.KE% %/?>?W$_.C?>?W$_.KE% %/?>?W$_.
MC?>?W$_.KE% %/?>?W$_.C?>?W$_.KE% %/?>?W$_.C?>?W$_.KE% %/?>?W
M$_.C?>?W$_.KE% %/?>?W$_.C?>?W$_.KE% %/?>?W$_.C?>?W$_.KE% %/?
M>?W$_.C?>?W$_.KE% %/?>?W$_.C?>?W$_.KE% %/?>?W$_.C?>?W$_.KE%
M%/?>?W$_.C?>?W$_.KE% %/?>?W$_.C?>?W$_.KE% %/?>?W$_.C?>?W$_.K
ME% %/?>?W$_.C?>?W$_.KE% %/?>?W$_.C?>?W$_.KE% %/?>?W$_.C?>?W$
M_.KE% %/?>?W$_.C?>?W$_.KE% %/?>?W$_.C?>?W$_.KE% %/?>?W$_.C?>
M?W$_.KE% %/?>?W$_.C?>?W$_.KE% %/?>?W$_.C?>?W$_.KE% %/?>?W$_.
MC?>?W$_.KE% %/?>?W$_.C?>?W$_.KE% %/?>?W$_.C?>?W$_.KE% %/?>?W
M$_.C?>?W$_.KE% %/?>?W$_.C?>?W$_.KE% %/?>?W$_.C?>?W$_.KE% %/?
M>?W$_.C?>?W$_.KE% %/?>?W$_.C?>?W$_.KE% %/?>?W$_.C?>?W$_.KE%
M%/?>?W$_.C?>?W$_.KE% %+?>?W$_.C?>?W$_.KM)0!2WW?]Q/SI-]W_ '$_
M.KM(: *6^Z_N)^=)ONO[B_G5PTTT 4RUS_=7\Z6-[G=PJ_G5@T^'[Y^E $6^
M\_N)^=&^\_N)^=7** *>^\_N)^=&^\_N)^=7** *>^\_N)^=&^\_N)^=7**
M*>^\_N)^=&^\_N)^=7** *>^\_N)^=&^\_N)^=7** *>^\_N)^=&^\_N)^=7
M** *>^\_N)^=&^\_N)^=7** *>^\_N)^=&^\_N)^=7** *>^\_N)^=&^\_N)
M^=7** *>^\_N)^=&^\_N)^=7** *>^\_N)^=&^\_N)^=7** *>^\_N)^=&^\
M_N)^=7** *>^\_N)^=&^\_N)^=7** *>^\_N)^=&^\_N)^=7** *>^\_N)^=
M&^\_N)^=7** *>^\_N)^=&^\_N)^=7** *>^\_N)^=&^\_N)^=7** *>^\_N
M)^=&^\_N)^=7** *>^\_N)^=&^\_N)^=7** *>^\_N)^=&^\_N)^=7** *>^
M\_N)^=&^\_N)^=7** *>^\_N)^=&^\_N)^=7** *>^\_N)^=&^\_N)^=7**
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MD5)H>I-J%JWFG][&VUOK64<13FXJ/VE=%RH3BFWTW-6BBBMS(**** "BBB@
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M: ,# K#ZO%3C);1V1K[:3BT]WU"BBBN@Q"BBB@ HHHH **** "BBB@ HHHH
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M0 X4\4P4\4 .%.IHIU "T444 +1110!7N7"A<FJWG)ZU9ND5PNX=*K>1'Z4
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M1%_>H^T1?WJ;]DA_N_K1]DA_N_K0 [[1%_>H^T1?WJ;]DA_N_K1]DA_N_K0
M[[1%_>H^T1?WJ;]DA_N_K1]DA_N_K0 [[1%_>H^T1?WJ;]DA_N_K1]DA_N_K
M0 [[1%_>H^T1?WJ;]DA_N_K1]DA_N_K0 [[1%_>H^T1?WJ;]DA_N_K1]DA_N
M_K0 [[1%_>H^T1?WJ;]DA_N_K1]DA_N_K0 [[1%_>H^T1?WJ;]DA_N_K1]DA
M_N_K0 [[1%_>H^T1?WJ;]DA_N_K1]DA_N_K0 [[1%_>H^T1?WJ;]DA_N_K1]
MDA_N_K0 [[1%_>H^T1?WJ;]DA_N_K1]DA_N_K0 [[1%_>H^T1?WJ;]DA_N_K
M1]DA_N_K0 [[1%_>H^T1?WJ;]DA_N_K1]DA_N_K0 [[1%_>H^T1?WJ;]DA_N
M_K1]DA_N_K0 [[1%_>H^T1?WJ;]DA_N_K1]DA_N_K0 [[1%_>H^T1?WJ;]DA
M_N_K1]DA_N_K0 [[1%_>H^T1?WJ;]DA_N_K1]DA_N_K0 [[1%_>H^T1?WJ;]
MDA_N_K1]DA_N_K0 [[1%_>H^T1?WJ;]DA_N_K1]DA_N_K0 [[1%_>H^T1?WJ
M;]DA_N_K1]DA_N_K0 [[1%_>H^T1?WJ;]DA_N_K1]DA_N_K0 [[1%_>H^T1?
MWJ;]DA_N_K1]DA_N_K0 [[1%_>H^T1?WJ;]DA_N_K1]DA_N_K0 [[1%_>H^T
M1?WJ;]DA_N_K1]DA_N_K0 [[1%_>H^T1?WJ;]DA_N_K1]DA_N_K0 [[1%_>H
M^T1?WJ;]DA_N_K1]DA_N_K0 [[1%_>H^T1?WJ;]DA_N_K1]DA_N_K0 [[1%_
M>H^T1?WJ;]DA_N_K1]DA_N_K0 [[1%_>H^T1?WJ;]DA_N_K1]DA_N_K0 [[1
M%_>H^T1?WJ;]DA_N_K1]DA_N_K0 [[1%_>H^T1?WJ;]DA_N_K1]DA_N_K0 [
M[1%_>I/M$?\ >I/LD/\ =_6D^R0_W?UH 7[1'_>I#<1_WJ3[)#_=_6@VL7]W
M]:  SQ_WJ:9X_6@VL7]W]::;:+^[^M "&9/6G13QASDTPV\?I^M.BMHBYR/U
MH L?:(O[U'VB+^]3?LD/]W]:/LD/]W]: '?:(O[U'VB+^]3?LD/]W]:/LD/]
MW]: '?:(O[U'VB+^]3?LD/\ =_6C[)#_ '?UH =]HB_O4?:(O[U-^R0_W?UH
M^R0_W?UH =]HB_O4?:(O[U-^R0_W?UH^R0_W?UH =]HB_O4?:(O[U-^R0_W?
MUH^R0_W?UH =]HB_O4?:(O[U-^R0_P!W]:/LD/\ =_6@!WVB+^]1]HB_O4W[
M)#_=_6C[)#_=_6@!WVB+^]1]HB_O4W[)#_=_6C[)#_=_6@!WVB+^]1]HB_O4
MW[)#_=_6C[)#_=_6@!WVB+^]1]HB_O4W[)#_ '?UH^R0_P!W]: '?:(O[U'V
MB+^]3?LD/]W]:/LD/]W]: '?:(O[U'VB+^]3?LD/]W]:/LD/]W]: '?:(O[U
M'VB+^]3?LD/]W]:/LD/]W]: '?:(O[U'VB+^]3?LD/\ =_6C[)#_ '?UH =]
MHB_O4?:(O[U-^R0_W?UH^R0_W?UH =]HB_O4?:(O[U-^R0_W?UH^R0_W?UH
M=]HB_O4?:(O[U-^R0_W?UH^R0_W?UH =]HB_O4?:(O[U-^R0_P!W]:/LD/\
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MW33X8#MQ79:'%?Q:<!J,A>X)R<GI[5I44-W!1L%%%%(H**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I
M*6DH 2D-+2&@!IIIIQIIH 8:?#]\_2F&GP_?/TH GHHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@#'\2:*-=TF2U$ACDZHXZANU<79-\0-)L
MO[+CTV*[C0;$NWGPV/7%>F44TQ-'%^%/"MQHL&I:C=R&34[W,CL?X6VXZU#X
M O==N;G4H-;F:;RF'EDG(Q7<.H=&1ONL,&J]CI]MIL AM8]B#WS1<+%@HN/N
MC\JXGP3X<U#1]2U":]A5$F=BA!SU8FNXHHN%CSS6_"NK:;XC.O>'0'F=-KP%
MMH;UYJG-X?\ $_C#4+8^(+=;&S@<2>3')O#,#D5Z?11S"Y3CO&?@[^W+2WEL
M7\B\M<>2RCMG./QK!NX_'NL6 TJXT^.TB.%:Y2;+$?2O3Z*+CL9'AO0H?#VC
M16$/(7+,<=2>M:]%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 (WW3]*JBK3?=/TJJ* '"GBF"GB@!PIU-%.H 6BBB@!:*** (
M9^@J"G7GFX79C\157-Q_L_E0!8HJOFX_V?RHS<?[/Y4 6**KYN/]G\J,W'^S
M^5 %BBJ^;C_9_*C-Q_L_E0!8HJOFX_V?RHS<?[/Y4 6**KYN/]G\J,W'^S^5
M %BBJ^;C_9_*C-Q_L_E0!8HJOFX_V?RHS<?[/Y4 6**KYN/]G\J,W'^S^5 %
MBBJ^;C_9_*C-Q_L_E0!8HJOFX_V?RHS<?[/Y4 6**KYN/]G\J,W'^S^5 %BB
MJ^;C_9_*C-Q_L_E0!:3[Z_6K=9:FYW#&W\JGW7OJGY4 7:*I;KWU3\J-U[ZI
M^5 %VBJ6Z]]4_*C=>^J?E0!=HJENO?5/RHW7OJGY4 7:*I;KWU3\J-U[ZI^5
M %VBJ6Z]]4_*C=>^J?E0!=HJENO?5/RHW7OJGY4 7:*I;KWU3\J-U[ZI^5 %
MVBJ6Z]]4_*C=>^J?E0!=HJENO?5/RHW7OJGY4 7:*I;KWU3\J-U[ZI^5 %VB
MJ6Z]]4_*C=>^J?E0!=HJENO?5/RHW7OJGY4 7:*I;KWU3\J-U[ZI^5 %VBJ6
MZ]]4_*C=>^J?E0!=HJENO?5/RHW7OJGY4 7:*I;KWU3\J-U[ZI^5 %VBJ6Z]
M]4_*C=>^J?E0!=HJENO?5/RHW7OJGY4 7:*I;KWU3\J-U[ZI^5 %VBJ6Z]]4
M_*C=>^J?E0!=HJENO?5/RHW7OJGY4 7:*I;KWU3\J-U[ZI^5 %VBJ6Z]]4_*
MC=>^J?E0!=HJENO?5/RHW7OJGY4 7:*I;KWU3\J-U[ZI^5 %VBJ6Z]]4_*C=
M>^J?E0!=HJENO?5/RHW7OJGY4 7:*I;KWU3\J-U[ZI^5 %VBJ6Z]]4_*C=>^
MJ?E0!=HJENO?5/RHW7OJGY4 7:*I;KWU3\J-U[ZI^5 %VBJ6Z]]4_*C=>^J?
ME0!=HJENO?5/RHW7OJGY4 7:*I;KWU3\J-U[ZI^5 %VBJ6Z]]4_*C=>^J?E0
M!=HJENO?5/RHW7OJGY4 7:*I;KWU3\J-U[ZI^5 %VBJ6Z]]4_*C=>^J?E0!=
MHJENO?5/RHW7OJGY4 7:*I;KWU3\J-U[ZI^5 %VBJ6Z]]4_*C=>^J?E0!=HJ
MENO?5/RHW7OJGY4 7:*I;KWU3\J-U[ZI^5 %VBJ6Z]]4_*C=>^J?E0!=HJEN
MO?5/RHW7OJGY4 7:*I;KWU3\J-U[ZI^5 %VBJ6Z]]4_*C=>^J?E0!=HJENO?
M5/RHW7OJGY4 7:*I;KWU3\J-U[ZI^5 %VDJGNO/5/RHW7GJOY4 6Z0U4S>>J
M_E2$W?JOY4 6C335;-WZK^5(3=>J_E0!.:?#]\_2J9-SZK^5+&;K=\I7/TH
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M^5 %QONGZ55%-)O,'E/RID/F<[\?@* )Q3Q3!3Q0 X4ZFBG4 +1110 M%%%
M$,_05!4\_05!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 Y/OK]:MU43[Z_6K= !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4E+
M24 )2&EI#0 TTTTXTTT ,-/A^^?I3#3X?OGZ4 3T444 %%%% !1110 4444
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M5 ,_6DI;C<=O(\K\ 6KWFC:[;(/FDFE4?G5GPAXJLO#D5UI>LR"UF24B,/\
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MI>GQ/OCL;9&_O+$H/\JM].E#:M9#47>["BBBI*"BBB@ HHHH **** "BBB@
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M113$%%%% !1110 48!ZT44 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %)2TE !24M)0 TTTT^FF@!AIT7WZ0TZ+[U $M%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "'H?I5<5
M8/0U7% #A3A2"E% #A2TE+0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** $I*6DH 2FFG4AH ;0A"MDTM-H D\Q:/-2HB*;B@";SD]
M31YR>IJ#%)B@"QYZ>I_*CST]3^55L48H L>?'ZG\J//C]3^55L48H L^?'ZG
M\J//C]3^55L48H L^?'ZG\J//C]3^55L48H L^?'ZG\J//C]3^55L48H L^?
M'ZG\J//C]3^55L48H L^?'ZG\J//C]3^55L48H L^?'ZG\J//C]3^55L48H
ML^?'ZG\J//C]3^55L48H L^?'ZG\J//C]3^55L48H L^?'ZG\J//C]3^55L4
M8H L^?'ZG\J//C]3^55L48H L^?'ZG\J//C]3^55L48H L^?'ZG\J//C]3^5
M5L48H L^?'ZG\J//C]3^55L48H L^?'ZG\J//C]3^55L48H L^?'ZG\J//C]
M3^55L48H L^?'ZG\J//C]3^55L48H L^?'ZG\J//C]3^55L48H L^?'ZG\J/
M/C]3^55L48H L^?'ZG\J7ST]3^55L48H L^>GJ:/.3U-5\48H L^:GK1YJU7
MQ3L4 3>8I%1@4@%.H 44HI!3J %I:2EH 6BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** $HHHH 2DIU)0 VDQ3J3% #"*3%/Q24 -Q28
MI^*3% #,48I^*,4 1XHQ3\48H 9BC%/Q1B@!F*,4_%&* &8HQ3\48H 9BC%/
MQ1B@!F*,4_%&* &8HQ3\48H 9BC%/Q1B@!F*,4_%&* &8HQ3\48H 9BC%/Q1
MB@!F*,4_%&* &8HQ3\48H 9BC%/Q1B@!F*,4_%&* &8HQ3\48H 9BC%/Q1B@
M!F*,4_%&* &8HQ3\48H ;BC%.Q2XH 9BEQ3L44 )BEQ2XI<4 )BEQ2XI: $I
MU)2T +1110 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@
MQ1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ HHHH *6BB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g23ode3tb50n000025.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g23ode3tb50n000025.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '"!"<# 2(  A$! Q$!_\0
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MW391I B-S\F\9YK)UNTFOM7^WP(6A9@=P^M59$MNQNQZGK%KJ=NMW.&AE&[
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &R1K+&R.,JPP
M16<F@:=')O6 !O6M.B@+%&[T>RO0HGB#;!@4Z/3+6*W$"1XC'05<HHN%C.@T
M2PMIO-BA"OG.:6?1;&YE\V6$,V<YK0HHN*R(H(([=-D2X6J>J6\4[1>8N<'B
MM&J%[*F^-<\YH&6K>-8X@JC J6F1_<%/H **** "BBB@ JM-8V]Q)OD3+>M6
M:* &H@1 JC '2G444 %%%% !1110 55DT^VED#O'E@<YJU10 @&!@=J6BB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ K-O8/WL;>]:54[WK']: +,?W!3Z9']P4^@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBD+*O
MWF ^IH 6BJ-QJUI;G#RK^#"G6^IVMR/DE7_OH4"N7**0$'H0?I2T#"BBB@ H
MHHH **** "J-[(F^,;AG-7JS+VW7S8W]Z -"/[@I],C^X*?0 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !7$>,+F5[J.T6=H5D&"X/2NV;.TXZXKB=;T>ZOM10.0<]#CI51W)EL<]9
M^!5U"4A/$,KR=UW'BK4GPVO;0^=#K-PQ7^$-UK1T33#INLR@2(C@?,217<)-
M$P"B5&;'0,*;DT2H)F#X:%["&M[I7(08#MWKHZ**ELM*P4444AA1110 4444
M %4[[[T?UJY5*]8;HQD=: +4?W!3Z9']P4^@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *0G S2TA (P: ('O(D^\X%*MU&Y # YJGJ5I#Y&[;SFK%O
M:0K&C!><4 6Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JK?N8;5Y40,ZCBK55-2?R[
M&1B,X'2@#R.X?5=8\0W$<2.N.?E.*WO#FC:O;:U#+<&7RQUW,<5R;V6MWWB:
MZ?3-06UR.A-=1X:TOQ1!K<$E_K"SVX^\@/7]:V>QA'<]-HHHK$W"BBB@ HHH
MH **** "LJ]MOWT;[CUZ5JU3OOO1_6@"S']P4^F1_<%/H **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@"EJ7_'N/K5F#_4)]*K:E_P >X^M68/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ JKJ#NEE(T?W@.*M5GZC>6B1FW
MFN4C=QP#0#/'DT74-4\5W<B$!B,GYL>M==X?\-ZE9:O#/,1Y:]?FK%O_  %?
MW6JRWEEK,D0?LG_ZJO:!X7U+1]9AN[W79984^\CG@_I6K=UN8)6>QZ?15>WO
MK6Z8K!,LA'4"K%9&X44R618HV=R JC))K+77[5I/]8OE_P!_/%%A7->BLZZU
MBVM@A,BG<,CWIT>K6K6XE:9%SVIV"Y?HK+M]:MYIQ$756)^4>M+<ZU;PS>4K
MJS _,/2BP71IU3O>L?UJ:VN8KJ/?$X8=\5#>]8_K2&68_N"GTR/[@I] !111
M0 4444 %%%% !1110 4444 %%%% !1110 4R5MD;,.PI](PRI![T >>Z_?RR
M7K(3\M3^'M1F6X6+/RL<4[Q!9*VHL$/)["M70]!%L%F=LD\C-,1TM%%%(844
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*FP1MU]*FM[TD)'Y3#MG%7MJ_P!T?E1M7T'Y4 +1110 4444 %%%% !1110
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M3DOY&N3)YIZX-<]ID>D6GQ"L8]*\SRR,G/KQ6NZ,-F>VT4@.1FEK(W"BBB@
MHHHH **** "LJ]N6\Y$\LXSUK5JG>@;H^.] %F+[@I],C^X*?0 4444 %%%%
M !1110 4444 %%%% !1110 5R^JR".9CGG/%=#=W"VMNTKG@5P.IZF+J[!!^
M0-30'3Z#&9H_M#CY@<<UO5DZ#+%+8@Q]*UJ0!1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2H88EEP":8C7@SY"9ZXJ2@<# HI#"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[3E?:NM P*Y3PG:30F1W!"MTKK*0!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M# -H& *OT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/0ZO_A+M*SCSZU[:ZBNHP\394C->,#J*[?2;NZ2U4)&Y&.U88;'SG*TD;XC
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M;K[0S#;MVT 6:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $(R
M,&N.N-&U6+5+B>T V3#!SZ5V5%-.PFKF/X>TMM+LWC<89VW&KMVFXI@=ZMUG
M7>JVMNV&D4D=?:C<-$B\@ 4<4[ ]*KV=Y#>0^9"X9?:K-(8F!Z48'I2T4 )@
M>E1M C2B0CYA4M% #7C5UP1P:IG2K8G.W]*O45+BGNBE)K8K064-N247K5C
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M4BN$L++4[*[D=K9I=SDAFYQ51(D1:58F>3[!?898NE:5LBZ=XFM[2V&(67)
M_"K-YIUSY*W449\Y_O*.U6=&TN1YEO+I2LJ< &G<21T=%%%0:!1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !2,RJ,L0![TM8WB:1HM*D920=K=#[4";L:)O[,'!NH?^^Q4D<T
M4O\ JY$?_=.:\/\ "GA^X\307ER]S<!HYF4!9#ZGWK5T#6KWP_KLMC=$^2#M
M5G.3^M6X$*IW1Z_17+ZEXVTVPF2!IP)F7(6I--\9:9J4,[PW 8P#,GM4V9?,
MCI**QM+\1V.J6YE@E# 57MO%^FW/VLI."MJ<2>U%F%T=#17&GXA:3N#BY7R6
M. W%=18W\&H0"6!]RD9S0TT"DGL6J***0PHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUV6C:-;Z-;>5!G!'.:4I)HJ$6F:5%%%9FH4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5#= -:R C(*]#110!RVEVUNFI;E@C5O4( :ZY?NBBBJD3'86BB
MBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g23ode3tb50n000006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g23ode3tb50n000006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /<!V8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI"<=: %HK+O?$&FZ
M>#]HN%0^]<U?_$.TBS]DD26C;<%KL=QD#J:0R1CJZC\:\=U'XHWX)5;90/6L
M9O&FL:B<6\3$GT-":>PVFMSWGSX?^>J?]]"CSX?^>J?]]"O"(7\773Y%K,%/
M?=6U::1XBF_UJSK_ ,"-5RD<QZ[Y\/\ SUC_ .^A1Y\/_/5/^^A7F'_".ZQM
MSYD^?]XUFW>E>)(<^4D[8_VJ.5!<]B\Z+_GJG_?0I1(AZ.I_&O!WN?%EJV9+
M6;:.Y:G1^.]4L6"RQG<.Q-*6A4=3WC(HKR73_B7?R8W6J[?6NHL?'UC)@74R
M1-Z5*E%[,IQDMT=E15"SUFPOP#;3A\^E7Z9(4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !111TYH **S;W7=/L,_:+A4QZUSE]X_LX\_9)$
ME(H>FX+78[7('4TTR(.KJ/QKR34/B9J"9_T50OK6')XXU6_8B"(ECV!I*2>P
MW%K<]U\Z+_GJG_?0H\^'_GJG_?0KPF.7Q;=-\MK-M/<-6Q::1XCFQYJSIG_:
M-7RD<QZ]Y\/_ #U3_OH4>?#_ ,]4_P"^A7F/_".ZQM_UL_\ WT:SKS2?$<(/
MDK.__ J.5!<]?\^+_GJG_?0IPD0]'4_C7@TDOBVU;+6LVT=RU(GCC5M.8">(
M@CL32:L.+N>^9!Z&BO'].^*%\Q :V7;ZUU5A\0;&4#[5*D1J;I]2G%KH=M16
M=9:W87XS;SJ_TK1IB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ I&947<Q  [FEKF?%NIM;V;VL!_P!(<?** (-:\6K:
MN8+:)IG)Q\G.*QA!KVI_O(KJ2$'L16SX5\/I#"M]< F>4?,&Y%=6$51@*!^%
M5>PK7/._[#\2?]!-Z/[#\2?]!-Z]%P/048'H*.8+'G7]A^)/^@F]']A^)/\
MH)O7HN!Z"C ]!1S!8\Z_L/Q)_P!!-Z/[#\2?]!-Z]%P/048'H*.8+'G7]A^)
M/^@F]']A^)/^@F]>BX'H*,#T%',%CSK^P_$G_03>C^P_$G_03>O1<#T%&!Z"
MCF"QYU_8?B3_ *";T?V'XD_Z";UZ+@>@HP/04<P6/.O[#\2?]!-Z/[#\2?\
M03>O1<#T%&!Z"CF"QYU_8?B3_H)O1_8?B3_H)O7HN!Z"C ]!1S!8\Z_L/Q)_
MT$WH_L/Q)_T$WKT7 ]!1@>@HY@L>=?V'XD_Z";T?V'XD_P"@F]>BX'H*,#T%
M',%CSK^P_$G_ $$WH_L/Q)_T$WKT7 ]!1@>@HY@L>=?V'XD_Z";T?V'XD_Z"
M;UZ+@>@HP/04<P6/.O[#\2?]!-Z/[#\2?]!-Z]%P/048'H*.8+'G7]A^)/\
MH)O1_8?B3_H)O7HN!Z"C ]!1S!8\Z_L/Q)_T$WH_L/Q)_P!!-Z]%P/048'H*
M.8+'G7]A^)/^@F]']A^)/^@F]>BX'H*,#T%',%CSK^P_$G_03>C^P_$G_03>
MO1<#T%&!Z"CF"QYU_8?B3_H)O1_8?B3_ *";UZ+@>@HP/04<P6/.O[#\2?\
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MCUKK_ _B=]Z:;>-B8G@>U=F$Q2K1L]SBQ6&=&5UL>CT4@((R.]+78<@4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5#<W,=K"9)7"J.Y-2.P1"S= ,FO+_ !OXD:[N6TNW?Y2,
M\&E*2BKL<8N3LBIXG\57&J71M;-VCC4[6(Z-6+!:I -[8,G=J=;6RPIGJQZY
MJ*<S7=P+.T&Z;/(]J\.K6GBJG)#8]NE1AA:?/+<5%N-3O$M;96PQP7 X%>F^
M&O"%OID*R3HKSXY?UI_A+PS#I%H)&3]Y(-S9'0UU->O0H1HQLCR:]>5:5V(
M%  Z"EHHK8Q"BBB@ HHHH **** "BBB@ HHHH 1E#*5(R#7'^*/!MOJ<+RVZ
M*D_]ZNQHZT ?.MQ!/IMT\%PK##8!(ZTR2$,=\9PXYS7KWC+PM%JUJTZ)^^C7
MY<#O7D(62TNFLK@8F3J*\[$T'3?M('HX:NJB]G,Z[P?XQFL;A;*^=G#' <]
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M<SW9EC*O-/E6R+/2BBBNLXPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M1E#*5(R",&O*_'FA?8KX:C;KLB1?F5>A->HS3+!&SMT R:X+Q-XPT6]T^:QE
M#[FXY%*4%-.+'&3@U)''6\HG@63U%5;OS+.7[; 2)%Z8ZU%IMTDMQ)%$#Y2?
M=S6E(@D0J>E?./FP];3H?0JV(HZ]3U+PQJR:EI<(W@R*GS>M;M>*>$/$:>'K
MVZ%X6\MV^7'X5Z%8>/-*U"Y$$.\N:^CA+GBI(^>G'DDXLZFBFHXD0..A&:=3
M$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !13))!%&SMT49-<O=?$#2+2<Q2%PPH D\8ZZNDZ>4_CF4J/:O*
M[*-Y,SSDM(3PQZU>\1ZY'XHO56+<4A;(S2*-J@>@KR<RK_\ +M'JY=0_Y>,B
MN9/+A;'WL<"NH^'^@&4IJLXY88VM7":C>K!J5GOSY6[Y\>G->H:#XQT58DL[
M8/Q[5MEU#EAS]699A6YI\G8[4  8 P!2TV-Q)&KCHPR*=7H'GA1110 4444
M%%%% !1110 4444 %%%% !1110 A 88(R#7EOQ%\._9P=2MT^=VP0H[5ZG5#
M5[&.^L)(Y!G"DC\J32:LQIM.Z/ XGW+[CK37\R&:.:%BC*P+$=ZEGM7L+Z>.
M08RYQ0PRA'J*\:2=&KIT/9BU6I:]3V3P=K8UC2@Y.&3"UT,IVQ,?05XWX U=
MK#68M,#865MQ'X__ %Z]BG.;9S_LU[,9*45)=3QY1<9.+Z'G]N/M'Q#CD;GY
M>E>B@8&!7G.F_P#(]Q_3^M>C53(04444AA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &1XCMDN
MM+:-P",]ZR_!TK-]IB)^6,X%;6L_\>#5@>"_^/B^_P![_"GT%U.PHHHI#"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH 1E#*5/0BO,?'?A0B8ZI;J3Y8_U8'!KT^HIX([F(Q2#*GJ*&KJP)V=SP
MNR:(C 15E'W@.U7"0!DU<\6^'I-$O#=VR?)*V3M&>*Q+5;O7+A;6R5D8]V4X
MKPZV!J>UM'9GM4<=3]E>6Z&2HVHW"V]M!YI)PS#^&O1?!_@N/3$2YG^:3'W6
M%:/AGPE;:1")'C'GL,LP[FNIKUJ%%48\J/+KUG6E=B !0 !@"EHHK8Q"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ I&&5(]12T4 >+_$2U%IX@MP@P&&
M3BL"NR^)\7_$R@EVD[5]*X=)P5!P:\W'0?,FCTL#-<K3)].<VFOP78_@'^%>
MZV<_VC15E_O)FO )IL1DJ#NKW/P^2WA2W)Z^773A&_9ZG/BTO:71RVF_\CY'
M]/ZUZ-7G.F_\CY']/ZUZ-77(Y$%%!Z56>_MD.&GC!]W%2,LT54_M*T_Y^(O^
M^Q3UOK9ERLT9'LXH L45!%=0S,521&([!@:GH **KO?6T;;7FC!'8N*1;^U<
MX$\6?]\4 6:*0,&&001[4M !137=44LQ  [DU E_;2/M6:,GV<4 6:*.HS10
M 4444 %%%% !1110 44C$*I)Z"LU=<LVO%M0Z^8?]H4 :=%(#D9I: "BD+ =
M2!]32@@]#F@ HHHH **** "BBB@#/UG_ (\&KG_!?_'Q??[W^%=!K/\ QX-7
M/^"_^/B^_P![_"FMA=3L****0PHHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#T-><:Y_R4
M73O]W_"O1ST-><:Y_P E%T[_ '?\*J(F>CK]T4M(OW12U(PHHHH **** "BB
MB@ HHHH **** .:U+P=9ZGJ7VV1L.?:KU]H%O?V2VTGW57:.*UZ*=V*R.''P
MUTT='_2M_1/#UOHD3)"<@G-;-%%V%D%8&M>%;;6IQ+,Y! Q6_12N,X?_ (5K
MIN<[^?I71Z-H<.C6XAA;(!K5HIW8K(9+&)8FC/1A@USL'@ZS@U=M05OWA'3%
M=+12N,15VH%'85AZ[X7L]<CVS *<YW <UNT47 XF/X<:>D#1-*7#=R.E;5AX
M9MK"S:VC/RLNWI6Y13NQ61SNC>$K31KCSH6R=Q/2C5?"-IJMW%<2MAHVW#BN
MBHHNPL9EWHL-WIWV-C\E5=(\,6ND13I$<B;KQ6[11<=CF[;P?:6VK/J"M^\8
M8(Q2WWA"TOM0ANW;#Q=.*Z.BB[%9&=>*EGI$R=A&V/RKPCP]IK:KXX27RQY8
MD8' ]Z^A)H$GC,<BY4C!%9MCX<TW3YO-M[<(Y.<CUIJ5A-7-"UA6WMTB7HHJ
M:BBI*,?5_#MEJ\>V6- <==M<U%\+]-CEW^:Q]L5WM%.[%9&?9Z?;Z5:%(E4*
M!S@=:\+\76K:OX\ECB0$!U.1]:^@W4.I5AD&LD>&M+%ZUW]F7SFZM3C*PI*Y
M+HEFMEI<"* /W8S^59VO>#[+70#+A&SG('-=$H"J% X' I:5RC"T/PQ:Z);&
M"-MZDY^85G:KX!T_5)C*3Y;$Y.T5UU%%V*R.5T?P-8:3,LJXE8?WA6GK'A^W
MUB%8Y?E51@8%:]%%V%C&L/#MK8Z4+  -&/45G6?@BSLKEIHI"-S;B!TKJJ*+
ML+'-0^#K.'5I-0#?O'ZC%.U+PA::E?Q7<C8:,8'%='11=A9%!]+B?3_L9/R;
M=M9^B>%;7123"V<MNZ5OT47&<UK/@VQUAMS@(WJHYK.L_AQ8VDH?SV?'9J[:
MBB[%9&+J7ARVU*TC@<[0B[00*P[3X<6%K.)6E:3'9N:[:BB["QG7FCV]WIK6
M14+&R[>!571/#=KH?^HYXQTK;HI7'8**** //M2_Y*)#_N?X5V5YI\>HV7DR
M' 9<5QNI?\E$A_W/\*[Z+_5+]*;$CB?^%:6':9A1_P *TL/^>[5W-%(9FZ/H
MT.CVB6\1RJ]ZTJ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB@ HHHH **** "BBB@ HHHH **** ,76_#MOK>/.;&!BL#_A6EA_SW:NYHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'S5_1?!%GH]^EU%&@9>A%-M,231X_=JK_$5PP!!N1U%=?\3O#B+IO]HP1A7
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M.?.X>E>D7'PSLI)R\:1HOI72:+X9L=&CQ#"BL>I%+F2V'9]3QKQLFSQTZ_\
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MMSZ5X4MY[H,PVG[WTKK?#/BB/Q#!)*B!=KE>/K6;1HF;EU_QZR?[IKP74_\
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444UW6-"S'
M'4T 9GB"=(-,9W.!61X.B*M=2=G.167XLU1M78Z79'>2<Y7K77:'9?8],A0C
M#[!NJMD+J:5%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *;)&LJ%'&5-.HH XK5_"
M=RMP;K1W6&5CER>]54U/6=-&R[D>5AW537?U&T$3'YHD/U%.XK'$?\)1=?\
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M_P#OD470'$_\)3=?\\YO^^#1_P )1=?\\YO^^#7;?9;?_GC'_P!\BC[+;_\
M/&/_ +Y%%T!Q/_"4W7_/.;_O@T?\)3=?\\YO^^#7;?9;?_GC'_WR*/LMO_SQ
MC_[Y%%T!Q/\ PE-U_P \YO\ O@T?\)3=?\\YO^^#7;?9;?\ YXQ_]\BC[+;_
M //&/_OD470'$?\ "477_/.;_O@TO_"477_/.;_O@UVWV6W_ .>,?_?(H^RV
M_P#SQC_[Y%%T!Q/_  E-U_SSF_[X-'_"4W7_ #SF_P"^#7;?9;?_ )XQ_P#?
M(H^RV_\ SQC_ .^11= <3_PE-U_SSF_[X-'_  E-U_SSF_[X-=M]EM_^>,?_
M 'R*/LMO_P \8_\ OD470'$_\)3=?\\YO^^#1_PE-U_SSF_[X-=M]EM_^>,?
M_?(H^RV__/&/_OD470'$_P#"4W7_ #SF_P"^#1_PE-U_SSF_[X-=M]EM_P#G
MC'_WR*/LMO\ \\8_^^11= <3_P )3=?\\YO^^#1_PE%U_P \YO\ O@UVWV6W
M_P">,?\ WR*/LMO_ ,\8_P#OD470'$?\)1=?\\YO^^#2_P#"4W7_ #SF_P"^
M#7;?9;?_ )XQ_P#?(H^RV_\ SQC_ .^11= <3_PE-U_SSF_[X-)_PE%U_P \
MYO\ O@UV_P!EM_\ GC'_ -\BC[+;_P#/&/\ [Y%%T!Q/_"4W7_/.;_O@TG_"
M477_ #SF_P"^#7;_ &6W_P">,?\ WR*/LMO_ ,\8_P#OD470'$_\)3=?\\YO
M^^#1_P )3=?\\YO^^#7;?9;?_GC'_P!\BC[+;_\ /&/_ +Y%%T!Q/_"4W7_/
M.;_O@T?\)3=?\\YO^^#7;?9;?_GC'_WR*/LMO_SQC_[Y%%T!Q/\ PE-U_P \
MYO\ O@T?\)3=?\\YO^^#7;?9;?\ YXQ_]\BC[+;_ //&/_OD470'$?\ "477
M_/.;_O@TO_"4W7_/.;_O@UVWV6W_ .>,?_?(H^RV_P#SQC_[Y%%T!Q'_  E%
MU_SSF_[X-+_PE-U_SSF_[X-=M]EM_P#GC'_WR*/LMO\ \\8_^^11= <3_P )
M1=?\\YO^^#1_PE-U_P \YO\ O@UVWV6W_P">,?\ WR*/LMO_ ,\8_P#OD470
M'$_\)3=?\\YO^^#1_P )3=?\\YO^^#7;?9;?_GC'_P!\BC[+;_\ /&/_ +Y%
M%T!Q/_"4W7_/.;_O@T?\)3=?\\YO^^#7;?9;?_GC'_WR*/LMO_SQC_[Y%%T!
MQ/\ PE%U_P \YO\ O@T?\)3=?\\YO^^#7;?9;?\ YXQ_]\BC[+;_ //&/_OD
M470'$_\ "477_/.;_O@T?\)3=?\ /.;_ +X-=M]EM_\ GC'_ -\BC[+;_P#/
M&/\ [Y%%T!PS:WJEX/+MC(C'H2II;'PKJ5]<B?5Y4FC!W(/2NY%O"IXB0?11
M4@  P!1<+$5O;QVT0CC7"@5+112&%87BT'_A'KO']RMVJM]9I?6LD#_=<8-
M'F_@92-)?((_=-V]JS?!.H16.I7?G<9G;KQWKTO3O#MMIL!BC)(*E:P9_AO8
MS3M*+B1"QR=I(H W1XCLI#L#KD\?>K$UKPB-<NEN5VXQW--A^'5K#*KB\G.T
MYY8_XUV%K;BVA$8)( QDT 8'AOPS_8<DC?+\WI2^-P?^$>DP,\UTM4]1L(]1
MM3!(<*: ./\ AT"$NL@C_(K \;1>9XE8%21N';WKTC2M&ATH.(B3OZU6U#PU
M;:A>?:9&(;.: ,V]\,6FI>'$41#S3$,$UQ7A?4[CPSK[Z9=;C"@VK@<9/%>O
MQ1+%"L0Y"C%8&J>$;/4[D3NQ1]P;*B@#?AD$L2..C &I*@MK<6\*Q@DA0!S4
M] ",,BN$U^S:*<OCAC7>5FZK8+=P'CD#BKA*S-*<N5GG-%6;RT>VE*L,55S7
M2=0M%%% !1113 BG^Z:S_P"UYK9# CX4GI6A-]PUS-^=MQ515RX;FTDAD7<3
MR:.]16IS OTJ7O6;.D****0!1110 46X+WT('/SBF.X45L>&-->[O?,*_*IR
M*3=D3.7+%MGI&G1^7:J/85<IB+L11Z"GUS'D-W84444""BBB@ HHHH ****
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M@T?\)3=?\\YO^^#7;?9;?_GC'_WR*/LMO_SQC_[Y%%T!Q/\ PE-U_P \YO\
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M1= <3_PE-U_SSF_[X-'_  E-U_SSF_[X-=M]EM_^>,?_ 'R*/LMO_P \8_\
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M,?\ WR*<L4:?=11]!1<+'/:!X933BL]RH:Z_OBNDHHI#"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I",TM% &/JFD)=J64
M-7&7FFRV\A&TXSZ5Z5BJUS8Q7*D,!^5:1FT:PJ-:,\P(*GFC-=?>^&QDF)2:
MP[O29[8$LF *V4TS=23,[M24M)5%$<OW#7+ZIQ*374R_=-<OJXPQJXEPW-*R
M.;=?I5CO573S_HZ_2K7>LWN=(4F:6H"6,NT4@)B::6/0"KD6G3. =O!K7L/#
MSSL"RG%+F2,W4BC%L=-EOI@H4@'VKTO1-+2PMU^4;B.:73-(BLT'R\CVK6 P
M*QE*YPUJSGHMA:***@YPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "F22"-2Q[4^LW59"D>!W%-*[L3.7+&YGW^IL6*H<5GKJ\L$@+,2O>J['+9
MJ*10PP:Z>16L>7*K-NZ9)J4R7"B92,L>E9XZ5%(K1OU.*>*N.B.64W*5V.Q5
M>:V$G:K I:H1G?V6Q/#@5(EBT#9W@U<Q2U/*4Y75ABK@<TXBEIK&J)-?0;ED
MNEBSP37:UQ?A^U9[A9<< UVE<M6W,>M@[^SU"BBBLCK"BBB@".6&.9=LBY%)
M%!' ,1K@&I:* (9[:*Y7;*H854_L+3_^?=:T:* *4.E6=N28H0N>M2I9P))Y
MBH P[U8HH 3'%5GT^VDF\UHP7]:M44 4KC2[2Y $T0;'2BVTNTM#F&(*?:KM
M% "#BEHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BHI)E3K49NUQD&@"S15;[6N>M(+M<]: +5%5OM:[<YI/M:^M %JB
MJINU]:7[6F.M %FBJHNUSC-!NU[&@"U1547:XY-)]K&>M %NBJOVM>>:07BX
MR30!;HJH;M>,&G"[7.,T 6:*J?;%SUI3=KZT 6J*JB[7')I#>*.] %NBJOVM
M>F:07:Y/- %NBJGVQ=N<TOVM>.: +5%5?M:[L9H-VOK0!:HJH+L9Y-!O%QD&
M@"W153[8N!S1]L&X#- %NBJGVQ>>:!>#&2: +=%5#>+QS3OM:8SF@"S157[6
MN>M!NU]: +5%51=KCK2&\7UH MT56^UIZT@O%YYH M454-XF,YIWVM,#F@"Q
MC-9&NQK]C<X[5=-XN>M9^KW"R64@'I3CN5#<X1NM-%/<?-3<5UG8,D^[7,ZR
M.M=._P!VN;UI>#5Q*CN6--.8!]*N51TO_58]JO=ZSEN=04ZSC$EZH/J*;4EF
M=MXI]Q4O84MF>F66CQK!&Q .5%:<=O'$/E4"JEK>*+>(9_A%3&\7L:YV>0Y-
MEK%+507B$9S1]L7/6D26Z*JF\3.,TBWBG//2@"W150WBXZT@O5]: +E%4_MB
M[L9I?MBXZT 6Z*J"\7'6D-XN>M %RBJGVQ<=:%O%)QF@"W15,W@YP:!>KMR3
M0!<HJD;T9'-+]M7UH N452%Z.YI3>#L: +E%4_MJXZT?;5SUH N52U"'S83[
M"E-ZN< TTW:L"#33LQ27,K'+2Q&-R"*A:MRZ@68EE%94UNRGI73&2:/*J4G!
MF=.NX551]IVM5^1<51GB)Y%6<LTT[H?GT-.!K.,[Q.%/K5Z(EER:8DTR2@\4
M4U_NTP$SD\5<LK"2YD'!Q2Z79_:"S.. :ZJT\FVC&T<UE.I;0[*&&<M7L6;"
MR6UA  &35VJ7VT9QFE-ZO8URMW/4225D7**I"]7')H^VCUH&7:*IF]7'6F_;
M>>M %ZBJ1O1V- O1CDT 7:*HF]]Z4WJ^M %VBJ(OAGDT&]&.#0!>HJF+U<=:
M3[<N>M %VBJ?VU?6@7JYZT 7**I&]7L:7[:N.M %RBJ7VU=W6E^VIZT 7**I
M"^7'6D-\.QH O452^W+CK0+U>YH NT52-ZO8TOVU?6@"Y15'[<,]:4WR]C0!
M=HJDM\IZFD-\.QH O452^VKCK1]N&>M %VBJ1OE]:!?+W- %VBJ)OESP:7[:
MN.M %VBJ0OESUI#>CL: +U%41?+CDTGVX9ZT 7Z*I?;E]:07P[F@"]15$WP[
M&E^W+ZT 7:*I"]!;&:MJP89% #J*** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "D8X%+44QPE %&=COQG.:B/\ =]*<WS/GTII^\<]*  <\^E)W)]:4?=-(
M?NCUH 7_ )9D4GI2GJ!0N/RH "?GQ0#PWM2'KF@< ^] !GC-'?ZTA'R>]*1T
MH 7J<4G?/I2KC<:3^$DT *#W]:3^'%!^Z*,#.*  ]%I<_/2'^5 /.: $'\1S
M2@_+FD&,-1_RS% "^U#=*.,BD.,XH 4'YA1W-(#2\<T )G]V:4G[M)_!1QQ0
M I^_0#2?\M*!CF@!>^:.QI..M':@ /04O&\4AQ@4'&\4 *.K4G\% QDTG&R@
M ;H*4'BD;&!1QMH <:,TG%+WH  >#2'H*.,&@XP* %S\PI >M+D;A3>,F@ S
M\E.STIO\-.&,4 !QFJM^,VC_ $JP<8J&\ -NP]J:W''<XV08<TVI;@8F85%7
M6=HU^E<[K(^1JZ)^E8&L?<-5'<I#=*/R'Z5HGK67I1X85J&IEN=702EAXN$_
MWA24B'$Z'_:%0]A/8]*M\>1%_NBI<\FH+8@VT7^Z*FXS7,>.]P'W32GH*3C.
M*4XH$&?FH!QFDXQ0<9% "TG>EXW4<8- ![T>U(<;11D9H 4=329R*.,T<=*
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW^'-!Z4 .XP.:#C>*:>@I<?.* %&/FI!C;2+U:C'R4 *V,"CC936Z"C@1XH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH :Y^4UF3-EMO>KT[;5ZUFE@9>M  3T _&C/S8
MINX$D@]*4,OWL]: %Z_-Z4#CYO6FY&T\TXL!&O- "=L'K2MT IN1Y@&:4D$X
M!Z4  ^_CM1]XY]*0,-V[-","'YH <#SNI >H]:0.HCSFC*AAR.: %/W0*/XQ
M02"V >E(&7=G/2@!W5C[4@/&[TH5AEN:3<HC)S0 HX_&D;A,49&%YZT,1]W/
M- "]"M*W+8II(RO-+D&0C-  .>?2@=2:0,,$YZ4!AC.: %Z(:0]%H)&PC-(2
M,+S0 XC+8I._TI6(\P &FAAD\]* %'+YH7HU(&!;.:56&UN: #H@-!]/6D+#
MRP<TK,.!GF@ ]J7JXIN1TS2Y'F#F@ 7JU&/DS0K+EN:0,-F<T *WW?K2=(P*
M1F 7K1D>4,F@!Q^\M*#\YII(W+S3EQYC<]J &_PFE_A%("-IYI<C;UH .@Q0
M>U(2 O6@D?+S0 [_ ):4T?Q4N1YO6FY&X\T .'W:3^$TH*YZTT$;6.: %ZJ*
M<?OBF;AY:\TXD;AS0 G\1I1]VD)&>M+QNQF@ Z"D/*T@(.[GI1D>5G- #CCY
M:#]ZDR,9S06&P<T +WI .32D@.O-)D;SS0 =4-*<86D!&.M (.>:  _>HI,C
M9G-#$#;SUH <OW\4G8T$@/UHR,=: #HHH/W@:08/>C(V$YH =W-(!SBC(VJ<
M]:#C>.: #/44G\- (R>:!@G&: %/44I^]FFY&#STH# Q@YH 7'-'<BD)&.M&
MX8SGK0 #[II2,@4<;P,]:0$;B,]*  ]:,<_6@$8ZT9&.M "_Q8I .#1D!=V:
M"P!7GK0 8RM+VI-R[NM&1TS0 8[T=\4;@21GI2 C83GI0 HZFCJ,4A(P.>M+
MD ]: "@],T9&>M&1G;F@ ]*,?-2 @@G/2@D; 0: %ZC!H[49'K2$CUH 7WHH
M^7.W(YI 02>>E "XYH^M)D%<YI<C'6@  XQ2=>?2C< ,YI20"!GK0 4F.:3(
MW$9I<CUH /K1B@8YYHR-N<T '6CWH. !SUI,C=C/% "D<T?RHR/6D# N5STH
M 6CK2Y!!.>E(",9S0 =*#S2'&,YI> !SUH ,_E11QNQFE!!SSTH 2@4 CUHR
M/6@ -'>@D 9S1QD#/6@ I.O%+QDC/2D&.N: #I2]:,@]Z3("YS0 N:3OF@XX
MYZTO&<9H *2@$9QFEXR1F@!/K1TH!&"<]*"1ZT '6C-+D =:0XXYZT +11QG
M&:08.>>E !THXHR/6C( ZT &:.^:"1@'-+P#C- "?6CI1QGDT$CUH .M&:!C
M!YI"1MSF@"U;S[&P3Q6HCAUR*PLCCFKMI*=^W.: -*BD'2EH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** *UY&6B)'85RL]\UO<,KG&*[%^5(KCO$-NJ.T@XH S9/$<4)8.^
M,]*8OBBW9<>9TKEM00F8&LZ52C%\XSVH [=?%=N48^9TI9/%=N(D;S.IK@.<
M$#O0I,@*9^Z* .^/BVV\Y?WG:@^++<,?WG6O.@S#*]?>GL&&T[J /1%\56^_
M;YE0Q>+("91YG2N#<,&\S<1[4UD<89<X/6@#O_\ A++<P#]YS3!XPMRPS)TK
MAASR/RJ('8&R,YH ] ;QA;*=WF<&E7Q;;^8J^9UKSYTW1*V>,TYE.5?.-HH
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MYL3;SCTH ]#'BVU#G,G:F1^+K=D?]YWK@GP\C8..*A@4F.0;N] 'HH\5V[(
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MN#8,%8!SS0L3?95!?F@#O1XMMWA9EDZ4S_A+[?RUS)SFN"9&$9"FD6,A 6-
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\IXH H31N9<'K43++O4-TK5N+*1WW &F26,C%!M- %*.+$C9^[BH[5/W<I[
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MFU[93U..:T: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG1 YP/RI?L$7H/RH XTV$'G%A$=OTI_V*#808CGMQ78"PB Z#\J/L$1[#\J
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKK/AEXO,UL]E<R<(NU037&_$X@^*\CN* /:O #L^B0EV)/ECK75S2"*)W8X
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
MC?=/TKP7XQ7,\6J0B.1E^7M7O3?=/TKP#XR_\A6'_=H Z/X1W+M$6FD) 3)S
M]*M_$7QY'I]O)96KAG8?>4\BO-?#_B]=#TTI$Q61D*G\JYP3RZ[K(\]L[B>O
MUH U=%L]6\2:J&#S;689-?07A_0!HFDB-GWOC.XU4\#>&[/2]+BFB0>8Z\D5
MUES_ *AOI0!\QZ]>7"^,9%$S >?TS[5[%%*__""*VX[N>?PKQ;7_ /D<Y/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^TZ2.WMD#$<;17844 <]X2TA=*T:"(Q!9%&"<<UT-%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT/:PU/V<-0HHHKG.@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/]X?S- '1^ O FG:YIKS7"$L#7HV@^!-.T.Y::W0AC6/\)?^0))]:]'H 0#
M ]*6BB@ HHHH **** "BBB@ HHHH **1F"J2>U9R:S:/?_8Q,OFX^[WH O\
MEKG.T9^E/I!TI: (_)C)SM'Y4HC4=%'Y5!>WT-C TLSA54<DT6-[%?VRSPN&
M1NA% %A45?N@"D,:DY*@_A3LUFIK5H]Q+")E+1_>'I0!H/$CC#*#]135MXU'
M"+^54[?6;6YN1!'*I<]A6C0 P1JO 4#\*8;:)CDHOY56O]5MM/&9Y53G'-2_
MVA;+$DC2J XR/>@"P$51A0!]*:\,;_>4'\*6*5)D#HP93T(I] $:0QQ_=4#Z
M"I*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ /D&2XEC#0L>G%>O?!C_C]?_KF?Y&N'\=^&WT756PIVR,2*[GX,J5O7R/\
MEF?Y&@"G\9O^0K'_ +G]*T_@RRB67+ ?)W-9WQE1FU6/ _@_I7":#XFO-!9C
M A.1CK0!]6O<11KN:1 /]X5\V_$C44U#63%&=VV3'!J&[\>:QJ,1B574GT:F
M^'O"6JZUJD<\\+E-X))H ]1^%5BT/AU9&&#@_P J\G\:@-XDD!Z>::^D='TN
M/2M*^SH.B_TKYN\<JZZ_,P'20T >L> _"^CWOAJWFN(U,AZ\CTKJ/^$+\/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQJY&0H_B'I5__A(]$]1_WT*\1MO!/B":%7C%QM(!&&-3?\()XCSTN/\ OHT
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M*6&9=K#'%<_X^\(+K]H&BCS(B\8'4T ?/?AHYU>,GU'\Z^K]'_Y!-K_US%>
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&&![5[^&Q,:T?,\JM0E39-111728!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9A11102%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM[1BT445T& 4444 %%07%W#;+NED5?J<5#;:I:W)PDR$^@:G9@7:*0'/2EI
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M53+<PQ'\67J%%%%(Q"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"=TA^:O6>L3V2[8P"/>LW-%3%N+O$J24E9FG)K,\LRRE1N4Y%+>:W<7L7ER
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M]Q!!Z4M>0^&_&=R;]8+AV8,V!FO6XW#H&'<5#5CR:]"5&7+(?1112, HHHH
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MK3PO<ZC>+(49%#9!Q7JFCV)T^Q6 MNQWK&=KGB9M.$I+EW-&BBBH/&"BBB@
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M HHHH **** "BJEWJ5K8KNN)0@]ZK6NOZ;>2B*"Y5W/0"G9A<OSSQP1EW8
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MH.)UE%,CE25 R'(/>G9%<Q8M%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 E+24M !1110 4444 %%%%
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M$DT[,****!!7F_Q#_P"/BT^O^->D5YO\0_\ CXM/K_C5T_B.W+_XZ.G\'_\
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MZ5G?#RTGM8[GSHRN3QFHO^[.=2OA7=G>4445D>>%%%% !1110 4444 %%%%
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MP?9Z';)A TF.2R\UU   P!0 V.-8HPBC"CI3Z** "F.H92#3Z* .;O[0PR9
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MY;G4I;JZ*O"IW(OI794C*&4J>XJE)H35SRV[B;6/%,%C(1]E*X9#WQBM?7-
MTK3;%'BC594&5Y'6C7]"N[74AJ>G1F29!PO:L*:VUK5)%FU6%H(H3NX/6MEK
M9IDG2:%KWV3PP;F[8E@V .]/\,ZEJ&IW5Q([MY(;Y01VKD+B=-0N?LZMMTX=
M77UK<L_$S6,:Q6<:-#&,.^.<42CIH"9Z)2URDOC.TCT^.<2KO9L8K9T[4OM4
M(>3 W#*UBXM%71I44@((R*6I&%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 )2TE+0 4444 %%%% !1110 4444 9VL
MF9=/F:!L,$)!KB?"FO7QO/(O92WS'^=>A3QB6%T/\0Q7G6IZ?)9:MB!?>JBK
MG9A81J7C(](1@Z!AT-#L%0DGH*P=)UN!H!%-( Z#!IFMZW&EOY=LX:4GI2MJ
M9>PGS\MBE?75YJ-R8[:4)&IPVZJ5UX-@OHRSR0M,>IW"LC7]:?1[)D7 DG7-
M<GIOBO4('5B2?JU7KT/1HT:L]*6EC:N?A]J$+DK(A7/&*YC6M.GTD?O?ITKU
M#1/&\%Q$%O2B'ITKD_B%J%EJD2I;,I*MG@4[RV9T4ZV+C+V<T4/AR/M'B"!V
M!.#_ %KW=0 H KR/X7Z:3MNBOW6Q7KM9L\O&SYJI1U2W^TV3QXSQ7@6H0/:Z
MQ<  CY_2OHI@"I!KS_Q5X4M2DEYN(9?F.*<6;Y;B(TIVGLS@(I91'G=5>:ZD
M )W8Q3#(&DVJ?EJGJD@11'G&X5OT/J)2C&/-8GL=4EBOXV#\;QG\Z]ZTC4X+
MVQC(D7(4 _-[5\W6\94 J2:Z+3=<NM/P5=CCL3635SR<1@?K*YEHSTOQ;X<T
M^YMIIP(Q(5))+"O(;" V]TR*1C<>GUK2U?Q7=WL?ELQ&>.#6?IH(7<W4G-.*
MU+P.%G3E:3N=/%:QO 6(&<5@:C$ 2*W[&*ZN%V0INS69K>GWMFY\Z+:*MM'6
MJBIR:G+<S+6]2UC< '?V-95V\EY=>9(<L3UKJ;7PK?30B<PGRR,YK'OK+[/>
M-%Z5)S3C"I*R=V>B> =9M])M3;SL-TAXYKU"WN$N8A(C @^AKYI59$PRR,,>
MAKT[P!XF\TBRF?[B\$FHE$\K&X"5-<YZ;135.0".].J#R@KS;XC@J;=@>1_]
M>O2:\V^(@S-:CU/^-:4_B.W+_P".CG-)\4ZA8P+$GF%!Z*:]&\*ZS/JD+M*'
M!7^\"*H^%-$M9M)CD=%)/J*ZNULXK0$1*!GT%.I*+T2-L;7I2;C&.I9HHS29
MK(\PBFM8;@8D7-0?V5:?\\ZNT47&I-$$5I##]Q<5-BEHH!NY7GLX+C_6)FF0
MZ=;0-F./!JW11<.9VL,>-73:PR*JC2K17WB/YJNT4 FUL5C86[.&*<CI3Y+6
M*5-C+E14U% 794BTZVA.4CP:<MC;K(7"?,>]6:*+AS,CE@CF3:XR*;#;109\
MM<9J;-% 7>P4444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHS0 R10Z$'N*XZ2P
MC@OS$Z@^<U=DS!5)-<I=3I>ZU!Y)SY;8:JB=.&;NQTGAB;?B*4+'_=J>YTY-
M)T:=T7YP,Y%=&!45S MS T3_ '6ZTKD.O.2LV?-.K7#2:U/(^<D]Z1)QCK7>
M^,_ BP^9>6ZL2>37F4:N&91U#$5:9[^#Q*<4HFL+H@8!ZU&SX(;WJ**/ RU1
M73\<4V]#OJ2?(W(^AO"DZRZ/;@,#A!6_7E?PPUPSI+!(WW>!^E>IUFSY'$4^
M2;0CG"DUXAXZOY)-<F@9CM4\#\:]P(R,5X=\0+;R==DF/"LX&?QIQW.C+Y*-
M9,QK>UGNXBD2,<]P*P9].O;:]??;R]>NVO1]"U_1M'MU#R#>>?F K3F\3Z#J
M 8R.@/;"BJD[GJ8C$U:E1<D=$>7QI<8_U+_E4=SYT8^>)U![D5V5WK%A%<;H
M2IC]<"NBOM%L-<\._:(!F2./=P*05<94II*:M<\JM -P;O74Z3$%<2.NX#FN
M8M;>2"Y*.,$&NOL)XXX"">U:1V.^$Y.A>/4Z!?%D-F?)2%@#\M5-0@>RN8M3
M@C8IC>P45S5],//#CLP->F^%98=;T=X9 " -O2IDDCS\=2A0C&:6^YYUXC\8
M?VM:I;K&R,K<YK!0X3=6WXVT!=,U$M$IVLX _.HK;PYJ$T:E(L@BB-C? SIQ
MA>+LCFIS-+)A2>3P*]G^%]K<0:(#-D?-T(KD[+PD]FPN=0C*(OS"NBMO'5AI
MTBV\4BB$<'@5,M3BQUZND-3TNBJ6G:C#J-LDL3;@PS5VH/%:MH%%%% @HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH YOQ#X8BU9-T859@<[C7-+X7\1Q@P+J6$/2O2:3'L*M5&E831S?A_P -
M#2RTLY#S/]YO4UTE+2$5+;;NQK0S[K6+6TF6.65%+'')JU'=03(3'*C<=C7E
M_C[2G.K61WNJN_.&/O5:XO=3\,1+<0@M:YP&<UJJ2:5F3S:FWK?DOXEM%NUR
MI;@FNBU!K'3;3S+8HN[C@]:XF?6=.\0I&\TQ%X!\@7UJY::%K%\(XIXS]E4@
MALG-4XZ*XKEF'P^GB M<QJ(V4XYKLM*TU;"U2)L%E')J73;!+"V6-!VYJ[64
MIMZ%)!1114#"BDJCJFJVVEVS37#[0HS0!:GN8K>,O(ZJ .YKROQG\1A'OL[
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MB'_Q\6GU_P :](KS?XA_\?%I]?\ &KI_$=>7_P ='3>#_P#D!QUT5<]X/_Y
M<==#4RW,,1_%EZGFOB[Q'>:?J4D4,C  X %8Z^(=<*;P9B/9:7QQ_P C ?\
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M.1N4XJ73:5S&IA)1AS7N=O11169R!1110 4444 %%%% !1110 4444 %%%%
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M*33](UCQQ?BXG!,+'WKV?PYX5M-$M55(_P!YCYLCO0!A^$/A_;:1$DMRJRR
M<DCFN\1%C4*HP!T%/'%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !114$MU%"ZJ[ $].:!I
M-[$]%-5PPR#FG4""BBB@ HHHH *0C(P:6B@#B?%_@BWUJ!I(U5)0.#CFO*;>
M[UGP1JFR0326ZD <<5]%D9K#U_PW9ZW:M'-'DX)&!WH I>&?&%GK=LN9$23
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M1>>:SG:YXF:NG*I[NYM5YO\ $/\ X^+3Z_XUWUO?P7)Q&W-<#\0O^/BT^O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8K--)C=,=U=%4O<XZS7.[!1112,@HHHH **** "BBB@ HHHH **** "BBB@
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MX4444 %%%% "8J*2UAE^_&I/J14U% TVMBG_ &;;?\\D_*GI8VR=(4_*K-%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<+BIK6TBM(5CA0*H&,"IZ "BBB@ HHHH **** "BBB@ HHHH AN;B.VB+R'
M S7FOBGQB9=]O:N"GJ.M=OXAM)KNP=8G*D*?QKQ2\L+F&[:-D8L2>U<F)J2B
MK(]_)L+1J-SF]5T*KR//*2Q)9CW-6FTF[6T^TF/]WZUU_A;P>\[">X'R]<,*
M] FT2TDL3;B)0N.E84\-*2NST<5F].C-0AKW/!4=HI P)!'I7H_@[Q2-J6EP
M^ !P3UKE_$OA^73+IF"DHQR,#I6%!.]O*'1B"#6<92HS.RM2I8Z@?1:.'0,.
MA&13JX?PAXG6[A$,S_-T&37;A@1D'(KTX34U='Q6(P\Z%1PD+1115F 4444
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MC8="* .PM;A+JW65#E6Z&IZJ:=:FRLT@)SMJW0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 E+24M !1110 4444
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MD^!M,N[<-),7"L. :RPLY)\IW9SAZ4J?M;V?YGH%+2"EKT#Y,**** "BBB@
MHHHH **** "BBB@ HHHH *YKQ=>7-K8?N/X@0:Z6H+FUBN8BDBA@1WJ9)M61
MK0G&G44I*Z1\]7,LDTS-)G=GO6WX:T"35+H$I\BGGBNKU?P,);[?$2%/H*['
M1M)BTZT1%0;L<G%<-/#/G]X^GQ6;TU07LMW^!/ING1:?:K#$N *O445WI6T/
ME92<G=A1113)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG_CS6JOA'_CT/^]5KQ3_ ,>:U5\(?\>A_P!ZO.E_OB]#OC_NK]3JJ***]$X
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MLQ98^IR:U_#_ (:M[.X4Q1X;/-<-;%4[M1U;-(QOJ>C>'(V6P4MUP*VZJV,
M@MU4#' JU771CR02.A!1116@PHHHH **** "BBB@ HI,B@D>M "T4FX>HHSG
MI0 M%%)D4 +1129]Z %HI,T9'K0 8JA?:1:WP_>Q(Q]2*OT9% TVG='GNN^
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MKD6B:2(5$CCYAZUT &*15"C Z4ZOH*5*-*/+$L****T **** "BBB@ HHHH
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M!/#&H+<Y%:8'%:132.?#PE"/O.XM%%%4;A1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ35D'(R*::>PFFMPP/048&>E+13$)CVI:** $P/2@@'M2T4 )@>@HP/2EHH
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MV#2QE5PV<UCZKXS6SRL,08#TJMI7Q 6X?;+&$&>IJJ3H0T@:U,+.<E4FKL]
MP,]*6J-EJMM>H#'*I)["KO6NM-/8AIK<JWUVMK'DGD]*PE@NM5ES)_J32:C*
M;R_6%3]QN:Z.")8HE"@#BL+.I*SV1M?V<;K<R&T.QMK=G?=@#)YK!CU:UL;W
M,#'RNG-=AJ$)GLI8P<$KBN%30@[?99)=C YW&HJQ4;<J+I2<K\S._M9UN+=)
M%.<C-35E:+8O90%&D+CMFM6NJ-[:G,]] HHHIB"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!*6DI: "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;\VAF^'780%"?XJZ&L/P_"RVI9A@EJW*SH7Y%<JM\;"BBBMC,**** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(?PYKQF*'[..RBNWL_&VFK;(NU@0,'FO.AA(<[<V>C/%SY%R(TM%\.P:7&"
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW+Y5NVY !CGBNY\$:W)>0^45)&[&:]# 5$Y6L<6/IOE4KG=4445ZYY 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:)=-.(4W'VK1  &!VK:AAHTC*OB95MQ:***Z3E"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M86BANM6Z0* ,"EK1*RL0W=A1113$%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2W5$7&1DUFZ/8X_TJ0?/(.:VQTHIIOWF.HU\*%HHHK4R"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D(!
M&",TM% &=<:1;3MN,2YJ,:':C_EDM:M%3R1[%<\NYEMHMLRX\M:FL]+M[(L8
MHU4GJ15ZBA0BMD#DWNPHHHJB0HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH 2EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** *]Q9PW*XDC#?6J T*U!_P!4M:]%2X1>Z*4I+9F8-%MATB6FKH5HLRR>
M4N16K125.*Z!SR[C4144*HP!3J**LD**** "BBB@ HHHH **** "BBB@ HHH
LH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g23ode3tb50n000030.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g23ode3tb50n000030.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )8 WX# 2(  A$! Q$!_\0
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M1JQ Z>]>J_%HEO"+,>IB4G_OFI:2EH6I-P=SE_@=_K;O_>']*M?&_P#U,?\
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M)JPT[H****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;3_?J"S9[44@Z"EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5C:U_P ?-I_OULUC:U_Q\VG^
M_0!L#H*6D'04M !1110 4456NI9(Q\E %FBLC[7=?Y%0RZI/"0&[G'2@#=HK
M'%Y=$ ^OM4L%S<O*H;H>O% &G1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 52O4G8#RG*U=HH QO)OO\ GL:JR3WD=XEN93EQUKHZQKO_ )#]O]*
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MH **** "BBB@ HHHH *QKO\ Y#]O]/\ "MFL:[_Y#]O]/\* -FBBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *QM:_P"/FT_WZV:QM:_X^;3_ 'Z -@=!2T@Z
M"EH *S]8_P"/&3_=-:%9VL?\>,G^Z: /,3]YOJ:*#]YOJ:*8!1110 4444 %
M=?X2ZBN0KK_"744 =A1112 **** "BBB@ HHHH **** "BBB@ HHHH ****
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MA6S6-=_\A^W^G^% &S1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MI)'&VSH/^$PUC_G]F_.F_P#"7:OG/VR;/UK!HHL@NS?_ .$PUC_G]F_,4?\
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M HHHH **** "BBB@ HHHH **** "BBB@ K*\1?\ ('E^E:M97B+_ ) \OTH
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M4445SG2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(EMI7((P2"Q%?2-HK+:0JWW@@!K.::W-:;36A-1114&@4444 %%%% !1110
M4444 %8VM?\ 'S:?[];-8VM?\?-I_OT ; Z"EI!T%+0 4444 %%%% !1110
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M% !1110 5SGC?_D6IZZ.N<\;_P#(M3TUN)['R7J7_(2N/]\U5JUJ7_(2N/\
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M3-<IXG\"^'VTZ>Y%NB3(A96)'6LSX57ER;/[,[EHPYP>U#2:NA)M.S._UO\
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M4X2=&/L:L5Y!>^&O&&DQ&ZM[J(+'\S#V'XUTG@/QA)K$0M+UB;P'G/%#CI=
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MM97B+_D#R_2@#Y#UO_D-WG_70UGUH:W_ ,AN\_ZZ&L^NQ;'"]PHHHH ****
M%7[P^M?1WP=_Y!,WU%?.*_>'UKZ.^#O_ ""9OJ*SJ[&M'<]2HHHKG.D****
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M%+0 4444 %%%% !1110 4444 %%%% !1110 5E>(O^0/+]*U:RO$7_('E^E
M'R'K?_(;O/\ KH:SZT-;_P"0W>?]=#6?78MCA>X4444 %%%% "K]X?6OH[X.
M_P#()F^HKYQ7[P^M?1WP=_Y!,WU%9U=C6CN>I4445SG2%%%% !1110 4444
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M.B[6A)+'S#GDTT[LF2LC"\7:5XBFT*XFU#4%=8T^Z>IKJO!5C)=?#A(5X:2
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MZ44#I10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%03WD%L?WK[:
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M>8_SK,+/N/+=:-S^K4P-/^QO^GF/\Z/[&_Z>8_SK,W/ZM1N?U;\Z -/^QO\
MIYC_ #H_L?\ Z>8_SK,W/ZM1N?U:@#2.C<?\?,?YUU7ANU^S0!=X;W%<&2^.
MK5VGA'/V09SU[T =31112 **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ K&UK_CYM/\ ?K9K&UK_ (^;3_?H V!T%+2#H*6@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *KW=JMW%L8X%6** .>/A2V)SYAJO/X?T^V.)9BM=34
M4MM#/_K$#?6@#E/[+TC_ )^?TJHUEIPN2@G^3UKL/[-L_P#G@M)_9=EG/D+0
M!S8TS2,?\?/Z5)%HNF3-MCN"3]*Z'^S;/_G@M/CLK>)LI$ : ,;_ (1.V_YZ
M&M/3]-CT^/8AR*O44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %8VM?\?-I_OULUC:U_Q\VG^_0!L#H*6D'04M !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !6-K7_'S:?[];-8VM?\?-
MI_OT ; Z"EI!T%+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1F>)3
M@RH#[L*R_$VL#0M#FOSC]WZUY_8Z+J7B@2W\EQ/"I^:((QPU4E?4ERL['JZL
MK#*L"/8TM>;^%-=N[+7Y]$OL[(1\KL<DFO1P<@$=Z35AIW%K&UK_ (^+3_?K
M9K&UK_CXM/\ ?I#-@=!2T@Z"EH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH*W/$'BRPBTV]M\MYGED"I:ULBE+2[.I@N8+E=T,JR+ZJ<U+7DOPZ\56EKI
MCN&<L7->HV5]%?1>9%G;[TFK,<9719HHHI%!1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %5[Y-]A<(.K1,/T-6*0@$$'H: /(?A],ND
M:Y+IDQVR2S.X!]-Q_P :]>SQFN#\5^");V]&I:=<?9IE&!L'-8GD>)?*^R^=
M<9QM\SBK=I:F:;CH=7=^,HXM:_LZ(JSJP5AZ5R?C [O%B-ZA36[X4\$/873Z
MAJ$_VF:0?Q#D&J?C;PM>:EJ7VFUD9",8VBFK)B=VM3T"P_Y!]O\ ]<Q_*O/?
MB9J,7G6-DK R2MMQ^=9Z:5XE$2Q+>W"@# -:.B?#^Z:_6^U6^-T5;<BN/N_I
M222=QMMJUCG=6L]<C\/6=A;6YVPRAN#UZ?X5'KFN:W'X::T?3HXHN,D#O^5>
MT&T@88,8(K$\3Z#%J.C26\485B>H%-274'!G&?#K5]2F0P26RB)C@M71^(/!
MUM<6]Y=F9PQ0G%7O"NAC2K9E9?F]:Z)T61&1QE6&"*EO70:CI9GC7@KPG;WL
MAWRL,$]*]8TK2X]*MS%&Q8$YYJ6VTZTLSFW@6/Z5:HE*XXQ2"BBBI*"BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
2*** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g23ode3tb50n000014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g23ode3tb50n000014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,'!$ # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** *>H0":W;CYJY>1"CE3VKLR,C!KF]4MO*E+XX8UO2ET./%4].9&>JEFP*
MZC3K<0PAL<L*Q]+MO,G5B/EKI%&U0!VHJRZ!A:?VF+1116!V!1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 8#O>S:O+#&X" <"M&UAN4/[U@:J6O_(=F^G^-;- !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 5;_P#U-1Z9_JF^M/O_ /4TS3/]4WUH
M O4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^/SKP$>+O&[C<(4Y^O\ A0?%?C@\>2GZ_P"%'LV/VB/?/M,/_/5?SH^TP_\
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MCTK,U,&ZU29T -JPYK0THY@)Z9-/OE'D]*9IG^J;ZT 7Z*** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH QK7_D.S?3_&MFN9-K//KLWES%./\ &M>T
MM+B$YDF+T 7Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"I?_P"IIFF?ZIOK3[__
M %-,TS_5-]: +U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M HHHH **9)*D2[I&"KZFJ1UO3 ^TWD6[TS0!H45'%/%.@>)PRGN*DH ****
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MQ'\07]JC65A)LDSU-<0G@SQ=/ M]]J@^8;A\W_UZ['QMID/B:S-WI4_G2DY
M2N'QXSBC^R+8W&P#:#FM([:&<M]3KOAUK^J+XADT+49@YA3)V]._^%>N5Y7\
M./"5Y8ZHVKWRNL\B896_'_&O5*SG:^AI"]M0HHK*\1ZB=*T*YO%QF-<\U)9?
M>ZMXSA[B)3Z%P*;]OL_^?N#_ +^"OF6^UKQ!XHU.4V(D.><(Y%1_\(]XT/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1IZ*!^E<%X:\7:1+K%Q801&*2,X)8]:]!!RH([BHFVRZ:26@M%%%0:!1110
M4444 %%%% !1110 5%/#YT93<5SW%2T4 8-WI&Q WGN<'UJ_I0Q 1Z&I+_\
MU-,TS_5-]: +U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7U22PM%;OM.#]:]!\+Z:NFZ1'%M^;Z5Q>F:?%=:A#(5!V-FO3T4*@ '&*]K
MS]K'F>YV8C$)T(TH]-QU%%%=YYX4444 %%%% "'IQ6+<:M<0RLNT8SQ6W6-J
M]KN =1TZUI3M>S,:W,HWB5SKDV/NBH(I7NKQ&([U1K9T:#=ER.AK:2C%71QP
ME.I))LVHQM0"GT45RGI!1110!5U&X%KI\\Y_@3-?/Y5O&GQ"P26CQV/'6O4/
MB5KXTG2#"#\TZ%1BN6^$.AL8UU61?G+'J*TCHKF4]9)'K.FVHL]/@MP,>6F*
MM445F:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 8]K_P AV;Z?XUL5CVO_ "'9OI_C6Q0 4444 %%%
M% !1110 4444 %>&^./'5X?$*:;;,/DE"D U[@^=IQ7SF1;_ /"R[PW>W;YP
MQNK2FD9U&SI]?\;7.@>'S;HP^U, P!/M7GJV?B?Q*QN(E8[N>&-=9\4;&)[^
M.\A8&%8P"!TZ"O3O![Z+_P (]9^68!)Y?SXZU5^571%N:5F>#Y\2^$W6>8$*
MIYRQKW/X>^*SXETYBS O$ &Q5/XA/HQT)P?),A/XUB_!NPDMTU!R"J.V5^G%
M*3YHW'%.,K'K5%%%9&QPGQ68KX6R/[Q_I7(_!2"*2WO97QN$IQGZUU_Q4B>7
MPP%1<G=T_*O"]"UW5?#OGQP6[D.V>#6L5>-C&;M.Y]6;T_O+^=(QC889E/XU
M\W?\+#UW_GVD_.C_ (6'KG_/M)^=+V;'[5$&K 1?$Q_+[W(Z5]+6W_'K#_N+
M_*OE73#?:CXJ@NI86!>8$YKZJMO^/6'_ '!_*G4Z"I=26BBBLC8**** "BBB
M@ HHHH **** "HIW9(R5ZU+2$ C!H P[J[G,8!]:O:7S V?6G7T:>3]T4W3/
M]4WUH OT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#'M?\ D.S?3_&MBL>U_P"0[-]/\:V* "BBB@ HHHH **** "BB
MB@ HHHH \P\>_#J\\4:O]K@:,+MQ\U<@?@AJ>.'A_3_&O<;_ %6STR(RW<HC
M0=2:H67B[1=0E\JVO%=\XP*M3DEH9N$6]3YV\3?#/4_#=O\ :[AXS$#C"_\
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M7F?AB.1AXAB&3$(B$_(52LU<G5.QN?"B%;K1FO9!F02D9/U-+\1[9/[5TN<
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M7"&[D5FSG[3J*KU%;T*[(E7TK66D4CGI^]4<A]%%%9'0%<=\0M973O#US'N
M=TXKL"<*2>PS7AOQ4U4ZGKEI86S9#?*P'-5!79$W9%CX1:*TU\=7G!;S4_B^
MG_UZ]J' P.U<QX#TL:9X7M8BN'4<UU%$G=C@K(****DH**** "BBB@ HHHH
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M=Z[WXLZ^+71OLD38E+XX-1_"31#:V,]Q.GS2G<"16D=(W,I>]*QZ;%&L2!%
M 'I3Z**S-0HHHH **** "BBB@ HHHH **** "BBB@ HJM+J%G ^R6YC1O1FJ
M2*>&<9BD5Q_LG- $M%137,-N 99%0$X&XXJ16#*&4Y!Z&@!:*** "BHI;F"
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M3Z"K6G> ])TZ0/$FXC^\M=313YF+E1'%#'"@6-%4#T&*DHHI#"BBB@ HHHH
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M*[$W9'D/BV5_$OCY[2(EH@0W7WKW71+1+/2;:)5 (C /%>-_"K1Y=0UH:Q<
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M%QXMU*Q2VT3[.(Y02Z#_ .O7O>CVS6NGQQL23M'7Z432'3;+]%%%9F@4444
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M8"X!+,>!7L>EW$MQ9J\R;7P,BLY(N+OH7:***DL**** "BBB@ HHHH ****
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M#D&H;B\@MAF9PHH GHJK!J%M<G$4H:K5 !1110 4444 %%%% !1110 4444
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MN,K*Q$H7=T>*>%M(UGQ#K9N[YFVY# .N*]OB3RX8T_NJ!2)!%%_JXD3_ '5
MJ2E*5QQCRC'C63AAG%*B*@PHP*=14E!1110 4444 %%%% !1110 4444 %,D
MB25"KC(-/HH R;S3+5(P1&,YJ?2QB%@.QJ2__P!33-,_U3?6@"]1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%(3A2?04
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MRBBBLC4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH J7_\
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M]9"0&'8FO:@ !Q6;H6EQ:5IL<,2XRH)^N*TZ4G=CC&R"BBBI*"BBB@ HHHH
M**** "BL_5+Q[2,,G4USQ\1W6>_Y5RU<73I2Y9#2N=C5:]NEM("[5RW_  D=
MUZG\JH:EK<]Y%Y3-QFN>IF5-1?+N/E9UFDZDMZ),\8.!6K7FFGZC+9/E#C)K
M9'B2Y(R"?RK/#YC#DM/<'$[*BN._X2.Z_P!K\JTM(U::\E99,\>U=5/'4IRY
M4)Q9OU!>L4LY6!P0M3U6U#_CPF_W:[!'F^@ZW>7'CV2T>9S$$)VD\4Z\UN[3
MQ;:VXF?RVDP165X:_P"2ER_]<S_6FZO.EMXRM99#A5ER:UMJ8W=CV1G5!EB
M/>A9$<95@1[5YGK'BF_UG5CINBO\Z,"V>F,__6KHM1N;W1_#DCH?]*V Y]ZC
ME-.8Z62\MHCAYE4^YI\<\4PS&X8>U>6V6G^)-8MQ=SR)AQD9.*JZ9K>M:'XS
MMM'O9E,,@W$*?I_C3Y1<YZZTJ)]Y@*8+J OL$BEO2O+_ (@^)M1L)K..Q?#3
MOM%6/#]AXH^VI?7[IY.W-'+I<.?6QZ6\J1KEV 'J:CCN[>5ML<JL?05Y5<>(
M=;\1:K)8Z7(-EN^R7-.U2U\3^'X5NXG4+GGZ4<H<YZU4$EY;Q-MDF53Z&N-@
M\8&?PG=WJ,3/;I\Q]ZY?2'USQ/ +_P Z/8XRH)YS24>X.?8]>CECE&8W##VI
M]>;:!<>(-/UJ*RO'5H7/\/I7I-)JQ2=PHHHI#"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#'M?\ D.S?3_&MBL>U_P"0[-]/\:V*
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MEZ=2\2PZ$ARLR9Q^7^->B37D":/+<1,H01DK@^U>'6SWVN>)?[6A21O)=D!
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MOF@U1E&G2MYF%) Z5;3L9IKF/<Z*;&V^-6QC< <4ZL3<**** "BBB@ HHHH
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MS7,^%(DEU-0Z@@$=:]XMHTBMT"*%&T=*[,/1C;R/(S&NL)^[HJU^I'964-E
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** ,>U_Y#LWT_QK8K&M?^0[-]/\:V: "B
MBL;6/$=AHX*W$P23&0#0%S9HKD[/QUIDTZQR7"@N<)[UU2.LBAE.0:;30DTQ
MU%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !5;4)3!I\\HZHA-6:H:USHMV!_SS- ,\UT2SC\2>)Q=W:^9'R"#]:N>,
M_#]KIMS9W=C$(O*.YL?C3?AU\LQ5OO;S_.MWQ\1_9^.Y7BM+^\9)>[<U_"NH
M-J6B17#')-;=<7X'^TQ^#H/(7+Y[UN>;J_\ SR6H>YI'8NW_ /J:9IG^J;ZU
MF7DNJ^5\T0Q3+"751&VR)2,T#.DHK&\[6/\ GDM'G:O_ ,\EI ;-%8_FZO\
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MY+2>=J__ #R6@#9HK&\[6/\ GDM'G:Q_SR6@#9HK&\[5_P#GDM+YVK_\\EH
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M7/\ Q]?C6O69<0LUQD#C- &DOW%^E+2+]T?2EH **** "BBB@ HHHH ****
M"BBB@ K+US_CU3_?%:E9VKQ-+;H%ZAJ +MO_ ,>\?^[4E1PC$" ]A4E !111
M0 4444 %%%% !1110 4444 %9VM?\>!^M:-4=6C:6R*KUS0!/9_\><7^[4]0
MVJE;6-3U J:@ HHHH **** "BBB@ HHHH **** "H+O_ (]VJ>H;D%H& H I
MZ=_K&K2JA8QLCL35^@ HHHH **** "BBB@ HHHH **** "BBB@#&M?\ D.S?
M3_&MFLJWA==8ED(^4BM6@!DB>9$R'^(8KRO6;>[\.^,X=0@MWE@5<E5'':O5
MZAN+6*ZC*2*"#[4T[$R5SS#7O$U[KAMK:&PE59#M<@=*[KPMI/\ 8^D+;^^:
MN6VD6MJY:-!D^HJ_3;TL@4=;L****DH**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BD)P"3VJM;7\%TSK&ZD
MJ<$;J +) /6@ #H*6B@ HHHH **** "BBB@ HHHH **** "BBL\ZQ:K<>2S@
M-G')H T*0*%Z#&: 01D'-+0 4444 %%%% !1110 4444 %%%% !116;JVM6V
MCB(W&<2-@4 :5(% .0,9J*VN8KJ(21,&4^AS4U !1110 4444 %%%% !1110
M 4444 %%%5KZ]CL8#+)G:/2@"S2%1GI63H_B&RUI9#;L 4;:03S6O0 4444
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M7^S[_P R2%WV1;5.%I_%J)7CHSUJBHX)A/$KKT(J2H- HHHH **** "BBB@
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M "FLBNI5E!![$4ZB@#&M?#EK:7<EQ$2K.V2 ,5LT44!8**** "BBB@ HHHH
M**** /)_B%9-K%^]G$6$BMN&TX/6H/#.NZAX6N(K#5!LBDZ%CDX_&O49-*M9
M;HW#1*9#U-9GB/PQ;ZS9, BK.%PC^E6I*UF9N+O="ZKI%AXITP,I&TC*LHY-
M<)'I7BCPQ*T>D6S7,1).9&)_QJ7P_JNH^&M6.FW:2S1+A5;'%>J1OYD2/C&X
M T; DI:GGF@^']2U*_-YK4)BDSN !XS7HB@*JKZ#%+14MW+2L%%%%(84444
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MX=6TN;J54,<9F8@=CR:])H;:81BFKLJ:=I\.G6PAA&%JW114&@4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% "$9&#7(^*?!T>L(TUJ5ANNOF#K77T4T[":3W/)8)M>T<-:.9Y\\*X'2N
M@\)>')XM5?6[IR99EP0W7O\ XUW!C0G)13^%*  ,  4W(2B+1114E!1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*-DNN3S42C8J,U(U:*:TB)]YU7ZG%-$\+' E0_1A4EDE%'6FM(B?>=5^IQ0
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8* "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g23ode3tb50n000028.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g23ode3tb50n000028.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +< GX# 2(  A$! Q$!_\0
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M]N-S)D12%03V&:KIX<_LZ]N+D7<C QD;">.AKC]'O9+70=;\LD-YAP1]:$M
M<G<]6.I6PE\O>N?7=5M65QE2"/8UXUI\5W=Z3'/YTF_&>O6N\\"W%Y<:9+]L
M0JRO@9/4<TG&P*5SJJ***DL**** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI%3U6L/^/*/Z59J#0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV@H?,-4I(AQ96\,:9*T,<UR#N0#;NJ*W\,!O$U_=S#<DR$ $=.M=BBA%"J.
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4 %%%% "'[I^E9^G?ZV;ZUH'[I^E9^G?ZV;ZT :-%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 (?NGZ5GZ=_K9OK6@?NGZ5GZ=_K9OK0!HT444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 A^Z?I6?IW^MF^M:!^Z?I6?IW^MF^M &C1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !5:Y%P?]00*LT4 8DTNHQ$ N.3BKEL+[>IE8%>],O_ +Z_[U:"?<7Z4 .H
MHHH **** "BBB@ HJI?:C;:=%YES)L7UK(/C?00<?;!Q3LQ71T5%9NFZ[I^K
M,RV<XD*]:TJ0PHHHH 0D 9)P*8+B$G FCSZ;A5751.]C(D"Y9EXKSK48Y-'M
M8;EYY/MC.%:,L<#D4TKDMV/42ZJ,LP ]2:19HG.$D1C[,#7#ZOJT\D^GZ;]U
M;F,98'GI5>\27P>RW(E>17;;\[$T^4.8] :6-/OR*OU.*59$895U(]C7 N\O
MB:_AQ(Z1%<,4.*9IFK3:?>:A8R,2D*D1LQY-'*',=^9X0<&5 ?0L*>"",@Y'
MM7F<%K<ZGI4VJ-+(LR.0J!C@CFNMT'5UEM1#*V&C&#2:!2N;Y^Z?I6?IW^MF
M^M6#>P8/SU7TTAI)B.A-(HT:*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,V_^^O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M HHHH **** $/W3]*S]._P!;-]:T#]T_2L_3O];-]: -&BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH ***:[A%+$\"@".YN%MXB[G'I7.P1RZM?"5\A$.,=C2WT\FIWAM8B=JG.>
MU;UG:I:PA5&"1S0!1NX(X]BA!PWI6J@ C7 [5GW_ -]?]ZM%/N+]* %HHHH
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M@MX[="L8P"<UBZ!XHL]>D=+:57*C)VUOU+T+33"BBBD,**** "BBB@ HHHH
M**** $/W3]*S]._ULWUK0/W3]*S]._ULWUH T:*** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *#THK-U2_6VBV@_
M,W H I:Q?,[&T@/[P]*NZ58+;1;R/G<?-5+1[!G;[3/G?G@&M_H,"@ HHHH
M*3('4TM5KFV:?I(5^E %6_(WKR/O5HH1L7D=*RVT9GZW#5/;V#0R!C,S =C0
M!?HHHH **** "BBB@#R7XIV9F$'VD@V[3 8_$4MEX)\%S6L;-!%N*@G,B]<4
MWXK1SW:00,"L9E ##ZBLZU^%CS6\<BZE=#<H. YK5/W=S%_%L>@^%- T/2)I
M&TI$5F'S;6!_E75UQ7@KPB_AR>5VNIIMXQB1B:[6LY;FD=@HHHI%!1110 44
M44 %%%% !1110 A^Z?I6?IW^MF^M:!^Z?I6?IW^MF^M &C1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !114;SQQGYFQ0!)14'VR#^_
M3H[B.0X1LF@"6BBFR.(T+'L,T 0W=TEK TC'IVK M8)-4O6EEYB!RH-)<S/J
MM\(H^8>C$5T-I;+;0*BCH.M $J*$4*.PIU%% !1110 4444 %%%% !1110 4
M444 %%%% 'G'Q'T*_P!6MHQ:S;"C[@3]:XJ.P\9Q($36@% P!_DUVOQ%\37^
MG0I#IT222L^W#>Y^E<<EIX_F02+ID>&&X<GO^%:QO8QE:YW/@"+7([B;^U;[
M[0NWY1Z5W]<#X!M_$4-Q,=9M5A7'RX/_ -:N^J);FD-@HHHJ2@HHHH ****
M"BBB@ HHHH 0_=/TK/T[_6S?6M _=/TK/T[_ %L_UH T:*** "BBB@ HHHH
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M'0FI*-*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHDB2#*G(I]>:^ ==O;KQ#?:9=S>9]G& 1TKTJI:LRT[H****0PHHHH ****
M"BBB@ HHHH 0_=/TK/T[_6S?6M _=/TK/T[_ %LWUH T:*** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\-ZDYB:W?+&(8R>]#0TSJ#]T_2L_3O\ 6S_6I#>'!^6HM,.7F/J:DHTJ***
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MSCBM&99G?9D>YQ7#-I?C?[.=0&I?+]X#'.#^-='\3]-NU6&\MHO,VRAF!Z
MBL\_%.%=,%MB'ST4+MVCL*UCMH8RWU.E^'WBB?59)-/NV9KB!?G)KOZ\J^&6
MGW3:W>ZM/'L2Y&5QTKU6HEN7"]M0HHHJ2PHHHH **** "BBB@ HHHH 0_=/T
MK/T[_6S?6M _=/TK/T[_ %LWUH T:*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBF2RK
M#&SL< "@#E?%;OL9<_+7'5V-Z7UJY,4:@P_WA5*+PX#<!&W8SS3$:?A5I/(5
M3G;BNGJI86,=C;K$G;O5ND,**** "BBB@ HHHH **** "BBB@ HHHH ****
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MMF^M &C1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1110 4444 %%%% !1110 4444 %%%% !7#?$J9HM N&4X(2NYKA/B8A?P_<
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 (?NGZ5GZ=_K9OK6@?NGZ5GZ
M=_K9OK0!HT444 %%%% !1110 4444 %%&0.M4;W5;:R4F5P,>] %TD 9)Q5.
MZU*WMD),BDCMFN%UWXA0VFY8W)'M7'G5-;\1RYTS/S?W@>E4HLER2.]U7QE!
MAD$JQM]:\_N/%.^_<.-RD_>KH]*^'%Q?,LFMJ<G^Z:J:E\,KW[0RV48\D'Y<
MU2426Y&7>:[#!!O7#'T!KK_ VE6&HB2YN+5'8C<,]JY?_A6&L?W!7I'A#1;K
M1[<QW  XP,4G9+0%=O4Z.*&.!-D2!5'85)114&@4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@W_/%ORH T**S_[0;_GBWY4?V@W_ #Q;\J -"BL_^T&_YXM^5']H-_SQ;\J
M-"BL_P#M!O\ GBWY4?V@W_/%ORH T**S_P"T&_YXM^5']H-_SQ;\J -"BL_^
MT&_YXM^51)JY:9HQ"V1[4 :M%9_]H-_SQ;\J/[0;_GBWY4 :%%9_]H-_SQ;\
MJ/[0;_GBWY4 :%%9_P#:#?\ /%ORH_M!O^>+?E0!H45G_P!H-_SQ;\J/[0;_
M )XM^5 &A16?_:#?\\6_*C^T&_YXM^5 &A16?_:#?\\6_*C^T&_YXM^5 &A1
M6?\ V@W_ #Q;\J/[0;_GBWY4 :%%94FKF.15,+?-4O\ :#?\\6_*@#0HK/\
M[0;_ )XM^5']H-_SQ;\J -"BL_\ M!O^>+?E1_:#?\\6_*@#0HK/_M!O^>+?
ME1_:#?\ /%ORH T**S_[0;_GBWY4?V@W_/%ORH T**S_ .T&_P">+?E1_:#?
M\\6_*@#0HK/_ +0;_GBWY4O]H-_SQ;\J +]%4/[0;_GBWY4V/4M]R(3$1GO0
M!HT4#D44 %%%% !1110 4444 %%%% !1110 4444 %4M5MOM-A*JC+;#M^M7
M:.HH \TM9K[3]&FT]E NF<E5]N:ZWPYIK6EOYTJXDD&6K6:QM7D\QH5+^M3@
M!0 !@"J;)4;"%1M/ Z>E4-.4>;-P.OI6@S*HRQP*B@\K+&-@<]<5)1+M'H/R
MHVCT'Y4M% ";1Z#\J-H]!^5+10 FT>@_*C:/0?E2T4 )M'H/RHVCT'Y4M% "
M;1Z#\J-H]!^5+10 FT>@_*C:/0?E2T4 )M'H/RIDJCRFX'3TJ2FN5"_,<"@"
ME8*-AX'7TJ]M'H/RJ&)H5X5U_"IZ $VCT'Y4;1Z#\J6B@!-H]!^5&T>@_*EH
MH 3:/0?E1M'H/RI:* $VCT'Y4;1Z#\J6B@!-H]!^5&T>@_*EHH 3:/0?E1M'
MH/RI:* $VCT'Y5G6ZC^TY>!T]*T"ZA@"1DTP1HCF3@9ZF@"3:/0?E1M7T'Y4
MU)8Y/N.#]*?0 FT>@_*C:/0?E2T4 )M'H/RHVCT'Y4M% ";1Z#\J-H]!^5+1
M0 FT>@_*C:/0?E2T4 )M'H/RHVCT'Y4M% ";1Z#\J-H]!^5+2,P498X% &=>
M*/M</ Z^E:.T>@_*HW1&(<XX[THGB/ <4 /VCT'Y4;1Z#\J6B@!-H]!^5&T>
M@_*EHH 3:/0?E1M'H/RI:* $VCT'Y4;1Z#\J6B@!-H]!^5&T>@_*EHH 3:/0
M?E1M'H/RI:* $VCT'Y5GR@#4%P.U77FCC.&<#/K2;$=MXP?>@"1?NBEJ,3Q;
MMH<9]*DH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#D->U:ZEU
M,Z79-B;&>:SO[1U+1-4L[:Y<?Z2V#BG7'^C_ !#-Q+Q%MQD]*C\6RI<>)=&:
M(A@'[?C5KL9ON>A44"BH- HHHH **** "BBB@ HHHH **** "N3\;:O<:7!;
MBW;!D;%=97+^+K&SOOLJW5T(=KC;GO36XI;&5HLVI3W:&21=IYZUW4>1&N[K
MBO.M9LQI<BW%K=L\BJ,1@]:[S2I'ETNW=P=S+DYIR[BCV+E%%%24%%%% !11
M10 4444 %%%% !4<THBB9CV%24C*&&&&10!YK=>)M1E\96=K$V+=FPP-=!XN
MU:ZM8H8K%L2,X5OIFLGQ%#%#XYTORT"YZX%3>*O]'O8I)>%:4 9^M7IH9ZZD
M:W>J:7JUL)&'V9U#/^.*[JWF$\"RKT:N,\03QRW%M C R-$, ?05U>E(T>FP
MJPY YI/8I;EVBBBI*"BBB@ HHHH **** "BBB@!LCB.-G/0#->?^*/$=_#+F
MU;;#N YKT$@$8(R#7&>/((DT<%$4'>.0*J.Y,MBWJ>K30>'HG1OWTD60?>N=
MT&[U:\V>;(N[ODUN75K;7.E6"7%P(LQC&>]<_P")=/32M+MY;.\))E ^4^XI
MJQ+ON>F0Y\E-W7'-/JGI;L^FVY;J8QS5RH- HHHH **** "BBB@ HHHH *9,
MQ2,D=:?37*A<MTH X>>/6Y[F[DD9?)0;HZJ0>*+ZS\/2SW#YE5\ C\:M:YXD
M6:Y:PLU#$G8Y7^$51UK28M/\#SQI+YKLV[/<=:T7F9OR+(_MG[(FIAAY1&]O
MI75>'M3_ +6TQ;G.<G%9*7<"^"4A+CS#!@#WS3O $;Q>'%5P0=W>D]AK<ZJB
MBBH+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#&UG0X]00O&H$Q[FJ.G
M>&2LZRWX5VB/[LCM73T4[L5D%%%%(84444 %%%% !1110 4444 %%%% !6/K
MFA0:Q''YB O&<H3V-;%%"!JYREGX9F:[66_*R!>!CTKJ(XUBC6-!A5&!3Z*;
M8DK!1112&%%%% !1110 4444 %%%% !1110!CW^B1WNKV]ZR@M%T-.UO18=7
M@5)%!9#N7V-:U%.XK'*V'AF47T=U>[7DCX0CL*ZE5"C Z4M%#=P2L%%%%(84
M444 %%%% !1110 4444 %9FLZ4FJVODN 1G-:=% &->:#;W=C'&R R1+A#Z5
MD0^%)IF6._*R6Z'*J/6NPHIW8N5#(HEAA2-1A5&!3Z**0PHHHH **** "BBB
M@ HHHH *BN8S+ R+U-2T4 <+_P (9<0W\UU;E%>4\FMFWT%Y+(VU_B1">0*Z
M&BG=B44CCQX7N3<A69?LZGY5]JZFTM(K. 10KM4=JGHH;N"5@HHHI#"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **ANIUMK:29CA4&2:X*
MZ^*>D6MP8FN5!'L* /0Z*X33/BAH-[<+ ;L>8QPHP*[>">.XB$D9RIZ&@"2B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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G %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g23ode3tb50n000022.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g23ode3tb50n000022.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '5!'(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** (YV*0.PZ@5QFI7NNH?M$%RJ09QANO\Z[29UCA9V^Z!DUQ^N)8:O9
M$"\\KG.%-5$F0D_B>?9!:QN1<RC ;MFDM]3U?3+ISJLP>(#@#UKF%GD?6K$,
MF(H&QO\ 45T7B:YAU$/#:N'D')Q56(N(VLZOJR23Z7,$BC.&!I\WBJ>ULHH9
M7/VMCM)]ZI>#[B+3],NUNF",6X!K%UF-Y=0AND&86D!![=:+*]@N[7.I@U#6
M[/4HOMTX:W<;L#TJWXPTF'7]!=R =B$KFJFK7<%RUO;Q.#*8EP!]!706VGF;
M2XXI&(RN"*EEQ/D+4;66RO)(I."&./SKJ?AWH$NLZS'+MRD+@MD5O_%+PB]I
MJK7-NA,>.2*]&^%WAE=(TL7+I\TZ \BI+._MK=+:!8XQA0*FHHH$%%%% !3)
M(UE0HXR#3Z* /F;XH^''TK5'NU3"S/Q@5P%M%)<SK&@)8GTKZC^(GAU-:T=G
MV_-"A88%>/\ PX\*2W7B5'N(CY08C)''6@9[!\.O#RZ-HT<P3:TZ FNUJ*WA
M6WMTA7[J# J6@04444 %%%% 'G?Q3\.+J.ASW<:9G48!_"OFJ>.2WF:)_O*<
M&OM.ZMDNX&AD *GJ#7S-XP\)RVOBOB,B.>; H&C6^$GAM[S5(K^5,PCCI7T/
M&BQ1JBC"J,"N7\"Z"NAZ%' 4^;@Y(YKJJ!!1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(64=6 _&EK
MF_$:SPQ^9$S<GL:QKU?90<[7&M3HO,3^^OYTZO/]+GN;F]6/>^">>:[R!2D*
MJ3DBL\+B?;IM*P-6)****ZA!1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 -DC66-HW&588(K!G\,V[R_NT C]*Z"BBXFKF0WAZR,&T1#>!P:BL?#MO;3
MF5D!8C!-;E%.["R,&[\-6TS_ "1@*?O#UJQ_8%D;-8&B!"=*UJ*+L+(P;7PY
M!%=K<.@+K]T^U;H  P*6BE<$K&-XATFVU&Q99XPV:T-/A6WL(84&%1< 4FH?
M\>K5+;_\>Z?2@9+1110 4444 %%%% $<\2SP/$PRK#!%9VEZ%9Z9S#$%;.:U
M:* "BBB@ HHHH **** "L?4_#UEJ5Q#--$&:)MP-;%% "*H50HZ 8I:** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *R];*"T^<=>E:E<[XAD,RK$G4-S7/BI<M)C6Y%X:L5VM,1R
M'.*Z>LS1$"6A ]:TZ6$@H4DD#W"BBBND04444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !2'D$"EHH R[V&81EC)E?2K]O_P >Z?2H
MM0_X]6J:W_U"?2@"2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BJT]]!;MMD;!J$:O:$XWU+G
M%:-E*$GJD7ZCGD\J!Y/[HS20SI.FZ,Y%,OO^/*;_ ':&_=N@2]ZS.5N?&202
ME/+;BGV/C!+J[CA$;#><5Q>I?\?;5+HG_(6M_P#>KPEC*SJ<M^I[;P=+V=[=
M#UZBBBO?/""BBB@ HHHH **** "BBB@!&(49-<N89+_5YHU; '2M[49?)L9'
M]!5'18MW^D_WQUKCKKVE2-/YC0^WTZY@3:)JTXE98P&.2.]/HKHA3C#80444
M5H 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@"C?3QFW*AN:LV__ ![I]*JWUM$L!<+\U6K?_CW3Z4 2T444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6U*18QSFM;P_H<L-PEQ*O2I;:W\R;[4XR)#WKIK< 1  4Q$@&!2T4UI$3[S
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MJV$;1VL>XDG;WJU7J4U:")"BBBK **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I-JGJH/X4M% &3J^D
M1Z@@^7YE'%85MX5D$P,J_**[$NJ]3BD\Z/\ O"BX6(X+:.&)4"C@8Z5-@#H
M* 0>AI: "JU_#Y]E,F,L4(%6:9)(D:DNP"]\T >;Z#H5]#KRK<+_ *.6)/YU
MJ>.?#SZH+%HU_=VYRV/3FNGBU#37FVQS1F3T'6IKF[M(D'VB5%5NF[O5<SO<
MCE5K'G,6D0SR>79AC)C^*MKP3I=Q8-?"=<;CQ^E=#'>Z-$^Z.6%6]15U);94
M,B,H4\DBFY,%%7N>?:SHUU-XCDF1?D/^-.O-*N[;4[.]5?W,(RYKT!/LTZ^<
MH5E/\559=0TOF.2:+T(-',PY4<Q+?:EJLLBP &$CC(K D\*W#[KN9>%/.*]&
MM[G2\[8)(L^BU(]U8*?)>2,;OX3WI<U@Y4]SSJ#1TN)[;[$&,D;@ONKT^(%8
M4!ZA0*BAMK5/GAB09[@43WMM;'$TRI]:3=QI6+%%5(]3LYFVQW",?:K=(H**
M** "BBB@ HHHH **C,\0E\LN-Y[5)0 4444 %%1S7$5NFZ5PB^IJ**_M9FVQ
MSJQ/84 6:*** "BBB@ HHJ&2[@B;;)(JGT- $U%(&#*"#D'I2T %%%% !139
M)$B0N[!5'<U475K!WV+<H6]* +M%1M/$@RS@"AIHT3>S@+US0!)14<<T<T>^
M-@R^HHCGBF)$;AMO7% $E%%% !1110 444=* (Y$C88? 'O3(HH$^YM_ UYG
MXD\5ZC<ZU<:78PEC!\Q*GM_D51TOQ9J5O$UP\3-'&V&)/2KY'8CG5SV&BJ.D
M7O\ :&F0W6,>8,U>J"R&ZD,-K)(.JKFO-Y]7CN]5QJ,4CP>@4UZ:0&&",@]:
MKG3[,G)MHR?]VFG8EILXS4D2^GLKVUC80VHR01SBBXG;Q+</#&K!<9&X5VXM
MH NT1*%/;%)':P0MF.)%/J!3Y@Y3@M/9_#-M/:RJQ>4Y7:*KWVA7%\D.HH/X
M@QR.<"O19+6"4YDB1CZD4\0QA-@1=OIBCF%RG#R7AUB^@MHD<($"-D=Q@5VE
MG!]GM4B_NBE2TMXVW)"BMZ@5-2;*2L5;_P#X]6J6W_U"?2HM0_X]6J6W_P"/
M=/I2&2T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M<[K<[372V:'[XK=N95BA9B<<'%8.DQ->7#7$@Y1B!3 E2UN4MHXE(^6KUO\
M:5(#'BK^T>E&!Z4@ 9QS4,]N)AS4],DF2)<NV!2=K:C5[Z&)-;E)T4=">:I:
MPY!%K!_K W-6M2U&",^8K@E>:JZ.@U#43?,<JPZ=JX)V;]G'J=T+I<\NANZ9
M:+:VRX&&89-7J0# Q2UW1BHJR.&4G)W9%);QRMEAS3/L</\ =JQ13Y4',T,C
MC6-<*.*?113$%%%% !1110 51NO^/E?I5ZJ-U_Q\K]*SJ_""+<?^K%/ID?\
MJQ6=JFH^0ACB^:7LM$IJ$>9@0:O?@K]GC^\_RUF:-I+PZ@#,!5FTM9T8SO&7
M+\X/:KJM<K<>9Y->?R^TFJDUL4:X&T8':EJ&"1W'SKMJ:O33NB0HHHI@%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQY::C*-MM&F&<]!TK0UCQEI\=A(JSH2ZD+[U6NEB=-;F#)K5XWA=YI7S<J^
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M$8& *XB36/$%M#]I^QC;UYK4U'4M7.EP7%M;AI&7+CTIM,E-&W'I5G%/YR(
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M4[06OVGS!Y7]ZDL]6L[\L+:4/MZTM1Z$6HZ)9:D/](BW<YJ&R\.:?9RK)'"
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M?9U/S2#BM9SM0GT%<TF=3U(2#D1-@T :NCVWD6*;A\_<UHT@  P*6@ HHHH
M*P?$L^VP*+][/:MTD*I)[5R&I237>N>3"-RXKGQ,K0LNIT8:-YW?0LV%DD0@
M<CE^372JH7H*Y_RM1!CQ$,+6Q;/<M_KE I4+1TL%:\M;EJBBBNDYPHHHH **
M** "BBB@ HHHH :Y 0D] *XG5(EO]441+\O0UTNL7OV>$*#RQVUGV-E]G;<P
MY8[N:\_%KVLE3Z=2EH;&G6XM[2-0.0*MTR/_ %8I]=T$HQ21(44450!1110
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M00*6B@#,O8)5B+&0E?2KUO\ \>Z?2HM0_P"/5JEM_P#CW3Z4 2T444 %%%%
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M-AP/QIV38KM([30==76M*6\\ORW(SY9Z]*P-2\=W&G-)NTN4JA^]BLSPSK<
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M]BADMIG1HFW$+_%[5T=4=2U2#3(?,GZ&FMR7L</>W6HZS:'39M.D0'CS3_\
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MF+22$@>G-=(=&N?^$8M;9'97BY('?VK?TG1[32(F6V4+O.6^M:.Y>@(_.DY
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M[PK93_5K]!6-J'_'PO\ O"ME/]6OT%2MS:I\,1U%%%48A1110 4444 %%%%
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MT2;I2V,5TOAAKJ:U$]P&'F#< :Y.\T>.XT!);2!D&\?*1S7HFEH8]+MD/4(
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MC:A_Q\+_ +PK93_5K]!4K<VJ?#$=1115&(4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !3617&&4$>XIU% $ LK4'(MX@?7:
M*F"@#  QZ4M% #?+0'(1<_2A8T0DJ@7/7 IU% #7C208=0P]Q044KM*@KZ8I
MU% "!55=H  ] *B-K;L<F&,GW45-10 BJJC"@ >@IDD$,IS)$C'_ &AFI**
M(5M+=#E8(P?913WC20;716'H13Z* (#:0;2%B1<]PN*Y:_\ #;-J$DZ R;Q@
MYKL**:=A-)F%X>\/0Z-!*J_-YIW,"*VO+3;MV+M],4^BDW<:5B'[);?\\(_^
M^13F@B90K1H5'0$5)10!$MM C;DA13ZA10UM YRT*$^ZBI:* (_)B"[!&FWT
MQQ3P !@# I:* "HGMX9#EXD8^ZYJ6B@!BQ1H,*BJ/0"F_98,Y\F//KM%2T4
M(  , 8%)Y:;MVT;O7%.HH :(T4DA%&>N!UK,UO2(]4LO)R4.<Y7@UJT4 <3%
MX3\ZZB:52HB. ?6NOM[2*VC"HB_7%3T4V[B22&"*-00$4 ]<"L?7M#CU2!%!
M*%#GY>,UMT4KCL<9:>%1)J$=S,NPH,8]:Z2TTJ&TD9TZGVJ_13NQ))!4+6MN
MYRT,;'W45-12&0BTMU.5AC4^H44\Q1L06121TR*?10 A52,%01Z8I%1$&%4+
M]!3J* "BBB@ II53R5!^HIU% &9;Z]I]QJ<FG12YN(OO+Z5IUX7K^HZGHGC>
M]NK:PGD1CC<HZ]:U+#XBZK/,D9TBY Z$[:MP?0S53N>P453TRX>[T^*:1"C,
M,E3VJY4&@449Q7/:WXFBTH[=F\YQQ32N)NQT-%8=[X@2TM()-F6F7*KWJCI_
MBQKBZ:&>U:$*,[FHLPNCJJ*Y*\\7F-B;>U:95ZE:L-XLB33XYWCP[\;#U%'*
MPYD=+17)VGBUY=1CM9;1XU?G>>E=4KAU# Y!H:L"=RO?_P#'J:EM_P#CW3Z5
M#J'_ !ZM4UO_ ,>Z?2D,EHHHH **** "BBB@ HHHH **** "BBB@ KGO%<)E
MM$QV-= S!1DG KE=3NGO;OR$!*HW..] ')):RR2;%7)KT#0K-[:V4N,$BJ2Q
MQI>QL+;@#GBMZWE\P8";0*8B>BBBD,**** $)P"3VKEM7N&U&]6SB.8GX8BM
M76M0%G;X7EF.W JKH.GE$::;YG9L@GM7+6;J2]DOF=-)*$?:/Y#X/#L"0(A9
M@15R'2XX6!#MQ[UH45K&C".R,I59RW8@&!BEHHK4S"BBB@ HHHH **** "J]
MY,(;9VSSCBK%<_K5PTLL4,7<X;%8UZG)!L:*D4)N8_MCCG.*Z>W_ ./=/I6,
MEA*MJ(E8@=:N0I,FU2QP*PP\7!ZK<&:-%(.E+7:(**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHJIJ5VME8R3MT44,<4Y.R,#5=5MHK]8F?#;P
M,5T\1S$A'=17@VL:M-=:\UPC'9O! KUWPIJG]I:8';@KA>:PIU.:31ZN.P3H
MT8S^\WZ***W/)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHI",B@#RWQ3XFU"?5YM,T:.-[F,_,&7M698:UXCT74(U
MUF&%(&^9B%HU)[OPSXXO=5-B]Q'-\H]!U_QIFK>(;GQ1=1VD6ELF]<>8.WZU
MLD8-GKVFW27MA%<1_=<9%6ZR_#UJ]GH=M ^=R+@YK4K%FRV$90P(/>N+\;:7
M!'8"Z&?,WBNUK+UW2?[8L?L^_9\V<TT[,)*Z.0U;/V[01VP,_K5WQ>%6)C"
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M7'4U?J*%-QC=[LJM/F=EL@HHHK<Q"BBB@ HHHH **** "BBB@"&ZG6WA,C'
M%8NEPM<7DTL@RN<K3]:G,Q-FA^9AVK2L(!!:QC'S8YKD?[VM;I$?0M8%+117
M6(**** "BBB@ HHHH **** "BBB@ HHHH **** "BF22"--QZ53?5;>-@&D4
M$]*5T4HREL7Z*JQ7T<K[585:ZBF)IK<*Y+QA?*T)TU3^\F' KI+ZZ2TMFD=@
M.#C-<7HMO+KFJ->S@@0N0 >XK.;^RCLPD$FZLME^9GV?@^T6TA-PI\TGYJ[G
M2=%MM*@"6^<'GFJ]^H6= HP-PK:3_5K]!1""3'B<35J17,]&.HHHK0X0HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$>58$UI:K>""!D!^=AP*K:+9DJ+J4?.PY!H TK.V6WA55&"1S5BBB@ HHHH
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M$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH ***P]7\0P:7>Q6TCA6DZ"@&[&#K:^&3J<OVVUC>?/S$FN/UW_
M (1Z.0/IUFHF ^4J<UV5YX!TSQ!<-J,ES.K2\D*3C^=+8_#'2;&Z6=9IG9>S
M$D?SK1-(R<6^AT'AEB_A^U8@@E>AK7J."%;>%8D^ZO2I*S9JM@HHHH ****
M"BBB@ HHI",C% %._D4VY&:L6_\ Q[I]*IWULJPE\G-7+?\ X]T^E $M%%%
M!1110 4444 %-=U1<L0![TV6984+N< "N>N;R?4Y?)M^83W% $>L:D;H^1"C
M'L2!7.-H]P),;6_*N]L--CM8\D98]<BKOEI_<7\J ,'P_;"UC(,9!/?%=!2!
M0.@ _"EH *SM2D>) 1,$Y[FM&N/\<LRV<6UB/F[&L,3/DIN1OAX<]11)&U&8
M72Q_:EP>^:@EU"[O)?L\3DC."1TKA?,DZ[VS]:] \'QKY;,>21WKS*%>5>?)
ML>E6HQHQY]S8TK2DLXPS@&7KFM6BBO8A!05D>1*3D[L****HD**** "BBB@
MJM<SB%<DX%6:H:M:FYLV09S[5G5;4&X[@53K,88+N'/O4IU:)(]V0Q] :X)T
ME^V&$$[MV!S74Z3H)VK)<%@?3->70Q=>K)QBBVDAYENM4EQ&62,'!!'6M:ST
MR*V 8J#)W-6XX4B4*H''M4E>A3H)/FEJR;E2XAG=AY4FT5433[I)6<2C)K6H
MJY4HR=V%R*!)$3$C;C4M%%:)65A!1113 **** "BBB@ HHHH **** "BBB@
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MGBK$-LD'W<U6'HNE=6!NY/11174(**** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJTZ:IQLB0HHHJP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#-O=1FMB
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6'^X*/LL/]P4 ,^WV_\ ?H^WV_\ ?I_V6'^X*/LL/]P4 ,^WV_\ ?H^WV_\
M?I_V6'^X*/LL/]P4 ,^WV_\ ?H^WV_\ ?I_V6'^X*/LL/]P4 ,^WV_\ ?J=)
M%D&5.:KRVT(3(04EET8>AH MT444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ"&%(EZ(H4?A4S:>Q4$UN24445!H%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5D:IX:TK69$DOK82LGW2>U%% -7+M
MCI]MIMNL%K&$C7H!5JBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
3"BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g23ode3tb50n000017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g23ode3tb50n000017.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -5!YX# 2(  A$! Q$!_\0
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M=QIM+0 N32YXIM+VH 6EI*6@ HHHH **** "FNQ!&*=4<G44 &\TF\^U-HH
M?O-&\TVB@!V\T;S3:* ';S1O-)WHH =N-&XTWM2T +N-+N--I: %R:7--I:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<,/S%03ZQIEM+Y5QJ-I%)TV23JI_(F@+EZBF1RQS1AXG5T/1E.0:?0 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM%_Y 6G_ /7M'_Z"*SFDHZ&E-MR=R_11169J%%%% !4<G45)4<G44 ,HHHH
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M\+?+_P"$[UC^PA,N@E<H&'R9XZ9YI:\KN5IS*Q[0>AJ'O4QZ&H>]8FX4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 0GJ:2L*;5M32>15T\%0Q
M/F#D9IG]L:K_ - T?]_17/\ 68]G]S_R-O82[K[T= *6N>_MC5?^@:/^_HH_
MMC5?^@:/^_HH^LQ[/[G_ )!["7=?>CH:*Y[^V-5_Z!H_[^BC^V-5_P"@:/\
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MZY\-Z2GAF;2A9Q+9K"P";>%XZ_6DDDM0;DVTNA>M-8L+[2EU."Y1K0IO,@/
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MBB@ HHHH ANKF.SM9;F7/EQJ6; R<54T36K3Q!I<6HV7F>1)]WS%P?RHU_\
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M(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;3[N*YC!P6B;(JY7D?V.+P5\5-.M-.9HK#40$^S@DJ#Q7KE F%%%%,04444
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M'->EPPQV\*Q0H$C4855' IL%O!:Q>5;PQPQ@D[(U"C)Z\"I: "BBBF(****
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M8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6_O5C:?XMT;5-9FTJSN?-NH1EPJG;_WUT/2K6L:YI^@V9NM1N%BB'XD_0=Z
M+^UO[U&UO[U<]H7CG0/$4[0:?>;I1_#(I0GZ9ZU8U[Q9HWAI%;4[H1ENB*-S
M?D.:- -G:W]ZC:W]ZLC0?%.D>)(6DTRZ$NWJK#:WY'FMFBP#=K?WJ-K?WJ=1
M18+C=K?WJ-K?WJ=118+FG8Y^RKDYY-6:KV7_ ![#ZFK%0RT%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% &+)_K7_WC3:=)_K7_P!XTVK("BBBF(*\\^*7^L\-_P#813_T
M)*]#KSSXJ95= FVL8XKY7<JI.U0RDGBDQK<]#KS[Q7')X4\00^)[5#]FD!CO
M47N.<'\]HKHX/&>@7,Z00ZANDD.U5\F09/\ WS5;XA(9O 6JJB%V,:[0!D_?
M6@#/\#Z=)?RW7BF^0BXU#_4J3]R+J,>G4UT)32O"VFW-R=MO;[FEE8GJ3DG^
MM1^%_P!QX0TTN"NRV4D$=,"O.=2U^V\6>)FM]5N9++1+1_\ 4F)S]H8>N >.
MOYT ;W@"PDU'^VM6N8V2VU.;,:Y^\F ,_I6]KM]IGA'PJT0"QQB(PP1#JS$8
M _45+:^)=$_LN>33YO,BM(\E$B9<#H.H%>>Z5K>G^(M?.M>)+MH(8&(M;%X7
M(7_:.%^G?M0,W="N)O!7PTEO[U")W9YTBSQER64?K6?H#^(/#UI/KMWHT5Q]
MK/FW$QF/FJO;"XZ<#O71>*?)\6>#;C^QG^TF)@ZH$*[B,_+R!4%[XLM+KP\V
MGVL,TFHO$(OLOED%3TY/3]:0%O7?&EM;^%H-0L#YDU^H6T3N6;@<>V17*:1X
M:?0O%&A3W;&34+S?+.Q.<$L#C\,UK:?\-W.FZ2TNK75I>6<(7]RJD XY^\#5
M36/#>JIXKT>,^)-3F9PV)S''F+D=,+C\Z /3J*BMXGAMTCDF>9E&#(^,M[G%
M2U1(4444 %%%% !1110 4444 %%%% &=K_\ R +[_KBU<[\+?^1"L?\ /85T
M6O MH-\ "28FP!7#?#[Q1H^D^#[2SO[MH+A/O(T+Y' ]%I=1]#O9M+M)]2AO
MY8MUQ"I6-B?N@XS_ "KA/$%ROB?QYI6G:<?,73I/-NI%/W.",?J*E\:^.1%8
MP6FC2-OO./M7E-MB'<],_I4_A&_\+:'9I:V^H>=>3G,LK0R;I&/OMH H^-+Z
M_P#$'B&/PSI</FI!B:Y!<JK<\*2.@RM;FB>(YH-4A\/ZKIL>GW)CS L+EXW4
M8'!('/([508_\(OX]U'4[V-_L%_"BB<+D1L"QP<<]Q0N_P 4^/-/U6SB8:?I
M\3J9V4CS&8J< 'GL:0QMK9^*](U[6M0MM,L[J.[F#@R7!1@H51@ *?2MBT\0
MQ:[X>U0&(P75O%+'/"W5&"FD/CK3(FFBN8Y[>="0L3QDE_H1D5F:#I]TUCXB
MUFX@:!M064QP-U"X)!X^M,1D_#KQ9H6D>#4MKW4K>*Y6XF)@+C?RYQQ6OX L
M+H7NL:O+"\%O?3[X488)7 &<?A2?"^PB_P"$*B-Q:)YOVB;F2,;OOGUKN@ H
M 4  = *$#%HHHIB"BBB@ HHHH **** "BBB@ HHHH \;OM*FNO%'B+4K+(O=
M.G$R8_B4,2P_(5U6N^,!/X'AN=.;=?7X$,*+U$A&#^1I_A>%CXU\3^9&WENX
M'S#AADU'I/P^_L_Q:^HO<B2QB8O;6Y_@9CDG\ZDHR/A_HJZ%XXO;3),IT\-*
MQ[L7!_K6O\3/^/?1/^PC#_Z&M3:7&X^*>J.48(;$ -CC[XJ/XDQR26^B[$9L
M:A$3M&<#>M'0.IW-%%%42%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 >>^-/\ D=_#G_71OY"J
MFOZC9Z7\7+&ZO[F.W@%JP,DC8 /RU>\912/XU\.LL;,JR-D@9 X%1:G:^=\8
M+$R0>9#]E;)9,K_#4E$>LW,/C+Q3HRZ*_P!HM[*7S9[J/E%&", _B*@U2_\
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MB=)995E$F7'3I]WJ>M 'IBL&4,.A&12TR+:84*'*;1M/M3ZHD**** "BBB@
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MAJVNB:[AU33(XQ#"9$GA)\MR.W)S5OPK;PVWA;3$@ "&VC8X/<J"?UK0O_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-I_O&G446 ;M/]XT;3_>-.HHL W:?[QHVG^\:=118!NT_P!XT;3_ 'C3J*+
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ME6?&%GXM\06UM:6VEB&S<YNHA=H&8>@-:^CR:MIEK;V$'A06]L@"Y%]&<>^
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]\_TH TZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHK/UR^73=#OKMVV^5 [ ^^#B@#Q@/_P )=\>%9?FAL2&QV!C(
M!KW<<# KQCX'V!O+G5]?F7YYI2$)]R=U>SUI4WMV,J6U^X4445F:A1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &6_^L;ZFFTY_]8WU
M--KSGN=RV"BBBD 5PWQ%U2_TR301974L'GWR1R^6V-ZEEX/MR:[FO._BG_K?
M#?\ V$4_]"2M:*O45S*LVH.QZ$Z[T*[BN1U4\BN*\,:M?V'B2_\ #^LW,DS[
MO-M)I#DNG'&?KG\J[>N&^)6GLFCC7[5O+O-.^97'<'Y<?^/44[-\KZCJ72YE
MT"?5+_7?'?\ 9VGW4T%AIPW73Q' D;GY??I^M36=IK?B*\O+B\OKS3;6.0QV
M\5N^PL 2-Q]<X_6K?@'3$L?"UM<%B]S>+Y\TAZLS=:7QAXK3P_9K#; 3:I/\
MMO;CJQ]<5;?O<D$0E[O/-F?X4\0:A<#6M.N6-U=:<Y6.3NXP",^^33;71?$-
MYI$NHZCK5Y:W[(9%@AEQ$G&<$=_SJ]X)\/OH&F375\X-]>/YUPQ/ /I^0%6O
M$^GZEJ^DL-+U(0HR$L@C!\T>F[J/PH<ESVB"B^2\A/!>M3Z[X>2YN@//CD>%
MR!PQ5BN?QQ7%>,/&M_/XGMM.T2>6.VM90+J6,X#$_P .>XY%(/&<6E?#PPV4
M26EZ)FM?F;Y48$@N3]1FL^YN?#.E>%[6WM=8M+F\DN%EN760$D]_PK6%.TG)
MHRG4O!13/1/'&HS:9X;:6WF>&:2:.)60X8;F X_.ET_PW)&MM<2:[K,CA59D
M>ZRI..01CI4FHV&D>-](C"W0GM!('62WD[@@]1^%<UK^F/X*CMM6TN^NWC$Z
M1S07$[2AE.<XW$XZ5C#5<JT9K+1\SU1Z)VHID+^;!')_>4-^8I]8&X4444 %
M%%% !1110 4444 %%%% !1110!RGQ$FU&T\(W%[I=S);SVS"4M&<94 Y!]JT
M8M;C?PBNK[CM^S[\^_3^=:&HV2:CIUQ9RC*3(4;Z&O'K75IW\)1^%58BZ:_^
MR;,\A?\ 69^E=%.*G&W9_@85).$K]U^)T?PR\3:EJL]Y::O+(T[(MS$)#R$;
M. /RJWJEY?ZM\1H]$M=0NK:SAMB\YMY-IR=I'/KUJOX@B@\)>*]%U=<);.AM
M)<<#&,+^K58^'B?VA>ZUKL@+-<7+1Q,?[J%E_H*N5M:B6EOQ(C?2FWK?\"EX
MPL;[0Y='6T\0ZUB[N_)EWW6?EVD\<=>*[33=#.FSF7^U=3NLC&RZGWJ/PQ7,
M_$G_ %_AK_L(_P#LC5WE9SD^2)I"*YV%%%%8&P4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>47/B[4M*^*-
MS#/<32:2I6-XR?EC+$JI]N:]7KS&#28M:\;>,+*49WV\>P_W6W/@_G6]'EUY
MNQC6YM.7N>DRW,4-LUS(X$*KN+9XQZUY;X5\4ZIXD\>7T4ES<Q:;)$3!&K$
M '&1^.:JMKU_JVB1>"SN356E-O*WI""5W?E@UMZ7I\6E?$>WLH5 2'3]HQ_O
M\UI&"A%WW,W-SDK;#?&MA>Z!IEM<67B'6M\ES'$WF761AF /;WKK-)T)K.2*
MZ;6-5N24&8[BXWH<^V*POBA_R K+_K^A_P#0UKM+;_CUA_W%_E6<I/V:^9I&
M*]H_D2T445@;!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2"-=?^*UQ.RB2TTZ#RP",C<P!_H:MTDI-7T1"JMQ3MJSHO\ A._"G_0?L/\
MO\*N:;XET35YS!IVIVMU*!DI%("0*Y+XC6=M'/X<\NVA7=J&#M0#(V-7>16M
MO VZ*WBC;U1 *B48**:ZE1E)R:?0FHHHK(U"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BN.\>P>(+^VM
M-/T1)$2:3%S<*1\B<?\ UZX.[TFX\%>)-+&E:[<7TT\H$T#ONSSST[5O"DI+
M?4QG5<7MH>VT5Y+XAN=1\9^./^$:MKR2SMK2,&Y,9Y)(SG]14=JE_P##OQK9
MZ>=0GO-+O<(//.6#'_\ 6*?L--]=["]OKMIM<]>HHHKG-PHHHH **** +]K_
M *@?4U/4%K_J!]34]=\/A1QS^)A1115DA1110 4444 %%%% %#6]2_LC1;O4
M-F_[.F_;G&:\2_X:0C&<:&HY_P">I_PKWB>"*Y@>&9 \;C#*>A%<OJO@WPY:
MZ/?7$6C6WF16\CKP>H4D4 >7_P##2*?] -?^_I_PH_X:13_H!K_W]/\ A4OP
M4\/^'M:T_5+J_L[>>]:Y.4?J@RW %=UXP\"^%O\ A%K\G3[:V98BR2\@J10!
MH?#[QI_PG.@MJ8M?LP69H]F[/3'/ZUUM>9? [6GU;P%''*BK);2M%N4 ;@ ,
M'ZUZ;0 4444 %%(2 ,DX [FO-?%/Q=LM&U^UTC385O99)A'-)SLC)[9]: /2
MZ*.U>4R_$GQ;>ZK?V_A_PH-1MK28PM,KXY!([L/2@#U:BN:\'ZSX@U:RN9?$
M.B?V3+&^(T+ [UQG/4U@:C\1[ZXURYTKPMH<FJR6AQ/," BGT'(YXH ]$HKD
M/"'CE/$5S<:=>V4FG:M;_P"LM9,9(]1@GBJWB;Q_)INLIHFAZ9)JNJ$;GCC(
MQ&/?)% '<45P?A_XAS76OC0?$&E2:5J3+NC#D;)![')]*[R@!LG^K;Z&L[0O
M^0>?]\_TK1D_U;?0UG:%_P @\_[Y_I0!IT444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% 'D7QTU-ETS3M(B;#W,P+ 'JO(
M_G7H7A#2O[%\*:=8%</%"H?W->1^)7/BSXVV6FCYH+)PC$= ,;OYFO=@,#%:
M2TBD90UDV+11169J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% &6_^L;ZFFTY_P#6-]33:\Y[G<M@HHHI %>=_%/_ %OAO_L(
MI_Z$E>B5D:_X:TWQ+#!%J*2LL#[XS'(4*GCG(^E:4I*,TV15BY0:1KUR'Q-M
M(;CP-?S2+F2W4/&?[I+ ?R)JU;>!],M;F.=+K5"T;;@'OY6!^H)YK9U32[76
M-+FTZ\5GMYE"N Q!(!!Z_A1%QC)-,4E*46FC-\%P16W@[2TB0*OV=2<=SCK7
M.>*/$%WKNHGPOX?9O.;_ (^;I?NQ+W&?7G]*[BUL(+/3H["$,L$<?EJ-QR!]
M:YA/AIX?BN)9X3J$,DK%G:.]D7<3]#50E#F<I$RC/E48FIIVG67A#PZ4AC8Q
MP)OD(&6<]SQ5*Z@\/>,M CU*>.%XQ&9(Y6(W1'&?P-:.E>&[+1_-\B6\E$J[
M6%S<O*,?\")K/?P!H3S-(JW4:L<M%%<ND9_X #BDI1O>[N-QE:UE8X-YM0NO
M D6H3-),NFZD6C=@26B5FY_("O2-3UBU@\)S7_G(T;6_RD,.21C _.M-+"TC
ML19+;QBV"[?+VC!'TK#B\"Z)%<"41W#*&W"%[AFB!_W"<53J1EN2J<H[$7PZ
ML9M/\#Z?%.I5V0/M(P1D#BL_PS_R4#Q#_P!L_P#T&NMU+2[?5-/:RF::.(D'
M,$IC88]"O-<_#\.="M[DW$4FI+*Q!9Q?29;'KSS0IQ?,WU&X27*ET.MHI%4(
MBJ,X P,FEK V"BBB@ HHHH **** "BBB@ HHHH **** &21K-&T;C*L,$5X=
M9?:)=77P4P;:FI;W)Z>5LW8_[ZKW2LF/PWI<6O2:TL!^W2+M9]W'Y5M2J*%[
MF56FYM6.5^(Q;0WTSQ';(<V<A23']UL#_&K'PQ@=]&O-5D!#ZA=/)R.=H8[?
MT-=5J^DV>MZ=)87T9DMY,;E!QT]ZEL+&WTVRBL[5-D,2A5&<\4.HO9\O4%3?
MM.;H<9\2?]?X:_["/_LC5WE9NJZ'8ZTUHU[&SFUE\Z+:Y7#8([=>#6E42DG%
M+L5&+4F^X4445!84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO^0>?]\_TH TZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "J]]=QV%A/=RG$<*%V^@JQ7#?%K51I?@&]PV'N,0#'7Y@::5W84
MG97.)^#EH^K>*];U^<;_ )S&K>^01^E>WUP/P@T?^R_ UO*RXDNR97^N2/Z5
MWU5-WD135HA1114&@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 9;QS>8Q"#&32>5/_<%7SU-)6?LH=B_:2[E'RI_[@H\J?\
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M QD 5I3WOV,JNW+W/;-+M4L=*M;9%VK'$JX_"K=%%9FH4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $)ZFDI3U-)0 "E
MI!2T %>;?%G_ %OAC_L))_Z&E>DUYM\6?];X8_["2?\ H:5</B(J?">D,H92
MK $'J"*\WTL_\(+XXGTV9MNE:H3+;DGA'QR/R4FO2:XKXJ6,-QX&OKIAB:T
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M10 RBBB@!:*** "BBB@#,\1_\B[?_P#7%JYOX2_\D]L?Q_D*Z3Q'_P B[?\
M_7%JYOX2_P#)/;'\?Y"K7PD/XS3\0>'KK7M7L!+-MTN'+S1!L&5LC&?;K7+>
M*X;?P_XV\-_V-$EO//*5DAB&U73:W4#@\BNS\3^)K+POI3WET=S](X5^](WH
M*YKP9X>OK_4W\5:_N-W-_P >T#=($_Q_QIQ>EV*23=EN6OB'XM&B6,>G6TT:
M7U[\FYS@1(?O,?3 )/X5=\!P:%::&MOH]]!>MG=/-&^XLYY.3]<US^FV%OJ'
MQ?UI]302-!;Q_9EDZ8)?.!]*=J5O#I_Q;T5=+41^?!)]J2+[N,IC(Z=*+*UA
M7=^8IV&K^&7\<^(Y->GT]0LZQ0+>*IR-JGC/OFN[FCTU?"U^^EQ6R6[VTA!M
MT"J?E//%66TW2)EG8VUJ^_\ UC;0?S-<)X7#0IXRM+9F;3(O.%OSD X.0/;I
M2W'JM ^%>A:5J/@%'N].M997N)P96B4O]\_Q8S5CX9W,\>I>(-*$KRV5I<X@
M9V)VC"G'ZFL7X;^&K[5O!:2Q^)-0L[=[B8&UA2/9PYSR5SS]:]-T/0;'P_8_
M9;*/:"=SN?O.?4TY/5H4$VDS4HHHK,U"BBB@ HHHH :_W:CJ1_NU'0 4444
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MMW)X:F$[.]NEU*ML\A)+1ASC],5VW:N&^&-]=7&DWUK/)YL5G=/##+C&Y0S
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M->.P6WB7QCXJU#4/!=A)86;2E9'A?"9R>3D]3R>*W?\ A OBK_T$Y?\ OH4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4V0PH$4?058HI7'86BBB@ HHHH *CDZBI*8X)QB@".BG;#1L- "44NPTNTT
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MUM%";0-)[E+2]*L]&L4L[&%8H4Z #J?7ZU=[44E(9#13MAHV&@!**=M-&TT
M-I:7::-IH *QO$7A;2O%-D+74X-Z@_*Z\,OT-;6TT;30G8&K[G'>'?AEX;\-
M7HO+."62<?=>=PQ7Z<"NRI,&EQ3;;W$DEL%+112&+1110 4444 %%%% !111
M0 4444 %%%% !1110 55U/R?[*O/M()@\A_,QUV[3G]*M4C*KHR.H96&"",@
MB@#Y>\&_%>R\ 7>K6,6GRWMA+<%X-KA"@R>#D>]==_PTMIW_ $+=U_X$K_\
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M10 ZBFT4 .HIM% #J*;10 ZBFT4 .HIM% #J*;10 ZBFT4 .HIM% #J*;10
MZBFT4 .HIM% #J*;10 ZBFT4 .HIM% #J*;10 ZBFT4 .HIM% #J*;10 ZBF
MT4 .HIM% #J*;10 ZBFT4 .HIM% #J*;10 ZBFT4 .HIM% #J*;10 ZBFT4
M.HIM% #J*;10 ZBFT4 .HIM% #J*;10 ZBFT4 .HIM% #J*;10 ZBFT4 .HI
MM% #J*;10 ZBFT4 .HIM% #J*;10 ZBDHH 6BDHH 6EI** %HI*6@ HHHH *
M*** "BBB@ ) &2<"N<USQWX;\/*?[1U6"-^R DD_E5CQ9IE_J_AR[L],OVL;
MN1<).IQMYYS^&:\M\.?!?PPDSSZWK<.J7:?-*(YU"@]]PYH U9?C_P"%DF9$
MANI0#PR@8-2V7QZ\)W4XCE\^V4_QR 8'Y5MZ7X$^'<CD6.F:1=2+U*%'8?E4
MMW\*/!-VI']@6D1(QF) IH W=(\3:+KT(ETS48+E3_=;!_(UK5XK?_ IM.UB
M#4/"FKS6&UP75SEL9YP1C'%>R6L<D-I#%+(99$C56D/5B!R?QH FHHHH ***
M* "BBB@ HHHH **** "BBB@!LG^K;Z&L[0O^0>?]\_TK1D_U;?0UG:%_R#S_
M +Y_I0!IT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%<9XX^(NF^
M#(ECE4SWCC*0J<''J:\YM?C]<K>9N=,#6^?NHP#?G5J$FKHB52,79GMVHZE:
M:3927=[.D,,8R68UX?KOBK7?B=JQT3P[')#IH;]Y*.-P]2?3Z55A_P"$B^,N
MLDL_V71K=^4SPO\ B>:]N\/>&]-\,:<MEIL C0?>8_>8^I-5I#U(NZFVQE>"
M_ >F^#[!5B437C#,EPPY)]O:NLHHK-MMW9JDDK(****0PHHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2BBDH **2DS0 N:,TW
M-)F@!V:3-)FDS0 [-&:;FC- #LT9IN:3- #\T9IF:,T /S1FF9HS0 _-&:9F
MC- #\T9IF:,T /S1FF9HS0 _-&:9FC- #\T9IF:,T /S1FF9HS0 _-&:9FC-
M #\T9IF:,T /S1FF9HS0 _-&:9FC- #\T9IF:,T /S1FF9HS0 _-&:9FC- #
M\T9IF:,T /S1FF9HS0 _-&:9FC- #\T9IF:,T /S1FF9HS0 _-&:9FC- #\T
M9IF:,T /S1FF9HS0 _-&:9FC- #\T9IF:,T /S1FF9HS0 _-&:9FC- #\T9I
MF:,T /S1FF9HS0 _-&:9FC- #\T9IF:,T /S1FF9HS0 _-&:9FC- #\T9IF:
M,T /S1FF9HS0 _-&:9FC- #\T9IF:,T /S1FF9HS0 _-&:9FC- #\T9IFZC=
M0 _-&:9NHW4 /S1FF;J-U #\T9IFZC=0 _-&:9FC- #\T9IF:,T /S1FF9HS
M0 _-&:9FC- #\T9IF:,T /S1FF9HS0 _-&:9FC- #\T9IF:,T /S1FF9HS0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"QE&'YQQ^57M0U2PTF#S]0NXK:+IOE; KR/X5>"](UG0?[0U:#[9(DO[@.Q
MB .>,'UJ.YL?^$U^,EYIFJRL^GV0(%ONP&QG_"CD5[=A\\K)]SUC3/$.CZT6
M&F:C;7>WKY+AL4ZYU[2K.\%G<ZA;Q7)7<(G<!L>N*\:\<Z+:?#_Q7HFH>'PU
MJDC'? K':<$>M.\96$>O?%S0+"X=TBNX0)"AP<8)_I1R)@ZC6G4]=T_Q1H6K
M7!M]/U6UN9AU2*0$U;U'5M/TF#S]0O(;:+^_*V!7B'CS0;#P5XL\/SZ%&;3S
M;A$D5&.&&1GKZYJY\51Y7BW2-1U.VEO=)DC&ZUC;DGY<C&1UYHY$VK"]HTG?
MH>F+X^\).P5?$.GEB< "8<UT EC,/FAP8\;MV>,5\\Z!X:T_Q9X\L[C2_#L]
MCHL'S7$<^1D]N_KBOH7R8_(\C:/+*[=OM2G%+8J$G+<\RU3XFQ6OQ%MM-CU6
MT71PG^D2'& W'\7;O7=3>*=!@LK:\EU:T2VNCB"5I!MD^A[]#7B^H^%M%;XZ
M_P!CFP0V#I&[0[FP68 D]<]2:T_C'IUII&E^'+"PA$-K#<A8XU)(4<GO]:IQ
MBVD0IR2;9[!?:MI^F6!OKV\AM[08'G2-A>>G-13Z_I-K9PW<^HV\=O,0(I&<
M!7STP:X/XK_\D@D_WX/_ $,5RGQ 8K\)-"93@CRL'_@-*,+E2J-7/8HO$^AS
MZ@+"+5;5[L](1(-WY4V3Q7H$6H_V?)J]HMYG;Y)D&[/TKQ_X@^$-,\->%-)U
M32U>"_9E#SAR6?*YYR?>HO%7@_2[#X3V?B*%'&JXB=[DL=SEB <\TU"(G4DK
MZ'OA=0F\D;<9S6)_PF7AO[7]D_MNR^T9V^7YHW9^E>;>.=?O[;X0:88IF62X
M2)'D!Y*[>15VY^%N@1>!3<^5_P 3%;?S?M8<[B>OKBI45U&YMO0]/O-1L]/L
MVO+RYC@MEQF61L*/QJG_ ,)-HAN[:T_M2U^T7(!@C\P;I,],#OUKQ?3]8N=3
M^!5]'=.SM;S!%=CD[01@5V'PT\%Z0V@Z;K5W!]IU)2'CGD8Y3'0 9QQ3<$EJ
M"FY/0]-K$OO&'AW3+@V][K-G;S+U224 BM._2233[A(FVR-&P5O0XKYGL9-(
MT^'4=/\ $&@7>J:N)'1+F,E@K=!W]:4(\PYS<3Z'L?%OA_4FD6RUBSN#&I=Q
M'(#M4=2:1_%WAZ.".=]9LUBE;:CF488^@KS?X?\ A(Z/X&U34KVP-O>SQN$W
MGY@G/OCIBJ?PH\':3K^F7=[K$'VLPW!2%'8@1]\C!'.:;C'42G)VTW/8;[5]
M.TRU%U?7D-O W221L U#IGB'1]:+#3-1MKO;U\EPV*\EFTY?&/QANM)U*1FT
MVQ4JMMN(# 9Q_*JWCG1;3X?^*]$U#P^&M4D8EX%8[3@CUHY%MU!U'OT/9H]=
MTJ759-+CU"W:^C^_;AQO7ZBEN=;TNSOX[&YOX(KN7[D+OAF^@KRCQ@/^$?\
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MU"UXZ$.E?$5[7X80ZU?E9+]F>"&,=964D#^5;/P_T?5;:TFU;6KN>2]OCO\
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MPINEP"?PKE/A, ?B#XER/^7F;_T,UV_Q+\,Z?K'A.]N)8$%W;IOBEQRIS_\
MKH:BG8<7-QYKFYXB\0Q^']$;5/LD]["N"5M\9QZ\GI3?"OBFQ\6Z0NHV(9%+
M%6C?&Y2/7%<G\(]3;Q#X ^QW_P"]\HM;G=W3 &/U-<!>ZE>_"+Q9J-I;$2V5
MW&TD* _=8\C\LTE"]X]1NI:TNAZO=_$*P@\7Q^&[>SN;R[8X=H=NV,]><FNP
MKS/X3>&&MK&7Q)?E9;[4B75\Y*KGIGZBO3*F22=D7!MJ[.(B^)NDOXR_X1I[
M>XBN"VP2N5V%O3KFNWKYE\1Z1=ZCXZURYL'9;JQ!N%V]2%]/>O9_#7C6VO\
MP%_;$\@62UBQ."?NL.!_2JE"R31$)MMIB>*?B7I/A75[?3+B&>XN)B 1#CY,
MG SDUV$$HN+>*900LB!@#VR,U\MZO;7NL20>+[W<!?WX2%#V 93^7S5[AXJ\
M;P^#_#>GE8C/>W$*"&(=^!S3E"UDA1J7NWL=Q17CMSX[\?Z#%%JFN:1:_P!E
M28/[D?.H/KR<5V&N?$+3]+\%P^(85,JW*CR(^Y)_PR*AP9:J(WO$.MP^'=$N
M=4N(I)8H%+,D>,G\ZB\,>(K?Q3HD.J6T,L44O1),9'Y5Y#XD\1>.]2\%7ESJ
MVEVR:3=1'8\> Z@C@D9ST]JZ#P1XCM?"_P ([?4;H%MJD(@ZLV3Q5.&A*J7E
MY'J]8GBKQ+;>$]#?5+J&6:)'"E(L9YSZ_2O.(_'7Q!.GKKSZ-:_V*1N*XQ+M
M]>O]*N_$?6[?Q#\(1J5KGRYI$)!['!R/SI*&JN-U%9V/2=*U"/5=+M[^)&2.
M=-RJW45<KRS4/&\OA+P-H45G;B:]NXPL6[[HY/7\JU/"NL^.Y-7CMO$>EVPM
MY4++-;L %X[\FAQ>XU-;'?T445!84444 %%%% !1110 4444 %%%% !1110
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MT-9VA?\ (//^^?Z5HR?ZMOH:SM"_Y!Y_WS_2@#3HHHH **** "BBB@ HHHH
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MQJ20HSGO]:ERNAJ%I71XY\9[6#_A)_#\OE+ODN%1SC[PR.#^=>S6:A+&W50
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MW\]I<&XED\QB+A@,_2NHTG0=+T.(Q:;916Z'KM']36C4RF[Z%1II*S/(OCC
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M^)EX\<@&;>0Y8?52]>\6FA:98Z9_9UM9QI9XQY74?K61%\.O"4-Y]KCT6 3
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ,@XXSUQQ0!EVD$WQ'UJX\0WB,-#L-R6,)^[*P/WSZ\C]:W/@X /!I & )Y
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]#6=H7_(//\ OG^E:,G^K;Z&L[0O^0>?]\_TH TZ*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M**Q=;\5Z)X>VC4[^*!VY5&8;C^%"5P;MN1>,M>B\-^%[W4)&PP0I'CKN/ _4
MBO/?@EH3R07OB>\7-Q=2,(V/7&3N_,XK!^(_BV#QUJNEZ#HLK2V[2 R,O?)
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MC4\96>GW6G6W]I:I+I\0N4V21GEGYPOXU=O_ !#I&AQ0+?WZ1;E&S(+%AZX
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M NI-(_LBYU^:73U&$B6$(0,YY8')KN**$VAN*>YRE[X'MKW0]-L/M4D=QIP
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M0 4444 %5K^_MM,L9;R\E6*")2S.QX%6:RM?\/V/B736L-10O;L02H8C/Y4
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MBJ_K7;VMI;V5ND%M"D42#"J@P!0!-1110 4444 %%%% !1110 4444 %%%%
M!1110!$:8:>:8: $C_UBU9JM'_K%JS0 4444 %%%% !1110 5R=]XX6V\1RZ
M'!ID]S>*FY C8#?4X^7ZFNLKSS3;B"#XR:JLTB(TEB%0,?O'>.!511,FU:QN
M:/XQ6_UFXT>_T^73]0A3S/*9Q)N7GD$#!Z&JE[XYNK6VN;Y?#UT^G6S,)+AI
M A '4A",D<5C:E?Q-\6%N[4"8:9I\LER4[?(V%/XBJ>I:UKFO^!M1U:;5+73
M[&2-U2W$2R%QZ%C@@FJY41S,T_B+KT\_@3SM.LS/9WBH6F\P+L^<<8/)Y%9O
MC>_U"?X9[K_26LECN+8J?/67?^\'9>E,U3_DB-@<YPJDG_MI6E\0YHY/AK"$
M=6(N+4G!_P"F@IK2R\Q/6[\BXOCF;2]*L;F^T.>'3&5(S=F4?+QU*8R!6X_B
MF&+Q/::+);NINX/.@GW<-STQZ\5SGQ*_Y)1)_P!<8_\ T&L[Q8LMGX=\->)8
M\E].*M*W^P5(_F:228W)HZR3QM9Q^.$\,- _FO%YGVC=\H//R_7C]:ENO%D5
MOXH;1%LY96CMS/)*AR$ QQC&23G]*\_GLWN_#TGC&-_](.I"X1O^F!921],9
MJ]X=UX+HWB/QV\!F#']P">JQY!&?3@4<J#G9T-UX[N;&W6^NO#]S%II?:;EI
M1E><9*8R.:T!XNM_^$J@T1[=E6XA\V"Y+C:_!)&/7C]:X;Q5?:WJ'@">_P!0
MUBU@@NU4QV21*QD&\<!^#VS^%:/BC3I7\$Z+K-HO^E:;Y<N0.2F1N_0&CE0<
MS.MU7Q1#IGB#3]'%NTT]X"Q(< 1J" 2?S%95MXZN=1\R?3= GNK&-]C7 F5>
M^.%(R:S?!+IXKU6^\6W2 1,@@MP>@4##_J!65?:3=^#;&XUOPQKJ26&_<UK+
MAE.6P0I)-'*M@YGOT/5X9/-A20J5W#.#U%/JGI-Y)?Z3:W<L?E/-&'9/[I/:
MKE9FH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %13_='UJ6HI_NCZT 1+4BU&M2+0 ^EI*6@
M!:6DI: "BBB@"&ZN8;.UDN9W"11C+,>PKDY_B/X.N;>6"758C'(A1AZ@C!KI
MM5TZ/5M+N+"8D1SIL8CK7E7_  SOX;_Y_+G]?\: *3Z-\'7=G:6/+')Y'^%$
M>C?!R.17WPMM.<,1@_I2ZA\#/!FE0^=?ZO);1_WI6P/YU2T[X1_#O5YO*T[Q
M&MU(>-L4NX_SH ]B\-W^BWVDI_831&RB/EJL0PJX[5L5SG@SP=9>"=';3;&1
MY(FD,A+]<G'^%='0 4444 %%%% !1110 4444 %%%% !1110 V3_ %;?0UG:
M%_R#S_OG^E:,G^K;Z&L[0O\ D'G_ 'S_ $H TZ*** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS;XN>,&
MT311I5C)_P 3"]^0!3R%/'Z\BN]U748-)TNXO[EPD,"%F)KQ#P7I]Q\1O']Q
MXDU&,FQMVS&IZ9&< ?0XJX+J^AG4;^%;L[[X5^#QX9\-K-<*#?7>))&QR >0
M/R-=[2  # & *6I;N[EQ2BK(****0PHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHKG/'6I76D>#[^]LW"3Q)E6(SB@#HZ*\4\,0_$?Q+
MH$&K0:_;HLN<*T2U<D\:^-_!%]"/&-I!=Z9*P3[7:J!L]R !_.@#U^BJ]O?6
MUU8)?0S*ULZ>8) >-OK7C/Q!^+E^(;F'PC'YD%L<7%_MW(I_NCMV/Y4 >W45
MFZ!<RWF@V-S.VZ62)68XZG%:5 !17,>._%:^$/#4NH+'YMPS"."+^\YSC\.*
MXQ;/XHS:8=9.JV<<^WS5M/*4KMQG!./3VH ]7DBCF0I(@93U!%$<4<2!(T"J
M.@ KE?AWXLD\7^&5OKF(174<AAF0?W@!G^==;0 4444 %%%% $7V:#SO.\I/
M,QC=CFI:*Y?XB:A<Z7X%U2\LY#'/%"S(P['!H ZBBN?\#WL^H^#=-N[IS)-)
M%EF/<Y-=!0 4444 %%%% !1110 4444 %%>9>&-?U*[^+WB+2Y[AFL[<#RHS
MT7DUZ;0 4444 %%%% !1110 4444 1&F&GFF&@!(_P#6+5FJT?\ K%JS0 44
M44 %%%% !1110 5P/_")G4OB+J=WJ>GL^G26@2.0L0"^X<#!STKOJ*:=A-)[
MF9IGA[2M'ADBL;-(ED&'Y+%A[DDFJ47@CPY#,\L>FH&<DL-[%23UXSBN@HHN
MPLB@=%TXZ1_91M4-CMV^3SC&<_SK/3P7X?CT]K%=.7[,[*YC:1R,J<KU/8UO
MT478611U#1M/U73#IU[;+-:$!3$2<8 P.E%SH^GW>DMI<]LKV3*$,1)Q@=O6
MKU%*X612CTBPBT@:4EL@L1'Y0AYQMQC%,M-#TRPTG^RK:TCCL<$>3R1@]>M:
M%%%V%D<]#X'\.6ZNL>FIM?[RM([#UX!/%-\56]Y#X3EL-&LFFDD40+&F/D1N
M">?0'-='13NPY5;0R?#VC0Z-X=M-.5  D0\P>K$?-^M55\$>'5NOM(TY?,W;
MN9'(S],XKH**+L+(0 *,   = *6BBD,**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ[UU=2O0R6]WY</F$+M7+<?H*;B)2.UHIJ2)(NY'5E/=3D5&UU;J^QKB(/\
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M>BD\FF/=6\;['GB5O1G -(9+12 @C(.0>XKSGXK^(]9\._V')I$SIYD[F=$
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MCJ2<"D,6BHH[F"8XBFC<^BN#2M<0INWS1KMZY8#% $E%1-=6Z(KM/$JMT8N
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M#X;E\/"UTZWMRK+]L23+R G(RNW^M6FM[D-/:QD^(KZZU+X>>#KF:=OM%U+
M)) ><LR@FM3XB^'M,T7X>:BUE:1QS28\V4#YI#@\D^M37G@K5I_!OA;2D\C[
M3IDD+7&9/EPC*3@XYZ&NB\=:%=>)/"MQIEH4$TI&"YP!P:5U=!RMIG-:YX-T
MNW\$_P!I1(1JEO;I*EX3^\SQU/ICBJ!U:]\6_P#")Z3<3O'%?VOVFZ*G'F87
M=@_E^M;%]I7C/5=+30[B.Q@L658Y;J.7+LHQ_#CCIZU=UCP6XM=*FT.18;W2
MQL@W='3@%3Z<?SHOW"SZ(Q?%VD67@=-.UO0H19E;N.&:*(8656SG([]*BTO3
M+;7_ (D:Y%J"F6U\I)# ?NN2%ZCN.:U[C0O$?BB^LAX@AM+2QM95E,5O-YGF
ML.F>!CO5_1?#M[I_C?5]5D$8M+J-4BPV6XV]1^%%]/,?+=[:''>*[*+1_%$)
MU31I+SPS';K%;P0(62$C.3M /M^5=WX,ET.;1M^@.3:%C\A&"A],=JCUAO%:
M7[_V;:6%Y9.N!'<2["I]?NG-)X+\-2^'K&Z-RR?:;N8S2)&/E0DDX'YTF[Q&
ME:1-XL31Y+*+^V;N2*!7SY2/CS?8KU8>PKA?#U[I-O\ %&SM/#L$]I8W$$GG
M0- T2,54D$ @9KJ/&7AO4M3U?2M6TV.WN);%B3;7+;4<8/?!YY]*AM/#VO7'
MC73=?U%;6&.".6-[>)]PC!7"X.!GDTU:PI)N1UVI_P#(,N?^N9KRKP[X;TW4
MOAS-?WD1FN81(T,CG)BPQ/R^G_UZ]9O8FGLIHDQN=2!FN5\/^&M0TWP+/I%Q
MY7VIU<#:^5Y)(Y_&E%V14E=G&V>AVFI_"\>(;T--JWD^<MTQ^="!D 'TS4+Z
MC+JGBGX>74S%I&B8,2>I#)S79Z=X6U&U^&*^'Y/)^W"W,?#_ "YVXZUF?\(+
MJUOHFA3VQMSK&DG*1LWR.,Y(W8XZ#M5<R,^5DOQ"_P"1I\)CUO#_ .@/6=J'
MAC1+OXQ1V]QIEM)#-:F61&3AGPW)]^*T=2\/>*M>UK1-1OX[*W6RN-\D$<NX
M ;2,AL#)YZ5?U_0=;7QA;>(=%CMIY$A,+Q3R[ !@C(.#ZTD[:#:OK87Q)9>%
M+5[6+5=SPPIMCT^,;U(XY\L#-<UX,?3]0UGQ+H]M#(=$,6]+6XB*!?N_PD#
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MUZX %    '  I: *NGZ;9:3:+:V%M';0+TCC& *M444 %%%% !1110 4444
M%%%% !1110 4444 -D_U;?0UG:%_R#S_ +Y_I6C)_JV^AK.T+_D'G_?/]* -
M.BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*:[K&C.[!549)/:O-?%OQATG1RUII&+^^)VC:?D!^OK[4U%O8F4E%:GH=]J%
MIIMLUQ>7$<,2C)9V KYI^+'B6P\6^(()])662.UA,;R;3@_-G/3WKIK/P?XQ
M^(UXM]XBN)++3V.1%RN1VPG _&O5-$\!^']"TXV<%A%(KKAWE4,S?B:T7+#U
M,I<U16V1\A5Z-\&]"NM0\90WRQG[-:_,SXXSD8'\Z];N/@SX0N+LSFUF7)RR
M+,P'_P!:NQT?1-/T*R6TTZV2&(>@Y/U/>JE535D3"@U*[-"BBBL#I"BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *BFN;>V"
MF>>.(,<*9'"Y/XU+6!XQ\-Q>*/#T]BSM',!OAD0X*N.1S]0* -[<-N[(QUS6
M=J&L06NCWE];NMU]G0DK"=YSZ<5XS%X^UN?P\W@H1./$_F_9 YX_=\KOS^7/
MO7K?A/PY#X;\/P6"DR28W3._)=CR<T >=Z/X?\:>-K+^V]1\17>EK.=UO:19
M7RQV)'^>E:GP]U_7(?$VI>%->NS?36N'BN3U*^_Z5U'C&Y\2V>FQ?\(O9P3W
M!)WB5L!1CC P<UQ/PLGM3XBU1=6:9?%,AW3QRIMPO/W1Z4 >KS3PVZ;YY8XE
MZ;G8*/UIX92NX,"N,Y!XKF_'ND/K7@S4K6+(G\K=$RG!!!!_I7'>'_&>WX(_
MVC+(6N((3:%B>3*1@?CDB@#U**>&<$PRI( <$HP.#^%(;F!9Q T\8F89$9<;
MC^%>/_"6:_T'Q!<Z!JD[RR7UO'?1%STRNY@/Q:I/#=\VK_$'Q1XFED9['3D,
M, W?*K *?\: /6I[VUM?^/BYAAS_ ,]) O\ .I(IHIXQ)#(DB'HR,"*^?O#O
MB#PKXGEO-9\9:T4NII2L5G]H*I$G;C/7D]JV? FNV-C\2Y-#T'56OM%NH#*J
MM*9#$XQP"2>.30![-/<P6R[KB>.)3WD<*/UH@N;>Z3?;SQ2K_>C<,/TKP-/%
M.@^+/&.IS^*]8-M86DABM+59S&#C&6.",]ZN:3KNAZ%\1-/3PMJ[76G7V8Y[
M7SC($..".>.3^E &\]_=_P##17V+[1)]F_L_=Y6?ESA>:]2FN;>V"F>>.+<<
M#>X7)_&O$?$6OZ?X:_:!EU+4YO*MTTX GN3M7 'O6[X7LK_XA:ROBK6&:/2X
MF/\ 9]HK':P'&YAW[T >I37$-O'YDTT<:?WG8 ?K2075O=+NMYXI5]8W#?RK
MQGXD7*+\1]/M_$DUU;^&#!PT,A16DYZD$>U=IX,\/>%[>[;5?#>HS7$138R+
M=M)&,^V<9H [>BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"EHHJ#0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#6+5FJT?\ K%JS0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXYUF?XA"=YG'AV6<V2(0-HD!V[L]>QKH=:,'P_\ AD;2W;>RQ"W0@9+LWRY
M_$5QEW>Z0/AHND6UOJ0U&/\ TE&_LZ4#SN2>=OJ3S2BD.4GHKGIGCO4;K2_
M^IW]A,8;B*-6CD4 XRRCO[&JL?BI=+\!6.K:A)YMS+;J5'>60]!^>*P_$&L+
MKOP0O+Y"-[VRAACH1(!R/PKF;*.^TV3PSJ?B8I>:,(46V$2E5@<]"P.><XYX
MZ4E'34;EKH=E9S>)+7P5JNLZG?R+=21/-;P[5Q .2HZ>F.M53XAU?_A1[:XM
MV_\ :GV?<)\#.[S=O3&.G%=1XMD2;P1JDD;!D>T8J0>",5P\?_)NZ_\ 7O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI,@.-R'(S4] !1110 4444 %%%% !1110 445C:]XJT3PU&C:MJ$-MO&45V
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M^5'V:'_GDOY5$J4).[292J32LF8P_P"$=!R%BR/]EJO#6--50HN5  P!M/\
MA5O[-#_SR7\J/LT/_/)?RIQA"/PJP2G*6[N5?[:T[_GY7_OD_P"%,;6M,;<A
MN4) Z;3_ (5=^S0_\\E_*LF""(^*+Q?+7:+:/C'NU42>87P+ZA<,BDJ96(('
M;-0;&_NG\J]E.E6!))M(B3U^6D_LG3_^?2+_ +YKYN60R;;Y_P #W(YO%*W*
M>::#IEG?F87MS);[0"A4=:TY- MT.;;6R,=-V[^@KO(]/M(<^7;QKGK@5)]F
MA_YY+^5=]'**$::C-7??8Y*N8U93<H.R['G1&K67^HU97QTV@G^8IT?B;7[<
MX<&;'<KUKT/[-#_SR7\J/LT'_/)?RJ_[-4?X=22^9'UYOXX)_(XF/QW>+Q/I
MX^J@US_B+5UUB]2=8FCVK@AJ]5:TMV&&A0CZ5YQXVMX;;5HUAC5%*9(4>]>?
MF="O3H7G4YE?L=N JT9UO=A9^IS-7M&N8[/5[:XE.$C<,:HUH:'!'=:U:PS*
M&C>0!@>XKY^C?VD>7>Z/8JVY'?:QZ!_PFNE?WVIC^.-+7H)&^F*N_P#"+:/_
M ,^4?Y5+_P (YHW_ $#K?_OFOL.3,']J/XGS7-@UTD<_JOC'3[S2KJVC23?+
M&5&<5P%>HZUH6EV^B7LL-C"DBPL58+R#7EU>#FT:ZJ1]LTW;H>OESI.#]DFE
M?J%=CX>\6VND:0EI+;S.ZLQW)C')KCJ]&\(:78W7A^*6>UBDD+L"S+SUK/*H
MU95VJ+L[=?D7F#IJE>HKJXG_  L"P_Y\[G]/\:/^%@6'_/G<_I_C6]_8>E_\
M^,'_ 'S6;JND:?$]KLLXEW28.%Z]*^B5+'7UJ+[CQ74PG2#^\I_\+ L/^?.Y
M_3_&C_A/[#'_ !YW/Z?XUO?V'I?_ #XP?]\TAT/2\?\ 'C!_WS2]EC_^?B^X
M/:8/^1_>>3ZG=+>ZE<7**561RP#=156K^MQI#K5Y'&H5%E("CH*H5\A5O[25
M][L^EIVY%;L;WAC6X=$NII9HI) Z;0$QZUT__"?V&?\ CTN?T_QK%\#V=M>7
MUPMS"DJB/(##..17<?V'I?\ SXP?]\U]#EM/%RPZ=*:2UZ'C8Z>'59JI%M^I
MC_\ "=:;CF*8?@*PO%'B2SUC3XX;=7#*^X[L>E=FWA_27^]I\!_X#7,^,])L
M+'2XI+6TBA<R8)1<<8-:XV&,5"7/)-6[&>%GA76CRQ=SA****^5/H#T>'QQI
ML<$:&.7*J >GI3_^$[TS_GG+^E:-OX>T=K:)FTZW)* D[?:I/^$<T;_H&V__
M 'S7V4:>/LO?C]Q\PYX._P +^\RO^$[TS_GG+^E'_"=Z9_SSE_2M7_A'-&_Z
M!MO_ -\T?\(YHW_0-M_^^:KV>8?SQ^X7/@_Y7]YBW7C;3IK.>)4EW/&RCIW%
M>=5ZQ>^'](CL+ETT^ ,L3$$+T.#7D]>'F\:ZE'VS3WV/6RUT7&7LDUZA78^&
M/$UGI&E&VG5RYD+?+COBN.KMO#FEV-SX5N;B>UCDF5GP[#D8%896JKQ%J32=
MNIKF#IJC^\5T:;^.].5<B"=O8 5'_P + L/^?.Y_3_&M:PT33'T^W9K*$LT2
MDDKU.*L?V'I?_/C!_P!\U]&Z6.OI47W'B*IA.L']YYMXEUB+6;];B&-XU"!<
M/UK%KI?&EI;VFK(EO$L:F,'"C'K7-5\IC%-5Y*;N[GT.%<71BX*R+>F72V6I
M07+J66-LD+U-=U_PG]A_SYW/Z?XUQ6AQI-K5K'(H9&?!!Z'BO4_[#TO_ )\8
M/^^:]7*88F5.7L9)*_5'GYC*@IKVL6W8P?\ A8%A_P ^=S^G^-'_  L"P_Y\
M[G]/\:WO[#TO_GQ@_P"^:/[#TO\ Y\8/^^:]7V6/_P"?B^X\[VF#_D?WF#_P
ML"P_Y\[G]/\ &LKQ#XLM=7TIK6*WF1BX;+XQQ79_V'I?_/C!_P!\U@^+]+L;
M706E@M8HW\Q1N5>>]<^+I8U4).<TU;L;8>IA75CRP=[]SSJBBBOE#Z([VP\<
M65K8P0-:W!:- I(Q@X'UJQ_PL"P_Y\[G]/\ &M+2M&TV32K5WLH69HU))7KQ
M5S^P]+_Y\8/^^:^PITL=R*U1?<?-3J83F=X/[S!_X6!8?\^=S^G^-<)J5RMY
MJ$UPBE5=B0#UKUG^P]+_ .?&#_OFO*]9C2+5KE(U"JKD #MS7F9M#$QIQ]M)
M-7Z([LNE0<W[*+10KJ?!%U!:ZA.T\@12@P2#[URU=;X#C234K@.H(V#K^-<&
M6?[W#U.S'?[O(] MKN"[C+V\@=0<$BIJR=$ 4W8 P!*?YFM:ON#Y0**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@"(TPT\TPT )'_ *Q:LU6C_P!8
MM6: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH **** "BBB@ HHHH **** "BBB@"(TPT\TPT )'_K%JS5:/_6+5F@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM6:K1_ZQ:LT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^9-'UO0[K4+^]\4Z3J6KSRRG8(^409/N*[;X3ZA))J7B*RMX;N'2_L[301W
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MEI*6@!:6DI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT73Y8)$202 DDD8XZ]J] UFVEO-&N[:$!I9(BJ@G&35ZBAR;=Q**2L>&>%=
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MA?2-'F-AJ4-_=.A6-+=PPS[GM7!? SPO?ZCXBG\8Z@I"?,(F(_UC,""?R(H
M[7QG\,-1\8>(_M5]X@=-&51BT&05/<@]*\K\9>&D^%^NZ5J/A[5V?S' ;$H8
M@Y/IVQ6S=^(=7^(?Q/N?#;ZS+I6GP-(H\D[2VQL8X(SFN?\ BGX9T?PS-IMM
M8ZM->W;.#*))BQ YYP2<4 ;OQ@TZ5?[$\=V2E&F"-+MZ*0<@_B37JO\ PG<
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8KD,8VQQM&2#^-<WKNDVVN?'K^SKQ2T$\J(P!]:^FQ9VPO&O!"GVAE"&3')
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M_:"A7C.-J 9Z?G7744 <1X:^&6E>&/$UQKMI<3O<3[]RN!@;CDU>\;>!M/\
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MQCC!7'ZFNE^&^F%_A_/IUU T7F2RQM'(.0"H%#22U!-MZ&AXF\52VG@^WO\
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MIGAC6M)T/15TG7["."_M,H ]ON,W)(((!]>].\=S#4O!VFSVVGR6JM?PD0E
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH 8:8:>::: &&ID;<OO41IH)4Y% %FBHQ*._%
M.\Q?[PH =13?,3^\*/,3^\/SH =13/,3^\/SH\U/[P_.@!]&!G.*9YJ?WA^=
M'FI_?'YT /HP,YQ3/-C_ +X_.CS8_P"^/SH =M&<X'Y4V57,,BQ,%D*D*2.
M>QH\V/\ OC\Z/-C_ +X_.@#"\)^&V\.V5RL]P+BZN9WFEE P#EB0/PS704SS
M8_[X_.CS8_[X_.FW<25E9#MH/8?E2].E,\V/^^/SH\V/^^/SI#';5]!^5+3/
M-C_OC\Z/-C_OC\Z '$ ]1F@ #H *;YL?]\?G1YL?]\?G0 [:N<X'Y4N >HIG
MFQ_WQ^='FQ_WQ^= #L ]105!Z@?E3?-C_OC\Z/-C_OC\Z '8&,8XHP#U IOF
MQ_WQ^='FQ_WQ^= #@ .@Q1@9S@?E3?-C_OC\Z/-C_OC\Z ';0>H'Y48'I3?-
MC_OC\Z/-C_OC\Z '$ C!%! /4"F^;'_?'YT>;'_?'YT /Z=*0@'J*;YL?]\?
MG1YL?]\?G0 _ /448&,8IGFQ_P!\?G1YL?\ ?'YT .P",8HVCT'Y4WS8_P"^
M/SH\V/\ OC\Z 'D ]113/-C_ +X_.CS8_P"^/SH =@9SCFEP/2F>;'_?'YT>
M;'_?'YT /I,#TIOFQ_WQ^='FQ_WQ^= #L#&,#%&Q?[H_*F^;'_?'YT>;'_?'
MYT /HIGFQ_WQ^='FQ_WQ^= #MJ_W1^5+@'M3/-C_ +X_.CS8_P"^/SH < !T
M %&!G.!GZ4WS8_[X_.CS8_[X_.@!^ .@I,#.<4WS8_[X_.CS8_[X_.@!^!G.
M*0@'J :;YL?]\?G1YL?]\?G0!@^*_#DWB2&RMENEAMHIUFG0J29 I! 'ITK?
M1%CC5$&%4  >@%)YL?\ ?'YT>;'_ 'Q^=.XK:W'TFU<YP/RIOFQ_WQ^='FQ_
MWQ^=(8_ ]**9YL?]\?G1YL?]\?G0 [ SG%+UIGFQ_P!\?G1YL?\ ?'YT /HP
M!T%,\V/^^/SH\V/^^/SH ?13/-C_ +X_.CS8_P"^/SH ?CG-(0#U --\V/\
MOC\Z/-C_ +X_.@!P51T4?E00#U /X4WS8_[X_.CS4_OC\Z '].E%,\U/[P_.
MCS4_O#\Z 'T4SS4_O#\Z/,3^\/SH ?13?,3^\/SH\Q/[P_.@!U%-\Q/[P_.C
MS$_O#\Z '44WS$_O#\Z/,3^\/SH =13?,3^\/SH\Q/[P_.@!U%-\Q/[P_.CS
M$_O#\Z '44WS$_O#\Z/,3^\/SH =13?,3^\/SH\Q/[P_.@!U%-\Q/[P_.CS$
M_O#\Z '44WS$_O#\Z/,3^\/SH =13?,3^\/SH\Q/[P_.@!U%-\Q/[P_.CS$_
MO#\Z '44WS$_O#\Z/,3^\/SH =13?,3^\/SH\Q/[P_.@!U%-\Q/[P_.CS$_O
M#\Z '44WS$_O#\Z/,3^\/SH =13?,3^\/SH\Q/[P_.@!U%-\Q/[P_.CS$_O#
M\Z '44WS$_O#\Z/,3^\/SH =13?,3^\/SH\Q/[P_.@!U%-\Q/[P_.CS$_O#\
MZ '44WS$_O"CS$_O"@!U%-\Q/[PI#(H[T /J!CN:AG+?2D% "BGBD%.% "TM
M)2T %+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]M&V@!FVC;3]M&V@!FVC;3]M&V@!FVC;3]M&V@!FVC;3]M&V@!FVC%/VT;:
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M4/6CRAZT44 'E#UH\H>M%% !Y0]:/*'K110 >4/6CRAZT44 'E#UH\H>M%%
M!Y0]:/*'K110 >4/6CRAZT44 'E#UH\H>M%% !Y0]:/*'K110 >4/6CRAZT4
M4 'E#UH\H>M%% !Y0]:/*'K110 >4/6CRAZT44 'E#UH\H>M%% !Y0]:/*'K
M110 >4/6CRAZT44 'E#UH\H>M%% !Y0]:/*'K110 >4/6CRAZT44 'E#UH\H
M>M%% !Y0]:/*'K110 >4/6CRAZT44 'E#UH\H>M%% !Y0]:/*'K110 >4/6C
MRAZT44 'E#UH\H>M%% !Y0]:/*'K110 >4/6CRAZT44 'E#UH\H>M%% !Y0]
M:/*'K110 >4/6CRAZT44 'E#UH\H>M%% !Y0]:/*'K110 >4/6CRAZT44 'E
M#UH\H>M%% !Y0]:/*'K110 >4/6CRAZT44 'E#UH\H>M%% !Y0]:/*'K110
M>4/6CRAZT44 'E#UH\H>M%% !Y0]:/*'K110 >4/6CRAZT44 'E#UH\H>M%%
M !Y0]:/*'K110 >4/6CRAZT44 'E#UH\H>M%% !Y0]:/*'K110 >5[T>5[T4
M4 +Y?O1Y?O110 ;/>EV>]%% !M]Z7'O110 8]Z,444 &*,444 &*,444 &*,
M444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444
M&*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,4
M44 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &
M*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,44
M4 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*
M,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444
3 &*,444 &*,444 &*,444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g23ode3tb50n000019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g23ode3tb50n000019.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -R _4# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH ***2@!:*2B@!:2DS1F@!U%-S1F@!U%-S1F@!U%-S1F@!U%-S1F@!U%-S1
MF@!U%-S1F@!U%-S1F@!U%-S1F@!U%-S1F@!U%-S1F@!U%-S1F@!U%-S1F@!U
M%-S1F@!U%-S1F@!U%-S1F@!U%-S1F@!U%-S1F@!U%-S1F@!U%-S1F@!U%-S1
MF@!U%-S1F@!U%-S1F@!U%-S1F@!U%-S1F@!U%-S1F@!U%-S1F@!U%-S1F@!U
M%-S1F@!U%-S1F@!U%-S1F@!U%-S1F@!U%-S1F@!U%-S1F@!U%-S1F@!U%-S1
MF@!U%-S1F@!U%-S1F@!U%-S1F@!U%-S1F@!U%-S1F@!U%-S1F@!U%-S1F@!U
M%-S1F@!U%-S1F@!U%-S1F@!U%-S1F@!U%-S1F@!U%-S1F@!U%-S1F@!U%-S1
MF@!U%-S1F@!U%-S1F@!U%-S1F@!U%-S1F@!U%)10 M%)2T %%%% !1110 44
M44 %%%% !244E "TF:0FFEJ '9I-U1%Z87H FWTF^H"]-\R@"SOI/,JMYE)Y
ME %KS*/,JKYE'F4 6O,H\RJOF4>90!:\RCS*J^91YE %KS*/,JKYE'F4 6O,
MH\RJOF4>90!:\RCS*J^91YE %KS*/,JKYE'F4 6O,H\RJOF4>90!:\RCS*J^
M91YE %KS*/,JKYE'F4 6O,H\RJOF4>90!:\RCS*J^91YE %KS*/,JKYE'F4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!K
M_=K,8_O#6F_W366W^L- $RU,M0)4RT 3CI3J8M/H 6EI*6@ HHHH *2EI* $
M-,;I3S3&Z4 0M4+U,U0O0!$G^M7ZUJKTK*7_ %J_6M5>E "T444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 -?[IK+;_ %K5J/\ =-99
M_P!:U $J5,M0K4RT 3#I3Z8.E/H 6EI*6@ HHHH *2EI* $-,;I3S3&Z4 0M
MUJ%ZF;K4+T 1+_K5^M:J]*RE_P!:OUK57I0 M%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1110 4444 -?[IK+/^M:M1_NFLL_ZUJ )5J9:A6IEH F'2GTP=*?0 M+24M
M!1110 4E+24 (:8W2GFF-TH A;K4+U,W6H7H B7_ %J_6M5>E92_ZU?K6JO2
M@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $9@HR
M3BJD_P!FN1LD(/XTFJH[V$@0D-CC%<&+FXM[L!Y&X/.37%BL5[)J+5TSKPV'
M]JFT]4=5<^&K9^8DZUCW?AJXC4N@&T5T=CJ]O- NZ0!@,8J2ZU*U6!\R+G'
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M5-%ZN!\1?\A*3ZUWU<#XB_Y"4GUK3,OX1G@/XAM>$?\ CR?_ 'JZ2N:\(_\
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M"BBBMC(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH :_P!TUEG_ %K5J/\ =-99_P!:U $JU,M0K4RT 3#I3Z8.
ME/H 6EI*6@ HHHH *2EI* $-,;I3S3&Z4 0MUJ%ZF;K4+T 1+_K5^M:J]*RE
M_P!:OUK57I0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% #7^Z:RS_K6K4?[IK+/^M:@"5:F6H5J9: )ATI],'2GT +2TE+0 4444
M %)2TE "&F-TIYIC=* (6ZU"]3-UJ%Z (E_UJ_6M5>E92_ZU?K6JO2@!:***
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHIKN
ML:EF( 'J: '45GP:Q;7%W]GC8%SZ&G:CJL&FJ#-GGH!18+EZBL*R\46E]/Y4
M<<@/N*M:AK=MIR@R9;(SA:=F*Z-.BLW3=:MM3 ,65/HW6M*D,**** "BBB@
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MA6IEH F'2GTP=*?0 M+24M !1110 4E+24 (:8W2GFF-TH A;K4+U,W6H7H
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MH_VE:I/Y9CW#.#63BT:IIE+7->735,<1!N.RFLBQ\1ZP]S&MW;HD<A^4CO\
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M* "BBB@ HHHH HZCTC_WJNK]Q?I5+4>D?^]5U?N+]* %HHHH **** "BBB@
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M!1110 4444 %%%% !1110!1U'I'_ +U75^XOTJEJ/2/_ 'JNK]Q?I0 M%%%
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M!P:Z.AJP)W*.H](_]ZKJ_<7Z52U#_EG_ +U75^XOTI#%HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH R]0T2VOW5I8\D5SFO>'K6SL1)#%\V>U=O45
MQ EPFQP"*YZN&A-/35G12Q$X-:Z'C+0R!B/+;\JM:=:&>Y5'C;!([5Z?_8MM
M_<7\J='I-O&VY57/TKSHY9).[9Z$LRBU9(RX_"EB8U)A&2!6Y:VL=I"L<:X
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MYTK(TTIW9##K78UR=CX(BLKJ.=;R9MAR%+'%=6.!2D4A:***D84444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MIB"BBB@ HHHH *CN/^/>3_=J2H[C_CWD_P!VD]AK<H:+_P >K?[U:=9FB_\
M'JW^]6G44O@1=7XV%%%%:&84444 %%%% !1110 4444 %%%% !1110 4444
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MVZ],\=37U)+CRFRN1Z5XEX\\$3W^HRWMO&V7/1150J1@_>)E3E->Z>0Q/+O
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M''Q&FO0L5F[1 C#;37)Z!XUU/3;V,O<R/&2!MS5K QY="7C9<UV>[[?$,/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M HHHH **** "BBB@ HHHH **** &O]TUEG_6M6H_W366?]:U $JU,M0K4RT
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M% %'4>D?^]5U?N+]*I:CTC_WJNK]Q?I0 M%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%(1D8H I7<=N8),E<X]:J:9%;B%<E1^-32:-'
M(S,97Y]S3!H<*])7_,U@_:<U[&R]GRVN::! /D(Q[4KH)(V1AD,,&HK:V%LN
MT,3]:GK97MJ9.U]#R;Q;I$GAW6X]8LE*01C+JHZFN\T35TU?0EG#9=DR1GFK
MNLZ9%JNG26LH&'[XKQVV\03>#M8O;:4X@^ZFXUI;FC;J9_#*YZ_HO_'JW^]6
MG7EWAGXE6#R""XF50QSP!7IEO/'=0)-$<HXR#64(N,4F:SDI2;1+2,,J12T5
M1)0DL2[$Y&#6#J_A\0PO<PJ Z\\5UM,DC$J%&Z&L*E"$U9FU.O*#NC#\.7GF
MVRQ.?WBCG-;]<7+OT;66F'$<A"C/2NQAD$D2L.X!J<--M<CW1>(@D^=;,?11
M172<P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 U_N
MFLL_ZUJU'^Z:RS_K6H E6IEJ%:F6@"8=*?3!TI] "TM)2T %%%% !24M)0 A
MIC=*>:8W2@"%NM0O4S=:A>@")?\ 6K]:U5Z5E+_K5^M:J]* %HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH ***S]8U>UT2P:\NVVQ+U- '+_$&!7CMYFY
M6(9*^O6L+1/%6DQ:>JO8@$>M;VK>(/#NJV2R7,[>7MSQZ5Q_V[P"/^7N4?Y^
MM:I:69FWK=':Z3XCTV[NDCAM0C$X!KLJ\Q\.W?A"34(QI]Q(TN[Y0?7\Z].J
M)*S*BPHHHJ2@HHHH *PM4\1?V:ZK]F>3/H*W:IW=I;NADE PO/2FA,P(/&L<
MLXB:V9"?6K^J>(XM-$.Z/<91D 5R\-FNH>+7C0?Z*!D$>M2^*;&Z?4[%H5S'
M$,&JLKDW=CHM(\1?VI<F+[,\>!G)%;M<IH.KV<E^]H"!=(N6 %= UPX-2]RD
M,U'I'_O5=7[B_2LJ[F9S&#_>K53[B_2D,6BBB@ HHHH **** "BBB@ HHHH
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MZM>KH_"15^(****U,@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :
M_P!TUEG_ %K5J/\ =-99_P!:U $JU,M0K4RT 3#I3Z8.E/H 6EI*6@ HHHH
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M 4444 %%%% !1110 U_NFLL_ZUJU'^Z:RS_K6H E6IEJ%:F6@"8=*?3!TI]
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M!2TF[C2L4=1Z1_[U75^XOTJEJ/2/_>JZOW%^E(8M%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5'-)Y4
M+/Z"I*:ZAT*GH: /F_XF^(+JZ\07%F7_ '"G('XUQ>GZC/I]TD\+D,IR*]3^
M(_@2\N=5FU"RB>0N?NBO/1X7U.WD#7=J\40^\Q[5U1:L<LD[GT?X&U234_#5
MK-,29&')KIJY?P%%#%X5M%B8,,=:ZBN:6YTQV&NNY"OJ*Y^\\+VUU,9&3)KH
MJ.U95*4:BM)&M.I*#O%G#67ABWGN9D9.$/%6-5T==-TT- N"&K:TK_C]NO\
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M@"CJ/2/_ 'JNK]Q?I5+4>D?^]5U?N+]* %HHHH **** "BBB@ HHHH ****
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M 4444 %%%% !1110 U_NFLL_ZUJU'^Z:RS_K6H E6IEJ%:F6@"8=*?3!TI]
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M*I:CTC_WJNK]Q?I0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'<&LG2/B]&UZJ7 D97( ZT>SD'/$]AN[6.[A:-P.>]<F\5UH=V7C5GB8\YZ
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M444 %%%% !1110 53U/3HM4LVMION-5RB@#R"\^%SM?/Y<UQY+MR YQC\Z]
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M(_\ >JZOW%^E4M1Z1_[U75^XOTH 6BBB@ HHHH **** "BBB@ HHHH ****
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MS(S  _+UXH%^3-Y>#D>U68+98G=L?>- M5%T9<=: *SWY214(.3[42WYB +
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M11Q[A)*%/YUZ%7C'Q._Y"EC_ -?"_P ZN"NR9NR/7-.N#<V<<I&"R@_I5LG
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ&G[347)H<KH&L#5/"TBY!,*!37%^!_^2C:A_N?XUZ;I7AV'3+>>&-5"RG)
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M#W'S']*[2E-W8XJR"BBBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@!K_=-99_UK5J/]TUEG_6M0!*M3+4*U,M $PZ4^F#I3Z %
MI:2EH **** "DI:2@!#3&Z4\TQNE $+=:A>IFZU"] $2_P"M7ZUJKTK*7_6K
M]:U5Z4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M3)(8Y5PZ*WU&:?10!373+56SY*?]\BK2HJ#"J /84ZB@!C0QO]^-&^J@TY45
M!A5"CV&*6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $*AA@@
M$>]5'TRU=LF%/^^15RB@".*"*$8CC5?H,5)110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** &O]TUEG_6M6H_W366?]:U $JU,M0K4RT 3#I3Z8.E/H 6EI*6@
MHHHH *2EI* $-,;I3S3&Z4 0M4+U,U0/0!&O^M7ZUJKTK*7_ %J_6M5>E "T
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/M4M &C16=]JEH^U2T :-%9WVJ6C[5+0!HT5G?:I:/M4M &C16=]JEH^U2T
M:-%9WVJ6C[5+0!HT5G?:I:/M4M &C16=]JEH^U2T :-%9WVJ6C[5+0!HT5G?
M:I:/M4M &C16=]JEH^U2T :-%9WVJ6C[5+0!HT5G?:I:/M4M &C16=]JEH^U
M2T :-%9WVJ6C[5+0!HT5G?:I:/M4M &C16=]JEH^U2T :-%9WVJ6C[5+0!HT
M5G?:I:/M4M &C16=]JEH^U2T :-%9WVJ6C[5+0!HT5G?:I:/M4M &C16=]JE
MH^U2T :-%9WVJ6C[5+0!HT5G?:I:/M4M &C16=]JEH^U2T :-%9WVJ6C[5+0
M!HT5G?:I:/M4M &C16=]JEH^U2T :-%9WVJ6C[5+0!HT5G?:I:/M4M &C16=
M]JEH^U2T :-%9WVJ6C[5+0!HT5G?:I:/M4M &C16=]JEH^U2T :-%9WVJ6C[
M5+0!HT5G?:I:/M4M &C16=]JEH^U2T :-%9WVJ6C[5+0!HT5G?:I:/M4M &C
M16=]JEH^U2T :-%9WVJ6C[5+0!HT5G?:I:/M4M &C16=]JEH^U2T :-%9WVJ
M6C[5+0!HT5G?:I:7[5+0!H45G_:9:7[3+0!?HJC]HD]J43R4 6W^[5$K\YJ7
MSF-(!DYH 114RBD"T\"@!PIU)2T %+110 4444 %%%% "44M)0 F*:13Z3%
M$12FE*GQ28H K%*3RZL[:3;0!7V4GEU9VT;* *NRC95K91L% %791LJUL%&P
M4 5=E&RK6P4;!0!5V4;*M;!1L% %791LJUL%&P4 5=E&RK6P4;!0!5V4;*M;
M!1L% %791LJUL%&P4 5=E&RK6P4;!0!5V4;*M;!1L% %791LJUL%&P4 5=E&
MRK6P4;!0!5V4;*M;!1L% %791LJUL%&P4 5=E&RK6P4;!0!5V4;*M;!1L% %
M791LJUL%&P4 5=E&RK6P4;!0!5V4;*M;!1L% %791LJUL%&P4 5=E&RK6P4;
M!0!5V4;*M;!1L% %791LJUL%&P4 5=E&RK6P4;!0!5V4;*M;!1L% %791LJU
ML%&P4 5=E&RK6P4;!0!5V4;*M;!1L% %791LJUL%&P4 5=E&RK6P4;!0!5V4
M;*M;!1L% %791LJUL%&P4 5=E&RK6P4;!0!5V4;*M;!1L% %791LJUL%&P4
M5=E&RK6P4;!0!5V4;*M;!1L% %791LJUL%&P4 5=E&RK6P4;!0!5V4;*M;!1
ML% %791LJUL%&P4 5=E&RK6P4;!0!5V4;*M;!1L% %791LJUL%&P4 5=E&RK
M6P4;!0!5V4;*M;!1L% %791LJUL%&P4 5=E&RK6P4;!0!5V4;*M;!1L% %79
M1LJUL%&P4 5=E&RK6P4;!0!6\NE\NK&P4;: *_ET[94VVEVT 0[*>%J3%&*
M$ IP%+10 444M !1110 4444 %%%% !1110 4444 )12T4 )28IU% "8HQ2T
M4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4
MM% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC
M%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8
MHQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10
MF*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4
M )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M
M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BDQ3J* $Q12T4 )12T4 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>g23ode3tb50n000033.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g23ode3tb50n000033.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +K!,L# 2(  A$! Q$!_\0
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MI:3% !1110 8HQ110 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10
ME%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10
ME%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10
ME%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10
ME%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10
ME%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10
ME%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10
ME%+10 E%+10 E%+10 E%+10 8HHHH *6DI: "BBB@ HHHH **** $Q1BEHH
M3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:*
M $Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6
MB@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q1B
MEHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,4
M8I:* $Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3
M%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:*
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M#8#)G! VYKT"L9*SL;1=U<****0PHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#YB^,6?\ A.AP3T[>]?07AZ&.X\*6
M<4J!D:$ @BGW_A?1]2N?M%W8Q2R_WF'-:L,,=O"L42A448 ':KE*Z2(C"S;/
MG/XB>$+SP?KRZUI(=82^[Y.U>L_#SQO;^*M'C5CMNXAMD4]ZZV^T^UU&W,%W
M"LL9ZAA5/3O#FE:3*9+&TCA8]2HIN::LQ*#4KHLZK_R"KK_KFW\J^9/"6?\
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MY0=[H\%\8>*=0^)5[!I^F6<@MP<9VFO7-)\'RV7@ Z0)"MP\1RP/0XKI-/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M$\]G)J)M-/1MOWL<5*A=Z%.=EJ?146KZ?.^R*\A=O0-5PLJJ6) 4<YKYBO\
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M8YKJJEZ,M.Z"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_>P^MS[+[CE/[+U__G_/Y4?V7K__ #_G\JZNBCZC3[O[V'UN?9?<<I_9>O\
M_/\ G\J/[+U__G_/Y5U=%'U&GW?WL/K<^R^XY3^R]?\ ^?\ /Y4?V7K_ /S_
M )_*NKHH^HT^[^]A];GV7W'*?V7K_P#S_G\J/[+U_P#Y_P _E75T4?4:?=_>
MP^MS[+[CE/[+U_\ Y_S^5']EZ_\ \_Y_*NKHH^HT^[^]A];GV7W'*?V7K_\
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M7_\ G_/Y4?V7K_\ S_G\JZNBCZC3[O[V'UN?9?<<I_9>O_\ /^?RH_LO7_\
MG_/Y5U=%'U&GW?WL/K<^R^XY3^R]?_Y_S^5']EZ__P _Y_*NKHH^HT^[^]A]
M;GV7W'*?V7K_ /S_ )_*C^R]?_Y_S^5=711]1I]W][#ZW/LON.4_LO7_ /G_
M #^5']EZ_P#\_P"?RKJZ*/J-/N_O8?6Y]E]QRG]EZ_\ \_Y_*C^R]?\ ^?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ N3Z\5T/Q4U^[TZRMK"T<QM=N$+@\@$UF?#^ZMT\<^(&>>,!B,$MUZ5TOQ
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M8KU>O*-506WQ<M3%QYB?-7JPZ"IGW+AU0M%%%06%%%% !1110 4444 %%%%
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M8W'F201!9!CH:NI=Q3)IV4FD=3)&DJ%)%#*1@@CK64?"^ADECI=KD\D^4O\
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M'\.O#<^F07.H7ZXN[IRQSVKO*)O4(+2["BBBI+"BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!#=6L-Y"89T#QGJ#6(G@G0$E$JV";@<UT-
M%.[%9,C$$0A\D(/+QC;CBL5?!NA+=?:!81^9NW9QWK>HHNPLA%4(H51A0, 4
MM%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1UHHH 0 #H,4
MM%% !1110 4444 %'4<T44  &!@4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?V'_ *:-^='V'_IHWYU<HH I_8?^FC?G1]A_Z:-^=7** *?V'_IHWYT?8?\
MIHWYU<HH I_8?^FC?G1]A_Z:-^=7** *?V'_ *:-^='V'_IHWYU<HH I_8?^
MFC?G1]A_Z:-^=7** *?V'_IHWYT?8?\ IHWYU<HH I_8?^FC?G1]A_Z:-^=7
M** *?V'_ *:-^='V'_IHWYU<HH I_8?^FC?G1]A_Z:-^=7** *?V'_IHWYT?
M8?\ IHWYU<HH I_8?^FC?G1]A_Z:-^=7** *?V'_ *:-^='V'_IHWYU<HH I
M_8?^FC?G1]A_Z:-^=7** *?V'_IHWYT?8?\ IHWYU<HH I_8?^FC?G1]A_Z:
M-^=7** *?V'_ *:-^='V'_IHWYU<HH I_8?^FC?G1]A_Z:-^=7** *?V'_IH
MWYT?8?\ IHWYU<HH I_8?^FC?G1]A_Z:-^=7** *?V'_ *:-^='V'_IHWYU<
MHH I_8?^FC?G1]A_Z:-^=7** *?V'_IHWYT?8?\ IHWYU<HH I_8?^FC?G1]
MA_Z:-^=7** *?V'_ *:-^='V'_IHWYU<HH I_8?^FC?G1]A_Z:-^=7** *?V
M'_IHWYT?8?\ IHWYU<HH I_8?^FC?G1]A_Z:-^=7** *?V'_ *:-^='V'_IH
MWYU<HH I_8?^FC?G1]A_Z:-^=7** *?V'_IHWYT?8?\ IHWYU<HH I_8?^FC
M?G1]A_Z:-^=7** *?V'_ *:-^='V'_IHWYU<HH I_8?^FC?G1]A_Z:-^=7**
M *?V'_IHWYT?8?\ IHWYU<HH I_8?^FC?G1]A_Z:-^=7** *?V'_ *:-^='V
M'_IHWYU<HH I_8?^FC?G1]A_Z:-^=7** *?V'_IHWYT?8?\ IHWYU<HH I_8
M?^FC?G1]A_Z:-^=7** *?V'_ *:-^='V'_IHWYU<HH I_8?^FC?G1]A_Z:-^
M=7** *?V'_IHWYT?8?\ IHWYU<HH I_8?^FC?G1]A_Z:-^=7** *?V'_ *:-
M^='V'_IHWYU<HH I_8?^FC?G1]A_Z:-^=7** *?V'_IHWYT?8?\ IHWYU<HH
M I_8?^FC?G1]A_Z:-^=7** *?V'_ *:-^='V'_IHWYU<HH I_8?^FC?G1]A_
MZ:-^=7** *?V'_IHWYT?8?\ IHWYU<HH I_8?^FC?G2K9;6!\QN/>K=% " 8
M&*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHK@_%WQ/TOPS/]E4&YNN\:'FFDWL)M+<[RBO(
M]+^-]I<7BPZA82VB,<!WKU6SNX;ZUCN8'#QR#*D4.+6XE)/8GHHHI%!1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQQKN8^@KQ?XJ>,M'UK0$@LK@22"3) KVN6*.>)HI4#QL,,I[BLC_ (1'P_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 07D33VDD:,59E(!':O!8O$.O?#WQ;=/JJ3W%A*Q(."1BOH&JEYI=CJ"
M[;RUBF'^VN:J,K;DRBWL>#^,/B#-X^M4TC1+.8I(0')4UZS\/_#K>'/#%O:R
M_P"N*Y?ZULVF@:38/OM=/@B;U5:T:<I)JR%&+3NPHHHJ"PHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** &2PQSH4E0.IZ@BJ"Z!I2R;UL( PYSLK2HH"PT(H38%&W&,8JB-#TP3><
M+*$29SNV\YK0HH 0  8 P!2T44 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !17!R^,]63QM_8XTES9Y_X^,'%=V#D ^M-JPDTQ:**J:E=-9:=/<JNYHT+
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MHE2TT[,I--704444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^,_#=_>72Z$SFY?<1N''ZU[O15J=E:Q#A=WN4]*GN;G389;N'R9V7+IZ&K9
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M** "BBB@ HHHH **** "BBB@ HKG_%GB>#PQIAN)!ND;Y8T]3VKB4U_X@WD
MO;:T@6!AN5&7DC\JI1;)<TG8]6HKDO"/B+5-6MIEU.Q-O/%GGL:PM!\<:IJ/
MCNZT>98Q;1$[2!S1RL.=:'I5%%>;^//&^J>'?%6DZ=9K&8;IL/N'-))L;=CT
MBBN>\5ZU<Z-X7FU&V"F9$W 'I7GOAWQ1X_\ $FE?VA:K:B//0K_]:FHMJXG-
M)V/8Z*\J@^(FLZ'JL-EXFLPBS'"RH.*]1AF2>%)4.5<9!I.+0*29)117E/Q%
M^(VI^$?$ME:6R1M:R &3(YQFA)MV0W))79ZM16=HFK0:UI<%[ P(D4$X[&M
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M[7/]X_S-;?BSQM?0ZXN@Z+#OO&'+'M0U[V@*7NZF1?Z[XX\+"._U4+/9;@)
MO\-=-XJU&+5OA[->1'Y98B?TKA_&FG^+H_"%U<:IJ2F XW1>M:]LQ;X,Y/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ML;*'3[..V@4+&@P *LTI.[N$596"BBBD4%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 R:))X6B<95A@BO&==^%FLZ?K,NI^%KKRI)&W%37M-%5&36Q,HJ6Y
MX3!\,_%_B*^B;Q1?;H4(. :]HTG2[?1]-ALK90L<2X%7J*)2;",4@HHHJ2@H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** $HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *6DI: &T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
,44 %*.E)2CI0!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>g23ode3tb50n000010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g23ode3tb50n000010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -?!- # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 45F:IKUCI"EKN3: ,UC_ /"Q/#__ #\G]*=F
M*Z1U=%<_IOC'2-5NQ;6LQ:0]!70=J&K#3N%%%%( HHHH *IZG_QY/5RJ>I_\
M>3T 36O_ !ZQ_2IJAM?^/6/Z5-0 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7,>(_$4.F36ZF0#<V#73USVOZ!#J<UNQ0'8V33
M5KZB=[:%#3_$/V_Q*D$+!H2O6NPKE;+PZ+/Q$EU$ L87&!754.W04;]0HHIB
M2QR9V.&QUP:10^BH6N[=7V-,@;T)ISSQ1C+R*H]S0!)5/4_^/)ZLI+'(,HX8
M>QJMJ?\ QY/0!-:_\>L?TJ:H;3_CUC^E34 %%%% !1110 44UP60A3@U0:SN
MBV1/@4 :-%9OV.[_ .>]5+6*[EGE7SS\IH W:*S?L=U_SWJ2*VN%<%ILCTH
MO4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% $%W_QZR?2H]-_X\DJ&^=_+8 '
M%3:;_P >24 6Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:_\ 'K']*FJ&U_X]8_I4U !1110!SWB?_CW/TK@:[[Q/_P >Y^E<#3 ****
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M9KSKX0S23>$(&D=G;/5CFO1:Q:L[&T7=7"BBBD,**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** (+S_ (]9/I4>F_\ 'DE27G_'K)]*CTW_ (\DH MT
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/6/Z5-4-K_QZQ_2IJ "BBB@#GO$__'N?I7 UWWB?_CW/TK@:8!1110 4444
M%%%% !4D/^M6HZDA_P!:M 'IFC?\@R+Z5?JAHW_(,B^E7Z0!1110!S_C+_D6
MK[_KD:^09/\ 6O\ [QKZ^\9?\BU??]<C7R#)_K7_ -XUO2V.>MN-HHHK4Q"B
MBB@ HHHH **** /I?X.?\B=!]?Z5Z37FWP<_Y$Z#Z_TKTFN6?Q,[(?"%%%%2
M4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $%Y_QZR?2H]-_X\DJ2
M\_X]7^E1Z;_QY)0!;HHHH **** "BBB@!DK,J949-43=7&?]2:T:* ,W[5<_
M\\34$FI7"3K%Y!^:MFLVZ_Y"4- !]JN?^>)H^U7/_/$UI44 0P.[K\ZXJ:BB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML?TJ:H;7_CUC^E34 %%%% '/>)_^/<_2N!KOO$__ ![GZ5P-, HHHH ****
M"BBB@ J2'_6K4=20_P"M6@#TS1O^09%]*OU0T;_D&1?2K]( HHHH Y_QE_R+
M5]_UR-?(,G^M?_>-?7WC+_D6K[_KD:^09/\ 6O\ [QK>EL<];<;1116IB%%%
M% !1110 4444 ?2_P<_Y$Z#Z_P!*])KS;X.?\B=!]?Z5Z37+/XF=D/A"BBBI
M*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !Y)0!;HHHH **** "BBB@ HHHH *S;K_D)0UI5FW7_(2AH TJ*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "JWV^W^V?9=_[WTJIK9D2U,J3^7L&3
M[UX\WC&>V\6L3ND&,9%5&-R92L>ZT5A>&I))[9IGN/-WC(']VMVI92"BBB@
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MO_'K']*FJ&U_X]8_I4U !1110!SWB?\ X]S]*X&N^\3_ /'N?I7 TP"BBB@
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MH ]/348'8*&Y/O5NO+M.N)CJ=N#(V"_K7J Z"@!:*** "BBB@ HHHH ****
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M]L@_YZ"@">BF)*DGW&S3Z "BBB@ HHHH **** /.KK0?&$$Y-A?1QP=E(_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?I %%%% '/\ C+_D6K[_ *Y&OD&3_6O_ +QKZ^\9?\BU??\ 7(U\@R?ZU_\
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M^0C%_O5ZC7EWAC_D(Q?[U>HU[V6_PF>'F/\ $04445Z)YX4444 <5\2X99M
MB\F S,LF=H_"N/M_%EQ;VZ1MX1)V+@MCK^M>A^+)+IM,!T^:,2*V6RPZ5P<O
MB^YU _8+*11<?=)/3-:1V,I;GI/AV[^W:+!<&V^S;A_JO2M6LKP['=1:+ EZ
MRM.!\Q7I6K4/<T6P4444AA1110!!>?\ 'K)]*CTW_CR2I+S_ (]9/I46F?\
M'DE %RBBB@ HHHH \^\7?\AC_@-8-;WB[_D,?\!K!I@%%%% !1110 4444 %
M%%% %G3?^0I;?[]>JCH*\JTW_D*6W^_7JHZ"A@+1112 **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *S[K_75H5GW7^NH O1_ZM?I3J;'_ *M?I3J "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KF-;U27^TX
MM/@!_>#[X[5TQY!%<7K,PT[Q';S2*QC R<"G$F6Q>T+6FEOYM/F&#"/OGO6O
MJ,\36; .":Y;P[$+[Q#>7)4B)_NY%=8VE6S#!6B6X1V'6MS"+9 9!TJ;[3#_
M ,]%JN-+M@,;:/[,M_[II%%C[3#_ ,]%H^TP_P#/1:K_ -F6_P#=-']F6W]T
MT 9'B21)("$8'CM7#^4_]TUZ:^CVL@PRU#_PC]C_ ,\Z8'G'E/\ W31Y3_W3
M7H__  C]C_SSH_X1^Q_YYT ><>4_]TTFQC_":](_X1^Q_P">=4;/1;-[F963
M@'B@#AO+?^Z:/*?^Z:]'_P"$?L?^>='_  C]C_SSH \X\I_[II\,;B494UZ)
M_P (_8_\\Z7^P+$?\LZ %TB>)--B5G .*O?:8?\ GHM5ETJV1<!3BG?V9;_W
M32 G^TP_\]%H^TP_\]%J#^S+?^Z:/[,M_P"Z: ,CQ=*DOAV]2-@S&(@ 5\I2
M:1J'F-_HDG4]J^P9-(M94*,N0>M9_P#PA^D_\\:TA/E,YPYCY,_L?4/^?23\
MJ3^Q]1_Y])/RKZT_X0_2?^>-'_"'Z3_SQJO:D>Q/DS^Q]0_Y])/RI/[(U#_G
MUD_*OK3_ (0_2?\ GC5&;PII:RX$/>CVH>Q/EG^Q]0_Y])/RI?['U#_GTD_*
MOK(>#])VC]SVI?\ A#])_P">-'M0]B?)G]CZA_SZ2?E1_8^H?\^DGY5]9_\
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MK_0;*.T9ECY%/^R_[P?VGY'F?D2G^ T>1+_<->H6WA^Q:W0F/DBI?^$>L/\
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M)/4](\+A1H%N%F,PQ]\]ZV:Y[P7:R6GAJUBD(+*.:Z&LWN:K8****0PHHHH
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MO^/:/Z56U,@VIP<\U8MV MTY'2@":BDW+ZBC<OJ* %HI-R^HHW+ZB@!:***
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MYQO/^-==XO\ !QUH^8+A8LMG)J&'X?L8$CDN Z8P1ZUIS:;F3CKL=!X.-O\
M\(W;"VD:2/'#,>36]5+2M.CTRPCM8P J>E7:A[FBV"BBBD,**** (+S_ (]9
M/I4>F_\ 'DE27G_'K)]*CTW_ (\DH MT444 %%%% 'GWB[_D,?\  :P:WO%W
M_(8_X#6#3 **** "BBB@ HHHH **** +.F_\A2V_WZ]5'05Y5IO_ "%+;_?K
MU4=!0P%KG/&.L3:+I/VB$ MD]:Z.N)^)O_(N_B:%N)['EDOQCU9)G7;'P2/\
M\4S_ (7-J_\ =B_S^%>87/\ Q]2_[QJ*NGDB<OM)'JG_  N;5_[L7^?PH_X7
M-J_]V+_/X5Y711R1#VDCU-OC)JS#!2+_ #^%*/C+JP&-L7^?PKRNBCDB'M)'
MJG_"YM7_ +L7^?PH_P"%S:O_ '8O\_A7E=%')$/:2/5/^%S:O_=B_P _A4D/
MQBU:24*5CY_SZ5Y/4]G_ ,?*T<D0]I(^P/#&I2ZKHMO=2@;G7)Q6S7+^ _\
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M1>A9HHHKTSS0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK7_CUC^E35#:_P#'K']*FH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ3J%M:N%GS$!PH]*ZND(!&",T[L5D4=&5ETR(."#[U?I  !@#'TI:0PHHHH
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M!]:S-]U_=%7M*,AG'F#'-=&&C:HC&N[P.KHHHKTC@.!\9]?^!5QU=CXSZ_\
M JXZOGLQ_CGOY?\ P$%%%%<)VA1110 4444 %%%% %S2_P#C_2O6K#_CRC^E
M>2Z7_P ?Z5ZU8?\ 'E']*]S*_P"&_4\7,OXB]"S1117IGFA1110 4444 %%%
M% !1110 4444 %%%% !2-]T_2EI&Y4B@#SO4;B*;Q];6EQ@QLO(/X4ZQO=)N
M]0U"V$*CR. 2:SO%FBZC-XNAN;&,M($XY^E<O/IFL:-=2S31E7N#SR:U231D
MVTST#P[=+_;BPQ'Y/:N\KSKP'I=UYB7LRD>]>BU$MRX[!1114E!1110 53U/
M_CR>KE4]3_X\GH FM?\ CUC^E35#:_\ 'K']*FH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!2U/_CT/UJQ;?\>\?TJOJG_'H?K5BV_X]X_I0!+1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=?ZZM"L^Z_UU %Z/_5K]*=38_P#5K]*=0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 97B$3'1Y1 "9.V*\SMYM C-T+Z]*W&.5/
M8UZAK<ABTR1@<8KSS3+/P[J5_<?:EA60'YB[8S5QV(EN7O ^&NE:TD:2TS]X
MFO1JR-%MM)LX!%IQBV^B-FM>ID[L<59!1112*"BBB@ JGJ?_ !Y/5RJ>I_\
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M^0_S''6CV<@]K$]_HK&\,ZH=7T>.Z*D;NU;-9F@4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH S[Z[VQ,GEGD=:DTS_CR2I+P#[,_ Z4S3?\ CR2@"W1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#_ST%'VF'_GH*K_V?%_=H_L^+^[0!8^T0_WQ1]HA_OBJ_P#9\7]VC^SXO[M
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M !1110 444QW7:06 _&@#SWQ?X@U!-?CTFQB+^8N<@\]O\:Q(O&.K1&6QN+
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M8Z>UG^T1[ZGJAI/_ !['ZU?KTJ3<H)LX:B2DT@HHHJR HHHH **** "BBB@
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M4M_-B$$?-M(H9V[@UIZ!H/E*'DW>6.4S4VE^&Y+:59)[GS4/.TUTBJJ*%48
MZ"DWT&EU *%& ,4M%%24%%%% !1110 4444 %&<#-(S!5+,< =37-:KXI-G*
MT5M:FX&.JTTKB;L&J:W>-.(=+"NP.&!JE%K6JVESMUF-$MVX!]ZR-.UA[74C
M(;<N)GRW^Q6KXANQJT:06\6XAP=R_6JL3?J.U+PZTTL=W8)N+#=6UHNE?9%%
MQ,N+AAAA6C9*4L8%(Y" &K%2V4DMPHHHI#"BBB@ HHHH **** "LW5]2%A:L
MR']X!P*;JVL1Z;%NP'8\;:XK5O$,UZ^]K1E<#"Q'JU4E<ENQIMJOB78MP($^
MS=2?;\JM26UKXJTII4Y;.#@=Z;#K22:'Y+1;9"A&SN*L^#()(=+??&8\N3@T
MQ%+2O#MS)<*-0CVQVY_<D=Z[$# QZ4M%2W<I*P4444AA1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !110>10!POC2]T42&VO)F2X9>-M<+
M(XO9(XKIC]FC/[INY%=GXL\+R7VLI?#+JJXVX^E:&A^$HHH)&N '\Q?E!'W:
MT321DTVR;PEI5E%;+<V[$D>M=76%I>ARZ;<;A<$Q?W.U;M0]S1;!1112&%%%
M% !5/4_^/)ZN53U/_CR>@":U_P"/6/Z5-4-K_P >L?TJ:@ HHHH Y;Q7T'TK
MB:[;Q7T'TKB:8!1110 4444 %%%% !5K3_\ C]C^M5:M:?\ \?L?UH ],L/^
M/1*LU6L/^/1*LT@"BBB@#@?BA_R!C_N&OEY_OM]:^H?BA_R!C_N&OEY_OM]:
MZ*6QS5=Q****T,@HHHH **** "K.G_\ '_#_ +U5JLZ?_P ?\/\ O4 ?5OP^
M_P"17AKJJY7X??\ (KPUU5<DMSMCL%%%%(9!=?ZIOI7,M]]OK7377^J;Z5S+
M??;ZUY^,W1VX79B4445QG4%%%% !1110 4=Z*.] &_I/_'L?K5^J&D_\>Q^M
M7Z]>C_#1YE7XV%%%%:F856-] I(+<BII?]4_^Z:\FO[^Z6^F F8 .:Y,5B?8
M).VYU87#>W;5]CU+[?!_>JI<ZDX<>3@K7E_]HW?_ #W:C^T;O_GNU<7]J?W3
ML_LSS/2O[3N?05%)J]RG85YU_:-W_P ]VIIO[H]9F-']J>0?V9YGI2ZI<E0<
M"G?VG<^@KS0:A=@8$[4O]HW?_/=J/[4\@_LSS/6(M0C*#>W-/^WP?WJ\D_M&
M[_Y[M1_:-W_SW>C^U/[H?V9YGL$4\<PRASBI:XWP7<2S0R&1RV#WKLJ]*A5]
MK!3/.KTO93< HHHK8R"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K'U'
MQ#:::X6?=R<<"MBJUQ8VUR/WL*,?4BA"9P&L/;7FIC5,D0 8.33].T/5_,,T
M(7[/*<C/I6KK/@<:H"L=V8$/\*UTVG6GV'3X;7?O\M=N[UJ[Z$\NNI'IEHUK
M:JC@;Q5ZBBH+"BBB@ HHHH **** "BBL^]U*WAW1>:OF@?=[T 7RP49)X%<#
MXDEN8KUYM.8"1CB3)XV]_P"M6)O$LLVGWD,R&"7I%GJU8LL7VK1;7-R1=%QO
M7OCBK2L1)W"2STZ]MB\(<RX^?/KWKJ-#\,6*VD,Y5O,ZU-IN@1J(I3@ *,KZ
MUT*HJ*%48 ["DY HBJ-J@#L,4M%%26%%%% !1110 4444 %%%0W-PEM"9)&"
MJ.I- #IXQ- \9Z,,&O.]9BU#P]>&> #[)TY&3700^)YGOC%+;[(BV$<_Q5IS
MSV=]/]CDV.2,X-4KHEV9E:!I-O<6LDTB\SC)K:LM&M;!MT2\^].L-/\ L)?#
MY5N@]*O4FQI!1112&%%%% !1110 4444 %%!.!DUSVL>(FL) L$7FK_$P[4)
M7$W8J^*]'N;B%;BR'[Q&W-GT%8NA%]8U:&YN1\\/R=/3C^E==!K$4NG13RX7
MS."#1%I5N;Z.[MF"*.2J]#57T)MK<<?#]D;CS]IW9S6FB*BA5& *=14EA111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@V_>K3J'N6EH%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;6;PR>3J85)F.5 ]*=A7U.G P,"BD5@R@CH:6D,**** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7*#'0\UR)2<:L(%RMQN(B<CH*M(SDSIK4S:3=M:766@/RH[\YK6M_#T*7B7
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
M@>(_#D.LVS,$'VG&%8U5T/P^($$5TH;8.,5U-)@#H*=W:PK*]QL420IL08%/
MHHI#"BBB@ HHHH **** "BBB@ K(\0VM[<Z>5L7"2#G)K7HZB@&>26[:W>:B
MJ0SB-XFP=XQD_G7=Z1;:TDQ_M"X62,CM_P#KJQ>:!!=7T5TK>48SG"\9K61=
MBXZU3=R5&PR&". $(,9Y-2T45)04444 %%%% !1110 4444 %%%% !1110 4
2444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>g23ode3tb50n000011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g23ode3tb50n000011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,O!3H# 2(  A$! Q$!_\0
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MFHKEF\1WGVQD2W!A5N7]!706EY%=P"6-@5-%@3N6:*0$'I2TAA1110 4444
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M;C6X4M[A KA<FO0J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BF2RK#&7<X4=ZP].\0B_U2XM@!LB&0:+"N;]%<
MQ>>(KM;\06D D4]34M[K\\,$?DQ!YC]]?2G9A='145D:5K!NU"7"B.8_PUK;
MAZTABT444 %%%% !1110 4444 %%%% !7$>,?'=OH"^4N[SBVWY:[>O$?B1H
MFH1ZK_:$,#3)Y@;:>G!H G/Q'U2W'GS&8P]?NGI7HGA7Q5;^(;53&&#A<MNK
MRZ+QS9WMB+#4;*WM^ I;:,\<5VOA.'2[6PN;K3KH2L8R2H[4 =[O7^\OYT"1
M"<!U/T->)/XYU>;7#86EN9'). #[T/XKU[0-4M_M]JR1W#_Q'I_G% 'HGC;Q
M&WAW2_M*L1\V.*T/#>KG5[!9R2<J#S7GWQ-U!-2\&I<(009!T_"M'0M;31/!
MK7&1O6$%0>] 'I!DC!P74'ZTX$'H<UX;!XE\0:VG]H0V[^41N&T\<<UUG@SQ
MVVH6LRWX6)XFVX^E 'HI=5^\P'U-*'5ONL#]#7C6K>--4U?7;C3M/A+K"<@J
M>M3Z#XTU+3_$$&DZC#L$O)9CSV_QH ]>+J.K ?4TAD0'!=1^->3>./&5WIMU
M:_9%W^8^!SUK,UCQ#XBBT_\ M-[5T48&,\4 >W @C(HKDO WB.37K#]ZH5HU
MYKK: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *Y[Q=:P2Z-,[J"X'%=#5'4-,BU&(QR,P!]*:W$]C
M)L(HIM MH]R\+Z]*YNY%_!K*V4,VZ!ADA>1780>'H+>(QK+)@C'6GV.A6]E)
MO5B[>K<T[BLS!@N(A87<)7$I7'U-6_#-I<II"@MMYZ&K[^';9[KS][ YS@=*
MUU18TVJ  /04FP2U,^W,R2[7?/-:54!_Q\?C5^D4%%%% !1110 4444 %%%%
M !7E'QA_X\9/]S^E>KUS7BGPG;>)86CN&=01CY: .!\&_#K2]4\/6MW/;JS.
MN237H6B>#M(T1UDM;94D7H15[0=(BT32H;*$DI&, FM.@#P/XEK&_B*P68#R
MS-\V?3FNOMM(\&G3P9(8"VW^^/2M3Q1\.K'Q),LD\LBLIR-I/^-8(^#-CT^W
MWF/^NC?XT#.)T:=K7QM%#I0*VS3X8+R,5M>/1N\8S+ZL!^M>@>'/AUIGAZ0R
MPR/*Y.<R<_SJ36/ MGJVK-?RNX<D' ^M CQ3QQ'-HK6BQ942QAC@>U7[FP*^
M#-/OW'S2-R?RKU;Q'\/;#Q"UL9V=?(0*-M37?@6RN?#]KI19Q' <J1U[?X4
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MG^J;Z4FRDK%73Y'DA8N<D'%7*I:;_J7_ -ZKM(84444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !0>E%!Z4 9Z_\?'XUH5GK_Q\?C6A0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M )**J'4K0''VB+_OL5,EU!)]R:-CZ!P: ):*** "BBB@ JG>_?2KE4[W[Z4
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MYS5F@=**R-@HHHH *;)_JF^E.ILG^J;Z4 5--_U+_P"]5VJ6F_ZE_P#>J[0
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M9Q B)0>H'-/HHK(U"BBB@ JG>_?2KE4[W[Z4 6(/]6*DJ.#_ %8J2@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 >87?VG0M?NKR>)3#,WR[QG^=)HPN=6\:0:E%$HM57!*C
M [5%?W\UAXAN6O(&NX&;Y$/1:Z70->MKB[2V@T\0!NXK1[&2W.O' I:.U-,B
M X+#-9FHZBF/-'']]P,^M E0IO##;ZT /IDG^K;Z4)-'+G8X;'I1)_JF^E %
M73?]2_\ O5=JEIO^I?\ WJNT %%%% "'H:X+Q5_Q]I7>GH:X+Q5_Q]I0!S]%
M%%,04C=*6D;[M 'I^C?\@N#_ ':T*S]&_P"07!_NUH4AA1110 4444 %%%%
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MI=DOJ?SI_P!K_P!BE^U_[% '1^$]XNF#$_=KL:X_PI+YEVW&/EKL*0PHHHH
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M^^:!$_V";VJS9V4J7"DXZBL_SI/[YJU8RR&Y7+GJ* /3+<8MHQ_LBI:BMO\
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M%K;ALB% ?7%2@ # %-RN)1L<2_A?4EM9K2%T%O*Q9E]?\YI+CPC=O91PH5!
MP:[BBES,.5'#3Z ^G>%'M95W$MG"UM^&-(33;3>B[3(N36XZ*Z[74,/0TH 4
M8 P!1<:BD+1112&<MJPM_$J&P5067Y@W;-<K-X<U>RNE2^O%DL_[GM5KPMJU
MM8:F;2[E*W"K\P-7O&6N6$NGO;Q3?Z0Z_(!6FJ=C/1JYU>C1P1:9$EN (P.,
M5H5@>#%E3PQ:K-G?CG)K?J'N6M@HHHI#"@]**#TH SU_X^/QK0K/7_CX_&M"
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "N>\2WD2P-:W%J9HF')[5T-5KRSAO(6CFQM--">QY9_84=PY:#4XK6,
M_P#+,GI6MIS:?X>42HB7=R#PZ')K5N?A_HTS-(\D@[G#58TKPCI-HPDMV9\'
M^(YJW)$*+N=#97)N[6.8H4WC.#VJQ3401H%7H.E.K,T"BBB@ ILG^J;Z4ZFR
M?ZIOI0!4TW_4O_O5=JEIO^I?_>J[0 4444 %8FIZ#_:$JON Q6W10!RO_"(_
M]-!4$OA?9*J[QS7627"1?>-4)[N)IU()XH R!X2R,^8*#X1_Z:"N@2^AP!DU
M:5@PR* (;2#[-;)%_=&*GHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N)\57%M=7
M#6,]IQU\T]*[:LW4M'M=30K/QGN*:W$U='FJ>'4<Y;6(A#_SR+=O2NDTC4;/
M2$2UM+82L#C>E.E^'VAB3<TLH)_VO_KULZ1X;T_30&MR6_WN:IM$*+-J-O,C
M5\8W#.*?0!@8HJ#0**** "J=[]]*N53O?OI0!8@_U8J2HX/]6*DH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ KE/&/^KAKJZY?Q<C/'#M%<>/_P!WD..YQM%2^1)_=H\B3TKYCE9H
M;_A/_C^_"MSQ+;VTNE3-.JDA>,UB^%8V2^R1VKI=3TY-1MVADSM88.*^DRS2
M@C.1P4A T2SCM2,*XR%].*V=8>S;PXZV[)Y^T<*><XK2T_PM:V2%!N*D8YID
M'A"RAN?-!<\YP3Q7I71G9G)^#BD7VW[00K&,_>[UO>'25M7,/$>\]*T)O"5D
MSLZ[@7ZXK1T[1[?3;,V\.=I.>:&TP46C@&;4Y=1N<7C!5;@>E364^H0WY:2[
M9E"]*[%?#MJLLD@!RYYJO=^'D5&>W!,E',@Y6<+:ZO?7.L&(7+!=^*Z=/,O;
MR>SF?S%1"P/;O6-%X7N(;F1XT_>,V178:+I#6]OYER,3LNUJ;:%%,X/1K^>"
M_FLHPR1M(07[#FKUSJ-S;W4L/VHR*!A2#771^&;..*9 #^].2:Y>?PQ/#>RY
M4^2?]6?>BZ86:'Z?/<SZ)/:S7!EF=LJ>X'-,G>X:&.W$YMRG!)[UI^'/#UQ;
M3BXNEPRGCZ5L:GX<M=293)D8.>*5U<=G8XQ9&LIPWVD$_P!_-076K7H=4BF;
M,G (KKI?!MC)#Y9WX^M/7PI9QF-P#F+E:+H7*SGHM4O)+&/3/-;[6K EN^*[
M.%9A!&&8YVC/Y5B6F@.OBQ]39?E*X]JZO I-E),\;U2[UB+6Y89IYH+<#B0G
M@U!91:E<:K"L>IRNI/8__6KTB\@TKQ/;&*4 GJ 2,YKG+32(_#=T9YV4HK94
M \XJTR''4[S38I(;&..5RSCJ35NJUA>QZA9I<Q A'Z9JS61J%%%% !0>E%!Z
M4 9Z_P#'Q^-:%9Z_\?'XUH4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ4E1P?ZL5)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !52^OX;"+S)7"C&>:MU3O].M]1A,<Z;AC%
M #-,U.'4[?SH6#+G&15^N7N[-M!T<IIZE"#Q@9JKHNIZE/<!9V<KGNIJK$W-
MK4M:%E(8U 9QVI+#78KAQ',0DC?=7UKFO$:R/K$@C8*?4UCW=PVES12S-OE
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M)K5/0R:UN>G0Q+#$(T "CIBI*RO#KS/HL#3R>9)CEO6M6LF:HBN+A+>(NYP
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW[Z4 6(/]6*DJ.#_ %8J2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHH **** "BBB@ HHHH **** "BBB@ HI*J0ZI:3WTEG')F:/[R^E %RBBB@
MHHHH **** "BD+!1D]JCAN8K@-Y;9VG!I76P[/<EHHHIB"BBB@ HHHH **C>
M9(S\QQ3E8.N5/%*ZV =1113 **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *IWOWTJY5.]^^E %B#_5BI*C@_U8J2@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!0>E-\R/.-ZY],TO:@"@O_'Q^-:%9Z_\?'XUH4 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%(6"]2!]: %
MILG^J;Z4!T;HRGZ&B3_5-]* *FF_ZE_]ZKM4M-_U+_[U7: "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBD+
MJOWF ^IH 6J=[]]*MAE894@_0U4O?OI0!8@_U8J2HX/]6*DH **** "BBB@
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MVG:_)>D!HPM:GVL^E)#IEI;G]W'BI_(C_NTF-$/VL^E'VL^E3>1'_=H\B/\
MNTAD/VL^E13:@T8R%S5OR(_[M-:UA?JM*5[:#C:^IF'6G7J@I1K+GH@J>ZL(
M,+B.I(+"W\OE*QY:G<UYJ?82.^9UR5J3[6?2I1;1*,!:7R(_[M;*]M3)[Z$/
MVL^E'VL^E3>1'_=H\B/^[3$0_:SZ5!)J+*<!:N_9X_2FFTA/5:B:DU[H%#^U
MSNV[1FGC4W)QLICV<7]I(-GRXJ^+.$'[E9J%7N,C%V?[M'VL^E3?9X_[M'D1
M_P!VMQ$/VL^E'VL^E3>1'_=H\B/^[0!#]K/I1]K/I4WD1_W:/L\?]V@ BE\S
MM4M-5%3H*=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MN_2X2Y,S&%SNQ[5UEE=+>6ZRKT-#5AIW+%%%%(84444 %%%% !1110 4444
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M2HJ>H- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML>7ZYX=OM"7[18D+9*/FC R2:XZ)-5M;S[3;[E9VW?=->_21),FR10RGL15
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MIOA\KH @G -R4(+>]<@? WB1;"XL([F(6TKEBOY^_O7JO3I14J3*<4SRZ_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%)D9QD4 +12$@=2!1D8SD4 +12;@>XI: "BBB@ HHHH **** "BBB@ HHHH
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M*J3:C;0/L>09^M6(Y4E0,C @^AH ?1110 4444 %%%% !1110 4444 %%%%
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M[USG% 'A_AG1+W6_%<>I3VOEI'(3TX->Y3644UOY)4;<8QBFV>G6M@I6WCV
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "@]**#TH SU_X^/QK0K/7_ (^/QK0H **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FR?ZI
MOI3J;)_JF^E %33?]2_^]5VJ6F_ZE_\ >J[0 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4[W[Z5<JG
M>_?2@"Q!_JQ4E1P?ZL5)0 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %!Z44'I0!
MGK_Q\?C6A6>O_'Q^-:% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4V3_5-]*=39/\ 5-]* *FF_P"I
M?_>J[5+3?]2_^]5V@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF(]"2"-#D$?G5C</4?G7G']O7'JWYU8L];G>=02>3ZTAGH%%1P-N@1CW%24
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MHI)U1<YJL;\ 9.,"@"]15!=05QD$8JQ%<*XR30!/12!@W0TM !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 >::G>ZSK6LW%E87:0B!N?,.,_K1H5[K.G^*H=,O;
MM)8V&2$.?ZTW5-,M[S69_L-P_P!H#?.JG%:GAWPB]OJD>J7,DAF3C:Q)K32Q
MEK<[@'(S2T45F:A1110 4V3_ %3?2G4V3_5-]* *FF_ZE_\ >J[5+3?]2_\
MO5=H **** "BBC- !143W$<9^9L5&;ZW!QOYH LT5 +N$G >I@0>E "T444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !4-S+Y,#OW .*FJ*XV^0^_I@T >5Q/XCUR]
MO#!J,2+$Y"ASC'ZUT/A+4]0&J/I5_.)I(UR67H?\XKG8=!%S?WATRYE?<Y\S
M:QXKL_#/AI=*Q<R.S3L,'=6DFK&44[G3T445F:A1110 53O?OI5RJ=[]]* +
M$'^K%25'!_JQ4E !1110!'<?\>\G^Z:\RU/_ (^V^IKTVX_X]Y/]TUYEJ?\
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M3D$;1@TQ' B"<C(1J7[//_SS;\J[M-)=%P%%6H-+3!\U1^5 &#X2CD2[8NI
MV]Z[&H(;6. Y08J>D,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#R345N]6\0W=
MNFJ_85C;J3UK9\-:)=6FKQRR>(!=J/\ EEGK^E9/C&+1+._>:Z,@=VYV5+X)
M;2+C58Y+1I/,[!C6KV,5\1ZE_#BN=U+P[<7UZ9UN2JGM71]J*R3-6KG/7GAQ
MYTB$,WEE1@D=Z<WAJ-[%8I"&F!SYAK?HIW861A:?H#6\RRW$OFLI^4GL*VY/
M]4WTIU-D_P!4WTI#2L5--_U+_P"]5VJ6F_ZE_P#>J[0 4444 (>AK@?%7_'V
ME=\>E<CK^BW=Y<*T*@@4 <A16O\ \(UJ/]T5&WA^_5PI49-,1F4C?=K7_P"$
M;U#^Z*4^&-1(^Z* .YT?_D%6_P#NU>JIIL+V]A#$_P!Y5P:MTAA1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#RI;K4_"VN21I:E[51A7/>C5->U7Q#(MC'9YAD&'<=JM7L&JVI
MV:D[7*C^Z,U%;7D@/EV5O+"YZ,5-:^9EY'=^'+ Z9HD%J<Y0=ZU:YSP];:PD
MIFO[D21,.%]*Z.LWN:+8****0PH/2B@]* ,]?^/C\:T*SU_X^/QK0H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y?QIIDM[H\SV
MZEY@,*H[UU%8'B&UU652]A<"-0.E-;B>QQVF>+M3TRP6SFLPK1+@9[T:#!J.
MM^,8=:NK<Q*HV^U1RNT,G^F6\LTH/+!3UJW ^L7R>3IDC6P/3<M69GI &!2U
M5T^.>*RB2Y??*%^9O4U:K,U"BBB@ ILG^J;Z4ZFR?ZIOI0!4TW_4O_O5=JEI
MO^I?_>J[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5P'C+3KRUNVU6QA,LN<;:[^N.\0V>M?;6G@N?]$Q_JQUJH[DRV,1_&VI?V
M=Y M 9MN-OO5_P %:;=O>'5[R(Q32K@KZ?YS6.+B.*7+6<IE!^]M/6MC3DUV
M^F5H+@Q0YSM853V(6YWM%,B#+$@<Y8#DT^LS4**** "J=[]]*N53O?OI0!8@
M_P!6*DJ.#_5BI* "BBB@ HHHH J233JQ"QY%5-US]J\SRJUJ* *B3SLP#18%
M6Z** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .9N
MO&GAV&1HY[A-X[%0:SH_'WA]KM8TDBP3U""L+Q%X-^QZA)J?E^?$W B4=*H:
M%IUCJ&K1$Z=Y01L'(K2RL9-RN>N6ES#=VZS6Y!C;H14]16T$5M L4*A4'0"I
M:S-0HHHH *#THH/2@#/7_CX_&M"L]?\ CX_&M"@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ JCJ.JV>F0M+=R!$'4FKU8_B'11K6
MG26V0K.."::$_(R9O'7A@1,PGB+ 9&4%/\.^,='UF00P21^>3PJJ!7!7.BP:
M D\-QIYN2RE58#I73?#71;./3#=FV"3AS@D<@5;22(4FV>A4445F:!1110 4
MV3_5-]*=39/]4WTH J:;_J7_ -ZKM4M-_P!2_P#O5=H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *R-3\1Z5I;%+V8*1U!%:]<AX
MO\)_V[ S1L%DSG--6OJ)WMH07?C[PW$1Y<L1SZH*V]#\0:;K"#[&ZEL9PH K
MR6>RMX+J.RDTQBP.W>1UKU/PII5I8Z=&\4(23&#5222(BVV=%1114&@4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5A>(K^\TZU>X@ VJ*W:P_$>HFPL9
M&^Q?:@!]SUIK<3V,2/Q9H^H:>1=L/.1<OP*I>&=7NKW6533E!TS/S-CG.:\^
MUB[U"YOXYK?2)(4WY9%'4>G6O0?"'B)I+R*Q&B&U4CE\?_7K1QLC-2NST,=*
M6D'(I:R-0HHHH *;)_JF^E.ILG^J;Z4 5--_U+_[U7:I:;_J7_WJNT %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5W8BR3W.D'2EHHJ#0**** "FR?ZIOI3J;)_JF^E %33?]2_^]5VJ6F_ZE_\
M>J[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Q7
MBM+TSM]GW8]A7:U0EU&R6[^S2%3+Z$"FA-7/,/+U?UD_*NM\)+>+-_I&[&WN
M*UM7UO3M)V+-L5Y!\HVCFET?7;+4G\J%E\X#)  JF[HE))FU1114%A1110 5
M3O?OI5RJ=[]]* +$'^K%25'!_JQ4E !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YAKTATW4)9[6] B8
M;1&IK#TK3?[3F=)IA"\C<;N]7]0\'ZM/=*BKD!@3^==;/X0C:"WGB4BZB0 >
MF:UNDC*S9O:)8_V=I45MOW[!]ZM&JFFQSQV,:W'^M'6K=9,U04444 %!Z44'
MI0!GK_Q\?C6A6>O_ !\?C6A0 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5D:_%!)I\@DD6-L?>/:M>N;\6Z7<ZCITB6WWB.*:W$]
MCSJ_N;A)/)6X-Q%G''1:W?"'AY!J\6I+=JV/X!3/#'@^]BFE%ZHV,,5TFG>'
M9=)U=#:#%KU.?6M&UL9I=6=710.E%9&H4444 %-D_P!4WTIU-D_U3?2@"IIO
M^I?_ 'JNU2TW_4O_ +U7: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "N4\600R0L8KE8;D'.<\UU=<%XKT"_O-0>X@'R$8%..Y,M
MCCKV:;5;N%'E++"=I<]J[SPCH2VD_P!N2Y6577&!5#PSX-D2TNDU%/\ 6_=Q
M70:'I5SI5P8%_P"/-1\N>M7)]$3%.]V=#11169H%%%% !5.]^^E7*IWOWTH
ML0?ZL5)4<'^K%24 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% #=B[L[1FG444 %%%% !1110 4'I10>E
M &>O_'Q^-:%9Z_\ 'Q^-:% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !2$ C!I:* $"JO08I:** "BBB@ HHHH *;)_JF^E.ILG^
MJ;Z4 5--_P!2_P#O5=JEIO\ J7_WJNT %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %(RAAAAFEHH 0  <#%+110 4444 %%%% !5.
M]^^E7*IWOWTH L0?ZL5)4<'^K%24 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MNL:PE8$>>>:&@3':;CR7_P!ZKV165#I4L*D"X/)S4OV";_GX-(9H9%&16?\
M8)O^?@T?8)O^?@T :&11D5G_ &";_GX-'V";_GX- &AD49%9_P!@F_Y^#4$L
M$L<H3SB<T :^11D5G"QE(S]H-+]@F_Y^#0!H9%&16?\ 8)O^?@T?8)O^?@T
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M;_GX-'V";_GX- &A156WM9(GW-*6'I5J@ HHHH **** "BBB@ HHHH ****
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M.=ML<RL?:@"Y15 :S8&;R1<+YF<8J_UH **** "BBB@ HHHH **** "BBB@
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M!:K6\#132,?XC0M];/-Y*R@R'M4;ZM91R>6\ZALXQ0!=HID<J2IN1LKZT^@
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M?,CJ"0!DG J'[9;;]OGIN]-U<_J7B:VG\.3WUC)N"<9K@)KNXCN+*]9V"S2
MGYJ:C<3E8]FHKG#XNTR&>*V>;$A0'%5F^(&BQW'E/<X.<=J7*Q\R.K9@HRQ
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M!.6MCT*BBBD4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ME<K:/)]-3[+I?V6_7-V>1*_4"L^VM(+S55,Q6-(WY9N]>G>)/"L&H0F:$ 7
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M.BC:N\_)^=7]'M[$PP74\D<3PC< W\5=EXF\(--9R)8;0QY^8US,'P_OKJ:
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M G0[C S^[KG_  1K=M8>"8H9'7S0I&PGGI7?WUA#J%NT,PRK#!KGH_A_HT3
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)HH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>g23ode3tb50n000005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g23ode3tb50n000005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 7<!T<# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO$:@GOMH&>9>$KFZT\W5E+%(07PIV\8KGY+JXT?QU=W9M)G1A@;5/O7MJZ?
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M: %I**,T &::",XH8X4U#&WS]: +&>:6F9IV>* %I**:WW30 H;-.JM$V:L
MT %%!I* #- .:8[ #K3(7!SS0%F3T4W-.!H 6FD\4IJ*0_(: ) <TM0QGBI
MW- #Z3O2TE  3BD!STIDIPIHB^[0!)10*6@ II.*6HI21B@"4&EJ*,Y%2T %
M%%% #2?6E!S4,Y(Q]:E3[M #J**3/% !2%A25%,<"@"?-%,C(*BGB@!:2@]*
M;G- "Y]:4&H)6YXI\9.T4 2T4@-+0 4PGFG&J\I(9: +%%-4\4M "T4E(30
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M1ES>K#P.36>NIGS/N]ZHW4Q:4DYJLK\UDYG=##KEN=5!=+,.*LYS7.6$Y67
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M $VCTHVCTI:* &,H]*X?QEISN_GHN0HKN35:[MX[F(HZ@@T >:Z7JJ1)Y4Q
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M(3Z5NVDKF8Z1@!S44+*2>:Q+W426(4U7M;YT?)8GFN5XI7L:JEI<ZNEJK;7
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M0 4444 %%%% !1110 4444 %%%% &7KW_(&NO^N9KB?A[U'U-=MKW_(&NO\
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MN<U8OA&ILL;E2!5A6#+D4UV5>IKUF_=.;K<Y&\A99F)]:@49;BNAO%MI <N
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M48=11GA(*@XX-:0'%>>_"YG.DR[V)(?N:]"%!$X\KL+11102%%%% !BC%%%
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MM '.^*KADT[*\9-</HN&=W(YW&N_\26GGZ>0HZ9->>:9((+EHFXRQK&O?DT
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M'2D=0#3PHVUH!%+)^[/%5K9_WC<5;D3,9JO;Q8D/%1)-L"UOXZ4PGFI=HIA
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MI'0%<42V R=_[[/O6G$Y*#BL_P L^?CWK3C0*@%8T[@(S9-*&]J5@,TJJ*W
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M@#+U[_D#77_7,UQ/P]ZCZFNVU[_D#77_ %S-<3\/>H^IH ])%+2"EH ****
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M_MHHB6X_.M:F%M\)3DDM3&?[U/'2JTLP$F*N6>R5@&KF5&5R%6B]"2"W:9@
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH R]>_Y
MUU_US-<3\/>H^IKMM>_Y UU_US-<3\/>H^IH ])%+2"EH ***3- "T444 %%
M%)F@!:*** "DI:2@!CFN7\8Z7!?Z+.7 #8X..:ZA\8)/:O./'OB$QQMIUL29
M)!QMH-*2;EH>6P>9-J\=@TK^5&X YKW_ $+38-/TU$B Y .<5XV_A*_MK.#5
M0Q+GYF&.:]%\%>(QJ%D(93B0';@GGBDCHKZK0XZT_P"1VN/^NU=EX_U+[)H)
M5&PW%<7;MM\8W+'H)LTOCBZGU;6?[/@)*E0<"F-QYG$?;>'2VA7%^5^8Q[P:
MZ7X<:H9M+CM'.7 SBN;BT_7!IGV82R>64VXQ53PC-/H7B1K>X)"@8YH"2YE*
MYH?$J58=?LI).% YS6M8>,]$AT40F2(R;2,%1Z5C_$0+=ZUIX(RKKFNHT/P5
MI-QID,KVJ%CWH)?)R*YR7ABWGO\ Q/'>11XA#GE>!UKVE!A0*SM/T6STX8MX
M0GTK3H,:L^=BBEI!2T&0F>:,U'(K'H:9LD_O4 3YHS5?9)_>HV2?WJ )F/%<
M1XOU1HCY"-C</6NP='V'YNU>:>+8Y5U-"Q)&*!/8S[6Q,_[R0GFIWTR,K\A.
M:LVA!MEP>U2)D')XKF<G<\^4Y<Q1TN^FTZ_5-QVEL<FO5+.?SX%<>E>0S OJ
M4>T_QUZAH\<BV*Y-="=T=\+\IL T9JOLD_O4;9/[U,HL9HS5?9)_>I=LG]Z@
M">EI%Z<TM !1110 4444 %--*>E0N'/0T 9&M7?EQ;1US7(RC>Q)[UNZZKY.
M3WK!.>]<U2S>IY]>3<ABQKGI5^RG,,H(J@,YJ2(,7P#4670RBVF=_9R>9 K>
MHJOJESY,!]:;IRO]E3GM6?KBR;&YXKI?PGH3DU3N<_<RF1R2:@C&#FFN&SUI
M5!QUKGNCSFVV;NDWC)($)ZFNLC;<F:X*P5VN4P>]=I DGE ;JW@W8[<-)M%7
M5[LPPLH/)%<C-<._))_.MW75?U[5S1![UG4;N95Y-RL/C=@>IK<TK4&5PA/7
MBL!1D5<L$<W"X]:4&S*$FF=ZARF:P=:O"@V*>M:\:/Y0Y[5RVMJ_FC)[UM.]
MCMK2:AH93L6/)IJ,0:3FDY-<[//N;FDWK)*%)XKJT;<@/M7!V*.9A@]Z[6%'
M\E>>U;T[V.W#R;1D:U=;<H*YF0[LDUJ:S'(+AB3QFL?D=3653<YZLFY#EX((
MKHM%O"'5#7.X..*T=)1VN%P:4%9Z"IR:D=H[@0EO:N/U6Y,L[ 'BNEG23[&>
M?X:XNZ#B8@UK5>AOB)NUB%T!'2DC0#M0<^M*N?6L+(X^IKZ5<&.=5[&NO1MT
M6ZN"L@YNDP:[2%7^RCGM713V.W#R=C'UN\PYC'<5S;_,<FM'6$?[3R:S.1UK
M">^IA5DW(DA;RSD5UNC78D3:>U<> 3T-;NA*^]JNF[#HR:D=5(^U":Y'5;QI
M)" >E=+<)(83@]JXN[1UF?)[UI4;L;XB32*DG/:I86*$$5"P]Z<,XX-<W4XD
M]3K=&O"YV$]!6K=R^5 7KEM#60S'![5NZ@DGV)N<UTQ;<3NIR;@<Q?W+2S-S
MQFJ!YITZMYI'O3=I'4U@]6<4I-L<C%2,&NDT2\+.(V-<R 2:U='1_M8P:JF[
M,TI2:DCK[B4)"6]JX[4;MI)V^8XKI;U)#:-SVKC)U82')YJZDFC;$2>Q&YR:
M?'*R$8/0U$0?6E )/%9')=W.RT>\\V':3S6K*X2(MZ"N7T*.3(.>,UOW2/\
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M?]RMJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH R]>_Y UU_P!<S7$_#WJ/J:[;7O\
MD#77_7,UQ/P]ZCZF@#TD4M(*6@ HI*AFF2%"[L% '4T 3T5G6>K6M\3Y$R/M
M.#@U?S0-JPO2C-9][JMK8G]_,B?[QJ>*X2>%948%",@B@&G:Y8I:R[O7+"S.
MV:YC0^YJ&#Q)IEPVU+R(D]@: LS:I:@299%RK CUJ.YO(K2(R32!5'4F@26M
MB:1=R,OJ,5Q\G@NVGU=+Z3<64\9Z5O6>N6-_(4@N$=AV!K1X"YIE)N#*DEA%
M)8FV*C:5QTKF],\&6^FZD+F+<.<X[5O7>M6%D<37$:'W-10^(]+G8(EW$6/8
M&D-.21D?\(9;?;Y;G#;G;)J2W\'VT6L"_8$N!CFNB>YC6'S2XV 9S6:?%.D@
MX:\A!'O3'S29J)!&%V[%P/:N<U/PA;7VHF[P0Y/:KP\5:26"B\AR?>M6WN([
MJ(2Q.&4]Q03K'4YO4O"%OJ,]M+(&S","NBL;9;.U2%>BU8-5[F]@M4W32*@]
MZ <G+0M"EJG9WT%ZI:"174'!(JX*1-K"BEHHH **** "BBD[4 ,>N6\4:/\
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M.U*RL,;I4*?>-6&Z577[U RP**!10 &N4\>?\B_<?2NK-<GX]8+X=N"?\\4
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M2" 1[TP3LSPOP[?7OAZ:X7R)B&E9N$/J:ZN'QQ>/*BFWN,$X^X:]"6RM2?\
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M*JYP^PG?8;H]J3(6(XJQK%J"I8#M6O;6H@0 "BZ@\Z(J1UJ;ZG:J-J=CAS&
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M 'I(I:04M #365K=RUI8R2KG(4G]*U>]8OB8?\2F;_<;^5 XJ[1S/@7Q%+K
MG\S=\LI7GZFN_P"U>1_"OK=?]=V_]"->N4%UE:1P/CCQ#-H[,(RW SQ6]I^J
MJ/#T-[*>3'N.:X?XJ??;_=IVMWTEMX.TV-#@218/YFF:*"<8DE]XQO-0N&CL
M8)-O]Y:ICQ7JFES(;J"9T)YR.E;OP_LX8=!%PZ@MGJ13->U_0[G?;W((V\'
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M.*]KP*,#TH Y>P\*6UEH[VB1J&=-K,.]<-)\+[U=4:6WO?+B(^Z!7L5)@>E
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MDY&A&6\L<5G:OO\ (/6MH+M%5[N 31E<5R1=I'IU(WA8XH[L]*!5ZZLI(V;
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ML:LE)G9AX.$;,IW1<P-C-<I<;_-;.:[9T#*0:P=0TYBQ9!549),SQ5-R5T8
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M77_7,UQ/P]ZCZFNVU[_D"W7_ %S-<3\/>H^IH ])%% H/2@!#4%Q.D$9>0X
M&:FK%\2DKI4I!_@;^5 XJ[L3V&L6FH!OL\H?:<&M$'->4?"^627[5O;/[]OY
MFO6 .*"IPY78SM0U>TT[B>4+5B"Y2X@65#E&&0:\T^*$LD;ML;'RUM?VL=-\
M&6KEOWCP\'WIE>S]U2[G1WNNV%CE9Y@I%0V_B?3+E@D5P&->?>']'OO$P^VW
M,V8B<8:K&M>$KFQ59;*=4*\G;2+5.%[-ZGJ,<BR+N4\5%=WL-G"TDS[5 Y-<
M_P"#9;IM*C%VQ:0#DFL'Q_JS>:EA$V&E&.*#-4[SLSL=/U^PU&4QV\P=@,\5
MJGIFO"_#TMSH&I*\[G:Y"U[%=W;#1_.C.6V \?2@=2FHO09>Z[8Z><3S!344
M'BK2[F0)'<@L>U>4023:SXBN8;RX"QJ> YQ6SJ?A:2*#S].ND#@<;3F@OV44
MM6>HO=1K!YQ;Y ,YK';QAI"/AKI0165&;J+PM,MPQ9UA/)KSWPS91:G>$7,J
M#)/WC0*G2BTVSU=?&&CLP"W2Y-;5K=Q7< EA8,I[UPL/A?31(I$T!.?[PKM-
M,M4M+-8HR"!Z4$34%\):9P@)-9%WXETZSDV33A6!Z5=U&.26RD2)MKD<&O-[
MGPK<_:)KJ^NE*%21N]:!0C%[L]%L-6M+\9MY0XK2KQ;PC>7,?B"."*0F'>0<
M=.M>SH<K0.I#E8\4M(*6@S"BBDS0 M%&:3- !4%S;I/&4=0<^HJ?/-,=@HR3
MB@#E+[P?;SNSAB,^E4X/!-N'R9&K6U3Q+;V.5^\1Z&LRR\9P23!6C(YZFC43
M29TFGZ1!8H B@^^*U,52M+V.[0,A!S[U<S0,6BDS2T %%%)0 M%%% !1110
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MQ011FD)H 3M4+_>6ICTJ!V =>: )P*=30V:=0 E)BG&FGI0! RCS*F&,5 S
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MZU7XA:M?W[06>UL,5'-=7X\N(-%\/QP6^U>=ORUS?PQT:._N3=31!@)#U^M
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MGFK1YJ^M/V+Z4;%]* (_-7UK,UV^%OILK*?F XK6\M<]*R]>L_M&G2*J\D4
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MP]ZCZFNVU[_D#77_ %S-<3\/>H^IH ])%+2"EH 0U0U.R-]:O#G&X$5?I"*
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M97#-5Z[CWP%<=JL* HP*4C(Q4-W9FY79R4T1C<C%5GSBNFNK 2 D#FLF;3Y
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M\]: *W@@%=(A4]0E=77->$A_H"8_NUTM !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** #O1110 P\BHT0@U-BEH 2EHHH **** "BBB@ HHHH **** "BB
MB@ HHHH 0TC#(IU% $"QX<G%2@8I<4M 7$-)3J* (W&13(TQ4]&* &TZBB@
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MHH ;400[\U/1B@ HHHH *:PS3J* *Z(0Y-3]J,"EH **** &L,BHT4AJFHH
M04M%% !36&5-.HH @B0@\U,*6B@ HHHH 8XS38E*YJ6B@ HHHH *CD!*XJ2B
M@".-=HJ2BB@ I#2T4 1R E:(UPHJ2B@ HHHH *BE!.,5+10!'&"!S4E%% !1
M110!#*A('UJ51@4M% !1110 AJ.5<K4M)B@!$'RBG444 %)2T4 02*2:D086
MGXHH **** &GK4;J2PJ:B@!%&!2T44 %--.I* *[+EJF (%+@9IU ""EHHH
M0BH"A\S.*L44 - Z4ZBB@!*2G44 0;#YH..*DQ3J6@!!2T44 (:A1"')J>C%
M !1110 AK%\36DMWHLT,2Y8]!6W2%0PP1D4 87ANTFM+14E7! K>I H7H,4M
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 AZ5$\J("68 >YJ20[49CV&:\=\>>+KA;P65D26;CY30!ZP7@G
M0_=(Q7-:KIFAWX99]N3QU%97A!]0.A.]V'!\IN6/M7E-]+JU_KCP6]Q,278
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M1110 4444 %%%% !1110 4F*6B@!*6BB@ HHHH **** "BBB@ HHHH ****
M"BBB@ I*6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M 3%+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&Q2YJ!)U>(2 _*1G-9-]XGT^QD*33A6!Z4 Y);F[FEK)T[6[34AFWD#5J@T
MFGJA:***!A1110 4444 %%%(:  FD# TUB<&HHR: +-%-S3J "BBB@ HHHH
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M/_6&K JHD@#DU+YR^M $](>E0^<OK1YRXH 62144Y(%5HKB,RX#"LO6+LK@
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MZ5'YJTAE7% #!_KA5BJ@<>9FIA*OK0!-147FK1YJT 2-TJ!?O4[S5J%9%W4
M6Q2U%YJTGFKZT 35QOQ%_P"18N?\]C77A]W2N0^(O_(L7/\ GL: )O O_(&@
M_P!RNLKD_ O_ "!H/]RNLH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% #)&V1LWH":\M\0_$>YTJ],*0J0"17JC*&4@]QBN9O\ P3I6H3>9-;*S
M9H \Z_X6Y>?\^Z4?\+<O/^?=*[K_ (5SHG_/HE'_  KG1?\ GT6@#QO7?%4_
MB"\MP\87$@/%>W^!\_V&N?:JR?#S14<.+100<BNFL;**P@\J)=J^E %;7O\
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M*6D/2@"NO^N%6:K+_KA5F@ HHHH 1NE0+]ZIVZ5 OWJ )Q2T@I: "N-^(O\
MR+%S_GL:[*N-^(O_ "+%S_GL: )O O\ R!H/]RNLKD_ O_(&@_W*ZR@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *3<*&.%KF->\5VNB*?,96;&<9H Z?(-&:\_TSXE65_(R,JQX&<DUB^(
M_B2T$_EVD+2 CJAH ]:R*,UY3X<^)@N9EM[F$HQ.,L:]0MI1-$KJ<@C- %+7
MO^0-=?\ 7,UQ/P]ZCZFNWU[_ ) MU_US-<1\/>H^IH ])%+2"EH ::R/$'_(
M+E_W#_*M>LCQ""=,E _N'^5!,_A9PWPV/_'S_P!=F_F:]/S7C7A#5&TEK@21
M'F5C^IKMXO&2.ZKY/4TC"A-*%F8/Q(&7;_=IFN2.GAC357H8^?UIGCN5[Z-G
MCC/*]JWFTLWWA&V4K\ZQ<4[&;7-*5A?!2(GAX.J@MGTK-U?Q1<022))%&44X
MY JAH.K7.@+]DN+=V0'J:37];@OH&BAT[+N,;A4]!>T7LTD[6.I\+ZPE[8AU
M"@;2>![5R&N7BZEXGMDW916P:M^'EN-+T%6>)@2I&"/:LC2/#=[K%Y/<B9HB
MKDC-'04I2G&,46O%%O%8)!+;]?,&?S%=UHUQ'JNC!&;(V@&N/U/P7?M;%I+U
MI O.*=X4ENH]-GM3N63>0#^)IK0J-XU/(AU'P[J.G:C+=Z?$7W'/)IJ>+-2L
MOW>HP1*@ZY&?Z5/;Z_>:;J<T=W#)+'T&[I47B'5+?4K-XX;#]XPX(J2=(W<7
MKV.J.HVU_P"'IWA(R8B3@5YUH+ZHMV?L,0?D]:ZO1+">VT&Z,@8;XN%/:L/P
MSJ7]EW7[V G!/6FPFG)Q;T-^VD\3?:$WVJA<\\__ %J[BR:4VZ^<,/W%<TOC
M&#./LU=!I]\M];+,J[<]JI'33MT9->AFM) G+$<5YA/X2U"[UF:X,1VL."":
M](U+S!92>7G=CC%<1:^);K3[V2.X@=@!C)I,FMRW7,9]K=7GA_6H;2881N22
M:]0LI_/MDD'0BO+9Y)O$'B2WF6!E0<$UZAI\)@M4C_NBA"H;OL712T@I:9TB
M9%&X5&Z%CP<4SRF_O4 3[A1N%0>4W]^CRF_OT 22, ,UP'C&]=KE85/!'K7<
MM$V#\U>>^+K62._23D@"@:W$TK3$6%97&21WJ[-8PSQ%" /H*BTNY22U5=PR
M!5QG1$+%P*P=TST8*'*<S%NTW5$"$A2_K7J-A<">W5\]J\JN";O5$"<X?M7I
MFEVSQ6:J6[5LMC@G\1K BC<*KB)O[U+Y3_WZ9!/N%&X5!Y3?WZ41M_>H GHI
MH&*=0 4444 %%%% !2;A2FH'C8GAL4 3;A2,1BH1$W]ZD,38^]0 1D>8:L;A
M514); -2>4_]Z@"?(IC,!4?E-_>I&B;'WJ3 RK^\.XJIZ51ANG63.?UJ2]MW
M61CSR:JQQL6XS6+O<]"G&/(=+9W D3DU;R*S;&!ECY/6K?EM_>K97.*=N;0G
MR*8Q&#3/*;^]2-&P'WJ9 Z @*?K4VX54CC8CK3_+?^]0!8R*-PJ#RG_OT>4_
M]Z@!\K#;38B,&FM&P'+4U(V(.#0!9!%+D5!Y3?WJ/*?^_0!/N%0S$;#2>4W]
M^F21,%/S4 2QD;14NX552-BOWJ?Y3_WZ )]PHR,5!Y3?WZ/*;^]0 RXF6->3
M2VTJR1@@U7NK5I%^]2VELT<8&ZD4[6+X(I=PJ#RF_O4>4W]ZF23%A56YG1 ,
MFI/*;^]52ZM6D ^:@<2U;RJ\>0:G!%4K6W:./&ZIO+;^]0#L3DBJ-]<>6A /
M6I_+;^]5#4+=W7(;I2EL53MS:F/-*7Y)/YU8M;AHW7!XJFZ,IP:EMXV=P!FL
M$W<]"48\IU$,GF1AO6I,BJEO"PA49J7RF_O5NCS7:XVZG\J,GVKGY[MV8\UL
M7MN[1_>KGWB8$@YK.;=SKP\8]33L;T[@I-;BL"*YNRMG:13R,&MX1-C[U5!F
M>(MS:%G<*3(J'RG_ +]'EMC[U6<X2GYQ4JD;:K.C!@":>(VQ]Z@"<$4NX5!Y
M3?WJ/*?^]0!*2.M4YKE$D4$]34WE-C[U4;BR9I5.[H:"H[FDCJPR#4F152.%
M@,;JD\I_[] GN3Y%&14'E-_?H\I_[U A&(\RIPPQ54H=V,U)Y38^]0!/N%&X
M5!Y3_P!^CRG_ +] $I85#D>=FE\IL<M480[\9H M!A2[A4/E-_>I/*;^]0!/
MN%(6&*A\IO[U'EMC[U "*1YE3[A50(=V,U+Y3_WJ )]PHW"H/*;^_2>4W]Z@
M"9F '6J27,;3%0><U,T+$8W51CLF68MN[T%)+J:H(I<BH/*;^]1Y3?WJ!-(L
M;A36(J+RG_OTAB;'WJ! A'F&IPPJJJ$L1FI/*;^]0!,2*3(J'RF_O4&)_P"]
M0!5OKSR1@=ZSX-1?S><8J;4;61L$$G%9L5M(T@&#6<F[G;3C#DU.HBD#J&J7
M<*IP0LL8!;M4OE-_>JT<<DKZ$N1FLV^O3%P*N^6W]ZLC4+5R=PR:4MC2BDY>
M\-MM18/SBMR*42(#FN8@MWD?H1700PLL2C=VI0N:5XP3T+0(IVX57\IO[U+Y
M3_WJLYA\A%,A.,TUHVQ]ZFQQL<_-0!;W"C<*@\I_[U'E-_>H GW"HY2-E,\I
MO[U,>-@O+4 2Q$8J7<*K)&2.#3O*?^]0!/N%(2*A\IO[U)Y3?WJ 'RD;:(B-
M@J)XV Y:A(V*\-0!:W"C<*K^4_\ >I?*?^]0!/N%0RD'%)Y3_P!ZFO&1U- $
ML9&VI-PJLD;'^*G>4W]Z@"?<*-PJ#RF_OT>4W]Z@!)ST^M3(PVU7D0@<G-.6
M)B/O4 6-PHW"H/*;^]1Y3?WJ )2156YG2,8)J3RV_O52N[1I.=U T7X7#("/
M2I0PJI! R1@;NU2^4W]Z@&3;A1N%0>4W]ZE\IO[U A)3\U2(1MJ%XR#UI5B8
M_P 5 %G<*-PJ#RG_ +]'E/\ WJ )BPJE/=(LJ@GO4WE-_>JC<69:53N[T%*W
M4TD=67(-.!YJO'"RIC=3_*;^]0)I$^13214?E-_>IIB;'WJ!$$MTBR!2><U<
M1P0.:RYK-FESN[U=6%@H^:@J1:W"D+#%0^4W]ZD,38^]029NH7>#M!K(\P^9
MG<?SJ_J%NX?-9Q0[JQE>YZ-&,>4U;"[.\*3UK;# BN;L;=VE4^];ZQ,!]ZK@
M]#EKI<VA8W"@D8JOY3?WJ7RF_O59@("/.%6-PJIL._K3_+;^]0!8W"C<*@\I
MO[]'E/\ WZ )F(Q4"D;J/*?^]4:QMN/S4 6P12[A5?RG_O4>6W]Z@"QD&N/^
M(O\ R+%S_GL:ZQ%(ZG-<G\1?^18N?I_0T 2^!?\ D#0?[E=97*>!O^0-!_N5
MU= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!'/Q Y]%-?/_ (L=M3\3Q6T['86(ZU]!.-R$>HQ7DWCGP9/<
MWBW=INWKS\M &-?_  _6+3([C3P=['GFMOP=X&MY[)Y-10^8K8%=1X-L)XM&
MACO0S,!R'K8U:%K?2Y?LJ8;L%H \6\8Z19Z/JT#6?#>:._O7L/A">2XT9&DZ
M@ 5Y(GAK5=8\1%[E)1&D@(STKVW2;-;&R2)>P% $6O?\@:Z_ZYFN)^'O4?4U
MVVO?\@:Z_P"N9KB?A[U'U- 'I(I:04M "&H+B!;B,HXX-3FFL1B@3V.?_P"$
M0TTDG8<DY-.7PCIR,&"G(-;H84_/%!*A'L8\V@6<R[74D5?AMD@A6)!\JC J
M8L :3>,4%**1EWNB6MZ3YJ=?05!!X7L('#*G/O6UN%+O'K18GDBWJBG/IL,\
M B9?E%.LM-ALD81+C/6K@(H+ 4%<JO<C>%9%*D<$8JA!HEK;3>9&N&SFM$.,
M]:<30%D9-YH-I>MF5.?:H8/"]A;R!U0Y'K6WO%&]?6E87+$K-9QM 8MORD8K
M)/A+36;<4.:WR1ZTW>*8.*>Y@_\ "(Z;G.TUKV=A#90B*(8458W"G T HI;#
M3$".167>>'K*^?=*G)]*U\TPR 4#DD]&4+#1;6P_U2]^]:( %(&S3J 22V%%
M+24M PI,4M% "8HQ2T4 (16-KFCKJ,#?+EL<5LFD/H: /*+C2[_2Y&*#Y>U5
M5?4;MO*P>?:O6)X(7'SQJ?J*K0VEIORL*9^E)HKGD<SX=\-%)/.N%YZBNW5
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MDHHH @E_U@J5?NU%+_K!4J_=H <*6D%%  >E5Y/OK4]0R_?6@"8=*=31TI:
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M+0!!\_K1EJGIIZ4 56SNJ4;L4UOO587I0!#\WK1\WK4U!H @;?M.#65)'/\
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MM_!.LZ8(W-ALU[EX4OVU#0K>X<Y9AS0!O4444 %%%% !1110 4444 9>O?\
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M))-';(W249_.ABK6Y=45?!FBK<WINV7&QSCCWKU2-=B@#M6)X;L([2P3"X+
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M:.AI_G^QH L45!Y_L://]C0!)+]RF0]#3'FW#&#34EVYX- %L45!Y_L://\
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MT;Q=XW+--:HO/]C36G]C3*%3_6&IQ51)/F)P:E\_'8T 3TAZ5#Y_L:#/GL:
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M6B*TV1GFM.PT]+9!@<U<E WBI5'RU/*EJ9QIQ3N 08Z4H0>E%.JC03:/2H'
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MC5@=*I/<QA\;AUJRDBL.#FFTT%R2@T@-+FD =JKG_758JN?]=0!.*=30:7-
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M0BL.K)DM%%%,Z"-G /--\X>AI[+NIOE"@!OG+Z&CSE]#3_*%'E"@"&291&Q
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M4AE$]QSSD9KNXHA&@51@"E50O  %25(PQ12T4 )2T44 %%%% !1110 4444
M)12T4 -J":V25>15BD;[M"=@,V*PB\T_**T(XP@P!BHX_P#6&IZ;DWN))!BC
M%%+2&,D^Z:BBZU+)]VHHOO4 3T4M% "4Q_NU)4;=#0 V#[I^M35#!]T_6IJ
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MZ )Q10*6@!*#WI:0]* *Z?ZRK%0+_K!5B@!**6B@!,564?O/QJUVJL/]9^-
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M3(^'WW)/]VN[%<)\/ON2?[M=V* %HHHH **** "BBB@ HHHH **** "BBB@
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M*^!])!S]F%;UAIL.GP+# @51VIF\.;J1ZFS1V4C+'O('3UKSB6XM);N07*I
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MXU8I,4 <WJ,+;\\]:RI%(-===6HF7@5AW&GN&K2+.NG45K%".,^O6NATV!A
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M&!0 ^BBB@ J":IZC=-QH <GW!3J11@8I: "DI:2@""7[XJ9/NTUTRP-/ P*
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M*6D%+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )2T44 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 )BEQ110 4444 %)BEHH 3%+110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 9>O?\ (&NO^N9KB?A[U'U-=MKW_(&NO^N9
MKB?A[U'U- 'I(I:04M !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !132<"FH^Z@"2BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHI#TH 6BHE?<Q%2T %%%% !12,<"F*
M^: )**** "BBFL<#- #J*9&VX4^@ HHHH **:QP*:C;LT 244@Z4M !113';
M"YH ?14:-FI* "BBB@ HIC':,TJ-N7- #J*** "BDIKMMH ?13$;<,T^@ HH
MHH **CD;%*IS0 ^BBB@ HHJ)WVT 2T4B\C-+0 444E "T5&[[6 IX.10 M%%
M% !114;/AL4 244@Y%+0 4444 %%1%\-BI>U !1110 44AIF_P"?% $E%%%
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M **** ,O7O\ D#77_7,UQ/P]ZCZFNVU[_D#77_7,UQ/P]ZCZF@#TD4M(*6@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@!C=#4453/]VH8NM %@=**.U% !1110 4444 %%%%
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MHHH **** "BBB@ HHHH **** "D;[M+2-]V@""/_ %AJQ5>/_6&K% !1110
MR3[M11?>J63[M11?>H L4444 %1MT-25&W0T -@^Z?K4U0P?=/UJ:@ HHHH
M9+]RF0]#3Y?N4R'H: )1TI:0=*6@ J*;[AJ6HION&@ C^Z*EJ*/[HJ6@ HHH
MH BE^Z:(?]6*)?NFB'_5B@"6BBB@!*BFZ"I:BFZ"@!T7W:DJ.+[M24 %%%%
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M^@ HHHH KR_>J2/[M1R_>J2/[M $E%%% !5>;_6+5BJ\W^L6@"=>E+2+TI:
M"D/2EI#TH KO][\:L+TJN_WOQJPO2@!:*** $[57/^NJQVJN?]=0!.*=313J
M "D/2EI#TH KK_KA5FJR_P"N%6: "BBDS0 'I5=?OU.:@3[Y^M %@4M- I10
M M5+_P#X\WJT:JW_ /QZ-0!YGX%_Y&_5O][_  KU9>E>4^!/^1OU;_>KU84
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MT9I&/RT 0Q_ZPU8JM%_K#5C- "T4F:,T -D^[447WJE?[M0Q_>H LT4F:,T
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M $$?^L-6!5>/_6M5C/% "T4F:,T (WW34,7^L-2L?E-0Q']Y0!8[TM)GFC-
M"TC?=/THS2,?E- $,']:L56A//XU8S0 M%)FC- #'Z4R'J?K3WZ4R'O]: )Z
M*3-&: %J*7[E29J.4_(: "'I4M10]*DS0 M(:,TA- #)ONT0_<%$I^6B'[@H
M EHI,T9H 6H9NU2YJ*;M0 L72I:BCZ5)F@!:*3-&: (9^@^M2I]VH9ST^M2H
M?EH ?129HS0 =ZAG^[4QJ&?[M $D?W13ZC3[HI^: %HI,T=J ()?O5)']VHY
M?O5)']V@"2BDS1F@!:KS??6I\U!-]]: )UZ4M-4\4N: %I#THS0>E %=_O?C
M5A>E5W^]4X/% "TM)1F@ [57/^NJQFJY_P!=0!.*=312YH 6D/2C-!/% %<?
MZX59JM_RV%6 : %IC. .:4D8K.U"X\M< \FDW9%0CS.Q)-?)'G!!JHFI /T%
M93.S'DTP=:QYW<[%AT=-#>))W%6@1BN5BD:-@0:W[.?SHZUC*YA5I<NJ+>:K
M7_\ QYM5C%5[_P#X\VJC \S\"?\ (X:M_O?X5ZL.U>4^!/\ D<-6_P![_"O5
MAVH 6BBHIWV1.WHI- $%YJ=I8KFXF5/K52U\3:5=R;(;M&;T%>*>*=7U/Q!X
M@73[:X"+O*$-5/4?#'B'PLL=Y%.&!< [!GC/L: /HQ75QE3D&ER*Y'P1J\NI
M:5ON-P9  =PQ6_+J5I$V&N(@?=Q0!?S56\U*UL=OVB54W=,T^&XBF7*2*P_V
M6S7D7Q0U2<:CI\$+X!E (H ]?M[F*ZC\R)PR^HJ:N<\-/'::,GFR*G /S'%:
ML>J6DK[5N(B?9Q0!>HJ(R*!G(QZU5?5+1'VM<1 ^A<4 7LBD:14&6.!4 N(Y
M(MZ.I&,Y!KS;Q=XU:UUB&PMYP XYP>* /2+C4+:UB$DLH53T)I;._M[Z,R6\
M@=0<9%><Z^EWJWARR6WNXED+?,2PY_6M[PC;?V'I+1W<T>XG=G<* .PS2Y%0
M)/&T7F!@5(ZYJ);ZWDDV+*A;V84 7**J2W]M!_K)HU^K@4L-];S_ .KFC;_=
M8&@"U130<]*=0 4444 %%%% !1110 4444 %%%% &7KW_(%NO^N9KA_A]U'^
M\:[C7O\ D#77_7,UQ'P^ZC_>- 'HZUPWC+_6C_?'\Z[H<5PGC4-N#*I.''\Z
M3.S .U74ZG1_^/"+_=%7)R?(D_W37*:=XD2WM$1HB2% K2@U^.\21!&0=IID
M5*,^=LY>Q&/$:8_O'^=,N3YOB%UDZ!QBGZ<DA\1QMM.-Q_G5OQ#IDL%TMW$"
M?FR<"DCTY27M>5]4=!=WC6-D&A0$@#@US;Z\6O(Q+%&"S=<"K</B.%[;9/;,
M2..:P+F3^TM2A,%LR!'Y.*###T-6I+;J=GJ5Z(-),N17,Z);Q7*WCRGECD5+
MK[S/;_9%#9XIEEX5U$P!X[O8'&2*'N714*=#WI6;8:+<BR\0O #^[ XKI==T
MX:E9DKDMMX KC+_1;W2)UN7E,C%@"16[?7MW]CAEA+ *@R!WH05H\TXSINYD
M0/JNCCRU@RB^M:NE^(DN+M([F.-'/H!3;3Q!%);[+FV9F Y)K)95U'68WM;=
MHE'!.*"^55.93C;S-+QDP,5N\?.6XJ"QN=96 >3;!EI_B6*2.UM006*MS5S3
MO$$,%J$,)R*742DUATE&YH://J<DI^U0!!VKINHKG+;Q#%-*J"(@DXKHE.0#
M5'EU[\UW&QGZCID=Z5+L1MK@]5LTM=:,:#@$?SKTMS@5Y[KR.=>8A3C(_G29
MU8"=IM-]#:UT[?#_  ?^68JMX04-IZD]=I_E6G?V;76A[1U*"N:TG4'T@M \
M;':I%-EP][#RBM[C;_Y/%=N%XKT&U/[E:\_T])-4UR.Y,; *<<BO1(DV(!09
MXUV48OHB04M%%!P$3EAT%-WOZ5-BC H @WOZ4;W]*GP/2C ]* *[/)CI7 ^,
MYYC<JI&%*UZ*0#VKE?%FDM=0M*@Y44 C&T=%%FI"C./2KK8*G(%<U9:A)IQ,
M<J-@#O4\VOJ\16.,AC633N=T*L>6Q2+M'K*>6/\ EI7J5G)(;=21VKSW0-*F
MOK_SY 0 V>17IL482,#'05HE9'')W8W>_I1O?TJ? ]*,#TIDD&]_2C<_I4^!
MZ48'I0 BDXYIU)2T %%%% !1110 5 S.#P*GI,"@"#>_I06?'2I\#TIK 8H
MJJ6WG J7>_I21C]X:G % $.]_2C>_I4^!Z48'I0!79WQTIB%^PJQ(/EJ*+K0
M N]_2C>_I4^!Z48% $&]_2FEGP<BK.!3' VT 5XRP' J3?)Z4L(&/QJ7 ]*
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M2@"#>_I4;L^X<5;P/2H)?OK0 !W]*-[^E2J*=@>E $&]_2C>_I4^!Z4A ]*
M*I+;NE2!W]*:P_>58 &.E $6]_2DWOZ5/@>E&!Z4 5R[^E1AF\S.*M,*A _>
MT +O?THWOZ5-@>E+@>E $&]_2D+OZ58P/2FD#% %4%@^<5+O?TI%'[RK&!Z4
M 0;W]*-[^E3X'I1@>E $&]_2H@3NSBK9 Q5=1^\_&@!V]_2C>_I4V!Z4N!Z4
M 0;W]*3>_I5C ]*:1Q0!50MO)Q4N]_2DC_UAJ?'M0!#O?THWOZ5-@>E+@>E
M%<L^.E1H6#\"K3#@U#&/WE "[W]*-[^E38%+@>E $&]_2@N^#Q4V!Z4C ;30
M!6C+ \"I-[^E)",_G5C H @WOZ4;W]*GP/2C ]* *[,^.E,C9QGBIW%-A'6@
M!-[^E&]_2I\#THP/2@"#>_I3'9RO(JS@4R0#8: (8V8#@4_>_I3H@,5+@>E
M$&]_2@N_I4^!Z4F!Z4 5I&<CD4(SA1@5+*!MHBQM'% #=[^E&]_2I\"C ]*
M(-[^E-=G/459P/2H9N * &([XZ4[>_I3HA\M2X'I0!!O?THWOZ5/@>E&!Z4
M5)"W&13U9\=*)QT^M2H!MH CWOZ4;W]*GP/2C ]* (=[^E12,Q7D5:P*AF'%
M "*SA1Q2[W]*>@^45)@>E $.]_2DWOZ5/@>E)@>E %5RY/2GJ[@=*6;@U(@^
M44 1[W]*7>_I4V!Z48'I0!!O?TJ*0L67(JX0/2J\H^=: %#/CI1O?TJ50,4[
M ]* (-[^E&]_2I\#TI"!F@"JS.6Z4\,^.E#CYZF &.E $6]_2C>_I4^!Z48'
MI0!!O?TJ,EO,SBK6/:H3CS: #=)Z4;W]*F XI<#TH @WOZ4;G]*GP/2D(&*
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M1110 4444 %%%% !1110 4444 9>O?\ (%NO^N9KB?A[U'^\:[;7O^0-=?\
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M["&T0+&.GM5ZDQ2T %%%% !1110 4444 %%%% !1110 4444 %(WW:6D;[M
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MTJO)]]: )QTIU-'2G4 %%%% %9_OU87I5=_OU87I0 M%%% "&H/^6]3FH/\
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M (:BG^Y4IJ&?[M $D?W13Z9']T4^@ HHHH KR_>J2/[M1R_>J2/[M $E%%%
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M[L%&V@#QC5OAI>)>R2:>K[)6RW)KJ/!W@==&*W$^_P"T=\FN^* TH4"@!%
M I](!2T %%%% !1110 4444 %%%% !1110!EZ]_R!;K_ *YFN)^'O4?[QKM]
M>YT:Z _YYFN)\ *RD9&/F- 'I%% I: $Q1BEHH 3%)BG44 -%+BEHH *2EHH
M ::,4ZB@!M&*=10 W%&*=10 VEQ2T4 )12T4 )BBEHH 2EHHH **** "BBB@
M HHHH **** &-]VHHNM2M]VHHNM %BBBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ I&^[2TC?=H @C_P!8:L57C_UAJQ0 4444 ,D^[447WJED^[447WJ
M+%%%% !4;=#4E1MT- #8/NGZU-4,'W3]:FH **** &2_<ID/0T^7[M,AZ&@"
M4=*6D'2EH *BF^X:EJ&;[IH 6/[HJ6HHONBI: "BBB@"*7[IHA_U8HE^Z:(?
M]6* ):*** $J*;H*EJ*;H* '1?=J2HXONU)0 4444 03]!]:?'TID_0?6GQ]
M* )**** "H)JGJO-0!,GW!3J:GW!3J "DI:0T 02_P"L%2K]VHI?]8*E7[M
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%)WH CF@2>)HW&588(JG9Z1:V)S!&%K1I*  4M%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% #&^[4476IFZ5'&I% $M+24M !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M$Q2XHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!,4M%% !11
M10 AHQ2T4 %%%% !28I:* #%%%% !1110 A&:3%.HH 2EHHH *3%+24 &!2T
MF*6@ HHHH **** "BBB@ I"*6B@! ,4M%% !1110 A&:,4N*3% "T444 %-Q
MDTZB@ HHHH **** "BBB@ HHHH *3%+10 F*6BB@ HHHH ,4444 %%%% "8H
M I:* "BBB@ HHHH **** "BBB@ I,4M% !1110 4A%+10 F*6BB@ HHHH **
M** "BBB@ HHHH ;C%**6B@ HHHH *3 I:3% "T444 )28IU% ""EHHH ****
M "BBB@ HHHH *3%+10 @'-+110 4444 )BEHHH **** "BBB@ HHHH ****
M$(H I:* "BBB@ I,4M% !1110 4444 %%%% !1110 4444 %%%% !1110 W%
M.HHH **** $Q1@4M% !1110 AZ54O\_96 JY37C#KM- 'EO@>WFB\6ZJ[QL%
M9N":]2'6J=MI5M:SO+&N&?K5T "@!:*** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BD) I
M P/0T .HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH 3-+3:0-D\4 /HHHH **** "BBB@
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M#BD+@4 .YHYJ/SE]12^8*+A8?149E4=Q1YR_WA1= 2<T<TP2@]#FCS .M*Z
M?S1S3/-4G@YH,@'6G<!_-'-1B=3W%'G+ZBE=!8DYHYIGF#UH$RYZBBZ DHI
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MLM44P,#R#1NIDCJ@FZ4]IE4<D53FNTZ9%%QJ+9?C^X*=56*Y1E'S"IPX/0T
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ML?K4E_<;FV@]JTYM#C=)*=AMQJ#,2%-4_M+[LYJ,GWIO>LW,[%2BD:$%^ZD
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M "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ /,_ G_ "-^K?[U>JCI7E7@3_D<-6_WJ]6':@!:*** "BBB@ HHHH ****
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M%% !1110 444AH :WW:BBZTLDJJ#EA^=017$>?O#\Z +U%,5@1P:?0 4444
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MVJLO^L_&K/:JP_UGXT 6:*2C- "TUJ=36H A3_6&IQ4"?ZQJG% "TAZ4M(:
M&M]TU#'_ *PU,WW34,7^LH L4M-I<T +2-]T_2EIK_=- $,']:L56A_K5@4
M+1110!&_2F0]3]:>],A[T 3T4F:!0 M12_<J6HI?N&@ AZ5+44-2T %(:6B@
M"*;[M$/W!1-]VB'&P4 2T444 %0S=JFJ&;M0 L7W:EJ*/[M2T %%%% $$_0?
M6I4^[44_0?6I4^[0 ZDI:2@ -0S?=J:H9^E #X_NBI*CC/RBI* "BBB@"O+]
MZI(_NU'+]ZI(_NT 24444 %5YOOK4_:J\OWUH L+TI:1?NTM !2'I1F@T 5W
M^]5A>E5W^]5A>E !2T4AH #TJN?]=5CM5?\ Y;4 3CI3J0=*6@ I#THS1VH
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M2O@.2>:A2N[&"KIRL=1GBC-0"7CH:/-^M6;V">X6%22:Q+K7%!P #46MW;
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M#6ATDQZ5 GWC2^=[&HED ;H: +8HJ'SL=C1YX]#0!-56_P#^/-JF5]U17_\
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MRI(IHBYYK*K352-F7";@[HP;VREDT]8PI+;<8J;1[5X+14D7!Q6R8\TUHCM
M%91PRC/G13JRY;'-ZOI;O<">!3N [5'=6]W/:0QE#D=:Z@0GO2F$8X%3+"1;
M;74<:S25S$T[1XXX,.HR?44S4M%5TW1+\P]!6^J$"E*$U;P\'#DL+VLN;F.9
MAL[@Z5Y+(=V:GT2QDMO-WIC/2M[R^*!'BE##*+3[#=9M./<P]7TPW4.4'SYS
MQ2Z7;R&%H[A.G S6YLXIHBP:KZO'GYQ>U?)RF7<:3"T;;47./2LC2M(>"\WN
MF,,<5UNPTWROFS4RPL')270%5DHM#E&% IXZ4@%.KI,@HHHI@%%%% !1110
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MY2%<T-#:NK'%7.D2";Y5.":U])TTP?,PP2*UI47>.*E5<+Q4J"3,HT%%W!5
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BDHH 8X&*BB ]!4S?=J**@">EI*6@ HHHH **** "BB
MB@ HHHH **** "BBB@ ICC(Y%/I&Z4 58U'F'@5:48JO'_K#5@=* L+1110
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M^LJP.E5V_P!95@=* %HHHH 0U!_RWJ<U!_RWH G%+2"EH *0]*6D/>@"!/\
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MXK=\,:ZYD6VF/XDU$H.)HFF=[FEIB,&4$=Z=4#%HHHH **** "BBB@ HHHH
M*3-+2'I0 9I&(V]:K7%PL"YS6//J3N3BKC!LER2-J,CS#R*L9%<HE]('ZFM*
MUU+)"M3=-H2FF;.:,U&KAP".])+,L:\FLTG>Q5T/<_*:BBZUEW.J=0M5HM4=
M6Z5HJ3L2YHZ3-&:HVU\LHP2,U<!S42312=QV:8W0TZF.>#2&-@^Z?K4]5X&'
MZU-F@!<TM)030 R4_+3(>AI)I$5<$TR">-L@,*=F%T6@:,TT$'I2T@%S44Q^
M0TYF &3Q5*YOHU4_,*$F]@ND6XCP*ES6=!?1L -PJ^CAAD&FTUN*Z>P[-&::
MQP,UG7>H"(D#FA)O8&[%V5P!UH@<; ,US<]\\F>2*(+UX\<DUK[)V(]HCJLT
MM9=KJ EP#P:T5;(K)IK<M.XXU%-T%/9L#FJDUU&#@L*238[I%F+[E254@N8V
M& PJT"#19K<+BYI,TIZ4PL ,GB@!DW0?6GIT%4Y[N,#&X5)#<QOC#"GRL5T7
M*3-)FCWI#%S4$Q%075\L(P,9K)EU1R>E7&G)DN:1T2-\@IV:P[;53P&&*U89
MED&0:4H-#4DRQFDHH) J1D,OWQ4J_=JO+(N\<U,C@K19A<>*6DH-  >E5Y/O
MK4_:H)/OK1U G'2G4Q33Z $S1F@FDR* (&_UE6!TJLS#S*LJ<B@!:*** $-0
M?\MJF:H ?WU %@49I,T9H 7-(3Q2,P5<DUG7&HK'D#!IJ+>PFTBVA_>58S7/
M+JS>9]VM&WOUEX) JG3DB5-,T,T9IJD$<&ESBH+%)XJLO^L_&B:Z2/JPJBNH
M)YG4=:I0;%S)&OGBC-013K*.#FIJEZ;C3N+FD/2BHI)43JV*%J U/]8:L"L^
M.ZC,I^<5=1PPR#FG9H5Q]!-&:KSW"PKDFDE?8;=B5C\IYJ*)AYG6L:XU-F)"
MCBJT=^ZR9R:U5)V,^='4YI<UD6NI;R%;C-:BL",@UG*+B]2TTQY--8_*:&(Q
MDU4FO(T4C<*23>P-V)H>*GS63!?H3@D=:T8I%<9!IN+0)IDN:**8S!1DFD,'
MZ5'#WJI/J"IP"#4-OJ2LQS@<U7)+<GF1L TM01S+(/E-35+T* U'+]PTYF &
M35&>^1 1D4TF]A-I%N(U+FLVWOHV.-PJ\CAQD'-#36X)IDM(:!12&1R_=HA^
MX*28@*:(3\@H EHS24M !44W:I<U#,PXH ='TJ6HHB"M2T )2TE!/% $$YX'
MUJ5/NU7GD48R>]31R*0,&C4-"6BFYI:  FH9C\M/=@!DFJ<MW'TW"FDV)NQ<
MC^Z*?FJT-Q&Z\,*LBDTT,6DS0>E1E@!DT@&2_>J1/NBJ<UU&&QN%3Q3(RC#5
M5F*Z+&:6FTM(89JO-]]:L'I5>;[ZT 6%Z49IH^[3J #-(:*AEG2(9)H2N C_
M 'OQJ<'BL>34EW]NM7(;Q) ,,*KDDB>9%W-(6IH.12.X1<FI*'D\57S^^JC<
MZF$.%P:SSJC^9G%:*FV3SHZ4&G;JQK?4]Q ;BM2-PZY!J91<=QJ29+FD)XIC
ML%7)K,N-3V9"\THQ;!M(OJ1YPJQFN9&J/YN<5HVVI>8V&&*MTVB5-,U:6F*P
M89!I]9EB-TJ!?O5.W2H%^]0!.*6D%+0 54O_ /CS:K=5+_\ X\VH \S\"?\
M(X:M_O?X5ZL.U>4^!/\ D<-6_P![_"O5AVH 6BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@""\)6UE(_N'^5>
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MYYKN/#^@)I\:R.N)*PJ5+[%PBUN;=E#Y-M&GH,59H'3BEK(U$I:** "BBB@
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MZ=:]*UGXA:7=Z.;=%?=M(KE/ WB33]'N));E6),I88^M ST;PK\/[;3HTFN
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M^%[5'R54\^E=(Y 4\U#"1GK2L!'!IUM;@;(E'T%6ME+FG4P$ Q2T44 %%%%
M!1110 4444 %%%% !24M% "8IK#BGTC=* *\8_>&I\5#'_K#5@46 3%%+10
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MU(>E %<?ZX58Q5=?]<*LT )CFEHHH 1NE0+]ZIVZ5 OWJ )Q2T@I: "JE_\
M\>;5;JI?_P#'FU 'F?@3_D<-6_WO\*]6':O*? G_ ".&K?[W^%>K#M0 M%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,",T*2>P#J**0G%,!LOW*9#T-17%RB+@L/SI+>YC?."/SI<R MCI2T@.113
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M,T9H 9)TID/4_6F3W"1Y!(_.F6US&Y(!'7UJ>97L!=HI :6J *BE^Y4M0S,
MAR<47 6&I:K0S(> P_.K&[-)-,!:0TM)BF!'-]VB'[@HE^[20_=% $U%%% !
M4,W:I:BF[4 +%TJ6HHNE2T %%%% $$_0?6I4^[4,_0?6ID^[0 ZDH-&:  U7
MG(V5'=W:P+DU@W.JNV<$BL*E>,'J!TT9^05(*YNTU8\!LUNP3B5 PITZT9[
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M_P CAJW^]_A7JP[5Y3X$_P"1PU;_ 'O\*]6':@!:*** "BBB@ HHHH ****
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M9PH$55'88JP*I69<QKOSG'>KHKV5:QPO<=1113$1M)MIOG#UJ0J#U%)L7TH
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MS\"?\CAJW^]_A7JP[5Y3X$_Y'#5O][_"O5AVH 6BBB@ HHHH **** "BBB@
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MHN!)FC-1&0 <TGF9Z4P)LT9J'?ZT&3 XI70$V:6H/,-'FFG<">BHO-I=YI7
MDHJ/S*;YAH;2 FHIBL33Z8!1110 4444 %%%% !112'I0 U_NFHHOZU(QX-1
M1&@"P*6FYIU !1110 4444 %%%% !1110 4444 %%%% !2-]VBD;[M $,?\
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M!/% %<?ZX59JM_RU%6 >* %HI,TM "-TJ!?O5.W2H%^]0!.*6D%+0 54O_\
MCS:K=5+_ /X\VH \S\"?\CAJW^]_A7JP[5Y3X$_Y'#5O][_"O5AVH 6BBB@
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M+C+2QW<$@>-6]14^:I6S QQ[>FT5<%>G!W1QO<=1115B"BFYI<T +129HS0
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M \S\"?\ (X:M_O?X5ZL.U>4^!/\ D<-6_P![_"O5AVH 6BBB@ HHHH ****
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MU1+&=W6K1^[4*_>IB%$)_O4ODG^]4HI: (U0KWS4%_\ \>;5:-5;_P#X\WH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBB@ I,4M% #-F&S3J6B@ HHHH #48CYS4E% ""EHHH *3%+10 Q4PQ-/HHH
M*2@T9H 0C--";6S4E% "8I:** "D(R*6B@"-$VU)110 444TM0 K#(IJ+BG#
MI2T %%%(3@4 %(RY7%*#2T -5=HIU%% !2&EHH :RY%(BX&*?10 @I:** "F
MLNZ@FE% "*,"G444 %%%% #'3=3@,"EHH **** $(IK)N%/HH :%P!2TM% !
M1110 QTW'-*!@ 4ZB@ HHHH *C=-Q!]*DHH 0<4M%% !24M% $93)S3@*=10
M 4444 %1[/FS4E% ""EHHH **** &;/FS3Z** "BBB@!*:$P<T^B@ HHHH 2
MF2+N7%244 8&FZ ECJ5Q=#.93DUNCK3J* "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME '<:/XVL]2G6$,=Y]:ZQ'WJ&'0UY!?Z>NF>)XX[9NB_PUZOIV?[/A+==O-
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MR",USVM^%+*2S=XT1#Z@5A^"[F:WU6XM,ED3@4 >FUA>(->CT>-69L9K:4Y
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MT@Z4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<DI/W5S7F%WXNU&:[,D-NKPYZT 9%UI>M">*:=]QCY4A:FU#5]4GLX[63S&
M;^Z:V'\;EX-J6\3.!@C JUH?B"#4KD6]U!"C#GA10!T?@VV,&GDE2"PSTKH9
MI!%&S'L":;;1HD2[  ".PJGJ]VMK:LSG ((H XG6?%]R;AK>T$@.<9VFL.'P
MSJFM7!GE8<G(W"NST&.QN89;I@C!7.21[UT%G=V4KM' 5RO4 4 >=3>&-<M%
M_<S*,>W_ ->N^\/PW,5F@N6W/MYJY+>VB3B%V&\]B*MH5V H!@T 172-)"RK
MU(KRN_\ "^K6]_+/;2*N]L]*]:ZTTI&>J@_A0!XBUCK%MJ#7,I+/W(4U/<ZG
M?W\T4$RR$8Q]TU["]M 028D/']VN7O+VTBU>&V$,6YS_ '10!L^'(/(T6!,8
MQ5^^_P"/5N0/<U);J%A  Q["L7Q9<^1H<Y#8.* //[_0=1.IS7-G*F6.>.:S
M9=/UF"^6YE8M(HX(4UUWA'4K126N)LLPZ-S7:))87 RJHW_ 10!Y'>:IJ-[+
M;6\RR$*<?=->H>&K<V^E*F,5;?3+.1E<0QY'(^45=CC6-,*,"@#-UFXEALI/
M))#[>,5YVFD:UK<^9Y08SV(KN/$6IOI\8*HK9'0URUOX[\HXEBBC^@% &;JW
M@:2S@\^)1N49.*T?!^N^1(+*<-N4=Q6K%XWTVZ7;/*@!Z\57M++3-0U1KBSF
MRQ.<+0!W<1W(&]1FH[N$3P/&?XABGPC9$H]!BH;N^@M%W3/M% 'G.J>#+XW+
M?9658SSBM?3/#YT.PFFVCSBF<CUK4O/%NDP@_OU+#VK O/B!;C*1%'[8(H R
MK>UU+7M4S<,3'GHPKTZQ@%M:118^ZN*XWPYK\NI:BJ?9XU0]U%=XH^6@#'U_
M5AI5D92&/..*\YO-:U77BT$)=8VX^937=>+)K2*RS<.  >]<OI?BNR2Y6'RX
M0I.,[10!G6?@?4EC\Y70.16GH^E:Y::G'YTRF('D ?\ UZ[E+^U^R+/N 0^U
M5K76;&[N1' ZL<XZ4 :T61$,]:SM4U2WL8F^T#*]Q6IVKS?Q]>!+ORF;:I6@
M#6O_  O9:O;BZMX@'8;@37!ZWI6JV"F&0EH0<X5:[C0O%NFQZ?#!)< %5Q6P
M^IZ/J"[-Z-GU H R/".O026J6VU@ZC:<UVJGBN5L-!LX[PSV\A/S9P*ZD4 <
M]XGUTZ/#D$@XR,5PDGC:[NX\+,1GUKN?$FDVVK%4ED*G&,"N/E\ !>8&=J ,
M*YM;G5GSYB[CW-;_ (2T34[.\R\JE/:JY\.:K9']S S8]374>%/[26=DO+<(
MH'!H [-!A%SUQ7(^-["YOK>(6[ %:Z\_=KBO$7B*YT^8".%7&>] '#21ZY:V
MAM6<F+.<!32Z5K5YHRRJ4E_>=<*:Z%/&\3<7$$*_\!%:%OK>B:@0C^4&/'"B
M@##\*O)JGBEKN1& 9?XA7JH&U /05E:9IEG"PGM\8/H*USPN: .'\<:;=:C:
MJEN<%6W<BN(N!K<=B]M)(6C/! 4UWOB/Q3'8,88@CR@X*D5S#^*;\_,UC%M_
MW10!0TWQ!=:59M"R2_=QPIK5\&![[54NY%8$,>H]ZGTS7['4)/(NXH8V/'"B
MNUTS2[:U4/!C!YX% &KT%<7XUL+J_@:.%@,UVI^X:X7Q%J6J6M\?L]JLD8'4
MT <O9WFOZ6AC\UBJ\ !35Q?&FH1(5G$S9&/N&I8_%=U'G[390@=\J*E7Q3IE
MR^V9(5)]%% %?P>'U#4WN)$88?/(KU1QA#CTKG?#L=E*C2VVTCKP*Z&3(0GT
M% 'F_C#2]0N=12XMVQL'I65#J^OV"*CR.5'HIKH]:\1WEE>!5MD9?4BJ2>,K
M=SBX@A7U^44 9=YXRO7M6AE68D_[)KH/ L!:66X92#(,\BHQK.@7@Q*\2Y]%
M%=9HT=H(0UJP*D<$"@#5J&ZS]G?;UQ5C'%4M2F^S6$THZJN: /+M9TS54UE[
MVV?&?:E7Q#KMF%$KR$#T0UU>@ZP=2<^;$FW&<XJW!J%C>730>5$2&Q]T4 <!
MJWBFZU&".W=)<[QG*FN^\'VAM].)(P7YJOJ\.EVLBB41H=P'W1ZUTNGI&+93
M']T@8H M#I3J3%+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% "'I7-^*]3?2[19$)!/I72UQ7Q"_Y!J4 6O".N_P!HZ4]Q/)C#XRQKHOM]
MJ,9G3GIS7B U"XL/ ]U) <,'XY^M:@M]5D\/0ZB^1MCW@AC0![ )HRNX,"OK
MFHOM]KNV^?'N],UY1;>,KQ/!GVG(\[?MJ6STS5KR%;],EF&\?,<4 >J/=0QK
MN>10OJ32)>V\GW)D;Z&O)_%^I:I9>&(&E^6=I IP?I5NT6[TKPZVI3%MP0.,
MF@#TUKVW5MK3(&]":D\Y-N[<-OKFO!%\6-?2FYDE8'J,&NNT7Q/<ZGX;N68_
MO$;:OTYH ]'_ +0M=VWSX\^FZI3/&J;V<!?7->$ZIJTEE)%*LC><S?,,\5T-
M[K^I3^#)KF/&Y< '/L: /4!J%JQVK/&3Z UBZOJK6MQM5J\NTC49I;JU:.1C
M(S#S 36YXMU.>WO %QT% 'I=O?0_9XVDE52P[FIA?6S/M69"?3->+:SJ^H-=
MZ5!"?];P>?K4^N7&I>'95NB2"7"G)/K0![*]Q'&NYW51ZDU&+^U(!$Z<^]>6
MZUXDO+R?3K* C_2$&[FLWQ(-6T&VMB,@&4*<L?44 >U)(KC*D$4^L'PQ.]QI
ML;R'YMHK>H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@!#TKF/%]V]MI4P0D$KUKIS6!XFTXZAITJ(,OMP* .'\/V20Z=_:
MD[JSNIZ_2LR"WO/$U^0)#Y:L5YI39:XENFGB,>4IKI+*)?"VEO(XQ(?FYH P
M=.2YT77&@\W(# <5Z[;L6A0GNHKRS18KG7-;>Z9<H2&!KU.%=D2KZ "@#"\7
MW(@TUAG[RD5R?AG4H+70GW2J'W'C-=+XN%K+;QQW+$ \#%<4G@_[2A:R+E3[
MT 7_  7)$^J:A,\BC+Y&3]*369?MWBMH%;<HP>/K68GAC6],9F@CZ]>35[PU
MI.H-XD-Q>IC(H ],LDV642^BBN<\=7)ATF/#8R^/Y5U2#;$H]!7,^*M+.JV@
MA'4'- '/:1<0V?AF[8RIO)SC-+X-PUY<7!8?,N:Q;CP?JT4+)$AV'W-16UMK
M^CQL(XA@C'- &M>2"\\<VRCD;2/Y5Z7;H$MU7T%>7>%+6ZN->BNKI<,I/\Z]
M5'3B@#D?'5Q)!H\FQL<U6\(:+;&%;IE5I&&[-:_BK2FU/3'C098UP5EXBU#P
M_*UO* $!P* /3-8L_MMBT8., FO-]!EN+'7S;F0E6DQBKDOQ">2,JC#)&*;X
M7T^XO]1-[,O1]PQ0!Z>IXJ"XABF&) "/>I#E4)]!7G/BKQC>Z==>5!MP?6@#
MKI](T<@F2.,?4UAWNBZ!R0( ?]ZN36[UW6+<RJHVXSP:SM/TR\U+4EMY&?D\
MX8T >@^&],LXKN1K8)_P$UVG\-<[X<T :0I.6RPYR:Z!^%S0!D:SI,.I1@2[
M>!U-</J7AVULD9H[F(,.V:E\6^*KVTE,,&,9P:XRWOAJ5UF^D=5/7!H )KS4
MX+C;;2LP!XV\UWW@F35)I0]X[E"O1A4.BP>'X0I60LY_O"N\L1 T"M !M[8%
M %D\)7FNI:G*WB)X?/"*KCJ:]&NW\FV9_2O&[K3[G6?$UUY )(.>#0!ZM$UA
M/ BM)&Q*C/-1R:+I=P.84:O.QH_B"Q8&-"0/4FI(=8\264H5XUVDXH ](L-)
MM+'_ (]XE3Z5H-]T@5E:#<W%W8"2X #^U7[B86\#R-T49- '%>(O#>I7U^\]
MO=;%/05SYTKQ#9$E;IR!Z"NR_P"$TTQ9=DDO/TJ_#X@TRY7*,I_ 4 >>Q^(]
M3TR=?MOFLA('(KTK1[J.]M5E1<9 )KAO'5[9SVT4<.W?Y@Z#W%=3X2B:+30&
M[@8H Z,D8YK%U:?3%4FY,;8[$UJ7&?(<+UP<5Y-XFT;6;NZ9T4[.>A- $^LZ
MEH\@:*WL-[=,KS7-VWAJ[U*XW11M$I/<4_3X+[2YB\R9^O-=;8^-(H"J2A%'
MLHH Z3PIH$NDP'S&W%A72R';$Y/]TU#I]TEW:QS)T89%37"EX64=QB@#RB"5
M9_%&^610(Y3U-3^);I+W7/(CD!57!X/O3M3\&7C7DD\"G+-GK6,WAO6[:Z,_
MEY;W)H [3Q+.L7ADQ!ADQ#^56? T 31X9,<E:X.\FUJZ9;>YC 3&.*]/\,V_
MV?1($Q@@4 ;#, *\NNG6[\3LI(PD@KTRX#&([>M>3:EI6L6NL374$0(9LC-
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MU8Q7F^TVAOJ* /18I$E0.C J>A%)<RB*(L>@JII$1BTV%6ZA:MS0K-&4?H:
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MY" HZDUPVJ>-;>*X:*.T6;!ZBM3QS=/!I,P1L'%9'ACPQ8W=HMS<*"[C)YH
MI)XOLI'Q/IB*#W;_ /771:?9Z/JP66&&$,.<#M3K_P $:5/"VV+YJY/PVTFE
MZY-;(?D\S;B@#U*VMUMH@B !1Z5A^*-8_LRU8*,NR\5T )*@^U>>>/F8W]J#
M]WO0 WPUJ.H74LEQ,)!$4)&>G2L6\\3WR7<GEQR.BL0<5W6A11RZ B1%<D$=
M?:LR/P['96]R]P%^9B>M $OA'Q"-3D,+1;'49-=H#QFO,_!Z*OB>Z$0^3;Q^
MM>ECA: (;B]AMQF614'O63=>)].A4_OXV/UK$\=0WLEJIM^@ZUY]I%O;7-SY
M>H*VXGG/% '=7OCNS0E5MTD_&FZ)KL>JZD$_LX(#_%_DUR%SI=B=4M8K9?E9
M\-S7JNCZ%:6"*T28;% &U$H$:@#''2L7Q/9M>:<43.1D\5N#@5B:UKMKI:,9
MS[8% ' >']??09Y8+B$@%SRU=;-XTLOLI8.A8@\9KG3-H7B"YV&-O,8X&:MG
MP-ID?SN!M_WA0!C:<\NN>*8;M4*HI(_6O6($V1!?2L#0=.TVT 6T7D'UKH^E
M '/Z]':7"-#<3H@/]ZN1D\)V<Q)@U-%STQ_^JN@\4:#-J<I>-E''<UR9\,ZW
M;'-O(G'O0!(_@^]"XBU)R/;_ /570>'/"/V"7SIIO-?.<FN9:Z\36!P\@./0
M&NR\*:C?7L4GVLY9>G% '6#I3'4,,'D4H.%J&2ZCC;:S@$^IH Y[6O"-OJ>7
M3;&YYW 5S#> KM,A=0<+Z?Y%>E+-&_1U/XU!?RI%:.^1Q0!RGA_PW:65P2\R
M32CKGJ*[90 @ [5YUX:NI;KQ)> G*@\5Z)G"<T <+XMN-3CEC-HDI /.VL&/
MQ-JMJ<S64S@>M>D-?6KR,C.N1UR13'L[&Z7!V$'W% '&VOC2"618[JQ5,\9;
M_P#77::4ME<1BYMXT&[NM<=XMT+38+1I8E D"Y'(K6^'[.= @W?YXH ZXC K
MBM?\13Z?<L@LVE4'K7:,<#FN>UB7354FY(/T(H YF+QE:N-L^G*N?[W_ .NK
M::KH-X,/! A/KFN9UFZT6XW):Q2>9V(%9.G^%K^_N=\0PF<\B@#UK1+2P51+
M:"/&?X:VIFV0LWH*Q?#6DMI5@(G'S=:V;@;H67U% 'F&M/=:SXB-C',T:=>*
M[W0],;3K,(S[V(ZUP&IS2:'XG-VX/E@=A766?C73I(%))!QSF@#G_&4U_I^H
M&Z2201%@,#IUKK_#FI?VA8*Q7!51FN,\9>(;;5;5+:WR6WC^==3X2M)+73QO
M&-P!H Z20D1L1U KR7QAKNH07^R,R1KCJ*]8=PD;,W0#FN4O]/TOQ 6&S=(#
MMH X.VL;W4K1ISJC\+DK_D4S0]"FU/4!&]P67."35_4M$U71!)]EP(6&,8[4
M[P5JL-E.$N@PFW9SCWH ]&T?1DTR+:I!..36E<-LA;'I2V\HFB61>C#(J*\D
M6.$LW2@#R&XU&:QUZ29[=G"R9&:ZRU^(,+@*\ 3ZFL^YU;0);F6.YAD+!L=*
MC33O#=[S'&1GU(H D\2^([74;1HXRI9E[&ND\%P>7H4#=\5RZ^$+!YU>WVX'
M^T*[_2+46=C'".BT 6KA_+B+>E<'INJ7%QXCNHO,;8AZ5V6LR"+397]*\ST/
M4K:UUF]EEX+#B@#L+KQ)]GUV+3Q'NW+G/Y4_Q!=6L%K$\UNKEQQFN.M;N*]\
M8P3EAM QR?I6GXSO%=[&*-@<MC@_6@#JO#+QRZ8'CB$8ST%;;=*Q_#L)@TM5
MJUJ]T]KITTJ?>5<B@!\T%I)S,B'ZUEW5OH2_ZU8 ?>O-YO%NLWMT8(I=O^]4
M>IV6L?93-<2H>,\&@#JKZ'03(HB:W!+#IFNQT6WCM[/$>-IYXKS;POX2_M&&
M*ZN!D'D5ZI:6ZVT"QKT  H EEVF,AL8(YKD]5L-%^9Y3 K>]:GB*ZFM[)C ?
MF(->,ZE<:I=3M]I#%<GH#0!IZPT&XQV(5CT!2J^BZ5K-Q<+\TR+GK5S1;G1K
M3:UQ#+Y@Z\5Z%HVNZ;=,L5LI!]Z -O3(WAL8D<DL%P2:342OV9@\@0$=35M,
M$9KF_&ER+?2MV>] '+-X0-_/++;:AGYLG;_^JJ\GA35[7/E7\Q]A_P#JK1\(
M:U9VJRJYPSMZUVL6IVLO(=>?<4 >;V'A34KV[5KNXD*@XPU>F:=9K8V4<"_P
MBIDEB8C:RGZ&IJ *>IWJ6-D\[XPOK7%VGB0:C?.AL_W:G[W:M#Q[+(-$F5>F
M*YZVN;/3]"#K_KI(_7O0!?UOQ#IEG-Y2V<4K8J?P[J^F7TQ"VD43YXKG?#.A
M+K4_VR]&4YZT6]G%9>(XTM1A?-P: /7$ "\=*J:CJ$=C:O+(1\HS@U:BSL&:
MX?Q[<.FR$'Y''- &/J?B^ZO9#':V;LH.=R]_UJK!XGFMF"WFFL5/4M_^NNM\
M(:/:#289MH+$<U>US0+&ZLG+Q_-CB@"MHITO5D61+:(/UP.U=4B!4 48 KR_
MP83;>(;JV0_(@P!7J*_='TH BEF2$9=@![UG3:QIR [YX_Q-8OC>>\AM%-L>
MW/%>:Z>)]2NO+N3U]>* /1[WQ+I$>[Y89/QJA8:WIVI7HBCT^,=]P_\ UUQN
MH:)!%J%I$G/FMAL&O2M \*6-C&LJQXD]: .CM\"%=HP,<"GR,JKEL8I50* !
MT%<7XYU:^T^T!M20=V.E '23SZ<H/FO&/K6'=W^@*3D6[&O/K";4]<?;)*O)
MQR<57N=%==16&0@Y< X- '=V%UI5WJ:1V]K%D]&6N[@4+$J@8 %<OH'A2STW
MRKA$Q)@'-=6HP* !C@5Q/BCQ2UBZP01EW;CBNTE_U9QZ5Y+J#JGB'?=#Y5EX
MH Z*S\0-:Z(MS=H1(?X6ZUAMXX#W/S:?F//WO\FJ/B"\_M;4?L=KDQY!Q6SJ
M6A6-GX>+8 E,>>O>@#K-!FLM0MDNHH41F]*WUZ5Q'@%&72H2>F*[=>E "T44
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 AZ5Q/CGQ4WA
M^VC:(!G8XQ7:NX5<FO!_&VL1WVO-:R*72*3I0!VW@GQE+K16*Y0)(S<"K?C'
MQ/+H=W9(BY69\$_G7F>CZM%8^-K3R%,< 3D>_%=!\37:\;1VC8 NW!_.@#TC
M3]?M+B%=\JAR.E:$M[!'M+R ;NE>27VE7^F^'EODN5$@(Y!JK=^(KV=+-#*<
MJ,$^M 'LYO(EB$I<;#WJ+^U+3'^M%</J&H3)X'@F$F)"W7\JXA]6U"5&1)\,
M>AH ]L.LV(8 SKDU;-S$(?-+#9ZUXW?6&IP>'K6^:X&]GY/Y5+)XDOI=#DMU
ME(DQ@-VH ]"UCQ);6MJ[0R*S*"<53\(>)&U?3Y+B8!0KE?YUQ%[HE^WAR.[:
MX0LZDL<]:/"DDD7@VY"S*D@E/S$_6@#U7^VK'S-GGKNSC%237T$*;WD 7UKP
MW6-2N;62!HF._/+#O5[6-:U"7P;YPF/FEP,T >P?VS8@J//7+=*LFZB\OS"X
MV>M>12Z?J4/AV+4&G!81;P:S%\6:C<>'+>-9R)2X!8_A0![/'JUE+)Y:S MG
M&*LR7,,";Y' 7UKSB'P_J(2VNH[N-2RACDU@^)_$NH6LHL?-9V1N2HZT >Q6
M^HVMRV(I0QSVJ[7@^EZ]J$.LVPB258B,L-IYKVO3KAKBRCD;()'.: +M%(*6
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI#0!!< F
M-@.I%>3Z_P"&]4NKF21?-*Y.!FO5KJX2WB:1SP!7GNJ^-G:5XK5)"5.,J":
M.:L+;4=(?+:?YF.["NDLO%]W'*L;6*QKWK+C\4SHV;N"9E/7*FNKT-]'UI-R
MP8;.,$T =3I]Q]JM$F(QN%2W#A(R2<"GP01P1+'&N%'04VYA\Z$IZT >:WD.
MDSZI*9[P!MW0UL:?;:"JA1)$Y]Q4>H>!%N9VEC"AF.2:R9? ^J6YW03HN* .
M[MK72]H"11'/^S6C'#'&N(U"CT KRV&TUZSO85>[!7=R*],T\R&T7S3ENYH
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M[:XC3_#"7NF7%U+*0V[(KI/B"9VT]%B5FVOG@9]*X^'Q--:Z;);&&8%O]DT
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M:Y;4)=0MC]GN(V$?3)-:D&HZOH%QY=RTDD8X^5370PWND^((=D\0$A&/G.*
M+W@W4+5M+BMTD!=1R*ZU?NUQNB>&QIVHM-$R>41@ &NQ4844 <WXGUD::(08
MU?>V,&FR/8_V4UW/;Q(!URM<YXVF,U_;1[QA91G\ZE\5W21^'&MXW4DH.A]J
M -8:+IVI6QF0(JXSD"JVC:780:L!!<[G'\(JSI&VV\*^82,F&L?P:!<ZL+C'
M<C- 'HZ#"@>E<)\09]UJ( >KXKO:Y/Q//I<1S=1B1@W0'F@#F+/P&UQ:+,MS
M(A9<X!J&X\(ZI:_ZFXG?'^U7H6A7L5Y:?ND*JHP :DEU:WAN#"[J&!QR: ..
M\-V&JPW\?VGS=@/.XUZ'CC%,CV.H9<'-.D(5"Q["@#-UK38]2L'@<XW=ZX$>
M!I6N^9Y#&#P,\5=\3>);I;_['9,P9AQ@9JW<^(WTK286G8M,Z]NN: %U*TFT
M?1S!91EV]JI^%O#]P]RUW=A@V=P!K$7QC<M-YDZ2F+/=37IFBWL=[91NG=<T
M :8Z5R7C+2'O[<RQ@ED7@"NL8A4)]!7&ZEXQ@L[@PRPR,,XX!H YC2/%=WHD
M:V<\.%3N:T-2\=&XM6AA569AVJ5K[P_J;;YK7YC_ 'C5RTTOPX\BND<8(_VA
M0!2\$Z;.U_+?3(5\P5Z.O053L8K>.%1;@;!TP:MYH AN+6*Y0K(@8'U%<9K?
M@M)2TULY1^P3BNYS0<$4 >&2V=_I>IPR7".R1OD%J]7\/ZQ'J5JC*1D]A5;Q
M/#9BT9IX]WR\5!X,BMS8I)!'M4T =9UJC?:=#?1%)44Y]15_ HXH \RU?P;-
M9RF>R=\CG:M<Q:R7%GJVZ]!7##EJ]R9 PP:X_P 5:?IL<:R30@LQZT ;VD:E
M#?VBO$P8  <5JCI7+^$K>.&P;RUPNZNG'2@ ?[M<1XFT*QO'#R7'DL.>*Z?5
M[X6%BTQ/2O,4BU?Q)>SB.?$:MP".U &SH>DZ78RF478F?'\54;S2K_5[_;F1
M8-V.#QBH;CPCK-C'YB7"\>E6_"FNW,5X;2]9F8MM&: .XT+2UTS3XX <[>]:
MXZ4U.5S3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* *.J+,UA((1E^PKS73?A\]]K5S=:BKHK\@BO5R,C%-"@4 >6^(/ATL$+7&F
MAWN%'R@U#XF\-ZM?Z;I(B@+2VX^89Z=:]8*@\$4;%/:@#R"XTWQ->V"Z;-:
M0Y!R#S_*M'4/ TO]F1/ C-<(GW?>O3?+3.<<TN.,4 >-2Z3XIN]%CT^2R C5
MLY!Y_E3H?!NIKMW0'..:]CV*!TI-B^E '$:EH=U/X6MK18\R(<D?E6/'X.NF
MT"X!B/VC/RBO4-HQTH"C&,4 >0/8>*)=-6P-F/+08!SS_*HXO!NK?\(I<6OE
M.LSOD $^]>Q>6OI2[0!C% 'B,7A;7Y;98);,8C& >_\ *M"[\):G+X7%H(#Y
MF_.*]>V+Z4FQ?2@#C+S1;J7PDEFL?[P0[<>]<C!X"O!X;A3RF%PK9V_E7L6T
M8QCBC: .!Q0!Y;:P^*)IH+>:T"P1C;D'M^5.U[P9=,JW5M$9)]V2&KT\1J.0
M*=M!'- 'F.DP^(6OX5N-,@6)>"P49_E7I%LC)"H*@'T%2A%4\"GT (*6BB@
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MQ\<WL:ZW")&PFWFH]1\0V,FB0VT,@9L8/%=5KFB6-_)NF>,/CC=7/W'P^\U
M\-PH7MB@"IX4TC3)(C+/(?-+<*>E>CV,%M%&!"JXQU"UYC-X/U.U_P"/>^88
M["NX\+VEY;P;;F1G..] '1'&*Q]0\0:?8Y$\H4^F*V&^Z1[5YMXBTN,W+237
MB8SG:30!8U+Q;H]S$5WQG/?:*X+4KA?MBRV$C'G. <5T-E#I'F!)/*/N37::
M9H^B31@I%"Q]J *G@BZO+FV3[0O&WKFNS%06UG!:KMAC" >E23S+!$9&X H
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M55.0#0!Z)X0^73>3V'>NDX[5X_I^I:UI@$?V*4J.]>FZ)=2W5A'),A1B.0:
M-/H:YKQ!#I13=>DUOW,ODQ&3TKRNY6X\2:Y-;B5D2-^U $5Q%X8DE(!DJ>T\
M-VEUDV+-GMDUN-\/8C#_ ,?'S8ZXKF;FQN_#&K6X$[NCOTH [_P[I-SIT:B;
MM[ULZAN^Q2;/O8XJ/2[K[;9++C&:NM&&&#R* /&KF74]-UN:[C7[PQTK/EUV
M=]8ANKD'Y/:O;)-+M)OOP(?J*I3>&M/E!'V:,'UQ0!YOJ_B>/5(K:"(DG>,\
M5Z+X;MOL^G*,8W8-9S^!K0SK(I5=IS@"NHMX!;Q*@[#% $HH*@]12T4 ,,:$
M8*C\JJRZ;!+]Y!^57*6@"O!;);KA!@5GZ]=&TL6<'!P:V*Y'QU<^1I2@=2V*
M *'A"ZDOTN#<[#B0@?G72RZ-93#+*O/IBO)+"QU>+=-;>=M)SA:TX];UZS;#
MVDS >M '</X/TUY-^TYK?M;=+6W2%!\JC KAM"\67UWJ$=M-9L@;N:[V-MR@
MF@".Y5&B(DZ5PNJP>'?/;SBV_/.*UO&NI/9:7((B0WJ*YC2/!\VJQ&YFNW'F
M#< : *S:-X>NYOW+/N/O5R#P0QNX9H@3&ISR:34/ <]HAFAO')'.!5SP7J\X
MFEM+@L2K;06- '<Z?;_9K18L8Q2WUY%9V[2RG"KUJST%<EXVN2FF2Q+U9: (
M+O0-*\0'[2N[+<DBK>F^';33;5OLHRX/&:S=(E:S\+1RLQW,A'Z4O@J:>XAF
MEFD9@)3U^IH SSX7N[[6&ENO]6'R.:]"LK1+.W6.,8 %>?\ VV>?Q))$DS!4
MDZ UZ-'_ *M<^@H 9<7,=O&7D. !6%/XNTN(D,V2*;XLM[BXL&%N6W!?X:\G
ML;>XAO\ ;?LR+W+T =WJ'C^Q4%8B/Q%95IKTFJWBJB KD?PUEZK961O;..WD
M23S.N*])\/Z):VVG1GR4WCOCF@#9M%VVT?\ NBIF=5&6(H"X  Z"N3\<W-W;
M:<K6JL6SSMH WKF_M+?_ %A7]*P;WQ%HJ[A(1GV KS;3C=:K/LN=0DB).,$U
M+J6B&WN;=$O#-YC@&@#K;74-&U'4UB@!W'VKOK90ENBKT KFO#_A6"R$<Y(+
MX!Z5U84(N/2@#$\26MW=:>4M?OYKSJ\C\0:3F5L!1SUKTR\UJTM)S'/*JX]:
MY3Q;K%C<VOEPS(Q9>U '.VGBK7#$)/E*'VK9T34FU+48S<+\^>PK3\'VE@^A
M0B41L_?(KJ+?3;.-P\4**1W H O1J%0 5DZ[82W]E)%%U-:_05@ZIXD@TRZ$
M4NT9&<F@#S[4]$U;25\U>!]356PU+Q!)#YL6"@.*Z3Q-XFL[NVC2.1#G@XJY
MX0DTY=+*RR1EBV<&@"MH&M:O-<".Z5=N<=*[]?NBJD%O9L=T*)]0*N=!0!S7
MBB^N[:(1VN-SCBN.M= U?5W#7@RA]#6_XMU.ZM;B+RK,S"L:#Q]/9X273_+Q
MZT ;$7P]L/)PZL&/I4FG>"8=/N_-C#8SW-16OQ"AE($B*F:ZG3-6AU)<Q,#Q
MGB@"^B[$4>@Q7G'CN5KJ>WMAD@O@UZ.3BN-U"YM)=56.14+*_>@#$A\ EH5D
MB#9(SUJ"?POK=J1Y X'J37I O+:V"H\BJ<#@U.\L'E^8[#;C.: ./\+VVK0W
M:_;0-N*[@=*K6\MM,NZ!E;W%6>U &+K>O6VEP$R-@]*Q=--IXHCD>5<[3@<5
MS_B/=>^+);620B,$'!Z=:] TK3H+.TC$2J,J"<=Z .4O]!T*PE43;@2V!74Z
M1IUG;P VP&T\YKG/&VD-+ )UF*D'.!4WP_O);C39!(Q;:^T$_4T =ET%9\^K
M6MO/Y,C88UH,,J1ZUQ/B'PM<:A=_:([MX^.@H ZZ&^@F'R./SJ;S%/1A^=>0
MW>G7VEAF.HR_+VSUK.M?&%_#.%&^7\: /<0P/2D8X!(K!\,7UQ?6I>>,H<9&
M:VY3MC9O0$T <1XHU?4K2Y4VH4H.N17.GQ9-_P O2#WPM==9:Q97EY);7$<9
M;>0-U:\NAZ=(N3;18^E 'GZ:UH=US<!@?85V'AFTTP$S6.?F'>L[4M!T=0P,
ML41^E;N@645I;KY,@=2."* -P],5CWV@V6H,3*,FM*Z=D@+*,MZ5YG>Z]K5K
MJ$NVSE9-W% '17/@+39E( ;\ZY;6_"O]B8GMBPV\\FKD/CV_A;;+8,/<U2U3
MQ1<Z^RVZ6I&>#B@#M?!5[+>Z)"\IRQKIF^[6!X1L&L-%BC<$,/6MR>98HF=R
M !US0!YSXJ\/WCWKW=FHWN>]4M'\-7US?1W-^ 0G'%:>N>,F6Y>VMK83;>XK
M(A\8:A:'=)I[!>O- %G6]7N&E_LRU'RJ=O2NI\':4^G:=B489FW51T'5-.UB
M8N\,2S=3ZUV<:JJ *,"@"*ZR;>0+UQQ7E.L:?JT&LM>P*/QKU*^N%M;:25OX
M1FO,M3\73SW;""Q\Q/44 8EY=ZD]W!-<KS$<C J]JGBI[^RCM3G=O':NC\.Z
MO9ZNQAN+*-&!QR*Z:;PKI\I!6&-2#G@4 0>$[7[/8!L8W@&MJ^G^SVSR>BDT
M^VM5MHPB] ,56U="]C(%Y^4_RH \X6[U#7]5_=',:L5/->AV\4EMI00_ZQ5K
MS[POJ,.EWDL5T%C+2D@M]:[X:UIS1Y^U1D&@#BCXDOK/7EM[G C.:]%LI5GM
M8Y5_B&:\N\2W%O>^($2TVN2O5?PKTK1D9-+@5NH6@!=6NA9V32DXQ7E]II\W
MBK4I_,),<;]CVKT?Q+"\^DNJ D^U<'X/U:#3;Z[BN2L99\#- %VY^'5LD),(
M?>/>L;3I;WP_K<-K(<1NWK7I9UBP:(L+E,8KSC6;J/4O%%H;<A@K8)6@#U2W
MD\Z(..AK,\2N5T6<KUQ5ZP0I9HK<$4Z\MENH&A;HU 'G_@R"VEU"5Y/OX[UZ
M&\<<D6PD;:\KUC1=1T?4'N;+S'4GHM1KXHUI0%-G+QQUH =X@LXK'Q!;O 3N
M>7GFO3]-9FM4+=<"O-=&T>]UC4ENKQ70*VX!J]2BB$<:J.PH H:QJ:Z=;M(Q
MQ@9K-M;ZUUO2%GFY1N^*I>.9PB119^^,51MY%LO!T7.TYQ0!:B\-Z)J3L8@Q
M(/-7+'3-(TZ[\J,?O%]:S_!Q<6UU*Y.-V1FLVTFEN_&=PH<[0 <?G0!Z6F-@
MV],<5C>(98EM-LI(W<#%:\?$2CV%<1X_O/*@MP#M^?F@#!7PO=W&Z>RR5SW-
M,;2O$=D<H!CW)KH_#?B"PM['RI;A 2>]=&NJ:7.!B>-LT <7H6H:Z-16*Y5=
MG?BO1X"3"I;J1S5.'["[YB5"WJ*O+TH :\8?@CBJ4VCVLX.]!S[56UC7H])3
M<^.N.:IVWC+3YP-\T:_C0 ^;P?ILV<J<GTJI!X(L;6^2XC#97WK:CU[3I!\M
MTA_&KD-U#<#,;AA[4 /C3RXPHZ"N>\8ZFUAI$IC.' XKI.E<1\0(7?3)74$@
M"@#*\.6%[,DM]-G:PW#FL;53J5_K12V)SBNP\*:I9R:4MN\J*P3!%73;Z;9R
MFZ,T><4 <KX1UB]COWM;H\AMM>I X7BO+-#VWOB":2)1M67.17J/\/X4 <?X
MQUJ:U46T#?/(.*H>'H[^&R>ZN?XHSCGVJIXTW)KEI(P_=@\FNKTYK6_TA(XY
M5&0>E 'FCZKK#2SS0D&-'(.?K7;^#M:FU']U<8+*/2EN=)L]'TJY+.K%CNYK
M/\%1[]3FD080CC% 'HJCB@TJ]*9(VU&;T% "TTH#U -<1J_C6XTW43 +0LH'
MWJ;;_$.-V DB5,^M '4ZK.ME:&4*H(]JRO#>M3:H\X?&(VP,5C^(O%5K=:6%
MBD4N3T%7O MMLMYI/[YS0!V0Z4ZD Q2T %%%% !1110 4444 %%%% !1110
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M),RQ3L2Q[UYU3E=D.5)!]J /<()TG4.IR#[U9KSWPIK[%O(E/3@9KOE;(!H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM>6BW4!C<9!JU10!YW<_#YI;HR(ZA&.2*T+S2'TC1DBLAMEZ$J*[/%-9%;J
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MUW750NA$8 'RL: /0="-AN,=I&%VCJ*Z#(Q7/>&]"_LF ;MV\C!R:WG^5<T
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M\/ZDVH6BLR,IQWK7F8"-B?2LO08_^);#(0 S+SBM"\1WMV"#YB* /*TCCO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBHQX&30 ^YU#2VB8AHV/TKA?#UC;:GKM\652@?CCZ5!)X6UME9XKE"A/;_\
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M-MX?:[#XDV@_I5CQCI-]=7K2P$X# CCWK!O]2UAM/:UF\UEQCA#0!VW@,O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!2U&PBU"W:"7.UNM<C=_#ZR<DQA\GWKNZ3;0!Y?/X N(P3;[]W;YC4
M>F^#]3@U**2=,JC9Y->J8I-@STH CC78@%4]2U>#34WSM@8S6B165J^BKJL1
M1GV\8H H6WC32KCA93FM*+6;2=<HX_.N,G^'3*28KTK]/_U5DW7A+5+(YCO9
MF4>E $][-]O\4/$ASL<']:]-MP1!&/11_*O-?".B7*:O)-<!FR/O-WKTU>$
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M0;-58AFC_P :P_&3W4>O^<MNSH%K)U;Q#-?I9Q/;F-8N#[]: /0/#UTY\/\
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M.O;Z=6O+F3W#4 ='X%B=+4NPX9>*[*J6G6"6-JD*8^48S5[M0 4444 %%%%
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M3[W28+V3=,JL/0BIK?3[:V4"*)5^@H \QB\ W\=J&16$GU-;'A[0=4LKM3<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML3I+P,'"FO1=!UI-7M%F4,,_WA7*WFJZ#+)L0P[F.!\HKJ?#\426*F(#;[4
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M?2]0,)60J!V!JO;?$>T!Q+'+D^Q_PKKKO1;6\<M)&I)[D5CW/@FRFR1A?H*
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MLF\IDC[IJ;19='C=3>VTAD[G'_UJ[@:_H-R2LGD@D_W12?8- O3E+A QZ8%
M&CHVK:3E8;5"OUKJ8\,H8=#7&V?A""*Z$\-PY KL($\N%4SG:,4 3"EI!TI:
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBD- ",1CFJDPM&!$C)^)JCXBU"73].::+&[WK
MR9_$NJZI?&!1U; P: /4;N#1=A\PQ'_@0KG+B'PZ\WEI;H6/H:Y+6-*U&VM4
MGN&D7>VW[QKH?"_@\2[+J9Y-PY')H [_ $>"*"PC6%=J <"GZK,\&GR21@[A
MTQ4]M +>%8UZ"GR('7:1D&@#Q'4->U>?4WA,[QJ6P-PJ?4M&NETLW<EY')[
MUW6N>#+74-TB B3J-HQS7G^LZ5JNF0M Z-Y&<Y)- &UX3\*1WG[^90V.1FO3
M;.U6TA$2#"BN,\&ZY9?9TM_,_> 8(]Z[P$$4 5=1B>6PECC.&8<5XGK6E7EK
MJC-.K2)D=!7NW%4;[3K>]C*2(O/?% 'DTRZ2VBR;( LP7N><UU/@?1K5K&.=
MXP2169K_ (%=2TED';OC)Q4OA?5+_3Y5L)T50G% 'I<4:QKM08%25'#S$I]1
MFI* "BBB@ HHHH **** "BBB@ HHHH **** "D-+36Z4 8FO60O[5X/-5-PQ
M\QKSRZ^'=PO[R*=#SD$5T7B^^:/4(848@L.QJ:ZU1]-T&V?(+L<<T <O#8Z]
MI:_)<,57L!6[H&KZE+=&.Y\PC/<5N:1J#76E23S1ID'CBL_1=6GO=9N(/*C"
M(>" * .T3E03Z4ZD3H*=0 4444 %(3Q2TU^E $4D,<ZX<9%49= T^<_/ #4%
MQXCT^TN&AFFPPZBK-OK=E.N8Y<T 8NH>#]*\MI!;J,#)K.\/:591WZS6Z*-I
MQP:Z#7K](],E*M]Y#BN:\!J\T;3DD@2'^= 'H$8PN*?2+TI: "BBB@ IC-M4
MGT%.[5'*,Q,/8T >;^*]3GOM9CTZW<J)!S3[?X?^;;J\A4N1UK,UF3^SO%]O
M/<?*@!)/Y5Z%IVM6=U;J8Y,\4 ><:MH5_P"&\W<4V(T["O0?"^I'4=/C+$[@
MO)-87CO5;5M&EME8&4]!5[P+"\=B'88#+Q0!UX%+110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %+
M47=+*0QYW <8KS.^UC6[:X8@RE/0*:]+U&\BLK=Y92 JC)KSZ^\<JUPZ6T<+
MJ/510!4B\9W*?\?%M.V/]DU?M?$^FWLR)-9/N)QR*S(_%-K-)MNUB12><**Z
M;3=$T;5 EQ!(Q8'=P* .LL4B2W7R5VJ1G%6Q4$,7E($7H!BIUH ,4FVG44 -
MVT;:=2'I0 VF-$C_ 'A65KNLIH]N)78 $XYK#A^(&F,V))P/7I0!T\VEV<H)
M>(&N.U*/2+;7X[3[+EV&<C\*W%\6Z5/$WEW&3BN-$Z:CXVMV4[EP?Z4 >F62
MHEI&(UVKC@5S_C6\:WT=]AP<UTD "0JOH*XGQ^938.D8SS0!S]EX72[TVXO9
M "VW<":S;#6;VRC^Q6V\D=U%6(?%TL&DR6DFU<IM%)X7UO3;219;MU#=\@&@
M#4T32=6O=0CNKF4[0V<$5Z;"A2,+Z5F:5K&GZBO^BLIQZ 5LXH ;69JFE0ZG
M'LE4,!ZUIFN'U_Q1=Z;=,D(4@'O0 V?X?V[ONA5%K&U#P9J&GQM/#<* @S@5
M<MOB(,XN75?6GZEX[L;FQDBCE4LZXQQ0!-X&U:YG9;:X<NV<9KT#%><> ;62
M1Q=D?Q5Z10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %)2TTGF@"M=VT=S&8Y5#*>QK
MA-;\%D.;FR;RV'.%%;?B7Q*FCY!8@@UC6OQ%LF&)68_A0!Q>IR:FGEV]V)61
M'!W-TZUZCX7U*VGLXXT==P ! -8UWK&A:W%ME!R?:IO#.C6UO<>;;9V[L]:
M.ZKF/%.HW5E$QMXG<@?PUTI;%9>IZA9VZ'[01B@#A8/&M]!CSK&7\:M2>+[&
M^39=6J@GLU4=9\1:5.6BMP2_3I7-Q>'=0UBZ#QK\IH [31+*RN+[S[5D'S9*
MK7H X45R/A3PJVD*S2CYFZUUY&%H YGQ5KITN#8G,CCC%8_AS5;Z>)[BX$@4
MH<;OI5+QJQ.NV(;[N>:ZRUM4GT58X-O((_2@#SR3Q=?+=38CDDC5R#Z5UWAF
M]M-7(8VZK+C))ZU47PTEAIMXUR!\S$U!X*C":O,$_P!7MXH ]&C&%QZ4^FI]
MVG4 %%%% !1110 4444 %%%% !1110 4444 %,?A2?:GTA&1CUH \I\6WNSQ
M!;R,F53K5#7O$$-Y:6T*84+(,\^]>C:GX4L=2;=,A)KG[GX<6+#]TAS]: &C
M5[2W\,R+',F\@< ^U/\  T)DNIK@_P 8SFLF[^'MR(RL X]S7:>&=(ETNT5)
M0 P&#0!T-%%% !1110 4UAD4M,FF6&,NYPHZT <;K?A&34;IYDGV%JYR;P?J
MUKDQ7TGT%=K>>,--M"59B2/2N?OOB'9IGRBWXB@#F;G3=<P(Y)9G7IR*[SP1
M8/9:5MD4ABV>:Y6/QG?7MTBP\JS<_+7H^F%WM5:0<D4 : Z4M(*6@ HHHH #
MTJ-W5%)8@"I#TK+UAG6RDV==IH P=?LM,U=6'GQ++C .>17'GP[?0.5M=18K
MV"USUS-?P7S[]V=QQU]:U].N];^] Z?C0!LZ=X-N[JX62\NFD7N&KT;3[1+.
MW2) !M&.*\_TW6]=^UK',5V^PKT2S=I+=&?[Q'- %FBDI: "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I.]
M+32* .(\=73*JP*V-ZTOA?0;%])BDFA1Y".2:K>-M)O[ZXCDM@/E%<_!J/B+
M2HEB!&U?8T =EJWA6PDM',<*(<=:YWP=)+;:[<6FXLB<"J<_C34! 8Y]W/H#
M6EX$C:YU2>Z93\XSR* /2E^Z/I2T@Z4M !1110 4AZ4M(Q &30!G:CID.HQ>
M7*H8>]<U=>!;64YC")^%6=:\:V.ESM [$.M<S<^/[B7/V4GVXH ?>>!98@3'
M>[![58\,^&WLM3CG>?S2IZUSZ^*-<U2<P1,"1UXKO?"EK?):;KW&\G- '3C@
M5AZY?:?;1-]J$;G^ZU;%P_EV[L.PS7EU]&VO>)OLTAS&1ZT 33ZKHLCD?8H@
M#WJ6UTK2-4XB:&-CV%;'_"O]->W7*'=CUKE-;T*3PU*+FVRJ;@.M '=>'_#W
M]E%B)0RL<C%=16)X=O#>:?&S=0HS6W0 F*HW.E65R29;=&)ZDU?I,4 <[-X2
MTZ3.+:,?A5%? UF)M^Q, YQBNPQ1B@"E8V$-C$(X4"@>E7J3%+0 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MNH)K9?*=2/8T 7HX]B*/05)29I: "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%-+4;) PSGB@#H!TI:04M !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "'I28IU% ""D
M?&WFG50U9I4T^0P@EP.!0!0N] TV^D9Y4!9NO(K)G\!:5+G$/)]ZYN?6M<M9
MR?LK%0?6K,7CO4(1B6U QZT 9FMZ"?#MW!);84,]>D>';E[K35=SEN!7FVHZ
MO=^);RW00X5'&<5ZAHUI]DL%C]A0!I"EI!2T %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 8HQ110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !364,,'I3J* *<FFVTO
MWXP:I3>&=,F^];@ULT4 9%KX=T^S?=% %-:H4 8IU% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
E%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>g23ode3tb50n000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g23ode3tb50n000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 6+!V8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI* %
MHI*6@ HHHH **** "BDS10 M%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444E "
MT4E&: %HHI":  G YJ/S4SC>OYU3UFZ-IITDHZBO,CXIG6_8ECC=ZT&D:;D>
MN@YI:Y71/$@O76-L9-=.&RH([T$RBX[CZ*044$BT444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !129HR*  G%(6'>J6H:K:Z="TM
MQ)M4=:\V\0_%:*U+1V#I(>G(%-1;$Y)'J+W4$?WYHU^K"J,_B"P@ZW$1Q_MB
MOG'5O'NIZFS;FV _W6Q7.S:C=RMEKF;G_;-:*D9^T/J%_&FFH<>8A_X$*?%X
MPTV4X\U!]7%?*OVFXS_KY?\ OLTOVJX'_+Q+_P!]FG[(7M#ZZ@UBQG^[<Q?]
M]BK:SQ/]R16^AS7R+;:S>VQ!6XE./5S76Z)\3-3T]E5@K+ZL<U+IL:J'TAFG
M5Y]X?^)-AJ05+F=5D/88KNX+B.>,/&V0:AIHT33)J*3-+2&%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%&: "DS0363K6K)IEH92P!'K0-*YJ>8F<;A^=.R*\SB\7&:Z)+@
M 'BNTTK6(+N%?G&[O18N5-I7-BF22+&N6.,56;4[4':9.:YGQ+X@2.'9"X)Z
M4"C!MV%\3ZS$]K);J1S[UYE+$#.6##DT[5-0>1&.XG/O6)'?.K]<U21UPARH
M['2;L64JOGI74_\ "<0Q"-.<]#7FB7;,F:K/*YDR2>OK3:"4%(]\T?5XM2@5
MT/)]ZU<UXWX5U_[%,B,_'3DUZY:3K<6Z2 YR,U!RU(<K+-%)2T&84444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^M(:9OT444B@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *IZA>)96KRR,  IQFK9KS/XI>(/L6E^1$^)-V#32NQ2=D>7>.O$TNLZ
MFP5R$0E<9ZUQO:GRN9)6<]6.:970M#F8"EHHI@%%*JEC@5NV7A'4;Y T2<'U
M%%UU"Q@YI*[1/AMK##(5:H7_ ()U33T+R)D#T%*Z'8YK-+2R1-$Y5P01ZBFU
M3$+1112 56*,&4X(Z&O7OA?XM998]/N)#CU8UY!5W2KZ33[Y)HS@@BI:NBHN
MS/KZ.0.BL.0>E25S_A/5%U+1X"&RRH,UT%<YT)A1110 4444 %%%% !1110
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M% !1110 4444 %%%% !1110 444G:@!::S +FHYIEA0LY  K-_MRSERFX?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MKO6P[%+112.<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;GO7J2ZE8PC9YBJ1VI,YZDVM$+I^EP6401%Q6A@"JT-[!-]R0&GRW<,*[G<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;<UCB:24;I%86M+VEFSH\T9I 117GGJ#J*04M !1110 4444 %%%% !1110
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MI=(E:UNEV>H%#)FN9'KJD$ ^U/JI8R-);J6'85;J#A>@4444 %%%% !1110
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MKGBO/MK+*2?6MNUNL0JKG@5Z$X*2U.*[6QVT/B1\!=QKH](U+[5P3S7F$5W
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)20V\(N)F;M5"215..*?+/LCP.M4"KR/067%( +=*:-LK?>IKHXA JO$C[J
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M7!SVD<J'REP:]O#\T::3/.G).6AGK<-D<UL6UR1;*0*QTMG+D8/!]*O<Q1!
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MFAF$]HO R%KFH+0MVK8M)?(PC X-;)G)*W0AD>5)> <5>MKV3 %6VM8Y8O,
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS59D-;^J0^7.P"UEO"W]TT 46X%0N":MO'@]*9Y1(Z4 4>AIW45(T1#4;>U
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M1 .M>IZ'IXL[*-64;@/2O)M.U<QW4;] M>K:3K,%S9*2ZA@,GFDS"M>VAM<
M=J X)QFN%\0^+1;S&&'G(^\#6=H?B2>:]"L[,&..M28JFVKGIM<'\0-1GLX8
MQ$<!ASS7<1MOC#>HKC?']D+BPW_W%H%#XCQR?5KAR09&Q_O5G/.7))-$R[2>
M:CC7<>M4=EET)E?BG[@PI&4*N*C.1TIC)0N#5B$GM5>$%C@U?BCQ0!>M@#@G
MM6U9SLKJ :Q[6%W; !KHM/TIY)%Y(H&]CTS0)&>S4M_=K8K/TBV^SVB#.?EK
M1J#@EN%%%%!(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MLU7P&%5MWO2-(0, TS0FE;RTRM-@W2-\U5RQ(Y-#70C7:M S5DCC\O!JBEO
M20_K53[2Q'+&H_-;.030!:O=-A*!HASWK+:U5>".:MK,Y."QQ4C0C'F;L^U
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M%9FC:0FFI@=<5LTF<U2?,PHHHI&84444 %%%% !1110 4444 %%%% !1110
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MXJ:+K0!T-A=84(33+W31-*KH!@]:H6Y(/6MJTFQP>:!D4=O';1@XYJU;W9#
M \56U&38NX>M9\-^4?H* UN=UI,\OVE"IZD5Z1%(HB7<P!P.IKR32-61"&;
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M6INK)HQ6C3'YX--/E=Q25U8\>N-'DCO',@^4-Z5B:[$%C*QC%>I>)5AMTWD
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M+=%':BD8!1110 AKQKX@02"[9L\%J]E/2O,O'EH&^8^M-&U'XCS>SB^:N_\
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M;2(M<9Z"K,[N\Y&.,UH6UJBP[L?-3-2CJP0I'P.!62H#' K2U  G%9P'EC-
MBPK)"F3@FH'D5SD=ZKR%I6YH52* '2 GD4+%NIW.,5)&I)H D@1489YK5:,O
M"-@Z#G%44@)'2MG3=QC9".V.E ]3";,<G(I78G%;5QIFYB=IS67=P&!UR*F7
MPNP+<ELXNYK5C*] 16,MXJQ *?FJ)+^59ASQ7CRPTYWE(ZE4458Z57*GBKUK
M<H?ED((]#6)!<>8F32^: _6N'E<7H;*TEJ=5IND)=WJNDJJ V<5Z79V_V:!4
M%>5>'+U([Q=S=6KUBWF66-64YXKV<)6<X69Y6+CRRTV)Q2TE+78<84AI:0T
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M5A-*"2<55FU"02;0: +%RGV?#=<T0ZBH%5;FX:6)<^E458*?F- #]:1)2KH
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MR\;!WYCLPLE\)I"EI%Z4M<)VA1110 4444 %%%% "&L+7="CU9%#-C%;V*3
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M]GCQ]T?E3DB1/N@#\*DQ0!479=D+1110,**** "BBB@ HHHH **** "BBB@
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MK5AL((!A$ JSC Q0V.=1R,ZXT:VN'W%0/H*LVUE';+A /RJR*6D9W8W:#P:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=HEK"(UZ"O.Q5=6Y4=&'HOFYF6>U.'2FTZO//0"BBB@ HHHH **** "BBB@
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M5$S;N[G3^'O%T]M<#SI"4Z8KU#3];MKN$/YBCCNU> HC1GO6A%J,\"X61O\
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M,CI3Z1F%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'=E!P:NVE[(9.>E8RI=2U+4]6\,>66!R,Y]:[A"*\9T?6'M!N![UZ'H&MF_
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M4JCDK *6BBD9!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MLJ,YX!I">QZQI4ADM%9NM7ZQM*U"V:V4(U:RR!AD&I.&2=Q]%)FB@D6BFEL
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MD%HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]8CO(GP XR:L UYWINH2B>/>>IKOK:421!L]:1A4ARD]%%%(S"BBB@ HHHH
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MULD4V5+<]JF16L9_D).*KWL8LI4=" &.:KW.IAES_%ZTN5L:.WL=1$T0#X!
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M<<5+,JDDD7$&U<4^D% I'(+1110 4444 %%%% !1110 4444 %%%% !1110
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M16A(&F4\TVD!S'BO3DN[)VQ\U>3ZI (@4'4<5[S/ LR%6&0:\F\4V0BNV(3
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-9[2Y'6I)I_,!JJ!EJL[.I<MV)'-/9BK<5$AVC%2/CB@":.9JT+663.:RHV
M-78G/:@#7^TMP,UI6RF8"L&*3<<8K?TJ,1X>1]H'K0,74YOL\"J#U'-<YO5F
MK0UFY6:0JK< ]:Q1E7ZT 6R@QD56D!/%3"0!>M5Y)5SUH 9Y>.33@5 JO++Z
M&B)&<9)(% A[/E]HJP@*X-1K;%7#9S5R%3(VW% SH-%*%!OK4OKJ(HJH>16
MN;2U+9PWI4ND6%UJ=R2-^,T"V.T\+0M/(NX?+7H$2!$ 'I6'X=T@V%LN\_-[
MUT&.*EG'4E=BT444C,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***3- "TAZ4'I4<D@1"S'
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=6W<5/$,G!HN)%@?:0#Q4G00JOK5DC$&5ZU$DJ/W HFN$B0X.3Z4,#,+,TS
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4AI:::& V1MJ$^@S7GWB?Q@;:0V\3X!ZUVFJR2
M1V,AC&3M/\J\#U=KF>]D+J1\QQ79@Z2F[R,:LFMB"]N#=7;S$Y+&F1(#RP^6
MJZHZOR#6@H'V?CK7J[;')/8JR0*JLR"JD<K;L&M/EHRN.U4?LA5\GBJ3,!X(
M:J\FY9,]JL!<=*5DW+@BF%M2L 7-/*@#%"#!Q4XCR,FI;.B*T*P1=W(JPL0Q
MQ0%C#<M4V452<TFRBM,Y0X6J[Y9#FB692_6CS 5JD!3$7S<U9C7%(HW-Q5Q(
MP%R:&P#EHP*11BE+@G:M-DD6->O-("*1N:C,H88ICR[LU5R=W6G89(V=U)N_
M.GJNX4AB.:H0T'FK"J334@).:EPR]J38@&Y:<)]II5Y&#2>6N>M(9/L66/>!
MS216X:09'>IX%^7 K3L=&N[B0,D3%?45#DEN%M!PM$$8&.U9]S;*"<"NIGTB
MX@BW[#P.E95S92$9*D5E>^IR7=SF)(\'I56<'(Q75+HTLR[E0FLN?29EFP4/
M6EHRT[&7;M*#@]*DG )%:J::RCE>:I7=JT1Y%%@YKF:_R<U868^5Q44BAAC-
M/B4 8J1D7GON(S3P2W6I_LN5W 5#AE/W: #8:=Y>*> 2.E2*AQ3Z"ZD04YJP
M RKF@(>PJ[''NA"D4Q-E:,MUKH-'E<D#/ K$:(IQCK6QHT1WDDXXJB&=C9:B
M(R"3TKO=(O!<P+CL*\PME+RA17HGA^(QPCZ5R8N*Y;FV$DU.QT HI!2UYQZA
M#.2(SBN1OMS2-SWKI]1=HX"0*Y"XG+.3[UR8AZV.F@M"FT$GF9SQ1.=J_A4I
MD)7-4I2Q-9&NQ&#EJO0$8YJ@.#S5J(^]-BN6+AUC52M,MI7D?GI3+ELJHJ6U
MQMI-:#3.@TR2,.!WKHATKE;&)Q(K#)YKIH22@)K?#O2QSUEK<E%+2"EKI,0H
MHHH *;BG4E $?DJ6W8YIV,4ZBE:P"8HQQ2TG/I3 4=*6BB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *.U%% '(^(/"\^IWD5Q RJT?()J&#P]K22!GN4*@_Y[
MUVE% '+:MH^J7/EFUG5"JX.:H67A&\DN%DU-TE"G*X]:[C%% $:+L15'11BI
M*** "BBB@"O>+NMG_P!TUX)XAAF_M.3*-]\XXKZ!897%<_J/A>TOYA(XP?85
MU8:LJ3U,*U-S6AX[:6<H@\PQL01_=K+DA=)3GIFO>TT&UM[%HE13A3C(]J\E
MUNP:WO74K@%C7?1Q"J-I'+.DZ:,2+;Z<U4OU,DGX5H/Y4*Y9L&L:ZNLW(9>0
M*Z4M10;>X1H00*6XBR<U)%)N&<"D9EW]:9H46A.,U".&Q6D6P<$<&F2P(1O!
MYIW @5"15F*)A@TV-<5HP;6CQZ"DV*P@^?"BFW,WEQJN:FM5W38]ZSK^-OM+
M=>M2M6,%C67D#FJ;H5D(]#6A:+M()IEW$%;<>,]*I/4"LJ!ZBDB8=*D!QWJ6
M-LG!%,"F@8&K/G;![TZ92IR!55@QH#J.:Y9F'/0U=@E$HQ6<J$=:GB*J>M*P
MV:<=KN;/%3.H5/+%4A=,%P*GMF:20 U+3$36T)$H)Z9K7U6>(:,(^^:CM[=9
M,8ZBLO78KF,D!3Y>>M93:>Y,F8<B(&+8JLTJLV"*LS8V8/7%460]JYWY$H<\
M7/% A-,#L.M3P@LP]Z2&[H;L*]:GB.35B6U(CR1421E:TBR![28.*DB;/2F&
M,$U(L>.E4B31MYL#:W(J0Q!6WKTJK"AJ_$/D.:FI34XN+ZCIS<)*2!6R!Q5J
M/+$9JNBEGPHR*OQQ\<U\CC:4*,^6+N?4X6M*K"\E8>L8JY;Q#&:K?='%3V[N
M!TKSI:G8E8VK/*L,5W&B;C&I:N1T^/>@9QC%=;H\N["KTKMR_#3E/VG1'GX[
M$0C:'5F\*&.%)]!0O2AAD$>HKVSSSSWQ3XKDL;H)&S+46G_$" VVRXWLV.:L
M^,?"QNP;B(,S 5Y=/:2VLS(P((JDCJA&,D:WB:[MM5N#+"I''>N-DA*R$8K;
MA!W8-5KID5CTIFR5E8SO+XYIZJ-IQ36D+'BI8U)!S0!!Y6YJGC@"#)I\<>&I
M6#DX H 4=>*OV"L) 1UJG'&X&2*W=&57D"GKF@9?95A@65ZR-0UF.>!H4!&:
MT-<FC2(1JW(ZBN3V@29)H 1CW-/CEJ&=N.*@23GK0(NO.AZBJ[RDMP>*A=SF
MF DF@9=B8FI&!8TRT&6&:L21'>=HXH$.LV*2C%;$T@6 -ZBLS3X&>=01WJ[>
MSK&OED].*!E%+@-+FO2?!L =@YQZUYI;0B67Y3U->C>'?,M(@6XXXI$R5U8]
M17! J2LC3+_SE"L>:UAR*DXI1<79BT444$A1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2&EII
MZT ,DC$B%6&016'<>$]+G<NUN"QK?H/2FI2C\+$TGN<?=>"=,$$CK  0I/45
MY1K2"QNVAC(QD]*]TUJ?R=/E(/5#7S_J;-->R,Q/WC_.O2P<I2NY,YZJ2'6]
MRN/GIUQ*KQ96LF:38,"HH[IE.#TKO2.:4%T-& ,Q)-3#[YSTQ2VKB2,D8J;R
M^,FALRLTRBI7><CO3I)!MPM-O'4'"5GF<@T6N="V'REMV132\CKC-*)=YVGO
M4H3 S3&4&R#4D>3Q5EH1(O'6H5C,;XIW N6T/.31>,T8 !X-6+=@4QWJ&[3S
M&&.U3U I1L^<@TDNXGYC4VTQ+TIK?-5 0A#MJ$H0:O*AQG%,8@=0* *P9@.*
M<DIS@FAF&:80#R*8RP9]B\=:@6YD+<GBFJA8\U*( 34M#T+J+O4$4GDN6XHA
M;R^*Z_P_X>DU90X0[2.HJ)S4%=BM?8RM%LVN;Z.$J2&]J]NT?1[>VL(QY>&Q
MS6-X>\(Q6#B5P=X/&178*-HP*\K%8A3=HG13A9:E*73+:92K)D&J;^&K%^L(
MK;%+7,JDULRG3@^AD0>'K&%-HAJG>>%+.;YDB :NCI>*:J33O<3I0:M8\[N?
M!T@F)7;BN*\8Z2]@R#:>1V%>[E%/85S7BO0DU*PD95S(%XXKHCB97LS"6&25
MT?.#[M_%30DC[U=!>>&KNVE;?"0HK->V"-BNV-GJF<KNG9DL,B[<&ITLA<-E
M.*J+$W&*ZG0M*DN8/E4ELT]MR;]CG'LWB?#5(L''2NGN='FW%6CQBF1Z/+C.
MSBGHR7)F/!8%N=M;-EHS2C.PD8]*V]-T@MPRUVFDZ0D2 L@Z>E9U*L8(JG"5
M1V/,)-%9Y,",_E6A9Z'-$<XX/M7I_P#8]OG=M'Y4?V5%GI^E8_7$;2PDNC.4
MTC1E,B[EKM+6V6!  *9;6*0-D5<^E<M6JYLZ,/05-:[BCI2T45B=)1U(C[.1
M7(21Y=R?6NROD#0FN/N\K(P'K7'7^(ZJ.QGS3JC$8J!KE#VI;@#))JBS8/%2
ME<ID[2"G1S;35;=D4S=@4^45S6\Q' S5B(C'RUCH[8JY;3D-@TI1&CK-%D$A
M(8=*Z(8 P*X[2[X0N>G)KJ+>Z69>M;4I16AC5B[W+0I:04M=!B%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 E--.I#2 AF<)$S,> #7COB_58);P^4N,9!KU+7FD73W\H<[
M3FO M3,CSS;O[QKT,#!7<C"NT]#-O+EI&ZU7C7>>15B"S::3;CKTKL]#\#W-
MR@EEB/E^M>E.I&"U,%%LXI2RG;@T\0L9,DUW>K:+H-A;L#,PG4=/?\ZXEY0S
MG9TI0J*:NAM-$4G%1[B>*DE[5#G'2K$6(@2:OQKY:Y]:I02885JE/-M\KU(J
M9,"JMPD#;\CBJ;3B>=C56YBDBD(;(J.%BK9JDD!JQ@9JS<6PFA# CY16:MQQ
M5J"[RI5CP:EIC*P@#"HB=CXQ5J;*GY.E478DU2$6P5=>:ADCX^6F D+D=:<L
MW9J+ 0.#MJ$$YJRWS,14!7#507)[<,S8K4BQ$PJG9XW#WJ].,/42W O6-SMF
M ]35S5L2VY!K/L8#)(&[ \UJ:C )[';'RU8RM<B6QPUT,N0.U0;2JY(K5>R\
MN7,G S44ZPMD1G-86)1GB,/VJ[;VX3#'%4S*T)Z"G?;,CDT]A[FA=S?+P>*I
M+.,U7EE+]Z;&IS0@L:T6V0<5,B$MC%4[7*-GM6A%=(K\XJT9LNP08&6%.1UE
MRJ\8XJ*>^3RL(>:CT_:'))ZFN;%\[I-0W-\+R*HN<UK>(**LB-L\4V+8>AJR
M98XDR3S7R4J-:4^5K4^HC5HJ/-<9LVX+5;C**,D8K/63[1,N3QFI-6E%KWPN
M*]S#Y134$ZNYXM?-9N3C3-RWU!00@Z=*Z/3+Y86 # 5YI:WRDYW5J1:HZG@U
MZL<-"$.2)Y%2K4E/G9Z3)KHB8+@G-:ME>"YB#>M><VNH"X*^:<8Z5UFF7 $:
M[3Q7/5H*,3>CB92EJ='*BR1E6&0:\9\7VHBU28H,<U[%!+YB5Q?B3PS<7D\D
MT49;)S7)L>K1FD[GE438DP:JW4!=R0>*UM8TZ;3KC9(NTUGH=RG-4=B[F>4$
M?)YIT#[GQCJ:;,I\WBKMG922,&"T@+"6A8\"GI9_/@FN@L-)GGC&$J6/09FN
ME4H>M,+F(MH=^W;D5;AMC:S*1Q7H-CX1B\C?(ISBN4\26WV.?9$.U%R8S3=C
ME=8;?*3G)S63(I7DFK\V?,8R50G93]TT%LJ2G(-0Q(6?K3V)S4D8VKF@0OV?
MWIODX.<TXN>U"DGB@">W7:>M;%H$<@,,UD1*<UJ6:$.":!FH]NEM(KJ.U<UJ
M,K27+'WKI;B9&=5SQBL"Y@#W#;?6@!=-?:ZFO2],!G@AVGH.:\]L[-P0<<5Z
MAX6TYVASCM0R9/EU.CTNU.0_:MX< "JUI (8PM6J@XYRYG<****" HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ I,4M% "4'I2TC=* .=\3WT%I8-YF#N4@5X?=.LMP[ 8&XUW
M'C^^E>4PYX5O6O/CG::];"4^6%^YRU7=E"Y.6P*A$>*N);O<W"QJ,LQP*[S1
MOAY)<P"2YC89':NJ=6-->\0DV<!;W)@..<5;DNWDCRA(K:USPE-ILA^0A<\5
MSC!HABG&49*Z)<;/4A!=MVXY-*("PR:$#M*#CBKDK 1@"J>@RND('-.9MHI
MYS4;G)H DC;!S2'YGIJ$"K$(4Y)H FMP$Y)%(Q#/Q5:5R&QFB*0#J:5@)KC
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MN1.:2L/C^Z,T^D I:[4K',%%%%, HHHH **** "BBB@ HHHH **** "BBB@
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MM-IU2<@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MFPV#"7;CH:Z.QA,,0!%533;U(J2LM"Q'"D8X %24M%=:5CEW$%+113 ****
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M'@BDNHMDG IT"L5)]*70";[,K/A35E+81Q-N.*BM6"/N:G3S^8:G4"M=C9;
MK67%<,).:W6BS:AG'RFLV6R"OD#K51: >(6F^;)K3TNS9YU"INIMC 28T ^\
M<5ZKX:\,6L5NLLD>7ZYK"M65-:E1BY&OX=MO)L8\IM.VMRHXXEC0*HX'2I:\
M:3YG<ZXJRL)12XHI#(V16Z@&H);*"0$&->?:K=)M%";0FDSGY_"]I,Q(51^%
M/B\.6L4#H8U.Y<=*W<"C J^>7<GV<=['E6I^ B;[?%G:?05BZEX:NK9=HB;%
M>W[15>XLX;@8D7-:PQ$EN8SPZ>Q\^OH=R4R(&K)OK(VO##!KZ._L6S5,"/BO
M-_'_ (91 LEK%VR<"NB&)4G8QE0E%7/(I' /%(&#CDTZYMGA<AE(/N*@5&S6
M]S.Q<B4#IS4[1;AFHK=<$ UK06X?  JB69RJ4[5I6L:RK@FIY]+?RPRXJH-U
MJ,=&H)W!\*Y7TI\0!(-0C<[9]:L1QMNXJD2S<L0'A8=^U6+<,DV&XJ+3(BI!
MP:T)HRTN0IR3Z4UN9-G3Z!*$7KWKMK.0N@KB= LF."17<VT6Q!7FXFW,=^$O
M8F*JW49I0H'08I:*Y3O%I*6B@ HHHH **** $J&YMEN83&P&#ZU/10!Y]K'@
MO?(TD3'DYP!7,WOA>\@@)".U>S$9IDD"2KM89%.YK&JT>"IX9OIF.8'_ "JM
M?:8]@FR0$,/6O>+A;>R@>0C  R:\A\77\%_>2&#UIIF].HY'+Q<M5UHBT7R]
M:@L8C)+CMFMU;3"C&*9J8=II<LTFYL]:O-831L%4&M+>;5,]ZGL[Z.65?,_A
M.:!="72/#US=%2ZLJ^M=;I]Y#I#B'<">AJ[I6KV8M0H./QK@M:NV;4W,><%Z
M1CK-V9ZW:W27,0=6!S5JN'\*ZD=BPNU=JIRH/K4F$X\K'T4@I:" HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH ***#0 AHJ.1PB%B< 5A2^*K**Z\@D[OK3C&4MD)M+<Z
M&EJO#<+-"LBD;2,UG:OKD.FP,[-T]#0HMNR!M)7-:1U5"6. *\T\>:U'+&UH
MC X/:J=]XWNYO-2.4A3TKC;V::[G:65LDUZ%##.,N:1A.HFK(H3J7.15<PDB
MK4F50XJO'<X.&KT5<Q*SQE:CVUJO"L_W,57:R=2>E-,"HHQ4P;'(H:(CY<<T
M];9\9XHN!-'<?)S2%DD/:JLOR<4V-\&BP&AY:A P J>$!N#4*'?$HJU&N!4,
M#:T+2!?WH7J 0:]ATS2X;"W58T4' Z"N#\!64OVII2/E(XXKT\ ;17EXN;<N
M4Z*,=+C* O-/P*,"N*QL-V*>H%&T <"GTF*8!B@TM&* $%+110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)@4M% "=JAG@69"
M#4]%)I,:=BE#8I&<\&K008QBGT4E%+8')O<B\F,'.T9I_ IU&*=A7"BBBF 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 AH-!Z4AZ4 <;XVU66PLAY>1DXKRR35)3/
MN,C9SZUZ%\0[N!;,1LN6#5Y+*_[S(Z5ZV$@O9WL<E1^\+J-Q]H<DGFJ*$KP"
M:6XSG-0QN=U=R5D9LT(KAU[FKL5T6X-9J#C-2QM@U+0RW*23D5)&5DCV-Q4
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MR36<CW&>%?'TK11"\0+ @^]4;BW!$BY%9S95N.*M.61MM1O [X(H%L-CU&>
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:?$S1D-CJ:ZH#BO)Q-=R?)8ZJ<$E<7%***6N4U"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC4(B+#@5-!:NQ[TG8#3MH//C"QC)%:^CZ=-)?QQE.":Z+P#X=WRBXG7=&R\
MCBO2HM(LHF#);H&'<5Y];%*#<4;0IW5QNCVHMK"-,8(%:=-50HP*?7F-W=SH
M2LK!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MFT*6D I<5P'0+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4 %%%% !1110 4444 %%%% !1110 4A-+2$9H :0",>M0_98@^\*-U6,48H
M:!@4A4'((ZT_%&*0&)>^&["\DWO ":9%X6TU!C[.O%;V*,5I[2=K7%RHH6^E
M6EJ<Q1!2*NC IV*,5#;>XQM.%&*,4 %+110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% "$56O(?-M9%'4BK5(1F@$[
M'EU_H=S]J;@D?2JHTV6%P"A_*O6&A1CDJOY56FTV"9@2H&/04[G1&MW,/0-,
MB,*R2)S73HH5<#H*CAMTA0*O05-2,92YF%%%%!(4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **2C\: %HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "DHS36=5^\P'U- #Z*HW&J6ELI
M+SQ<?[8K"N_'NEVA(9@V/1J+,5T=517!-\5-(4X*/^=30?$W29B %89]33LQ
M<R.WS16'9^*-/O<;)47/JXK6CN89 "DJ-]&!I6'=$]%-S2@T#%HHHH ****
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M\PSM!K4XK(U%HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** $-<'\2(=VBEL?Q5WAKD_'L7F:$>.]5
M#XA/8\;M?ND>E>L> Y?]'1/1:\GM^'D'H:].\ /E]OHM=];6D<\/C/0A2T@Z
M4M><=(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9_=R:TX'.:VHRL[&-1%VEI!2UW'.%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !24II* ,7Q/+Y6@W9_Z9FOE2^D,MV['^\:^HO&1
M(T&Y_P"N9KY7F_US_P"\:VI[&-3<91116AF%%%% !Q2A&;[JD_04VNQ\$MIB
MW$G]H2(JXXW"DQI')""7_GD__?)KT?X::'<->-<R+L1&#?,,5U,,_A-6!-Q
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "5%(W%.9L"
MJ4\W7%2V4D1SR@=ZSY9^:)Y"<U3)YK)FB1960FI5-4U>IE8U#*+6[%+YV.E0
M#FG <TAEV&1FJ_%G%9<4@4U>BD)JX,SFBY2TU3D4ZN@R"BBB@ HHHH ****
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MFT.R.PM%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\01!P*ZJU>\;(RA3L[LG48&!3J0=*6N,V"BBB@ HHHH **** "BBB@ HHHH
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MR2I.*J,E>QY&:4'4AS]CU*G9J,?=S0&STK4^;)**;FDSS0 [ HI:* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "H)>E3U%(,B@"A**I2BM*1*J2+5IDM&5*IS5<\&K\RBJ3#FK1
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M['SN&<-UKR6PO6=B W '%=1I'B:\TY/+$I"DYQ332.''495Z=J;/:=V>U*&
M->4S^/YH8^9&R:S_ /A8EZW28U3J)'BQRRL]SVC(/>D&/6O'H?'M^TBYG.,\
MUZ/X?U,ZG8),V23ZTXU%+8SQ. J8=<TC>'2BF!J=FK.(6BD!S2T %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M 444F1ZT +129%% "TTF@D>M9VJ:G#86K2,ZY';-)NQ48N3LB#6M;CTJ#>Q
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MBK\MJA0[5YK):3RY"#V-$IOH9JFH_$1W$/EOO'2I@X>U8=Z<6$R@5.++%NS
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(>*6B@"!P6J
M$PYZU<P*-HIW%8I>0/2D\CVJ[M%+M%%PL9_V?VH,'M5_:*38*=PL9QM_45"\
M8'%:K)FJ[Q47%8R7BR:B-O[5J-#[4BVY8]*JY+B9R6[$]*LBVP*TDM@HZ4OD
MY/2CF#E,^.VR>E7HK8+VJ=(@O-25+D4HC54**?28I:DH**** "BBB@ HHHH
M**** "BBB@ HHHH **** "HFC!J6B@"N8?:H7BXJ]3&0&FF2U<S?(RW2K4$0
M45+Y?-2!<4W(E0L*!Q2T45)H%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)WDGBFR,[-U-%BHR2C=(NM('[U!<!]F14:,0,FGK-SANAH2LQRE=&<S-WJ2
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ME(@!20J:]'\#ZL]R_E2R;L+WK:G5OH>+CLMY(NK!G?)TI]-3I3JV/#"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!***:[!%+'H*
M(KFX6WB+L<5RU[XJ\MF",.*=XDUB/R3$C#(]Z\[N;DM*?FZFJ2.BG3TNST33
M/$PGEV2,*ZJ)UD0,#7C-K?"UVL>379:1XD#P8)YH:'.DNAW%%4K.^2X0'(S5
MSMFI.=IH6EK,O=5CM%.<<5E1^*8GFVXZ^]!2@VKG445#;S">(..XJ:@@****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%)N% "T4FX49% "T4F:"0* "D-&<CBL[4]5@TZ%GE?! S2;MJ5&
M+D[(FO;M+>!V9@"%/4UX[X@\47,MVRI*0H)%3>(_&,MY,T43#R\\$&N1G/G-
MO8\=ZX:U7F=D?18# NDN>:U-VQ\67MO\OGMBNJTGQJR*!-N>O+RFYAY7-:MH
M[6Z;I>,5FJDHZHZIX:C4TE$]6U;Q*BZ<'C^5G7BO,KW5[FXD9GE)HO\ 5A/
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC0*HP!3Z0=*6I.,**** &NNY"*\D\=:;+!>27.258XKUVN?\4:,=6T_RE7+
MYH1=.7*SP)]SOUH\MAU&:[NS\ 7C7N98QY>ZM34? T<%OOC2JN=3J1Z'E<@/
MI5W39]C,#WJ]?Z8(7( Z5G" *]!?2Y>F'\6<UGSRD<5?3[G/2H9[=7&5IC,M
MI#BH_,%6VLFJM)!MH$1Y!.:;*01@4AR!4<>6DYH 6.(E@<5?*G;2!E1>.HJM
M)>G.!0!>,@V*M0R1ACG-5XY-V2:1I6WT 6/NK]*IS29<U.TPV\U!L#MD4 -1
MN:GWC%1F';3<'- R82'M4JR&H56I@E BPC9%3+P:AB0U8V@"@9I:><,#FNGL
M;AHQO4XVUR%JQ1LYXK5M-1)W)GVH ]3T#65GB5)&&[WKI 0PR#7B]EJ$T%V
MAP,BO3M,U(/:*TC=JEHY:E/70VZ2J\-U'-]TU8%(P::%HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT*W=8D1M_7\J+#N.\2>)ELKJ'8_RNN:NVFMVFHV">9(<XR<5S]]!'/+"9D#
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MC-+;017'B>)9E##IM-%@N=%9>)K*\+!9,E>M0W/BZP@G,!D^?TKFO$Z)8WL
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M6_M 3XX#9J2;2&?56N@.#6Y2TAC(EVH!Z4^BB@ HHHH **** "BBB@ HHHH
M**** "BBDH ,TFY>F161K=_-90%XT+<<URVE^*#)?YG;:/0FL9UHQ=F:1IMJ
MYZ%152SO([J/<C U;K5--:&;5@HHHI@%%%% !1110 4444 %-/6G4UNM !S4
M4\PAB+L< 4LTJQ1,['  S7GGBGQ9E'MX3QZBDW8Z<-AIUY<L2YJ/C:*"26-7
MY4XKS?7]:;5;QI"V<UG7%P\\S,6/)YJL\83G=DUDY-GTM'!TZ&L5J2+:*X/J
M:8^ES ?+C%/$Y '%317)&<G/%8N;3L=CIPEL,@A>!,'K0YZYZU"]XS-@"G<L
MOO3B[CC9:(JR'+U+#$&YIODL6YS4B_(#S0VTKF26MV22+A<?PUG3)@DK5Z*0
M,=K=*9-;9^93G-8WYGJ*5F9?S=Z8< U:>%O2F2P,P  JM#FDF,0@'BIMRK34
M@9%&ZI3 &'6H;*CL-610K?2J#,V2:U8[#(R6-,FL24.T4)H4XR>IG?:3@#-2
MQR,SU(EA@\FG/ 8NE5=$1Y]V60!LR?2H255N:A>60+C!JL2['O4J)M.LNB+D
MFQN:1",8JNY?9G!IT,W0$4[$*HFR1MP/%,(!Z]:G9TQU%0.P;O05*Q'(O'%-
M@.U^:G"[DH$/-,S<-;HD:95HBN/FQ4<BTZ"/@\4M+&EY7+.=S$U$V<U)C8M1
MLW&<=*2-'L($YIS@TV.7+8(ITI ZF@FZL,V\4BJ<U$UQS@"G"7(ID<T6.8X-
M*#D8IA<4X.,4#N 0LX J8H8QS1;L#(/K2WSX.!ZTNMBTDH.1$!N>K2L -OI5
M>'[N11DB2AA%VU)Y1QFL]N'K2D&Y.*HR)@T1'50W.14+KDU.J\5&XQ5&,EH0
M?=-/$E1L:C!):F<_-9Z%R-N:GSFJ\:$BK2)\M2SIA>PWG-2*3BD"'-2*,'FD
M:)!EC3FDV1\TI(QQ2#;L^:A%/1:$0<8)%5W)9LBK*Q9)(.14,Q",16D3&6VH
M1=>:M<8XK/#'-6(V--L<)%A0".:J3L V%JSDXXJI(I#YJ1U'I8B W2<5?C&T
M"H8=K-TJT$)/%)R"E"VHYEW"DV8%.VD"F[]IJ3?3J1,#5*:)&>KTCYSBJ9'S
MUI!V.:K%,A\O9TJ6"0LX4U(R92HK=?\ 216T9W1CRN,E8MR-L6HHB7>I)UXI
MEN,/2-VGS6)V4GBD$0')J8*<YIDS 'K2BKFC26H!]O2G%R14$9&?O5(S;>G-
M4T)2T'B->II&E5!BH,2/ZBCR6QSFBXKOH@^UX?%+*Y9,U4F&UJ=&Q?C-)NQD
MIMZ,C6,R28J;[)CDBIXX,/FKFT$8Q64IETZ%U=F7Y?S8K1@3@5&\/S9%3+A!
MUJ;W-J<.5ZED_<P*K9V-DU81QM)/I6?),-_6FD7.:1.;ARV!TJS$XQDU5C=6
M P!2RN1TI[;BC)I7"[G[+68^6/-6L%SS3)X=B[A6D6CGJ7EJQ+*WWRCZUVGA
M_P /R:A>*@&0I!KDK6-@01FO5OAW(K7.QL%@M:12;,ZLI4J#E$]%TJS%G:)&
M!C &:OTR/[M/K8^5;;=V%%%% @HHHH **** "BBB@!C':I/I7GWC/5$D+6X/
M45W\HW1LOJ*\S\4:+=/<L\:,U-&M*W-J><WTA#D=JSF/-;][ILT8/FQE3[UB
M/"0^,51UD8J>- PYI F!S1N(Z4 2D!>*=O"K4 #LW0U,87P#@T#&DLU.Z"G!
M2.HJ-QS0!(K9IX..:@4X-2L<KD4 3K-CO37.[FJJL:EW'% #77(IL"L90OK4
M@:IX !*& H EV;1@U1N&*G(J[<O@'%9A<D\T /\ ]:H]:?$J(WSU2W$,<&ER
MV<Y- C1ED79A*?;1EHN*STDR<5MZ>,)R.U S,EC^?YA3/*!^[5^YCS(<56\O
MG&<4 5)8OW9K,>,[C6K/E6]JJ.Z^U B& \XJV_W:@CV[LU)(2<"@"!@:MVB$
M,&J$)FK49"+@4 6GDRU:>GW&PA3T-9D$1DK0BB\H@T#.^\-)#).&>O18=HC
M7&,5X;;ZR]HPV&NX\.^)VG*QOW]:31SU8-ZG?4M10OYD8<=ZEJ3F"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"D/2EI&^Z: .(GUC4KK7KBQM)=OE\\BG#6=0TZ[5+Z0LIY) XINB 'QS?Y'\
M/^-7?&L:+HD\@ #@<&F1?2YT-M=QS6RS;@%89&33UN(W.%D0GT#"O-9M7VZ+
M80R2F-3P6!IPN+?3[I9K2]>9L9VEJ+#4CTAYT3[TBCZFFBZA8X$J$_[PKSN2
M[?5ID%U,\ !XVGK3;*PQXE>*.[E>,)D?,:+!S'I'G1?\]4_[Z%!GB"Y\Q,>N
MX5YQ8VUSJ.H2P^=(%5\9#&MN_P!.L[>S6WGOY$*GKN.:+#N=8MQ&Y^61#]&H
MDN$C'S2*/J:\YM+F.QURWAM[IYD8\[C5C$WB#7[FS:5XTBY!4T6%<U[C79AX
MOMK&.4&%UR0#]*Z=KB-/O2*/JPKS,Z:-(\=6BB5Y/DSEC]*5K^#4M5NX;F\>
M$1'Y=IZT[!<],657&5=2/8U5O+Z.&UF994#*./F%<)9ZV=/D^S02F:+^^QI\
M6C/J=O>W$ES*O&0 QI6"YTN@ZG-?2#?)N%6->U"6R@/E-AL<5A^#+;[,%BW%
ML#J:O^+'6*'>QPH'-'4%L9L-[KDEHMR)QLZD8K9T#6QJ-N[.V&1MI+<5D:=X
MBT\:*(A(I<J1C'M65!%<6_AV^GP4)<E<>G-,#T83QGI*A_X$*5KB)>LJ#ZL*
MX31M-FDTLWLD\N=A;&XTS2M+D\1*US)<RQ[&*X5C2L%SNI[J..V>7>I"C/!J
MAIFM0WZY61<Y[M7(V;2;=2LWE<K&I4$GZ5%X5\.C)G^U2\$\;C3L.YZ,TT:C
MYI%'U:FF974^7(I..QKSR[O(;Z]:"XNWA$+;05/6I-(O5@UF>V@N&FB5#@D_
M6E87,=I82S?O3/*I /'/2K?VJ$?\MH_^^A7!17DS:'J;[VW*QP<U#I6@O?Z*
MMZ]Y,&VEL;CVHL%ST=9%<95@1[&I*Y'P1=R7-E,)"24D*@D^A-==28T[A111
M0,***0]* #FC-5FNXU?86YJ7?D9I)H!7<(,L<57.H0X)WCCWKF_$FO"$&%&&
MX<5S5A)<7C$;WY/K7)6Q7([(R=2SLCU".42*&4\&I*S=,3RK5 S$D#O5\.".
MM=,)75V:G)^,)KJ. "%L*1S7"Z=8M>3=@_J:]+\1Q++9.>ZK7F<=_);S>6%
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ME1*GI4M(*6D9!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M  !2% PP0"/>BX6,'2+=QX;$+ AC&1S6!I.HOX=62VDMI)-SELJI]:[T( ,
M #TIC6T3')C0_P# 11<+'#Z1:2W4NHW#(RB494$?2ET>^?3K@VCV\C=?F"\5
MW*Q(HPJ*/H*;]GCW;O+3/KM%%PL><SVL-C?M-<VCS"9MPP.E;6EC3I9I#;V#
MPR%#\Q%=8T$;?>C0_5:%@1/NHH^@HN%C@H;.8:+J:;&RS' Q6WX?@>+PN(F4
MAO+/!'M71B) "-BX/7BE$8 P% 'H!1<+'*>"+:2WMKD2*1F9CR/<UU^:C6-4
M^ZH'T%24AAFD+J#R<4CL$7)KC-<\3K!<*D+ E3\U9SJ*"NPUZ'9F11W'YU5O
MKY+>!B2.G%<$?%EQ)+QC;4.L:]).(D!ZCFN=XN/0*Z=.',R2ZUJ7[>SACMKI
M="U@W\>TYR#CFN-L["?4& 5<KZUV^BZ(NGJ",Y/)S44.=NYQ4'-ROT(+OPR+
MN[>9\$,:Q-6M#I$H\GY0!VKT"N<\3V4=S:.^3NQVJL113A=;G;"*3N<PNNW2
MQ\2GBK%OK]Y)%P7)^E9^FZ1-<S,BJ2HKMM,T"&WB!=?F]Q7'0A5J/<V<HHXM
M[K5[YY(]T@4\<BDMO"=TSB64Y/TKTR.UAC'$:_\ ?-2"-?[H_*NY86Z]YC59
MK8R=%M?L%LP<XJ'4/$UM9,5/./0UH:K'(UC((1\V.*\SFTNZNKIXY@P8=LU-
M:<J:48$+WG=G70^*XKFX55X!KIK:X6>,$$&O*X]"O[<&01G ]Z[7PV)TA)F!
M "^M10K5'.T@DE;0NZYJR6%LW/S5YE>W1N;O?R=[5N>,[N*6Z,:R'=CI6':1
MAVC]1TK'%U+R:.FBE&-SOO"=J%M5D(^:NIK!\.B06JAE %;U=^&_AHY:CO*X
M9IAD5>I JAJ&J0V:-EL,!7"WGB^XEN"B[=H..**N(C3W*A2E,]%+JV?F&/K7
MF?Q$TDSW F4C 6KNG:[?74XC100/>J7CB^NHV5"@Y09_*ICB%-7.W!4Y0K)(
MB\'>#H'7S[H(X89 JGXYT6WLK@R0J  O054TOQ7?V48557 %5-:\02ZI(6FP
M..U-U(M6/3I8;$*OSR>AR]Q&=N0>M4XU=7ZU>E;>_MFHR #D5S'I2C=W(;CH
M*=:Q @$BDG*XJ.*ZVMM[543-M*>IIKB-:C>0YSFFROO4$>E5=YSBM364[:(F
M=P4-(C,PQ@X%,"EVQ5P.(%  &3UI2FD9V;U()>$YJB5WMQ4]_,=I JI [<U@
MNYG.=Y6+(;RUP*BDF/:D8DFH]N33L#;Z$\4K$=:261R,9H0!:;)DT [V(XRQ
M;K4Q0GO381SS4M#%%:#XK;(YJ"YMO+.X$5>A)VFD\D2MM-2F[E3IIQN9(E.<
M4X-SS4DEJ4EP1P3Q4<B%&Q5Z'.KK<DXQQ3,\TY.E2+%NI&MK[%=O:EAC+2#C
MO5A(%:IT78< 47$J;;N3;=J]:K2<9-2ON9>*B4;T<'J*2-IO2Q3+@OQTJ5G&
MWBJSY1L4W<U4<RG8G\HOR*0PE>M31/\ (*1VW&BY7*MR)05.:E><8I43-.-J
M&/>E=%<LK>Z(D@9>*A>4],TKQB,XJ%QW%-(SG-Q5F3(V.:22<8Q4 ))Q4XMM
MPYH9*E)KW0A4,=QJV74# JHP,0P*;'*6?%*QI&2CH2R3,K9!J1969<TK0AAD
MTNU52@NTDQ2Q:,@FF(#DY-,) Z&FM*47/K18')+5DY1<YXH3&<51-PQ-2(YZ
MCM18A54WH6G3YJ/+Q21RAS\U2'IQ2-4TQF.12S-QBDP<C-.N4RN5]*8/8@PH
M%1F4+THPV.:A.:9C)VV$>9]PYXJ02C%1RKN5<4P1'&356,>:29<$O%)OW&H1
MG%.A!9\&IL;*3;+<;,5(IN2K=#4P  &*<" >E3<WY0QY@Y!!J&12G45=\P,N
M" *9*RLH#=J$QN.A21LG':K@50HQCFJ[(JKE:8TA(X[545=D<W*M2Z$([TUP
M1WJO;3L[;6JT_2G47*S6#4HW17R<T[R]PZTULYII9@AI+5D-I;@6$!SFG1WR
ML<8-9[!Y'P:N06V.371;0PA.3?NE]2LB]*CDM^<BG1@)3VN.U)HZ]&O>(#$=
MA!J)( #5OS59#44>&.2:9FU&X\@1ISTK*N9/,;"]*L7MPV-HJG"06^:F[VT.
M>K-.7*A8@4.33Y)01TJSLC(^4U$T )XK'6X^5I61' _S8(JYL4C(%10V^U\F
MKHAXR*ALVI0=M2 )S4ZKM[=:5(SNYJ3S%4@=Z2-U%+4&C^3)I8H=PX'-;^E>
M&[W58Q(D64/0UIQ>#=02[13!\G>M%3;,I8FC%V;*&G>";G4K8S*0!MSR*P[O
M1;FQN#$T;'GTKZ T73Q9Z;'"R@$#!XIEYH%I=S>8Z@'_ ':W=%-'C+-.6H^;
M8\WT;P<VIV*L4VMMSDBM>U^'4BK\S+UKT&VM8[6%4C P!Z586KC%(YI9E6N^
M5Z&#H7AN/25; &YNXK=V>M2459PU*DJDN:6XF*,4M%! BC%+110 4444 %%%
M% !1110 4444 <1XTO;FWB'E%@,]A7FMSJ5Q*"&<U[?JNEPZC"4D';CBO(O%
M&BG2[IEC4[.O--'51E'8Y]"TC'<>!1))%%R!1(Y6+CTK+E<D\FJ-V6)+GS#4
M>6/W:AC0L:T(8Q&-S4")K9G1<G(J4:A(C_>.*JW%\6&T 8JLLF>M SIK>]%U
M%L?G-8M_#LE) P,U-ITH$@&:M:K$&C1A0!A/TJ(*=U6Y8RJTR-=S<T 2Q0;E
MZ5*;8J.*UM'TQ[^40HN379V_@7]WEE;)%%R934=SS>*!GD "DY/I6ZGANY?:
MVQN1Z5W^G^";:&02.&R/:NKCM(HXPHC7@8Z4FS*59)Z'GUCX2>2Q^<#(7O7&
M:UI,MC.R,I_*O>0@ P% _"N9\4Z-;W%J\[C! ["E<F-9MZGAXLI)6. 14B6#
MJ<8K>NFCMW*(!QQTIBSCRN ,_2J.@H1V@B(<L..:NB\.W :LNYD8N>:B1VS0
M,T'N96;AJ@DE+Y!YHA8EL&G-&?-/I0(RI%);I48M99#\L;'Z"NAL],^US *,
MDUZ5H'A"V2V#RKRP[BAD2FH[GBWD,AVLI!]Q2K;;FYKT+QGX<BLKDRP@[0/2
MN'D&U@*$.,E)7016VP^M3M;MMRL;'Z"K5C%YFT'N:]1T3PK:O8@R _.N>E(<
MYJ"U/([<NK[=K#\*WK&6:">-DR#]*]";P'I_GEP6_*K4?@ZR257!;*^U%T9>
MUC8T=#FDFTV)I,Y(YS6K4-O MO"L:#@5,*DYGN+1110(**** "BBB@ HHHH
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M)/%<R1[^-V!BL36+MKF+S&.<FO,KXF,O=L85[.!-H,<T]Q&YG;@]*](@!6(
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MYS<Y<T@HHHH)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"9A<H2.AKTNU.Z!3C%8MMX<2WE#!1@&MZ)!&H %/#494V^8*47&-F2&FTK$
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MS*M2@Z3W1R5OX%M%M]K$9QZ5L:?X?M;' 6-3COBMH"CH:JQP3Q-6>\AJIMX
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M#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MR#D4L657&*JR(4FW8<ID[U"\98\U,=Q/>I%P!R,T7'RWW*JV_-3I\GRBG^8
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MPG%0&)JI,QG3&(6C'/2IDE4MQUII7"D&HX05?.*&"NBP\FT4Q9S3K@*=N#4
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M&(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )2&G4F*0'*Z]I
M%Y?2L8V&SL*JZ)I4\$_[T=#79E1W%((T'(45SO#1<^8 4!$Q4+7<:OMW#/UJ
M#4YIH;8F%-S5PG]I7)OPTN5P>F:G$8CV25@O8](5MPR*=WK/TRX,]NI/I6@*
MWA+GBF M%%%: %(:6FD4 5IKV*!@KG!/O4(U2 OMW#/UKG_%*3>:K1%N!VK)
MTNTN;R8*[.".3S7!5KU%4Y8H#T-9 R;A6/-XBM8)VB?(*UI6T)BA"DD\=ZYO
M7?#AN2TT3MN/.!73.4U&Z+A9NS->WUVTN#A6Q]36@DT<@RK#\Z\DN;'4;%RV
M' 'O4VG^(;Z.98BI.3CDUS1Q4D[21M*@OLGK(P>E&.:SM(N&FLU9_O&M&NY.
MZN<[5G8?129XK+O]9AL9 LC@9]:'))79+:6K-6BN1E\7Q)(0&4KZU8A\66SK
MDNH-9^VAW,_;0[G2,,J17#^(='EN;\F(=O2M-/%$<LP0%>3BMV'9,@<J"345
M(PKQL:0J)['-^'-&-OO,R\]JZCY8DSV%/"*HX %-=-Z%<]154Z2IQLBF[G/W
MWBFVM]R@D,O%89\:,9#ASBI]7\(F199TD<MU"USJ^%KF15RK!L\USU95;Z'1
M!4[:F];^,'922S$YKJ-)U(W\8.&Z=Q7,:;X5AMW6620\=0:ZNS>VC'EQ$9'I
M54>=/WV14E#9&B*6D'2EKL,0HI#10 M-P*7=29H 38,YI<4M--("O<6<4Z,"
MN=PQ7$Z]X82*T>2*/YL]J[ZHY5C<;7 /L:B<%)$3@I'A]WX1N7A:94Z#)XKD
M+RWEMF*,I!!]*^F_LD!0C8N#[5P?C7PQ;M:M<PJ V>@%2J:C'0]S!8YM*E4^
M\\B1Y,*":EX/#4LL9AF*XZ&D<C!-9NY[T(\JL-VKCBHI$&":C$QW;1369F9A
M51MN92FGHB 2_/BK =E&0:IF)R^0*E0.."*RGJS.$F78IBW!-*RDFHXX]IS4
MI85F=2>FI&5"&H^K5/MW\TW9MYI"<>PPJ.M/ 7&*>J[NM0S?+PM"5V#]U7&W
M P@VU7AG<-M8\5/$#\VZJX8>?BJ:MH83U:9+(0U5V(QMJRR #-0.@=LYQ21-
M1,J!,.3[U-D4-"01CFI4A!')IMF,(M;#X^5J5)=G6F#]WQ3)!N&0:DZ4[+0M
M!UE'%,D&1M:H;;(?FK,GK2V8_BCJ5?LXW9QQ5DV^Q%([TT=*NQ%&C(8].E#;
M!02*+L$3)J.*,RDD$4E[@.0#38-V1BJ6QE?FE8E:)D? J18]R\U)M)ZBG(AS
M4MFZIA'#Q32#&#BG/(8SP*>49H]^*16FQ &8]::[J.M+YAW8V]*@NCW'6FD1
M*5E<D4"4\=J5X@BY-4(C*C9 )%2R3._!&*KE9C[1..NY$SDOGTJS#(IZU5V&
ME3AJ9G!M,T@W''2J5T@!W>M3J?EJ.3#C!/2I1K4U17C&XU:"8&14<**K=:M'
M&.*;'3CIJ4KA=PR:2*,;:GE7<N*2-<<47(Y/>N5V7YZM0I\M!C!;-3C"8I-F
MD(6=QCQ_)FHDD96J=F+_ "@4>6/2EZEM:Z#'<[<^M-";A[5O:!X?;6IVC.0%
M]*ZN?X<&WAW(SMQ5J#:NCEGB(0GRS9YQ%'\^/6KZ1".3(%.N+-[2\>-UQM;%
M=5X9\.'5Y$D8'94<KE*R.EU84J?.SH/A_I<X+3.,+G(XKT[;S573;".QM4C1
M0,#!XJ]7H4X\L;'RN*KNM4<B)XPZ%2.#6#>>$M.NYO-:'+$Y)KH]M&*II/<R
MA4E!WB[%+3]/@T^'RH5VK5LJ&&#3MO-&*+6);;=V0+;QHVX#FI13L48H$R-H
MU<889%5$TJU27S%3YLYJ_BDVT[#4FMANP#@4 4_%&V@0@%+1BEH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ I,4M% "8HI:3% !2$4N*,4 5KRQAO83'*N5-<
MU?\ @W3S!(ZP@$#-==VJGJ.XV,VT<[305&36QX-K5HME<-&N,"L,O\V*Z#7H
MIOM+F12#DUSK##59VK8L+PF:B56>3/85(ARF*DR AQ0-$,SE!P:?!.SG!-57
MW,:DMU.X4 6G7<:2.-%;+CBIPN 35.9R,XH&2S)!)P@P:6*%XEZC%9OFN'XK
M0AN2R8- %&Y)W&JHD(-2W;$NU58\LU &E!,7X-3/CI44"A1[T-N+T"+$;&/D
M5*]PTT1#'H*CC4XP13[G;%!GN10,QF;YB?>D\W%,'S,?K4GE=Z )(=SM6E H
M7DU4APBYQ5N,&0<4 65D0O@"IXYBDJE3P*;;6ZJ,L><5#(?+<^E 'KO@[58Y
M8%B9@"!W-=FK*1P0?QKYWLM:FLI=T;'\#7<:#XVFDF2.4 +ZDU+1SU*3;NCU
M(4M5[.<7,"R _>&:L4CF"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/O)?,\A=Q.36GI&C6^E0".) N/2M6DQS6B@D[G+*M4E'E;T#%+115&0M%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4UD#*5/0TZB@#E]:\*6U_$Q2,"0]S7C_B'1'TJY(8<$\5]
M#D5YO\1-,DF6.2.,8').*:9M3F[V/)PV.*<"<$TV2)EDP:)?D3 [BJ.H RFD
M#;&R*A0$GBK(A9ESB@"S%-Y@Q4JVBN><5':VKDYQ5ME:./G@T#,^>QP25Q4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6^EP(/+7?CK6Z(T#9"@?A3C50I*)GB,;4K:/015&>E/VCTIJGFGUH<84444
M%%%% !1110 445&[A>IH DHJ$3H3C=4@8'I0 ZBBB@ HI*!0 M%%% !1110
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MNSU%=*,UA>&49;0;O[M;]=-%>XCJI?"A5I<4V/O3ZU-!,48I:* #%-*9IU%
M#-E+MIU% $,L"R(5/0C%<VOA"W%^+GY?O9Q754F*32>YI3JS@K1>Y#';1+&$
MV# J4(H& ,4X44R+L:5HVTZB@1%);QRC#H&'O7GOCWPNMS:/+;Q#=Z**]'J"
M6-91M89!J91YD:T:SI34D?,<VEW-J7#0L,>U9Y:16YS7T=JGA6RO(7Q'\S"O
M&?%&@'2[R2,+A5KCG3<-SW\/BHU]%HS!6;"U#<7(D0)CI5=C(K%13A QY-9I
M(ZY2E)6)K5!M.>F:5E0/T%/ME(&SUJR-)N)LNJD@<]*.HTK1&0,JCI4SSEN
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M$(T"CH*DI'(&*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7/[N0,<?45U5% '!ZYX;=[B#4(T,DD,84)Z\#_"GZ9+>&55DTK8 ?O8KN:*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%%  :CDD$:%CT%/-5[N(RV
MSH#C(J9.R ABU*&60HK<CWJPLZ,< C->9ZC<W&F:E(JLQ XZU/:>(YED7(S^
M->>L8T[21IR:'<:K8B_AV<$BO.]:L9M+G*_P=:[C1]0-VY+'J.E3ZKHL6J(0
MYQD=:J<5B(<T=Q)\IQ?AB666Y^4\9YKTE/N#-8&F>&H]/DW*Y-="!@5IA*+I
MIIBD[CJ***["0HHHH 0TA/&:=33R,4@,#5->2SN/*)(.*Y]/%$S7+ /\N:TO
M$ND*X:ZWD$#I7#Q02-.RH"<&O-Q$ZBD<U24E+0]3TK4!>0!LY)K3KFO#$,L=
MHOF*0:Z3FNVA)R@FSHCL.HHHK89#/,L"%W/ &:X/Q)KUM>1O%&3GI72>)C/]
MC"P*6)X.*\[_ .$?OY2SF)^37%B9S^"*-J=*,E[S,QI1D"/.3UKJO"VE--<I
M.PXJ?3?!Y8*\N0?>NOM+*'3(1R !65&@[WD-^S@K1-&) D87T%/%5XKJ.7A6
M!JQ7HIKH87N-D<(NX]!6!KVHD67[EADY[U9U^Y>"RD"=2*X6VFGNG*-DY[5Q
MXG$.G[J0T[,QC>.EPRL?F8DUVGA6>1I#D\8K%D\*W$MVCA6VGG-=)H6EMIDK
M-*2%QQFN:E2FIIG7*:<+'5;@!R12YR.M<IKFK^2Q\IL@#J*TM%U'[7",GD"N
MZ->+GR'#S+FY3:[TCJ"I'K2*03UIYK<H\U\7Z>Z7;S)@9-8.GSM'( YYS7>^
M+K1I;(LHYS7G,".UX%&>#BO.KPM,\VO!JI='H<][&N@(7[@@5P%G;O/?D*IY
M8]O>N_@TP7ND0PEB"M7=-\.P6_S$ G/I6SIN:1M.E*HT6=#@>&T0-Z5L4Q(Q
M&H4=J?VKJBK*QUQ5E86BBBJ&%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4A'%+2&@#G]:T.WND:3R\R'O7+66AF._42H2N?2O2"H(Y%1^1'G.Q
M<_2N6IAE.5RE(IV&G06R[HTP36AB@# I171&*BK(3=PQ12T50@HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ Q1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
H% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>g23ode3tb50n000027.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g23ode3tb50n000027.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &*!$8# 2(  A$! Q$!_\0
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M J+TQ7$?VCXG_P"?=/\ /X4?VCXG_P"?=/\ /X468'<86C"YS7#_ -H^)_\
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MM,_:X]IW5ZE7"ZL?^)J?]ZA;@;"?<7Z4ZFH?D7Z4N16HQ:*3-&: %HI,T9H
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MGQ?WQ1Y\7]\5RC)**C\^+^^M'GQ?WQ0!)39/]4WT--\^+^^*;)/%Y;?..AH
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M8M8F$H.*Z>+_ %2_2NS#*R9$A_2BN?\ $6J7-C&GE1%@7 S6IITS3VRNPP2
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M#Y<"M>H;B&.:,^8@; [B@#R_0O$^K7?B<VUQ)^[QTJ7Q)K\VG:Y9,S'R]WS
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M/:1A!R'S5S3HS';J&ZXJV0&X(!HP!T%;DBT444 %%%% !1110 4444 %%%%
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M&"*X]O 4'F[4C40@Y"UW%% ',2>$+3:@CB P,&MZPM196:0*,!:LT4 %%%%
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ME?+/0UU1 /4 U7O;A;.U>4X&T9HV#<H>(+-[RVB5/X7!_447VGM/IFQ#APH
M-98UC4I\31!3 >A-;5GJL4]HTS'A.&H YZ/3;RY\JWD=L1'.3WJUJ.FSP7L=
MU"QPBXVBK5GKD=U?R0QXPOM3=5U::.Z6VM@#(PR : *-MI=P?.>1B?-'0]JT
M=,\/VL5H5GB5W)ZFF6&LN\<PN,!XASBJ)\07A_?IC[/G&: +NF:8^FWDI3[D
MC< =JLW%F[ZBTHZ5<6\4Z?\ :.,A<FLS3-=%]?F'(QB@.A5U^*[DDB6+=L ^
M8#O3M',T3A#$R@=\5>UG4FM9$AB ,CCY<BJVDZM-+>-;W04.HYP*$!O-!'*
M70'BO/=?BCBU'Y5 ^:O1LC'6O-O%38O^#_%50^("RK+M'(Z4NY?45EK(VT?2
ME\QJ[.49I[E]11N7U%9GF-1YC4^4#3W+ZBDWKZBLWS&H\QJ.4"74F7RAR.M9
M6]?44NIRMY(^M9'FMZUI&.@&MO7U%&]?45D^:WK1YK>M581K;U]11N7U%9/F
MMZT>:WK18#6WKZBFQ$&\3!_B'\ZR_-;UJ;3W+7Z _P!X5G57N,#VRR_X\H?]
MP5/4%G_QY0_[@J>O. **** "BBB@ HHJ&Y,@MW,0_> <4 345Q=]J^NV>"ZJ
M%)P*M#4]7AT][BX51@9% '545A:'K1U%,.?F R:@N]?>/7(K.,C8PYH Z2LG
M6-+:]B+1-LD[-6-)K>ISWDD-IM.P\YJYI]QK;W(%TJ^5CG% %06VH,HM_-?
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MR9OF'2I/#'_'FGTKFM5F<Z?(,UT7A,YT^/\ W:B<;".CHHHK, HHHH ****
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MFK6H$E%1^:M'FK0!)39/N&D\U::\JE: *C?>-)0QYHS5C"BDS1F@!:*3-&:
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M,"IJ?_'A)74>$_\ D'1_[M<OJ?\ QX25U'A/_D'1_P"[6%41T=%%%8@%%%%
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M>?,QP*ZR.\^RZ;')*=Y"Y)%+H'4R?'G_ "+<GUK#T^/_ $"'_=I?%GB6WO\
M1WMT0AB:DT__ )!T'^[6M(:)/*H\JI:*VN!%Y5'E5+11<"+RJ:Z;5S4]1S?Z
MLT[@43< ,11]I%4Y/]8:;5V0%[[2/6C[2/6J-%/E0%[[2/6C[2/6J-%'*@'Z
MC.#8R"NN\(G.FQ?[M<+?_P#'F]=SX0_Y!D7^[7-65A'2T445@ 4444 %%%%
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M4(SU9]%Z=,DMC"4.<(*MUA>%V+:8F3_"*W:Y8NZN>75AR3<>P4444S,****
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M "BBB@ HHHH Y;QT6'A^XV]<5X@YE?J#7TG<6T-U$8YHPZGJ#5#_ (1W2O\
MGRB_*NNAB%3C9HEJY\[[']#2A9 >AKZ'_P"$=TK_ )\HORI/^$=TK_GRB_*M
MOKL>P<K/#]">7^T$&#C(KWS3\_V?!G^X*K1Z#IL3;DLX@?4"M%5"*%48 Z"N
M:O6539#2L02V<4S;F'-8VM65[Y#16" JPYKH:*YQG->'K;4K8[;M % ZUTM)
MBEH **** "BBB@ HHHH **** "BBB@ HHHH 1ON-]*\QUG_D<K#_ 'Z].;[C
M?2O,=9_Y'.P_WZPK[(]3*_CEZ/\ (])E;9:R-Z*3^E<%86I\07TCSLVU'*\'
MWKOG3?;NGJI%<&4N_#M\S0V[SHS%CBMUN>8]C4AT!].GE> L5([FLE--CU#7
M8XYF?!ZX-6K*74M5N99'66!,9"FJ,UY>:7K*2I9/*%'4"A;ZBZ:#KZV.@:I;
MB!FVRO@Y-6O%O]HR0AE&+<@<@U"B7?B'4(I9;=X%B?<,BNB\30.^C;(T+,,<
M"A[#6YGQW+6_AN0Y.[RJX^TN+*>&.6XE<2%AT-=Q%823:#)&RD,8\8KCC:3Q
MVT=@-/8LK9\W%'42V.KO=.CO;.&7<WE(@R0:R?#"^5XCG2)F,(7C)^M7+K[;
MI\$#+$\J!1N056T2*YO-9>X^S/;*PZ8IK<.AT.N>(HM'=5D;&1FN"N-:CU6_
M)1L_-FO4)]-M;M5^T0I(0,9:O/\ 6K*WM-0Q!$J?-VIQ^("TOW!]*6FJ?D'T
MIV:ZQA11FC- !11FC- '.^*O^/-/]ZN-KLO%7_'FG^]7&UUTOA)84445H(**
M** "FK_KX_\ >'\Z=35_U\?^\/YUS8S^!([LM_WJ'J>\^%?^06G^Z*WJP?"O
M_(,3_=%;U>5#X49XK^-(****HYPHHHH ;)_JV'J*XM;.XM;J:1QE&;/-=G(I
M9" <<5RCB[TV>7?$]RLAR!Z4#%TY[1KN<QN?-\LY';H:Q=)F=9+K !_>'K]:
MVM-L9);V:\,1B#H1L_.L^P>?3))U:P:7<Y(.*!&U:.S6\V0!\A_E7-V%X;>"
M=F VB0]?J:Z6RO9;Q98S9&'Y3S3M&TJ,6DR3P@EG)Y'N: ,32;>>7[7<?P,N
M14>GW]M;QLDQ^;<:TX[&XL;BZ"[FCD&%4=!5K2-,ACM&:X@#-G/S4 8MO;32
MQW4T>?+QFD<%M 49/WJ@OO&T<3W5E;Z>/E^7*_\ ZZQ?^$CN#IZP?8'X;.:R
M]M#8[_[,Q35^7\4=)92R:0%C<G;-SS2F3??2LIXVUBW?BF2YL!$=,/F*N WI
M^M9MCKMW;CY[-W..IH]M#N4LLQ/\OXHZ".9_LTP '6MC1H(;R(([-N49/-<I
M#XKDA@D0Z26+'K_DU#;>)[NWEDD2Q<!Q@ =J;KPN2LKQ/\OXHZ_5;:WYM+<D
MS,.!6M]H?3-'C\SAE7FN!L/%MQ;L7FTUI9,Y#'M^M:S^.WFCVR:26'H?_P!=
M+VT.X?V9B?Y?Q1G:_P"*_P"TK!K;=U:NYT?_ ) ]K_N5YSKFNV]QI[)'I"P,
M3G>!_P#7K4L/&\MO80Q#3V8(N,^OZU,JL'U&LLQ/\OXH] HKA_\ A/9O^@:W
M^?QI?^$]F_Z!S?Y_&I]K$?\ 9N)_E_%';T5Q'_">S?\ 0.;_ #^-'_">S?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3J* (5M8$.5B4'V%/\F,MN*#=ZT^B@",P1$Y*#(I1%&K;@@#'O3Z* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
G **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>g23ode3tb50n000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g23ode3tb50n000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (:!V8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBFET!Y8?G0
MZBF>8G]]?SI?,3^^OYT7"PZBD!!Z$&EH **** "BBB@ HHHH ***,CUH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %-=Q&A9C@"DDE2)"SL !ZFL'4/$5D(98M
MP+;2/O4(B<U%:EQM<M02/-6O+_$VI>==OY<O&[L:S-4UEDO&6$D DUST^H,[
MMD\FM4DCQJU>=968^YN5R<OSZU1-\V[CFH9(WFDSUIWV=HT/K09J,4BTU\YC
MP"15,RN[9+&H@2I^:G*&)XH*Y$D3QER>IK<T'>EXC<CWK)MHSNYK9AG%NNY>
M&%4D8R9[CH5T)K&-=V2%YK5R/6O']+\7FQ@;+')'&*L1>.KN23/FG;4.&NAZ
M=/'04%S'K.0:*Y#PYXF%\[)*Q+'@5U_:H:L=M*K&I'FB%%%%(T"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%(6"C)('U-5;G4+>VC+-(AP.@84
M 6Z1F"*68X KDKGQM;LY@A@G\SLVTX_E53[-XFU%]\5TJP-SM8<X_.G85SIK
MC7].MR5:Y0..U8%WXIU!I-EG8F9#_$*M6_@ZSE DOXA)-W(K?M+"WL4V0)M6
MC0-3CUT;4=<(EFGEM<\E0:V]/\,PVJXN&%P?5QFMZBBX6(8K2W@_U4*I]!4U
M%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3)7$:%C3Z@NHS
M+ 57K0!E27C2.P!P*J/.PDV_>ILP,,A4]<U#(_E_.U6B3(U>5O.0=/:L]]S<
M<\<UH2%;VY&1G::LFTA#XV\U6PMS.MKQC$T;K@=*K/>11R;2P%;<NG(T)V+@
MUQ>K6$\<S'<..10F)G46U_#".7!/I6PQCN+7?QTKR-M1GBG"N^2.E=7I?B>,
MP>3(3NQB@#82X2&;#-BM2VN?,5B!D=JXZZ:2:;<C YK9L+O[/$JR')(I#-C>
MKN=P%,AY+<8&:K/."-R]:L0N-M RRD?>H9Y"J' Z5+YFQ<TQ]K(>*2&9WFM(
M<%:S]4MP$.&P<5?FE\DDUAW^IAGV,#N-4B'J)$6)1%&<=ZZ&TM-ZC?U]ZYO2
M;V-[DJ0<@UU@EZ%/2D,K%FL68JF<TMOKDDDGELN/>G3%IP5[UFO92QMN!&:!
MG1+JDJ+GDU?M]>'EX< '%<O'=JJ;9,DTU[N$+G:>:5AW-NYUM_.PAS[5N:?J
M:2PJ'8!JX:$J#YLG;I5I+T%QY>0<]:+!<]"!!&0:6N+;6;N!,M)D"K2:]))&
M-K'..:FP7.JHK/TR[:Y@#,<FM"D,**** "BBB@ HHHH **** "BBB@ HHHH
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MHW >4G:>]7_'",&A/J:M>#9D\I4R-U*45/%\LMD.+<,+S1W9H7OABW:T8+U
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M110 444A( Y- "T56EO[>$@-*@)_VJDBN(IAE'5OH: ):*** "BBB@ HHHH
M**** "DS2T4 %)2TQI40<L!^- #F.%)K-FU18VP,8J:[O(D@8[UZ>M<3>ZJG
MS(#SGUJDA-DFIZR!= M@#=5.]UF*6/Y6%<]K=V2JX4DGH:H:1!<W5X(GSM]Q
M5V(N=/I5Y)+*^Y  #P:V=Z"3<6Y]*KBR6V@4I@''-0RDF $?>]: -A9]R^U<
MYJELT\[8'%3V\TRG#$XHN8IC\ZOP>U)#;.0O=%A\\%G(-9]]I_V94:)VR378
M36FY"\@R15*\BAFM\*N&09IB,O3I;N&#<R$^YK:7>6B9\C-85K>-O\ICD9Z5
MOM<)Y*,1G:* -R'R6B"E_FJ>U0ACZ9KFO[238'7CFNATV[CDC&2/SI7T'8OR
M$;:KI-P<TFH7")%\K#.?6LI;DL< T) V.U"XCR=K98=JY?49Y&G#!!@"M6X8
M/<$ <YI[:/)<1\'&:H1E:1&@NMY;!)YKM!+$@'S=JQ;/2?LYRPR16DL(=OF'
M'O4C19DFA4!E:JLEWYIV@#%03PDMA3@4^"#RUWN0:!DOV-9%W \U6DBPP7J0
M>E3-<'[L9Q4ULB[M\I!-%Q%&[@N)I%"H0F.2*<LHLE59.,\#-:,UW'C:@Q7/
M7H>ZG4%N%.>:8CH(P+J')ID<1C+ =*2S<Q6V,$U*\@:-F!Q@5)5SJ=!Q]B7U
MS6O7":5JDFT1QOW[5V\#%H$)ZD5+&B2BBBD,**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBJ>I2O#:LR DX
M/2@3=E<GDGCC&6.*R[[Q#96L;9E^;%><ZMK.I^9(,RHH)KD;K4;R68[YF-7R
M'G3Q_2*.RUWQ))=0R)D;#7GEV%,C/GK5[?)(N&8U3N8^.36C6AYW/*;O)E-9
ML<&F/*":=A<U V,]:DVBD.\QL8[59C;@8ZU50@G%6K:,F9?3--:C=K&G'<E+
M<;P,U%O6Y1A4,X/VED'2M+3K"20_+&6SZ"J,):;%-+0!>!4D=N8QNQ7>Z%X?
M#B1KB+ 5<_,*YC7C&EZ8X5 49'%&C8W"7)S,P)G;?T[TF>,U9DC^3=MS5)W.
M>F*FUB-RTDH S5RWU>6V8%7(Q[UEJV14,K>E4FAJ&IZ5I/C^:.6*%BNT\$FN
MT3Q;:[ 6D%> P2%9E8'I6Z+UVA WD&HY4V=*Q52FK(]?/C"U-RL:RC:>M=%:
MW4=U$KH<@UX+IYEN;I%#')[U[3X>MWATZ+>V>*F44D=>%Q$ZDVGL;%%%%0>@
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 ,E_U3?2O+_$O_(8->ID9&#5.72K*>3?) K-ZFN3%X=UX\J9U86NJ,KM%
M#PW_ ,>*_P"[6R_W&^E-B@C@7;&H4>U///%=%.'+!1,*DN:3D>7>)O\ C]_&
MNU\+C.C1#VK1ETJRG;=) K'WJQ#!%;H$B0*HZ 5R4<+*G5=1O<ZJV*C4I*"6
MQP7C'3I?M8F1<H!R:IZ5XEN+!/* 7 &!FO1Y[6&Y7;*@8'UJA_8%@'W?9TK.
MI@ZBJ.I3E:YI#%P=-0J*]CA=7N;[4H&NI4 CZ9!J]X)_ULWUKMO[-M##Y1A7
M8>U.M]/M;4DPPJF>N*<,%-554<KBEC(NDZ:5CE?&?_'NWUJ+P+]R;ZUV,]E;
MW0Q-&''O26]C;6@/D1!,]<5I]5E[?VMS/ZRO8>RL97BG_D&#ZUQWAK_D+I_O
M5Z5-!%<)ME0,OH:@BTNS@??' JMZBBMA95*JJ)[!1Q,84G!K<DO/^/*;_<->
M5:=_R&3_ +Y_G7K;*&4J1D'K5)=(L$DWK;J&]:>*PTJTHM/86&Q*I1DFMS*U
MBRDN](CV#.U:XC3KV72+_>5&0>]>L>6NS9CY?2LZ;0[&9MQ@7-9U\)*<E.#L
MT:4,7&$7":NF<G=^([S4+=HH54@C#5A:>&M=1 E&#FO38=(LH1\L"BG'2;%G
MWFW4MZUG/!59M2E+5%QQE."<8QT*.K'=X=<CO'7#^&1_Q,*]/>")XO*9 4QC
M%5X=*LH&W10*I]16];"RJ5(SOL94<3&%.4+;EE/]4OTKRS6A_P 5#)_OUZMC
M Q5*32;*64RO I<\YJL5AW6BDGL1A<0J,FVMR#0O^/ ?A6I3(XDB7:BA1Z4^
MNF$>6*1SSES2;$;[A^E>4:R/^)F_^_7K':J4FDV,K[WMU+>M<V+P[KQ23.C"
MXA46VT4_#'_($BK9J.&&.",1Q*%4= *DKHIQY8*/8PJ2YI.7<*R_$'_('FK4
MIDL231E)%#*>H-.<>:+0H2Y9)GEFD#_B9C_>%>J)_JU^@JHFE64;[TMU#>M7
M>@Q7-A<.Z*:;.C%8A5FFD8GB'2O[1ML@99!Q7 PRWNA76[;AAV)KUDC(P:I7
M&EVESS)"K'U-1B,)[27/!V9>'Q?LX\DU='!W/B^]N8/)VK\PP<5'HVBW&H78
MFF4[.H-=NGA^Q5L^0E:,-M# N(D"@>E91P52<E*M*]C66,A&+5*-KD$UO_Q+
M_)4<A<5Y=J:/::JS$8*MFO7:S[G1[.Y;<\*ECU-;8O"NLERNUC'"XE4F^9;G
M/Z!XCN+ZYBMY%7;C%4/$VB2I.;F%"<G)KL;72K2T8-'"JL.A%6Y88YEVR*&%
M+ZK*=+DJ.[']9C"KSTU9'F^F^)[G3X?((7 ]:@GU.]U>Z4+G@\;37>RZ!8R-
MD0)4T&CV5N04@4,.]8_4Z[7+*6AM];HI\RCJ5]#M9H=/43YWXY!-<SXFT&42
M^=;H2.K&N\  &!39(DE4JZY!KKJ8:,Z?(SEIXF4*G.CS/3_$=YI:"':,*.]1
M7VL7NM2!-HYXP#7H,VA6,IS]G3-.@T6R@.5@7/K7']3KM<CGH=?URBGSJ.IB
M>%M#:T'G2K@L*J>,Q\Q_W:[95"+M48 J"XL;:Z_UT0?ZUU2PJ]C[*)S1Q3]M
M[21R7@;K-]*UO%__ "!&^M:]O96]IGR(@F>N*?/;Q7,?ES(&7T-.&'<:'LKB
MG74J_M+'G/A;_C\_X%7?:E_QZ-]#3H=,L[=MT4"J?:K+HKKM89%+#X=TJ;@V
M%?$*K44TCRBP'_%0+_OFO0]0L1?Z=L(R0"15E=)L4E\Q;=0^<YJX% & .*G#
MX1TXRC)WN5B,5[22E%6L>4 7>AW_ )A7!!)&:T[CQA=36_E@+EA@XKN;C3+2
MYYDA5CZFJJ^'[%6SY"5A]3K0NJ<M#?ZW2G9U(ZG)^'+>]N+Q97W>43R=QKT!
M%VH%]*CAM8;=<1(%'M4U=F'H>QC:]SCQ%;VLKVL%%%%=!@%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !112,P498X% "T52FU:RA!W7$>X=LUSMYXQD23RX+"24'^)13
ML*YUQ( R>U9-]XETS3VVW$^TUSOV#6-;;S8[N2V4\[36M9>%XU7_ $\K<-ZM
M19!<H7/B34KP_P#$GC29?4U%'H^IZW_R%5:#/7RV/_UJZVVT^UM!B"%4^E6J
M+A8P-.\*6>GMD2/)_O\ -;:P1)]V)!]%%244AA1110 4444 %%%% !1110 4
M444 %%%% "$@#)[5R?B;Q1'IR-'&XW^E=->OY=E,_HI->'ZQ=-J6L-%NZYJH
MHELGOK^\NV\\LP4\\,:U?#7B*XMIE5VS'ZDUAV9>S62WN5)\WA&/:H=QL+@P
MDY _BJ]'H2]-4>Y6-]%>0AD;)QS5NO)_#OB-K:Y6-V)5C7J%K=Q740=&!SV%
M1)6+3N2S2I!$9'.%'6LV/Q#ITLWE+-E_2F>)I3#H5PX."!7C.AWEQ/XB($AQ
MO%)(#WT$$ CH:6HX/^/>//\ ='\JDI#"BBB@ HHI&8*N3VH 21MJ,?:N)UK4
MIUW>7]X=!FNCO=3BCC;<0!CK7'R7$-U<DEUQGUJXHF3*!O+^Z0*PX^M5I;,*
M/,F9A6]'%$&RK*:I:I$7.T#Y<59 RTTN"^ +]%Z5IQ:9;VS>8O&/:J4$PM+?
M.>U5TU0W4OE@XH=QJQ>N;HNX1>G2E\I5BW&DCM-OSLX.>:LE5>(#@TAE#S^Q
M  J1)-^ O-1:G:D6S%&P<5BZ1?O!>,DQ)'O0!TTEHI3)K"EL%\R3!/S5T0N$
MD0<CD57F2-5+<'-),;1Q2Z*T.H!P#L]:NM):(#')(1G@UIO&TS%5./>N3UG3
M+A+A760XSDTR33EL[1K<>5(Q&:G1I[=%\O) 'K5#29U)6!R"1ZUO7,D7E*J
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M11169Z 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"YJRFIVDGW9E-:*I![,S=.:W1;HIB2(XRIS3ZL@**** "BBB@ HHHH ****
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M59M T^0?\>ZYK4HJ73@]T6JDULSE+KP?'*#Y05:P;SP?<V^2'W?2O2:0J#U
M-<U3 T9]#IIXZK#J>,S6%Q"Q#1/QWQ5<@@X(Q7LMS807*[711]!7-ZCX.@<%
MX Q;TKSZN6SCK#4[Z68PEI-6//:N6NI7-HP\J0J!5B_T*\LB3)'A>U9=>>U.
MF]=&=Z<*BTU1W>D>+E.V*<$L>YKKK>ZBN$#(ZG/8&O%P2.AQ6MI>NW&GR#:V
M5[Y->CA\PE'W:FQY^(R]2UI[GK-%8VD:_;Z@BKO_ 'A[5LU[$)QFKQ9Y$X2@
M[2"BBBK("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BLO4-?L-,S]IEVXK$N/%,U\,:/ME;WI
MV8KG5R3Q1#,DBK]369?^(+:S0LA$QQT0YKGX[#7-7.W4XO*0]2A-:=AX.LK*
M3S!)(S$Y(8YHL@U,Q_$]SJA\BVM9H6/\14TZ#P[K4[A[F^WQ-R5/I78);Q1C
M"QH/^ BI:+A8Q+;PQIL.':W4R=VK8CB2)=J# I]%(84444 %%%% !12&CM0
MM%(*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MF"?>H/-.%0]#4@=(^%J29*^@Z=%!#;:JL@?) Q5_:9(S4(A8 U2,6N5D5JY
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M:91L])M;1%"Q+N'>KP  XI:*]2,5%61YDI.3NPHHHJB0HHHH **** "BBB@
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ME YF_P!.U*W8Y@D*^M8[ED?YQM:O<]'LVO=)4ZG\TG<GBN1\8>&].CA:>TV
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MD19!@FO,H-)@'BZ!K>,*JN<XIIB9ZM:L6MU)J:F1IL0+Z4^I*"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HH/ S54WBAL4 6J*8DBN,@T\G'6@!DD:R
M+A@#]17(:UK=SHMV4\I!:_WB*Z_S$SC<*J7^F6NHPE)HU?/K30'F^M6%KK4
MOM/<F2,;G"\#/X5P[+*;QA(@$W<5UOB:QNO#ETHMYB(I3DHM5]&LENIS>3I]
MX=#5HAG,O'<VTRR;>G/)KN-!^:U\YQ\S+6?>:?Y\A .!VJ6.VN(H%C1RH6J$
M274-PUUNC!/MFK#QND:-)P>]:.AH98RTHR0<<U)K$ ,8"CK2 H?;1]G\N'#5
M.(T6-6?[S4NE:;LAWR>O>I'>-Y=IQA#30,?#.T*\ 8K$U[5X[>)E)&]AP#3]
M?UN"QMB$ +=.*XAYY+R^B>8DH3G!I 4KJ*2YD,[+@-Z5<TO0)[]"RH2H/)K>
MU;3XQI$<L*@ GM5'2-6DM;*6% =Y/&*!F/<Z5+#=/%&"63K6YX4UDV>HQVLC
M?*3SDUT?A[21,9+NZ&?-7^*N9\6:;'IVHBYM75=HZ"I&CTQXDN55UZ&I8XD@
M]A6)X4U,7UC&A.65>:V+[=M.*8#;BZ4*0IK U5C);;0QR3ZU5O-36"0JSC.:
M6W+7RC!S32)N1Z/IIMUD=B3DYYK51@S[1U%.CB>--O-7-/L2TI)0GB@:*NQG
M("C)K7L+"=%WE."*NV6G 3J63BM\1HJ[0O%2V-(YIU.-O>MO3H?+BSZBI3:1
M%]VT5850JX%2V,6BBBD,**** "BBB@!",@CUKSWQSH(DC-Q&O09->@22".,L
MQP ,UYCXN\3I*[0(PQT.#73A5)SO$PKN/+J>77D#HQXK.P1R:VKV02DE165L
M+/BO:M<\]2L0,,FGK$67BIO+4\'C%301C')I)%.>A1\ME;D5I65NLI'7--D@
M&,@U+IKK%-\Q%.UEH)R;.I\/7;Q:E"F>C8KVZR<R6JL>IKPS3YTBO8IE4$*<
MFO9]"ODO=.C=<#/:O-QL=F=.%>K1J4445YQVA1110 5EZY=/:V$K)UVUJ5'-
M!'.A610P/K51:3NQ23:LCP#6OM=],URZCFN<DA9B>.17T5?^';.>S:-($4XZ
M@5Y3J?A.>RNI'VL4W9Z5ZU&O&IIL>75HRIZ[GGL\3@X(J:U;9UKH;FRB)Y %
M4S9J3\HK?EUN9>TNK$(GR,5-$K'D4GV79SUJ5)2#L$?XU2(9*Z"./=CFI](O
M&-RH-6;:S:2/+C@CO6II.DA[E0L??M2;21-[Z'IGA:)DM-S9^89%=!5'2X/(
MLXUQ_#5ZO#JRYIMGMTH\L$@HHHK,T"BBB@!" 1R*\L\83S7%ZL2*,!L<"O5*
MH3:1:SR;WA0G.<FJB[,Y\12=6/*F>1GPA<75C]H2,G-<_/ISV<_ERKCFOH1+
M2&.'RU0!?2N*\6>&!,AGA7E1G %4I79Q5L&X0O$\EGA D(%;/AW2VO[R- N0
M3BH1I5TUUL,3YSZ5Z7X2\-&S19GX/7!JV[(Y*%*52=K'2Z3ID5C:(FP9 [BM
M!XD<8*C\J?56^NDMK=G9@,>M<\I65V>_""LHHX#Q=:Z0KY=B'SV%><W<4 N-
MT))6NB\3W@N;J0[\C/%<JKAFQG->7/%3J72V/1IX&E!J=M29-QJ[;,T3ALXJ
M-4$<+2=<#-9OVQIKCY<@5RV<CLYDM#USPQX@ 012O["NYAG2904.:\&L)IDD
M1D+<5Z5X9FNYB"X?9CJ:Z,-B)1:IVNCEQ-"+7.CLR,UGW6CVUR&W+R?:M ?=
M%+7KH\R45+1GD?C#PQ]BWSPJ=H%<?;HTA*'KTKW_ %/3H]1M&A<#YNYKGK+P
M3;VUPTC%6!.<8JU(\RM@FYWAL>23:?+%R5XJKY9.17O-WX=L[B$H(D!]<5Q.
MH^!W2XS$203V%6I)G-5P=2&JU/.6A*T@1R#L%=?>^%+J%L+&S>^*V_#7A+G=
M<Q=^C"AVL9TZ4Y2Y;'G,-K<MDE3TIR0NCX8<U[;)X2M6?*JBCTQ44G@RU>97
M 0 #IBES(W>!J'DJ:?-,F57@4^STF>YG$:KDFO:8O#]I'#L$2=,9I+70+:VF
M\P(N:.<I9?*ZU.!U?PJEKI,4H4[RF37):< DVQZ]B\2V+W%H!'D!1T%>47NF
M203,X8K50E<RQ=-4YV2T(;I05;'2L9W )4]*TF)6)@3FL.X<B1J':YA!7'/)
M&.,TQIL+A36>TQW\TX29I72-G"Q960JIR:EMKG9*#GO54-GBE7@T7(=F=2]W
M&]@3P:YNYC#N2.]7[2<%?+;I5K[ KQ.X/09I[F2?*<\D!+X K4M-.DDE50O)
MJ2QMBUS]W-=WH>B22WD+F$A0>>*++<U4G.2BB@G@R\ET]95BK#N;*33W*.,-
M7OL%LD=L(MHQBO._&NC,;H211_+CG J8SU.K$X50AS(\_CF<OBM5&D9-H8_G
M4(T^5/F,1KIO"^AO>7:/(I"9P<UHVC@A!U)*,3$^Q[QELUT_A2:VLKI=Y_.N
MEO?"T;6[>60"!VKDX-"O$U#8 X'KBHYE)'1["K0J)VN>AW+V\]FTA ("YZ5Y
M!XBE3^U)#$?EKT.ZTB[73B%N'Y7H*\RU>RFMYF$N[/O2A8VQTY-)-6&1W61P
MW(I1(TC\DU4M+62:50A)^E;D>GRQ%=T1.35IGF.+Z$# XP*E10B9R>:WD\/S
M2VIE"$$=L5AW$30RF-N".U<F-KJG2;6YZF68"57$Q4EH0FI((C-.D8_B.*CK
MH?"VG?:[OS".(SFOEZ4'4FHGZ!4FJ<&^QVWA[3A9:>JE<-6S2*H50 ,4M?44
MX*$5%'S,YN<G)A1115D!5:^NDL[5IG. M6:YWQ:[#2I0,XQ65:?)!R1I1ASS
M469!U/5-5N'6T4,BGBDDO=8TH[YU C'4UK^%HHUM%8 ;BO-6O$D2/I;[@/K7
M$J4W2]KS.YVNK%5/9\JL6M.U&.]M5D!R0,M5DW,87=NXKC-"E<:9J.&(VK\I
M_*JFBV][J:[3=.HZU4<7*T5:[9$L+&\G>R1Z!',DOW3G%#3(IP37#P2W6E:M
M%!).TBNW>DUN[N&U-DBE906 X^M4\9:-VM4)82\K)Z';?:HMX7=R:FR",UP]
M_I-[9V/VS[8[84'%6[?7'72%#9+E>M5'%6=IJQ+PUU>#N=/)=11-AFYJ5'5Q
ME3Q7#Z;IE[K$33F\=/FQBG:7?7&GZB]M-(T@+;032CBW=.4;)CEA59J+NT=H
MTR*VTGFJMUJ,4-M(X;E!7'Z[-=/X@\J*9D!7H*LS:!=1Z9+.]ZS KDJ:3Q4V
MY*$=AK#02BY2W-;2-;:_EPQ&W%;8F0M@'FN!\,V,KN768@;>E6H+B<:Y%&96
M*[L$5%'$R4$Y+<JKAHN;47L=J\BQ_>-!E55R3Q7,>+;B6&.#RW*YD'3ZU#JM
MS,FC%ED(;:.?PK>>)Y925MC&&'YE%WW.J>YB102>O2GK(LB94YKB;/3;R[TS
MSS>.,+G%6/#-W,7\F61FY/)J88IN23C:Y4L,E%M.]B_:27_]H3>: (@W'TI+
MK7S%JGV52,"LBQFGFU:\B,K8WX'MTK/OK"7_ (2$P^<=W7=7-*O-0O#N=,:$
M7.TNQZ%'=(T:$GEA4^X8SVKC=5M[JSB@E29BJKDXJS+JQ'AZ*;?\SG'\JZEB
M;-J2V.5X>Z3B]SITE5_NGI3ZY_PPD_V>1YG9MS9&:Z"MZ4^>*D85(<DG$***
M*T("BBB@"GJ-HMY:M&PSP37DVHVS6UW(I&!N.*]D(XQ7#^+-'>2YC>&,G/7%
M>;F%#GAS+='HY?6Y)<KV9Q*G:P/H:]%\(:CY]H4<_-G KE8-$@ W7=VL&.H:
MK*>)=-T ^7;3173^BFN? X>M&?-;0Z,=B*,H<M]3TO(JA?ZO::<A:X? %<DE
M[J7B1 8EEM%/1A6A8>$IXG#7MZURO4JW_P"JO;L>+<2X\7QWF8]+;?)Z&JBP
M>(]2;R[V(+">ZFNJ@TBPM\&.VC5O4"KH  P*+A8YBT\%V,,@F9Y3)U()XKH8
M;2&% JQKQWQ4]%*X["8 Z"EHHH *J7]_#I]NTLS8 &:MUP/Q-FFCTM!$6&<Y
MQ36H&9J7Q6M+:[,<4PVBM*Q^*.C319EN/FQSTKYROO,-PQ).<FH5EF7@,10(
M^G8_B5H4DH07'7Z5U-EJ5O?Q"2!\J1FOCM;F=&R'8&NM\.^.;[3;B-7ED= >
MA-%AGU'16%X7UQ-:TJ*X& S=JW:0!1110 4444 %%%% !7)>)?"%KJJ2S$$R
M$$UUM(PW*0>] 'S!J^D-IMTZ,N/F.*PY@&Z]J^@_&/A..\LI;B) 9 . !R:\
MEN?"EY"CR- ^,<<5=R;''G?C"]*F6WW1DGTJQ_9MX$:4V[B-3@G'%/5'5#\A
M/%" R3')$<@<5;T[7+JSBFA1L+)P>:=N#':R8IRZ%>2@RQP.5ZY I-#(6=F'
MF'J:B<.XSZ5<-M)&NR1"I'K3K:!Y3Y:H6)]*8BA [!L5.9"BY/2NRT#P#=ZE
M,&=7B4]R*U?$WPSFLK)IH)#(0OW0*+C/-A-&_&:NZ7IJZEJ*6B DM4;:+>0N
MJ-;NI)QDBO0?A]X+N8]8AOIMP4=B*3 R-6\#7>GV23)&=NW)S6=X92Z?4TBB
M)R#TS7H?CG6IT4645HS?PY%>?V:7FD3_ &R2W=1ZFA SUCQ7KITKP_#"7P[Q
M<\UY-9+J&MSE+<%RWO5K7-7DUVU#%R/*7&/6I_AOJL&F:P3=JNS;@%J-4&Y7
MOOAQJ\,1N3"<8R>M84MJ]L/*E&''6OHR\US3)=+=_,B8;>F:^?/$,_VK7;AK
M=<IG@+0@93**O-9]]<G 5*LQ1REMS@A1US5*Y0&0\]Z;$BN#E/>KUD77.>G:
MJNW:/6K.]A%PN.*2&S5BN)8<R1@'(QS52.V<N\DHQN.:@LKAG(5LXK69EVCZ
M52$,38$PM,WEC@]*>2I7 JNV2V!0(EWA.E:OAR5?[7B\PD+68( (PQ;-7-$(
M;58T4<T ?2FDE3I<&TY&WBKM9^B KI%N#_=K0K,L**AGNH;==TLBJ/>L&_\
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M-&2YH[GK=%06DXN(%<=Q4]>RG=71Y;5G8****8@HHHH **** "BBB@ HHHH
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MIU%(IR*6O:/)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "H[C_CVE_P!T_P JDIDHS"X_V32>PUN>/:DFR\<?[1JK
M'Q(I]ZU-?B\N_(]2:R>AKY6HK3:/J:;O!,]3\*/OTK/O6[7+^"YLZ5M)YW5U
M%?285WHQ9\YB5:K)!1116Y@%%%% !1110 4444 %%%% !1110 4444 %%%%
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M$@V]S4<D))W=Z ()ER0Q%:VAZ:VI2M''G<%S@52,1<*#79>"-(OOMZS6F &
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4C#*D>HI:*
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MT!'\+TQ'IEHI6W4&IZ:@P@'M3JD84444 %%%% !1110 4444 %%%% !1110
MF!UQ2T44 )M&<XYI:** "BBB@ HHHH **** "BBB@ HHHH ***1F"C)/2@#(
M\1V27>D3AA_#UQ7SUJUE]FNFC7) ->S>+/%,-O;R01L"Q&.#7C]Y(U[(7[FO
M5P491CJ<6)L]2G&0BX-.8*X%,>/# &I  BUWG()D@XZ59CPR[6JHS;CQ2[G7
M&#2944WL6&MU'&3BHDM44LP-*C2'J:1IMJ,*6INK]1/.C#8S4<@\T\=*I#+2
MUH1#"4QD/DHM-PF<YJPP&,D55<#:: &R$$_*:=$G.>]0!@#4B2?-Q3 [/3M3
MBM[=56-&;'.0*H:G-]HG,FT+]*R(K@I4DDS2I@'FL'3UN1/FD,:(2&JTT/EG
M.*L6RR&3!.<FK%W;,%YI25C)JS,R*8%MIQ5]/+0$@\XK.:+RVSZ4Y)2_ XJ!
M[FSITJ,#NX.>*M3N%4[3UKFUE>%LAJN"^R@W<UYL\MIRJ^T;.^&83C2]FD7D
MG:.(G/-5/[18NPS5=KS=TZ55)RQ('6O122V.!N^YN6^I.F,']:W=/O2\BR%B
M"OO7%HY!K1M[MHACGFJ,W$]:T76Y/. )RI]Z[R&3S(U;U%>,^']10A PY%>I
MZ-J"7,  [<5QXJG]I(Z<)4L^5FO114-U)Y<#-Z5P-V5ST4KNQ'<7B0CDU0;6
MXP.6%<]J6I/YI')&:R)KSOS7$ZTV]#KC1C;4VM1U42L>:S/M)85223SS4V!$
M<&LGJ[LU5EHCI-"NCYFUCU-=:*Y#0HU:0-[UUPKKP_PG+7^(6BBBN@P,W7+/
M[9ITD8&2:\/UO3F6\>)5Y!Q7T"1D8-<Q>^%8[F\$P"_>R:X<50E*2E'<[,-6
M4$XR/#_[#E_BCKJ/#_@^Z::.7R3M!SFO5&\-63(!Y*Y]:U+:TCMHPB*!@5,<
M+-NTGH7+%12]U:D6E6QM;%(B,8J[117?%<JL<+=W<****8@HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#$\36WG:3,
M0,MBO+'4HY4]17M%U"+BW:,]Z\EUB P:E,N, &O&S.GJIGL994T<"O93FWN%
MD!Y%>N:9,)M/A8'DKS7C?>O1?!^H?:(6B8_<&!49;5Y9N#ZEYE3YH*2Z'5T4
M45[AX@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %4-7NQ::?*X/S <5?KB_&6H;-L*GA
MASBL,34]G3<C?#T_:5%$QX_%DRO\T,;C_: -:MOJNG:D!%/;VZLW_3,5PU;'
MART-QJD1QE<\UXM#%UN=13N>S7PE'D<K6/0-(T:VL7:>W/#CH!Q6Q3(HQ%&$
M'04^OH5>VI\^[7T"BBB@"IJ=NUWIL\"D@NN 1UKRMK7Q1HER\%GIPNX<8#R\
MG]17K])C--.PFKGDNC^$]3GL[J>[MC!,S95%X!K6TGP_?V\5P)(""T3*/RKT
M6BGS,.4\NT3PSJ5MX,U2RDMR)IIF9%]1D_XU4N_"VL?V5;+%$XDCY(!(KURB
MCF"QXBV@>([J/;)IX!Z9[_RK:F\,ZF\FF-]G/[H_/[=:]4HHYA<IYY8Z!?Q?
M$@ZDT)%MY>-]=?XBMI+S0;NWA7=(Z8 K4HI7'8\:O?!.I7'A"UM!;L)U?+ =
M>U/L/!.HV4 5;<DD<U[%13YF+E1Y5JWA74;>PMKBR@,ERK LM,M],\0:_K=O
M+JEEY$2+L)7T&*]8HHY@Y3R]/"5ZE_.@A/DL<!O:LJ^\.:YI6J Z=9>=%CJU
M>RT4<S#E/-].\-WD^D7WVFV$4\B<!1U/%8UA!XLTW3X]*BT[-NK9WYY_E7L-
M)CO1S!RGF_B+P]J-S#:W<,)>XB0';[USNIZ1XGUBSLX9]/VB.96./J/:O:Z*
M.8'$\RU+PUJ$_C31;Q8"88(55V]#@5FZOX8U?3O$%WJ&G6GGF<X(:O7Z*.9A
MRG#^#-/U"-1-J%HL,@;H!7;TM%)NY2$HI:*0"44M% "45G:MK-MI$2O.Z@,<
M<FI["_AU"'S86#+[&@"U24ZD)"C)( H 0J#U&::(T'10/H*@&H0,LI217\L?
M, >E4CX@MUMO.8 +G')H$:V*,57LKZ.]3=&015J@8RCFGT4 ,HJC?:M!8RB.
M0C)&>35R"59X5D7HPH =13\44 ,HI]% #**?BC% "=JRO$6KKHFD2WK$?)ZU
MK5Y9\3=9#2MI .X2+G _S[TTKL3=D;7@[QU_PD5W<12[%5/NX[UV;7,2-M9L
M&O --OET.^L!!&4\UP'(KJ_$VIWUSX@6"RNMBE!TJG'42EH>HQW]M*S!),D=
M:PY?%MK'KDFF^8OF(,XKSC4)=5T;6](@-V2+M_FQWZ_X5%>:?/)\4;J-90K!
M,Y_.CE"YZ8-=OFU.& 0KY3GEJVYM0MK=MLDF#TKS!KV[BU^SA$QQG!K%UO7-
M2MO%-U&XEEA'W<#@=>:.6X7/;TF21-ZG(J$:A;-*8Q)\P[5Y7'XBN[3P-?7'
MVDM,K?*0>1UKFX-=UB2*TNE:7+L"QQUHY0YCWYYXT.&;%0IJ%M(^Q9,L#TKR
MC6M;U*ZMQY,SQ/M'6JNK'5M'N-#E-X2+EAO []:7*',>R3W<-LNZ5L"BWNX;
MD$Q-NQ7D7B_6M2M]6+(TDD&T?NU%3>&]=NA9W,TDQ0CD(>M'+H',>JS7]O ^
MR1\&IU<.H93D&O!KC7]4O=8F=6D9 N0H%=[\,]8O=4LKK[9OS&^U=P]Z'&R!
M2U.^HHHJ2@HHHH ***JW5XENA/WCZ"@"RS!%R3Q6%JWB.WLHV"2 N!TJ"XFN
M]2)6$M$O3D5QOB<&QC5&'G3;P&V^E4DNI+;Z%.[-_P"+KHA%;R0=IVFFKX6O
M=%D601LR9YW>E=KX->Q%G\@5')R1GG-=5-;Q7,>V10RFCF"QSWA^\T^>)4!0
MR],8%=*%3'"C\JY>X\,21WXGLG$2#J!72VZO';HLC98#DTF44]7TY-1LVA8=
M?:O*=;\*2Q.^Z'$>>N*]C\Z/=MWKN],UE:]+;)9N)5#$KQ0A,^<=4L193'RB
M=HZ&F6U_<%=@);ZFNG\46B/ 9HP%4GI5/P=:VUQ,RS*&;=QFJ$.TWQ%+IY59
M$4 <$FO0-%U:WU.,%'!/H*H:UX3MI[!GAC5& )S7#>%[V73_ ! EOO.S>01^
M- SVM%"+4,\O8&F+<!X@P[U S9-(""YE\N%VSR!7*22-=7!<UJ:U=D;40]>#
M6=!'30%VSAWL..*NWDBQ1^4O:H8'$,9]:JSR%V)/>@1FW9R#72:,#]@C^E<[
M<+V]:Z?25VZ?']*&/J7:1NE+3'.!2&4[EL*:M>%+;[3=RN1]PYK,O9.#76^$
MK(V\+R$?ZP9H>PCINU%%%2,**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "J&K-,MBWDC+8-7Z1E#C##(IIV=P
M/G_5M.U*2^F9U."Q[FL\PF%0K##]Q7T!=:=9"%Y&MT/>O#_%[JNMS+"FU1V%
M>MAZ_M':QR5:=D9%Q;LQ#XX%1A.,5&;_ /@-6HD#H&!ZUV'(XM%;RB'XIS!5
M'S5)<8C^;=T[52:?S.*6YM"UBP9XECX-53,IW8/6F^7D8S48B*OSTII(HFAC
MW-FI]Z+P#4D2 0Y%4]A#,3ZT;@.EF'*BJ9<E\&K&W+9Q3'C[TP&; >E2)%MY
MJ$Y'0TI+N, D4,+%SJ.:EMU&\8J*U0L0I.2:[#0_"D]\Z.%8+ZXK.<U%78TK
M[#=(\,WMY^\CBRO7-7;[PW>+E?*KUC2-+CL;-(]HSMP:N-9P.<M&#7FRQCOL
M7+#<VMSP6?PC>M$S"*LW_A'YX<[T(-?1?V&VVX\I<&J%SH%I,K8A0$BB.+75
M$2PS2]UGS;>P&!MK\5!$H?BN]\;^%IX+[,*,RX["N*%I) ^&!!':NF,E)71A
M).+LR,VS1G@<4Y8R>U;6EV4EY.J>66S5^309EDP(FZ^E5H1<YU+=B>!5PV3%
M 0.E=1IWAV25U#1D?A7:0>#4DA7.!QZ5,JD8;CC&4_A/.]&C=6 ->F>%89 ,
MMG&:=#X1C@8$8.*Z6RLTMHPJJ!7/6KQ<;(UHT)<]V7*H:M(8[)V%7ZS]77=9
M.*\VI\+/4A\2.%N)=[L367<EF/3BKNHDJ2%XQ6&\[9P37!%'<R];2!6Z\U8?
M+S9/2L43E6SFKD%V21FJ:$=IHBN64KT%=>F=O-<7X?NT1AN(Y-=G'(LBY!%;
MX>R1S5KW'T445TF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %<#XRTXQE9E'WCS7?5F
M:W9+>63Y&2JDBN;%4O:4VCHPM7V=1,\B[UM>'=0-G>JN<!VP:RKB)H9F5ACD
MTV)S'(KCJ#FOG(2=.:?8^BG%5(-=SVJ-Q(@84^N>\+ZF+JQ1&;+UT-?44JBJ
M04D?,U(.$G%A1116AF%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 0W,RP0,[' P:\GUF]:[O7R
M<A6.*['Q=JHBMV@1L.#VKSUF+,6/4UXF95^:7LUT/:RZC:/.P R0/6N^\&Z?
MMMS*X^8'BN+T^U:[ND103@@FO6M/MEM;5%4 949J<MH\T^=]"LQK<L.1=2W1
M117NGAA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(YS7I%A (+.- .BXKE/"]AYDBW+#H:[,# Q0P0M%%%2,**** "BBB@ HHHH
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MKTL!A;?O)'G8_$W_ '<1:***]4\H**** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5MCPV[A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MN+YQO5D4]R*[S2] M[%%W*KL.]:L4*0H%08 J2O9P^#A2UW9X]?&3JZ;(0
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MYY;5G8****8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX(E\]*\J\1G&O3'T:O53TKRGQ*,Z[,/4UIF?\->IEEO\1^AT>@Z]:VEF4DD
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M@ HHHH **** "BBB@ J*?_4M]*EIKKO0CU%)[#6YY)+_ ,AU_P#KI7IVC_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%&>*0&@!:,T$TV@!V12$TE% "BG4T&G4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !2,,J1ZC%+10!R]GX5BMM2>Z"#+/NIFO>#[?5+
MK[4L?[XL"3^-=713NQ6.2N/"27&L6%\Z@M;* #3O$W@VTUTQ.T>71PV?QKJZ
M*+L+'%2^"8IKZ"1T!C10O\JWY="M'TYK7R_E*[:UJ*+L+'GR?#R&*Q>T2,"-
MFW8KN-/MA9V$-L!@1KBK-%#;86"BBBD,**** "BBB@ HHHH **** "BBB@ H
5HHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>g23ode3tb50n000032.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g23ode3tb50n000032.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )2!2$# 2(  A$! Q$!_\0
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M<\UZ#2 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#JFJQ;?\>Z?2H+_P#U1J>V_P"/=/I0!+1110 4444 %%%% !1110 4444
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M7FNOHJ>57N5S.UCF]/\ #TMG-O#+C-=&.E+11&*0.3844451)F:KI\E\FU&
M&.]88\(R8ZK77T5/*KW*YG:QS^EZ%+83JQ8;0>@KH***(Q40E)L****HD***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5S
M/B#4=*6ZCLKU8G>4<!ZZ1\[&QZ5XMXNDC_X3:QEO/NH>]5%79,G9$VOW6@Z-
M<!H[2WE;< 4QTKN/!>NZ=J=A_HL44!SC8G>O(8;"V\0>,]11EW6Z(67]:Z7P
M-'%:Z]'#9+B$.0WUS5R6AG%NY[-11161L%%%% !1110 4444 4[_ /U1J>V_
MX]T^E07_ /JC4]M_Q[I]* ):*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I&(523
MT%+6?JUT+>T<9^8CB@#$OW;4=6:V7)13FNFMXQ% B@8P*P_#UJ647CCYF')K
MH: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "O/?'G@RUUN5+E[EH&C'&VO06.%)]!7C7Q U;5KWQ%:Z;IMQY7F<'
M-5"]]")VMJ7="\*Z7I5M(XORTLB%6)Z]*V_ VA6&E>;LN?-D:0L"W7DFO*K7
M2O%%UJ]UIRWZB2W4LQ/?K[^U=K\-1?"X*WTX>19"/UJY+3<B+UV/7J***R-@
MHHHH **** "BBB@"G?\ ^J-3VW_'NGTJ"_\ ]4:GMO\ CW3Z4 2T444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% "$X&:Y74IFO]2AB3E5;#8K<U6[%I:%\\]*S-!M"
MTDT\@SN.5H W+:!;>$1KT%3444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X7QKJ.OVC+_94NP>8
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MMO\ CW3Z5!?_ .J-3VW_ ![I]* ):*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHIKL$0L>@H RM=O/L]IA3\Q..*;H=GY,;2D<R<UG2EM2UHQ]
M8NM=/"@CB5!V&* 'T444 %%%% !1110 4444 %%%% !1110!S'B=_,1K;^\.
ME;>EIY>FP+Z+7.:H_G^)XH!R"O\ A75VZ;($7T%<E'WJLI?(ZJNE*,?F2444
M5UG*%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% %6YT^VNQB>(/]:K?\(_IG_/LM<QXI\9S:%>F(%0@8#GZU4D
M^)-LFJ65MYJ[9@"U5RLERB=E_P (_IG_ #[+5BWTVTM#F&$+]*H?\)3I?_/:
MK=GK%G?'$$FZEJ/0OT444AA1110 4444 %%%% %._P#]4:GMO^/=/I4%_P#Z
MHU/;?\>Z?2@"6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S-9N
MQ!;F//S.,"M(G S7*W3MJFIJB\B%^: +_A^T*VXFD'SGN:W*9%&(HPJ]*?0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJCI4/DVBCU -7J=&/+32)K2YIMA1116IF%%%% !1110 4444 %%%% !1110
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M.6YK;TC0[71K=8;8':/6ART$HZFG1114&@4444 %%%% !1110 4444 %%%%
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MPYXL5/"*:C?,6.[;1_PFP!,YW^2.3QVJ>5CYD=S17,7/BVW71H-2C#F*5]H
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M8\[JU_$$OE:1,W<"JGAJ+_1EF_O"N2I[U>*[:G53]VC)]]#?HHHKK.4****
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M)W0O9+O29%@FE.78]ZET?PQ=07ZWVI2+-<+P&%/F0*+.E@FC*!-V6'6I9O\
M42?[I_E7*Z>EZVKSY8B,/P"*ZMEW1E?48J&6G<\7T7PT==UK42+R6#;,?N$C
M-=?;?#A(9U>;49IP#G:Y)%;&A^'#I5Y<S<?OGW<5T=4Y/H2H+J>8^++'[#XP
MTN^VXM[= &;MT%>@V6I6]Y:+/&X*$9R*CU;2;?5+5HID#9&.:Y%O">OVY\JQ
MO$CMAP$]OSI:-!JF5/$EW'J/BZ"TMR'W)U'X5WE@R6UE%"[88#%8VB>%([*9
M;N\57NU/#BHM46].I1>2Q";^>.U#L] 5UJ=6W*'W%>7Z<ZZ#XFN/M1V?:9?D
MSW_SBO3T_P!6N?2L+7O#=OJ^V38//CY1CV-"8Y(LWNO6%E"SSSJBXZFO.UD7
M7=4:ZM3NCB?DBKMWX#UJ_)2ZNHWB_N_Y-7M \%WVB%HTE01R'+ =Z:LB7=LK
M>%IDC\976YL?)_C6YXWU2V3PY<PK(#*PX7UK*N?!>JKJTMY97"1[^*L6O@V\
MFG5M4E291U%&E[AK:Q>\#6[+HD$S C<O2NKJ&UM8K.W6"%=L:]!4U2]RTK(*
M***0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!",@
MCU%>2>/M$U.SUVVU;38/-\GDYZ5ZYVS7G_C/Q=%I^H0Z:(6E:8?PU4;W)G:V
MIY7:^(?$,.NW=ZMFGG7*[&'US[>]=_\ #KP_?^:=0U&$Q2[RP'L35_4+2U@\
M.PWZ6#><>6 '/%6? ?BV/5H7@:(QNKE0&]CBK;NM#.*L]3O:***R-@K.OM=T
M_3G*7,P1A6@3@9KRGQ!>$>.9$FMVG@V_= XH ]$LM>T_4#BVG#FB\U[3["3R
M[B<(V<8KFM+N].BL9YH85@=!G!/-5M+LAK6HSW=S^\C:,E5/8\T =S:7L%['
MO@?<OK5BN"\.7$NG7TEH[%E>0[1Z#-=DU[M;&PT )?\ ^J-3VW_'NGTK/NKO
MS%*[",UH6W_'NGTH EHHHH **** "BBB@ HHHH **** "BBB@ HHHH CGD\J
M(N>U<YHT9FU>YD;H3D5K:W+Y6F2MGD55T&+$7G8^^* -NBBB@ HHHH ****
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M=E=^ 4N+R2:.^EB5_P"!20*N:3X-M],&#*903D[J5T.S>AQ&@Q:Z876"ZCC
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M^6U2=U_NECBNHATJ.QTMX( -^PC<!R:-%L*S;U-".9)/N,#]#6=XE_Y%N_\
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MZ"0YQ576Y+3V.AMIHXX8(BP#F->,^U6ZY&^TR[D\8VURC.+=$P0#QVKK$&$
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M]KXE\2W^E1WZV:^41NR/_P!5%IXK\0ZO8R7%O:(RQML)'K^7M1RL.='J-(6
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M4 4[_P#U1J>V_P"/=/I4%_\ ZHU/;?\ 'NGTH EHHHH **** "BBB@ HHHH
M**** "BBB@#$U^7]R8<_?%6M%B\K3(EQR!63K$GG:S;QKR#P:Z."/RH53TH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB@!&4,I5AD'M3(X(HCE$"GVJ2B@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)&TF1C:22*])HH X_3K+4G!AN(BD9XX/2JMSHVI:=J$DEDKRJXV_,QZ5W5%
M',>'/#OV#?--N\QFW?-SBNGHHH IW_\ JC4]M_Q[I]*KW_\ JC5BV_X]T^E
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M)BFV=?11161J%%%% !1110 4444 4[__ %1J>V_X]T^E07_^J-3VW_'NGTH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MIHUZN!3?M,/_ #T6N$U+7Q%J0M68[W.%J.2[NUDP#Q7-7K3HV?+=$*<6['H
MGB/204\$$9%><7&N_86$4C_O2,CFN[TF?[1IL,I/+"MX.3C>2L$9J6Q=HHR*
M,BJ+"BC(HR* "BC(HR* "BC(HR* "BC(HR* "BC(HR* "BC(HR* "BC(HR*
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M'*GHIS_6G;05]3LZ*1,A #UQS2U)0C*K## $>AJ/[-!_SR3\JEHH B^RP?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH \9^*FF75S-') I)24-P,]ZHV?BWQ%;6:P
M1/("J@#Y37MTMI;S_P"MA1_]X9J+^R['_GTB_P"^:M3TL9N#O=,\8\/^#]6U
M[6FU'4R' 8.N13?'VAWD'BB._P!A:".,*0HSZ5[A'!%",1QJOT%-FM+>X_UT
M*/\ [PS1SZW#V:M8\%UM[[6].MH[1'585^8,IKT+P/IX?P,+:Z7!P>#QVKM%
MTZR486VB ]EKF/%TVIZ?IS+H]CYA/&U>*.:^@<MM3PF:PN(/&#V$9'E7$Q!
MKWJUTN_TOPC'9Z:PCEC!Z_05P?@WP9J%UK)U/5('BD63> U>T;1C&.*<Y"IQ
MZGA;ZI?QR30ZZDDS%CM**>E,\(>%KB\\2RWL$92 D,H88KVY],LI6R]K$Q]2
MM20VMO;_ .IA1/\ =&*7./DUU'Q*4B13U"@4^BBH- HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
>*** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>g23ode3tb50n000008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g23ode3tb50n000008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ';!9@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBZAMS*,HLSA&/X&G3ZE86I N+VVAR,CS)57C\32*N2>0?^>\OYC_  H\@_\
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M\]Y?S'^%'D'_ )[R_F/\*FHH A\@_P#/>7\Q_A1Y!_Y[R_F/\*FHH A\@_\
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MH A\@_\ />7\Q_A1Y!_Y[R_F/\*FHH A\@_\]Y?S'^%'D'_GO+^8_P *FHH
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MP,'VYI\S%RH\WU;3)]2TW4FTC0;RR0:5+!)$T#1F>0J< +_$<]ZZG7+6;_A
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHJ&ZN8K.TFN9VVQ1(7=O0#DT 345R2>-M^F:1<_V:XG
MU2?RX;?S>=O/SYQ^GO76TVFA)I[!1112&%%%% !1110 4444 %%%% !1110
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M&#!1GY@,%?QK6T/4_P"U](@O&01R,,2(/X6'44-- FF:-%%%(84444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !158ZC9K<RVQNHA/#'YLD>X;
MD3^\1V%/M;J"]MDN+69)H7^[(C9![<&@":BBB@ HHHH **** "BBB@ HHHH
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MD#@CO4^GVFHOKE[JFGZ-)IHDMF,D=R0//G)!S@$\=>?TKL_])_Z9?K1_I/\
MTR_6CF'RG%V<-U/XFM]6.BS:6R1L=0FD(VS';@;<$Y''4XK;\'(_]@+.Z,GV
MF1IPK=0&[5L,L[J580LI&"""0:%6=5"J(0!T !H;N"C8GHJ'_2?^F7ZT?Z3_
M -,OUJ2B:BH?])_Z9?K1_I/_ $R_6@":BH?])_Z9?K1_I/\ TR_6@":BH?\
M2?\ IE^M'^D_],OUH FHJ'_2?^F7ZT?Z3_TR_6@":BH?])_Z9?K1_I/_ $R_
M6@":BH?])_Z9?K1_I/\ TR_6@":BH?\ 2?\ IE^M'^D_],OUH FHJ'_2?^F7
MZT?Z3_TR_6@":BH?])_Z9?K1_I/_ $R_6@":BH?])_Z9?K1_I/\ TR_6@":B
MH?\ 2?\ IE^M'^D_],OUH FHJ'_2?^F7ZT?Z3_TR_6@":BH?])_Z9?K1_I/_
M $R_6@":BH?])_Z9?K1_I/\ TR_6@":BH?\ 2?\ IE^M'^D_],OUH FHJ'_2
M?^F7ZT?Z3_TR_6@":BH?])_Z9?K1_I/_ $R_6@":BH?])_Z9?K1_I/\ TR_6
M@":BH?\ 2?\ IE^M'^D_],OUH FJEJD][;:?)-80033H,A)Y3&N._(!_E4_^
MD_\ 3+]:Y+XB7&IVGAB6:UU#[*['R@D<:MYI;@#Y@<=^E-*[%)V5SS\ZMXCE
MT?4]76QLMVOW/V.*3[4V]%SM 4;.5QWR..<5ZWX7M+VPT"VL[ZUM[>2!0BI!
M*9%(QUR5').>U>:1>%M7_P"$BT;PTFNR>7IEO]JXMXR(6QM'\/S?>[YKUFWC
MO8K=(Y9HYI%&&D9<%CZX'%7-HSIIWU+5%0_Z3_TR_6C_ $G_ *9?K69J345#
M_I/_ $R_6C_2?^F7ZT 345#_ *3_ -,OUH_TG_IE^M $U%0_Z3_TR_6C_2?^
MF7ZT 345#_I/_3+]:/\ 2?\ IE^M $U%0_Z3_P!,OUH_TG_IE^M $U%0_P"D
M_P#3+]:/])_Z9?K0!-14/^D_],OUH_TG_IE^M $U%0_Z3_TR_6C_ $G_ *9?
MK0!-14/^D_\ 3+]:/])_Z9?K0!-3)I#%"\@C>0JI(1!\S>PSWIG^D_\ 3+]:
M#]IP<>3GMG- 'DEQXB#^+=9UV70=0-O86OV51Y4?[MSG<6^;_=Z9KJ_AG"\'
MAF&.XTNYMKALSO+,B@2%SN.T@DXY[XJ$^!M0;PM-I+7MN9KJ\^TW,N&^<=U_
M05VB)/'&J((0JC  SP*N4E:R,XQ=[LL45#_I/_3+]:/])_Z9?K4&A-14/^D_
M],OUH_TG_IE^M $U%0_Z3_TR_6C_ $G_ *9?K0!-14/^D_\ 3+]:/])_Z9?K
M0!-14/\ I/\ TR_6C_2?^F7ZT 345#_I/_3+]:/])_Z9?K0!AZ[_ ,C/X;_Z
M[3?^BZZ*N8USS_\ A)O#F?+SYLV.O_/.NA_TG_IE^M-[(2W9-14/^D_],OUH
M_P!)_P"F7ZTADU%0_P"D_P#3+]:/])_Z9?K0!-14/^D_],OUH_TG_IE^M $U
M%0_Z3_TR_6C_ $G_ *9?K0!-6)<_\CC8?]>LW\TK5_TG_IE^M8UQY_\ PE]A
M_J\_99O7U2IEL;4/B?H_R-^BH?\ 2?\ IE^M'^D_],OUJC$FHJ'_ $G_ *9?
MK1_I/_3+]: )J*A_TG_IE^M'^D_],OUH FHJ'_2?^F7ZT?Z3_P!,OUH FHJ'
M_2?^F7ZT?Z3_ -,OUH FHJ'_ $G_ *9?K1_I/_3+]: )J*A_TG_IE^M9FKZ_
M#HBJUZ2%8$YC@=P![[0<4 W8V:*P](\1V^N$BQ9F 7=F2"1 1[$@9K6_TG_I
ME^M&P)W)J*A_TG_IE^M'^D_],OUH FHJ'_2?^F7ZT?Z3_P!,OUH FHJ'_2?^
MF7ZT?Z3_ -,OUH FHJ'_ $G_ *9?K6!J]I*NH:?B61?-F(8+.X!_6DW9&E*"
MG*S=CI:*K0PS01B-"A _O,S'\S3_ /2?^F7ZTS-^1-14/^D_],OUH_TG_IE^
MM $U%0_Z3_TR_6C_ $C_ *9?K0!-12#..>M+0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 >0^/?#HMO%#Z]-XVCT>25/+CC\C+!
M?3[PS5CPQH>IC6=.N7^(!OXI5\Y+8P;?.0=<?-6!\0/LVF^-M7N==M'FAN;'
M98SLFY$;/3V-1^#KO^W];\)0Z7%(S:9 PNKC80J@@_+G\:WL^4Y[KF/>:***
MP.@*KRV5O->0W4D8::$$1L?X<XS_ "JQ10 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7O%#'8.>#6[#!%;ILAC6-?11@4DW<UG"*BI)[DE%%%,R"BBB@ HHHH ****
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M\.?$+1=+T];9+*]B*2VT4:J0><-Q^%0>*M#\+^*O%4EI+<7%MK%G;>;)<0\
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MN2=SCQF&C0E'DE=22:Z;A1116AQA1110 4444 %%%% !1110 50UO_D!7_\
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M4****U/."BBB@ HHHH **** "BBB@ JAK?\ R K_ /Z]W_D:OU0UO_D!7_\
MU[O_ "--;B>Q#X:_Y%NP_P"N0K5K*\-?\BW8?]<A6K0]P6P4444AA1110 44
M44 %8VL_\A'2?^NY_E6S6-K/_(1TG_KN?Y5,MC:A\?W_ ),V:***HQ"BBB@
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MTI)O[)M/WP_U2_P>WUJWY<__ #W'_?'_ ->H=*_Y!-I_UQ7^57*0+8A\N?\
MY[C_ +X_^O1Y<_\ SW'_ 'Q_]>IJ*!D/ES_\]Q_WQ_\ 7H\N?_GN/^^/_KU-
M10!#Y<__ #W'_?'_ ->CRY_^>X_[X_\ KU-10!#Y<_\ SW'_ 'Q_]>CRY_\
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M<^].$6GJ34G%QLF?0_ES_P#/<?\ ?'_UZ/+G_P">X_[X_P#KU-161N0^7/\
M\]Q_WQ_]>CRY_P#GN/\ OC_Z]344 0^7/_SW'_?'_P!>CRY_^>X_[X_^O4U4
M-2U>TTRTGGFD#>0H9XU.6 /3C\: +/ES_P#/<?\ ?'_UZ/+G_P">X_[X_P#K
MTEO=PW2 QNI8J&*9Y7(R,CM4] 'D7CJ\6Q\?:==3,S+;^6[%5YP&SP,UN_\
M"U-'_P"GW_P'7_XJL?QT+=?B'I1N0@@)C,N_IMW<Y_"NI\SP-ZZ9_P".URIR
MYI6=CZ*I&B\/1]I"4O=Z'):7K$.O_%6UO;1I%1D(!D0 \1D= 37JWES_ //<
M?]\?_7KR^P.G'XNVITOR?LOEG'DXVY\HYZ5ZM6E"]G?N<6;**E3Y59<BT?S(
M?+G_ .>X_P"^/_KT>7/_ ,]Q_P!\?_7J:BMCRB'RY_\ GN/^^/\ Z]'ES_\
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MVS.UO&S$QCDE16$G.4G%'K4(8>CAXUZJ;;;6A%HGC"P\07QL[*XD\T(7P\(
MP,>_O70^7/\ \]Q_WQ_]>N)LK*VL/BRT-I"D,?\ 9N=J# SN%=Y6E-MK4Y,9
M3IPG'V5[-)Z^9#Y<_P#SW'_?'_UZ/+G_ .>X_P"^/_KU-15G(0^7/_SW'_?'
M_P!>EV39_P!</^^/_KU+10 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %9FM^(-,\.VBW.J7*V\+-M#-ZUIUQ'Q*OHK+3M.6:PM+
MR.>Z6,I<Q!P,D<@$=:<5=V%)V5SB-?OO"&N:Q-?CQM<6PD_Y91M\HJUX.M?!
M$/B>WN%\1S:IJ.=MNLK<*2/2N@\16/A/P_<:3"WA33)3?RB+(MD&WCKTKJ[7
MPCX<L;E+BUT/3X)T.5DCMU5E/L0*T<E8R47<V:***R-@HHHH **** "BBB@
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M/"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6Z\U^+/^KTO_ *Z&O2J\U^+/^KTO_KH:FO\ PV>GE'^^0^?Y'HMK_P >D/\
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M:);3-=O=F1=QE=-A/X=JIQLKD1E=V.4^+7_(M6O_ %]C_P!!:NQT;_D!Z?\
M]>T?_H(KCOBU_P BU:_]?8_]!:NQT;_D!Z?_ ->T?_H(KGC_ !6>K6_W"EZR
M.77_ )*^W_8,_P#9A7:UQ2_\E?;_ +!G_LPKM:JGU]3+&_\ +O\ PH****T.
M(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ*8=P*^HQP/QKT"BBM(1Y58Y<3B'7FI-)65K(****HYPHHHH **** "BBB@
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M7Y#Z$U%0XN?[\7_?)_QHQ<_WXO\ OD_XUL(S=*_Y#FM?]=(__0*V*PM+$_\
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MM8VY-3&7-[3W>QJ?%7QMX=UOP3+9Z=J<<]P9D8(JL#@ ^HKN/AL0?A_I&/\
MG@O\J\R^(_PTT7PSX2DU&R0B9954$D]#G_"O2/ANLX\ :3L:,+Y /*GT^M$K
M<F@1YN?4["BH<7/]^+_OD_XT8N?[\7_?)_QK(V)J*AQ<_P!^+_OD_P"-&+G^
M_%_WR?\ &@":J6D?\@R/_>?_ -"-3XN?[\7_ 'R?\:I:4)_[.CVM'C+=5/\
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MQHQ<_P!^+_OD_P"-9&Q-14.+G^_%_P!\G_&C%S_?B_[Y/^- $"_\AE_^N/\
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MJ%U<-9Z<1<NI8"Z?Y<#''R<UT@SM&[ ..<4M%)*QI5J^T=[)!1113,@HHHH
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M1Y@B(V^_2MWPA_R!6_Z[-_(5AEN-JSKJ@Y)QMV:V]1RBK7-^BBBOH3,****
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M^Q4T<:1($C144= HP*=10H1B[I$A1115 %%%% !1110 4444 %%%% !1110
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M/_? J:B@"'RYO^>Y_P"^!1Y<W_/<_P#? J:B@"'RYO\ GN?^^!1Y<W_/<_\
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MW_/<_P#? J:B@"'RYO\ GN?^^!1Y<W_/<_\ ? J:B@"'RYO^>Y_[X%'ES?\
M/<_]\"IJ* (?+F_Y[G_O@4>7-_SW/_? J:B@"'RYO^>Y_P"^!1Y<W_/<_P#?
M J:B@"'RYO\ GN?^^!1Y<W_/<_\ ? J:B@"'RYO^>Y_[X%'ES?\ /<_]\"IJ
M* (?+F_Y[G_O@4>7-_SW/_? J:B@"'RYO^>Y_P"^!1Y<W_/<_P#? J:B@"'R
MYO\ GN?^^!1Y<W_/<_\ ? J:B@"'RYO^>Y_[X%'ES?\ /<_]\"IJ* (?+F_Y
M[G_O@4>7-_SW/_? J:B@"'RYO^>Y_P"^!1Y<W_/<_P#? J:B@"'RYO\ GN?^
M^!1Y<W_/<_\ ? J:B@"'RYO^>Y_[X%'ES?\ /<_]\"IJ* (?+F_Y[G_O@4>7
M-_SW/_? J:B@"'RYO^>Y_P"^!1Y<W_/<_P#? J:B@"'RYO\ GN?^^!1Y<W_/
M<_\ ? J:B@"'RYO^>Y_[X%'ES?\ /<_]\"IJ* (?+F_Y[G_O@4>7-_SW/_?
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M+F_Y[G_O@4>7-_SW/_? J:B@"'RYO^>Y_P"^!1Y<W_/<_P#? J:B@"'RYO\
MGN?^^!1Y<W_/<_\ ? J:B@"'RYO^>Y_[X%'ES?\ /<_]\"IJ* (?+F_Y[G_O
M@4>7-_SW/_? J:B@"'RYO^>Y_P"^!1Y<W_/<_P#? J:B@"'RYO\ GN?^^!1Y
M<W_/<_\ ? J:B@"'RYO^>Y_[X%'ES?\ /<_]\"IJ* (?+F_Y[G_O@4>7-_SW
M/_? J:B@"'RYO^>Y_P"^!1Y<W_/<_P#? J:B@"'RYO\ GN?^^!1Y<W_/<_\
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MK&2B[WL_O/2J***Q-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2BS#F5[&W16/XDUP:#IJSK%YT\LBPPQ9QO=C@#]:R9?&-\WB6;0['0_M5Q!
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M?1%L/#%OH]V4G6.+RY#CY6Z]C5<R)Y&_D>9W&IKJ-KXZU#2I?-2:WB9&7NI
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M<<"BZN'*^4WZX'0UU'QA'J&I3:O>V<<=R\-M#:RE H7C+8^]SFMC^S_%=U)
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ME<]X&PWB;Q8\V?M/VX+S_<\M<5W5<Q>>'=0M]>GUC0KJW@GN4"W$5PA:-R.
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MNXFAVL"3OJ:=%%%0:!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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*HI:* "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>43
<FILENAME>kymr-20201231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Instance Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-11T04:08:03.4243335+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 393cc6ba0c39453d8ef47a8f7fceea15 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xbrli:xbrl xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2019-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:kymr="http://www.kymeratx.com/20201231" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="kymr-20201231.xsd" />
  <xbrli:unit id="U_xbrlishares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_iso4217USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_iso4217USD_xbrlishares">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="U_xbrlipure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_kymrSegment">
    <xbrli:measure>kymr:Segment</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_kymrSecurity">
    <xbrli:measure>kymr:Security</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_utrsqft">
    <xbrli:measure>utr:sqft</xbrli:measure>
  </xbrli:unit>
  <xbrli:context id="C_0001815442_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_20210226">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-02-26</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_20200630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesSeedConvertiblePreferredStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kymr:SeriesSeedConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesAConvertiblePreferredStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kymr:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesBConvertiblePreferredStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kymr:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesB1ConvertiblePreferredStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kymr:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesSeedConvertiblePreferredStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kymr:SeriesSeedConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesAConvertiblePreferredStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kymr:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesBConvertiblePreferredStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kymr:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesB1ConvertiblePreferredStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kymr:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesSeedConvertiblePreferredStockMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kymr:SeriesSeedConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesAConvertiblePreferredStockMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kymr:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesBConvertiblePreferredStockMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kymr:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesAConvertiblePreferredStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kymr:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesBConvertiblePreferredStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kymr:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesAConvertiblePreferredStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kymr:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesBConvertiblePreferredStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kymr:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesSeedConvertiblePreferredStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kymr:SeriesSeedConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesBConvertiblePreferredStocksMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kymr:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesB1PreferredStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kymr:SeriesB1PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesB1ConvertiblePreferredStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kymr:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesCConvertiblePreferredStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kymr:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesB1ConvertiblePreferredStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kymr:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_20200820_20200820">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-08-20</xbrli:startDate>
      <xbrli:endDate>2020-08-20</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200825_20200825">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-08-25</xbrli:startDate>
      <xbrli:endDate>2020-08-25</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20200825_20200825">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-08-25</xbrli:startDate>
      <xbrli:endDate>2020-08-25</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200825">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-08-25</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_srtConsolidatedEntitiesAxis_kymrVertexPharmaceuticalsIncorporatedMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20200825_20200825">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">kymr:VertexPharmaceuticalsIncorporatedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-08-25</xbrli:startDate>
      <xbrli:endDate>2020-08-25</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_srtConsolidatedEntitiesAxis_kymrVertexPharmaceuticalsIncorporatedMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20200825">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">kymr:VertexPharmaceuticalsIncorporatedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-08-25</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_srtRangeAxis_srtMinimumMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapPropertyPlantAndEquipmentByTypeAxis_kymrLabEquipmentMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">kymr:LabEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201904Member_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201904Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201815Member_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201815Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201813Member_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201813Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapFinancialInstrumentAxis_us-gaapUSTreasurySecuritiesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapFinancialInstrumentAxis_us-gaapUSTreasurySecuritiesMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapTypeOfArrangementAxis_kymrSanofiCollaborationArrangementMember_20200707_20200707">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kymr:SanofiCollaborationArrangementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-07-07</xbrli:startDate>
      <xbrli:endDate>2020-07-07</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_kymrSanofiCollaborationArrangementMember_20200707_20200707">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kymr:SanofiCollaborationArrangementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-07-07</xbrli:startDate>
      <xbrli:endDate>2020-07-07</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_srtRangeAxis_srtMinimumMember_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_kymrIRAK4Member_us-gaapTypeOfArrangementAxis_kymrSanofiCollaborationArrangementMember_20200707_20200707">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kymr:SanofiCollaborationArrangementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">kymr:IRAK4Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-07-07</xbrli:startDate>
      <xbrli:endDate>2020-07-07</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_kymrCollaborationTargetOneMember_us-gaapTypeOfArrangementAxis_kymrSanofiCollaborationArrangementMember_20200707_20200707">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kymr:SanofiCollaborationArrangementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">kymr:CollaborationTargetOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-07-07</xbrli:startDate>
      <xbrli:endDate>2020-07-07</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_kymrCollaborationTargetTwoMember_us-gaapTypeOfArrangementAxis_kymrSanofiCollaborationArrangementMember_20200707_20200707">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kymr:SanofiCollaborationArrangementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">kymr:CollaborationTargetTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-07-07</xbrli:startDate>
      <xbrli:endDate>2020-07-07</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapTypeOfArrangementAxis_kymrSanofiCollaborationArrangementMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kymr:SanofiCollaborationArrangementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_kymrCollaborationTargetOneMember_us-gaapTypeOfArrangementAxis_kymrSanofiCollaborationArrangementMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kymr:SanofiCollaborationArrangementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">kymr:CollaborationTargetOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_kymrCollaborationTargetTwoMember_us-gaapTypeOfArrangementAxis_kymrSanofiCollaborationArrangementMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kymr:SanofiCollaborationArrangementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">kymr:CollaborationTargetTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapTypeOfArrangementAxis_kymrSanofiCollaborationArrangementMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kymr:SanofiCollaborationArrangementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapTypeOfArrangementAxis_kymrVertexAgreementMember_20190509_20190509">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kymr:VertexAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-05-09</xbrli:startDate>
      <xbrli:endDate>2019-05-09</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesB1ConvertiblePreferredStockMember_us-gaapTypeOfArrangementAxis_kymrVertexAgreementMember_20190509_20190509">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kymr:VertexAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kymr:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-05-09</xbrli:startDate>
      <xbrli:endDate>2019-05-09</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesB1ConvertiblePreferredStockMember_us-gaapTypeOfArrangementAxis_kymrVertexAgreementMember_20190509">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kymr:VertexAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kymr:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-05-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_kymrVertexAgreementMember_20190509">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kymr:VertexAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-05-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapTypeOfArrangementAxis_kymrVertexAgreementMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kymr:VertexAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapTypeOfArrangementAxis_kymrVertexAgreementMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kymr:VertexAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapTypeOfArrangementAxis_kymrVertexAgreementMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kymr:VertexAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapTypeOfArrangementAxis_kymrVertexAgreementMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kymr:VertexAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_kymrVertexAgreementMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kymr:VertexAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesAPreferredUnitsMember_us-gaapTypeOfArrangementAxis_kymrCompoundCollaborationAgreementMember_20171031_20171031">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kymr:CompoundCollaborationAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kymr:SeriesAPreferredUnitsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-10-31</xbrli:startDate>
      <xbrli:endDate>2017-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesAPreferredUnitsMember_us-gaapTypeOfArrangementAxis_kymrCompoundCollaborationAgreementMember_20181101_20181101">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kymr:CompoundCollaborationAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kymr:SeriesAPreferredUnitsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-01</xbrli:startDate>
      <xbrli:endDate>2018-11-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesAPreferredUnitsMember_us-gaapTypeOfArrangementAxis_kymrCompoundCollaborationAgreementMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kymr:CompoundCollaborationAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kymr:SeriesAPreferredUnitsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesAPreferredUnitsMember_us-gaapTypeOfArrangementAxis_kymrCompoundCollaborationAgreementMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kymr:CompoundCollaborationAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kymr:SeriesAPreferredUnitsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapTypeOfArrangementAxis_kymrCompoundCollaborationAgreementMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kymr:CompoundCollaborationAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapBalanceSheetLocationAxis_kymrBilledReceivablesSanofiMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">kymr:BilledReceivablesSanofiMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapBalanceSheetLocationAxis_kymrUnbilledReceivablesSanofiMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">kymr:UnbilledReceivablesSanofiMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapBalanceSheetLocationAxis_kymrBilledReceivablesSanofiMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">kymr:BilledReceivablesSanofiMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapBalanceSheetLocationAxis_kymrUnbilledReceivablesSanofiMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">kymr:UnbilledReceivablesSanofiMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapBalanceSheetLocationAxis_kymrDeferredRevenueVertexMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">kymr:DeferredRevenueVertexMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapBalanceSheetLocationAxis_kymrDeferredRevenueSanofiMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">kymr:DeferredRevenueSanofiMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapBalanceSheetLocationAxis_kymrDeferredRevenueVertexMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">kymr:DeferredRevenueVertexMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapBalanceSheetLocationAxis_kymrDeferredRevenueVertexMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">kymr:DeferredRevenueVertexMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapBalanceSheetLocationAxis_kymrDeferredRevenueSanofiMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">kymr:DeferredRevenueSanofiMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapPropertyPlantAndEquipmentByTypeAxis_kymrLabAndOfficeEquipmentMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">kymr:LabAndOfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapPropertyPlantAndEquipmentByTypeAxis_kymrLabAndOfficeEquipmentMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">kymr:LabAndOfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapPropertyPlantAndEquipmentByTypeAxis_kymrLabEquipmentMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">kymr:LabEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapPropertyPlantAndEquipmentByTypeAxis_kymrLabEquipmentMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">kymr:LabEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapPropertyPlantAndEquipmentByTypeAxis_kymrAssetsNotYetInServiceMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">kymr:AssetsNotYetInServiceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapPropertyPlantAndEquipmentByTypeAxis_kymrAssetsNotYetInServiceMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">kymr:AssetsNotYetInServiceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_srtStatementGeographicalAxis_kymrCambridgeMassachusettsMember_us-gaapTypeOfArrangementAxis_kymrNoncancelableFacilityLeaseAgreementMember_20180228">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">kymr:CambridgeMassachusettsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kymr:NoncancelableFacilityLeaseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_srtStatementGeographicalAxis_kymrCambridgeMassachusettsMember_us-gaapTypeOfArrangementAxis_kymrNoncancelableFacilityLeaseAgreementMember_20200301_20200331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">kymr:CambridgeMassachusettsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kymr:NoncancelableFacilityLeaseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-03-01</xbrli:startDate>
      <xbrli:endDate>2020-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_srtStatementGeographicalAxis_kymrCambridgeMassachusettsMember_us-gaapBalanceSheetLocationAxis_us-gaapOtherAssetsMember_us-gaapCreditFacilityAxis_us-gaapLetterOfCreditMember_us-gaapTypeOfArrangementAxis_kymrNoncancelableFacilityLeaseAgreementMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">kymr:CambridgeMassachusettsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kymr:NoncancelableFacilityLeaseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_srtStatementGeographicalAxis_kymrCambridgeMassachusettsMember_us-gaapBalanceSheetLocationAxis_us-gaapOtherCurrentAssetsMember_us-gaapCreditFacilityAxis_us-gaapLetterOfCreditMember_us-gaapTypeOfArrangementAxis_kymrNoncancelableFacilityLeaseAgreementMember_20201031">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">kymr:CambridgeMassachusettsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kymr:NoncancelableFacilityLeaseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_srtStatementGeographicalAxis_kymrCambridgeMassachusettsMember_us-gaapTypeOfArrangementAxis_kymrFacilitySubleaseAgreementMember_20190430">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">kymr:CambridgeMassachusettsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kymr:FacilitySubleaseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_srtStatementGeographicalAxis_kymrCambridgeMassachusettsMember_us-gaapTypeOfArrangementAxis_kymrFacilitySubleaseAgreementMember_20190401_20190430">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">kymr:CambridgeMassachusettsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kymr:FacilitySubleaseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_srtStatementGeographicalAxis_kymrWatertownMassachusettsMember_us-gaapTypeOfArrangementAxis_kymrNoncancelableFacilityLeaseAgreementMember_20191031">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">kymr:WatertownMassachusettsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kymr:NoncancelableFacilityLeaseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_srtStatementGeographicalAxis_kymrWatertownMassachusettsMember_us-gaapTypeOfArrangementAxis_kymrNoncancelableFacilityLeaseAgreementMember_20191001_20191031">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">kymr:WatertownMassachusettsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kymr:NoncancelableFacilityLeaseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-10-01</xbrli:startDate>
      <xbrli:endDate>2019-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_srtStatementGeographicalAxis_kymrWatertownMassachusettsMember_us-gaapBalanceSheetLocationAxis_us-gaapOtherAssetsMember_us-gaapCreditFacilityAxis_us-gaapLetterOfCreditMember_us-gaapTypeOfArrangementAxis_kymrNoncancelableFacilityLeaseAgreementMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">kymr:WatertownMassachusettsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kymr:NoncancelableFacilityLeaseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapLossContingenciesByNatureOfContingencyAxis_us-gaapIndemnificationGuaranteeMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapLossContingenciesByNatureOfContingencyAxis_us-gaapIndemnificationGuaranteeMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20200820">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-08-20</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesSeedConvertiblePreferredStockMember_20200820">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kymr:SeriesSeedConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-08-20</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesAConvertiblePreferredStockMember_20200820">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kymr:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-08-20</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesBConvertiblePreferredStockMember_20200820">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kymr:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-08-20</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesB1ConvertiblePreferredStockMember_20200820">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kymr:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-08-20</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesCConvertiblePreferredStockMember_20200820">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kymr:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-08-20</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesBConvertiblePreferredStockMember_20200131">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kymr:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesBConvertiblePreferredStockMember_20200101_20200131">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kymr:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesCConvertiblePreferredStockMember_us-gaapTypeOfArrangementAxis_kymrSeriesCPreferredStockPurchaseAgreementMember_20200331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kymr:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kymr:SeriesCPreferredStockPurchaseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesCConvertiblePreferredStockMember_us-gaapTypeOfArrangementAxis_kymrSeriesCPreferredStockPurchaseAgreementMember_20200301_20200331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kymr:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kymr:SeriesCPreferredStockPurchaseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-03-01</xbrli:startDate>
      <xbrli:endDate>2020-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesCConvertiblePreferredStockMember_20200331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kymr:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200821_20200821">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-08-21</xbrli:startDate>
      <xbrli:endDate>2020-08-21</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20200821_20200821">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-08-21</xbrli:startDate>
      <xbrli:endDate>2020-08-21</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapPlanNameAxis_kymrTwoThousandTwentyStockOptionAndIncentivePlanMember_20200820">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kymr:TwoThousandTwentyStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-08-20</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapPlanNameAxis_kymrTwoThousandTwentyStockOptionAndIncentivePlanMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kymr:TwoThousandTwentyStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapPlanNameAxis_kymrTwoThousandTwentyStockOptionAndIncentivePlanMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kymr:TwoThousandTwentyStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapPlanNameAxis_kymrTwoThousandTwentyEmployeeStockPurchasePlanMember_20200820">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kymr:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-08-20</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapPlanNameAxis_kymrTwoThousandTwentyEmployeeStockPurchasePlanMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kymr:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_kymrScenarioPotentialOutcomeAxis_kymrLesserOfPotentialOutcomeOneMember_us-gaapPlanNameAxis_kymrTwoThousandTwentyEmployeeStockPurchasePlanMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kymr:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="kymr:ScenarioPotentialOutcomeAxis">kymr:LesserOfPotentialOutcomeOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_kymrScenarioPotentialOutcomeAxis_kymrLesserOfPotentialOutcomeTwoMember_us-gaapPlanNameAxis_kymrTwoThousandTwentyEmployeeStockPurchasePlanMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kymr:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="kymr:ScenarioPotentialOutcomeAxis">kymr:LesserOfPotentialOutcomeTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapPlanNameAxis_kymrTwoThousandTwentyEmployeeStockPurchasePlanMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kymr:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapPlanNameAxis_kymrTwoThousandAndTwentyStockOptionAndGrantPlanMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kymr:TwoThousandAndTwentyStockOptionAndGrantPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapPlanNameAxis_kymrTwoThousandAndTwentyStockOptionAndGrantPlanMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kymr:TwoThousandAndTwentyStockOptionAndGrantPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapPlanNameAxis_kymrTwoThousandAndTwentyStockOptionAndGrantPlanMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kymr:TwoThousandAndTwentyStockOptionAndGrantPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapPlanNameAxis_kymrTwoThousandAndTwentyStockOptionAndGrantPlanMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kymr:TwoThousandAndTwentyStockOptionAndGrantPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapPlanNameAxis_kymrTwoThousandEighteenStockOptionAndGrantPlanMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kymr:TwoThousandEighteenStockOptionAndGrantPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapPlanNameAxis_kymrTwoThousandEighteenStockOptionAndGrantPlanMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kymr:TwoThousandEighteenStockOptionAndGrantPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapPlanNameAxis_kymrTwoThousandEighteenStockOptionAndGrantPlanMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kymr:TwoThousandEighteenStockOptionAndGrantPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapPlanNameAxis_kymrTwoThousandEighteenStockOptionAndGrantPlanMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kymr:TwoThousandEighteenStockOptionAndGrantPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_us-gaapInvestorMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_us-gaapInvestorMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapIncomeTaxAuthorityAxis_kymrFederalAndStateMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">kymr:FederalAndStateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapTaxPeriodAxis_us-gaapEarliestTaxYearMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapTaxPeriodAxis_us-gaapLatestTaxYearMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001815442_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <dei:DocumentType id="F_000000" contextRef="C_0001815442_20200101_20201231">10-K</dei:DocumentType>
  <dei:AmendmentFlag id="F_000001" contextRef="C_0001815442_20200101_20201231">false</dei:AmendmentFlag>
  <dei:DocumentPeriodEndDate id="F_000002" contextRef="C_0001815442_20200101_20201231">2020-12-31</dei:DocumentPeriodEndDate>
  <dei:DocumentFiscalYearFocus id="F_000003" contextRef="C_0001815442_20200101_20201231">2020</dei:DocumentFiscalYearFocus>
  <dei:DocumentFiscalPeriodFocus id="F_000004" contextRef="C_0001815442_20200101_20201231">FY</dei:DocumentFiscalPeriodFocus>
  <dei:TradingSymbol id="F_000005" contextRef="C_0001815442_20200101_20201231">KYMR</dei:TradingSymbol>
  <dei:EntityRegistrantName id="F_000006" contextRef="C_0001815442_20200101_20201231">Kymera Therapeutics, Inc.</dei:EntityRegistrantName>
  <dei:EntityCentralIndexKey id="F_000007" contextRef="C_0001815442_20200101_20201231">0001815442</dei:EntityCentralIndexKey>
  <dei:CurrentFiscalYearEndDate id="F_000008" contextRef="C_0001815442_20200101_20201231">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityCurrentReportingStatus id="F_000009" contextRef="C_0001815442_20200101_20201231">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityFilerCategory id="F_000010" contextRef="C_0001815442_20200101_20201231">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityWellKnownSeasonedIssuer id="F_000011" contextRef="C_0001815442_20200101_20201231">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:EntityVoluntaryFilers id="F_000012" contextRef="C_0001815442_20200101_20201231">No</dei:EntityVoluntaryFilers>
  <dei:EntitySmallBusiness id="F_000013" contextRef="C_0001815442_20200101_20201231">true</dei:EntitySmallBusiness>
  <dei:EntityEmergingGrowthCompany id="F_000014" contextRef="C_0001815442_20200101_20201231">true</dei:EntityEmergingGrowthCompany>
  <dei:EntityExTransitionPeriod id="F_000015" contextRef="C_0001815442_20200101_20201231">false</dei:EntityExTransitionPeriod>
  <dei:EntityCommonStockSharesOutstanding id="F_000016" contextRef="C_0001815442_20210226" decimals="INF" unitRef="U_xbrlishares">44811485</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityPublicFloat id="F_000017" contextRef="C_0001815442_20200630" decimals="0" unitRef="U_iso4217USD">0</dei:EntityPublicFloat>
  <dei:EntityShellCompany id="F_000018" contextRef="C_0001815442_20200101_20201231">false</dei:EntityShellCompany>
  <dei:EntityFileNumber id="F_000019" contextRef="C_0001815442_20200101_20201231">001-39460</dei:EntityFileNumber>
  <dei:EntityTaxIdentificationNumber id="F_000020" contextRef="C_0001815442_20200101_20201231">81-2992166</dei:EntityTaxIdentificationNumber>
  <dei:EntityAddressAddressLine1 id="F_000021" contextRef="C_0001815442_20200101_20201231">200 Arsenal Yards Blvd</dei:EntityAddressAddressLine1>
  <dei:EntityAddressAddressLine2 id="F_000022" contextRef="C_0001815442_20200101_20201231">Suite 230</dei:EntityAddressAddressLine2>
  <dei:EntityAddressCityOrTown id="F_000023" contextRef="C_0001815442_20200101_20201231">Watertown</dei:EntityAddressCityOrTown>
  <dei:EntityAddressStateOrProvince id="F_000024" contextRef="C_0001815442_20200101_20201231">MA</dei:EntityAddressStateOrProvince>
  <dei:EntityAddressPostalZipCode id="F_000025" contextRef="C_0001815442_20200101_20201231">02472</dei:EntityAddressPostalZipCode>
  <dei:CityAreaCode id="F_000026" contextRef="C_0001815442_20200101_20201231">857</dei:CityAreaCode>
  <dei:LocalPhoneNumber id="F_000027" contextRef="C_0001815442_20200101_20201231">285-5300</dei:LocalPhoneNumber>
  <dei:EntityInteractiveDataCurrent id="F_000028" contextRef="C_0001815442_20200101_20201231">Yes</dei:EntityInteractiveDataCurrent>
  <dei:EntityIncorporationStateCountryCode id="F_000029" contextRef="C_0001815442_20200101_20201231">DE</dei:EntityIncorporationStateCountryCode>
  <dei:DocumentAnnualReport id="F_000030" contextRef="C_0001815442_20200101_20201231">true</dei:DocumentAnnualReport>
  <dei:DocumentTransitionReport id="F_000031" contextRef="C_0001815442_20200101_20201231">false</dei:DocumentTransitionReport>
  <dei:Security12bTitle id="F_000032" contextRef="C_0001815442_20200101_20201231">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
  <dei:SecurityExchangeName id="F_000033" contextRef="C_0001815442_20200101_20201231">NASDAQ</dei:SecurityExchangeName>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000034" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">31004000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000035" contextRef="C_0001815442_20191231" decimals="-3" unitRef="U_iso4217USD">76015000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent id="F_000036" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">265198000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent id="F_000037" contextRef="C_0001815442_20191231" decimals="-3" unitRef="U_iso4217USD">15942000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
  <us-gaap:DueFromRelatedPartiesCurrent id="F_000038" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">577000</us-gaap:DueFromRelatedPartiesCurrent>
  <us-gaap:ContractWithCustomerAssetNetCurrent id="F_000039" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">856000</us-gaap:ContractWithCustomerAssetNetCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="F_000040" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">4704000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="F_000041" contextRef="C_0001815442_20191231" decimals="-3" unitRef="U_iso4217USD">888000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsCurrent id="F_000042" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">302339000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent id="F_000043" contextRef="C_0001815442_20191231" decimals="-3" unitRef="U_iso4217USD">92845000</us-gaap:AssetsCurrent>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent id="F_000044" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">162531000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000045" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">10841000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000046" contextRef="C_0001815442_20191231" decimals="-3" unitRef="U_iso4217USD">3794000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:OperatingLeaseRightOfUseAsset id="F_000047" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">9845000</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:OperatingLeaseRightOfUseAsset id="F_000048" contextRef="C_0001815442_20191231" decimals="-3" unitRef="U_iso4217USD">18289000</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:OtherAssetsNoncurrent id="F_000049" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">30000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:RestrictedCashNoncurrent id="F_000050" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">1589000</us-gaap:RestrictedCashNoncurrent>
  <us-gaap:RestrictedCashNoncurrent id="F_000051" contextRef="C_0001815442_20191231" decimals="-3" unitRef="U_iso4217USD">1774000</us-gaap:RestrictedCashNoncurrent>
  <us-gaap:Assets id="F_000052" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">487175000</us-gaap:Assets>
  <us-gaap:Assets id="F_000053" contextRef="C_0001815442_20191231" decimals="-3" unitRef="U_iso4217USD">116702000</us-gaap:Assets>
  <us-gaap:AccountsPayableCurrent id="F_000054" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">4368000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent id="F_000055" contextRef="C_0001815442_20191231" decimals="-3" unitRef="U_iso4217USD">3276000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="F_000056" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">10330000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="F_000057" contextRef="C_0001815442_20191231" decimals="-3" unitRef="U_iso4217USD">4568000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:ContractWithCustomerLiabilityCurrent id="F_000058" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">92552000</us-gaap:ContractWithCustomerLiabilityCurrent>
  <us-gaap:ContractWithCustomerLiabilityCurrent id="F_000059" contextRef="C_0001815442_20191231" decimals="-3" unitRef="U_iso4217USD">23349000</us-gaap:ContractWithCustomerLiabilityCurrent>
  <us-gaap:OperatingLeaseLiabilityCurrent id="F_000060" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">2572000</us-gaap:OperatingLeaseLiabilityCurrent>
  <us-gaap:OperatingLeaseLiabilityCurrent id="F_000061" contextRef="C_0001815442_20191231" decimals="-3" unitRef="U_iso4217USD">2696000</us-gaap:OperatingLeaseLiabilityCurrent>
  <us-gaap:FinanceLeaseLiabilityCurrent id="F_000062" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">689000</us-gaap:FinanceLeaseLiabilityCurrent>
  <us-gaap:FinanceLeaseLiabilityCurrent id="F_000063" contextRef="C_0001815442_20191231" decimals="-3" unitRef="U_iso4217USD">681000</us-gaap:FinanceLeaseLiabilityCurrent>
  <us-gaap:OtherLiabilitiesCurrent id="F_000064" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">106000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000065" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">110617000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000066" contextRef="C_0001815442_20191231" decimals="-3" unitRef="U_iso4217USD">34570000</us-gaap:LiabilitiesCurrent>
  <us-gaap:ContractWithCustomerLiabilityNoncurrent id="F_000067" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">77838000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
  <us-gaap:ContractWithCustomerLiabilityNoncurrent id="F_000068" contextRef="C_0001815442_20191231" decimals="-3" unitRef="U_iso4217USD">29642000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
  <us-gaap:OperatingLeaseLiabilityNoncurrent id="F_000069" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">14128000</us-gaap:OperatingLeaseLiabilityNoncurrent>
  <us-gaap:OperatingLeaseLiabilityNoncurrent id="F_000070" contextRef="C_0001815442_20191231" decimals="-3" unitRef="U_iso4217USD">16651000</us-gaap:OperatingLeaseLiabilityNoncurrent>
  <us-gaap:FinanceLeaseLiabilityNoncurrent id="F_000071" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">604000</us-gaap:FinanceLeaseLiabilityNoncurrent>
  <us-gaap:FinanceLeaseLiabilityNoncurrent id="F_000072" contextRef="C_0001815442_20191231" decimals="-3" unitRef="U_iso4217USD">1165000</us-gaap:FinanceLeaseLiabilityNoncurrent>
  <us-gaap:OtherLiabilitiesNoncurrent id="F_000073" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">100000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:Liabilities id="F_000074" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">203287000</us-gaap:Liabilities>
  <us-gaap:Liabilities id="F_000075" contextRef="C_0001815442_20191231" decimals="-3" unitRef="U_iso4217USD">82028000</us-gaap:Liabilities>
  <us-gaap:CommitmentsAndContingencies id="F_000076" xsi:nil="true" contextRef="C_0001815442_20201231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommitmentsAndContingencies id="F_000077" xsi:nil="true" contextRef="C_0001815442_20191231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000078" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesSeedConvertiblePreferredStockMember_20191231" decimals="-3" unitRef="U_iso4217USD">5900000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000079" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesAConvertiblePreferredStockMember_20191231" decimals="-3" unitRef="U_iso4217USD">29237000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000080" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesBConvertiblePreferredStockMember_20191231" decimals="-3" unitRef="U_iso4217USD">59918000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000081" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesB1ConvertiblePreferredStockMember_20191231" decimals="-3" unitRef="U_iso4217USD">14025000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:PreferredStockValue id="F_000082" xsi:nil="true" contextRef="C_0001815442_20201231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:PreferredStockValue id="F_000083" xsi:nil="true" contextRef="C_0001815442_20191231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommonStockValue id="F_000084" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">4000</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="F_000085" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">412777000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="F_000086" contextRef="C_0001815442_20191231" decimals="-3" unitRef="U_iso4217USD">2044000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000087" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">-128765000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000088" contextRef="C_0001815442_20191231" decimals="-3" unitRef="U_iso4217USD">-76456000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax id="F_000089" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">-128000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax id="F_000090" contextRef="C_0001815442_20191231" decimals="-3" unitRef="U_iso4217USD">6000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:StockholdersEquity id="F_000091" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">283888000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000092" contextRef="C_0001815442_20191231" decimals="-3" unitRef="U_iso4217USD">-74406000</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000093" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">487175000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000094" contextRef="C_0001815442_20191231" decimals="-3" unitRef="U_iso4217USD">116702000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000095" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesSeedConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000096" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesSeedConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000097" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesSeedConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000098" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesSeedConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">3000000</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesIssued id="F_000099" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesSeedConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesIssued id="F_000100" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesSeedConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">3000000</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000101" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesSeedConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000102" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesSeedConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">3000000</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityLiquidationPreference id="F_000103" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesSeedConvertiblePreferredStockMember_20191231" decimals="-3" unitRef="U_iso4217USD">3000000</us-gaap:TemporaryEquityLiquidationPreference>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000104" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesAConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000105" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesAConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000106" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesAConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000107" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesAConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">14886305</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesIssued id="F_000108" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesAConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesIssued id="F_000109" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesAConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">14886305</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000110" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesAConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000111" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesAConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">14720126</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityLiquidationPreference id="F_000112" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesAConvertiblePreferredStockMember_20191231" decimals="-3" unitRef="U_iso4217USD">29440000</us-gaap:TemporaryEquityLiquidationPreference>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000113" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesBConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000114" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesBConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000115" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesBConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000116" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesBConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">16009848</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesIssued id="F_000117" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesBConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesIssued id="F_000118" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesBConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">14827580</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000119" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesBConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000120" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesBConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">14827580</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityLiquidationPreference id="F_000121" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesBConvertiblePreferredStockMember_20191231" decimals="-3" unitRef="U_iso4217USD">60200000</us-gaap:TemporaryEquityLiquidationPreference>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000122" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesB1ConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000123" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesB1ConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000124" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesB1ConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000125" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesB1ConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">3059695</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesIssued id="F_000126" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesB1ConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesIssued id="F_000127" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesB1ConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">3059695</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000128" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesB1ConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000129" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesB1ConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">3059695</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityLiquidationPreference id="F_000130" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesB1ConvertiblePreferredStockMember_20191231" decimals="-3" unitRef="U_iso4217USD">20000000</us-gaap:TemporaryEquityLiquidationPreference>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="F_000131" contextRef="C_0001815442_20201231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="F_000132" contextRef="C_0001815442_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized id="F_000133" contextRef="C_0001815442_20201231" decimals="INF" unitRef="U_xbrlishares">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized id="F_000134" contextRef="C_0001815442_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued id="F_000135" contextRef="C_0001815442_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued id="F_000136" contextRef="C_0001815442_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding id="F_000137" contextRef="C_0001815442_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding id="F_000138" contextRef="C_0001815442_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000139" contextRef="C_0001815442_20201231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000140" contextRef="C_0001815442_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="F_000141" contextRef="C_0001815442_20201231" decimals="INF" unitRef="U_xbrlishares">150000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized id="F_000142" contextRef="C_0001815442_20191231" decimals="INF" unitRef="U_xbrlishares">45000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued id="F_000143" contextRef="C_0001815442_20201231" decimals="INF" unitRef="U_xbrlishares">44592288</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="F_000144" contextRef="C_0001815442_20191231" decimals="INF" unitRef="U_xbrlishares">2208982</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="F_000145" contextRef="C_0001815442_20201231" decimals="INF" unitRef="U_xbrlishares">44482186</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding id="F_000146" contextRef="C_0001815442_20191231" decimals="INF" unitRef="U_xbrlishares">1929516</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="F_000147" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">34034000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="F_000148" contextRef="C_0001815442_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">2934000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList id="F_000149" contextRef="C_0001815442_20200101_20201231">kymr:CollaborationRevenueFromRelatedPartyMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
  <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList id="F_000150" contextRef="C_0001815442_20190101_20191231">kymr:CollaborationRevenueFromRelatedPartyMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000151" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">62105000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000152" contextRef="C_0001815442_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">37158000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000153" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">18233000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000154" contextRef="C_0001815442_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">7981000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses id="F_000155" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">80338000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_000156" contextRef="C_0001815442_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">45139000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss id="F_000157" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-46304000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_000158" contextRef="C_0001815442_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-42205000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherNonoperatingIncome id="F_000159" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">826000</us-gaap:OtherNonoperatingIncome>
  <us-gaap:OtherNonoperatingIncome id="F_000160" contextRef="C_0001815442_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1005000</us-gaap:OtherNonoperatingIncome>
  <us-gaap:OtherNonoperatingExpense id="F_000161" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">115000</us-gaap:OtherNonoperatingExpense>
  <us-gaap:OtherNonoperatingExpense id="F_000162" contextRef="C_0001815442_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">46000</us-gaap:OtherNonoperatingExpense>
  <us-gaap:OtherNonoperatingIncomeExpense id="F_000163" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">711000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense id="F_000164" contextRef="C_0001815442_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">959000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:NetIncomeLoss id="F_000165" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-45593000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000166" contextRef="C_0001815442_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-41246000</us-gaap:NetIncomeLoss>
  <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent id="F_000167" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-134000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent id="F_000168" contextRef="C_0001815442_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">6000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
  <us-gaap:ComprehensiveIncomeNetOfTax id="F_000169" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-45727000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax id="F_000170" contextRef="C_0001815442_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-41240000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:TemporaryEquityDividendsAdjustment id="F_000171" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">9050000</us-gaap:TemporaryEquityDividendsAdjustment>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000172" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-54643000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000173" contextRef="C_0001815442_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-41246000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000174" contextRef="C_0001815442_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-3.15</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000175" contextRef="C_0001815442_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-24.28</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000176" contextRef="C_0001815442_20200101_20201231" decimals="0" unitRef="U_xbrlishares">17349582</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000177" contextRef="C_0001815442_20190101_20191231" decimals="0" unitRef="U_xbrlishares">1698522</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <kymr:TemporaryEquityAdjustedSharesOutstanding id="F_000178" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesSeedConvertiblePreferredStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">3000000</kymr:TemporaryEquityAdjustedSharesOutstanding>
  <kymr:TemporaryEquityAdjustedCarryingAmountAttributableToParent id="F_000179" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesSeedConvertiblePreferredStockMember_20181231" decimals="-3" unitRef="U_iso4217USD">5900000</kymr:TemporaryEquityAdjustedCarryingAmountAttributableToParent>
  <kymr:TemporaryEquityAdjustedSharesOutstanding id="F_000180" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesAConvertiblePreferredStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">14498547</kymr:TemporaryEquityAdjustedSharesOutstanding>
  <kymr:TemporaryEquityAdjustedCarryingAmountAttributableToParent id="F_000181" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesAConvertiblePreferredStockMember_20181231" decimals="-3" unitRef="U_iso4217USD">28794000</kymr:TemporaryEquityAdjustedCarryingAmountAttributableToParent>
  <kymr:TemporaryEquityAdjustedSharesOutstanding id="F_000182" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesBConvertiblePreferredStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">9605905</kymr:TemporaryEquityAdjustedSharesOutstanding>
  <kymr:TemporaryEquityAdjustedCarryingAmountAttributableToParent id="F_000183" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesBConvertiblePreferredStockMember_20181231" decimals="-3" unitRef="U_iso4217USD">38735000</kymr:TemporaryEquityAdjustedCarryingAmountAttributableToParent>
  <kymr:TemporaryEquityStockSharesVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement id="F_000184" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesAConvertiblePreferredStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">221579</kymr:TemporaryEquityStockSharesVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement>
  <kymr:TemporaryEquityStockValueVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement id="F_000185" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesAConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">443000</kymr:TemporaryEquityStockValueVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement>
  <kymr:TemporaryEquityConvertiblePreferredStockIssuedDuringPeriodShares id="F_000186" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesBConvertiblePreferredStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">5221675</kymr:TemporaryEquityConvertiblePreferredStockIssuedDuringPeriodShares>
  <kymr:TemporaryEquityConvertiblePreferredStockIssuedDuringPeriodValue id="F_000187" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesBConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">21183000</kymr:TemporaryEquityConvertiblePreferredStockIssuedDuringPeriodValue>
  <kymr:TemporaryEquityAdjustedSharesOutstanding id="F_000188" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesSeedConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">3000000</kymr:TemporaryEquityAdjustedSharesOutstanding>
  <kymr:TemporaryEquityAdjustedCarryingAmountAttributableToParent id="F_000189" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesSeedConvertiblePreferredStockMember_20191231" decimals="-3" unitRef="U_iso4217USD">5900000</kymr:TemporaryEquityAdjustedCarryingAmountAttributableToParent>
  <kymr:TemporaryEquityAdjustedSharesOutstanding id="F_000190" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesAConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">14720126</kymr:TemporaryEquityAdjustedSharesOutstanding>
  <kymr:TemporaryEquityAdjustedCarryingAmountAttributableToParent id="F_000191" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesAConvertiblePreferredStockMember_20191231" decimals="-3" unitRef="U_iso4217USD">29237000</kymr:TemporaryEquityAdjustedCarryingAmountAttributableToParent>
  <kymr:TemporaryEquityAdjustedSharesOutstanding id="F_000192" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesBConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">14827580</kymr:TemporaryEquityAdjustedSharesOutstanding>
  <kymr:TemporaryEquityAdjustedCarryingAmountAttributableToParent id="F_000193" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesBConvertiblePreferredStockMember_20191231" decimals="-3" unitRef="U_iso4217USD">59918000</kymr:TemporaryEquityAdjustedCarryingAmountAttributableToParent>
  <kymr:TemporaryEquityStockSharesVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement id="F_000194" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesAConvertiblePreferredStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">110788</kymr:TemporaryEquityStockSharesVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement>
  <kymr:TemporaryEquityStockValueVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement id="F_000195" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesAConvertiblePreferredStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">222000</kymr:TemporaryEquityStockValueVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement>
  <kymr:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues id="F_000196" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesBConvertiblePreferredStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">1182265</kymr:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues id="F_000197" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesBConvertiblePreferredStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">4800000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
  <kymr:TemporaryEquityExchangeOfConvertiblePreferredStockShares id="F_000198" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesAConvertiblePreferredStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">-1988802</kymr:TemporaryEquityExchangeOfConvertiblePreferredStockShares>
  <kymr:TemporaryEquityExchangeOfConvertiblePreferredStockValue id="F_000199" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesAConvertiblePreferredStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-3950000</kymr:TemporaryEquityExchangeOfConvertiblePreferredStockValue>
  <kymr:TemporaryEquitySharesConverted id="F_000200" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesSeedConvertiblePreferredStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">3000000</kymr:TemporaryEquitySharesConverted>
  <kymr:TemporaryEquityValueOfSharesConverted id="F_000201" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesSeedConvertiblePreferredStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">5900000</kymr:TemporaryEquityValueOfSharesConverted>
  <kymr:TemporaryEquitySharesConverted id="F_000202" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesAConvertiblePreferredStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">12842112</kymr:TemporaryEquitySharesConverted>
  <kymr:TemporaryEquityValueOfSharesConverted id="F_000203" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesAConvertiblePreferredStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">25509000</kymr:TemporaryEquityValueOfSharesConverted>
  <kymr:TemporaryEquitySharesConverted id="F_000204" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesBConvertiblePreferredStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">16009845</kymr:TemporaryEquitySharesConverted>
  <kymr:TemporaryEquityValueOfSharesConverted id="F_000205" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesBConvertiblePreferredStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">64718000</kymr:TemporaryEquityValueOfSharesConverted>
  <us-gaap:PaymentsOfStockIssuanceCosts id="F_000206" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesBConvertiblePreferredStocksMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">17000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsOfStockIssuanceCosts id="F_000207" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesB1PreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">49000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsOfStockIssuanceCosts id="F_000208" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsOfStockIssuanceCosts id="F_000209" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">320000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsOfStockIssuanceCosts id="F_000210" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">17003000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:SharesOutstanding id="F_000211" contextRef="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">1479188</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000212" contextRef="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231" decimals="-3" unitRef="U_iso4217USD">774000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000213" contextRef="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231" decimals="-3" unitRef="U_iso4217USD">-35210000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000214" contextRef="C_0001815442_20181231" decimals="-3" unitRef="U_iso4217USD">-34436000</us-gaap:StockholdersEquity>
  <kymr:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues id="F_000215" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesB1ConvertiblePreferredStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">3059695</kymr:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues id="F_000216" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesB1ConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">14025000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000217" contextRef="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">95904</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000218" contextRef="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">74000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000219" contextRef="C_0001815442_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">74000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <kymr:StockIssuedDuringPeriodSharesRestrictedStockVested id="F_000220" contextRef="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">354424</kymr:StockIssuedDuringPeriodSharesRestrictedStockVested>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000221" contextRef="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1196000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000222" contextRef="C_0001815442_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1196000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax id="F_000223" contextRef="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">6000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax id="F_000224" contextRef="C_0001815442_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">6000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:NetIncomeLoss id="F_000225" contextRef="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-41246000</us-gaap:NetIncomeLoss>
  <kymr:TemporaryEquityAdjustedSharesOutstanding id="F_000226" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesB1ConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">3059695</kymr:TemporaryEquityAdjustedSharesOutstanding>
  <kymr:TemporaryEquityAdjustedCarryingAmountAttributableToParent id="F_000227" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesB1ConvertiblePreferredStockMember_20191231" decimals="-3" unitRef="U_iso4217USD">14025000</kymr:TemporaryEquityAdjustedCarryingAmountAttributableToParent>
  <us-gaap:SharesOutstanding id="F_000228" contextRef="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">1929516</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000229" contextRef="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231" decimals="-3" unitRef="U_iso4217USD">2044000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000230" contextRef="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231" decimals="-3" unitRef="U_iso4217USD">-76456000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000231" contextRef="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231" decimals="-3" unitRef="U_iso4217USD">6000</us-gaap:StockholdersEquity>
  <kymr:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues id="F_000232" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesCConvertiblePreferredStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">13539141</kymr:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues id="F_000233" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesCConvertiblePreferredStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">88180000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
  <kymr:TemporaryEquityExchangeOfConvertiblePreferredStockShares id="F_000234" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesCConvertiblePreferredStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">1988802</kymr:TemporaryEquityExchangeOfConvertiblePreferredStockShares>
  <kymr:TemporaryEquityExchangeOfConvertiblePreferredStockValue id="F_000235" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesCConvertiblePreferredStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">13000000</kymr:TemporaryEquityExchangeOfConvertiblePreferredStockValue>
  <kymr:ExchangeOfConvertiblePreferredStockImpactOnEquity id="F_000236" contextRef="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-2334000</kymr:ExchangeOfConvertiblePreferredStockImpactOnEquity>
  <kymr:ExchangeOfConvertiblePreferredStockImpactOnEquity id="F_000237" contextRef="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-6716000</kymr:ExchangeOfConvertiblePreferredStockImpactOnEquity>
  <kymr:ExchangeOfConvertiblePreferredStockImpactOnEquity id="F_000238" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-9050000</kymr:ExchangeOfConvertiblePreferredStockImpactOnEquity>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000239" contextRef="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">78852</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000240" contextRef="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">162000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000241" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">162000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <kymr:StockIssuedDuringPeriodSharesRestrictedStockVested id="F_000242" contextRef="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">184410</kymr:StockIssuedDuringPeriodSharesRestrictedStockVested>
  <kymr:StockIssuedDuringPeriodValueRestrictedStockVested id="F_000243" contextRef="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">112000</kymr:StockIssuedDuringPeriodValueRestrictedStockVested>
  <kymr:StockIssuedDuringPeriodValueRestrictedStockVested id="F_000244" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">112000</kymr:StockIssuedDuringPeriodValueRestrictedStockVested>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000245" contextRef="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">5190000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000246" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">5190000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax id="F_000247" contextRef="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-134000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax id="F_000248" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-134000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000249" contextRef="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">9987520</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000250" contextRef="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000251" contextRef="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">182747000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000252" contextRef="C_0001815442_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">182748000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <kymr:TemporaryEquitySharesConverted id="F_000253" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesB1ConvertiblePreferredStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">3059695</kymr:TemporaryEquitySharesConverted>
  <kymr:TemporaryEquityValueOfSharesConverted id="F_000254" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesB1ConvertiblePreferredStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">14025000</kymr:TemporaryEquityValueOfSharesConverted>
  <kymr:TemporaryEquitySharesConverted id="F_000255" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesCConvertiblePreferredStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">15527943</kymr:TemporaryEquitySharesConverted>
  <kymr:TemporaryEquityValueOfSharesConverted id="F_000256" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesCConvertiblePreferredStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">101180000</kymr:TemporaryEquityValueOfSharesConverted>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="F_000257" contextRef="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">31625534</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000258" contextRef="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000259" contextRef="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">211329000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000260" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">211332000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000261" contextRef="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">676354</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000262" contextRef="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">13527000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000263" contextRef="C_0001815442_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">13527000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:NetIncomeLoss id="F_000264" contextRef="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-45593000</us-gaap:NetIncomeLoss>
  <us-gaap:SharesOutstanding id="F_000265" contextRef="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">44482186</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000266" contextRef="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="-3" unitRef="U_iso4217USD">4000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000267" contextRef="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231" decimals="-3" unitRef="U_iso4217USD">412777000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000268" contextRef="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231" decimals="-3" unitRef="U_iso4217USD">-128765000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000269" contextRef="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231" decimals="-3" unitRef="U_iso4217USD">-128000</us-gaap:StockholdersEquity>
  <us-gaap:ProfitLoss id="F_000270" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-45593000</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss id="F_000271" contextRef="C_0001815442_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-41246000</us-gaap:ProfitLoss>
  <us-gaap:ShareBasedCompensation id="F_000272" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">5190000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="F_000273" contextRef="C_0001815442_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1196000</us-gaap:ShareBasedCompensation>
  <us-gaap:DepreciationDepletionAndAmortization id="F_000274" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">1763000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization id="F_000275" contextRef="C_0001815442_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">825000</us-gaap:DepreciationDepletionAndAmortization>
  <kymr:NonCashResearchAndDevelopmentExpense id="F_000276" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">332000</kymr:NonCashResearchAndDevelopmentExpense>
  <kymr:NonCashResearchAndDevelopmentExpense id="F_000277" contextRef="C_0001815442_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">443000</kymr:NonCashResearchAndDevelopmentExpense>
  <kymr:NetAmortizationOfPremiumsAndDiscountsOnInvestments id="F_000278" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-1571000</kymr:NetAmortizationOfPremiumsAndDiscountsOnInvestments>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="F_000279" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">3816000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="F_000280" contextRef="C_0001815442_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">564000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties id="F_000281" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">577000</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
  <kymr:IncreaseDecreaseInContractWithCustomerAssetRelatedParties id="F_000282" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">856000</kymr:IncreaseDecreaseInContractWithCustomerAssetRelatedParties>
  <us-gaap:IncreaseDecreaseInDueFromRelatedParties id="F_000283" contextRef="C_0001815442_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-148000</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="F_000284" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">990000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="F_000285" contextRef="C_0001815442_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">904000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities id="F_000286" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">5754000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities id="F_000287" contextRef="C_0001815442_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">2248000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInContractWithCustomerLiability id="F_000288" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">117400000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
  <us-gaap:IncreaseDecreaseInContractWithCustomerLiability id="F_000289" contextRef="C_0001815442_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">52991000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets id="F_000290" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">30000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
  <kymr:IncreaseDecreaseInOperatingLeaseRightOfUseAssets id="F_000291" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-8444000</kymr:IncreaseDecreaseInOperatingLeaseRightOfUseAssets>
  <kymr:IncreaseDecreaseInOperatingLeaseRightOfUseAssets id="F_000292" contextRef="C_0001815442_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-1350000</kymr:IncreaseDecreaseInOperatingLeaseRightOfUseAssets>
  <kymr:IncreaseDecreaseInOperatingLeaseLiabilities id="F_000293" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-2647000</kymr:IncreaseDecreaseInOperatingLeaseLiabilities>
  <kymr:IncreaseDecreaseInOperatingLeaseLiabilities id="F_000294" contextRef="C_0001815442_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-383000</kymr:IncreaseDecreaseInOperatingLeaseLiabilities>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities id="F_000295" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">205000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities id="F_000296" contextRef="C_0001815442_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-7000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="F_000297" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">88130000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="F_000298" contextRef="C_0001815442_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">17905000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000299" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">9096000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000300" contextRef="C_0001815442_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">532000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquireMarketableSecurities id="F_000301" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">529382000</us-gaap:PaymentsToAcquireMarketableSecurities>
  <us-gaap:PaymentsToAcquireMarketableSecurities id="F_000302" contextRef="C_0001815442_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">15954000</us-gaap:PaymentsToAcquireMarketableSecurities>
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities id="F_000303" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">115890000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="F_000304" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-422588000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="F_000305" contextRef="C_0001815442_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-16486000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock id="F_000306" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesBConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">21183000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock id="F_000307" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesB1ConvertiblePreferredStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">4800000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock id="F_000308" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesB1ConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">14025000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock id="F_000309" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesCConvertiblePreferredStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">88181000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:ProceedsFromStockOptionsExercised id="F_000310" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">162000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised id="F_000311" contextRef="C_0001815442_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">74000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:PaymentsOfFinancingCosts id="F_000312" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">554000</us-gaap:PaymentsOfFinancingCosts>
  <us-gaap:PaymentsOfFinancingCosts id="F_000313" contextRef="C_0001815442_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">371000</us-gaap:PaymentsOfFinancingCosts>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering id="F_000314" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">183146000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <kymr:ProceedsFromConcurrentPrivatePlacement id="F_000315" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">13527000</kymr:ProceedsFromConcurrentPrivatePlacement>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="F_000316" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">289262000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="F_000317" contextRef="C_0001815442_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">34911000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect id="F_000318" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-45196000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect id="F_000319" contextRef="C_0001815442_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">36330000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations id="F_000320" contextRef="C_0001815442_20191231" decimals="-3" unitRef="U_iso4217USD">77789000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations id="F_000321" contextRef="C_0001815442_20181231" decimals="-3" unitRef="U_iso4217USD">41459000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations id="F_000322" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">32593000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
  <us-gaap:InterestPaidNet id="F_000323" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">115000</us-gaap:InterestPaidNet>
  <us-gaap:InterestPaidNet id="F_000324" contextRef="C_0001815442_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">46000</us-gaap:InterestPaidNet>
  <kymr:PurchasesOfPropertyAndEquipmentThroughFinanceAndLeaseLiabilities id="F_000325" contextRef="C_0001815442_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1642000</kymr:PurchasesOfPropertyAndEquipmentThroughFinanceAndLeaseLiabilities>
  <kymr:PropertyAndEquipmentPurchasesIncludedInAccountsPayableAndAccruedExpenses id="F_000326" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">27000</kymr:PropertyAndEquipmentPurchasesIncludedInAccountsPayableAndAccruedExpenses>
  <kymr:PropertyAndEquipmentPurchasesIncludedInAccountsPayableAndAccruedExpenses id="F_000327" contextRef="C_0001815442_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">315000</kymr:PropertyAndEquipmentPurchasesIncludedInAccountsPayableAndAccruedExpenses>
  <kymr:OfferingCostsIncludedInAccountsPayable id="F_000328" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">397000</kymr:OfferingCostsIncludedInAccountsPayable>
  <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability id="F_000329" contextRef="C_0001815442_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">16522000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
  <kymr:TenantImprovementReceivableIncludedInOtherAssets id="F_000330" contextRef="C_0001815442_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">287000</kymr:TenantImprovementReceivableIncludedInOtherAssets>
  <kymr:ReductionOfRightOfUseAssetAndLiabilityDueToLeaseModification id="F_000331" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">2161000</kymr:ReductionOfRightOfUseAssetAndLiabilityDueToLeaseModification>
  <us-gaap:RestrictedCash id="F_000332" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">1589000</us-gaap:RestrictedCash>
  <us-gaap:RestrictedCash id="F_000333" contextRef="C_0001815442_20191231" decimals="-3" unitRef="U_iso4217USD">1774000</us-gaap:RestrictedCash>
  <dei:DocumentsIncorporatedByReferenceTextBlock id="F_000334" contextRef="C_0001815442_20200101_20201231">
&lt;p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Portions of the registrant&amp;#8217;s Proxy Statement for its 2021 Annual Meeting of Stockholders, which the registrant intends to file with the Securities and Exchange Commission not later&lt;font style="color:#000000;font-family:Arial;"&gt; &lt;/font&gt;than 120 days after the registrant&amp;#8217;s fiscal year ended December&amp;#160;31, 2020, are incorporated by reference into Part III of this Annual Report on Form 10-K&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
  <us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock id="F_000335" contextRef="C_0001815442_20200101_20201231">
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="Background-color:#FFFFFF;"&gt;Note 1. Description of Business and Summary of Significant Accounting Policies&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Kymera Therapeutics, Inc., together with its subsidiary Kymera Securities Corporation, is referred to on a consolidated basis as the &amp;#8220;Company&amp;#8221;. The Company is a biopharmaceutical company focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body&amp;#8217;s own natural cellular process, a method known as targeted protein degradation. The Company has devoted its efforts principally to research and development since formation. The Company has not yet completed product development, filed for or obtained regulatory approvals for any products, nor verified the market acceptance and demand for such products. As a result, the Company is subject to a number of risks common to emerging companies in the biotech industry. Principal among these risks are the uncertainties of the product discovery and development process, dependence on key individuals, development of the same or similar technological innovations by the Company&amp;#8217;s competitors, protection of proprietary technology, compliance with government regulations and approval requirements, the Company&amp;#8217;s ability to access capital and uncertainty of market acceptance of products.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has historical net losses and anticipates that it will continue to incur losses for the foreseeable future and had an accumulated deficit of $128.8&amp;#160;million as of December 31, 2020. The Company has funded these losses principally through issuance common stock, including its initial public offering (&amp;#8220;IPO), which was completed in August 2020, preferred stock, convertible notes and from cash proceeds received in connection with the Company&amp;#8217;s collaboration agreements with Vertex Pharmaceuticals Incorporated (&amp;#8220;Vertex&amp;#8221;) and Genzyme Corporation (&amp;#8220;Sanofi&amp;#8221;) (see Note 5). The Company expects to continue to incur operating losses and negative cash flows until such time as it generates a level of revenue that is sufficient to support its cost structure.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020, the Company had cash, cash equivalents and marketable securities of $458.7 million. The Company believes these cash, cash equivalents and marketable securities will be sufficient to fund its operations and capital expenditure requirements through at least twelve months from the issuance of these consolidated financial statements.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company expects to finance the future research and development costs of its product portfolio with its existing cash, cash equivalents and marketable securities, or through strategic financing opportunities that could include, but are not limited to future offerings of its equity, collaboration agreements, or the incurrence of debt. However, there is no guarantee that any of these strategic or financing opportunities will be executed or realized on favorable terms, if at all, and some could be dilutive to existing stockholders. If the Company fails to obtain additional future capital, it may be unable to complete its planned preclinical studies and clinical trials.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Reverse Stock Split&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On August&amp;#160;20, 2020, the Board approved a 1-for-1.5949 reverse stock&amp;#160;split of the Company&amp;#8217;s issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for each of the Company&amp;#8217;s outstanding series of preferred stock.&amp;#160;&amp;#160;All share and per share amounts in the accompanying consolidated financial statements and notes thereto have been retroactively adjusted for all periods presented to give effect to this reverse stock split, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital.&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Initial Public Offering&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On August 20, 2020, the Company&amp;#8217;s registration statement on Form S-1 relating to its initial public offering of its common stock was declared effective by the Securities and Exchange Commission (&amp;#8220;SEC&amp;#8221;). In the IPO, which closed on August 25, 2020, the Company issued and sold&amp;#160;9,987,520&amp;#160;shares of common stock, including full exercise of the underwriters&amp;#8217; over-allotment option to purchase an additional 1,302,720 shares, at a public offering price of $20.00 per share and the aggregate gross proceeds before deducting before deducting underwriting discounts and commissions, and other estimated offering expenses payable by the Company, were approximately $199.8 million. Concurrent with the IPO, the Company issued and sold 676,354 shares of common stock at $20.00 per share in a private placement to Vertex.&lt;/p&gt;</us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock>
  <us-gaap:SignificantAccountingPoliciesTextBlock id="F_000336" contextRef="C_0001815442_20200101_20201231">
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="Background-color:#FFFFFF;"&gt;Note 2. Summary of Significant Accounting Policies&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying consolidated financial statements reflect the application of certain significant accounting policies as described in this note, and elsewhere in the accompanying consolidated financial statements and&amp;#160;notes.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Principles of Consolidation&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary Kymera Securities Corporation. All intercompany transactions and balances have been eliminated in consolidation.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Basis of Presentation&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&amp;#8220;GAAP&amp;#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) and Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) of the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;).&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Use of Estimates&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosure of contingencies at the date of the financial statements and the reported amounts of expenses during the reporting period. Management&amp;#8217;s estimates and judgments are derived and continually evaluated based on available information, historical experience and various other assumptions that are believed to be reasonable under the circumstances. Because the use of estimates is inherent in the financial reporting process, actual results could differ from those estimates. In recording transactions and balances resulting from business operations, management makes estimates based on the best information available at the time the estimate is made. Significant estimates relied upon in preparing these financial statements include revenue recognized under our collaboration agreement with Sanofi and Vertex, accrual for research and development expenses, equity-based compensation expense, and the valuation of equity. As better information becomes available or actual amounts are determinable, the recorded estimates are revised. Consequently, operating results can be affected by revisions to prior estimates.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Segment and Geographic Information&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company&amp;#8217;s chief operating decision maker is the Chief Executive Officer. The Company views its operations and manages its business in one operating segment.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Cash and &lt;font style="color:#000000;"&gt;Cash&lt;/font&gt; Equivalents&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents are highly liquid investments that are readily convertible into cash with original maturities of three months or less when purchased. These assets include investments in money market funds that invest in U.S. Treasury obligations and corporate bonds. The Company maintains its bank accounts at major financial institutions.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Restricted Cash&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash represents the cash held to secure a letter of credit associated with the Company&amp;#8217;s facility lease.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Marketable Securities&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company classifies marketable securities with a remaining maturity of greater than three months when purchased as available-for-sale. The Company classifies investments available to fund current operations as current assets on its balance sheets. Marketable securities with a remaining maturity date greater than one year are classified as non-current. Available-for-sale securities are maintained by investment managers and consist of U.S. Treasury securities and corporate bonds. Available-for-sale securities are carried at fair value with the unrealized gains and losses included in other comprehensive income (loss) as a component of stockholders&amp;#8217; equity until realized. Any premium or discount arising at purchase is amortized and/or accreted to interest income and/or expense over the life of the instrument. Realized gains and losses are determined using the specific identification method and are included in other (expense) income, net.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;If any adjustment to fair value reflects a decline in value of the investment, the Company considers all available evidence to evaluate the extent to which the decline is &amp;#8220;other-than-temporary&amp;#8221; and, if so, marks the investment to market through a charge to the Company&amp;#8217;s statement of operations and comprehensive loss.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Level&amp;#160;1&amp;#8212;&lt;font style="font-style:normal;"&gt;Quoted prices in active markets for identical assets&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Level&amp;#160;2&amp;#8212;&lt;font style="font-style:normal;"&gt;Observable inputs (other than Level&amp;#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar asset, or other inputs that are observable or can be corroborated by observable market data.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Level&amp;#160;3&amp;#8212;&lt;font style="font-style:normal;"&gt;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying values of the Company&amp;#8217;s cash equivalents, prepaid expenses, accounts payable, and certain accruals approximate their fair value due to their short-term nature.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company adopted ASC Topic 842, &lt;font style="font-style:italic;"&gt;Leases&lt;/font&gt; (&amp;#8220;ASC 842&amp;#8221;) on January&amp;#160;1, 2019. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Leases that are economically similar to the purchase of assets are generally classified as finance leases; otherwise the leases are classified as operating leases. The Company has elected not to recognize leases with an original term of one year or less on the balance sheet. Options to renew a lease are not included in the Company&amp;#8217;s assessment unless there is reasonable certainty that the Company will renew. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. However, certain adjustments to the right-of-use asset may be required for items such as incentives received. The Company has elected as an accounting policy to combine lease and non- lease components, such as common area maintenance, for all classes of underlying assets. The interest rate implicit in lease contracts has not historically been readily determinable. As a result, the Company utilizes its incremental borrowing rates, which are the rates incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. To estimate its incremental borrowing rate, a credit rating applicable to the Company is estimated using synthetic credit rating analysis since the Company does not currently have a rating agency-based credit rating.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Property and Equipment&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are recorded at cost, net of accumulated depreciation. Major additions and betterments are capitalized; maintenance and repairs, which do not improve or extend the life of the respective assets, are charged to operations as incurred. Depreciation expense is recorded using the straight-line method over the estimated useful life of the related asset as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.86%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated Useful Life&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in years)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.86%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furnitures and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.86%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Office equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.86%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.86%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.86%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shorter of life of lease or remaining lease term&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon retirement or sale, the cost and related accumulated depreciation of assets disposed of are removed from the accounts and any resulting gain or loss is included in loss from operations.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction-in-progress is stated at cost, which includes direct costs attributable to the setup or construction of the related asset. Depreciation expense is not recorded on construction-in-progress until the relevant assets are completed and put into use.&lt;/p&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Impairment of Long-Lived Assets&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its fair value, determined based on discounted cash flows. The Company did not record any impairment losses on long-lived assets during the years ended December&amp;#160;31, 2020 and 2019.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Convertible Preferred Stock&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company classified convertible preferred stock as temporary equity in the accompanying consolidated balance sheet due to terms that allow for redemption of the shares in cash upon certain change in control events that are outside of the Company&amp;#8217;s control, including the sale or transfer of the Company as holders of the convertible preferred stock which could trigger redemption of the shares. The Company did not accrete the value of the convertible preferred stock to the redemption values since a liquidation event was not considered probable as of December&amp;#160;31, 2019. Subsequent adjustments of the carrying values to the ultimate redemption values will be made only when it becomes probable that such liquidation events will occur. In connection with the Company&amp;#8217;s initial public offering on August 21, 2020, all outstanding shares of convertible preferred stock converted to common stock.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Research and Development Costs&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development costs consist primarily of costs incurred in connection with the discovery and development of targeted protein degradation therapeutics, including those in the Company&amp;#8217;s most advanced development programs, IRAK4, IRAKIMiD and STAT3. These research efforts and costs, which also support the development of, and enhancements to, the Company&amp;#8217;s Pegasus targeted protein degradation platform, include external research costs, personnel costs, supplies, license fees and facility related expenses. The Company expenses research and development costs as incurred.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Patent Costs&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recoverability of the expenditure. Amounts incurred are classified as general and administrative expenses.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Financing Costs&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Costs incurred in connection with the issuance of equity units and shares are recorded as a reduction of proceeds to the equity carrying value. The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process financings as deferred offering costs until such financings are consummated. After consummation of the financing, these costs are recorded as a reduction of the proceeds received from the financing. If a planned financing is abandoned, the deferred offering costs are expensed immediately as a charge to operating expenses in the consolidated statement of operations and comprehensive loss. There was $0.4 million of deferred financing costs included in accounts payable on the Company&amp;#8217;s consolidated balance sheet as of December 31, 2020. There was no deferred offering costs on the Company&amp;#8217;s consolidated balance sheet at December 31, 2019.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Revenue Recognition&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company adopted ASC Topic 606, &lt;font style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt; (&amp;#8220;ASC 606&amp;#8221;) on January&amp;#160;1, 2017. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, the Company performs the following five steps: (i)&amp;#160;identification of the contract(s) with the customer; (ii)&amp;#160;identification of the promised goods or services in the contract and determination of whether the promised goods or services are performance obligations; (iii)&amp;#160;measurement of the transaction price; (iv)&amp;#160;allocation of the transaction price to the performance obligations; and (v)&amp;#160;recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As part of the accounting for these arrangements, the Company must use significant judgment to determine: a) the number of performance obligations based on the determination under step (ii)&amp;#160;above and whether those performance obligations are distinct from other performance obligations in the contract; b) the transaction price under step (iii)&amp;#160;above; and c) the standalone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv)&amp;#160;above. The Company uses judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. In determining the stand-alone selling price of a license to the Company&amp;#8217;s proprietary technology or a material right provided by a customer option, the Company considers market conditions as well as entity-specific factors, including those factors contemplated in negotiating the agreements as well as internally developed estimates that include assumptions related to the market opportunity, estimated development costs, probability of success and the time needed to commercialize a product candidate pursuant to the license. In validating its estimated stand-alone selling prices, the Company evaluates whether changes in the key assumptions used to determine its estimated stand-alone selling prices will have a significant effect on the allocation of arrangement consideration between performance obligations.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company estimates the transaction price based on the amount of consideration the Company expects to be received for transferring the promised goods or services in the contract. The consideration may include both fixed consideration and variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of the potential payments and the likelihood that the payments will be received. The Company utilizes either the most likely amount method or expected value method to estimate the transaction price based on which method better predicts the amount of consideration expected to be received. If it is probable that a significant revenue reversal would not occur, the variable consideration is included in the transaction price.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer. Promised goods or services are considered distinct when: (i)&amp;#160;the customer can benefit from the good or service on its own or together with other readily available resources and (ii)&amp;#160;the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on their own and whether the required expertise is readily available.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation in order to determine whether the combined performance obligation is satisfied over time or at a point in time. The Company receives payments from customers based on billing schedules established in each contract. Up-front payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion. Amounts are recorded as accounts receivable when the Company&amp;#8217;s right to consideration is unconditional. Amounts recognized as revenue, but not yet received or invoiced are generally recognized as contract assets.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Exclusive Licenses&lt;font style="font-style:normal;"&gt;&amp;#8212;If the license granted in the arrangement is determined to be distinct from the other promises or performance obligations identified in the arrangement, which generally include research and development services, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whether a license is distinct from the other promises, the Company considers relevant facts and circumstances of each arrangement, including the research and development capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the collaboration partner can benefit from the license for its intended purpose without the receipt of the remaining promise, whether the value of the license is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the arrangement.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Research and Development Services&lt;font style="font-style:normal;"&gt;&amp;#8212;The promises under the Company&amp;#8217;s collaboration and license agreements generally include research and development services to be performed by the Company on behalf of the collaboration partner. For performance obligations that include research and development services, the Company generally recognizes revenue allocated to such performance obligations based on an appropriate measure of progress. The Company utilizes judgment to determine the appropriate method of measuring progress for purposes of recognizing revenue, which is generally an input measure, such as costs incurred. The Company evaluates the measure of progress each reporting period as described under Exclusive Licenses above. Reimbursements from the partner that are the result of a collaborative relationship with the partner, instead of a customer relationship, such as co-development activities, are generally recorded as a reduction to research and development expense.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Customer Options&lt;font style="font-style:normal;"&gt;&amp;#8212;The Company&amp;#8217;s arrangements may provide a collaborator with the right to certain optional purchases, such as the right to license a target either at the inception of the arrangement or within a pre-defined option period. Under these agreements, fees may be due to the Company at the inception of the arrangement as an upfront fee or payment or upon the exercise of an option to acquire a license. If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. The Company evaluates the customer options for material rights, or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the inception of the arrangement. The Company allocates the transaction price to material rights based on the relative stand-alone selling price, which is determined based on the identified discount, and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised or expires.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Milestone Payments&lt;font style="font-style:normal;"&gt;&amp;#8212;At the inception of each arrangement that includes milestone payments based on certain events, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. If a milestone or other variable consideration relates specifically to the Company&amp;#8217;s efforts to satisfy a single performance obligation or to a specific outcome from satisfying the performance obligation, the Company generally allocates the milestone amount entirely to that performance obligation once it is probable that a significant revenue reversal would not occur.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Royalties&lt;font style="font-style:normal;"&gt;&amp;#8212;For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i)&amp;#160;when the related sales occur or (ii)&amp;#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Collaboration revenue&amp;#8212;&lt;font style="font-style:normal;"&gt;The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808,&lt;/font&gt;&amp;#160;Collaborative Arrangements&lt;font style="font-style:normal;"&gt;&amp;#160;(&amp;#8220;ASC 808&amp;#8221;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities.&amp;#160;This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement.&amp;#160;For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship and therefore within the scope of Topic 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently, generally by analogy to Topic 606. For those elements of the arrangement that are accounted for pursuant to Topic 606, the Company applies the five-step model described above.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Costs associated with License and Collaborative Arrangements&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Costs associated with licenses of technology acquired as part of collaborative arrangements are expensed as incurred and are generally included in research and development expense in the consolidated statements of operations.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for all stock-based awards granted to employees, directors, and nonemployees based on their fair value on the date of the grant and recognize compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. Stock-based payments include stock options and grants of common stock, including common stock subject to vesting. The measurement date for stock awards is the date of grant, and stock-based compensation costs are recognized as expense over the requisite service period, which is the vesting period, on a straight-line basis. The Company has issued stock options and restricted stock with performance-based vesting conditions and records the expense for these awards if the Company concludes that it is probable that the performance condition will be achieved. Stock-based compensation is classified in the accompanying consolidated statements of operations and comprehensive loss based on the function to which the related services are provided. The Company recognizes stock-based compensation expense for the portion of awards that have vested. Forfeitures are accounted for as they occur.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes options-pricing model, which requires inputs based on certain subjective assumptions, including the expected stock price volatility, the expected term of the option, the risk-free interest rate for a period that approximates the expected term of the option, and the Company&amp;#8217;s expected dividend yield. Prior to the IPO, as there was no active market for the Company&amp;#8217;s common stock, the Company estimated the fair value of common stock on the date of grant based on the then current facts and circumstances. Upon becoming a public company, the fair value of the underlying common shares equals the closing price of the Company&amp;#8217;s stock on the date of grant. The Company historically has been a private company and lacks company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of guideline companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company&amp;#8217;s stock options has been determined utilizing the &amp;#8220;simplified&amp;#8221; method for awards that qualify as &amp;#8220;plain-vanilla&amp;#8221; options. The expected term of stock options granted to non-employees is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future. The fair value of each restricted common stock award is estimated on the date of grant based on the fair value of the Company&amp;#8217;s common stock on that same date.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Compensation expense for discounted purchases under the employee stock purchase plan is measured using the Black-Scholes model to compute the fair value of the lookback provision plus the purchase discount and is recognized as compensation expense over the offering period.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Common and Preferred Stock Valuation&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company utilized significant estimates and assumptions in determining the fair value of its equity and equity-based awards. The Company utilized various valuation methodologies in accordance with the framework of the 2013 American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its equity awards.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company used a hybrid of the probability-weighted expected returns method (&amp;#8220;PWERM&amp;#8221;), and the option pricing method (&amp;#8220;OPM&amp;#8221;) when allocating enterprise value to classes of securities.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the probability-weighted expected return method, or PWERM, the value of an enterprise, and its underlying common securities, are estimated based on an analysis of future values for the enterprise, assuming various outcomes. The value of the common securities is based on the probability-weighted present value of expected future investment returns considering each of the possible outcomes and the rights of each class of equity. The future values of the common securities under the various outcomes are discounted back to the valuation date at an appropriate risk-adjusted discount rate and then probability weighted to determine the value for the common securities.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The option pricing method, or OPM, treats common securities and preferred securities as call options on the enterprise&amp;#8217;s equity value, with exercise prices based on the liquidation preferences of the preferred securities. Under this method, the common securities have value only if the funds available for distribution to shareholders exceed the value of the liquidation preferences at the time of a liquidity event. The Black-Scholes model is used to price the call option, and the model includes assumptions for the time to liquidity and the volatility of equity value.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The hybrid method is a hybrid between the PWERM and OPM, estimating the probability-weighted value across multiple scenarios but using the OPM to estimate the allocation of value within one or more of those scenarios.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuations performed in the year ended December&amp;#160;31, 2020 and 2019, used a hybrid of the PWERM and OPM when allocating the Company&amp;#8217;s enterprise value to classes of securities.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;When using the hybrid method, the Company assumed two scenarios: an IPO scenario and a trade-sale scenario. The IPO scenario estimated an equity value based on the guideline public company method under a market approach. The guideline public companies considered for this scenario consist of biopharmaceutical companies with recently completed initial public offerings. The Company converted its estimated future value in an IPO to present value using a risk-adjusted discount rate. The equity value for the trade-sale scenario was estimated using the price of a recently issued preferred security, as well as a milestone-based tranche closing. The Company utilized an option pricing model to quantify or attribute value to these economic rights of convertible preferred stock vs. the common stock (e.g. liquidation preferences, dividend provisions, participation rights after liquidation preferences.)&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In the OPM, volatility is estimated based on the trading histories of selected guideline public companies. The relative probability of each scenario was determined based on an assessment of then-current market conditions and the Company&amp;#8217;s expectations as to timing and prospects of an IPO.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Each valuation methodology includes estimates and assumptions that require significant judgment. These estimates and assumptions include a number of objective and subjective factors, including the prices at which shares were traded between holders of the Company, external market conditions, the prices at which the Company sold convertible preferred shares, the superior rights and preferences of securities senior to common shares at the time, and the likelihood of achieving a voluntary or involuntary liquidity event.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant changes to the key assumptions used in the valuations could result in different fair values of common shares at each valuation date, as applicable.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Income Taxes&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income taxes for Kymera Therapeutics, Inc. are recorded in accordance with FASB Accounting Standards Codification Topic 740, &lt;font style="font-style:italic;"&gt;Income Taxes&lt;/font&gt; (&amp;#8220;ASC 740&amp;#8221;), which provides for deferred taxes using an asset and liability approach. Under this method, deferred income tax assets and liabilities are recognized based on future income tax consequences attributable to differences between the financial statement carrying amount of existing assets and liabilities, and their respective income tax basis. Deferred income tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of changes in income tax rates on deferred income tax assets and liabilities is recognized as income or expense in the period that a valuation allowance for any income tax benefits of which future realization is not more likely than not.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions. The tax benefits recorded are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filings or positions is &amp;#8220;more likely than not&amp;#8221; to be realized following resolution of any uncertainty related to the tax benefit, assuming that the matter in question will be raised by the tax authorities.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Off Balance Sheet Risk and Concentration of Credit Risk&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has no significant off-balance sheet risk such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, and restricted cash. The Company&amp;#8217;s cash, cash equivalents, and restricted cash are deposited in accounts at large financial institutions. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash, cash equivalents and restricted cash are held. The Company maintains its cash equivalents in money market funds that invest in U.S. Treasury securities and U.S. Treasury obligations and corporate bonds. The Company&amp;#8217;s marketable securities primarily consist of corporate bonds and U.S. Treasury securities paper, and potentially subject the Company to concentrations of credit risk. The Company has adopted an investment policy that limits the amounts the Company may invest in any one type of investment. The Company has not experienced any credit losses and does not believe it is exposed to any significant credit risk on these funds.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Comprehensive Loss&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive loss includes net loss as well as unrealized gains on marketable securities and other changes in stockholders&amp;#8217; equity (deficit) that result from transactions and economic events other than those with stockholders.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Net Loss Per Share&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company applies the two-class method to compute basic and diluted net income (loss) per share attributable to common stockholders when it has issued shares that meet the definition of participating securities. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income (loss) available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to share in the earnings as if all income (loss) for the period had been distributed. The Company&amp;#8217;s convertible preferred stock participates in any dividends declared by the Company and are therefore considered to be participating securities. The participating securities are not required to participate in the losses of the Company, and therefore during periods of loss there is no allocation required under the two-class method.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net income (loss) per share attributable to common stockholders is computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) attributable to common stockholders is computed by adjusting net income (loss) per share attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period, including potential dilutive common shares. For purpose of this calculation, outstanding options to purchase common stock, unvested restricted stock awards, and shares of convertible preferred stock are considered potential dilutive common shares. The Company has generated a net loss in all periods presented, and therefore the basic and diluted net loss per share attributable to common stockholders are the same as the inclusion of the potentially dilutive securities would be anti-dilutive.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Emerging Growth Company Status&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is an emerging growth company (&amp;#8220;EGC&amp;#8221;), as defined in the Jumpstart Our Business Startups Act (the &amp;#8220;JOBS Act&amp;#8221;), and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not EGCs. The Company may take advantage of these exemptions until it is no longer an EGC under Section&amp;#160;107 of the JOBS Act, which provides that an EGC can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to use this exemption to delay adopting new or revised.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Recent Accounting Pronouncements&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Recently Adopted Accounting Standards&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In April 2019, the FASB issued ASU 2019-04,&amp;#160;&lt;font style="font-style:italic;"&gt;Codification Improvements to Topic 326, Financial Instruments&amp;#8212;Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments&lt;/font&gt;. This update provides clarifications for three topics related to financial instruments accounting, some of which apply to the Company. The Company adopted as of January&amp;#160;1, 2020 and it did not have a significant impact on its financial position or results of operation&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2018, the FASB issued ASU 2018-15, &lt;font style="font-style:italic;"&gt;Customer&amp;#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract&lt;/font&gt;. The new standard will align the requirements for capitalizing implementation costs for hosting arrangements (services) with costs for internal-use software (assets). As a result, certain implementation costs incurred in hosting arrangements will be deferred and amortized. The Company adopted as of January&amp;#160;1, 2020 and it did not have a significant impact on its financial position or results of operation.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework&amp;#8212;Changes to the Disclosure Requirements for Fair Value Measurement. The new standard will be effective beginning January&amp;#160;1, 2020. The Company adopted as of January&amp;#160;1, 2020 and it did not have a significant impact on its financial position or results of operation.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Recently Issued Accounting Standards Not Yet Adopted&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, the FASB issued ASU 2019-12, &lt;font style="font-style:italic;"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/font&gt;, which is intended to simplify the accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. The new standard will be effective beginning January&amp;#160;1, 2021. The Company is currently evaluating the potential impact ASU 2019-12 may have on its financial position and results of operations upon adoption.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016, the FASB issued ASU 2016-13,&amp;#160;&lt;font style="font-style:italic;"&gt;Financial Instruments&amp;#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Statements&lt;/font&gt;. The new standard requires that expected credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. It also limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value increases. As an emerging growth company, the Company expects to delay adoption until January 1, 2023 and is evaluating the impact that the adoption of ASU 2016-13 will have on its consolidated financial statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:FairValueDisclosuresTextBlock id="F_000337" contextRef="C_0001815442_20200101_20201231">
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="Background-color:#FFFFFF;"&gt;Note 3. Fair Value Measurements&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table presents information about the Company&amp;#8217;s financial assets measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values as of December 31,&amp;#160;2020 and December 31, 2019 (in thousands): &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.44%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market fund&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,943&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,943&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,499&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,499&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities, current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;US treasuries&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;192,275&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;192,275&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;72,923&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;72,923&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities, non-current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;US treasuries&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;132,589&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;132,589&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,942&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,942&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,589&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,589&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;346,396&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;113,364&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;459,760&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31, 2019:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,942&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,942&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,774&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,774&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,716&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,716&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the years ended December 31, 2020 and 2019, there were no transfers between Level&amp;#160;1, Level&amp;#160;2 and Level&amp;#160;3. &lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock id="F_000338" contextRef="C_0001815442_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 4. Marketable Securities&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the available-for-sale debt securities held at December 31, 2020 and 2019 and (in thousands): &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Description&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. treasury securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;324,917&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(53&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;324,864&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;102,946&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(81&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;102,865&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;427,863&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(134&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;427,729&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.24%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Description&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.24%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.24%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. treasury securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,936&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,942&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.24%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,936&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,942&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020, the Company held&amp;#160;65 securities that had been in an unrealized loss position for less than&amp;#160;12 months with an aggregate fair value of $392.2 million. As of December 31, 2019, the Company did not hold any securities that were in an unrealized loss position.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020, the Company had 48 securities with a fair value of $295.6 million with a contractual maturity of less than 12 months and 25 securities with a fair value of $162.5 million with a contractual maturity of greater than 12 months. As of December&amp;#160;31, 2019, all of the Company&amp;#8217;s marketable securities had remaining contractual maturity dates of less than one year from the consolidated balance sheet date. During the year ending December 31, 2020, the Company sold one security prior maturity which resulted in an immaterial realized gain on the sale. There were no sales of marketable securities during the year ended December&amp;#160;31, 2019. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company evaluates securities for other-than-temporary impairments based on quantitative and qualitative factors, and considered the decline in market value for the&amp;#160;65&amp;#160;securities in an unrealized loss position as of&amp;#160;December&amp;#160;31, 2020, to be primarily attributable to the then current economic and market conditions. &lt;font style="color:#000000;"&gt;The Company&lt;/font&gt;&lt;font style="Background-color:#FFFFFF;color:#000000;"&gt; neither intends to sell these investments nor concludes that it is more-likely-than-not that the Company will have to sell them before recovery of their carrying values. The Company also believe that it will be able to collect both principal and interest amounts due to it at maturity.&lt;/font&gt;&lt;/p&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
  <us-gaap:CollaborativeArrangementDisclosureTextBlock id="F_000339" contextRef="C_0001815442_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_20200101_20201231">
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 5. Collaborations&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;&lt;font style="Background-color:#FFFFFF;"&gt;Sanofi Collaboration Arrangement&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Agreement Terms&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On July&amp;#160;7, 2020, the Company entered into a collaboration agreement, or the Sanofi Agreement, with Sanofi, to co-develop drug candidates directed to two biological targets. Under the Sanofi Agreement, the Company granted to Sanofi a worldwide exclusive license to develop, manufacture and commercialize certain lead compounds generated during the collaboration directed against IRAK4, or Collaboration Target 1, and one additional undisclosed target in an undisclosed field of use, or Collaboration Target 2. Such license is exercisable on a collaboration target-by-collaboration target basis only after specified milestones. For compounds directed against IRAK4, the field of use includes diagnosis, treatment, cure, mitigation or prevention of any diseases, disorders or conditions, excluding oncology and immune-oncology.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pursuant to the Sanofi Agreement, the Company is responsible for discovery and preclinical research and conducting a Phase&amp;#160;1 clinical trial for at least one degrader directed against IRAK4 plus up to three backup degraders. With respect to both targets, Sanofi is responsible for development, manufacturing, and commercialization of product candidates after a specified development milestone occurs with respect to each collaboration candidate.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In addition, pursuant to the Sanofi Agreement, Sanofi will grant to the Company an exclusive option, or Opt-In Right, exercisable on a collaboration target-by-collaboration target basis that will include the right to (i)&amp;#160;to fund 50% of the United States development costs for collaboration products directed against such target in the applicable field of use and (ii)&amp;#160;share equally in the net profits and net losses of commercializing collaboration products directed against such target in the applicable field of use in the United States. In addition, if the Company exercises the Opt-In Right, Sanofi will grant to the Company an exclusive option, applicable to each collaboration target, which upon exercise will allow the Company to conduct certain co-promotion activities in the field in the United States.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Sanofi Agreement, unless earlier terminated, will expire on a product-by-product basis on the date of expiration of all payment obligations under the Sanofi Agreement with respect to such product. The Company or Sanofi may terminate the agreement upon the other party&amp;#8217;s material breach or insolvency or for certain patent challenges. In addition, Sanofi may terminate the agreement for convenience or for a material safety event upon advance prior written notice, and the Company may terminate the agreement with respect to any collaboration candidate if, following Sanofi&amp;#8217;s assumption of responsibility for the development, commercialization or manufacturing of collaboration candidates with respect to a particular target, Sanofi ceases to exploit any collaboration candidates directed to such target for a specified period.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In consideration for the exclusive licenses granted to Sanofi under the Sanofi Agreement, Sanofi paid to the Company an upfront payment of $150.0&amp;#160;million. The Company will also be reimbursed for certain research activities for a certain backup degrader under the IRAK4 program, unless certain criteria are not met for an initial IRAK4 degrader. In addition to the upfront payment and the reimbursements, the Company is eligible to receive certain development milestone payments of up to $1.48&amp;#160;billion in the aggregate, of which more than $1.0 billion relates to the IRAK4 program, upon the achievement of certain developmental or regulatory events. The Company will be eligible to receive certain commercial milestone payments up to $700.0&amp;#160;million in the aggregate, of which $400&amp;#160;million relates to the IRAK4 program, which are payable upon the achievement of certain net sales thresholds. The Company will be eligible to receive tiered royalties for each program on net sales ranging from the high single digits to high teens, subject to low-single digits upward adjustments in certain circumstances.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-align:justify;margin-left:4.54%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Accounting Treatment &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company analyzed the discovery and pre-clinical research activities as well as the exclusive license grants under the Sanofi Agreement and concluded that the arrangement was indicative of a vendor-customer relationship and would be accounted for under ASC 606. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company identified the following material promises under the arrangement: (1) research services for Collaboration Target 1, (2) research license for Collaboration Target 1, (3) exclusive license for Collaboration Target 1, (4) research services for Collaboration Target 2, (5) research license for Collaboration Target 2, (6) exclusive license for Collaboration Target 2, (7) option to extend the research term, and (8) optional research services during the development period. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determined that Collaboration Targets 1 and 2 are distinct from each other. The research associated with degraders directed to each target is at different stages and the licensed field, should development activities be successful, are different from each other. As such, all promises associated with each target are considered distinct from promises associated with the other target.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The research and development services for each collaboration target were determined not to be distinct from the research license and the exclusive license and have been combined into a single performance obligation for each collaboration target. That is, two performance obligations were identified, the combined research services, research license and exclusive license for Collaboration Target 1 and the combined research services, research license and exclusive license for Collaboration Target 2. The exclusive license for each target is not distinct from the pre-clinical and clinical research and development services under the Sanofi Agreement, primarily due to the highly specialized nature of the research and novel technology involved with developing protein degraders &amp;#8211; the pre-clinical activities and studies and first phase 1 clinical trial could not be conducted by another party in the manner required.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The option to extend the research term and optional research services during the development period were evaluated as material rights. The fees associated with each option are at or above the standalone selling price. As such, the underlying options are not performance obligations and fees associated with each option are excluded from the transaction price until the underlying option is exercised.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="Background-color:#FFFFFF;"&gt;The Company determined the total transaction price to be $&lt;/font&gt;150.0&lt;font style="Background-color:#FFFFFF;"&gt;&amp;#160;million, which consists solely of the upfront payment. All milestones payments and option payments are constrained as the achievement of such milestones are contingent upon the success of the underlying research and development activities and are generally outside the control of the Company. The reimbursement of costs for the IRAK4 backup degrader is also treated as constrained variable consideration as the criteria for reimbursement may not always be met, under which circumstances the Company would be responsible for the costs related to the backup degrader. Upon becoming unconstrained, the reimbursement consideration will be added to the transaction price and allocated to Collaboration Target 1.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="Background-color:#FFFFFF;"&gt;The Company allocated the upfront payment to each performance obligation based on the relative standalone selling price, as follows:&lt;/font&gt;&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-align:justify;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-align:justify;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-align:justify;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Collaboration Target 1: $120.0 million&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-align:justify;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-align:justify;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-align:justify;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Collaboration Target 2: $30.0 million&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determined the allocation of the $150.0 million transaction price between Collaboration Target 1 and Collaboration Target 2 based on the value of the research and development for the programs from projected research and development costs for each collaboration target plus a developer&amp;#8217;s profit and the total potential milestones for each collaboration target.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="Background-color:#FFFFFF;"&gt;The Company recognizes revenue associated with each performance obligation as the research and development services are provided using an input method, according to costs incurred as related to the research and development activities for each individual program and the costs expected to be incurred in the future to satisfy that individual performance obligation. The transfer of control occurs over this time period and, in management&amp;#8217;s judgment, is the best measure of progress towards satisfying each performance obligation. The amounts received that have not yet been recognized as revenue are deferred as a contract liability on the Company&amp;#8217;s consolidated balance sheet and will be recognized over the remaining research and development period until the performance obligation is satisfied. Reimbursement consideration added to the transaction price will be recognized as revenue on the same pattern as Collaboration Target 1, with a cumulative catch-up upon becoming unconstrained. &lt;/font&gt;The performance obligation has not been fully satisfied as of December 31, 2020. During the year ended December 31, 2020, the Company recognized $18.8 million&lt;font style="color:#000000;"&gt; &lt;/font&gt;in revenue under the Sanofi Agreement, of which $16.7 million was associated with Collaboration Target 1 and $2.1 million was associated with Collaboration Target 2. The aggregate amount of the transaction price allocated to the Company&amp;#8217;s unsatisfied performance obligations and recorded in deferred revenue at December 31, 2020 is &lt;font style="color:#000000;"&gt;$132.6 &lt;/font&gt;million. As of December&amp;#160;31, 2020, the Company had not received cost reimbursement payments, and no milestone or royalty payments under the Sanofi Agreement. As of December&amp;#160;31, 2020, the Company recorded unbilled accounts receivable of $0.9 million related to reimbursable research and development costs&lt;font style="font-size:12pt;color:#000000;"&gt; &lt;/font&gt;under the Sanofi Agreement for activities performed during the three months ended December&amp;#160;31, 2020 and $0.6 million in accounts receivable for amounts billed under the Sanofi Agreement as of December 31, 2020. The Company will recognize the deferred revenue related to the performance obligations based on a cost input method, as described, over the remaining research term, which is a maximum of three years as of December 31, 2020.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Any consideration related to performance-based milestones will be recognized when the risk of probable reversal is resolved, at which point the Company shall adjust the transaction price determined for the agreement accordingly and recognize revenue on a cumulative-catch up basis, reallocating the revised arrangement consideration to the performance obligations. Any consideration related to sales milestone payments and royalties will be recognized when the related milestone events or sales occur and therefore are recognized at the later of when the related sales occur or the relevant performance obligation is satisfied. &lt;font style="Background-color:#FFFFFF;"&gt;As part of its evaluation of constraining the milestones, the Company considered numerous factors, including the fact that the achievement of the research and development milestones are contingent upon the results of the underlying research and development activities and are thus outside of the control of the Company.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sanofi participated in the Company&amp;#8217;s Series B Convertible Preferred Stock offering and as a result of this, is considered a related party.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Vertex Agreement &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On May&amp;#160;9, 2019 (the &amp;#8220;Effective Date&amp;#8221;), the Company entered into a collaboration agreement (the &amp;#8220;Vertex Agreement&amp;#8221;) with Vertex to advance small molecule protein degraders against up to six targets. Under the Vertex Agreement, Vertex has the exclusive option to license the rights to the product candidates developed for the designated targets at which point Vertex will control development and commercialization. Pursuant to the Vertex Agreement, the Company is only responsible for discovery and preclinical research on the targets, and Vertex is responsible for development, manufacturing, and commercialization of the product candidates after it exercises its option to license. The initial research term of the collaboration is four (4)&amp;#160;years, extendable for an additional one (1)&amp;#160;year period upon mutual agreement by the parties and payment by Vertex of certain per-target fees. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vertex provided the Company with a non-refundable upfront payment of $50.0&amp;#160;million and purchased 3,059,695 shares of the Company&amp;#8217;s Series B-1 Convertible Preferred Stock (&amp;#8220;Series B-1&amp;#8221;) at $6.54 a share, pursuant to a separate, but simultaneously executed Share Purchase Agreement. The shares were purchased at a premium of $5.9&amp;#160;million, which was included in the transaction price and will be recognized as revenue over the period of performance. As a result of this purchase, Vertex is considered a related party. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is eligible to receive up to $170.0&amp;#160;million in payments per target, including development, regulatory and commercial milestones as well as option exercise payments. In addition, Vertex is obligated to pay the Company tiered royalties on future net sales on any products that may result from the Vertex Agreement. None of the payments under the Vertex Agreement are refundable. The Company may also perform follow-on research for an optioned target upon Vertex&amp;#8217;s request and at Vertex&amp;#8217;s expense. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The term of the Vertex Agreement began on the Effective Date and expires upon the expiration of all payment obligations from Vertex to Company under the Vertex Agreement or, if Vertex does not exercise any of its options, the lapse of all Vertex&amp;#8217;s option rights under the Vertex Agreement. Vertex also has the ability to terminate for convenience with prior written notice to the Company, and either party may terminate for an uncured material breach. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Accounting Treatment &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company analyzed the joint research activities required under the Vertex Agreement and concluded that the arrangement was indicative of a vendor-customer relationship and would be accounted for under ASC&amp;#160;606. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company identified the following material promises under the arrangement: (1)&amp;#160;the non-exclusive, royalty-free research license; and (2)&amp;#160;the research and development services to be performed on up to six targets; and (3)&amp;#160;the option to license each of the targets for development, manufacturing, and commercialization efforts. The research and development services were determined not to be distinct from the research and development license and have been combined into a single performance obligation. The Company determined that the option to license the targets in the future was not priced at a discount, and that the option exercise fee for each target is at or above the standalone selling price for research at this stage of development; as such, the options and the underlying licenses are excluded from the performance obligation and the option exercise fees are excluded from the transaction price until the underlying option is exercised. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As part of its evaluation of constraining the research and development milestones, the Company considered numerous factors, including the fact that the achievement of the research and development milestones are contingent upon the results of the underlying research and development activities and are thus outside of the control of the Company. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At the commencement of the arrangement, two units of accounting were identified, the issuance of&amp;#160;3,059,695 shares of the Company&amp;#8217;s Series B-1 Convertible Preferred Stock and the research activities the Company will perform over the&amp;#160;Research Term. The Company determined the total transaction price to be $55.9&amp;#160;million, which consists of $5.9&amp;#160;million attributed to the premium from the Series B-1 shares sold to Vertex and the $50.0&amp;#160;million upfront payment. To determine the fair value of the Series B-1 issued to Vertex, the Company performed a valuation of the shares of the Company&amp;#8217;s common and preferred stock, which took into consideration recent financings, and the Company&amp;#8217;s recent development and future exit strategies, as well as a discount for lack of marketability. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes revenue associated with the performance obligation as the research and development services are provided using an input method, according to the costs incurred as related to the research and development activities on each program and the costs expected to be incurred in the future to satisfy the performance obligation. The transfer of control occurs over this time period and, in management&amp;#8217;s judgment, is the best measure of progress towards satisfying the performance obligation. The amounts received that have not yet been recognized as revenue are deferred as a contract liability on the Company&amp;#8217;s consolidated balance sheet and will be recognized over the remaining research and development period until the performance obligation is satisfied. The performance obligation has not been fully satisfied as of December 31, 2020. During the years ended December 31, 2020 and 2019, the Company recognized $15.2 million and $2.9 million in revenue under the Vertex Agreement. All $15.2&amp;#160;million revenue recognized during the year ended December 31, 2020 was recognized from amounts that were recorded in deferred revenue as of December&amp;#160;31, 2019. The aggregate amount of the transaction price allocated to the Company&amp;#8217;s unsatisfied performance obligation and recorded in deferred revenue at December&amp;#160;31, 2020 and 2019 is $37.7 million and $53.0&amp;#160;million, respectively. The Company will recognize the deferred revenue related to the research and development services based on a cost input method, over the remaining research term, which is a maximum of 2.0 years as of December&amp;#160;31, 2020. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Any consideration related to sales milestone payments (including royalties) will be recognized when the related milestone events or sales occur and therefore are recognized at the later of when the related sales occur or the relevant performance obligation is satisfied. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Compound Collaboration &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In October 2017, the Company entered into a collaboration agreement (the &amp;#8220;Collaboration&amp;#8221;) with a pharmaceutical company to jointly identify, research and conduct preclinical development of collaboration compounds against specified collaboration targets to identify drug candidates. Under the terms of the Collaboration, both parties provided one another with a non-exclusive, royalty-free, sub-licensable research and development license to each party&amp;#8217;s intellectual property to develop five agreed-upon collaboration targets, as well as an exclusive, royalty-bearing development and commercialization license to sell any licensed products that stem from such research. The parties also have the ability to nominate additional collaboration targets if agreed-upon, as long as there are no more than five targets at any given time. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In exchange for the non-exclusive license rights, the Company provided the pharmaceutical company with an equity grant and is required to make tiered royalty payments based on net sales of all products licensed under the agreement in the low single-digit percentages. In conjunction with the Collaboration, the Company initially issued 886,305 Series A Preferred Units (&amp;#8220;Series A Preferred Units&amp;#8221;) to the pharmaceutical company. On November&amp;#160;1, 2018, these Series A Preferred Units were exchanged on a one-for-one basis for shares of Series A Convertible Preferred Stock (the &amp;#8220;Series A Preferred Stock&amp;#8221;). These shares vest in equal installments over three years. The Company is recording expense over the remaining vesting period based on the fair value of the shares under the Collaboration. The Company recorded $0.3&amp;#160;million and $0.4 million to research and development expense related to the vesting of 166,183 and 221,579 shares of Series A Preferred Stock during the years ended December 31, 2020 and 2019, respectively. As of December 31, 2020, all shares under the Collaboration were fully vested and all expense had been recognized.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The royalty payments are contingent and as such are not being recorded until incurred. The Company determined that the license is representative of an in-process research and development asset, with no future alternative use. As such, the Company records the expense related to the vesting of shares as research and development expense in the Company&amp;#8217;s consolidated statements of operations and comprehensive loss. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Collaboration can be terminated by either party for convenience with 60-days written notice and may also be terminated in the event of a material breach. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The &lt;font style="color:#000000;"&gt;following table presents the changes in accounts receivable, contract assets and liabilities for the year ended December 31,&amp;#160;2020 (in thousands)&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.26%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deductions&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.26%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accounts receivable and contract assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.26%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Billed receivables &amp;#8211; Sanofi&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;150,577&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(150,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;577&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.26%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unbilled receivables &amp;#8211; Sanofi&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,433&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(577&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;856&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.26%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total accounts receivable and contract assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;152,010&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(150,577&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,433&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.26%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contract Liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.26%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred Revenue &amp;#8211; Vertex&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;52,991&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(15,243&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,748&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.26%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred Revenue &amp;#8211; Sanofi&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;151,433&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(18,791&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;132,642&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.26%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total contract liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;52,991&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;151,433&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(34,034&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;170,390&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock id="F_000340" contextRef="C_0001815442_20200101_20201231">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 6. Property and equipment&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment consist of the following as of December&amp;#160;31, 2020 and 2019 (in thousands): &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lab and office equipment under and financing&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; right-of-use asset&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,771&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,751&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,636&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;919&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;89&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;71&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture &amp;amp; fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;861&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;104&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,599&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;545&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets not yet in service&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;453&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total property and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,988&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,843&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less accumulated depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,147&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,049&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,841&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,794&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation expense for the years ended December&amp;#160;31, 2020 and 2019 was $1.8 million and $0.9&amp;#160;million, respectively.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Included in property and equipment is lab and office equipment right-of-use assets under financing leases with a cost basis of $2.8&amp;#160;million and accumulated amortization expense of $1.2 million and $0.5&amp;#160;million as of December 31, 2020 and 2019.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization expense related to right-of-use assets was $0.7 million and $0.4&amp;#160;million the years ended December&amp;#160;31, 2020 and 2019 and is included in depreciation expense.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <kymr:LesseeOperatingAndFinanceLeasesTextBlock id="F_000341" contextRef="C_0001815442_20200101_20201231">
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 7. Leases&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2018, the Company entered into a noncancelable facility lease agreement (the &amp;#8220;Lease&amp;#8221;) for 9,836 square feet of research and development and office space in Cambridge, Massachusetts. In March 2020, the Company signed a termination agreement for this lease which was determined to be a lease modification that resulted in a reduction of the right-of-use asset and liability of $2.2 million. The lease termination was effective July&amp;#160;31, 2020 and the Company no longer has any obligations under the Lease.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In accordance with the lease agreement, the Company was required to maintain a security deposit and provided a letter of credit to the landlord for $0.2&amp;#160;million, which was recorded in other assets as of December&amp;#160;31, 2019. In October 2020, the Company was released from the security deposit and letter of credit and collected the $0.2 million previously classified in other current assets. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In April 2019, the Company entered into a facility sublease agreement (the &amp;#8220;Sublease&amp;#8221;) for 1,471 square feet of office space in Cambridge, Massachusetts. The term of the lease began on June&amp;#160;24, 2019 and terminated on June 30, 2020, and following termination, the Company had no further obligations under the Sublease. The Sublease required the Company to share in prorated operating expenses and property taxes based upon actual amounts incurred; those amounts were considered variable lease costs and, therefore, are not included in the measurement of the lease and are instead recognized to expense as incurred.&lt;font style="font-weight:bold;"&gt; &lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In October 2019, the Company entered into a noncancelable facility lease agreement (the &amp;#8220;New Lease&amp;#8221;) for 34,522 square feet of research and development and office space in Watertown, Massachusetts. The term of the New Lease is 120 months and expires on March&amp;#160;31, 2030. The New Lease has an option to be extended for an additional five years. The lease is not reasonably certain to be extended and as such the additional term is not included in the measurement of the lease. The New Lease includes a rent escalation clause, and rent expense is being recorded on a straight-line basis. The Company received a tenant incentive allowance of $5.5&amp;#160;million in 2020 as the tenant improvements were completed all of which has been collected from its landlord as of December 31, 2020. In accordance with the lease agreement, the Company is required to maintain a security deposit and provided a letter of credit to the landlord for $1.6&amp;#160;million, which is recorded in other assets as of December 31, 2020. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s financing lease obligations consist of certain property and equipment financed through capital leases. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The components of the lease costs for the years ended December 31, 2020 and 2019 (in thousands): &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.9%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.86%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease costs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,719&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,597&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.86%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financing lease costs:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.86%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization of right-to-use assets, financing&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; leases&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;716&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;385&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.86%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest expense for financing lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;121&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Variable lease costs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;621&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;340&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.86%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total lease costs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,177&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,368&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Supplemental cash flow information relating to the Company&amp;#8217;s leases for the years ended December 31, 2020 and 2019 was as follows (in thousands): &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash paid for amounts included in the measurement&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; of lease liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating cash flows used in (provided by)&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; operating leases&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,024&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;635&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating cash flows used in finance leases&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;587&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financing cash flows used in finance leases&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;121&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;385&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average remaining lease terms and discount rates as of December 31, 2020 and 2019 were as follows: &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining lease term:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financing lease&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.8 Years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.7 Years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Discount Rate:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financing lease&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The undiscounted future lease payments for operating and finance leases as of December&amp;#160;31, 2020, were as follows (in thousands): &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="text-decoration:underline;"&gt;Fiscal Year&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financing&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,691&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;712&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,581&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;459&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,659&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;245&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,732&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,814&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,925&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total minimum lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26,402&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,416&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less amounts representing interest or imputed interest&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9,702&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(123&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Present value of lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,700&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,293&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</kymr:LesseeOperatingAndFinanceLeasesTextBlock>
  <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock id="F_000342" contextRef="C_0001815442_20200101_20201231">
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 8. Accrued Expenses&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses consist of the following as of December 31, 2020 and 2019 (in thousands): &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,821&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,617&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Payroll and payroll-related&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,918&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,256&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Professional fees&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,585&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;606&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;89&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,330&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,568&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock id="F_000343" contextRef="C_0001815442_20200101_20201231">
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 9. Other Commitments and Contingencies&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In the ordinary course of business, the Company may be subject to legal proceedings, claims and litigation as the Company operates in an industry susceptible to patent legal claims. The Company accounts for estimated losses with respect to legal proceedings and claims when such losses are probable and estimable. Legal costs associated with these matters are expensed when incurred.&amp;#160;The Company is not currently a party to any legal proceedings.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Indemnification Arrangements&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As permitted under Delaware law, the Company has agreements whereby it indemnifies its investors, employees, officers, and directors (collectively, the &amp;#8220;Indemnified Parties&amp;#8221;) for certain events or occurrences while the Indemnified Parties are, or were serving, at its request in such capacity. The term of the indemnification period is for the Indemnified Parties&amp;#8217; lifetime. The Company believes the estimated fair value of these indemnification agreements is minimal. The Company enters into standard indemnification agreements in the ordinary course of business. Pursuant to these agreements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified party for losses suffered or incurred by the indemnified party, generally the Company&amp;#8217;s business partners or customers, in connection with any U.S. patent or any copyright or other intellectual property infringement claim by any third party with respect to the Company&amp;#8217;s products. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited. The Company is not aware of any claims under indemnification arrangements, and it has not accrued any liabilities related to such obligations as of December&amp;#160;31, 2020 or 2019.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:PreferredStockTextBlock id="F_000344" contextRef="C_0001815442_20200101_20201231">
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 10. Convertible Preferred Stock&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Immediately prior to the IPO, the Company&amp;#8217;s Articles of Association (the &amp;#8220;Articles&amp;#8221;), as further amended and restated (the &amp;#8220;2018 Amended Articles&amp;#8221;), authorized a total of 52,483,788 convertible preferred stocks with a par value of $0.0001 per share, of which 3,000,000 shares have been designated as Series Seed Preferred Stock, 14,886,305 shares have been designated as Series A Preferred Stock, 16,009,845 shares have been designated as Series B Preferred Stock, 3,059,695 shares have been designated as Series B-1 Preferred Stock and 15,527,943 shares have been designated as Series C Preferred Stock. The Series A, Series B, Series B-1 and Series C convertible preferred stocks will be collectively referred to as the Convertible Preferred Stock. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In January 2020, the Company issued 1,182,265 shares of Series B Preferred Stock at $4.06 per share to complete the second closing of the Series B Preferred Stock issuance for total proceeds of $4.8&amp;#160;million. The issuance costs related to the second tranche were insignificant.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2020, the Company executed a Series&amp;#160;C Preferred Stock Purchase Agreement (the &amp;#8220;Series&amp;#160;C SPA&amp;#8221;) to issue 13,539,141 shares of Series&amp;#160;C Preferred Stock at a purchase price of $6.5366 per share for a total consideration of $88.2&amp;#160;million, net of issuance costs of $0.3&amp;#160;million. In conjunction with the Series&amp;#160;C SPA, the Company exchanged 1,988,802 shares of Series A Preferred Stock for an equal number of shares of Series&amp;#160;C Preferred Stock related to a transaction amongst investors. This resulted in a total issuance of 15,527,943 shares of Series&amp;#160;C Preferred Stock. The fair value of the shares of Series&amp;#160;C Preferred Stock issued exceeded the carrying value of the shares of Series&amp;#160;A Preferred Stock exchanged by $9.1&amp;#160;million, which was recognized as a deemed dividend through a reduction of $2.3&amp;#160;million to additional&amp;#160;paid-in&amp;#160;capital and an increase of $6.7&amp;#160;million to the accumulated deficit. The $9.1&amp;#160;million deemed dividend increased the net loss for the year ending December 31, 2020 to arrive at net loss attributable to common stockholders in the calculation of earnings per share.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with the Company&amp;#8217;s August 21, 2020, IPO all issued and outstanding Convertible Preferred Stock of 50,439,595 were converted to 31,625,534 shares of the Company&amp;#8217;s common stock and are no longer issued or outstanding as of December 31, 2020.&lt;/p&gt;</us-gaap:PreferredStockTextBlock>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock id="F_000345" contextRef="C_0001815442_20200101_20201231">
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 11. Equity-Based Compensation &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;2018 Stock Option and Grant Plan &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November 2018, the Company adopted, and its stockholders approved, the 2018 Stock Option and Grant Plan (the &amp;#8220;2018 Plan&amp;#8221;), which provides for the granting of stock options and other equity-based awards at the discretion of the Board of Directors or any subcommittee of the Board of Directors to its employees, officers, directors, and independent contractors. No further grants will be made under the 2018 Plan. However, the 2018 Plan will continue to govern outstanding equity awards granted thereunder. To the extent outstanding options granted under the 2018 Plan are cancelled, forfeited or otherwise terminated without being exercised and would otherwise have been returned to the share reserve under the 2018 Plan, the number of shares underlying such awards will be available for future grant under the 2020 Stock Option and Incentive Plan. Following the completion of the Company&amp;#8217;s initial public offering no additional shares will be granted under the 2018 Plan. However, the 2018 Plan will continue to govern outstanding equity awards granted thereunder.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;2020 Stock Option and Incentive Plan &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2020, the Company and its stockholders approved the 2020 Stock Option and Incentive Plan (the &amp;#8220;2020 Plan&amp;#8221;), which became effective on August 20, 2020. The 2020 Plan replaced the 2018 Plan as the Company&amp;#8217;s board of directors has determined not to make additional awards under the 2018 Plan following the closing of the Company&amp;#8217;s IPO. The 2020 Plan allows the Company to make equity-based and cash-based incentive awards to its officers, employees, directors and consultants. The Company has initially reserved 4,457,370 shares of its common stock for the issuance of awards under the 2020 Plan, which includes the shares of common stock remaining available for issuance under its 2018 Plan as of the business day immediately prior to the effective date of the registration statement. The 2020 Plan provides that the number of shares reserved and available for issuance will automatically increase on January 1, 2021 and each January 1 thereafter, by 4% of the Company&amp;#8217;s outstanding number of shares of common stock on the immediately preceding December 31, or such lesser number of shares as determined by the Company&amp;#8217;s compensation committee. These limits are subject to adjustment in the event of a stock split, stock dividend or other change in the Company&amp;#8217;s capitalization. As of December&amp;#160;31, 2020, there were an aggregate of 3,148,671 shares remaining available for future grants. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;2020 Employee Stock Purchase Plan &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2020, the Company and its stockholders approved the 2020 Employee Stock Purchase Plan (the &amp;#8220;2020 ESPP&amp;#8221;), which became effective August 20, 2020. The 2020 ESPP initially reserves and authorizes the issuance of up to a total of 445,653 shares of common stock to participating employees. The 2020 ESPP provides that the number of shares reserved and available for issuance will automatically increase on January 1, 2021 and each January 1 thereafter through January 1, 2030, by the least of (i) 438,898 shares of common stock, (ii) 1% of the Company&amp;#8217;s outstanding number of shares of common stock on the immediately preceding December 31 or (iii) such lesser number of shares of common stock as determined by the administrator of the 2020 ESPP. The number of shares reserved under the 2020 ESPP is subject to adjustment in the event of a stock split, stock dividend or other change in the Company&amp;#8217;s capitalization. As of December&amp;#160;31, 2020, there were an aggregate of 445,653 shares remaining available for future grants. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Stock Options &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of stock option activity under the 2020 Stock Option and Grant Plan during the year ended December 31, 2020 is as follows (in thousands except share and per share data): &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Strike&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price per&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Option&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,945,297&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.03&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.93&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,798&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,213,204&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.22&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(78,852&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.06&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(246,937&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.55&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,832,712&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.17&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.08&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;314,001&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,580,924&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.38&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.76&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;92,674&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The i&lt;font style="Background-color:#FFFFFF;color:#000000;"&gt;ntrinsic value of stock options exercised during the years ended December 31, 2020 and 2019 was $1.6 million, $0.1 million, respectively.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The weighted-average fair value of options granted during the years ended December&amp;#160;31, 2020 and 2019 was $8.35 and $1.69 per share, respectively.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020, the total unrecognized stock-based compensation expense for unvested stock options was $25.6&amp;#160;million, which is expected to be recognized over 3.3 years. The total fair value of stock options vested during the years ended December&amp;#160;31, 2020 and 2019 was $4.0 million, $0.2&amp;#160;million, respectively.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table outlines our equity-based compensation expense for stock options for the years ended December 31, 2020 and 2019:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.5%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="8" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.72%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ending December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.5%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,084&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;380&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.5%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,864&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;212&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.5%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total equity-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,948&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;592&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The weighted-average assumptions that the Company used in Black-Scholes option pricing model to determine the grant date fair value of stock options granted to employees and non-employees for the years ended December 31, 2020 and 2019: &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="8" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.32%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ending December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.3%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.09&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.49&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;71&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.83&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Restricted Common Stock &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has granted shares of restricted common stock with service-based and performance-based vesting conditions. A summary of restricted stock activity under the 2018 Plan during the year ended December 31, 2020 is as follows: &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Units&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant Date&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;per Share&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;232,434&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.60&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(102,651&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.60&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19,679&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.60&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;110,104&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.60&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;There were no grants of restricted stock during the years ended December 31, 2020 and 2019.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2020, the total unrecognized stock-based compensation expense for unvested restricted stock was $0.3&amp;#160;million, which is expected to be recognized over 1.6 years. The total fair value of restricted stock vested during the years ended December&amp;#160;31, 2020 and 2019 was $0.1 million and $0.5&amp;#160;million, respectively.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the years ended December 31, 2020 and 2019, the Company recorded stock-based compensation expense for restricted stock of $0.2 million and $0.4&amp;#160;million, of which $0.2 million and $0.2 million was included in research and development expense and an immaterial amount and $0.2 million was included in general and administrative expense, respectively. Included within the 2019 general and administrative stock-based compensation expense was $0.1&amp;#160;million from a modification of an employee&amp;#8217;s awards.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Equity-Based Compensation Expense &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total equity-based compensation expense recorded as research and development and general and administrative expenses for employees, directors, and non-employees during the years ended December 31, 2020 and 2019 is as follows (in thousands): &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="8" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ending December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,305&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;688&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,885&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;508&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total equity-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,190&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,196&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock id="F_000346" contextRef="C_0001815442_20200101_20201231">
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 12. Related-Party Transactions&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In addition to the collaboration discussed in Note 5, the Company had the following related party transactions for the periods presented in the accompanying consolidated financial statements, which has not otherwise been discussed in these notes to the consolidated financial statement. The Company made payments of $0.8 million and $1.0&amp;#160;million to an investor for rent expenses for the years ended December 31, 2020 and 2019, respectively. &lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:IncomeTaxDisclosureTextBlock id="F_000347" contextRef="C_0001815442_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 13. Income Taxes &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.53%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company records income tax expense related to profits realized by its U.S. operating subsidiaries.&amp;#160;For the years ended December&amp;#160;31, 2020 and 2019, no income tax expense was recorded due the group&amp;#8217;s net operating loss (&amp;#8220;NOL&amp;#8221;) and full valuation allowance.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.53%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The rate reconciliation of the U.S. statutory income tax rate to the Company&amp;#8217;s effective tax rate for the years ended December&amp;#160;31, 2020 and 2019 are as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax effect at statutory rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State taxes&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.9&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal research and development credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(28.8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(29.4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.53%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company&amp;#8217;s net deferred income taxes are as&amp;#160;follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160; &lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Deferred Tax Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,621&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,011&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,866&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,319&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development credit carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,757&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,637&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,563&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,286&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,313&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accruals and reserves, stock and other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,589&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;525&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,709&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26,778&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(34,075&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(20,949&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,634&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,829&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fixed and intangible assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,506&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(754&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,128&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,075&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax asset&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.53%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As required by ASC 740, management of the Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, which are composed principally of NOL carryforwards and research and development credit carryforwards. Management has determined that it is more likely than not that the Company will not recognize the benefits of its federal and state deferred tax assets, and, as a result, a valuation allowance of $34.1&amp;#160;million and $20.9&amp;#160;million has been established at December&amp;#160;31, 2020 and 2019, respectively. During 2020, the valuation allowance increased by $13.1&amp;#160;million primarily due to the increase in the Company&amp;#8217;s NOL during the period.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.53%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has incurred NOLs from inception. At December&amp;#160;31, 2020 and 2019, the Company has federal NOL carryforwards of approximately $74.4&amp;#160;million and $71.5&amp;#160;million, respectively, and state NOL carryforwards of approximately $61.2&amp;#160;million and $68.3&amp;#160;million, respectively. Of the federal net operating loss carryovers, $64.6 million is not subject to expiration and the remaining federal and state NOLs begin to expire in 2036. These loss carryforwards are subject to review and possible adjustment by the appropriate taxing authorities.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.53%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Utilization of net operating loss and research and development credit carryforwards may generally be subject to limitation under Sections 382 and 383 of the Internal Revenue Code due to ownership changes that have occurred previously, or that could occur in the future. These ownership changes may limit the amount of net operating loss and research and development credit carryforwards that can be utilized annually to offset any post-ownership change taxable income and tax, respectively. The latest Section 382 study was performed through December 31, 2020, noting that a historic ownership change has likely occurred. Nonetheless, the Company has determined that as of December 31, 2020 the prospective utilization of all net operating loss and tax credit carryforwards generated from inception through December 31, 2020, and therefore the corresponding Federal and Massachusetts deferred tax assets, should not be restricted by Sections 382 and 383, although ownership changes after December 31, 2020 could impact the Company&amp;#8217;s ability to utilize these tax attributes in the future.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.53%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At December&amp;#160;31, 2020 and 2019, the Company had federal research and development credit carryforwards of $2.7&amp;#160;million and $1.1&amp;#160;million, respectively, and state research and development credit carryforwards of $1.3&amp;#160;million and $0.7&amp;#160;million, respectively. These carryforwards begin to expire in&amp;#160;2036.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.53%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company follows the provisions of ASC 740-10, &amp;#8220;Accounting for Uncertainty in Income Taxes,&amp;#8221; which specifies how tax benefits for uncertain tax positions are to be recognized, measured, and recorded in financial statements; requires certain disclosures of uncertain tax matters; specifies how reserves for uncertain tax positions should be classified on the balance sheet; and provides transition and interim period guidance, among other provisions.&amp;#160;As of December 31, 2020, and 2019, the Company has not recorded any amounts for uncertain tax positions.&amp;#160;The Company&amp;#8217;s policy is to recognize interest and penalties accrued on any uncertain tax positions as a component of income tax expense, if any, in its statements of income. As of December&amp;#160;31, 2020 and 2019, the Company had no reserves for uncertain tax positions.&amp;#160;For the years ended December&amp;#160;31, 2020 and 2019, no estimated interest or penalties were recognized on uncertain tax positions.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.53%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&apos;s tax returns for the years ended December 31, 2017 to December 31, 2020 remain open and subject to examination by the Internal Revenue Service and state taxing authorities.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:EarningsPerShareTextBlock id="F_000348" contextRef="C_0001815442_20200101_20201231">
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 14. Net Loss per Share&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Net Loss per Share&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic and diluted loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding (in thousands, except for share and per share data):&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.46%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="8" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.76%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(45,593&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(41,246&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.46%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deemed dividend from exchange of convertible&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9,050&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.46%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss attributable to common stockholders&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(54,643&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(41,246&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average common shares outstanding, basic&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,349,582&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,698,522&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.46%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3.15&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(24.28&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s potentially dilutive securities, which include convertible preferred stock, restricted stock, and stock options, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following from the computation of diluted net loss per share attributable to common stockholders at December&amp;#160;31, 2020 and 2019 because including them would have had an anti-dilutive effect:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.9%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="8" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.48%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.9%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Convertible Preferred Stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,325,780&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested Restricted Stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;110,104&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;232,434&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.9%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options to purchase Common Stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,580,924&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,945,298&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.9%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,691,028&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,503,512&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:ConsolidationPolicyTextBlock id="F_000349" contextRef="C_0001815442_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Principles of Consolidation&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary Kymera Securities Corporation. All intercompany transactions and balances have been eliminated in consolidation.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock id="F_000350" contextRef="C_0001815442_20200101_20201231">
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Basis of Presentation&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&amp;#8220;GAAP&amp;#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) and Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) of the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;).&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:UseOfEstimates id="F_000351" contextRef="C_0001815442_20200101_20201231">
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Use of Estimates&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosure of contingencies at the date of the financial statements and the reported amounts of expenses during the reporting period. Management&amp;#8217;s estimates and judgments are derived and continually evaluated based on available information, historical experience and various other assumptions that are believed to be reasonable under the circumstances. Because the use of estimates is inherent in the financial reporting process, actual results could differ from those estimates. In recording transactions and balances resulting from business operations, management makes estimates based on the best information available at the time the estimate is made. Significant estimates relied upon in preparing these financial statements include revenue recognized under our collaboration agreement with Sanofi and Vertex, accrual for research and development expenses, equity-based compensation expense, and the valuation of equity. As better information becomes available or actual amounts are determinable, the recorded estimates are revised. Consequently, operating results can be affected by revisions to prior estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
  <kymr:SegmentAndGeographicInformationPolicyTextBlock id="F_000352" contextRef="C_0001815442_20200101_20201231">
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Segment and Geographic Information&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company&amp;#8217;s chief operating decision maker is the Chief Executive Officer. The Company views its operations and manages its business in one operating segment.&lt;/p&gt;</kymr:SegmentAndGeographicInformationPolicyTextBlock>
  <us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy id="F_000353" contextRef="C_0001815442_20200101_20201231">
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Cash and &lt;font style="color:#000000;"&gt;Cash&lt;/font&gt; Equivalents&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents are highly liquid investments that are readily convertible into cash with original maturities of three months or less when purchased. These assets include investments in money market funds that invest in U.S. Treasury obligations and corporate bonds. The Company maintains its bank accounts at major financial institutions.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy>
  <kymr:RestrictedCashPolicyPolicyTextBlock id="F_000354" contextRef="C_0001815442_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Restricted Cash&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash represents the cash held to secure a letter of credit associated with the Company&amp;#8217;s facility lease.&lt;/p&gt;</kymr:RestrictedCashPolicyPolicyTextBlock>
  <us-gaap:MarketableSecuritiesPolicy id="F_000355" contextRef="C_0001815442_20200101_20201231">
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Marketable Securities&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company classifies marketable securities with a remaining maturity of greater than three months when purchased as available-for-sale. The Company classifies investments available to fund current operations as current assets on its balance sheets. Marketable securities with a remaining maturity date greater than one year are classified as non-current. Available-for-sale securities are maintained by investment managers and consist of U.S. Treasury securities and corporate bonds. Available-for-sale securities are carried at fair value with the unrealized gains and losses included in other comprehensive income (loss) as a component of stockholders&amp;#8217; equity until realized. Any premium or discount arising at purchase is amortized and/or accreted to interest income and/or expense over the life of the instrument. Realized gains and losses are determined using the specific identification method and are included in other (expense) income, net.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;If any adjustment to fair value reflects a decline in value of the investment, the Company considers all available evidence to evaluate the extent to which the decline is &amp;#8220;other-than-temporary&amp;#8221; and, if so, marks the investment to market through a charge to the Company&amp;#8217;s statement of operations and comprehensive loss.&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
  <us-gaap:FairValueMeasurementPolicyPolicyTextBlock id="F_000356" contextRef="C_0001815442_20200101_20201231">
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Level&amp;#160;1&amp;#8212;&lt;font style="font-style:normal;"&gt;Quoted prices in active markets for identical assets&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Level&amp;#160;2&amp;#8212;&lt;font style="font-style:normal;"&gt;Observable inputs (other than Level&amp;#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar asset, or other inputs that are observable or can be corroborated by observable market data.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Level&amp;#160;3&amp;#8212;&lt;font style="font-style:normal;"&gt;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying values of the Company&amp;#8217;s cash equivalents, prepaid expenses, accounts payable, and certain accruals approximate their fair value due to their short-term nature.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
  <us-gaap:LesseeLeasesPolicyTextBlock id="F_000357" contextRef="C_0001815442_20200101_20201231">
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company adopted ASC Topic 842, &lt;font style="font-style:italic;"&gt;Leases&lt;/font&gt; (&amp;#8220;ASC 842&amp;#8221;) on January&amp;#160;1, 2019. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Leases that are economically similar to the purchase of assets are generally classified as finance leases; otherwise the leases are classified as operating leases. The Company has elected not to recognize leases with an original term of one year or less on the balance sheet. Options to renew a lease are not included in the Company&amp;#8217;s assessment unless there is reasonable certainty that the Company will renew. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. However, certain adjustments to the right-of-use asset may be required for items such as incentives received. The Company has elected as an accounting policy to combine lease and non- lease components, such as common area maintenance, for all classes of underlying assets. The interest rate implicit in lease contracts has not historically been readily determinable. As a result, the Company utilizes its incremental borrowing rates, which are the rates incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. To estimate its incremental borrowing rate, a credit rating applicable to the Company is estimated using synthetic credit rating analysis since the Company does not currently have a rating agency-based credit rating.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock id="F_000358" contextRef="C_0001815442_20200101_20201231">
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Property and Equipment&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are recorded at cost, net of accumulated depreciation. Major additions and betterments are capitalized; maintenance and repairs, which do not improve or extend the life of the respective assets, are charged to operations as incurred. Depreciation expense is recorded using the straight-line method over the estimated useful life of the related asset as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.86%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated Useful Life&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in years)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.86%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furnitures and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.86%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Office equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.86%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.86%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.86%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shorter of life of lease or remaining lease term&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon retirement or sale, the cost and related accumulated depreciation of assets disposed of are removed from the accounts and any resulting gain or loss is included in loss from operations.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction-in-progress is stated at cost, which includes direct costs attributable to the setup or construction of the related asset. Depreciation expense is not recorded on construction-in-progress until the relevant assets are completed and put into use.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock id="F_000359" contextRef="C_0001815442_20200101_20201231">
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Impairment of Long-Lived Assets&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its fair value, determined based on discounted cash flows. The Company did not record any impairment losses on long-lived assets during the years ended December&amp;#160;31, 2020 and 2019.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
  <kymr:ConvertiblePreferredStockPolicyTextBlock id="F_000360" contextRef="C_0001815442_20200101_20201231">
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Convertible Preferred Stock&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company classified convertible preferred stock as temporary equity in the accompanying consolidated balance sheet due to terms that allow for redemption of the shares in cash upon certain change in control events that are outside of the Company&amp;#8217;s control, including the sale or transfer of the Company as holders of the convertible preferred stock which could trigger redemption of the shares. The Company did not accrete the value of the convertible preferred stock to the redemption values since a liquidation event was not considered probable as of December&amp;#160;31, 2019. Subsequent adjustments of the carrying values to the ultimate redemption values will be made only when it becomes probable that such liquidation events will occur. In connection with the Company&amp;#8217;s initial public offering on August 21, 2020, all outstanding shares of convertible preferred stock converted to common stock.&lt;/p&gt;</kymr:ConvertiblePreferredStockPolicyTextBlock>
  <us-gaap:ResearchAndDevelopmentExpensePolicy id="F_000361" contextRef="C_0001815442_20200101_20201231">
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Research and Development Costs&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development costs consist primarily of costs incurred in connection with the discovery and development of targeted protein degradation therapeutics, including those in the Company&amp;#8217;s most advanced development programs, IRAK4, IRAKIMiD and STAT3. These research efforts and costs, which also support the development of, and enhancements to, the Company&amp;#8217;s Pegasus targeted protein degradation platform, include external research costs, personnel costs, supplies, license fees and facility related expenses. The Company expenses research and development costs as incurred.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <kymr:PatentCostsPolicyTextBlock id="F_000362" contextRef="C_0001815442_20200101_20201231">
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Patent Costs&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recoverability of the expenditure. Amounts incurred are classified as general and administrative expenses.&lt;/p&gt;</kymr:PatentCostsPolicyTextBlock>
  <kymr:FinancingCostsPolicyTextBlock id="F_000363" contextRef="C_0001815442_20200101_20201231">
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Financing Costs&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Costs incurred in connection with the issuance of equity units and shares are recorded as a reduction of proceeds to the equity carrying value. The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process financings as deferred offering costs until such financings are consummated. After consummation of the financing, these costs are recorded as a reduction of the proceeds received from the financing. If a planned financing is abandoned, the deferred offering costs are expensed immediately as a charge to operating expenses in the consolidated statement of operations and comprehensive loss. There was $0.4 million of deferred financing costs included in accounts payable on the Company&amp;#8217;s consolidated balance sheet as of December 31, 2020. There was no deferred offering costs on the Company&amp;#8217;s consolidated balance sheet at December 31, 2019.&lt;/p&gt;</kymr:FinancingCostsPolicyTextBlock>
  <us-gaap:RevenueRecognitionPolicyTextBlock id="F_000364" contextRef="C_0001815442_20200101_20201231">
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Revenue Recognition&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company adopted ASC Topic 606, &lt;font style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt; (&amp;#8220;ASC 606&amp;#8221;) on January&amp;#160;1, 2017. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, the Company performs the following five steps: (i)&amp;#160;identification of the contract(s) with the customer; (ii)&amp;#160;identification of the promised goods or services in the contract and determination of whether the promised goods or services are performance obligations; (iii)&amp;#160;measurement of the transaction price; (iv)&amp;#160;allocation of the transaction price to the performance obligations; and (v)&amp;#160;recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As part of the accounting for these arrangements, the Company must use significant judgment to determine: a) the number of performance obligations based on the determination under step (ii)&amp;#160;above and whether those performance obligations are distinct from other performance obligations in the contract; b) the transaction price under step (iii)&amp;#160;above; and c) the standalone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv)&amp;#160;above. The Company uses judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. In determining the stand-alone selling price of a license to the Company&amp;#8217;s proprietary technology or a material right provided by a customer option, the Company considers market conditions as well as entity-specific factors, including those factors contemplated in negotiating the agreements as well as internally developed estimates that include assumptions related to the market opportunity, estimated development costs, probability of success and the time needed to commercialize a product candidate pursuant to the license. In validating its estimated stand-alone selling prices, the Company evaluates whether changes in the key assumptions used to determine its estimated stand-alone selling prices will have a significant effect on the allocation of arrangement consideration between performance obligations.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company estimates the transaction price based on the amount of consideration the Company expects to be received for transferring the promised goods or services in the contract. The consideration may include both fixed consideration and variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of the potential payments and the likelihood that the payments will be received. The Company utilizes either the most likely amount method or expected value method to estimate the transaction price based on which method better predicts the amount of consideration expected to be received. If it is probable that a significant revenue reversal would not occur, the variable consideration is included in the transaction price.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer. Promised goods or services are considered distinct when: (i)&amp;#160;the customer can benefit from the good or service on its own or together with other readily available resources and (ii)&amp;#160;the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on their own and whether the required expertise is readily available.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation in order to determine whether the combined performance obligation is satisfied over time or at a point in time. The Company receives payments from customers based on billing schedules established in each contract. Up-front payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion. Amounts are recorded as accounts receivable when the Company&amp;#8217;s right to consideration is unconditional. Amounts recognized as revenue, but not yet received or invoiced are generally recognized as contract assets.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Exclusive Licenses&lt;font style="font-style:normal;"&gt;&amp;#8212;If the license granted in the arrangement is determined to be distinct from the other promises or performance obligations identified in the arrangement, which generally include research and development services, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whether a license is distinct from the other promises, the Company considers relevant facts and circumstances of each arrangement, including the research and development capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the collaboration partner can benefit from the license for its intended purpose without the receipt of the remaining promise, whether the value of the license is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the arrangement.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Research and Development Services&lt;font style="font-style:normal;"&gt;&amp;#8212;The promises under the Company&amp;#8217;s collaboration and license agreements generally include research and development services to be performed by the Company on behalf of the collaboration partner. For performance obligations that include research and development services, the Company generally recognizes revenue allocated to such performance obligations based on an appropriate measure of progress. The Company utilizes judgment to determine the appropriate method of measuring progress for purposes of recognizing revenue, which is generally an input measure, such as costs incurred. The Company evaluates the measure of progress each reporting period as described under Exclusive Licenses above. Reimbursements from the partner that are the result of a collaborative relationship with the partner, instead of a customer relationship, such as co-development activities, are generally recorded as a reduction to research and development expense.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Customer Options&lt;font style="font-style:normal;"&gt;&amp;#8212;The Company&amp;#8217;s arrangements may provide a collaborator with the right to certain optional purchases, such as the right to license a target either at the inception of the arrangement or within a pre-defined option period. Under these agreements, fees may be due to the Company at the inception of the arrangement as an upfront fee or payment or upon the exercise of an option to acquire a license. If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. The Company evaluates the customer options for material rights, or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the inception of the arrangement. The Company allocates the transaction price to material rights based on the relative stand-alone selling price, which is determined based on the identified discount, and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised or expires.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Milestone Payments&lt;font style="font-style:normal;"&gt;&amp;#8212;At the inception of each arrangement that includes milestone payments based on certain events, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. If a milestone or other variable consideration relates specifically to the Company&amp;#8217;s efforts to satisfy a single performance obligation or to a specific outcome from satisfying the performance obligation, the Company generally allocates the milestone amount entirely to that performance obligation once it is probable that a significant revenue reversal would not occur.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Royalties&lt;font style="font-style:normal;"&gt;&amp;#8212;For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i)&amp;#160;when the related sales occur or (ii)&amp;#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Collaboration revenue&amp;#8212;&lt;font style="font-style:normal;"&gt;The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808,&lt;/font&gt;&amp;#160;Collaborative Arrangements&lt;font style="font-style:normal;"&gt;&amp;#160;(&amp;#8220;ASC 808&amp;#8221;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities.&amp;#160;This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement.&amp;#160;For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship and therefore within the scope of Topic 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently, generally by analogy to Topic 606. For those elements of the arrangement that are accounted for pursuant to Topic 606, the Company applies the five-step model described above.&lt;/font&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <kymr:CostsAssociatedWithLicenseAndCollaborativeArrangementsPolicyTextBlock id="F_000365" contextRef="C_0001815442_20200101_20201231">
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Costs associated with License and Collaborative Arrangements&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Costs associated with licenses of technology acquired as part of collaborative arrangements are expensed as incurred and are generally included in research and development expense in the consolidated statements of operations.&lt;/p&gt;</kymr:CostsAssociatedWithLicenseAndCollaborativeArrangementsPolicyTextBlock>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy id="F_000366" contextRef="C_0001815442_20200101_20201231">
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for all stock-based awards granted to employees, directors, and nonemployees based on their fair value on the date of the grant and recognize compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. Stock-based payments include stock options and grants of common stock, including common stock subject to vesting. The measurement date for stock awards is the date of grant, and stock-based compensation costs are recognized as expense over the requisite service period, which is the vesting period, on a straight-line basis. The Company has issued stock options and restricted stock with performance-based vesting conditions and records the expense for these awards if the Company concludes that it is probable that the performance condition will be achieved. Stock-based compensation is classified in the accompanying consolidated statements of operations and comprehensive loss based on the function to which the related services are provided. The Company recognizes stock-based compensation expense for the portion of awards that have vested. Forfeitures are accounted for as they occur.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes options-pricing model, which requires inputs based on certain subjective assumptions, including the expected stock price volatility, the expected term of the option, the risk-free interest rate for a period that approximates the expected term of the option, and the Company&amp;#8217;s expected dividend yield. Prior to the IPO, as there was no active market for the Company&amp;#8217;s common stock, the Company estimated the fair value of common stock on the date of grant based on the then current facts and circumstances. Upon becoming a public company, the fair value of the underlying common shares equals the closing price of the Company&amp;#8217;s stock on the date of grant. The Company historically has been a private company and lacks company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of guideline companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company&amp;#8217;s stock options has been determined utilizing the &amp;#8220;simplified&amp;#8221; method for awards that qualify as &amp;#8220;plain-vanilla&amp;#8221; options. The expected term of stock options granted to non-employees is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future. The fair value of each restricted common stock award is estimated on the date of grant based on the fair value of the Company&amp;#8217;s common stock on that same date.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Compensation expense for discounted purchases under the employee stock purchase plan is measured using the Black-Scholes model to compute the fair value of the lookback provision plus the purchase discount and is recognized as compensation expense over the offering period.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <kymr:CommonAndPreferredStockValuationPolicyTextBlock id="F_000367" contextRef="C_0001815442_20200101_20201231">
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Common and Preferred Stock Valuation&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company utilized significant estimates and assumptions in determining the fair value of its equity and equity-based awards. The Company utilized various valuation methodologies in accordance with the framework of the 2013 American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its equity awards.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company used a hybrid of the probability-weighted expected returns method (&amp;#8220;PWERM&amp;#8221;), and the option pricing method (&amp;#8220;OPM&amp;#8221;) when allocating enterprise value to classes of securities.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the probability-weighted expected return method, or PWERM, the value of an enterprise, and its underlying common securities, are estimated based on an analysis of future values for the enterprise, assuming various outcomes. The value of the common securities is based on the probability-weighted present value of expected future investment returns considering each of the possible outcomes and the rights of each class of equity. The future values of the common securities under the various outcomes are discounted back to the valuation date at an appropriate risk-adjusted discount rate and then probability weighted to determine the value for the common securities.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The option pricing method, or OPM, treats common securities and preferred securities as call options on the enterprise&amp;#8217;s equity value, with exercise prices based on the liquidation preferences of the preferred securities. Under this method, the common securities have value only if the funds available for distribution to shareholders exceed the value of the liquidation preferences at the time of a liquidity event. The Black-Scholes model is used to price the call option, and the model includes assumptions for the time to liquidity and the volatility of equity value.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The hybrid method is a hybrid between the PWERM and OPM, estimating the probability-weighted value across multiple scenarios but using the OPM to estimate the allocation of value within one or more of those scenarios.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuations performed in the year ended December&amp;#160;31, 2020 and 2019, used a hybrid of the PWERM and OPM when allocating the Company&amp;#8217;s enterprise value to classes of securities.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;When using the hybrid method, the Company assumed two scenarios: an IPO scenario and a trade-sale scenario. The IPO scenario estimated an equity value based on the guideline public company method under a market approach. The guideline public companies considered for this scenario consist of biopharmaceutical companies with recently completed initial public offerings. The Company converted its estimated future value in an IPO to present value using a risk-adjusted discount rate. The equity value for the trade-sale scenario was estimated using the price of a recently issued preferred security, as well as a milestone-based tranche closing. The Company utilized an option pricing model to quantify or attribute value to these economic rights of convertible preferred stock vs. the common stock (e.g. liquidation preferences, dividend provisions, participation rights after liquidation preferences.)&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In the OPM, volatility is estimated based on the trading histories of selected guideline public companies. The relative probability of each scenario was determined based on an assessment of then-current market conditions and the Company&amp;#8217;s expectations as to timing and prospects of an IPO.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Each valuation methodology includes estimates and assumptions that require significant judgment. These estimates and assumptions include a number of objective and subjective factors, including the prices at which shares were traded between holders of the Company, external market conditions, the prices at which the Company sold convertible preferred shares, the superior rights and preferences of securities senior to common shares at the time, and the likelihood of achieving a voluntary or involuntary liquidity event.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant changes to the key assumptions used in the valuations could result in different fair values of common shares at each valuation date, as applicable.&lt;/p&gt;</kymr:CommonAndPreferredStockValuationPolicyTextBlock>
  <us-gaap:IncomeTaxPolicyTextBlock id="F_000368" contextRef="C_0001815442_20200101_20201231">
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Income Taxes&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income taxes for Kymera Therapeutics, Inc. are recorded in accordance with FASB Accounting Standards Codification Topic 740, &lt;font style="font-style:italic;"&gt;Income Taxes&lt;/font&gt; (&amp;#8220;ASC 740&amp;#8221;), which provides for deferred taxes using an asset and liability approach. Under this method, deferred income tax assets and liabilities are recognized based on future income tax consequences attributable to differences between the financial statement carrying amount of existing assets and liabilities, and their respective income tax basis. Deferred income tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of changes in income tax rates on deferred income tax assets and liabilities is recognized as income or expense in the period that a valuation allowance for any income tax benefits of which future realization is not more likely than not.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions. The tax benefits recorded are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filings or positions is &amp;#8220;more likely than not&amp;#8221; to be realized following resolution of any uncertainty related to the tax benefit, assuming that the matter in question will be raised by the tax authorities.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <kymr:OffBalanceSheetRiskAndConcentrationOfCreditRiskPolicyTextBlock id="F_000369" contextRef="C_0001815442_20200101_20201231">
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Off Balance Sheet Risk and Concentration of Credit Risk&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has no significant off-balance sheet risk such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, and restricted cash. The Company&amp;#8217;s cash, cash equivalents, and restricted cash are deposited in accounts at large financial institutions. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash, cash equivalents and restricted cash are held. The Company maintains its cash equivalents in money market funds that invest in U.S. Treasury securities and U.S. Treasury obligations and corporate bonds. The Company&amp;#8217;s marketable securities primarily consist of corporate bonds and U.S. Treasury securities paper, and potentially subject the Company to concentrations of credit risk. The Company has adopted an investment policy that limits the amounts the Company may invest in any one type of investment. The Company has not experienced any credit losses and does not believe it is exposed to any significant credit risk on these funds.&lt;/p&gt;</kymr:OffBalanceSheetRiskAndConcentrationOfCreditRiskPolicyTextBlock>
  <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock id="F_000370" contextRef="C_0001815442_20200101_20201231">
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Comprehensive Loss&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive loss includes net loss as well as unrealized gains on marketable securities and other changes in stockholders&amp;#8217; equity (deficit) that result from transactions and economic events other than those with stockholders.&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
  <us-gaap:EarningsPerSharePolicyTextBlock id="F_000371" contextRef="C_0001815442_20200101_20201231">
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Net Loss Per Share&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company applies the two-class method to compute basic and diluted net income (loss) per share attributable to common stockholders when it has issued shares that meet the definition of participating securities. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income (loss) available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to share in the earnings as if all income (loss) for the period had been distributed. The Company&amp;#8217;s convertible preferred stock participates in any dividends declared by the Company and are therefore considered to be participating securities. The participating securities are not required to participate in the losses of the Company, and therefore during periods of loss there is no allocation required under the two-class method.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net income (loss) per share attributable to common stockholders is computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) attributable to common stockholders is computed by adjusting net income (loss) per share attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period, including potential dilutive common shares. For purpose of this calculation, outstanding options to purchase common stock, unvested restricted stock awards, and shares of convertible preferred stock are considered potential dilutive common shares. The Company has generated a net loss in all periods presented, and therefore the basic and diluted net loss per share attributable to common stockholders are the same as the inclusion of the potentially dilutive securities would be anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <kymr:EmergingGrowthCompanyStatusPolicyTextBlock id="F_000372" contextRef="C_0001815442_20200101_20201231">
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Emerging Growth Company Status&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is an emerging growth company (&amp;#8220;EGC&amp;#8221;), as defined in the Jumpstart Our Business Startups Act (the &amp;#8220;JOBS Act&amp;#8221;), and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not EGCs. The Company may take advantage of these exemptions until it is no longer an EGC under Section&amp;#160;107 of the JOBS Act, which provides that an EGC can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to use this exemption to delay adopting new or revised.&lt;/p&gt;</kymr:EmergingGrowthCompanyStatusPolicyTextBlock>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock id="F_000373" contextRef="C_0001815442_20200101_20201231">
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Recent Accounting Pronouncements&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Recently Adopted Accounting Standards&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In April 2019, the FASB issued ASU 2019-04,&amp;#160;&lt;font style="font-style:italic;"&gt;Codification Improvements to Topic 326, Financial Instruments&amp;#8212;Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments&lt;/font&gt;. This update provides clarifications for three topics related to financial instruments accounting, some of which apply to the Company. The Company adopted as of January&amp;#160;1, 2020 and it did not have a significant impact on its financial position or results of operation&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2018, the FASB issued ASU 2018-15, &lt;font style="font-style:italic;"&gt;Customer&amp;#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract&lt;/font&gt;. The new standard will align the requirements for capitalizing implementation costs for hosting arrangements (services) with costs for internal-use software (assets). As a result, certain implementation costs incurred in hosting arrangements will be deferred and amortized. The Company adopted as of January&amp;#160;1, 2020 and it did not have a significant impact on its financial position or results of operation.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework&amp;#8212;Changes to the Disclosure Requirements for Fair Value Measurement. The new standard will be effective beginning January&amp;#160;1, 2020. The Company adopted as of January&amp;#160;1, 2020 and it did not have a significant impact on its financial position or results of operation.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Recently Issued Accounting Standards Not Yet Adopted&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, the FASB issued ASU 2019-12, &lt;font style="font-style:italic;"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/font&gt;, which is intended to simplify the accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. The new standard will be effective beginning January&amp;#160;1, 2021. The Company is currently evaluating the potential impact ASU 2019-12 may have on its financial position and results of operations upon adoption.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016, the FASB issued ASU 2016-13,&amp;#160;&lt;font style="font-style:italic;"&gt;Financial Instruments&amp;#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Statements&lt;/font&gt;. The new standard requires that expected credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. It also limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value increases. As an emerging growth company, the Company expects to delay adoption until January 1, 2023 and is evaluating the impact that the adoption of ASU 2016-13 will have on its consolidated financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <kymr:SummaryOfEstimatedUsefulLifeOfRelatedAssetTableTextBlock id="F_000374" contextRef="C_0001815442_20200101_20201231">Depreciation expense is recorded using the straight-line method over the estimated useful life of the related asset as follows:
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.86%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated Useful Life&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in years)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.86%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furnitures and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.86%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Office equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.86%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.86%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.86%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shorter of life of lease or remaining lease term&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</kymr:SummaryOfEstimatedUsefulLifeOfRelatedAssetTableTextBlock>
  <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock id="F_000375" contextRef="C_0001815442_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table presents information about the Company&amp;#8217;s financial assets measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values as of December 31,&amp;#160;2020 and December 31, 2019 (in thousands): &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.44%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market fund&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,943&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,943&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,499&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,499&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities, current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;US treasuries&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;192,275&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;192,275&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;72,923&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;72,923&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities, non-current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;US treasuries&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;132,589&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;132,589&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,942&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,942&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,589&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,589&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;346,396&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;113,364&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;459,760&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31, 2019:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,942&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,942&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,774&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,774&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,716&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,716&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
  <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock id="F_000376" contextRef="C_0001815442_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the available-for-sale debt securities held at December 31, 2020 and 2019 and (in thousands): &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Description&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. treasury securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;324,917&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(53&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;324,864&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;102,946&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(81&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;102,865&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;427,863&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(134&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;427,729&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.24%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Description&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.24%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.24%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. treasury securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,936&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,942&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.24%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,936&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,942&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
  <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock id="F_000377" contextRef="C_0001815442_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The &lt;font style="color:#000000;"&gt;following table presents the changes in accounts receivable, contract assets and liabilities for the year ended December 31,&amp;#160;2020 (in thousands)&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.26%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deductions&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.26%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accounts receivable and contract assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.26%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Billed receivables &amp;#8211; Sanofi&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;150,577&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(150,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;577&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.26%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unbilled receivables &amp;#8211; Sanofi&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,433&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(577&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;856&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.26%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total accounts receivable and contract assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;152,010&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(150,577&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,433&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.26%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contract Liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.26%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred Revenue &amp;#8211; Vertex&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;52,991&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(15,243&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,748&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.26%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred Revenue &amp;#8211; Sanofi&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;151,433&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(18,791&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;132,642&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.26%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total contract liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;52,991&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;151,433&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(34,034&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;170,390&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
  <us-gaap:PropertyPlantAndEquipmentTextBlock id="F_000378" contextRef="C_0001815442_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment consist of the following as of December&amp;#160;31, 2020 and 2019 (in thousands): &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lab and office equipment under and financing&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; right-of-use asset&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,771&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,751&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,636&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;919&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;89&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;71&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture &amp;amp; fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;861&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;104&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,599&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;545&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets not yet in service&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;453&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total property and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,988&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,843&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less accumulated depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,147&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,049&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,841&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,794&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:LeaseCostTableTextBlock id="F_000379" contextRef="C_0001815442_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The components of the lease costs for the years ended December 31, 2020 and 2019 (in thousands): &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.9%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.86%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease costs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,719&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,597&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.86%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financing lease costs:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.86%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization of right-to-use assets, financing&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; leases&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;716&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;385&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.86%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest expense for financing lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;121&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Variable lease costs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;621&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;340&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.86%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total lease costs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,177&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,368&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:LeaseCostTableTextBlock>
  <kymr:SupplementalCashFlowInformationRelatingToLeasesTableTextBlock id="F_000380" contextRef="C_0001815442_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Supplemental cash flow information relating to the Company&amp;#8217;s leases for the years ended December 31, 2020 and 2019 was as follows (in thousands): &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash paid for amounts included in the measurement&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; of lease liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating cash flows used in (provided by)&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; operating leases&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,024&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;635&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating cash flows used in finance leases&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;587&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financing cash flows used in finance leases&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;121&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;385&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</kymr:SupplementalCashFlowInformationRelatingToLeasesTableTextBlock>
  <kymr:SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock id="F_000381" contextRef="C_0001815442_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average remaining lease terms and discount rates as of December 31, 2020 and 2019 were as follows: &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining lease term:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financing lease&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.8 Years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.7 Years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Discount Rate:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financing lease&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</kymr:SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock>
  <kymr:LesseeOperatingAndFinancingLeaseLiabilityMaturityTableTextBlock id="F_000382" contextRef="C_0001815442_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The undiscounted future lease payments for operating and finance leases as of December&amp;#160;31, 2020, were as follows (in thousands): &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="text-decoration:underline;"&gt;Fiscal Year&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financing&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,691&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;712&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,581&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;459&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,659&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;245&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,732&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,814&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,925&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total minimum lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26,402&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,416&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less amounts representing interest or imputed interest&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9,702&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(123&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Present value of lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,700&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,293&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</kymr:LesseeOperatingAndFinancingLeaseLiabilityMaturityTableTextBlock>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock id="F_000383" contextRef="C_0001815442_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses consist of the following as of December 31, 2020 and 2019 (in thousands): &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,821&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,617&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Payroll and payroll-related&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,918&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,256&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Professional fees&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,585&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;606&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;89&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,330&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,568&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock id="F_000384" contextRef="C_0001815442_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of stock option activity under the 2020 Stock Option and Grant Plan during the year ended December 31, 2020 is as follows (in thousands except share and per share data): &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Strike&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price per&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Option&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,945,297&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.03&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.93&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,798&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,213,204&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.22&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(78,852&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.06&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(246,937&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.55&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,832,712&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.17&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.08&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;314,001&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,580,924&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.38&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.76&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;92,674&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock id="F_000385" contextRef="C_0001815442_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table outlines our equity-based compensation expense for stock options for the years ended December 31, 2020 and 2019:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.5%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="8" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.72%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ending December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.5%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,084&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;380&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.5%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,864&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;212&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.5%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total equity-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,948&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;592&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock id="F_000386" contextRef="C_0001815442_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The weighted-average assumptions that the Company used in Black-Scholes option pricing model to determine the grant date fair value of stock options granted to employees and non-employees for the years ended December 31, 2020 and 2019: &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="8" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.32%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ending December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.3%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.09&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.49&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;71&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.83&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock id="F_000387" contextRef="C_0001815442_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has granted shares of restricted common stock with service-based and performance-based vesting conditions. A summary of restricted stock activity under the 2018 Plan during the year ended December 31, 2020 is as follows: &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Units&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant Date&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;per Share&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;232,434&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.60&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(102,651&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.60&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19,679&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.60&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;110,104&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.60&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock id="F_000388" contextRef="C_0001815442_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total equity-based compensation expense recorded as research and development and general and administrative expenses for employees, directors, and non-employees during the years ended December 31, 2020 and 2019 is as follows (in thousands): &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="8" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ending December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,305&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;688&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,885&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;508&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total equity-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,190&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,196&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock id="F_000389" contextRef="C_0001815442_20200101_20201231">
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.53%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The rate reconciliation of the U.S. statutory income tax rate to the Company&amp;#8217;s effective tax rate for the years ended December&amp;#160;31, 2020 and 2019 are as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax effect at statutory rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State taxes&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.9&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal research and development credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(28.8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(29.4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock id="F_000390" contextRef="C_0001815442_20200101_20201231">Significant components of the Company&amp;#8217;s net deferred income taxes are as&amp;#160;follows (in thousands):
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160; &lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Deferred Tax Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,621&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,011&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,866&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,319&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development credit carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,757&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,637&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,563&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,286&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,313&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accruals and reserves, stock and other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,589&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;525&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,709&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26,778&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(34,075&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(20,949&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,634&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,829&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fixed and intangible assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,506&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(754&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,128&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,075&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax asset&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock id="F_000391" contextRef="C_0001815442_20200101_20201231">
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic and diluted loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding (in thousands, except for share and per share data):&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.46%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="8" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.76%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(45,593&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(41,246&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.46%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deemed dividend from exchange of convertible&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9,050&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.46%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss attributable to common stockholders&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(54,643&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(41,246&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average common shares outstanding, basic&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,349,582&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,698,522&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.46%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3.15&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(24.28&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock id="F_000392" contextRef="C_0001815442_20200101_20201231">The Company excluded the following from the computation of diluted net loss per share attributable to common stockholders at December&amp;#160;31, 2020 and 2019 because including them would have had an anti-dilutive effect:
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.9%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="8" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.48%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.9%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Convertible Preferred Stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,325,780&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested Restricted Stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;110,104&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;232,434&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.9%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options to purchase Common Stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,580,924&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,945,298&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.9%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,691,028&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,503,512&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:InvestmentsAndCash id="F_000393" contextRef="C_0001815442_20201231" decimals="-5" unitRef="U_iso4217USD">458700000</us-gaap:InvestmentsAndCash>
  <us-gaap:StockholdersEquityReverseStockSplit id="F_000394" contextRef="C_0001815442_20200101_20201231">On August 20, 2020, the Board approved a 1-for-1.5949 reverse stock split of the Company&#8217;s issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for each of the Company&#8217;s outstanding series of preferred stock.  All share and per share amounts in the accompanying consolidated financial statements and notes thereto have been retroactively adjusted for all periods presented to give effect to this reverse stock split, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital.</us-gaap:StockholdersEquityReverseStockSplit>
  <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 id="F_000395" contextRef="C_0001815442_20200820_20200820" decimals="4" unitRef="U_xbrlipure">1.5949</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000396" contextRef="C_0001815442_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200825_20200825" decimals="INF" unitRef="U_xbrlishares">9987520</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000397" contextRef="C_0001815442_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20200825_20200825" decimals="INF" unitRef="U_xbrlishares">1302720</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:SaleOfStockPricePerShare id="F_000398" contextRef="C_0001815442_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200825" decimals="INF" unitRef="U_iso4217USD_xbrlishares">20.00</us-gaap:SaleOfStockPricePerShare>
  <kymr:ProceedsFromIssuanceInitialPublicOfferingGross id="F_000399" contextRef="C_0001815442_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200825_20200825" decimals="-5" unitRef="U_iso4217USD">199800000</kymr:ProceedsFromIssuanceInitialPublicOfferingGross>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000400" contextRef="C_0001815442_srtConsolidatedEntitiesAxis_kymrVertexPharmaceuticalsIncorporatedMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20200825_20200825" decimals="INF" unitRef="U_xbrlishares">676354</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:SaleOfStockPricePerShare id="F_000401" contextRef="C_0001815442_srtConsolidatedEntitiesAxis_kymrVertexPharmaceuticalsIncorporatedMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20200825" decimals="INF" unitRef="U_iso4217USD_xbrlishares">20.00</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:NumberOfOperatingSegments id="F_000402" contextRef="C_0001815442_20200101_20201231" decimals="INF" unitRef="U_kymrSegment">1</us-gaap:NumberOfOperatingSegments>
  <kymr:MarketableSecuritiesRemainingMaturityPeriod id="F_000403" contextRef="C_0001815442_srtRangeAxis_srtMinimumMember_20200101_20201231">P3M</kymr:MarketableSecuritiesRemainingMaturityPeriod>
  <kymr:MarketableSecuritiesRemainingMaturityPeriodClassifiedAsNonCurrent id="F_000404" contextRef="C_0001815442_srtRangeAxis_srtMinimumMember_20200101_20201231">P1Y</kymr:MarketableSecuritiesRemainingMaturityPeriodClassifiedAsNonCurrent>
  <us-gaap:LesseeOperatingLeaseTermOfContract id="F_000405" contextRef="C_0001815442_20201231">P1Y</us-gaap:LesseeOperatingLeaseTermOfContract>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000406" contextRef="C_0001815442_us-gaapPropertyPlantAndEquipmentByTypeAxis_kymrLabEquipmentMember_20200101_20201231">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000407" contextRef="C_0001815442_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20200101_20201231">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000408" contextRef="C_0001815442_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20200101_20201231">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000409" contextRef="C_0001815442_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20200101_20201231">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives id="F_000410" contextRef="C_0001815442_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20200101_20201231">Shorter of life of lease or remaining lease term</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
  <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf id="F_000411" contextRef="C_0001815442_20200101_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
  <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf id="F_000412" contextRef="C_0001815442_20190101_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
  <us-gaap:DeferredOfferingCosts id="F_000413" contextRef="C_0001815442_20201231" decimals="-5" unitRef="U_iso4217USD">400000</us-gaap:DeferredOfferingCosts>
  <us-gaap:DeferredOfferingCosts id="F_000414" contextRef="C_0001815442_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:DeferredOfferingCosts>
  <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted id="F_000415" contextRef="C_0001815442_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201904Member_20201231">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
  <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted id="F_000416" contextRef="C_0001815442_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201815Member_20201231">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
  <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted id="F_000417" contextRef="C_0001815442_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201813Member_20201231">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
  <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate id="F_000418" contextRef="C_0001815442_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201904Member_20201231">2020-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
  <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate id="F_000419" contextRef="C_0001815442_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201815Member_20201231">2020-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
  <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate id="F_000420" contextRef="C_0001815442_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201813Member_20201231">2020-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
  <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect id="F_000421" contextRef="C_0001815442_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201904Member_20201231">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
  <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect id="F_000422" contextRef="C_0001815442_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201815Member_20201231">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
  <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect id="F_000423" contextRef="C_0001815442_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201813Member_20201231">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000424" contextRef="C_0001815442_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231" decimals="-3" unitRef="U_iso4217USD">19943000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000425" contextRef="C_0001815442_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231" decimals="-3" unitRef="U_iso4217USD">19943000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000426" contextRef="C_0001815442_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20201231" decimals="-3" unitRef="U_iso4217USD">10499000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000427" contextRef="C_0001815442_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20201231" decimals="-3" unitRef="U_iso4217USD">10499000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:AvailableForSaleSecuritiesCurrent id="F_000428" contextRef="C_0001815442_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20201231" decimals="-3" unitRef="U_iso4217USD">192275000</us-gaap:AvailableForSaleSecuritiesCurrent>
  <us-gaap:AvailableForSaleSecuritiesCurrent id="F_000429" contextRef="C_0001815442_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20201231" decimals="-3" unitRef="U_iso4217USD">192275000</us-gaap:AvailableForSaleSecuritiesCurrent>
  <us-gaap:AvailableForSaleSecuritiesCurrent id="F_000430" contextRef="C_0001815442_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20201231" decimals="-3" unitRef="U_iso4217USD">72923000</us-gaap:AvailableForSaleSecuritiesCurrent>
  <us-gaap:AvailableForSaleSecuritiesCurrent id="F_000431" contextRef="C_0001815442_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20201231" decimals="-3" unitRef="U_iso4217USD">72923000</us-gaap:AvailableForSaleSecuritiesCurrent>
  <us-gaap:AvailableForSaleSecuritiesNoncurrent id="F_000432" contextRef="C_0001815442_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20201231" decimals="-3" unitRef="U_iso4217USD">132589000</us-gaap:AvailableForSaleSecuritiesNoncurrent>
  <us-gaap:AvailableForSaleSecuritiesNoncurrent id="F_000433" contextRef="C_0001815442_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20201231" decimals="-3" unitRef="U_iso4217USD">132589000</us-gaap:AvailableForSaleSecuritiesNoncurrent>
  <us-gaap:AvailableForSaleSecuritiesNoncurrent id="F_000434" contextRef="C_0001815442_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20201231" decimals="-3" unitRef="U_iso4217USD">29942000</us-gaap:AvailableForSaleSecuritiesNoncurrent>
  <us-gaap:AvailableForSaleSecuritiesNoncurrent id="F_000435" contextRef="C_0001815442_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20201231" decimals="-3" unitRef="U_iso4217USD">29942000</us-gaap:AvailableForSaleSecuritiesNoncurrent>
  <kymr:RestrictedCashFairValue id="F_000436" contextRef="C_0001815442_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" unitRef="U_iso4217USD">1589000</kymr:RestrictedCashFairValue>
  <kymr:RestrictedCashFairValue id="F_000437" contextRef="C_0001815442_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" unitRef="U_iso4217USD">1589000</kymr:RestrictedCashFairValue>
  <us-gaap:AssetsFairValueDisclosure id="F_000438" contextRef="C_0001815442_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" unitRef="U_iso4217USD">346396000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000439" contextRef="C_0001815442_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" unitRef="U_iso4217USD">113364000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000440" contextRef="C_0001815442_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" unitRef="U_iso4217USD">459760000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000441" contextRef="C_0001815442_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">15942000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000442" contextRef="C_0001815442_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">15942000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <kymr:RestrictedCashFairValue id="F_000443" contextRef="C_0001815442_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">1774000</kymr:RestrictedCashFairValue>
  <kymr:RestrictedCashFairValue id="F_000444" contextRef="C_0001815442_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">1774000</kymr:RestrictedCashFairValue>
  <us-gaap:AssetsFairValueDisclosure id="F_000445" contextRef="C_0001815442_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">17716000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000446" contextRef="C_0001815442_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">17716000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount id="F_000447" contextRef="C_0001815442_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
  <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount id="F_000448" contextRef="C_0001815442_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
  <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount id="F_000449" contextRef="C_0001815442_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
  <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount id="F_000450" contextRef="C_0001815442_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
  <kymr:FairValueAssetsLevel1ToLevel3TransfersAmount id="F_000451" contextRef="C_0001815442_20201231" decimals="INF" unitRef="U_iso4217USD">0</kymr:FairValueAssetsLevel1ToLevel3TransfersAmount>
  <kymr:FairValueAssetsLevel1ToLevel3TransfersAmount id="F_000452" contextRef="C_0001815442_20191231" decimals="INF" unitRef="U_iso4217USD">0</kymr:FairValueAssetsLevel1ToLevel3TransfersAmount>
  <kymr:FairValueAssetsLevel3ToLevel1TransfersAmount id="F_000453" contextRef="C_0001815442_20201231" decimals="INF" unitRef="U_iso4217USD">0</kymr:FairValueAssetsLevel3ToLevel1TransfersAmount>
  <kymr:FairValueAssetsLevel3ToLevel1TransfersAmount id="F_000454" contextRef="C_0001815442_20191231" decimals="INF" unitRef="U_iso4217USD">0</kymr:FairValueAssetsLevel3ToLevel1TransfersAmount>
  <kymr:FairValueAssetsLevel3ToLevel2TransfersAmount id="F_000455" contextRef="C_0001815442_20201231" decimals="INF" unitRef="U_iso4217USD">0</kymr:FairValueAssetsLevel3ToLevel2TransfersAmount>
  <kymr:FairValueAssetsLevel3ToLevel2TransfersAmount id="F_000456" contextRef="C_0001815442_20191231" decimals="INF" unitRef="U_iso4217USD">0</kymr:FairValueAssetsLevel3ToLevel2TransfersAmount>
  <kymr:FairValueAssetsLevel2ToLevel3TransfersAmount id="F_000457" contextRef="C_0001815442_20201231" decimals="INF" unitRef="U_iso4217USD">0</kymr:FairValueAssetsLevel2ToLevel3TransfersAmount>
  <kymr:FairValueAssetsLevel2ToLevel3TransfersAmount id="F_000458" contextRef="C_0001815442_20191231" decimals="INF" unitRef="U_iso4217USD">0</kymr:FairValueAssetsLevel2ToLevel3TransfersAmount>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000459" contextRef="C_0001815442_us-gaapFinancialInstrumentAxis_us-gaapUSTreasurySecuritiesMember_20201231" decimals="-3" unitRef="U_iso4217USD">324917000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000460" contextRef="C_0001815442_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231" decimals="-3" unitRef="U_iso4217USD">102946000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000461" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">427863000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax id="F_000462" contextRef="C_0001815442_us-gaapFinancialInstrumentAxis_us-gaapUSTreasurySecuritiesMember_20201231" decimals="-3" unitRef="U_iso4217USD">53000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax id="F_000463" contextRef="C_0001815442_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231" decimals="-3" unitRef="U_iso4217USD">81000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax id="F_000464" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">134000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000465" contextRef="C_0001815442_us-gaapFinancialInstrumentAxis_us-gaapUSTreasurySecuritiesMember_20201231" decimals="-3" unitRef="U_iso4217USD">324864000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000466" contextRef="C_0001815442_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231" decimals="-3" unitRef="U_iso4217USD">102865000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000467" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">427729000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000468" contextRef="C_0001815442_us-gaapFinancialInstrumentAxis_us-gaapUSTreasurySecuritiesMember_20191231" decimals="-3" unitRef="U_iso4217USD">15936000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000469" contextRef="C_0001815442_20191231" decimals="-3" unitRef="U_iso4217USD">15936000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax id="F_000470" contextRef="C_0001815442_us-gaapFinancialInstrumentAxis_us-gaapUSTreasurySecuritiesMember_20191231" decimals="-3" unitRef="U_iso4217USD">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax id="F_000471" contextRef="C_0001815442_20191231" decimals="-3" unitRef="U_iso4217USD">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000472" contextRef="C_0001815442_us-gaapFinancialInstrumentAxis_us-gaapUSTreasurySecuritiesMember_20191231" decimals="-3" unitRef="U_iso4217USD">15942000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000473" contextRef="C_0001815442_20191231" decimals="-3" unitRef="U_iso4217USD">15942000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions id="F_000474" contextRef="C_0001815442_20191231" decimals="INF" unitRef="U_kymrSecurity">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
  <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions id="F_000475" contextRef="C_0001815442_20201231" decimals="INF" unitRef="U_kymrSecurity">65</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
  <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months id="F_000476" contextRef="C_0001815442_20201231" decimals="-5" unitRef="U_iso4217USD">392200000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
  <kymr:DebtSecuritiesAvailableForSaleContractualMaturityOfLessThan12MonthsNumberOfSecurities id="F_000477" contextRef="C_0001815442_20200101_20201231" decimals="INF" unitRef="U_kymrSecurity">48</kymr:DebtSecuritiesAvailableForSaleContractualMaturityOfLessThan12MonthsNumberOfSecurities>
  <kymr:FairValueOfAvailableForSaleDebtSecuritiesContractualMaturityOfLessThanTwelveMonths id="F_000478" contextRef="C_0001815442_20201231" decimals="-5" unitRef="U_iso4217USD">295600000</kymr:FairValueOfAvailableForSaleDebtSecuritiesContractualMaturityOfLessThanTwelveMonths>
  <kymr:DebtSecuritiesAvailableForSaleContractualMaturityOf12MonthsOrLongerNumberOfSecurities id="F_000479" contextRef="C_0001815442_20200101_20201231" decimals="INF" unitRef="U_kymrSecurity">25</kymr:DebtSecuritiesAvailableForSaleContractualMaturityOf12MonthsOrLongerNumberOfSecurities>
  <kymr:NumberOfMarketableSecuritiesSold id="F_000480" contextRef="C_0001815442_20200101_20201231" decimals="INF" unitRef="U_kymrSecurity">1</kymr:NumberOfMarketableSecuritiesSold>
  <us-gaap:AvailableforsaleSecuritiesSoldAtPar id="F_000481" contextRef="C_0001815442_20190101_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:AvailableforsaleSecuritiesSoldAtPar>
  <kymr:DebtSecuritiesAvailableForSaleDeclineInMarketValueForUnrealizedLossPositionNumberOfSecurities id="F_000482" contextRef="C_0001815442_20200101_20201231" decimals="INF" unitRef="U_kymrSecurity">65</kymr:DebtSecuritiesAvailableForSaleDeclineInMarketValueForUnrealizedLossPositionNumberOfSecurities>
  <kymr:UpfrontPayment id="F_000483" contextRef="C_0001815442_us-gaapTypeOfArrangementAxis_kymrSanofiCollaborationArrangementMember_20200707_20200707" decimals="-5" unitRef="U_iso4217USD">150000000</kymr:UpfrontPayment>
  <kymr:DevelopmentMilestonePayments id="F_000484" contextRef="C_0001815442_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_kymrSanofiCollaborationArrangementMember_20200707_20200707" decimals="-7" unitRef="U_iso4217USD">1480000000</kymr:DevelopmentMilestonePayments>
  <kymr:DevelopmentMilestonePayments id="F_000485" contextRef="C_0001815442_srtRangeAxis_srtMinimumMember_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_kymrIRAK4Member_us-gaapTypeOfArrangementAxis_kymrSanofiCollaborationArrangementMember_20200707_20200707" decimals="-8" unitRef="U_iso4217USD">1000000000</kymr:DevelopmentMilestonePayments>
  <kymr:CommercialMilestonePayments id="F_000486" contextRef="C_0001815442_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_kymrSanofiCollaborationArrangementMember_20200707_20200707" decimals="-5" unitRef="U_iso4217USD">700000000</kymr:CommercialMilestonePayments>
  <kymr:CommercialMilestonePayments id="F_000487" contextRef="C_0001815442_srtRangeAxis_srtMinimumMember_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_kymrIRAK4Member_us-gaapTypeOfArrangementAxis_kymrSanofiCollaborationArrangementMember_20200707_20200707" decimals="-6" unitRef="U_iso4217USD">400000000</kymr:CommercialMilestonePayments>
  <kymr:CollaborationAgreementTransactionPrice id="F_000488" contextRef="C_0001815442_us-gaapTypeOfArrangementAxis_kymrSanofiCollaborationArrangementMember_20200707_20200707" decimals="-5" unitRef="U_iso4217USD">150000000</kymr:CollaborationAgreementTransactionPrice>
  <kymr:CollaborationAgreementTransactionPrice id="F_000489" contextRef="C_0001815442_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_kymrCollaborationTargetOneMember_us-gaapTypeOfArrangementAxis_kymrSanofiCollaborationArrangementMember_20200707_20200707" decimals="-5" unitRef="U_iso4217USD">120000000</kymr:CollaborationAgreementTransactionPrice>
  <kymr:CollaborationAgreementTransactionPrice id="F_000490" contextRef="C_0001815442_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_kymrCollaborationTargetTwoMember_us-gaapTypeOfArrangementAxis_kymrSanofiCollaborationArrangementMember_20200707_20200707" decimals="-5" unitRef="U_iso4217USD">30000000</kymr:CollaborationAgreementTransactionPrice>
  <us-gaap:ContractWithCustomerLiabilityRevenueRecognized id="F_000491" contextRef="C_0001815442_us-gaapTypeOfArrangementAxis_kymrSanofiCollaborationArrangementMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">18800000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
  <us-gaap:ContractWithCustomerLiabilityRevenueRecognized id="F_000492" contextRef="C_0001815442_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_kymrCollaborationTargetOneMember_us-gaapTypeOfArrangementAxis_kymrSanofiCollaborationArrangementMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">16700000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
  <us-gaap:ContractWithCustomerLiabilityRevenueRecognized id="F_000493" contextRef="C_0001815442_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_kymrCollaborationTargetTwoMember_us-gaapTypeOfArrangementAxis_kymrSanofiCollaborationArrangementMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">2100000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
  <us-gaap:RevenueRemainingPerformanceObligation id="F_000494" contextRef="C_0001815442_us-gaapTypeOfArrangementAxis_kymrSanofiCollaborationArrangementMember_20201231" decimals="-5" unitRef="U_iso4217USD">132600000</us-gaap:RevenueRemainingPerformanceObligation>
  <kymr:CostReimbursementReceivable id="F_000495" contextRef="C_0001815442_us-gaapTypeOfArrangementAxis_kymrSanofiCollaborationArrangementMember_20201231" decimals="INF" unitRef="U_iso4217USD">0</kymr:CostReimbursementReceivable>
  <kymr:MilestoneReceivable id="F_000496" contextRef="C_0001815442_us-gaapTypeOfArrangementAxis_kymrSanofiCollaborationArrangementMember_20201231" decimals="INF" unitRef="U_iso4217USD">0</kymr:MilestoneReceivable>
  <kymr:RoyaltyReceivable id="F_000497" contextRef="C_0001815442_us-gaapTypeOfArrangementAxis_kymrSanofiCollaborationArrangementMember_20201231" decimals="INF" unitRef="U_iso4217USD">0</kymr:RoyaltyReceivable>
  <us-gaap:UnbilledContractsReceivable id="F_000498" contextRef="C_0001815442_us-gaapTypeOfArrangementAxis_kymrSanofiCollaborationArrangementMember_20201231" decimals="-5" unitRef="U_iso4217USD">900000</us-gaap:UnbilledContractsReceivable>
  <us-gaap:BilledContractReceivables id="F_000499" contextRef="C_0001815442_us-gaapTypeOfArrangementAxis_kymrSanofiCollaborationArrangementMember_20201231" decimals="-5" unitRef="U_iso4217USD">600000</us-gaap:BilledContractReceivables>
  <kymr:RemainingResearchTermOfCollaboration id="F_000500" contextRef="C_0001815442_us-gaapTypeOfArrangementAxis_kymrSanofiCollaborationArrangementMember_20200101_20201231">P3Y</kymr:RemainingResearchTermOfCollaboration>
  <kymr:InitialResearchTermOfCollaboration id="F_000501" contextRef="C_0001815442_us-gaapTypeOfArrangementAxis_kymrVertexAgreementMember_20190509_20190509">P4Y</kymr:InitialResearchTermOfCollaboration>
  <kymr:ExtendedResearchTermOfCollaboration id="F_000502" contextRef="C_0001815442_us-gaapTypeOfArrangementAxis_kymrVertexAgreementMember_20190509_20190509">P1Y</kymr:ExtendedResearchTermOfCollaboration>
  <kymr:NonRefundableUpfrontPaymentReceived id="F_000503" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesB1ConvertiblePreferredStockMember_us-gaapTypeOfArrangementAxis_kymrVertexAgreementMember_20190509_20190509" decimals="-5" unitRef="U_iso4217USD">50000000</kymr:NonRefundableUpfrontPaymentReceived>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000504" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesB1ConvertiblePreferredStockMember_us-gaapTypeOfArrangementAxis_kymrVertexAgreementMember_20190509_20190509" decimals="INF" unitRef="U_xbrlishares">3059695</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:SaleOfStockPricePerShare id="F_000505" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesB1ConvertiblePreferredStockMember_us-gaapTypeOfArrangementAxis_kymrVertexAgreementMember_20190509" decimals="2" unitRef="U_iso4217USD_xbrlishares">6.54</us-gaap:SaleOfStockPricePerShare>
  <kymr:PreferredStockIssuancePremium id="F_000506" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesB1ConvertiblePreferredStockMember_us-gaapTypeOfArrangementAxis_kymrVertexAgreementMember_20190509_20190509" decimals="-5" unitRef="U_iso4217USD">5900000</kymr:PreferredStockIssuancePremium>
  <kymr:PotentialReceivableMilestonePayments id="F_000507" contextRef="C_0001815442_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_kymrVertexAgreementMember_20190509" decimals="-5" unitRef="U_iso4217USD">170000000</kymr:PotentialReceivableMilestonePayments>
  <kymr:CollaborationAgreementTransactionPrice id="F_000508" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesB1ConvertiblePreferredStockMember_us-gaapTypeOfArrangementAxis_kymrVertexAgreementMember_20190509_20190509" decimals="-5" unitRef="U_iso4217USD">55900000</kymr:CollaborationAgreementTransactionPrice>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="F_000509" contextRef="C_0001815442_us-gaapTypeOfArrangementAxis_kymrVertexAgreementMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">15200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="F_000510" contextRef="C_0001815442_us-gaapTypeOfArrangementAxis_kymrVertexAgreementMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">2900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:ContractWithCustomerLiabilityRevenueRecognized id="F_000511" contextRef="C_0001815442_us-gaapTypeOfArrangementAxis_kymrVertexAgreementMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">15200000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
  <us-gaap:RevenueRemainingPerformanceObligation id="F_000512" contextRef="C_0001815442_us-gaapTypeOfArrangementAxis_kymrVertexAgreementMember_20201231" decimals="-5" unitRef="U_iso4217USD">37700000</us-gaap:RevenueRemainingPerformanceObligation>
  <us-gaap:RevenueRemainingPerformanceObligation id="F_000513" contextRef="C_0001815442_us-gaapTypeOfArrangementAxis_kymrVertexAgreementMember_20191231" decimals="-5" unitRef="U_iso4217USD">53000000</us-gaap:RevenueRemainingPerformanceObligation>
  <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 id="F_000514" contextRef="C_0001815442_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_kymrVertexAgreementMember_20201231">P2Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000515" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesAPreferredUnitsMember_us-gaapTypeOfArrangementAxis_kymrCompoundCollaborationAgreementMember_20171031_20171031" decimals="INF" unitRef="U_xbrlishares">886305</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 id="F_000516" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesAPreferredUnitsMember_us-gaapTypeOfArrangementAxis_kymrCompoundCollaborationAgreementMember_20181101_20181101" decimals="0" unitRef="U_xbrlipure">100</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="F_000517" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesAPreferredUnitsMember_us-gaapTypeOfArrangementAxis_kymrCompoundCollaborationAgreementMember_20181101_20181101">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000518" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesAPreferredUnitsMember_us-gaapTypeOfArrangementAxis_kymrCompoundCollaborationAgreementMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">300000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000519" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesAPreferredUnitsMember_us-gaapTypeOfArrangementAxis_kymrCompoundCollaborationAgreementMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">400000</us-gaap:ResearchAndDevelopmentExpense>
  <kymr:TemporaryEquityStockSharesVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement id="F_000520" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesAPreferredUnitsMember_us-gaapTypeOfArrangementAxis_kymrCompoundCollaborationAgreementMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">166183</kymr:TemporaryEquityStockSharesVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement>
  <kymr:TemporaryEquityStockSharesVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement id="F_000521" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesAPreferredUnitsMember_us-gaapTypeOfArrangementAxis_kymrCompoundCollaborationAgreementMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">221579</kymr:TemporaryEquityStockSharesVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement>
  <kymr:WrittenNoticePeriodToTerminateCollaborationAgreement id="F_000522" contextRef="C_0001815442_us-gaapTypeOfArrangementAxis_kymrCompoundCollaborationAgreementMember_20200101_20201231">P60D</kymr:WrittenNoticePeriodToTerminateCollaborationAgreement>
  <kymr:ContractWithCustomerAssetNetAdditions id="F_000523" contextRef="C_0001815442_us-gaapBalanceSheetLocationAxis_kymrBilledReceivablesSanofiMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">150577000</kymr:ContractWithCustomerAssetNetAdditions>
  <kymr:ContractWithCustomerAssetNetAdditions id="F_000524" contextRef="C_0001815442_us-gaapBalanceSheetLocationAxis_kymrUnbilledReceivablesSanofiMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">1433000</kymr:ContractWithCustomerAssetNetAdditions>
  <kymr:ContractWithCustomerAssetNetAdditions id="F_000525" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">152010000</kymr:ContractWithCustomerAssetNetAdditions>
  <kymr:ContractWithCustomerAssetNetDeductions id="F_000526" contextRef="C_0001815442_us-gaapBalanceSheetLocationAxis_kymrBilledReceivablesSanofiMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-150000000</kymr:ContractWithCustomerAssetNetDeductions>
  <kymr:ContractWithCustomerAssetNetDeductions id="F_000527" contextRef="C_0001815442_us-gaapBalanceSheetLocationAxis_kymrUnbilledReceivablesSanofiMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-577000</kymr:ContractWithCustomerAssetNetDeductions>
  <kymr:ContractWithCustomerAssetNetDeductions id="F_000528" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-150577000</kymr:ContractWithCustomerAssetNetDeductions>
  <us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLoss id="F_000529" contextRef="C_0001815442_us-gaapBalanceSheetLocationAxis_kymrBilledReceivablesSanofiMember_20201231" decimals="-3" unitRef="U_iso4217USD">577000</us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLoss>
  <us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLoss id="F_000530" contextRef="C_0001815442_us-gaapBalanceSheetLocationAxis_kymrUnbilledReceivablesSanofiMember_20201231" decimals="-3" unitRef="U_iso4217USD">856000</us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLoss>
  <us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLoss id="F_000531" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">1433000</us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLoss>
  <us-gaap:ContractWithCustomerLiability id="F_000532" contextRef="C_0001815442_us-gaapBalanceSheetLocationAxis_kymrDeferredRevenueVertexMember_20191231" decimals="-3" unitRef="U_iso4217USD">52991000</us-gaap:ContractWithCustomerLiability>
  <us-gaap:ContractWithCustomerLiability id="F_000533" contextRef="C_0001815442_20191231" decimals="-3" unitRef="U_iso4217USD">52991000</us-gaap:ContractWithCustomerLiability>
  <kymr:ContractWithCustomerLiabilityAdditions id="F_000534" contextRef="C_0001815442_us-gaapBalanceSheetLocationAxis_kymrDeferredRevenueSanofiMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">151433000</kymr:ContractWithCustomerLiabilityAdditions>
  <kymr:ContractWithCustomerLiabilityAdditions id="F_000535" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">151433000</kymr:ContractWithCustomerLiabilityAdditions>
  <kymr:ContractWithCustomerLiabilityDeductions id="F_000536" contextRef="C_0001815442_us-gaapBalanceSheetLocationAxis_kymrDeferredRevenueVertexMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-15243000</kymr:ContractWithCustomerLiabilityDeductions>
  <kymr:ContractWithCustomerLiabilityDeductions id="F_000537" contextRef="C_0001815442_us-gaapBalanceSheetLocationAxis_kymrDeferredRevenueSanofiMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-18791000</kymr:ContractWithCustomerLiabilityDeductions>
  <kymr:ContractWithCustomerLiabilityDeductions id="F_000538" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-34034000</kymr:ContractWithCustomerLiabilityDeductions>
  <us-gaap:ContractWithCustomerLiability id="F_000539" contextRef="C_0001815442_us-gaapBalanceSheetLocationAxis_kymrDeferredRevenueVertexMember_20201231" decimals="-3" unitRef="U_iso4217USD">37748000</us-gaap:ContractWithCustomerLiability>
  <us-gaap:ContractWithCustomerLiability id="F_000540" contextRef="C_0001815442_us-gaapBalanceSheetLocationAxis_kymrDeferredRevenueSanofiMember_20201231" decimals="-3" unitRef="U_iso4217USD">132642000</us-gaap:ContractWithCustomerLiability>
  <us-gaap:ContractWithCustomerLiability id="F_000541" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">170390000</us-gaap:ContractWithCustomerLiability>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000542" contextRef="C_0001815442_us-gaapPropertyPlantAndEquipmentByTypeAxis_kymrLabAndOfficeEquipmentMember_20201231" decimals="-3" unitRef="U_iso4217USD">2771000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000543" contextRef="C_0001815442_us-gaapPropertyPlantAndEquipmentByTypeAxis_kymrLabAndOfficeEquipmentMember_20191231" decimals="-3" unitRef="U_iso4217USD">2751000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000544" contextRef="C_0001815442_us-gaapPropertyPlantAndEquipmentByTypeAxis_kymrLabEquipmentMember_20201231" decimals="-3" unitRef="U_iso4217USD">1636000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000545" contextRef="C_0001815442_us-gaapPropertyPlantAndEquipmentByTypeAxis_kymrLabEquipmentMember_20191231" decimals="-3" unitRef="U_iso4217USD">919000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000546" contextRef="C_0001815442_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20201231" decimals="-3" unitRef="U_iso4217USD">89000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000547" contextRef="C_0001815442_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20191231" decimals="-3" unitRef="U_iso4217USD">71000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000548" contextRef="C_0001815442_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231" decimals="-3" unitRef="U_iso4217USD">861000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000549" contextRef="C_0001815442_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20191231" decimals="-3" unitRef="U_iso4217USD">104000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000550" contextRef="C_0001815442_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231" decimals="-3" unitRef="U_iso4217USD">7599000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000551" contextRef="C_0001815442_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231" decimals="-3" unitRef="U_iso4217USD">545000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000552" contextRef="C_0001815442_us-gaapPropertyPlantAndEquipmentByTypeAxis_kymrAssetsNotYetInServiceMember_20201231" decimals="-3" unitRef="U_iso4217USD">32000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000553" contextRef="C_0001815442_us-gaapPropertyPlantAndEquipmentByTypeAxis_kymrAssetsNotYetInServiceMember_20191231" decimals="-3" unitRef="U_iso4217USD">453000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000554" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">12988000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000555" contextRef="C_0001815442_20191231" decimals="-3" unitRef="U_iso4217USD">4843000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="F_000556" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">2147000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="F_000557" contextRef="C_0001815442_20191231" decimals="-3" unitRef="U_iso4217USD">1049000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:Depreciation id="F_000558" contextRef="C_0001815442_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">1800000</us-gaap:Depreciation>
  <us-gaap:Depreciation id="F_000559" contextRef="C_0001815442_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">900000</us-gaap:Depreciation>
  <kymr:AccumulatedAmortization id="F_000560" contextRef="C_0001815442_us-gaapPropertyPlantAndEquipmentByTypeAxis_kymrLabAndOfficeEquipmentMember_20201231" decimals="-5" unitRef="U_iso4217USD">1200000</kymr:AccumulatedAmortization>
  <kymr:AccumulatedAmortization id="F_000561" contextRef="C_0001815442_us-gaapPropertyPlantAndEquipmentByTypeAxis_kymrLabAndOfficeEquipmentMember_20191231" decimals="-5" unitRef="U_iso4217USD">500000</kymr:AccumulatedAmortization>
  <us-gaap:FinanceLeaseRightOfUseAssetAmortization id="F_000562" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">716000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
  <us-gaap:FinanceLeaseRightOfUseAssetAmortization id="F_000563" contextRef="C_0001815442_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">385000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
  <us-gaap:AreaOfRealEstateProperty id="F_000564" contextRef="C_0001815442_srtStatementGeographicalAxis_kymrCambridgeMassachusettsMember_us-gaapTypeOfArrangementAxis_kymrNoncancelableFacilityLeaseAgreementMember_20180228" decimals="INF" unitRef="U_utrsqft">9836</us-gaap:AreaOfRealEstateProperty>
  <us-gaap:ImpairmentOfLeasehold id="F_000565" contextRef="C_0001815442_srtStatementGeographicalAxis_kymrCambridgeMassachusettsMember_us-gaapTypeOfArrangementAxis_kymrNoncancelableFacilityLeaseAgreementMember_20200301_20200331" decimals="-5" unitRef="U_iso4217USD">2200000</us-gaap:ImpairmentOfLeasehold>
  <kymr:LeaseTerminationDate id="F_000566" contextRef="C_0001815442_srtStatementGeographicalAxis_kymrCambridgeMassachusettsMember_us-gaapTypeOfArrangementAxis_kymrNoncancelableFacilityLeaseAgreementMember_20200301_20200331">2020-07-31</kymr:LeaseTerminationDate>
  <us-gaap:SecurityDeposit id="F_000567" contextRef="C_0001815442_srtStatementGeographicalAxis_kymrCambridgeMassachusettsMember_us-gaapBalanceSheetLocationAxis_us-gaapOtherAssetsMember_us-gaapCreditFacilityAxis_us-gaapLetterOfCreditMember_us-gaapTypeOfArrangementAxis_kymrNoncancelableFacilityLeaseAgreementMember_20191231" decimals="-5" unitRef="U_iso4217USD">200000</us-gaap:SecurityDeposit>
  <us-gaap:SecurityDeposit id="F_000568" contextRef="C_0001815442_srtStatementGeographicalAxis_kymrCambridgeMassachusettsMember_us-gaapBalanceSheetLocationAxis_us-gaapOtherCurrentAssetsMember_us-gaapCreditFacilityAxis_us-gaapLetterOfCreditMember_us-gaapTypeOfArrangementAxis_kymrNoncancelableFacilityLeaseAgreementMember_20201031" decimals="-5" unitRef="U_iso4217USD">200000</us-gaap:SecurityDeposit>
  <us-gaap:AreaOfRealEstateProperty id="F_000569" contextRef="C_0001815442_srtStatementGeographicalAxis_kymrCambridgeMassachusettsMember_us-gaapTypeOfArrangementAxis_kymrFacilitySubleaseAgreementMember_20190430" decimals="INF" unitRef="U_utrsqft">1471</us-gaap:AreaOfRealEstateProperty>
  <kymr:LeaseCommencementDate id="F_000570" contextRef="C_0001815442_srtStatementGeographicalAxis_kymrCambridgeMassachusettsMember_us-gaapTypeOfArrangementAxis_kymrFacilitySubleaseAgreementMember_20190401_20190430">2019-06-24</kymr:LeaseCommencementDate>
  <us-gaap:AreaOfRealEstateProperty id="F_000571" contextRef="C_0001815442_srtStatementGeographicalAxis_kymrWatertownMassachusettsMember_us-gaapTypeOfArrangementAxis_kymrNoncancelableFacilityLeaseAgreementMember_20191031" decimals="INF" unitRef="U_utrsqft">34522</us-gaap:AreaOfRealEstateProperty>
  <kymr:LeaseTerm id="F_000572" contextRef="C_0001815442_srtStatementGeographicalAxis_kymrWatertownMassachusettsMember_us-gaapTypeOfArrangementAxis_kymrNoncancelableFacilityLeaseAgreementMember_20191001_20191031">P120M</kymr:LeaseTerm>
  <us-gaap:LeaseExpirationDate1 id="F_000573" contextRef="C_0001815442_srtStatementGeographicalAxis_kymrWatertownMassachusettsMember_us-gaapTypeOfArrangementAxis_kymrNoncancelableFacilityLeaseAgreementMember_20191001_20191031">2030-03-31</us-gaap:LeaseExpirationDate1>
  <kymr:LeaseAdditionalTerm id="F_000574" contextRef="C_0001815442_srtStatementGeographicalAxis_kymrWatertownMassachusettsMember_us-gaapTypeOfArrangementAxis_kymrNoncancelableFacilityLeaseAgreementMember_20191001_20191031">P5Y</kymr:LeaseAdditionalTerm>
  <kymr:TenantIncentiveAllowanceReceivable id="F_000575" contextRef="C_0001815442_srtStatementGeographicalAxis_kymrWatertownMassachusettsMember_us-gaapTypeOfArrangementAxis_kymrNoncancelableFacilityLeaseAgreementMember_20191031" decimals="-5" unitRef="U_iso4217USD">5500000</kymr:TenantIncentiveAllowanceReceivable>
  <us-gaap:SecurityDeposit id="F_000576" contextRef="C_0001815442_srtStatementGeographicalAxis_kymrWatertownMassachusettsMember_us-gaapBalanceSheetLocationAxis_us-gaapOtherAssetsMember_us-gaapCreditFacilityAxis_us-gaapLetterOfCreditMember_us-gaapTypeOfArrangementAxis_kymrNoncancelableFacilityLeaseAgreementMember_20201231" decimals="-5" unitRef="U_iso4217USD">1600000</us-gaap:SecurityDeposit>
  <us-gaap:OperatingLeaseCost id="F_000577" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">2719000</us-gaap:OperatingLeaseCost>
  <us-gaap:OperatingLeaseCost id="F_000578" contextRef="C_0001815442_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1597000</us-gaap:OperatingLeaseCost>
  <us-gaap:FinanceLeaseInterestExpense id="F_000579" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">121000</us-gaap:FinanceLeaseInterestExpense>
  <us-gaap:FinanceLeaseInterestExpense id="F_000580" contextRef="C_0001815442_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">46000</us-gaap:FinanceLeaseInterestExpense>
  <us-gaap:VariableLeaseCost id="F_000581" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">621000</us-gaap:VariableLeaseCost>
  <us-gaap:VariableLeaseCost id="F_000582" contextRef="C_0001815442_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">340000</us-gaap:VariableLeaseCost>
  <us-gaap:LeaseCost id="F_000583" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">4177000</us-gaap:LeaseCost>
  <us-gaap:LeaseCost id="F_000584" contextRef="C_0001815442_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">2368000</us-gaap:LeaseCost>
  <kymr:OperatingLeasePaymentsProceeds id="F_000585" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-3024000</kymr:OperatingLeasePaymentsProceeds>
  <kymr:OperatingLeasePaymentsProceeds id="F_000586" contextRef="C_0001815442_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">635000</kymr:OperatingLeasePaymentsProceeds>
  <us-gaap:FinanceLeaseInterestPaymentOnLiability id="F_000587" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">587000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
  <us-gaap:FinanceLeaseInterestPaymentOnLiability id="F_000588" contextRef="C_0001815442_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">46000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
  <us-gaap:FinanceLeasePrincipalPayments id="F_000589" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">121000</us-gaap:FinanceLeasePrincipalPayments>
  <us-gaap:FinanceLeasePrincipalPayments id="F_000590" contextRef="C_0001815442_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">385000</us-gaap:FinanceLeasePrincipalPayments>
  <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 id="F_000591" contextRef="C_0001815442_20201231">P9Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
  <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 id="F_000592" contextRef="C_0001815442_20191231">P9Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
  <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 id="F_000593" contextRef="C_0001815442_20201231">P2Y9M18D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
  <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 id="F_000594" contextRef="C_0001815442_20191231">P3Y8M12D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
  <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent id="F_000595" contextRef="C_0001815442_20201231" decimals="3" unitRef="U_xbrlipure">0.105</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
  <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent id="F_000596" contextRef="C_0001815442_20191231" decimals="3" unitRef="U_xbrlipure">0.103</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
  <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent id="F_000597" contextRef="C_0001815442_20201231" decimals="3" unitRef="U_xbrlipure">0.080</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
  <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent id="F_000598" contextRef="C_0001815442_20191231" decimals="3" unitRef="U_xbrlipure">0.078</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths id="F_000599" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">2691000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo id="F_000600" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">2581000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree id="F_000601" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">2659000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour id="F_000602" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">2732000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive id="F_000603" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">2814000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive id="F_000604" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">12925000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue id="F_000605" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">26402000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
  <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount id="F_000606" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">9702000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
  <us-gaap:OperatingLeaseLiability id="F_000607" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">16700000</us-gaap:OperatingLeaseLiability>
  <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths id="F_000608" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">712000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
  <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo id="F_000609" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">459000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
  <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree id="F_000610" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">245000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
  <us-gaap:FinanceLeaseLiabilityPaymentsDue id="F_000611" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">1416000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
  <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount id="F_000612" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">123000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
  <us-gaap:FinanceLeaseLiability id="F_000613" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">1293000</us-gaap:FinanceLeaseLiability>
  <kymr:AccruedResearchAndDevelopmentExpensesCurrent id="F_000614" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">5821000</kymr:AccruedResearchAndDevelopmentExpensesCurrent>
  <kymr:AccruedResearchAndDevelopmentExpensesCurrent id="F_000615" contextRef="C_0001815442_20191231" decimals="-3" unitRef="U_iso4217USD">2617000</kymr:AccruedResearchAndDevelopmentExpensesCurrent>
  <us-gaap:AccruedSalariesCurrent id="F_000616" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">2918000</us-gaap:AccruedSalariesCurrent>
  <us-gaap:AccruedSalariesCurrent id="F_000617" contextRef="C_0001815442_20191231" decimals="-3" unitRef="U_iso4217USD">1256000</us-gaap:AccruedSalariesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent id="F_000618" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">1585000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent id="F_000619" contextRef="C_0001815442_20191231" decimals="-3" unitRef="U_iso4217USD">606000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent id="F_000620" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">6000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent id="F_000621" contextRef="C_0001815442_20191231" decimals="-3" unitRef="U_iso4217USD">89000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:LossContingencyAccrualAtCarryingValue id="F_000622" contextRef="C_0001815442_us-gaapLossContingenciesByNatureOfContingencyAxis_us-gaapIndemnificationGuaranteeMember_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:LossContingencyAccrualAtCarryingValue>
  <us-gaap:LossContingencyAccrualAtCarryingValue id="F_000623" contextRef="C_0001815442_us-gaapLossContingenciesByNatureOfContingencyAxis_us-gaapIndemnificationGuaranteeMember_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:LossContingencyAccrualAtCarryingValue>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000624" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20200820" decimals="INF" unitRef="U_xbrlishares">52483788</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000625" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20200820" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000626" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesSeedConvertiblePreferredStockMember_20200820" decimals="INF" unitRef="U_xbrlishares">3000000</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000627" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesAConvertiblePreferredStockMember_20200820" decimals="INF" unitRef="U_xbrlishares">14886305</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000628" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesBConvertiblePreferredStockMember_20200820" decimals="INF" unitRef="U_xbrlishares">16009845</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000629" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesB1ConvertiblePreferredStockMember_20200820" decimals="INF" unitRef="U_xbrlishares">3059695</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000630" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesCConvertiblePreferredStockMember_20200820" decimals="INF" unitRef="U_xbrlishares">15527943</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesIssued id="F_000631" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesBConvertiblePreferredStockMember_20200131" decimals="INF" unitRef="U_xbrlishares">1182265</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000632" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesBConvertiblePreferredStockMember_20200131" decimals="INF" unitRef="U_iso4217USD_xbrlishares">4.06</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock id="F_000633" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesBConvertiblePreferredStockMember_20200101_20200131" decimals="-5" unitRef="U_iso4217USD">4800000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:TemporaryEquitySharesIssued id="F_000634" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesCConvertiblePreferredStockMember_us-gaapTypeOfArrangementAxis_kymrSeriesCPreferredStockPurchaseAgreementMember_20200331" decimals="INF" unitRef="U_xbrlishares">13539141</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000635" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesCConvertiblePreferredStockMember_us-gaapTypeOfArrangementAxis_kymrSeriesCPreferredStockPurchaseAgreementMember_20200331" decimals="INF" unitRef="U_iso4217USD_xbrlishares">6.5366</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock id="F_000636" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesCConvertiblePreferredStockMember_us-gaapTypeOfArrangementAxis_kymrSeriesCPreferredStockPurchaseAgreementMember_20200301_20200331" decimals="-5" unitRef="U_iso4217USD">88200000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:PaymentsOfStockIssuanceCosts id="F_000637" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesCConvertiblePreferredStockMember_us-gaapTypeOfArrangementAxis_kymrSeriesCPreferredStockPurchaseAgreementMember_20200301_20200331" decimals="-5" unitRef="U_iso4217USD">300000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion id="F_000638" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesCConvertiblePreferredStockMember_20200331" decimals="INF" unitRef="U_xbrlishares">1988802</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:TemporaryEquitySharesIssued id="F_000639" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesCConvertiblePreferredStockMember_20200331" decimals="INF" unitRef="U_xbrlishares">15527943</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquityDividendsAdjustment id="F_000640" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesCConvertiblePreferredStockMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">9100000</us-gaap:TemporaryEquityDividendsAdjustment>
  <kymr:AdjustmentsToAdditionalPaidInCapitalRelatedToTemporaryEquityDeemedDividend id="F_000641" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesCConvertiblePreferredStockMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">-2300000</kymr:AdjustmentsToAdditionalPaidInCapitalRelatedToTemporaryEquityDeemedDividend>
  <kymr:IncreaseInAccumulatedDeficitRelatedToTemporaryEquityDeemedDividend id="F_000642" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_kymrSeriesCConvertiblePreferredStockMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">6700000</kymr:IncreaseInAccumulatedDeficitRelatedToTemporaryEquityDeemedDividend>
  <us-gaap:ConversionOfStockSharesIssued1 id="F_000643" contextRef="C_0001815442_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200821_20200821" decimals="INF" unitRef="U_xbrlishares">50439595</us-gaap:ConversionOfStockSharesIssued1>
  <us-gaap:ConversionOfStockSharesConverted1 id="F_000644" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20200821_20200821" decimals="INF" unitRef="U_xbrlishares">31625534</us-gaap:ConversionOfStockSharesConverted1>
  <us-gaap:TemporaryEquitySharesIssued id="F_000645" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000646" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="F_000647" contextRef="C_0001815442_us-gaapPlanNameAxis_kymrTwoThousandTwentyStockOptionAndIncentivePlanMember_20200820" decimals="INF" unitRef="U_xbrlishares">4457370</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum id="F_000648" contextRef="C_0001815442_us-gaapPlanNameAxis_kymrTwoThousandTwentyStockOptionAndIncentivePlanMember_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant id="F_000649" contextRef="C_0001815442_us-gaapPlanNameAxis_kymrTwoThousandTwentyStockOptionAndIncentivePlanMember_20201231" decimals="INF" unitRef="U_xbrlishares">3148671</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="F_000650" contextRef="C_0001815442_us-gaapPlanNameAxis_kymrTwoThousandTwentyEmployeeStockPurchasePlanMember_20200820" decimals="INF" unitRef="U_xbrlishares">445653</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription id="F_000651" contextRef="C_0001815442_us-gaapPlanNameAxis_kymrTwoThousandTwentyEmployeeStockPurchasePlanMember_20200101_20201231">The 2020 ESPP provides that the number of shares reserved and available for issuance will automatically increase on January 1, 2021 and each January 1 thereafter through January 1, 2030, by the least of (i) 438,898 shares of common stock, (ii) 1% of the Company&#8217;s outstanding number of shares of common stock on the immediately preceding December 31 or (iii) such lesser number of shares of common stock as determined by the administrator of the 2020 ESPP.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized id="F_000652" contextRef="C_0001815442_kymrScenarioPotentialOutcomeAxis_kymrLesserOfPotentialOutcomeOneMember_us-gaapPlanNameAxis_kymrTwoThousandTwentyEmployeeStockPurchasePlanMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">438898</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum id="F_000653" contextRef="C_0001815442_kymrScenarioPotentialOutcomeAxis_kymrLesserOfPotentialOutcomeTwoMember_us-gaapPlanNameAxis_kymrTwoThousandTwentyEmployeeStockPurchasePlanMember_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant id="F_000654" contextRef="C_0001815442_us-gaapPlanNameAxis_kymrTwoThousandTwentyEmployeeStockPurchasePlanMember_20201231" decimals="INF" unitRef="U_xbrlishares">445653</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000655" contextRef="C_0001815442_us-gaapPlanNameAxis_kymrTwoThousandAndTwentyStockOptionAndGrantPlanMember_20191231" decimals="INF" unitRef="U_xbrlishares">2945297</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000656" contextRef="C_0001815442_us-gaapPlanNameAxis_kymrTwoThousandAndTwentyStockOptionAndGrantPlanMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">3213204</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000657" contextRef="C_0001815442_us-gaapPlanNameAxis_kymrTwoThousandAndTwentyStockOptionAndGrantPlanMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">78852</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod id="F_000658" contextRef="C_0001815442_us-gaapPlanNameAxis_kymrTwoThousandAndTwentyStockOptionAndGrantPlanMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">246937</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000659" contextRef="C_0001815442_us-gaapPlanNameAxis_kymrTwoThousandAndTwentyStockOptionAndGrantPlanMember_20201231" decimals="INF" unitRef="U_xbrlishares">5832712</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="F_000660" contextRef="C_0001815442_us-gaapPlanNameAxis_kymrTwoThousandAndTwentyStockOptionAndGrantPlanMember_20201231" decimals="INF" unitRef="U_xbrlishares">1580924</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000661" contextRef="C_0001815442_us-gaapPlanNameAxis_kymrTwoThousandAndTwentyStockOptionAndGrantPlanMember_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">2.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="F_000662" contextRef="C_0001815442_us-gaapPlanNameAxis_kymrTwoThousandAndTwentyStockOptionAndGrantPlanMember_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">13.22</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="F_000663" contextRef="C_0001815442_us-gaapPlanNameAxis_kymrTwoThousandAndTwentyStockOptionAndGrantPlanMember_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">2.06</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice id="F_000664" contextRef="C_0001815442_us-gaapPlanNameAxis_kymrTwoThousandAndTwentyStockOptionAndGrantPlanMember_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">2.55</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000665" contextRef="C_0001815442_us-gaapPlanNameAxis_kymrTwoThousandAndTwentyStockOptionAndGrantPlanMember_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">8.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="F_000666" contextRef="C_0001815442_us-gaapPlanNameAxis_kymrTwoThousandAndTwentyStockOptionAndGrantPlanMember_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">3.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="F_000667" contextRef="C_0001815442_us-gaapPlanNameAxis_kymrTwoThousandAndTwentyStockOptionAndGrantPlanMember_20190101_20191231">P8Y11M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="F_000668" contextRef="C_0001815442_us-gaapPlanNameAxis_kymrTwoThousandAndTwentyStockOptionAndGrantPlanMember_20200101_20201231">P9Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 id="F_000669" contextRef="C_0001815442_us-gaapPlanNameAxis_kymrTwoThousandAndTwentyStockOptionAndGrantPlanMember_20200101_20201231">P8Y9M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="F_000670" contextRef="C_0001815442_us-gaapPlanNameAxis_kymrTwoThousandAndTwentyStockOptionAndGrantPlanMember_20191231" decimals="-3" unitRef="U_iso4217USD">7798000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="F_000671" contextRef="C_0001815442_us-gaapPlanNameAxis_kymrTwoThousandAndTwentyStockOptionAndGrantPlanMember_20201231" decimals="-3" unitRef="U_iso4217USD">314001000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 id="F_000672" contextRef="C_0001815442_us-gaapPlanNameAxis_kymrTwoThousandAndTwentyStockOptionAndGrantPlanMember_20201231" decimals="-3" unitRef="U_iso4217USD">92674000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue id="F_000673" contextRef="C_0001815442_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">1600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue id="F_000674" contextRef="C_0001815442_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000675" contextRef="C_0001815442_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">8.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000676" contextRef="C_0001815442_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">1.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions id="F_000677" contextRef="C_0001815442_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231" decimals="-5" unitRef="U_iso4217USD">25600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="F_000678" contextRef="C_0001815442_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">P3Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 id="F_000679" contextRef="C_0001815442_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">4000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 id="F_000680" contextRef="C_0001815442_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000681" contextRef="C_0001815442_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">2084000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000682" contextRef="C_0001815442_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">380000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000683" contextRef="C_0001815442_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">2864000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000684" contextRef="C_0001815442_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">212000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000685" contextRef="C_0001815442_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">4948000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000686" contextRef="C_0001815442_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">592000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000687" contextRef="C_0001815442_20200101_20201231">P6Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000688" contextRef="C_0001815442_20190101_20191231">P6Y5M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="F_000689" contextRef="C_0001815442_20200101_20201231" decimals="2" unitRef="U_xbrlipure">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="F_000690" contextRef="C_0001815442_20190101_20191231" decimals="2" unitRef="U_xbrlipure">0.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="F_000691" contextRef="C_0001815442_20200101_20201231" decimals="3" unitRef="U_xbrlipure">0.005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="F_000692" contextRef="C_0001815442_20190101_20191231" decimals="4" unitRef="U_xbrlipure">0.0183</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="F_000693" contextRef="C_0001815442_20200101_20201231" decimals="4" unitRef="U_xbrlipure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="F_000694" contextRef="C_0001815442_20190101_20191231" decimals="4" unitRef="U_xbrlipure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="F_000695" contextRef="C_0001815442_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapPlanNameAxis_kymrTwoThousandEighteenStockOptionAndGrantPlanMember_20191231" decimals="INF" unitRef="U_xbrlishares">232434</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod id="F_000696" contextRef="C_0001815442_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapPlanNameAxis_kymrTwoThousandEighteenStockOptionAndGrantPlanMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">102651</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod id="F_000697" contextRef="C_0001815442_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapPlanNameAxis_kymrTwoThousandEighteenStockOptionAndGrantPlanMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">19679</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="F_000698" contextRef="C_0001815442_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapPlanNameAxis_kymrTwoThousandEighteenStockOptionAndGrantPlanMember_20201231" decimals="INF" unitRef="U_xbrlishares">110104</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue id="F_000699" contextRef="C_0001815442_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapPlanNameAxis_kymrTwoThousandEighteenStockOptionAndGrantPlanMember_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">1.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue id="F_000700" contextRef="C_0001815442_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapPlanNameAxis_kymrTwoThousandEighteenStockOptionAndGrantPlanMember_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">1.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue id="F_000701" contextRef="C_0001815442_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapPlanNameAxis_kymrTwoThousandEighteenStockOptionAndGrantPlanMember_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">1.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue id="F_000702" contextRef="C_0001815442_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapPlanNameAxis_kymrTwoThousandEighteenStockOptionAndGrantPlanMember_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">1.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod id="F_000703" contextRef="C_0001815442_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapPlanNameAxis_kymrTwoThousandEighteenStockOptionAndGrantPlanMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod id="F_000704" contextRef="C_0001815442_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapPlanNameAxis_kymrTwoThousandEighteenStockOptionAndGrantPlanMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions id="F_000705" contextRef="C_0001815442_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20201231" decimals="-5" unitRef="U_iso4217USD">300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="F_000706" contextRef="C_0001815442_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20200101_20201231">P1Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue id="F_000707" contextRef="C_0001815442_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue id="F_000708" contextRef="C_0001815442_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000709" contextRef="C_0001815442_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">200000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000710" contextRef="C_0001815442_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">400000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000711" contextRef="C_0001815442_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">200000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000712" contextRef="C_0001815442_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">200000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000713" contextRef="C_0001815442_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">200000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000714" contextRef="C_0001815442_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">100000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000715" contextRef="C_0001815442_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">2305000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000716" contextRef="C_0001815442_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">688000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000717" contextRef="C_0001815442_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">2885000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000718" contextRef="C_0001815442_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">508000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000719" contextRef="C_0001815442_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">5190000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000720" contextRef="C_0001815442_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1196000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty id="F_000721" contextRef="C_0001815442_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_us-gaapInvestorMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">800000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty id="F_000722" contextRef="C_0001815442_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_us-gaapInvestorMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">1000000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
  <us-gaap:IncomeTaxExpenseBenefit id="F_000723" contextRef="C_0001815442_20200101_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit id="F_000724" contextRef="C_0001815442_20190101_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="F_000725" contextRef="C_0001815442_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="F_000726" contextRef="C_0001815442_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes id="F_000727" contextRef="C_0001815442_20200101_20201231" decimals="3" unitRef="U_xbrlipure">0.058</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes id="F_000728" contextRef="C_0001815442_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.070</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost id="F_000729" contextRef="C_0001815442_20200101_20201231" decimals="3" unitRef="U_xbrlipure">-0.009</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
  <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost id="F_000730" contextRef="C_0001815442_20190101_20191231" decimals="3" unitRef="U_xbrlipure">-0.006</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
  <kymr:EffectiveIncomeTaxRateReconciliationPermanentDifferences id="F_000731" contextRef="C_0001815442_20200101_20201231" decimals="3" unitRef="U_xbrlipure">0.000</kymr:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
  <kymr:EffectiveIncomeTaxRateReconciliationPermanentDifferences id="F_000732" contextRef="C_0001815442_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.000</kymr:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch id="F_000733" contextRef="C_0001815442_20200101_20201231" decimals="3" unitRef="U_xbrlipure">0.036</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch id="F_000734" contextRef="C_0001815442_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.020</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments id="F_000735" contextRef="C_0001815442_20200101_20201231" decimals="3" unitRef="U_xbrlipure">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments id="F_000736" contextRef="C_0001815442_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance id="F_000737" contextRef="C_0001815442_20200101_20201231" decimals="3" unitRef="U_xbrlipure">-0.288</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance id="F_000738" contextRef="C_0001815442_20190101_20191231" decimals="3" unitRef="U_xbrlipure">-0.294</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations id="F_000739" contextRef="C_0001815442_20200101_20201231" decimals="3" unitRef="U_xbrlipure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations id="F_000740" contextRef="C_0001815442_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic id="F_000741" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">15621000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic id="F_000742" contextRef="C_0001815442_20191231" decimals="-3" unitRef="U_iso4217USD">15011000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal id="F_000743" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">3866000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal id="F_000744" contextRef="C_0001815442_20191231" decimals="-3" unitRef="U_iso4217USD">4319000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch id="F_000745" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">3757000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch id="F_000746" contextRef="C_0001815442_20191231" decimals="-3" unitRef="U_iso4217USD">1637000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <kymr:DeferredTaxAssetsLeaseLiabilities id="F_000747" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">4563000</kymr:DeferredTaxAssetsLeaseLiabilities>
  <kymr:DeferredTaxAssetsLeaseLiabilities id="F_000748" contextRef="C_0001815442_20191231" decimals="-3" unitRef="U_iso4217USD">5286000</kymr:DeferredTaxAssetsLeaseLiabilities>
  <us-gaap:DeferredTaxAssetsDeferredIncome id="F_000749" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">10313000</us-gaap:DeferredTaxAssetsDeferredIncome>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpense id="F_000750" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">1589000</us-gaap:DeferredTaxAssetsTaxDeferredExpense>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpense id="F_000751" contextRef="C_0001815442_20191231" decimals="-3" unitRef="U_iso4217USD">525000</us-gaap:DeferredTaxAssetsTaxDeferredExpense>
  <us-gaap:DeferredTaxAssetsGross id="F_000752" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">39709000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsGross id="F_000753" contextRef="C_0001815442_20191231" decimals="-3" unitRef="U_iso4217USD">26778000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsValuationAllowance id="F_000754" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">34075000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsValuationAllowance id="F_000755" contextRef="C_0001815442_20191231" decimals="-3" unitRef="U_iso4217USD">20949000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsNet id="F_000756" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">5634000</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:DeferredTaxAssetsNet id="F_000757" contextRef="C_0001815442_20191231" decimals="-3" unitRef="U_iso4217USD">5829000</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets id="F_000758" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">1506000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets>
  <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets id="F_000759" contextRef="C_0001815442_20191231" decimals="-3" unitRef="U_iso4217USD">754000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets>
  <kymr:DeferredTaxLiabilitiesRightOfUseAssets id="F_000760" contextRef="C_0001815442_20201231" decimals="-3" unitRef="U_iso4217USD">4128000</kymr:DeferredTaxLiabilitiesRightOfUseAssets>
  <kymr:DeferredTaxLiabilitiesRightOfUseAssets id="F_000761" contextRef="C_0001815442_20191231" decimals="-3" unitRef="U_iso4217USD">5075000</kymr:DeferredTaxLiabilitiesRightOfUseAssets>
  <us-gaap:ValuationAllowancesAndReservesBalance id="F_000762" contextRef="C_0001815442_20201231" decimals="-5" unitRef="U_iso4217USD">34100000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:ValuationAllowancesAndReservesBalance id="F_000763" contextRef="C_0001815442_20191231" decimals="-5" unitRef="U_iso4217USD">20900000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense id="F_000764" contextRef="C_0001815442_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">13100000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
  <us-gaap:OperatingLossCarryforwards id="F_000765" contextRef="C_0001815442_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231" decimals="-5" unitRef="U_iso4217USD">74400000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards id="F_000766" contextRef="C_0001815442_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20191231" decimals="-5" unitRef="U_iso4217USD">71500000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards id="F_000767" contextRef="C_0001815442_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231" decimals="-5" unitRef="U_iso4217USD">61200000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards id="F_000768" contextRef="C_0001815442_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20191231" decimals="-5" unitRef="U_iso4217USD">68300000</us-gaap:OperatingLossCarryforwards>
  <kymr:FederalNetOperatingLossCarryoversNotSubjectToExpiration id="F_000769" contextRef="C_0001815442_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">64600000</kymr:FederalNetOperatingLossCarryoversNotSubjectToExpiration>
  <kymr:NetOperatingLossBeginToExpireYear id="F_000770" contextRef="C_0001815442_us-gaapIncomeTaxAuthorityAxis_kymrFederalAndStateMember_20200101_20201231">2036</kymr:NetOperatingLossBeginToExpireYear>
  <kymr:ResearchAndDevelopmentCreditCarryforwards id="F_000771" contextRef="C_0001815442_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">2700000</kymr:ResearchAndDevelopmentCreditCarryforwards>
  <kymr:ResearchAndDevelopmentCreditCarryforwards id="F_000772" contextRef="C_0001815442_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">1100000</kymr:ResearchAndDevelopmentCreditCarryforwards>
  <kymr:ResearchAndDevelopmentCreditCarryforwards id="F_000773" contextRef="C_0001815442_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">1300000</kymr:ResearchAndDevelopmentCreditCarryforwards>
  <kymr:ResearchAndDevelopmentCreditCarryforwards id="F_000774" contextRef="C_0001815442_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">700000</kymr:ResearchAndDevelopmentCreditCarryforwards>
  <us-gaap:UnrecognizedTaxBenefits id="F_000775" contextRef="C_0001815442_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefits id="F_000776" contextRef="C_0001815442_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense id="F_000777" contextRef="C_0001815442_20200101_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
  <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense id="F_000778" contextRef="C_0001815442_20190101_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
  <us-gaap:OpenTaxYear id="F_000779" contextRef="C_0001815442_us-gaapTaxPeriodAxis_us-gaapEarliestTaxYearMember_20200101_20201231">2017</us-gaap:OpenTaxYear>
  <us-gaap:OpenTaxYear id="F_000780" contextRef="C_0001815442_us-gaapTaxPeriodAxis_us-gaapLatestTaxYearMember_20200101_20201231">2020</us-gaap:OpenTaxYear>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000781" contextRef="C_0001815442_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231" decimals="0" unitRef="U_xbrlishares">22325780</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000782" contextRef="C_0001815442_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockMember_20200101_20201231" decimals="0" unitRef="U_xbrlishares">110104</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000783" contextRef="C_0001815442_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockMember_20190101_20191231" decimals="0" unitRef="U_xbrlishares">232434</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000784" contextRef="C_0001815442_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="0" unitRef="U_xbrlishares">1580924</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000785" contextRef="C_0001815442_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="0" unitRef="U_xbrlishares">2945298</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000786" contextRef="C_0001815442_20200101_20201231" decimals="0" unitRef="U_xbrlishares">1691028</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000787" contextRef="C_0001815442_20190101_20191231" decimals="0" unitRef="U_xbrlishares">25503512</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>44
<FILENAME>kymr-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-11T04:08:03.4243335+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 393cc6ba0c39453d8ef47a8f7fceea15 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:kymr="http://www.kymeratx.com/20201231" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.kymeratx.com/20201231" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" namespace="http://xbrl.sec.gov/country/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2019-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" namespace="http://fasb.org/srt/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd" namespace="http://fasb.org/srt-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" namespace="http://fasb.org/srt-types/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" namespace="http://fasb.org/us-gaap/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" namespace="http://fasb.org/us-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" namespace="http://fasb.org/us-types/2020-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.kymeratx.com/20201231/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="kymr-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="kymr-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="kymr-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="kymr-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" id="Role_StatementConsolidatedStatementsOfStockholdersEquity">
        <link:definition>100040 - Statement - Consolidated Statements of Stockholders&apos; Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" id="Role_StatementConsolidatedStatementsOfStockholdersEquityParenthetical">
        <link:definition>100050 - Statement - Consolidated Statements of Stockholders&apos; Equity (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100060 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" id="Role_DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies">
        <link:definition>100070 - Disclosure - Description of Business and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100080 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100090 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureMarketableSecurities" id="Role_DisclosureMarketableSecurities">
        <link:definition>100100 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureCollaborations" id="Role_DisclosureCollaborations">
        <link:definition>100110 - Disclosure - Collaborations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipment" id="Role_DisclosurePropertyAndEquipment">
        <link:definition>100120 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureLeases" id="Role_DisclosureLeases">
        <link:definition>100130 - Disclosure - Leases</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureAccruedExpenses" id="Role_DisclosureAccruedExpenses">
        <link:definition>100140 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureOtherCommitmentsAndContingencies" id="Role_DisclosureOtherCommitmentsAndContingencies">
        <link:definition>100150 - Disclosure - Other Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStock" id="Role_DisclosureConvertiblePreferredStock">
        <link:definition>100160 - Disclosure - Convertible Preferred Stock</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensation" id="Role_DisclosureEquityBasedCompensation">
        <link:definition>100170 - Disclosure - Equity-Based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions" id="Role_DisclosureRelatedPartyTransactions">
        <link:definition>100180 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100190 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureNetLossPerShare" id="Role_DisclosureNetLossPerShare">
        <link:definition>100200 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100210 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100220 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100230 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesTables" id="Role_DisclosureMarketableSecuritiesTables">
        <link:definition>100240 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureCollaborationsTables" id="Role_DisclosureCollaborationsTables">
        <link:definition>100250 - Disclosure - Collaborations (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentTables" id="Role_DisclosurePropertyAndEquipmentTables">
        <link:definition>100260 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureLeasesTables" id="Role_DisclosureLeasesTables">
        <link:definition>100270 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureAccruedExpensesTables" id="Role_DisclosureAccruedExpensesTables">
        <link:definition>100280 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationTables" id="Role_DisclosureEquityBasedCompensationTables">
        <link:definition>100290 - Disclosure - Equity-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100300 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureNetLossPerShareTables" id="Role_DisclosureNetLossPerShareTables">
        <link:definition>100310 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100320 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100330 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfRelatedAssetDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfRelatedAssetDetails">
        <link:definition>100340 - Disclosure - Summary of Significant Accounting Policies - Summary of Estimated Useful Life of Related Asset (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" id="Role_DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>100350 - Disclosure - Fair Value Measurements - Schedule of Assets Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" id="Role_DisclosureFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>100360 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleDebtSecuritiesDetails" id="Role_DisclosureMarketableSecuritiesSummaryOfAvailableForSaleDebtSecuritiesDetails">
        <link:definition>100370 - Disclosure - Marketable Securities - Summary of Available-for-Sale Debt Securities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" id="Role_DisclosureMarketableSecuritiesAdditionalInformationDetails">
        <link:definition>100380 - Disclosure - Marketable Securities - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetails" id="Role_DisclosureCollaborationsAdditionalInformationDetails">
        <link:definition>100390 - Disclosure - Collaborations - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureCollaborationsChangeInAccountsReceivableContractAssetAndLiabilitiesDetails" id="Role_DisclosureCollaborationsChangeInAccountsReceivableContractAssetAndLiabilitiesDetails">
        <link:definition>100400 - Disclosure - Collaborations - Change in Accounts Receivable, Contract Asset and Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" id="Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails">
        <link:definition>100410 - Disclosure - Property and Equipment - Summary of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" id="Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails">
        <link:definition>100420 - Disclosure - Property and Equipment - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" id="Role_DisclosureLeasesAdditionalInformationDetails">
        <link:definition>100430 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostsDetails" id="Role_DisclosureLeasesComponentsOfLeaseCostsDetails">
        <link:definition>100440 - Disclosure - Leases - Components of Lease Costs (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureLeasesSupplementalCashFlowInformationRelatingToLeasesDetails" id="Role_DisclosureLeasesSupplementalCashFlowInformationRelatingToLeasesDetails">
        <link:definition>100450 - Disclosure - Leases - Supplemental Cash Flow Information Relating to Leases (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRatesDetails" id="Role_DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRatesDetails">
        <link:definition>100460 - Disclosure - Leases - Summary of Weighted Average Remaining Lease Terms and Discount Rates (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfUndiscountedFutureLeasePaymentsForOperatingAndFinanceLeasesDetails" id="Role_DisclosureLeasesSummaryOfUndiscountedFutureLeasePaymentsForOperatingAndFinanceLeasesDetails">
        <link:definition>100470 - Disclosure - Leases - Summary of Undiscounted Future Lease Payments for Operating and Finance Leases (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfUndiscountedFutureLeasePaymentsForOperatingAndFinanceLeasesDetails2" id="Role_DisclosureLeasesSummaryOfUndiscountedFutureLeasePaymentsForOperatingAndFinanceLeasesDetails2">
        <link:definition>100480 - Disclosure - Leases - Summary of Undiscounted Future Lease Payments for Operating and Finance Leases (Details)2</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" id="Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails">
        <link:definition>100490 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureOtherCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureOtherCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100500 - Disclosure - Other Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails" id="Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails">
        <link:definition>100510 - Disclosure - Convertible Preferred Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAdditionalInformationDetails" id="Role_DisclosureEquityBasedCompensationAdditionalInformationDetails">
        <link:definition>100520 - Disclosure - Equity-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfStockOptionActivityDetails" id="Role_DisclosureEquityBasedCompensationSummaryOfStockOptionActivityDetails">
        <link:definition>100530 - Disclosure - Equity-Based Compensation - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfEquityBasedCompensationExpenseDetails" id="Role_DisclosureEquityBasedCompensationSummaryOfEquityBasedCompensationExpenseDetails">
        <link:definition>100540 - Disclosure - Equity-Based Compensation - Summary of Equity-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfWeightedAverageAssumptionsDetails" id="Role_DisclosureEquityBasedCompensationSummaryOfWeightedAverageAssumptionsDetails">
        <link:definition>100550 - Disclosure - Equity-Based Compensation - Summary of Weighted-Average Assumptions (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfRestrictedStockActivityDetails" id="Role_DisclosureEquityBasedCompensationSummaryOfRestrictedStockActivityDetails">
        <link:definition>100560 - Disclosure - Equity-Based Compensation - Summary of Restricted Stock Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>100570 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100580 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureIncomeTaxesRateReconciliationOfUSStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetails" id="Role_DisclosureIncomeTaxesRateReconciliationOfUSStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetails">
        <link:definition>100590 - Disclosure - Income Taxes - Rate Reconciliation of U.S. Statutory Income Tax Rate to Company&apos;s Effective Tax Rate (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfNetDeferredIncomeTaxesDetails" id="Role_DisclosureIncomeTaxesScheduleOfSignificantComponentsOfNetDeferredIncomeTaxesDetails">
        <link:definition>100600 - Disclosure - Income Taxes - Schedule of Significant Components of Net Deferred Income Taxes (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedLossPerShareDetail" id="Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedLossPerShareDetail">
        <link:definition>100610 - Disclosure - Net Loss per Share - Summary of Basic and Diluted Loss Per Share (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfDilutedNetLossPerShareAttributableToCommonStockholdersAntiDilutedEffectDetail" id="Role_DisclosureNetLossPerShareScheduleOfDilutedNetLossPerShareAttributableToCommonStockholdersAntiDilutedEffectDetail">
        <link:definition>100620 - Disclosure - Net Loss per Share - Schedule of Diluted Net Loss Per Share Attributable to Common Stockholders Anti-Diluted Effect (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="kymr_RestrictedCashFairValue" name="RestrictedCashFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="kymr_SeriesSeedConvertiblePreferredStockMember" name="SeriesSeedConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="kymr_SeriesAConvertiblePreferredStockMember" name="SeriesAConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="kymr_SeriesBConvertiblePreferredStockMember" name="SeriesBConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="kymr_SeriesB1ConvertiblePreferredStockMember" name="SeriesB1ConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="kymr_TemporaryEquityStockValueVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement" name="TemporaryEquityStockValueVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="kymr_TemporaryEquityStockSharesVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement" name="TemporaryEquityStockSharesVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="kymr_TemporaryEquityConvertiblePreferredStockIssuedDuringPeriodValue" name="TemporaryEquityConvertiblePreferredStockIssuedDuringPeriodValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="kymr_TemporaryEquityConvertiblePreferredStockIssuedDuringPeriodShares" name="TemporaryEquityConvertiblePreferredStockIssuedDuringPeriodShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="kymr_StockIssuedDuringPeriodValueRestrictedStockVested" name="StockIssuedDuringPeriodValueRestrictedStockVested" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="kymr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="kymr_TemporaryEquityExchangeOfConvertiblePreferredStockValue" name="TemporaryEquityExchangeOfConvertiblePreferredStockValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="kymr_TemporaryEquityExchangeOfConvertiblePreferredStockShares" name="TemporaryEquityExchangeOfConvertiblePreferredStockShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="kymr_TemporaryEquitySharesConverted" name="TemporaryEquitySharesConverted" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="kymr_TemporaryEquityValueOfSharesConverted" name="TemporaryEquityValueOfSharesConverted" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="kymr_TemporaryEquityAdjustedCarryingAmountAttributableToParent" name="TemporaryEquityAdjustedCarryingAmountAttributableToParent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="kymr_ExchangeOfConvertiblePreferredStockImpactOnEquity" name="ExchangeOfConvertiblePreferredStockImpactOnEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="kymr_SeriesCConvertiblePreferredStockMember" name="SeriesCConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="kymr_TemporaryEquityAdjustedSharesOutstanding" name="TemporaryEquityAdjustedSharesOutstanding" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="kymr_SeriesBConvertiblePreferredStocksMember" name="SeriesBConvertiblePreferredStocksMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="kymr_SeriesB1PreferredStockMember" name="SeriesB1PreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="kymr_StockIssuedDuringPeriodSharesRestrictedStockVested" name="StockIssuedDuringPeriodSharesRestrictedStockVested" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="kymr_NonCashResearchAndDevelopmentExpense" name="NonCashResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="kymr_NetAmortizationOfPremiumsAndDiscountsOnInvestments" name="NetAmortizationOfPremiumsAndDiscountsOnInvestments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="kymr_IncreaseDecreaseInContractWithCustomerAssetRelatedParties" name="IncreaseDecreaseInContractWithCustomerAssetRelatedParties" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="kymr_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="kymr_IncreaseDecreaseInOperatingLeaseLiabilities" name="IncreaseDecreaseInOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="kymr_ProceedsFromConcurrentPrivatePlacement" name="ProceedsFromConcurrentPrivatePlacement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="kymr_PurchasesOfPropertyAndEquipmentThroughFinanceAndLeaseLiabilities" name="PurchasesOfPropertyAndEquipmentThroughFinanceAndLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="kymr_PropertyAndEquipmentPurchasesIncludedInAccountsPayableAndAccruedExpenses" name="PropertyAndEquipmentPurchasesIncludedInAccountsPayableAndAccruedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="kymr_OfferingCostsIncludedInAccountsPayable" name="OfferingCostsIncludedInAccountsPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="kymr_TenantImprovementReceivableIncludedInOtherAssets" name="TenantImprovementReceivableIncludedInOtherAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="kymr_ReductionOfRightOfUseAssetAndLiabilityDueToLeaseModification" name="ReductionOfRightOfUseAssetAndLiabilityDueToLeaseModification" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="kymr_SupplementalDisclosureOfNoncashOperatingActivitiesAbstract" name="SupplementalDisclosureOfNoncashOperatingActivitiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesAbstract" name="DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="kymr_LesseeOperatingAndFinanceLeasesTextBlock" name="LesseeOperatingAndFinanceLeasesTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="kymr_SegmentAndGeographicInformationPolicyTextBlock" name="SegmentAndGeographicInformationPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="kymr_RestrictedCashPolicyPolicyTextBlock" name="RestrictedCashPolicyPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="kymr_ConvertiblePreferredStockPolicyTextBlock" name="ConvertiblePreferredStockPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="kymr_PatentCostsPolicyTextBlock" name="PatentCostsPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="kymr_FinancingCostsPolicyTextBlock" name="FinancingCostsPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="kymr_CostsAssociatedWithLicenseAndCollaborativeArrangementsPolicyTextBlock" name="CostsAssociatedWithLicenseAndCollaborativeArrangementsPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="kymr_CommonAndPreferredStockValuationPolicyTextBlock" name="CommonAndPreferredStockValuationPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="kymr_OffBalanceSheetRiskAndConcentrationOfCreditRiskPolicyTextBlock" name="OffBalanceSheetRiskAndConcentrationOfCreditRiskPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="kymr_EmergingGrowthCompanyStatusPolicyTextBlock" name="EmergingGrowthCompanyStatusPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="kymr_SummaryOfEstimatedUsefulLifeOfRelatedAssetTableTextBlock" name="SummaryOfEstimatedUsefulLifeOfRelatedAssetTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="kymr_SupplementalCashFlowInformationRelatingToLeasesTableTextBlock" name="SupplementalCashFlowInformationRelatingToLeasesTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="kymr_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock" name="SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="kymr_LesseeOperatingAndFinancingLeaseLiabilityMaturityTableTextBlock" name="LesseeOperatingAndFinancingLeaseLiabilityMaturityTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" name="DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" name="DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="kymr_VertexPharmaceuticalsIncorporatedMember" name="VertexPharmaceuticalsIncorporatedMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="kymr_ProceedsFromIssuanceInitialPublicOfferingGross" name="ProceedsFromIssuanceInitialPublicOfferingGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="kymr_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="kymr_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="kymr_MarketableSecuritiesRemainingMaturityPeriod" name="MarketableSecuritiesRemainingMaturityPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="kymr_MarketableSecuritiesRemainingMaturityPeriodClassifiedAsNonCurrent" name="MarketableSecuritiesRemainingMaturityPeriodClassifiedAsNonCurrent" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="kymr_LabEquipmentMember" name="LabEquipmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="kymr_FairValueAssetsLevel1ToLevel3TransfersAmount" name="FairValueAssetsLevel1ToLevel3TransfersAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="kymr_FairValueAssetsLevel3ToLevel1TransfersAmount" name="FairValueAssetsLevel3ToLevel1TransfersAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="kymr_FairValueAssetsLevel3ToLevel2TransfersAmount" name="FairValueAssetsLevel3ToLevel2TransfersAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="kymr_FairValueAssetsLevel2ToLevel3TransfersAmount" name="FairValueAssetsLevel2ToLevel3TransfersAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="kymr_DebtSecuritiesAvailableForSaleContractualMaturityOfLessThan12MonthsNumberOfSecurities" name="DebtSecuritiesAvailableForSaleContractualMaturityOfLessThan12MonthsNumberOfSecurities" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="kymr_FairValueOfAvailableForSaleDebtSecuritiesContractualMaturityOfLessThanTwelveMonths" name="FairValueOfAvailableForSaleDebtSecuritiesContractualMaturityOfLessThanTwelveMonths" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="kymr_DebtSecuritiesAvailableForSaleContractualMaturityOf12MonthsOrLongerNumberOfSecurities" name="DebtSecuritiesAvailableForSaleContractualMaturityOf12MonthsOrLongerNumberOfSecurities" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="kymr_DebtSecuritiesAvailableForSaleDeclineInMarketValueForUnrealizedLossPositionNumberOfSecurities" name="DebtSecuritiesAvailableForSaleDeclineInMarketValueForUnrealizedLossPositionNumberOfSecurities" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="kymr_NumberOfMarketableSecuritiesSold" name="NumberOfMarketableSecuritiesSold" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="kymr_UpfrontPayment" name="UpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="kymr_DevelopmentMilestonePayments" name="DevelopmentMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="kymr_CommercialMilestonePayments" name="CommercialMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="kymr_SanofiCollaborationArrangementMember" name="SanofiCollaborationArrangementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="kymr_IRAK4Member" name="IRAK4Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="kymr_CollaborationTargetOneMember" name="CollaborationTargetOneMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="kymr_CollaborationTargetTwoMember" name="CollaborationTargetTwoMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="kymr_VertexAgreementMember" name="VertexAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="kymr_CompoundCollaborationAgreementMember" name="CompoundCollaborationAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="kymr_SeriesAPreferredUnitsMember" name="SeriesAPreferredUnitsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="kymr_CollaborationAgreementTransactionPrice" name="CollaborationAgreementTransactionPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="kymr_CostReimbursementReceivable" name="CostReimbursementReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="kymr_MilestoneReceivable" name="MilestoneReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="kymr_RoyaltyReceivable" name="RoyaltyReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="kymr_RemainingResearchTermOfCollaboration" name="RemainingResearchTermOfCollaboration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="kymr_InitialResearchTermOfCollaboration" name="InitialResearchTermOfCollaboration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="kymr_ExtendedResearchTermOfCollaboration" name="ExtendedResearchTermOfCollaboration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="kymr_NonRefundableUpfrontPaymentReceived" name="NonRefundableUpfrontPaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="kymr_PreferredStockIssuancePremium" name="PreferredStockIssuancePremium" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="kymr_PotentialReceivableMilestonePayments" name="PotentialReceivableMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="kymr_WrittenNoticePeriodToTerminateCollaborationAgreement" name="WrittenNoticePeriodToTerminateCollaborationAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="kymr_ContractWithCustomerAssetNetAdditions" name="ContractWithCustomerAssetNetAdditions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="kymr_ContractWithCustomerAssetNetDeductions" name="ContractWithCustomerAssetNetDeductions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="kymr_BilledReceivablesSanofiMember" name="BilledReceivablesSanofiMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="kymr_UnbilledReceivablesSanofiMember" name="UnbilledReceivablesSanofiMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="kymr_DeferredRevenueVertexMember" name="DeferredRevenueVertexMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="kymr_DeferredRevenueSanofiMember" name="DeferredRevenueSanofiMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="kymr_ContractWithCustomerLiabilityAdditions" name="ContractWithCustomerLiabilityAdditions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="kymr_ContractWithCustomerLiabilityDeductions" name="ContractWithCustomerLiabilityDeductions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="kymr_LabAndOfficeEquipmentMember" name="LabAndOfficeEquipmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="kymr_AssetsNotYetInServiceMember" name="AssetsNotYetInServiceMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="kymr_AccumulatedAmortization" name="AccumulatedAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="kymr_LeaseTerminationDate" name="LeaseTerminationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="kymr_CambridgeMassachusettsMember" name="CambridgeMassachusettsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="kymr_NoncancelableFacilityLeaseAgreementMember" name="NoncancelableFacilityLeaseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="kymr_FacilitySubleaseAgreementMember" name="FacilitySubleaseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="kymr_WatertownMassachusettsMember" name="WatertownMassachusettsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="kymr_LeaseCommencementDate" name="LeaseCommencementDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="kymr_LeaseTerm" name="LeaseTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="kymr_LeaseAdditionalTerm" name="LeaseAdditionalTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="kymr_TenantIncentiveAllowanceReceivable" name="TenantIncentiveAllowanceReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="kymr_OperatingLeasePaymentsProceeds" name="OperatingLeasePaymentsProceeds" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="kymr_AccruedResearchAndDevelopmentExpensesCurrent" name="AccruedResearchAndDevelopmentExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="kymr_SeriesCPreferredStockPurchaseAgreementMember" name="SeriesCPreferredStockPurchaseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="kymr_AdjustmentsToAdditionalPaidInCapitalRelatedToTemporaryEquityDeemedDividend" name="AdjustmentsToAdditionalPaidInCapitalRelatedToTemporaryEquityDeemedDividend" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="kymr_IncreaseInAccumulatedDeficitRelatedToTemporaryEquityDeemedDividend" name="IncreaseInAccumulatedDeficitRelatedToTemporaryEquityDeemedDividend" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="kymr_TwoThousandTwentyStockOptionAndIncentivePlanMember" name="TwoThousandTwentyStockOptionAndIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="kymr_TwoThousandTwentyEmployeeStockPurchasePlanMember" name="TwoThousandTwentyEmployeeStockPurchasePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="kymr_ScenarioPotentialOutcomeAxis" name="ScenarioPotentialOutcomeAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="kymr_ScenarioPotentialOutcomeDomain" name="ScenarioPotentialOutcomeDomain" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="kymr_LesserOfPotentialOutcomeOneMember" name="LesserOfPotentialOutcomeOneMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="kymr_LesserOfPotentialOutcomeTwoMember" name="LesserOfPotentialOutcomeTwoMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="kymr_TwoThousandEighteenStockOptionAndGrantPlanMember" name="TwoThousandEighteenStockOptionAndGrantPlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="kymr_TwoThousandAndTwentyStockOptionAndGrantPlanMember" name="TwoThousandAndTwentyStockOptionAndGrantPlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="kymr_IncomeTaxDisclosureLineItems" name="IncomeTaxDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="kymr_IncomeTaxDisclosureTable" name="IncomeTaxDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="kymr_FederalAndStateMember" name="FederalAndStateMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="kymr_EffectiveIncomeTaxRateReconciliationPermanentDifferences" name="EffectiveIncomeTaxRateReconciliationPermanentDifferences" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="kymr_DeferredTaxAssetsLeaseLiabilities" name="DeferredTaxAssetsLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="kymr_DeferredTaxLiabilitiesRightOfUseAssets" name="DeferredTaxLiabilitiesRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="kymr_FederalNetOperatingLossCarryoversNotSubjectToExpiration" name="FederalNetOperatingLossCarryoversNotSubjectToExpiration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="kymr_NetOperatingLossBeginToExpireYear" name="NetOperatingLossBeginToExpireYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="kymr_ResearchAndDevelopmentCreditCarryforwards" name="ResearchAndDevelopmentCreditCarryforwards" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>45
<FILENAME>kymr-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-11T04:08:03.4243335+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 393cc6ba0c39453d8ef47a8f7fceea15 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="kymr-20201231.xsd#TemplateLink" roleURI="http://www.kymeratx.com/20201231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="kymr-20201231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10210.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="10220.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="10230.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10240.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" order="10250.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10260.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10270.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10280.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10290.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10300.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10310.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DueFromRelatedPartiesCurrent" order="10320.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent" order="10330.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10340.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="kymr-20201231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDividendsAdjustment" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDividendsAdjustment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_TemporaryEquityDividendsAdjustment" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncome" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingExpense" order="10080.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="10100.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10120.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="kymr-20201231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="locator" xlink:label="kymr_IncreaseDecreaseInOperatingLeaseLiabilities" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:type="locator" xlink:label="kymr_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedParties" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_IncreaseDecreaseInContractWithCustomerAssetRelatedParties" xlink:type="locator" xlink:label="kymr_IncreaseDecreaseInContractWithCustomerAssetRelatedParties" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_NetAmortizationOfPremiumsAndDiscountsOnInvestments" xlink:type="locator" xlink:label="kymr_NetAmortizationOfPremiumsAndDiscountsOnInvestments" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_NonCashResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="kymr_NonCashResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_ProceedsFromConcurrentPrivatePlacement" xlink:type="locator" xlink:label="kymr_ProceedsFromConcurrentPrivatePlacement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfFinancingCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfFinancingCosts" order="10080.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="kymr_ProceedsFromConcurrentPrivatePlacement" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10110.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="10120.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="kymr_NonCashResearchAndDevelopmentExpense" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="kymr_NetAmortizationOfPremiumsAndDiscountsOnInvestments" order="10180.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10190.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" order="10200.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="kymr_IncreaseDecreaseInContractWithCustomerAssetRelatedParties" order="10210.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedParties" order="10220.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10230.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="10240.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="10250.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="10260.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="kymr_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" order="10270.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="kymr_IncreaseDecreaseInOperatingLeaseLiabilities" order="10280.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="10290.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="kymr-20201231.xsd#Role_DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:href="kymr-20201231.xsd#kymr_RestrictedCashFairValue" xlink:type="locator" xlink:label="kymr_RestrictedCashFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AvailableForSaleSecuritiesCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AvailableForSaleSecuritiesNoncurrent" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="kymr_RestrictedCashFairValue" order="10080.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleDebtSecuritiesDetails" xlink:href="kymr-20201231.xsd#Role_DisclosureMarketableSecuritiesSummaryOfAvailableForSaleDebtSecuritiesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleDebtSecuritiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10010.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" xlink:href="kymr-20201231.xsd#Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostsDetails" xlink:href="kymr-20201231.xsd#Role_DisclosureLeasesComponentsOfLeaseCostsDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:type="locator" xlink:label="us-gaap_LeaseCost" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="10040.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfUndiscountedFutureLeasePaymentsForOperatingAndFinanceLeasesDetails" xlink:href="kymr-20201231.xsd#Role_DisclosureLeasesSummaryOfUndiscountedFutureLeasePaymentsForOperatingAndFinanceLeasesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfUndiscountedFutureLeasePaymentsForOperatingAndFinanceLeasesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="10120.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfUndiscountedFutureLeasePaymentsForOperatingAndFinanceLeasesDetails2" xlink:href="kymr-20201231.xsd#Role_DisclosureLeasesSummaryOfUndiscountedFutureLeasePaymentsForOperatingAndFinanceLeasesDetails2" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfUndiscountedFutureLeasePaymentsForOperatingAndFinanceLeasesDetails2">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiability" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="10040.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:href="kymr-20201231.xsd#Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedSalariesCurrent" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_AccruedResearchAndDevelopmentExpensesCurrent" xlink:type="locator" xlink:label="kymr_AccruedResearchAndDevelopmentExpensesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="kymr_AccruedResearchAndDevelopmentExpensesCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureIncomeTaxesRateReconciliationOfUSStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetails" xlink:href="kymr-20201231.xsd#Role_DisclosureIncomeTaxesRateReconciliationOfUSStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureIncomeTaxesRateReconciliationOfUSStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:type="locator" xlink:label="kymr_EffectiveIncomeTaxRateReconciliationPermanentDifferences" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="kymr_EffectiveIncomeTaxRateReconciliationPermanentDifferences" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10070.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfNetDeferredIncomeTaxesDetails" xlink:href="kymr-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfSignificantComponentsOfNetDeferredIncomeTaxesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfNetDeferredIncomeTaxesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_DeferredTaxAssetsLeaseLiabilities" xlink:type="locator" xlink:label="kymr_DeferredTaxAssetsLeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_DeferredTaxLiabilitiesRightOfUseAssets" xlink:type="locator" xlink:label="kymr_DeferredTaxLiabilitiesRightOfUseAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="kymr_DeferredTaxLiabilitiesRightOfUseAssets" order="10030.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10050.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="kymr_DeferredTaxAssetsLeaseLiabilities" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpense" order="10110.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>46
<FILENAME>kymr-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-11T04:08:03.4243335+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 393cc6ba0c39453d8ef47a8f7fceea15 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef xlink:type="simple" xlink:href="kymr-20201231.xsd#TemplateLink" roleURI="http://www.kymeratx.com/20201231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="kymr-20201231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesB1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="kymr_SeriesB1ConvertiblePreferredStockMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="kymr_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="kymr_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesSeedConvertiblePreferredStockMember" xlink:type="locator" xlink:label="kymr_SeriesSeedConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10350.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="kymr_SeriesSeedConvertiblePreferredStockMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="kymr_SeriesAConvertiblePreferredStockMember" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="kymr_SeriesBConvertiblePreferredStockMember" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="kymr_SeriesB1ConvertiblePreferredStockMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DueFromRelatedPartiesCurrent" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="11080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="11120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="11160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="11240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="11320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="11360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="11400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="11440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="11480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="11520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="11600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="11680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="11720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="11760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="11800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="11840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="11920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="12080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="12160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="12200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="12240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="12280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="12320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="12360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="12400.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="kymr-20201231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesB1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="kymr_SeriesB1ConvertiblePreferredStockMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="kymr_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="kymr_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesSeedConvertiblePreferredStockMember" xlink:type="locator" xlink:label="kymr_SeriesSeedConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="kymr_SeriesSeedConvertiblePreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="kymr_SeriesAConvertiblePreferredStockMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="kymr_SeriesBConvertiblePreferredStockMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="kymr_SeriesB1ConvertiblePreferredStockMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="11300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="11340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="11380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="11420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="11460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="11500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="11540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="11580.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:href="kymr-20201231.xsd#Role_StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_StockIssuedDuringPeriodSharesRestrictedStockVested" xlink:type="locator" xlink:label="kymr_StockIssuedDuringPeriodSharesRestrictedStockVested" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TemporaryEquitySharesConverted" xlink:type="locator" xlink:label="kymr_TemporaryEquitySharesConverted" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TemporaryEquityExchangeOfConvertiblePreferredStockShares" xlink:type="locator" xlink:label="kymr_TemporaryEquityExchangeOfConvertiblePreferredStockShares" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="kymr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TemporaryEquityValueOfSharesConverted" xlink:type="locator" xlink:label="kymr_TemporaryEquityValueOfSharesConverted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_StockIssuedDuringPeriodValueRestrictedStockVested" xlink:type="locator" xlink:label="kymr_StockIssuedDuringPeriodValueRestrictedStockVested" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_ExchangeOfConvertiblePreferredStockImpactOnEquity" xlink:type="locator" xlink:label="kymr_ExchangeOfConvertiblePreferredStockImpactOnEquity" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TemporaryEquityExchangeOfConvertiblePreferredStockValue" xlink:type="locator" xlink:label="kymr_TemporaryEquityExchangeOfConvertiblePreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TemporaryEquityConvertiblePreferredStockIssuedDuringPeriodShares" xlink:type="locator" xlink:label="kymr_TemporaryEquityConvertiblePreferredStockIssuedDuringPeriodShares" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TemporaryEquityConvertiblePreferredStockIssuedDuringPeriodValue" xlink:type="locator" xlink:label="kymr_TemporaryEquityConvertiblePreferredStockIssuedDuringPeriodValue" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TemporaryEquityStockSharesVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement" xlink:type="locator" xlink:label="kymr_TemporaryEquityStockSharesVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TemporaryEquityStockValueVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement" xlink:type="locator" xlink:label="kymr_TemporaryEquityStockValueVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TemporaryEquityAdjustedSharesOutstanding" xlink:type="locator" xlink:label="kymr_TemporaryEquityAdjustedSharesOutstanding" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TemporaryEquityAdjustedCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="kymr_TemporaryEquityAdjustedCarryingAmountAttributableToParent" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesCConvertiblePreferredStockMember" xlink:type="locator" xlink:label="kymr_SeriesCConvertiblePreferredStockMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesB1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="kymr_SeriesB1ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="kymr_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="kymr_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesSeedConvertiblePreferredStockMember" xlink:type="locator" xlink:label="kymr_SeriesSeedConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="kymr_SeriesSeedConvertiblePreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="kymr_SeriesAConvertiblePreferredStockMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="kymr_SeriesBConvertiblePreferredStockMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="kymr_SeriesB1ConvertiblePreferredStockMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="kymr_SeriesCConvertiblePreferredStockMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="kymr_TemporaryEquityAdjustedCarryingAmountAttributableToParent" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="kymr_TemporaryEquityAdjustedSharesOutstanding" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="kymr_TemporaryEquityStockValueVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="kymr_TemporaryEquityStockSharesVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="kymr_TemporaryEquityConvertiblePreferredStockIssuedDuringPeriodValue" order="11100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="kymr_TemporaryEquityConvertiblePreferredStockIssuedDuringPeriodShares" order="11200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="11240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="kymr_TemporaryEquityExchangeOfConvertiblePreferredStockValue" order="11380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="kymr_ExchangeOfConvertiblePreferredStockImpactOnEquity" order="11520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="11660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="kymr_StockIssuedDuringPeriodValueRestrictedStockVested" order="11800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="11940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="12080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="kymr_TemporaryEquityValueOfSharesConverted" order="12220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="12360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="12460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="12500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="12640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="kymr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="13300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="kymr_TemporaryEquityExchangeOfConvertiblePreferredStockShares" order="13540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="kymr_TemporaryEquitySharesConverted" order="14480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="16750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="kymr_StockIssuedDuringPeriodSharesRestrictedStockVested" order="16970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="17850.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:href="kymr-20201231.xsd#Role_StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesB1PreferredStockMember" xlink:type="locator" xlink:label="kymr_SeriesB1PreferredStockMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesBConvertiblePreferredStocksMember" xlink:type="locator" xlink:label="kymr_SeriesBConvertiblePreferredStocksMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="kymr_SeriesBConvertiblePreferredStocksMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="kymr_SeriesB1PreferredStockMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="10400.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="kymr-20201231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash" xlink:type="locator" xlink:label="us-gaap_RestrictedCash" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_ReductionOfRightOfUseAssetAndLiabilityDueToLeaseModification" xlink:type="locator" xlink:label="kymr_ReductionOfRightOfUseAssetAndLiabilityDueToLeaseModification" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TenantImprovementReceivableIncludedInOtherAssets" xlink:type="locator" xlink:label="kymr_TenantImprovementReceivableIncludedInOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SupplementalDisclosureOfNoncashOperatingActivitiesAbstract" xlink:type="locator" xlink:label="kymr_SupplementalDisclosureOfNoncashOperatingActivitiesAbstract" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_OfferingCostsIncludedInAccountsPayable" xlink:type="locator" xlink:label="kymr_OfferingCostsIncludedInAccountsPayable" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_PropertyAndEquipmentPurchasesIncludedInAccountsPayableAndAccruedExpenses" xlink:type="locator" xlink:label="kymr_PropertyAndEquipmentPurchasesIncludedInAccountsPayableAndAccruedExpenses" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_PurchasesOfPropertyAndEquipmentThroughFinanceAndLeaseLiabilities" xlink:type="locator" xlink:label="kymr_PurchasesOfPropertyAndEquipmentThroughFinanceAndLeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_ProceedsFromConcurrentPrivatePlacement" xlink:type="locator" xlink:label="kymr_ProceedsFromConcurrentPrivatePlacement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfFinancingCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="locator" xlink:label="kymr_IncreaseDecreaseInOperatingLeaseLiabilities" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:type="locator" xlink:label="kymr_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedParties" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_IncreaseDecreaseInContractWithCustomerAssetRelatedParties" xlink:type="locator" xlink:label="kymr_IncreaseDecreaseInContractWithCustomerAssetRelatedParties" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_NetAmortizationOfPremiumsAndDiscountsOnInvestments" xlink:type="locator" xlink:label="kymr_NetAmortizationOfPremiumsAndDiscountsOnInvestments" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_NonCashResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="kymr_NonCashResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesCConvertiblePreferredStockMember" xlink:type="locator" xlink:label="kymr_SeriesCConvertiblePreferredStockMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesB1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="kymr_SeriesB1ConvertiblePreferredStockMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="kymr_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10300.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="kymr_SeriesBConvertiblePreferredStockMember" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="kymr_SeriesB1ConvertiblePreferredStockMember" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="kymr_SeriesCConvertiblePreferredStockMember" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="kymr_NonCashResearchAndDevelopmentExpense" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="kymr_NetAmortizationOfPremiumsAndDiscountsOnInvestments" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="kymr_IncreaseDecreaseInContractWithCustomerAssetRelatedParties" order="10970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedParties" order="11010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="11090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="11130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="11170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="kymr_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" order="11210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="kymr_IncreaseDecreaseInOperatingLeaseLiabilities" order="11250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="11290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="11490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="11530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="11690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="11810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfFinancingCosts" order="11850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="11890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="kymr_ProceedsFromConcurrentPrivatePlacement" order="11930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="11970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="12010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="12050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="12130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="12210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="12250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="kymr_PurchasesOfPropertyAndEquipmentThroughFinanceAndLeaseLiabilities" order="12330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="kymr_PropertyAndEquipmentPurchasesIncludedInAccountsPayableAndAccruedExpenses" order="12370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="kymr_OfferingCostsIncludedInAccountsPayable" order="12410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="kymr_SupplementalDisclosureOfNoncashOperatingActivitiesAbstract" order="12450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="kymr_SupplementalDisclosureOfNoncashOperatingActivitiesAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="12530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="kymr_SupplementalDisclosureOfNoncashOperatingActivitiesAbstract" xlink:to="kymr_TenantImprovementReceivableIncludedInOtherAssets" order="12570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="kymr_SupplementalDisclosureOfNoncashOperatingActivitiesAbstract" xlink:to="kymr_ReductionOfRightOfUseAssetAndLiabilityDueToLeaseModification" order="12610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="12680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCash" order="12720.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureCollaborations" xlink:href="kymr-20201231.xsd#Role_DisclosureCollaborations" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureCollaborations">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201409Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201409Member" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="10120.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationTables" xlink:href="kymr-20201231.xsd#Role_DisclosureEquityBasedCompensationTables" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" order="10270.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="kymr-20201231.xsd#Role_DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="kymr-20201231.xsd#kymr_ProceedsFromIssuanceInitialPublicOfferingGross" xlink:type="locator" xlink:label="kymr_ProceedsFromIssuanceInitialPublicOfferingGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsAndCash" xlink:type="locator" xlink:label="us-gaap_InvestmentsAndCash" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_VertexPharmaceuticalsIncorporatedMember" xlink:type="locator" xlink:label="kymr_VertexPharmaceuticalsIncorporatedMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain_2" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="kymr_VertexPharmaceuticalsIncorporatedMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_InvestmentsAndCash" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="kymr_ProceedsFromIssuanceInitialPublicOfferingGross" order="10570.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="kymr-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_MarketableSecuritiesRemainingMaturityPeriodClassifiedAsNonCurrent" xlink:type="locator" xlink:label="kymr_MarketableSecuritiesRemainingMaturityPeriodClassifiedAsNonCurrent" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_MarketableSecuritiesRemainingMaturityPeriod" xlink:type="locator" xlink:label="kymr_MarketableSecuritiesRemainingMaturityPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201813Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201813Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201815Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201815Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201904Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201904Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="kymr_SummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="kymr_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="kymr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="kymr_SummaryOfSignificantAccountingPoliciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="kymr_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="kymr_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201904Member" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201815Member" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201813Member" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="kymr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="kymr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="kymr_MarketableSecuritiesRemainingMaturityPeriod" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="kymr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="kymr_MarketableSecuritiesRemainingMaturityPeriodClassifiedAsNonCurrent" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="kymr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="kymr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="kymr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="kymr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="kymr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="kymr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="10690.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfRelatedAssetDetails" xlink:href="kymr-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfRelatedAssetDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfRelatedAssetDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_LabEquipmentMember" xlink:type="locator" xlink:label="kymr_LabEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="kymr_LabEquipmentMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="10280.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="kymr-20201231.xsd#Role_DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_RestrictedCashFairValue" xlink:type="locator" xlink:label="kymr_RestrictedCashFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateBondSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="locator" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="10090.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_2" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_2" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateBondSecuritiesMember" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasurySecuritiesMember" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesCurrent" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesNoncurrent" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="11340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="kymr_RestrictedCashFairValue" order="11420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="11500.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleDebtSecuritiesDetails" xlink:href="kymr-20201231.xsd#Role_DisclosureMarketableSecuritiesSummaryOfAvailableForSaleDebtSecuritiesDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleDebtSecuritiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesTable" order="10040.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10530.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetails" xlink:href="kymr-20201231.xsd#Role_DisclosureCollaborationsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetails">
    <link:loc xlink:href="kymr-20201231.xsd#kymr_WrittenNoticePeriodToTerminateCollaborationAgreement" xlink:type="locator" xlink:label="kymr_WrittenNoticePeriodToTerminateCollaborationAgreement" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TemporaryEquityStockSharesVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement" xlink:type="locator" xlink:label="kymr_TemporaryEquityStockSharesVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_PotentialReceivableMilestonePayments" xlink:type="locator" xlink:label="kymr_PotentialReceivableMilestonePayments" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_PreferredStockIssuancePremium" xlink:type="locator" xlink:label="kymr_PreferredStockIssuancePremium" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_NonRefundableUpfrontPaymentReceived" xlink:type="locator" xlink:label="kymr_NonRefundableUpfrontPaymentReceived" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_ExtendedResearchTermOfCollaboration" xlink:type="locator" xlink:label="kymr_ExtendedResearchTermOfCollaboration" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_InitialResearchTermOfCollaboration" xlink:type="locator" xlink:label="kymr_InitialResearchTermOfCollaboration" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_RemainingResearchTermOfCollaboration" xlink:type="locator" xlink:label="kymr_RemainingResearchTermOfCollaboration" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BilledContractReceivables" xlink:type="locator" xlink:label="us-gaap_BilledContractReceivables" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnbilledContractsReceivable" xlink:type="locator" xlink:label="us-gaap_UnbilledContractsReceivable" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_RoyaltyReceivable" xlink:type="locator" xlink:label="kymr_RoyaltyReceivable" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_MilestoneReceivable" xlink:type="locator" xlink:label="kymr_MilestoneReceivable" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_CostReimbursementReceivable" xlink:type="locator" xlink:label="kymr_CostReimbursementReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_CollaborationAgreementTransactionPrice" xlink:type="locator" xlink:label="kymr_CollaborationAgreementTransactionPrice" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_CommercialMilestonePayments" xlink:type="locator" xlink:label="kymr_CommercialMilestonePayments" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_DevelopmentMilestonePayments" xlink:type="locator" xlink:label="kymr_DevelopmentMilestonePayments" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_UpfrontPayment" xlink:type="locator" xlink:label="kymr_UpfrontPayment" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesAPreferredUnitsMember" xlink:type="locator" xlink:label="kymr_SeriesAPreferredUnitsMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_CompoundCollaborationAgreementMember" xlink:type="locator" xlink:label="kymr_CompoundCollaborationAgreementMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesB1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="kymr_SeriesB1ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_VertexAgreementMember" xlink:type="locator" xlink:label="kymr_VertexAgreementMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_CollaborationTargetTwoMember" xlink:type="locator" xlink:label="kymr_CollaborationTargetTwoMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_CollaborationTargetOneMember" xlink:type="locator" xlink:label="kymr_CollaborationTargetOneMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_IRAK4Member" xlink:type="locator" xlink:label="kymr_IRAK4Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember" xlink:type="locator" xlink:label="us-gaap_ProjectMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember" xlink:type="locator" xlink:label="us-gaap_ProjectMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:type="locator" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SanofiCollaborationArrangementMember" xlink:type="locator" xlink:label="kymr_SanofiCollaborationArrangementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="kymr_SanofiCollaborationArrangementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_ProjectMember_2" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_ProjectMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProjectMember" xlink:to="kymr_IRAK4Member" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="kymr_CollaborationTargetOneMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="kymr_CollaborationTargetTwoMember" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="kymr_VertexAgreementMember" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="11080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="kymr_SeriesB1ConvertiblePreferredStockMember" order="11130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="kymr_CompoundCollaborationAgreementMember" order="11710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="kymr_SeriesAPreferredUnitsMember" order="11850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="kymr_UpfrontPayment" order="12020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="kymr_DevelopmentMilestonePayments" order="12040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="kymr_CommercialMilestonePayments" order="12080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="kymr_CollaborationAgreementTransactionPrice" order="12150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="12240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="12300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="kymr_CostReimbursementReceivable" order="12320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="kymr_MilestoneReceivable" order="12340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="kymr_RoyaltyReceivable" order="12360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_UnbilledContractsReceivable" order="12380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_BilledContractReceivables" order="12400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="kymr_RemainingResearchTermOfCollaboration" order="12420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="kymr_InitialResearchTermOfCollaboration" order="12470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="kymr_ExtendedResearchTermOfCollaboration" order="12490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="kymr_NonRefundableUpfrontPaymentReceived" order="12540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="12560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="12580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="kymr_PreferredStockIssuancePremium" order="12600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="kymr_PotentialReceivableMilestonePayments" order="12650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="12750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" order="12870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="13020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="13100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="13180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="kymr_TemporaryEquityStockSharesVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement" order="13260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="kymr_WrittenNoticePeriodToTerminateCollaborationAgreement" order="13370.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureCollaborationsChangeInAccountsReceivableContractAssetAndLiabilitiesDetails" xlink:href="kymr-20201231.xsd#Role_DisclosureCollaborationsChangeInAccountsReceivableContractAssetAndLiabilitiesDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureCollaborationsChangeInAccountsReceivableContractAssetAndLiabilitiesDetails">
    <link:loc xlink:href="kymr-20201231.xsd#kymr_ContractWithCustomerLiabilityDeductions" xlink:type="locator" xlink:label="kymr_ContractWithCustomerLiabilityDeductions" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_ContractWithCustomerLiabilityAdditions" xlink:type="locator" xlink:label="kymr_ContractWithCustomerLiabilityAdditions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_ContractWithCustomerAssetNetDeductions" xlink:type="locator" xlink:label="kymr_ContractWithCustomerAssetNetDeductions" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_ContractWithCustomerAssetNetAdditions" xlink:type="locator" xlink:label="kymr_ContractWithCustomerAssetNetAdditions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_DeferredRevenueSanofiMember" xlink:type="locator" xlink:label="kymr_DeferredRevenueSanofiMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_DeferredRevenueVertexMember" xlink:type="locator" xlink:label="kymr_DeferredRevenueVertexMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_UnbilledReceivablesSanofiMember" xlink:type="locator" xlink:label="kymr_UnbilledReceivablesSanofiMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_BilledReceivablesSanofiMember" xlink:type="locator" xlink:label="kymr_BilledReceivablesSanofiMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="kymr_BilledReceivablesSanofiMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="kymr_UnbilledReceivablesSanofiMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="kymr_DeferredRevenueVertexMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="kymr_DeferredRevenueSanofiMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="kymr_ContractWithCustomerAssetNetAdditions" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="kymr_ContractWithCustomerAssetNetDeductions" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="11010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="kymr_ContractWithCustomerLiabilityAdditions" order="11190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="kymr_ContractWithCustomerLiabilityDeductions" order="11370.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" xlink:href="kymr-20201231.xsd#Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_AssetsNotYetInServiceMember" xlink:type="locator" xlink:label="kymr_AssetsNotYetInServiceMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_LabEquipmentMember" xlink:type="locator" xlink:label="kymr_LabEquipmentMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_LabAndOfficeEquipmentMember" xlink:type="locator" xlink:label="kymr_LabAndOfficeEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="kymr_LabAndOfficeEquipmentMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="kymr_LabEquipmentMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="kymr_AssetsNotYetInServiceMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10560.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:href="kymr-20201231.xsd#Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_AccumulatedAmortization" xlink:type="locator" xlink:label="kymr_AccumulatedAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_LabAndOfficeEquipmentMember" xlink:type="locator" xlink:label="kymr_LabAndOfficeEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="kymr_LabAndOfficeEquipmentMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_Depreciation" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="kymr_AccumulatedAmortization" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="10320.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:href="kymr-20201231.xsd#Role_DisclosureLeasesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails">
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TenantIncentiveAllowanceReceivable" xlink:type="locator" xlink:label="kymr_TenantIncentiveAllowanceReceivable" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_LeaseAdditionalTerm" xlink:type="locator" xlink:label="kymr_LeaseAdditionalTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_LeaseTerm" xlink:type="locator" xlink:label="kymr_LeaseTerm" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_LeaseCommencementDate" xlink:type="locator" xlink:label="kymr_LeaseCommencementDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit" xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_LeaseTerminationDate" xlink:type="locator" xlink:label="kymr_LeaseTerminationDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLeasehold" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLeasehold" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:type="locator" xlink:label="us-gaap_AreaOfRealEstateProperty" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_WatertownMassachusettsMember" xlink:type="locator" xlink:label="kymr_WatertownMassachusettsMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_FacilitySubleaseAgreementMember" xlink:type="locator" xlink:label="kymr_FacilitySubleaseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:type="locator" xlink:label="us-gaap_LetterOfCreditMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMember" xlink:type="locator" xlink:label="us-gaap_OtherAssetsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_NoncancelableFacilityLeaseAgreementMember" xlink:type="locator" xlink:label="kymr_NoncancelableFacilityLeaseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_CambridgeMassachusettsMember" xlink:type="locator" xlink:label="kymr_CambridgeMassachusettsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="kymr_CambridgeMassachusettsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="kymr_NoncancelableFacilityLeaseAgreementMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherAssetsMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherCurrentAssetsMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_CreditFacilityAxis" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_2" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_LetterOfCreditMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="kymr_FacilitySubleaseAgreementMember" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="kymr_WatertownMassachusettsMember" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ImpairmentOfLeasehold" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="kymr_LeaseTerminationDate" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_SecurityDeposit" order="10950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="kymr_LeaseCommencementDate" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="kymr_LeaseTerm" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="11130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="kymr_LeaseAdditionalTerm" order="11150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="kymr_TenantIncentiveAllowanceReceivable" order="11170.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureOtherCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="kymr-20201231.xsd#Role_DisclosureOtherCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureOtherCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndemnificationGuaranteeMember" xlink:type="locator" xlink:label="us-gaap_IndemnificationGuaranteeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:type="locator" xlink:label="us-gaap_LossContingencyNatureDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:type="locator" xlink:label="us-gaap_LossContingencyNatureDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="locator" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:type="locator" xlink:label="us-gaap_LossContingenciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:type="locator" xlink:label="us-gaap_LossContingenciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingencyNatureDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingencyNatureDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="us-gaap_IndemnificationGuaranteeMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue" order="10120.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:href="kymr-20201231.xsd#Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_IncreaseInAccumulatedDeficitRelatedToTemporaryEquityDeemedDividend" xlink:type="locator" xlink:label="kymr_IncreaseInAccumulatedDeficitRelatedToTemporaryEquityDeemedDividend" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_AdjustmentsToAdditionalPaidInCapitalRelatedToTemporaryEquityDeemedDividend" xlink:type="locator" xlink:label="kymr_AdjustmentsToAdditionalPaidInCapitalRelatedToTemporaryEquityDeemedDividend" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDividendsAdjustment" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDividendsAdjustment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesCPreferredStockPurchaseAgreementMember" xlink:type="locator" xlink:label="kymr_SeriesCPreferredStockPurchaseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesCConvertiblePreferredStockMember" xlink:type="locator" xlink:label="kymr_SeriesCConvertiblePreferredStockMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesB1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="kymr_SeriesB1ConvertiblePreferredStockMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="kymr_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="kymr_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesSeedConvertiblePreferredStockMember" xlink:type="locator" xlink:label="kymr_SeriesSeedConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="kymr_SeriesSeedConvertiblePreferredStockMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="kymr_SeriesAConvertiblePreferredStockMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="kymr_SeriesBConvertiblePreferredStockMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="kymr_SeriesB1ConvertiblePreferredStockMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="kymr_SeriesCConvertiblePreferredStockMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="kymr_SeriesCPreferredStockPurchaseAgreementMember" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="11030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="11240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="11280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityDividendsAdjustment" order="11360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="kymr_AdjustmentsToAdditionalPaidInCapitalRelatedToTemporaryEquityDeemedDividend" order="11400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="kymr_IncreaseInAccumulatedDeficitRelatedToTemporaryEquityDeemedDividend" order="11440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="11550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="11590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="11670.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAdditionalInformationDetails" xlink:href="kymr-20201231.xsd#Role_DisclosureEquityBasedCompensationAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:type="locator" xlink:label="us-gaap_GranteeStatusDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:type="locator" xlink:label="us-gaap_GranteeStatusDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:type="locator" xlink:label="us-gaap_GranteeStatusAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TwoThousandEighteenStockOptionAndGrantPlanMember" xlink:type="locator" xlink:label="kymr_TwoThousandEighteenStockOptionAndGrantPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_LesserOfPotentialOutcomeTwoMember" xlink:type="locator" xlink:label="kymr_LesserOfPotentialOutcomeTwoMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_LesserOfPotentialOutcomeOneMember" xlink:type="locator" xlink:label="kymr_LesserOfPotentialOutcomeOneMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_ScenarioPotentialOutcomeDomain" xlink:type="locator" xlink:label="kymr_ScenarioPotentialOutcomeDomain" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_ScenarioPotentialOutcomeDomain" xlink:type="locator" xlink:label="kymr_ScenarioPotentialOutcomeDomain_2" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_ScenarioPotentialOutcomeAxis" xlink:type="locator" xlink:label="kymr_ScenarioPotentialOutcomeAxis" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="kymr_TwoThousandTwentyEmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TwoThousandTwentyStockOptionAndIncentivePlanMember" xlink:type="locator" xlink:label="kymr_TwoThousandTwentyStockOptionAndIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="kymr_TwoThousandTwentyStockOptionAndIncentivePlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="kymr_TwoThousandTwentyEmployeeStockPurchasePlanMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="kymr_ScenarioPotentialOutcomeAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="kymr_ScenarioPotentialOutcomeAxis" xlink:to="kymr_ScenarioPotentialOutcomeDomain_2" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="kymr_ScenarioPotentialOutcomeAxis" xlink:to="kymr_ScenarioPotentialOutcomeDomain" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="kymr_ScenarioPotentialOutcomeDomain" xlink:to="kymr_LesserOfPotentialOutcomeOneMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="kymr_ScenarioPotentialOutcomeDomain" xlink:to="kymr_LesserOfPotentialOutcomeTwoMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="kymr_TwoThousandEighteenStockOptionAndGrantPlanMember" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain_2" order="11030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="11100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="11140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" order="11290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="11330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="11480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="11550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="11620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="11700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="11770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="11860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" order="11940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="12010.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfStockOptionActivityDetails" xlink:href="kymr-20201231.xsd#Role_DisclosureEquityBasedCompensationSummaryOfStockOptionActivityDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfStockOptionActivityDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue" xlink:type="locator" xlink:label="kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue" xlink:type="locator" xlink:label="kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract" xlink:type="locator" xlink:label="kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TwoThousandAndTwentyStockOptionAndGrantPlanMember" xlink:type="locator" xlink:label="kymr_TwoThousandAndTwentyStockOptionAndGrantPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="kymr_TwoThousandAndTwentyStockOptionAndGrantPlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="11130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="11330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="11430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="11530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="11630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" order="11960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="12160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="12360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract" order="12490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="12690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract" xlink:to="kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue" order="12790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="12890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract" xlink:to="kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue" order="12990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="13190.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfEquityBasedCompensationExpenseDetails" xlink:href="kymr-20201231.xsd#Role_DisclosureEquityBasedCompensationSummaryOfEquityBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfEquityBasedCompensationExpenseDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10280.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfRestrictedStockActivityDetails" xlink:href="kymr-20201231.xsd#Role_DisclosureEquityBasedCompensationSummaryOfRestrictedStockActivityDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfRestrictedStockActivityDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TwoThousandEighteenStockOptionAndGrantPlanMember" xlink:type="locator" xlink:label="kymr_TwoThousandEighteenStockOptionAndGrantPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="kymr_TwoThousandEighteenStockOptionAndGrantPlanMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="10990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="11050.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="kymr-20201231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestorMember" xlink:type="locator" xlink:label="us-gaap_InvestorMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_InvestorMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="10120.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="kymr-20201231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OpenTaxYear" xlink:type="locator" xlink:label="us-gaap_OpenTaxYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_ResearchAndDevelopmentCreditCarryforwards" xlink:type="locator" xlink:label="kymr_ResearchAndDevelopmentCreditCarryforwards" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_NetOperatingLossBeginToExpireYear" xlink:type="locator" xlink:label="kymr_NetOperatingLossBeginToExpireYear" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_FederalNetOperatingLossCarryoversNotSubjectToExpiration" xlink:type="locator" xlink:label="kymr_FederalNetOperatingLossCarryoversNotSubjectToExpiration" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LatestTaxYearMember" xlink:type="locator" xlink:label="us-gaap_LatestTaxYearMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarliestTaxYearMember" xlink:type="locator" xlink:label="us-gaap_EarliestTaxYearMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:type="locator" xlink:label="us-gaap_TaxPeriodAxis" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_FederalAndStateMember" xlink:type="locator" xlink:label="kymr_FederalAndStateMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_IncomeTaxDisclosureTable" xlink:type="locator" xlink:label="kymr_IncomeTaxDisclosureTable" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_IncomeTaxDisclosureLineItems" xlink:type="locator" xlink:label="kymr_IncomeTaxDisclosureLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="kymr_IncomeTaxDisclosureLineItems" xlink:to="kymr_IncomeTaxDisclosureTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="kymr_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="kymr_FederalAndStateMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="kymr_IncomeTaxDisclosureTable" xlink:to="us-gaap_TaxPeriodAxis" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain_2" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_EarliestTaxYearMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_LatestTaxYearMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="kymr_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="kymr_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="kymr_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="kymr_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="kymr_IncomeTaxDisclosureLineItems" xlink:to="kymr_FederalNetOperatingLossCarryoversNotSubjectToExpiration" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="kymr_IncomeTaxDisclosureLineItems" xlink:to="kymr_NetOperatingLossBeginToExpireYear" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="kymr_IncomeTaxDisclosureLineItems" xlink:to="kymr_ResearchAndDevelopmentCreditCarryforwards" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="kymr_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="kymr_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="kymr_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_OpenTaxYear" order="10940.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfDilutedNetLossPerShareAttributableToCommonStockholdersAntiDilutedEffectDetail" xlink:href="kymr-20201231.xsd#Role_DisclosureNetLossPerShareScheduleOfDilutedNetLossPerShareAttributableToCommonStockholdersAntiDilutedEffectDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfDilutedNetLossPerShareAttributableToCommonStockholdersAntiDilutedEffectDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10200.00" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>47
<FILENAME>kymr-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-11T04:08:03.4243335+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 393cc6ba0c39453d8ef47a8f7fceea15 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_RestrictedCashFairValue" xlink:type="locator" xlink:label="kymr_RestrictedCashFairValue" />
    <link:label xml:lang="en-US" xlink:label="kymr_RestrictedCashFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted cash fair value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_RestrictedCashFairValue" xlink:to="kymr_RestrictedCashFairValue_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well Known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line2</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Class Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Domain]</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesSeedConvertiblePreferredStockMember" xlink:type="locator" xlink:label="kymr_SeriesSeedConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="kymr_SeriesSeedConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series seed convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_SeriesSeedConvertiblePreferredStockMember" xlink:to="kymr_SeriesSeedConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_SeriesSeedConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series Seed Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_SeriesSeedConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series Seed Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="kymr_SeriesAConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="kymr_SeriesAConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_SeriesAConvertiblePreferredStockMember" xlink:to="kymr_SeriesAConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_SeriesAConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_SeriesAConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="kymr_SeriesBConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="kymr_SeriesBConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_SeriesBConvertiblePreferredStockMember" xlink:to="kymr_SeriesBConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_SeriesBConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_SeriesBConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series B Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesB1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="kymr_SeriesB1ConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="kymr_SeriesB1ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B-1 convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_SeriesB1ConvertiblePreferredStockMember" xlink:to="kymr_SeriesB1ConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_SeriesB1ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B-1 Convertible Preferred</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_SeriesB1ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series B1 Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities (Note 4)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable&#8212;due from related parties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedPartiesCurrent" xlink:to="us-gaap_DueFromRelatedPartiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Due From Related Parties Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract assets&#8212;due from related parties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Asset Net Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities, non-current (Note 4)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net (Note 6)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets, operating leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses (Note 8)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease liabilities, current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Noncurrent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, net of current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, net of current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease liabilities, net of current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 9)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Carrying Amount Attributable To Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity (deficit):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.0001 par value; 10,000,000 and 0 shares authorized as of December 31, 2020 and December 31, 2019, respectively; 0 shares issued or outstanding as of December 31, 2020 and December 31, 2019</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.0001 par value; 150,000,000 and 45,000,000 shares authorized at December 31, 2020 and December 31, 2019, respectively, 44,592,288 and 2,208,982 shares issued at December 31, 2020 and December 31, 2019, respectively; 44,482,186 and 1,929,516 shares outstanding at December 31, 2020 and December 31, 2019, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive (loss) income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity (deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities, convertible preferred stock and stockholders&#8217; equity (deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock, authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock, issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock, outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock, liquidation preference</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Liquidation Preference</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock, outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Revenue&#8212;from related party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Excluding Assessed Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue from Contract with Customer, Product and Service [Extensible List]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:to="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Product And Service Extensible List</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest Income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive loss:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized (loss) gain on marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of net loss to net loss attributable to common stockholders:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss Available To Common Stockholders Basic [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDividendsAdjustment" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDividendsAdjustment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityDividendsAdjustment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deemed dividend from exchange of convertible preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityDividendsAdjustment" xlink:to="us-gaap_TemporaryEquityDividendsAdjustment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityDividendsAdjustment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Dividends Adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss attributable to common stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss Available To Common Stockholders Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to common stockholders, basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average common stocks outstanding, basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TemporaryEquityStockValueVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement" xlink:type="locator" xlink:label="kymr_TemporaryEquityStockValueVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement" />
    <link:label xml:lang="en-US" xlink:label="kymr_TemporaryEquityStockValueVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock value vesting of series A preferred stock in connection with collaboration arrangement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_TemporaryEquityStockValueVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement" xlink:to="kymr_TemporaryEquityStockValueVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement_lbl" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TemporaryEquityStockSharesVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement" xlink:type="locator" xlink:label="kymr_TemporaryEquityStockSharesVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement" />
    <link:label xml:lang="en-US" xlink:label="kymr_TemporaryEquityStockSharesVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock shares vesting of series A preferred stock in connection with collaboration arrangement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_TemporaryEquityStockSharesVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement" xlink:to="kymr_TemporaryEquityStockSharesVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement_lbl" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TemporaryEquityConvertiblePreferredStockIssuedDuringPeriodValue" xlink:type="locator" xlink:label="kymr_TemporaryEquityConvertiblePreferredStockIssuedDuringPeriodValue" />
    <link:label xml:lang="en-US" xlink:label="kymr_TemporaryEquityConvertiblePreferredStockIssuedDuringPeriodValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity convertible preferred stock issued during period value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_TemporaryEquityConvertiblePreferredStockIssuedDuringPeriodValue" xlink:to="kymr_TemporaryEquityConvertiblePreferredStockIssuedDuringPeriodValue_lbl" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TemporaryEquityConvertiblePreferredStockIssuedDuringPeriodShares" xlink:type="locator" xlink:label="kymr_TemporaryEquityConvertiblePreferredStockIssuedDuringPeriodShares" />
    <link:label xml:lang="en-US" xlink:label="kymr_TemporaryEquityConvertiblePreferredStockIssuedDuringPeriodShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity convertible preferred stock issued during period shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_TemporaryEquityConvertiblePreferredStockIssuedDuringPeriodShares" xlink:to="kymr_TemporaryEquityConvertiblePreferredStockIssuedDuringPeriodShares_lbl" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_StockIssuedDuringPeriodValueRestrictedStockVested" xlink:type="locator" xlink:label="kymr_StockIssuedDuringPeriodValueRestrictedStockVested" />
    <link:label xml:lang="en-US" xlink:label="kymr_StockIssuedDuringPeriodValueRestrictedStockVested_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value restricted stock vested.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_StockIssuedDuringPeriodValueRestrictedStockVested" xlink:to="kymr_StockIssuedDuringPeriodValueRestrictedStockVested_lbl" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="kymr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="kymr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during period shares new issues.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="kymr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TemporaryEquityExchangeOfConvertiblePreferredStockValue" xlink:type="locator" xlink:label="kymr_TemporaryEquityExchangeOfConvertiblePreferredStockValue" />
    <link:label xml:lang="en-US" xlink:label="kymr_TemporaryEquityExchangeOfConvertiblePreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity, exchange of convertible preferred stock, value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_TemporaryEquityExchangeOfConvertiblePreferredStockValue" xlink:to="kymr_TemporaryEquityExchangeOfConvertiblePreferredStockValue_lbl" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TemporaryEquityExchangeOfConvertiblePreferredStockShares" xlink:type="locator" xlink:label="kymr_TemporaryEquityExchangeOfConvertiblePreferredStockShares" />
    <link:label xml:lang="en-US" xlink:label="kymr_TemporaryEquityExchangeOfConvertiblePreferredStockShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity, exchange of convertible preferred stock, shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_TemporaryEquityExchangeOfConvertiblePreferredStockShares" xlink:to="kymr_TemporaryEquityExchangeOfConvertiblePreferredStockShares_lbl" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TemporaryEquitySharesConverted" xlink:type="locator" xlink:label="kymr_TemporaryEquitySharesConverted" />
    <link:label xml:lang="en-US" xlink:label="kymr_TemporaryEquitySharesConverted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity shares converted.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_TemporaryEquitySharesConverted" xlink:to="kymr_TemporaryEquitySharesConverted_lbl" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TemporaryEquityValueOfSharesConverted" xlink:type="locator" xlink:label="kymr_TemporaryEquityValueOfSharesConverted" />
    <link:label xml:lang="en-US" xlink:label="kymr_TemporaryEquityValueOfSharesConverted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity value of shares converted.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_TemporaryEquityValueOfSharesConverted" xlink:to="kymr_TemporaryEquityValueOfSharesConverted_lbl" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TemporaryEquityAdjustedCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="kymr_TemporaryEquityAdjustedCarryingAmountAttributableToParent" />
    <link:label xml:lang="en-US" xlink:label="kymr_TemporaryEquityAdjustedCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity adjusted carrying amount attributable to parent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_TemporaryEquityAdjustedCarryingAmountAttributableToParent" xlink:to="kymr_TemporaryEquityAdjustedCarryingAmountAttributableToParent_lbl" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_ExchangeOfConvertiblePreferredStockImpactOnEquity" xlink:type="locator" xlink:label="kymr_ExchangeOfConvertiblePreferredStockImpactOnEquity" />
    <link:label xml:lang="en-US" xlink:label="kymr_ExchangeOfConvertiblePreferredStockImpactOnEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Exchange of convertible preferred stock impact on equity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_ExchangeOfConvertiblePreferredStockImpactOnEquity" xlink:to="kymr_ExchangeOfConvertiblePreferredStockImpactOnEquity_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">I P O [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid In Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesCConvertiblePreferredStockMember" xlink:type="locator" xlink:label="kymr_SeriesCConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="kymr_SeriesCConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series C convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_SeriesCConvertiblePreferredStockMember" xlink:to="kymr_SeriesCConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_SeriesCConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_SeriesCConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series C Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_TemporaryEquityAdjustedCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Temporary Equity, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_TemporaryEquityAdjustedCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Adjusted Carrying Amount Attributable To Parent</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TemporaryEquityAdjustedSharesOutstanding" xlink:type="locator" xlink:label="kymr_TemporaryEquityAdjustedSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="kymr_TemporaryEquityAdjustedSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity adjusted shares outstanding.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_TemporaryEquityAdjustedSharesOutstanding" xlink:to="kymr_TemporaryEquityAdjustedSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_TemporaryEquityAdjustedSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Temporary Equity, Beginning Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_TemporaryEquityAdjustedSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Adjusted Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_TemporaryEquityStockValueVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of Series A Preferred Stock in connection with collaboration arrangement (Note 5)</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_TemporaryEquityStockValueVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Value Vesting Of Series A Preferred Stock In Connection With Collaboration Arrangement</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_TemporaryEquityStockSharesVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of Series A Preferred Stock in connection with collaboration arrangement (Note 5), Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_TemporaryEquityStockSharesVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Shares Vesting Of Series A Preferred Stock In Connection With Collaboration Arrangement</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_TemporaryEquityConvertiblePreferredStockIssuedDuringPeriodValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Convertible Preferred Stock, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_TemporaryEquityConvertiblePreferredStockIssuedDuringPeriodValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Convertible Preferred Stock Issued During Period Value</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_TemporaryEquityConvertiblePreferredStockIssuedDuringPeriodShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Convertible Preferred Stock,net of issuance cost, shares</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_TemporaryEquityConvertiblePreferredStockIssuedDuringPeriodShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Convertible Preferred Stock Issued During Period Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Preferred Stock, net of issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Value New Issues</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_TemporaryEquityExchangeOfConvertiblePreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity, Exchange of Series A Convertible Preferred Stock for Series C Preferred Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_TemporaryEquityExchangeOfConvertiblePreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Exchange Of Convertible Preferred Stock Value</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_ExchangeOfConvertiblePreferredStockImpactOnEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exchange of Series A Convertible Preferred Stock for Series C Preferred Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_ExchangeOfConvertiblePreferredStockImpactOnEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Exchange Of Convertible Preferred Stock Impact On Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of Stock Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_StockIssuedDuringPeriodValueRestrictedStockVested_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting Restricted Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_StockIssuedDuringPeriodValueRestrictedStockVested_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Restricted Stock Vested</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain on marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_TemporaryEquityValueOfSharesConverted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Temporary equity, conversion of convertible preferred stock into common</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_TemporaryEquityValueOfSharesConverted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Value Of Shares Converted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock into common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Conversion Of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock into common, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_TemporaryEquityAdjustedCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary Equity, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_TemporaryEquityAdjustedSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary Equity, Beginning Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Preferred Stock, net of issuance costs, Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_TemporaryEquityExchangeOfConvertiblePreferredStockShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity, Exchange of Series A Convertible Preferred Stock for Series C Preferred Convertible Preferred Stock, Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_TemporaryEquityExchangeOfConvertiblePreferredStockShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Exchange Of Convertible Preferred Stock Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_TemporaryEquitySharesConverted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Temporary equity, conversion of convertible preferred stock into common, Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_TemporaryEquitySharesConverted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Converted</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesBConvertiblePreferredStocksMember" xlink:type="locator" xlink:label="kymr_SeriesBConvertiblePreferredStocksMember" />
    <link:label xml:lang="en-US" xlink:label="kymr_SeriesBConvertiblePreferredStocksMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_SeriesBConvertiblePreferredStocksMember" xlink:to="kymr_SeriesBConvertiblePreferredStocksMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_SeriesBConvertiblePreferredStocksMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_SeriesBConvertiblePreferredStocksMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series B Convertible Preferred Stocks [Member]</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesB1PreferredStockMember" xlink:type="locator" xlink:label="kymr_SeriesB1PreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="kymr_SeriesB1PreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B1 preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_SeriesB1PreferredStockMember" xlink:to="kymr_SeriesB1PreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_SeriesB1PreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B-1 Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_SeriesB1PreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series B1 Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series B Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series C Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting discounts, offering costs and issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Stock Issuance Costs</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_StockIssuedDuringPeriodSharesRestrictedStockVested" xlink:type="locator" xlink:label="kymr_StockIssuedDuringPeriodSharesRestrictedStockVested" />
    <link:label xml:lang="en-US" xlink:label="kymr_StockIssuedDuringPeriodSharesRestrictedStockVested_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares restricted stock vested.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_StockIssuedDuringPeriodSharesRestrictedStockVested" xlink:to="kymr_StockIssuedDuringPeriodSharesRestrictedStockVested_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of Stock Options, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_StockIssuedDuringPeriodSharesRestrictedStockVested_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting Restricted Stock, Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_StockIssuedDuringPeriodSharesRestrictedStockVested_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Restricted Stock Vested</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of shares, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, Shares</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_NonCashResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="kymr_NonCashResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="kymr_NonCashResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non cash research and development expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_NonCashResearchAndDevelopmentExpense" xlink:to="kymr_NonCashResearchAndDevelopmentExpense_lbl" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_NetAmortizationOfPremiumsAndDiscountsOnInvestments" xlink:type="locator" xlink:label="kymr_NetAmortizationOfPremiumsAndDiscountsOnInvestments" />
    <link:label xml:lang="en-US" xlink:label="kymr_NetAmortizationOfPremiumsAndDiscountsOnInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Net amortization of premiums and discounts on investments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_NetAmortizationOfPremiumsAndDiscountsOnInvestments" xlink:to="kymr_NetAmortizationOfPremiumsAndDiscountsOnInvestments_lbl" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_IncreaseDecreaseInContractWithCustomerAssetRelatedParties" xlink:type="locator" xlink:label="kymr_IncreaseDecreaseInContractWithCustomerAssetRelatedParties" />
    <link:label xml:lang="en-US" xlink:label="kymr_IncreaseDecreaseInContractWithCustomerAssetRelatedParties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in contract with customer asset related parties.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_IncreaseDecreaseInContractWithCustomerAssetRelatedParties" xlink:to="kymr_IncreaseDecreaseInContractWithCustomerAssetRelatedParties_lbl" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:type="locator" xlink:label="kymr_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" />
    <link:label xml:lang="en-US" xlink:label="kymr_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in operating lease right-of-use assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:to="kymr_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_lbl" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="locator" xlink:label="kymr_IncreaseDecreaseInOperatingLeaseLiabilities" />
    <link:label xml:lang="en-US" xlink:label="kymr_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in operating lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="kymr_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_ProceedsFromConcurrentPrivatePlacement" xlink:type="locator" xlink:label="kymr_ProceedsFromConcurrentPrivatePlacement" />
    <link:label xml:lang="en-US" xlink:label="kymr_ProceedsFromConcurrentPrivatePlacement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from concurrent private placement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_ProceedsFromConcurrentPrivatePlacement" xlink:to="kymr_ProceedsFromConcurrentPrivatePlacement_lbl" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_PurchasesOfPropertyAndEquipmentThroughFinanceAndLeaseLiabilities" xlink:type="locator" xlink:label="kymr_PurchasesOfPropertyAndEquipmentThroughFinanceAndLeaseLiabilities" />
    <link:label xml:lang="en-US" xlink:label="kymr_PurchasesOfPropertyAndEquipmentThroughFinanceAndLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchases of property and equipment through finance and lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_PurchasesOfPropertyAndEquipmentThroughFinanceAndLeaseLiabilities" xlink:to="kymr_PurchasesOfPropertyAndEquipmentThroughFinanceAndLeaseLiabilities_lbl" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_PropertyAndEquipmentPurchasesIncludedInAccountsPayableAndAccruedExpenses" xlink:type="locator" xlink:label="kymr_PropertyAndEquipmentPurchasesIncludedInAccountsPayableAndAccruedExpenses" />
    <link:label xml:lang="en-US" xlink:label="kymr_PropertyAndEquipmentPurchasesIncludedInAccountsPayableAndAccruedExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Property and equipment purchases included in accounts payable and accrued expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_PropertyAndEquipmentPurchasesIncludedInAccountsPayableAndAccruedExpenses" xlink:to="kymr_PropertyAndEquipmentPurchasesIncludedInAccountsPayableAndAccruedExpenses_lbl" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_OfferingCostsIncludedInAccountsPayable" xlink:type="locator" xlink:label="kymr_OfferingCostsIncludedInAccountsPayable" />
    <link:label xml:lang="en-US" xlink:label="kymr_OfferingCostsIncludedInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Offering costs included in accounts payable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_OfferingCostsIncludedInAccountsPayable" xlink:to="kymr_OfferingCostsIncludedInAccountsPayable_lbl" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TenantImprovementReceivableIncludedInOtherAssets" xlink:type="locator" xlink:label="kymr_TenantImprovementReceivableIncludedInOtherAssets" />
    <link:label xml:lang="en-US" xlink:label="kymr_TenantImprovementReceivableIncludedInOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tenant improvement receivable included in other assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_TenantImprovementReceivableIncludedInOtherAssets" xlink:to="kymr_TenantImprovementReceivableIncludedInOtherAssets_lbl" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_ReductionOfRightOfUseAssetAndLiabilityDueToLeaseModification" xlink:type="locator" xlink:label="kymr_ReductionOfRightOfUseAssetAndLiabilityDueToLeaseModification" />
    <link:label xml:lang="en-US" xlink:label="kymr_ReductionOfRightOfUseAssetAndLiabilityDueToLeaseModification_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reduction of right of use asset and liability due to lease modification.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_ReductionOfRightOfUseAssetAndLiabilityDueToLeaseModification" xlink:to="kymr_ReductionOfRightOfUseAssetAndLiabilityDueToLeaseModification_lbl" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SupplementalDisclosureOfNoncashOperatingActivitiesAbstract" xlink:type="locator" xlink:label="kymr_SupplementalDisclosureOfNoncashOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="kymr_SupplementalDisclosureOfNoncashOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Supplemental disclosure of noncash operating activities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_SupplementalDisclosureOfNoncashOperatingActivitiesAbstract" xlink:to="kymr_SupplementalDisclosureOfNoncashOperatingActivitiesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_SeriesCConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series C Convertible Preferred Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation Depletion And Amortization</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_NonCashResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash research and development expense</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_NonCashResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Research And Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_NetAmortizationOfPremiumsAndDiscountsOnInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net amortization of premiums and discounts on investments</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_NetAmortizationOfPremiumsAndDiscountsOnInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Amortization Of Premiums And Discounts On Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable&#8212;due from related party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Receivable Related Parties</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_IncreaseDecreaseInContractWithCustomerAssetRelatedParties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Contract asset&#8212;due from related parties</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_IncreaseDecreaseInContractWithCustomerAssetRelatedParties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Contract With Customer Asset Related Parties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedParties" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedParties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other receivables&#8212;due from related parties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedParties_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedParties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Due From Related Parties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Contract With Customer Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other non-current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Noncurrent Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating lease right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Right Of Use Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Noncurrent Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Marketable Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturities of marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale And Maturity Of Marketable Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the issuance of Convertible Preferred Stock, net of issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Convertible Preferred Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from stock option exercises</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfFinancingCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments on financing leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Financing Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from initial public offering, net of underwriting discounts and offering costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_ProceedsFromConcurrentPrivatePlacement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from concurrent private placement</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_ProceedsFromConcurrentPrivatePlacement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Concurrent Private Placement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net (decrease) increase in cash, cash equivalents and restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of cash flow activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of noncash investing and financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Investing And Financing Items [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_PurchasesOfPropertyAndEquipmentThroughFinanceAndLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of property and equipment through finance and lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_PurchasesOfPropertyAndEquipmentThroughFinanceAndLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Purchases Of Property And Equipment Through Finance And Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_PropertyAndEquipmentPurchasesIncludedInAccountsPayableAndAccruedExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment purchases included in accounts payable and accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_PropertyAndEquipmentPurchasesIncludedInAccountsPayableAndAccruedExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property And Equipment Purchases Included In Accounts Payable And Accrued Expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_OfferingCostsIncludedInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering costs included in accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_OfferingCostsIncludedInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Offering Costs Included In Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_SupplementalDisclosureOfNoncashOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of noncash operating activities</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_SupplementalDisclosureOfNoncashOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Disclosure Of Noncash Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets obtained in exchange for operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Right Of Use Asset Obtained In Exchange For Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_TenantImprovementReceivableIncludedInOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant improvement receivable included in other assets</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_TenantImprovementReceivableIncludedInOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tenant Improvement Receivable Included In Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_ReductionOfRightOfUseAssetAndLiabilityDueToLeaseModification_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reduction of right-of-use asset and liability due to lease modification</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_ReductionOfRightOfUseAssetAndLiabilityDueToLeaseModification_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reduction Of Right Of Use Asset And Liability Due To Lease Modification</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash" xlink:type="locator" xlink:label="us-gaap_RestrictedCash" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated By Reference [Text Block]</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesAbstract" xlink:type="locator" xlink:label="kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesAbstract" />
    <link:label xml:lang="en-US" xlink:label="kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of business and summary of significant accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesAbstract" xlink:to="kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Business And Summary Of Significant Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of Business and Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Description And Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments For New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Adoption [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201409Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201409Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Topic 606</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201409Member" xlink:to="us-gaap_AccountingStandardsUpdate201409Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201409Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201409 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_LesseeOperatingAndFinanceLeasesTextBlock" xlink:type="locator" xlink:label="kymr_LesseeOperatingAndFinanceLeasesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="kymr_LesseeOperatingAndFinanceLeasesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating and finance leases.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_LesseeOperatingAndFinanceLeasesTextBlock" xlink:to="kymr_LesseeOperatingAndFinanceLeasesTextBlock_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_LesseeOperatingAndFinanceLeasesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_LesseeOperatingAndFinanceLeasesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating And Finance Leases [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Accrued Liabilities And Other Liabilities Disclosure Current [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:type="locator" xlink:label="us-gaap_PreferredStockTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockTextBlock" xlink:to="us-gaap_PreferredStockTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Accounting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SegmentAndGeographicInformationPolicyTextBlock" xlink:type="locator" xlink:label="kymr_SegmentAndGeographicInformationPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="kymr_SegmentAndGeographicInformationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Segment and geographic information.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_SegmentAndGeographicInformationPolicyTextBlock" xlink:to="kymr_SegmentAndGeographicInformationPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_SegmentAndGeographicInformationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment and Geographic Information</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_SegmentAndGeographicInformationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment And Geographic Information Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Unrestricted Cash And Cash Equivalents Policy</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_RestrictedCashPolicyPolicyTextBlock" xlink:type="locator" xlink:label="kymr_RestrictedCashPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="kymr_RestrictedCashPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted cash policy.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_RestrictedCashPolicyPolicyTextBlock" xlink:to="kymr_RestrictedCashPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_RestrictedCashPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_RestrictedCashPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Leases Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Or Disposal Of Long Lived Assets Policy [Text Block]</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_ConvertiblePreferredStockPolicyTextBlock" xlink:type="locator" xlink:label="kymr_ConvertiblePreferredStockPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="kymr_ConvertiblePreferredStockPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_ConvertiblePreferredStockPolicyTextBlock" xlink:to="kymr_ConvertiblePreferredStockPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_ConvertiblePreferredStockPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_ConvertiblePreferredStockPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_PatentCostsPolicyTextBlock" xlink:type="locator" xlink:label="kymr_PatentCostsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="kymr_PatentCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Patent costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_PatentCostsPolicyTextBlock" xlink:to="kymr_PatentCostsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_PatentCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patent Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_PatentCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Patent Costs Policy [Text Block]</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_FinancingCostsPolicyTextBlock" xlink:type="locator" xlink:label="kymr_FinancingCostsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="kymr_FinancingCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Financing costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_FinancingCostsPolicyTextBlock" xlink:to="kymr_FinancingCostsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_FinancingCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_FinancingCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financing Costs Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Policy [Text Block]</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_CostsAssociatedWithLicenseAndCollaborativeArrangementsPolicyTextBlock" xlink:type="locator" xlink:label="kymr_CostsAssociatedWithLicenseAndCollaborativeArrangementsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="kymr_CostsAssociatedWithLicenseAndCollaborativeArrangementsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Costs associated with license and collaborative arrangements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_CostsAssociatedWithLicenseAndCollaborativeArrangementsPolicyTextBlock" xlink:to="kymr_CostsAssociatedWithLicenseAndCollaborativeArrangementsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_CostsAssociatedWithLicenseAndCollaborativeArrangementsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Costs Associated with License and Collaborative Arrangements</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_CostsAssociatedWithLicenseAndCollaborativeArrangementsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Costs Associated With License And Collaborative Arrangements Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Option And Incentive Plans Policy</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_CommonAndPreferredStockValuationPolicyTextBlock" xlink:type="locator" xlink:label="kymr_CommonAndPreferredStockValuationPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="kymr_CommonAndPreferredStockValuationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common and preferred stock valuation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_CommonAndPreferredStockValuationPolicyTextBlock" xlink:to="kymr_CommonAndPreferredStockValuationPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_CommonAndPreferredStockValuationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common and Preferred Stock Valuation</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_CommonAndPreferredStockValuationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common And Preferred Stock Valuation Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Policy [Text Block]</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_OffBalanceSheetRiskAndConcentrationOfCreditRiskPolicyTextBlock" xlink:type="locator" xlink:label="kymr_OffBalanceSheetRiskAndConcentrationOfCreditRiskPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="kymr_OffBalanceSheetRiskAndConcentrationOfCreditRiskPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Off balance sheet risk and concentration of credit risk.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_OffBalanceSheetRiskAndConcentrationOfCreditRiskPolicyTextBlock" xlink:to="kymr_OffBalanceSheetRiskAndConcentrationOfCreditRiskPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_OffBalanceSheetRiskAndConcentrationOfCreditRiskPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Off Balance Sheet Risk and Concentration of Credit Risk</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_OffBalanceSheetRiskAndConcentrationOfCreditRiskPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Off Balance Sheet Risk And Concentration Of Credit Risk Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:type="locator" xlink:label="kymr_EmergingGrowthCompanyStatusPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="kymr_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Emerging growth company status.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:to="kymr_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Emerging Growth Company Status</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Emerging Growth Company Status Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SummaryOfEstimatedUsefulLifeOfRelatedAssetTableTextBlock" xlink:type="locator" xlink:label="kymr_SummaryOfEstimatedUsefulLifeOfRelatedAssetTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="kymr_SummaryOfEstimatedUsefulLifeOfRelatedAssetTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of estimated useful life of related asset.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_SummaryOfEstimatedUsefulLifeOfRelatedAssetTableTextBlock" xlink:to="kymr_SummaryOfEstimatedUsefulLifeOfRelatedAssetTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_SummaryOfEstimatedUsefulLifeOfRelatedAssetTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Estimated Useful Life of Related Asset</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_SummaryOfEstimatedUsefulLifeOfRelatedAssetTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Estimated Useful Life Of Related Asset Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Assets Measured at Fair Value on Recurring Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Available-for-Sale Debt Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in Accounts Receivable, Contract Asset and Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Asset And Liability Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Lease Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Cost Table [Text Block]</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SupplementalCashFlowInformationRelatingToLeasesTableTextBlock" xlink:type="locator" xlink:label="kymr_SupplementalCashFlowInformationRelatingToLeasesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="kymr_SupplementalCashFlowInformationRelatingToLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Supplemental cash flow information relating to leases.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_SupplementalCashFlowInformationRelatingToLeasesTableTextBlock" xlink:to="kymr_SupplementalCashFlowInformationRelatingToLeasesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_SupplementalCashFlowInformationRelatingToLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental Cash Flow Information Relating to Leases</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_SupplementalCashFlowInformationRelatingToLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information Relating To Leases Table [Text Block]</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock" xlink:type="locator" xlink:label="kymr_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="kymr_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of weighted average remaining lease terms and discount rates.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock" xlink:to="kymr_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Weighted Average Remaining Lease Terms and Discount Rates</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Weighted Average Remaining Lease Terms And Discount Rates Table [Text Block]</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_LesseeOperatingAndFinancingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="kymr_LesseeOperatingAndFinancingLeaseLiabilityMaturityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="kymr_LesseeOperatingAndFinancingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating and financing lease liability maturity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_LesseeOperatingAndFinancingLeaseLiabilityMaturityTableTextBlock" xlink:to="kymr_LesseeOperatingAndFinancingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_LesseeOperatingAndFinancingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Undiscounted Future Lease Payments for Operating and Finance Leases</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_LesseeOperatingAndFinancingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating And Financing Lease Liability Maturity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Equity-Based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Weighted-Average Assumptions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restricted Stock Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Unvested Restricted Stock Units Roll Forward Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rate Reconciliation of U.S. Statutory Income Tax Rate to Company&apos;s Effective Tax Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Significant Components of Net Deferred Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Basic and Diluted Loss Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Diluted Net Loss Per Share Attributable to Common Stockholders Anti-Diluted Effect</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of business and summary of significant accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" />
    <link:label xml:lang="en-US" xlink:label="kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of business and summary of significant accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description Of Business And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Business And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Initial Public Offering</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriters</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Over Allotment Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidated Entities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidated Entities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ConsolidatedEntitiesDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_VertexPharmaceuticalsIncorporatedMember" xlink:type="locator" xlink:label="kymr_VertexPharmaceuticalsIncorporatedMember" />
    <link:label xml:lang="en-US" xlink:label="kymr_VertexPharmaceuticalsIncorporatedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Vertex Pharmaceuticals Incorporated.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_VertexPharmaceuticalsIncorporatedMember" xlink:to="kymr_VertexPharmaceuticalsIncorporatedMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_VertexPharmaceuticalsIncorporatedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vertex Pharmaceuticals Incorporated</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_VertexPharmaceuticalsIncorporatedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Vertex Pharmaceuticals Incorporated [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description Of Business And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Business And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsAndCash" xlink:type="locator" xlink:label="us-gaap_InvestmentsAndCash" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsAndCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents and marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAndCash" xlink:to="us-gaap_InvestmentsAndCash_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsAndCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments And Cash</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split, description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Reverse Stock Split</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Stock Split Conversion Ratio1</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_ProceedsFromIssuanceInitialPublicOfferingGross" xlink:type="locator" xlink:label="kymr_ProceedsFromIssuanceInitialPublicOfferingGross" />
    <link:label xml:lang="en-US" xlink:label="kymr_ProceedsFromIssuanceInitialPublicOfferingGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance initial public offering gross.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_ProceedsFromIssuanceInitialPublicOfferingGross" xlink:to="kymr_ProceedsFromIssuanceInitialPublicOfferingGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Common stock shares issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_ProceedsFromIssuanceInitialPublicOfferingGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds from issuance initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_ProceedsFromIssuanceInitialPublicOfferingGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Initial Public Offering Gross</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="kymr_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="kymr_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="kymr_SummaryOfSignificantAccountingPoliciesLineItems_lbl" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="kymr_SummaryOfSignificantAccountingPoliciesTable" />
    <link:label xml:lang="en-US" xlink:label="kymr_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_SummaryOfSignificantAccountingPoliciesTable" xlink:to="kymr_SummaryOfSignificantAccountingPoliciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201904Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201904Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201904Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2019-04</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201904Member" xlink:to="us-gaap_AccountingStandardsUpdate201904Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201904Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201904 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201815Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201815Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201815Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2018-15</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201815Member" xlink:to="us-gaap_AccountingStandardsUpdate201815Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201815Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201815 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201813Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201813Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201813Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2018-13</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201813Member" xlink:to="us-gaap_AccountingStandardsUpdate201813Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201813Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201813 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Operating Segments</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_MarketableSecuritiesRemainingMaturityPeriod" xlink:type="locator" xlink:label="kymr_MarketableSecuritiesRemainingMaturityPeriod" />
    <link:label xml:lang="en-US" xlink:label="kymr_MarketableSecuritiesRemainingMaturityPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Marketable securities, remaining maturity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_MarketableSecuritiesRemainingMaturityPeriod" xlink:to="kymr_MarketableSecuritiesRemainingMaturityPeriod_lbl" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_MarketableSecuritiesRemainingMaturityPeriodClassifiedAsNonCurrent" xlink:type="locator" xlink:label="kymr_MarketableSecuritiesRemainingMaturityPeriodClassifiedAsNonCurrent" />
    <link:label xml:lang="en-US" xlink:label="kymr_MarketableSecuritiesRemainingMaturityPeriodClassifiedAsNonCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Marketable securities, remaining maturity period classified as non-current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_MarketableSecuritiesRemainingMaturityPeriodClassifiedAsNonCurrent" xlink:to="kymr_MarketableSecuritiesRemainingMaturityPeriodClassifiedAsNonCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_MarketableSecuritiesRemainingMaturityPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities, remaining maturity period</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_MarketableSecuritiesRemainingMaturityPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Remaining Maturity Period</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_MarketableSecuritiesRemainingMaturityPeriodClassifiedAsNonCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities, remaining maturity period classified as non-current</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_MarketableSecuritiesRemainingMaturityPeriodClassifiedAsNonCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Remaining Maturity Period Classified As Non Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases original term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Term Of Contract</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_LabEquipmentMember" xlink:type="locator" xlink:label="kymr_LabEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="kymr_LabEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lab equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_LabEquipmentMember" xlink:to="kymr_LabEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_LabEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lab Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_LabEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lab Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furnitures and Fixtures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Office Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful life of related asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful life of related asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Estimated Useful Lives</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment losses on long-lived assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of Long Lived Assets To Be Disposed Of</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred offering costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, adopted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Adopted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting standards update, adoption date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Adoption Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, immaterial effect</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Immaterial Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="locator" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value By Balance Sheet Grouping [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Recurring</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type Categorization [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Fund</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateBondSecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Bonds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateBondSecuritiesMember" xlink:to="us-gaap_CorporateBondSecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">US Treasuries</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">U S Treasury Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Inputs, Level 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_RestrictedCashFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_RestrictedCashFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_FairValueAssetsLevel1ToLevel3TransfersAmount" xlink:type="locator" xlink:label="kymr_FairValueAssetsLevel1ToLevel3TransfersAmount" />
    <link:label xml:lang="en-US" xlink:label="kymr_FairValueAssetsLevel1ToLevel3TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value assets level 1 to level 3 transfers amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_FairValueAssetsLevel1ToLevel3TransfersAmount" xlink:to="kymr_FairValueAssetsLevel1ToLevel3TransfersAmount_lbl" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_FairValueAssetsLevel3ToLevel1TransfersAmount" xlink:type="locator" xlink:label="kymr_FairValueAssetsLevel3ToLevel1TransfersAmount" />
    <link:label xml:lang="en-US" xlink:label="kymr_FairValueAssetsLevel3ToLevel1TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value assets level 3 to level 1 transfers amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_FairValueAssetsLevel3ToLevel1TransfersAmount" xlink:to="kymr_FairValueAssetsLevel3ToLevel1TransfersAmount_lbl" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_FairValueAssetsLevel3ToLevel2TransfersAmount" xlink:type="locator" xlink:label="kymr_FairValueAssetsLevel3ToLevel2TransfersAmount" />
    <link:label xml:lang="en-US" xlink:label="kymr_FairValueAssetsLevel3ToLevel2TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value assets level 3 to level 2 transfers amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_FairValueAssetsLevel3ToLevel2TransfersAmount" xlink:to="kymr_FairValueAssetsLevel3ToLevel2TransfersAmount_lbl" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_FairValueAssetsLevel2ToLevel3TransfersAmount" xlink:type="locator" xlink:label="kymr_FairValueAssetsLevel2ToLevel3TransfersAmount" />
    <link:label xml:lang="en-US" xlink:label="kymr_FairValueAssetsLevel2ToLevel3TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value assets level 2 to Level 3 transfers amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_FairValueAssetsLevel2ToLevel3TransfersAmount" xlink:to="kymr_FairValueAssetsLevel2ToLevel3TransfersAmount_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value, assets, level 1 to level 2 transfers, amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Level1 To Level2 Transfers Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value, assets, level 2 to level 1 transfers, amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Level2 To Level1 Transfers Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_FairValueAssetsLevel1ToLevel3TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value assets, level 1 to level 3 transfers, amount</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_FairValueAssetsLevel1ToLevel3TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Level1 To Level3 Transfers Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_FairValueAssetsLevel3ToLevel1TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value assets, level 3 to level 1 transfers, amount</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_FairValueAssetsLevel3ToLevel1TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Level3 To Level1 Transfers Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_FairValueAssetsLevel3ToLevel2TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value assets, level 3 to level 2 transfers, amount</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_FairValueAssetsLevel3ToLevel2TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Level3 To Level2 Transfers Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_FairValueAssetsLevel2ToLevel3TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value assets, level 2 to level 3 transfers, amount</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_FairValueAssetsLevel2ToLevel3TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Level2 To Level3 Transfers Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instrument</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">U.S. Treasury Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Gains</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized Losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_DebtSecuritiesAvailableForSaleContractualMaturityOfLessThan12MonthsNumberOfSecurities" xlink:type="locator" xlink:label="kymr_DebtSecuritiesAvailableForSaleContractualMaturityOfLessThan12MonthsNumberOfSecurities" />
    <link:label xml:lang="en-US" xlink:label="kymr_DebtSecuritiesAvailableForSaleContractualMaturityOfLessThan12MonthsNumberOfSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt securities, available-for-sale, contractual maturity of less than 12 months, number of securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_DebtSecuritiesAvailableForSaleContractualMaturityOfLessThan12MonthsNumberOfSecurities" xlink:to="kymr_DebtSecuritiesAvailableForSaleContractualMaturityOfLessThan12MonthsNumberOfSecurities_lbl" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_FairValueOfAvailableForSaleDebtSecuritiesContractualMaturityOfLessThanTwelveMonths" xlink:type="locator" xlink:label="kymr_FairValueOfAvailableForSaleDebtSecuritiesContractualMaturityOfLessThanTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="kymr_FairValueOfAvailableForSaleDebtSecuritiesContractualMaturityOfLessThanTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of available-for-sale debt securities contractual maturity of less than twelve months.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_FairValueOfAvailableForSaleDebtSecuritiesContractualMaturityOfLessThanTwelveMonths" xlink:to="kymr_FairValueOfAvailableForSaleDebtSecuritiesContractualMaturityOfLessThanTwelveMonths_lbl" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_DebtSecuritiesAvailableForSaleContractualMaturityOf12MonthsOrLongerNumberOfSecurities" xlink:type="locator" xlink:label="kymr_DebtSecuritiesAvailableForSaleContractualMaturityOf12MonthsOrLongerNumberOfSecurities" />
    <link:label xml:lang="en-US" xlink:label="kymr_DebtSecuritiesAvailableForSaleContractualMaturityOf12MonthsOrLongerNumberOfSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt securities, available-for-sale, contractual maturity of 12 months or longer, number of securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_DebtSecuritiesAvailableForSaleContractualMaturityOf12MonthsOrLongerNumberOfSecurities" xlink:to="kymr_DebtSecuritiesAvailableForSaleContractualMaturityOf12MonthsOrLongerNumberOfSecurities_lbl" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_DebtSecuritiesAvailableForSaleDeclineInMarketValueForUnrealizedLossPositionNumberOfSecurities" xlink:type="locator" xlink:label="kymr_DebtSecuritiesAvailableForSaleDeclineInMarketValueForUnrealizedLossPositionNumberOfSecurities" />
    <link:label xml:lang="en-US" xlink:label="kymr_DebtSecuritiesAvailableForSaleDeclineInMarketValueForUnrealizedLossPositionNumberOfSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt securities available for sale decline in market value for unrealized loss position number of securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_DebtSecuritiesAvailableForSaleDeclineInMarketValueForUnrealizedLossPositionNumberOfSecurities" xlink:to="kymr_DebtSecuritiesAvailableForSaleDeclineInMarketValueForUnrealizedLossPositionNumberOfSecurities_lbl" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_NumberOfMarketableSecuritiesSold" xlink:type="locator" xlink:label="kymr_NumberOfMarketableSecuritiesSold" />
    <link:label xml:lang="en-US" xlink:label="kymr_NumberOfMarketableSecuritiesSold_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of marketable securities sold.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_NumberOfMarketableSecuritiesSold" xlink:to="kymr_NumberOfMarketableSecuritiesSold_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of available-for-sale debt securities, continuous unrealized loss position for less than 12 months</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate fair value of available-for-sale debt securities, continuous unrealized loss position for less than 12 months</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_DebtSecuritiesAvailableForSaleContractualMaturityOfLessThan12MonthsNumberOfSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of available-for-sale debt securities, contractual maturity of less than 12 months</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_DebtSecuritiesAvailableForSaleContractualMaturityOfLessThan12MonthsNumberOfSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Contractual Maturity Of Less Than12 Months Number Of Securities</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_FairValueOfAvailableForSaleDebtSecuritiesContractualMaturityOfLessThanTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of available-for-sale debt securities, contractual maturity of less than 12 months</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_FairValueOfAvailableForSaleDebtSecuritiesContractualMaturityOfLessThanTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Available For Sale Debt Securities Contractual Maturity Of Less Than Twelve Months</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_DebtSecuritiesAvailableForSaleContractualMaturityOf12MonthsOrLongerNumberOfSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of available-for-sale debt securities, contractual maturity of greater than 12 months</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_DebtSecuritiesAvailableForSaleContractualMaturityOf12MonthsOrLongerNumberOfSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Contractual Maturity Of12 Months Or Longer Number Of Securities</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair value of available-for-sale debt securities, contractual maturity of greater than 12 months</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_NumberOfMarketableSecuritiesSold_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of marketable securities sold</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_NumberOfMarketableSecuritiesSold_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Marketable Securities Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableforsaleSecuritiesSoldAtPar" xlink:type="locator" xlink:label="us-gaap_AvailableforsaleSecuritiesSoldAtPar" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableforsaleSecuritiesSoldAtPar_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales of marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableforsaleSecuritiesSoldAtPar" xlink:to="us-gaap_AvailableforsaleSecuritiesSoldAtPar_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableforsaleSecuritiesSoldAtPar_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Availableforsale Securities Sold At Par</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_DebtSecuritiesAvailableForSaleDeclineInMarketValueForUnrealizedLossPositionNumberOfSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of securities decline in market value for in an unrealized loss position</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_DebtSecuritiesAvailableForSaleDeclineInMarketValueForUnrealizedLossPositionNumberOfSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Decline In Market Value For Unrealized Loss Position Number Of Securities</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_UpfrontPayment" xlink:type="locator" xlink:label="kymr_UpfrontPayment" />
    <link:label xml:lang="en-US" xlink:label="kymr_UpfrontPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_UpfrontPayment" xlink:to="kymr_UpfrontPayment_lbl" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_DevelopmentMilestonePayments" xlink:type="locator" xlink:label="kymr_DevelopmentMilestonePayments" />
    <link:label xml:lang="en-US" xlink:label="kymr_DevelopmentMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Development milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_DevelopmentMilestonePayments" xlink:to="kymr_DevelopmentMilestonePayments_lbl" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_CommercialMilestonePayments" xlink:type="locator" xlink:label="kymr_CommercialMilestonePayments" />
    <link:label xml:lang="en-US" xlink:label="kymr_CommercialMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_CommercialMilestonePayments" xlink:to="kymr_CommercialMilestonePayments_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SanofiCollaborationArrangementMember" xlink:type="locator" xlink:label="kymr_SanofiCollaborationArrangementMember" />
    <link:label xml:lang="en-US" xlink:label="kymr_SanofiCollaborationArrangementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sanofi collaboration arrangement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_SanofiCollaborationArrangementMember" xlink:to="kymr_SanofiCollaborationArrangementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_SanofiCollaborationArrangementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sanofi Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_SanofiCollaborationArrangementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sanofi Collaboration Arrangement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:type="locator" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Project</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Costs Of Unproved Properties Excluded From Amortization By Property Or Project [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember" xlink:type="locator" xlink:label="us-gaap_ProjectMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProjectMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Project</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProjectMember" xlink:to="us-gaap_ProjectMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProjectMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Project [Member]</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_IRAK4Member" xlink:type="locator" xlink:label="kymr_IRAK4Member" />
    <link:label xml:lang="en-US" xlink:label="kymr_IRAK4Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">IRAK4.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_IRAK4Member" xlink:to="kymr_IRAK4Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_IRAK4Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IRAK4 Program</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_IRAK4Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">I R A K4 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others Type [Domain]</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_CollaborationTargetOneMember" xlink:type="locator" xlink:label="kymr_CollaborationTargetOneMember" />
    <link:label xml:lang="en-US" xlink:label="kymr_CollaborationTargetOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration target one.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_CollaborationTargetOneMember" xlink:to="kymr_CollaborationTargetOneMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_CollaborationTargetOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Target 1</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_CollaborationTargetOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Target One [Member]</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_CollaborationTargetTwoMember" xlink:type="locator" xlink:label="kymr_CollaborationTargetTwoMember" />
    <link:label xml:lang="en-US" xlink:label="kymr_CollaborationTargetTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration target two.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_CollaborationTargetTwoMember" xlink:to="kymr_CollaborationTargetTwoMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_CollaborationTargetTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Target 2</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_CollaborationTargetTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Target Two [Member]</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_VertexAgreementMember" xlink:type="locator" xlink:label="kymr_VertexAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="kymr_VertexAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Vertex Agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_VertexAgreementMember" xlink:to="kymr_VertexAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_VertexAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vertex Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_VertexAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Vertex Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Maximum</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_CompoundCollaborationAgreementMember" xlink:type="locator" xlink:label="kymr_CompoundCollaborationAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="kymr_CompoundCollaborationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Compound Collaboration Agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_CompoundCollaborationAgreementMember" xlink:to="kymr_CompoundCollaborationAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_CompoundCollaborationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Compound Collaboration</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_CompoundCollaborationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Compound Collaboration Agreement [Member]</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesAPreferredUnitsMember" xlink:type="locator" xlink:label="kymr_SeriesAPreferredUnitsMember" />
    <link:label xml:lang="en-US" xlink:label="kymr_SeriesAPreferredUnitsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A Preferred Units.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_SeriesAPreferredUnitsMember" xlink:to="kymr_SeriesAPreferredUnitsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_SeriesAPreferredUnitsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Preferred Units</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_SeriesAPreferredUnitsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A Preferred Units [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_UpfrontPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_UpfrontPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_DevelopmentMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_DevelopmentMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Development Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_CommercialMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_CommercialMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Milestone Payments</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_CollaborationAgreementTransactionPrice" xlink:type="locator" xlink:label="kymr_CollaborationAgreementTransactionPrice" />
    <link:label xml:lang="en-US" xlink:label="kymr_CollaborationAgreementTransactionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement transaction price.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_CollaborationAgreementTransactionPrice" xlink:to="kymr_CollaborationAgreementTransactionPrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_CollaborationAgreementTransactionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration agreement transaction price</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_CollaborationAgreementTransactionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Transaction Price</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_CostReimbursementReceivable" xlink:type="locator" xlink:label="kymr_CostReimbursementReceivable" />
    <link:label xml:lang="en-US" xlink:label="kymr_CostReimbursementReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cost reimbursement receivable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_CostReimbursementReceivable" xlink:to="kymr_CostReimbursementReceivable_lbl" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_MilestoneReceivable" xlink:type="locator" xlink:label="kymr_MilestoneReceivable" />
    <link:label xml:lang="en-US" xlink:label="kymr_MilestoneReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone receivable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_MilestoneReceivable" xlink:to="kymr_MilestoneReceivable_lbl" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_RoyaltyReceivable" xlink:type="locator" xlink:label="kymr_RoyaltyReceivable" />
    <link:label xml:lang="en-US" xlink:label="kymr_RoyaltyReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty receivable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_RoyaltyReceivable" xlink:to="kymr_RoyaltyReceivable_lbl" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_RemainingResearchTermOfCollaboration" xlink:type="locator" xlink:label="kymr_RemainingResearchTermOfCollaboration" />
    <link:label xml:lang="en-US" xlink:label="kymr_RemainingResearchTermOfCollaboration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Remaining research term of collaboration.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_RemainingResearchTermOfCollaboration" xlink:to="kymr_RemainingResearchTermOfCollaboration_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognized recorded in deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Revenue Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unsatisfied performance obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligation" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Remaining Performance Obligation</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_CostReimbursementReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost reimbursement receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_CostReimbursementReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cost Reimbursement Receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_MilestoneReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_MilestoneReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_RoyaltyReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_RoyaltyReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnbilledContractsReceivable" xlink:type="locator" xlink:label="us-gaap_UnbilledContractsReceivable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnbilledContractsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unbilled accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnbilledContractsReceivable" xlink:to="us-gaap_UnbilledContractsReceivable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnbilledContractsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unbilled Contracts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BilledContractReceivables" xlink:type="locator" xlink:label="us-gaap_BilledContractReceivables" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BilledContractReceivables_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Billed accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BilledContractReceivables" xlink:to="us-gaap_BilledContractReceivables_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BilledContractReceivables_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Billed Contract Receivables</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_RemainingResearchTermOfCollaboration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining research term of collaboration</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_RemainingResearchTermOfCollaboration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Remaining Research Term Of Collaboration</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_InitialResearchTermOfCollaboration" xlink:type="locator" xlink:label="kymr_InitialResearchTermOfCollaboration" />
    <link:label xml:lang="en-US" xlink:label="kymr_InitialResearchTermOfCollaboration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial research term of collaboration.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_InitialResearchTermOfCollaboration" xlink:to="kymr_InitialResearchTermOfCollaboration_lbl" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_ExtendedResearchTermOfCollaboration" xlink:type="locator" xlink:label="kymr_ExtendedResearchTermOfCollaboration" />
    <link:label xml:lang="en-US" xlink:label="kymr_ExtendedResearchTermOfCollaboration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Extended research term of collaboration.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_ExtendedResearchTermOfCollaboration" xlink:to="kymr_ExtendedResearchTermOfCollaboration_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_InitialResearchTermOfCollaboration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial research term of collaboration</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_InitialResearchTermOfCollaboration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Initial Research Term Of Collaboration</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_ExtendedResearchTermOfCollaboration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Extended research term of collaboration</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_ExtendedResearchTermOfCollaboration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Extended Research Term Of Collaboration</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_NonRefundableUpfrontPaymentReceived" xlink:type="locator" xlink:label="kymr_NonRefundableUpfrontPaymentReceived" />
    <link:label xml:lang="en-US" xlink:label="kymr_NonRefundableUpfrontPaymentReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non refundable upfront payment received.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_NonRefundableUpfrontPaymentReceived" xlink:to="kymr_NonRefundableUpfrontPaymentReceived_lbl" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_PreferredStockIssuancePremium" xlink:type="locator" xlink:label="kymr_PreferredStockIssuancePremium" />
    <link:label xml:lang="en-US" xlink:label="kymr_PreferredStockIssuancePremium_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock issuance premium.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_PreferredStockIssuancePremium" xlink:to="kymr_PreferredStockIssuancePremium_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_NonRefundableUpfrontPaymentReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non refundable upfront payment received</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_NonRefundableUpfrontPaymentReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Refundable Upfront Payment Received</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_PreferredStockIssuancePremium_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock premium</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_PreferredStockIssuancePremium_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Issuance Premium</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_PotentialReceivableMilestonePayments" xlink:type="locator" xlink:label="kymr_PotentialReceivableMilestonePayments" />
    <link:label xml:lang="en-US" xlink:label="kymr_PotentialReceivableMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential receivable milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_PotentialReceivableMilestonePayments" xlink:to="kymr_PotentialReceivableMilestonePayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_PotentialReceivableMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Eligible to receive payments including development, regulatory and commercial milestones</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_PotentialReceivableMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Potential Receivable Milestone Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue remaining research term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation vesting period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_WrittenNoticePeriodToTerminateCollaborationAgreement" xlink:type="locator" xlink:label="kymr_WrittenNoticePeriodToTerminateCollaborationAgreement" />
    <link:label xml:lang="en-US" xlink:label="kymr_WrittenNoticePeriodToTerminateCollaborationAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Written notice period to terminate collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_WrittenNoticePeriodToTerminateCollaborationAgreement" xlink:to="kymr_WrittenNoticePeriodToTerminateCollaborationAgreement_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_WrittenNoticePeriodToTerminateCollaborationAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written notice period to terminate collaboration agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_WrittenNoticePeriodToTerminateCollaborationAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Notice Period To Terminate Collaboration Agreement</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_ContractWithCustomerAssetNetAdditions" xlink:type="locator" xlink:label="kymr_ContractWithCustomerAssetNetAdditions" />
    <link:label xml:lang="en-US" xlink:label="kymr_ContractWithCustomerAssetNetAdditions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer asset net additions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_ContractWithCustomerAssetNetAdditions" xlink:to="kymr_ContractWithCustomerAssetNetAdditions_lbl" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_ContractWithCustomerAssetNetDeductions" xlink:type="locator" xlink:label="kymr_ContractWithCustomerAssetNetDeductions" />
    <link:label xml:lang="en-US" xlink:label="kymr_ContractWithCustomerAssetNetDeductions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer asset net deductions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_ContractWithCustomerAssetNetDeductions" xlink:to="kymr_ContractWithCustomerAssetNetDeductions_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_BilledReceivablesSanofiMember" xlink:type="locator" xlink:label="kymr_BilledReceivablesSanofiMember" />
    <link:label xml:lang="en-US" xlink:label="kymr_BilledReceivablesSanofiMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Billed receivables - Sanofi.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_BilledReceivablesSanofiMember" xlink:to="kymr_BilledReceivablesSanofiMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_BilledReceivablesSanofiMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Billed receivables - Sanofi</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_BilledReceivablesSanofiMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Billed Receivables Sanofi [Member]</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_UnbilledReceivablesSanofiMember" xlink:type="locator" xlink:label="kymr_UnbilledReceivablesSanofiMember" />
    <link:label xml:lang="en-US" xlink:label="kymr_UnbilledReceivablesSanofiMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Unbilled receivables - Sanofi.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_UnbilledReceivablesSanofiMember" xlink:to="kymr_UnbilledReceivablesSanofiMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_UnbilledReceivablesSanofiMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unbilled receivables - Sanofi</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_UnbilledReceivablesSanofiMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unbilled Receivables Sanofi [Member]</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_DeferredRevenueVertexMember" xlink:type="locator" xlink:label="kymr_DeferredRevenueVertexMember" />
    <link:label xml:lang="en-US" xlink:label="kymr_DeferredRevenueVertexMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred revenue - Vertex.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_DeferredRevenueVertexMember" xlink:to="kymr_DeferredRevenueVertexMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_DeferredRevenueVertexMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Revenue - Vertex</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_DeferredRevenueVertexMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue Vertex [Member]</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_DeferredRevenueSanofiMember" xlink:type="locator" xlink:label="kymr_DeferredRevenueSanofiMember" />
    <link:label xml:lang="en-US" xlink:label="kymr_DeferredRevenueSanofiMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred revenue - Sanofi.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_DeferredRevenueSanofiMember" xlink:to="kymr_DeferredRevenueSanofiMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_DeferredRevenueSanofiMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Revenue - Sanofi</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_DeferredRevenueSanofiMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue Sanofi [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accounts receivable and contract assets, Beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss" xlink:to="us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Receivable After Allowance For Credit Loss</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_ContractWithCustomerAssetNetAdditions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable and contract assets, Additions</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_ContractWithCustomerAssetNetAdditions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Asset Net Additions</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_ContractWithCustomerAssetNetDeductions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable and contract assets, Deductions</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_ContractWithCustomerAssetNetDeductions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Asset Net Deductions</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accounts receivable and contract assets, Ending balance</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_ContractWithCustomerLiabilityAdditions" xlink:type="locator" xlink:label="kymr_ContractWithCustomerLiabilityAdditions" />
    <link:label xml:lang="en-US" xlink:label="kymr_ContractWithCustomerLiabilityAdditions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer liability additions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_ContractWithCustomerLiabilityAdditions" xlink:to="kymr_ContractWithCustomerLiabilityAdditions_lbl" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_ContractWithCustomerLiabilityDeductions" xlink:type="locator" xlink:label="kymr_ContractWithCustomerLiabilityDeductions" />
    <link:label xml:lang="en-US" xlink:label="kymr_ContractWithCustomerLiabilityDeductions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer liability deductions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_ContractWithCustomerLiabilityDeductions" xlink:to="kymr_ContractWithCustomerLiabilityDeductions_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Contract Liabilities, Beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_ContractWithCustomerLiabilityAdditions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract Liabilities, Additions</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_ContractWithCustomerLiabilityAdditions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Additions</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_ContractWithCustomerLiabilityDeductions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract Liabilities, Deductions</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_ContractWithCustomerLiabilityDeductions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Deductions</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Contract Liabilities, Ending balance</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_LabAndOfficeEquipmentMember" xlink:type="locator" xlink:label="kymr_LabAndOfficeEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="kymr_LabAndOfficeEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lab and office equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_LabAndOfficeEquipmentMember" xlink:to="kymr_LabAndOfficeEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_LabAndOfficeEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lab and Office Equipment Under and Financing Right of Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_LabAndOfficeEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lab And Office Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Furniture &amp; Fixtures</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_AssetsNotYetInServiceMember" xlink:type="locator" xlink:label="kymr_AssetsNotYetInServiceMember" />
    <link:label xml:lang="en-US" xlink:label="kymr_AssetsNotYetInServiceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Assets not yet in service.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_AssetsNotYetInServiceMember" xlink:to="kymr_AssetsNotYetInServiceMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_AssetsNotYetInServiceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets Not Yet in Service</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_AssetsNotYetInServiceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Not Yet In Service [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less accumulated depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_AccumulatedAmortization" xlink:type="locator" xlink:label="kymr_AccumulatedAmortization" />
    <link:label xml:lang="en-US" xlink:label="kymr_AccumulatedAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accumulated amortization.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_AccumulatedAmortization" xlink:to="kymr_AccumulatedAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Property and equipment right of use assets under financing leases with cost basis</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_AccumulatedAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated amortization</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_AccumulatedAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization expense related to right-of-use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Right Of Use Asset Amortization</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_LeaseTerminationDate" xlink:type="locator" xlink:label="kymr_LeaseTerminationDate" />
    <link:label xml:lang="en-US" xlink:label="kymr_LeaseTerminationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease termination date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_LeaseTerminationDate" xlink:to="kymr_LeaseTerminationDate_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Lease Description [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Geographical [Domain]</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_CambridgeMassachusettsMember" xlink:type="locator" xlink:label="kymr_CambridgeMassachusettsMember" />
    <link:label xml:lang="en-US" xlink:label="kymr_CambridgeMassachusettsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cambridge, Massachusetts.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_CambridgeMassachusettsMember" xlink:to="kymr_CambridgeMassachusettsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_CambridgeMassachusettsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cambridge, Massachusetts</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_CambridgeMassachusettsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cambridge Massachusetts [Member]</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_NoncancelableFacilityLeaseAgreementMember" xlink:type="locator" xlink:label="kymr_NoncancelableFacilityLeaseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="kymr_NoncancelableFacilityLeaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Noncancelable facility lease agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_NoncancelableFacilityLeaseAgreementMember" xlink:to="kymr_NoncancelableFacilityLeaseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_NoncancelableFacilityLeaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncancelable Facility Lease Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_NoncancelableFacilityLeaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncancelable Facility Lease Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMember" xlink:type="locator" xlink:label="us-gaap_OtherAssetsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsMember" xlink:to="us-gaap_OtherAssetsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherCurrentAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Current Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsMember" xlink:to="us-gaap_OtherCurrentAssetsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherCurrentAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Current Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Facility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Facility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:type="locator" xlink:label="us-gaap_LetterOfCreditMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of Credit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LetterOfCreditMember" xlink:to="us-gaap_LetterOfCreditMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Letter Of Credit [Member]</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_FacilitySubleaseAgreementMember" xlink:type="locator" xlink:label="kymr_FacilitySubleaseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="kymr_FacilitySubleaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Facility sublease agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_FacilitySubleaseAgreementMember" xlink:to="kymr_FacilitySubleaseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_FacilitySubleaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Facility Sublease Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_FacilitySubleaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Facility Sublease Agreement [Member]</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_WatertownMassachusettsMember" xlink:type="locator" xlink:label="kymr_WatertownMassachusettsMember" />
    <link:label xml:lang="en-US" xlink:label="kymr_WatertownMassachusettsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Watertown, Massachusetts.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_WatertownMassachusettsMember" xlink:to="kymr_WatertownMassachusettsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_WatertownMassachusettsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Watertown, Massachusetts</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_WatertownMassachusettsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Watertown Massachusetts [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Lease Description [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:type="locator" xlink:label="us-gaap_AreaOfRealEstateProperty" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of office space</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Area Of Real Estate Property</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLeasehold" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLeasehold" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfLeasehold_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reduction of right-of-use asset and liability due to lease modification</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLeasehold" xlink:to="us-gaap_ImpairmentOfLeasehold_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfLeasehold_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of Leasehold</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_LeaseTerminationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease termination date</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_LeaseTerminationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Termination Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit" xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security deposit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Deposit</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_LeaseCommencementDate" xlink:type="locator" xlink:label="kymr_LeaseCommencementDate" />
    <link:label xml:lang="en-US" xlink:label="kymr_LeaseCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease commencement date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_LeaseCommencementDate" xlink:to="kymr_LeaseCommencementDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_LeaseCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease commencement date</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_LeaseCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Commencement Date</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_LeaseTerm" xlink:type="locator" xlink:label="kymr_LeaseTerm" />
    <link:label xml:lang="en-US" xlink:label="kymr_LeaseTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_LeaseTerm" xlink:to="kymr_LeaseTerm_lbl" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_LeaseAdditionalTerm" xlink:type="locator" xlink:label="kymr_LeaseAdditionalTerm" />
    <link:label xml:lang="en-US" xlink:label="kymr_LeaseAdditionalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease additional term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_LeaseAdditionalTerm" xlink:to="kymr_LeaseAdditionalTerm_lbl" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TenantIncentiveAllowanceReceivable" xlink:type="locator" xlink:label="kymr_TenantIncentiveAllowanceReceivable" />
    <link:label xml:lang="en-US" xlink:label="kymr_TenantIncentiveAllowanceReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tenant incentive allowance receivable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_TenantIncentiveAllowanceReceivable" xlink:to="kymr_TenantIncentiveAllowanceReceivable_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_LeaseTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease term</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_LeaseTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date1</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_LeaseAdditionalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease additional term</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_LeaseAdditionalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Additional Term</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_TenantIncentiveAllowanceReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant incentive allowance receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_TenantIncentiveAllowanceReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tenant Incentive Allowance Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense for financing lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:type="locator" xlink:label="us-gaap_LeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Cost</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_OperatingLeasePaymentsProceeds" xlink:type="locator" xlink:label="kymr_OperatingLeasePaymentsProceeds" />
    <link:label xml:lang="en-US" xlink:label="kymr_OperatingLeasePaymentsProceeds_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease payments (proceeds).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_OperatingLeasePaymentsProceeds" xlink:to="kymr_OperatingLeasePaymentsProceeds_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_OperatingLeasePaymentsProceeds_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating cash flows used in (provided by) operating leases</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_OperatingLeasePaymentsProceeds_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Payments Proceeds</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating cash flows used in finance leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Interest Payment On Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing cash flows used in finance leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Principal Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, remaining lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Remaining Lease Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing lease, remaining lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Weighted Average Remaining Lease Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, discount rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Discount Rate Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing lease, discount rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Weighted Average Discount Rate Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liabilities Payments Due [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due After Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total minimum lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less amounts representing interest or imputed interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Undiscounted Excess Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Present value of lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liabilities Payments Due [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Payments Due Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Payments Due Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Payments Due Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Payments Due Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Payments Due Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Payments Due After Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total minimum lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less amounts representing interest or imputed interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Undiscounted Excess Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Present value of lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_AccruedResearchAndDevelopmentExpensesCurrent" xlink:type="locator" xlink:label="kymr_AccruedResearchAndDevelopmentExpensesCurrent" />
    <link:label xml:lang="en-US" xlink:label="kymr_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development expenses current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_AccruedResearchAndDevelopmentExpensesCurrent" xlink:to="kymr_AccruedResearchAndDevelopmentExpensesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expenses Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedSalariesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payroll and payroll-related</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Salaries Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accrued expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:type="locator" xlink:label="us-gaap_LossContingenciesTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingencies [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="locator" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingency Nature</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies By Nature Of Contingency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:type="locator" xlink:label="us-gaap_LossContingencyNatureDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingencyNatureDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingency, Nature</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="us-gaap_LossContingencyNatureDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingencyNatureDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency Nature [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndemnificationGuaranteeMember" xlink:type="locator" xlink:label="us-gaap_IndemnificationGuaranteeMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IndemnificationGuaranteeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Indemnified Parties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndemnificationGuaranteeMember" xlink:to="us-gaap_IndemnificationGuaranteeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IndemnificationGuaranteeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Indemnification Guarantee [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:type="locator" xlink:label="us-gaap_LossContingenciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingencies [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities accrued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency Accrual At Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity By Class Of Stock [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity By Class Of Stock [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesCPreferredStockPurchaseAgreementMember" xlink:type="locator" xlink:label="kymr_SeriesCPreferredStockPurchaseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="kymr_SeriesCPreferredStockPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series C preferred stock purchase agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_SeriesCPreferredStockPurchaseAgreementMember" xlink:to="kymr_SeriesCPreferredStockPurchaseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_SeriesCPreferredStockPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C SPA</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_SeriesCPreferredStockPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series C Preferred Stock Purchase Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible preferred stock, par or stated value per share</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of convertible preferred stock</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_AdjustmentsToAdditionalPaidInCapitalRelatedToTemporaryEquityDeemedDividend" xlink:type="locator" xlink:label="kymr_AdjustmentsToAdditionalPaidInCapitalRelatedToTemporaryEquityDeemedDividend" />
    <link:label xml:lang="en-US" xlink:label="kymr_AdjustmentsToAdditionalPaidInCapitalRelatedToTemporaryEquityDeemedDividend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital related to temporary equity deemed dividend.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_AdjustmentsToAdditionalPaidInCapitalRelatedToTemporaryEquityDeemedDividend" xlink:to="kymr_AdjustmentsToAdditionalPaidInCapitalRelatedToTemporaryEquityDeemedDividend_lbl" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_IncreaseInAccumulatedDeficitRelatedToTemporaryEquityDeemedDividend" xlink:type="locator" xlink:label="kymr_IncreaseInAccumulatedDeficitRelatedToTemporaryEquityDeemedDividend" />
    <link:label xml:lang="en-US" xlink:label="kymr_IncreaseInAccumulatedDeficitRelatedToTemporaryEquityDeemedDividend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase in accumulated deficit related to temporary equity deemed dividend.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_IncreaseInAccumulatedDeficitRelatedToTemporaryEquityDeemedDividend" xlink:to="kymr_IncreaseInAccumulatedDeficitRelatedToTemporaryEquityDeemedDividend_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock issuance costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued upon exchange of Series A convertible preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Shares Issued Upon Conversion</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityDividendsAdjustment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deemed dividend from exchange of convertible preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_AdjustmentsToAdditionalPaidInCapitalRelatedToTemporaryEquityDeemedDividend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Reduction of additional paid-in-capital related to temporary equity deemed dividend</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_AdjustmentsToAdditionalPaidInCapitalRelatedToTemporaryEquityDeemedDividend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Related To Temporary Equity Deemed Dividend</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_IncreaseInAccumulatedDeficitRelatedToTemporaryEquityDeemedDividend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in accumulated deficit related to temporary equity deemed dividend</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_IncreaseInAccumulatedDeficitRelatedToTemporaryEquityDeemedDividend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase In Accumulated Deficit Related To Temporary Equity Deemed Dividend</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of stock, shares issued and outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Stock Shares Issued1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of preferred Stock converted to common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Stock Shares Converted1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TwoThousandTwentyStockOptionAndIncentivePlanMember" xlink:type="locator" xlink:label="kymr_TwoThousandTwentyStockOptionAndIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="kymr_TwoThousandTwentyStockOptionAndIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">2020 stock option and incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_TwoThousandTwentyStockOptionAndIncentivePlanMember" xlink:to="kymr_TwoThousandTwentyStockOptionAndIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_TwoThousandTwentyStockOptionAndIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_TwoThousandTwentyStockOptionAndIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Stock Option And Incentive Plan [Member]</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="kymr_TwoThousandTwentyEmployeeStockPurchasePlanMember" />
    <link:label xml:lang="en-US" xlink:label="kymr_TwoThousandTwentyEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">2020 Employee stock purchase plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:to="kymr_TwoThousandTwentyEmployeeStockPurchasePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_TwoThousandTwentyEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 ESPP</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_TwoThousandTwentyEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_ScenarioPotentialOutcomeAxis" xlink:type="locator" xlink:label="kymr_ScenarioPotentialOutcomeAxis" />
    <link:label xml:lang="en-US" xlink:label="kymr_ScenarioPotentialOutcomeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Scenario potential outcome.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_ScenarioPotentialOutcomeAxis" xlink:to="kymr_ScenarioPotentialOutcomeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_ScenarioPotentialOutcomeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario Potential Outcome</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_ScenarioPotentialOutcomeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Scenario Potential Outcome [Axis]</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_ScenarioPotentialOutcomeDomain" xlink:type="locator" xlink:label="kymr_ScenarioPotentialOutcomeDomain" />
    <link:label xml:lang="en-US" xlink:label="kymr_ScenarioPotentialOutcomeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Scenario potential outcome.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_ScenarioPotentialOutcomeDomain" xlink:to="kymr_ScenarioPotentialOutcomeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_ScenarioPotentialOutcomeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario Potential Outcome</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_ScenarioPotentialOutcomeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Scenario Potential Outcome [Domain]</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_LesserOfPotentialOutcomeOneMember" xlink:type="locator" xlink:label="kymr_LesserOfPotentialOutcomeOneMember" />
    <link:label xml:lang="en-US" xlink:label="kymr_LesserOfPotentialOutcomeOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lesser of potential outcome one.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_LesserOfPotentialOutcomeOneMember" xlink:to="kymr_LesserOfPotentialOutcomeOneMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_LesserOfPotentialOutcomeOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lesser of Potential Outcome 1</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_LesserOfPotentialOutcomeOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lesser Of Potential Outcome One [Member]</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_LesserOfPotentialOutcomeTwoMember" xlink:type="locator" xlink:label="kymr_LesserOfPotentialOutcomeTwoMember" />
    <link:label xml:lang="en-US" xlink:label="kymr_LesserOfPotentialOutcomeTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lesser of potential outcome two.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_LesserOfPotentialOutcomeTwoMember" xlink:to="kymr_LesserOfPotentialOutcomeTwoMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_LesserOfPotentialOutcomeTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lesser of Potential Outcome 2</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_LesserOfPotentialOutcomeTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lesser Of Potential Outcome Two [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TwoThousandEighteenStockOptionAndGrantPlanMember" xlink:type="locator" xlink:label="kymr_TwoThousandEighteenStockOptionAndGrantPlanMember" />
    <link:label xml:lang="en-US" xlink:label="kymr_TwoThousandEighteenStockOptionAndGrantPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">2018 stock option and grant plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_TwoThousandEighteenStockOptionAndGrantPlanMember" xlink:to="kymr_TwoThousandEighteenStockOptionAndGrantPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_TwoThousandEighteenStockOptionAndGrantPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_TwoThousandEighteenStockOptionAndGrantPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Eighteen Stock Option And Grant Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and Development Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">General and Administrative Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:type="locator" xlink:label="us-gaap_GranteeStatusAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GranteeStatusAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grantee Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GranteeStatusAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Grantee Status [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:type="locator" xlink:label="us-gaap_GranteeStatusDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GranteeStatusDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grantee Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_GranteeStatusDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GranteeStatusDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Grantee Status [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Modification of Employee&apos;s Awards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Payment Arrangement Employee [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares authorized for issuance under plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum number of shares to be issued, percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares remaining available for future grants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation, description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Description</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of additional shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TwoThousandAndTwentyStockOptionAndGrantPlanMember" xlink:type="locator" xlink:label="kymr_TwoThousandAndTwentyStockOptionAndGrantPlanMember" />
    <link:label xml:lang="en-US" xlink:label="kymr_TwoThousandAndTwentyStockOptionAndGrantPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty stock option and grant plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_TwoThousandAndTwentyStockOptionAndGrantPlanMember" xlink:to="kymr_TwoThousandAndTwentyStockOptionAndGrantPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_TwoThousandAndTwentyStockOptionAndGrantPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_TwoThousandAndTwentyStockOptionAndGrantPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty Stock Option And Grant Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding at beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable at December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Strike Price Per Option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Rollforward</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding at beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable at December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term (in years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable at December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract" xlink:type="locator" xlink:label="kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract" />
    <link:label xml:lang="en-US" xlink:label="kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award aggregate intrinsic value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract" xlink:to="kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract_lbl" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue" xlink:type="locator" xlink:label="kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options granted in period intrinsic value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue" xlink:to="kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue_lbl" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue" xlink:type="locator" xlink:label="kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options forfeited in period intrinsic value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue" xlink:to="kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Aggregate Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding at beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Granted In Period Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable at December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Intrinsic value of stock options exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average fair value of options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost, recognition period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of stock options vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total equity-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Units Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Roll Forward</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unvested at beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unvested at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant Date Fair Value per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value Roll Forward</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unvested at beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unvested at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of restricted stock vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions By Related Party [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestorMember" xlink:type="locator" xlink:label="us-gaap_InvestorMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestorMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investor</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestorMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investor [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Expenses From Transactions With Related Party</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_IncomeTaxDisclosureLineItems" xlink:type="locator" xlink:label="kymr_IncomeTaxDisclosureLineItems" />
    <link:label xml:lang="en-US" xlink:label="kymr_IncomeTaxDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_IncomeTaxDisclosureLineItems" xlink:to="kymr_IncomeTaxDisclosureLineItems_lbl" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_IncomeTaxDisclosureTable" xlink:type="locator" xlink:label="kymr_IncomeTaxDisclosureTable" />
    <link:label xml:lang="en-US" xlink:label="kymr_IncomeTaxDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_IncomeTaxDisclosureTable" xlink:to="kymr_IncomeTaxDisclosureTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_IncomeTaxDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_IncomeTaxDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Country [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">State And Local Jurisdiction [Member]</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_FederalAndStateMember" xlink:type="locator" xlink:label="kymr_FederalAndStateMember" />
    <link:label xml:lang="en-US" xlink:label="kymr_FederalAndStateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Federal and state.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_FederalAndStateMember" xlink:to="kymr_FederalAndStateMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_FederalAndStateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal and State</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_FederalAndStateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Federal And State [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:type="locator" xlink:label="us-gaap_TaxPeriodAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarliestTaxYearMember" xlink:type="locator" xlink:label="us-gaap_EarliestTaxYearMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarliestTaxYearMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earliest Tax Year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarliestTaxYearMember" xlink:to="us-gaap_EarliestTaxYearMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarliestTaxYearMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earliest Tax Year [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LatestTaxYearMember" xlink:type="locator" xlink:label="us-gaap_LatestTaxYearMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LatestTaxYearMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Latest Tax Year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LatestTaxYearMember" xlink:to="us-gaap_LatestTaxYearMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LatestTaxYearMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Latest Tax Year [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_IncomeTaxDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_IncomeTaxDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:type="locator" xlink:label="kymr_EffectiveIncomeTaxRateReconciliationPermanentDifferences" />
    <link:label xml:lang="en-US" xlink:label="kymr_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation permanent differences.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:to="kymr_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax effect at statutory rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation State And Local Income Taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Permanent differences</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Permanent Differences</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal research and development credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Tax Credits Research</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Other Adjustments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Continuing Operations</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_DeferredTaxAssetsLeaseLiabilities" xlink:type="locator" xlink:label="kymr_DeferredTaxAssetsLeaseLiabilities" />
    <link:label xml:lang="en-US" xlink:label="kymr_DeferredTaxAssetsLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_DeferredTaxAssetsLeaseLiabilities" xlink:to="kymr_DeferredTaxAssetsLeaseLiabilities_lbl" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_DeferredTaxLiabilitiesRightOfUseAssets" xlink:type="locator" xlink:label="kymr_DeferredTaxLiabilitiesRightOfUseAssets" />
    <link:label xml:lang="en-US" xlink:label="kymr_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities right-of-use assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_DeferredTaxLiabilitiesRightOfUseAssets" xlink:to="kymr_DeferredTaxLiabilitiesRightOfUseAssets_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Tax Assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Components Of Deferred Tax Assets And Liabilities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards Domestic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards State And Local</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credit carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards Research</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_DeferredTaxAssetsLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_DeferredTaxAssetsLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Lease Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Deferred Income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accruals and reserves, stock and other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Fixed and intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Goodwill And Intangible Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Right Of Use Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Liabilities Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowances And Reserves Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase of valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowances And Reserves Charged To Cost And Expense</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_FederalNetOperatingLossCarryoversNotSubjectToExpiration" xlink:type="locator" xlink:label="kymr_FederalNetOperatingLossCarryoversNotSubjectToExpiration" />
    <link:label xml:lang="en-US" xlink:label="kymr_FederalNetOperatingLossCarryoversNotSubjectToExpiration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Federal net operating loss carryovers, not subject to expiration.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_FederalNetOperatingLossCarryoversNotSubjectToExpiration" xlink:to="kymr_FederalNetOperatingLossCarryoversNotSubjectToExpiration_lbl" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_NetOperatingLossBeginToExpireYear" xlink:type="locator" xlink:label="kymr_NetOperatingLossBeginToExpireYear" />
    <link:label xml:lang="en-US" xlink:label="kymr_NetOperatingLossBeginToExpireYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">NOLs begin to expire year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_NetOperatingLossBeginToExpireYear" xlink:to="kymr_NetOperatingLossBeginToExpireYear_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NOL carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_FederalNetOperatingLossCarryoversNotSubjectToExpiration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal net operating loss carryovers, not subject to expiration</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_FederalNetOperatingLossCarryoversNotSubjectToExpiration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Federal Net Operating Loss Carryovers Not Subject To Expiration</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_NetOperatingLossBeginToExpireYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NOLs begin to expire year</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_NetOperatingLossBeginToExpireYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Operating Loss Begin To Expire Year</link:label>
    <link:loc xlink:href="kymr-20201231.xsd#kymr_ResearchAndDevelopmentCreditCarryforwards" xlink:type="locator" xlink:label="kymr_ResearchAndDevelopmentCreditCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="kymr_ResearchAndDevelopmentCreditCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development credit carryforwards.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="kymr_ResearchAndDevelopmentCreditCarryforwards" xlink:to="kymr_ResearchAndDevelopmentCreditCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="kymr_ResearchAndDevelopmentCreditCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credit carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:label="kymr_ResearchAndDevelopmentCreditCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Credit Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reserves for uncertain tax positions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated interest or penalties recognized on uncertain tax positions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination Penalties And Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OpenTaxYear" xlink:type="locator" xlink:label="us-gaap_OpenTaxYear" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Open tax year subject to examination</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="us-gaap_OpenTaxYear_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Open Tax Year</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average common shares outstanding, basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per share, basic and diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unvested Restricted Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options to Purchase Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti-dilutive stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>48
<FILENAME>kymr-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-11T04:08:03.4253334+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 393cc6ba0c39453d8ef47a8f7fceea15 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/role/TemplateLink" xlink:href="kymr-20201231.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="kymr-20201231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="kymr-20201231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesB1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="kymr_SeriesB1ConvertiblePreferredStockMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="kymr_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="kymr_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesSeedConvertiblePreferredStockMember" xlink:type="locator" xlink:label="kymr_SeriesSeedConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="kymr_SeriesSeedConvertiblePreferredStockMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="kymr_SeriesAConvertiblePreferredStockMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="kymr_SeriesBConvertiblePreferredStockMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="kymr_SeriesB1ConvertiblePreferredStockMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DueFromRelatedPartiesCurrent" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="11470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="11590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="11670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="11790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="11830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="11910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="12070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="12150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="12190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="12230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="12270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="12310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="12350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="12390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="kymr-20201231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesB1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="kymr_SeriesB1ConvertiblePreferredStockMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="kymr_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="kymr_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesSeedConvertiblePreferredStockMember" xlink:type="locator" xlink:label="kymr_SeriesSeedConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="kymr_SeriesSeedConvertiblePreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="kymr_SeriesAConvertiblePreferredStockMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="kymr_SeriesBConvertiblePreferredStockMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="kymr_SeriesB1ConvertiblePreferredStockMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="kymr-20201231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDividendsAdjustment" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDividendsAdjustment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncome" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingExpense" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_TemporaryEquityDividendsAdjustment" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:href="kymr-20201231.xsd#Role_StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_StockIssuedDuringPeriodSharesRestrictedStockVested" xlink:type="locator" xlink:label="kymr_StockIssuedDuringPeriodSharesRestrictedStockVested" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TemporaryEquitySharesConverted" xlink:type="locator" xlink:label="kymr_TemporaryEquitySharesConverted" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TemporaryEquityExchangeOfConvertiblePreferredStockShares" xlink:type="locator" xlink:label="kymr_TemporaryEquityExchangeOfConvertiblePreferredStockShares" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="kymr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_li0l2" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TemporaryEquityAdjustedSharesOutstanding" xlink:type="locator" xlink:label="kymr_TemporaryEquityAdjustedSharesOutstanding_li0l2" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TemporaryEquityAdjustedCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="kymr_TemporaryEquityAdjustedCarryingAmountAttributableToParent_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TemporaryEquityValueOfSharesConverted" xlink:type="locator" xlink:label="kymr_TemporaryEquityValueOfSharesConverted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_StockIssuedDuringPeriodValueRestrictedStockVested" xlink:type="locator" xlink:label="kymr_StockIssuedDuringPeriodValueRestrictedStockVested" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_ExchangeOfConvertiblePreferredStockImpactOnEquity" xlink:type="locator" xlink:label="kymr_ExchangeOfConvertiblePreferredStockImpactOnEquity" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TemporaryEquityExchangeOfConvertiblePreferredStockValue" xlink:type="locator" xlink:label="kymr_TemporaryEquityExchangeOfConvertiblePreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TemporaryEquityConvertiblePreferredStockIssuedDuringPeriodShares" xlink:type="locator" xlink:label="kymr_TemporaryEquityConvertiblePreferredStockIssuedDuringPeriodShares" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TemporaryEquityConvertiblePreferredStockIssuedDuringPeriodValue" xlink:type="locator" xlink:label="kymr_TemporaryEquityConvertiblePreferredStockIssuedDuringPeriodValue" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TemporaryEquityStockSharesVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement" xlink:type="locator" xlink:label="kymr_TemporaryEquityStockSharesVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TemporaryEquityStockValueVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement" xlink:type="locator" xlink:label="kymr_TemporaryEquityStockValueVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TemporaryEquityAdjustedSharesOutstanding" xlink:type="locator" xlink:label="kymr_TemporaryEquityAdjustedSharesOutstanding" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TemporaryEquityAdjustedCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="kymr_TemporaryEquityAdjustedCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesCConvertiblePreferredStockMember" xlink:type="locator" xlink:label="kymr_SeriesCConvertiblePreferredStockMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesB1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="kymr_SeriesB1ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="kymr_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="kymr_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesSeedConvertiblePreferredStockMember" xlink:type="locator" xlink:label="kymr_SeriesSeedConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="kymr_SeriesSeedConvertiblePreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="kymr_SeriesAConvertiblePreferredStockMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="kymr_SeriesBConvertiblePreferredStockMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="kymr_SeriesB1ConvertiblePreferredStockMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="kymr_SeriesCConvertiblePreferredStockMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="kymr_TemporaryEquityAdjustedCarryingAmountAttributableToParent" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="kymr_TemporaryEquityAdjustedSharesOutstanding" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="kymr_TemporaryEquityStockValueVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="kymr_TemporaryEquityStockSharesVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="kymr_TemporaryEquityConvertiblePreferredStockIssuedDuringPeriodValue" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="kymr_TemporaryEquityConvertiblePreferredStockIssuedDuringPeriodShares" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="kymr_TemporaryEquityExchangeOfConvertiblePreferredStockValue" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="kymr_ExchangeOfConvertiblePreferredStockImpactOnEquity" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="11650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="kymr_StockIssuedDuringPeriodValueRestrictedStockVested" order="11790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="11930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="12070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="kymr_TemporaryEquityValueOfSharesConverted" order="12210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="12350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="12450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="12490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="12630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="kymr_TemporaryEquityAdjustedCarryingAmountAttributableToParent_li0l2" order="12770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="kymr_TemporaryEquityAdjustedSharesOutstanding_li0l2" order="12790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_li0l2" order="12910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="kymr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="13290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="kymr_TemporaryEquityExchangeOfConvertiblePreferredStockShares" order="13530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="kymr_TemporaryEquitySharesConverted" order="14470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="16740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="kymr_StockIssuedDuringPeriodSharesRestrictedStockVested" order="16960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="17840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_li0l2" order="18280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:href="kymr-20201231.xsd#Role_StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesB1PreferredStockMember" xlink:type="locator" xlink:label="kymr_SeriesB1PreferredStockMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesBConvertiblePreferredStocksMember" xlink:type="locator" xlink:label="kymr_SeriesBConvertiblePreferredStocksMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="kymr_SeriesBConvertiblePreferredStocksMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="kymr_SeriesB1PreferredStockMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="kymr-20201231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash" xlink:type="locator" xlink:label="us-gaap_RestrictedCash" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_ReductionOfRightOfUseAssetAndLiabilityDueToLeaseModification" xlink:type="locator" xlink:label="kymr_ReductionOfRightOfUseAssetAndLiabilityDueToLeaseModification" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TenantImprovementReceivableIncludedInOtherAssets" xlink:type="locator" xlink:label="kymr_TenantImprovementReceivableIncludedInOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SupplementalDisclosureOfNoncashOperatingActivitiesAbstract" xlink:type="locator" xlink:label="kymr_SupplementalDisclosureOfNoncashOperatingActivitiesAbstract" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_OfferingCostsIncludedInAccountsPayable" xlink:type="locator" xlink:label="kymr_OfferingCostsIncludedInAccountsPayable" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_PropertyAndEquipmentPurchasesIncludedInAccountsPayableAndAccruedExpenses" xlink:type="locator" xlink:label="kymr_PropertyAndEquipmentPurchasesIncludedInAccountsPayableAndAccruedExpenses" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_PurchasesOfPropertyAndEquipmentThroughFinanceAndLeaseLiabilities" xlink:type="locator" xlink:label="kymr_PurchasesOfPropertyAndEquipmentThroughFinanceAndLeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_ProceedsFromConcurrentPrivatePlacement" xlink:type="locator" xlink:label="kymr_ProceedsFromConcurrentPrivatePlacement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfFinancingCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="locator" xlink:label="kymr_IncreaseDecreaseInOperatingLeaseLiabilities" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:type="locator" xlink:label="kymr_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedParties" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_IncreaseDecreaseInContractWithCustomerAssetRelatedParties" xlink:type="locator" xlink:label="kymr_IncreaseDecreaseInContractWithCustomerAssetRelatedParties" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_NetAmortizationOfPremiumsAndDiscountsOnInvestments" xlink:type="locator" xlink:label="kymr_NetAmortizationOfPremiumsAndDiscountsOnInvestments" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_NonCashResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="kymr_NonCashResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesCConvertiblePreferredStockMember" xlink:type="locator" xlink:label="kymr_SeriesCConvertiblePreferredStockMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesB1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="kymr_SeriesB1ConvertiblePreferredStockMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="kymr_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="kymr_SeriesBConvertiblePreferredStockMember" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="kymr_SeriesB1ConvertiblePreferredStockMember" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="kymr_SeriesCConvertiblePreferredStockMember" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="kymr_NonCashResearchAndDevelopmentExpense" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="kymr_NetAmortizationOfPremiumsAndDiscountsOnInvestments" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="kymr_IncreaseDecreaseInContractWithCustomerAssetRelatedParties" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedParties" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="kymr_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="kymr_IncreaseDecreaseInOperatingLeaseLiabilities" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="11680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="11800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfFinancingCosts" order="11840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="11880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="kymr_ProceedsFromConcurrentPrivatePlacement" order="11920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="11960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="12000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="12040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" order="12080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="12120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="12200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="12240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="kymr_PurchasesOfPropertyAndEquipmentThroughFinanceAndLeaseLiabilities" order="12320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="kymr_PropertyAndEquipmentPurchasesIncludedInAccountsPayableAndAccruedExpenses" order="12360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="kymr_OfferingCostsIncludedInAccountsPayable" order="12400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="kymr_SupplementalDisclosureOfNoncashOperatingActivitiesAbstract" order="12440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="kymr_SupplementalDisclosureOfNoncashOperatingActivitiesAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="12520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="kymr_SupplementalDisclosureOfNoncashOperatingActivitiesAbstract" xlink:to="kymr_TenantImprovementReceivableIncludedInOtherAssets" order="12560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="kymr_SupplementalDisclosureOfNoncashOperatingActivitiesAbstract" xlink:to="kymr_ReductionOfRightOfUseAssetAndLiabilityDueToLeaseModification" order="12600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="12670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCash" order="12710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" xlink:href="kymr-20201231.xsd#Role_DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesAbstract" xlink:type="locator" xlink:label="kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesAbstract" xlink:to="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="kymr-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureFairValueMeasurements" xlink:href="kymr-20201231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureFairValueMeasurements">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureMarketableSecurities" xlink:href="kymr-20201231.xsd#Role_DisclosureMarketableSecurities" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureMarketableSecurities">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureCollaborations" xlink:href="kymr-20201231.xsd#Role_DisclosureCollaborations" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureCollaborations">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201409Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201409Member" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipment" xlink:href="kymr-20201231.xsd#Role_DisclosurePropertyAndEquipment" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipment">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureLeases" xlink:href="kymr-20201231.xsd#Role_DisclosureLeases" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureLeases">
    <link:loc xlink:href="kymr-20201231.xsd#kymr_LesseeOperatingAndFinanceLeasesTextBlock" xlink:type="locator" xlink:label="kymr_LesseeOperatingAndFinanceLeasesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="kymr_LesseeOperatingAndFinanceLeasesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureAccruedExpenses" xlink:href="kymr-20201231.xsd#Role_DisclosureAccruedExpenses" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureAccruedExpenses">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureOtherCommitmentsAndContingencies" xlink:href="kymr-20201231.xsd#Role_DisclosureOtherCommitmentsAndContingencies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureOtherCommitmentsAndContingencies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStock" xlink:href="kymr-20201231.xsd#Role_DisclosureConvertiblePreferredStock" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStock">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:type="locator" xlink:label="us-gaap_PreferredStockTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_PreferredStockTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensation" xlink:href="kymr-20201231.xsd#Role_DisclosureEquityBasedCompensation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensation">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions" xlink:href="kymr-20201231.xsd#Role_DisclosureRelatedPartyTransactions" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="kymr-20201231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureIncomeTaxes">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureNetLossPerShare" xlink:href="kymr-20201231.xsd#Role_DisclosureNetLossPerShare" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureNetLossPerShare">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="kymr-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:type="locator" xlink:label="kymr_EmergingGrowthCompanyStatusPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_OffBalanceSheetRiskAndConcentrationOfCreditRiskPolicyTextBlock" xlink:type="locator" xlink:label="kymr_OffBalanceSheetRiskAndConcentrationOfCreditRiskPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_CommonAndPreferredStockValuationPolicyTextBlock" xlink:type="locator" xlink:label="kymr_CommonAndPreferredStockValuationPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_CostsAssociatedWithLicenseAndCollaborativeArrangementsPolicyTextBlock" xlink:type="locator" xlink:label="kymr_CostsAssociatedWithLicenseAndCollaborativeArrangementsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_FinancingCostsPolicyTextBlock" xlink:type="locator" xlink:label="kymr_FinancingCostsPolicyTextBlock" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_PatentCostsPolicyTextBlock" xlink:type="locator" xlink:label="kymr_PatentCostsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_ConvertiblePreferredStockPolicyTextBlock" xlink:type="locator" xlink:label="kymr_ConvertiblePreferredStockPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_RestrictedCashPolicyPolicyTextBlock" xlink:type="locator" xlink:label="kymr_RestrictedCashPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SegmentAndGeographicInformationPolicyTextBlock" xlink:type="locator" xlink:label="kymr_SegmentAndGeographicInformationPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="kymr_SegmentAndGeographicInformationPolicyTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="kymr_RestrictedCashPolicyPolicyTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="kymr_ConvertiblePreferredStockPolicyTextBlock" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="kymr_PatentCostsPolicyTextBlock" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="kymr_FinancingCostsPolicyTextBlock" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="kymr_CostsAssociatedWithLicenseAndCollaborativeArrangementsPolicyTextBlock" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="kymr_CommonAndPreferredStockValuationPolicyTextBlock" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="kymr_OffBalanceSheetRiskAndConcentrationOfCreditRiskPolicyTextBlock" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="kymr_EmergingGrowthCompanyStatusPolicyTextBlock" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="kymr-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables">
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SummaryOfEstimatedUsefulLifeOfRelatedAssetTableTextBlock" xlink:type="locator" xlink:label="kymr_SummaryOfEstimatedUsefulLifeOfRelatedAssetTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="kymr_SummaryOfEstimatedUsefulLifeOfRelatedAssetTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:href="kymr-20201231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesTables" xlink:href="kymr-20201231.xsd#Role_DisclosureMarketableSecuritiesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureCollaborationsTables" xlink:href="kymr-20201231.xsd#Role_DisclosureCollaborationsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureCollaborationsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentTables" xlink:href="kymr-20201231.xsd#Role_DisclosurePropertyAndEquipmentTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureLeasesTables" xlink:href="kymr-20201231.xsd#Role_DisclosureLeasesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureLeasesTables">
    <link:loc xlink:href="kymr-20201231.xsd#kymr_LesseeOperatingAndFinancingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="kymr_LesseeOperatingAndFinancingLeaseLiabilityMaturityTableTextBlock" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock" xlink:type="locator" xlink:label="kymr_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SupplementalCashFlowInformationRelatingToLeasesTableTextBlock" xlink:type="locator" xlink:label="kymr_SupplementalCashFlowInformationRelatingToLeasesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="kymr_SupplementalCashFlowInformationRelatingToLeasesTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="kymr_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="kymr_LesseeOperatingAndFinancingLeaseLiabilityMaturityTableTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureAccruedExpensesTables" xlink:href="kymr-20201231.xsd#Role_DisclosureAccruedExpensesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureAccruedExpensesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationTables" xlink:href="kymr-20201231.xsd#Role_DisclosureEquityBasedCompensationTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="kymr-20201231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureNetLossPerShareTables" xlink:href="kymr-20201231.xsd#Role_DisclosureNetLossPerShareTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureNetLossPerShareTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="kymr-20201231.xsd#Role_DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="kymr-20201231.xsd#kymr_ProceedsFromIssuanceInitialPublicOfferingGross" xlink:type="locator" xlink:label="kymr_ProceedsFromIssuanceInitialPublicOfferingGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsAndCash" xlink:type="locator" xlink:label="us-gaap_InvestmentsAndCash" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_VertexPharmaceuticalsIncorporatedMember" xlink:type="locator" xlink:label="kymr_VertexPharmaceuticalsIncorporatedMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesAbstract" xlink:type="locator" xlink:label="kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesAbstract" xlink:to="kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="kymr_VertexPharmaceuticalsIncorporatedMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_InvestmentsAndCash" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="kymr_ProceedsFromIssuanceInitialPublicOfferingGross" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="kymr-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_MarketableSecuritiesRemainingMaturityPeriodClassifiedAsNonCurrent" xlink:type="locator" xlink:label="kymr_MarketableSecuritiesRemainingMaturityPeriodClassifiedAsNonCurrent" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_MarketableSecuritiesRemainingMaturityPeriod" xlink:type="locator" xlink:label="kymr_MarketableSecuritiesRemainingMaturityPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="kymr_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201813Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201813Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201815Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201815Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201904Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201904Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="kymr_SummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="kymr_SummaryOfSignificantAccountingPoliciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="kymr_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="kymr_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201904Member" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201815Member" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201813Member" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="kymr_SummaryOfSignificantAccountingPoliciesTable" xlink:to="kymr_SummaryOfSignificantAccountingPoliciesLineItems" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="kymr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="kymr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="kymr_MarketableSecuritiesRemainingMaturityPeriod" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="kymr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="kymr_MarketableSecuritiesRemainingMaturityPeriodClassifiedAsNonCurrent" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="kymr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="kymr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="kymr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="kymr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="kymr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="kymr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfRelatedAssetDetails" xlink:href="kymr-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfRelatedAssetDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfRelatedAssetDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_LabEquipmentMember" xlink:type="locator" xlink:label="kymr_LabEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="kymr_LabEquipmentMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="kymr-20201231.xsd#Role_DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_RestrictedCashFairValue" xlink:type="locator" xlink:label="kymr_RestrictedCashFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateBondSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="locator" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10110.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10110.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateBondSecuritiesMember" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasurySecuritiesMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesCurrent" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesNoncurrent" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="kymr_RestrictedCashFairValue" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="kymr-20201231.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails">
    <link:loc xlink:href="kymr-20201231.xsd#kymr_FairValueAssetsLevel2ToLevel3TransfersAmount" xlink:type="locator" xlink:label="kymr_FairValueAssetsLevel2ToLevel3TransfersAmount" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_FairValueAssetsLevel3ToLevel2TransfersAmount" xlink:type="locator" xlink:label="kymr_FairValueAssetsLevel3ToLevel2TransfersAmount" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_FairValueAssetsLevel3ToLevel1TransfersAmount" xlink:type="locator" xlink:label="kymr_FairValueAssetsLevel3ToLevel1TransfersAmount" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_FairValueAssetsLevel1ToLevel3TransfersAmount" xlink:type="locator" xlink:label="kymr_FairValueAssetsLevel1ToLevel3TransfersAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="kymr_FairValueAssetsLevel1ToLevel3TransfersAmount" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="kymr_FairValueAssetsLevel3ToLevel1TransfersAmount" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="kymr_FairValueAssetsLevel3ToLevel2TransfersAmount" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="kymr_FairValueAssetsLevel2ToLevel3TransfersAmount" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleDebtSecuritiesDetails" xlink:href="kymr-20201231.xsd#Role_DisclosureMarketableSecuritiesSummaryOfAvailableForSaleDebtSecuritiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleDebtSecuritiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTable" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesLineItems" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:href="kymr-20201231.xsd#Role_DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails">
    <link:loc xlink:href="kymr-20201231.xsd#kymr_DebtSecuritiesAvailableForSaleDeclineInMarketValueForUnrealizedLossPositionNumberOfSecurities" xlink:type="locator" xlink:label="kymr_DebtSecuritiesAvailableForSaleDeclineInMarketValueForUnrealizedLossPositionNumberOfSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableforsaleSecuritiesSoldAtPar" xlink:type="locator" xlink:label="us-gaap_AvailableforsaleSecuritiesSoldAtPar" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_NumberOfMarketableSecuritiesSold" xlink:type="locator" xlink:label="kymr_NumberOfMarketableSecuritiesSold" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_DebtSecuritiesAvailableForSaleContractualMaturityOf12MonthsOrLongerNumberOfSecurities" xlink:type="locator" xlink:label="kymr_DebtSecuritiesAvailableForSaleContractualMaturityOf12MonthsOrLongerNumberOfSecurities" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_FairValueOfAvailableForSaleDebtSecuritiesContractualMaturityOfLessThanTwelveMonths" xlink:type="locator" xlink:label="kymr_FairValueOfAvailableForSaleDebtSecuritiesContractualMaturityOfLessThanTwelveMonths" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_DebtSecuritiesAvailableForSaleContractualMaturityOfLessThan12MonthsNumberOfSecurities" xlink:type="locator" xlink:label="kymr_DebtSecuritiesAvailableForSaleContractualMaturityOfLessThan12MonthsNumberOfSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="kymr_DebtSecuritiesAvailableForSaleContractualMaturityOfLessThan12MonthsNumberOfSecurities" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="kymr_FairValueOfAvailableForSaleDebtSecuritiesContractualMaturityOfLessThanTwelveMonths" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="kymr_DebtSecuritiesAvailableForSaleContractualMaturityOf12MonthsOrLongerNumberOfSecurities" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="kymr_NumberOfMarketableSecuritiesSold" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_AvailableforsaleSecuritiesSoldAtPar" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="kymr_DebtSecuritiesAvailableForSaleDeclineInMarketValueForUnrealizedLossPositionNumberOfSecurities" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetails" xlink:href="kymr-20201231.xsd#Role_DisclosureCollaborationsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetails">
    <link:loc xlink:href="kymr-20201231.xsd#kymr_WrittenNoticePeriodToTerminateCollaborationAgreement" xlink:type="locator" xlink:label="kymr_WrittenNoticePeriodToTerminateCollaborationAgreement" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TemporaryEquityStockSharesVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement" xlink:type="locator" xlink:label="kymr_TemporaryEquityStockSharesVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_PotentialReceivableMilestonePayments" xlink:type="locator" xlink:label="kymr_PotentialReceivableMilestonePayments" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_PreferredStockIssuancePremium" xlink:type="locator" xlink:label="kymr_PreferredStockIssuancePremium" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_NonRefundableUpfrontPaymentReceived" xlink:type="locator" xlink:label="kymr_NonRefundableUpfrontPaymentReceived" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_ExtendedResearchTermOfCollaboration" xlink:type="locator" xlink:label="kymr_ExtendedResearchTermOfCollaboration" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_InitialResearchTermOfCollaboration" xlink:type="locator" xlink:label="kymr_InitialResearchTermOfCollaboration" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_RemainingResearchTermOfCollaboration" xlink:type="locator" xlink:label="kymr_RemainingResearchTermOfCollaboration" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BilledContractReceivables" xlink:type="locator" xlink:label="us-gaap_BilledContractReceivables" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnbilledContractsReceivable" xlink:type="locator" xlink:label="us-gaap_UnbilledContractsReceivable" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_RoyaltyReceivable" xlink:type="locator" xlink:label="kymr_RoyaltyReceivable" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_MilestoneReceivable" xlink:type="locator" xlink:label="kymr_MilestoneReceivable" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_CostReimbursementReceivable" xlink:type="locator" xlink:label="kymr_CostReimbursementReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_CollaborationAgreementTransactionPrice" xlink:type="locator" xlink:label="kymr_CollaborationAgreementTransactionPrice" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_CommercialMilestonePayments" xlink:type="locator" xlink:label="kymr_CommercialMilestonePayments" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_DevelopmentMilestonePayments" xlink:type="locator" xlink:label="kymr_DevelopmentMilestonePayments" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_UpfrontPayment" xlink:type="locator" xlink:label="kymr_UpfrontPayment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesAPreferredUnitsMember" xlink:type="locator" xlink:label="kymr_SeriesAPreferredUnitsMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_CompoundCollaborationAgreementMember" xlink:type="locator" xlink:label="kymr_CompoundCollaborationAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember_li0l2" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesB1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="kymr_SeriesB1ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_VertexAgreementMember" xlink:type="locator" xlink:label="kymr_VertexAgreementMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_CollaborationTargetTwoMember" xlink:type="locator" xlink:label="kymr_CollaborationTargetTwoMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_CollaborationTargetOneMember" xlink:type="locator" xlink:label="kymr_CollaborationTargetOneMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_IRAK4Member" xlink:type="locator" xlink:label="kymr_IRAK4Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember" xlink:type="locator" xlink:label="us-gaap_ProjectMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:type="locator" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SanofiCollaborationArrangementMember" xlink:type="locator" xlink:label="kymr_SanofiCollaborationArrangementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="kymr_SanofiCollaborationArrangementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_ProjectMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProjectMember" xlink:to="kymr_IRAK4Member" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="kymr_CollaborationTargetOneMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="kymr_CollaborationTargetTwoMember" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="kymr_VertexAgreementMember" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="kymr_SeriesB1ConvertiblePreferredStockMember" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember_li0l2" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="kymr_CompoundCollaborationAgreementMember" order="11700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="kymr_SeriesAPreferredUnitsMember" order="11840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="12000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="kymr_UpfrontPayment" order="12010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="kymr_DevelopmentMilestonePayments" order="12030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="kymr_CommercialMilestonePayments" order="12070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="kymr_CollaborationAgreementTransactionPrice" order="12140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="12230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="12290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="kymr_CostReimbursementReceivable" order="12310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="kymr_MilestoneReceivable" order="12330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="kymr_RoyaltyReceivable" order="12350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_UnbilledContractsReceivable" order="12370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_BilledContractReceivables" order="12390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="kymr_RemainingResearchTermOfCollaboration" order="12410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="kymr_InitialResearchTermOfCollaboration" order="12460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="kymr_ExtendedResearchTermOfCollaboration" order="12480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="kymr_NonRefundableUpfrontPaymentReceived" order="12530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="12550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="12570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="kymr_PreferredStockIssuancePremium" order="12590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="kymr_PotentialReceivableMilestonePayments" order="12640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="12740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" order="12860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="13010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="13090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="13170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="kymr_TemporaryEquityStockSharesVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement" order="13250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="kymr_WrittenNoticePeriodToTerminateCollaborationAgreement" order="13360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureCollaborationsChangeInAccountsReceivableContractAssetAndLiabilitiesDetails" xlink:href="kymr-20201231.xsd#Role_DisclosureCollaborationsChangeInAccountsReceivableContractAssetAndLiabilitiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureCollaborationsChangeInAccountsReceivableContractAssetAndLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability_li0l2" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_ContractWithCustomerLiabilityDeductions" xlink:type="locator" xlink:label="kymr_ContractWithCustomerLiabilityDeductions" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_ContractWithCustomerLiabilityAdditions" xlink:type="locator" xlink:label="kymr_ContractWithCustomerLiabilityAdditions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss_li0l2" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_ContractWithCustomerAssetNetDeductions" xlink:type="locator" xlink:label="kymr_ContractWithCustomerAssetNetDeductions" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_ContractWithCustomerAssetNetAdditions" xlink:type="locator" xlink:label="kymr_ContractWithCustomerAssetNetAdditions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_DeferredRevenueSanofiMember" xlink:type="locator" xlink:label="kymr_DeferredRevenueSanofiMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_DeferredRevenueVertexMember" xlink:type="locator" xlink:label="kymr_DeferredRevenueVertexMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_UnbilledReceivablesSanofiMember" xlink:type="locator" xlink:label="kymr_UnbilledReceivablesSanofiMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_BilledReceivablesSanofiMember" xlink:type="locator" xlink:label="kymr_BilledReceivablesSanofiMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="kymr_BilledReceivablesSanofiMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="kymr_UnbilledReceivablesSanofiMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="kymr_DeferredRevenueVertexMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="kymr_DeferredRevenueSanofiMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="kymr_ContractWithCustomerAssetNetAdditions" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="kymr_ContractWithCustomerAssetNetDeductions" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss_li0l2" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="kymr_ContractWithCustomerLiabilityAdditions" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="kymr_ContractWithCustomerLiabilityDeductions" order="11360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability_li0l2" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" xlink:href="kymr-20201231.xsd#Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_AssetsNotYetInServiceMember" xlink:type="locator" xlink:label="kymr_AssetsNotYetInServiceMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_LabEquipmentMember" xlink:type="locator" xlink:label="kymr_LabEquipmentMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_LabAndOfficeEquipmentMember" xlink:type="locator" xlink:label="kymr_LabAndOfficeEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="kymr_LabAndOfficeEquipmentMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="kymr_LabEquipmentMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="kymr_AssetsNotYetInServiceMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:href="kymr-20201231.xsd#Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_AccumulatedAmortization" xlink:type="locator" xlink:label="kymr_AccumulatedAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_LabAndOfficeEquipmentMember" xlink:type="locator" xlink:label="kymr_LabAndOfficeEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="kymr_LabAndOfficeEquipmentMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_Depreciation" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="kymr_AccumulatedAmortization" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:href="kymr-20201231.xsd#Role_DisclosureLeasesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails">
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TenantIncentiveAllowanceReceivable" xlink:type="locator" xlink:label="kymr_TenantIncentiveAllowanceReceivable" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_LeaseAdditionalTerm" xlink:type="locator" xlink:label="kymr_LeaseAdditionalTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_LeaseTerm" xlink:type="locator" xlink:label="kymr_LeaseTerm" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_LeaseCommencementDate" xlink:type="locator" xlink:label="kymr_LeaseCommencementDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit" xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_LeaseTerminationDate" xlink:type="locator" xlink:label="kymr_LeaseTerminationDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLeasehold" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLeasehold" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:type="locator" xlink:label="us-gaap_AreaOfRealEstateProperty" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_WatertownMassachusettsMember" xlink:type="locator" xlink:label="kymr_WatertownMassachusettsMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_FacilitySubleaseAgreementMember" xlink:type="locator" xlink:label="kymr_FacilitySubleaseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:type="locator" xlink:label="us-gaap_LetterOfCreditMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMember" xlink:type="locator" xlink:label="us-gaap_OtherAssetsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_NoncancelableFacilityLeaseAgreementMember" xlink:type="locator" xlink:label="kymr_NoncancelableFacilityLeaseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_CambridgeMassachusettsMember" xlink:type="locator" xlink:label="kymr_CambridgeMassachusettsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="kymr_CambridgeMassachusettsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="kymr_NoncancelableFacilityLeaseAgreementMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherAssetsMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherCurrentAssetsMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_CreditFacilityAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_LetterOfCreditMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="kymr_FacilitySubleaseAgreementMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="kymr_WatertownMassachusettsMember" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ImpairmentOfLeasehold" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="kymr_LeaseTerminationDate" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_SecurityDeposit" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="kymr_LeaseCommencementDate" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="kymr_LeaseTerm" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="kymr_LeaseAdditionalTerm" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="kymr_TenantIncentiveAllowanceReceivable" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostsDetails" xlink:href="kymr-20201231.xsd#Role_DisclosureLeasesComponentsOfLeaseCostsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:type="locator" xlink:label="us-gaap_LeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_VariableLeaseCost" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCost" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureLeasesSupplementalCashFlowInformationRelatingToLeasesDetails" xlink:href="kymr-20201231.xsd#Role_DisclosureLeasesSupplementalCashFlowInformationRelatingToLeasesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureLeasesSupplementalCashFlowInformationRelatingToLeasesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_OperatingLeasePaymentsProceeds" xlink:type="locator" xlink:label="kymr_OperatingLeasePaymentsProceeds" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="kymr_OperatingLeasePaymentsProceeds" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRatesDetails" xlink:href="kymr-20201231.xsd#Role_DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRatesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRatesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfUndiscountedFutureLeasePaymentsForOperatingAndFinanceLeasesDetails" xlink:href="kymr-20201231.xsd#Role_DisclosureLeasesSummaryOfUndiscountedFutureLeasePaymentsForOperatingAndFinanceLeasesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfUndiscountedFutureLeasePaymentsForOperatingAndFinanceLeasesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiability" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:href="kymr-20201231.xsd#Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedSalariesCurrent" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_AccruedResearchAndDevelopmentExpensesCurrent" xlink:type="locator" xlink:label="kymr_AccruedResearchAndDevelopmentExpensesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="kymr_AccruedResearchAndDevelopmentExpensesCurrent" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedSalariesCurrent" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureOtherCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="kymr-20201231.xsd#Role_DisclosureOtherCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureOtherCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:type="locator" xlink:label="us-gaap_LossContingenciesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndemnificationGuaranteeMember" xlink:type="locator" xlink:label="us-gaap_IndemnificationGuaranteeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:type="locator" xlink:label="us-gaap_LossContingencyNatureDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="locator" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:type="locator" xlink:label="us-gaap_LossContingenciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingenciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingencyNatureDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="us-gaap_IndemnificationGuaranteeMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:href="kymr-20201231.xsd#Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_IncreaseInAccumulatedDeficitRelatedToTemporaryEquityDeemedDividend" xlink:type="locator" xlink:label="kymr_IncreaseInAccumulatedDeficitRelatedToTemporaryEquityDeemedDividend" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_AdjustmentsToAdditionalPaidInCapitalRelatedToTemporaryEquityDeemedDividend" xlink:type="locator" xlink:label="kymr_AdjustmentsToAdditionalPaidInCapitalRelatedToTemporaryEquityDeemedDividend" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDividendsAdjustment" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDividendsAdjustment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesCPreferredStockPurchaseAgreementMember" xlink:type="locator" xlink:label="kymr_SeriesCPreferredStockPurchaseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesCConvertiblePreferredStockMember" xlink:type="locator" xlink:label="kymr_SeriesCConvertiblePreferredStockMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesB1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="kymr_SeriesB1ConvertiblePreferredStockMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="kymr_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="kymr_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_SeriesSeedConvertiblePreferredStockMember" xlink:type="locator" xlink:label="kymr_SeriesSeedConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="kymr_SeriesSeedConvertiblePreferredStockMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="kymr_SeriesAConvertiblePreferredStockMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="kymr_SeriesBConvertiblePreferredStockMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="kymr_SeriesB1ConvertiblePreferredStockMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="kymr_SeriesCConvertiblePreferredStockMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="kymr_SeriesCPreferredStockPurchaseAgreementMember" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityLineItems" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityDividendsAdjustment" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="kymr_AdjustmentsToAdditionalPaidInCapitalRelatedToTemporaryEquityDeemedDividend" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="kymr_IncreaseInAccumulatedDeficitRelatedToTemporaryEquityDeemedDividend" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAdditionalInformationDetails" xlink:href="kymr-20201231.xsd#Role_DisclosureEquityBasedCompensationAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:type="locator" xlink:label="us-gaap_GranteeStatusDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:type="locator" xlink:label="us-gaap_GranteeStatusAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TwoThousandEighteenStockOptionAndGrantPlanMember" xlink:type="locator" xlink:label="kymr_TwoThousandEighteenStockOptionAndGrantPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_LesserOfPotentialOutcomeTwoMember" xlink:type="locator" xlink:label="kymr_LesserOfPotentialOutcomeTwoMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_LesserOfPotentialOutcomeOneMember" xlink:type="locator" xlink:label="kymr_LesserOfPotentialOutcomeOneMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_ScenarioPotentialOutcomeDomain" xlink:type="locator" xlink:label="kymr_ScenarioPotentialOutcomeDomain" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_ScenarioPotentialOutcomeAxis" xlink:type="locator" xlink:label="kymr_ScenarioPotentialOutcomeAxis" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="kymr_TwoThousandTwentyEmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TwoThousandTwentyStockOptionAndIncentivePlanMember" xlink:type="locator" xlink:label="kymr_TwoThousandTwentyStockOptionAndIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="kymr_TwoThousandTwentyStockOptionAndIncentivePlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="kymr_TwoThousandTwentyEmployeeStockPurchasePlanMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="kymr_ScenarioPotentialOutcomeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="kymr_ScenarioPotentialOutcomeAxis" xlink:to="kymr_ScenarioPotentialOutcomeDomain" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="kymr_ScenarioPotentialOutcomeDomain" xlink:to="kymr_LesserOfPotentialOutcomeOneMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="kymr_ScenarioPotentialOutcomeDomain" xlink:to="kymr_LesserOfPotentialOutcomeTwoMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="kymr_TwoThousandEighteenStockOptionAndGrantPlanMember" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="11470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="11760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="11850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" order="11930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="12000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfStockOptionActivityDetails" xlink:href="kymr-20201231.xsd#Role_DisclosureEquityBasedCompensationSummaryOfStockOptionActivityDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfStockOptionActivityDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_li0l2" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue" xlink:type="locator" xlink:label="kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue" xlink:type="locator" xlink:label="kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract" xlink:type="locator" xlink:label="kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TwoThousandAndTwentyStockOptionAndGrantPlanMember" xlink:type="locator" xlink:label="kymr_TwoThousandAndTwentyStockOptionAndGrantPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="kymr_TwoThousandAndTwentyStockOptionAndGrantPlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="11620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="11720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" order="11950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="12150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="12350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract" order="12480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="12680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract" xlink:to="kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue" order="12780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="12880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract" xlink:to="kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue" order="12980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_li0l2" order="13080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="13180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfEquityBasedCompensationExpenseDetails" xlink:href="kymr-20201231.xsd#Role_DisclosureEquityBasedCompensationSummaryOfEquityBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfEquityBasedCompensationExpenseDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfWeightedAverageAssumptionsDetails" xlink:href="kymr-20201231.xsd#Role_DisclosureEquityBasedCompensationSummaryOfWeightedAverageAssumptionsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfWeightedAverageAssumptionsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfRestrictedStockActivityDetails" xlink:href="kymr-20201231.xsd#Role_DisclosureEquityBasedCompensationSummaryOfRestrictedStockActivityDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfRestrictedStockActivityDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_TwoThousandEighteenStockOptionAndGrantPlanMember" xlink:type="locator" xlink:label="kymr_TwoThousandEighteenStockOptionAndGrantPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="kymr_TwoThousandEighteenStockOptionAndGrantPlanMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_li0l2" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="kymr-20201231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestorMember" xlink:type="locator" xlink:label="us-gaap_InvestorMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_InvestorMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="kymr-20201231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OpenTaxYear" xlink:type="locator" xlink:label="us-gaap_OpenTaxYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_ResearchAndDevelopmentCreditCarryforwards" xlink:type="locator" xlink:label="kymr_ResearchAndDevelopmentCreditCarryforwards" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_NetOperatingLossBeginToExpireYear" xlink:type="locator" xlink:label="kymr_NetOperatingLossBeginToExpireYear" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_FederalNetOperatingLossCarryoversNotSubjectToExpiration" xlink:type="locator" xlink:label="kymr_FederalNetOperatingLossCarryoversNotSubjectToExpiration" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_IncomeTaxDisclosureLineItems" xlink:type="locator" xlink:label="kymr_IncomeTaxDisclosureLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LatestTaxYearMember" xlink:type="locator" xlink:label="us-gaap_LatestTaxYearMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarliestTaxYearMember" xlink:type="locator" xlink:label="us-gaap_EarliestTaxYearMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:type="locator" xlink:label="us-gaap_TaxPeriodAxis" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_FederalAndStateMember" xlink:type="locator" xlink:label="kymr_FederalAndStateMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_IncomeTaxDisclosureTable" xlink:type="locator" xlink:label="kymr_IncomeTaxDisclosureTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="kymr_IncomeTaxDisclosureTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="kymr_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="kymr_FederalAndStateMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="kymr_IncomeTaxDisclosureTable" xlink:to="us-gaap_TaxPeriodAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_EarliestTaxYearMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_LatestTaxYearMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="kymr_IncomeTaxDisclosureTable" xlink:to="kymr_IncomeTaxDisclosureLineItems" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="kymr_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="kymr_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="kymr_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="kymr_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="kymr_IncomeTaxDisclosureLineItems" xlink:to="kymr_FederalNetOperatingLossCarryoversNotSubjectToExpiration" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="kymr_IncomeTaxDisclosureLineItems" xlink:to="kymr_NetOperatingLossBeginToExpireYear" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="kymr_IncomeTaxDisclosureLineItems" xlink:to="kymr_ResearchAndDevelopmentCreditCarryforwards" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="kymr_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="kymr_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="kymr_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_OpenTaxYear" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureIncomeTaxesRateReconciliationOfUSStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetails" xlink:href="kymr-20201231.xsd#Role_DisclosureIncomeTaxesRateReconciliationOfUSStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureIncomeTaxesRateReconciliationOfUSStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:type="locator" xlink:label="kymr_EffectiveIncomeTaxRateReconciliationPermanentDifferences" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="kymr_EffectiveIncomeTaxRateReconciliationPermanentDifferences" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfNetDeferredIncomeTaxesDetails" xlink:href="kymr-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfSignificantComponentsOfNetDeferredIncomeTaxesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfNetDeferredIncomeTaxesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_DeferredTaxLiabilitiesRightOfUseAssets" xlink:type="locator" xlink:label="kymr_DeferredTaxLiabilitiesRightOfUseAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:loc xlink:href="kymr-20201231.xsd#kymr_DeferredTaxAssetsLeaseLiabilities" xlink:type="locator" xlink:label="kymr_DeferredTaxAssetsLeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="kymr_DeferredTaxAssetsLeaseLiabilities" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpense" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="kymr_DeferredTaxLiabilitiesRightOfUseAssets" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedLossPerShareDetail" xlink:href="kymr-20201231.xsd#Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedLossPerShareDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedLossPerShareDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDividendsAdjustment" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDividendsAdjustment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_TemporaryEquityDividendsAdjustment" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfDilutedNetLossPerShareAttributableToCommonStockholdersAntiDilutedEffectDetail" xlink:href="kymr-20201231.xsd#Role_DisclosureNetLossPerShareScheduleOfDilutedNetLossPerShareAttributableToCommonStockholdersAntiDilutedEffectDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.kymeratx.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfDilutedNetLossPerShareAttributableToCommonStockholdersAntiDilutedEffectDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760656532472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 26, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">KYMR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Kymera Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001815442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,811,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-2992166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">200 Arsenal Yards Blvd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Watertown<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">285-5300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Portions of the registrant&#8217;s Proxy Statement for its 2021 Annual Meeting of Stockholders, which the registrant intends to file with the Securities and Exchange Commission not later<font style="color:#000000;font-family:Arial;"> </font>than 120 days after the registrant&#8217;s fiscal year ended December&#160;31, 2020, are incorporated by reference into Part III of this Annual Report on Form 10-K</p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 20-F, 40-F<br> -Number 240<br> -Section 15<br> -Subsection d-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760657978872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 31,004<span></span>
</td>
<td class="nump">$ 76,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities (Note 4)</a></td>
<td class="nump">265,198<span></span>
</td>
<td class="nump">15,942<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Accounts receivable&#8212;due from related parties</a></td>
<td class="nump">577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets&#8212;due from related parties</a></td>
<td class="nump">856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,704<span></span>
</td>
<td class="nump">888<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">302,339<span></span>
</td>
<td class="nump">92,845<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Marketable securities, non-current (Note 4)</a></td>
<td class="nump">162,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net (Note 6)</a></td>
<td class="nump">10,841<span></span>
</td>
<td class="nump">3,794<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, operating leases</a></td>
<td class="nump">9,845<span></span>
</td>
<td class="nump">18,289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">1,589<span></span>
</td>
<td class="nump">1,774<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">487,175<span></span>
</td>
<td class="nump">116,702<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,368<span></span>
</td>
<td class="nump">3,276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses (Note 8)</a></td>
<td class="nump">10,330<span></span>
</td>
<td class="nump">4,568<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">92,552<span></span>
</td>
<td class="nump">23,349<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current portion</a></td>
<td class="nump">2,572<span></span>
</td>
<td class="nump">2,696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities, current portion</a></td>
<td class="nump">689<span></span>
</td>
<td class="nump">681<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">110,617<span></span>
</td>
<td class="nump">34,570<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">77,838<span></span>
</td>
<td class="nump">29,642<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">14,128<span></span>
</td>
<td class="nump">16,651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities, net of current portion</a></td>
<td class="nump">604<span></span>
</td>
<td class="nump">1,165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">203,287<span></span>
</td>
<td class="nump">82,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 10,000,000 and 0 shares authorized as of December 31, 2020 and December 31, 2019, respectively; 0 shares issued or outstanding as of December 31, 2020 and December 31, 2019</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 150,000,000 and 45,000,000 shares authorized at December 31, 2020 and December 31, 2019, respectively, 44,592,288 and 2,208,982 shares issued at December 31, 2020 and December 31, 2019, respectively; 44,482,186 and 1,929,516 shares outstanding at December 31, 2020 and December 31, 2019, respectively</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">412,777<span></span>
</td>
<td class="nump">2,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(128,765)<span></span>
</td>
<td class="num">(76,456)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive (loss) income</a></td>
<td class="num">(128)<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity (deficit)</a></td>
<td class="nump">283,888<span></span>
</td>
<td class="num">(74,406)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred stock and stockholders&#8217; equity (deficit)</a></td>
<td class="nump">$ 487,175<span></span>
</td>
<td class="nump">116,702<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=kymr_SeriesSeedConvertiblePreferredStockMember', window );">Series Seed Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=kymr_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,237<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=kymr_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,918<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=kymr_SeriesB1ConvertiblePreferredStockMember', window );">Series B-1 Convertible Preferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,025<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=kymr_SeriesSeedConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=kymr_SeriesSeedConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=kymr_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=kymr_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=kymr_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=kymr_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=kymr_SeriesB1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=kymr_SeriesB1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760658948760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued</a></td>
<td class="nump">44,592,288<span></span>
</td>
<td class="nump">2,208,982<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, outstanding</a></td>
<td class="nump">44,482,186<span></span>
</td>
<td class="nump">1,929,516<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=kymr_SeriesSeedConvertiblePreferredStockMember', window );">Series Seed Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible Preferred Stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible Preferred Stock, authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible Preferred Stock, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible Preferred Stock, outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Convertible Preferred Stock, liquidation preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=kymr_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible Preferred Stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible Preferred Stock, authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,886,305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible Preferred Stock, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,886,305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible Preferred Stock, outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,720,126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Convertible Preferred Stock, liquidation preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,440<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=kymr_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible Preferred Stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible Preferred Stock, authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,009,848<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible Preferred Stock, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,827,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible Preferred Stock, outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,827,580<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Convertible Preferred Stock, liquidation preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=kymr_SeriesB1ConvertiblePreferredStockMember', window );">Series B-1 Convertible Preferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible Preferred Stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible Preferred Stock, authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,059,695<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible Preferred Stock, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,059,695<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible Preferred Stock, outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,059,695<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Convertible Preferred Stock, liquidation preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=kymr_SeriesSeedConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=kymr_SeriesSeedConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=kymr_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=kymr_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=kymr_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=kymr_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=kymr_SeriesB1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=kymr_SeriesB1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760656645944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration Revenue&#8212;from related party</a></td>
<td class="nump">$ 34,034<span></span>
</td>
<td class="nump">$ 2,934<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList', window );">Revenue from Contract with Customer, Product and Service [Extensible List]</a></td>
<td class="text">kymr:CollaborationRevenueFromRelatedPartyMember<span></span>
</td>
<td class="text">kymr:CollaborationRevenueFromRelatedPartyMember<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 62,105<span></span>
</td>
<td class="nump">$ 37,158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">18,233<span></span>
</td>
<td class="nump">7,981<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">80,338<span></span>
</td>
<td class="nump">45,139<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(46,304)<span></span>
</td>
<td class="num">(42,205)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Interest Income</a></td>
<td class="nump">826<span></span>
</td>
<td class="nump">1,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Interest Expense</a></td>
<td class="num">(115)<span></span>
</td>
<td class="num">(46)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">711<span></span>
</td>
<td class="nump">959<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(45,593)<span></span>
</td>
<td class="num">(41,246)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized (loss) gain on marketable securities</a></td>
<td class="num">(134)<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">(45,727)<span></span>
</td>
<td class="num">(41,240)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Reconciliation of net loss to net loss attributable to common stockholders:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(45,593)<span></span>
</td>
<td class="num">(41,246)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDividendsAdjustment', window );">Deemed dividend from exchange of convertible preferred stock</a></td>
<td class="num">(9,050)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (54,643)<span></span>
</td>
<td class="num">$ (41,246)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to common stockholders, basic and diluted</a></td>
<td class="num">$ (3.15)<span></span>
</td>
<td class="num">$ (24.28)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common stocks outstanding, basic and diluted</a></td>
<td class="nump">17,349,582<span></span>
</td>
<td class="nump">1,698,522<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121551570&amp;loc=SL49130690-203046-203046<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDividendsAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accretion of temporary equity during the period due to cash, stock, and in-kind dividends. This item is an adjustment to net income necessary to derive net income apportioned to common stockholders and is to be distinguished from Temporary Equity, Accretion of Dividends (Temporary Equity, Accretion of Dividends).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDividendsAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760652482408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Private Placement</div></th>
<th class="th">
<div>Private Placement </div>
<div>Common Stock</div>
</th>
<th class="th">
<div>Private Placement </div>
<div>Additional Paid In Capital</div>
</th>
<th class="th"><div>IPO</div></th>
<th class="th">
<div>IPO </div>
<div>Common Stock</div>
</th>
<th class="th">
<div>IPO </div>
<div>Additional Paid In Capital</div>
</th>
<th class="th"><div>Series Seed Convertible Preferred Stock</div></th>
<th class="th"><div>Series A Convertible Preferred Stock</div></th>
<th class="th"><div>Series B Convertible Preferred Stock</div></th>
<th class="th"><div>Series B-1 Convertible Preferred</div></th>
<th class="th"><div>Series C Convertible Preferred Stock</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_TemporaryEquityAdjustedCarryingAmountAttributableToParent', window );">Temporary Equity, Beginning Balance at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,900<span></span>
</td>
<td class="nump">$ 28,794<span></span>
</td>
<td class="nump">$ 38,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_TemporaryEquityAdjustedSharesOutstanding', window );">Temporary Equity, Beginning Balance, Shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">14,498,547<span></span>
</td>
<td class="nump">9,605,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2018</a></td>
<td class="num">$ (34,436)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 774<span></span>
</td>
<td class="num">$ (35,210)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,479,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_TemporaryEquityStockValueVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement', window );">Vesting of Series A Preferred Stock in connection with collaboration arrangement (Note 5)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_TemporaryEquityStockSharesVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement', window );">Vesting of Series A Preferred Stock in connection with collaboration arrangement (Note 5), Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">221,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_TemporaryEquityConvertiblePreferredStockIssuedDuringPeriodValue', window );">Issuance of Convertible Preferred Stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_TemporaryEquityConvertiblePreferredStockIssuedDuringPeriodShares', window );">Issuance of Convertible Preferred Stock,net of issuance cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,221,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Preferred Stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of Stock Options</a></td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on marketable securities</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(41,246)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41,246)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_TemporaryEquityAdjustedCarryingAmountAttributableToParent', window );">Temporary Equity, Ending Balance at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,900<span></span>
</td>
<td class="nump">$ 29,237<span></span>
</td>
<td class="nump">$ 59,918<span></span>
</td>
<td class="nump">$ 14,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_TemporaryEquityAdjustedSharesOutstanding', window );">Temporary Equity, Beginning Balance, Shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">14,720,126<span></span>
</td>
<td class="nump">14,827,580<span></span>
</td>
<td class="nump">3,059,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2019</a></td>
<td class="num">(74,406)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,044<span></span>
</td>
<td class="num">(76,456)<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Preferred Stock, net of issuance costs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,059,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of Stock Options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_StockIssuedDuringPeriodSharesRestrictedStockVested', window );">Vesting Restricted Stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">354,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,929,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_TemporaryEquityStockValueVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement', window );">Vesting of Series A Preferred Stock in connection with collaboration arrangement (Note 5)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_TemporaryEquityStockSharesVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement', window );">Vesting of Series A Preferred Stock in connection with collaboration arrangement (Note 5), Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Preferred Stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_TemporaryEquityExchangeOfConvertiblePreferredStockValue', window );">Temporary Equity, Exchange of Series A Convertible Preferred Stock for Series C Preferred Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,950)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_ExchangeOfConvertiblePreferredStockImpactOnEquity', window );">Exchange of Series A Convertible Preferred Stock for Series C Preferred Convertible Preferred Stock</a></td>
<td class="num">(9,050)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,334)<span></span>
</td>
<td class="num">(6,716)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of Stock Options</a></td>
<td class="nump">162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_StockIssuedDuringPeriodValueRestrictedStockVested', window );">Vesting Restricted Stock</a></td>
<td class="nump">112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">5,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on marketable securities</a></td>
<td class="num">(134)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(134)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_TemporaryEquityValueOfSharesConverted', window );">Temporary equity, conversion of convertible preferred stock into common</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,900)<span></span>
</td>
<td class="num">$ (25,509)<span></span>
</td>
<td class="num">$ (64,718)<span></span>
</td>
<td class="num">$ (14,025)<span></span>
</td>
<td class="num">$ (101,180)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock into common stock</a></td>
<td class="nump">211,332<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">211,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock into common, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,625,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,527<span></span>
</td>
<td class="nump">$ 182,748<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 182,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(45,593)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45,593)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 283,888<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 412,777<span></span>
</td>
<td class="num">$ (128,765)<span></span>
</td>
<td class="num">$ (128)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Preferred Stock, net of issuance costs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,182,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,539,141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_TemporaryEquityExchangeOfConvertiblePreferredStockShares', window );">Temporary Equity, Exchange of Series A Convertible Preferred Stock for Series C Preferred Convertible Preferred Stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,988,802)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,988,802<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_TemporaryEquitySharesConverted', window );">Temporary equity, conversion of convertible preferred stock into common, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,000,000)<span></span>
</td>
<td class="num">(12,842,112)<span></span>
</td>
<td class="num">(16,009,845)<span></span>
</td>
<td class="num">(3,059,695)<span></span>
</td>
<td class="num">(15,527,943)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of Stock Options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_StockIssuedDuringPeriodSharesRestrictedStockVested', window );">Vesting Restricted Stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">676,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,987,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,482,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_ExchangeOfConvertiblePreferredStockImpactOnEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exchange of convertible preferred stock impact on equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_ExchangeOfConvertiblePreferredStockImpactOnEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_StockIssuedDuringPeriodSharesRestrictedStockVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares restricted stock vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_StockIssuedDuringPeriodSharesRestrictedStockVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_StockIssuedDuringPeriodValueRestrictedStockVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value restricted stock vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_StockIssuedDuringPeriodValueRestrictedStockVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_TemporaryEquityAdjustedCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity adjusted carrying amount attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_TemporaryEquityAdjustedCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_TemporaryEquityAdjustedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity adjusted shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_TemporaryEquityAdjustedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_TemporaryEquityConvertiblePreferredStockIssuedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity convertible preferred stock issued during period shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_TemporaryEquityConvertiblePreferredStockIssuedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_TemporaryEquityConvertiblePreferredStockIssuedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity convertible preferred stock issued during period value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_TemporaryEquityConvertiblePreferredStockIssuedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_TemporaryEquityExchangeOfConvertiblePreferredStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity, exchange of convertible preferred stock, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_TemporaryEquityExchangeOfConvertiblePreferredStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_TemporaryEquityExchangeOfConvertiblePreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity, exchange of convertible preferred stock, value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_TemporaryEquityExchangeOfConvertiblePreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_TemporaryEquitySharesConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity shares converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_TemporaryEquitySharesConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock issued during period shares new issues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_TemporaryEquityStockSharesVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock shares vesting of series A preferred stock in connection with collaboration arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_TemporaryEquityStockSharesVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_TemporaryEquityStockValueVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock value vesting of series A preferred stock in connection with collaboration arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_TemporaryEquityStockValueVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_TemporaryEquityValueOfSharesConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity value of shares converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_TemporaryEquityValueOfSharesConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760656400200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Underwriting discounts, offering costs and issuance costs</a></td>
<td class="nump">$ 17,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=kymr_SeriesBConvertiblePreferredStocksMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Underwriting discounts, offering costs and issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=kymr_SeriesB1PreferredStockMember', window );">Series B-1 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Underwriting discounts, offering costs and issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Underwriting discounts, offering costs and issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Underwriting discounts, offering costs and issuance costs</a></td>
<td class="nump">$ 320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=kymr_SeriesBConvertiblePreferredStocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=kymr_SeriesBConvertiblePreferredStocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=kymr_SeriesB1PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=kymr_SeriesB1PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760657470696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (45,593)<span></span>
</td>
<td class="num">$ (41,246)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">5,190<span></span>
</td>
<td class="nump">1,196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,763<span></span>
</td>
<td class="nump">825<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_NonCashResearchAndDevelopmentExpense', window );">Non-cash research and development expense</a></td>
<td class="nump">332<span></span>
</td>
<td class="nump">443<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_NetAmortizationOfPremiumsAndDiscountsOnInvestments', window );">Net amortization of premiums and discounts on investments</a></td>
<td class="nump">1,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(3,816)<span></span>
</td>
<td class="num">(564)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties', window );">Accounts receivable&#8212;due from related party</a></td>
<td class="num">(577)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_IncreaseDecreaseInContractWithCustomerAssetRelatedParties', window );">Contract asset&#8212;due from related parties</a></td>
<td class="num">(856)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties', window );">Other receivables&#8212;due from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">990<span></span>
</td>
<td class="nump">904<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">5,754<span></span>
</td>
<td class="nump">2,248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">117,400<span></span>
</td>
<td class="nump">52,991<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_IncreaseDecreaseInOperatingLeaseRightOfUseAssets', window );">Operating lease right-of-use assets</a></td>
<td class="nump">8,444<span></span>
</td>
<td class="nump">1,350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(2,647)<span></span>
</td>
<td class="num">(383)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="nump">205<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">88,130<span></span>
</td>
<td class="nump">17,905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment, net</a></td>
<td class="num">(9,096)<span></span>
</td>
<td class="num">(532)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="num">(529,382)<span></span>
</td>
<td class="num">(15,954)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">115,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(422,588)<span></span>
</td>
<td class="num">(16,486)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock option exercises</a></td>
<td class="nump">162<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payments on financing leases</a></td>
<td class="num">(554)<span></span>
</td>
<td class="num">(371)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering, net of underwriting discounts and offering costs</a></td>
<td class="nump">183,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_ProceedsFromConcurrentPrivatePlacement', window );">Proceeds from concurrent private placement</a></td>
<td class="nump">13,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">289,262<span></span>
</td>
<td class="nump">34,911<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents and restricted cash</a></td>
<td class="num">(45,196)<span></span>
</td>
<td class="nump">36,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">77,789<span></span>
</td>
<td class="nump">41,459<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">32,593<span></span>
</td>
<td class="nump">77,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">115<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of noncash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_PurchasesOfPropertyAndEquipmentThroughFinanceAndLeaseLiabilities', window );">Purchases of property and equipment through finance and lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_PropertyAndEquipmentPurchasesIncludedInAccountsPayableAndAccruedExpenses', window );">Property and equipment purchases included in accounts payable and accrued expenses</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">315<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_OfferingCostsIncludedInAccountsPayable', window );">Offering costs included in accounts payable</a></td>
<td class="nump">397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_SupplementalDisclosureOfNoncashOperatingActivitiesAbstract', window );"><strong>Supplemental disclosure of noncash operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_TenantImprovementReceivableIncludedInOtherAssets', window );">Tenant improvement receivable included in other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_ReductionOfRightOfUseAssetAndLiabilityDueToLeaseModification', window );">Reduction of right-of-use asset and liability due to lease modification</a></td>
<td class="nump">2,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">31,004<span></span>
</td>
<td class="nump">76,015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">1,589<span></span>
</td>
<td class="nump">1,774<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=kymr_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from the issuance of Convertible Preferred Stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,183<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=kymr_SeriesB1ConvertiblePreferredStockMember', window );">Series B-1 Convertible Preferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from the issuance of Convertible Preferred Stock, net of issuance costs</a></td>
<td class="nump">4,800<span></span>
</td>
<td class="nump">$ 14,025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=kymr_SeriesCConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from the issuance of Convertible Preferred Stock, net of issuance costs</a></td>
<td class="nump">$ 88,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_IncreaseDecreaseInContractWithCustomerAssetRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in contract with customer asset related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_IncreaseDecreaseInContractWithCustomerAssetRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_IncreaseDecreaseInOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in operating lease right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_IncreaseDecreaseInOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_NetAmortizationOfPremiumsAndDiscountsOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net amortization of premiums and discounts on investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_NetAmortizationOfPremiumsAndDiscountsOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_NonCashResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non cash research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_NonCashResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_OfferingCostsIncludedInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Offering costs included in accounts payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_OfferingCostsIncludedInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_ProceedsFromConcurrentPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from concurrent private placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_ProceedsFromConcurrentPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_PropertyAndEquipmentPurchasesIncludedInAccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property and equipment purchases included in accounts payable and accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_PropertyAndEquipmentPurchasesIncludedInAccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_PurchasesOfPropertyAndEquipmentThroughFinanceAndLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchases of property and equipment through finance and lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_PurchasesOfPropertyAndEquipmentThroughFinanceAndLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_ReductionOfRightOfUseAssetAndLiabilityDueToLeaseModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction of right of use asset and liability due to lease modification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_ReductionOfRightOfUseAssetAndLiabilityDueToLeaseModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_SupplementalDisclosureOfNoncashOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental disclosure of noncash operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_SupplementalDisclosureOfNoncashOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_TenantImprovementReceivableIncludedInOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tenant improvement receivable included in other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_TenantImprovementReceivableIncludedInOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=kymr_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=kymr_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=kymr_SeriesB1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=kymr_SeriesB1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=kymr_SeriesCConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=kymr_SeriesCConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760761060552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Description Of Business And Summary Of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock', window );">Description of Business and Summary of Significant Accounting Policies</a></td>
<td class="text">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Note 1. Description of Business and Summary of Significant Accounting Policies</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kymera Therapeutics, Inc., together with its subsidiary Kymera Securities Corporation, is referred to on a consolidated basis as the &#8220;Company&#8221;. The Company is a biopharmaceutical company focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body&#8217;s own natural cellular process, a method known as targeted protein degradation. The Company has devoted its efforts principally to research and development since formation. The Company has not yet completed product development, filed for or obtained regulatory approvals for any products, nor verified the market acceptance and demand for such products. As a result, the Company is subject to a number of risks common to emerging companies in the biotech industry. Principal among these risks are the uncertainties of the product discovery and development process, dependence on key individuals, development of the same or similar technological innovations by the Company&#8217;s competitors, protection of proprietary technology, compliance with government regulations and approval requirements, the Company&#8217;s ability to access capital and uncertainty of market acceptance of products.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has historical net losses and anticipates that it will continue to incur losses for the foreseeable future and had an accumulated deficit of $128.8&#160;million as of December 31, 2020. The Company has funded these losses principally through issuance common stock, including its initial public offering (&#8220;IPO), which was completed in August 2020, preferred stock, convertible notes and from cash proceeds received in connection with the Company&#8217;s collaboration agreements with Vertex Pharmaceuticals Incorporated (&#8220;Vertex&#8221;) and Genzyme Corporation (&#8220;Sanofi&#8221;) (see Note 5). The Company expects to continue to incur operating losses and negative cash flows until such time as it generates a level of revenue that is sufficient to support its cost structure.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the Company had cash, cash equivalents and marketable securities of $458.7 million. The Company believes these cash, cash equivalents and marketable securities will be sufficient to fund its operations and capital expenditure requirements through at least twelve months from the issuance of these consolidated financial statements.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expects to finance the future research and development costs of its product portfolio with its existing cash, cash equivalents and marketable securities, or through strategic financing opportunities that could include, but are not limited to future offerings of its equity, collaboration agreements, or the incurrence of debt. However, there is no guarantee that any of these strategic or financing opportunities will be executed or realized on favorable terms, if at all, and some could be dilutive to existing stockholders. If the Company fails to obtain additional future capital, it may be unable to complete its planned preclinical studies and clinical trials.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Reverse Stock Split</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August&#160;20, 2020, the Board approved a 1-for-1.5949 reverse stock&#160;split of the Company&#8217;s issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for each of the Company&#8217;s outstanding series of preferred stock.&#160;&#160;All share and per share amounts in the accompanying consolidated financial statements and notes thereto have been retroactively adjusted for all periods presented to give effect to this reverse stock split, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital.&#160;&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Initial Public Offering</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 20, 2020, the Company&#8217;s registration statement on Form S-1 relating to its initial public offering of its common stock was declared effective by the Securities and Exchange Commission (&#8220;SEC&#8221;). In the IPO, which closed on August 25, 2020, the Company issued and sold&#160;9,987,520&#160;shares of common stock, including full exercise of the underwriters&#8217; over-allotment option to purchase an additional 1,302,720 shares, at a public offering price of $20.00 per share and the aggregate gross proceeds before deducting before deducting underwriting discounts and commissions, and other estimated offering expenses payable by the Company, were approximately $199.8 million. Concurrent with the IPO, the Company issued and sold 676,354 shares of common stock at $20.00 per share in a private placement to Vertex.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of business and summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and accounting policies concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760660211144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Note 2. Summary of Significant Accounting Policies</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements reflect the application of certain significant accounting policies as described in this note, and elsewhere in the accompanying consolidated financial statements and&#160;notes.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Principles of Consolidation</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary Kymera Securities Corporation. All intercompany transactions and balances have been eliminated in consolidation.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Presentation</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosure of contingencies at the date of the financial statements and the reported amounts of expenses during the reporting period. Management&#8217;s estimates and judgments are derived and continually evaluated based on available information, historical experience and various other assumptions that are believed to be reasonable under the circumstances. Because the use of estimates is inherent in the financial reporting process, actual results could differ from those estimates. In recording transactions and balances resulting from business operations, management makes estimates based on the best information available at the time the estimate is made. Significant estimates relied upon in preparing these financial statements include revenue recognized under our collaboration agreement with Sanofi and Vertex, accrual for research and development expenses, equity-based compensation expense, and the valuation of equity. As better information becomes available or actual amounts are determinable, the recorded estimates are revised. Consequently, operating results can be affected by revisions to prior estimates.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Segment and Geographic Information</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company&#8217;s chief operating decision maker is the Chief Executive Officer. The Company views its operations and manages its business in one operating segment.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash and <font style="color:#000000;">Cash</font> Equivalents</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents are highly liquid investments that are readily convertible into cash with original maturities of three months or less when purchased. These assets include investments in money market funds that invest in U.S. Treasury obligations and corporate bonds. The Company maintains its bank accounts at major financial institutions.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Restricted Cash</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash represents the cash held to secure a letter of credit associated with the Company&#8217;s facility lease.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Marketable Securities</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies marketable securities with a remaining maturity of greater than three months when purchased as available-for-sale. The Company classifies investments available to fund current operations as current assets on its balance sheets. Marketable securities with a remaining maturity date greater than one year are classified as non-current. Available-for-sale securities are maintained by investment managers and consist of U.S. Treasury securities and corporate bonds. Available-for-sale securities are carried at fair value with the unrealized gains and losses included in other comprehensive income (loss) as a component of stockholders&#8217; equity until realized. Any premium or discount arising at purchase is amortized and/or accreted to interest income and/or expense over the life of the instrument. Realized gains and losses are determined using the specific identification method and are included in other (expense) income, net.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any adjustment to fair value reflects a decline in value of the investment, the Company considers all available evidence to evaluate the extent to which the decline is &#8220;other-than-temporary&#8221; and, if so, marks the investment to market through a charge to the Company&#8217;s statement of operations and comprehensive loss.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Fair Value Measurements</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Level&#160;1&#8212;<font style="font-style:normal;">Quoted prices in active markets for identical assets</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Level&#160;2&#8212;<font style="font-style:normal;">Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar asset, or other inputs that are observable or can be corroborated by observable market data.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Level&#160;3&#8212;<font style="font-style:normal;">Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets, including pricing models, discounted cash flow methodologies and similar techniques.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying values of the Company&#8217;s cash equivalents, prepaid expenses, accounts payable, and certain accruals approximate their fair value due to their short-term nature.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Leases</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company adopted ASC Topic 842, <font style="font-style:italic;">Leases</font> (&#8220;ASC 842&#8221;) on January&#160;1, 2019. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Leases that are economically similar to the purchase of assets are generally classified as finance leases; otherwise the leases are classified as operating leases. The Company has elected not to recognize leases with an original term of one year or less on the balance sheet. Options to renew a lease are not included in the Company&#8217;s assessment unless there is reasonable certainty that the Company will renew. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. However, certain adjustments to the right-of-use asset may be required for items such as incentives received. The Company has elected as an accounting policy to combine lease and non- lease components, such as common area maintenance, for all classes of underlying assets. The interest rate implicit in lease contracts has not historically been readily determinable. As a result, the Company utilizes its incremental borrowing rates, which are the rates incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. To estimate its incremental borrowing rate, a credit rating applicable to the Company is estimated using synthetic credit rating analysis since the Company does not currently have a rating agency-based credit rating.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property and Equipment</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are recorded at cost, net of accumulated depreciation. Major additions and betterments are capitalized; maintenance and repairs, which do not improve or extend the life of the respective assets, are charged to operations as incurred. Depreciation expense is recorded using the straight-line method over the estimated useful life of the related asset as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated Useful Life</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.86%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furnitures and fixtures</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shorter of life of lease or remaining lease term</p></td>
</tr>
</table>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon retirement or sale, the cost and related accumulated depreciation of assets disposed of are removed from the accounts and any resulting gain or loss is included in loss from operations.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction-in-progress is stated at cost, which includes direct costs attributable to the setup or construction of the related asset. Depreciation expense is not recorded on construction-in-progress until the relevant assets are completed and put into use.</p></div>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its fair value, determined based on discounted cash flows. The Company did not record any impairment losses on long-lived assets during the years ended December&#160;31, 2020 and 2019.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Convertible Preferred Stock</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classified convertible preferred stock as temporary equity in the accompanying consolidated balance sheet due to terms that allow for redemption of the shares in cash upon certain change in control events that are outside of the Company&#8217;s control, including the sale or transfer of the Company as holders of the convertible preferred stock which could trigger redemption of the shares. The Company did not accrete the value of the convertible preferred stock to the redemption values since a liquidation event was not considered probable as of December&#160;31, 2019. Subsequent adjustments of the carrying values to the ultimate redemption values will be made only when it becomes probable that such liquidation events will occur. In connection with the Company&#8217;s initial public offering on August 21, 2020, all outstanding shares of convertible preferred stock converted to common stock.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Costs</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs consist primarily of costs incurred in connection with the discovery and development of targeted protein degradation therapeutics, including those in the Company&#8217;s most advanced development programs, IRAK4, IRAKIMiD and STAT3. These research efforts and costs, which also support the development of, and enhancements to, the Company&#8217;s Pegasus targeted protein degradation platform, include external research costs, personnel costs, supplies, license fees and facility related expenses. The Company expenses research and development costs as incurred.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Patent Costs</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recoverability of the expenditure. Amounts incurred are classified as general and administrative expenses.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Financing Costs</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs incurred in connection with the issuance of equity units and shares are recorded as a reduction of proceeds to the equity carrying value. The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process financings as deferred offering costs until such financings are consummated. After consummation of the financing, these costs are recorded as a reduction of the proceeds received from the financing. If a planned financing is abandoned, the deferred offering costs are expensed immediately as a charge to operating expenses in the consolidated statement of operations and comprehensive loss. There was $0.4 million of deferred financing costs included in accounts payable on the Company&#8217;s consolidated balance sheet as of December 31, 2020. There was no deferred offering costs on the Company&#8217;s consolidated balance sheet at December 31, 2019.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company adopted ASC Topic 606, <font style="font-style:italic;">Revenue from Contracts with Customers</font> (&#8220;ASC 606&#8221;) on January&#160;1, 2017. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identification of the contract(s) with the customer; (ii)&#160;identification of the promised goods or services in the contract and determination of whether the promised goods or services are performance obligations; (iii)&#160;measurement of the transaction price; (iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the accounting for these arrangements, the Company must use significant judgment to determine: a) the number of performance obligations based on the determination under step (ii)&#160;above and whether those performance obligations are distinct from other performance obligations in the contract; b) the transaction price under step (iii)&#160;above; and c) the standalone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv)&#160;above. The Company uses judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. In determining the stand-alone selling price of a license to the Company&#8217;s proprietary technology or a material right provided by a customer option, the Company considers market conditions as well as entity-specific factors, including those factors contemplated in negotiating the agreements as well as internally developed estimates that include assumptions related to the market opportunity, estimated development costs, probability of success and the time needed to commercialize a product candidate pursuant to the license. In validating its estimated stand-alone selling prices, the Company evaluates whether changes in the key assumptions used to determine its estimated stand-alone selling prices will have a significant effect on the allocation of arrangement consideration between performance obligations.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimates the transaction price based on the amount of consideration the Company expects to be received for transferring the promised goods or services in the contract. The consideration may include both fixed consideration and variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of the potential payments and the likelihood that the payments will be received. The Company utilizes either the most likely amount method or expected value method to estimate the transaction price based on which method better predicts the amount of consideration expected to be received. If it is probable that a significant revenue reversal would not occur, the variable consideration is included in the transaction price.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer. Promised goods or services are considered distinct when: (i)&#160;the customer can benefit from the good or service on its own or together with other readily available resources and (ii)&#160;the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on their own and whether the required expertise is readily available.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation in order to determine whether the combined performance obligation is satisfied over time or at a point in time. The Company receives payments from customers based on billing schedules established in each contract. Up-front payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion. Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional. Amounts recognized as revenue, but not yet received or invoiced are generally recognized as contract assets.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Exclusive Licenses<font style="font-style:normal;">&#8212;If the license granted in the arrangement is determined to be distinct from the other promises or performance obligations identified in the arrangement, which generally include research and development services, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whether a license is distinct from the other promises, the Company considers relevant facts and circumstances of each arrangement, including the research and development capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the collaboration partner can benefit from the license for its intended purpose without the receipt of the remaining promise, whether the value of the license is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the arrangement.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development Services<font style="font-style:normal;">&#8212;The promises under the Company&#8217;s collaboration and license agreements generally include research and development services to be performed by the Company on behalf of the collaboration partner. For performance obligations that include research and development services, the Company generally recognizes revenue allocated to such performance obligations based on an appropriate measure of progress. The Company utilizes judgment to determine the appropriate method of measuring progress for purposes of recognizing revenue, which is generally an input measure, such as costs incurred. The Company evaluates the measure of progress each reporting period as described under Exclusive Licenses above. Reimbursements from the partner that are the result of a collaborative relationship with the partner, instead of a customer relationship, such as co-development activities, are generally recorded as a reduction to research and development expense.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Customer Options<font style="font-style:normal;">&#8212;The Company&#8217;s arrangements may provide a collaborator with the right to certain optional purchases, such as the right to license a target either at the inception of the arrangement or within a pre-defined option period. Under these agreements, fees may be due to the Company at the inception of the arrangement as an upfront fee or payment or upon the exercise of an option to acquire a license. If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. The Company evaluates the customer options for material rights, or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the inception of the arrangement. The Company allocates the transaction price to material rights based on the relative stand-alone selling price, which is determined based on the identified discount, and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised or expires.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Milestone Payments<font style="font-style:normal;">&#8212;At the inception of each arrangement that includes milestone payments based on certain events, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. If a milestone or other variable consideration relates specifically to the Company&#8217;s efforts to satisfy a single performance obligation or to a specific outcome from satisfying the performance obligation, the Company generally allocates the milestone amount entirely to that performance obligation once it is probable that a significant revenue reversal would not occur.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Royalties<font style="font-style:normal;">&#8212;For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i)&#160;when the related sales occur or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Collaboration revenue&#8212;<font style="font-style:normal;">The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808,</font>&#160;Collaborative Arrangements<font style="font-style:normal;">&#160;(&#8220;ASC 808&#8221;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities.&#160;This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement.&#160;For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship and therefore within the scope of Topic 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently, generally by analogy to Topic 606. For those elements of the arrangement that are accounted for pursuant to Topic 606, the Company applies the five-step model described above.</font></p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Costs associated with License and Collaborative Arrangements</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs associated with licenses of technology acquired as part of collaborative arrangements are expensed as incurred and are generally included in research and development expense in the consolidated statements of operations.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for all stock-based awards granted to employees, directors, and nonemployees based on their fair value on the date of the grant and recognize compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. Stock-based payments include stock options and grants of common stock, including common stock subject to vesting. The measurement date for stock awards is the date of grant, and stock-based compensation costs are recognized as expense over the requisite service period, which is the vesting period, on a straight-line basis. The Company has issued stock options and restricted stock with performance-based vesting conditions and records the expense for these awards if the Company concludes that it is probable that the performance condition will be achieved. Stock-based compensation is classified in the accompanying consolidated statements of operations and comprehensive loss based on the function to which the related services are provided. The Company recognizes stock-based compensation expense for the portion of awards that have vested. Forfeitures are accounted for as they occur.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes options-pricing model, which requires inputs based on certain subjective assumptions, including the expected stock price volatility, the expected term of the option, the risk-free interest rate for a period that approximates the expected term of the option, and the Company&#8217;s expected dividend yield. Prior to the IPO, as there was no active market for the Company&#8217;s common stock, the Company estimated the fair value of common stock on the date of grant based on the then current facts and circumstances. Upon becoming a public company, the fair value of the underlying common shares equals the closing price of the Company&#8217;s stock on the date of grant. The Company historically has been a private company and lacks company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of guideline companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options. The expected term of stock options granted to non-employees is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future. The fair value of each restricted common stock award is estimated on the date of grant based on the fair value of the Company&#8217;s common stock on that same date.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compensation expense for discounted purchases under the employee stock purchase plan is measured using the Black-Scholes model to compute the fair value of the lookback provision plus the purchase discount and is recognized as compensation expense over the offering period.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Common and Preferred Stock Valuation</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company utilized significant estimates and assumptions in determining the fair value of its equity and equity-based awards. The Company utilized various valuation methodologies in accordance with the framework of the 2013 American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its equity awards.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company used a hybrid of the probability-weighted expected returns method (&#8220;PWERM&#8221;), and the option pricing method (&#8220;OPM&#8221;) when allocating enterprise value to classes of securities.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the probability-weighted expected return method, or PWERM, the value of an enterprise, and its underlying common securities, are estimated based on an analysis of future values for the enterprise, assuming various outcomes. The value of the common securities is based on the probability-weighted present value of expected future investment returns considering each of the possible outcomes and the rights of each class of equity. The future values of the common securities under the various outcomes are discounted back to the valuation date at an appropriate risk-adjusted discount rate and then probability weighted to determine the value for the common securities.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The option pricing method, or OPM, treats common securities and preferred securities as call options on the enterprise&#8217;s equity value, with exercise prices based on the liquidation preferences of the preferred securities. Under this method, the common securities have value only if the funds available for distribution to shareholders exceed the value of the liquidation preferences at the time of a liquidity event. The Black-Scholes model is used to price the call option, and the model includes assumptions for the time to liquidity and the volatility of equity value.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The hybrid method is a hybrid between the PWERM and OPM, estimating the probability-weighted value across multiple scenarios but using the OPM to estimate the allocation of value within one or more of those scenarios.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuations performed in the year ended December&#160;31, 2020 and 2019, used a hybrid of the PWERM and OPM when allocating the Company&#8217;s enterprise value to classes of securities.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When using the hybrid method, the Company assumed two scenarios: an IPO scenario and a trade-sale scenario. The IPO scenario estimated an equity value based on the guideline public company method under a market approach. The guideline public companies considered for this scenario consist of biopharmaceutical companies with recently completed initial public offerings. The Company converted its estimated future value in an IPO to present value using a risk-adjusted discount rate. The equity value for the trade-sale scenario was estimated using the price of a recently issued preferred security, as well as a milestone-based tranche closing. The Company utilized an option pricing model to quantify or attribute value to these economic rights of convertible preferred stock vs. the common stock (e.g. liquidation preferences, dividend provisions, participation rights after liquidation preferences.)</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the OPM, volatility is estimated based on the trading histories of selected guideline public companies. The relative probability of each scenario was determined based on an assessment of then-current market conditions and the Company&#8217;s expectations as to timing and prospects of an IPO.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each valuation methodology includes estimates and assumptions that require significant judgment. These estimates and assumptions include a number of objective and subjective factors, including the prices at which shares were traded between holders of the Company, external market conditions, the prices at which the Company sold convertible preferred shares, the superior rights and preferences of securities senior to common shares at the time, and the likelihood of achieving a voluntary or involuntary liquidity event.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant changes to the key assumptions used in the valuations could result in different fair values of common shares at each valuation date, as applicable.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income taxes for Kymera Therapeutics, Inc. are recorded in accordance with FASB Accounting Standards Codification Topic 740, <font style="font-style:italic;">Income Taxes</font> (&#8220;ASC 740&#8221;), which provides for deferred taxes using an asset and liability approach. Under this method, deferred income tax assets and liabilities are recognized based on future income tax consequences attributable to differences between the financial statement carrying amount of existing assets and liabilities, and their respective income tax basis. Deferred income tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of changes in income tax rates on deferred income tax assets and liabilities is recognized as income or expense in the period that a valuation allowance for any income tax benefits of which future realization is not more likely than not.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions. The tax benefits recorded are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filings or positions is &#8220;more likely than not&#8221; to be realized following resolution of any uncertainty related to the tax benefit, assuming that the matter in question will be raised by the tax authorities.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Off Balance Sheet Risk and Concentration of Credit Risk</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has no significant off-balance sheet risk such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, and restricted cash. The Company&#8217;s cash, cash equivalents, and restricted cash are deposited in accounts at large financial institutions. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash, cash equivalents and restricted cash are held. The Company maintains its cash equivalents in money market funds that invest in U.S. Treasury securities and U.S. Treasury obligations and corporate bonds. The Company&#8217;s marketable securities primarily consist of corporate bonds and U.S. Treasury securities paper, and potentially subject the Company to concentrations of credit risk. The Company has adopted an investment policy that limits the amounts the Company may invest in any one type of investment. The Company has not experienced any credit losses and does not believe it is exposed to any significant credit risk on these funds.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Comprehensive Loss</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss includes net loss as well as unrealized gains on marketable securities and other changes in stockholders&#8217; equity (deficit) that result from transactions and economic events other than those with stockholders.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss Per Share</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company applies the two-class method to compute basic and diluted net income (loss) per share attributable to common stockholders when it has issued shares that meet the definition of participating securities. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income (loss) available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to share in the earnings as if all income (loss) for the period had been distributed. The Company&#8217;s convertible preferred stock participates in any dividends declared by the Company and are therefore considered to be participating securities. The participating securities are not required to participate in the losses of the Company, and therefore during periods of loss there is no allocation required under the two-class method.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net income (loss) per share attributable to common stockholders is computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) attributable to common stockholders is computed by adjusting net income (loss) per share attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period, including potential dilutive common shares. For purpose of this calculation, outstanding options to purchase common stock, unvested restricted stock awards, and shares of convertible preferred stock are considered potential dilutive common shares. The Company has generated a net loss in all periods presented, and therefore the basic and diluted net loss per share attributable to common stockholders are the same as the inclusion of the potentially dilutive securities would be anti-dilutive.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Emerging Growth Company Status</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is an emerging growth company (&#8220;EGC&#8221;), as defined in the Jumpstart Our Business Startups Act (the &#8220;JOBS Act&#8221;), and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not EGCs. The Company may take advantage of these exemptions until it is no longer an EGC under Section&#160;107 of the JOBS Act, which provides that an EGC can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to use this exemption to delay adopting new or revised.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Recently Adopted Accounting Standards</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2019, the FASB issued ASU 2019-04,&#160;<font style="font-style:italic;">Codification Improvements to Topic 326, Financial Instruments&#8212;Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments</font>. This update provides clarifications for three topics related to financial instruments accounting, some of which apply to the Company. The Company adopted as of January&#160;1, 2020 and it did not have a significant impact on its financial position or results of operation</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU 2018-15, <font style="font-style:italic;">Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</font>. The new standard will align the requirements for capitalizing implementation costs for hosting arrangements (services) with costs for internal-use software (assets). As a result, certain implementation costs incurred in hosting arrangements will be deferred and amortized. The Company adopted as of January&#160;1, 2020 and it did not have a significant impact on its financial position or results of operation.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement. The new standard will be effective beginning January&#160;1, 2020. The Company adopted as of January&#160;1, 2020 and it did not have a significant impact on its financial position or results of operation.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Recently Issued Accounting Standards Not Yet Adopted</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU 2019-12, <font style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</font>, which is intended to simplify the accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. The new standard will be effective beginning January&#160;1, 2021. The Company is currently evaluating the potential impact ASU 2019-12 may have on its financial position and results of operations upon adoption.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU 2016-13,&#160;<font style="font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Statements</font>. The new standard requires that expected credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. It also limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value increases. As an emerging growth company, the Company expects to delay adoption until January 1, 2023 and is evaluating the impact that the adoption of ASU 2016-13 will have on its consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760660167112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Note 3. Fair Value Measurements</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values as of December 31,&#160;2020 and December 31, 2019 (in thousands): </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market fund</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,943</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,943</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,499</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,499</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities, current</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US treasuries</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">192,275</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">192,275</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,923</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,923</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities, non-current</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US treasuries</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132,589</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132,589</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,942</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,942</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,589</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,589</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">346,396</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113,364</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">459,760</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,942</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,942</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,774</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,774</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,716</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,716</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December 31, 2020 and 2019, there were no transfers between Level&#160;1, Level&#160;2 and Level&#160;3. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760664087608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 4. Marketable Securities</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the available-for-sale debt securities held at December 31, 2020 and 2019 and (in thousands): </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">324,917</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(53</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">324,864</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,946</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(81</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,865</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">427,863</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(134</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">427,729</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,936</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,942</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,936</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,942</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the Company held&#160;65 securities that had been in an unrealized loss position for less than&#160;12 months with an aggregate fair value of $392.2 million. As of December 31, 2019, the Company did not hold any securities that were in an unrealized loss position.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the Company had 48 securities with a fair value of $295.6 million with a contractual maturity of less than 12 months and 25 securities with a fair value of $162.5 million with a contractual maturity of greater than 12 months. As of December&#160;31, 2019, all of the Company&#8217;s marketable securities had remaining contractual maturity dates of less than one year from the consolidated balance sheet date. During the year ending December 31, 2020, the Company sold one security prior maturity which resulted in an immaterial realized gain on the sale. There were no sales of marketable securities during the year ended December&#160;31, 2019. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluates securities for other-than-temporary impairments based on quantitative and qualitative factors, and considered the decline in market value for the&#160;65&#160;securities in an unrealized loss position as of&#160;December&#160;31, 2020, to be primarily attributable to the then current economic and market conditions. <font style="color:#000000;">The Company</font><font style="Background-color:#FFFFFF;color:#000000;"> neither intends to sell these investments nor concludes that it is more-likely-than-not that the Company will have to sell them before recovery of their carrying values. The Company also believe that it will be able to collect both principal and interest amounts due to it at maturity.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760660294216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">Topic 606</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborations</a></td>
<td class="text">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 5. Collaborations</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Sanofi Collaboration Arrangement</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Agreement Terms</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July&#160;7, 2020, the Company entered into a collaboration agreement, or the Sanofi Agreement, with Sanofi, to co-develop drug candidates directed to two biological targets. Under the Sanofi Agreement, the Company granted to Sanofi a worldwide exclusive license to develop, manufacture and commercialize certain lead compounds generated during the collaboration directed against IRAK4, or Collaboration Target 1, and one additional undisclosed target in an undisclosed field of use, or Collaboration Target 2. Such license is exercisable on a collaboration target-by-collaboration target basis only after specified milestones. For compounds directed against IRAK4, the field of use includes diagnosis, treatment, cure, mitigation or prevention of any diseases, disorders or conditions, excluding oncology and immune-oncology.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the Sanofi Agreement, the Company is responsible for discovery and preclinical research and conducting a Phase&#160;1 clinical trial for at least one degrader directed against IRAK4 plus up to three backup degraders. With respect to both targets, Sanofi is responsible for development, manufacturing, and commercialization of product candidates after a specified development milestone occurs with respect to each collaboration candidate.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, pursuant to the Sanofi Agreement, Sanofi will grant to the Company an exclusive option, or Opt-In Right, exercisable on a collaboration target-by-collaboration target basis that will include the right to (i)&#160;to fund 50% of the United States development costs for collaboration products directed against such target in the applicable field of use and (ii)&#160;share equally in the net profits and net losses of commercializing collaboration products directed against such target in the applicable field of use in the United States. In addition, if the Company exercises the Opt-In Right, Sanofi will grant to the Company an exclusive option, applicable to each collaboration target, which upon exercise will allow the Company to conduct certain co-promotion activities in the field in the United States.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Sanofi Agreement, unless earlier terminated, will expire on a product-by-product basis on the date of expiration of all payment obligations under the Sanofi Agreement with respect to such product. The Company or Sanofi may terminate the agreement upon the other party&#8217;s material breach or insolvency or for certain patent challenges. In addition, Sanofi may terminate the agreement for convenience or for a material safety event upon advance prior written notice, and the Company may terminate the agreement with respect to any collaboration candidate if, following Sanofi&#8217;s assumption of responsibility for the development, commercialization or manufacturing of collaboration candidates with respect to a particular target, Sanofi ceases to exploit any collaboration candidates directed to such target for a specified period.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In consideration for the exclusive licenses granted to Sanofi under the Sanofi Agreement, Sanofi paid to the Company an upfront payment of $150.0&#160;million. The Company will also be reimbursed for certain research activities for a certain backup degrader under the IRAK4 program, unless certain criteria are not met for an initial IRAK4 degrader. In addition to the upfront payment and the reimbursements, the Company is eligible to receive certain development milestone payments of up to $1.48&#160;billion in the aggregate, of which more than $1.0 billion relates to the IRAK4 program, upon the achievement of certain developmental or regulatory events. The Company will be eligible to receive certain commercial milestone payments up to $700.0&#160;million in the aggregate, of which $400&#160;million relates to the IRAK4 program, which are payable upon the achievement of certain net sales thresholds. The Company will be eligible to receive tiered royalties for each program on net sales ranging from the high single digits to high teens, subject to low-single digits upward adjustments in certain circumstances.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-align:justify;margin-left:4.54%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Accounting Treatment </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company analyzed the discovery and pre-clinical research activities as well as the exclusive license grants under the Sanofi Agreement and concluded that the arrangement was indicative of a vendor-customer relationship and would be accounted for under ASC 606. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company identified the following material promises under the arrangement: (1) research services for Collaboration Target 1, (2) research license for Collaboration Target 1, (3) exclusive license for Collaboration Target 1, (4) research services for Collaboration Target 2, (5) research license for Collaboration Target 2, (6) exclusive license for Collaboration Target 2, (7) option to extend the research term, and (8) optional research services during the development period. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined that Collaboration Targets 1 and 2 are distinct from each other. The research associated with degraders directed to each target is at different stages and the licensed field, should development activities be successful, are different from each other. As such, all promises associated with each target are considered distinct from promises associated with the other target.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The research and development services for each collaboration target were determined not to be distinct from the research license and the exclusive license and have been combined into a single performance obligation for each collaboration target. That is, two performance obligations were identified, the combined research services, research license and exclusive license for Collaboration Target 1 and the combined research services, research license and exclusive license for Collaboration Target 2. The exclusive license for each target is not distinct from the pre-clinical and clinical research and development services under the Sanofi Agreement, primarily due to the highly specialized nature of the research and novel technology involved with developing protein degraders &#8211; the pre-clinical activities and studies and first phase 1 clinical trial could not be conducted by another party in the manner required.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The option to extend the research term and optional research services during the development period were evaluated as material rights. The fees associated with each option are at or above the standalone selling price. As such, the underlying options are not performance obligations and fees associated with each option are excluded from the transaction price until the underlying option is exercised.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The Company determined the total transaction price to be $</font>150.0<font style="Background-color:#FFFFFF;">&#160;million, which consists solely of the upfront payment. All milestones payments and option payments are constrained as the achievement of such milestones are contingent upon the success of the underlying research and development activities and are generally outside the control of the Company. The reimbursement of costs for the IRAK4 backup degrader is also treated as constrained variable consideration as the criteria for reimbursement may not always be met, under which circumstances the Company would be responsible for the costs related to the backup degrader. Upon becoming unconstrained, the reimbursement consideration will be added to the transaction price and allocated to Collaboration Target 1.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The Company allocated the upfront payment to each performance obligation based on the relative standalone selling price, as follows:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;text-align:justify;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;text-align:justify;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;text-align:justify;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaboration Target 1: $120.0 million</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;text-align:justify;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;text-align:justify;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;text-align:justify;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaboration Target 2: $30.0 million</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined the allocation of the $150.0 million transaction price between Collaboration Target 1 and Collaboration Target 2 based on the value of the research and development for the programs from projected research and development costs for each collaboration target plus a developer&#8217;s profit and the total potential milestones for each collaboration target.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The Company recognizes revenue associated with each performance obligation as the research and development services are provided using an input method, according to costs incurred as related to the research and development activities for each individual program and the costs expected to be incurred in the future to satisfy that individual performance obligation. The transfer of control occurs over this time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying each performance obligation. The amounts received that have not yet been recognized as revenue are deferred as a contract liability on the Company&#8217;s consolidated balance sheet and will be recognized over the remaining research and development period until the performance obligation is satisfied. Reimbursement consideration added to the transaction price will be recognized as revenue on the same pattern as Collaboration Target 1, with a cumulative catch-up upon becoming unconstrained. </font>The performance obligation has not been fully satisfied as of December 31, 2020. During the year ended December 31, 2020, the Company recognized $18.8 million<font style="color:#000000;"> </font>in revenue under the Sanofi Agreement, of which $16.7 million was associated with Collaboration Target 1 and $2.1 million was associated with Collaboration Target 2. The aggregate amount of the transaction price allocated to the Company&#8217;s unsatisfied performance obligations and recorded in deferred revenue at December 31, 2020 is <font style="color:#000000;">$132.6 </font>million. As of December&#160;31, 2020, the Company had not received cost reimbursement payments, and no milestone or royalty payments under the Sanofi Agreement. As of December&#160;31, 2020, the Company recorded unbilled accounts receivable of $0.9 million related to reimbursable research and development costs<font style="font-size:12pt;color:#000000;"> </font>under the Sanofi Agreement for activities performed during the three months ended December&#160;31, 2020 and $0.6 million in accounts receivable for amounts billed under the Sanofi Agreement as of December 31, 2020. The Company will recognize the deferred revenue related to the performance obligations based on a cost input method, as described, over the remaining research term, which is a maximum of three years as of December 31, 2020.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any consideration related to performance-based milestones will be recognized when the risk of probable reversal is resolved, at which point the Company shall adjust the transaction price determined for the agreement accordingly and recognize revenue on a cumulative-catch up basis, reallocating the revised arrangement consideration to the performance obligations. Any consideration related to sales milestone payments and royalties will be recognized when the related milestone events or sales occur and therefore are recognized at the later of when the related sales occur or the relevant performance obligation is satisfied. <font style="Background-color:#FFFFFF;">As part of its evaluation of constraining the milestones, the Company considered numerous factors, including the fact that the achievement of the research and development milestones are contingent upon the results of the underlying research and development activities and are thus outside of the control of the Company.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sanofi participated in the Company&#8217;s Series B Convertible Preferred Stock offering and as a result of this, is considered a related party.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Vertex Agreement </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May&#160;9, 2019 (the &#8220;Effective Date&#8221;), the Company entered into a collaboration agreement (the &#8220;Vertex Agreement&#8221;) with Vertex to advance small molecule protein degraders against up to six targets. Under the Vertex Agreement, Vertex has the exclusive option to license the rights to the product candidates developed for the designated targets at which point Vertex will control development and commercialization. Pursuant to the Vertex Agreement, the Company is only responsible for discovery and preclinical research on the targets, and Vertex is responsible for development, manufacturing, and commercialization of the product candidates after it exercises its option to license. The initial research term of the collaboration is four (4)&#160;years, extendable for an additional one (1)&#160;year period upon mutual agreement by the parties and payment by Vertex of certain per-target fees. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vertex provided the Company with a non-refundable upfront payment of $50.0&#160;million and purchased 3,059,695 shares of the Company&#8217;s Series B-1 Convertible Preferred Stock (&#8220;Series B-1&#8221;) at $6.54 a share, pursuant to a separate, but simultaneously executed Share Purchase Agreement. The shares were purchased at a premium of $5.9&#160;million, which was included in the transaction price and will be recognized as revenue over the period of performance. As a result of this purchase, Vertex is considered a related party. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is eligible to receive up to $170.0&#160;million in payments per target, including development, regulatory and commercial milestones as well as option exercise payments. In addition, Vertex is obligated to pay the Company tiered royalties on future net sales on any products that may result from the Vertex Agreement. None of the payments under the Vertex Agreement are refundable. The Company may also perform follow-on research for an optioned target upon Vertex&#8217;s request and at Vertex&#8217;s expense. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The term of the Vertex Agreement began on the Effective Date and expires upon the expiration of all payment obligations from Vertex to Company under the Vertex Agreement or, if Vertex does not exercise any of its options, the lapse of all Vertex&#8217;s option rights under the Vertex Agreement. Vertex also has the ability to terminate for convenience with prior written notice to the Company, and either party may terminate for an uncured material breach. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Accounting Treatment </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company analyzed the joint research activities required under the Vertex Agreement and concluded that the arrangement was indicative of a vendor-customer relationship and would be accounted for under ASC&#160;606. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company identified the following material promises under the arrangement: (1)&#160;the non-exclusive, royalty-free research license; and (2)&#160;the research and development services to be performed on up to six targets; and (3)&#160;the option to license each of the targets for development, manufacturing, and commercialization efforts. The research and development services were determined not to be distinct from the research and development license and have been combined into a single performance obligation. The Company determined that the option to license the targets in the future was not priced at a discount, and that the option exercise fee for each target is at or above the standalone selling price for research at this stage of development; as such, the options and the underlying licenses are excluded from the performance obligation and the option exercise fees are excluded from the transaction price until the underlying option is exercised. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of its evaluation of constraining the research and development milestones, the Company considered numerous factors, including the fact that the achievement of the research and development milestones are contingent upon the results of the underlying research and development activities and are thus outside of the control of the Company. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the commencement of the arrangement, two units of accounting were identified, the issuance of&#160;3,059,695 shares of the Company&#8217;s Series B-1 Convertible Preferred Stock and the research activities the Company will perform over the&#160;Research Term. The Company determined the total transaction price to be $55.9&#160;million, which consists of $5.9&#160;million attributed to the premium from the Series B-1 shares sold to Vertex and the $50.0&#160;million upfront payment. To determine the fair value of the Series B-1 issued to Vertex, the Company performed a valuation of the shares of the Company&#8217;s common and preferred stock, which took into consideration recent financings, and the Company&#8217;s recent development and future exit strategies, as well as a discount for lack of marketability. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes revenue associated with the performance obligation as the research and development services are provided using an input method, according to the costs incurred as related to the research and development activities on each program and the costs expected to be incurred in the future to satisfy the performance obligation. The transfer of control occurs over this time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligation. The amounts received that have not yet been recognized as revenue are deferred as a contract liability on the Company&#8217;s consolidated balance sheet and will be recognized over the remaining research and development period until the performance obligation is satisfied. The performance obligation has not been fully satisfied as of December 31, 2020. During the years ended December 31, 2020 and 2019, the Company recognized $15.2 million and $2.9 million in revenue under the Vertex Agreement. All $15.2&#160;million revenue recognized during the year ended December 31, 2020 was recognized from amounts that were recorded in deferred revenue as of December&#160;31, 2019. The aggregate amount of the transaction price allocated to the Company&#8217;s unsatisfied performance obligation and recorded in deferred revenue at December&#160;31, 2020 and 2019 is $37.7 million and $53.0&#160;million, respectively. The Company will recognize the deferred revenue related to the research and development services based on a cost input method, over the remaining research term, which is a maximum of 2.0 years as of December&#160;31, 2020. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any consideration related to sales milestone payments (including royalties) will be recognized when the related milestone events or sales occur and therefore are recognized at the later of when the related sales occur or the relevant performance obligation is satisfied. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Compound Collaboration </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2017, the Company entered into a collaboration agreement (the &#8220;Collaboration&#8221;) with a pharmaceutical company to jointly identify, research and conduct preclinical development of collaboration compounds against specified collaboration targets to identify drug candidates. Under the terms of the Collaboration, both parties provided one another with a non-exclusive, royalty-free, sub-licensable research and development license to each party&#8217;s intellectual property to develop five agreed-upon collaboration targets, as well as an exclusive, royalty-bearing development and commercialization license to sell any licensed products that stem from such research. The parties also have the ability to nominate additional collaboration targets if agreed-upon, as long as there are no more than five targets at any given time. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In exchange for the non-exclusive license rights, the Company provided the pharmaceutical company with an equity grant and is required to make tiered royalty payments based on net sales of all products licensed under the agreement in the low single-digit percentages. In conjunction with the Collaboration, the Company initially issued 886,305 Series A Preferred Units (&#8220;Series A Preferred Units&#8221;) to the pharmaceutical company. On November&#160;1, 2018, these Series A Preferred Units were exchanged on a one-for-one basis for shares of Series A Convertible Preferred Stock (the &#8220;Series A Preferred Stock&#8221;). These shares vest in equal installments over three years. The Company is recording expense over the remaining vesting period based on the fair value of the shares under the Collaboration. The Company recorded $0.3&#160;million and $0.4 million to research and development expense related to the vesting of 166,183 and 221,579 shares of Series A Preferred Stock during the years ended December 31, 2020 and 2019, respectively. As of December 31, 2020, all shares under the Collaboration were fully vested and all expense had been recognized.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The royalty payments are contingent and as such are not being recorded until incurred. The Company determined that the license is representative of an in-process research and development asset, with no future alternative use. As such, the Company records the expense related to the vesting of shares as research and development expense in the Company&#8217;s consolidated statements of operations and comprehensive loss. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Collaboration can be terminated by either party for convenience with 60-days written notice and may also be terminated in the event of a material breach. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The <font style="color:#000000;">following table presents the changes in accounts receivable, contract assets and liabilities for the year ended December 31,&#160;2020 (in thousands)</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additions</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deductions</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable and contract assets:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Billed receivables &#8211; Sanofi</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">150,577</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(150,000</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">577</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unbilled receivables &#8211; Sanofi</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,433</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(577</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">856</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accounts receivable and contract assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">152,010</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(150,577</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,433</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract Liabilities:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred Revenue &#8211; Vertex</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,991</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,243</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,748</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred Revenue &#8211; Sanofi</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">151,433</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,791</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132,642</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total contract liabilities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,991</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">151,433</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34,034</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">170,390</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760658905400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 6. Property and equipment</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consist of the following as of December&#160;31, 2020 and 2019 (in thousands): </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab and office equipment under and financing</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; right-of-use asset</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,771</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,751</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,636</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">919</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture &amp; fixtures</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">861</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,599</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">545</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets not yet in service</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">453</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,988</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,843</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,147</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,049</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,841</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,794</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense for the years ended December&#160;31, 2020 and 2019 was $1.8 million and $0.9&#160;million, respectively.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Included in property and equipment is lab and office equipment right-of-use assets under financing leases with a cost basis of $2.8&#160;million and accumulated amortization expense of $1.2 million and $0.5&#160;million as of December 31, 2020 and 2019.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization expense related to right-of-use assets was $0.7 million and $0.4&#160;million the years ended December&#160;31, 2020 and 2019 and is included in depreciation expense.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760664024136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_LesseeOperatingAndFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 7. Leases</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2018, the Company entered into a noncancelable facility lease agreement (the &#8220;Lease&#8221;) for 9,836 square feet of research and development and office space in Cambridge, Massachusetts. In March 2020, the Company signed a termination agreement for this lease which was determined to be a lease modification that resulted in a reduction of the right-of-use asset and liability of $2.2 million. The lease termination was effective July&#160;31, 2020 and the Company no longer has any obligations under the Lease.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with the lease agreement, the Company was required to maintain a security deposit and provided a letter of credit to the landlord for $0.2&#160;million, which was recorded in other assets as of December&#160;31, 2019. In October 2020, the Company was released from the security deposit and letter of credit and collected the $0.2 million previously classified in other current assets. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2019, the Company entered into a facility sublease agreement (the &#8220;Sublease&#8221;) for 1,471 square feet of office space in Cambridge, Massachusetts. The term of the lease began on June&#160;24, 2019 and terminated on June 30, 2020, and following termination, the Company had no further obligations under the Sublease. The Sublease required the Company to share in prorated operating expenses and property taxes based upon actual amounts incurred; those amounts were considered variable lease costs and, therefore, are not included in the measurement of the lease and are instead recognized to expense as incurred.<font style="font-weight:bold;"> </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2019, the Company entered into a noncancelable facility lease agreement (the &#8220;New Lease&#8221;) for 34,522 square feet of research and development and office space in Watertown, Massachusetts. The term of the New Lease is 120 months and expires on March&#160;31, 2030. The New Lease has an option to be extended for an additional five years. The lease is not reasonably certain to be extended and as such the additional term is not included in the measurement of the lease. The New Lease includes a rent escalation clause, and rent expense is being recorded on a straight-line basis. The Company received a tenant incentive allowance of $5.5&#160;million in 2020 as the tenant improvements were completed all of which has been collected from its landlord as of December 31, 2020. In accordance with the lease agreement, the Company is required to maintain a security deposit and provided a letter of credit to the landlord for $1.6&#160;million, which is recorded in other assets as of December 31, 2020. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s financing lease obligations consist of certain property and equipment financed through capital leases. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of the lease costs for the years ended December 31, 2020 and 2019 (in thousands): </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease costs</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,719</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,597</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing lease costs:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of right-to-use assets, financing</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; leases</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">716</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">385</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense for financing lease liabilities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Variable lease costs</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">621</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">340</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease costs</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,177</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,368</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental cash flow information relating to the Company&#8217;s leases for the years ended December 31, 2020 and 2019 was as follows (in thousands): </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for amounts included in the measurement</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; of lease liabilities:</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flows used in (provided by)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; operating leases</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,024</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">635</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flows used in finance leases</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">587</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing cash flows used in finance leases</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">385</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average remaining lease terms and discount rates as of December 31, 2020 and 2019 were as follows: </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Remaining lease term:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing lease</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.8 Years</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.7 Years</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discount Rate:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing lease</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.8</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The undiscounted future lease payments for operating and finance leases as of December&#160;31, 2020, were as follows (in thousands): </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Fiscal Year</font></p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Leases</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Financing</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Leases</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,691</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">712</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,581</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">459</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,659</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">245</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,732</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,814</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,925</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total minimum lease payments</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,402</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,416</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less amounts representing interest or imputed interest</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,702</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(123</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of lease liabilities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,700</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,293</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_LesseeOperatingAndFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating and finance leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_LesseeOperatingAndFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760663994584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses</a></td>
<td class="text">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 8. Accrued Expenses</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consist of the following as of December 31, 2020 and 2019 (in thousands): </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,821</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,617</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll and payroll-related</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,918</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,256</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional fees</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,585</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">606</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,330</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,568</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760666044952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Other Commitments and Contingencies</a></td>
<td class="text">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 9. Other Commitments and Contingencies</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the ordinary course of business, the Company may be subject to legal proceedings, claims and litigation as the Company operates in an industry susceptible to patent legal claims. The Company accounts for estimated losses with respect to legal proceedings and claims when such losses are probable and estimable. Legal costs associated with these matters are expensed when incurred.&#160;The Company is not currently a party to any legal proceedings.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Indemnification Arrangements</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As permitted under Delaware law, the Company has agreements whereby it indemnifies its investors, employees, officers, and directors (collectively, the &#8220;Indemnified Parties&#8221;) for certain events or occurrences while the Indemnified Parties are, or were serving, at its request in such capacity. The term of the indemnification period is for the Indemnified Parties&#8217; lifetime. The Company believes the estimated fair value of these indemnification agreements is minimal. The Company enters into standard indemnification agreements in the ordinary course of business. Pursuant to these agreements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified party for losses suffered or incurred by the indemnified party, generally the Company&#8217;s business partners or customers, in connection with any U.S. patent or any copyright or other intellectual property infringement claim by any third party with respect to the Company&#8217;s products. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited. The Company is not aware of any claims under indemnification arrangements, and it has not accrued any liabilities related to such obligations as of December&#160;31, 2020 or 2019.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760664025464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">Convertible Preferred Stock</a></td>
<td class="text">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 10. Convertible Preferred Stock</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Immediately prior to the IPO, the Company&#8217;s Articles of Association (the &#8220;Articles&#8221;), as further amended and restated (the &#8220;2018 Amended Articles&#8221;), authorized a total of 52,483,788 convertible preferred stocks with a par value of $0.0001 per share, of which 3,000,000 shares have been designated as Series Seed Preferred Stock, 14,886,305 shares have been designated as Series A Preferred Stock, 16,009,845 shares have been designated as Series B Preferred Stock, 3,059,695 shares have been designated as Series B-1 Preferred Stock and 15,527,943 shares have been designated as Series C Preferred Stock. The Series A, Series B, Series B-1 and Series C convertible preferred stocks will be collectively referred to as the Convertible Preferred Stock. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2020, the Company issued 1,182,265 shares of Series B Preferred Stock at $4.06 per share to complete the second closing of the Series B Preferred Stock issuance for total proceeds of $4.8&#160;million. The issuance costs related to the second tranche were insignificant.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, the Company executed a Series&#160;C Preferred Stock Purchase Agreement (the &#8220;Series&#160;C SPA&#8221;) to issue 13,539,141 shares of Series&#160;C Preferred Stock at a purchase price of $6.5366 per share for a total consideration of $88.2&#160;million, net of issuance costs of $0.3&#160;million. In conjunction with the Series&#160;C SPA, the Company exchanged 1,988,802 shares of Series A Preferred Stock for an equal number of shares of Series&#160;C Preferred Stock related to a transaction amongst investors. This resulted in a total issuance of 15,527,943 shares of Series&#160;C Preferred Stock. The fair value of the shares of Series&#160;C Preferred Stock issued exceeded the carrying value of the shares of Series&#160;A Preferred Stock exchanged by $9.1&#160;million, which was recognized as a deemed dividend through a reduction of $2.3&#160;million to additional&#160;paid-in&#160;capital and an increase of $6.7&#160;million to the accumulated deficit. The $9.1&#160;million deemed dividend increased the net loss for the year ending December 31, 2020 to arrive at net loss attributable to common stockholders in the calculation of earnings per share.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Company&#8217;s August 21, 2020, IPO all issued and outstanding Convertible Preferred Stock of 50,439,595 were converted to 31,625,534 shares of the Company&#8217;s common stock and are no longer issued or outstanding as of December 31, 2020.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760664022472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity-Based Compensation</a></td>
<td class="text">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 11. Equity-Based Compensation </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2018 Stock Option and Grant Plan </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2018, the Company adopted, and its stockholders approved, the 2018 Stock Option and Grant Plan (the &#8220;2018 Plan&#8221;), which provides for the granting of stock options and other equity-based awards at the discretion of the Board of Directors or any subcommittee of the Board of Directors to its employees, officers, directors, and independent contractors. No further grants will be made under the 2018 Plan. However, the 2018 Plan will continue to govern outstanding equity awards granted thereunder. To the extent outstanding options granted under the 2018 Plan are cancelled, forfeited or otherwise terminated without being exercised and would otherwise have been returned to the share reserve under the 2018 Plan, the number of shares underlying such awards will be available for future grant under the 2020 Stock Option and Incentive Plan. Following the completion of the Company&#8217;s initial public offering no additional shares will be granted under the 2018 Plan. However, the 2018 Plan will continue to govern outstanding equity awards granted thereunder.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2020 Stock Option and Incentive Plan </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, the Company and its stockholders approved the 2020 Stock Option and Incentive Plan (the &#8220;2020 Plan&#8221;), which became effective on August 20, 2020. The 2020 Plan replaced the 2018 Plan as the Company&#8217;s board of directors has determined not to make additional awards under the 2018 Plan following the closing of the Company&#8217;s IPO. The 2020 Plan allows the Company to make equity-based and cash-based incentive awards to its officers, employees, directors and consultants. The Company has initially reserved 4,457,370 shares of its common stock for the issuance of awards under the 2020 Plan, which includes the shares of common stock remaining available for issuance under its 2018 Plan as of the business day immediately prior to the effective date of the registration statement. The 2020 Plan provides that the number of shares reserved and available for issuance will automatically increase on January 1, 2021 and each January 1 thereafter, by 4% of the Company&#8217;s outstanding number of shares of common stock on the immediately preceding December 31, or such lesser number of shares as determined by the Company&#8217;s compensation committee. These limits are subject to adjustment in the event of a stock split, stock dividend or other change in the Company&#8217;s capitalization. As of December&#160;31, 2020, there were an aggregate of 3,148,671 shares remaining available for future grants. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2020 Employee Stock Purchase Plan </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, the Company and its stockholders approved the 2020 Employee Stock Purchase Plan (the &#8220;2020 ESPP&#8221;), which became effective August 20, 2020. The 2020 ESPP initially reserves and authorizes the issuance of up to a total of 445,653 shares of common stock to participating employees. The 2020 ESPP provides that the number of shares reserved and available for issuance will automatically increase on January 1, 2021 and each January 1 thereafter through January 1, 2030, by the least of (i) 438,898 shares of common stock, (ii) 1% of the Company&#8217;s outstanding number of shares of common stock on the immediately preceding December 31 or (iii) such lesser number of shares of common stock as determined by the administrator of the 2020 ESPP. The number of shares reserved under the 2020 ESPP is subject to adjustment in the event of a stock split, stock dividend or other change in the Company&#8217;s capitalization. As of December&#160;31, 2020, there were an aggregate of 445,653 shares remaining available for future grants. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock Options </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of stock option activity under the 2020 Stock Option and Grant Plan during the year ended December 31, 2020 is as follows (in thousands except share and per share data): </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Strike</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price per</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,945,297</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.03</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.93</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,798</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,213,204</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.22</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(78,852</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.06</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(246,937</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.55</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,832,712</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.17</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.08</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">314,001</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at December 31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,580,924</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.38</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.76</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92,674</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The i<font style="Background-color:#FFFFFF;color:#000000;">ntrinsic value of stock options exercised during the years ended December 31, 2020 and 2019 was $1.6 million, $0.1 million, respectively.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average fair value of options granted during the years ended December&#160;31, 2020 and 2019 was $8.35 and $1.69 per share, respectively.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the total unrecognized stock-based compensation expense for unvested stock options was $25.6&#160;million, which is expected to be recognized over 3.3 years. The total fair value of stock options vested during the years ended December&#160;31, 2020 and 2019 was $4.0 million, $0.2&#160;million, respectively.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table outlines our equity-based compensation expense for stock options for the years ended December 31, 2020 and 2019:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="8" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ending December 31,</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,084</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">380</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,864</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">212</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total equity-based compensation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,948</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">592</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average assumptions that the Company used in Black-Scholes option pricing model to determine the grant date fair value of stock options granted to employees and non-employees for the years ended December 31, 2020 and 2019: </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="8" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ending December 31,</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.3%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.09</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.49</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.5</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.83</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Restricted Common Stock </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has granted shares of restricted common stock with service-based and performance-based vesting conditions. A summary of restricted stock activity under the 2018 Plan during the year ended December 31, 2020 is as follows: </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Units</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">per Share</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at December 31, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">232,434</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.60</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(102,651</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.60</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,679</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.60</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at December 31, 2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,104</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.60</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no grants of restricted stock during the years ended December 31, 2020 and 2019.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the total unrecognized stock-based compensation expense for unvested restricted stock was $0.3&#160;million, which is expected to be recognized over 1.6 years. The total fair value of restricted stock vested during the years ended December&#160;31, 2020 and 2019 was $0.1 million and $0.5&#160;million, respectively.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December 31, 2020 and 2019, the Company recorded stock-based compensation expense for restricted stock of $0.2 million and $0.4&#160;million, of which $0.2 million and $0.2 million was included in research and development expense and an immaterial amount and $0.2 million was included in general and administrative expense, respectively. Included within the 2019 general and administrative stock-based compensation expense was $0.1&#160;million from a modification of an employee&#8217;s awards.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Equity-Based Compensation Expense </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total equity-based compensation expense recorded as research and development and general and administrative expenses for employees, directors, and non-employees during the years ended December 31, 2020 and 2019 is as follows (in thousands): </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="8" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years ending December 31,</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,305</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">688</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,885</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">508</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total equity-based compensation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,190</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,196</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760737585464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 12. Related-Party Transactions</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the collaboration discussed in Note 5, the Company had the following related party transactions for the periods presented in the accompanying consolidated financial statements, which has not otherwise been discussed in these notes to the consolidated financial statement. The Company made payments of $0.8 million and $1.0&#160;million to an investor for rent expenses for the years ended December 31, 2020 and 2019, respectively. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760663851672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 13. Income Taxes </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.53%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company records income tax expense related to profits realized by its U.S. operating subsidiaries.&#160;For the years ended December&#160;31, 2020 and 2019, no income tax expense was recorded due the group&#8217;s net operating loss (&#8220;NOL&#8221;) and full valuation allowance.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.53%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The rate reconciliation of the U.S. statutory income tax rate to the Company&#8217;s effective tax rate for the years ended December&#160;31, 2020 and 2019 are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax effect at statutory rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State taxes</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.8</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.9</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.6</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent differences</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal research and development credits</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.6</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.7</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28.8</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29.4</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.53%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company&#8217;s net deferred income taxes are as&#160;follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160; </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Deferred Tax Assets:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal net operating loss carryforwards</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,621</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,011</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State net operating loss carryforwards</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,866</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,319</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credit carryforwards</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,757</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,637</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liabilities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,563</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,286</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,313</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accruals and reserves, stock and other</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,589</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">525</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,709</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,778</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34,075</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,949</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,634</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,829</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed and intangible assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,506</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(754</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,128</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,075</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax asset</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.53%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As required by ASC 740, management of the Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, which are composed principally of NOL carryforwards and research and development credit carryforwards. Management has determined that it is more likely than not that the Company will not recognize the benefits of its federal and state deferred tax assets, and, as a result, a valuation allowance of $34.1&#160;million and $20.9&#160;million has been established at December&#160;31, 2020 and 2019, respectively. During 2020, the valuation allowance increased by $13.1&#160;million primarily due to the increase in the Company&#8217;s NOL during the period.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.53%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has incurred NOLs from inception. At December&#160;31, 2020 and 2019, the Company has federal NOL carryforwards of approximately $74.4&#160;million and $71.5&#160;million, respectively, and state NOL carryforwards of approximately $61.2&#160;million and $68.3&#160;million, respectively. Of the federal net operating loss carryovers, $64.6 million is not subject to expiration and the remaining federal and state NOLs begin to expire in 2036. These loss carryforwards are subject to review and possible adjustment by the appropriate taxing authorities.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.53%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Utilization of net operating loss and research and development credit carryforwards may generally be subject to limitation under Sections 382 and 383 of the Internal Revenue Code due to ownership changes that have occurred previously, or that could occur in the future. These ownership changes may limit the amount of net operating loss and research and development credit carryforwards that can be utilized annually to offset any post-ownership change taxable income and tax, respectively. The latest Section 382 study was performed through December 31, 2020, noting that a historic ownership change has likely occurred. Nonetheless, the Company has determined that as of December 31, 2020 the prospective utilization of all net operating loss and tax credit carryforwards generated from inception through December 31, 2020, and therefore the corresponding Federal and Massachusetts deferred tax assets, should not be restricted by Sections 382 and 383, although ownership changes after December 31, 2020 could impact the Company&#8217;s ability to utilize these tax attributes in the future.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.53%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2020 and 2019, the Company had federal research and development credit carryforwards of $2.7&#160;million and $1.1&#160;million, respectively, and state research and development credit carryforwards of $1.3&#160;million and $0.7&#160;million, respectively. These carryforwards begin to expire in&#160;2036.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.53%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company follows the provisions of ASC 740-10, &#8220;Accounting for Uncertainty in Income Taxes,&#8221; which specifies how tax benefits for uncertain tax positions are to be recognized, measured, and recorded in financial statements; requires certain disclosures of uncertain tax matters; specifies how reserves for uncertain tax positions should be classified on the balance sheet; and provides transition and interim period guidance, among other provisions.&#160;As of December 31, 2020, and 2019, the Company has not recorded any amounts for uncertain tax positions.&#160;The Company&#8217;s policy is to recognize interest and penalties accrued on any uncertain tax positions as a component of income tax expense, if any, in its statements of income. As of December&#160;31, 2020 and 2019, the Company had no reserves for uncertain tax positions.&#160;For the years ended December&#160;31, 2020 and 2019, no estimated interest or penalties were recognized on uncertain tax positions.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.53%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company's tax returns for the years ended December 31, 2017 to December 31, 2020 remain open and subject to examination by the Internal Revenue Service and state taxing authorities.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760737599544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 14. Net Loss per Share</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss per Share</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding (in thousands, except for share and per share data):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="8" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,593</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41,246</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deemed dividend from exchange of convertible</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; preferred stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,050</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(54,643</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41,246</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average common shares outstanding, basic</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; and diluted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,349,582</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,698,522</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share, basic and diluted</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.15</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24.28</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s potentially dilutive securities, which include convertible preferred stock, restricted stock, and stock options, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following from the computation of diluted net loss per share attributable to common stockholders at December&#160;31, 2020 and 2019 because including them would have had an anti-dilutive effect:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="8" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible Preferred Stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,325,780</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested Restricted Stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,104</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">232,434</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase Common Stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,580,924</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,945,298</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,691,028</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,503,512</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760657433336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Principles of Consolidation</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary Kymera Securities Corporation. All intercompany transactions and balances have been eliminated in consolidation.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Presentation</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosure of contingencies at the date of the financial statements and the reported amounts of expenses during the reporting period. Management&#8217;s estimates and judgments are derived and continually evaluated based on available information, historical experience and various other assumptions that are believed to be reasonable under the circumstances. Because the use of estimates is inherent in the financial reporting process, actual results could differ from those estimates. In recording transactions and balances resulting from business operations, management makes estimates based on the best information available at the time the estimate is made. Significant estimates relied upon in preparing these financial statements include revenue recognized under our collaboration agreement with Sanofi and Vertex, accrual for research and development expenses, equity-based compensation expense, and the valuation of equity. As better information becomes available or actual amounts are determinable, the recorded estimates are revised. Consequently, operating results can be affected by revisions to prior estimates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_SegmentAndGeographicInformationPolicyTextBlock', window );">Segment and Geographic Information</a></td>
<td class="text">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Segment and Geographic Information</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company&#8217;s chief operating decision maker is the Chief Executive Officer. The Company views its operations and manages its business in one operating segment.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents</a></td>
<td class="text">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash and <font style="color:#000000;">Cash</font> Equivalents</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents are highly liquid investments that are readily convertible into cash with original maturities of three months or less when purchased. These assets include investments in money market funds that invest in U.S. Treasury obligations and corporate bonds. The Company maintains its bank accounts at major financial institutions.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_RestrictedCashPolicyPolicyTextBlock', window );">Restricted Cash</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Restricted Cash</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash represents the cash held to secure a letter of credit associated with the Company&#8217;s facility lease.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Marketable Securities</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies marketable securities with a remaining maturity of greater than three months when purchased as available-for-sale. The Company classifies investments available to fund current operations as current assets on its balance sheets. Marketable securities with a remaining maturity date greater than one year are classified as non-current. Available-for-sale securities are maintained by investment managers and consist of U.S. Treasury securities and corporate bonds. Available-for-sale securities are carried at fair value with the unrealized gains and losses included in other comprehensive income (loss) as a component of stockholders&#8217; equity until realized. Any premium or discount arising at purchase is amortized and/or accreted to interest income and/or expense over the life of the instrument. Realized gains and losses are determined using the specific identification method and are included in other (expense) income, net.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any adjustment to fair value reflects a decline in value of the investment, the Company considers all available evidence to evaluate the extent to which the decline is &#8220;other-than-temporary&#8221; and, if so, marks the investment to market through a charge to the Company&#8217;s statement of operations and comprehensive loss.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Fair Value Measurements</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Level&#160;1&#8212;<font style="font-style:normal;">Quoted prices in active markets for identical assets</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Level&#160;2&#8212;<font style="font-style:normal;">Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar asset, or other inputs that are observable or can be corroborated by observable market data.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Level&#160;3&#8212;<font style="font-style:normal;">Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets, including pricing models, discounted cash flow methodologies and similar techniques.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying values of the Company&#8217;s cash equivalents, prepaid expenses, accounts payable, and certain accruals approximate their fair value due to their short-term nature.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Leases</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company adopted ASC Topic 842, <font style="font-style:italic;">Leases</font> (&#8220;ASC 842&#8221;) on January&#160;1, 2019. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Leases that are economically similar to the purchase of assets are generally classified as finance leases; otherwise the leases are classified as operating leases. The Company has elected not to recognize leases with an original term of one year or less on the balance sheet. Options to renew a lease are not included in the Company&#8217;s assessment unless there is reasonable certainty that the Company will renew. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. However, certain adjustments to the right-of-use asset may be required for items such as incentives received. The Company has elected as an accounting policy to combine lease and non- lease components, such as common area maintenance, for all classes of underlying assets. The interest rate implicit in lease contracts has not historically been readily determinable. As a result, the Company utilizes its incremental borrowing rates, which are the rates incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. To estimate its incremental borrowing rate, a credit rating applicable to the Company is estimated using synthetic credit rating analysis since the Company does not currently have a rating agency-based credit rating.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property and Equipment</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are recorded at cost, net of accumulated depreciation. Major additions and betterments are capitalized; maintenance and repairs, which do not improve or extend the life of the respective assets, are charged to operations as incurred. Depreciation expense is recorded using the straight-line method over the estimated useful life of the related asset as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated Useful Life</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.86%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furnitures and fixtures</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shorter of life of lease or remaining lease term</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon retirement or sale, the cost and related accumulated depreciation of assets disposed of are removed from the accounts and any resulting gain or loss is included in loss from operations.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction-in-progress is stated at cost, which includes direct costs attributable to the setup or construction of the related asset. Depreciation expense is not recorded on construction-in-progress until the relevant assets are completed and put into use.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its fair value, determined based on discounted cash flows. The Company did not record any impairment losses on long-lived assets during the years ended December&#160;31, 2020 and 2019.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_ConvertiblePreferredStockPolicyTextBlock', window );">Convertible Preferred Stock</a></td>
<td class="text">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Convertible Preferred Stock</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classified convertible preferred stock as temporary equity in the accompanying consolidated balance sheet due to terms that allow for redemption of the shares in cash upon certain change in control events that are outside of the Company&#8217;s control, including the sale or transfer of the Company as holders of the convertible preferred stock which could trigger redemption of the shares. The Company did not accrete the value of the convertible preferred stock to the redemption values since a liquidation event was not considered probable as of December&#160;31, 2019. Subsequent adjustments of the carrying values to the ultimate redemption values will be made only when it becomes probable that such liquidation events will occur. In connection with the Company&#8217;s initial public offering on August 21, 2020, all outstanding shares of convertible preferred stock converted to common stock.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Costs</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs consist primarily of costs incurred in connection with the discovery and development of targeted protein degradation therapeutics, including those in the Company&#8217;s most advanced development programs, IRAK4, IRAKIMiD and STAT3. These research efforts and costs, which also support the development of, and enhancements to, the Company&#8217;s Pegasus targeted protein degradation platform, include external research costs, personnel costs, supplies, license fees and facility related expenses. The Company expenses research and development costs as incurred.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_PatentCostsPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Patent Costs</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recoverability of the expenditure. Amounts incurred are classified as general and administrative expenses.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_FinancingCostsPolicyTextBlock', window );">Financing Costs</a></td>
<td class="text">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Financing Costs</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs incurred in connection with the issuance of equity units and shares are recorded as a reduction of proceeds to the equity carrying value. The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process financings as deferred offering costs until such financings are consummated. After consummation of the financing, these costs are recorded as a reduction of the proceeds received from the financing. If a planned financing is abandoned, the deferred offering costs are expensed immediately as a charge to operating expenses in the consolidated statement of operations and comprehensive loss. There was $0.4 million of deferred financing costs included in accounts payable on the Company&#8217;s consolidated balance sheet as of December 31, 2020. There was no deferred offering costs on the Company&#8217;s consolidated balance sheet at December 31, 2019.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company adopted ASC Topic 606, <font style="font-style:italic;">Revenue from Contracts with Customers</font> (&#8220;ASC 606&#8221;) on January&#160;1, 2017. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identification of the contract(s) with the customer; (ii)&#160;identification of the promised goods or services in the contract and determination of whether the promised goods or services are performance obligations; (iii)&#160;measurement of the transaction price; (iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the accounting for these arrangements, the Company must use significant judgment to determine: a) the number of performance obligations based on the determination under step (ii)&#160;above and whether those performance obligations are distinct from other performance obligations in the contract; b) the transaction price under step (iii)&#160;above; and c) the standalone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv)&#160;above. The Company uses judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. In determining the stand-alone selling price of a license to the Company&#8217;s proprietary technology or a material right provided by a customer option, the Company considers market conditions as well as entity-specific factors, including those factors contemplated in negotiating the agreements as well as internally developed estimates that include assumptions related to the market opportunity, estimated development costs, probability of success and the time needed to commercialize a product candidate pursuant to the license. In validating its estimated stand-alone selling prices, the Company evaluates whether changes in the key assumptions used to determine its estimated stand-alone selling prices will have a significant effect on the allocation of arrangement consideration between performance obligations.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimates the transaction price based on the amount of consideration the Company expects to be received for transferring the promised goods or services in the contract. The consideration may include both fixed consideration and variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of the potential payments and the likelihood that the payments will be received. The Company utilizes either the most likely amount method or expected value method to estimate the transaction price based on which method better predicts the amount of consideration expected to be received. If it is probable that a significant revenue reversal would not occur, the variable consideration is included in the transaction price.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer. Promised goods or services are considered distinct when: (i)&#160;the customer can benefit from the good or service on its own or together with other readily available resources and (ii)&#160;the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on their own and whether the required expertise is readily available.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation in order to determine whether the combined performance obligation is satisfied over time or at a point in time. The Company receives payments from customers based on billing schedules established in each contract. Up-front payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion. Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional. Amounts recognized as revenue, but not yet received or invoiced are generally recognized as contract assets.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Exclusive Licenses<font style="font-style:normal;">&#8212;If the license granted in the arrangement is determined to be distinct from the other promises or performance obligations identified in the arrangement, which generally include research and development services, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whether a license is distinct from the other promises, the Company considers relevant facts and circumstances of each arrangement, including the research and development capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the collaboration partner can benefit from the license for its intended purpose without the receipt of the remaining promise, whether the value of the license is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the arrangement.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development Services<font style="font-style:normal;">&#8212;The promises under the Company&#8217;s collaboration and license agreements generally include research and development services to be performed by the Company on behalf of the collaboration partner. For performance obligations that include research and development services, the Company generally recognizes revenue allocated to such performance obligations based on an appropriate measure of progress. The Company utilizes judgment to determine the appropriate method of measuring progress for purposes of recognizing revenue, which is generally an input measure, such as costs incurred. The Company evaluates the measure of progress each reporting period as described under Exclusive Licenses above. Reimbursements from the partner that are the result of a collaborative relationship with the partner, instead of a customer relationship, such as co-development activities, are generally recorded as a reduction to research and development expense.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Customer Options<font style="font-style:normal;">&#8212;The Company&#8217;s arrangements may provide a collaborator with the right to certain optional purchases, such as the right to license a target either at the inception of the arrangement or within a pre-defined option period. Under these agreements, fees may be due to the Company at the inception of the arrangement as an upfront fee or payment or upon the exercise of an option to acquire a license. If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. The Company evaluates the customer options for material rights, or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the inception of the arrangement. The Company allocates the transaction price to material rights based on the relative stand-alone selling price, which is determined based on the identified discount, and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised or expires.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Milestone Payments<font style="font-style:normal;">&#8212;At the inception of each arrangement that includes milestone payments based on certain events, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. If a milestone or other variable consideration relates specifically to the Company&#8217;s efforts to satisfy a single performance obligation or to a specific outcome from satisfying the performance obligation, the Company generally allocates the milestone amount entirely to that performance obligation once it is probable that a significant revenue reversal would not occur.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Royalties<font style="font-style:normal;">&#8212;For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i)&#160;when the related sales occur or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Collaboration revenue&#8212;<font style="font-style:normal;">The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808,</font>&#160;Collaborative Arrangements<font style="font-style:normal;">&#160;(&#8220;ASC 808&#8221;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities.&#160;This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement.&#160;For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship and therefore within the scope of Topic 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently, generally by analogy to Topic 606. For those elements of the arrangement that are accounted for pursuant to Topic 606, the Company applies the five-step model described above.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_CostsAssociatedWithLicenseAndCollaborativeArrangementsPolicyTextBlock', window );">Costs Associated with License and Collaborative Arrangements</a></td>
<td class="text">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Costs associated with License and Collaborative Arrangements</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs associated with licenses of technology acquired as part of collaborative arrangements are expensed as incurred and are generally included in research and development expense in the consolidated statements of operations.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for all stock-based awards granted to employees, directors, and nonemployees based on their fair value on the date of the grant and recognize compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. Stock-based payments include stock options and grants of common stock, including common stock subject to vesting. The measurement date for stock awards is the date of grant, and stock-based compensation costs are recognized as expense over the requisite service period, which is the vesting period, on a straight-line basis. The Company has issued stock options and restricted stock with performance-based vesting conditions and records the expense for these awards if the Company concludes that it is probable that the performance condition will be achieved. Stock-based compensation is classified in the accompanying consolidated statements of operations and comprehensive loss based on the function to which the related services are provided. The Company recognizes stock-based compensation expense for the portion of awards that have vested. Forfeitures are accounted for as they occur.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes options-pricing model, which requires inputs based on certain subjective assumptions, including the expected stock price volatility, the expected term of the option, the risk-free interest rate for a period that approximates the expected term of the option, and the Company&#8217;s expected dividend yield. Prior to the IPO, as there was no active market for the Company&#8217;s common stock, the Company estimated the fair value of common stock on the date of grant based on the then current facts and circumstances. Upon becoming a public company, the fair value of the underlying common shares equals the closing price of the Company&#8217;s stock on the date of grant. The Company historically has been a private company and lacks company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of guideline companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options. The expected term of stock options granted to non-employees is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future. The fair value of each restricted common stock award is estimated on the date of grant based on the fair value of the Company&#8217;s common stock on that same date.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compensation expense for discounted purchases under the employee stock purchase plan is measured using the Black-Scholes model to compute the fair value of the lookback provision plus the purchase discount and is recognized as compensation expense over the offering period.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_CommonAndPreferredStockValuationPolicyTextBlock', window );">Common and Preferred Stock Valuation</a></td>
<td class="text">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Common and Preferred Stock Valuation</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company utilized significant estimates and assumptions in determining the fair value of its equity and equity-based awards. The Company utilized various valuation methodologies in accordance with the framework of the 2013 American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its equity awards.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company used a hybrid of the probability-weighted expected returns method (&#8220;PWERM&#8221;), and the option pricing method (&#8220;OPM&#8221;) when allocating enterprise value to classes of securities.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the probability-weighted expected return method, or PWERM, the value of an enterprise, and its underlying common securities, are estimated based on an analysis of future values for the enterprise, assuming various outcomes. The value of the common securities is based on the probability-weighted present value of expected future investment returns considering each of the possible outcomes and the rights of each class of equity. The future values of the common securities under the various outcomes are discounted back to the valuation date at an appropriate risk-adjusted discount rate and then probability weighted to determine the value for the common securities.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The option pricing method, or OPM, treats common securities and preferred securities as call options on the enterprise&#8217;s equity value, with exercise prices based on the liquidation preferences of the preferred securities. Under this method, the common securities have value only if the funds available for distribution to shareholders exceed the value of the liquidation preferences at the time of a liquidity event. The Black-Scholes model is used to price the call option, and the model includes assumptions for the time to liquidity and the volatility of equity value.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The hybrid method is a hybrid between the PWERM and OPM, estimating the probability-weighted value across multiple scenarios but using the OPM to estimate the allocation of value within one or more of those scenarios.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuations performed in the year ended December&#160;31, 2020 and 2019, used a hybrid of the PWERM and OPM when allocating the Company&#8217;s enterprise value to classes of securities.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When using the hybrid method, the Company assumed two scenarios: an IPO scenario and a trade-sale scenario. The IPO scenario estimated an equity value based on the guideline public company method under a market approach. The guideline public companies considered for this scenario consist of biopharmaceutical companies with recently completed initial public offerings. The Company converted its estimated future value in an IPO to present value using a risk-adjusted discount rate. The equity value for the trade-sale scenario was estimated using the price of a recently issued preferred security, as well as a milestone-based tranche closing. The Company utilized an option pricing model to quantify or attribute value to these economic rights of convertible preferred stock vs. the common stock (e.g. liquidation preferences, dividend provisions, participation rights after liquidation preferences.)</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the OPM, volatility is estimated based on the trading histories of selected guideline public companies. The relative probability of each scenario was determined based on an assessment of then-current market conditions and the Company&#8217;s expectations as to timing and prospects of an IPO.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each valuation methodology includes estimates and assumptions that require significant judgment. These estimates and assumptions include a number of objective and subjective factors, including the prices at which shares were traded between holders of the Company, external market conditions, the prices at which the Company sold convertible preferred shares, the superior rights and preferences of securities senior to common shares at the time, and the likelihood of achieving a voluntary or involuntary liquidity event.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant changes to the key assumptions used in the valuations could result in different fair values of common shares at each valuation date, as applicable.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income taxes for Kymera Therapeutics, Inc. are recorded in accordance with FASB Accounting Standards Codification Topic 740, <font style="font-style:italic;">Income Taxes</font> (&#8220;ASC 740&#8221;), which provides for deferred taxes using an asset and liability approach. Under this method, deferred income tax assets and liabilities are recognized based on future income tax consequences attributable to differences between the financial statement carrying amount of existing assets and liabilities, and their respective income tax basis. Deferred income tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of changes in income tax rates on deferred income tax assets and liabilities is recognized as income or expense in the period that a valuation allowance for any income tax benefits of which future realization is not more likely than not.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions. The tax benefits recorded are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filings or positions is &#8220;more likely than not&#8221; to be realized following resolution of any uncertainty related to the tax benefit, assuming that the matter in question will be raised by the tax authorities.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_OffBalanceSheetRiskAndConcentrationOfCreditRiskPolicyTextBlock', window );">Off Balance Sheet Risk and Concentration of Credit Risk</a></td>
<td class="text">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Off Balance Sheet Risk and Concentration of Credit Risk</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has no significant off-balance sheet risk such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, and restricted cash. The Company&#8217;s cash, cash equivalents, and restricted cash are deposited in accounts at large financial institutions. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash, cash equivalents and restricted cash are held. The Company maintains its cash equivalents in money market funds that invest in U.S. Treasury securities and U.S. Treasury obligations and corporate bonds. The Company&#8217;s marketable securities primarily consist of corporate bonds and U.S. Treasury securities paper, and potentially subject the Company to concentrations of credit risk. The Company has adopted an investment policy that limits the amounts the Company may invest in any one type of investment. The Company has not experienced any credit losses and does not believe it is exposed to any significant credit risk on these funds.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Comprehensive Loss</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss includes net loss as well as unrealized gains on marketable securities and other changes in stockholders&#8217; equity (deficit) that result from transactions and economic events other than those with stockholders.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss Per Share</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company applies the two-class method to compute basic and diluted net income (loss) per share attributable to common stockholders when it has issued shares that meet the definition of participating securities. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income (loss) available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to share in the earnings as if all income (loss) for the period had been distributed. The Company&#8217;s convertible preferred stock participates in any dividends declared by the Company and are therefore considered to be participating securities. The participating securities are not required to participate in the losses of the Company, and therefore during periods of loss there is no allocation required under the two-class method.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net income (loss) per share attributable to common stockholders is computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) attributable to common stockholders is computed by adjusting net income (loss) per share attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period, including potential dilutive common shares. For purpose of this calculation, outstanding options to purchase common stock, unvested restricted stock awards, and shares of convertible preferred stock are considered potential dilutive common shares. The Company has generated a net loss in all periods presented, and therefore the basic and diluted net loss per share attributable to common stockholders are the same as the inclusion of the potentially dilutive securities would be anti-dilutive.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_EmergingGrowthCompanyStatusPolicyTextBlock', window );">Emerging Growth Company Status</a></td>
<td class="text">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Emerging Growth Company Status</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is an emerging growth company (&#8220;EGC&#8221;), as defined in the Jumpstart Our Business Startups Act (the &#8220;JOBS Act&#8221;), and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not EGCs. The Company may take advantage of these exemptions until it is no longer an EGC under Section&#160;107 of the JOBS Act, which provides that an EGC can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to use this exemption to delay adopting new or revised.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Recently Adopted Accounting Standards</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2019, the FASB issued ASU 2019-04,&#160;<font style="font-style:italic;">Codification Improvements to Topic 326, Financial Instruments&#8212;Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments</font>. This update provides clarifications for three topics related to financial instruments accounting, some of which apply to the Company. The Company adopted as of January&#160;1, 2020 and it did not have a significant impact on its financial position or results of operation</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU 2018-15, <font style="font-style:italic;">Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</font>. The new standard will align the requirements for capitalizing implementation costs for hosting arrangements (services) with costs for internal-use software (assets). As a result, certain implementation costs incurred in hosting arrangements will be deferred and amortized. The Company adopted as of January&#160;1, 2020 and it did not have a significant impact on its financial position or results of operation.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement. The new standard will be effective beginning January&#160;1, 2020. The Company adopted as of January&#160;1, 2020 and it did not have a significant impact on its financial position or results of operation.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Recently Issued Accounting Standards Not Yet Adopted</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU 2019-12, <font style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</font>, which is intended to simplify the accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. The new standard will be effective beginning January&#160;1, 2021. The Company is currently evaluating the potential impact ASU 2019-12 may have on its financial position and results of operations upon adoption.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU 2016-13,&#160;<font style="font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Statements</font>. The new standard requires that expected credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. It also limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value increases. As an emerging growth company, the Company expects to delay adoption until January 1, 2023 and is evaluating the impact that the adoption of ASU 2016-13 will have on its consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_CommonAndPreferredStockValuationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common and preferred stock valuation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_CommonAndPreferredStockValuationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_ConvertiblePreferredStockPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_ConvertiblePreferredStockPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_CostsAssociatedWithLicenseAndCollaborativeArrangementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs associated with license and collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_CostsAssociatedWithLicenseAndCollaborativeArrangementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_EmergingGrowthCompanyStatusPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Emerging growth company status.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_EmergingGrowthCompanyStatusPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_FinancingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_FinancingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_OffBalanceSheetRiskAndConcentrationOfCreditRiskPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Off balance sheet risk and concentration of credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_OffBalanceSheetRiskAndConcentrationOfCreditRiskPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_PatentCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Patent costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_PatentCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_RestrictedCashPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted cash policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_RestrictedCashPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_SegmentAndGeographicInformationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Segment and geographic information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_SegmentAndGeographicInformationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760737544744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_SummaryOfEstimatedUsefulLifeOfRelatedAssetTableTextBlock', window );">Summary of Estimated Useful Life of Related Asset</a></td>
<td class="text">Depreciation expense is recorded using the straight-line method over the estimated useful life of the related asset as follows:
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated Useful Life</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.86%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furnitures and fixtures</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shorter of life of lease or remaining lease term</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_SummaryOfEstimatedUsefulLifeOfRelatedAssetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of estimated useful life of related asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_SummaryOfEstimatedUsefulLifeOfRelatedAssetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760664001464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Assets Measured at Fair Value on Recurring Basis</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values as of December 31,&#160;2020 and December 31, 2019 (in thousands): </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market fund</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,943</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,943</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,499</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,499</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities, current</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US treasuries</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">192,275</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">192,275</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,923</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,923</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities, non-current</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US treasuries</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132,589</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132,589</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,942</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,942</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,589</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,589</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">346,396</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113,364</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">459,760</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,942</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,942</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,774</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,774</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,716</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,716</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760663807176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Summary of Available-for-Sale Debt Securities</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the available-for-sale debt securities held at December 31, 2020 and 2019 and (in thousands): </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">324,917</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(53</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">324,864</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,946</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(81</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,865</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">427,863</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(134</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">427,729</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,936</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,942</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,936</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,942</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760737505608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Change in Accounts Receivable, Contract Asset and Liabilities</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The <font style="color:#000000;">following table presents the changes in accounts receivable, contract assets and liabilities for the year ended December 31,&#160;2020 (in thousands)</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additions</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deductions</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable and contract assets:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Billed receivables &#8211; Sanofi</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">150,577</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(150,000</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">577</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unbilled receivables &#8211; Sanofi</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,433</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(577</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">856</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accounts receivable and contract assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">152,010</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(150,577</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,433</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract Liabilities:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred Revenue &#8211; Vertex</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,991</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,243</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,748</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred Revenue &#8211; Sanofi</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">151,433</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,791</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132,642</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total contract liabilities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,991</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">151,433</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34,034</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">170,390</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760664012088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consist of the following as of December&#160;31, 2020 and 2019 (in thousands): </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab and office equipment under and financing</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; right-of-use asset</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,771</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,751</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,636</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">919</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture &amp; fixtures</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">861</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,599</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">545</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets not yet in service</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">453</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,988</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,843</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,147</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,049</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,841</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,794</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760660207176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Components of Lease Costs</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of the lease costs for the years ended December 31, 2020 and 2019 (in thousands): </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease costs</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,719</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,597</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing lease costs:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of right-to-use assets, financing</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; leases</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">716</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">385</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense for financing lease liabilities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Variable lease costs</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">621</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">340</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease costs</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,177</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,368</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_SupplementalCashFlowInformationRelatingToLeasesTableTextBlock', window );">Supplemental Cash Flow Information Relating to Leases</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental cash flow information relating to the Company&#8217;s leases for the years ended December 31, 2020 and 2019 was as follows (in thousands): </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for amounts included in the measurement</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; of lease liabilities:</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flows used in (provided by)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; operating leases</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,024</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">635</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flows used in finance leases</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">587</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing cash flows used in finance leases</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">385</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock', window );">Summary of Weighted Average Remaining Lease Terms and Discount Rates</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average remaining lease terms and discount rates as of December 31, 2020 and 2019 were as follows: </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Remaining lease term:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing lease</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.8 Years</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.7 Years</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discount Rate:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing lease</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.8</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_LesseeOperatingAndFinancingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Undiscounted Future Lease Payments for Operating and Finance Leases</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The undiscounted future lease payments for operating and finance leases as of December&#160;31, 2020, were as follows (in thousands): </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Fiscal Year</font></p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Leases</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Financing</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Leases</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,691</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">712</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,581</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">459</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,659</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">245</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,732</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,814</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,925</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total minimum lease payments</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,402</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,416</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less amounts representing interest or imputed interest</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,702</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(123</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of lease liabilities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,700</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,293</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_LesseeOperatingAndFinancingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating and financing lease liability maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_LesseeOperatingAndFinancingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of weighted average remaining lease terms and discount rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_SupplementalCashFlowInformationRelatingToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental cash flow information relating to leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_SupplementalCashFlowInformationRelatingToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760737589544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consist of the following as of December 31, 2020 and 2019 (in thousands): </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,821</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,617</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll and payroll-related</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,918</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,256</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional fees</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,585</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">606</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,330</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,568</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760663743384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of stock option activity under the 2020 Stock Option and Grant Plan during the year ended December 31, 2020 is as follows (in thousands except share and per share data): </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Strike</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price per</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,945,297</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.03</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.93</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,798</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,213,204</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.22</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(78,852</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.06</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(246,937</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.55</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,832,712</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.17</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.08</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">314,001</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at December 31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,580,924</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.38</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.76</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92,674</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Equity-Based Compensation Expense</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total equity-based compensation expense recorded as research and development and general and administrative expenses for employees, directors, and non-employees during the years ended December 31, 2020 and 2019 is as follows (in thousands): </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="8" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years ending December 31,</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,305</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">688</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,885</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">508</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total equity-based compensation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,190</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,196</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Weighted-Average Assumptions</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average assumptions that the Company used in Black-Scholes option pricing model to determine the grant date fair value of stock options granted to employees and non-employees for the years ended December 31, 2020 and 2019: </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="8" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ending December 31,</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.3%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.09</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.49</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.5</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.83</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock', window );">Summary of Restricted Stock Activity</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has granted shares of restricted common stock with service-based and performance-based vesting conditions. A summary of restricted stock activity under the 2018 Plan during the year ended December 31, 2020 is as follows: </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Units</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">per Share</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at December 31, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">232,434</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.60</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(102,651</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.60</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,679</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.60</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at December 31, 2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,104</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.60</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Equity-Based Compensation Expense</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table outlines our equity-based compensation expense for stock options for the years ended December 31, 2020 and 2019:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="8" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ending December 31,</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,084</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">380</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,864</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">212</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total equity-based compensation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,948</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">592</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in restricted stock units (RSUs).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760652334648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Rate Reconciliation of U.S. Statutory Income Tax Rate to Company's Effective Tax Rate</a></td>
<td class="text">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.53%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The rate reconciliation of the U.S. statutory income tax rate to the Company&#8217;s effective tax rate for the years ended December&#160;31, 2020 and 2019 are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax effect at statutory rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State taxes</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.8</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.9</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.6</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent differences</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal research and development credits</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.6</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.7</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28.8</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29.4</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Significant Components of Net Deferred Income Taxes</a></td>
<td class="text">Significant components of the Company&#8217;s net deferred income taxes are as&#160;follows (in thousands):
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160; </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Deferred Tax Assets:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal net operating loss carryforwards</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,621</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,011</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State net operating loss carryforwards</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,866</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,319</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credit carryforwards</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,757</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,637</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liabilities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,563</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,286</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,313</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accruals and reserves, stock and other</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,589</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">525</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,709</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,778</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34,075</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,949</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,634</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,829</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed and intangible assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,506</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(754</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,128</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,075</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax asset</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760746709784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Summary of Basic and Diluted Loss Per Share</a></td>
<td class="text">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding (in thousands, except for share and per share data):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="8" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,593</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41,246</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deemed dividend from exchange of convertible</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; preferred stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,050</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(54,643</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41,246</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average common shares outstanding, basic</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; and diluted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,349,582</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,698,522</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share, basic and diluted</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.15</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24.28</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Diluted Net Loss Per Share Attributable to Common Stockholders Anti-Diluted Effect</a></td>
<td class="text">The Company excluded the following from the computation of diluted net loss per share attributable to common stockholders at December&#160;31, 2020 and 2019 because including them would have had an anti-dilutive effect:
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="8" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible Preferred Stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,325,780</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested Restricted Stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,104</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">232,434</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase Common Stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,580,924</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,945,298</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,691,028</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,503,512</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760658061144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 25, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Aug. 20, 2020</div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Description Of Business And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 128,765<span></span>
</td>
<td class="nump">$ 76,456<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAndCash', window );">Cash, cash equivalents and marketable securities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 458,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On August 20, 2020, the Board approved a 1-for-1.5949 reverse stock split of the Company&#8217;s issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for each of the Company&#8217;s outstanding series of preferred stock.  All share and per share amounts in the accompanying consolidated financial statements and notes thereto have been retroactively adjusted for all periods presented to give effect to this reverse stock split, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Description Of Business And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares issued | shares</a></td>
<td class="nump">9,987,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock per share | $ / shares</a></td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_ProceedsFromIssuanceInitialPublicOfferingGross', window );">Gross proceeds from issuance initial public offering | $</a></td>
<td class="nump">$ 199,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwriters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Description Of Business And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares issued | shares</a></td>
<td class="nump">1,302,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Vertex Pharmaceuticals Incorporated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Description Of Business And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares issued | shares</a></td>
<td class="nump">676,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock per share | $ / shares</a></td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of business and summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_ProceedsFromIssuanceInitialPublicOfferingGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance initial public offering gross.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_ProceedsFromIssuanceInitialPublicOfferingGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of investments and unrestricted cash as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=kymr_VertexPharmaceuticalsIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=kymr_VertexPharmaceuticalsIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760656633432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Leases original term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment losses on long-lived assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201904Member', window );">ASU 2019-04</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Accounting standards update, adoption date</a></td>
<td class="text">Jan.  01,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle, accounting standards update, immaterial effect</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201815Member', window );">ASU 2018-15</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Accounting standards update, adoption date</a></td>
<td class="text">Jan.  01,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle, accounting standards update, immaterial effect</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201813Member', window );">ASU 2018-13</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Accounting standards update, adoption date</a></td>
<td class="text">Jan.  01,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle, accounting standards update, immaterial effect</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_MarketableSecuritiesRemainingMaturityPeriod', window );">Marketable securities, remaining maturity period</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_MarketableSecuritiesRemainingMaturityPeriodClassifiedAsNonCurrent', window );">Marketable securities, remaining maturity period classified as non-current</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_MarketableSecuritiesRemainingMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Marketable securities, remaining maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_MarketableSecuritiesRemainingMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_MarketableSecuritiesRemainingMaturityPeriodClassifiedAsNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Marketable securities, remaining maturity period classified as non-current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_MarketableSecuritiesRemainingMaturityPeriodClassifiedAsNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121329987&amp;loc=SL120154346-209984<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120320025-210437<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120320025-210437<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120240428&amp;loc=SL120254526-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120254519-210437<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date accounting standards update was adopted, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121329987&amp;loc=SL120154346-209984<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120320025-210437<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120320025-210437<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120254519-210437<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120240428&amp;loc=SL120254526-165497<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=112272810&amp;loc=d3e31010-122693<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011391&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201904Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201904Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201815Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201815Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201813Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201813Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760746697448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Estimated Useful Life of Related Asset (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=kymr_LabEquipmentMember', window );">Lab Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of related asset</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furnitures and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of related asset</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of related asset</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of related asset</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Estimated useful life of related asset</a></td>
<td class="text">Shorter of life of lease or remaining lease term<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68071081&amp;loc=d3e1205-110223<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=kymr_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=kymr_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760657553240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Assets Measured at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 427,729<span></span>
</td>
<td class="nump">$ 15,942<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,942<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_RestrictedCashFairValue', window );">Restricted cash</a></td>
<td class="nump">1,589<span></span>
</td>
<td class="nump">1,774<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">459,760<span></span>
</td>
<td class="nump">17,716<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Money Market Fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">19,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Corporate Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">10,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">72,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">29,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | US Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">192,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">132,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_RestrictedCashFairValue', window );">Restricted cash</a></td>
<td class="nump">1,589<span></span>
</td>
<td class="nump">1,774<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">346,396<span></span>
</td>
<td class="nump">$ 17,716<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 1 | Money Market Fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">19,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 1 | US Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">192,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">132,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">113,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 2 | Corporate Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">10,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">72,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">$ 29,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_RestrictedCashFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted cash fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_RestrictedCashFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments in debt and equity securities which are categorized neither as held-to-maturity nor trading and which are intended to be sold or mature more than one year from the balance sheet date or operating cycle, if longer. Such securities are reported at fair value; unrealized gains (losses) related to Available-for-sale Securities are excluded from earnings and reported in a separate component of shareholders' equity (other comprehensive income), unless the Available-for-sale security is designated as a hedge or is determined to have had an other than temporary decline in fair value below its amortized cost basis. All or a portion of the unrealized holding gain (loss) of an Available-for-sale security that is designated as being hedged in a fair value hedge is recognized in earnings during the period of the hedge, as are other than temporary declines in fair value below the cost basis for investments in equity securities and debt securities that an entity intends to sell or it is more likely than not that it will be required to sell before the recovery of its amortized cost basis. Other than temporary declines in fair value below the cost basis for debt securities categorized as Available-for-sale that an entity does not intend to sell and for which it is not more likely than not that the entity will be required to sell before the recovery of its amortized cost basis are bifurcated into credit losses and losses related to all other factors. Other than temporary declines in fair value below cost basis related to credit losses are recognized in earnings, and losses related to all other factors are recognized in other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760747127720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount', window );">Fair value, assets, level 1 to level 2 transfers, amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount', window );">Fair value, assets, level 2 to level 1 transfers, amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_FairValueAssetsLevel1ToLevel3TransfersAmount', window );">Fair value assets, level 1 to level 3 transfers, amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_FairValueAssetsLevel3ToLevel1TransfersAmount', window );">Fair value assets, level 3 to level 1 transfers, amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_FairValueAssetsLevel3ToLevel2TransfersAmount', window );">Fair value assets, level 3 to level 2 transfers, amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_FairValueAssetsLevel2ToLevel3TransfersAmount', window );">Fair value assets, level 2 to level 3 transfers, amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_FairValueAssetsLevel1ToLevel3TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value assets level 1 to level 3 transfers amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_FairValueAssetsLevel1ToLevel3TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_FairValueAssetsLevel2ToLevel3TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value assets level 2 to Level 3 transfers amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_FairValueAssetsLevel2ToLevel3TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_FairValueAssetsLevel3ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value assets level 3 to level 1 transfers amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_FairValueAssetsLevel3ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_FairValueAssetsLevel3ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value assets level 3 to level 2 transfers amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_FairValueAssetsLevel3ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760657638936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Summary of Available-for-Sale Debt Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 427,863<span></span>
</td>
<td class="nump">$ 15,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(134)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">427,729<span></span>
</td>
<td class="nump">15,942<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">324,917<span></span>
</td>
<td class="nump">15,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(53)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">324,864<span></span>
</td>
<td class="nump">$ 15,942<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">102,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(81)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 102,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760657486392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Security</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>Security</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Number of available-for-sale debt securities, continuous unrealized loss position for less than 12 months</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Aggregate fair value of available-for-sale debt securities, continuous unrealized loss position for less than 12 months | $</a></td>
<td class="nump">$ 392,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_DebtSecuritiesAvailableForSaleContractualMaturityOfLessThan12MonthsNumberOfSecurities', window );">Number of available-for-sale debt securities, contractual maturity of less than 12 months</a></td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_FairValueOfAvailableForSaleDebtSecuritiesContractualMaturityOfLessThanTwelveMonths', window );">Fair value of available-for-sale debt securities, contractual maturity of less than 12 months | $</a></td>
<td class="nump">$ 295,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_DebtSecuritiesAvailableForSaleContractualMaturityOf12MonthsOrLongerNumberOfSecurities', window );">Number of available-for-sale debt securities, contractual maturity of greater than 12 months</a></td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Fair value of available-for-sale debt securities, contractual maturity of greater than 12 months | $</a></td>
<td class="nump">$ 162,531,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_NumberOfMarketableSecuritiesSold', window );">Number of marketable securities sold</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableforsaleSecuritiesSoldAtPar', window );">Sales of marketable securities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_DebtSecuritiesAvailableForSaleDeclineInMarketValueForUnrealizedLossPositionNumberOfSecurities', window );">Number of securities decline in market value for in an unrealized loss position</a></td>
<td class="nump">65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_DebtSecuritiesAvailableForSaleContractualMaturityOf12MonthsOrLongerNumberOfSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt securities, available-for-sale, contractual maturity of 12 months or longer, number of securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_DebtSecuritiesAvailableForSaleContractualMaturityOf12MonthsOrLongerNumberOfSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_DebtSecuritiesAvailableForSaleContractualMaturityOfLessThan12MonthsNumberOfSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt securities, available-for-sale, contractual maturity of less than 12 months, number of securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_DebtSecuritiesAvailableForSaleContractualMaturityOfLessThan12MonthsNumberOfSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_DebtSecuritiesAvailableForSaleDeclineInMarketValueForUnrealizedLossPositionNumberOfSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt securities available for sale decline in market value for unrealized loss position number of securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_DebtSecuritiesAvailableForSaleDeclineInMarketValueForUnrealizedLossPositionNumberOfSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_FairValueOfAvailableForSaleDebtSecuritiesContractualMaturityOfLessThanTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of available-for-sale debt securities contractual maturity of less than twelve months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_FairValueOfAvailableForSaleDebtSecuritiesContractualMaturityOfLessThanTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_NumberOfMarketableSecuritiesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of marketable securities sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_NumberOfMarketableSecuritiesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableforsaleSecuritiesSoldAtPar">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with interest rate reset through auction process, sold at par value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableforsaleSecuritiesSoldAtPar</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922890-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760653235640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 20, 2020</div></th>
<th class="th">
<div>Jul. 07, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 09, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Nov. 01, 2018</div></th>
<th class="th">
<div>Oct. 31, 2017 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration Revenue&#8212;from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,034,000<span></span>
</td>
<td class="nump">$ 2,934,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split</a></td>
<td class="nump">1.5949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,105,000<span></span>
</td>
<td class="nump">37,158,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=kymr_SanofiCollaborationArrangementMember', window );">Sanofi Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_UpfrontPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_CollaborationAgreementTransactionPrice', window );">Collaboration agreement transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized recorded in deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Unsatisfied performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_CostReimbursementReceivable', window );">Cost reimbursement receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_MilestoneReceivable', window );">Milestone receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_RoyaltyReceivable', window );">Royalty receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnbilledContractsReceivable', window );">Unbilled accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BilledContractReceivables', window );">Billed accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_RemainingResearchTermOfCollaboration', window );">Remaining research term of collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=kymr_SanofiCollaborationArrangementMember', window );">Sanofi Agreement | Collaboration Target 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_CollaborationAgreementTransactionPrice', window );">Collaboration agreement transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized recorded in deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=kymr_SanofiCollaborationArrangementMember', window );">Sanofi Agreement | Collaboration Target 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_CollaborationAgreementTransactionPrice', window );">Collaboration agreement transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized recorded in deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=kymr_SanofiCollaborationArrangementMember', window );">Sanofi Agreement | Minimum | IRAK4 Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_DevelopmentMilestonePayments', window );">Development milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_CommercialMilestonePayments', window );">Commercial milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=kymr_SanofiCollaborationArrangementMember', window );">Sanofi Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_DevelopmentMilestonePayments', window );">Development milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,480,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_CommercialMilestonePayments', window );">Commercial milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=kymr_VertexAgreementMember', window );">Vertex Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized recorded in deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Unsatisfied performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,700,000<span></span>
</td>
<td class="nump">53,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_InitialResearchTermOfCollaboration', window );">Initial research term of collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_ExtendedResearchTermOfCollaboration', window );">Extended research term of collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration Revenue&#8212;from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,200,000<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=kymr_VertexAgreementMember', window );">Vertex Agreement | Series B-1 Convertible Preferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_CollaborationAgreementTransactionPrice', window );">Collaboration agreement transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_NonRefundableUpfrontPaymentReceived', window );">Non refundable upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares, Shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,059,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_PreferredStockIssuancePremium', window );">Preferred stock premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=kymr_VertexAgreementMember', window );">Vertex Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_PotentialReceivableMilestonePayments', window );">Eligible to receive payments including development, regulatory and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 170,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue remaining research term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=kymr_CompoundCollaborationAgreementMember', window );">Compound Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_WrittenNoticePeriodToTerminateCollaborationAgreement', window );">Written notice period to terminate collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=kymr_CompoundCollaborationAgreementMember', window );">Compound Collaboration | Series A Preferred Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares, Shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">886,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based compensation vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_TemporaryEquityStockSharesVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement', window );">Vesting of Series A Preferred Stock in connection with collaboration arrangement (Note 5), Shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,183<span></span>
</td>
<td class="nump">221,579<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_CollaborationAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration agreement transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_CollaborationAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_CommercialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commercial milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_CommercialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_CostReimbursementReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost reimbursement receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_CostReimbursementReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_DevelopmentMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_DevelopmentMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_ExtendedResearchTermOfCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Extended research term of collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_ExtendedResearchTermOfCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_InitialResearchTermOfCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial research term of collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_InitialResearchTermOfCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_MilestoneReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_MilestoneReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_NonRefundableUpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non refundable upfront payment received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_NonRefundableUpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_PotentialReceivableMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential receivable milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_PotentialReceivableMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_PreferredStockIssuancePremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock issuance premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_PreferredStockIssuancePremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_RemainingResearchTermOfCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining research term of collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_RemainingResearchTermOfCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_RoyaltyReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_RoyaltyReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_TemporaryEquityStockSharesVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock shares vesting of series A preferred stock in connection with collaboration arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_TemporaryEquityStockSharesVestingOfSeriesAPreferredStockInConnectionWithCollaborationArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_WrittenNoticePeriodToTerminateCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Written notice period to terminate collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_WrittenNoticePeriodToTerminateCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BilledContractReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts due for billed services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the Company and, at a minimum, one other party. An example would be amounts billed to customers under contracts or programs but not paid as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BilledContractReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnbilledContractsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118261985&amp;loc=d3e55302-109406<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(c)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnbilledContractsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=kymr_SanofiCollaborationArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=kymr_SanofiCollaborationArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=kymr_CollaborationTargetOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=kymr_CollaborationTargetOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=kymr_CollaborationTargetTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=kymr_CollaborationTargetTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=kymr_IRAK4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=kymr_IRAK4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=kymr_VertexAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=kymr_VertexAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=kymr_SeriesB1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=kymr_SeriesB1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=kymr_CompoundCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=kymr_CompoundCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=kymr_SeriesAPreferredUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=kymr_SeriesAPreferredUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760658739976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations - Change in Accounts Receivable, Contract Asset and Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_ContractWithCustomerAssetNetAdditions', window );">Accounts receivable and contract assets, Additions</a></td>
<td class="nump">$ 152,010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_ContractWithCustomerAssetNetDeductions', window );">Accounts receivable and contract assets, Deductions</a></td>
<td class="num">(150,577)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss', window );">Accounts receivable and contract assets, Ending balance</a></td>
<td class="nump">1,433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract Liabilities, Beginning balance</a></td>
<td class="nump">52,991<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_ContractWithCustomerLiabilityAdditions', window );">Contract Liabilities, Additions</a></td>
<td class="nump">151,433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_ContractWithCustomerLiabilityDeductions', window );">Contract Liabilities, Deductions</a></td>
<td class="num">(34,034)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract Liabilities, Ending balance</a></td>
<td class="nump">170,390<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=kymr_BilledReceivablesSanofiMember', window );">Billed receivables - Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_ContractWithCustomerAssetNetAdditions', window );">Accounts receivable and contract assets, Additions</a></td>
<td class="nump">150,577<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_ContractWithCustomerAssetNetDeductions', window );">Accounts receivable and contract assets, Deductions</a></td>
<td class="num">(150,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss', window );">Accounts receivable and contract assets, Ending balance</a></td>
<td class="nump">577<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=kymr_UnbilledReceivablesSanofiMember', window );">Unbilled receivables - Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_ContractWithCustomerAssetNetAdditions', window );">Accounts receivable and contract assets, Additions</a></td>
<td class="nump">1,433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_ContractWithCustomerAssetNetDeductions', window );">Accounts receivable and contract assets, Deductions</a></td>
<td class="num">(577)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss', window );">Accounts receivable and contract assets, Ending balance</a></td>
<td class="nump">856<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=kymr_DeferredRevenueVertexMember', window );">Deferred Revenue - Vertex</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract Liabilities, Beginning balance</a></td>
<td class="nump">52,991<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_ContractWithCustomerLiabilityDeductions', window );">Contract Liabilities, Deductions</a></td>
<td class="num">(15,243)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract Liabilities, Ending balance</a></td>
<td class="nump">37,748<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=kymr_DeferredRevenueSanofiMember', window );">Deferred Revenue - Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_ContractWithCustomerLiabilityAdditions', window );">Contract Liabilities, Additions</a></td>
<td class="nump">151,433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_ContractWithCustomerLiabilityDeductions', window );">Contract Liabilities, Deductions</a></td>
<td class="num">(18,791)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract Liabilities, Ending balance</a></td>
<td class="nump">$ 132,642<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_ContractWithCustomerAssetNetAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with customer asset net additions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_ContractWithCustomerAssetNetAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_ContractWithCustomerAssetNetDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with customer asset net deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_ContractWithCustomerAssetNetDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_ContractWithCustomerLiabilityAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with customer liability additions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_ContractWithCustomerLiabilityAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_ContractWithCustomerLiabilityDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with customer liability deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_ContractWithCustomerLiabilityDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right to consideration is unconditional.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130534-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=kymr_BilledReceivablesSanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=kymr_BilledReceivablesSanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=kymr_UnbilledReceivablesSanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=kymr_UnbilledReceivablesSanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=kymr_DeferredRevenueVertexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=kymr_DeferredRevenueVertexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=kymr_DeferredRevenueSanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=kymr_DeferredRevenueSanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760656423080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Summary of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 12,988<span></span>
</td>
<td class="nump">$ 4,843<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(2,147)<span></span>
</td>
<td class="num">(1,049)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">10,841<span></span>
</td>
<td class="nump">3,794<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=kymr_LabAndOfficeEquipmentMember', window );">Lab and Office Equipment Under and Financing Right of Use Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">2,771<span></span>
</td>
<td class="nump">2,751<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=kymr_LabEquipmentMember', window );">Lab Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">1,636<span></span>
</td>
<td class="nump">919<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture &amp; Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">861<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">7,599<span></span>
</td>
<td class="nump">545<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=kymr_AssetsNotYetInServiceMember', window );">Assets Not Yet in Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">$ 453<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=kymr_LabAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=kymr_LabAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=kymr_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=kymr_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=kymr_AssetsNotYetInServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=kymr_AssetsNotYetInServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760660854888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment right of use assets under financing leases with cost basis</a></td>
<td class="nump">12,988<span></span>
</td>
<td class="nump">4,843<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization expense related to right-of-use assets</a></td>
<td class="nump">716<span></span>
</td>
<td class="nump">385<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=kymr_LabAndOfficeEquipmentMember', window );">Lab and Office Equipment Under and Financing Right of Use Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment right of use assets under financing leases with cost basis</a></td>
<td class="nump">2,771<span></span>
</td>
<td class="nump">2,751<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_AccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_AccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_AccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=kymr_LabAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=kymr_LabAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760657878808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2019 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Apr. 30, 2019 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2018 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=kymr_CambridgeMassachusettsMember', window );">Cambridge, Massachusetts | Noncancelable Facility Lease Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of office space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,836<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLeasehold', window );">Reduction of right-of-use asset and liability due to lease modification</a></td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_LeaseTerminationDate', window );">Lease termination date</a></td>
<td class="text">Jul. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=kymr_CambridgeMassachusettsMember', window );">Cambridge, Massachusetts | Noncancelable Facility Lease Agreement | Other Assets | Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=kymr_CambridgeMassachusettsMember', window );">Cambridge, Massachusetts | Noncancelable Facility Lease Agreement | Other Current Assets | Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=kymr_CambridgeMassachusettsMember', window );">Cambridge, Massachusetts | Facility Sublease Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of office space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_LeaseCommencementDate', window );">Lease commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 24,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=kymr_WatertownMassachusettsMember', window );">Watertown, Massachusetts | Noncancelable Facility Lease Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of office space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_LeaseTerm', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">120 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 31,  2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_LeaseAdditionalTerm', window );">Lease additional term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_TenantIncentiveAllowanceReceivable', window );">Tenant incentive allowance receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=kymr_WatertownMassachusettsMember', window );">Watertown, Massachusetts | Noncancelable Facility Lease Agreement | Other Assets | Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_LeaseAdditionalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease additional term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_LeaseAdditionalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_LeaseCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease commencement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_LeaseCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_LeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_LeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_LeaseTerminationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease termination date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_LeaseTerminationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_TenantIncentiveAllowanceReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tenant incentive allowance receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_TenantIncentiveAllowanceReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLeasehold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The adjustment to reduce the value of existing agreements that specify the lessee's rights to use the leased property. This expense is charged when the estimates of future profits generated by the leased property are reduced.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLeasehold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=kymr_CambridgeMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=kymr_CambridgeMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=kymr_NoncancelableFacilityLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=kymr_NoncancelableFacilityLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=kymr_FacilitySubleaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=kymr_FacilitySubleaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=kymr_WatertownMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=kymr_WatertownMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760658942792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 2,719<span></span>
</td>
<td class="nump">$ 1,597<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization expense related to right-of-use assets</a></td>
<td class="nump">716<span></span>
</td>
<td class="nump">385<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest expense for financing lease liabilities</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="nump">621<span></span>
</td>
<td class="nump">340<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease costs</a></td>
<td class="nump">$ 4,177<span></span>
</td>
<td class="nump">$ 2,368<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760660151816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Supplemental Cash Flow Information Relating to Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_OperatingLeasePaymentsProceeds', window );">Operating cash flows used in (provided by) operating leases</a></td>
<td class="num">$ (3,024)<span></span>
</td>
<td class="nump">$ 635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash flows used in finance leases</a></td>
<td class="nump">587<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash flows used in finance leases</a></td>
<td class="nump">$ 121<span></span>
</td>
<td class="nump">$ 385<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_OperatingLeasePaymentsProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease payments (proceeds).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_OperatingLeasePaymentsProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760660528328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Weighted Average Remaining Lease Terms and Discount Rates (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease, remaining lease term</a></td>
<td class="text">9 years 3 months 18 days<span></span>
</td>
<td class="text">9 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Financing lease, remaining lease term</a></td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">3 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease, discount rate</a></td>
<td class="nump">10.50%<span></span>
</td>
<td class="nump">10.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Financing lease, discount rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">7.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760656421272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Undiscounted Future Lease Payments for Operating and Finance Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 2,691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">2,581<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">2,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">2,732<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2025</a></td>
<td class="nump">2,814<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">12,925<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">26,402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less amounts representing interest or imputed interest</a></td>
<td class="num">(9,702)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">16,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Financing Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">712<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">459<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">245<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">1,416<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less amounts representing interest or imputed interest</a></td>
<td class="num">(123)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 1,293<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760659746120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_AccruedResearchAndDevelopmentExpensesCurrent', window );">Research and development expenses</a></td>
<td class="nump">$ 5,821<span></span>
</td>
<td class="nump">$ 2,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Payroll and payroll-related</a></td>
<td class="nump">2,918<span></span>
</td>
<td class="nump">1,256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">1,585<span></span>
</td>
<td class="nump">606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 10,330<span></span>
</td>
<td class="nump">$ 4,568<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_AccruedResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_AccruedResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760660233032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Commitments and Contingencies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember', window );">Indemnified Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Liabilities accrued</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760652956248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 21, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Aug. 20, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDividendsAdjustment', window );">Deemed dividend from exchange of convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of stock, shares issued and outstanding</a></td>
<td class="nump">50,439,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible Preferred Stock, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,483,788<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par or stated value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible Preferred Stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of preferred Stock converted to common stock</a></td>
<td class="nump">31,625,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible Preferred Stock, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=kymr_SeriesSeedConvertiblePreferredStockMember', window );">Series Seed Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible Preferred Stock, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par or stated value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible Preferred Stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible Preferred Stock, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=kymr_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible Preferred Stock, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,886,305<span></span>
</td>
<td class="nump">14,886,305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par or stated value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible Preferred Stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,886,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible Preferred Stock, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,720,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=kymr_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible Preferred Stock, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,009,848<span></span>
</td>
<td class="nump">16,009,845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par or stated value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.06<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible Preferred Stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,182,265<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,827,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible Preferred Stock, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,827,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=kymr_SeriesB1ConvertiblePreferredStockMember', window );">Series B-1 Convertible Preferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible Preferred Stock, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,059,695<span></span>
</td>
<td class="nump">3,059,695<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par or stated value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible Preferred Stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,059,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="nump">$ 14,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible Preferred Stock, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,059,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=kymr_SeriesCConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible Preferred Stock, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,527,943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible Preferred Stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,527,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Shares issued upon exchange of Series A convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,988,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDividendsAdjustment', window );">Deemed dividend from exchange of convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_AdjustmentsToAdditionalPaidInCapitalRelatedToTemporaryEquityDeemedDividend', window );">Reduction of additional paid-in-capital related to temporary equity deemed dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_IncreaseInAccumulatedDeficitRelatedToTemporaryEquityDeemedDividend', window );">Increase in accumulated deficit related to temporary equity deemed dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=kymr_SeriesCConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock | Series C SPA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par or stated value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.5366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible Preferred Stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,539,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_AdjustmentsToAdditionalPaidInCapitalRelatedToTemporaryEquityDeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital related to temporary equity deemed dividend.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_AdjustmentsToAdditionalPaidInCapitalRelatedToTemporaryEquityDeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_IncreaseInAccumulatedDeficitRelatedToTemporaryEquityDeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase in accumulated deficit related to temporary equity deemed dividend.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_IncreaseInAccumulatedDeficitRelatedToTemporaryEquityDeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDividendsAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accretion of temporary equity during the period due to cash, stock, and in-kind dividends. This item is an adjustment to net income necessary to derive net income apportioned to common stockholders and is to be distinguished from Temporary Equity, Accretion of Dividends (Temporary Equity, Accretion of Dividends).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDividendsAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=kymr_SeriesSeedConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=kymr_SeriesSeedConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=kymr_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=kymr_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=kymr_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=kymr_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=kymr_SeriesB1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=kymr_SeriesB1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=kymr_SeriesCConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=kymr_SeriesCConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=kymr_SeriesCPreferredStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=kymr_SeriesCPreferredStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760652636040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Aug. 20, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 5,190<span></span>
</td>
<td class="nump">$ 1,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">2,305<span></span>
</td>
<td class="nump">688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">2,885<span></span>
</td>
<td class="nump">508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of stock options exercised</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of options granted</a></td>
<td class="nump">$ 8.35<span></span>
</td>
<td class="nump">$ 1.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation expense</a></td>
<td class="nump">$ 25,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost, recognition period</a></td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of stock options vested</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">4,948<span></span>
</td>
<td class="nump">592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">2,084<span></span>
</td>
<td class="nump">380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2,864<span></span>
</td>
<td class="nump">212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost, recognition period</a></td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized stock-based compensation expense</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of restricted stock vested</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | General and Administrative Expense | Modification of Employee's Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=kymr_TwoThousandTwentyStockOptionAndIncentivePlanMember', window );">2020 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance under plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,457,370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Maximum number of shares to be issued, percentage</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares remaining available for future grants</a></td>
<td class="nump">3,148,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=kymr_TwoThousandTwentyEmployeeStockPurchasePlanMember', window );">2020 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance under plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">445,653<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares remaining available for future grants</a></td>
<td class="nump">445,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Share-based compensation, description</a></td>
<td class="text">The 2020 ESPP provides that the number of shares reserved and available for issuance will automatically increase on January 1, 2021 and each January 1 thereafter through January 1, 2030, by the least of (i) 438,898 shares of common stock, (ii) 1% of the Company&#8217;s outstanding number of shares of common stock on the immediately preceding December 31 or (iii) such lesser number of shares of common stock as determined by the administrator of the 2020 ESPP.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=kymr_TwoThousandTwentyEmployeeStockPurchasePlanMember', window );">2020 ESPP | Lesser of Potential Outcome 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized</a></td>
<td class="nump">438,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=kymr_TwoThousandTwentyEmployeeStockPurchasePlanMember', window );">2020 ESPP | Lesser of Potential Outcome 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Maximum number of shares to be issued, percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=kymr_TwoThousandEighteenStockOptionAndGrantPlanMember', window );">2018 Plan | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=kymr_TwoThousandTwentyStockOptionAndIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=kymr_TwoThousandTwentyStockOptionAndIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=kymr_TwoThousandTwentyEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=kymr_TwoThousandTwentyEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_ScenarioPotentialOutcomeAxis=kymr_LesserOfPotentialOutcomeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_ScenarioPotentialOutcomeAxis=kymr_LesserOfPotentialOutcomeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_ScenarioPotentialOutcomeAxis=kymr_LesserOfPotentialOutcomeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_ScenarioPotentialOutcomeAxis=kymr_LesserOfPotentialOutcomeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=kymr_TwoThousandEighteenStockOptionAndGrantPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=kymr_TwoThousandEighteenStockOptionAndGrantPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760657855912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Summary of Stock Option Activity (Details) - 2020 Plan - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period</a></td>
<td class="nump">2,945,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">3,213,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="num">(78,852)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="num">(246,937)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period</a></td>
<td class="nump">5,832,712<span></span>
</td>
<td class="nump">2,945,297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at December 31, 2020</a></td>
<td class="nump">1,580,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Strike Price Per Option</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period</a></td>
<td class="nump">$ 2.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">13.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
<td class="nump">2.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited</a></td>
<td class="nump">2.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period</a></td>
<td class="nump">8.17<span></span>
</td>
<td class="nump">$ 2.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at December 31, 2020</a></td>
<td class="nump">$ 3.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Term (in years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">9 years 29 days<span></span>
</td>
<td class="text">8 years 11 months 4 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable at December 31, 2020</a></td>
<td class="text">8 years 9 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at beginning of period</a></td>
<td class="nump">$ 7,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at end of period</a></td>
<td class="nump">314,001<span></span>
</td>
<td class="nump">$ 7,798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable at December 31, 2020</a></td>
<td class="nump">$ 92,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award aggregate intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=kymr_TwoThousandAndTwentyStockOptionAndGrantPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=kymr_TwoThousandAndTwentyStockOptionAndGrantPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760657706136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Summary of Equity-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity-based compensation</a></td>
<td class="nump">$ 5,190<span></span>
</td>
<td class="nump">$ 1,196<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity-based compensation</a></td>
<td class="nump">2,305<span></span>
</td>
<td class="nump">688<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity-based compensation</a></td>
<td class="nump">2,885<span></span>
</td>
<td class="nump">508<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity-based compensation</a></td>
<td class="nump">4,948<span></span>
</td>
<td class="nump">592<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity-based compensation</a></td>
<td class="nump">2,084<span></span>
</td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity-based compensation</a></td>
<td class="nump">$ 2,864<span></span>
</td>
<td class="nump">$ 212<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760660527464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Summary of Weighted-Average Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 1 month 2 days<span></span>
</td>
<td class="text">6 years 5 months 26 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">71.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">1.83%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760657726696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Summary of Restricted Stock Activity (Details) - Restricted Stock - 2018 Plan - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Units Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at beginning of period</a></td>
<td class="nump">232,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested</a></td>
<td class="num">(102,651)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited</a></td>
<td class="num">(19,679)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at end of period</a></td>
<td class="nump">110,104<span></span>
</td>
<td class="nump">232,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Grant Date Fair Value per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested at beginning of period</a></td>
<td class="nump">$ 1.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested</a></td>
<td class="nump">1.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited</a></td>
<td class="nump">1.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested at end of period</a></td>
<td class="nump">$ 1.60<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=kymr_TwoThousandEighteenStockOptionAndGrantPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=kymr_TwoThousandEighteenStockOptionAndGrantPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760660304008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Rent expenses</a></td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760656512376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Valuation allowance</a></td>
<td class="nump">34,100,000<span></span>
</td>
<td class="nump">20,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Increase of valuation allowance</a></td>
<td class="nump">13,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_FederalNetOperatingLossCarryoversNotSubjectToExpiration', window );">Federal net operating loss carryovers, not subject to expiration</a></td>
<td class="nump">64,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Reserves for uncertain tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Estimated interest or penalties recognized on uncertain tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember', window );">Earliest Tax Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open tax year subject to examination</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember', window );">Latest Tax Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open tax year subject to examination</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">$ 74,400,000<span></span>
</td>
<td class="nump">71,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_ResearchAndDevelopmentCreditCarryforwards', window );">Research and development credit carryforwards</a></td>
<td class="nump">2,700,000<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">61,200,000<span></span>
</td>
<td class="nump">68,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_ResearchAndDevelopmentCreditCarryforwards', window );">Research and development credit carryforwards</a></td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=kymr_FederalAndStateMember', window );">Federal and State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_NetOperatingLossBeginToExpireYear', window );">NOLs begin to expire year</a></td>
<td class="text">2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_FederalNetOperatingLossCarryoversNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Federal net operating loss carryovers, not subject to expiration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_FederalNetOperatingLossCarryoversNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_NetOperatingLossBeginToExpireYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>NOLs begin to expire year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_NetOperatingLossBeginToExpireYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_ResearchAndDevelopmentCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_ResearchAndDevelopmentCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in CCYY format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=kymr_FederalAndStateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=kymr_FederalAndStateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760652317192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Rate Reconciliation of U.S. Statutory Income Tax Rate to Company's Effective Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax effect at statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="nump">5.80%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="num">(0.90%)<span></span>
</td>
<td class="num">(0.60%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_EffectiveIncomeTaxRateReconciliationPermanentDifferences', window );">Permanent differences</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Federal research and development credits</a></td>
<td class="nump">3.60%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.70%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(28.80%)<span></span>
</td>
<td class="num">(29.40%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_EffectiveIncomeTaxRateReconciliationPermanentDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation permanent differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_EffectiveIncomeTaxRateReconciliationPermanentDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760657706344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Significant Components of Net Deferred Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract', window );"><strong>Deferred Tax Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal net operating loss carryforwards</a></td>
<td class="nump">$ 15,621<span></span>
</td>
<td class="nump">$ 15,011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State net operating loss carryforwards</a></td>
<td class="nump">3,866<span></span>
</td>
<td class="nump">4,319<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforwards</a></td>
<td class="nump">3,757<span></span>
</td>
<td class="nump">1,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_DeferredTaxAssetsLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">4,563<span></span>
</td>
<td class="nump">5,286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">10,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpense', window );">Accruals and reserves, stock and other</a></td>
<td class="nump">1,589<span></span>
</td>
<td class="nump">525<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">39,709<span></span>
</td>
<td class="nump">26,778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(34,075)<span></span>
</td>
<td class="num">(20,949)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">5,634<span></span>
</td>
<td class="nump">5,829<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets', window );">Fixed and intangible assets</a></td>
<td class="num">(1,506)<span></span>
</td>
<td class="num">(754)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kymr_DeferredTaxLiabilitiesRightOfUseAssets', window );">Right-of-use assets</a></td>
<td class="num">$ (4,128)<span></span>
</td>
<td class="num">$ (5,075)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_DeferredTaxAssetsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_DeferredTaxAssetsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kymr_DeferredTaxLiabilitiesRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kymr_DeferredTaxLiabilitiesRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kymr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowances, of deferred tax asset attributable to deductible differences from reserves and accruals, compensation and benefit costs, and other provisions, reserves, and allowances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760761051288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Summary of Basic and Diluted Loss Per Share (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (45,593)<span></span>
</td>
<td class="num">$ (41,246)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDividendsAdjustment', window );">Deemed dividend from exchange of convertible preferred stock</a></td>
<td class="num">(9,050)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (54,643)<span></span>
</td>
<td class="num">$ (41,246)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares outstanding, basic and diluted</a></td>
<td class="nump">17,349,582<span></span>
</td>
<td class="nump">1,698,522<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (3.15)<span></span>
</td>
<td class="num">$ (24.28)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDividendsAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accretion of temporary equity during the period due to cash, stock, and in-kind dividends. This item is an adjustment to net income necessary to derive net income apportioned to common stockholders and is to be distinguished from Temporary Equity, Accretion of Dividends (Temporary Equity, Accretion of Dividends).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDividendsAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139760657473816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Schedule of Diluted Net Loss Per Share Attributable to Common Stockholders Anti-Diluted Effect (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive stock</a></td>
<td class="nump">1,691,028<span></span>
</td>
<td class="nump">25,503,512<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,325,780<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Unvested Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive stock</a></td>
<td class="nump">110,104<span></span>
</td>
<td class="nump">232,434<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive stock</a></td>
<td class="nump">1,580,924<span></span>
</td>
<td class="nump">2,945,298<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>111
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M_6'FC(Q!]L;7@&_5P34Q4UD*\61N;KS+CF48\9"[VD P^+?A4QZ&!@EX_%V
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MESYG,&WS OR^$D+O;\P Y=>B\3]02P,$%     @ =CIK4LL=^/=V!P  IR$
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MK-G9;DX$/=:;P\]4"%K4AP>"4\*J 'E_1ZEX.ZGVF[O?%Y;_ U!+ P04
M" !V.FM2O#PFX$$%  !O$@  &    'AL+W=O<FMS:&5E=',O<VAE970T+GAM
M;+58WV_;-A#^5PBO&%J@C45*\H_,,= X[1:@[8*D71^*/=#2V1(BB2Y).^G^
M^ATI1;(E2LT>]F)+U/'XW=W'NR,7#T+>JP1 D\<\*]3%*-%Z=SX>JRB!G*LS
ML8,"OVR$S+G&5[D=JYT$'MM)>39FGC<9YSPM1LN%';N1RX78ZRPMX$82M<]S
M+G]<0B8>+D9T]#1PFVX3;0;&R\6.;^$.])?=C<2W<:TE3G,H5"H*(F%S,7I+
MSU<L,!.LQ%\I/*BC9V),60MQ;UZNXXN19Q!!!I$V*CC^'6 %668T(8[OE=)1
MO::9>/S\I/V]-1Z-67,%*Y%]36.=7(QF(Q+#AN\S?2L>_H#*H-#HBT2F["]Y
MJ&2]$8GV2HN\FHP(\K0H__ECY8BC"<&L9P*K)K#G3O"K";XUM$1FS;KBFB\7
M4CP0::11FWFPOK&ST9JT,&&\TQ*_ICA/+U>B4")+8ZXA)G<:_S!&6A&Q(7_N
M0'+C:T5X$9.5R)$HB8G@ <@'H11Y0[[<79&7+UZ1%R0MR.=$[!6*JL58(S2S
MP#BJ8%R6,%@/#,K(1U'H1)%W10SQJ8(QVE0;QIX,NV2#&J\@.B,^?4V8QSP'
MH-6SI]/Y !R_]K-O]?D]^JZ+2.30>)A\>[M66B*+_Q[0'M3: ZL]Z(UBEO&U
M*,-%;N$ Q1Y^_67&*/MM(T6.&RZS$=YQJ7^XPE/JGUC]9NL?EG[@^<%B?#CV
M65>*S8^$3K"'-?9P$'N%EEB<2$?K%-P%.B$KRW^0K\F-%/$>APT1[T >T@C(
MMW>/VK!QG2$=4]5V9&G7\-KW/W)Y?N*\"LU[!'-;^NS&N.PCY&N0+AK]CPN<
MN'-2NW,R2+1JUQ9; H^8ZQ6H\P&MTUKK]"=!4L!EE-@ Q&A")G:&QBZ73SLD
MF3#JA2TJ=:7\*0UG;B[-:IBS09B_0X'69Q8ECS%=IF:/F4+A EKJ"H\@T!GS
M_1;0KM1T/J-NG/,:YWP0YV>A$:7HA,J%<MY9?^;Y_JR%LBL5A-2?NV%2KZD.
MWB!0F^;MSA1U-7!F=Z^S_IM@XGOM!.*48^R(':= C\H8'::]3D!B$;)9]F7E
MSU=#U*>LT<T&G7!=:)"@-"F3N--^UHT2F[2-[PI1K]?TIK)0_WGPWI56._'Y
M7;]3VMZ3+JE@TH.OJ4UTN#A59#\*D!-AT-UGE+8!=H7F81_)FP)$AY/T)^R6
M,R2Z$U;H<$D8SMM9PBE'6:_WFG1.?Y+/K=^BD^;+@!VD=I/6Z7!>_U)@[Y^E
M_V!K\-)H?46VV/H3;"*PJ;\'S4UQ51#M9:I3=WZJ5CBE5J=S<$CUN:9)]G0X
MVY?$ZKK&B;*;QC&.4S9MXW3)81R]'K!-QJ?SP3C>0B2**,W2LD?#_KJH:$>T
M:)ZYUC)=[TO'XP>T+D=Q[(.B^T1D,<C!R+,FL[/AS&Y(_Z''6<R5I1VD=\KU
MDYXUV9S107!7@$TR-AKI(8T!:[FM0/ 8);S8@O$=^O( 4MO>#Z._ 2E1WGK)
M:1#M IU[84]065,9V'!E^/0?PN;$Q3I=T)LPF 0=1SODAAS=U XV7#MJ ["Z
M$Y5P"<\QY;4Y.:=1V0RFV5ZW3VR5=>7:LV/4_EFGZKC$6'#&>GI!UA0>-EQX
MOMHS//*"(U<X$N?8%#SB[K72: (V8,\UJ%M^Z-0/YN&,M6UR2$[FLY"QEE'C
MHZ,[GG2V]D9#(=)]H<O#;CU:WYJ\M7<%K?%+>KXJ[SX:->55S$<NMRD>XC/8
MH$KO;(JH9'F[4;YHL;,7!&NA\;AE'Q/@&&@C@-\W0NBG%[- ?<>T_!=02P,$
M%     @ =CIK4A"RQ-@_"   (RP  !@   !X;"]W;W)K<VAE971S+W-H965T
M-2YX;6S%6EEOVT80_BL+H4 3P(JX%X_"-A#)3N+FD!(WZ3--K2TB)%<A*=OM
MK^^2HDAQ+U&.T>0A%J69V3EVY_MFI=,'GG\O5HR5X#%-LN)LM"K+]1^321&M
M6!H6K_B:9>*36YZG82D>\[M)L<Y9N*R5TF2"',>=I&&<C<Y/Z_<6^?DIWY1)
MG+%%#HI-FH;Y/U.6\(>S$1SMWO@2WZW*ZHW)^>DZO&/7K/RZ7N3B:=):6<8I
MRXJ89R!GMV>CU_"/SP17"K7$MY@]%'NO017*#>??JX>KY=G(J3QB"8O*RD0H
M_MRS&4N2RI+PXT=C=-2N62GNO]Y9?U,'+X*Y"0LVX\G?\;)<G8W\$5BRVW"3
ME%_XPSO6!$0K>Q%/BOI_\-#(.B,0;8J2IXVR\""-L^W?\+%)Q)X"Q 8%U"B@
MH0JX4<"2 O(,"J11(+*"*0;:*%!)@;@&!;=1<.48?(."URAXD@(VN>0W"K[L
M$C$H!(U",#2MT-E5SI%53&'#MMARM8UQP%VYH5QO8E39%1S*%<>FBL-=R:%<
M<[/*KNA0KCHV9FQ7=BC7W;S*KO"PKOQD>Z[J0WD1EN'Y:<X?0%[)"WO5B_ID
MU_KB+,99U82NRUQ\&@N]\GS&LX(G\3(LV1)<E^*/Z#!E ?BM>.+1]Q5/EBPO
M?@>7/S9Q^0\8@Z_7%^#%;R_!;R#.P%\KOBG";%F<3DKA365S$C4K3[<K(\/*
M?_$R3#1J,[O:C*>I:%ZU<QKM"[OVZ^4RKII?F(!%&"_!509FX3K6>W)YP%84
M;=)-4F?N@MW&45QJC+P9;F1>KE@.1( "3E95G[]GPL&(IPR\^,"+XJ7&_%N[
M^44>WPO;8)&$45U9C8EW1YHX4(&K(\T=59(_[<:O%G.-TON#2@="^G#0P%%!
M?+2;NV9YS IPS<26$,?SGN5E?).(C EX9GE>GU.]GY\&&7Y]I-7Y(*O3(ZTN
MAED=0[U=C<7/@RS.AOLY$;VT;:BH;:BH7H:8VAI+USP7?*[IF"=@RN[B+(NS
M.S -DS"+& A+T3"B5P##$X <Z.OVR'85MUZE8I+WYS1PG-/)_7Z]52'D>P'I
M2\U5*>Q[F+92O3AQ&R?^V3A/P/4JS$7.A\2[78WN.^G4_Z2053E(2.!3XDE1
MJX*!ZX@<&N(F;=S$&O>3JCDE2@G&F!#L]GV^4,4\3ZKFI<X41=#1AT7;L.CS
MAS6CFF)X ?1]O3-NZXQK=>8;*\K*E8J$['J6=%(K\A'Q+&MFF8>X7(GG) EO
MQ*;<CC=Y'F9W-<2 %Y^X@!RJ ]!/KI)/41B]_U[KO_=K_-^=*%T<GE(+A"#U
M GTH?AN*;PWEJB@V]780L5@:YPG(Q, L9.*=?,2+4N?GW%=[%H2^(>-!ZV;P
M+&[JO#P!A2FI\T!)*A59=3U#$X%.1[N=P0X_.9>+9A&W=P =9/)N;RB 5N\N
M'UD>Q05KQP P7U>;4D_SH9(DN6E=V&7Z7G9("^U06WLVKJX@EB)%Z5I0YNW1
M88_5:Z9U%JDM"P9R'SXDU7>X@TQHQ\RO6<[")/Y7^'L7B@8@7$W#_#LKPVJO
M%BS:Y()%:G?B%*IX)GG]IA%QM2)]ESNT@W:X^R2V8C5[:%TBBDMC A&1_+H\
M+-=WKL,L: <ME8-<9DL+A@5:,DZ',"V-% H0EDF'UE@ _;[80B-F.[<=;D([
M</X$*=/GQAW(RC2"@@D(L\B5,Z23])%'?4=.DFYQ&KB!*4T=/$,[/A^_2Z90
MA=>Q1XBC= X-##M$YG!::RZARHE6Y4R'I@-T.!S1AR&/A74LFL6&%ZE#=&B'
M=",&6=R9016P W&:#5"#.KA&=KC>,;HOXF\>1V67,;,OC<E>:B@AR.1,A\[H
M #KWMN\Q!WJ&5!R& 0HH-&PKM#?VVL'X?^7L2#/X(F0(H8-G9(?G7T+;D6:@
MA8YG&J%0A]S(CMS/PC#G2!TWB2^W_\\:*=^'OF$F11W HZ,!_C%:5?GM%<G"
M^,$MST%[]=-]>.3%&E(!>XP#JN1!,Q#C?;3LYZ'#=63']5\3]12I"#P.'#GJ
M"YT8PE@&/9V8ZQD[3X?FZ ":'S.L(!51H8OD@.Q"?3\[X$5VX#5AB-9-%58A
M5-RT"_7=[' 7V7'W*5,5TLS),%#VR0&I_CUDA\W8CLT_,U5A%:/'4-ZY;PY)
M]1WO<!S;<;SK;JSI;E%]/NLO^,5FCO9.Z[H]K46#0R6ORI/R3'N;"M5^I9EJ
M=&*(4B>02+M.SB6>,M?HY/J#S;9/:N4<:$0,W-$0;*<ALZ=D</N.=G^H%P$(
M0HREHSC#FCMV:?<;3"'#!1W>NXBWTY8GA6PCKEAS%R_Z'Z7&+=^1$CR<E!AO
MW=YBE4Y 3)$T;%\-$_M3)R8&3B)MWO<ZN;[(!Y,ISY"7CNA@.]&Q7;-@E52,
M":6!M,$N#\OUG>O8!S[ /FSC,G*T/JNWZLC'ON_+YT9S^RZ?&XT(1)[GR>&K
M<F.(?,^E<C?7"QJRU-$0;*<ASSI7S[&&@HBMAN1H/NL$,<4!)- 044=8L)VP
M_!+V;9N5L$IXQC 0N\I!<E8TU$@2[">EHT?83H^>";0M87[$*D\:&[X,U4B*
MK4R00A;G6E'7<0*?4!G%M>OW+W6:-.N,4M&" ]-7:*2C=<1.ZYYT_T-4IB9&
M:6JH.NFH&K%3M:?<_Q#-78M/B.F;6M)Q'&+G."J(6MQX1U3>X7HNIE*??:^1
M"P+?H\CD;T=0B)V@#+JOTN+(C*A4A!#B(^C+8^-D[S=PU<]G/X;Y79P5(&&W
M0M5YY0D;^?87J=N'DJ_KG\7=\++D:?URQ<(ERRL!\?DMY^7NH?JE7?N[X//_
M %!+ P04    " !V.FM28\6PR+L"  #("   &    'AL+W=O<FMS:&5E=',O
M<VAE970V+GAM;+U6VT[C,!#]%2M"6I" 7'JCJ(U$ ZO=!Z2*+KO/;C)M+!R[
MV$X+?[]C)PU9MJW*2U\2>^)SYIRQD\EH(]6+S@$,>2NXT&,O-V9UZ_LZS:&@
M^EJN0."3A50%-3A52U^O%-#,@0KN1T'0]PO*A!>/7&RJXI$L#6<"IHKHLBBH
M>I\ EYNQ%WK;P!-;YL8&_'BTHDN8@7E>317._(8E8P4(S:0@"A9C[RZ\34('
M<"M^,]CHUIA8*W,I7^SD9S;V JL(.*3&4E"\K2$!SBT3ZGBM2;TFIP6VQUOV
M[\X\FIE3#8GD?UAF\K%WXY$,%K3DYDEN?D!MJ&?Y4LFUNY)-O3;P2%IJ(XL:
MC H*)JH[?:L+T0*$_3V J 9$GP'=/8!.#>@XHY4R9^N>&AJ/E-P095<CFQVX
MVC@TNF'";N/,*'S*$&?B1 HM.<NH@8S,#-YPCXPF<H$SF;[DDF>@]#?R\%HR
M\T[.IU3A@AP,2RF_(%?D>79/SL\NR!EA@OS*9:FIR/3(-ZC.YO#36LFD4A+M
M41)&Y%$BLR8/(H/L7P(?;37>HJVW2720\1[2:]()+TD41,$.0<G1\'!X0$ZG
M*77'\77W\#VC+;51S#"Q)!G3J2RQTI=8Z@4H&TNEQLIC]0C3NJ0BA2JTJY95
MJKY+95_5=1P.@J S\M<[%'8;A=V#"F>H S29$#P5:U"&S3F0*;Y7H)0['G@@
M#A2BUZ3IG:P026]'(797H=_(ZQ]5A:OP"]X'#?G@=-X'_WGO#G=[OVGDW1QW
M HYW/FRHAZ<[_E6J7LMYL-MX&'Q\"(-CK"=?L!ZVOK+AZ<S7N=K[WHD^^_=;
M/:$ M72M4A.7N/J$-M&F'=^Y)O0I/K%MVO6:#YJJQS]2M61"$PX+I RN![@?
MJFJ;U<3(E>L\<VFPC[EACK\:H.P"?+Z0TFPG-D'S\Q+_!5!+ P04    " !V
M.FM2ETA+,I4(   *)@  &    'AL+W=O<FMS:&5E=',O<VAE970W+GAM;+U:
MVW+;.!+]%91W:FNF*HJ(FTAF'5?%RJ9F'I*X[+D\TR1D<4,2&A"TX_WZ!4!*
MD(B+[*G=?;$EJ@&>;G3WZ6[R\HF+;_V6,0F^MTW7O[_82KE[MUSVY9:U1?^6
M[UBG?MEPT192?14/RWXG6%&916VS1$FR6K9%W5U<79IK-^+JD@^RJ3MV(T _
MM&TAGJ]9PY_>7\"+_87;^F$K]87EU>6N>&!W3/ZVNQ'JV_*P2U6WK.MKW@'!
M-N\O/L!W:YKJ!4;B]YH]]4>?@5;EGO-O^LLOU?N+1"-B#2NEWJ)0_Q[9FC6-
MWDGA^'/:].)P3[WP^/-^]T]&>:7,?=&S-6_^J"NY?7^178"*;8JAD;?\Z6<V
M*43U?B5O>O,7/$VRR04HAU[R=EJL$+1U-_XOOD^&.%H 5X$%:%J Y@M(8 &>
M%F"CZ(C,J/6QD,75I>!/0&AIM9O^8&QC5BMMZDX?XYT4ZM=:K9-7:][UO*FK
M0K(*W$GU3YV1[ '?@'71;\$G=<X]6(#?[CZ"'W_X"?P Z@[\NN5#7W15?[F4
M"H/>:5E.][L>[X<"]X,(?.:=W/;@GUW%JM,-E@K\00.TU^ :17?\R,JW ,,W
M "4H\0!:OW@YS"-P\,&@V.R' _M]W3%1R+I[&#VTEC7K(]N2P[;$;$L"VWY1
M$=WPWFOQ<>7*K-1A^WBU()3F^'+Y>&P'GQA$9'40.P%&#\!H5-\/U;^4EXY.
M([F*[))W9=TPT$V(]57]N=3N-/3*S90'<8^5WD7,M#J@647-="=Y^6VAX[H"
M)6]5LNL+DR[8=_V9^<PW[DB/[$)AGLR,YPI!F =,EQ[ IE&P'YG*O&4] E3A
M!(J6"UG_VUSP(4U=$.EJ?LRN4(:H'VAV )K%G8]W"W-\@O6L$.76H*W8HV*!
MG3[ZF'DS!P_&:(;9E2$$^S'G!\SYV8 YMJ?.:,K<;3VT_0B_[DL^F%S7*9=\
M9),7^W3(7</3%/H!PL2FWB0:.NMMT3VP?A8/?<_DB+"IB_NZ.1L;\"C7PZA-
M;@3;%76U/ZWQ+EQNF9ANZ\WGT%%^@3.XFAVA3XRN2,!&R$)&4<@?RNF05*2P
M^K&X;]C?_Y8AB/Y1#0QL!&_5+XUAKUTAY+-7 ^2!EJ8!:#;10QR%IJA3"I6^
M1MO%4#D4,.'"+JZ,!I(*M$P!XU3QU1RHM5?_>FCKZ18G'D^R #)+%9"^[#!W
MQ;-&YC4*=>Z<.]G8)Y2$?,UR!XR3AX(G!N8-CW(00N>YHY#T@O=P24K)'+TK
MA5#0NI9-X#DZV3"%LE+G^\BZP6]=#X7 E"2.@5TYBO(\E/(LD< XDXR^V6D^
MF2P:23PN*RQP$D!@:0'&><'69PU390(0NLY?\,U"E28Q,"X%9(0X)^LA"DP#
MF)$E"I2\"O,9+YQV.S$<6I%T!M8GAK, [2)+,BA.,NX1GX/K,@=*Z!RLAUX"
M&1Q9<D%Q<OFR+TMW@C_6JAT!]\_>TM0+VV65+(-X'DD>,9CF2: B0Y9]4+S/
M^,54+"_N,Y"E#Q2GCYM!%7C:RTS!I*TAGTTF9'\.M:GVWNAZWFL2ES46>9+/
M2P6?&#VJ"4^!6W9!<78Y!MX6XAN3FF- SY0?AD_199*%RG0XFY>H/D%(<QI@
M'619!\59YW,A)WRO ^[K2&B6AY*-I1$4IY$O\UZM/NMI$R*7,Q8$(9IE<U-Z
M!.&*9('*!UEV05DT)C[57:&:SQ?'A"4-%">-&\%+QJI^K)]ZW62J/#$UEDR4
M=1\PB8</5HYGN4)IP*NPI0P<IXR;XGD:Y'1@<S"+H0\O4NPA ^I4+CXI'&J$
ML*4,?*XO.39OW:F#*QJP&^Z;NE1!H<H:!=YD'1TB0U<Q\:0C0VEDNSA3K$VR
MJO?O_3R.71Z!&8:A*0BV7(+C7'*J@QZ"3.RW$ZH,EPSLFJ(TPS4O+ ]+8(H"
M#(>/AE'Q'L7+<)NS83*!<OL3E.7(<6"/'"8Y#+F%92)\?N;U8\5*H;WV)^47
MXR>=D[1.;T;--"T]%@W;^X!0R4K4I6YP].]>Q3P$1"ATB,HCAU<X5(-BRU0X
MSE3K%Z,'A03W[*'N.GU<FI&5?_/*JY1+4&F:9OE<)U>,0$+S@$Z6QG"<QEZG
M$S/!&M/&I3>,W)FF1^Q4Z5-M+ GB-,HD=\-NUYAH58E(YYB&]X,PI8518=.H
M'5]$,MBR%X[W1F;>;N8S&RZ4DTNF#><UCML9*>Z?F\8S5 ME.4N$./^K=E$5
MOS'-4;F@#OE\KCD=AUN"(V<(;JKV^G"="N16\.%A.X%@XU#M!1W4FK@\IPJ4
M0(5*+,^1LSSG@[D[J*)27#-48]E5S(8EXX1X-J+P/@[P]%/SWL\C@V&@)R&6
M TF< [^>T&]4&R]PEP1Q'J! 8BF0Q!NE%[CL^9;O]-Y'#VWB#';K#A< OY>%
M$C-68=]+,P,V$<]?U>6OB6=$MZ(HY*26G$B<G'YE*E@DJ%M=,AB['<T23\[T
MS.1X35RJ05GH/"W1D#C1W+)J*/<3?7=Z<S(Y?P9ZZ"GY9-&65_6F+H//5XAG
M, =7@3J&6#(A\8[*)'8-:\Z.7@QN<X1ADLPK<8]8NDJ"(6Q)B,1)Z/9\]40\
M[$.=.L,GE8;Z&F()B,0[L3N58%2BO 9KKGA&R%H[Y8W8CS[-\[](Z%+++S3^
M<.:5O22U)$!?T^RH$ )UWP^&G_1#][!:AP;H(!_J<M;40P$0AF9[U"9X&D_P
M>^LOH!]HS$ V8=-XPGZMY6TVIF<F6_][RU]3-RN3S!FO4_=9/"1)Z#$M/7H6
M'\_=T_FL_VITV"1,5__5,[*YDL9SY?_EC%+'^ED&LWF>7QZ]5=,R\6!>-NJ!
MJ6/&UU,.5P\O-'TPK_',KE_#=^OQM22[S?B6U.="J-ZN5_2T45LF;U-UO&)\
M\6C\(OG.O+MSSZ7DK?FX947%A!90OV\XE_LO^@:'U[^N_@-02P,$%     @
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M-NA"C&XS^%3U9=PV4ZC:-/@)=A3_+2+Z#JX]+1%J="")[K#O7C=!%K'U; <
M6-SA+-6&*0('P-@[G*G+DKJHV</D=\L?O#_TB&4P,%&7S C$",TOQ, 654#4
M7Y!(1D$KV[<+L!C%X$VX"QQ5"Y[@-P*'EYR\1"-F,7"73!J@B^.,K2#\?C-1
M-P.X2F.WY#M0MJB]D$GU\-HS#%(0.)!OCM!E7FZ>Y&,D145H\!5Q['#PCC9\
MOKDW50\,BYT]V7C0+3'ZP;2&^<5.6]>XI52'L1;P<XZ%K5L@C2SER"D:I L'
M"//*05)P!491Y'(?[6Z*Q HC&1)E6')45KS*N9<#.<J! /CAU]YXXD6A>-81
MO3"-B4)<I@"4K-2=B8PW##TB*ZKVE"O)WTR-;_F\,FC>7B"QV-:X$"@[B%1Q
M5B-E!3 1034L+"R4/;$_2'SOAUW,1/8?GR  Z06$I.Y1YHFO*\U&V;.^92B(
M4PW]-9*R-[/YZ>04PT/3R!PD)$&W)&'HT#&?!E#WW)DSY[(C.]6^\JY?@JXA
M] )'YCC"+N\*#J#I*R8ZRX6Q$&Q T?4+- %X4">Q_"[+\)>;Z[>%6J\,^+_6
M84L%4!R7_1(%(6XR7P:-SP<!-7 A&@8%(I)!KKUKD<VP2DRGBIM#29!9,8E-
M-K-.^/0\39M&+W)[47KI*7$I[?@99]*#NMGI#8';6.Y).&B(+JW-/>:M^/<7
MLK^AG6UWL''YK;:N-N/R[Y!R)2WX^.UNFNBA0Q"!^?*4.QC<V2Y WN*>I:7F
M7I.@J3&3!\7MN4E*%S%P,T/ G"59WL_[5,,B(&*&+W*(T)8UKV:><1GBW-!W
MB"5*PDN'C$'%4!R@J2CG<[3;55$F,CM6)/>X?E'(@CD[GRI0V!\>9P"F^-'Q
MZ>1DH/@N1@MJ#+P.F<A_V+Q4YH*^"96+0^+,* _B,^@'9P8R*B6ZK4-CU0"_
M!BT>QM;4(!]MFH:%M@S)6%5)=-GS[5&F-A:_<D6%B!MB^T5NI,6I7639>+%/
M<]X$4R/-/;41SFJ-L]WC6$8/T#=I8W\0T$*)F"44>#2.A,8Q! 2#3DC4VP2_
M, TC9%-E1:%"+?HH[8]'A@9-**:!+X<V:,L8!;L5I8<\7\_9(TIUXRFC7M$B
M3M2/;@UTO/#4<UIPJEKVVD/%*1<"PSVFZ3$D6'TIJH%4] !<V'VLQ3-U8WY+
M\V2M[^$G Q?)M_#0U,P8Z&XAR ;74D9EP=-BTTM1\W@QY$74<>6:BCR8\:7>
M*;1:FT:HD28HI2MP%:B 3QG%3.2"I:#57$;0B>21&]4YD:31ULJX1B4>'*3C
MA0CISY(SWHP>?(4O7QE0('7+'JI;]/6HKK=4?EL9KISV0TO'&5K-]M$$]V>3
MX[.C,Y$C+YBSI2"67/VLF',]L0$XY/J(HK'2FP+D.VG(=O=*;5J&$20MX:*K
M7^!>F^N?CW@L >E Z3T%DRLU;-(HKQ>\V7$!;$TN?-/:()I@B7@H#D%IAJN6
MGZG&P1&-/]G/SKPN$ZD/N#1]@-.(9J5!G@41OV>)WNGA<23%G.=M?HR!"\95
M+ R@NLUUMV3JX7D@#[]Q)0]B3S*S/1(P532>8>I->F+*$7&I,E$2O@"B3RT:
M<788-*$M/3W)%0]OC_3MM*GVN<$G_H+Y>?*X29/']3!YO,2X;U.%\=)(31LY
M,:/(1<JOA=3M_@Q+FM1HN?>^,NQD/=KQ?BW/54"#TYY 9#CSY+SUJ,M9^_Q0
MKK1=BI,M&+TS-'S^.$P,'+1LQU0U#%4EAH"D+4/4Q\]UX*TR 8LJ=5:<G9X4
MQ_/I"Y6RG=2Z;[CQD2_Q]#HPGX=(OT8,H$/&5/'LO@\ZN51.+KU0 'A=CY:$
MYUYAQ&-.9\7A=%Z<C$X4HH5/X,5PFI3[#<;9Z72[7FQZW--+B#X&(%)+CYGH
M<31<$(_62(0P#K:>W!CCX MYK.J'6BK'9(2DSD[>8!#$H94J'#V4J4#F:+T1
M+=U]0$*NN,>(VCW(7M3@F]G9V>/X/L':W*7BX^0J>7XMC>].WA6'QT<OREU\
MBAEW!8;TGN&"QI<T:%^:9B?/O<\ZV'H3R<^Y\KZ5&0^PTDO)\>[X2O<RO<E\
M7)[>!_^D^3$Y8$JJL74Z.3G>PY.OO&--%]%U\EYSX6)TK7Q=D4:6> %^KQTT
M+E_P >.+[HO_ %!+ P04    " !V.FM2\2*<-M@G  #/A0  &    'AL+W=O
M<FMS:&5E=',O<VAE970Y+GAM;+T]79/<MI'O_A4LW=655#6[DE9*XI-E5:W6
M4J**==[32LG#U3UP2,P,+0XY)LA=37Y]^A-H\&-6]OGR$$?+(8!&H[^[T7QY
MUW:?_<ZY/ONRKQO__8-=WQ]>/'[LBYW;Y_Z\/;@&?MFTW3[OX<]N^]@?.I>7
M-&A?/[YX\N2/C_=YU3QX]9*>77>O7K9#7U>-N^XR/^SW>7=\[>KV[OL'3Q_H
M@P_5=M?C@\>O7A[RK;MQ_:?#=0=_/0ZSE-7>-;YJFZQSF^\?7#Y]\?HYOD\O
M_*UR=][\.\.=K-OV,_[QKOS^P1,$R-6NZ'&&'/[OUEVYNL:) (Q?9,X'84D<
M:/^ML[^EO<->UKEW5VW]]ZKL=]\_^/9!5KI-/M3]A_;N+T[V\P><KVAK3__-
M[OC=Y\\>9,7@^W8O@P&"?=7P_^=?! ]FP+=/%@9<R( +@IL7(BA_R/O\U<NN
MO<LZ?!MFPW_05FDT %<U>"@W?0>_5C"N?W7#AY&UF^RFVC;5IBKRIL\NBZ(=
MFKYJMMEU6U=%Y?S+QSVLAZ,>%S+W:Y[[8F'NIQ?9^[;I=SY[TY2N3"=X#( &
M:"\4VM<7)V?\P17GV;.GJ^SBR<63$_,]"[M_1O,]6YAO9IO9_URN?=\!M?SO
MB06>AP6>TP+/_U_0>WKN_VI[EUV<9U^_1O9QYX /BG9_R)LC_E*TC8<?R[QW
M9;:IFKPIJKS.? \/@/5ZCXR'')3U./1P@(ER8B=8K7!=#VR?>;-J'E<]Z*JY
M!S[Q15>M81%XO]]5/FL ^E66-V7F:N_N=JYS_-NOAA#GP-G\>7;=5?#SH89%
M ;ZK,!0!_@U[A\GJH70!J $?PL3X]Q5/1*M7\/ANU]8U',)= [/Y8>VKLL)3
M^>MQ[[H\NW'%T%4]HN.J[0YM1T"=9Y=U#<OTKA/ ,B"]QN<DLGAKZ[P&R&#<
M+K]UV=JY!C!6@2@@N %EA=WF>?8Z]Q5!>=TY#]OXS;N/ZX&X/^1=6 U50=4?
M05+UN^3 (_:WKH%=(T+@=W?H]>!=]JFI\*\;7(? O 3\ .UD#__CW[Z]N'CR
MW9\O+Z_IGT^_>P3X 90 "0)U  YD#N_XO+.^59)<UR[;#K ;>LMG>X?$"+_3
M6/P'G>'0[UHXA1PUP0B2&8CGMP;4O(''84.&SV"JILR[$L^X)(X@W.O.+F^N
M=&-TLK,C/QWP2,R83V&,4-[;<%BS$[QNX?_"^+>7-Z\C-C\!ZF"6-[ZO]K1K
M) L^W<#5"YPP.?A/YS?G&1X6X/B7H0)B [W4@"+'$8CQ??[992XLA3O^>2BW
M/&&_RT%8;#8J6@"&MB.D[P.;Y=X[X>^ZRM=5S?R#?Y>5+^K6#QWM!T!#) ")
MT.\\(Z%14+8H-Y:6=E_ ZO$P60E<"^B-[Q$U ,6VY7GV/NP74?ST3]_YQ?T"
M^X 0[(#N2OJ%01Z(X-QM7@_$AVA?E!D:*[=Y51-55PU;7G ZJPP$9]\BM]0$
M85<15^!\MSF - #L &F'F!OV!Y8AC.D.6;FN'*X/9[/&[>2^;6@-H&9D$MAC
M477%L <DH<0!6>**?/ L  >FG;C!"LD"Y38<M_!"Q+-!5M?"7'Z%!MA OWBP
MF#Q@8*CQ(#?(H)NNW<,,K3<4<YZ]0[NO:+N2CF!1,/*,^ Y-LQX\:$H/N  ,
M$>)@<4.:2)?VH +2<0=K>&YQ;DY"Z J&,4)T!I(W>>G.$_4;Y^\0[V4V'&"V
M2H6I$)5?H$W5/!T<6#,X0@/,_0^<APZK'3K 8 V0B2K)\FWG>(/$GC=YTVXJ
M0M3?0$^[+W@ 18<G )M#G+F\*W;,3;!*W1YHL%+^*D.N[H]GC![4'/"<EY)W
M5H&%F(!%@/ X$-V 6M>#:DOPN8:=[)$] EX!&B$-94!F%AB)6@Y>60G_(2D
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M@YV TX9V%V(7M=<=^03DG!2.?"6T=7(! QG@D%=$R^0-H.>0![B.V4,TK[Z
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MNF(UC7?(RZ'FZS: Y K<4)(AI"TBK7XZG,%4&,&TPIV#>*-H17"&5:0-7!@
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M5O3G@LH:T'HIZ4;M!4LP_ MMO@)02P,$%     @ =CIK4@\8OSL3!0  L0P
M !D   !X;"]W;W)K<VAE971S+W-H965T,3$N>&ULM5?;;ALW$'W75Q!J4"2
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M3OCSI7?X(@6GEE4M'S;9$WX,.B'GP$P0PK2ERF+(36!8RJ,??RB?(<4Z(;@
MN3WCH1O4#.B9V!WY4,ME0 HHF:[R?0E1^(>DMXZ.M;HEO:OEYK(3][M9ML5K
MQ$NXHZZ+$LP@%B&%,GM';M<\++SF3#JWXW2(DGX3M=2>1=&*&*\))7J 4GM=
MT/5Q6RN6R 26SV1J@VQE49@M\CD(6=J*R>55- $*L/:)/WBHW1EVVLB2W#HV
MRQ[.@%-WE.UJVX]?U&WHU^-U,X_>98U/(=[\"J:CP<FT+US=(->38#>Q*04#
MM+AQ6.!O"G)\ /LKBRZHF;"#]J^4\[\!4$L#!!0    ( '8Z:U*\,52ER18
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M;/@ W%\94[L?N('_V.2K_P-02P,$%     @ =CIK4EL]0,B4 P  =@@  !D
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MG5GA$PG*!N!Y*?%B^XU-,#RZR]]02P,$%     @ =CIK4B1O0)CB!   EPL
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MB8IJV9OXR:U^IL&?-XRGG GI5ZRR[)MB)%0?HFL'93!HM<W_\F&(PX["Z?2
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MGPU>SN19 .>U0S:'!1O8OL4O_@502P,$%     @ =CIK4F1]4PN)!0   @X
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M\1:DX4H2#?59>)Z>7N3.WAO\Q6%C]L;$1;)4ZMY]_%Z=A8DC! )*ZQ 8_CW
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MFKI@AI>$R8I47'06*B*V!L8;<$-*U:[]TO()K1YXA3D@$K&\*;-6\V5GV5(
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MRF@1G4R3X M:&Q?B[4YZO7&:)E&:Y '-:)1G>?!GKS\7Z[K3>$ 8GU87]."
M?99$,XHNT0P/&SJ;!I^59<+W7AHEV$*X:Y%D49'2EZZ/>.]"QB-LY9\=[CSN
MI.WOYG%V?-F<]Q?ZSKQ_%GUB>L61K8 :79/)21$2W3\U^@^KUOYZ1^'A8\$/
M&WR=@78&N%XK[.OAPVTPOO<6_P)02P,$%     @ =CIK4D%9W(P'+@   *0
M !D   !X;"]W;W)K<VAE971S+W-H965T,C(N>&ULQ7U9<]S(T>#[_ J$=F-#
MBFA2)#6CD35'!,61;-K2)ZXHV;&QL0_H[FHV1FB@!P60:O_ZS;,J"Q=US'H?
M[!'10!UY7Y7U\UW=?/1;Y]KLTZZL_"\/MFV[?_[XL5]MW2[WQ_7>5?#+IFYV
M>0M_-C>/_;YQ^9H^VI6/STY.GC[>Y47UX->?Z=E5\^O/==>61>6NFLQWNUW>
M'%ZXLK[[Y<'I WWPKKC9MOC@\:\_[_,;=^W:#_NK!OYZ'$99%SM7^:*NLL9M
M?GEP?OK\Q=DS_(#>^&?A[KSY=X9;6=;U1_SC<OW+@Q-<D2O=JL4A<OC/K;MP
M98DCP3K^D$$?A#GQ0_MO'?T5;1XVL\R]NZC+?Q7K=OO+@V</LK7;Y%W9OJOO
M_N9D0S_@>*NZ]/3_V1V_^Q1F7'6^K7?R,?R]*RK^;_Y) &$^>'8R\<&9?'!&
MZ^:):)6_Y6W^Z\]-?9<U^#:,AO^@K=+7L+BB0JQ<MPW\6L!W[:_7C(VLWF37
MQ4U5;(I57K79^6I5=U5;5#?955T6J\+Y[*'^Z]'/CUN8&@=XO))I7O T9Q/3
MG)YE;^JJW?KL9;5VZW2 Q[#FL/ S7?B+L]D1?W.KX^S)Z2([.SD[F1GO20#$
M$QKOR<1X8SO^W^=+WS9 ./]G9H+OPP3?TP3?3TQPU135JMB7,"X ^Z*N/$RS
MSI$VQ^#YU8-E[[<.B'U5[_9Y=<#]K,+/;IUMBBJ'3_,R\RT\  9K?0:#E=W:
M9:U\VN%#&!C_ON"!LKQ:9P4\OMO690D$<U?!:+Y;^F)=( 7]X[!S39Y=NU77
M%"V"[Z)N]G5#BSK.SLL2IFE=(PO+ +"5SXDW/0V^S$M8&7RWS6]=MG2NREQ9
M ,W3NHO*[ -'G$')#P$E/\Q"\47N"]KG5>,\ &(2&5\QS->@(6X<).P^;\*V
M4?H6[0%D0[M5!.&0^T@&-ZX"\"-FX'>W%Y A C]4!?YUC?/0,L\!4<#FV</_
M\=^>G9V=_/37\_,K^N?I3X\ 48 ;D(RN<8 ,&<.[K*KQZ[;.\OT>V"-?EBZ[
MZ6 W]);/=@[E!OQ.W^(_B)BZ=EL#.>0H>WLK&5GQ^-9RGVW@<=B08548JEKG
MS1J);4W"BV"O.SN_OM"-$8F-?OEACR@QWWP(WP@+O K(&AW@10W_"=^_.K]^
M$: Y0Z1/ Y$^G:6N#P!\6,=+WQ8[A-L8?7[9"$2:3&$,+OAQ0BP,B._#\?5Q
MA@0#>/ZC*X#@01M5H+_Q"\3Z+O_H,A>F0JC_WJUO>,!VF[=9OMF 2B; PAKJ
MAA"_"S(G]]ZU_&%9Y,NB9&&"?Z\+ORIKWS6T'U@:(@+(E'[G$0F5@K;1/>$X
M4U.[3V#L>!AL#2(,4!S?(XH$KJG7Q]F;L%]$\^F//_G)_0(+@XG0 .VOZ1=>
M<D=$[V[SLB-9@%;%.D,3Y38O2N*LHF*#"["SR+8%F '(L26ML"F(,W&\VQR6
MU,':8:4-0J[;[5F@,J0;%"=EX7!^P,T2MY/[NJ(Y@*.046&/JZ)9=3L $HK?
MX^R%6^6=9VW0,>W$#19(%EN4#JWR8X2S 593PUA^@6971[]XL),\0* K$9$;
M%!*;IM[!"+4W%'.<7:*YMZJ;-:%@4DOPB/@.#;/L/)"]!U@ A AP,+DA3:1+
MBZ@ =-S!$IY;F!M,"%W!9PP0'8%D7KYVQXG=%,=O$.[KK-O#:(4*="$J/T&;
MJH8;0%C5.0(#C/UO'(>057<-0+"$E8E>S?*;QO$&B3VO\ZK>% 2H?SH@[T^(
M@%6#&(#-(<Q<WJRVS$TP2UGOZ6.E_$6&7-T>CA@\J+W@.4\E[RP""S$!BP#A
M[T!] &A="WH^@><2=K)#]@APA=4(:2@#,K/ EZCRX96%\!^2 JS%\%A#("I@
MA<=D^\#<L(GRL%#D Y@#P>4XNP@=9+8#?\M<4J.>@:5$\IN1V#\&B?WCK+R]
M=L3^!*>_NOJFR??;8@5T'> Q)L._=<SL;=B[=XG\ 5I#^>,)G77E5- "2M$@
M P@ 00))=4!$,.@6OB?5X$C@-JY-Y!$2?D0C4I6+A #0)8&R+=S&(&/M5@1Q
MXL)F@<C71T?P"%^Y:>INOT!6P5^(][< =C0XRK)>X6H I<  *Y&R\":J"N]%
M-M,"03(<DWH3JS5(Z/D5X9[(UJ6W7GX"&Y8,EK<;X&O7)$-FM^@9DBD<10VM
MB*4-_Q3$$2P30&YF%N3,$=JS0&C/9HGB(O?,RO2/E\"!@ E$[QA]?<E0]'\N
MCD>$M 4'%_166<!S!/\M,(U5Z\25^;J =T#/W8+X*5B5 0Y7."!)*%!D-\#?
M)4"K54>!]#7(L6S'/B*01XFPN]NB*0PHW^;$Z^])=(J!H,+2+@2 #4.X PS>
M?'1MM@&Q*<OCU_ -,F'>HR+LT/%=EL6-0>)*G!90"C5\G*(>PQPM_$]PG%<?
MH[N4HX[Y'98>13N\V!9M1X//X?LO =]_F472.]@!V $HQA!#8UC^H@$R\S=A
M")04NS#,#O1LZTHR'CPZ=@!]0 V)=[3 P$,I6D1(#?O%40C%[0C_;?(56G)
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MGUN7@[K"%^#W30W&D?R!$R 'T/)^_;]02P,$%     @ =CIK4B5\(X.K @
MU@4  !D   !X;"]W;W)K<VAE971S+W-H965T,C,N>&ULA51+;]LP#+[G5Q ^
MM<!6.TZR%442(.D#&]!B0;-NAV$'Q:9MH7JXDKRD_WZ4[+@9D&876WQ]_$B)
MG&ZU>;85HH.=%,K.HLJY^BJ.;5:A9/9"UZC(4F@CF2/1E+&M#;(\!$D1ITGR
M*9:,JV@^#;J5F4]UXP17N#)@&RF9>5VBT-M9-(SVBD=>5LXKXOFT9B6NT3W5
M*T-2W*/D7**R7"LP6,RBQ?!J.?;^P>$'QZT].(.O9*/ULQ>^YK,H\8108.8\
M J/?'[Q&(3P0T7CI,*,^I0\\/._1[T+M5,N&6;S6XB?/736++B/(L6"-<(]Z
M^P6[>B8>+]/"AB]L6]])&D'66*=E%TP,)%?MG^VZ/AP$7";O!*1=0!IXMXD"
MRQOFV'QJ]!:,]R8T?PBEAF@BQY6_E+4S9.44Y^;K]C) %[#FI>(%SYARL,@R
MW2C'50DK+7C&T<+9=[81:,^GL:/$/CS.NB3+-DGZ3I)A"@]:N<K"K<HQ_Q<@
M)L8][71/>YF>1+S![ )&PP^0)FER F_4MV$4\$;OX!VK]]=B8YVA9_/[1()Q
MGV <$HS_W^=;ZS@])\SAR6+1"+CG!7K#(XJ@7EB+[EB73Z>X01K+C+/PVG%'
M8VL1N*71R;2AMD-C?7VN0O!U^>?ZT6. 1%?I'/0?-,&*/<&F)2@Z@MYH.I+,
MDZ0O%%K09-NKP?&ZSKB"5V3&G@_NV0;PI>$U#;4;3%KUX*XQBKO&4,>9RJ'@
MNR#T]F\%O4D\$GBM9=TXXOQF&G6F>Z1!K;3(@<O:4&'>:@?K2AL?0*7L2Q+>
M$[2ANOP*\PUJ5>0GC]U[?#!K$DT9-HJ%\'S:L>NU_=):M+/ZYMYNO =F2JXL
M)2PH-+GX/(G M%ND%9RNP^1NM*,]$(X5+5XTWH'LA=9N+_@$_2J?_P502P,$
M%     @ =CIK4JK=!:2. P  G@@  !D   !X;"]W;W)K<VAE971S+W-H965T
M,C0N>&ULE5;?;^,V#'[W7R%XA^$.\.KX1^(ZEP1HTATV8 6*MG=[&/:@V'0L
M5)9RDMQ<]]>/DATO[<7=]A*)%/GQ(T5:61RD>M0U@"'?&B[TTJ^-V<_#4!<U
M-%1?R#T(/*FD:JA!4>U"O5= 2^?4\#">3&9A0YGP5PNGNU6KA6P-9P)N%=%M
MTU#UO 8N#TL_\H^*.[:KC56$J\6>[N >S.?]K4(I'%!*UH#03 JBH%KZ5]%\
MG5I[9_"%P4&?[(G-9"OEHQ5^+9?^Q!("#H6Q"!27)]@ YQ8(:7SM,?TAI'4\
MW1_1/[G<,9<MU;"1_'=6FGKI7_JDA(JVW-S)PR_0YS.U>(7DVOV20V<[PXA%
MJXUL>F>4&R:ZE7[KZW#B<#D9<8A[A]CQ[@(YEM?4T-5"R0-1UAK1[,:EZKR1
M'!/V4NZ-PE.&?F;UB3)%OE#> KD!JEL%6'&CR?L'NN6@/RQ"@U&L;5CTB.L.
M,1Y!C&)R(X6I-?E9E%"^! B1WL Q/G)<QV\B7D-Q09(H(/$DGKR!EPPY)PXO
M^?><KYDNN+1I:_+'U58;A6WRYQLQTB%&ZF*D(S'N<7K*E@.1%;G2&K"D?7U+
M0@TYH8"M>0=%JQ03.[*FFNES-7\[VD,-I)(<)\R"&'MU!&=4NZMDHIM=-P1;
M'$QBT'PCFST5SS_^<!E'V4=-*B:H*!CEA'9TFQ.ZE:7[=*1+<1J/A+>6,*&B
MQ# E*ZC!0EIX#D_ ;?)6.'&O&2BJBOJ9M(9Q]A?B&XEC9$!A=P-^'(KZQ!ZA
MM47!%H!F"VIH Q?RE3;*R7LF,*)L-1[K#W-OK+TQI^\@Y]YOCG34KW&_)MZ#
M-)1[W37.O0W5-8&O+4.&%LS#=H=G'$KUB!_1JA6E]\Z+\B!/$]RX L<?7^SZ
MPXU4>ZFP9&0KD>Y@$$V"-,]?BS<.WUVMMN5GAH$.B+T(9.%]OB=&N111C1'B
M(,ZF \: U>O'0F=QD,?):W$DM)#BIY'P21Q,+_/OP_?ZL?"Q+4S\6KP#G$M6
M&.R5 FOO1>>QG;:[JG=>DLZ"))_98D=)D,S2%Q>03O,@FTW^1WM$^7]MC[/%
MLCRF+IF1CIB.9)IEZ9E,K?:8:90%630;PW6'Y[YGX<F;T8#:N9=1DT*VPG3/
MQZ ='M^K[LWYQ[Q[N3'C'1,:9[Y"U\E%-O6)ZE[#3C!R[UZ@K33XGKEMC7\@
M0%D#/*^D-$?!!AC^DJS^!E!+ P04    " !V.FM2H?PE!M@"  "=!@  &0
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MYM)@BW;#&M]$4-8!URLI33^Q"897=OD'4$L#!!0    ( '8Z:U+F9]FZ_ (
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MB)T@$%!:Q\#P<P\W((0C0AF_]YS!&-(!C]<']EN?.^:R809NE/C.*]LL@EE
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M:GO<BWI/#Z[X:FW=@V QS^D*KL'>Y$N-JZ!&27@&TG EB8;TN'<2??H<39V
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M[&2P^&H'YN'8KIS>=K#M!J?_UNST/S^A++DUD.N_/)H[E>:.T]PYHOG73;X
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MI:#L GR_E-*\/%@%U=72^%]02P,$%     @ =CIK4KRRACGP @  X H  !D
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M85H3'#2+BDI1T>N+$OP"-SRE/\$AF> J2Y>.TH"^Q:U_!J4**_B'SM7/=(T
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M@=$ST!P6)(WD ]M^@^) GLXW8Y'(?M&VB+4,-$N%9'$!5A7$-,G_R6O1B!H
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ME*-G$J6PC]%O,*HY!':X,X=FF)J#:^^O+"@K"]I;TIUTT:-JBTC5%UJIL46
MO3)U[_-4'I8DX8DJ#QMM<VPWQ,%.=YMA+2K'5F6)ULDZ+U(<(71<LV)\NM2+
M'.^T[CD'J"MSP_8)8B_ ._/H^>[./(HX_SBYX\H5<;LMCAA?,TXD'"=V7!D:
M=C]/[KBR,-SN81\+'C<=#%MVZ![25&5BN-W%CM-4TZ8Z/7R NG(IW&Y3'V@J
M:&K%LGN^MT-KUNXV^F*I1K94WR2*8*& 5C=05?/\KI9O)%MGUYTID^KRE"U7
MZGX+7 >H]PO&Y-M&WZ#*&_/P'U!+ P04    " !V.FM2#B2Q;4H#  !3"P
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M0;L-^'ZNE'V:N !U'SWZ!5!+ P04    " !V.FM2.-2,\Z '   =*   &0
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M #LTJ6O04240'0J,.@1&E<#H6(%Q)3 NO%NZH_#EE!M^?:G5$]&V-6BS#T5
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M)M)8(YKYL+&QWJB&<9/&)RUQE:&?'LXD5H34[X3RB-R\Y&R%.=+DDHRBB)E
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M; ],M&5^.I0/M%B[LX:YT%HD[G(%- 9I)YC_%T+H[< N4)[1C?\%4$L#!!0
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MS&!)GJ"XV,!9M8&[3(P[EM.Q>N886PU@K$$;CU1*1!*-$PD<AV^'! =ZXS$
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MS]&Y1U?*6V.?7 . [%E)[:91@[B]B6-7-J"X&YDM:%JIC54<*;2;V&TM\"J
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M,,GHXU7$;'=]N@#--G3@VB#U<Q@V].* ]0FT7AN#A\ W]?"&%7\!4$L#!!0
M   ( '8Z:U+A)H_ZL08  /8E   9    >&PO=V]R:W-H965T<R]S:&5E=#4Q
M+GAM;+5:77.;.!3]*QK//K0S:8R^,.XDF4EL-YN=[4ZF;G<?=O9! 3EF"L@%
M.6EW]L>O  5A X+:<1\:P/=>'5WIGB,D+IY%^C5;<R[!]SA*LLO16LK-^_$X
M\]<\9MFYV/!$_;(2:<RDNDT?Q]DFY2PHG.)HC!S''<<L3$97%\6S^_3J0FQE
M%";\/@79-HY9^N.&1^+Y<@1'+P\^A8]KF3\87UULV"-?<OEE<Y^JNW$5)0AC
MGF2A2$#*5Y>C:_C^EM+<H;#X,^3/6>T:Y%UY$.)K?G,77(Z<'!&/N"_S$$S]
M>>(S'D5Y)(7CFPXZJMK,'>O7+]$_%)U7G7E@&9^)Z*\PD.O+D3<" 5^Q;20_
MB>=?N>Y0 = 745;\#YZUK3,"_C:3(M;."D$<)N5?]ETGHN8 28<#T@YHJ /6
M#GBH ]$.9*@#U0YTJ(.K'=RA#A/M,"D&J\QN,31S)MG512J>09I;JVCY13&^
MA;<:D3#)I^)2INK74/G)JYE(GG@JPX>(@WLU"WB:\@ LI?"_@G?@.@C"?,:P
M"-PEY;S/Y\^;.9<LC+*WRN3+<@[>_/(6_ +&(%NSE&<@3,"7))39F7JHKC^O
MQ39C29!=C*5"G+<[]C6ZFQ(=ZD!WO7T\!PB> >0@I\5]9G?_R-)S@+O=YW;W
MWUAB=5_8W>?<M[I_&.P.IRWNMT-2Y[2U/E9SI)HHJ)HHJ(B'.^)]YO%&I(JM
MP.+;-I0_P-^_*PMP)WF<_6.)CZOXN(A/.N*74R[,LBU+? Y\D<FV";,HH[A%
ME)QGGZ[@Q''PQ?BII7%2-4ZLC<\YC]6T#\*G,.!) %:IB '_[J]9\LB!6"DX
MIDPV59ED.>8VD*0!<NI0IQTCK3!2*\:9B&-5>\MFFSOAW"J<>Y+QG%3Q)SUP
M\XP5BJ7R5V3JK"((-<HJ?8H3@%+'3*J+,'ELHX>R#5I+)'4(GM(I;4^F5Z'S
M!J!KI3U+WZ=5].E)<@L=P]K.H?C/ -O*M4C#?WG02AM.,Z>(>'CB>>TYA34M
M@8-1[57)&=BP% BU")),JH=/+-HJ(YZ6<Z(5:-G8I ;4.7<<!W; -$P&T>')
M*^=F*]NC1N(Z2AH:TH-VUOMC&S^H'*@*V>R)KV8<=2^%NBEJOXMO;G0K=6@8
MNHA23#H0&F:$=FJT)LM>O0L=>DC&# M".PTN>1HJ"EERA>*P*H:&(N%I.!(:
MDH1#6/*0.E[ )C>:Y.H%1M,$.\6_7</; 8:['30\"X<3[=&4L-"-62A!=[S7
M;K<[AMCA]"34,>T?JZ:)=0B0T0ITA%;T5#!JBL4^\!83.W C)\@N)[K4KP^L
M<U1;VIYF;8L,SR,[SQ]1YZC)[8TA:)I XGDN=NA>H0^QW.VB$0HT7"B.KW3=
M6&^E]]OM=L?H#.I;;A]4Z3JJ=;2:)CUC8 0+N:<K=;<?>=,$DHEZ/T5N!W(C
MA,@NA+K6;PZM=2-(R#M-K1N-0$=H1$^M]^M$BPET'6?J$6^_UCLM.^89-I*"
MATO*T;4^UXUY-:#DW'%WN[/05KV,T&^WVVDC1WCXV\UP1ICKJ#O# #V$7+K?
MP:;A_N"WQ2(>FE"O0VRQT4!L?RFZ3X6OUM19N?=1[</\]-['7+=3W_P@WOZ*
M\T.+%5)IZ=C'P;5=I".$MH<!<;_2MICT#(#13VS7SQ<&? ?;.="VQV94#=/3
M[.(9"<)'2)"=_7"_ K68*-F<NM/]A<X P]T.&J7"PU_9CE_GZ,;Z6:W7;K<[
M1@_QP3MAMG6.CFH=JZ:)?0B,PF*[PKX65RUT.WU<U;2"Q$$=W2!&1<GI7LQ(
M_XM9BXDU_\0H(1GT8C8[<+%&C"B1T[R8$:,7Y%0O9K>D10LH19,IZ3J-J!U'
M'+'IUEF4,]+<;^M!9(2#V%^'7JWD=#OU8O(\Z'7P&#&Z0^RZL]PY6MAN1+)S
M@%/M)?P<W!EI>>69>I[GH [ 1D>(74=>_<RIN8<WA5V;,,3H ['KPR<>;,NO
M!A0D9LZ#-RP,WH7).Y]M0JGN4QXQO5LMJZKE9=4&NUUM1=\4"X0[T1NE(':E
MN$O\E+.,Y^?0S/>W\;9$&?!5Z(?R:-1-97 G7:BI$09J%X8A_ K^ Y79\O[:
M0H;4\#J%)Z%;:@B=#C]Z.7KQ--.-U1=%[CG%;L=N!#6J0(]0A6[^I2V*@"F>
M0M)!;]0H K4KPFOQ[XPVSZ8]#W7.V=KI=,^YS+#S^QEM\G^SSL>U#UKR+Z(^
MLO0Q3#(0\97R<LXG*DA:?F14WDBQ*;YQ>1!2BKBX7',6\#0W4+^OA) O-_EG
M,]6G7E?_ U!+ P04    " !V.FM2G2\ >WX'  "$)@  &0   'AL+W=O<FMS
M:&5E=',O<VAE970U,BYX;6S-6EUSVS86_2L8;=M-9AR+!$B)2FW/^*MM=IJM
M)VZV#SO[ ).0A E)J  H1YW^^+T :4$224BQ_:"'.!1Y<7%P+W#.!<BS1R&_
MJ#EC&GTM\E*=#^9:+]X/ARJ=LX*J4[%@)3R9"EE0#3_E;*@6DM',-BKR(0Z"
MT;"@O!Q<G-E[=_+B3%0ZYR6[DTA514'EZHKEXO%\$ Z>;GSBL[DV-X879PLZ
M8_=,?U[<2?@U7'O)>,%*Q46)))N>#R[#]S=Q8AI8B_]P]J@VKI$9RH,07\R/
M#]GY(#"(6,Y2;5Q0^&_)KEF>&T^ X\_&Z6#=IVFX>?WD_2<[>!C, U7L6N1_
M\$S/SP?) &5L2JM<?Q*/O[!F0+'QEXI<V;_HL;$-!BBME!9%TQ@0%+RL_Z=?
MFT <T@ W#?!.@S#J:4":!N30!E'3(+*1J8=BXW!#-;TXD^(126,-WLR%#:9M
M#</GI<G[O9;PE$,[?7'[9\7UZMT5A"Y#UZ* ^:2HS<@[=)EEW%S2''THZREF
M'KRY89KR7+T%D\_W-^C-=V_1=VB(U)Q*IA OT>>2:W4"-^'Z][FH%"TS=3;4
M@-?T.DP;;%<U-MR#+<3HHRCU7*';,F/9MH,A#'0]6OPTVBOL]7C#TE-$PA.$
M QQT +H^N'DXZ6A^XV]^6<U.H6E7[UNC(>O<$>N/]/B[-P%'':F[E)*6,P;+
M4Z.K%=JTNZ,K>_ORD<H,_?=7<(D^:%:H_WD 16M D044]0'2(OWR[L%VE&X"
M8E_-->N: K7'D?5H2&IY$8<3B,YR,RUMHS"<C-9&6V#C-=C8"_834XS*=(Y@
M<J(;M@0*7-C0W':!W>IBM.YB=!P)&J\!C5\]0;7'>"/VF 3Q3H+:1J,DZ<Y/
MLL::>+'^S$HF@7I,>BXSH#ZNM*1&)0[(T&3=R>0X,A0&CI"#5\]1XW(K24FR
MFZ0.JSCHR5*X(2#A?KSHMX7!J'P1P,XC/I*D.*8-B7>0'THM.10[*5K2O&)(
M3)&RXQ;UN"$Y3*9<[:I4DQ[2YJ]1L$MR758;1MO('26'?D[^PU8^+'M'E["<
M9@Q-*9=N%$_X9Q!9W8.^[B#9P)6<DM;D:EN%IZ-)#WQ'TJ&?I3^7DJ5B5O*_
M(,GJ.4LC;D45QZ/>N#IJ#T>' ]L"DPJE3U#SU-Y9,,E%=VS]G1"T HU2B*"B
M+H3"!&5TY5UF3@M"OQC\M#41MJ?SDJF^V3!NQ3,*VG.Y;85[8^X4(?1+PK.H
M,6F17C2)DEV\;:MX@GOP.G$))X=3(_H;O:#DP$X_<' <[(F=1. #).(;\]:X
MW)*T((EV\M9A19*>>8:= &'\37E[42F"G<C@(ZGGL5,/_/H5/6Y7ZS@9M3(7
MM?,;]JPX[.0"[RWJ0:A3X"YDH?N"X*@>'TD9CQUW8S]WOX[Z[.DDM.J#QD_B
M,]JG/=@Q.?8S^8MEO?&_.<E(G\!@1]C83]C;DBC=9*K5L5\5&[]Q3^W63/FV
M4=R'F3B^)Z^_7R =^X46W ZCJ!>NTP+BUX+=%?HR622.T\F1;"K(QO&-?U/Q
MK,R10S+G-]J&Z[2 ^+6@(W,O$D;B6)W$1Y([IPG$7YD_*W>CPXMBXJ2 ^%GZ
M66D!HX\BXU.>UJB![6Z+12Y6C/U3U3'S$3UQ1$^2(TF=(WER0%7^;:F[;EP>
MM#>/''5'?NHVY\#H+J>E[^S5,6L4'D>H(T>ZD;^0_G=5/#!IMY?URP%:Z;F0
M5O6G0B*N5$7+E*&JS,!NT0I%?:S>]+*E1%$\)N.^##@*COP4_)%^Y455H'(7
MJ!;H@5E\+#LQ)50*8:*S[B-L?Q_1:1!\[POGQO'ZGFJ\QB:9>:''RQFB2\IS
M^I S&\UII2O(K#W*Z7S=$K5K;A)&R6@<]L31,73DK[OM3+Z]O[OSC=.1:W0D
M!7?D6#;RL^QKS>3V03G,Y%%,>A+@>#;:<S3RTJG1<4SB ^;8-MK#M@98!]N>
MH(RI5'*[R>Y$Y/?[^YRA]:Q#"RF6/#/K=DXU_&'M%0W_F%P""J.*V]%9)^^1
MY[G)K#"O.E.:YRO$RU0R0(]@^OV+EA65*U2_0 RM)T:A<%T_,%V#^51#UWHN
M136;;[<BP0EZ6%F$.;C5!N ;_A9%)#E))LD36+@+P8)]5[WS. $;, J_-P],
M6[,J:+GZX1\)#L<_@GVEE08X)O.MD>\X,R,Q/GA1L(Q3S6"4"]B.,=OZ!BYL
M>Q(B" WT"QVK"@:9,P41W.^>*D@M! #J#HAV,UCJRA AGT:QSM^I9XW&3D[C
M ^343H>_T:\U6.CH3FC@!0[ET&^5!J ,A;[>G-S&1R*WL9/;^%"YI>[5?8NO
MNA9;W*&P)($)V?..U0EL[!>_0W."?0%P AE'1Y*3C;?,?F5\E0IC3Q_AG@HC
M=LH;^[<U. @36Y'6V_)#S])BIZ/Q^$@RY*0SWO.BN?_55]Q6Q=V]MM>D1C3<
M^#RG8')F/W-20)I5J>MO5]9WUY]27=H/B';N7X7OK^L/HIR;^ONLCU3.>*F
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M;?O-,%4G,^ Z0-U?,":?)_H!S5EO_!=02P,$%     @ =CIK4NQ 2Q;$ @
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MI0-VUT?VSSYV&\L3,SA1XCLOJ!P%-P$4N&);04NU_X)-/%Y@KH3Q7]@WOE$
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M6=JAB-HYV/.54G3<N O:,9O]!E!+ P04    " !V.FM2!J#DW30$  "I$
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M22MN;N7F*VP-]2Q?)KEVOV2SG1L')*NTD>46C I*)NI_^K3=B#U TC\ 2+>
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MQ)S"JU75U53=,'+M"I)[:;"\<9\%5J"@[ 0<7TII=@V[0%/33O\"4$L#!!0
M   ( '8Z:U*9UDE\C0,  "H+   9    >&PO=V]R:W-H965T<R]S:&5E=#8P
M+GAM;)V6VV[;.!"&7X40>M$"=70^.+ -I#:*+;"[".*TO::EL4V$(KTD9:=O
MWZ&D*(XEJ\'>V*(T\_.;(3F<V4FJ)[T',.2YY$+/G;TQAUO7U?D>2JIOY $$
M?ME*55*#0[5S]4$!+6JGDKN!YR5N29EP%K/ZW;U:S&1E.!-PKXBNRI*J7U^
MR]/<\9V7%P]LMS?VA;N8'>@.UF"^'^X5CMQ.I6 E",VD( JV<^?.OUWZH76H
M+7XP..FS9V)#V4CY9 ??BKGC62+@D!LK0?'O"$O@W"HAQW^MJ-/-:1W/GU_4
MO];!8S ;JF$I^4]6F/W<R1Q2P)96W#S(TU_0!A1;O5QR7?^24VOK.22OM)%E
MZXP$)1/-/WUN$W'FX$=7'(+6(7BO0]@ZU)ES&[(ZK!4U=#%3\D24M48U^U#G
MIO;&:)BPR[@V"K\R]#.+;R*7)9!'^@R:3,@:MTE1<2!R2]9L)]B6Y508LI3E
M00H01MLO_^+V6L$6E(*"O%'XN )#&=>?4.O[>D4^?OA$/A FR.->5IJ*0L]<
M@]AV<C=O$;\TB,$5Q!7D-R3T/Y/ "[P!]^6[W?WI6W<7D]5E+.@R%M1ZX56]
M-G",F-QI#4;?CLB&G6Q8RT979+]" 8IR(C"W>$@5-4SL")=:DYPJ]0M/[(FJ
MX?PURDFM;,_M<>''2>#/W.-YFH:L//_5Z@UVU&%'H]AK0PW\+^A&-S[#";,D
MN6#N&T6A7<4AY+A#CD>1'T #5?F>X';$$W_$4G; PF1(CJO*S)_)XSYY&J<7
MY'TC/PG38?*D(T]&R?\&+%B$,[IAG!D&@W1)/V5Q$E[0]8WB($N&Z=*.+AVE
MZPZ&PIR*"H;@TGY6O- /AR?.NHFST8GO\EQ5E.MZ016NKCJ"_DRP=N9/]3MI
M]J"&<+(^3IQ-+W+5-XJ#>)AXVA%/1XD?I<&C7KPDS& EH74E&8*<]K?;-/4N
M*?M609*FV3"G[[U>#]XHZ0_**]I<N!RO?"KRP75M5<ZGGX21E\87E$-V@3>-
MKAQI_^P:\]^W^<9SV:J\6<PDC"XI!ZRRX!KCZ\7A!^,EGCTCH-V03!@J=FR#
M%^T(:]#/%5;LRQ(Y9);&T178U^O('[^/ZH9N(K>32H]"]F^52>0'V27D@%E\
MOCT:2O>LD;%=Y#]4[9C0A,,6_;R;%*-436/6#(P\U+W-1AKLE.K'/3:SH*P!
M?M]*:5X&MEWJVN/%;U!+ P04    " !V.FM2ZZ//&Q<#   J"   &0   'AL
M+W=O<FMS:&5E=',O<VAE970V,2YX;6R-5EUOVC 4_2M6M(=6:LEW@ J0"G3:
MI'5"95T?ICV8Y$*L)C:S#73_?M=.R"@-M"_$=NX].>?8OI?!3LAGE0-H\E(6
M7 V=7.OUC>NJ-(>2JHY8 \<W2R%+JG$J5ZY:2Z"932H+-_"\Q"TIX\YH8-=F
M<C00&UTP#C-)U*8LJ?P[AD+LAH[O[!<>V"K79L$=#=9T!7/0C^N9Q)G;H&2L
M!*Z8X$3"<NC<^C>3GHFW 3\9[-3!F!@E"R&>S>1K-G0\0P@*2+5!H/C8P@2*
MP@ AC3\UIM-\TB0>CO?HGZUVU+*@"B:B>&*9SH=.SR$9+.FFT ]B]P5J/;'!
M2T6A["_9U;&>0]*-TJ*LDY%!R7CUI"^U#P<)?G(B(:@3@N.$Z$1"6">$5FC%
MS,J:4DU' REV1)IH1#,#ZXW-1C6,FUV<:XEO&>;IT7<\*-^$4F0-DLQS*H%<
MDWFUI40LR9@JEA+*,S)EQ49#5D7/FNB+*6C*BDM,>YQ/R<6G2_*)N$29EXHP
M3AXYT^H*%W'\(Q<;A6!JX&HD;RBX:4UT7!$-3A#U W(ON,X5N>,99*\!7%3=
M2 _VTL?!6<0II!T2^E<D\ *OA=#DP^E^_PR=L-F)T.*%)_#NJ.2,KPZ]_76[
M4%KB2?]]!C]J\".+'[VSTVW65YF)S33W?CNZCN*X'P[<[:$A;6%^$"5-V"MB
M<4,L/DML"E#BN<K8EF6 !VTI14G@)<TI7X$Y@ZG@6Y":+0H@6*J6("7&X]5(
MG]O$5%^+#UGVO=AK)YDT))-WW2O,R:=:2[;8:&K8:('DRA++D663BR(#V>IP
M\M:Z.$JB8X=;PLXXW&W(=\^2?[+%##VCZ"/6YH9T=4FQN"N-MQ)/WY6IB?6%
MSZH+WZ:F^\9BOQM&_;@7'.EI"4SZO3@(V@7U&D&]C^V&J5I6Q0>)5["]0W_#
MCA\?L6Z)"J).T#LB[1Z4W1+DRG8CA>9NN*[*4+/:-+Q;6^>/UL?8"*N^]1^F
MZJ+W5*X85Z2 )4)ZG2Y:*:O.5$VT6-OBOA :6X4=YMC,09H ?+\40N\GY@/-
MWX/1/U!+ P04    " !V.FM2QT/032T#  !-"@  &0   'AL+W=O<FMS:&5E
M=',O<VAE970V,BYX;6S-5DU/XS 0_2M63KO20A*GZ0=J*T$!+1(L%16[A]4>
MW&326"1QUG8H^^]W[*9N2TO%@0.7)G9GGM^\%]LS7 KYI'( 35[*HE(C+]>Z
M/O-]E>10,G4J:JCPGTS(DFD<RH6O:@DLM4EEX=,@Z/HEXY4W'MJYJ1P/1:,+
M7L%4$M64)9/_+J 0RY$7>NN)![[(M9GPQ\.:+6 &^K&>2ASY#B7E)52*BXI(
MR$;>>7@V"2.38"-^<EBJK7=B2ID+\60&-^G("PPC*"#1!H+AXQDF4!0&"7G\
M;4$]MZ9)W'Y?HU_;XK&8.5,P$<4OGNI\Y/4]DD+&FD(_B.5W: N*#5XB"F5_
MR;*-#3R2-$J+LDU&!B6O5D_VT@JQE1!VWTB@;0)]G=!Y(R%J$ZQR_HJ9+>N2
M:38>2K$DTD0CFGFQVMALK(97QL:9EO@OQSP]_H%?RJU0BM0@R2QG$L@)F>''
MDC8%$)&12UXT&E+B J<N\%QKR>>-9G,,U8),1%FB,S,MDJ=<%"E(1<XKS4_6
M&%=9ANZ1+Y>@&2^^XDK* *FAK[$40\A/6MH7*]KT#=HA)7>BTKDB5U4*Z2Z
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M_1Y($X#_9T+H]< LX#K(\7]02P,$%     @ =CIK4FQC>1-2 @  9 P   T
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M3DG-KKM9#^8@VEF]_<-LSU_8A/W_BO@O4$L#!!0    ( '8Z:U*7BKL<P
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M+?Y3UF=KEW\</SSSUM3=(9\-?S*:O0%02P$"% ,4    " !V.FM2!T%-8H$
M  "Q    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4
M Q0    ( '8Z:U)(]W]?[@   "L"   1              "  :\   !D;V-0
M<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( '8Z:U*97)PC$ 8  )PG   3
M          "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @
M=CIK4L'\+[%H!@  .1H  !@              ("!#0@  'AL+W=O<FMS:&5E
M=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( '8Z:U++'?CW=@<  *<A   8
M          " @:L.  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M    " !V.FM2_32*_'T$  !K&   &               @(%7%@  >&PO=V]R
M:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ =CIK4KP\)N!!!0  ;Q(
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M965T."YX;6Q02P$"% ,4    " !V.FM2\2*<-M@G  #/A0  &
M    @(%$/@  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @
M=CIK4DLA.X:W P  %PD  !D              ("!4F8  'AL+W=O<FMS:&5E
M=',O<VAE970Q,"YX;6Q02P$"% ,4    " !V.FM2#QB_.Q,%  "Q#   &0
M            @(% :@  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4
M Q0    ( '8Z:U*\,52ER18  'A2   9              " @8IO  !X;"]W
M;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ =CIK4EL]0,B4 P
M=@@  !D              ("!BH8  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX
M;6Q02P$"% ,4    " !V.FM2U0%@O=$'  "Y%   &0              @(%5
MB@  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( '8Z:U))
MU ']D (  ( %   9              " @5V2  !X;"]W;W)K<VAE971S+W-H
M965T,34N>&UL4$L! A0#%     @ =CIK4B1O0)CB!   EPL  !D
M     ("!))4  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( '8Z:U)XIE5H.P0  /L)   9              "
M@5ZW  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ =CIK
M4D%9W(P'+@   *0  !D              ("!T+L  'AL+W=O<FMS:&5E=',O
M<VAE970R,BYX;6Q02P$"% ,4    " !V.FM2)7PC@ZL"  #6!0  &0
M        @($.Z@  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0
M   ( '8Z:U*JW06DC@,  )X(   9              " @?#L  !X;"]W;W)K
M<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ =CIK4J'\)0;8 @  G08
M !D              ("!M?   'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q0
M2P$"% ,4    " !V.FM205^X44,#  !Q!P  &0              @('$\P
M>&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( '8Z:U+F9]FZ
M_ (  %@&   9              " @3[W  !X;"]W;W)K<VAE971S+W-H965T
M,C<N>&UL4$L! A0#%     @ =CIK4H9_RHG%!   D P  !D
M ("!<?H  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " !V
M.FM2TEDPIYL"  !_!0  &0              @(%M_P  >&PO=V]R:W-H965T
M<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( '8Z:U*R!G)\@@4  !T/   9
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M970S-"YX;6Q02P$"% ,4    " !V.FM2O+*&.? "  #@"@  &0
M    @($R&@$ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    (
M '8Z:U(@KT$(AP0  (<7   9              " @5D= 0!X;"]W;W)K<VAE
M971S+W-H965T,S8N>&UL4$L! A0#%     @ =CIK4C<_\H9U @  2P@  !D
M             ("!%R(! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"
M% ,4    " !V.FM2&'1:JQT#   ]"P  &0              @('#) $ >&PO
M=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( '8Z:U(.)+%M2@,
M %,+   9              " @1<H 0!X;"]W;W)K<VAE971S+W-H965T,SDN
M>&UL4$L! A0#%     @ =CIK4CC4C/.@!P  '2@  !D              ("!
MF"L! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " !V.FM2
M3P]R-P8$  !;$P  &0              @(%O,P$ >&PO=V]R:W-H965T<R]S
M:&5E=#0Q+GAM;%!+ 0(4 Q0    ( '8Z:U+&HVX#I0,  ,8.   9
M      " @:PW 0!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%
M  @ =CIK4A^VG.HC P  0@D  !D              ("!B#L! 'AL+W=O<FMS
M:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " !V.FM2LXE,&:L$  "O$P
M&0              @('B/@$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+
M 0(4 Q0    ( '8Z:U+;(=+\U@(  ,('   9              " @<1# 0!X
M;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ =CIK4HP1S+B6
M @  N@8  !D              ("!T48! 'AL+W=O<FMS:&5E=',O<VAE970T
M-BYX;6Q02P$"% ,4    " !V.FM2&H8?]VT"  !P!P  &0
M@(&>20$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( '8Z
M:U)(E'@>- ,  " +   9              " @4), 0!X;"]W;W)K<VAE971S
M+W-H965T-#@N>&UL4$L! A0#%     @ =CIK4G"&5168 @  !@<  !D
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M=#4S+GAM;%!+ 0(4 Q0    ( '8Z:U(!E; *9@,  /<-   9
M  " @=%G 0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @
M=CIK4NQ 2Q;$ @  V@<  !D              ("!;FL! 'AL+W=O<FMS:&5E
M=',O<VAE970U-2YX;6Q02P$"% ,4    " !V.FM2OZA+P!$#  #$"0  &0
M            @(%I;@$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4
M Q0    ( '8Z:U+XU%B*3 (  '(%   9              " @;%Q 0!X;"]W
M;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ =CIK4@:@Y-TT!
MJ1   !D              ("!-'0! 'AL+W=O<FMS:&5E=',O<VAE970U."YX
M;6Q02P$"% ,4    " !V.FM2T5"'#RX#  #?"@  &0              @(&?
M> $ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( '8Z:U*9
MUDE\C0,  "H+   9              " @01\ 0!X;"]W;W)K<VAE971S+W-H
M965T-C N>&UL4$L! A0#%     @ =CIK4NNCSQL7 P  *@@  !D
M     ("!R'\! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"% ,4
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M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( '8Z:U)W2W&%!@(  /$D   :
M          "  0./ 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    ( '8Z:U+_)Z=UXP$  &PD   3              "  4&1 0!;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@    !& $8 (1,  %63 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>206</ContextCount>
  <ElementCount>462</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>78</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Description of Business and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureMarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Collaborations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureCollaborations</Role>
      <ShortName>Collaborations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureAccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Other Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureOtherCommitmentsAndContingencies</Role>
      <ShortName>Other Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStock</Role>
      <ShortName>Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Equity-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensation</Role>
      <ShortName>Equity-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureMarketableSecurities</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Collaborations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureCollaborationsTables</Role>
      <ShortName>Collaborations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureCollaborations</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kymeratx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipment</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureLeases</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureAccruedExpenses</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Equity-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationTables</Role>
      <ShortName>Equity-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensation</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureNetLossPerShare</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Summary of Significant Accounting Policies - Summary of Estimated Useful Life of Related Asset (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfRelatedAssetDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Estimated Useful Life of Related Asset (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Fair Value Measurements - Schedule of Assets Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Assets Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Marketable Securities - Summary of Available-for-Sale Debt Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleDebtSecuritiesDetails</Role>
      <ShortName>Marketable Securities - Summary of Available-for-Sale Debt Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Marketable Securities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails</Role>
      <ShortName>Marketable Securities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Collaborations - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetails</Role>
      <ShortName>Collaborations - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Collaborations - Change in Accounts Receivable, Contract Asset and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureCollaborationsChangeInAccountsReceivableContractAssetAndLiabilitiesDetails</Role>
      <ShortName>Collaborations - Change in Accounts Receivable, Contract Asset and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Property and Equipment - Summary of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment - Summary of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Property and Equipment - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Leases - Components of Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostsDetails</Role>
      <ShortName>Leases - Components of Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Leases - Supplemental Cash Flow Information Relating to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureLeasesSupplementalCashFlowInformationRelatingToLeasesDetails</Role>
      <ShortName>Leases - Supplemental Cash Flow Information Relating to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Leases - Summary of Weighted Average Remaining Lease Terms and Discount Rates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRatesDetails</Role>
      <ShortName>Leases - Summary of Weighted Average Remaining Lease Terms and Discount Rates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Leases - Summary of Undiscounted Future Lease Payments for Operating and Finance Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfUndiscountedFutureLeasePaymentsForOperatingAndFinanceLeasesDetails</Role>
      <ShortName>Leases - Summary of Undiscounted Future Lease Payments for Operating and Finance Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses - Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Other Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureOtherCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Other Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Convertible Preferred Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails</Role>
      <ShortName>Convertible Preferred Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Equity-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Equity-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Equity-Based Compensation - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfStockOptionActivityDetails</Role>
      <ShortName>Equity-Based Compensation - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Equity-Based Compensation - Summary of Equity-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfEquityBasedCompensationExpenseDetails</Role>
      <ShortName>Equity-Based Compensation - Summary of Equity-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Equity-Based Compensation - Summary of Weighted-Average Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfWeightedAverageAssumptionsDetails</Role>
      <ShortName>Equity-Based Compensation - Summary of Weighted-Average Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Equity-Based Compensation - Summary of Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfRestrictedStockActivityDetails</Role>
      <ShortName>Equity-Based Compensation - Summary of Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Income Taxes - Rate Reconciliation of U.S. Statutory Income Tax Rate to Company's Effective Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureIncomeTaxesRateReconciliationOfUSStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetails</Role>
      <ShortName>Income Taxes - Rate Reconciliation of U.S. Statutory Income Tax Rate to Company's Effective Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Income Taxes - Schedule of Significant Components of Net Deferred Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfNetDeferredIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Significant Components of Net Deferred Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Net Loss per Share - Summary of Basic and Diluted Loss Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedLossPerShareDetail</Role>
      <ShortName>Net Loss per Share - Summary of Basic and Diluted Loss Per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="kymr-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100620 - Disclosure - Net Loss per Share - Schedule of Diluted Net Loss Per Share Attributable to Common Stockholders Anti-Diluted Effect (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfDilutedNetLossPerShareAttributableToCommonStockholdersAntiDilutedEffectDetail</Role>
      <ShortName>Net Loss per Share - Schedule of Diluted Net Loss Per Share Attributable to Common Stockholders Anti-Diluted Effect (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>kymr-20201231.xml</File>
    <File>kymr-20201231.xsd</File>
    <File>kymr-20201231_cal.xml</File>
    <File>kymr-20201231_def.xml</File>
    <File>kymr-20201231_lab.xml</File>
    <File>kymr-20201231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>116
<FILENAME>0001564590-21-012240-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-21-012240-xbrl.zip
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M:_<'?CJ4L2:E^"0?#XT^6855CDBEU(E5:JI5/C$[8D^!Y]Q,J,$Z7G64:J4
M$8U>68E9CDBQU(I9ZJ99<$MX&44LCGX/XG^P^,:_9^&S.V+'I%9H7UR A4:G
M+&>3(U H]6.3URIH5]40O['@,;2G3^[(]I(<?GOR$+K.(_ML1Y$]>IH!AE:O
M<?D]\$=X8.9A@M>U/7(]0 /I[*QRR7:W.]PW)L/"\UP,RNS_ APNXZLRC%Y4
M@; R)7; Z,-6N]OJ#H^%T;OM=D^DV+1[^Z=6&XY?D^/3&3^]TAD_<,N6,WXJ
M$9/<]!#Q._7TYK;6O/$J9(X;2UJ9&YXX9N'MF%^Q%?.SUSY.?F**O&(!Z57(
MX='I@C( +7*SOF]=Y.?&Q=Q0I5S-PA#I7C/- GC>XPXY*VJ6#-PW"N;H%0R&
M.MI[H6#R15WB]WX&I,UQ'=K]7GO?!'Q?1&L)_G=B-=O]5J]]^$PM^HXTW'WP
MW)WN-](OW6_$$(G=[$W_#C^&<?#B;S]6>;&/+MTJ,E&$P[USIK:S8]J]0_.Z
MC"Z[3S4<?SP<G[('G7;Y_E-;;_19B9CL9:QROX_MJ]ZV'DB<M-%#M<F:^!1$
M$0XC=0%#_@@'/<U_MS%I$1A3?6W(_(WOL(D/HL)9ZK>9#>B-V:%DVJR.D$20
MBE'2,%!)!MKO\ZE#8*#73._+[SNK*E6*AP92=L&PNW=QFQ5ZM"9U*C6;O8<G
M],-6=[N!P1*-B>\9<XZ83[1>OBM@HF&7RX975D%#PRCO&T99!0T-HRR?;7PD
MG%*_.<%U8Y6KAE-604/#**L9G\[^;I7WV?AT=KX]+LTH,A._X9@='"VMU_C2
M8+-=3_]9:KB6GOR(YY@WW\W"T5-N^<BA\^JF9K"J\Y RI-F-QNW52./N1!3V
MN)*JD8EMV90ZEE95OAEJ./XX-"[6J\=S&B'FPY]1JF'9)/ S]LD=]6'O>21K
M_4:W,A,#N](YL$DNJW/T6W:C<\J=)AX04]7^6/'8V&N?LQOVAZMVU(7&L_W?
M[4G2;N;K2_#U*9A%MN]\?0'HYX2*VRFEX_G.C3_")3TSO/% XK\Z#H274QX+
MAQW^K8Q-#F&"S5[QRQX-LZF*R1K>.G*3]7$R]8(Y8T;\X\@,UA(<'+NY6HE%
MCL58U817]L%44200%*X-3[D+8ER<[=W.XE&@<=LG%D58*I.^X-:72>,-G^Z
M3U<!A\<X"P@LQWDL(W$C-!4)#7!!(S2'+32*Q(W0;,F5:9C\2#=$E]F;QM^P
M7LO@D?TN8BOFD=60\/I,\JI=Z:M@DJ,PF_7BE@,Q5258K.&LQE@M-59"#S56
M:Q=Z"'N*E=1#:5.W33UT^6*'3GHNC^$A<F0>&CL9ZT[.MW-7WK#.YJRSW^:J
MKARS&]-4DOBJ/0B&,%2>25:GJB\L8C;L24%[?V#/S MHQLW''U.@!SLTY[H
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ME(5U25O0]=#:::>1NA:PBPIJ24O0-=5K9PFPV8II!6BW8<CZ2]A@-6 Y_C-
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MZ1?X[#'J0ND[EQ,< ?B?!<"W<H8.7JX!^"I ;;:,M>=Z%4X:'JRY"HKI_!Z
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M!WO]=$)A!FC<;9N%H$$C%F$N)0]ZZ_'NKT^ _\<G[B!@F#+_A+)7.']@[7C
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M<Z/*QV8  3",/45O%7P6N@B?+IX#" "&M)!28Q?9!0"84+*298]&;!KCKEO
M/<%_\/YH!FN1#SBU+I$K8(TS#T")378!IOT71J@!"[;ES]"PH#H(W>A[A*N:
M *_ ;V"%46P?!2M1$,+GU'0!N_ ZD&&0^7!^"K9;(->RX6ZB><3$$]% X5TS
M@#I$-)!P"%] H4[PYGR!'HHI'#9%:XAK!P"_LSF^WWUV'3!E]'-RCWAX9$\8
M8C]R07D ?R'0/JB:1Y(0U_<!_=PS 8[5D&1P*JX>G X@&;R$N&\D%2O\!5S%
M8A1_]>SY"><,EZA$FN(15^839(+^]%)<J60"^('R[LC6GN0"(_>02+H1HL4:
M\:X@]+ $PZ3?%WF&P\Q9I"J-3B:UWBH]+<'@ @$YB0E\0) 71)'P!.%6%_DX
M9D+ON3&0T/,L&11%S+MXZBKO0ME#:L&_P/*,HA?C&2@V+J%/-CX4:2"[@ "C
M@LUUB4G_T.D.3X>)5P<(\9"W;)(/Z?59TME;U$7C&?F'7-P$1(:BXY$ZD'I^
MY"W%.T+G^017PL/ I"E=?AYN3>E '" 0I_4_:=;HYN[V9^EMO]B1I@1!-US.
M'H%CA%\Z5>9.O&R4),B@#A48'X?!!)@X>N*"SARTD[AWYX^$FWPA<,I[SY92
MS[,?A+6U[,>0<5'B=_T-NU3^L.X,$QE9ND]KK))?KYG<GPG6WYC_'[#RNF$W
M;KNW_6#L&K?]!#QAD5\V^-DD'_LQA871YF21N0(9CM&9TV>/-II@CJZQ%[Q$
M%OIL'E?^,0@2<@ZPUB/S\7Z\S_)0+Y)^AP_T$N)K- -C9$342O#>:#:ES0 R
MPBB(T.,,04\ 'Q^3IKC,%CS3A*),(PE.."%8<JQ"9)JHO&+PFI0SB-+>'PQ/
MSRTAY"8W/##/!?I$0I1+/YZ4U -+$175 U$T2,ZG\!G2:" /@@TE;:4;(*4W
M@%,\\/'@82_, \X#W1$_15QH$25*KW"+BY#K/NV8)SS FR*YK3]:PZ/).T<+
M]XJ$K<AU1T>4[P7H=<F'Y=X22NH8L!PD.Q'VPZ4$Z=*L<V*1!>/TQFA$S, _
MDJ3#6 LI!@RIN=(JPE[1<X3U8"?6PRPF+X]B)N!KQ7R/(Y8F[8A:!:/F5">Y
M.EM Q+@NY'$,N-5A#_&I]=_!"V G)(G$R ?ZX];CS,8H"A/*#=&M&#)9$CPU
M;U52?-@/P N"#]?*F0_H;8[M9X 3$1>S< (0NF.4#;"Q)X39*)@P@94'W!AY
M,U+4Z$5+ND1:O.K4NAD;*F5LNQZQ!M\H6+;J_2:Q*$3V!-7[Q$:% ;J?0Q0H
M*\R9Q+-]GW8E;.2!31^1^(&9%V9$?1ECO*I">1PF?WML+.5Q66Q%DS%<H#M:
M7X++"><7Y"-@$)Z1? \>>WP\48Y;Z:TESB>:N<38O0_L4&Y/@)ELJ]."Y[8Z
MIX.+_@7Y$B$)%^ N>42$2)2[KRPWS:6>G\2&@=;LDK>7Q!MU_Y1[Y+3+XA%D
MW.:H\4+(]_B:1/&IKK\6J13NFS,;E&H!1 88E$G.=TF&\WJ:+#'Y= DJ@P G
M.,' RK]HA+K:+(/KSU\K8"RVCMS1"_C^ Q0<+/+)!DWRP!@LB\5A8,LPC"U&
MM_/P 0 SI1PNM!*@]WRAA!]1#S&>DD88HT"41CV+B*;O!5!OV%$$7,XC16)%
MJ+=1:P0B=BT.HW"=4]A</].XJ30)<:.:Z#+L.-1"KYXKLTRT'JLZ$MG(%D]'
MMN2I]!&J),O41%E2*T].B &5]*B3C/M6!R[Q^ X*-U4%NUOAE!A<^T(Q1) "
MU !<>%",1)1HA=,C8U?X\4K?$H+MYXH!MM)R)SV"71YW-"0&!ED;#TU[@A9Q
M$IFY.+D8GI\,NFU-%6>J5%W,QS,/=P"\3$*J2(PGA"^P.E 0&L8MC& !NWD!
MU[T!/UP U$Y%/@CIB432.R>]=O?DO-L6NOV$W*4%Y$]#ESMW?^BV3]MM78OZ
M//!I/X)?"/M>9CV&V"5410D>&(9<@$RDA^!9"U^HM> ?CFQ;QWT@1:J(.W !
MQ?6QQG!"NEE!R&3BS52DIIBA0J @NJ%D)W_0O:"9_]"YN#@=)AN])$\_"6(0
M]0N(:YV=GYWT!OU<VQ@OX@P=1T0IE@*@&R@*%(!*/*!QJI_NK7U4EVI FAPB
MK7B\5RY[J]SQWO#@C_>ZIZ]WA"?M1C%&<RU)"1Q6O^TNZ7:!O^>1B_1$PNS)
M!!\4.QY3MR(-UW:"ZZG M44V V7H@8<NR=5"5XYK&.9%[(7O6==U#!/M3A[B
MT>[<Q&F3Q]7BE4(=$.QXW*4UF%P$;!3WD3DT]T;$JN@/O3P%>( 0O& H8=5C
M[E,+-T68=A/*\V=:CSU*8H\/MH?!KTC;US ,&OEVK$+^"3W7X/$"0U %CY=0
M;>4(^IX2 ( <=WS_MB8_EU':>Z>F$YZ98O_:4'$,O@\/1LF_TK5SHBKXH0@R
M-3\1E5J:6=]\"EE2ZAE1X!)X'!2]X<;_=GEY9_KQE[Z9:24"CF+W'D@[@D[C
MXPQ615=%UH39W"FC>^5^VI[%3P%(%#_A,2'*@#Q[B7@B&%#,GR],<PGN,<AA
MAP[*JY; JJ_P\M[8J)"T9C[AVQ1)E+KWFW&OT"K7BHB9#^)!)OTYUY?W[PTL
M'X_\?^.[L(]B#Q(=NNAS"59N5H[%6A#N;Z?WIQ8*HSRQ HFR??M1[74F]G>F
M=G+<YOQKYCS*@RW<AXIP&(6Q,+:( C51YM#F^>MXHZ=5X-#)#.PB8:_.CS7$
MN2U()_?_^!-)- 3[YT;X\EZM=IL.C472KB-)IP#?J?59K=<(BN2MV:9=<4A'
MZGSS2\?-I% 8ANUD_AD/0=C/MNOQ*@Q?I4&=Z$D3"&7H,IF%A!0.9I'80P/V
M9A/>@T%@.V3R>),BD@^X)#L*^.D%;=)IG2,W',TF$66J1*?6>X9Y92)UB(M&
MLD 760.=:<KR3>%:0YA**!O%,_H%$Z(B<5(#:A 5L#C,#"*-:RA($[)1$%*H
M)-^)X4^D< H^YD&F6B8'KB<Z>R)OZH122*>T*OA>Q[E&"<%;=,1/06_Q!+(G
MML-.C9U@\OP0\>Y8LZF(TY+(N2I!J]!+E/D"B 9X-IZ$<6(%LS#O[(Z+*,^#
M($3QP ,28!0B!<9TL)9SUBFY_T0<$;8X>D;Z9!-QS8D2(\[ 0HGP^RC][8'%
MF&>MX_.!X;B=2,,K1LXY:T@AY,*"IWPN,>B)D$%D!0P&)C)&I[;/V&*$(CP1
MO!L6X<U/M.P-Q7 VOETH'IFC#?=R*0G0A@>AQG['8_7N&6DID5\3/(;V],D=
M@?@ILAVR'51E5U;$#&T]IFQ1D6#%ITJ1:0(!P-T5\ N&7!^"62Q"R!$WII25
M.PKI+%CC?%=G>CH62\1&!#1'3RX;:ZR+%344RT:=%=*9O/RJ!5_A)1BJFF)(
MF7XA3?D4O)#KZWG!"*$! 0!U,1(V"0.4F,X4"6M& ((>-7)AS+RN0JAP7;1Y
MI:L^TN$]NL^WF 3#0C/%YMEE+U%6-@S7S_PGI< !5$"[]F9!H/J)YMJ1MW*L
M2G59B*[B@AAUK1%[M+3:\^,)T5PM).& ;#_!&\#Q\ESX'B4BF?&CO"5PCQP
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M&3VU9E.9(\H-'<>8S7/;!#ZY@P4&Q*<Z2U?EAKI\DYJ\4E0^)MRP)-%6!+$
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M@%?N8I)R_)<]ZK[)+F6R5B]C8B_]D"6W42J@-?&*[F9Z(*GR=+Z)[KNH(?A
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MG[?"333.0O#7V3_>,'4FZZI;+KE<7S+DJ0N_#+N=_N,.WY:P4N,_QB&^II_
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M1:BF@4=>LOE0/^)R!/*2+?62!,KYEN(Q?UGV]PT)*V/7W7>P*-HI811B.U9
MIVT2,H*P^MVAL5#2.7]3D:%R,J8@001%!'7&!#6:3(P%DNC)5&2(G@Z?[)JV
MIG5FF/U[XZZ,$V>1Z,! DW. ='+@>%/BR>30*3&=UF^E\=%1.*/A(68[3_2(
MV?:#=-@]="Y-O-9*TR->:]P2,\VZ#SE<86PBBP*4QB?X*2YY,"ZQ["LZK-\$
MI(Q)_5-D8C0\1&A$:"TF-!L(;62&AR1":X;'-)K0J#C0IM/EO0>$LG$8WWV;
MBLL;QUF\?N\+-XA$&O/?9N6B![_SP$FX]RX2B?AT"XC+N@@?G27NEQ:?H4L_
M!)'[Y?M__H.Q[[+&]$,?G3A9?D8Q.RZV)8J7Y \RWWM[\>%/ +D_&%W =#C$
M8?[.9V\OWN&G]L0>#@:]/_$H7M?NVO(?=J]O7WR_3]V5T:+.O>]4=6(/K_ (
M)?LU2C@#BF-:=I=2>*PLO0*VXX[<A((S/X4,O9$L,9%$LKJ#K%8 /DC5G?!
M=5(A5(T5*:QAM>;,K>/)OU6=!SQP'2M)LH649%*2I"PX@3]>\-B//,$66,(B
M3%3K^(7CNJI=; B44GH_V=K,#YW0Q8HP(H$/I!ED18YN'0&C2E@$3<3WON!L
MROE*W^$K@46M$I!P/M+M[:N"2-E YXX''=<&J&OE3*JE;^Q.=[WN"[P,*]K(
M$DXP?%5YIRAY4PAEUXH_U2HV=4YE#S]0=2 _A2!^_MGY^H#'&#_&8VRH2F.R
M?^C+:D$@&@:R@=<]H4OHG]HE?%XK*"4++>'@$^=KJ1"-LG)0[T4<S?P$Z]'
MT+&NV'3)\.\_.I\Z+ );!U<"YBS2J? ]'][)1:>PDP];U']+!3$+"]35].M>
M%L;117*\E,NV;^(H753**X4\*74-5%VPE]D/>MTWO_[V<_Z7_>:5?.LL#0)9
M$TUY1@?]';@,_J0ER8Q0!Y"2JCP$#C+P\])5*%F),7K,%)S;L@R(?$A[6JU/
M%03X;*:\6/'K;9YP6S$Y"(]*I89>;\+CH$COM),3.>"5\9R@8M&8*A9MFC"9
MH"6T6GR4T\CO0$C3V'\N3/(:#*/35I'J=OH[YO=:5V)AM]I15&JA":?Z6\I/
MC4*1F,ILIJ)J08TU/ZJI1LYO@_,[MYIJY!W).U(MM09)W^@]U1L-KC5ENSYC
M>EUF:_&6U2+9BSE;8W<M41$ 4Y"@&C6-A8Z*U>P30^#ROZE(MK1:S3?& D+\
M9 H2Q$^-A8[XB?BIT9ALX:>3E>ZB">^G1.Y=PJU^)TX*4?Q@2N*<7%?SD%'A
M ;$_CG;8.77Y%[*@(TU.B5S:X\)::AH-0(;(I8!K?/#,DBRH 3-+6DH]WLP2
M3](UHO@4Q0"F(-%2#]8 9"@&*.!ZV>T<NH6*3.BI@H!7QB)"]&(*$BVUC08@
M0_12H9=3%]4B$]J#7FCY\F2P?.3P[Q!KS'C^;,9C'KJTD'EJ4!J0T6RI%VL
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MBF9D0''6NE..@V<13C=$YL+N?"'-&L2N9[:7-GB6S!I[7;PX&;E&!FG 7W^
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M.491U&OHE[+W<"147J-CEW+/D\08\55[*.<BK4BEHO3;C5U7_?NOJZ_+"KX
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M%6MZ6L.W\(0:+#?H&8/GG-3"56TO5B*D_Z;85Y^ P[\LU]O<5,^7=U:?=?,
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M!81A-<@!P ;V/SOM@2=E)-1S8 =<O)4E!1O!7*P?9MR4*YP&J]P;Y4VR9UR
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M1?-TRF.'%;O]]AEYD/[PDV]"'2].Q2A/@BP0Z9Y#]FQ=4,E;8IU6KVH?;!+
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MS'*,#1&6.V^?W5$HH+$D=R&G#%K*$RE0Q'IN_QB@GN,Y9_U5!R#?BG$^(J7
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M_8<9I(]2TK'N5NFN(WN]O6\:W%DF7^:14#W53KN[89"H<>52_R='+HDG&]#
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M8 X,,?J9GMR=Z;#A[96LT"> ^-"#MKU^KS7H#VBH6^[55 _Y9'8D#0^SXV/
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M Y"4!%(2") @"5JHRIHE2[QT?PUT-QJ-[AZ*)4QDL81#NEJ$42(#U5P.0EU
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M(I(<A(F/2E,RE++AF:LF/3'$[8^F-;)FAJBB.M:YTW=!%&E6I%D15#+2K Q
M2#^:VD@WZQ:5EG-'FI77*0"A,PM(N=M'?+;Z$H EF&<'O( _5Q9AL$3GKAYM
M_P$HP0(=E'L"88QZ@VRE^JHAP8;QYI.R"M=%=-(C;CW'#PF9[4<\E@<0WB6+
M2^Z""2V]XBZ8/.U?Z2?/1JI5]PS"41[T'YSO+ W:<:M$:="&+#UIT&3Y&CD#
MI7D36#P]-^R1\:(#F2$T!8!ZCL?*23?8O3_I4PYS?U"ZDO3=#LS1V.P[-46Z
MD4/86)2&3!JRUR8]:<A>B2#%2(:1ADP:LJ%*1>BT&7D6YA+XP=+U94D. 60A
M3$!7)E\.3C(R@WE(TI+S2%C)2%LCBB3D'!%4,M+6#$E:<AX)*QEI:\3.A.BX
M0K1(,OLS;VND5+8U&BGWJ-_2,1^?P5I-B1N#/.+!/,3--%E ;CC2V[NK)FO(
M'92H-AD9YFQD374QU"6]KI034 !Q2>LFIGBD=7N5TI/6C=&ZC<:SZ<C2I7$;
M@K2$F7_2N TN?42>HB&?HMDTL\YC1!P")?+,6M^SK??=#-96<#(MN6E:LB@5
M^&7>,G7>LG&J66*H6)FU+&N3#$XJTA"^:O%*0W@TAE W3_6I&#I66D)I">M*
M)4-^#3Q)1OW&7WY.2V9LKIJ[3^CSKS\GT9L'VUZ]O74>P3SQP/7BO1WZ4 +1
M#0AO48S@'$4(SOSY918?N$//N8.TGGN!\\^[?_]+47[=?<B9'[MI0,%] K?
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M<UA0#YWK>\]]L+.68ULI4)S=X8 +R_ T]'$)$"JF"B8L@D]VE_=)&*640+2
M^X36\#CK%#D9+;!.DRA)8 #O>;+V)O>S1Y%IT1-[>PC'#YP%+[:'!OH^IBC.
MM??$U [9Q8GYU8?SUT-KGFQR1_OYZ\:G9YB.L])<)/!19/B\<-GV*GPU2=.!
MK%MVRZKG(!>%$Y*Y7EJ;JW63'(RP+=,6L>586Z8HZR1"32[&7=YZC9*W1FYH
MU@ILXRICV_KPR;/-!\B,N6:FFCJ,E??/,?#G8$[)"X7#R(.737\H"O+P/8[
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M?(3G!=^1C#X$X04TC6Z,SDWAW%%XX@T'/$M=JDFQ;%MM#OD#1=,&KO%\8"E
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M]I5A%$R(K;-%5=EB#0=&\#LVU.B($M. J+O5* =$'>1%-A$38JMVP3P L8:
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M@&$35Z,M$#,==V<_Y[>?0X6V<&,<G-H9LX<;=1>BY =(8*:S=FXJ3SK?+Q;
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M!,+H<Q#?)O=_ R>^"^!4=[/8,8Y$_916 C?FNH]+$RHQ/LNWGH,'U\^O!=^
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M^V49^!YFX<V_(A@GF\"AI+8) N\:0"#+_K_1.@C_UU&M]*[?B^L;#0A-6)E
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MS2:-P3]GQ<P&<)";R@XLQAS)I/=2^\GB%I+&MLGCLV):Q#YY['RG_^IW$?<
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ML#'TO@+$BBFH'D8=AU%"=1-RLA);IY]#/(_\>S+'C_-X-W44AICOCJWF;9D
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M\P#RAIY10M]J9+3O!KND4,)F.92PRX[561&;S,GAP+5VCKK-2J"V9A<']X>
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M.K164C93QR;FH&,$F7>/;YXR>L;-12O<'XQ>.PM3<#3,&;W-EPL[96XJG11
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M],^(F"=XAJYPFEZC;#*]]UX@D,"D=>"]11E1Q2@X]Y*8V+)IA<DSLO'\,(-
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M)D-=GYZ2.037/]3D79Q[87#^,D<Q6>1Q4-G#$@B$R)FR%QD;9.TK,A>WR.G
M=9:CBP3/;A$+"-QXB:3!V$[')MT@LX^@I+6L2'*B4S\H^1^JB)\)7]0SFJV\
MOO!PA!A![1I/QM!L(*"/=WFF1;G=#N_3G_QQAQ*R$D\.B(9Y)H=U2%;M>LCF
M^S+#HYLO&+T^W"IF=DA>C]7RVDVN!Z]W" 5JV16BJ$7[15Z:3J9LW+-E=A5
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M;BC1%B]R(](FKS?'[H265 7=C8=&),(A%2DTA:4X<OO5GASRCJBB"Z^H]!-
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M)6,.Q[8G5!K+E>&8J2A +#@IKR1&*K*^<>=.M#$06M=-34PC80%]Z4@7-36
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MCK(7?H&@[+:[VM'2T5519,G#@;4_N<<WD>[RR("X.7K:S-R[724":T91O)R
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MY=2- 5GS'<V]FV>FO+8)[+;2\8: BQNHUDDJ$P P"6A1Q&=ZRC+1L+TNV]O
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M^9#N5;K%V8[IQ^C-9%62%F\BJ;'P\&15_PO@#,TM$22X'($NQMA0T0O!$W5
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M7D$I"YTXJJ-8(DYO5]&1)]A4(ND])"O9XFI'2[!8)*N?_JHG3^</#LJ.PB4
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MI6Z#NOF<P^T!72=;N-Z*%Y38=;E[VD-%?TU@SL"T,:4A0S]=1[DP-"L#2W'
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MXAEO_'F&4PR&/>/-7)YQE3[#O"B;.>GNIKJ^;5&C?$3-0V5YQ8-UD@K##09
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M)QZZ:>[Y,^N+0_:O]$Q1N^VA#^[F*USWTGC8PP@9Z6*C(260Q60]BMJ"RI\
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MU6C0T$"THI5BH1S,Z&W5&_(9F&5P\SE-"HTRUG$:IC56_33]5,,Q?F %*HZ
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M+"/X:K-,!IF_5:E&S#0@*Q#W$Y=+QE+R,M!W++70Q-J*#1ZYQLH?)8\)A:K
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M] []$W35=(%.:M>M&-J8VD[H+>.)@Z<,@$X ;'[/W$)E.CY*"R7S@E]I YM
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M![BY)2 393^MTLTE?(8([^F4*=[#R2\.6:;8XLJ J&&7?ATF7MY5$ * 3$@
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M9);ZV7G8 #->#%;BM ?"#<"O9,N8/K+EDMA8KLS634%D#A5L0R6;. ;* NU
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MVU7\&6890P:GJ)3)YWK[8W&DB.1UH>!24)XPYV&RI_;C6O'E<>I7@9-J+ I
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M^E)D\9\8<<EL<B&ANPYRG(!>/PE2([^?'U*]IEA/H%_V18*_T9MUDC1 9EX
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M'(!1J36*2[71"],;PJ6#WM%)9G'Z7V:-S&:I&MZ5FWEM_?R'IYX6<\>HCE9
M Y7(D>)1Z$[#5>[/K2IPC< [.7KUX1 DA*NZC,!!/*I'H# >T0MX(.]+[=<=
MRKH@=A7,6J!8Y=RPN6ZN!*)*(N(BI]]%#-L(SG8L>BT8>+/"38F1^4@R@Q(@
MCLCY&$-^G<[LAYR?\YAN2'\A\/)ZYA+.^#'?XLWXJ-]*^NT<2%+G1BFN-IQ
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MV1J#C_&KY]JW'K: Y^?.AZVQ1P!84M."F.G/"XOL@FD<)7X.UY_#^*VGU)H
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M\FUTA<,(5&>@GHZ)1=H4<9T&SHI6V^ BHT^.2S5R5)"1*D2GI/J<>KXJ[Q*
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M3C$X;[L?M<7;$[7*89SM?-(J7Y#([,('+9ZML)!-A:&9JG6S2'0F#Y7.XU\
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MYYYX9U+S>WF:NHTBEYRYNU=>H;GFH*=EWWI6&&ZOO? 2"V5?Z[DM9]6I"PQ
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MLSTF[>)9=3'Z,!Y*XJ 6<51_&O7I.M0"CAR7H _J-&@_+T$MP%J$3[G"++L
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M9Z?7/:?J!-'7THN#B]%S;+KGN,7%P]P4IT8;U"W-2ML:DDV/V3D7/9^><K.
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M8$YV'Z8IA.3G MI)<(#N9;^T//HC=;+F!#6?-PFB6^TI>*[LDA#2%3DU9D:
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MO]#_>;5"]&__'U!+ 0(4 Q0    ( '8Z:U**_JY7_8T! !^2'@ 1
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M &MY;7(M,C R,#$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( '8Z:U*/.:+LZ58
M "G=!@ 5              "  6F% @!K>6UR+3(P,C Q,C,Q7W!R92YX;6Q0
52P4&      8 !@"* 0  A=P"

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
